"","AU","AF","TI","SO","SO_CO","LA","DT","DE","ID","MESH","AB","C1","CR","TC","SN","J9","JI","PY","PY_IS","VL","DI","PG","GRANT_ID","GRANT_ORG","UT","PMID","DB","AU_UN"
"1","Duval L;Allignet B;Chevreau C;Gravis G;Mazza C;Gross-Goupil M;Laguerre B;Peyrat P;Izarn F;Patrikidou A;Fléchon A","Duval, Lucile;Allignet, Benoît;Chevreau, Christine;Gravis, Gwenaelle;Mazza, Camille;Gross-Goupil, Marine;Laguerre, Brigitte;Peyrat, Patrice;Izarn, Floriane;Patrikidou, Anna;Fléchon, Aude","Metastatic Pure Seminomas With Early Relapse: Prognostic Roles of High Dose Chemotherapy and Surgery of Residual Disease.","Clinical genitourinary cancer","United States","eng","Journal Article","Germ cell tumor;High-dose chemotherapy with hematopoietic stem cell transplantation;Metastatic seminoma;Retroperitoneal lymph node dissection;Salvage therapy","","","Metastatic seminomatous germ cell tumors (mSGCT) are a rare form of cancer. Few studies focused on early relapse (<12 months) after first-line chemotherapy (ChT). We aimed to retrospectively evaluate the impact of salvage retroperitoneal lymph node dissection (RPLND) and high-dose ChT with hematopoietic stem cell transplantation (HDCT-HSCT) in mSGCT patients in a situation of early relapse. Ninety-one mSGCT patients treated between 2005 and 2023 in 7 French expert centers for an early recurrence after an initial favorable response to first-line ChT were retrospectively included. Patient clinical characteristics, progression-free survival after first relapse (PFS) and overall survival (OS) were evaluated. We also assessed the role of HDCT-HSCT as first salvage treatment, and the impact of complementary RPLND after salvage ChT. After a median follow-up of 56 months, 3-year PFS and OS rates were 77.6% (95% CI, 68.3-88.1) and 88.4% (95% CI, 81.0-96.4), respectively. HDCT-HSCT was not associated with longer PFS or OS compared to standard-dose second-line ChT. In contrast, patients who underwent RPLND after salvage ChT demonstrated significantly longer PFS (at 3-years: 97.1% vs. 63%; HR 0.15; 95% CI, 0.03-0.65; P = .012) and a notable trend towards improved OS (at 3-years: 97.0% vs. 81.8%; HR 0.15; 95% CI, 0.02-1.23; P = .078). RPLND after salvage treatment could be associated with improved PFS and OS in mSGCT patients with first-year relapse. However, the retrospective nature of the study limits causal inference, and prognostic factors influencing treatment selection should be further explored. Identifying subpopulations that might benefit from HDCT-HSCT is warranted.","Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon;Department of Radiation Oncology, Centre Léon Bérard, Lyon, France; Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, Inserm, Lyon, France.;Department of Medical Oncology, Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon, France.;Departments of Medical Oncology and Early Drug Development, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.","NA",0,"1938-0682","Clin Genitourin Cancer","Clin Genitourin Cancer",2024,"2025",NA,"10.1016/j.clgc.2025.102310","102310","","","40037955","40037955","PUBMED","Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon;Department of Radiation Oncology, Centre Léon Bérard, Lyon, France; Univ Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, Inserm, Lyon, France.;Department of Medical Oncology, Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France; University Claude Bernard Lyon 1, Lyon, France.;Departments of Medical Oncology and Early Drug Development, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France."
"2","Archimbaud C;Dommergues MA;Lafolie J;Pereira B;Verdan M;Adam MN;Madhi F;L'Honneur AS;Mirand A;Bailly JL;Henquell C;Marque-Juillet S","Archimbaud, Christine;Dommergues, Marie-Aliette;Lafolie, Jeremy;Pereira, Bruno;Verdan, Matthieu;Adam, Marie Noelle;Madhi, Fouad;L'Honneur, Anne-Sophie;Mirand, Audrey;Bailly, Jean-Luc;Henquell, Cécile;Marque-Juillet, Stéphanie","Blood Parechovirus RT-PCR Testing in Neonates and Infants: Comparison of Clinical and Biologic Features With Those of Enterovirus Infections.","The Pediatric infectious disease journal","United States","eng","Journal Article","","","","To assess human parechovirus (HPeV) detection by real-time polymerase chain reaction in blood with or without cerebrospinal fluid samples in neonates and infants and compare the clinical and biological characteristics of HPeV patients with those of patients with or without enterovirus (EV) infection. In all, 92 HPeV-infected patients (40 newborns and 52 infants) presenting with fever without source, sepsis-like disease or suspected meningitis were evaluated in 2 French hospitals from 2007 to 2018. The clinical and biological characteristics of HPeV patients were compared with those of 100 EV-infected patients and of 95 control patients with fever without source or sepsis-like disease. HPeV was detected more frequently in blood [100% (51/51)] than in cerebrospinal fluid specimens [89% (67/75), P = 0.02]. Genotyping identified HPeV3 in 76/85 (89%) positive specimens. HPeV-infected patients were more likely than EV-infected or control patients to have sepsis-like disease and required more frequent vascular filling (39% in newborns and 26% in infants) and empirical antibiotics (91% in newborns and 69% in infants). HPeV patients had lower peripheral white blood cell counts and lower lymphocyte levels (P = 0.002) and longer lengths of hospital stay than EV or control patients (P = 0.03). A white blood cell count <7×109/L can be helpful in differentiating HPeV patients from control patients. Detection of HPeV should be part of the differential diagnosis of EV infections. The use of small automata to perform real-time polymerase chain reaction assays in emergency units should allow faster diagnosis and, if the result is positive, avoid prolonged length of hospital stay and unnecessary administration of antibiotics in patients without virus-bacteria co-infection.","Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Centre Hospitalier de Versailles André Mignot, Service de Pédiatrie, Versailles, France.;Centre Hospitalier Jacques Lacarin, Vichy, Laboratoire de Biologie Médicale, Vichy, France.;Université d'Auvergne, Service de Biostatistiques, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Pôle Pédiatrie, Clermont Ferrand, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Groupe Hospitalo-Universitaire AP-HP. Centre, Hôpital Cochin, Service de Virologie, Paris, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Centre Hospitalier de Versailles André Mignot, Laboratoire de Microbiologie - Hygiène, Versailles, France.","NA",0,"1532-0987","Pediatr Infect Dis J","Pediatr Infect Dis J",2025,"2025",NA,"10.1097/INF.0000000000004772",NA,"EA4843, MinistÃ¨re de lâ€™Education Nationale, de lâ€™Enseignement SupÃ©rieur et de la Recherche","// see below","40020157","40020157","PUBMED","Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Centre Hospitalier de Versailles André Mignot, Service de Pédiatrie, Versailles, France.;Centre Hospitalier Jacques Lacarin, Vichy, Laboratoire de Biologie Médicale, Vichy, France.;Université d'Auvergne, Service de Biostatistiques, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Pôle Pédiatrie, Clermont Ferrand, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Groupe Hospitalo-Universitaire AP-HP. Centre, Hôpital Cochin, Service de Virologie, Paris, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Laboratoire de Microbiologie, Groupe Hospitalier Nord Essonne, Orsay, France.;Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France.;Centre Hospitalier de Versailles André Mignot, Laboratoire de Microbiologie - Hygiène, Versailles, France."
"3","Cabrit N;Cheugoua-Zanetsie M;Tierney J;Thirion P;Nankivell M;Winter K;Yang H;Wijnhoven B;Vernerey D;Smithers BM;Piessen G;Nilsson M;Boonstra J;Ychou M;Law S;Cunningham D;Vathaire F;Stahl M;Urba S;Valmasoni M;Williaume D;Thomas J;Lordick F;Tepper J;Gebski V;Burmeister B;Paoletti X;Sandick JV;Fu J;Pignon JP;Ducreux M;Faron M;Michiels S","Cabrit, Nicolas;Cheugoua-Zanetsie, Maurice;Tierney, Jayne;Thirion, Pierre;Nankivell, Matthew;Winter, Kathryn;Yang, Hong;Wijnhoven, Bas;Vernerey, Dewi;Smithers, B Mark;Piessen, Guillaume;Nilsson, Magnus;Boonstra, Jurjen;Ychou, Marc;Law, Simon;Cunningham, David;Vathaire, Florent de;Stahl, Michael;Urba, Susan;Valmasoni, Michele;Williaume, Danièle;Thomas, Janine;Lordick, Florian;Tepper, Joel;Gebski, Val;Burmeister, Bryan;Paoletti, Xavier;Sandick, Johanna van;Fu, Jianhua;Pignon, Jean-Pierre;Ducreux, Michel;Faron, Matthieu;Michiels, Stefan","Disease-free survival as surrogate for overall survival in esophageal cancer: An individual patient data meta-analysis of neoadjuvant chemotherapy and chemoradiotherapy.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Chemotherapy;Esophageal cancer;Gastroesophageal junction;Individual patient data network meta-analysis;Preoperative;Radiotherapy;Surrogate endpoint","Humans;Esophageal Neoplasms;Neoadjuvant Therapy;Disease-Free Survival;Chemoradiotherapy;Male;Female;Esophagogastric Junction;Middle Aged;Aged;Randomized Controlled Trials as Topic;Esophagectomy;Chemoradiotherapy, Adjuvant;Chemotherapy, Adjuvant","Humans;Esophageal Neoplasms;Neoadjuvant Therapy;Disease-Free Survival;Chemoradiotherapy;Male;Female;Esophagogastric Junction;Middle Aged;Aged;Randomized Controlled Trials as Topic;Esophagectomy;Chemoradiotherapy, Adjuvant;Chemotherapy, Adjuvant","The use of surrogate endpoints may expedite the reporting of study outcomes of clinical trials. The validity of disease-free survival (DFS) as a surrogate for overall survival (OS) in the neoadjuvant treatment of esophageal (E) or gastroesophageal junctional (GEJ) carcinomas remains uncertain. To evaluate DFS as a surrogate end-point for OS in E/GEJ using the meta-analytical approach DESIGN, SETTING, AND PARTICIPANTS: individual patient data from an international meta-analysis on operable locally advanced E/GEJ, which including randomized trials comparing at least two of the neo-adjuvant treatment strategies: upfront surgery (S), chemotherapy followed by surgery (CS), and/or chemoradiotherapy followed by surgery (CRS). Individual (Kendall's tau) and trial-level (R2) correlations between DFS and OS were estimated using a Clayton copula. DFS and OS data were available for a total of 4518 pts: 2222 pts included in CS vs S, 1908 pts in CRS vs S, and 388 in CS vs CRS comparisons. 3440 patients had a DFS event and 3303 patients died. Kendall's tau was 0.73 [95 % CI 0.71 - 0.75] and R2 trial-level correlation was 0.95 [0.84 - 0.99] for CS vs S, Kendall's tau was 0.76 [0.74 - 0.77] and R2 was 0.96 [0.87 - 0.99] for CRS vs S, Kendall's tau was 0.87 [0.78 - 0.92] and R2 was 0.93 [0.43 - 1] for CRS vs CS. In a multistate model, the median time in the recurrence state was shorter in older vs more recent trials: mean time of 10.8 [10.2 - 11.4] vs 16.5 months [15.4-17.6]. DFS is a validated surrogate endpoint for OS in trials evaluating neoadjuvant chemotherapy or chemoradiotherapy in E/GEJ. DFS may be more useful as an endpoint when delays between recurrences and death become larger.","Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;St Luke's Radiation Oncology Network Dublin, Trinity College Dublin, Ireland; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Sun Yat-Sen University Cancer Center, Guangzhou, China; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Erasmus University Medical Center, Rotterdam, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CHRU Jean Minjoz, Besançon, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;University of Queensland, Princess Alexandra Hospital, Australia; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Univ. Lille, CNRS, Inserm, Chu Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille F-59000, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Leiden University Medical Center, Leiden, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Val d'Aurelles, Montpellier, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, UK; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Evang, Kliniken Essen-Mitte, Essen, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of Michigan, Ann Arbor, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Centre Eugène Marquis, Rennes, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Princess Alexandra Hospital, Woolloongabba, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Department of Oncology, University of Leipzig Medical Center, Leipzig, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of North Carolina School of Medicine, Chapel Hill, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; NHMRC, Sydney, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Institut Curie, Paris, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University Paris-Saclay, Medical Oncology Department, Gustave Roussy, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2024,"2025","218","10.1016/j.ejca.2025.115292","115292","","","39938127","39938127","PUBMED","Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;St Luke's Radiation Oncology Network Dublin, Trinity College Dublin, Ireland; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;MRC Clinical trial Unit at UCL, London, United Kingdom; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Sun Yat-Sen University Cancer Center, Guangzhou, China; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Erasmus University Medical Center, Rotterdam, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CHRU Jean Minjoz, Besançon, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;University of Queensland, Princess Alexandra Hospital, Australia; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Univ. Lille, CNRS, Inserm, Chu Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille F-59000, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet and Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Leiden University Medical Center, Leiden, the Netherlands; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Val d'Aurelles, Montpellier, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, UK; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Evang, Kliniken Essen-Mitte, Essen, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of Michigan, Ann Arbor, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Centre Eugène Marquis, Rennes, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Princess Alexandra Hospital, Woolloongabba, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Department of Oncology, University of Leipzig Medical Center, Leipzig, Germany.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University of North Carolina School of Medicine, Chapel Hill, USA.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; NHMRC, Sydney, Australia.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Padova University Hospital, Center for Esophageal Diseases, Department of Surgery, Oncology and Gastroenterology, Padova, Italy.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; Institut Curie, Paris, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA, USA; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France; University Paris-Saclay, Medical Oncology Department, Gustave Roussy, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, Université Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France; Biostatistics and Epidemiology Office, Gustave Roussy, Villejuif, France; CESP U1018, Inserm, Université Paris-Saclay, Villejuif"
"4","Alyamani N;Clementel E;Sargos P;Blanchard P;Supiot S;Ronchin P;Pommier P;Duberge T;Silva M;Hammoud Y;Hasbini A;Khalifa J;Gnep K;Scrase C;Saez J;Vieillevigne L;Christiaens M;Zilli T;Ribault H;Bossi A;Fizazi K;Andratschke N","Alyamani, Najlaa;Clementel, Enrico;Sargos, Paul;Blanchard, Pierre;Supiot, Stephane;Ronchin, Philippe;Pommier, Pascal;Duberge, Thomas;Silva, Marlon;Hammoud, Yasser;Hasbini, Ali;Khalifa, Jonathan;Gnep, Khemara;Scrase, Christopher;Saez, Jordi;Vieillevigne, Laure;Christiaens, Melissa;Zilli, Thomas;Ribault, Hélène;Bossi, Alberto;Fizazi, Karim;Andratschke, Nicolaus","Radiotherapy quality assurance for the PEACE 1 trial: An individual case review analysis.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","PEACE-1;Prostate cancer;Quality assurance;RTQA","","","Radiotherapy quality assurance (RTQA) is essential for ensuring adherence to trial protocols. This paper summarizes the individual case review (ICR) results from the PEACE-1 trial, a phase-III study investigates standard of care (androgen deprivation therapy with or without docetaxel) with or without local radiotherapy; and with or without abiraterone acetate plus prednisone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Participating institutions submitted radiotherapy (RT) plans for central review, assessing protocol compliance in target volume and organs at risk (OARs) delineation, as well as dose specifications. ICRs were conducted either retrospectively (r-ICRs), after starting RT, or prospectively (p-ICRs), before RT initiation. Case reviews were categorized as acceptable per protocol, acceptable variation, or unacceptable variation based on delineation and dose and plan parameters. Out of 585 patients in the RT arms, 527 (90%) had r-ICRs, primarily using intensity-modulated radiotherapy (IMRT). Delineation review approved 417 (87%) r-ICRs and 44 (92%) p-ICRs. The main reasons for unacceptable delineation were erroneous clinical target volume (CTV) delineation. In dose and plan reviews, 399 (96%) r-ICRs cases and 46 (96%) p-ICRs were approved, with unacceptable cases primarily due to PTV dose distribution issues. RTQA is crucial in prostate cancer trials, primarily for proper target volume delineation. It is recommended to omit r-ICRs due to resource demands and lack of impact on RTQA outcomes, using limited p-ICRs with early feedback for site deviations and reserving full p-ICRs for trails with new techniques or dose regimens. gov: NCT01957436.","European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;Department of Radiotherapy Institut Bergonie Bordeaux France.;Department of Radiation Oncology Institut Gustave Roussy University of Paris Saclay Villejuif France.;Department of Radiation Oncology Institut de Cancérologie de l'Ouest - site René Gauducheau Nantes France.;Department of Radiation Oncology Centre Azuréen de Cancérologie Mougins France.;Department of Radiation Oncology Centre Léon Bérard Lyon France; Department of Radiation Oncology Institut Curie Paris France.;Department of Radiation Oncology La Croix-Rouge française Centre Saint Louis Toulon France.;Department of Radiation Oncology Centre François Baclesse Caen France.;Department of Radiation Oncology CHU Jean-Minjoz Besançon France.;Department of Radiation Oncology CFRO-Clinique Pasteur Brest France.;Department of Radiation Oncology Oncopole Claudius Regaud Toulouse France.;Department of Radiation Oncology Centre Eugène Marquis Rennes France; Department of Radiation Oncology Centre Armoricain de Radiothérapie d'Imagerie et d'Oncologie Plérin France.;Department of Oncology North Wales Cancer Centre Betsi Cadwaladr University Health Board and Bangor University Bangor UK.;Department of Radiation Oncology Hospital Clínic de Barcelona Barcelona Spain.;Department of Medical Physics Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse Toulouse France.;Department of Radiation Oncology University Hospitals Leuven Leuven Belgium.;Department of Radiation Oncology Oncology Institute of Southern Switzerland EOC Bellinzona Switzerland; Faculty of Biomedical Sciences Università Della Svizzera Italiana (USI) Lugano Switzerland; Faculty of Medicine University of Geneva Geneva Switzerland.;UNICANCER Paris France.;Department of Radiation Oncology Institut Gustave Roussy Villejuif France.;Department of Cancer Medicine Institut Gustave Roussy University of Paris Saclay Villejuif France.;","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2024,"2025","206","10.1016/j.radonc.2025.110780","110780","","","39924002","39924002","PUBMED","European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;European Organisation for Research and Treatment of Cancer (EORTC) Headquarters Brussels Belgium.;Department of Radiotherapy Institut Bergonie Bordeaux France.;Department of Radiation Oncology Institut Gustave Roussy University of Paris Saclay Villejuif France.;Department of Radiation Oncology Institut de Cancérologie de l'Ouest - site René Gauducheau Nantes France.;Department of Radiation Oncology Centre Azuréen de Cancérologie Mougins France.;Department of Radiation Oncology Centre Léon Bérard Lyon France; Department of Radiation Oncology Institut Curie Paris France.;Department of Radiation Oncology La Croix-Rouge française Centre Saint Louis Toulon France.;Department of Radiation Oncology Centre François Baclesse Caen France.;Department of Radiation Oncology CHU Jean-Minjoz Besançon France.;Department of Radiation Oncology CFRO-Clinique Pasteur Brest France.;Department of Radiation Oncology Oncopole Claudius Regaud Toulouse France.;Department of Radiation Oncology Centre Eugène Marquis Rennes France; Department of Radiation Oncology Centre Armoricain de Radiothérapie d'Imagerie et d'Oncologie Plérin France.;Department of Oncology North Wales Cancer Centre Betsi Cadwaladr University Health Board and Bangor University Bangor UK.;Department of Radiation Oncology Hospital Clínic de Barcelona Barcelona Spain.;Department of Medical Physics Institut Claudius Regaud-Institut Universitaire du Cancer de Toulouse Toulouse France.;Department of Radiation Oncology University Hospitals Leuven Leuven Belgium.;Department of Radiation Oncology Oncology Institute of Southern Switzerland EOC Bellinzona Switzerland; Faculty of Biomedical Sciences Università Della Svizzera Italiana (USI) Lugano Switzerland; Faculty of Medicine University of Geneva Geneva Switzerland.;UNICANCER Paris France.;Department of Radiation Oncology Institut Gustave Roussy Villejuif France.;Department of Cancer Medicine Institut Gustave Roussy University of Paris Saclay Villejuif France.;"
"5","Van der Voort V;Legros R;Albouys J;Lepetit H;Wallenhorst T;Pioche M;Jacques J","Van der Voort, Véronique;Legros, Romain;Albouys, Jérémie;Lepetit, Hugo;Wallenhorst, Timothée;Pioche, Mathieu;Jacques, Jérémie","Multi-strategy endoscopic submucosal dissection of a challenging lesion.","Endoscopy","Germany","eng","Journal Article","","","","NA","Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Rennes, Site de Pontchaillou, Rennes, France.;Department of Gastroenterology and Hepatology, Hôpital Edouard Herriot, Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.","NA",0,"1438-8812","Endoscopy","Endoscopy",2025,"2025","57","10.1055/a-2517-1878","E114-E115","","","39914475","39914475","PUBMED","Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Rennes, Site de Pontchaillou, Rennes, France.;Department of Gastroenterology and Hepatology, Hôpital Edouard Herriot, Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Limoges, Limoges, France."
"6","Balogun OJ;Oladele RO;Ajibola OOE;Davies AA;Fashanu TA;Nwosu AO;Ekeng BE;Gangneux JP","Balogun, O J;Oladele, R O;Ajibola, O O E;Davies, A A;Fashanu, T A;Nwosu, A O;Ekeng, B E;Gangneux, J P","Evaluation of the LDBio ICT IgG/IgM lateral flow assay versus the Bordier Elisa assay for the diagnosis of chronic pulmonary aspergillosis in Nigeria.","Microbiology spectrum","United States","eng","Journal Article","Aspergillus flavus;Aspergillus fumigatus;antibodies;chronic pulmonary aspergillosis;point-of-care diagnosis","Humans;Nigeria;Immunoglobulin G;Enzyme-Linked Immunosorbent Assay;Pulmonary Aspergillosis;Sensitivity and Specificity;Immunoglobulin M;Antibodies, Fungal;Male;Aspergillus;Female;Chronic Disease;Middle Aged;Adult;Point-of-Care Systems","Humans;Nigeria;Immunoglobulin G;Enzyme-Linked Immunosorbent Assay;Pulmonary Aspergillosis;Sensitivity and Specificity;Immunoglobulin M;Antibodies, Fungal;Male;Aspergillus;Female;Chronic Disease;Middle Aged;Adult;Point-of-Care Systems","The detection of anti-  antibodies is key for diagnosing chronic pulmonary aspergillosis (CPA). Available techniques are limited and pose a considerable challenge in resource-limited settings. The objective of this study was to evaluate the performance of the point-of-care test LDBio ICT IgG/IgM lateral flow assay (LDBio) versus that of the Bordier Elisa assay in a field study in Nigeria. Of the 97 serum samples tested in the CPA patient group, 71 tested positive by the LDBio assay with 69.4% sensitivity. In the non-CPA group, 286 of the 289 sera tested negative by the LDBio assay with 98.7% specificity. The Bordier test was positive for 97 of the 97 CPA serum samples tested, showing 100% sensitivity, significantly different from the LDBio test in detecting   antibodies (  < 0.0001). However, there was no significant difference in the specificity between the two tests (  = 0.617). The results were in agreement for 353 of the 386 samples tested (91.5%), with a Cohen's kappa coefficient of 0.75, indicating substantial agreement between the LDBio and Bordier test results. The LDBio lateral flow assay (LFA) test is a simple and rapid point-of-care test that can be used in field studies in which the Elisa test is not available. The lower sensitivity of the LDBio LFA in our field study could have been due to   being the species involved in only 50%-60% of cases in Nigeria, with   being more frequent than in Northern countries.IMPORTANCEAvailable techniques for the detection of   IgG are limited and pose a considerable challenge in resource-limited settings in terms of affordability, skilled personnel, equipment, and a regular power supply. A point-of-care test would address most of these challenges. The LDBio lateral flow assay (LFA) test is a simple and rapid point-of-care test that can be used in field studies in which the Elisa test is not available. When combined with clinical features, the LFA can be used as a screening tool for chronic pulmonary aspergillosis in settings such as ours; however, a lower sensitivity was observed compared to the Elisa.","Department of Biomedical Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.;Department of Systems Engineering, Faculty of Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Department of Systems Engineering, Faculty of Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, University of Calabar Teaching Hospital, Calabar, Nigeria.;Centre National de Référence des Mycoses et Antifongiques LA-AspC Aspergilloses Chroniques, European Excellence Center for Medical Mycology (ECMM EC), Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR_S 1085, Rennes, France.","NA",0,"2165-0497","Microbiol Spectr","Microbiol Spectr",2025,"2025","13","10.1128/spectrum.01533-24","e0153324","","","39912682","39912682","PUBMED","Department of Biomedical Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.;Department of Systems Engineering, Faculty of Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Department of Systems Engineering, Faculty of Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, University of Calabar Teaching Hospital, Calabar, Nigeria.;Centre National de Référence des Mycoses et Antifongiques LA-AspC Aspergilloses Chroniques, European Excellence Center for Medical Mycology (ECMM EC), Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR_S 1085, Rennes, France."
"7","Nicosia L;Bonù ML;Angelicone I;Lunardi G;Niespolo RM;Zannetti M;Agolli L;Chiloiro G;Romano A;Jafari F;Aghili M;Ghalehtaki R;Montesi G;De Felice F;De Renzi F;Magli A;Le Guevelou J;Lupattelli M;Minniti G;Gambacorta MA;Habermehl D;Franco P;Arcangeli S;Buglione di Monale E Bastia M;Alongi F;Osti MF","Nicosia, Luca;Bonù, Marco Lorenzo;Angelicone, Ilaria;Lunardi, Gianluigi;Niespolo, Rita Marina;Zannetti, Micol;Agolli, Linda;Chiloiro, Giuditta;Romano, Angela;Jafari, Fatemeh;Aghili, Mahdi;Ghalehtaki, Reza;Montesi, Giampaolo;De Felice, Francesca;De Renzi, Filippo;Magli, Alessandro;Le Guevelou, Jennifer;Lupattelli, Marco;Minniti, Giuseppe;Gambacorta, Maria Antonietta;Habermehl, Daniel;Franco, Pierfrancesco;Arcangeli, Stefano;Buglione di Monale E Bastia, Michela;Alongi, Filippo;Osti, Mattia Falchetto","RT for the management of locally advanced rectal cancer: Don't throw the baby with the bath water!","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Letter","Boost;Locally advanced;Neoadjuvant radiochemotherapy;Pathological complete response;Radiotherapy;Rectal cancer","","","NA",";Radiation Oncology Department ASST Spedali Civili di Brescia - Brescia University Brescia Italy.;Department of Radiation Oncology, ""Sapienza"" University, Sant'Andrea Hospital, Via di Grottarossa 1035-1039 00189 Rome, Italy.;Clinical Analysis Laboratory and Transfusional Medicine, Clinical Pharmacology, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.;Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;Division of Radiation Oncology, Department of Translational Medicine, University of Eastern Piedmont and University Hospital ""Maggiore della Carità"", Novara, Italy.;Department of Radiation Oncology, Justus-Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Radiotherapy Unit ULSS5, Rovigo, Italy.;Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, ""Sapienza"" University of Rome, Rome, Italy.;Radiotherapy Unit, San Martino Hospital, Belluno, Italy.;Radiotherapy Unit, San Martino Hospital, Belluno, Italy.;Department of Radiation Therapy, Centre Eugène Marquis, Rennes, France.;Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital 06129 Perugia, Italy.;University of Brescia, Brescia, Italy.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Department of Radiation Oncology, Justus-Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany.;Division of Radiation Oncology, Department of Translational Medicine, University of Eastern Piedmont and University Hospital ""Maggiore della Carità"", Novara, Italy.;Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;Radiation Oncology Department ASST Spedali Civili di Brescia - Brescia University Brescia Italy.;Advanced Radiation Oncology Department IRCCS Sacro Cuore Don Calabria Hospital Cancer Care Center Negrar di Valpolicella Italy; University of Brescia, Brescia, Italy.;Department of Radiation Oncology, ""Sapienza"" University, Sant'Andrea Hospital, Via di Grottarossa 1035-1039 00189 Rome, Italy.","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2025,"2025","205","10.1016/j.radonc.2025.110772","110772","","","39904412","39904412","PUBMED",";Radiation Oncology Department ASST Spedali Civili di Brescia - Brescia University Brescia Italy.;Department of Radiation Oncology, ""Sapienza"" University, Sant'Andrea Hospital, Via di Grottarossa 1035-1039 00189 Rome, Italy.;Clinical Analysis Laboratory and Transfusional Medicine, Clinical Pharmacology, IRCCS-Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy.;Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;Division of Radiation Oncology, Department of Translational Medicine, University of Eastern Piedmont and University Hospital ""Maggiore della Carità"", Novara, Italy.;Department of Radiation Oncology, Justus-Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Department of Radiation Oncology, Cancer Institute, Imam-Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.;Radiotherapy Unit ULSS5, Rovigo, Italy.;Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, ""Sapienza"" University of Rome, Rome, Italy.;Radiotherapy Unit, San Martino Hospital, Belluno, Italy.;Radiotherapy Unit, San Martino Hospital, Belluno, Italy.;Department of Radiation Therapy, Centre Eugène Marquis, Rennes, France.;Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia and Perugia General Hospital 06129 Perugia, Italy.;University of Brescia, Brescia, Italy.;UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Department of Radiation Oncology, Justus-Liebig-University Giessen, Giessen-Marburg University Hospital, Giessen, Germany.;Division of Radiation Oncology, Department of Translational Medicine, University of Eastern Piedmont and University Hospital ""Maggiore della Carità"", Novara, Italy.;Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;Radiation Oncology Department ASST Spedali Civili di Brescia - Brescia University Brescia Italy.;Advanced Radiation Oncology Department IRCCS Sacro Cuore Don Calabria Hospital Cancer Care Center Negrar di Valpolicella Italy; University of Brescia, Brescia, Italy.;Department of Radiation Oncology, ""Sapienza"" University, Sant'Andrea Hospital, Via di Grottarossa 1035-1039 00189 Rome, Italy."
"8","Adamus N;Edeline J;Henriques J;Fares N;Lecomte T;Turpin A;Vernerey D;Vincens M;Chanez B;Tougeron D;Tournigand C;Assenat E;Delaye M;Manfredi S;Bouché O;Williet N;Vienot A;Blaise L;Mas L;Neuzillet C;Boilève A;Roth GS","Adamus, Nicolas;Edeline, Julien;Henriques, Julie;Fares, Nadim;Lecomte, Thierry;Turpin, Anthony;Vernerey, Dewi;Vincens, Mathilde;Chanez, Brice;Tougeron, David;Tournigand, Christophe;Assenat, Eric;Delaye, Matthieu;Manfredi, Sylvain;Bouché, Olivier;Williet, Nicolas;Vienot, Angelique;Blaise, Lorraine;Mas, Léo;Neuzillet, Cindy;Boilève, Alice;Roth, Gaël S","First-line chemotherapy with selective internal radiation therapy for intrahepatic cholangiocarcinoma: The French ACABi GERCOR PRONOBIL cohort.","JHEP reports : innovation in hepatology","Netherlands","eng","Journal Article","CISGEM;GEMOX;SIRT;biliary tract cancer;cholangiocarcinoma;radioembolization","","","Selective internal radiation therapy (SIRT) is a promising option for liver-only unresectable intrahepatic cholangiocarcinoma (iCCA). The Real-SIRTCCA study retrospectively assessed the benefit of adding SIRT to chemotherapy in this setting within the French nationwide observational cohort ACABi-GERCOR-PRONOBIL. Inclusion criteria were advanced iCCA with limited or no extrahepatic disease, treated with first-line gemcitabine plus platinum chemotherapy +/- concurrent SIRT. All patients treated with chemotherapy and concurrent SIRT were included. To ensure groups' similarity, a rigorous selection was applied to the chemo-only group, with exclusion of patients with liver involvement >50% and extrahepatic metastases. The primary outcome was progression-free survival (PFS). Secondary outcomes were overall survival (OS), objective response rate (ORR) and tumor resection rate. Propensity score and inverse probability of treatment weighting (IPTW) propensity approaches were used to address confounding factors between groups. Between July 2007 and December 2023, 277 patients met the Real-SIRTCCA inclusion criteria, with 88 in the chemo-SIRT group and 189 in chemo-only group. Chemo-SIRT was associated with longer PFS (median = 10.8   5.5 months, hazard ratio [HR] 0.54, 95% CI 0.41-0.71,  0.0001), a trend for longer OS (median = 22.5   15.1 months, HR 0.76, 95% CI 0.57-1.01), higher ORR (58.3%   28.5%, odds ratio [OR] 3.51, 95% CI 2.03-6.09,  0.0001), and resection rate (18.7%  . 8.8%,   = 0.0279) compared to chemo-alone. After IPTW, the superiority of chemo-SIRT was confirmed with better PFS (HR 0.55, 95% CI 0.45-0.66,  0,0001), OS (HR 0.70, 95% CI 0.58-0.85,   = 0.0004), ORR (OR 3.17, 95% CI 2.18-4.49,  0.0001) and resection rate (OR 2.94, 95% CI 1.71-5.03,  0.0001). Adding SIRT to first-line chemotherapy significantly improved survival outcomes, ORR, and secondary tumor resection rates in locally advanced iCCA. Prospective randomized data are needed to confirm these results. Herein, we report the results of the Real-SIRTCCA study, comparing the efficacy of the gemcitabine-platinum systemic first-line chemotherapy with or without selective internal radiation therapy (SIRT) in 277 patients with locally advanced intrahepatic cholangiocarcinoma within the cohort ACABi-PRONOBIL. An improvement of progression-free survival, overall survival, tumor response and secondary surgical resection rate was observed in favor of chemo-SIRT, before adjustment and after inverse probability of treatment weighting propensity score analyses. Even though prospective randomized data would be needed to confirm these findings, we believe that this study constitutes new evidence of the potential benefit of combining SIRT with chemotherapy. The safety and efficacy of this strategy whether as a bridge to intent-to-cure strategies or in a palliative setting, should encourage its adoption in a larger panel of clinical centers, or at very least, prompt clinicians to refer their patients to centers where SIRT is performed. NCT04935853.","Univ. Grenoble Alpes, Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble; Association pour l'étude des Cancers et Affections des voies Biliaires (ACABi); GERCOR, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France and INSERM, Univ Rennes, COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Rennes, France.;Department of Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon; University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.;Department of Digestive Oncology, CHU of Toulouse, Rangueil Hospital, Toulouse, France.;Department of Hepato-Gastroenterology and Digestive Oncology, CHU Tours and UMR INSERM U 1069, Trousseau Hospital, Tours University, Tours, France.;Department of Medical Oncology, CHU Lille, CNRS UMR9020, INSERM UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille University; GERCOR, Paris, France.;Department of Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon; University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.;Department of Medical Oncology and Hepato-Gastroenterology, Hospices Civils de Lyon, Lyon, France.;Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France.;Department of Hepato-Gastroenterology, Poitiers University Hospital, Poitiers, France.;Department of Medical Oncology, Henri Mondor Hospital, AP-HP, Paris-East Créteil University and INSERM, IMRB, Creteil, France.;Department of Medical Oncology, CHU St Eloi, Montpellier University 2, CNRS, UMR 5535, Institute of Molecular Genetic, Montpellier 1 University, Montpellier, France.;GI Oncology, Department of Medical Oncology, Institute Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud; Molecular Oncology, UMR144, Institute Curie, Paris, France.;Bourgogne University, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, Dijon, France.;Department of Gastroenterology and Digestive Oncology, CHU Reims, Université Reims Champagne Ardennes (URCA), Reims, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), Saint-Etienne, France.;Department of Medical Oncology, University Hospital of Besançon, Besançon, France.;Liver unit, Avicenne Hospital, Universitaires Paris-Seine-Saint-Denis Hospital, Assistance-Publique Hôpitaux de Paris, Bobigny; Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d'Universités et Etablissements Sorbonne Paris Cité; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, team « Functional Genomics of Solid Tumors », Paris, France.;Department of Oncology, Pitié-Salpêtrière Hospital, AP-HP; University of La Sorbonne, Paris, France.;GI Oncology, Department of Medical Oncology, Institute Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud; Molecular Oncology, UMR144, Institute Curie, Paris, France.;Department of Medicine, Gustave Roussy Hospital, INSERM U1279, Villejuif; University of Paris Saclay, Orsay, France.;Univ. Grenoble Alpes/Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.","NA",0,"2589-5559","JHEP Rep","JHEP Rep",2024,"2025","7","10.1016/j.jhepr.2024.101279","101279","","","39897613","39897613","PUBMED","Univ. Grenoble Alpes, Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes, Grenoble; Association pour l'étude des Cancers et Affections des voies Biliaires (ACABi); GERCOR, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France and INSERM, Univ Rennes, COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Rennes, France.;Department of Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon; University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.;Department of Digestive Oncology, CHU of Toulouse, Rangueil Hospital, Toulouse, France.;Department of Hepato-Gastroenterology and Digestive Oncology, CHU Tours and UMR INSERM U 1069, Trousseau Hospital, Tours University, Tours, France.;Department of Medical Oncology, CHU Lille, CNRS UMR9020, INSERM UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille University; GERCOR, Paris, France.;Department of Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon; University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.;Department of Medical Oncology and Hepato-Gastroenterology, Hospices Civils de Lyon, Lyon, France.;Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France.;Department of Hepato-Gastroenterology, Poitiers University Hospital, Poitiers, France.;Department of Medical Oncology, Henri Mondor Hospital, AP-HP, Paris-East Créteil University and INSERM, IMRB, Creteil, France.;Department of Medical Oncology, CHU St Eloi, Montpellier University 2, CNRS, UMR 5535, Institute of Molecular Genetic, Montpellier 1 University, Montpellier, France.;GI Oncology, Department of Medical Oncology, Institute Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud; Molecular Oncology, UMR144, Institute Curie, Paris, France.;Bourgogne University, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, Dijon, France.;Department of Gastroenterology and Digestive Oncology, CHU Reims, Université Reims Champagne Ardennes (URCA), Reims, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, University Institute of Cancerology and Hematology of Saint-Etienne (ICHUSE), Saint-Etienne, France.;Department of Medical Oncology, University Hospital of Besançon, Besançon, France.;Liver unit, Avicenne Hospital, Universitaires Paris-Seine-Saint-Denis Hospital, Assistance-Publique Hôpitaux de Paris, Bobigny; Unité de Formation et de Recherche Santé Médecine et Biologie Humaine, Université Paris 13, Communauté d'Universités et Etablissements Sorbonne Paris Cité; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, Université de Paris, team « Functional Genomics of Solid Tumors », Paris, France.;Department of Oncology, Pitié-Salpêtrière Hospital, AP-HP; University of La Sorbonne, Paris, France.;GI Oncology, Department of Medical Oncology, Institute Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud; Molecular Oncology, UMR144, Institute Curie, Paris, France.;Department of Medicine, Gustave Roussy Hospital, INSERM U1279, Villejuif; University of Paris Saclay, Orsay, France.;Univ. Grenoble Alpes/Department of Hepato-Gastroenterology and Digestive Oncology, CHU Grenoble Alpes/Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France."
"9","Faurie B;Peyronnet B","Faurie, Brice;Peyronnet, Benoit","Reply to Editorial Comment on ""Outpatient Periurethral Injections of Polyacrylamide Hydrogel (Bulkamid) Under Local Anesthesia in the Office: A Prospective Single-center Series"".","Urology","United States","eng","Journal Article","","","","NA","Centre Hospitalier Universitaire de Rennes, Rennes;Department of Urology, University of Rennes, Rennes, France.","NA",0,"1527-9995","Urology","Urology",2025,"2025",NA,"10.1016/j.urology.2025.01.041",NA,"","","39892567","39892567","PUBMED","Centre Hospitalier Universitaire de Rennes, Rennes;Department of Urology, University of Rennes, Rennes, France."
"10","Guévelou JL;Sargos P;Ost P;Alongi F;Arcangeli S;Berlin A;Blanchard P;Bruynzeel A;Chapet O;Dal Pra A;Dess RT;Guckenberger M;Loblaw A;Kishan AU;Jereczek-Fossa B;Pasquier D;Shelan M;Siva S;Tree AC;Zamboglou C;Supiot S;Murthy V;Zilli T","Guévelou, Jennifer Le;Sargos, Paul;Ost, Piet;Alongi, Filippo;Arcangeli, Stefano;Berlin, Alejandro;Blanchard, Pierre;Bruynzeel, Anna;Chapet, Olivier;Dal Pra, Alan;Dess, Robert T;Guckenberger, Matthias;Loblaw, Andrew;Kishan, Amar U;Jereczek-Fossa, Barbara;Pasquier, David;Shelan, Mohamed;Siva, Shankar;Tree, Alison C;Zamboglou, Costantinos;Supiot, Stephane;Murthy, Vedang;Zilli, Thomas","Urethra-sparing prostate cancer radiotherapy: Current practices and future insights from an international survey.","Clinical and translational radiation oncology","Ireland","eng","Journal Article","Prostate cancer;Radiotherapy;SBRT;Toxicity;Urethra","","","In prostate cancer patients, high radiation doses to the urethra have been associated with an increased risk of severe genitourinary toxicity following dose-escalated radiotherapy. Urethra-sparing techniques have emerged as a promising approach to reduce urinary toxicity. This international survey aims to evaluate current global practices in urethra-sparing and explore future directions for the implementation of this technique in external beam radiotherapy (EBRT) for prostate cancer. In April 2024, a survey consisting of 20 questions was distributed to 26 international radiation oncology experts in prostate cancer EBRT, with 23 experts participating. The survey focused on clinical scenarios which might take benefit from urethra-sparing, the definition of the urethra and urinary organs-at-risk, and urethral dose constraints. Magnetic resonance imaging with T2-weighted sequences is the preferred method for urethra contouring (83 % consensus). Based on the experts opinion, urethra-sparing should be considered for prostate cancer EBRT, regardless of pelvic irradiation, except in cases where the tumor is located within 2 mm of the urethra and/or transitional zone, or in T4 disease. Most experts would not apply specific dose constraints to the urethra for either conventional or moderate hypofractionation regimens. When delivering stereotactic body radiotherapy (SBRT), urethra-sparing with dose hotspot limitation (urethra steering) is recommended by 70 % of the experts, in particular when combined with focal boosting (91 %). Urethra dose-reduction is also the favored approach for salvage prostate reirradiation with SBRT (70 % agreement). Large variations exists regarding urethral dose constraints. Urethra-sparing is a promising technique for the mitigation of urinary toxicity in prostate cancer patients undergoing EBRT, particularly recommended for ultra-hypofractionation and reirradiation with SBRT. The lack of consensus on specific urethral dose constraints and optimal sparing techniques underscores the need for further research to standardize practices in this field.","Department of Clinical Research, Centre Eugène Marquis, Rennes, France.;Laboratoire du traitement du signal et de l'image, Université De Rennes, Rennes, France.;Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.;Department of Radiotherapy, Charlebourg Center, La Garenne-Colombes, France.;Department of Human Structure and Repair, Ghent University, Ghent, Belgium.;Iridium Network, Radiation Oncology, Wilrijk, Belgium.;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;University of Brescia, Brescia, Italy.;Radiation Oncology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of Radiation Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, Ontario, Canada.;Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands.;Department of Radiation Oncology, Hôpital Lyon Sud, Lyon, France.;Université Claude-Bernard Lyon 1, Villeurbanne, France.;Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health Systems, Miami, FL, USA.;Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.;Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.;Institute of Healthcare Policy and Management, Department of Radiation Oncology, Ontario Institute of Cancer Research, University of Toronto, Toronto, Ontario, Canada.;Department of Radiation Oncology, University of California, Los Angeles, CA, USA.;Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.;Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;CRIStAL UMR CNRS 9189, Lille University, Lille, France.;Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.;Division of Radiation Oncology and Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.;Department of Radiation Oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK.;The Institute of Cancer Research, London, UK.;German Oncology Center, European University of Cyprus, 1 Nikis Avenue, 4108, Agios Athanasios, Cyprus.;Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.;Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.;Radiation Oncology Department, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France.;CNRS US2B, University of Nantes, Nantes, France.;Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.","NA",0,"2405-6308","Clin Transl Radiat Oncol","Clin Transl Radiat Oncol",2024,"2025","51","10.1016/j.ctro.2024.100907","100907","","","39845565","39845565","PUBMED","Department of Clinical Research, Centre Eugène Marquis, Rennes, France.;Laboratoire du traitement du signal et de l'image, Université De Rennes, Rennes, France.;Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.;Department of Radiotherapy, Charlebourg Center, La Garenne-Colombes, France.;Department of Human Structure and Repair, Ghent University, Ghent, Belgium.;Iridium Network, Radiation Oncology, Wilrijk, Belgium.;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;University of Brescia, Brescia, Italy.;Radiation Oncology Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of Radiation Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, Ontario, Canada.;Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Amsterdam UMC Location Vrije Universiteit Amsterdam, Department of Radiation Oncology, Cancer Center Amsterdam, De Boelelaan 1117, Amsterdam, Netherlands.;Department of Radiation Oncology, Hôpital Lyon Sud, Lyon, France.;Université Claude-Bernard Lyon 1, Villeurbanne, France.;Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health Systems, Miami, FL, USA.;Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.;Department of Radiation Oncology, University Hospital Zürich, University of Zürich, Zürich, Switzerland.;Institute of Healthcare Policy and Management, Department of Radiation Oncology, Ontario Institute of Cancer Research, University of Toronto, Toronto, Ontario, Canada.;Department of Radiation Oncology, University of California, Los Angeles, CA, USA.;Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.;Department of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;CRIStAL UMR CNRS 9189, Lille University, Lille, France.;Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.;Division of Radiation Oncology and Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.;Department of Radiation Oncology, The Royal Marsden NHS Foundation Trust, Sutton, UK.;The Institute of Cancer Research, London, UK.;German Oncology Center, European University of Cyprus, 1 Nikis Avenue, 4108, Agios Athanasios, Cyprus.;Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.;Department of Radiation Oncology, University Hospital Freiburg, Robert-Koch-Straße 3, 79106, Freiburg, Germany.;Radiation Oncology Department, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France.;CNRS US2B, University of Nantes, Nantes, France.;Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.;Faculty of Medicine, University of Geneva, Geneva, Switzerland."
"11","Houben NAM;Fustolo-Gunnink S;Fijnvandraat K;Caram-Deelder C;Aguar Carrascosa M;Beuchée A;Brække K;Cardona FS;Debeer A;Domingues S;Ghirardello S;Grizelj R;Hadžimuratović E;Heiring C;Lozar Krivec J;Maly J;Matasova K;Moore CM;Muehlbacher T;Szabo M;Szczapa T;Zaharie G;de Jager J;Reibel-Georgi NJ;New HV;Stanworth SJ;Deschmann E;Roehr CC;Dame C;le Cessie S;van der Bom JG;Lopriore E","Houben, Nina A M;Fustolo-Gunnink, Suzanne;Fijnvandraat, Karin;Caram-Deelder, Camila;Aguar Carrascosa, Marta;Beuchée, Alain;Brække, Kristin;Cardona, Francesco Stefano;Debeer, Anne;Domingues, Sara;Ghirardello, Stefano;Grizelj, Ruža;Hadžimuratović, Emina;Heiring, Christian;Lozar Krivec, Jana;Maly, Jan;Matasova, Katarina;Moore, Carmel Maria;Muehlbacher, Tobias;Szabo, Miklos;Szczapa, Tomasz;Zaharie, Gabriela;de Jager, Justine;Reibel-Georgi, Nora Johanna;New, Helen V;Stanworth, Simon J;Deschmann, Emöke;Roehr, Charles C;Dame, Christof;le Cessie, Saskia;van der Bom, Johanna G;Lopriore, Enrico","Plasma transfusions in neonatal intensive care units: a prospective observational study.","Archives of disease in childhood. Fetal and neonatal edition","England","eng","Journal Article","Epidemiology;Intensive Care Units, Neonatal;Neonatology","","","Despite lack of evidence supporting efficacy, prophylactic fresh frozen plasma and Octaplas transfusions may be administered to very preterm infants to reduce bleeding risk. International variation in plasma transfusion practices in neonatal intensive care units (NICUs) is poorly understood, therefore, we aimed to describe neonatal plasma transfusion practice in Europe. Prospective observational study. 64 NICUs in 22 European countries, with a 6-week study period per centre between September 2022 and August 2023. Preterm infants born below 32 weeks of gestational age. Admission to the NICU. Plasma transfusion prevalence, cumulative incidence, indications, transfusion volumes and infusion rates and adverse effects. A total of 92 of 1143 infants included (8.0%) received plasma during the study period, collectively receiving 177 transfusions. Overall prevalence was 0.3 plasma transfusion days per 100 admission days, and rates varied substantially across Europe. By day 28 of life, 13.5% (95% CI 10.0% to 16.9%) of infants received at least one plasma transfusion, accounted for competing risks of death or discharge. Transfusions were given for a broad range of indications, including active bleeding (29.4%), abnormal coagulation screen results (23.7%) and volume replacement/hypotension (21.5%). Transfusion volumes and infusion rates varied significantly; the most common volume was 15 mL/kg (range: 5-30 mL/kg) and the most common duration was 2 hours (range: 30 min to 6 hours). We found wide variation in plasma transfusion practices in Europe, highlighting the need for evidence to inform neonatologists in daily practice and guidelines, in particular for non-bleeding indications. ISRCTN17267090.","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands.;Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University of Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Unidade Local de Saúde de Santo António, Centro Materno-Infantil do Norte, Porto, Portugal.;Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Neonatal Department, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.;Jessenius Faculty of Medicine, Department of Neonatology, University Hospital Martin, Martin, Slovakia.;Department of Neonatology, University College Dublin, Dublin, Ireland.;Neonatology, National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University of Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;Department of Neonatology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Department of Neonatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS Blood and Transplant, London, UK.;NHS Blood and Transplant, London, UK.;University of Oxford, Oxford, UK.;Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, UK.;Faculty of Health Sciences, University of Bristol, Bristol, UK.;Department of Neonatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden","NA",0,"1468-2052","Arch Dis Child Fetal Neonatal Ed","Arch Dis Child Fetal Neonatal Ed",2024,"2025",NA,"10.1136/archdischild-2024-327926",NA,"","","39832820","39832820","PUBMED","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands.;Department of Molecular and Cellular Hemostasis, Sanquin Research, Amsterdam, The Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University of Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Unidade Local de Saúde de Santo António, Centro Materno-Infantil do Norte, Porto, Portugal.;Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Neonatal Department, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.;Jessenius Faculty of Medicine, Department of Neonatology, University Hospital Martin, Martin, Slovakia.;Department of Neonatology, University College Dublin, Dublin, Ireland.;Neonatology, National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University of Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;Department of Neonatology, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, The Netherlands.;Department of Neonatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS Blood and Transplant, London, UK.;NHS Blood and Transplant, London, UK.;University of Oxford, Oxford, UK.;Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, UK.;Faculty of Health Sciences, University of Bristol, Bristol, UK.;Department of Neonatology, Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden"
"12","Le Guévelou J;Murthy V;Zilli T;Nicosia L;Bossi A;Bokhorst LP;Barret E;Ouzaid I;Nguyen PL;Ferrario F;Chargari C;Arcangeli S;Magne N;Sargos P","Le Guévelou, Jennifer;Murthy, Vedang;Zilli, Thomas;Nicosia, Luca;Bossi, Alberto;Bokhorst, Leonard P;Barret, Eric;Ouzaid, Idir;Nguyen, Paul L;Ferrario, Federica;Chargari, Cyrus;Arcangeli, Stefano;Magne, Nicolas;Sargos, Paul","« Augmented radiotherapy » in the management of high-risk prostate cancer (PCa): A systematic review.","Critical reviews in oncology/hematology","Netherlands","eng","Journal Article","Androgen receptor pathway inhibitor;Dose-escalation;High-risk;Prostate cancer;Radiotherapy;Whole pelvic radiotherapy","Humans;Male;Prostatic Neoplasms;Androgen Antagonists;Disease Management","Humans;Male;Prostatic Neoplasms;Androgen Antagonists;Disease Management","In patients with high-risk (HR) prostate cancer (PCa) treated with radiotherapy and androgen deprivation therapy (ADT), intensification with androgen receptor pathway inhibitor (ARPI) improves overall survival (OS), at the cost of significant side-effects. We hypothesized that ""augmented RT"" schedules (defined as either dose-escalation on the prostate gland over 78 Gy and/or addition of whole pelvic radiotherapy (WPRT)), combined with long-term ADT can reach excellent prostate cancer specific survival (PCSS) in this population with little detrimental impact on quality of life. We searched Pubmed database until February 8, 2024. Studies reporting both oncological and toxicity outcomes after ""augmented RT"" were deemed eligible. Studies without ADT or with ARPI intensification were deemed ineligible. Dose-escalation within the prostate gland at doses over 78 Gy halved the risk of biochemical recurrence at 5 years, with however no impact on PCSS. The addition of WPRT provides a 5-year disease-free survival (DFS) reaching 89.5 % at 5 years, with no significant increase in late grade≥ 2 genito-urinary (GU) or gastrointestinal (GI) toxicity. Combined approaches result in 9-year PCSS ranging between 96.1 % and 100 %. Most approaches demonstrated excellent safety profiles. ""Augmented RT"" reached excellent oncological outcomes, with minimal additional toxicity. The development of biomarkers might lead to further treatment personalization, in the rapidly evolving landscape of systemic therapies.","Department of Radiation Oncology, Centre Eugène Marquis, Rennes;Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, La Garenne-Colombes 92250, France.;Department of Urology, Erasmus MC, Rotterdam, the Netherlands.;Department of Urology, Institut Mutualiste Montsouris, Paris, France.;Department of Urology, Bichat Claude Bernard Hospital, Paris Cité University, Paris, France.;Department of Radiation Oncology, Dana Farber Harvard Cancer Center, Boston, MA, USA.;Department of Radiation Oncology, School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of radiation oncology, Hopital Pitié Salpétrière, Paris, France.;Department of Radiation Oncology, School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of radiation oncology, Institut Bergonié, Bordeaux, France.;Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, La Garenne-Colombes 92250, France; Department of radiation oncology, Institut Bergonié, Bordeaux, France.","NA",0,"1879-0461","Crit Rev Oncol Hematol","Crit Rev Oncol Hematol",2024,"2025","207","10.1016/j.critrevonc.2025.104623","104623","","","39827978","39827978","PUBMED","Department of Radiation Oncology, Centre Eugène Marquis, Rennes;Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Homi Bhabha National Institute (HBNI), Mumbai, India.;Department of Radiation Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, La Garenne-Colombes 92250, France.;Department of Urology, Erasmus MC, Rotterdam, the Netherlands.;Department of Urology, Institut Mutualiste Montsouris, Paris, France.;Department of Urology, Bichat Claude Bernard Hospital, Paris Cité University, Paris, France.;Department of Radiation Oncology, Dana Farber Harvard Cancer Center, Boston, MA, USA.;Department of Radiation Oncology, School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of radiation oncology, Hopital Pitié Salpétrière, Paris, France.;Department of Radiation Oncology, School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy.;Department of radiation oncology, Institut Bergonié, Bordeaux, France.;Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, La Garenne-Colombes 92250, France; Department of radiation oncology, Institut Bergonié, Bordeaux, France."
"13","Jeanne M;Ronce N;Remizé S;Arpin S;Baujat G;Breton S;Petit F;Vanlerberghe C;Coeslier-Dieux A;Manouvrier-Hanu S;Vincent-Delorme C;Khau Van Kien P;Van-Gils J;Quélin C;Pasquier L;Odent S;Demurger F;Laffargue F;Francannet C;Martin-Coignard D;Afenjar A;Whalen S;Verloes A;Capri Y;Delahaye A;Plaisancié J;Labrune P;Destree A;Maystadt I;Ciorna Monferrato V;Isidor B;Vincent M;Jean Marçais N;Nambot S;Schaefer E;El Chehadeh S;Lespinasse J;Collignon P;Busa T;Philip N;Willems M;Planes M;Vanakker OM;Lambert L;Leheup B;Mathieu-Dramard M;Morin G;Dieterich K;Ginglinger E;Bayat A;Balasubramanian M;Dauriat B;Haye D;Amiel J;Rio M;Cormier-Daire V;Toutain A","Jeanne, Médéric;Ronce, Nathalie;Remizé, Solène;Arpin, Stéphanie;Baujat, Geneviève;Breton, Sylvain;Petit, Florence;Vanlerberghe, Clémence;Coeslier-Dieux, Anne;Manouvrier-Hanu, Sylvie;Vincent-Delorme, Catherine;Khau Van Kien, Philippe;Van-Gils, Julien;Quélin, Chloé;Pasquier, Laurent;Odent, Sylvie;Demurger, Florence;Laffargue, Fanny;Francannet, Christine;Martin-Coignard, Dominique;Afenjar, Alexandra;Whalen, Sandra;Verloes, Alain;Capri, Yline;Delahaye, Andrée;Plaisancié, Julie;Labrune, Philippe;Destree, Anne;Maystadt, Isabelle;Ciorna Monferrato, Viorca;Isidor, Bertrand;Vincent, Marie;Jean Marçais, Nolwen;Nambot, Sophie;Schaefer, Elise;El Chehadeh, Salima;Lespinasse, James;Collignon, Patrick;Busa, Tiffany;Philip, Nicole;Willems, Marjolaine;Planes, Marc;Vanakker, Olivier M;Lambert, Laetitia;Leheup, Bruno;Mathieu-Dramard, Michèle;Morin, Gilles;Dieterich, Klaus;Ginglinger, Emmanuelle;Bayat, Allan;Balasubramanian, Meena;Dauriat, Benjamin;Haye, Damien;Amiel, Jeanne;Rio, Marlène;Cormier-Daire, Valérie;Toutain, Annick",NA,"Journal of medical genetics","England","eng","Journal Article","Congenital, Hereditary, and Neonatal Diseases and Abnormalities","","","Aarskog-Scott syndrome (AAS) is a rare condition with multiple congenital anomalies, caused by hemizygote variants in the   gene. Its description was based mostly on old case reports, in whom a molecular diagnosis was not always available, or on small series. The aim of this study was to better delineate the phenotype and the natural history of AAS and to provide clues for the diagnosis and the management of the patients. Phenotypic characterisation of the largest reported AAS cohort, comprising 111 male patients with proven causative variants in  , through comprehensive analyses of clinical data including congenital anomalies, growth and neurodevelopment. Review of photographs and radiographs by experts in dysmorphology and skeletal disorders. This study refines the phenotypic spectrum of AAS, with the description of new morphological and radiological features, and refines the prevalence of the features. Short stature is less frequent than previously reported and has a prenatal onset in more than half of the patients. The growth has a specific course with a catch-up during the first decade often leading to low-normal stature in adulthood. Whereas intellectual disability is rare, patients with AAS have a high prevalence of specific learning difficulties and attention hyperactivity disorder. In light of this better knowledge of AAS, we provide management recommendations. A better knowledge of the natural history and phenotypic spectrum of AAS will be helpful for the clinical diagnosis and for the interpretation of   variants using a retrophenotyping strategy, which is becoming the most common way of diagnosis nowadays. Recommendations for care will improve the management of the patients.","Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de radiologie pédaitrique, Necker-Enfants Malades Hospitals, Paris, Île-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Unité fonctionnelle de Génétique Médicale et cytogénétique, Centre Hospitalier Universitaire de Nimes, Nimes, Languedoc-Roussillon, France.;Département de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique, Centre Hospitalier de Vannes, Vannes, France.;Service de Génétique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Génétique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Medical Genetics, Le Mans Hospital, Le Mans 72037, France.;UF de Génétique Clinique, APHP, Hôpital Armand Trousseau, Paris, France.;UF de Génétique Clinique, APHP, Hôpital Armand Trousseau, Paris, France.;Département de Génétique, UF de Génétique Clinique, APHP Hôpital Robert Debré, Paris, France.;Département de Génétique, UF de Génétique Clinique, APHP Hôpital Robert Debré, Paris, France.;Service d'Histologie-Embryologie-Cytogénétique, APHP, Hôpital Jean verdier, Bondy, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, Occitanie, France.;Service de Pédiatrie, APHP, Hôpital Antoine Béclère, Paris, France.;Département de Génétique Clinque, Institut de Pathologie et de Génétique asbl, Gosselies, Belgium.;Département de Génétique Clinque, Institut de Pathologie et de Génétique asbl, Gosselies, Belgium.;Service de Génétique, Centre Hospitalier Régional de Metz-Thionville, Metz, Lorraine, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique, FHU Translad, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, France.;Service de Génétique, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Service de Génétique, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Service de Génétique, Centre Hospitalier Metropole Savoie, Chambery, Auvergne-Rhône-Alpes, France.;Service de Génétique Médicale, Centre Hospitalier Intercommunal de Toulon, Toulon, France.;Département de Génétique Médicale, Assistance Publique Hopitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Département de Génétique Médicale, Assistance Publique Hopitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Departement de Génétique Medicale, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France.;Service de Pédiatrie et de Génétique Médicale, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.;Service de Génétique, Centre Hospitalier Universitaire d'Amiens, Amiens, Hauts-de-France, France.;Service de Génétique, Centre Hospitalier Universitaire d'Amiens, Amiens, Hauts-de-France, France.;Département de Génétique et Procréation, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Service de Génétique, GHR Mulhouse Sud Alsace, Mulhouse, Grand Est, France.;Department of Regional Health Research, University of Southern Denmark, Odense, Syddanmark, Denmark.;Department of epilepsy genetics and personalized medicine, Danish Epilepsy Centre, Dianalund, Denmark.;Sheffield clinical genetics service, Sheffield children NHS foundation trust, Sheffield, UK.;Service de Cytogénétique et Génétique Médicale, Centre Hospitalier Universitaire de Limoges, Limoges, Nouvelle-Aquitaine, France.;Service de génétique médicale, Hospices civils de Lyon, Lyon, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.","NA",0,"1468-6244","J Med Genet","J Med Genet",2022,"2025",NA,"10.1136/jmg-2022-108868",NA,"","","39798962","39798962","PUBMED","Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;UMR1253, iBrain, Inserm, Université de Tours, Tours, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de radiologie pédaitrique, Necker-Enfants Malades Hospitals, Paris, Île-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Clinique de Génétique Guy Fontaine, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France.;Unité fonctionnelle de Génétique Médicale et cytogénétique, Centre Hospitalier Universitaire de Nimes, Nimes, Languedoc-Roussillon, France.;Département de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique, Centre Hospitalier de Vannes, Vannes, France.;Service de Génétique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Génétique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Medical Genetics, Le Mans Hospital, Le Mans 72037, France.;UF de Génétique Clinique, APHP, Hôpital Armand Trousseau, Paris, France.;UF de Génétique Clinique, APHP, Hôpital Armand Trousseau, Paris, France.;Département de Génétique, UF de Génétique Clinique, APHP Hôpital Robert Debré, Paris, France.;Département de Génétique, UF de Génétique Clinique, APHP Hôpital Robert Debré, Paris, France.;Service d'Histologie-Embryologie-Cytogénétique, APHP, Hôpital Jean verdier, Bondy, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Toulouse, Toulouse, Occitanie, France.;Service de Pédiatrie, APHP, Hôpital Antoine Béclère, Paris, France.;Département de Génétique Clinque, Institut de Pathologie et de Génétique asbl, Gosselies, Belgium.;Département de Génétique Clinque, Institut de Pathologie et de Génétique asbl, Gosselies, Belgium.;Service de Génétique, Centre Hospitalier Régional de Metz-Thionville, Metz, Lorraine, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Service de Génétique Clinique, CLAD Ouest, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Génétique, FHU Translad, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne-Franche-Comté, France.;Service de Génétique, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Service de Génétique, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Service de Génétique, Centre Hospitalier Metropole Savoie, Chambery, Auvergne-Rhône-Alpes, France.;Service de Génétique Médicale, Centre Hospitalier Intercommunal de Toulon, Toulon, France.;Département de Génétique Médicale, Assistance Publique Hopitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Département de Génétique Médicale, Assistance Publique Hopitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Departement de Génétique Medicale, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France.;Service de Pédiatrie et de Génétique Médicale, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Nancy, Nancy, Lorraine, France.;Service de Génétique, Centre Hospitalier Universitaire d'Amiens, Amiens, Hauts-de-France, France.;Service de Génétique, Centre Hospitalier Universitaire d'Amiens, Amiens, Hauts-de-France, France.;Département de Génétique et Procréation, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Service de Génétique, GHR Mulhouse Sud Alsace, Mulhouse, Grand Est, France.;Department of Regional Health Research, University of Southern Denmark, Odense, Syddanmark, Denmark.;Department of epilepsy genetics and personalized medicine, Danish Epilepsy Centre, Dianalund, Denmark.;Sheffield clinical genetics service, Sheffield children NHS foundation trust, Sheffield, UK.;Service de Cytogénétique et Génétique Médicale, Centre Hospitalier Universitaire de Limoges, Limoges, Nouvelle-Aquitaine, France.;Service de génétique médicale, Hospices civils de Lyon, Lyon, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de médecine génomique des maladies rares, Institut Imagine, Hopital universitaire Necker-Enfants malades, Paris, Île-de-France, France.;UMR 1163 Inserm, Université Paris Cité, Paris, Île-de-France, France.;Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours;UMR1253, iBrain, Inserm, Université de Tours, Tours, France."
"14","Cinotti R;Derouin Y;Chenet A;Oujamaa L;Glize B;Launey Y;Dahyot-Fizelier C;Cartron E;Renvoise M;Sautenet B;Sebille V","Cinotti, Raphael;Derouin, Yvan;Chenet, Amandine;Oujamaa, Lydia;Glize, Bertrand;Launey, Yoann;Dahyot-Fizelier, Claire;Cartron, Emmanuelle;Renvoise, Melodie;Sautenet, Benedicte;Sebille, Veronique","Standardized Outcomes for Randomized Controlled Trials Targeting Early Interventions in Patients With Moderate-to-Severe Traumatic Brain Injury: Protocol for the Development of a Core Outcome Set.","JMIR research protocols","Canada","eng","Journal Article","core outcome set;head trauma;outcomes research;patient outcome;patient-centered;patient-centered outcomes;traumatic brain injury","Humans;Brain Injuries, Traumatic;Randomized Controlled Trials as Topic;Outcome Assessment, Health Care;Research Design;Glasgow Outcome Scale","Humans;Brain Injuries, Traumatic;Randomized Controlled Trials as Topic;Outcome Assessment, Health Care;Research Design;Glasgow Outcome Scale",": With more than 60 million new cases around the world each year, traumatic brain injury (TBI) causes substantial mortality and morbidity. Managing TBI is a major human, social, and economic concern. In the last 20 years, there has been an increase in clinical trials in neurocritical care, leading mostly to negative results. The evaluation of neurological outcomes, predominantly as primary outcomes, using clinical scales (Glasgow Outcome Scale) has limitations that could explain these results. Moreover, patient-centered outcomes are seldom reported despite their recognized clinical relevance. : The aim of this project is to establish a core outcome set (COS) for patients with moderate-to-severe TBI in randomized control trials in neurocritical care research. This study will follow five distinct steps: (1) systematic review to identify outcomes that have been reported in trials; (2) semistructured interviews with patients and their families to identify their priorities after TBI and explore potential patient-centered outcomes; (3) health care stakeholder focus groups with clinicians, researchers, and policy makers to describe potential outcomes; (4) an eDelphi survey with stakeholder groups to make a list of previously identified core outcomes; and (5) a consensus workshop to establish a COS for moderate-to-severe TBI clinical trials. : The systematic review was published in August 2024. Regarding Step 2, 30 semistructured interviews of patients and relatives were performed from July 2021 to December 2023, and analyses were completed in October 2024. Step 3 is currently under development, and Step 4 is planned for the end of 2025. Step 5 is expected to occur during fall/winter 2026. Conclusions: Establishing a COS, to be consistently measured and reported in TBI trials in neurocritical care will ensure rigorous reporting, avoid bias, and improve the integrity, transparency, and usability of clinical research. The French context of the study is the main limitation, but we are seeking international collaboration on the project. The results of each step of the project will be disseminated through abstracts, publications, and patient associations. Establishing a COS, to be consistently measured and reported in TBI trials in neurocritical care will ensure rigorous reporting, avoid bias, and improve the integrity, transparency, and usability of clinical research. The French context of the study is the main limitation, but we are seeking international collaboration on the project. The results of each step of the project will be disseminated through abstracts, publications, and patient associations. DERR1-10.2196/54525.","Department of Anaesthesia and Critical Care, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Department of Anaesthesia and Critical Care, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Department of Rehabilitation, Hôpital Saint-Jacques, Centre Hospitalier Universitaire de Nantes, Nantes, France.;SRPR 42, Groupement de coopération sanitaire, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France.;GIN U1216, Grenoble Institute of Neurosciences, La Tronche, France.;Service de Médecine Physique et Réadaptation, Pôle de Beurosciences Cliniques, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;HACS team-U1219, Institut National de la Santé et de la Recherche Médicale Bordeaux Population Health & University of Bordeaux, Bordeaux, France.;Anesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Intensive Care and Anesthesia Department, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;INSERM U1070, PHAR2, Université de Poitiers, Poitiers, France.;Département Universitaire des Sciences Infirmières, Épidémiologie Clinique, Évaluation Économique Appliquées aux Populations Vulnérables, Paris, France.;Centre Nantais de Sociologie, Nantes Université, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Service de Néphrologie-Hypertension Artérielle, Dialyses, Transplantation Rénale, Centre Hospitalier Universitaire de Tours, Tours, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.","NA",0,"1929-0748","JMIR Res Protoc","JMIR Res Protoc",2023,"2025","14","10.2196/54525","e54525","","","39787594","39787594","PUBMED","Department of Anaesthesia and Critical Care, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Department of Anaesthesia and Critical Care, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Department of Rehabilitation, Hôpital Saint-Jacques, Centre Hospitalier Universitaire de Nantes, Nantes, France.;SRPR 42, Groupement de coopération sanitaire, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Etienne, France.;GIN U1216, Grenoble Institute of Neurosciences, La Tronche, France.;Service de Médecine Physique et Réadaptation, Pôle de Beurosciences Cliniques, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;HACS team-U1219, Institut National de la Santé et de la Recherche Médicale Bordeaux Population Health & University of Bordeaux, Bordeaux, France.;Anesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Intensive Care and Anesthesia Department, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;INSERM U1070, PHAR2, Université de Poitiers, Poitiers, France.;Département Universitaire des Sciences Infirmières, Épidémiologie Clinique, Évaluation Économique Appliquées aux Populations Vulnérables, Paris, France.;Centre Nantais de Sociologie, Nantes Université, Nantes, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France.;Service de Néphrologie-Hypertension Artérielle, Dialyses, Transplantation Rénale, Centre Hospitalier Universitaire de Tours, Tours, France.;INSERM, Methods in Patient-Centered Outcomes and Health Research, SPHERE, F-44000, Nantes Université, University of Tours, Nantes, France."
"15","Anselmi A;Daniel M;Aymami M;Chabanne C;Rosier S;Mancini J;Verhoye JP","Anselmi, Amedeo;Daniel, Morgan;Aymami, Marie;Chabanne, Celine;Rosier, Sebastien;Mancini, Julien;Verhoye, Jean Philippe","Comparison of Long-Term Performance of Porcine versus Pericardial Bioprostheses.","The Thoracic and cardiovascular surgeon","Germany","eng","Journal Article","","",""," The long-term comparative results between porcine and pericardial bioprostheses for surgical aortic valve replacement (SAVR) are debated. Scarce information exists concerning direct comparative evaluation among contemporary devices. We compared late and very late results in a single center series (  = 3,983 cases).  From a prospectively collected database we included 3,983 recipients of two current porcine bioprostheses (porcine group) or one current pericardial bioprosthesis (pericardial group). We evaluated the long-term freedom from structural valve deterioration (SVD) with both Kaplan-Meier and competing risk methods (primary endpoint). We distinguished between SVD and patient-prosthesis mismatch (PPM). Secondary endpoints were late survival, freedom from valve-related mortality, freedom from reoperation for SVD, freedom from nonstructural valve dysfunction (NSVD) and freedom from endocarditis.  Median follow-up was 10.4 years (99.7% complete, 32,219 patients/years). Overall survival was significantly lower in the porcine group (  = 0.002), related to baseline intergroup differences. At 10 years, Kaplan-Meier freedom from SVD was significantly better in the porcine group (98.0% ± 0.3 vs. 96.3% ± 0.8;   = 0.003). Competing risk freedom from SVD at 10 years was 98.6% ± 0.2 and 97.2% ± 0.6 (porcine and pericardial group, respectively;   = 0.001). The porcine group displayed a higher rate of PPM.  Despite the augmented risk of PPM compared with pericardial valves, in this series porcine bioprostheses seem to perform better concerning protection from late (>10 years) SVD. Smaller valve sizes (19-21 mm) may negatively impact the SVD risk among porcine valves but not among pericardial valves. These elements need to be considered for valve choice and surgical strategy in SAVR candidates according to their life expectancy, clinical context, and annulus size.","Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Cardiac Anesthesia, Centre Hospitalier Universitaire de Rennes Site de Pontchaillou, Rennes, Bretagne, France.;UMR1252 SESSTIM Research Unit, Biostatistics Department, Aix-Marseille University, Marseille, Provence-Alpes-Côte d'Azu, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.","NA",0,"1439-1902","Thorac Cardiovasc Surg","Thorac Cardiovasc Surg",2025,"2025",NA,"10.1055/a-2505-8447",NA,"","","39777629","39777629","PUBMED","Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France.;Division of Cardiac Anesthesia, Centre Hospitalier Universitaire de Rennes Site de Pontchaillou, Rennes, Bretagne, France.;UMR1252 SESSTIM Research Unit, Biostatistics Department, Aix-Marseille University, Marseille, Provence-Alpes-Côte d'Azu, France.;Division of Thoracic and Cardiovascular Surgery, CHU de Rennes, Rennes, Bretagne, France."
"16","Frenel JS;Mathiot L;Cropet C;Borcoman E;Hervieu A;Coquan E;De La Motte Rouge T;Saada-Bouzid E;Sabatier R;Lavaud P;Jimenez M;Legrand F;Le Saux O;Charafe E;Gonçalves A","Frenel, Jean-Sébastien;Mathiot, Laurent;Cropet, Claire;Borcoman, Edith;Hervieu, Alice;Coquan, Elodie;De La Motte Rouge, Thibault;Saada-Bouzid, Esma;Sabatier, Renaud;Lavaud, Pernelle;Jimenez, Marta;Legrand, François;Le Saux, Olivia;Charafe, Emmanuelle;Gonçalves, Anthony","Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study.","Journal for immunotherapy of cancer","England","eng","Journal Article","Cervical Cancer;Chemotherapy;Immune Checkpoint Inhibitor","Humans;Female;Uterine Cervical Neoplasms;Antineoplastic Combined Chemotherapy Protocols;Vinorelbine;Middle Aged;Antibodies, Monoclonal, Humanized;Adult;Aged;Antibodies, Monoclonal;Neoplasm Recurrence, Local;Administration, Metronomic;Administration, Oral","Humans;Female;Uterine Cervical Neoplasms;Antineoplastic Combined Chemotherapy Protocols;Vinorelbine;Middle Aged;Antibodies, Monoclonal, Humanized;Adult;Aged;Antibodies, Monoclonal;Neoplasm Recurrence, Local;Administration, Metronomic;Administration, Oral","The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort. Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression. The primary efficacy endpoint was the clinical benefit rate (CBR) based on the Response Evaluation Criteria in Solid Tumors V.1.1, which was analyzed using a Bayesian approach RESULTS: A total of 31 patients were enrolled and treated in the cervical cancer cohort. The median number of previous lines of chemotherapy for advanced disease was 2 (0-6), with all (100%) and 12 (38.7%) patients pretreated with cisplatin and bevacizumab, respectively. At the data cut-off, the median follow-up duration was 12.8 (Q1-Q3, 6.1-34.6) months. The CBR was 53.1% (95% CI, 36.0% to 69.8%), using a non-informative prior distribution (beta(1, 1)). The overall response rate was 41.9%, five patients achieved a complete response (16.1%), and eight patients (25.8%) had a partial response irrespective of histological subtype or programmed death-ligand 1 (PD-L1) expression. Of the 31 patients, 28 (90.3%) experienced treatment-related adverse events (TRAEs), 13 (41.9%) reported grade ≥3 immune-related adverse events (AEs), and 13 (41.9%) reported grade ≥3 chemotherapy-related AEs. The definitive discontinuation rate due to TRAEs was 16.1%. Dual checkpoint blockade of PD-L1 and cytotoxic T-lymphocyte-associated antigen-4 combined with metronomic oral vinorelbine demonstrated meaningful and durable clinical activity in patients with previously treated advanced cervical cancer. Toxicity was significant but manageable.","Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain;Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.","NA",0,"2051-1426","J Immunother Cancer","J Immunother Cancer",2024,"2025","13","10.1136/jitc-2024-010708",NA,"","","39773562","39773562","PUBMED","Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain;Department of Medical Oncology, Nantes Université, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France.;Department of Biopathology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM U1068, CNRS U7258, Marseille, France."
"17","Morin L;Zimmermann F;Lelong M;Ferrant J;Hemon P;Patry S;Le Tallec E;Uwambayinema F;Yakoub Y;Dumontet E;Huaux F;Lescoat A;Lecureur V","Morin, Laura;Zimmermann, François;Lelong, Marie;Ferrant, Juliette;Hemon, Patrice;Patry, Salomé;Le Tallec, Erwan;Uwambayinema, Francine;Yakoub, Yousof;Dumontet, Erwan;Huaux, François;Lescoat, Alain;Lecureur, Valérie","Pulmonary and systemic effects of inhaled crystalline silica in the HOCl-induced mouse model of systemic sclerosis: An experimental model of Erasmus syndrome.","Clinical immunology (Orlando, Fla.)","United States","eng","Journal Article","Autoimmunity;Crystalline silica;Mass cytometry;NLRP3 inflammasome;Silicosis;Systemic sclerosis","Animals;Scleroderma, Systemic;Silicon Dioxide;Disease Models, Animal;Mice;Hypochlorous Acid;Lung;Humans;Female;Male;NLR Family, Pyrin Domain-Containing 3 Protein;Mice, Inbred C57BL;Skin;Middle Aged;Inflammasomes","Animals;Scleroderma, Systemic;Silicon Dioxide;Disease Models, Animal;Mice;Hypochlorous Acid;Lung;Humans;Female;Male;NLR Family, Pyrin Domain-Containing 3 Protein;Mice, Inbred C57BL;Skin;Middle Aged;Inflammasomes","Occupational exposure to crystalline silica is etiologically linked to an increased incidence of systemic sclerosis (SSc), also called Erasmus syndrome. The underlying mechanisms of silica-related SSc are still poorly understood. We demonstrated that early and repeated silica exposure contribute to the severity of SSc symptoms in the hypochloric acid (HOCl)-induced SSc mouse model. Analyses of lung samples from silica-exposed HOCl mice revealed a slightly aggravation of fibrosis and an exacerbation of inflammation, notably an additionally overexpression of NLRP3 inflammasome genes and a recruitment of classical monocytes, macrophages, dendritic cells and neutrophils. Silica exposure showed systemic effects in SSc mouse model with an elevated circulating classical monocyte counts and an overexpression of inflammatory genes in the skin. Silica-exposed SSc patients also had more severe skin disease than unexposed patients. Overall, we provide new insights on immune cell populations and related pathways in early pathogenic mechanisms contributing to HOCl-induced and silica-related SSc.","Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France; Unité Mixte de Recherche (UMR)1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, Equipe Labellisée Ligue Contre le Cancer, Rennes, France.;LBAI, UMR1227, University of Brest, INSERM, Brest, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France; Unité Mixte de Recherche (UMR)1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, Equipe Labellisée Ligue Contre le Cancer, Rennes, France.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes","NA",0,"1521-7035","Clin Immunol","Clin Immunol",2024,"2025","271","10.1016/j.clim.2024.110423","110423","","","39732270","39732270","PUBMED","Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France; Unité Mixte de Recherche (UMR)1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, Equipe Labellisée Ligue Contre le Cancer, Rennes, France.;LBAI, UMR1227, University of Brest, INSERM, Brest, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France; Unité Mixte de Recherche (UMR)1236, Université Rennes, INSERM, Etablissement Français du Sang Bretagne, Equipe Labellisée Ligue Contre le Cancer, Rennes, France.;Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institute de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.;Univ Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, 35000 Rennes, France.;Univ Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes"
"18","Cappuyns S;Piqué-Gili M;Esteban-Fabró R;Philips G;Balaseviciute U;Pinyol R;Gris-Oliver A;Vandecaveye V;Abril-Fornaguera J;Montironi C;Bassaganyas L;Peix J;Zeitlhoefler M;Mesropian A;Huguet-Pradell J;Haber PK;Figueiredo I;Ioannou G;Gonzalez-Kozlova E;D'Alessio A;Mohr R;Meyer T;Lachenmayer A;Marquardt JU;Reeves HL;Edeline J;Finkelmeier F;Trojan J;Galle PR;Foerster F;Mínguez B;Montal R;Gnjatic S;Pinato DJ;Heikenwalder M;Verslype C;Van Cutsem E;Lambrechts D;Villanueva A;Dekervel J;Llovet JM","Cappuyns, Sarah;Piqué-Gili, Marta;Esteban-Fabró, Roger;Philips, Gino;Balaseviciute, Ugne;Pinyol, Roser;Gris-Oliver, Albert;Vandecaveye, Vincent;Abril-Fornaguera, Jordi;Montironi, Carla;Bassaganyas, Laia;Peix, Judit;Zeitlhoefler, Marcus;Mesropian, Agavni;Huguet-Pradell, Júlia;Haber, Philipp K;Figueiredo, Igor;Ioannou, Giorgio;Gonzalez-Kozlova, Edgar;D'Alessio, Antonio;Mohr, Raphael;Meyer, Tim;Lachenmayer, Anja;Marquardt, Jens U;Reeves, Helen L;Edeline, Julien;Finkelmeier, Fabian;Trojan, Jörg;Galle, Peter R;Foerster, Friedrich;Mínguez, Beatriz;Montal, Robert;Gnjatic, Sacha;Pinato, David J;Heikenwalder, Mathias;Verslype, Chris;Van Cutsem, Eric;Lambrechts, Diether;Villanueva, Augusto;Dekervel, Jeroen;Llovet, Josep M","Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.","Journal of hepatology","Netherlands","eng","Journal Article","Advanced Hepatocellular Carcinoma;Atezolizumab and bevacizumab;Biomarkers of Response;Primary Resistance;Single-Cell RNA-Sequencing","","","The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define ""Immune-competent"" and ""Angiogenesis-driven"" molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a ""Resistant"" subset. Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (""Immune-competent"" and ""Angiogenesis-driven"") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients (""Immune-competent"" and ""Angiogenesis-driven"" vs. ""Resistant"") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.","Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium; Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Radiology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory of Translational MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Pathology Department and Molecular Biology Core, Hospital Clínic of Barcelona, Barcelona, Spain.;Institut de Génomique Fonctionnelle, Univ. Montpellier, CNRS, INSERM, Montpellier, France.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.;Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.;Research Department of Oncology, UCL Cancer Institute, University College London, Royal Free Hospital, London, UK.;Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany.;Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK; Newcastle University Translational and Clinical Research Institute and Newcastle University Centre for Cancer, Medical School, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.;Department of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.;Department of Medicine I, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.;Department of Medicine I, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.;Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Liver Diseases Research Group, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; CIBERehd, Universitat Autònoma de Barcelona, Barcelona, Spain.;Department of Medical Oncology, Cancer Biomarkers Research Group, Hospital Universitari Arnau de Vilanova, IRBLleida, University of Lleida (UdL), Catalonia, Spain.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Translational Medicine, Università Del Piemonte Orientale ""A. Avogadro"", Novara, Italy.;Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.;Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, 08010","NA",0,"1600-0641","J Hepatol","J Hepatol",2024,"2024",NA,"10.1016/j.jhep.2024.12.016",NA,"P01 CA234212;P30 CA196521;U01 DK124165;U24 CA224319","NCI NIH HHS;NCI NIH HHS;NIDDK NIH HHS;NCI NIH HHS","39709141","39709141","PUBMED","Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium; Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Radiology Department, University Hospitals Leuven, Leuven, Belgium; Laboratory of Translational MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Pathology Department and Molecular Biology Core, Hospital Clínic of Barcelona, Barcelona, Spain.;Institut de Génomique Fonctionnelle, Univ. Montpellier, CNRS, INSERM, Montpellier, France.;Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.;Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.;Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.;Research Department of Oncology, UCL Cancer Institute, University College London, Royal Free Hospital, London, UK.;Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.;Department of Medicine I, University Medical Center Schleswig Holstein Campus Lübeck, Lübeck, Germany.;Hepatopancreatobiliary Multidisciplinary Team, Newcastle upon Tyne NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK; Newcastle University Translational and Clinical Research Institute and Newcastle University Centre for Cancer, Medical School, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.;Department of Gastroenterology, University Liver and Cancer Centre, Frankfurt, Germany.;Department of Medicine I, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.;Department of Medicine I, University Medical Center of the Johannes-Gutenberg University, Mainz, Germany.;Liver Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Liver Diseases Research Group, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; CIBERehd, Universitat Autònoma de Barcelona, Barcelona, Spain.;Department of Medical Oncology, Cancer Biomarkers Research Group, Hospital Universitari Arnau de Vilanova, IRBLleida, University of Lleida (UdL), Catalonia, Spain.;Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Translational Medicine, Università Del Piemonte Orientale ""A. Avogadro"", Novara, Italy.;Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.;Laboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium; VIB Centre for Cancer Biology, Leuven, Belgium.;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.;Digestive Oncology, Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium; Laboratory of Clinical Digestive Oncology, Department of Oncology, KU Leuven, Leuven;Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA; Liver Cancer Translational Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, 08010"
"19","Weaver D;Gago S;Bassetti M;Giacobbe DR;Prattes J;Hoenigl M;Reizine F;Guegan H;Gangneux J-P;Bromley MJ;Bowyer P","Weaver, Danielle;Gago, Sara;Bassetti, Matteo;Giacobbe, Daniele Roberto;Prattes, Juergen;Hoenigl, Martin;Reizine, Florian;Guegan, Hélène;Gangneux, Jean-Pierre;Bromley, Michael John;Bowyer, Paul","Mycobiome analyses of critically ill COVID-19 patients.","Microbiology spectrum","United States","eng","Journal Article","Aspergillus;CAPA;COVID-19;mycobiome","Humans;COVID-19;Mycobiome;Critical Illness;Male;Female;Middle Aged;Aged;SARS-CoV-2;Antifungal Agents;Pulmonary Aspergillosis;Candida;Lung;Intensive Care Units;Aspergillus fumigatus;Adult","Humans;COVID-19;Mycobiome;Critical Illness;Male;Female;Middle Aged;Aged;SARS-CoV-2;Antifungal Agents;Pulmonary Aspergillosis;Candida;Lung;Intensive Care Units;Aspergillus fumigatus;Adult","Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a life-threatening complication in patients with severe COVID-19. Previously, acute respiratory distress syndrome in patients with COVID-19 has been associated with lung fungal dysbiosis, evidenced by reduced microbial diversity and   colonization. Increased fungal burden in the lungs of critically ill COVID-19 patients is linked to prolonged mechanical ventilation and increased mortality. However, specific mycobiome signatures associated with severe COVID-19 in the context of survival and antifungal drug prophylaxis have not yet been determined, and such knowledge could have an important impact on treatment. To understand the composition of the respiratory mycobiome in critically ill COVID-19 patients with and without CAPA and the impact of antifungal use in patient outcome, we performed a multinational study of 39 COVID-19 patients in intensive care units (ICUs). Respiratory mycobiome was profiled using internal transcribed spacer 1 sequencing, and   burden was further validated using quantitative PCR. Fungal communities were investigated using alpha diversity, beta diversity, taxa predominance, and taxa abundances. Respiratory mycobiomes of COVID-19 patients were dominated by   and  . There was no significant association with corticosteroid use or CAPA diagnosis and respiratory fungal communities. Increased   burden was associated with mortality and, the use of azoles at ICU admission was linked with an absence of  . Our findings suggest that mold-active antifungal treatment at ICU admission may be linked with reduced  associated mortality in severe COVID-19. However, further studies are warranted on this topic.IMPORTANCEInvasive fungal infections are a serious complication affecting up to a third of patients with severe COVID-19. Nevertheless, our understanding of the fungal communities in the lungs during critically ill COVID-19 remains limited. Evidence suggests a higher fungal burden is associated with prolonged ventilation and higher mortality, although the particular organisms responsible for this link are unclear. Antifungal prophylaxis may be beneficial for reducing the burden of fungal co-infections in COVID-19 intensive care. However, the composition of the fungal microbiome in severe COVID-19 in relation to prophylactic antifungals, as well as how this is associated with survival outcomes, is yet to be studied. Our study provides insights into the lung fungal microbiome in severe COVID-19 and has found antifungal treatment to be associated with lower   burden and that higher levels of this pathogen are associated with mortality. Therefore, our study suggests mold-active antifungal prophylaxis may be beneficial in severe COVID-19.","University of Manchester, Manchester, United Kingdom.;University of Manchester, Manchester, United Kingdom.;Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.;Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.;Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.;Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Biotech Med, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Medical Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;CHU Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (IRSET), Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Centre National de Référence Mycoses et Antifongiques-Laboratoire Associé Asp-C, European Excellence Center for Medical Mycology (ECMM), Rennes, France.;CHU Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (IRSET), Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Centre National de Référence Mycoses et Antifongiques-Laboratoire Associé Asp-C, European Excellence Center for Medical Mycology (ECMM), Rennes, France.;University of Manchester, Manchester, United Kingdom.;University of Manchester, Manchester, United Kingdom.","NA",0,"2165-0497","Microbiol Spectr","Microbiol Spectr",2024,"2025","13","10.1128/spectrum.04110-23","e0411023","R01 AI143198;NIHR203308","Wellcome Trust;NIAID NIH HHS;NIHR | Manchester Biomedical Research Centre (BRC)","39699254","39699254","PUBMED","University of Manchester, Manchester, United Kingdom.;University of Manchester, Manchester, United Kingdom.;Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.;Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.;Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.;Infectious Diseases Unit, IRCCS San Martino Polyclinic Hospital, Genoa, Italy.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Biotech Med, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Medical Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;CHU Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (IRSET), Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Centre National de Référence Mycoses et Antifongiques-Laboratoire Associé Asp-C, European Excellence Center for Medical Mycology (ECMM), Rennes, France.;CHU Rennes, Inserm, EHESP, Institut de Recherche en Santé, Environnement et Travail (IRSET), Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Centre National de Référence Mycoses et Antifongiques-Laboratoire Associé Asp-C, European Excellence Center for Medical Mycology (ECMM), Rennes, France.;University of Manchester, Manchester, United Kingdom.;University of Manchester, Manchester, United Kingdom."
"20","Le Guevelou J;Palard-Novello X;Kammerer E;Baty M;Perazzi M;Larnaudie A;De Crevoisier R;Castelli J","Le Guevelou, J;Palard-Novello, X;Kammerer, E;Baty, M;Perazzi, M;Larnaudie, A;De Crevoisier, R;Castelli, J","Assessment and Prediction of Salivary Gland Function After Head and Neck Radiotherapy: A Systematic Review.","Cancer medicine","United States","eng","Systematic Review","MRI;PET/CT;head and neck cancer;radiotherapy;salivary gland;xerostomia","Humans;Head and Neck Neoplasms;Salivary Glands;Xerostomia;Magnetic Resonance Imaging;Positron Emission Tomography Computed Tomography;Radiation Injuries","Humans;Head and Neck Neoplasms;Salivary Glands;Xerostomia;Magnetic Resonance Imaging;Positron Emission Tomography Computed Tomography;Radiation Injuries","Modern imaging techniques with magnetic resonance imaging (MRI) or positron emission tomography/computed tomography (PET/CT) have recently been developed to assess radiation-induced damage to salivary structures. The primary aim of this review was to summarize evidence on the imaging modalities used for the assessment and prediction of xerostomia after head and neck radiotherapy (RT). A systematic review of the literature was performed using successively the MeSH terms ""PET,"" ""MRI,"" ""scintigraphy,"" ""xerostomia,"" and ""radiotherapy."" Salivary excretion flow following head and neck RT is correlated with the dose delivered to both parotid and submandibular glands. Salivary gland standardized uptake value extracted from PET/CT following RT has been shown to be correlated with SEF. Models including early SUV decline or ADC increase during RT and clinical parameters can help predict the loss of salivary function after RT. Modern imaging parameters appear to be correlated with salivary gland scintigraphy parameters. Models including functional parameters extracted from either PET/CT or MRI unveil new possibilities for adaptive treatment in a selected population of patients.","Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, Caen, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.","NA",0,"2045-7634","Cancer Med","Cancer Med",2024,"2024","13","10.1002/cam4.70494","e70494","","","39679450","39679450","PUBMED","Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, Caen, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France."
"21","Vitek L;Goronflot T;Dutriaux C;Deleuze A;Le Corre Y;Duval-Modeste AB;Fresnard C;Jeudy G;Lamoureux A;Gaudy-Marqueste C;Legoupil D;Baroudjian B;L'Orphelin JM;Peuvrel L;Khammari A;Mortier L;Quereux G","Vitek, Lucille;Goronflot, Thomas;Dutriaux, Caroline;Deleuze, Antoine;Le Corre, Yannick;Duval-Modeste, Anne-Bénédicte;Fresnard, Cécile;Jeudy, Géraldine;Lamoureux, Anouck;Gaudy-Marqueste, Caroline;Legoupil, Delphine;Baroudjian, Barouyr;L'Orphelin, Jean-Matthieu;Peuvrel, Lucie;Khammari, Amir;Mortier, Laurent;Quereux, Gaëlle","Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study.","Acta dermato-venereologica","Sweden","eng","Journal Article","","Humans;Melanoma;Retrospective Studies;Male;Uveal Neoplasms;Female;Middle Aged;Aged;Progression-Free Survival;Adult;France;Time Factors;Aged, 80 and over;Treatment Outcome;Uveal Melanoma","Humans;Melanoma;Retrospective Studies;Male;Uveal Neoplasms;Female;Middle Aged;Aged;Progression-Free Survival;Adult;France;Time Factors;Aged, 80 and over;Treatment Outcome;Uveal Melanoma","Metastatic uveal melanoma is a rare disease with a poor prognosis. Usual treatments have not proven effective. Tebentafusp, a bispecific protein targeting melanoma cells and T lymphocytes, is the first approved treatment with a proven survival benefit in a randomized clinical. Our purpose was to evaluate tebentafusp's real-life efficacy and tolerability for metastatic uveal melanoma. This retrospective study included patients from 14 French centres. Twenty-three patients were included. One-year survival was 66%; median progression-free survival was 5.7 months. Objective response rate was 23% and best overall response was complete remission for 4% of patients; partial remission for 18%, stable disease for 41%, and progressive disease for 36%. The most frequent adverse events were fever, chills, pruritus, and rash; 30% experienced severe adverse events. No death or treatment discontinuation was linked to adverse events. These data showed better overall survival with tebentafusp than that reported in historical cohorts.","Department of Dermatology, CHU de Nantes, Nantes, France.;Nantes University, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, CIC 1413, CHU Nantes, Nantes, France.;Department of Dermatology, Hôpital Saint-André, Bordeaux, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Dermatology, CHU d'Angers, Angers, France.;Université de Rouen, INSERM U519, Dermatologie, CHU de Rouen, Rouen, France.;Department of Dermatology, Hôpital Saint-Louis de La Rochelle, La Rochelle, France.;Department of Dermatology, Hôpital François-Mitterand, CHU Dijon Bourgogne, Dijon, France.;Department of Dermatology, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.;Department of Dermatology and Cutaneous Oncology, Aix-Marseille Université (AP-HM), Marseille, France.;Department of Dermatology, INNOVEO, le fonds de dotation du CHRU de Brest, Brest, France.;Department of Dermatology, Hôpital Saint-Louis (AP-HP), Paris, France.;Department of Dermatology, CHU Caen Normandie, Caen, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Nantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes, France.;Department of Dermatology, CHU de Lille, Lille, France.;Nantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes","NA",0,"1651-2057","Acta Derm Venereol","Acta Derm Venereol",2024,"2024","104","10.2340/actadv.v104.41297","adv41297","","","39670438","39670438","PUBMED","Department of Dermatology, CHU de Nantes, Nantes, France.;Nantes University, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, CIC 1413, CHU Nantes, Nantes, France.;Department of Dermatology, Hôpital Saint-André, Bordeaux, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Dermatology, CHU d'Angers, Angers, France.;Université de Rouen, INSERM U519, Dermatologie, CHU de Rouen, Rouen, France.;Department of Dermatology, Hôpital Saint-Louis de La Rochelle, La Rochelle, France.;Department of Dermatology, Hôpital François-Mitterand, CHU Dijon Bourgogne, Dijon, France.;Department of Dermatology, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France.;Department of Dermatology and Cutaneous Oncology, Aix-Marseille Université (AP-HM), Marseille, France.;Department of Dermatology, INNOVEO, le fonds de dotation du CHRU de Brest, Brest, France.;Department of Dermatology, Hôpital Saint-Louis (AP-HP), Paris, France.;Department of Dermatology, CHU Caen Normandie, Caen, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Nantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes, France.;Department of Dermatology, CHU de Lille, Lille, France.;Nantes University, Department of Dermatology, CIC 1413, INSERM UMR 1302/EMR6001 INCIT, CHU de Nantes, Nantes"
"22","Zgheib A;De Backer O;Afilalo J;Quagliana A;Campens L;Al Asmar M;Al Ismaili A;Angiolillo D;Ajmone-Marsan N;Von Bardeleben RS;Buithieu J;Cavalcante J;Chetrit M;Choi C;Coisne A;Delgado V;Donal E;Duncan A;Dreyfus J;Fam N;Grapsa J;Granada J;Gackowski A;Hahn R;Ho E;Latib A;Medina de Chazal HA;Martucci G;Maisano F;Messika-Zeitoun D;Modine T;Muraru D;Mousavi N;Praz F;Redwood S;Patterson T;Sarano M;Spaziano M;Swaans M;Sitges M;Zamorano JL;van Mieghem N;Tchetche D;Tournoux F;Wunderlich N;Prendergast B;Piazza N","Zgheib, Ali;De Backer, Ole;Afilalo, Jonathan;Quagliana, Angelo;Campens, Laurence;Al Asmar, Mike;Al Ismaili, Abdullah;Angiolillo, Dominick;Ajmone-Marsan, Nina;Von Bardeleben, Ralph Stephan;Buithieu, Jean;Cavalcante, Joao;Chetrit, Michael;Choi, Calvin;Coisne, Augustin;Delgado, Victoria;Donal, Erwan;Duncan, Alison;Dreyfus, Julien;Fam, Neil;Grapsa, Julia;Granada, Juan;Gackowski, Andrzej;Hahn, Rebecca;Ho, Edwin;Latib, Azeem;Medina de Chazal, Horacio A;Martucci, Giuseppe;Maisano, Francesco;Messika-Zeitoun, David;Modine, Thomas;Muraru, Denisa;Mousavi, Negareh;Praz, Fabien;Redwood, Simon;Patterson, Tiffany;Sarano, Maurice;Spaziano, Marco;Swaans, Martin;Sitges, Marta;Zamorano, José Luis;van Mieghem, Nicolas;Tchetche, Didier;Tournoux, François;Wunderlich, Nina;Prendergast, Bernard;Piazza, Nicolo","Tricuspid Valve S-Curves and Chamber Views: Implications for Transcatheter Tricuspid and Pulmonary Valve Interventions, Part 2 of the S-Curves and Chamber Views Series.","JACC. Cardiovascular interventions","United States","eng","Journal Article","chamber views;multimodality imaging;optimal projection curve;transcatheter tricuspid valve interventions","Humans;Tricuspid Valve;Cardiac Catheterization;Heart Valve Prosthesis Implantation;Pulmonary Valve;Fluoroscopy;Radiography, Interventional;Predictive Value of Tests;Multidetector Computed Tomography;Multimodal Imaging;Treatment Outcome;Heart Valve Diseases","Humans;Tricuspid Valve;Cardiac Catheterization;Heart Valve Prosthesis Implantation;Pulmonary Valve;Fluoroscopy;Radiography, Interventional;Predictive Value of Tests;Multidetector Computed Tomography;Multimodal Imaging;Treatment Outcome;Heart Valve Diseases","Despite the challenges associated with periprocedural imaging, transcatheter tricuspid valve interventions have shown important impact on outcomes. A comprehensive understanding of the anatomy of the right heart and surrounding structures is crucial. One way to optimize these interventions is by identifying the optimal fluoroscopic viewing angles along the S-curve of the tricuspid valve. Integration of chamber views using multimodality imaging (multislice computed tomography, fluoroscopy, and echocardiography) may increase operator confidence and reduce procedural duration, radiation exposure, contrast volume, and complication rates.","Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.;Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Universitätsmedizin Mainz, Mainz, Germany.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Cardiac MR and Structural CT Lab, Allina Health Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Centre Hospitalier Universitaire de Lille, Lille, France.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Cardiology Department, Laboratoire Traitement du Signal et de l'Image, UMR1099, Institut National de la Santé et de la Recherche Médicale, Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiac Department, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.;Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.;St. Michael's Hospital, Toronto, Ontario, Canada.;Department of Cardiovascular Sciences, Imperial College London, London, United Kingdom.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Department of Coronary Disease and Heart Failure, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland.;NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, New York, USA.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiothoracic Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.;Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.;Bordeaux University Hospital, Bordeaux, France.;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy; IRCCS Istituto Auxologico Italiano, San Luca Hospital, University of Milano-Bicocca, Milan, Italy.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.;Cardiology Department, Guys' and St Thomas' NHS Foundation Trust, London, United Kingdom.;Cardiology Department, Guys' and St Thomas' NHS Foundation Trust, London, United Kingdom.;Division of Cardiology, Mayo Clinic, Rochester, Minnesota, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.;Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain.;Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.;Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.;Cardiology Department, Clinique Pasteur, Toulouse, France.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Cardiovascular Center Darmstadt, Darmstadt, Germany.;Department of Cardiology, St Thomas' Hospital, London, United Kingdom.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec","NA",0,"1876-7605","JACC Cardiovasc Interv","JACC Cardiovasc Interv",2024,"2024","17","10.1016/j.jcin.2024.08.005","2713-2731","","","39663053","39663053","PUBMED","Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.;Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Universitätsmedizin Mainz, Mainz, Germany.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Cardiac MR and Structural CT Lab, Allina Health Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Centre Hospitalier Universitaire de Lille, Lille, France.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Cardiology Department, Laboratoire Traitement du Signal et de l'Image, UMR1099, Institut National de la Santé et de la Recherche Médicale, Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiac Department, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.;Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.;St. Michael's Hospital, Toronto, Ontario, Canada.;Department of Cardiovascular Sciences, Imperial College London, London, United Kingdom.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Department of Coronary Disease and Heart Failure, John Paul II Hospital, Jagiellonian University Medical College, Kraków, Poland.;NewYork-Presbyterian Hospital, Columbia University Medical Center, New York, New York, USA.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiothoracic Surgery, IRCCS Ospedale San Raffaele, Milan, Italy.;Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.;Bordeaux University Hospital, Bordeaux, France.;Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy; IRCCS Istituto Auxologico Italiano, San Luca Hospital, University of Milano-Bicocca, Milan, Italy.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.;Cardiology Department, Guys' and St Thomas' NHS Foundation Trust, London, United Kingdom.;Cardiology Department, Guys' and St Thomas' NHS Foundation Trust, London, United Kingdom.;Division of Cardiology, Mayo Clinic, Rochester, Minnesota, USA.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.;Cardiovascular Institute, Hospital Clínic, University of Barcelona, Barcelona, Spain.;Cardiology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.;Department of Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands.;Cardiology Department, Clinique Pasteur, Toulouse, France.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec, Canada.;Cardiovascular Center Darmstadt, Darmstadt, Germany.;Department of Cardiology, St Thomas' Hospital, London, United Kingdom.;Division of Cardiology, Department of Medicine, Glen Hospital, McGill University Health Center, Montreal, Quebec"
"23","Marchand T;Pastoret C;Moignet A;Roussel M;Lamy T","Marchand, Tony;Pastoret, Cédric;Moignet, Aline;Roussel, Mikael;Lamy, Thierry","Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations.","Hematology. American Society of Hematology. Education Program","United States","eng","Journal Article","","Humans;Leukemia, Large Granular Lymphocytic;Autoimmune Diseases;STAT3 Transcription Factor;Mutation;Signal Transduction;Autoimmunity;Immunosuppressive Agents","Humans;Leukemia, Large Granular Lymphocytic;Autoimmune Diseases;STAT3 Transcription Factor;Mutation;Signal Transduction;Autoimmunity;Immunosuppressive Agents","Large granular lymphocyte (LGL) leukemia is a rare lymphoproliferative disorder characterized by an expansion of clonal T or natural killer lymphocytes. Neutropenia-related infections and anemia represent the main manifestations. LGL leukemia is frequently associated with autoimmune disorders such as rheumatoid arthritis, Sjögren's syndrome, autoimmune endocrinopathies, vasculitis, or autoimmune cytopenia. Recent advances in the phenotypic and molecular characterization of LGL clones have underscored the pivotal role of a chronic antigenic stimulation and a dysregulation of the Jak/STAT signaling pathway in the pathophysiology linking leukemic-cell expansion and autoimmunity. In more than half of patients, there is a somatic STAT3 mutation. The disease is characterized by an indolent course, but approximately half of all patients will eventually require therapy. The first-line treatment for LGL leukemia is historically based on immunosuppressive agents (methotrexate, cyclophosphamide, or cyclosporine). However, cytokines blocking molecules or Jak/STAT inhibitors represent a new conceptual therapeutic approach for LGL leukemia. In this review, we present an overview of the spectrum of LGL proliferations, potential links between LGL expansion and autoimmunity, and therapeutic approaches.","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.","NA",0,"1520-4383","Hematology Am Soc Hematol Educ Program","Hematology Am Soc Hematol Educ Program",2024,"2024","2024","10.1182/hematology.2024000539","143-149","","","39644019","39644019","PUBMED","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Rennes, France.;UMR 1236, Rennes University, INSERM, Établissement Français du Sang Bretagne, Rennes, France."
"24","Lorscheider J;Signori A;Subramaniam S;Benkert P;Vukusic S;Trojano M;Hillert J;Glaser A;Hyde R;Spelman T;Magyari M;Elberling F;Pontieri L;Koch-Henriksen N;Sørensen PS;Gerlach O;Prat A;Girard M;Eichau S;Grammond P;Horakova D;Ramo-Tello C;Roos I;Buzzard K;Lechner Scott J;Sánchez-Menoyo JL;Alroughani R;Prévost J;Kuhle J;Gray O;Mathey G;Michel L;Ciron J;De Sèze J;Maillart E;Ruet A;Labauge P;Zephir H;Kwiatkowski A;van der Walt A;Kalincik T;Butzkueven H","Lorscheider, Johannes;Signori, Alessio;Subramaniam, Suvitha;Benkert, Pascal;Vukusic, Sandra;Trojano, Maria;Hillert, Jan;Glaser, Anna;Hyde, Robert;Spelman, Tim;Magyari, Melinda;Elberling, Frederik;Pontieri, Luigi;Koch-Henriksen, Nils;Sørensen, Per Soelberg;Gerlach, Oliver;Prat, Alexandre;Girard, Marc;Eichau, Sara;Grammond, Pierre;Horakova, Dana;Ramo-Tello, Cristina;Roos, Izanne;Buzzard, Katherine;Lechner Scott, Jeanette;Sánchez-Menoyo, José Luis;Alroughani, Raed;Prévost, Julie;Kuhle, Jens;Gray, Orla;Mathey, Guillaume;Michel, Laure;Ciron, Jonathan;De Sèze, Jérôme;Maillart, Elisabeth;Ruet, Aurelie;Labauge, Pierre;Zephir, Helene;Kwiatkowski, Arnaud;van der Walt, Anneke;Kalincik, Tomas;Butzkueven, Helmut","Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.","Journal of neurology, neurosurgery, and psychiatry","England","eng","Journal Article","MULTIPLE SCLEROSIS","","","Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains unclear. Our aim was to investigate the potential effect of DMT on disability worsening among patients with PPMS stratified by different disability trajectories. Within the framework of the Big MS Data network, we merged data from the Observatoire Français de la Sclérose en Plaques, the Swedish and Italian MS registries, and MSBase. We identified patients with PPMS that started DMT or were never treated during the observed period. Subpopulations with comparable baseline characteristics were selected by propensity score matching. Disability outcomes were analysed in time-to-recurrent event analyses, which were repeated in subclasses with different disability trajectories determined by latent class mixed models. Of the 3243 included patients, we matched 739 treated and 1330 untreated patients with a median follow-up of 3 years after pairwise censoring. No difference in the risk of confirmed disability worsening (CDW) was observed between the groups in the fully matched dataset (HR 1.11, 95% CI 0.97 to 1.23, p=0.127). However, we found a lower risk for CDW among the class of treated patients with an aggressive disability trajectory (n=360, HR 0.68, 95% CI 0.50 to 0.92, p=0.014). In line with previous studies, our data suggest that DMT does not ameliorate disability worsening in PPMS, in general. However, we observed a beneficial effect of DMT on disability worsening in patients with aggressive predicted disability trajectories.","Department of Neurology, University Hospital Basel, Basel;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;Department of Health Sciences, Section of Biostatistics, University of Genoa, Genova, Italy.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Lyon, France.;Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France.;Eugène Devic EDMUS Foundation against multiple sclerosis, Lyon, France.;Department of Translational Biomedicine and Neurosciences - DiBraiN, University of Bari ""Aldo Moro"", Bari, Italy.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Independent Healthcare and Real-World Evidence Consultant, Zug, Switzerland.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;MSBase Foundation, Melbourne, Victoria, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands.;School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hospital Universitario Virgen Macarena, Sevilla, Spain.;Hotel-Dieu de Levis, Levis, Quebec, Canada.;Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.;Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurosciences, Box Hill Hospital, Box Hill, Victoria, Australia.;Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.;Hunter New England Health, John Hunter Hospital, Newcastle, New South Wales, Australia.;Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.;Neurology, Galdakao Hospital, Spain, Spain.;Amiri Hospital, Kuwait City, Kuwait.;Centre Integre de Sante et de Services Sociaux des Laurentides, Saint-Jerome, Quebec, Canada.;Department of Neurology, University Hospital Basel, Basel, Switzerland.;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;South Eastern HSC Trust, Belfast, UK.;Department of Neurology, Nancy University Hospital, Université de Lorraine, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neurology and Clinical Investigation Center, CHU de Strasbourg and University of Strasbourg, Strasbourg, France.;Neurology, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.;Service de Neurologie, CHU de Bordeaux, Bordeaux, France.;Neurocentre Magendie, Université de Bordeaux, Bordeaux, France.;CHU de Montpellier, MS Unit, University of Montpellier (MUSE), Montpellier, France.;CHU Lille, CRCSEP Lille, Université de Lille, Lille, France.;Department of Neurology, Hôpital Saint Vincent de Paul, Lille, France.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.","NA",0,"1468-330X","J Neurol Neurosurg Psychiatry","J Neurol Neurosurg Psychiatry",2024,"2024",NA,"10.1136/jnnp-2024-334700",NA,"","","39643429","39643429","PUBMED","Department of Neurology, University Hospital Basel, Basel;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;Department of Health Sciences, Section of Biostatistics, University of Genoa, Genova, Italy.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University Hospital Basel, Basel, Switzerland.;Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, Lyon, France.;Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France.;Eugène Devic EDMUS Foundation against multiple sclerosis, Lyon, France.;Department of Translational Biomedicine and Neurosciences - DiBraiN, University of Bari ""Aldo Moro"", Bari, Italy.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;Independent Healthcare and Real-World Evidence Consultant, Zug, Switzerland.;Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.;MSBase Foundation, Melbourne, Victoria, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital - Rigshospitalet Glostrup, Glostrup, Denmark.;Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands.;School for Mental Health and Neuroscience, Department of Neurology, Maastricht University Medical Center, Maastricht, Netherlands.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hôpital Notre Dame, CHUM and Universite de Montreal, Montreal, Quebec, Canada.;Hospital Universitario Virgen Macarena, Sevilla, Spain.;Hotel-Dieu de Levis, Levis, Quebec, Canada.;Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital, Prague, Czech Republic.;Neurosciences, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurosciences, Box Hill Hospital, Box Hill, Victoria, Australia.;Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.;Hunter New England Health, John Hunter Hospital, Newcastle, New South Wales, Australia.;Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia.;Neurology, Galdakao Hospital, Spain, Spain.;Amiri Hospital, Kuwait City, Kuwait.;Centre Integre de Sante et de Services Sociaux des Laurentides, Saint-Jerome, Quebec, Canada.;Department of Neurology, University Hospital Basel, Basel, Switzerland.;Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University of Basel, Basel, Switzerland.;South Eastern HSC Trust, Belfast, UK.;Department of Neurology, Nancy University Hospital, Université de Lorraine, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Department of Neurology and Clinical Investigation Center, CHU de Strasbourg and University of Strasbourg, Strasbourg, France.;Neurology, AP-HP, Hôpital de la Pitié Salpêtrière, Paris, France.;Service de Neurologie, CHU de Bordeaux, Bordeaux, France.;Neurocentre Magendie, Université de Bordeaux, Bordeaux, France.;CHU de Montpellier, MS Unit, University of Montpellier (MUSE), Montpellier, France.;CHU Lille, CRCSEP Lille, Université de Lille, Lille, France.;Department of Neurology, Hôpital Saint Vincent de Paul, Lille, France.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.;Clinical Outcomes Research Unit (CORe), Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.;Department of Neurology, Neuroimunology Centre, The Royal Melbourne Hospital, Parkville, Victoria, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Victoria, Australia.;Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia."
"25","Ternoy L;Meneret P;Palard-Novello X;Russo D","Ternoy, Laura;Meneret, Pierre;Palard-Novello, Xavier;Russo, David","A metastatic melanoma with an atypical low 18F-FDG uptake.","Nuklearmedizin. Nuclear medicine","Germany","eng","Journal Article","","","","NA","Dermatology, CHU de Rennes, Rennes, France.;Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Bretagne, Centre Eugene Marquis, Rennes, France.;Dermatology, CHU de Rennes, Rennes, France.","NA",0,"2567-6407","Nuklearmedizin","Nuklearmedizin",2024,"2024",NA,"10.1055/a-2383-2584",NA,"","","39631754","39631754","PUBMED","Dermatology, CHU de Rennes, Rennes, France.;Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Bretagne, Centre Eugene Marquis, Rennes, France.;Dermatology, CHU de Rennes, Rennes, France."
"26","Durand-Dubief F;Shor N;Audoin B;Bourre B;Cohen M;Kremer S;Maillart E;Papeix C;Ruet A;Savatovsky J;Tourdias T;Ayrignac X;Ciron J;Collongues N;Laplaud D;Michel L;Deschamps R;Thouvenot E;Zephir H;Marignier R;Cotton F","Durand-Dubief, Françoise;Shor, Natalia;Audoin, Bertrand;Bourre, Bertrand;Cohen, Mickael;Kremer, Stéphane;Maillart, Elisabeth;Papeix, Caroline;Ruet, Aurélie;Savatovsky, Julien;Tourdias, Thomas;Ayrignac, Xavier;Ciron, Jonathan;Collongues, Nicolas;Laplaud, David;Michel, Laure;Deschamps, Romain;Thouvenot, Eric;Zephir, Hélène;Marignier, Romain;Cotton, François","MRI management of NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS.","Journal of neuroradiology = Journal de neuroradiologie","France","eng","Journal Article","Disease management;MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease;MRI, magnetic resonance imaging;NMOSD, neuromyelitis optica spectrum disorder;Recommendations","Humans;Neuromyelitis Optica;Magnetic Resonance Imaging;Myelin-Oligodendrocyte Glycoprotein;France;Consensus","Humans;Neuromyelitis Optica;Magnetic Resonance Imaging;Myelin-Oligodendrocyte Glycoprotein;France;Consensus","Currently, there are no available recommendations or guidelines on how to perform MRI monitoring in the management of neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The issue is to determine a valuable MRI monitoring protocol to be applied in the management of NMOSD and MOGAD, as previously proposed for the monitoring of multiple sclerosis. The objectives of this work are to establish proposals for a standardized and feasible MRI acquisition protocol, and to propose control time points for systematic MRI monitoring in the management of NMOSD and MOGAD. A steering committee composed of 7 neurologists and 5 neuroradiologists, experts in NMOSD and MOGAD from the French group NOMADMUS, defined 8 proposals based on their expertise and a review from the literature. These proposals were then submitted to a Rating Group composed of French NMOSD / MOGAD experts. In the management of NMOSD and MOGAD, a consensus has been reached to perform systematic MRI of the brain, optic nerve and spinal cord, including cauda equina nerve roots, at the time of diagnosis, both without and after gadolinium administration. Moreover, it has been agreed to perform a systematic MRI scan 6 months after diagnosis, focusing on the area of interest, both without and after gadolinium administration. For long-term follow-up of NMOSD and MOGAD, and in the absence of clinical activity, it has been agreed to perform gadolinium-free MRI of the brain (+/- optic nerves) and spinal cord, every 36 months. Ideally, these MRI scans should be performed on the same MRI system, preferably a 3T MRI system for brain and optic nerve MRI, and at least a 1.5T MRI system for spinal cord MRI. This expert consensus approach provides physicians with proposals for the MRI management of NMOSD and MOGAD.","Service de Sclérose en Plaques, Pathologies de la substance blanche et Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon;Service de Neuroradiologie, Hôpital de la Pitie-Salpetrière, AP-HP, Paris, France.;Service de Neurologie, Maladies Inflammatoires du Cerveau et de la Moelle Épinière (MICeME), Hôpital de la Timone, AP-HM, Marseille CEDEX 5, France.;Service de Neurologie, Centre Hospitalier Universitaire Rouen, Rouen F-76000, France.;CRC-SEP, Neurologie Pasteur 2, CHU de Nice, Nice, France; Université Cote d'Azur, UMR2CA (URRIS), Nice, France.;Service d'imagerie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Engineering Science, Computer Science and Imaging Laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.;Service de Neurologie, Hôpital de la Pitie-Salpetrière, Centre de Références des Maladies Inflammatoires Rares du Cerveau Et de la Moelle épinière, AP-HP, Paris, France.;Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Service de Neurologie et Maladies inflammatoires du Système nerveux Central, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Université de Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux, France.;Service d'Imagerie Médicale, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Neuroimagerie Diagnostique et Thérapeutique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France; Université Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux F-3300, France.;Université de Montpellier, Montpellier, France; Département de Neurologie, CRC-SEP, CRMR LEUKOFRANCE, Hôpital Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier, France.;Service de Neurologie, CRC-SEP, Centre Hospitalier Universitaire de Toulouse, France.;Service de Neurologie, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; Center for Clinical Investigation, INSERM U1434, Strasbourg, France; Department of Pharmacology, Addictology, Toxicology, and Therapeutics, Strasbourg University, Strasbourg, France.;Center for Research in Transplantation and Translational Immunology, Nantes Université, INSERM, CHU de Nantes, UMR 1064, CIC INSERM 1413, Service de Neurologie, Nantes F-44000, France.;Service de Neurologie, Centre Hospitalier Universitaire de Rennes, Rennes, France; Clinical Neuroscience Centre, University Hospital, Rennes University, CIC_P1414 INSERM, Rennes, France.;Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Service de Neurologie, Centre Hospitalier Universitaire de Nîmes, Nîmes, France; Institut de Génomique Fonctionnelle, Université Montpellier, CNRS INSERM, Montpellier, France.;CCMR MIRCEM, Université de Lille INSERM U1172, CHU de Lille, Lille, France; CCMR MIRCEM, CHU de Lille, Lille, France.;Service de Sclérose en Plaques, Pathologies de la substance blanche et Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France.;Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon, France.","NA",0,"0150-9861","J Neuroradiol","J Neuroradiol",2024,"2025","52","10.1016/j.neurad.2024.101235","101235","","","39626832","39626832","PUBMED","Service de Sclérose en Plaques, Pathologies de la substance blanche et Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon;Service de Neuroradiologie, Hôpital de la Pitie-Salpetrière, AP-HP, Paris, France.;Service de Neurologie, Maladies Inflammatoires du Cerveau et de la Moelle Épinière (MICeME), Hôpital de la Timone, AP-HM, Marseille CEDEX 5, France.;Service de Neurologie, Centre Hospitalier Universitaire Rouen, Rouen F-76000, France.;CRC-SEP, Neurologie Pasteur 2, CHU de Nice, Nice, France; Université Cote d'Azur, UMR2CA (URRIS), Nice, France.;Service d'imagerie 2, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; Engineering Science, Computer Science and Imaging Laboratory (ICube), Integrative Multimodal Imaging in Healthcare, UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.;Service de Neurologie, Hôpital de la Pitie-Salpetrière, Centre de Références des Maladies Inflammatoires Rares du Cerveau Et de la Moelle épinière, AP-HP, Paris, France.;Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Service de Neurologie et Maladies inflammatoires du Système nerveux Central, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Université de Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux, France.;Service d'Imagerie Médicale, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Neuroimagerie Diagnostique et Thérapeutique, Centre Hospitalier Universitaire de Bordeaux, Bordeaux F-33000, France; Université Bordeaux, INSERM, Neurocentre Magendie, U1215, Bordeaux F-3300, France.;Université de Montpellier, Montpellier, France; Département de Neurologie, CRC-SEP, CRMR LEUKOFRANCE, Hôpital Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier, France.;Service de Neurologie, CRC-SEP, Centre Hospitalier Universitaire de Toulouse, France.;Service de Neurologie, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; Center for Clinical Investigation, INSERM U1434, Strasbourg, France; Department of Pharmacology, Addictology, Toxicology, and Therapeutics, Strasbourg University, Strasbourg, France.;Center for Research in Transplantation and Translational Immunology, Nantes Université, INSERM, CHU de Nantes, UMR 1064, CIC INSERM 1413, Service de Neurologie, Nantes F-44000, France.;Service de Neurologie, Centre Hospitalier Universitaire de Rennes, Rennes, France; Clinical Neuroscience Centre, University Hospital, Rennes University, CIC_P1414 INSERM, Rennes, France.;Service de Neurologie, Hôpital Fondation Adolphe de Rothschild, Paris, France.;Service de Neurologie, Centre Hospitalier Universitaire de Nîmes, Nîmes, France; Institut de Génomique Fonctionnelle, Université Montpellier, CNRS INSERM, Montpellier, France.;CCMR MIRCEM, Université de Lille INSERM U1172, CHU de Lille, Lille, France; CCMR MIRCEM, CHU de Lille, Lille, France.;Service de Sclérose en Plaques, Pathologies de la substance blanche et Neuroinflammation, Hôpital Neurologique, Hospices Civils de Lyon, Bron, France.;Service de Radiologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France; Creatis LRMN, CNRS UMR 5220, Université Claude Bernard Lyon 1, INSERM U630, Lyon, France."
"27","Bouazzaoui A;Quélin C;Rozel C;Carré W;Dubourg C;Odent S;Rollier P","Bouazzaoui, Abdelhakim;Quélin, Chloé;Rozel, Céline;Carré, Wilfrid;Dubourg, Christèle;Odent, Sylvie;Rollier, Paul","Expanding the TUBB3-Related Phenotypic Landscape: Fetal Diagnosis of Novel TUBB3 Variant Linked With Phenotypic Variability Within a Single Family.","Prenatal diagnosis","England","eng","Case Reports","","","","NA","Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Anatomie et cytologie pathologiques, CHU de Rennes, Rennes, France.;Imagerie Médicale, CH de Saint-Malo, Saint-Malo, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.","NA",0,"1097-0223","Prenat Diagn","Prenat Diagn",2024,"2025","45","10.1002/pd.6715","134-137","","","39625365","39625365","PUBMED","Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Anatomie et cytologie pathologiques, CHU de Rennes, Rennes, France.;Imagerie Médicale, CH de Saint-Malo, Saint-Malo, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, ERN ITHACA, Hôpital Sud, Rennes, France.;Genetics of Disorders Related to Neuroectoderal Development, Université de Rennes, CNRS, Institut de Génétique et Développement de Rennes, UMR 6290, Rennes, France."
"28","Leboulleux S;Bournaud C;Chougnet CN;Lamartina L;Zerdoud S;Do Cao C;Catargi B;Dygai I;Kelly A;Barge ML;Vera P;Rusu D;Schneegans O;Roux J;Raymond P;Benisvy D;Eberle MC;Bidault S;Nascimento C;Bastie D;Giraudet AL;Bardet S;Le Moullec N;Roudaut N;Drui D;Godbert Y;Zalzali M;Drutel A;Morel O;Velayoudom FL;Al Ghuzlan A;Schlumberger M;Buffet C;Borget I","Leboulleux, Sophie;Bournaud, Claire;Chougnet, Cecile N;Lamartina, Livia;Zerdoud, Slimane;Do Cao, Christine;Catargi, Bogdan;Dygai, Inna;Kelly, Antony;Barge, Marie-Luce;Vera, Pierre;Rusu, Daniela;Schneegans, Olivier;Roux, Julie;Raymond, Perrine;Benisvy, Danielle;Eberle, Marie-Claude;Bidault, Sophie;Nascimento, Camila;Bastie, Delphine;Giraudet, Anne-Laure;Bardet, Stéphane;Le Moullec, Nathalie;Roudaut, Nathalie;Drui, Delphine;Godbert, Yann;Zalzali, Mohamad;Drutel, Anne;Morel, Olivier;Velayoudom, Fritz-Line;Al Ghuzlan, Abir;Schlumberger, Martin;Buffet, Camille;Borget, Isabelle","Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.","The lancet. Diabetes & endocrinology","England","eng","Clinical Trial, Phase III","","Adult;Female;Humans;Male;Middle Aged;Follow-Up Studies;Iodine Radioisotopes;Prospective Studies;Thyroglobulin;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome","Adult;Female;Humans;Male;Middle Aged;Follow-Up Studies;Iodine Radioisotopes;Prospective Studies;Thyroglobulin;Thyroid Neoplasms;Thyroidectomy;Treatment Outcome","ESTIMABL2, a multicentre randomised phase 3 trial in patients with low-risk differentiated thyroid cancer (ie, pT1am or pT1b, N0 [no evidence of regional nodal involvement] or Nx [involvement of regional lymph nodes that cannot be assessed in the absence of neck dissection]), showed the non-inferiority of a follow-up strategy without radioactive iodine ( I) administration compared with a postoperative  I administration at 3 years post-randomisation. Here, we report a pre-specified analysis after 5 years of follow-up. Patients treated with total thyroidectomy with or without prophylactic neck lymph node dissection, without postoperative suspicious findings on neck ultrasonography, were randomly assigned to the no-radioiodine group or to the radioiodine group (1·1 GBq-30 mCi after recombinant human thyrotropin-stimulating hormone). Follow-up consisted of annual thyroglobulin and thyroglobulin antibody determinations during levothyroxine treatment and neck ultrasonography in odd-numbered years. An event was defined as abnormal foci of  I uptake on the post-treatment whole-body-scan requiring subsequent treatment, abnormal neck ultrasonography, elevated thyroglobulin levels, increasing titres or appearance of thyroglobulin antibody (using the same laboratory assay), or a combination of these definitions. Non-inferiority of the proportion of patients without an event in one group compared with the other at 5 years after randomisation was shown if this proportion and its CI did not differ by more than -5%. This study was registered on ClinicalTrials.gov (NCT01837745) and is completed. Of the 776 patients (n=642 [82·7%] female and n=134 [17·3%] male, median age 52·9 years [IQR 42·6-63·1]) enrolled, 698 were evaluable at 5 years. The proportions of patients without events were 93·2% in the no-radioiodine group and 94·8% in the radioiodine group, for a difference of -1·6% (90% CI -4·5 to 1·4). Events consisted of structural or functional abnormalities (n=11) and biological abnormalities (n=31). The non-inferiority of a follow-up strategy compared with postoperative  I administration in low risk differentiated thyroid cancer was confirmed at 5 years. There is no loss of opportunity in following these patients without postoperative ablation. Programme de Recherche Hospitalier Clinique.","Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Department of Endocrinology and Diabetology, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva;Department of Nuclear Medicine, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.;Department of Endocrine Oncology, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France.;Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Nuclear Medicine, Nuclear Oncology, and Thyroid Oncology, IUCT Oncopole Toulouse-Institut Claudius Regaud, Toulouse, France.;Department of Endocrinology, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Department of Endocrinology-Metabolic Diseases, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, France.;Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Centre Henri Becquerel and Laboratoire QUANTif, Rouen, France.;Department of Nuclear Medicine, Centre René Gauducheau, Saint Herblain, France.;Department of Nuclear Medicine, Centre Paul Strauss, Strasbourg, France.;Department of Nuclear Medicine, CHU Grenoble-Alpes, Grenoble, France.;Department of Endocrinology, Centre Hospitalier Régional Universitaire de Nancy, Hôpitaux de Brabois, Vandoeuvre Les Nancy, France.;Department of Nuclear Medicine, Antoine Lacassagne, Nice, France.;Department of Nuclear Medicine, Institut du Cancer de Montpellier, Institut Régional du Cancer Val d'Aurelle, Montpellier, France.;Department of Radiology, Gustave Roussy, Paris, France.;Department of Nuclear Medicine, Nuclear Oncology, and Thyroid Oncology, IUCT Oncopole Toulouse-Institut Claudius Regaud, Toulouse, France; Department of Nuclear Medicine, Institut Curie Site Saint-Cloud, Saint-Cloud, France.;Department of Nuclear Medicine, CHU Rangueil Toulouse, France.;Department of Nuclear Medicine, Centre Léon Bérard, Lyon, France.;Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France.;Department of Endocrinology, CHU Saint Pierre, Saint Pierre, France.;Department of Endocrinology, CHU La Cavale Blanche, Brest, France.;Department of Endocrinology, L'institut du thorax, CHU de Nantes-Hopital Laennec Saint-Herblain, Nantes, France.;Department of Thyroid Oncology and Nuclear Medicine, Institut Bergonié, Bordeaux, France.;Thyroid Unit, Institut Jean Godinot, Reims, France.;Department of Endocrinology, CHU Dupuytren, Limoges, France.;Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Endocrinology, CHU de Guadeloupe, Hôpital Ricou, Les Abymes, France.;Department of Medical Biology and Pathology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Thyroid and Endocrine Tumors, Pitié-Salpêtrière Hospital, Paris, France; Thyroid Tumors Clinical Research Group 16, Sorbonne University, Cancer Institute, Inserm U1146, CNRS UMR 7371, Paris, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France.","NA",0,"2213-8595","Lancet Diabetes Endocrinol","Lancet Diabetes Endocrinol",2024,"2025","13","10.1016/S2213-8587(24)00276-6","38-46","","","39586309","39586309","PUBMED","Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Department of Endocrinology and Diabetology, Hôpitaux Universitaires de Genève, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva;Department of Nuclear Medicine, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.;Department of Endocrine Oncology, Assistance Publique-Hôpitaux de Paris Hôpital Saint-Louis, Paris, France.;Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Nuclear Medicine, Nuclear Oncology, and Thyroid Oncology, IUCT Oncopole Toulouse-Institut Claudius Regaud, Toulouse, France.;Department of Endocrinology, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Department of Endocrinology-Metabolic Diseases, Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Department of Nuclear Medicine, Centre Georges François Leclerc, Dijon, France.;Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Centre Henri Becquerel and Laboratoire QUANTif, Rouen, France.;Department of Nuclear Medicine, Centre René Gauducheau, Saint Herblain, France.;Department of Nuclear Medicine, Centre Paul Strauss, Strasbourg, France.;Department of Nuclear Medicine, CHU Grenoble-Alpes, Grenoble, France.;Department of Endocrinology, Centre Hospitalier Régional Universitaire de Nancy, Hôpitaux de Brabois, Vandoeuvre Les Nancy, France.;Department of Nuclear Medicine, Antoine Lacassagne, Nice, France.;Department of Nuclear Medicine, Institut du Cancer de Montpellier, Institut Régional du Cancer Val d'Aurelle, Montpellier, France.;Department of Radiology, Gustave Roussy, Paris, France.;Department of Nuclear Medicine, Nuclear Oncology, and Thyroid Oncology, IUCT Oncopole Toulouse-Institut Claudius Regaud, Toulouse, France; Department of Nuclear Medicine, Institut Curie Site Saint-Cloud, Saint-Cloud, France.;Department of Nuclear Medicine, CHU Rangueil Toulouse, France.;Department of Nuclear Medicine, Centre Léon Bérard, Lyon, France.;Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France.;Department of Endocrinology, CHU Saint Pierre, Saint Pierre, France.;Department of Endocrinology, CHU La Cavale Blanche, Brest, France.;Department of Endocrinology, L'institut du thorax, CHU de Nantes-Hopital Laennec Saint-Herblain, Nantes, France.;Department of Thyroid Oncology and Nuclear Medicine, Institut Bergonié, Bordeaux, France.;Thyroid Unit, Institut Jean Godinot, Reims, France.;Department of Endocrinology, CHU Dupuytren, Limoges, France.;Department of Nuclear Medicine, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Endocrinology, CHU de Guadeloupe, Hôpital Ricou, Les Abymes, France.;Department of Medical Biology and Pathology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France.;Department of Thyroid and Endocrine Tumors, Pitié-Salpêtrière Hospital, Paris, France; Thyroid Tumors Clinical Research Group 16, Sorbonne University, Cancer Institute, Inserm U1146, CNRS UMR 7371, Paris, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, Paris, France; University Paris-Saclay, Paris, France; Office of Biostatistics and Epidemiology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Inserm, Université Paris-Saclay, CESP U1018, Oncostat, labelled Ligue Contre le Cancer, Villejuif, France."
"29","Calvo J;Naguibneva I;Kypraios A;Gilain F;Uzan B;Gaillard B;Bellenger L;Renou L;Antoniewski C;Lapillonne H;Petit A;Ballerini P;Mancini SJ;Marchand T;Peyron JF;Pflumio F","Calvo, Julien;Naguibneva, Irina;Kypraios, Anthony;Gilain, Florian;Uzan, Benjamin;Gaillard, Baptiste;Bellenger, Lea;Renou, Laurent;Antoniewski, Christophe;Lapillonne, Helene;Petit, Arnaud;Ballerini, Paola;Mancini, Stéphane Jc;Marchand, Tony;Peyron, Jean-François;Pflumio, Françoise","High CD44 expression and enhanced E-selectin binding identified as biomarkers of chemoresistant leukemic cells in human T-ALL.","Leukemia","England","eng","Journal Article","","Humans;Hyaluronan Receptors;Drug Resistance, Neoplasm;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Biomarkers, Tumor;E-Selectin;Tumor Microenvironment;Prognosis","Humans;Hyaluronan Receptors;Drug Resistance, Neoplasm;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;Biomarkers, Tumor;E-Selectin;Tumor Microenvironment;Prognosis","T-cell acute lymphoblastic leukemia (T-ALL) is a hematopoietic malignancy characterized by increased proliferation and incomplete maturation of T-cell progenitors, for which relapse is often of poor prognosis. To improve patient outcomes, it is critical to understand the chemoresistance mechanisms arising from cell plasticity induced by the bone marrow (BM) microenvironment. Single-cell RNA sequencing of human T-ALL cells from adipocyte-rich and adipocyte-poor BM revealed a distinct leukemic cell population defined by quiescence and high CD44 expression (Ki67 CD44 ). During in vivo treatment, these cells evaded chemotherapy, and were further called Chemotherapy-resistant Leukemic Cells (CLCs). Patient sample analysis revealed Ki67 CD44  CLCs at diagnosis and during relapse, with each displaying a specific transcriptomic signature. Interestingly, CD44  expression in T-ALL Ki67  CLCs was associated with E-selectin binding. Analysis of 39 human T-ALL samples revealed significantly enhanced E-selectin binding activity in relapse/refractory samples compared with drug-sensitive samples. These characteristics of chemoresistant T-ALL CLCs provide key insights for prognostic stratification and novel therapeutic options.","Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;ARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.;ARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Université Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.;Université Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.;Service d'hématologie Clinique, Centre Hospitalier Universitaire de Rennes, 35003, Rennes, France.;Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.","NA",0,"1476-5551","Leukemia","Leukemia",2024,"2025","39","10.1038/s41375-024-02473-7","323-336","","","39580584","39580584","PUBMED","Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;ARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France.;ARTbio Bioinformatics Analysis Facility, IBPS, CNRS, Sorbonne Université, Institut Français de Bioinformatique, 75005, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne University, AP-HP, Laboratory of Hematology, Armand-Trousseau Hospital, 75012, Paris, France.;Sorbonne Université, Centre de Recherche Saint-Antoine UMR_S938, Pediatric Hematology Oncology Unit, AP-HP, Armand-Trousseau Hospital, 75012, Paris, France.;Université Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.;Université Rennes, EFS, Inserm, MOBIDIC-UMR_S 1236, F-35000, Rennes, France.;Service d'hématologie Clinique, Centre Hospitalier Universitaire de Rennes, 35003, Rennes, France.;Université Côte d'Azur, Centre Méditerranéen de Médecine Moléculaire (C3M), INSERM U1065, 06204, Nice, France.;Université Paris Cité, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Université Paris-Saclay, Inserm, CEA, Stabilité Génétique Cellules Souches et Radiations, iRCM/SGCSR/Laboratoire des cellules Souches Hématopoïétiques et des Leucémies (LSHL), F-92260, Fontenay-aux-Roses, France.;Laboratoire des cellules Souches Hématopoïétiques et des Leucémies, Equipe Niche et Cancer dans l'Hématopoïèse, équipe labellisée Ligue Nationale Contre le Cancer, Unité Mixte de Recherche (UMR) 1274-E008, Inserm, CEA, 92265, Fontenay-aux Roses, France.;OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Paris, France."
"30","Meyer C;Huger S;Bruand M;Leroy T;Palisson J;Rétif P;Sarrade T;Barateau A;Renard S;Jolnerovski M;Demogeot N;Marcel J;Martz N;Stefani A;Sellami S;Jacques J;Agnoux E;Gehin W;Trampetti I;Margulies A;Golfier C;Khattabi Y;Cravéreau O;Renan A;Py JF;Faivre JC","Meyer, Céline;Huger, Sandrine;Bruand, Marie;Leroy, Thomas;Palisson, Jérémy;Rétif, Paul;Sarrade, Thomas;Barateau, Anais;Renard, Sophie;Jolnerovski, Maria;Demogeot, Nicolas;Marcel, Johann;Martz, Nicolas;Stefani, Anaïs;Sellami, Selima;Jacques, Juliette;Agnoux, Emma;Gehin, William;Trampetti, Ida;Margulies, Agathe;Golfier, Constance;Khattabi, Yassir;Cravéreau, Olivier;Renan, Alizée;Py, Jean-François;Faivre, Jean-Christophe","Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas.","Radiation oncology (London, England)","England","eng","Journal Article","","Humans;Organs at Risk;Artificial Intelligence;Female;Male;Lymph Nodes;Radiotherapy Planning, Computer-Assisted;Adult;Child;Tomography, X-Ray Computed;Magnetic Resonance Imaging;Software","Humans;Organs at Risk;Artificial Intelligence;Female;Male;Lymph Nodes;Radiotherapy Planning, Computer-Assisted;Adult;Child;Tomography, X-Ray Computed;Magnetic Resonance Imaging;Software","The delineation of organs-at-risk and lymph node areas is a crucial step in radiotherapy, but it is time-consuming and associated with substantial user-dependent variability in contouring. Artificial intelligence (AI) appears to be the solution to facilitate and standardize this work. The objective of this study is to compare eight available AI software programs in terms of technical aspects and accuracy for contouring organs-at-risk and lymph node areas with current international contouring recommendations. From January-July 2023, we performed a blinded study of the contour scoring of the organs-at-risk and lymph node areas by eight self-contouring AI programs by 20 radiation oncologists. It was a single-center study conducted in radiation department at the Lorraine Cancer Institute. A qualitative analysis of technical characteristics of the different AI programs was also performed. Three adults (two women and one man) and three children (one girl and two boys) provided six whole-body anonymized CT scans, along with two other adult brain MRI scans. Using a scoring scale from 1 to 3 (best score), radiation oncologists blindly assessed the quality of contouring of organs-at-risk and lymph node areas of all scans and MRI data by the eight AI programs. We have chosen to define the threshold of an average score equal to or greater than 2 to characterize a high-performing AI software, meaning an AI with minimal to moderate corrections but usable in clinical routine. For adults CT scans: There were two AI programs for which the overall average quality score (that is, all areas tested for OARs and lymph nodes) was higher than 2.0: Limbus (overall average score = 2.03 (0.16)) and MVision (overall average score = 2.13 (0.19)). If we only consider OARs for adults, only Limbus, Therapanacea, MVision and Radformation have an average score above 2. For children CT scan, MVision was the only program to have a average score higher than 2 with overall average score = 2.07 (0.19). If we only consider OARs for children, only Limbus and MVision have an average score above 2. For brain MRIs: TheraPanacea was the only program with an average score over 2, for both brain delineation (2.75 (0.35)) and OARs (2.09 (0.19)). The comparative analysis of the technical aspects highlights the similarities and differences between the software. There is no difference in between senior radiation oncologist and residents for OARs contouring. For adult CT-scan, two AI programs on the market, MVision and Limbus, delineate most OARs and lymph nodes areas that are useful in clinical routine. For children CT-scan, only one IA, MVision, program is efficient. For adult brain MRI, Therapancea,only one AI program is efficient. CNIL-MR0004 Number HDH434.","Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Medical Physics Department, Institut de Cancérologie de Lorraine - Alexis-Vautrin, Vandœuvre-Lès-Nancy, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Radiation department, Clinique Les Dentelières, Valenciennes, France.;Medical Physics Department, Centre de la Baie, Avranches, France.;Medical Physics Department, CHR Metz-Thionville, Metz, France.;Radiation Department, AP-HP, Hôpital Tenon, Paris, France.;Medical Physics Department, Centre Eugène Marquis, Rennes, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex","NA",0,"1748-717X","Radiat Oncol","Radiat Oncol",2024,"2024","19","10.1186/s13014-024-02554-y","168","","","39574153","39574153","PUBMED","Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Medical Physics Department, Institut de Cancérologie de Lorraine - Alexis-Vautrin, Vandœuvre-Lès-Nancy, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Radiation department, Clinique Les Dentelières, Valenciennes, France.;Medical Physics Department, Centre de la Baie, Avranches, France.;Medical Physics Department, CHR Metz-Thionville, Metz, France.;Radiation Department, AP-HP, Hôpital Tenon, Paris, France.;Medical Physics Department, Centre Eugène Marquis, Rennes, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex, France.;Academic Department of Radiation Therapy & Brachytherapy, Institut de Cancérologie de Lorraine - Alexis-Vautrin CLCC - Unicancer, 6 avenue de Bourgogne - CS 30 519, 54 511, Vandoeuvre-Lès-Nancy Cedex"
"31","Guillin R;Ract I;Pesquer L;Drakonaki E","Guillin, Raphaël;Ract, Isabelle;Pesquer, Lionel;Drakonaki, Elena","Ultrasound Spot Diagnosis of Common Benign Subcutaneous Masses and Pseudomasses: What the Radiologist Needs to Know.","Seminars in musculoskeletal radiology","United States","eng","Journal Article","","Humans;Ultrasonography;Diagnosis, Differential;Subcutaneous Tissue;Soft Tissue Neoplasms;Epidermal Cyst","Humans;Ultrasonography;Diagnosis, Differential;Subcutaneous Tissue;Soft Tissue Neoplasms;Epidermal Cyst","Common benign subcutaneous benign masses and pseudomasses represent a wide spectrum of masses among which lipomas and epidermal cysts account for a vast majority of the lesions encountered in routine practice. Other types of tumors originate from various components of the skin, such as the pilous tract, nerves, veins, arteries, or eccrine glands. In some instances, pseudomasses may be distinguished from tumoral masses using specific signs. When the diagnosis of a subcutaneous lesion lacks specificity for benignity with ultrasound, radiologists should ensure proper management of the patient to rule out the possibility of a rare but possible sarcoma of the subcutaneous layer.","Department of Musculoskeletal Imaging, Centre Hospitalier Universitaire de Rennes, Rennes CEDEX, France.;Department of Musculoskeletal Imaging, Centre Hospitalier Universitaire de Rennes, Rennes CEDEX, France.;Department of Imaging, Clinique du Sport de Bordeaux Mérignac, Mérignac, France.;Department of Anatomy, Medical School, University of Crete, Heraklion, Crete, Greece.;Diagnostic and Interventional Ultrasound Practice, Heraklion, Crete, Greece.","NA",0,"1098-898X","Semin Musculoskelet Radiol","Semin Musculoskelet Radiol",2024,"2024","28","10.1055/s-0044-1791494","749-757","","","39561756","39561756","PUBMED","Department of Musculoskeletal Imaging, Centre Hospitalier Universitaire de Rennes, Rennes CEDEX, France.;Department of Musculoskeletal Imaging, Centre Hospitalier Universitaire de Rennes, Rennes CEDEX, France.;Department of Imaging, Clinique du Sport de Bordeaux Mérignac, Mérignac, France.;Department of Anatomy, Medical School, University of Crete, Heraklion, Crete, Greece.;Diagnostic and Interventional Ultrasound Practice, Heraklion, Crete, Greece."
"32","Le Guévelou J;Nicosia L;Blanchard P;Ralite F;Durand X;Marchesi V;Roubaud G;Sargos P","Le Guévelou, Jennifer;Nicosia, Luca;Blanchard, Pierre;Ralite, Flavien;Durand, Xavier;Marchesi, Vincent;Roubaud, Guilhem;Sargos, Paul","Radiation therapy for stage IIA/IIB seminomas: Back to the future?","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","Chemotherapy;Germ cell tumor;Protontherapy;Radio-induced malignancy;Radiotherapy;Seminoma","Humans;Male;Neoplasm Staging;Seminoma;Testicular Neoplasms","Humans;Male;Neoplasm Staging;Seminoma;Testicular Neoplasms","Seminoma is a highly curable disease; therefore, long-term morbidity of oncological treatment represents a crucial stake. In view of the considerable advances made in radiotherapy in the past decade, we aim to shed light on current and future strategies that hold promises for the management of stage II seminoma.","Department of Radiotherapy, Centre Eugène Marquis, Rennes;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.;Department of Radiotherapy, Institut Bergonié, Bordeaux, France.;Department of Urology, Hopital Saint Joseph, Paris, France.;Department of Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Radiotherapy, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France.","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2024,"2025","202","10.1016/j.radonc.2024.110626","110626","","","39557127","39557127","PUBMED","Department of Radiotherapy, Centre Eugène Marquis, Rennes;Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, Italy.;Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.;Department of Radiotherapy, Institut Bergonié, Bordeaux, France.;Department of Urology, Hopital Saint Joseph, Paris, France.;Department of Radiotherapy, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Radiotherapy, Institut Bergonié, Bordeaux, France; Centre de Radiothérapie Charlebourg, La Défense, Groupe Amethyst, 65, avenue Foch, 92250 La Garenne-Colombes, France."
"33","Favier M;Brischoux-Boucher E;Pyle LC;Mottet N;Auber-Lenoir M;Cattin J;Dahlen E;Cabrol C;Arbez-Gindre F;Attié-Bitach T;Boute O;Devisme L;Trost D;Boughalem A;Chitayat D;Prasov L;Chorin O;Rein-Rothschild A;Kassif E;Weissbach T;Hendon LG;Adam MP;Quelin C;Jaillard S;Mary L;Aukema SM;Heijligers M;de Die-Smulders C;Stegmann S;Badalato L;Ben-Yehuda A;Beneteau C;Forey PL;Kuentz P;Piard J","Favier, Maud;Brischoux-Boucher, Elise;Pyle, Louise C;Mottet, Nicolas;Auber-Lenoir, Marion;Cattin, Julie;Dahlen, Eric;Cabrol, Christelle;Arbez-Gindre, Francine;Attié-Bitach, Tania;Boute, Odile;Devisme, Louise;Trost, Detlef;Boughalem, Aicha;Chitayat, David;Prasov, Lev;Chorin, Odelia;Rein-Rothschild, Annick;Kassif, Eran;Weissbach, Tal;Hendon, Laura Godfrey;Adam, Margaret P;Quelin, Chloé;Jaillard, Sylvie;Mary, Laura;Aukema, Sietse M;Heijligers, Malou;de Die-Smulders, Christine;Stegmann, Sander;Badalato, Lauren;Ben-Yehuda, Adi;Beneteau, Claire;Forey, Pierre-Louis;Kuentz, Paul;Piard, Juliette","Fetal Presentation of MYRF-Related Cardiac Urogenital Syndrome: An Emerging and Challenging Prenatal Diagnosis.","Prenatal diagnosis","England","eng","Journal Article","","Humans;Female;Pregnancy;Heart Defects, Congenital;Urogenital Abnormalities;Male;Ultrasonography, Prenatal;Adult;Prenatal Diagnosis;Infant, Newborn","Humans;Female;Pregnancy;Heart Defects, Congenital;Urogenital Abnormalities;Male;Ultrasonography, Prenatal;Adult;Prenatal Diagnosis;Infant, Newborn","MYRF-related cardiac-urogenital syndrome (MYRF-CUGS) is a rare condition associated with heterozygous MYRF variants. The description of MYRF-CUGS phenotype is mostly based on postnatal cases and 36 affected individuals have been published so far. We aim now to delineate the prenatal phenotype of MYRF-CUGS by reporting clinical data from fetuses and neonates with a pathogenic MYRF variant. Detailed radiographic, pathological, clinical, and molecular data from 12 prenatal cases were collected through an international collaborative study. Adding the five fetuses previously published, we were able to study a cohort of 17 cases. Main ultrasound-accessible manifestations of MYRF-CUGS include congenital heart defects (13/17, 76%), congenital diaphragmatic hernia (10/17, 59%) and disorders of sexual differentiation in 46, XY fetuses (7/14; 50%). Postnatal examination and/or autopsy data highlighted additional birth defects and neurological findings with a large spectrum of severity. Molecular results revealed ten previously unpublished variants, one missense and nine predicted truncating variants (three frameshift, three nonsense and three splice site variants). We report the first prenatal cohort of MYRF-CUGS, allowing us to further characterize the variable expressivity of this rare disorder in fetuses. Severe congenital anomalies with a poor prognosis are more frequent than previously described in postnatal cases. Our data suggest that MYRF-CUGS is characterized by a recurrent recognizable malformative association, accessible to prenatal diagnosis, with a significant intrafamilial phenotypic variability making genetic counseling challenging.","Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département de Radiologie, Imagerie pédiatrique, prénatale et sénologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Anatomie et cytologie pathologiques, Foetopathologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Laboratoire de biologie médicale multisites SeqOIA, Assistance Publique Hôpitaux de Paris, Paris, France.;Institut Imagine, INSERM U1163, Université Paris Descartes, Paris, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Mount Sinai Hospital, University of Toronto, Toronto, Canada.;Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.;Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;Mississippi Medical Center, Jackson, Mississippi, USA.;Division of Genetic Medicine, Seattle Children's Hospital, Seattle, Washington, USA.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Medical Genetics, Carl von Ossietzky University, Oldenburg, Germany.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Pediatrics, Kingstone General Hospital, Queen's University, Kingston, Canada.;Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Grenoble, Université de Grenoble, Grenoble, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.","NA",0,"1097-0223","Prenat Diagn","Prenat Diagn",2024,"2024","44","10.1002/pd.6700","1647-1658","K08 EY032098","NEI NIH HHS","39542847","39542847","PUBMED","Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département de Radiologie, Imagerie pédiatrique, prénatale et sénologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Anatomie et cytologie pathologiques, Foetopathologie, Centre Hospitalier Universitaire de Besançon, Université de Bourgogne Franche-Comté, Besançon, France.;Laboratoire de biologie médicale multisites SeqOIA, Assistance Publique Hôpitaux de Paris, Paris, France.;Institut Imagine, INSERM U1163, Université Paris Descartes, Paris, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Pôle de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille, Lille, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Génétique et Cytogénétique, Laboratoire Cerba, Saint-Ouen l'Aumône, Paris, France.;Mount Sinai Hospital, University of Toronto, Toronto, Canada.;Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.;Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;Institute of Rare Diseases, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;School of Medicine, Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.;Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel.;Mississippi Medical Center, Jackson, Mississippi, USA.;Division of Genetic Medicine, Seattle Children's Hospital, Seattle, Washington, USA.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Medical Genetics, Carl von Ossietzky University, Oldenburg, Germany.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.;Department of Pediatrics, Kingstone General Hospital, Queen's University, Kingston, Canada.;Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.;SoFFoet - Société Française de Foetopathologie, Paris, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Département d'Obstétrique et de Gynécologie, Centre Hospitalier Universitaire de Grenoble, Université de Grenoble, Grenoble, France.;Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, Oncobiologie Génétique Bioinformatique, FHU-TRANSLAD et Institut GIMI, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France.;Centre de Génétique Humaine, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Besançon, France.;Université de Bourgogne, INSERM UMR1231 GAD ""Génétique des Anomalies du Développement"", Dijon, France."
"34","Macaire C;Lefevre W;Dalac S;Montaudié H;Legoupil D;Dereure O;Dutriaux C;Leccia MT;Aubin F;Grob JJ;Saiag P;De Quatrebarbes J;Maubec E;Lesimple T;Granel-Brocard F;Mortier L;Dalle S;Lebbé C;Prod'homme C","Macaire, Camille;Lefevre, Wendy;Dalac, Sophie;Montaudié, Henri;Legoupil, Delphine;Dereure, Olivier;Dutriaux, Caroline;Leccia, Marie Thérèse;Aubin, François;Grob, Jean Jacques;Saiag, Philippe;De Quatrebarbes, Julie;Maubec, Eve;Lesimple, Thierry;Granel-Brocard, Florence;Mortier, Laurent;Dalle, Stéphane;Lebbé, Céleste;Prod'homme, Chloé","Real-life effectiveness on overall survival of continued immune checkpoint inhibition following progression in advanced melanoma: estimation from the Melbase cohort.","Melanoma research","England","eng","Journal Article","","Humans;Melanoma;Immune Checkpoint Inhibitors;Male;Female;Disease Progression;Aged;Skin Neoplasms;Middle Aged;Cohort Studies;Adult;Aged, 80 and over","Humans;Melanoma;Immune Checkpoint Inhibitors;Male;Female;Disease Progression;Aged;Skin Neoplasms;Middle Aged;Cohort Studies;Adult;Aged, 80 and over","The link between palliative care and oncology must continue to develop, taking into account advances in treatment.Immune checkpoint inhibition (ICI) for metastatic melanoma is associated with different types of response, making it difficult to assess the benefits to the patient. Some clinical trials suggest a survival advantage of ICI even in the absence of an objective radiographic response. The aim of this study is to assess the impact of continuing ICI after progression of the disease on the overall survival (OS) in a cohort of final-line metastatic melanoma patients. Clinical data from 120 patients with metastatic melanoma were collected via Melbase, a French multicentric biobank, prospectively enrolling unresectable melanoma. Two groups were defined: patients continuing final-line ICI at progression (treated) and patients stopping ICI at progression (controls). The primary end-point is the OS from progression. Propensity score weighting was used to correct for indication bias. From the 120 patients, 72 (60%) continued ICI. Median OS from progression was 4.2 months [95% confidence interval (CI) 2.6-6.27] in the treated group and median OS was 1.3 months (95% CI 0.95-1.74) in the control group ( P  < 0.0001). The calculated hazard ratio was 0.20 (0.13-0.33). Continued ICI was discovered to have an association with a higher rate of hospitalization at the end of life; more treatments received in the last 15 days of life and less utilization of specialist palliative care. This study discovered that patients with metastatic melanoma show a significant decrease in the instantaneous probability of mortality when they continue with finale-line ICI after progression.","Dermatologie, CHU de Lille, Lille.;Dermatologie, Hôpital Saint-Louis AP-HP, Paris.;Dermatologie, CHU Dijon Bourgogne, Dijon.;Dermatologie, Hôpital l'Archet, Nice.;Dermatologie, CHU de Brest, Brest.;Dermatologie, CHU de Montpellier, Montpellier.;Dermatologie, Hôpital Saint-André, Bordeaux.;Dermatologie, CHU de Grenoble Hôpital Sud Services des urgences, Échirolles.;Dermatologie, Centre hospitalier régional universitaire de Besançon, Besançon.;Dermatologie, Hôpital AP-HM Timone, Université Aix Marseille, Marseille.;Dermatologie, Hôpital Ambroise-Paré AP-HP, Boulogne-Billancourt.;Dermatologie, C.H. Annecy Genevois, Epagny Metz-Tessy.;Dermatologie, Hôpital Avicenne AP-HP, Bobigny.;Oncologie Médicale, Centre Eugène Marquis, Rennes.;Dermatologie, CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy.;Dermatologie, CHU de Lille, Lille.;Dermatologie, Hôpital Lyon-Sud, Lyon.;Dermatologie, Hôpital Saint-Louis AP-HP, Paris.;Soins palliatifs, CHU de Lille, Lille, France.","NA",0,"1473-5636","Melanoma Res","Melanoma Res",2024,"2025","35","10.1097/CMR.0000000000000973","50-59","","","39527777","39527777","PUBMED","Dermatologie, CHU de Lille, Lille.;Dermatologie, Hôpital Saint-Louis AP-HP, Paris.;Dermatologie, CHU Dijon Bourgogne, Dijon.;Dermatologie, Hôpital l'Archet, Nice.;Dermatologie, CHU de Brest, Brest.;Dermatologie, CHU de Montpellier, Montpellier.;Dermatologie, Hôpital Saint-André, Bordeaux.;Dermatologie, CHU de Grenoble Hôpital Sud Services des urgences, Échirolles.;Dermatologie, Centre hospitalier régional universitaire de Besançon, Besançon.;Dermatologie, Hôpital AP-HM Timone, Université Aix Marseille, Marseille.;Dermatologie, Hôpital Ambroise-Paré AP-HP, Boulogne-Billancourt.;Dermatologie, C.H. Annecy Genevois, Epagny Metz-Tessy.;Dermatologie, Hôpital Avicenne AP-HP, Bobigny.;Oncologie Médicale, Centre Eugène Marquis, Rennes.;Dermatologie, CHRU de Nancy - Hôpitaux de Brabois, Vandœuvre-lès-Nancy.;Dermatologie, CHU de Lille, Lille.;Dermatologie, Hôpital Lyon-Sud, Lyon.;Dermatologie, Hôpital Saint-Louis AP-HP, Paris.;Soins palliatifs, CHU de Lille, Lille, France."
"35","de Hoog S;Walsh TJ;Ahmed SA;Alastruey-Izquierdo A;Arendrup MC;Borman A;Chen S;Chowdhary A;Colgrove RC;Cornely OA;Denning DW;Dufresne PJ;Filkins L;Gangneux J-P;Gené J;Groll AH;Guillot J;Haase G;Halliday C;Hawksworth DL;Hay R;Hoenigl M;Hubka V;Jagielski T;Kandemir H;Kidd SE;Kus JV;Kwon-Chung J;Lockhart SR;Meis JF;Mendoza L;Meyer W;Nguyen MH;Song Y;Sorrell TC;Stielow JB;Vilela R;Vitale RG;Wengenack NL;White PL;Ostrosky-Zeichner L;Zhang SX","de Hoog, Sybren;Walsh, Thomas J;Ahmed, Sarah A;Alastruey-Izquierdo, Ana;Arendrup, Maiken Cavling;Borman, Andrew;Chen, Sharon;Chowdhary, Anuradha;Colgrove, Robert C;Cornely, Oliver A;Denning, David W;Dufresne, Philippe J;Filkins, Laura;Gangneux, Jean-Pierre;Gené, Josepa;Groll, Andreas H;Guillot, Jaques;Haase, Gerhard;Halliday, Catriona;Hawksworth, David L;Hay, Roderick;Hoenigl, Martin;Hubka, Vit;Jagielski, Tomasz;Kandemir, Hazal;Kidd, Sarah E;Kus, Julianne V;Kwon-Chung, June;Lockhart, Shawn R;Meis, Jacques F;Mendoza, Leonel;Meyer, Wieland;Nguyen, M Hong;Song, Yinggai;Sorrell, Tania C;Stielow, J Benjamin;Vilela, Rachel;Vitale, Roxana G;Wengenack, Nancy L;White, P Lewis;Ostrosky-Zeichner, Luis;Zhang, Sean X","Nomenclature for human and animal fungal pathogens and diseases: a proposal for standardized terminology.","Journal of clinical microbiology","United States","eng","Journal Article","fungal disease;nomenclature;proposal","Humans;Animals;Terminology as Topic;Fungi;Mycoses;Opportunistic Infections","Humans;Animals;Terminology as Topic;Fungi;Mycoses;Opportunistic Infections","Medically important pathogenic fungi invade vertebrate tissue and are considered primary when part of their nature life cycle is associated with an animal host and are usually able to infect immunocompetent hosts. Opportunistic fungal pathogens complete their life cycle in environmental habitats or occur as commensals within or on the vertebrate body, but under certain conditions can thrive upon infecting humans. The extent of host damage in opportunistic infections largely depends on the portal and modality of entry as well as on the host's immune and metabolic status. Diseases caused by primary pathogens and common opportunists, causing the top approximately 80% of fungal diseases [D. W. Denning, Lancet Infect Dis, 24:e428-e438, 2024, https://doi.org/10.1016/S1473-3099(23)00692-8], tend to follow a predictive pattern, while those by occasional opportunists are more variable. For this reason, it is recommended that diseases caused by primary pathogens and the common opportunists are named after the etiologic agent, for example, histoplasmosis and aspergillosis, while this should not be done for occasional opportunists that should be named as [causative fungus] [clinical syndrome], for example,   cutaneous infection. The addition of a descriptor that identifies the location or clinical type of infection is required, as the general name alone may cover widely different clinical syndromes, for example, ""rhinocerebral mucormycosis."" A list of major recommended human and animal disease entities (nomenclature) is provided in alignment with their causative agents. Fungal disease names may encompass several genera of etiologic agents, consequently being less susceptible to taxonomic changes of the causative species, for example, mucormycosis covers numerous mucormycetous molds.","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Division of Infectious Diseases, Mount Auburn Hospital, and Harvard Medical School, Cambridge, Massachusetts, USA.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Manchester Fungal Infection Group, Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.;Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada.;Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de Référence Aspergilloses chroniques, ECMM Excellence Center in Mycology, Rennes, France.;Unitat de Micologia i Microbiologia Ambiental, Facultat de Medicina i Ciènces de la Salut, Universitat Rovira i Virgili, Reus, Spain.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.;Oniris, VetAgroBio Nantes, IRF, SFR ICAT, Université d'Angers, Angers, France.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Royal Botanic Gardens, Kew, Richmond, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;St. John's Institute of Dermatology, King's College London, London, United Kingdom.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, Medical University of Graz, Graz, Austria.;Department of Botany, Charles University, Prague, Czechia.;Department of Medical Microbiology, University of Warsaw, Warsaw, Poland.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;National Mycology Reference Centre, SA Pathology, Adelaide, Australia.;School of Biological Sciences, Faculty of Sciences Engineering and Technology, University of Adelaide, Adelaide, Australia.;Public Health Ontario Toronto, Toronto, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China.;Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.;Bioinformatics, Helmholtz Institute for One Health, Greifswald, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Hospital JM Ramos Mejía, Buenos Aires, Argentina.;Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;McGovern Medical School, Division of Infectious Diseases, University of Texas Health Science Center, Houston, Texas, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2024,"2024","62","10.1128/jcm.00937-24","e0093724","","","39526838","39526838","PUBMED","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Division of Infectious Diseases, Mount Auburn Hospital, and Harvard Medical School, Cambridge, Massachusetts, USA.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Manchester Fungal Infection Group, Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.;Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Canada.;Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de Référence Aspergilloses chroniques, ECMM Excellence Center in Mycology, Rennes, France.;Unitat de Micologia i Microbiologia Ambiental, Facultat de Medicina i Ciènces de la Salut, Universitat Rovira i Virgili, Reus, Spain.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany.;Oniris, VetAgroBio Nantes, IRF, SFR ICAT, Université d'Angers, Angers, France.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Centre for Infectious Diseases and Microbiology Laboratory Services, Westmead, Australia.;Royal Botanic Gardens, Kew, Richmond, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;St. John's Institute of Dermatology, King's College London, London, United Kingdom.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, Medical University of Graz, Graz, Austria.;Department of Botany, Charles University, Prague, Czechia.;Department of Medical Microbiology, University of Warsaw, Warsaw, Poland.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;National Mycology Reference Centre, SA Pathology, Adelaide, Australia.;School of Biological Sciences, Faculty of Sciences Engineering and Technology, University of Adelaide, Adelaide, Australia.;Public Health Ontario Toronto, Toronto, Canada.;Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne, Germany.;Excellence Center for Medical Mycology, Department I of Internal Medicine, University of Cologne, Cologne, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Department of Dermatology, Peking University First Hospital, Peking University, Beijing, China.;Sydney Infectious Diseases Institute, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.;Bioinformatics, Helmholtz Institute for One Health, Greifswald, Germany.;Microbiology and Molecular Genetics, Biomedical Laboratory Diagnostics, Michigan State University, East Lansing, Michigan, USA.;CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Hospital JM Ramos Mejía, Buenos Aires, Argentina.;Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;McGovern Medical School, Division of Infectious Diseases, University of Texas Health Science Center, Houston, Texas, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA."
"36","Léna H;Greillier L;Cropet C;Bylicki O;Monnet I;Audigier-Valette C;Falchero L;Vergnenègre A;Demontrond P;Geier M;Guisier F;Hominal S;Locher C;Corre R;Chouaid C;Ricordel C","Léna, Hervé;Greillier, Laurent;Cropet, Claire;Bylicki, Olivier;Monnet, Isabelle;Audigier-Valette, Clarisse;Falchero, Lionel;Vergnenègre, Alain;Demontrond, Pierre;Geier, Margaux;Guisier, Florian;Hominal, Stéphane;Locher, Chrystèle;Corre, Romain;Chouaid, Christos;Ricordel, Charles","Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.","The Lancet. Respiratory medicine","England","eng","Journal Article","","Humans;Carcinoma, Non-Small-Cell Lung;Aged;Male;Female;Lung Neoplasms;Carboplatin;Ipilimumab;Nivolumab;Antineoplastic Combined Chemotherapy Protocols;Aged, 80 and over;Treatment Outcome","Humans;Carcinoma, Non-Small-Cell Lung;Aged;Male;Female;Lung Neoplasms;Carboplatin;Ipilimumab;Nivolumab;Antineoplastic Combined Chemotherapy Protocols;Aged, 80 and over;Treatment Outcome","Combined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 or those with an ECOG performance status of 2 are scarce. We aimed to test the superiority of the PD-1 antibody nivolumab and the CTLA-4 antibody ipilimumab over platinum-based doublet chemotherapy as first-line treatment in patients with NSCLC aged 70 years or older or with an ECOG performance status of 2. This open-label, multicentre, randomised, controlled, phase 3 trial was done at 30 hospitals and cancer centres in France. Eligible patients had stage IV histologically proven NSCLC, with no known oncogenic alterations, and were either aged 70 years or older with ECOG performance status of 0-2 or younger than 70 years with an ECOG performance status of 2. Patients were randomly assigned (1:1) centrally, using a computer-generated algorithm stratified by age (<70 vs ≥70 years), ECOG performance status (0-1 vs 2), and histology (squamous vs non-squamous) to receive nivolumab plus ipilimumab or platinum-based doublet chemotherapy (carboplatin [area under the curve ≤700 mg] plus pemetrexed [500 mg/m  intravenous infusion every 3 weeks] or carboplatin [on day 1; area under the curve ≤700 mg] plus paclitaxel [90 mg/m  as intravenous infusion on days 1, 5, and 15, every 4 weeks]). The primary endpoint was overall survival; secondary endpoints included progression-free survival and safety. All efficacy analyses were performed in the intention-to-treat population, which included all randomly assigned patients. Safety was analysed in the safety analysis set, which included all randomly assigned patients who received at least one dose of study treatment and who had at least one safety follow-up. The trial is registered with ClinicalTrials.gov, NCT03351361. The trial was stopped early for futility on the basis of a pre-planned interim analysis after 33% of the expected events had occurred. Between Feb 12, 2018, and Dec 15, 2020, 217 patients were randomly assigned, of whom 216 patients were included in the final analysis, with 109 patients in the nivolumab plus ipilimumab group and 107 in the chemotherapy group; median age was 74 years (IQR 70-78). Median overall survival was 14·7 months (95% CI 8·0-19·7) in the nivolumab plus ipilimumab group and 9·9 months (7·7-12·3) in chemotherapy group (hazard ratio [HR] 0·85 [95% CI 0·62-1·16]). Among patients aged 70 years or older with an ECOG performance status of 0-1 (median age 76 years [IQR 73-79]), median overall survival was longer in the nivolumab plus ipilimumab group than the chemotherapy group: 22·6 months (95% CI 18·1-36·0) versus 11·8 months (8·9-20·5; HR 0·64 [95% CI 0·46-0·96]). Among patients with an ECOG performance status of 2 (median age 69 years [IQR 63-75]), median overall survival was 2·9 months (95% CI 1·4-4·8) in the nivolumab plus ipilimumab group versus 6·1 months (3·5-10·4) in the chemotherapy group (HR 1·32 [95% CI 0·82-2·11]). No new safety signals were reported. The most frequent grade 3 or worse adverse events were neutropenia (28 [27%] of 103 patients) in the chemotherapy group and endocrine disorders (five [5%] of 105 patients), cardiac disorders (ten [10%] patients), and gastrointestinal disorders (11 [11%] patients) in the nivolumab plus ipilimumab group. The study showed no benefit of nivolumab plus ipilimumab combination in the overall study population. As a result of early stopping, the trial was underpowered for primary and secondary endpoints; however, the finding of better survival with nivolumab plus ipilimumab compared with platinum doublet in the subgroup of older patients with NSCLC with an ECOG performance status of 0-1 warrants further study. Bristol-Myers Squibb.","Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Université Rennes 1, INSERM, UMR_S 1242, Centre Eugène Marquis, Rennes;Multidisciplinary Oncology and Therapeutic Innovations, Aix-Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.;Unité de Biostatistique-Direction de la Recherche et de l'Innovation, Centre Léon Bérard, Lyon, France.;Hôpital d'Instruction des Armées Desgenettes, Lyon, France.;Service de Pneumologie, Centre Hospitalier Intercommunal Créteil, Créteil, France.;Service de Pneumologie, Orientation Oncologique, Hôpital Sainte-Musse, Toulon, France.;Service de Pneumologie et Cancérologie Thoracique, Hôpitaux Nord-Ouest, Villefranche sur Saône, France.;Unité d'Oncologie Thoracique, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Centre de Lutte Contre le Cancer François Baclesse, Caen, France.;Institut de Cancérologie et Imagerie, Hopital Cavale Blanche Centre Hospitalier Universitaire Brest, Brest, France.;Service de Pneumologie, Centre Hospitalier Universitaire Rouen, Rouen, France.;Service de Pneumologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Pneumologie, Grand Hôpital de l'Est Francilien (Meaux), Meaux, France.;Centre Hospitalier de Cornouaille, Service de Pneumologie, Quimper, France.;Service de Pneumologie, Centre Hospitalier Intercommunal Créteil, Créteil, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Université Rennes 1, INSERM, UMR_S 1242, Centre Eugène Marquis, Rennes, France.","NA",0,"2213-2619","Lancet Respir Med","Lancet Respir Med",2024,"2025","13","10.1016/S2213-2600(24)00264-9","141-152","","","39486424","39486424","PUBMED","Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Université Rennes 1, INSERM, UMR_S 1242, Centre Eugène Marquis, Rennes;Multidisciplinary Oncology and Therapeutic Innovations, Aix-Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, France.;Unité de Biostatistique-Direction de la Recherche et de l'Innovation, Centre Léon Bérard, Lyon, France.;Hôpital d'Instruction des Armées Desgenettes, Lyon, France.;Service de Pneumologie, Centre Hospitalier Intercommunal Créteil, Créteil, France.;Service de Pneumologie, Orientation Oncologique, Hôpital Sainte-Musse, Toulon, France.;Service de Pneumologie et Cancérologie Thoracique, Hôpitaux Nord-Ouest, Villefranche sur Saône, France.;Unité d'Oncologie Thoracique, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Centre de Lutte Contre le Cancer François Baclesse, Caen, France.;Institut de Cancérologie et Imagerie, Hopital Cavale Blanche Centre Hospitalier Universitaire Brest, Brest, France.;Service de Pneumologie, Centre Hospitalier Universitaire Rouen, Rouen, France.;Service de Pneumologie, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Pneumologie, Grand Hôpital de l'Est Francilien (Meaux), Meaux, France.;Centre Hospitalier de Cornouaille, Service de Pneumologie, Quimper, France.;Service de Pneumologie, Centre Hospitalier Intercommunal Créteil, Créteil, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Université Rennes 1, INSERM, UMR_S 1242, Centre Eugène Marquis, Rennes, France."
"37","Becker O;Durand A;Chevrier M;Collet L;Gladieff L;Joly F;Sauterey B;Pomel C;Costaz H;Pautier P;Guillemet C;de la Motte Rouge T;Sabatier R;Classe JM;Petit T;Leblanc E;Marchal F;Colombo PE;Barranger E;Savoye AM;Bosquet L;Ray-Coquard I;Carton M;Colomban O;You B;Rodrigues M","Becker, Ondine;Durand, Alice;Chevrier, Marion;Collet, Laetitia;Gladieff, Laurence;Joly, Florence;Sauterey, Baptiste;Pomel, Christophe;Costaz, Hélène;Pautier, Patricia;Guillemet, Cécile;de la Motte Rouge, Thibault;Sabatier, Renaud;Classe, Jean-Marc;Petit, Thierry;Leblanc, Eric;Marchal, Frédéric;Colombo, Pierre-Emmanuel;Barranger, Emmanuel;Savoye, Aude-Marie;Bosquet, Lise;Ray-Coquard, Isabelle;Carton, Matthieu;Colomban, Oliver;You, Benoit;Rodrigues, Manuel",NA,"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","England","eng","Journal Article","BRCA1 Protein;BRCA2 Protein;Carboplatin;Ovarian Cancer","","","Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator of tumor primary chemosensitivity. Although it is well established that   mutations are associated with platinum sensitivity, the relationship between   status and KELIM score has yet to be elucidated. This study aimed to evaluate the interactions between   and KELIM, and their respective prognostic values. We retrospectively collected data from 743 patients with high-grade serous ovarian carcinomas included in a French nationwide registry (NCT03275298) treated with neoadjuvant platinum-based chemotherapy followed by surgery. We analyzed the interactions between   and KELIM, and their impacts on progression-free survival and overall survival. -mutated  m) patients had higher standardized KELIM than  -wild type ( wt) tumors (median 1.16 vs 1.06, respectively; p=0.001). The prognostic value of the KELIM score was independent of   in multivariate analyses. KELIM score and   could be combined to define three prognostic groups: (1) an unfavorable prognostic group with both  wt and unfavorable KELIM (median progression-free survival 12.0 months); (2) an intermediate prognostic group with either  m and unfavorable KELIM, or  wt and favorable KELIM (median progression-free survival of 16.0 and 18.8 months, respectively; HR 0.64 compared with the unfavorable group, p<0.001); and (3) a favorable prognostic group with both  m and favorable KELIM (median progression-free survival 28.8 months; HR 0.37 compared with the unfavorable group, p<0.001). The KELIM score provides complementary prognostic information with respect to   and discriminates different prognoses within  m or  wt patients. Patients with both  wt/unfavorable KELIM have a poor prognosis, underscoring the urgent need for novel therapeutic strategies.","Medical Oncology, Institut Curie, Paris, France.;Medical Oncology, Hospices Civils de Lyon, Lyon, France.;Biostatistical Unit, Institut Curie, Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, Brussels, Belgium.;Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Medical Oncology, Centre François Baclesse Centre de Lutte Contre le Cancer, Caen, France.;Medical Oncology, ICO Site Paul Papin, Angers, France.;Surgical Oncology, Jean Perrin Centre, Clermont-Ferrand, France.;Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Medical Oncology, Gustave Roussy, Villejuif, France.;Medical Oncology, Henri Becquerel Cancer Institute, Rouen, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Paoli-Calmettes Institute, Marseille, France.;SESSTIM (Economic and Social Sciences of Health & Medical Information Processing), Marseille, France.;Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Medical Oncology Department, Paul Strauss Cancer Centre, Strasbourg, France.;Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.;Surgical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, France.;Medical Oncology, Godinot Institute, Reims, France.;UNICANCER (Network of French Comprehensive Cancer Centres), Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Laboratoire HESPER, Université Claude Bernard Lyon 1, Villeurbanne, France.;Biostatistical Unit, Institut Curie, Paris, France.;Université Claude Bernard Lyon 1, Lyon, France.;Medical Oncology, Hospices Civils de Lyon, Lyon, France.;Université Claude Bernard Lyon 1, Lyon, France.;Medical Oncology, Institut Curie, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), PSL Research University, Paris, France.","NA",0,"1525-1438","Int J Gynecol Cancer","Int J Gynecol Cancer",2024,"2025",NA,"10.1136/ijgc-2024-005815",NA,"","","39481880","39481880","PUBMED","Medical Oncology, Institut Curie, Paris, France.;Medical Oncology, Hospices Civils de Lyon, Lyon, France.;Biostatistical Unit, Institut Curie, Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Breast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, Brussels, Belgium.;Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Medical Oncology, Centre François Baclesse Centre de Lutte Contre le Cancer, Caen, France.;Medical Oncology, ICO Site Paul Papin, Angers, France.;Surgical Oncology, Jean Perrin Centre, Clermont-Ferrand, France.;Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Medical Oncology, Gustave Roussy, Villejuif, France.;Medical Oncology, Henri Becquerel Cancer Institute, Rouen, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Paoli-Calmettes Institute, Marseille, France.;SESSTIM (Economic and Social Sciences of Health & Medical Information Processing), Marseille, France.;Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Medical Oncology Department, Paul Strauss Cancer Centre, Strasbourg, France.;Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France.;Surgical Oncology, Institut Régional du Cancer de Montpellier, Montpellier, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, France.;Medical Oncology, Godinot Institute, Reims, France.;UNICANCER (Network of French Comprehensive Cancer Centres), Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Laboratoire HESPER, Université Claude Bernard Lyon 1, Villeurbanne, France.;Biostatistical Unit, Institut Curie, Paris, France.;Université Claude Bernard Lyon 1, Lyon, France.;Medical Oncology, Hospices Civils de Lyon, Lyon, France.;Université Claude Bernard Lyon 1, Lyon, France.;Medical Oncology, Institut Curie, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), PSL Research University, Paris, France."
"38","Frat JP;Coudroy R;Quenot JP;Guitton C;Badie J;Gacouin A;Ehrmann S;Demoule A;Jarousseau F;Carteaux G;Rigaud JP;Reignier J;Sedillot N;Contou D;Beloncle F;Daubin C;Dureau AF;Fatah A;Besse MC;Ferre A;Turbil E;Merdji H;Galerneau LM;Lacombe B;Richard JC;Romen A;Delbove A;Prat G;Lautrette A;Colin G;Soum E;Bourdin G;Hernández G;Ragot S;Thille AW","Frat, Jean-Pierre;Coudroy, Remi;Quenot, Jean-Pierre;Guitton, Christophe;Badie, Julio;Gacouin, Arnaud;Ehrmann, Stephan;Demoule, Alexandre;Jarousseau, Fabien;Carteaux, Guillaume;Rigaud, Jean Philippe;Reignier, Jean;Sedillot, Nicholas;Contou, Damien;Beloncle, François;Daubin, Cédric;Dureau, Anne-Florence;Fatah, Abdelhamid;Besse, Marie-Catherine;Ferre, Alexis;Turbil, Emanuele;Merdji, Hamid;Galerneau, Louis-Marie;Lacombe, Béatrice;Richard, Jean-Christophe;Romen, Antoine;Delbove, Agathe;Prat, Gwenael;Lautrette, Alexandre;Colin, Gwenhaël;Soum, Edouard;Bourdin, Gaël;Hernández, Gonzalo;Ragot, Stéphanie;Thille, Arnaud W","Effect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO).","BMJ open","England","eng","Clinical Trial Protocol","Adult intensive & critical care;Pulmonary Disease;Respiratory Therapy;Respiratory infections","Humans;Acute Disease;Cannula;Hypoxia;Intensive Care Units;Multicenter Studies as Topic;Oxygen;Oxygen Inhalation Therapy;Randomized Controlled Trials as Topic;Respiratory Insufficiency","Humans;Acute Disease;Cannula;Hypoxia;Intensive Care Units;Multicenter Studies as Topic;Oxygen;Oxygen Inhalation Therapy;Randomized Controlled Trials as Topic;Respiratory Insufficiency","First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure. The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay. The study has been approved by the central Ethics Committee 'Sud Méditerranée III' (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. NCT04468126.","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Réanimation médicale, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Médecine intensive réanimation, Centre Hospitalier de Mans, Le Mans, France.;Réanimation, Centre Hospitalier Belfort-Montbéliard - Site de Belfort, Belfort, France.;Service des maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre-Val de Loire, France.;Service de Pneumologie et Réanimation Médicale du Département R3S, AP-HP, INSERM, UMRS1158 neurophysiologie respiratoire expérimentale et clinique, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, France.;Service de Réanimation polyvalente, CH Cholet, Cholet, France.;Médecine Intensive Réanimation, CHU Henri Mondor, Creteil, France.;Médecine Intensive Réanimation, Centre Hospitalier de Dieppe, Dieppe, France.;Médecine intensive réanimation, CHU Nantes, Nantes, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, France.;Service de Réanimation Polyvalente, Centre Hospitalier d'Argenteuil, Argenteuil, France.;Département de Médecine Intensive - Réanimation, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Medical Intensive Care, CHRU de Caen, Caen, France.;Médecine Intensive Réanimation, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France.;Réanimation Polyvalente, Groupement Hospitalier Nord-Dauphine, Bourgoin-Jallieu, France.;Réanimation polyvalente, CH de Bourges, Bourges, France.;Réanimation, CH de Versailles, Le Chesnay, France.;Service de Réanimation, CH Henri Mondor d'Aurillac, Aurillac, France.;Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Université de Strasbourg (UNISTRA), Faculté de Médecine, Hôpitaux Universitaires de Strasbourg,France; , Strasbourg, France.;Médecine Intensive Réanimation, CHU Grenoble Alpes, Grenoble, France.;Service de Réanimation polyvalente, Groupe Hospitalier Bretagne Sud, Lorient , France.;Médecine Intensive Réanimation, Hôpital de La Croix Rousse, Hospices civils de Lyon, Lyon , France.;Réanimation polyvalente, CH de Pau, Pau, France.;Réanimation, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Médecine Intensive Réanimation, CHU de Brest, Brest, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Clermont-Ferrand Site Gabriel-Montpied, Clermont-Ferrand, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, France.;Réanimation Polyvalente, Centre Hospitalier de Périgueux, Perigueux, France.;Réanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France.;Department of Critical Care Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.;Biostatistics, INSERM 1402, Poitiers, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2024,"2024","14","10.1136/bmjopen-2023-083232","e083232","","","39448217","39448217","PUBMED","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Réanimation médicale, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Médecine intensive réanimation, Centre Hospitalier de Mans, Le Mans, France.;Réanimation, Centre Hospitalier Belfort-Montbéliard - Site de Belfort, Belfort, France.;Service des maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre-Val de Loire, France.;Service de Pneumologie et Réanimation Médicale du Département R3S, AP-HP, INSERM, UMRS1158 neurophysiologie respiratoire expérimentale et clinique, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, France.;Service de Réanimation polyvalente, CH Cholet, Cholet, France.;Médecine Intensive Réanimation, CHU Henri Mondor, Creteil, France.;Médecine Intensive Réanimation, Centre Hospitalier de Dieppe, Dieppe, France.;Médecine intensive réanimation, CHU Nantes, Nantes, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, France.;Service de Réanimation Polyvalente, Centre Hospitalier d'Argenteuil, Argenteuil, France.;Département de Médecine Intensive - Réanimation, Université d'Angers, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Medical Intensive Care, CHRU de Caen, Caen, France.;Médecine Intensive Réanimation, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, France.;Réanimation Polyvalente, Groupement Hospitalier Nord-Dauphine, Bourgoin-Jallieu, France.;Réanimation polyvalente, CH de Bourges, Bourges, France.;Réanimation, CH de Versailles, Le Chesnay, France.;Service de Réanimation, CH Henri Mondor d'Aurillac, Aurillac, France.;Service de Médecine Intensive - Réanimation, Nouvel Hôpital Civil, Université de Strasbourg (UNISTRA), Faculté de Médecine, Hôpitaux Universitaires de Strasbourg,France; , Strasbourg, France.;Médecine Intensive Réanimation, CHU Grenoble Alpes, Grenoble, France.;Service de Réanimation polyvalente, Groupe Hospitalier Bretagne Sud, Lorient , France.;Médecine Intensive Réanimation, Hôpital de La Croix Rousse, Hospices civils de Lyon, Lyon , France.;Réanimation polyvalente, CH de Pau, Pau, France.;Réanimation, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Médecine Intensive Réanimation, CHU de Brest, Brest, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Clermont-Ferrand Site Gabriel-Montpied, Clermont-Ferrand, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, France.;Réanimation Polyvalente, Centre Hospitalier de Périgueux, Perigueux, France.;Réanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, France.;Department of Critical Care Medicine, Complejo Hospitalario Universitario de Toledo, Toledo, Spain.;Biostatistics, INSERM 1402, Poitiers, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France."
"39","Perez-Fidalgo A;Schmalfeldt B;George A;Gourley C;Pignata S;Lorusso D;Barretina-Ginesta MP;Romero I;Grimm C;Van Gorp T;Rossing M;Collins DC;Fernebro J;Bjørge L;Leary A;de la Motte Rouge T;Harter P;Kurzeder C;Savva-Bordalo J;You B","Perez-Fidalgo, Alejandro;Schmalfeldt, Barbara;George, Angela;Gourley, Charlie;Pignata, Sandro;Lorusso, Domenica;Barretina-Ginesta, Maria Pilar;Romero, Ignacio;Grimm, Christoph;Van Gorp, Toon;Rossing, Maria;Collins, Dearbhaile C;Fernebro, Josefin;Bjørge, Line;Leary, Alexandra;de la Motte Rouge, Thibault;Harter, Philipp;Kurzeder, Christian;Savva-Bordalo, Joana;You, Benoit","Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer.","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","England","eng","Journal Article","Ovarian Cancer","","","Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across Europe, a Delphi study was conducted among European experts to understand the heterogeneity of clinical practice and identify key factors driving maintenance treatment decisions for advanced ovarian cancer. A pragmatic literature review was conducted to identify key questions regarding maintenance treatment strategies in patients with advanced ovarian cancer. Utilizing a Delphi methodology, consensus was assessed among a panel of 16 experts using a questionnaire based on results of the pragmatic literature review. Panelists agreed that   mutation and homologous recombination status should be assessed in parallel at diagnosis, and that first-line platinum chemotherapy may be initiated concurrently. There was a consensus that alternative homologous recombination deficiency tests are acceptable provided they are clinically validated. Panelists agreed that Response Evaluation Criteria in Solid Tumors (RECIST) and CA-125 elimination rate constant K (KELIM) scores can help assess tumor chemosensitivity and guide treatment-related decisions. Panelists defined high-risk disease as International Federation of Gynecology and Obstetrics (FIGO) stage IV disease or stage III with residual disease after initial/interval cytoreduction. Risk of disease progression was a key determinant of choice between PARP inhibitor, bevacizumab, or both in combination, as maintenance therapy in advanced ovarian cancer. Key drivers for selecting advanced ovarian cancer maintenance treatments include tumor mutational status as a key biomarker and clinician perception of the risk for early disease progression.","INCLIVA, Hospital Clinico Universitario de Valencia, Valencia;Ciberonc, Instituto de Salud Carlos III, Madrid, Spain.;Clinic and Polyclinic for Gynaecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.;Genomics and Oncology, Royal Marsden Hospital, Sutton, UK.;CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.;Istituto Nazionale Tumori di Napoli IRCCS Fondazione G Pascale, Napoli, Italy.;Department of Biomedical Sciences, Humanitas University, Milan, Italy.;IRCCS Humanitas Research Hospital, Milan, Italy.;Catalan Institute of Oncology Girona, IDIBGI-CERCA, Girona, Spain.;Instituto Valenciano de Oncología, Valencia, Spain.;Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Center for Genomic Medicine, Diagnostic Center, Rigshospitalet, Copenhagen, Denmark.;CUH/UCC Cancer Centre, Cork University Hospital, Cork, Ireland.;Section of Gynecological Oncology, Karolinska University Hospital, Stockholm, Sweden.;Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.;Department of Clinical Science, Center for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.;Department of Adult Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France.;Centre Eugène Marquis, Rennes, France.;Kliniken Essen-Mitte, Essen, Germany.;University Hospital Basel, Basel, Switzerland.;Portuguese Institute of Oncology, Porto, Portugal.;Early phase trial unit in oncology (CITOHL- EPSILYON), Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Lyon University Hospital (HCL), Lyon, France.;GINECO, Paris, France.","NA",0,"1525-1438","Int J Gynecol Cancer","Int J Gynecol Cancer",2024,"2025",NA,"10.1136/ijgc-2024-005497",NA,"","","39448084","39448084","PUBMED","INCLIVA, Hospital Clinico Universitario de Valencia, Valencia;Ciberonc, Instituto de Salud Carlos III, Madrid, Spain.;Clinic and Polyclinic for Gynaecology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.;Genomics and Oncology, Royal Marsden Hospital, Sutton, UK.;CRUK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.;Istituto Nazionale Tumori di Napoli IRCCS Fondazione G Pascale, Napoli, Italy.;Department of Biomedical Sciences, Humanitas University, Milan, Italy.;IRCCS Humanitas Research Hospital, Milan, Italy.;Catalan Institute of Oncology Girona, IDIBGI-CERCA, Girona, Spain.;Instituto Valenciano de Oncología, Valencia, Spain.;Gynecologic Cancer Unit, Medical University of Vienna, Vienna, Austria.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Center for Genomic Medicine, Diagnostic Center, Rigshospitalet, Copenhagen, Denmark.;CUH/UCC Cancer Centre, Cork University Hospital, Cork, Ireland.;Section of Gynecological Oncology, Karolinska University Hospital, Stockholm, Sweden.;Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway.;Department of Clinical Science, Center for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.;Department of Adult Medicine, Institut de Cancerologie Gustave Roussy, Villejuif, France.;Centre Eugène Marquis, Rennes, France.;Kliniken Essen-Mitte, Essen, Germany.;University Hospital Basel, Basel, Switzerland.;Portuguese Institute of Oncology, Porto, Portugal.;Early phase trial unit in oncology (CITOHL- EPSILYON), Centre pour l'lnnovation en Cancérologie de Lyon (CICLY), Lyon University Hospital (HCL), Lyon, France.;GINECO, Paris, France."
"40","Poissonnet V;Chabrillac E;Uro-Coste E;Woisard V;Moya-Plana A;Espitalier F;Castelli J;Dedieu T;Salas S;Garrel R;Baudouin R;Poissonnet G;Castain C;Barbut J;Mirghani H;Evrard D;Bouchain O;Marie JP;Orliac H;Ceruse P;Dufour X;Brenet E;Rambeau A;Herman P;Abu Shama Y;Bertolus C;Atallah S;Morinière S;Righini C;Mouawad F;Duflo S;Segier B;Vergez S","Poissonnet, Valentine;Chabrillac, Emilien;Uro-Coste, Emmanuelle;Woisard, Virginie;Moya-Plana, Antoine;Espitalier, Florent;Castelli, Joel;Dedieu, Thibault;Salas, Sébastien;Garrel, Renaud;Baudouin, Robin;Poissonnet, Gilles;Castain, Claire;Barbut, Jonathan;Mirghani, Haitham;Evrard, Diane;Bouchain, Olivier;Marie, Jean Paul;Orliac, Hélène;Ceruse, Philippe;Dufour, Xavier;Brenet, Esteban;Rambeau, Audrey;Herman, Philippe;Abu Shama, Yazan;Bertolus, Chloé;Atallah, Sarah;Morinière, Sylvain;Righini, Christian;Mouawad, François;Duflo, Suzy;Segier, Bertille;Vergez, Sébastien","Therapeutic strategy for advanced stages salivary carcinomas of the tongue: A multicenter REFCOR study.","Oral oncology","England","eng","Journal Article","Locally-advanced stage;Minor salivary gland;Salivary gland carcinoma;Tongue;Totalglossectomy","Humans;Male;Female;Middle Aged;Tongue Neoplasms;Aged;Retrospective Studies;Salivary Gland Neoplasms;Adult;Neoplasm Staging;Aged, 80 and over","Humans;Male;Female;Middle Aged;Tongue Neoplasms;Aged;Retrospective Studies;Salivary Gland Neoplasms;Adult;Neoplasm Staging;Aged, 80 and over","Salivary carcinomas of the tongue represent a therapeutic challenge as their radical excision is particularly mutilating. We aimed to study the oncologic and functional outcomes of advanced stages salivary carcinomas of the tongue. This retrospective multicentric study, based on the French national network on rare head and neck cancers (REFCOR), included all patients with a T3-T4 salivary carcinoma of the tongue, diagnosed between January 2009 and December 2018. In total, 47 patients were included, of which 44.7 % underwent surgery. Histologies were mostly adenoid cystic carcinomas (61.7 %), followed by other adenocarcinomas (27.7 %) and mucoepidermoid carcinomas (10.6 %). Median follow-up duration was 63.9 months. In multivariable analysis, surgery was significantly associated with better Recurrence-Free Survival (HR = 0.23, 95 %CI [0.09;0.55]) and Local/Regional Recurrence-Free Survival (HR = 0.31, 95 %CI [0.10;0.95]). The rate of distant metastasis at the end of follow-up was 61.9 % in the surgical group and 57.7 % in the non-surgical group. The Distant Metastasis Free Survival was 54.9 % [38.3;68.7], without statistical difference between both groups. There were similar rates of definitive gastrostomies but the rate of normal oral diet at the last follow-up seemed higher in the surgery group (38.1 % vs 15.4 %). Radical surgery in that population mainly aims to improve local/regional control, which may result in better long-term swallowing functions. About half of these tumors may be associated with occult distant metastasis at initial presentation. More studies are warranted to establish the role of postoperative RT and non-surgical treatment with concurrent CRT.","Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Department of Anatomical Pathology, University Cancer Institute Toulouse, Toulouse France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Head and Neck Oncology Department, Gustave-Roussy Institute, Villejuif, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nantes, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Strasbourg, France.;AP-HM, Aix-Marseille University, Department of Medical Oncology, Marseille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Montpellier, France.;Otolaryngology, Head and Neck Surgery Department, Foch Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Head and Neck University Institute, Nice, France.;Department of Anatomical Pathology, Bordeaux University Hospital-CHU, F-33000, Bordeaux, France.;Otolaryngology, Head and Neck Surgery Department, Hospital of Toulon, France.;Otolaryngology, Head and Neck Surgery Department, George Pompidou European Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Bichat Hospital, Paris, France.;Head and Neck Surgery Department, CHU Sart Tilman, University Liege, Belgium.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Rouen, France.;Department of Radiation Therapy, University Hospital of Limoges, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lyon, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Poitiers, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Reims, France.;Oncology Department, François Baclesse Centre, Caen, France.;Otolaryngology, Head and Neck Surgery Department, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France.;Department of Oral and Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, France.;Head and Neck Surgery Department, Tenon Hospital, APHP, Sorbonne University, Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Tours, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Grenoble, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Point-à-Pitre, France.;Statistical Department, Institut Claudius Regaud, University Institute of Cancer, Toulouse, France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.","NA",0,"1879-0593","Oral Oncol","Oral Oncol",2024,"2024","159","10.1016/j.oraloncology.2024.107072","107072","","","39432991","39432991","PUBMED","Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Department of Anatomical Pathology, University Cancer Institute Toulouse, Toulouse France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.;Head and Neck Oncology Department, Gustave-Roussy Institute, Villejuif, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nantes, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Strasbourg, France.;AP-HM, Aix-Marseille University, Department of Medical Oncology, Marseille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Montpellier, France.;Otolaryngology, Head and Neck Surgery Department, Foch Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Head and Neck University Institute, Nice, France.;Department of Anatomical Pathology, Bordeaux University Hospital-CHU, F-33000, Bordeaux, France.;Otolaryngology, Head and Neck Surgery Department, Hospital of Toulon, France.;Otolaryngology, Head and Neck Surgery Department, George Pompidou European Hospital, Paris, France.;Otolaryngology, Head and Neck Surgery Department, Bichat Hospital, Paris, France.;Head and Neck Surgery Department, CHU Sart Tilman, University Liege, Belgium.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Rouen, France.;Department of Radiation Therapy, University Hospital of Limoges, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lyon, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Poitiers, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Reims, France.;Oncology Department, François Baclesse Centre, Caen, France.;Otolaryngology, Head and Neck Surgery Department, Lariboisière Hospital, 2 rue Ambroise Paré, 75010 Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Nancy, France.;Department of Oral and Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital, APHP, Sorbonne Université, France.;Head and Neck Surgery Department, Tenon Hospital, APHP, Sorbonne University, Paris, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Tours, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Grenoble, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Lille, France.;Otolaryngology, Head and Neck Surgery Department, University Hospital of Point-à-Pitre, France.;Statistical Department, Institut Claudius Regaud, University Institute of Cancer, Toulouse, France.;Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France."
"41","Rodrigues M;Ramtohul T;Rampanou A;Sandoval JL;Houy A;Servois V;Mailly-Giacchetti L;Pierron G;Vincent-Salomon A;Cassoux N;Mariani P;Dutriaux C;Pracht M;Ryckewaert T;Kurtz JE;Roman-Roman S;Piperno-Neumann S;Bidard FC;Stern MH;Renault S","Rodrigues, Manuel;Ramtohul, Toulsie;Rampanou, Aurore;Sandoval, José Luis;Houy, Alexandre;Servois, Vincent;Mailly-Giacchetti, Léah;Pierron, Gaelle;Vincent-Salomon, Anne;Cassoux, Nathalie;Mariani, Pascale;Dutriaux, Caroline;Pracht, Marc;Ryckewaert, Thomas;Kurtz, Jean-Emmanuel;Roman-Roman, Sergio;Piperno-Neumann, Sophie;Bidard, François-Clément;Stern, Marc-Henri;Renault, Shufang","Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp.","Nature communications","England","eng","Clinical Study","","Adult;Aged;Female;Humans;Male;Middle Aged;Biomarkers, Tumor;Circulating Tumor DNA;High-Throughput Nucleotide Sequencing;Melanoma;Neoplasm Metastasis;Prognosis;Prospective Studies;Uveal Neoplasms;Uveal Melanoma","Adult;Aged;Female;Humans;Male;Middle Aged;Biomarkers, Tumor;Circulating Tumor DNA;High-Throughput Nucleotide Sequencing;Melanoma;Neoplasm Metastasis;Prognosis;Prospective Studies;Uveal Neoplasms;Uveal Melanoma","Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM). Circulating tumor DNA (ctDNA) has emerged as a potential prognostic and predictive marker in the phase 3 IMCgp100-202 trial using multiplex PCR-based next-generation sequencing (NGS). In this study (NCT02866149), ctDNA dynamics were assessed using droplet digital PCR (ddPCR) in 69 MUM patients undergoing tebentafusp treatment. Notably, 61% of patients exhibited detectable ctDNA before treatment initiation, which was associated with shorter overall survival (median 12.9 months versus 40.5 months for patients with undetectable ctDNA; p < 0.001). Patients manifesting a 90% or greater reduction in ctDNA levels at 12 weeks demonstrated markedly prolonged overall survival (median 21.2 months versus 12.9 months; p = 0.02). Our findings highlight the potential of ddPCR-based ctDNA monitoring as an economical, pragmatic and informative approach in MUM management, offering valuable insights into treatment response and prognosis.","Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Radiology, Institut Curie, PSL Research University, Paris, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Radiology, Institut Curie, PSL Research University, Paris, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Somatic Genetic Unit, Department of Genetics, Institut Curie, PSL Research University, Paris, France.;Department of Pathology, Institut Curie, PSL Research University, Paris, France.;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.;Dermatology Department, Hôpital Saint André Centre Hospitalier Universitaire, Bordeaux, France.;Medical Oncology Department, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Oscar Lambret Center, Lille, France.;Department of Medical and Surgical Oncology & Hematology, ICANS, Strasbourg, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Translational Research, Institut Curie, PSL Research University, Paris, France.;Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;UVSQ, Paris-Saclay University, Saint Cloud, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris","NA",0,"2041-1723","Nat Commun","Nat Commun",2024,"2024","15","10.1038/s41467-024-53145-0","8851","","","39402032","39402032","PUBMED","Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Radiology, Institut Curie, PSL Research University, Paris, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Radiology, Institut Curie, PSL Research University, Paris, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Somatic Genetic Unit, Department of Genetics, Institut Curie, PSL Research University, Paris, France.;Department of Pathology, Institut Curie, PSL Research University, Paris, France.;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris, France.;Dermatology Department, Hôpital Saint André Centre Hospitalier Universitaire, Bordeaux, France.;Medical Oncology Department, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Oscar Lambret Center, Lille, France.;Department of Medical and Surgical Oncology & Hematology, ICANS, Strasbourg, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris, France.;Department of Translational Research, Institut Curie, PSL Research University, Paris, France.;Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris and Saint Cloud, France.;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris, France.;UVSQ, Paris-Saclay University, Saint Cloud, France.;Inserm U830, DNA Repair and Uveal Melanoma (D.R.U.M.) team, Institut Curie, PSL Research University, Paris;Circulating Tumor Biomarkers Laboratory, Inserm CIC-BT 1428, Department of Translational Research, Institut Curie, Paris"
"42","Malnoë D;Bories M;Pierre-Jean M;Marchand T;Le Corre P","Malnoë, David;Bories, Mathilde;Pierre-Jean, Morgane;Marchand, Tony;Le Corre, Pascal","Inflammation Decreases Ciclosporin Metabolism in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.","Journal of clinical pharmacology","England","eng","Journal Article","C‐reactive protein;allogeneic hematopoietic stem cell transplantation;ciclosporin;drug–drug interactions;inflammation;metabolism","Humans;Cyclosporine;Hematopoietic Stem Cell Transplantation;Male;Female;Middle Aged;Retrospective Studies;Adult;Inflammation;Immunosuppressive Agents;Drug Interactions;C-Reactive Protein;Graft vs Host Disease;Aged;Transplantation, Homologous;Young Adult","Humans;Cyclosporine;Hematopoietic Stem Cell Transplantation;Male;Female;Middle Aged;Retrospective Studies;Adult;Inflammation;Immunosuppressive Agents;Drug Interactions;C-Reactive Protein;Graft vs Host Disease;Aged;Transplantation, Homologous;Young Adult","Graft-versus-host disease (GVHd) remains a significant challenge following allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of GVHd relies mainly on the use of calcineurin inhibitors, notably ciclosporin that exhibits complex pharmacokinetics influenced by many factors including drug-drug interactions (DDIs). Due to the downregulation of drug metabolizing enzymes and transporters, it has been postulated that inflammation may be a contributing factor to the variability observed in ciclosporin pharmacokinetics. This study aimed to assess the impact of inflammation, as indicated by C-reactive protein (CRP) levels, on the metabolism of ciclosporin in adult allogeneic HSCT recipients. A retrospective observational study was conducted at Rennes University Hospital involving 71 adult HSCT patients. The relationship between the intensity of inflammation (no-to-mild, moderate, and severe), and the metabolism of ciclosporin (estimated by the concentration/dose ratio) was assessed. Severe inflammation significantly decreased the metabolism of ciclosporin, as evidenced by higher concentration/dose ratios. Thanks to the daily dose adjustment, inflammation did not influence the blood levels of ciclosporin. Interestingly, DDIs did not emerge as a significant covariate in influencing ciclosporin metabolism. This is likely because the CYP3A4 inhibitory potential of interacting drugs may be masked in HSCT patients where metabolism is already upstream downregulated by inflammation. The study highlights the intricate relationship between inflammation and ciclosporin pharmacokinetics in HSCT patients. This underscores the necessity for therapeutic monitoring and the potential adjustment of dosage strategies based on the inflammatory status. These insights could contribute to the development of more personalized, optimized, and effective management strategies for HSCT recipients.","Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes, France.;Faculté de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Université de Rennes, Rennes, France.;Inserm, EHESP, Institut de recherche en santé environnement et travail (IRSET) -UMR_S 1085, Université Rennes, Rennes, France.;CHU Rennes, INSERM, LTSI-UMR 1099,, Université de Rennes, Rennes, France.;CHU Rennes, INSERM, LTSI-UMR 1099,, Université de Rennes, Rennes, France.;Service d'Hématologie Clinique, CHU de Rennes, INSERM U1236, Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes, France.;Faculté de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Université de Rennes, Rennes, France.;Inserm, EHESP, Institut de recherche en santé environnement et travail (IRSET) -UMR_S 1085, Université Rennes, Rennes, France.","NA",0,"1552-4604","J Clin Pharmacol","J Clin Pharmacol",2024,"2025","65","10.1002/jcph.6141","328-339","","","39382849","39382849","PUBMED","Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes, France.;Faculté de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Université de Rennes, Rennes, France.;Inserm, EHESP, Institut de recherche en santé environnement et travail (IRSET) -UMR_S 1085, Université Rennes, Rennes, France.;CHU Rennes, INSERM, LTSI-UMR 1099,, Université de Rennes, Rennes, France.;CHU Rennes, INSERM, LTSI-UMR 1099,, Université de Rennes, Rennes, France.;Service d'Hématologie Clinique, CHU de Rennes, INSERM U1236, Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Pharmacie, Secteur Pharmacotechnie et Onco-Pharmacie, Rennes, France.;Faculté de Pharmacie, Laboratoire de Biopharmacie et Pharmacie Clinique, Université de Rennes, Rennes, France.;Inserm, EHESP, Institut de recherche en santé environnement et travail (IRSET) -UMR_S 1085, Université Rennes, Rennes, France."
"43","Margot H;Jones N;Matis T;Bonneau D;Busa T;Bonnet F;Conrad S;Crivelli L;Monin P;Fert-Ferrer S;Mortemousque I;Raad S;Lacombe D;Caux F;Sevenet N;Bubien V;Longy M","Margot, Henri;Jones, Natalie;Matis, Thibaut;Bonneau, Dominique;Busa, Tiffany;Bonnet, Françoise;Conrad, Solene;Crivelli, Louise;Monin, Pauline;Fert-Ferrer, Sandra;Mortemousque, Isabelle;Raad, Sabine;Lacombe, Didier;Caux, Frédéric;Sevenet, Nicolas;Bubien, Virginie;Longy, Michel",NA,"Journal of medical genetics","England","eng","Journal Article","Genetic Predisposition to Disease;Genetics, Medical;Mutation, Missense","PTEN Phosphohydrolase;Humans;Hamartoma Syndrome, Multiple;Germ-Line Mutation;Female;Male;Gene Frequency;Phenotype;Adult","PTEN Phosphohydrolase;Humans;Hamartoma Syndrome, Multiple;Germ-Line Mutation;Female;Male;Gene Frequency;Phenotype;Adult","PTEN hamartoma tumour syndrome (PHTS) encompasses distinct syndromes, including Cowden syndrome resulting from   pathogenic variants. Missense variants account for 30% of PHTS cases, but their classification remains challenging. To address these difficulties, guidelines were published by the Clinical Genome Resource PTEN Variant Curation Expert Panel. Between 2010 and 2020, the Bergonie Institute reference laboratory identified 76 different non-truncating   variants in 166 patients, 17 of which have not previously been reported. Variants were initially classified following the current guidelines. Subsequently, a new classification method was developed based on four main criteria: functional exploration, phenotypic features and familial segregation, in silico modelling, and allelic frequency. This new method of classification is more discriminative and reclassifies 25 variants, including 8 variants of unknown significance. This report proposes a revision of the current   variant classification criteria which at present rely on functional tests evaluating only the phosphatase activity of PTEN and apply a particularly stringent clinical PHTS score.The classification of non-truncating variants of   is facilitated by taking into consideration protein stability for variants with intact phosphatase activity, clinical and segregation criteria adapted to the phenotypic variability of PHTS and by specifying the allelic frequency of variants in the general population. This novel method of classification remains to be validated in a prospective cohort.","Medical Genetics Departement, CHU de Bordeaux, Bordeaux, Nouvelle-Aquitaine, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;U771-CNRS6214, UMR INSERM, Angers, France.;School of Medicine, University of Angers, Angers, France.;Medical Genetics Departement, Marseille Public University Hospital System, Marseille, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Medical Genetics Departement, University Hospital Centre Nantes, Nantes, Pays de la Loire, France.;Department of Oncogenetics, Centre Eugene Marquis, Rennes, Bretagne, France.;Medical Genetics Departement, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Medical Genetics Departement, Centre Hospitalier Métropole Savoie, Chambery, France.;Cancer Genetics Unit, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre-Val de Loire, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Department of Medical Genetics, CHU Bordeaux GH Pellegrin, Bordeaux, Aquitaine, France.;MRGM INSERM U1211, Universite de Bordeaux College Sciences de la Sante, Bordeaux, Nouvelle-Aquitaine, France.;Hospital Avicenne Internal Medicine Service, Bobigny, Île-de-France, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;UMR1312, INSERM, BoRdeaux Institute of onCology, Bordeaux, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;UMR1312, INSERM, BoRdeaux Institute of onCology, Bordeaux, France.","NA",0,"1468-6244","J Med Genet","J Med Genet",2024,"2024","61","10.1136/jmg-2024-109982","1071-1079","","","39358013","39358013","PUBMED","Medical Genetics Departement, CHU de Bordeaux, Bordeaux, Nouvelle-Aquitaine, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;U771-CNRS6214, UMR INSERM, Angers, France.;School of Medicine, University of Angers, Angers, France.;Medical Genetics Departement, Marseille Public University Hospital System, Marseille, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Medical Genetics Departement, University Hospital Centre Nantes, Nantes, Pays de la Loire, France.;Department of Oncogenetics, Centre Eugene Marquis, Rennes, Bretagne, France.;Medical Genetics Departement, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Medical Genetics Departement, Centre Hospitalier Métropole Savoie, Chambery, France.;Cancer Genetics Unit, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre-Val de Loire, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;Department of Medical Genetics, CHU Bordeaux GH Pellegrin, Bordeaux, Aquitaine, France.;MRGM INSERM U1211, Universite de Bordeaux College Sciences de la Sante, Bordeaux, Nouvelle-Aquitaine, France.;Hospital Avicenne Internal Medicine Service, Bobigny, Île-de-France, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;UMR1312, INSERM, BoRdeaux Institute of onCology, Bordeaux, France.;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine;Cancer Genetics Unit, Institut Bergonié, Bordeaux, Aquitaine, France.;UMR1312, INSERM, BoRdeaux Institute of onCology, Bordeaux, France."
"44","Bommier C;Donzel M;Rossi C;Fornecker LM;Bijou F;Chauchet A;Lebras L;Ysabaert L;Haioun C;Bouabdallah K;Gastinne T;Morineau N;Amorim S;Jardin F;Abraham J;Lamy de la Chapelle T;Gressin R;Fouillet L;Fruchart C;Olivier G;Morschhauser F;Cherblanc F;Belot A;Le Guyader S;Monnereau A;Ghesquieres H;Thieblemont C","Bommier, C;Donzel, M;Rossi, C;Fornecker, L M;Bijou, F;Chauchet, A;Lebras, L;Ysabaert, L;Haioun, C;Bouabdallah, K;Gastinne, T;Morineau, N;Amorim, S;Jardin, F;Abraham, J;Lamy de la Chapelle, T;Gressin, R;Fouillet, L;Fruchart, C;Olivier, G;Morschhauser, F;Cherblanc, F;Belot, A;Le Guyader, S;Monnereau, A;Ghesquieres, H;Thieblemont, C","Real-world data for marginal zone lymphoma patients in the French REALYSA cohort: The REALMA study.","Hematological oncology","England","eng","Journal Article","epidemiology;lymphoma;marginal zone lymphoma;real‐world data;real‐world evidence","Humans;Lymphoma, B-Cell, Marginal Zone;Middle Aged;Male;Female;Aged;Adult;France;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Prospective Studies;Rituximab;Survival Rate;Follow-Up Studies","Humans;Lymphoma, B-Cell, Marginal Zone;Middle Aged;Male;Female;Aged;Adult;France;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Prospective Studies;Rituximab;Survival Rate;Follow-Up Studies","Marginal Zone Lymphoma (MZL) comprises three subtypes: extranodal MZL (EMZL), splenic MZL (SMZL) and nodal MZL (NMZL). Since clinical trials have limited representativeness, there is a need for real-world data (RWD) evidence in MZL. Real-world data in Lymphoma and survival in Adults (REALYSA) is a prospective multicentric French cohort of newly diagnosed lymphoma patients. This study consists of the first abstraction of MZL patients prospectively included in REALYSA between 12/2018 and 01/2021 with at least 1 year of follow-up. It provides a landscape description of clinical characteristics, initial workup, quality of life and first-line therapy performed in routine practice. Among 207 included patients, 122 presented with EMZL, 51 with SMZL and 34 with NMZL. At baseline, median age was 67 years (range 28-96), and patients reported a favorable global health status (75/100 (IQR 58,83)) - which was higher in NMZL and lower in SMZL patients (p = 0.006).  FDG-PET/CT was frequently performed at initial workup (EMZL 72%, SMZL 73%, NMZL 85%). Active surveillance was the initial management for 58 (28%) patients. The most prescribed therapies were rituximab-chlorambucil in the EMZL population (30%), rituximab monotherapy in the SMZL population (37%) and R-CHOP (24%)/bendamustine-rituximab (15%) in the NMZL population. At end of first line, overall response rate was 93% among treated patients with 75% of complete response. This French nationwide study provided for the first time prospective RWD on clinical characteristics, initial management and treatment response of MZL patients.","Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.;Department of Pathology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.;Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.;Department of Hematology, Institut Bergonie, Bordeaux, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Leon Berard Cancer Center, Lyon, France.;Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Lymphoid Malignancies Unit, Assistante Publique Hôpitaux de Paris APHP, Hopital Henri Mondor, Creteil, France.;Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.;Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Hematology, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Department of Hematology, Hopital Saint Vincent de Paul, Lille, France.;Department of Clinical Hematology, INSERM, Centre Henri Becquerel, Rouen, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France.;Department of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Besancon, France.;Department of Hematology, Centre Hospitalier de Dunkerque, Dunkirk, France.;Department of Hematology, Centre Hospitalier de Niort, Niort, France.;Department of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.;Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.;Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.","NA",0,"1099-1069","Hematol Oncol","Hematol Oncol",2024,"2024","42","10.1002/hon.3314","e3314","","","39351974","39351974","PUBMED","Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.;Department of Pathology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.;Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.;Department of Hematology, Institut Bergonie, Bordeaux, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Leon Berard Cancer Center, Lyon, France.;Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Lymphoid Malignancies Unit, Assistante Publique Hôpitaux de Paris APHP, Hopital Henri Mondor, Creteil, France.;Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.;Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Hematology, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Department of Hematology, Hopital Saint Vincent de Paul, Lille, France.;Department of Clinical Hematology, INSERM, Centre Henri Becquerel, Rouen, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France.;Department of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Besancon, France.;Department of Hematology, Centre Hospitalier de Dunkerque, Dunkirk, France.;Department of Hematology, Centre Hospitalier de Niort, Niort, France.;Department of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre-Benite, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, UMR, Bordeaux, France.;Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Lyon, France.;Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France."
"45","Aucouturier C;Soirat N;Castéra L;Bertrand D;Atkinson A;Lavolé T;Goardon N;Quesnelle C;Levilly J;Barbachou S;Legros A;Caron O;Crivelli L;Denizeau P;Berthet P;Ricou A;Boulouard F;Vaur D;Krieger S;Leman R","Aucouturier, Camille;Soirat, Nicolas;Castéra, Laurent;Bertrand, Denis;Atkinson, Alexandre;Lavolé, Thibaut;Goardon, Nicolas;Quesnelle, Céline;Levilly, Julien;Barbachou, Sosthène;Legros, Angelina;Caron, Olivier;Crivelli, Louise;Denizeau, Philippe;Berthet, Pascaline;Ricou, Agathe;Boulouard, Flavie;Vaur, Dominique;Krieger, Sophie;Leman, Raphael","Fine mapping of RNA isoform diversity using an innovative targeted long-read RNA sequencing protocol with novel dedicated bioinformatics pipeline.","BMC genomics","England","eng","Journal Article","Automatic annotation;HBOC;Isoform assembly;Long read sequencing;RNA splicing","Humans;Sequence Analysis, RNA;Computational Biology;RNA Isoforms;Alternative Splicing;Female;BRCA2 Protein;BRCA1 Protein;High-Throughput Nucleotide Sequencing;Hereditary Breast and Ovarian Cancer Syndrome","Humans;Sequence Analysis, RNA;Computational Biology;RNA Isoforms;Alternative Splicing;Female;BRCA2 Protein;BRCA1 Protein;High-Throughput Nucleotide Sequencing;Hereditary Breast and Ovarian Cancer Syndrome","Solving the structure of mRNA transcripts is a major challenge for both research and molecular diagnostic purposes. Current approaches based on short-read RNA sequencing and RT-PCR techniques cannot fully explore the complexity of transcript structure. The emergence of third-generation long-read sequencing addresses this problem by solving this sequence directly. However, genes with low expression levels are difficult to study with the whole transcriptome sequencing approach. To fix this technical limitation, we propose a novel method to capture transcripts of a gene panel using a targeted enrichment approach suitable for Pacific Biosciences and Oxford Nanopore Technologies platforms. We designed a set of probes to capture transcripts of a panel of genes involved in hereditary breast and ovarian cancer syndrome. We present SOSTAR (iSofOrmS annoTAtoR), a versatile pipeline to assemble, quantify and annotate isoforms from long read sequencing using a new tool specially designed for this application. The significant enrichment of transcripts by our capture protocol, together with the SOSTAR annotation, allowed the identification of 1,231 unique transcripts within the gene panel from the eight patients sequenced. The structure of these transcripts was annotated with a resolution of one base relative to a reference transcript. All major alternative splicing events of the BRCA1 and BRCA2 genes described in the literature were found. Complex splicing events such as pseudoexons were correctly annotated. SOSTAR enabled the identification of abnormal transcripts in the positive controls. In addition, a case of unexplained inheritance in a family with a history of breast and ovarian cancer was solved by identifying an SVA retrotransposon in intron 13 of the BRCA1 gene. We have validated a new protocol for the enrichment of transcripts of interest using probes adapted to the ONT and PacBio platforms. This protocol allows a complete description of the alternative structures of transcripts, the estimation of their expression and the identification of aberrant transcripts in a single experiment. This proof-of-concept opens new possibilities for RNA structure exploration in both research and molecular diagnostics.","Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Normandie Univ, UNICAEN, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;SeqOne Genomics, Montpellier, 34000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;SeqOne Genomics, Montpellier, 34000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Département Médecine Oncologique, Institut Gustave Roussy, Villejuif, France.;Service d'Oncogénétique, Centre Eugène Marquis, Rennes, France.;Service de génétique clinique, Centre Hospitalier Universitaire Rennes, Rennes, France.;Service d'Oncogénétique, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Normandie Univ, UNICAEN, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183","NA",0,"1471-2164","BMC Genomics","BMC Genomics",2024,"2024","25","10.1186/s12864-024-10741-0","909","2018/06","French Cancéropôle Nord-Ouest (CNO)","39350015","39350015","PUBMED","Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Normandie Univ, UNICAEN, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;SeqOne Genomics, Montpellier, 34000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;SeqOne Genomics, Montpellier, 34000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Département Médecine Oncologique, Institut Gustave Roussy, Villejuif, France.;Service d'Oncogénétique, Centre Eugène Marquis, Rennes, France.;Service de génétique clinique, Centre Hospitalier Universitaire Rennes, Rennes, France.;Service d'Oncogénétique, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000, France.;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183, France.;Normandie Univ, UNICAEN, Caen, 14000, France.;Laboratoire de biologie et de génétique du cancer, Département de Biopathologie, Centre François Baclesse, Caen, 14000;Cancer and Brain Genomics, FHU G4 Genomics, Inserm U1245, Normandie University, Rouen, 76183"
"46","Tran KC;Asfar P;Cheng M;Demiselle J;Singer J;Lee T;Sweet D;Boyd J;Walley K;Haljan G;Sharif O;Geri G;Auchabie J;Quenot JP;Lee TC;Tsang J;Meziani F;Lamontagne F;Dubee V;Lasocki S;Ovakim D;Wood G;Turgeon A;Cohen Y;Lebas E;Goudelin M;Forrest D;Teale A;Mira JP;Fowler R;Daneman N;Adhikari NKJ;Gousseff M;Leroy P;Plantefeve G;Rispal P;Courtois R;Winston B;Reynolds S;Birks P;Bienvenu B;Tadie JM;Talarmin JP;Ansart S;Russell JA","Tran, Karen C;Asfar, Pierre;Cheng, Matthew;Demiselle, Julien;Singer, Joel;Lee, Terry;Sweet, David;Boyd, John;Walley, Keith;Haljan, Greg;Sharif, Omar;Geri, Guillaume;Auchabie, Johann;Quenot, Jean-Pierre;Lee, Todd C;Tsang, Jennifer;Meziani, Ferhat;Lamontagne, Francois;Dubee, Vincent;Lasocki, Sigismond;Ovakim, Daniel;Wood, Gordon;Turgeon, Alexis;Cohen, Yves;Lebas, Eddy;Goudelin, Marine;Forrest, David;Teale, Alastair;Mira, Jean-Paul;Fowler, Robert;Daneman, Nick;Adhikari, Neill K J;Gousseff, Marie;Leroy, Pierre;Plantefeve, Gaetan;Rispal, Patrick;Courtois, Roxane;Winston, Brent;Reynolds, Steve;Birks, Peter;Bienvenu, Boris;Tadie, Jean-Marc;Talarmin, Jean-Philippe;Ansart, Severine;Russell, James A","Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","United States","eng","Journal Article","COVID-19;angiotensin receptor blocker;losartan;mortality","Humans;Losartan;Male;Female;Aged;Middle Aged;Hospitalization;COVID-19;COVID-19 Drug Treatment;France;Hospital Mortality;SARS-CoV-2;Canada;Aged, 80 and over;Treatment Outcome;Hypotension;Angiotensin II Type 1 Receptor Blockers;Adult","Humans;Losartan;Male;Female;Aged;Middle Aged;Hospitalization;COVID-19;COVID-19 Drug Treatment;France;Hospital Mortality;SARS-CoV-2;Canada;Aged, 80 and over;Treatment Outcome;Hypotension;Angiotensin II Type 1 Receptor Blockers;Adult","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) down-regulates angiotensin-converting enzyme 2, potentially increasing angiotensin II. We hypothesized that losartan compared to usual care decreases mortality and is safe in patients hospitalized with coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19. Eligibility criteria included adults admitted for acute COVID-19. Exclusion criteria were hypotension, hyperkalemia, acute kidney injury, and use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors within 7 days. Participants were randomized to losartan 25-100 mg/day orally for the hospital duration or 3 months or the control arm (usual care) in 29 hospitals in Canada and France. The primary outcome was 28-day mortality. Secondary outcomes were hospital mortality, organ support, and serious adverse events (SAEs). The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were significantly higher in the losartan versus usual care groups (any SAE: 39.8% vs 27.2%, respectively, P = .01; hypotension: 30.4% vs 15.3%, respectively, P < .001) in both ward and intensive care patients. The 28-day mortality did not differ between losartan (6.5%) versus usual care (5.9%) (odds ratio, 1.11 [95% confidence interval, .47-2.64]; P = .81), nor did organ dysfunction or secondary outcomes. Caution is needed in deciding which patients to start or continue using ARBs in patients hospitalized with pneumonia to mitigate risk of hypotension, acute kidney injury, and other side effects. ARBs should not be added to care of patients hospitalized for acute COVID-19. NCT04606563.","Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.;Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;McGill's Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada.;Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.;Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.;Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.;Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.;Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Ambroise Paré, Boulogne, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet.;Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire Dijon, Dijon, France.;McGill's Interdisciplinary Initiative in Infection and Immunity, McGill University Health Centre, Montreal, Quebec, Canada.;Niagara Health, McMaster University, St Catherines, Ontario, Canada.;Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil Strasbourg, Strasbourg, France.;Centre Hospitalier Universitaire de Sherbrooke, University of Sherbrooke, Quebec, Canada.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire Angers, Angers, France.;Royal Jubilee Hospital, Island Health, Victoria, British Columbia.;Royal Jubilee Hospital, Island Health, Victoria, British Columbia.;Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Avicenne, Bobigny, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Limoges, Limoges, France.;Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.;Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris, Cochin, France.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Service de Médecine Interne-Maladies Infectieuses-Hématologie, Centre Hospitalier Bretagne-Atlantique, Vannes, France.;Service de médecine polyvalente et maladies infectieuses, Centre Hospitalier Melun, Melun, France.;Service de Réanimation Polyvalente, Centre Hospitalier Argenteuil, France.;Department of Medicine, Service de médecine interne, Centre Hospitalier Agen, Agen, France.;Service de Médecine post-urgences-Maladies infectieuses, Centre Hospitalier de Cholet, Cholet, France.;Departments of Critical Care Medicine, Medicine, and Biochemistry and Molecular Biology, Foothills Medical Centre, University of Calgary, Alberta, Canada.;Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.;Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.;Service de médecine interne, Hôpital St Joseph, Marseille, France.;Service de Médecine Intensive-Réanimation et de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de médecine interne, maladies du sang et infectiologie, Centre Hospitalier de Quimper, Quimper, France.;Service de Maladies Infectieuses, Centre Hospitalier Régional Universitaire Brest, Brest, France.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.","NA",0,"1537-6591","Clin Infect Dis","Clin Infect Dis",2024,"2024","79","10.1093/cid/ciae306","615-625","","CIHR","39325643","39325643","PUBMED","Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.;Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;McGill's Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada.;Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.;Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.;Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.;Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.;Department of Medicine and Critical Care Medicine, Surrey Memorial Hospital, British Columbia, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Ambroise Paré, Boulogne, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet.;Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire Dijon, Dijon, France.;McGill's Interdisciplinary Initiative in Infection and Immunity, McGill University Health Centre, Montreal, Quebec, Canada.;Niagara Health, McMaster University, St Catherines, Ontario, Canada.;Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil Strasbourg, Strasbourg, France.;Centre Hospitalier Universitaire de Sherbrooke, University of Sherbrooke, Quebec, Canada.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire Angers, Angers, France.;Royal Jubilee Hospital, Island Health, Victoria, British Columbia.;Royal Jubilee Hospital, Island Health, Victoria, British Columbia.;Department of Medicine, Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris Avicenne, Bobigny, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne-Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Limoges, Limoges, France.;Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.;Department of Medicine, Nanaimo Regional General Hospital, British Columbia, Canada.;Service de Médecine Intensive-Réanimation, Assistance Publique-Hôpitaux de Paris, Cochin, France.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.;Service de Médecine Interne-Maladies Infectieuses-Hématologie, Centre Hospitalier Bretagne-Atlantique, Vannes, France.;Service de médecine polyvalente et maladies infectieuses, Centre Hospitalier Melun, Melun, France.;Service de Réanimation Polyvalente, Centre Hospitalier Argenteuil, France.;Department of Medicine, Service de médecine interne, Centre Hospitalier Agen, Agen, France.;Service de Médecine post-urgences-Maladies infectieuses, Centre Hospitalier de Cholet, Cholet, France.;Departments of Critical Care Medicine, Medicine, and Biochemistry and Molecular Biology, Foothills Medical Centre, University of Calgary, Alberta, Canada.;Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.;Critical Care Medicine, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Department of Medicine, Simon Fraser University, Surrey, British Columbia, Canada.;Service de médecine interne, Hôpital St Joseph, Marseille, France.;Service de Médecine Intensive-Réanimation et de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de médecine interne, maladies du sang et infectiologie, Centre Hospitalier de Quimper, Quimper, France.;Service de Maladies Infectieuses, Centre Hospitalier Régional Universitaire Brest, Brest, France.;Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada."
"47","Loibl S;Loirat D;Tolaney SM;Punie K;Dieras V;Carey LA;Gianni L;Shah A;Phan S;Shi L;Spears PA;Piccart MJ","Loibl, Sibylle;Loirat, Delphine;Tolaney, Sara M;Punie, Kevin;Dieras, Véronique;Carey, Lisa A;Gianni, Luca;Shah, Anuj;Phan, See;Shi, Ling;Spears, Patricia A;Piccart, Martine J","Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer.","Future oncology (London, England)","England","eng","Journal Article","breast;chemotherapy;clinical trials;metastasis","Humans;Triple Negative Breast Neoplasms;Quality of Life;Female;Antibodies, Monoclonal, Humanized;Middle Aged;Adult;Camptothecin;Aged;Neoplasm Metastasis;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome;Immunoconjugates","Humans;Triple Negative Breast Neoplasms;Quality of Life;Female;Antibodies, Monoclonal, Humanized;Middle Aged;Adult;Camptothecin;Aged;Neoplasm Metastasis;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome;Immunoconjugates","A medicine called   (brand name TRODELVY ) has been proven to be an effective treatment for metastatic triple-negative breast cancer (mTNBC for short). Metastatic breast cancer is cancer that has spread to other parts of the body. In mTNBC, the breast cancer cells do not have 3 common proteins on the cell surface, called receptors. mTNBC is more difficult to treat and more likely to come back than other types of breast cancer. The ASCENT study showed that participants with mTNBC treated with sacituzumab govitecan had a higher likelihood of living longer and delayed progression (worsening) of their cancer than those treated with standard  . Here, we summarize the   of participants with mTNBC in the ASCENT study. We compared quality of life between 236 participants treated with sacituzumab govitecan and 183 participants treated with standard chemotherapy. All participants previously received 2 or more chemotherapies that no longer controlled their cancer. This analysis showed that participants treated with sacituzumab govitecan had better overall quality of life than participants treated with standard chemotherapy. They also had better ""physical functioning"", which is the ability to walk and do physical activities. Participants treated with sacituzumab govitecan maintained their overall quality of life for a longer time than those treated with standard chemotherapy. Participants treated with sacituzumab govitecan had less pain and were less tired than those treated with standard chemotherapy. On the other hand, participants treated with sacituzumab govitecan had worse diarrhea (loose or watery stools) and were more likely to have nausea/vomiting (feel sick or throw up) than participants treated with standard chemotherapy. Participants treated with sacituzumab govitecan had a higher likelihood of living longer and delayed progression (worsening) of their cancer. Participants also had a better overall quality of life, which was maintained (did not get worse) for a longer time. However, they experienced worsening of diarrhea and/or nausea/vomiting.  NCT02574455 (ASCENT) (ClinicalTrials.gov).","German Breast Group, Neu-Isenburg, Germany.;Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Institut Curie, Paris, France.;Dana-Farber Cancer Institute, Boston, MA, USA.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Gianni Bonadonna Foundation, Milano, Italy.;Gilead Sciences, Inc., Foster City, CA, USA.;Gilead Sciences, Inc., Foster City, CA, USA.;Evidera PPD, Bethesda, MD, USA.;Patient Author, University of North.;Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.","NA",0,"1744-8301","Future Oncol","Future Oncol",2024,"2024","20","10.1080/14796694.2024.2381408","2609-2616","","","39324726","39324726","PUBMED","German Breast Group, Neu-Isenburg, Germany.;Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Institut Curie, Paris, France.;Dana-Farber Cancer Institute, Boston, MA, USA.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Gianni Bonadonna Foundation, Milano, Italy.;Gilead Sciences, Inc., Foster City, CA, USA.;Gilead Sciences, Inc., Foster City, CA, USA.;Evidera PPD, Bethesda, MD, USA.;Patient Author, University of North.;Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium."
"48","La Rosa A;Groh M;Martin A;Tran Ba S;Cucherousset N;Mouriaux F;Sedira N;Héron E;Galatoire O;Saadoun D;Abbas A;Bassirou M;Vicaut E;Dhote R;Abad S","La Rosa, Ambre;Groh, Matthieu;Martin, Antoine;Tran Ba, Stéphane;Cucherousset, Nahla;Mouriaux, Frédéric;Sedira, Neila;Héron, Emmanuel;Galatoire, Olivier;Saadoun, David;Abbas, Aïcha;Bassirou, Mboup;Vicaut, Eric;Dhote, Robin;Abad, Sebastien",NA,"BMJ open ophthalmology","England","eng","Journal Article","Immunology;Inflammation;Lacrimal gland;Orbit;Treatment Medical","Humans;Prospective Studies;Female;Male;Middle Aged;Risk Factors;Adult;Orbital Pseudotumor;Glucocorticoids;France;Aged;Adipose Tissue;Treatment Failure;Prednisone;Follow-Up Studies;Orbit","Humans;Prospective Studies;Female;Male;Middle Aged;Risk Factors;Adult;Orbital Pseudotumor;Glucocorticoids;France;Aged;Adipose Tissue;Treatment Failure;Prednisone;Follow-Up Studies;Orbit","To better characterise the effects of corticosteroids on the course of pure idiopathic orbital inflammation syndrome (pIOIS). This was a national, multicentre, prospective, non-interventional cohort study ( ). Among the 35 patients with histologically proven orbital inflammation who had previously been studied for their IgG4 immunostaining status, we selected those with a negative IgG4 status (ie, pIOIS) who received corticosteroids as single first-line treatment. Clinical, morphological and pathological findings at diagnosis and during follow-up from treatment initiation to study completion were analysed. Patients were assessed for their response to prednisone after the 24-month prospective phase in terms of remission (≤10 mg/d) or failure (>10 mg/d). Daily standard doses of prednisone (DSDP) were calculated at different time-points and compared between response groups. Of the 17 patients with pIOIS included in the final analysis, two-thirds received corticosteroids only. DSDP (mg/kg-day) were significantly higher at the time of failure in eight patients (47%) than in nine (53%) remitting at M24 (0.16 vs 0.045; p: 0.03). Notably, patients with pIOIS with a cellular pattern or orbital fat involvement tended to receive higher daily corticosteroid doses in the event of failure than remission (0.16 vs 0.045 and 0.12 vs 0.042, respectively). During treatment, maximal DSDP was 0.52 in failed patients. The highest corticosteroid doses were insufficient to prevent failure in patients with pIOIS, particularly in those with a cellular pattern or orbital fat involvement. Large-scale interventional studies are now necessary to clarify prognostic factors and optimise corticosteroid management in patients with pIOIS.","Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France.;Médecine Interne, Centre National de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.;Université Versailles St-Quentin-en-Yvelines, Versailles, France.;Anatomopathologie, Hôpital Avicenne, APHP, Bobigny, France.;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;Radiologie, Hôpital Avicenne, AP-HP, Bobigny, France.;Imagerie, Fondation Adolphe de Rothschild, Paris, France.;Anatomopathologie, Hôpital Avicenne, APHP, Bobigny, France.;Ophtalmologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Médecine Interne, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, Île-de-France, France.;Médecine Interne, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, Île-de-France, France.;Chirurgie Oculoplastique, Fondation Adolphe de Rothschild, Paris, France.;Médecine Interne, Hôpital Pitié Salpétrière, APHP, Paris, France.;Université Pierre et Marie Curie (UPMC), Paris 6, DHU I2B, Paris, France.;Inserm UMRS 938, UPMC, Paris 6, Paris, France.;Immunologie Biologique, Hôpital Saint-Antoine, APHP, Paris, France.;Faculté de Médecine, UPMC, Paris 6, Paris, France.;Unité de Recherche Clinique, Hôpital Fernand Widal, AP-HP, Paris, France.;Unité de Recherche Clinique, Hôpital Fernand Widal, AP-HP, Paris, France.;Faculté de Médecine, Université Sorbonne Paris-Cité, Paris, France.;Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France.;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;UMR1125, LI2P, Université Sorbonne Paris Nord, Bobigny, France.;Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;UMR1125, LI2P, Université Sorbonne Paris Nord, Bobigny, France.","NA",0,"2397-3269","BMJ Open Ophthalmol","BMJ Open Ophthalmol",2024,"2024","9","10.1136/bmjophth-2024-001663",NA,"","","39313294","39313294","PUBMED","Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France.;Médecine Interne, Centre National de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.;Université Versailles St-Quentin-en-Yvelines, Versailles, France.;Anatomopathologie, Hôpital Avicenne, APHP, Bobigny, France.;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;Radiologie, Hôpital Avicenne, AP-HP, Bobigny, France.;Imagerie, Fondation Adolphe de Rothschild, Paris, France.;Anatomopathologie, Hôpital Avicenne, APHP, Bobigny, France.;Ophtalmologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Médecine Interne, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, Île-de-France, France.;Médecine Interne, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, Île-de-France, France.;Chirurgie Oculoplastique, Fondation Adolphe de Rothschild, Paris, France.;Médecine Interne, Hôpital Pitié Salpétrière, APHP, Paris, France.;Université Pierre et Marie Curie (UPMC), Paris 6, DHU I2B, Paris, France.;Inserm UMRS 938, UPMC, Paris 6, Paris, France.;Immunologie Biologique, Hôpital Saint-Antoine, APHP, Paris, France.;Faculté de Médecine, UPMC, Paris 6, Paris, France.;Unité de Recherche Clinique, Hôpital Fernand Widal, AP-HP, Paris, France.;Unité de Recherche Clinique, Hôpital Fernand Widal, AP-HP, Paris, France.;Faculté de Médecine, Université Sorbonne Paris-Cité, Paris, France.;Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny, France.;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;UMR1125, LI2P, Université Sorbonne Paris Nord, Bobigny, France.;Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (APHP), Bobigny;Faculté de Médecine SMBH, Université Sorbonne Paris Nord, Bobigny, France.;UMR1125, LI2P, Université Sorbonne Paris Nord, Bobigny, France."
"49","Houben NAM;Fustolo-Gunnink S;Fijnvandraat K;Caram-Deelder C;Carrascosa MA;Beuchée A;Brække K;Cardona F;Debeer A;Domingues S;Ghirardello S;Grizelj R;Hadžimuratovic E;Heiring C;Krivec JL;Malý J;Matasova K;Moore CM;Muehlbacher T;Szabó M;Szczapa T;Zaharie G;de Jager J;Reibel-Georgi NJ;New HV;Stanworth SJ;Deschmann E;Roehr CC;Dame C;le Cessie S;van der Bom J;Lopriore E","Houben, Nina A M;Fustolo-Gunnink, Suzanne;Fijnvandraat, Karin;Caram-Deelder, Camila;Carrascosa, Marta Aguar;Beuchée, Alain;Brække, Kristin;Cardona, Francesco;Debeer, Anne;Domingues, Sara;Ghirardello, Stefano;Grizelj, Ruza;Hadžimuratovic, Emina;Heiring, Christian;Krivec, Jana Lozar;Malý, Jan;Matasova, Katarina;Moore, Carmel Maria;Muehlbacher, Tobias;Szabó, Miklos;Szczapa, Tomasz;Zaharie, Gabriela;de Jager, Justine;Reibel-Georgi, Nora Johanna;New, Helen V;Stanworth, Simon J;Deschmann, Emöke;Roehr, Charles C;Dame, Christof;le Cessie, Saskia;van der Bom, Johanna;Lopriore, Enrico","Red Blood Cell Transfusion in European Neonatal Intensive Care Units, 2022 to 2023.","JAMA network open","United States","eng","Journal Article","","Humans;Erythrocyte Transfusion;Infant, Newborn;Intensive Care Units, Neonatal;Europe;Prospective Studies;Female;Male;Infant, Premature","Humans;Erythrocyte Transfusion;Infant, Newborn;Intensive Care Units, Neonatal;Europe;Prospective Studies;Female;Male;Infant, Premature","Red blood cell (RBC) transfusions are frequently administered to preterm infants born before 32 weeks of gestation in the neonatal intensive care unit (NICU). Two randomized clinical trials (Effects of Transfusion Thresholds on Neurocognitive Outcomes of Extremely Low-Birth-Weight Infants [ETTNO] and Transfusion of Prematures [TOP]) found that liberal RBC transfusion thresholds are nonsuperior to restrictive thresholds, but the extent to which these results have been integrated into clinical practice since publication in 2020 is unknown. To describe neonatal RBC transfusion practice in Europe. This international prospective observational cohort study collected data between September 1, 2022, and August 31, 2023, with a 6-week observation period per center, from 64 NICUs in 22 European countries. Participants included 1143 preterm infants born before 32 weeks of gestation. Admission to the NICU. Study outcome measures included RBC transfusion prevalence rates, cumulative incidence, indications, pretransfusion hemoglobin (Hb) levels, volumes, and transfusion rates, Hb increment, and adverse effects of RBC transfusion. A total of 1143 preterm infants were included (641 male [56.1%]; median gestational age at birth, 28 weeks plus 2 days [IQR, 26 weeks plus 2 days to 30 weeks plus 2 days]; median birth weight, 1030 [IQR, 780-1350] g), of whom 396 received 1 or more RBC transfusions, totaling 903 transfusions. Overall RBC transfusion prevalence rate during postnatal days 1 to 28 was 3.4 transfusion days per 100 admission days, with considerable variation across countries, only partly explained by patient mix. By day 28, 36.5% (95% CI, 31.6%-41.5%) of infants had received at least 1 transfusion. Most transfusions were given based on a defined Hb threshold (748 [82.8%]). Hemoglobin levels before transfusions indicated for threshold were below the restrictive thresholds set by ETTNO in 324 of 729 transfusions (44.4%) and TOP in 265 of 729 (36.4%). Conversely, they were between restrictive and liberal thresholds in 352 (48.3%) and 409 (56.1%) transfusions, respectively, and above liberal thresholds in 53 (7.3%) and 55 (7.5%) transfusions, respectively. Most transfusions given based on threshold had volumes of 15 mL/kg (470 of 738 [63.7%]) and were administered over 3 hours (400 of 738 [54.2%]), but there was substantial variation in dose and duration. In this cohort study of very preterm infants, most transfusions indicated for threshold were given for pretransfusion Hb levels above restrictive transfusion thresholds evaluated in recent trials. These results underline the need to optimize practices and for implementation research to support uptake of evidence.","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Sanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Centro Materno-Infantil do Norte-Unidade Local de Saúde de Santo António, Porto, Portugal.;Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Králové, Hradec Králové, Czech Republic.;Jessenius Faculty of Medicine, University Hospital Martin, Martin, Slovakia.;School of Medicine, University College Dublin, Dublin, Ireland.;National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Neonatology, Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.;Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.;Women's and Children's Division, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2024,"2024","7","10.1001/jamanetworkopen.2024.34077","e2434077","","","39298172","39298172","PUBMED","Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Sanquin Research, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Hematology, Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.;Sanquin Research, Department of Molecular Cellular Hemostasis, Amsterdam, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Neonatology, La Fe University Hospital, Valencia, Spain.;Department of Pediatrics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Women and Children's Division, Department of Neonatal Intensive Care, Oslo University Hospital, Oslo, Norway.;Division of Neonatology, Medical University Vienna, Vienna, Austria.;Department of Neonatology, Universitair Ziekenhuis Leuven, Leuven, Belgium.;Centro Materno-Infantil do Norte-Unidade Local de Saúde de Santo António, Porto, Portugal.;Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy.;Department of Pediatrics, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.;Paediatric Clinic, University Medical Center Sarajevo, Sarajevo, Bosnia and Herzegovina.;Department of Neonatal and Paediatric Intensive Care, Copenhagen University Hospital, Rigshospitalet, Denmark.;Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.;Department of Neonatology, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.;Department of Pediatrics, University Hospital Hradec Králové, Hradec Králové, Czech Republic.;Jessenius Faculty of Medicine, University Hospital Martin, Martin, Slovakia.;School of Medicine, University College Dublin, Dublin, Ireland.;National Maternity Hospital, Dublin, Ireland.;Department of Neonatology, University Hospital Zurich, Zurich, Switzerland.;Department of Neonatology, Semmelweis University, Budapest, Hungary.;II Department of Neonatology, Poznan University of Medical Sciences, Poznan, Poland.;University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;NHS (National Health Service) Blood and Transplant, London, United Kingdom.;Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.;Department of Neonatology, Karolinska Institute, Stockholm, Sweden.;National Perinatal Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, United Kingdom.;Faculty of Health Sciences, University of Bristol, Bristol, United Kingdom.;Women's and Children's Division, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.;Charité-Universitätsmedizin Berlin, Berlin, Germany.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.;Division of Neonatology, Willem-Alexander Children's Hospital, Leiden University Medical Center, Leiden, the Netherlands."
"50","Paillaud E;Galvin A;Doublet S;Poisson J;Gay P;Perrin C;Boudou-Rouquette P;Grellety T;Teyssonneau D;Ayati S;Saint-Lezer A;Culine S;Annonay M;Solem-Laviec H;Boulahssass R;Baldini C;Tchalla A;Lalet C;Hue L;Pulido M;Mathoulin-Pélissier S","Paillaud, Elena;Galvin, Angéline;Doublet, Solène;Poisson, Johanne;Gay, Pierre;Perrin, Christophe;Boudou-Rouquette, Pascaline;Grellety, Thomas;Teyssonneau, Diego;Ayati, Siavoshe;Saint-Lezer, Arnaud;Culine, Stéphane;Annonay, Mylène;Solem-Laviec, Heidi;Boulahssass, Rabia;Baldini, Capucine;Tchalla, Achille;Lalet, Caroline;Hue, Lucas;Pulido, Marina;Mathoulin-Pélissier, Simone","Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study.","Patient education and counseling","Ireland","eng","Journal Article","Cancer;Digital tools;Internet use;Literacy;Older adults","Humans;Health Literacy;Cross-Sectional Studies;Female;Neoplasms;Middle Aged;Male;Adult;France;Aged;Surveys and Questionnaires;Adolescent;Age Factors;Young Adult;Internet","Humans;Health Literacy;Cross-Sectional Studies;Female;Neoplasms;Middle Aged;Male;Adult;France;Aged;Surveys and Questionnaires;Adolescent;Age Factors;Young Adult;Internet","To evaluate health literacy (HL), assess the use of digital tools/sources, and identify factors associated with low or moderate HL in older (aged ≥65) and younger (18-64) patients with cancer. A cross-sectional multicenter study including patients with cancer was conducted in 26 centers in France. HL was assessed using the Functional, Communicative and Critical Health Literacy (FCCHL) scale. Factors associated with low/moderate HL (score<median) were studied using logistic regression models. The population comprised 669 patients aged 18-64 and 658 patients aged 65 + . The older patients used digital tools less than younger patients did. The median overall HL score was: 3.7 and 3.6, for younger and older patients respectively. The need for help to fill out the questionnaire was associated with low/moderate HL in both age groups. Then, older age and living in rural area were associated with low/moderate HL in younger patients only, and rare internet use in older patients. This article highlights the importance of considering HL in care management, as well as whom patients may present higher risk of low HL. It is crucial to assess HL in patients with cancer, and then to seize every opportunity to enhance HL.","Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France; Paris Est Créteil University, INSERM, IMRB, F-94010 Creteil, France.;Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR, 1219, Bordeaux;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Centre Eugène Marquis, Comprehensive Cancer Center, Rennes, France.;Department of Medical Oncology, Hôpital Cochin Port-Royal, ARIANE, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), Paris, France.;Centre Hospitalier de la Côte Basque, Bayonne, France.;Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Centre Georges-François Leclerc, Comprehensive Cancer Center, Dijon, France.;Centre hospitalier de Mont-de-Marsan, Mont-De-Marsan, France.;Université Paris-Cité, Department of Medical Oncology, Hospital Saint-Louis, AP-HP Nord, Paris, France.;Centre hospitalier de Martinique, Fort-De-France, France.;Centre Francois Baclesse, Comprehensive Cancer Center, Caen, France.;Geriatric Coordination Unit for Geriatric Oncology (UCOG), Centre Hospitalier Universitaire de Nice, Nice, France; FHU OncoAge, Nice, France; University Côte d'Azur, Nice, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Centre hospitalier universitaire de Limoges, Geriatric medicine unit, Limoges, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR, 1219, Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.","NA",0,"1873-5134","Patient Educ Couns","Patient Educ Couns",2024,"2025","130","10.1016/j.pec.2024.108420","108420","","","39303502","39303502","PUBMED","Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France; Paris Est Créteil University, INSERM, IMRB, F-94010 Creteil, France.;Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR, 1219, Bordeaux;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Université Paris Cité, Department of Geriatrics, European Georges Pompidou Hospital, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), F-75015 Paris, France.;Centre Eugène Marquis, Comprehensive Cancer Center, Rennes, France.;Department of Medical Oncology, Hôpital Cochin Port-Royal, ARIANE, Paris Cancer Institute CARPEM, Assistance-Publique Hôpitaux de Paris (AP-HP), Paris, France.;Centre Hospitalier de la Côte Basque, Bayonne, France.;Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Centre Georges-François Leclerc, Comprehensive Cancer Center, Dijon, France.;Centre hospitalier de Mont-de-Marsan, Mont-De-Marsan, France.;Université Paris-Cité, Department of Medical Oncology, Hospital Saint-Louis, AP-HP Nord, Paris, France.;Centre hospitalier de Martinique, Fort-De-France, France.;Centre Francois Baclesse, Comprehensive Cancer Center, Caen, France.;Geriatric Coordination Unit for Geriatric Oncology (UCOG), Centre Hospitalier Universitaire de Nice, Nice, France; FHU OncoAge, Nice, France; University Côte d'Azur, Nice, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Centre hospitalier universitaire de Limoges, Geriatric medicine unit, Limoges, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR, 1219, Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France."
"51","Novello S;Schoenmaker T;de Vries TJ;Doulabi BZ;Bakker AD;Laine ML;Jansen IDC","Novello, Solen;Schoenmaker, Ton;de Vries, Teun J;Doulabi, Behrouz Zandieh;Bakker, Astrid D;Laine, Marja L;Jansen, Ineke D C","Gingival fibroblasts produce paracrine signals that affect osteoclastogenesis in vitro.","Bone reports","United States","eng","Journal Article","Gingival fibroblasts;Inflammation;Osteoclastogenesis;Paracrine communication;Periodontitis;Peripheral blood mononuclear cells","","","In periodontitis, gingival fibroblasts (GF) appear to produce a multitude of paracrine factors. However, the influence of GF-derived soluble factors on osteoclastogenesis remains unclear. In this case study, production of paracrine factors by GF was assessed under inflammatory and non-inflammatory conditions, as well as their effect on osteoclastogenesis. Human primary GF were cultured in a transwell system and primed with a cocktail of IL-1β, IL-6 and TNF-α to mimic inflammation. GF were co-cultured directly and indirectly with human peripheral blood mononuclear cells (PBMC). Cytokines and chemokines in supernatants (flow cytometry based multiplex assay), osteoclastogenesis (TRAcP staining) and gene expression (qPCR) were quantified on days 7 and 21. Results from this case study showed that GF communicated via soluble factors with PBMC resulting in a two-fold induction of osteoclasts. Reversely, PBMC induced gene expression of IL-6, OPG and MCP-1 by GF. Remarkably, after priming of GF with cytokines, this communication was impaired and resulted in fewer osteoclasts. This could be partly explained by an increase in IL-10 expression and a decrease in MCP-1 expression. Intriguingly, the short priming of GF resulted in significantly higher expression of inflammatory cytokines that was sustained at both 7 and 21 days. GF appear to produce paracrine factors capable of stimulating osteoclastogenesis in the absence of physical cell-cell interactions. GF cultured in the presence of PBMC or osteoclasts had a remarkably inflammatory phenotype. Given profound expression of both pro- and anti-inflammatory cytokines after the inflammatory stimulus, it is probably the effector hierarchy that leads to fewer osteoclasts.","UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.","NA",0,"2352-1872","Bone Rep","Bone Rep",2024,"2024","22","10.1016/j.bonr.2024.101798","101798","","","39252697","39252697","PUBMED","UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Oral Cell Biology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.;Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, the Netherlands."
"52","Landes-Château C;Ricigliano VA;Mondot L;Thouvenot E;Labauge P;Louapre C;Zéphir H;Durand-Dubief F;Le Page E;Siva A;Cohen M;Yazdan Panah A;Azevedo CJ;Okuda DT;Stankoff B;Lebrun-Frénay C","Landes-Château, Cassandre;Ricigliano, Vito Ag;Mondot, Lydiane;Thouvenot, Eric;Labauge, Pierre;Louapre, Céline;Zéphir, Hélène;Durand-Dubief, Françoise;Le Page, Emmanuelle;Siva, Aksel;Cohen, Mikael;Yazdan Panah, Arya;Azevedo, Christina J;Okuda, Darin T;Stankoff, Bruno;Lebrun-Frénay, Christine","Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome.","Multiple sclerosis (Houndmills, Basingstoke, England)","England","eng","Journal Article","GFAP;Kappa index;MRI;NfL;Radiologically isolated syndrome;choroid plexus","Humans;Female;Male;Adult;Choroid Plexus;Middle Aged;Magnetic Resonance Imaging;Demyelinating Diseases;Retrospective Studies;Multiple Sclerosis","Humans;Female;Male;Adult;Choroid Plexus;Middle Aged;Magnetic Resonance Imaging;Demyelinating Diseases;Retrospective Studies;Multiple Sclerosis","Choroid plexus (ChP) enlargement is an emerging radiological biomarker in multiple sclerosis (MS). This study aims to assess ChP volume in a large cohort of patients with radiologically isolated syndrome (RIS) versus healthy controls (HC) and explore its relationship with other brain volumes, disease activity, and biological markers. RIS individuals were included retrospectively and compared with HC. ChPs were automatically segmented using an in-house automated algorithm and manually corrected. A total of 124 patients fulfilled the 2023 RIS criteria, and 55 HCs were included. We confirmed that ChPs are enlarged in RIS versus HC (mean (±SD) normalized ChP volume: 17.24 (±4.95) and 11.61 (±3.58), respectively,   < 0.001). Larger ChPs were associated with more periventricular lesions (ρ = 0.26;   = 0.27;   = 0.005 for the correlation with lesion volume, and ρ = 0.2;   = 0.21;   = 0.002 for the correlation with lesion number) and lower thalamic volume (ρ = -0.38;   = 0.44;   < 0.001), but not with lesions in other brain regions. Conversely, ChP volume did not correlate with biological markers. No significant difference in ChP volume was observed between subjects who presented or did not have a clinical event or between those with or without imaging disease activity. This study provides evidence that ChP volume is higher in RIS and is associated with measures reflecting periventricular pathology but does not correlate with biological, radiological, or clinical markers of disease activity.","Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;IGF, University Montpellier, CNRS, INSERM, Montpellier, France.;Centre hospitalier universitaire de Montpellier, Montpellier, France.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;University of Lille, INSERM U 1172, CHU of Lille, Lille, France.;Hospices Civils de Lyon, Lyon, France.;Centre hospitalier universitaire de Rennes, Rennes, France.;Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkiye.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, France.;Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.;The University of Texas Southwestern Medical Center, Peter O'Donnell Jr. Brain Institute, Dallas, TX, USA.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France.","NA",0,"1477-0970","Mult Scler","Mult Scler",2024,"2024","30","10.1177/13524585241272943","1278-1289","","","39246289","39246289","PUBMED","Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;IGF, University Montpellier, CNRS, INSERM, Montpellier, France.;Centre hospitalier universitaire de Montpellier, Montpellier, France.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;University of Lille, INSERM U 1172, CHU of Lille, Lille, France.;Hospices Civils de Lyon, Lyon, France.;Centre hospitalier universitaire de Rennes, Rennes, France.;Cerrahpasa School of Medicine, Istanbul University, Istanbul, Turkiye.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France.;Sorbonne Université, Institut du Cerveau-Paris Brain Institute-ICM, CNRS, Inria, Inserm, AP-HP, Hôpital de la Pitié Salpêtrière, France.;Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.;The University of Texas Southwestern Medical Center, Peter O'Donnell Jr. Brain Institute, Dallas, TX, USA.;Paris Brain Institute-ICM, CNRS, Inserm, Neurology Department, Pitié-Salpêtrière Hospital, Sorbonne Université, AP-HP, Paris, France.;Université Côte d'Azur, UMR2CA (URRIS), Nice, France."
"53","Semenchuk J;Naito Y;Charman SC;Carr SB;Cheng SY;Marshall BC;Faro A;Elbert A;Gutierrez HH;Goss CH;Karadag B;Burgel PR;Colombo C;Salvatore M;Padoan R;Daneau G;Harutyunyan S;Kashirskaya N;Kirwan L;Middleton PG;Ruseckaite R;de Monestrol I;Naehrlich L;Mondejar-Lopez P;Jung A;van Rens J;Bakkeheim E;Orenti A;Zomer-van Ommen D;da Silva-Filho LVR;Fernandes FF;Zampoli M;Stephenson AL","Semenchuk, Julie;Naito, Yumi;Charman, Susan C;Carr, Siobhán B;Cheng, Stephanie Y;Marshall, Bruce C;Faro, Albert;Elbert, Alexander;Gutierrez, Hector H;Goss, Christopher H;Karadag, Bulent;Burgel, Pierre-Régis;Colombo, Carla;Salvatore, Marco;Padoan, Rita;Daneau, Géraldine;Harutyunyan, Satenik;Kashirskaya, Nataliya;Kirwan, Laura;Middleton, Peter G;Ruseckaite, Rasa;de Monestrol, Isabelle;Naehrlich, Lutz;Mondejar-Lopez, Pedro;Jung, Andreas;van Rens, Jacqui;Bakkeheim, Egil;Orenti, Annalisa;Zomer-van Ommen, Domenique;da Silva-Filho, Luiz Vicente Rf;Fernandes, Flavia Fonseca;Zampoli, Marco;Stephenson, Anne L","Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.","Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","Netherlands","eng","Journal Article","COVID-19;Coronavirus;Cystic fibrosis","Humans;Cystic Fibrosis;COVID-19;Nutritional Status;Female;Male;Retrospective Studies;Adult;Forced Expiratory Volume;Body Mass Index;SARS-CoV-2;Respiratory Function Tests","Humans;Cystic Fibrosis;COVID-19;Nutritional Status;Female;Male;Retrospective Studies;Adult;Forced Expiratory Volume;Body Mass Index;SARS-CoV-2;Respiratory Function Tests","Factors associated with severe COVID-19 infection have been identified; however, the impact of infection on longer-term outcomes is unclear. The objective of this study was to examine the impact of COVID-19 infection on the trajectory of lung function and nutritional status in people with cystic fibrosis (pwCF). This is a retrospective global cohort study of pwCF who had confirmed COVID-19 infection diagnosed between January 1, 2020 and December 31, 2021. Forced expiratory volume in one second percent predicted (ppFEV ) and body mass index (BMI) twelve months prior to and following a diagnosis of COVID-19 were recorded. Change in mean ppFEV  and BMI were compared using a t-test. A linear mixed-effects model was used to estimate change over time and to compare the rate of change before and after infection. A total of 6,500 cases of COVID-19 in pwCF from 33 countries were included for analysis. The mean difference in ppFEV  pre- and post-infection was 1.4 %, (95 % CI 1.1, 1.7). In those not on modulators, the difference in rate of change pre- and post-infection was 1.34 %, (95 % CI -0.88, 3.56) per year (p = 0.24) and -0.74 % (-1.89, 0.41) per year (p = 0.21) for those on elexacaftor/tezacaftor/ivacaftor. No clinically significant change was noted in BMI or BMI percentile before and after COVID-19 infection. No clinically meaningful impact on lung function and BMI trajectory in the year following infection with COVID-19 was identified. This work highlights the ability of the global CF community to unify and address critical issues facing pwCF.","Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.;UK Trust, London, United Kingdom.;UK Trust, London, United Kingdom.;Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas's NHS Foundation Trust and Imperial College, London, United Kingdom.;Cystic Fibrosis Canada, Toronto, Canada.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Division of Pediatric Pulmonary and Sleep Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.;Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States.;Division of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.;National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France.;Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.;National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit; Italian CF, Registry, Istituto Superiore di Sanità, Rome, Italy.;Italian Cystic Fibrosis Registry, Scientific Board, Rome Italy.;Belgian Cystic Fibrosis Registry, Health services research, Department of epidemiology and public health, Sciensano, Belgium.;Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.;Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute (""MONIKI""), Moscow, Russia.;Cystic Fibrosis Registry of Ireland, Woodview House, University College Dublin, Ireland.;Bronchiectasis and CF service, Department of Respiratory & Sleep Medicine, Westmead Hospital, Sydney, Australia.;Department of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.;Department of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm CF Center, Karolinska University Hospital Huddinge, Sweden.;Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.;Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.;Department of Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.;Department of Paediatrics, University Hospital Leuven, Leuven, Belgium, European Cystic Fibrosis Society, Karup, Denmark.;National Resource Centre for Cystic Fibrosis, Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.;Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology ""G. A. Maccacaro"", Università degli Studi di Milano, Milan, Italy.;Dutch CF Foundation (NCFS), Baarn, the Netherlands.;Instituto da Criança e do Adolescente HCFMUSP, São Paulo, Brazil.;Medicine Department, Universidade Federal de Catalão, Catalão, Brazil, Hospital de Base do Distrito Federal, Brasília, Brazil.;Department of Paediatrics and Child Health, University of Cape Town, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.;Department of Respirology, St. Michael's Hospital, Toronto, Ontario","NA",0,"1873-5010","J Cyst Fibros","J Cyst Fibros",2024,"2024","23","10.1016/j.jcf.2024.07.019","815-822","","","39191560","39191560","PUBMED","Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.;UK Trust, London, United Kingdom.;UK Trust, London, United Kingdom.;Royal Brompton and Harefield Hospitals, part of Guy's and St Thomas's NHS Foundation Trust and Imperial College, London, United Kingdom.;Cystic Fibrosis Canada, Toronto, Canada.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Cystic Fibrosis Foundation, Bethesda, MD, USA.;Division of Pediatric Pulmonary and Sleep Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.;Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA, United States.;Division of Pediatric Pulmonology, Marmara University Faculty of Medicine, Istanbul, Turkey.;National Reference CF center and Respiratory Medicine, Cochin Hospital APHP and Université Paris Cité, Institut Cochin (InsermU1016), Paris, France.;Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.;National Center Rare Diseases, Undiagnosed Rare Diseases Interdepartmental Unit; Italian CF, Registry, Istituto Superiore di Sanità, Rome, Italy.;Italian Cystic Fibrosis Registry, Scientific Board, Rome Italy.;Belgian Cystic Fibrosis Registry, Health services research, Department of epidemiology and public health, Sciensano, Belgium.;Yerevan University CF Centre, Muratsan Hospital, Yerevan, Armenia.;Research Centre for Medical Genetics, Moscow Regional Research and Clinical Institute (""MONIKI""), Moscow, Russia.;Cystic Fibrosis Registry of Ireland, Woodview House, University College Dublin, Ireland.;Bronchiectasis and CF service, Department of Respiratory & Sleep Medicine, Westmead Hospital, Sydney, Australia.;Department of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.;Department of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm CF Center, Karolinska University Hospital Huddinge, Sweden.;Department of Pediatrics, Justus-Liebig-University Giessen, Giessen, Germany.;Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.;Department of Pulmonology, University Children`s Hospital Zurich, Zurich, Switzerland.;Department of Paediatrics, University Hospital Leuven, Leuven, Belgium, European Cystic Fibrosis Society, Karup, Denmark.;National Resource Centre for Cystic Fibrosis, Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.;Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology ""G. A. Maccacaro"", Università degli Studi di Milano, Milan, Italy.;Dutch CF Foundation (NCFS), Baarn, the Netherlands.;Instituto da Criança e do Adolescente HCFMUSP, São Paulo, Brazil.;Medicine Department, Universidade Federal de Catalão, Catalão, Brazil, Hospital de Base do Distrito Federal, Brasília, Brazil.;Department of Paediatrics and Child Health, University of Cape Town, Red Cross War Memorial Children's Hospital, Cape Town, South Africa.;Department of Respirology, St. Michael's Hospital, Toronto, Ontario"
"54","Dezellus A;Mirallie S;Leperlier F;Sauterey B;Bouet PE;Dessaint A;Duros S;Gremeau AS;Mouret-Reynier MA;Durand LM;Venat L;De Blay P;Robert M;Freour T;Campone M;Blanc-Lapierre A;Bordes V","Dezellus, A;Mirallie, S;Leperlier, F;Sauterey, B;Bouet, P-E;Dessaint, A;Duros, S;Gremeau, A S;Mouret-Reynier, M-A;Durand, L M;Venat, L;De Blay, P;Robert, M;Freour, T;Campone, M;Blanc-Lapierre, A;Bordes, V","Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Breast cancer;Fertility preservation;Neoadjuvant chemotherapy;Ovarian stimulation;Tamoxifen","Humans;Female;Fertility Preservation;Breast Neoplasms;Tamoxifen;Adult;Prospective Studies;Ovulation Induction;Follow-Up Studies;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Young Adult;Pregnancy;Neoadjuvant Therapy;Letrozole;Pregnancy Rate;Adolescent;Oocyte Retrieval;Cryopreservation","Humans;Female;Fertility Preservation;Breast Neoplasms;Tamoxifen;Adult;Prospective Studies;Ovulation Induction;Follow-Up Studies;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Young Adult;Pregnancy;Neoadjuvant Therapy;Letrozole;Pregnancy Rate;Adolescent;Oocyte Retrieval;Cryopreservation","Fertility issues are of great concern for young women undergoing treatment for breast cancer (BC). Fertility preservation (FP) protocols using controlled ovarian stimulation (COS) with letrozole have been widely used with overall good results. However, letrozole cannot be used in every country in this context. This study aimed to assess the efficacy of tamoxifen for COS in women with early BC undergoing FP. This multicentric prospective study included patients aged 18-40, diagnosed with stage I, II and III invasive BC, undergoing tamoxifen-COS before adjuvant or neoadjuvant chemotherapy (NAC). The primary endpoint was the efficacy of tamoxifen-COS protocol evaluated by the number of oocytes collected and vitrified. Secondary endpoints included the time interval before chemotherapy, breast cancer (BC) recurrence rates, and reproductive outcomes. Ninety-five patients were included between 2014 and 2017, aged 31.5 ± 4 years on average. 37.9 % received NAC and 62.1 % received adjuvant chemotherapy. FP procedure was successful in 89.5 % of the cycles. The mean number of collected and vitrified oocytes was 12.8 ± 7.9 and 9.8 ± 6.2, respectively. The mean duration of COS was 10.4 ± 1.9 days. Median time before chemotherapy initiation was 3.6 weeks (IQR 3.1; 4.1) for women receiving NAC. Five-year relapse-free and overall survival rates were in-line with those expected in this population. Twenty-one women had spontaneous full-term pregnancies, while 5 underwent IVF cycles with frozen-thawed oocytes, without pregnancy. Tamoxifen-COS protocols appear to be feasible before adjuvant or NAC treatment in young BC patients and efficient in terms of oocyte yield.","Institut de Cancérologie de l'Ouest, Saint Herblain et Angers;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU Angers, France.;Centre Eugène Marquis, Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Limoges, France.;Service d'oncologie, CHU de Limoges, France.;Service de Gynécologie-Obstétrique CH de Vendée, La Roche-sur-Yon, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France; Université Nantes/Angers, Inserm, CNRS, CRCI2NA, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.","NA",0,"1532-3080","Breast","Breast",2024,"2024","77","10.1016/j.breast.2024.103776","103776","","","39167853","39167853","PUBMED","Institut de Cancérologie de l'Ouest, Saint Herblain et Angers;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU Angers, France.;Centre Eugène Marquis, Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Rennes, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Limoges, France.;Service d'oncologie, CHU de Limoges, France.;Service de Gynécologie-Obstétrique CH de Vendée, La Roche-sur-Yon, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Service de Médecine et Biologie du Développement et de la Reproduction, CHU de Nantes, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France; Université Nantes/Angers, Inserm, CNRS, CRCI2NA, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France.;Institut de Cancérologie de l'Ouest, Saint Herblain et Angers, France."
"55","Kabirian R;Tredan O;Marmé F;Paoletti X;Eberst L;Lebreton C;De La Motte Rouge T;Sabatier R;Angelergues A;Fabbro M;Van Gorp T;Mansi L;Gladieff L;Kaczmarek E;Alexandre J;Grellety T;Favier L;Welz J;Frenel JS;Leary A","Kabirian, Rayan;Tredan, Olivier;Marmé, Frederik;Paoletti, Xavier;Eberst, Lauriane;Lebreton, Coriolan;De La Motte Rouge, Thibault;Sabatier, Renaud;Angelergues, Antoine;Fabbro, Michel;Van Gorp, Toon;Mansi, Laura;Gladieff, Laurence;Kaczmarek, Emilie;Alexandre, Jérôme;Grellety, Thomas;Favier, Laure;Welz, Julia;Frenel, Jean-Sébastien;Leary, Alexandra","TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.","Future oncology (London, England)","England","eng","Clinical Trial Protocol","OSE2101;anti PD1;maintenance;pembrolizumab;platinum-sensitive;recurrent ovarian cancer;vaccine","Female;Humans;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Cancer Vaccines;Clinical Trials, Phase II as Topic;Maintenance Chemotherapy;Multicenter Studies as Topic;Neoplasm Recurrence, Local;Ovarian Neoplasms;Randomized Controlled Trials as Topic;Platinum","Female;Humans;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Cancer Vaccines;Clinical Trials, Phase II as Topic;Maintenance Chemotherapy;Multicenter Studies as Topic;Neoplasm Recurrence, Local;Ovarian Neoplasms;Randomized Controlled Trials as Topic;Platinum","Ovarian cancer is a leading cause of death from gynecological cancers worldwide. Platinum-based chemotherapy provides the cornerstone of the medical management. In first line and subsequent relapses, maintenance strategies are offered to prolong intervals between lines of chemotherapy. Current maintenance options involve bevacizumab and poly ADP-ribose polymerase inhibitors, but these lines of therapy can only be used once in the disease course. Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.  NCT04713514 (ClinicalTrials.gov).","Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France.;Centre Léon Bérard, Lyon, & GINECO, France.;Medical Faculty Mannheim, Heidelberg University & AGO Study Group, Germany.;Biostatistic Unit, Institut Curie, Paris, France.;Institut de Cancérologie de Strasbourg Europe, ICANS, Strasbourg, & GINECO, France.;Institut Bergonié, Bordeaux, & GINECO, France.;Centre Eugène Marquis, Rennes, & GINECO, France.;Aix-Marseille Univ, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Department of Medical Oncology, Marseille, & GINECO, France.;Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, & GINECO, France.;Institut du Cancer de Montpellier (ICM), Montpellier, & GINECO, France.;Leuven Cancer Institute, Division of Gynaecological Oncology, University Hospital Leuven, BGOG, Belgium.;CHU Besançon - Hôpital jean Minjoz, Besançon, & GINECO, France.;Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, & GINECO, France.;Centre Oscar Lambret, Lille, & GINECO, France.;Université de Paris Cité, AP-HP, Hôpital Cochin, Paris, & GINECO, France.;Centre Hospitalier de la Côte Basque, Bayonne, & GINECO, France.;Centre Georges François Leclerc, Dijon, & GINECO, France.;Evang. Kliniken Essen-Mitte - ESSEN & AGO Study Group, Germany.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, 44800, Saint Herblain, & GINECO, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France.","NA",0,"1744-8301","Future Oncol","Future Oncol",2024,"2024","20","10.1080/14796694.2024.2386922","2699-2708","","Merck & Co., Inc., Kenilworth, NJ, USA","39155847","39155847","PUBMED","Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France.;Centre Léon Bérard, Lyon, & GINECO, France.;Medical Faculty Mannheim, Heidelberg University & AGO Study Group, Germany.;Biostatistic Unit, Institut Curie, Paris, France.;Institut de Cancérologie de Strasbourg Europe, ICANS, Strasbourg, & GINECO, France.;Institut Bergonié, Bordeaux, & GINECO, France.;Centre Eugène Marquis, Rennes, & GINECO, France.;Aix-Marseille Univ, CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Department of Medical Oncology, Marseille, & GINECO, France.;Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, & GINECO, France.;Institut du Cancer de Montpellier (ICM), Montpellier, & GINECO, France.;Leuven Cancer Institute, Division of Gynaecological Oncology, University Hospital Leuven, BGOG, Belgium.;CHU Besançon - Hôpital jean Minjoz, Besançon, & GINECO, France.;Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, & GINECO, France.;Centre Oscar Lambret, Lille, & GINECO, France.;Université de Paris Cité, AP-HP, Hôpital Cochin, Paris, & GINECO, France.;Centre Hospitalier de la Côte Basque, Bayonne, & GINECO, France.;Centre Georges François Leclerc, Dijon, & GINECO, France.;Evang. Kliniken Essen-Mitte - ESSEN & AGO Study Group, Germany.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, 44800, Saint Herblain, & GINECO, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, & GINECO, France."
"56","Ajzenberg N;Longrois D;Faille D;de Tymowski C;De Raucourt E;Boudaoud L;Sigaut S;Martin-Toutain I;Raux M;Helley D;Josserand J;Flaujac C;Duchemin J;Samama CM;Gouin-Thibault I;Beloeil H;Peynaud-Debayle E;Keita-Meyer H;Bourrienne MC;Quintin C;Paugam-Burtz C;Rosencher N;Valentin JB;Giboin C;Tubach F","Ajzenberg, Nadine;Longrois, Dan;Faille, Dorothée;de Tymowski, Christian;De Raucourt, Emmanuelle;Boudaoud, Larbi;Sigaut, Stéphanie;Martin-Toutain, Isabelle;Raux, Mathieu;Helley, Dominique;Josserand, Julien;Flaujac, Claire;Duchemin, Jérome;Samama, Charles-Marc;Gouin-Thibault, Isabelle;Beloeil, Hélène;Peynaud-Debayle, Edith;Keita-Meyer, Hawa;Bourrienne, Marie-Charlotte;Quintin, Caroline;Paugam-Burtz, Catherine;Rosencher, Nadia;Valentin, Jean-Baptiste;Giboin, Caroline;Tubach, Florence","Sensitivity and specificity of strategies to identify patients with hemostasis abnormalities leading to an increased risk of bleeding before scheduled intervention: the Hemorisk study.","Journal of thrombosis and haemostasis : JTH","England","eng","Journal Article","bleeding questionnaire;blood coagulation disorders, inherited;hemorrhagic disorders;surgery;women","Humans;Female;Male;Middle Aged;Surveys and Questionnaires;Aged;Hemostasis;Partial Thromboplastin Time;Prothrombin Time;Hemorrhage;Platelet Count;Risk Assessment;Risk Factors;Predictive Value of Tests;France;Adult;Reproducibility of Results;Blood Coagulation Disorders;Preoperative Care;Blood Coagulation Tests;Blood Coagulation;Sensitivity and Specificity;Prospective Studies","Humans;Female;Male;Middle Aged;Surveys and Questionnaires;Aged;Hemostasis;Partial Thromboplastin Time;Prothrombin Time;Hemorrhage;Platelet Count;Risk Assessment;Risk Factors;Predictive Value of Tests;France;Adult;Reproducibility of Results;Blood Coagulation Disorders;Preoperative Care;Blood Coagulation Tests;Blood Coagulation;Sensitivity and Specificity;Prospective Studies","Preoperative identification of patients with hemostasis abnormalities leading to an increased bleeding risk is based on routine hemostasis tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and platelet count. Because of their low predictive performance, guidelines recommend replacing them with structured bleeding risk questionnaires, but none is validated in this population. To assess the diagnostic accuracy of 3 strategies, performed at the preanesthesia visit before scheduled interventions, and to identify patients with hemostasis abnormalities leading to an increased bleeding risk METHODS: A multicenter study was performed in 7 French academic hospitals, involving patients scheduled for surgical intervention, without antiplatelet/anticoagulant treatment. The 3 strategies consisted of 1-a structured screening questionnaire; 2-PT, APTT, and platelet count ordered in selected patients; and 3-systematic PT, APTT, and platelet count. The reference standard comprised von Willebrand factor activity/antigen, factor (F)VIII, FIX, FXI, platelet function analyzer, and, when required, FII, FV, FX, and FVII and hemostasis consultation. Eighteen (1.2%) of 1484 patients had a hemostasis abnormality leading to an increased bleeding risk according to reference standard. In the overall cohort, sensitivity of the questionnaire-based strategy was 50% (95% CI, 26%-74%; specificity, 87% [95% CI, 85%-88%]); sensitivity was 0% (95% CI, 0%-41%) in men vs 82% (95% CI, 48%-98%) in women. For selective routine tests, sensitivity was 33% (95% CI, 13%-59%) and specificity 97% (95% CI, 96%-98%). Corresponding values for systematic routine tests were 44% (95% CI, 22%-69%) and 93% (95% CI, 91%-94%). Sensitivity was low for all 3 strategies investigated. The structured screening questionnaire had clinically acceptable diagnostic accuracy only in women.","Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris;Department of Anesthesia and Intensive Care, Hôpital Bichat-Claude Bernard, DMU (Département Médico-Universitaire) PARABOL, AP-HP, and INSERM (Institut National de la Santé et de la Recherche Médicale) 1148, LVTS, Paris, France.;Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Bichat-Claude Bernard, DMU PARABOL, AP-HP, INSERM UMR 1149, Paris, France.;Department of Biological Hematology, Hôpital Beaujon, AP-HP, Clichy, France.;Department of Biological Hematology, Hôpital Beaujon, AP-HP, Clichy, France.;Department of Anesthesia and Intensive Care, Hôpital Beaujon, DMU PARABOL, AP-HP, Clichy, France.;Department of Biological Hematology, Hôpital Pitié Salpétrière, AP-HP, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Pitié Salpétrière and Hôpital Charles Foix, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital européen Georges Pompidou, AP-HP, Paris, France; Universté Paris Cité, INSERM, PARCC, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital européen Georges Pompidou, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital Cochin, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital Cochin, AP-HP, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Cochin, AP-HP, Paris, France; Université Paris Cité, Paris, France.;Department of Biological Hematology, Hôpital Pontchaillou, CHU (Centre Hospitalier Universitaire) de Rennes, Université de Rennes, IRSET, INSERM, Rennes, France.;Department of Anesthesia and Intensive Care, CHU de Rennes, Université de Rennes, INSERM, (Centre d'Investigation Clinique) CIC-1414, COSS 1242, Rennes, France.;Department of Biological Hematology, Hôpital Louis Mourier, AP-HP, Colombes, France.;Department of Anesthesia, Hôpital Louis Mourier, AP-HP, Colombes, France; Department of Anesthesia and Intensive Care, Hôpital Necker, AP-HP, Paris, France.;Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris, France.;AP-HP, Groupe Hospitalier Universitaire AP-HP-Nord, Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Hôpital Bichat-Claude Bernard, DMU PRISME, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Beaujon, DMU PARABOL, AP-HP, Clichy, France.;Department of Anesthesia and Intensive Care, Hôpital Cochin, AP-HP, Paris, France; Université Paris Cité, Paris, France.;Department of Biological Hematology and Hemostasis, CHU de Tours - Hôpital Trousseau, Tours, France.;AP-HP, INSERM, Hôpital Pitié Salpétrière, Centre de Pharmaco - Epidémiologie (Cephepi), Centre d'Investigation Clinique CIC-1901, Paris, France.;AP-HP, Groupe Hospitalier Universitaire AP-HP-Nord, Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Hôpital Bichat-Claude Bernard, DMU PRISME, Paris, France; AP-HP, INSERM, Hôpital Pitié Salpétrière, Centre de Pharmaco - Epidémiologie (Cephepi), Centre d'Investigation Clinique CIC-1901, Paris, France; Université Paris Sorbonne, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpétrière, Département de Santé Publique, Centre de Pharmaco-Epidémiologie (Cephepi), CIC-1901, Paris, France.","NA",0,"1538-7836","J Thromb Haemost","J Thromb Haemost",2023,"2024","22","10.1016/j.jtha.2024.07.024","3048-3058","","","39128655","39128655","PUBMED","Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris;Department of Anesthesia and Intensive Care, Hôpital Bichat-Claude Bernard, DMU (Département Médico-Universitaire) PARABOL, AP-HP, and INSERM (Institut National de la Santé et de la Recherche Médicale) 1148, LVTS, Paris, France.;Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Bichat-Claude Bernard, DMU PARABOL, AP-HP, INSERM UMR 1149, Paris, France.;Department of Biological Hematology, Hôpital Beaujon, AP-HP, Clichy, France.;Department of Biological Hematology, Hôpital Beaujon, AP-HP, Clichy, France.;Department of Anesthesia and Intensive Care, Hôpital Beaujon, DMU PARABOL, AP-HP, Clichy, France.;Department of Biological Hematology, Hôpital Pitié Salpétrière, AP-HP, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Pitié Salpétrière and Hôpital Charles Foix, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital européen Georges Pompidou, AP-HP, Paris, France; Universté Paris Cité, INSERM, PARCC, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital européen Georges Pompidou, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital Cochin, AP-HP, Paris, France.;Department of Biological Hematology, Hôpital Cochin, AP-HP, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Cochin, AP-HP, Paris, France; Université Paris Cité, Paris, France.;Department of Biological Hematology, Hôpital Pontchaillou, CHU (Centre Hospitalier Universitaire) de Rennes, Université de Rennes, IRSET, INSERM, Rennes, France.;Department of Anesthesia and Intensive Care, CHU de Rennes, Université de Rennes, INSERM, (Centre d'Investigation Clinique) CIC-1414, COSS 1242, Rennes, France.;Department of Biological Hematology, Hôpital Louis Mourier, AP-HP, Colombes, France.;Department of Anesthesia, Hôpital Louis Mourier, AP-HP, Colombes, France; Department of Anesthesia and Intensive Care, Hôpital Necker, AP-HP, Paris, France.;Department of Biological Hematology, Assistance Publique-Hôpitaux de Pairs (AP-HP), Hôpital Bichat-Claude Bernard, Paris, France; Université Paris Cite and Université Sorbonne Paris, INSERM 1148, LVTS, Paris, France.;AP-HP, Groupe Hospitalier Universitaire AP-HP-Nord, Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Hôpital Bichat-Claude Bernard, DMU PRISME, Paris, France.;Department of Anesthesia and Intensive Care, Hôpital Beaujon, DMU PARABOL, AP-HP, Clichy, France.;Department of Anesthesia and Intensive Care, Hôpital Cochin, AP-HP, Paris, France; Université Paris Cité, Paris, France.;Department of Biological Hematology and Hemostasis, CHU de Tours - Hôpital Trousseau, Tours, France.;AP-HP, INSERM, Hôpital Pitié Salpétrière, Centre de Pharmaco - Epidémiologie (Cephepi), Centre d'Investigation Clinique CIC-1901, Paris, France.;AP-HP, Groupe Hospitalier Universitaire AP-HP-Nord, Université Paris Cité, Research Clinic, Epidemiology, Biostatistic Department, Hôpital Bichat-Claude Bernard, DMU PRISME, Paris, France; AP-HP, INSERM, Hôpital Pitié Salpétrière, Centre de Pharmaco - Epidémiologie (Cephepi), Centre d'Investigation Clinique CIC-1901, Paris, France; Université Paris Sorbonne, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital Pitié Salpétrière, Département de Santé Publique, Centre de Pharmaco-Epidémiologie (Cephepi), CIC-1901, Paris, France."
"57","Blay JY;Devin Q;Duffaud F;Toulmonde M;Firmin N;Collard O;Bompas E;Verret B;Ray-Coquard I;Salas S;Henon C;Honoré C;Brahmi M;Dufresne A;Pracht M;Hervieu A;Penel N;Bertucci F;Rios M;Saada-Bouzid E;Soibinet P;Perol D;Chabaud S;Italiano A;Cesne AL","Blay, Jean-Yves;Devin, Quentin;Duffaud, Florence;Toulmonde, Maud;Firmin, Nelly;Collard, Olivier;Bompas, Emmanuelle;Verret, Benjamin;Ray-Coquard, Isabelle;Salas, Sebastien;Henon, Clemence;Honoré, Charles;Brahmi, Mehdi;Dufresne, Armelle;Pracht, Marc;Hervieu, Alice;Penel, Nicolas;Bertucci, Francois;Rios, Maria;Saada-Bouzid, Esma;Soibinet, Pauline;Perol, David;Chabaud, Sylvie;Italiano, Antoine;Cesne, Axel Le","Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial.","The Lancet. Oncology","England","eng","Journal Article","","Humans;Gastrointestinal Stromal Tumors;Imatinib Mesylate;Male;Female;Middle Aged;Aged;Follow-Up Studies;Protein Kinase Inhibitors;Antineoplastic Agents;France;Gastrointestinal Neoplasms;Progression-Free Survival;Adult;Time Factors;Drug Resistance, Neoplasm;Withholding Treatment;Drug Administration Schedule","Humans;Gastrointestinal Stromal Tumors;Imatinib Mesylate;Male;Female;Middle Aged;Aged;Follow-Up Studies;Protein Kinase Inhibitors;Antineoplastic Agents;France;Gastrointestinal Neoplasms;Progression-Free Survival;Adult;Time Factors;Drug Resistance, Neoplasm;Withholding Treatment;Drug Administration Schedule","The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial. BFR14, an open-label, randomised, phase 3 trial, was done in 17 comprehensive cancer centres or hospitals across France. Patients with advanced GIST aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-3, no previous treatment with imatinib, and no previous malignancy were eligible. Patients were treated with oral imatinib 400 mg daily. Patients with a complete or partial response, or stable disease, according to Response Evaluation Criteria in Solid Tumours (1.0) at 1 year, 3 years, and 5 years from the start of treatment were randomly assigned (1:1) to treatment discontinuation until progression (interruption group) or treatment continuation until progression (continuation group). Randomisation was done centrally with computer-generated permuted blocks of two and six patients stratified by participating centre and presence or absence of residual disease on CT scan. The primary endpoint was progression-free survival. Secondary endpoints included time to imatinib resistance and overall survival. Analyses were conducted on an intention-to-treat basis in all randomly assigned patients who were not lost to follow-up. This trial is registered with ClinicalTrial.gov, NCT00367861. Between May 12, 2003, and March 16, 2004, after 1 year of imatinib, 32 patients were randomly assigned to the interruption group and 26 to the continuation group. Between June 13, 2005, and May 30, 2007, after 3 years of imatinib, 25 patients were randomly assigned to the interruption group and 25 to the continuation group. Between Nov 9, 2007, and July 12, 2010, after 5 years of imatinib, 14 patients were randomly assigned to the interruption group and 13 to the continuation group. Median follow-up was 235·2 months (IQR 128·8-236·6) after the 1-year randomisation, 200·9 months (190·2-208·4) after the 3-year randomisation, and 164·5 months (134·4-176·4) after the 5-year randomisation. Median progression-free survival in the interruption group versus the continuation group after 1 year of imatinib was 6·1 months (95% CI 2·5-10·1) versus 27·8 months (19·5-37·9; hazard ratio [HR] 0·36 [95% CI 0·20-0·64], log-rank p=0·0003), after 3 years of imatinib was 7·0 months (3·5-11·7) versus 67·0 months (48·8-85·6; 0·15 [0·07-0·32], log-rank p<0·0001), and after 5 years of imatinib was 12·0 months (9·0-16·6) versus not reached (NR; NR-NR; 0·13 [0·03-0·58], log-rank p=0·0016). The median time to imatinib resistance after 1 year of imatinib was 28·7 months (95% CI 18·1-39·1) versus 90·6 months (25·3-156·1; HR 0·93 [95% CI 0·51-1·71], log-rank p=0·82), after 3 years was 66·2 months (43·0-89·6) versus 127·3 months (15·0-239·7; 0·35 [0·17-0·72, log-rank p=0·0028), and after 5 years was 58·6 months (0·0-167·4) versus NR (NR-NR; 0·24 [0·05-1·12], log-rank p=0·049). Median overall survival after 1 year of imatinib was 56·0 months (95% CI 30·3-82·9) versus 105·0 months (20·6-189·6; HR 0·84 [95% CI 0·46-1·54], log-rank p=0·57), after 3 years was 104·0 months (90·7-118·7) versus 134·0 months (89·7-178·3; 0·40 [0·20-0·82], log-rank p=0·0096), and after 5 years was NR (NR-NR) versus 110·4 months (82·7-154·1; 1·28 [0·41-3·99]; log-rank p=0·67), INTERPRETATION: Imatinib interruption in patients with GIST without progressive disease is not recommended. Imatinib interruption in non-progressing patients with GIST was associated with rapid progression, faster resistance to imatinib, and shorter overall survival in the long-term follow-up when compared with imatinib continuation in patients after 3 years and 5 years of imatinib. Centre Léon Bérard, INCa, CONTICANET, Ligue Contre le Cancer, and Novartis.","Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologi Val d'Aurelle, Montpellier, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Hopitaux Privés de la Loire, St Etienne, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Hopitaux Privés de la Loire, St Etienne, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Eugene Marquis, Rennes, France.;Centre George-François Leclerc, Dijon, France.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Gustave Roussy, Villejuif, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2024","25","10.1016/S1470-2045(24)00318-8","1163-1175","","","39127063","39127063","PUBMED","Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologi Val d'Aurelle, Montpellier, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Hopitaux Privés de la Loire, St Etienne, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Hopital La Timone, Marseille, France.;Hopitaux Privés de la Loire, St Etienne, France; Institut Gustave Roussy, Villejuif, France.;Hopitaux Privés de la Loire, St Etienne, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France.;Centre Eugene Marquis, Rennes, France.;Centre George-François Leclerc, Dijon, France.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Centre Léon Bérard, Lyon, France; Centre de Recherche en Cancérologie de Lyon, Lyon, France; Direction Recherche Clinique et Innovation, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Gustave Roussy, Villejuif, France."
"58","Kudo M;Finn RS;Ikeda M;Sung MW;Baron AD;Okusaka T;Kobayashi M;Kumada H;Kaneko S;Pracht M;Meyer T;Nagao S;Saito K;Mody K;Ramji Z;Dubrovsky L;Llovet JM","Kudo, Masatoshi;Finn, Richard S;Ikeda, Masafumi;Sung, Max W;Baron, Ari D;Okusaka, Takuji;Kobayashi, Masahiro;Kumada, Hiromitsu;Kaneko, Shuichi;Pracht, Marc;Meyer, Tim;Nagao, Satoshi;Saito, Kenichi;Mody, Kalgi;Ramji, Zahra;Dubrovsky, Leonid;Llovet, Josep M","A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116.","Liver cancer","Switzerland","eng","Journal Article","Hepatocellular carcinoma;Lenvatinib;Overall survival;Pembrolizumab;Progression-free survival","","","Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October 31, 2019; median follow-up: 10.6 months). This analysis (updated data cutoff date: March 31, 2021) reports efficacy results from 17 months of additional follow-up time. 100 patients with uHCC were included in the primary analysis (median follow-up: 27.6 months). Endpoints included overall survival (OS), investigator-assessed progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) per modified RECIST. Landmark analyses of OS by the best response at 3 and 9 months were performed. Pembrolizumab antidrug antibodies (ADAs) and concentrations were also measured (cutoff date: August 7, 2020). ORR was 43.0% (95% CI 33.1-53.3%) and median DOR was 17.1 months (95% CI 6.9-19.3 months). Median PFS and OS were 9.3 months (95% CI 7.4-9.8 months) and 20.4 months (95% CI 14.4-25.9 months), respectively. No treatment-emergent ADAs were detected. Results show a sustained treatment effect with lenvatinib plus pembrolizumab in patients with uHCC in the first-line setting.","Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.;Department of Gastroenterology and Hepatology, Geffen School of Medicine, UCLA Medical Center, Santa Monica, CA, USA.;Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.;Division of Hematology-Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA.;Division of Hematology/Oncology, Sutter/California Pacific Medical Center, San Francisco, CA, USA.;Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;Department of Gastroenterology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Oncology, Royal Free London NHS Foundation Trust, London, UK.;UCL Cancer Institute, University College London, London, UK.;Japan and Asia Clinical Development, Eisai Co. Ltd., Tokyo, Japan.;Biostatistics Oncology, Eisai Inc., Nutley, NJ, USA.;Oncology Clinical Research, Eisai Inc., Nutley, NJ, USA.;Oncology Clinical Research, Eisai Inc., Nutley, NJ, USA.;Department of Medical Oncology, Merck & Co., Inc., Rahway, NJ, USA.;Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Liver Cancer Translational Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clinic, Barcelona, Spain.;Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.","NA",0,"2235-1795","Liver Cancer","Liver Cancer",2023,"2024","13","10.1159/000535154","451-458","","","39114764","39114764","PUBMED","Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.;Department of Gastroenterology and Hepatology, Geffen School of Medicine, UCLA Medical Center, Santa Monica, CA, USA.;Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.;Division of Hematology-Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA.;Division of Hematology/Oncology, Sutter/California Pacific Medical Center, San Francisco, CA, USA.;Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;Department of Gastroenterology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Oncology, Royal Free London NHS Foundation Trust, London, UK.;UCL Cancer Institute, University College London, London, UK.;Japan and Asia Clinical Development, Eisai Co. Ltd., Tokyo, Japan.;Biostatistics Oncology, Eisai Inc., Nutley, NJ, USA.;Oncology Clinical Research, Eisai Inc., Nutley, NJ, USA.;Oncology Clinical Research, Eisai Inc., Nutley, NJ, USA.;Department of Medical Oncology, Merck & Co., Inc., Rahway, NJ, USA.;Division of Liver Diseases, Liver Cancer Program, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.;Liver Cancer Translational Research Laboratory, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Liver Unit, Hospital Clinic, Barcelona, Spain.;Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain."
"59","Wolfgruber S;Sedik S;Klingspor L;Tortorano A;Gow NAR;Lagrou K;Gangneux JP;Maertens J;Meis JF;Lass-Flörl C;Arikan-Akdagli S;Cornely OA;Hoenigl M","Wolfgruber, Stella;Sedik, Sarah;Klingspor, Lena;Tortorano, Annamaria;Gow, Neil A R;Lagrou, Katrien;Gangneux, Jean-Pierre;Maertens, Johan;Meis, Jacques F;Lass-Flörl, Cornelia;Arikan-Akdagli, Sevtap;Cornely, Oliver A;Hoenigl, Martin","Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.","Mycopathologia","Netherlands","eng","Journal Article","Candida;Candidemia;European Confederation of Medical Mycology (ECMM)","Humans;Candidiasis, Invasive;Antifungal Agents;Candida;Drug Resistance, Fungal;Europe;Candidemia;Multicenter Studies as Topic","Humans;Candidiasis, Invasive;Antifungal Agents;Candida;Drug Resistance, Fungal;Europe;Candidemia;Multicenter Studies as Topic","Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive Candida infections. These studies revealed shifting trends in Candida species distribution, with an increase of non-albicans Candida species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of Candida infections. This review aims to summarize the findings of the three completed ECMM Candida studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM Candida IV study, which will focus on assessing candidemia caused by non-albicans Candida species, including Candida auris, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.","Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.;Dipartimento Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy.;Medical Research Council Centre for Medical Mycology, Department of Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, UK.;Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.;Department of Laboratory Medicine and National Reference Center for Mycosis, UZ Leuven, Leuven, Belgium.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, 35000, Rennes, France.;Laboratory of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de référence pour les mycoses et antifongiques - LA AspC, ECMM Excellence Center for Medical Mycology, Rennes, France.;Department of Haematology and ECMM Excellence Center for Medical Mycology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.;Department of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;Institute of Hygiene and Medical Microbiology Medical University of Innsbruck, Excellence Center for Medical Mycology (ECMM), Innsbruck, Austria.;Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz;BioTechMed-Graz, Graz","NA",0,"1573-0832","Mycopathologia","Mycopathologia",2024,"2024","189","10.1007/s11046-024-00871-0","70","MR/M026663/2;MR/N006364/2","Medical Research Council;Medical Research Council","39088098","39088098","PUBMED","Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.;Dipartimento Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy.;Medical Research Council Centre for Medical Mycology, Department of Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, UK.;Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.;Department of Laboratory Medicine and National Reference Center for Mycosis, UZ Leuven, Leuven, Belgium.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, 35000, Rennes, France.;Laboratory of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de référence pour les mycoses et antifongiques - LA AspC, ECMM Excellence Center for Medical Mycology, Rennes, France.;Department of Haematology and ECMM Excellence Center for Medical Mycology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.;Department of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;Institute of Hygiene and Medical Microbiology Medical University of Innsbruck, Excellence Center for Medical Mycology (ECMM), Innsbruck, Austria.;Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz;BioTechMed-Graz, Graz"
"60","Shahim A;Donal E;Hage C;Oger E;Savarese G;Persson H;Haugen-Löfman I;Ennezat PV;Sportouch-Dukhan C;Drouet E;Daubert JC;Linde C;Lund LH","Shahim, Angiza;Donal, Erwan;Hage, Camilla;Oger, Emmanuel;Savarese, Gianluigi;Persson, Hans;Haugen-Löfman, Ida;Ennezat, Pierre-Vladimir;Sportouch-Dukhan, Catherine;Drouet, Elodie;Daubert, Jean-Claude;Linde, Cecilia;Lund, Lars H","Rates and predictors of cardiovascular and non-cardiovascular outcomes in heart failure with preserved ejection fraction.","ESC heart failure","England","eng","Journal Article","Cardiovascular;Heart failure with preserved ejection fraction;Hospitalization;Trial design","Humans;Heart Failure;Female;Male;Stroke Volume;Aged;Prospective Studies;Aged, 80 and over;Hospitalization;Cause of Death;Prognosis;Follow-Up Studies;Survival Rate;Sweden;Natriuretic Peptide, Brain;Risk Factors;Ventricular Function, Left;Peptide Fragments","Humans;Heart Failure;Female;Male;Stroke Volume;Aged;Prospective Studies;Aged, 80 and over;Hospitalization;Cause of Death;Prognosis;Follow-Up Studies;Survival Rate;Sweden;Natriuretic Peptide, Brain;Risk Factors;Ventricular Function, Left;Peptide Fragments","The detailed sub-categories of death and hospitalization, and the impact of comorbidities on cause-specific outcomes, remain poorly understood in heart failure (HF) with preserved ejection fraction (HFpEF). We sought to evaluate rates and predictors of cardiovascular (CV) and non-CV outcomes in HFpEF. The Karolinska-Rennes study was a bi-national prospective observational study designed to characterize HFpEF (ejection fraction ≥45%). Patients were followed for cause-specific death and hospitalization. Baseline characteristics were pre-selected based on clinical relevance and potential eligibility criteria for HFpEF trials. The associations between characteristics and cause-specific outcomes were assessed with univariable and multivariable Cox regressions. Five hundred thirty-nine patients [56% females; median (inter-quartile range) age 79 (72-84) years; NT-proBNP/BNP 2448 (1290-4790)/429 (229-805) ng/L] were included. Over 1196 patient-years follow-up [median (min, max) 744 days (13-1959)], there were 159 (29%) deaths (13 per 100 patient-years: CV 5.1 per 100, dominated by HF 3.9 per 100; and non-CV 5.8 per 100, dominated by cancer, 2.3 per 100). There were 723 hospitalizations in 338 patients (63%; 60 per 100 patient-years: CV 33 per 100, dominated by HF 17 per 100; and non-CV 27 per 100, dominated by lung disease 5 per 100). Higher age and natriuretic peptides, lower serum natraemia and NYHA class III-IV were independent predictors of CV death; lower serum natraemia, anaemia and stroke of non-CV death; and anaemia and lower serum natraemia of non-CV death or hospitalizations. There were no apparent predictors of CV death or hospitalization. In a clinical cohort hospitalized and diagnosed with HFpEF, death and hospitalization rates were roughly similar for CV and non-CV causes. CV deaths were predicted primarily by severity of HF; non-CV deaths primarily by anaemia and prior stroke. Lower serum sodium predicted both. Hospitalizations were difficult to predict.","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Pharmacoepidemiology and Health Services Research, REPERES, University of Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.;Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Service de Cardiologie, CHU, Lille, France.;Département de Cardiologie, CHU Montpellier, Montpellier, France.;Société Française de Cardiologie, Paris, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2023,"2024","11","10.1002/ehf2.14928","3572-3583","2013-23897-104604-23;20080409;20100419;20080498;20110406;00556-2009;20110120;20090376;20110610","Fédération Française de Cardiologie;Medtronic Bakken Research Center, Maastricht, the Netherlands;Fédération Française de Cardiologie/Société Française de Cardiologie;Medtronic Bakken Research Center;Swedish Research Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Stockholm County Council;Stockholm County Council;Stockholm County Council;Stockholm County Council","39075721","39075721","PUBMED","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Pharmacoepidemiology and Health Services Research, REPERES, University of Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.;Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Service de Cardiologie, CHU, Lille, France.;Département de Cardiologie, CHU Montpellier, Montpellier, France.;Société Française de Cardiologie, Paris, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LTSI, Université Rennes 1, INSERM, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden."
"61","Decaux O;Garlantézec R;Belhadj-Merzoug K;Macro M;Frenzel L;Perrot A;Moreau P;Royer B;Caillot D;Leleu X;Mohty M;Karlin L;Feugier P;Rigaudeau S;Fontan J;Sonntag C;Vincent L;Chalopin T;Avet Loiseau H;Maarouf Z;Chanaz L;Texier N;Hulin C","Decaux, Olivier;Garlantézec, Ronan;Belhadj-Merzoug, Karim;Macro, Margaret;Frenzel, Laurent;Perrot, Aurore;Moreau, Philippe;Royer, Bruno;Caillot, Denis;Leleu, Xavier;Mohty, Mohamad;Karlin, Lionel;Feugier, Pierre;Rigaudeau, Sophie;Fontan, Jean;Sonntag, Cécile;Vincent, Laure;Chalopin, Thomas;Avet Loiseau, Herve;Maarouf, Zakaria;Chanaz, Louni;Texier, Nathalie;Hulin, Cyrille","The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.","Clinical hematology international","England","eng","Journal Article","Multiple myeloma;real-world data;therapeutic management","","","The therapeutic management of patients with multiple myeloma (MM) is complex. Despite substantial advances, MM remains incurable, and management involves cycles of treatment response, disease relapse, and further therapy. Currently, evidence to support the therapeutic decision is limited. Thus, the EMMY longitudinal, real-world study was designed to annually assess therapeutic management of MM in France to provide evidence to support physicians. During an annual prespecified 3-month recruitment period, eligible patients will be identified from their medical records. Adults aged ≥18 years diagnosed with symptomatic MM and requiring systemic treatment will be eligible. The primary objective, the evolution of MM therapeutic management, will be described, as well as the impact on the following outcomes: time-to-next treatment (TTNT), progression-free survival (PFS), and overall survival (OS). The study plans to recruit 5000 patients over 6 years: 700 to 900 patients annually. EMMY is a unique opportunity to collect real-world data to describe the evolving MM therapeutic landscape and record outcomes in France. These data will provide annual snapshots of various aspects of MM management. This knowledge will provide physicians with real-life, evidence-based data for therapeutic decision-making and ultimately improve treatment for MM patients.","Service d'hématologie clinique Centre Hospitalier Universitaire de Rennes.;Santé publique et épidémiologie Centre Hospitalier Universitaire de Rennes.;Unité Fonctionnelle Hémopathies Lymphoïdes Centre Hospitalier Universitaire Henri-Mondor.;Service d'hématologie clinique Centre Hospitalier Universitaire de Caen.;Service d'hématologie adulte Hôpital Necker-Enfants Malades.;Hématologie Centre Hospitalier Universitaire de Toulouse.;Hématologie clinique CHRU - Hôtel Dieu (Nantes).;Immuno-Hématologie Hôpital Saint-Louis (Paris).;Hématologie Clinique Centre Hospitalier Universitaire Dijon Bourgogne.;Hématologie Centre Hospitalier Universitaire de Poitiers.;Service d'Hématologie et Thérapie cellulaire Hôpital Saint-Antoine.;Hématologie clinique Hospices Civils de Lyon.;Service d'hématologie CHU de Nancy - Hôpitaux de Brabois.;Service d'Hématologie CHV André Mignot.;Service Hématologie CHRU Jean Minjoz (Besançon).;Département d'Hématologie et Oncologie Hôpitaux Universitaires de Strasbourg.;Département d'Hématologie et Oncologie Hôpital de Hautepierre et Hôpital Civil.;Département d'hématologie clinique CHU Montpellier.;Hématologie thérapie cellulaire CHRU de Tours.;IUCT Oncopole Toulouse.;CHU Toulouse.;Intergroupe Francophone du Myélome.;Intergroupe Francophone du Myélome.;Epidémiologie Kappa Santé.;Hématologie Hôpital Haut-Lévêque (Pessac).","NA",0,"2590-0048","Clin Hematol Int","Clin Hematol Int",2024,"2024","6","10.46989/001c.121371","22-27","","","39050939","39050939","PUBMED","Service d'hématologie clinique Centre Hospitalier Universitaire de Rennes.;Santé publique et épidémiologie Centre Hospitalier Universitaire de Rennes.;Unité Fonctionnelle Hémopathies Lymphoïdes Centre Hospitalier Universitaire Henri-Mondor.;Service d'hématologie clinique Centre Hospitalier Universitaire de Caen.;Service d'hématologie adulte Hôpital Necker-Enfants Malades.;Hématologie Centre Hospitalier Universitaire de Toulouse.;Hématologie clinique CHRU - Hôtel Dieu (Nantes).;Immuno-Hématologie Hôpital Saint-Louis (Paris).;Hématologie Clinique Centre Hospitalier Universitaire Dijon Bourgogne.;Hématologie Centre Hospitalier Universitaire de Poitiers.;Service d'Hématologie et Thérapie cellulaire Hôpital Saint-Antoine.;Hématologie clinique Hospices Civils de Lyon.;Service d'hématologie CHU de Nancy - Hôpitaux de Brabois.;Service d'Hématologie CHV André Mignot.;Service Hématologie CHRU Jean Minjoz (Besançon).;Département d'Hématologie et Oncologie Hôpitaux Universitaires de Strasbourg.;Département d'Hématologie et Oncologie Hôpital de Hautepierre et Hôpital Civil.;Département d'hématologie clinique CHU Montpellier.;Hématologie thérapie cellulaire CHRU de Tours.;IUCT Oncopole Toulouse.;CHU Toulouse.;Intergroupe Francophone du Myélome.;Intergroupe Francophone du Myélome.;Epidémiologie Kappa Santé.;Hématologie Hôpital Haut-Lévêque (Pessac)."
"62","Feys S;Carvalho A;Clancy CJ;Gangneux JP;Hoenigl M;Lagrou K;Rijnders BJA;Seldeslachts L;Vanderbeke L;van de Veerdonk FL;Verweij PE;Wauters J","Feys, Simon;Carvalho, Agostinho;Clancy, Cornelius J;Gangneux, Jean-Pierre;Hoenigl, Martin;Lagrou, Katrien;Rijnders, Bart J A;Seldeslachts, Laura;Vanderbeke, Lore;van de Veerdonk, Frank L;Verweij, Paul E;Wauters, Joost","Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients.","The Lancet. Respiratory medicine","England","eng","Journal Article","","Humans;COVID-19;Critical Illness;Influenza, Human;Antifungal Agents;SARS-CoV-2;Pulmonary Aspergillosis","Humans;COVID-19;Critical Illness;Influenza, Human;Antifungal Agents;SARS-CoV-2;Pulmonary Aspergillosis","Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are increasingly recognised as important complications in patients requiring intensive care for severe viral pneumonia. The diagnosis can typically be made in 10-20% of patients with severe influenza or COVID-19, but only when appropriate diagnostic tools are used. Bronchoalveolar lavage sampling for culture, galactomannan testing, and PCR forms the cornerstone of diagnosis, whereas visual examination of the tracheobronchial tract during bronchoscopy is required to detect invasive Aspergillus tracheobronchitis. Azoles are the first-choice antifungal drugs, with liposomal amphotericin B as an alternative in settings where azole resistance is prevalent. Despite antifungal therapy, IAPA and CAPA are associated with poor outcomes, with fatality rates often exceeding 50%. In this Review, we discuss the mechanistic and clinical aspects of IAPA and CAPA. Moreover, we identify crucial knowledge gaps and formulate directions for future research.","Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven;Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's Associate Laboratory, Braga/ Guimarães, Portugal.;Division of Infectious Diseases, University of Pittsburgh, PA, USA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.;Université de Rennes, CHU Rennes, INSERM, EHESP, IRSET, UMR_S 1085, Rennes, France; Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, ECMM Excellence Center in Medical Mycology, French National Reference Center on Mycoses and Antifungals (CNRMA-LA AspC), Rennes, France.;Division of Infectious Diseases, ECMM Excellence Center in Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Translational Medical Mycology Research Group, Medical University of Graz, Graz, Austria; Bio TechMed-Graz, Graz, Austria.;Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium; Department of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium.;Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.;Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.;Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.;Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.;Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands; Center of Expertise for Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, Netherlands.;Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium.","NA",0,"2213-2619","Lancet Respir Med","Lancet Respir Med",2023,"2024","12","10.1016/S2213-2600(24)00151-6","728-742","","","39025089","39025089","PUBMED","Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven;Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3B's Associate Laboratory, Braga/ Guimarães, Portugal.;Division of Infectious Diseases, University of Pittsburgh, PA, USA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.;Université de Rennes, CHU Rennes, INSERM, EHESP, IRSET, UMR_S 1085, Rennes, France; Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, ECMM Excellence Center in Medical Mycology, French National Reference Center on Mycoses and Antifungals (CNRMA-LA AspC), Rennes, France.;Division of Infectious Diseases, ECMM Excellence Center in Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Translational Medical Mycology Research Group, Medical University of Graz, Graz, Austria; Bio TechMed-Graz, Graz, Austria.;Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium; Department of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, Leuven, Belgium.;Department of Internal Medicine, Section of Infectious Diseases and Department of Medical Microbiology and Infectious Diseases, Erasmus MC, University Medical Center, Rotterdam, Netherlands.;Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.;Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium.;Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.;Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, Netherlands; Center of Expertise for Mycology, Radboud University Medical Center/Canisius Wilhelmina Hospital, Nijmegen, Netherlands.;Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium; Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium."
"63","Le Guévelou J;Zilli T;Ferretti L;Beuzit L;De Hertogh O;Palumbo S;Jolicoeur M;Crehange G;Derashodian T;De Crevoisier R;Chapet O;Terlizzi M;Supiot S;Salembier C;Sargos P","Le Guévelou, Jennifer;Zilli, Thomas;Ferretti, Ludovic;Beuzit, Luc;De Hertogh, Olivier;Palumbo, Samuel;Jolicoeur, Marjory;Crehange, Gilles;Derashodian, Talar;De Crevoisier, Renaud;Chapet, Olivier;Terlizzi, Mario;Supiot, Stéphane;Salembier, Carl;Sargos, Paul","Urinary Organs at Risk for Prostate Cancer External Beam Radiation Therapy: Contouring Guidelines on Behalf of the Francophone Group of Urological Radiation Therapy.","Practical radiation oncology","United States","eng","Journal Article","","Humans;Prostatic Neoplasms;Male;Organs at Risk;Radiotherapy Dosage;Urinary Bladder;Practice Guidelines as Topic","Humans;Prostatic Neoplasms;Male;Organs at Risk;Radiotherapy Dosage;Urinary Bladder;Practice Guidelines as Topic","The occurrence of genitourinary (GU) toxicity is a common adverse event observed after external beam radiation therapy (EBRT) for prostate cancer (PCa). Recent findings suggest that the dose delivered to specific urinary organs at risk (OARs) such as the ureters, bladder trigone, and urethra is involved in the development of GU toxicity. A multidisciplinary task force including 3 radiation oncologists, a uroradiologist, and a urologist was created in 2022. First, OARs potentially involved in GU toxicity were identified and discussed. A literature review was performed, addressing several questions relative to urinary OARs: anatomic and radiological definition, radiation-induced injury, and dose-volume parameters. Second, results were presented and discussed with a panel of radiation oncologists and members of the ""Francophone Group of Urological Radiation Therapy."" Thereafter, the ""Francophone Group of Urological Radiation Therapy"" experts were asked to answer a dedicated questionnaire, including 35 questions on the controversial issues related to the delineation of urinary OARs. The following structures were identified as critical for PCa EBRT: ureters, bladder, bladder neck, bladder trigone, urethra (intraprostatic, membranous, and spongious), striated sphincter, and postenucleation or posttransurethral resection of the prostate cavity. A consensus was obtained for 32 out of 35 items. This consensus highlights contemporary urinary structures in both the upper and lower urinary tract to be considered for EBRT treatment planning of PCa. The current recommendations also propose a standardized definition of urinary OARs for both daily practice and future clinical trials.","Department of Radiation Oncology, Centre Eugène Marquis, Rennes;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of urology, MSP Bordeaux Bagatelle, Talence, France.;Department of Radiology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Department of Radiation Oncology, CHR Verviers East Belgium, Verviers, Belgium.;Department of Radiation Oncology, Hôpital de Jolimont, La Louvière, Belgium.;Department of Radiation Oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.;Department of Radiation Oncology, Institut Curie, Saint-Cloud, France.;Department of Radiation Oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.;Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.;Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France; Unité en Sciences Biologiques et Biotechnologies, University of Nantes, Nantes, France.;Department of Radiation Oncology, Europe Hospitals Brussels, Brussels, Belgium.;Department of Radiation Oncology, Institut Bergonié, Bordeaux, France.","NA",0,"1879-8519","Pract Radiat Oncol","Pract Radiat Oncol",2024,"2024","14","10.1016/j.prro.2024.05.009","541-554","","","38986900","38986900","PUBMED","Department of Radiation Oncology, Centre Eugène Marquis, Rennes;Department of Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; Università della Svizzera Italiana, Lugano, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of urology, MSP Bordeaux Bagatelle, Talence, France.;Department of Radiology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Department of Radiation Oncology, CHR Verviers East Belgium, Verviers, Belgium.;Department of Radiation Oncology, Hôpital de Jolimont, La Louvière, Belgium.;Department of Radiation Oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.;Department of Radiation Oncology, Institut Curie, Saint-Cloud, France.;Department of Radiation Oncology, Charles LeMoyne Hospital, CISSS Montérégie-center, Montréal, Quebec, Canada.;Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.;Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes Saint-Herblain, France; Unité en Sciences Biologiques et Biotechnologies, University of Nantes, Nantes, France.;Department of Radiation Oncology, Europe Hospitals Brussels, Brussels, Belgium.;Department of Radiation Oncology, Institut Bergonié, Bordeaux, France."
"64","Rodriguez JE;Vasseur D;Bani MA;Cabaret O;Cotteret S;Muleris M;Golbarg V;Malka D;Pudlarz T;Caron O;Smolenschi C","Rodriguez, Julieta E;Vasseur, Damien;Bani, Mohamed Amine;Cabaret, Odile;Cotteret, Sophie;Muleris, Martine;Golbarg, Veronica;Malka, David;Pudlarz, Thomas;Caron, Olivier;Smolenschi, Cristina","Case report: Microsatellite instability determination is not always black and white in Lynch syndrome diagnosis.","Frontiers in oncology","Switzerland","eng","Case Reports","case report;circulating DNA;colorectal cancer;discordant MSI;next-generation sequencing","","","Microsatellite instability (MSI) is a genetic marker that is useful in the detection and treatment of Lynch syndrome (Sd). Although conventional techniques such as immunohistochemistry (IHC) and polymerase chain reaction (PCR) are the standards for MSI detection, the advent of next-generation sequencing (NGS) has offered new possibilities, especially with circulating DNA. We present the case of a 26-year-old patient with Lynch Sd and a  -mutated metastatic colon cancer. The discordant MSI results between the conventional methods and NGS posed challenges in making treatment decisions. Subsequent NGS analysis revealed a high MSI status, leading to participation in an immunotherapy trial, with remarkable clinical response. This case emphasizes the importance of comprehensive molecular profiling and strong interdisciplinary collaborations, especially in cases with ambiguous MSI results.","Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Biology and Genetics Department, Centre Eugène Marquis, Rennes, France.;Department of Genetics, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Gastroenterology and Hepatology Department, Institut Mutualiste Montsouris, Paris, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2024,"2024","14","10.3389/fonc.2024.1396869","1396869","","","38957326","38957326","PUBMED","Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Biology and Genetics Department, Centre Eugène Marquis, Rennes, France.;Department of Genetics, Hôpital Pitié-Salpêtrière, Assistance Publique - Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Gastroenterology and Hepatology Department, Institut Mutualiste Montsouris, Paris, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Biology and Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France.;Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France."
"65","Jarry U;Bostoen M;Archambeau J;Pineau R;Chaillot L;Jouan F;Solhi H;Ferrari H;Le Guevel R;Mennessier V;Lena H;Corre R;Ricordel C;Guillaudeux T;Pedeux R","Jarry, Ulrich;Bostoen, Megane;Archambeau, Jérome;Pineau, Raphaël;Chaillot, Laura;Jouan, Florence;Solhi, Hélène;Ferrari, Hugo;Le Guevel, Rémy;Mennessier, Valentine;Lena, Hervé;Corre, Romain;Ricordel, Charles;Guillaudeux, Thierry;Pedeux, Rémy","Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.","PloS one","United States","eng","Journal Article","","Animals;Aniline Compounds;Acrylamides;Afatinib;Bevacizumab;Carcinoma, Non-Small-Cell Lung;Lung Neoplasms;Mice;Humans;Cell Line, Tumor;Antineoplastic Combined Chemotherapy Protocols;Disease Models, Animal;Xenograft Model Antitumor Assays;ErbB Receptors;Quinazolines;Piperazines;Female;Indoles;Pyrimidines","Animals;Aniline Compounds;Acrylamides;Afatinib;Bevacizumab;Carcinoma, Non-Small-Cell Lung;Lung Neoplasms;Mice;Humans;Cell Line, Tumor;Antineoplastic Combined Chemotherapy Protocols;Disease Models, Animal;Xenograft Model Antitumor Assays;ErbB Receptors;Quinazolines;Piperazines;Female;Indoles;Pyrimidines","Lung cancer is one of the most common and deadliest cancers. Preclinical models are essential to study new therapies and combinations taking tumor genetics into account. We have established cell lines expressing the luciferase gene from lines with varied genetic backgrounds, commonly encountered in patients with pulmonary adenocarcinoma. We have characterized these lines by testing their response to multiple drugs. Thus, we have developed orthotopic preclinical mouse models of NSCLC with very high engraftment efficiency. These models allow the easy monitoring of tumor growth, particularly in response to treatment, and of tumor cells dissemination in the body. We show that concomitant treatment with osimertinib (3rd generation tyrosine kinase inhibitor targeting mutated EGFR) and bevacizumab (anti-angiogenic targeting VEGF) can have a beneficial therapeutic effect on EGFR-mutated tumors. We also show that the addition of afatinib to osimertinib-treated tumors in escape leads to tumor growth inhibition. No such effect is observed with selumetinib or simvastatin. These preclinical mouse models therefore make it possible to test innovative therapeutic combinations and are also a tool of choice for studying resistance mechanisms.","Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Biotrial Pharmacology, Unité de Pharmacologie Préclinique, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Biotrial Pharmacology, Unité de Pharmacologie Préclinique, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2023,"2024","19","10.1371/journal.pone.0304914","e0304914","","","38935790","38935790","PUBMED","Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Biotrial Pharmacology, Unité de Pharmacologie Préclinique, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Biotrial Pharmacology, Unité de Pharmacologie Préclinique, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Univ Rennes, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France.;Univ Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, Rennes, France.;Univ Rennes, INSERM, OSS (Oncogenesis Stress Signaling), UMR_S 1242, CLCC Eugene Marquis, Rennes, France."
"66","Poumeaud F;Morisseau M;Cabel L;Gonçalves A;Rivier C;Trédan O;Volant E;Frenel JS;Ladoire S;Jacot W;Jamelot M;Foka Tichoue H;Patsouris A;Teixeira L;Bidard FC;Loirat D;Brunet M;Levy C;Bailleux C;Cabarrou B;Deleuze A;Uwer L;Deluche E;Grellety T;Franchet C;Fiteni F;Bischoff H;Vion R;Pagliuca M;Verret B;Bécourt S;Reverdy T;de Nonneville A;Dalenc F","Poumeaud, F;Morisseau, M;Cabel, L;Gonçalves, A;Rivier, C;Trédan, O;Volant, E;Frenel, J-S;Ladoire, S;Jacot, W;Jamelot, M;Foka Tichoue, H;Patsouris, A;Teixeira, L;Bidard, F-C;Loirat, D;Brunet, M;Levy, C;Bailleux, C;Cabarrou, B;Deleuze, A;Uwer, L;Deluche, E;Grellety, T;Franchet, C;Fiteni, F;Bischoff, H;Vion, R;Pagliuca, M;Verret, B;Bécourt, S;Reverdy, T;de Nonneville, A;Dalenc, F","Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.","British journal of cancer","England","eng","Journal Article","","Humans;Female;Breast Neoplasms;Trastuzumab;Antibodies, Monoclonal, Humanized;Middle Aged;Camptothecin;Aged;Receptor, ErbB-2;Immunoconjugates;Retrospective Studies;Adult;Antineoplastic Combined Chemotherapy Protocols;Neoplasm Metastasis;Progression-Free Survival;Aged, 80 and over","Humans;Female;Breast Neoplasms;Trastuzumab;Antibodies, Monoclonal, Humanized;Middle Aged;Camptothecin;Aged;Receptor, ErbB-2;Immunoconjugates;Retrospective Studies;Adult;Antineoplastic Combined Chemotherapy Protocols;Neoplasm Metastasis;Progression-Free Survival;Aged, 80 and over","Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown. ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC. One hundred and seventy-nine patients were included: the majority with HR-negative tumours received SG first (ADC1) (n = 100/108) while most with HR-positive tumours received T-DXd first (n = 56/71). Median progression-free survival 2 was short: 2.7 months (95% CI: 2.4-3.3) in the whole population, respectively, 3.1 (95% CI: 2.6-3.6) and 2.2 months (95% CI: 1.9-2.7) for patients receiving T-DXd or SG second (ADC2). Intermediary lines of chemotherapy between ADC1 and ADC2 had no impact. Primary resistance to ADC2 occurred in 54.4% of patients. Certain patients showed initial response to ADC2. Clinical benefit of sequentially administered SG and T-DXd is limited for most patients. Nevertheless, a subset of patients might benefit-on the short term-from a second ADC. Additional studies are needed to identify patients who could benefit from two ADCs with similar payloads.","Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse;Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France.;Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Georges-François Leclerc, INSERM U1231, Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France.;Department of Medical Oncology and Cellular Therapy, Faculté de médecine Sorbonne Université, Hôpital Tenon, Paris, France.;Department of Medical Oncology, Hôpital de la Pitié-Salpêtrière, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de la Loire, Angers, France.;Department of Medical Oncology, INSERM U976, Université de Paris Cité, Hopital Saint Louis, Paris, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Versailles Saint-Quentin University, Paris Saclay, Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Clinical Trials Department - Breast Cancers, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Medical Oncology, Centre Hospitalier de la côte basque, Bayonne, France.;Department of Pathology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.;Department of Medical Oncology, University Hospital, Nimes, France.;UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;University Paris-Saclay, Gustave Roussy, INSERM U981, Molecular Predictors and New Targets in Oncology, Villejuif, France.;Division of Breast Medical Oncology, Instituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia.;Departmentof Medical Oncology, Institut Gustave Roussy, Paris, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université Lyon 1, Lyon, France.;Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2024,"2024","131","10.1038/s41416-024-02766-9","702-708","","","38918555","38918555","PUBMED","Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse;Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France.;Department of Medical Oncology, Centre Léon Bérard, Cancer Research Center of Lyon (UMR Inserm 1052 - CNRS 5286), Lyon, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Georges-François Leclerc, INSERM U1231, Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, Montpellier, France.;Department of Medical Oncology and Cellular Therapy, Faculté de médecine Sorbonne Université, Hôpital Tenon, Paris, France.;Department of Medical Oncology, Hôpital de la Pitié-Salpêtrière, Institut Universitaire de Cancérologie AP-HP, Sorbonne Université, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de la Loire, Angers, France.;Department of Medical Oncology, INSERM U976, Université de Paris Cité, Hopital Saint Louis, Paris, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Versailles Saint-Quentin University, Paris Saclay, Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Clinical Trials Department - Breast Cancers, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Biostatistics & Health Data Science Unit, Oncopole Claudius Regaud IUCT-O, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Medical Oncology, Centre Hospitalier de la côte basque, Bayonne, France.;Department of Pathology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.;Department of Medical Oncology, University Hospital, Nimes, France.;UMR INSERM IDESP-Desbrest Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;University Paris-Saclay, Gustave Roussy, INSERM U981, Molecular Predictors and New Targets in Oncology, Villejuif, France.;Division of Breast Medical Oncology, Instituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia.;Departmentof Medical Oncology, Institut Gustave Roussy, Paris, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université Lyon 1, Lyon, France.;Aix-Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France."
"67","Loubet P;Lelievre JD;François A;Botelho-Nevers E;Chidiac C;Chirio D;Dubee V;Dussol B;Galtier F;Hessamfar M;Hodaj E;Jaffuel S;Lacombe K;Laine F;Lefebvre M;Maakaroun-Vermesse Z;Makinson A;Portefaix A;Pourcher V;Rey D;Zucman D;Longobardi J;Bertheau M;Tartour E;de Lamballerie X;Launay O;Wittkop L","Loubet, Paul;Lelievre, Jean-Daniel;François, Alexis;Botelho-Nevers, Elisabeth;Chidiac, Christian;Chirio, David;Dubee, Vincent;Dussol, Bertrand;Galtier, Florence;Hessamfar, Mojgan;Hodaj, Enkelejda;Jaffuel, Sylvain;Lacombe, Karine;Laine, Fabrice;Lefebvre, Maeva;Maakaroun-Vermesse, Zoha;Makinson, Alain;Portefaix, Aurelie;Pourcher, Valerie;Rey, David;Zucman, David;Longobardi, Julie;Bertheau, Mathilde;Tartour, Eric;de Lamballerie, Xavier;Launay, Odile;Wittkop, Linda","Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: A French nationwide multicenter cohort study-ANRS0001s COV-POPART.","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","Canada","eng","Journal Article","COVID-19;HIV;Immunogenicity;SARS-CoV-2;Vaccines","Humans;Male;Female;COVID-19;Middle Aged;HIV Infections;France;Antibodies, Viral;Immunization, Secondary;SARS-CoV-2;Immunity, Humoral;COVID-19 Vaccines;Adult;CD4 Lymphocyte Count;Cohort Studies;Vaccination;Viral Load;Antibodies, Neutralizing;Immunoglobulin G","Humans;Male;Female;COVID-19;Middle Aged;HIV Infections;France;Antibodies, Viral;Immunization, Secondary;SARS-CoV-2;Immunity, Humoral;COVID-19 Vaccines;Adult;CD4 Lymphocyte Count;Cohort Studies;Vaccination;Viral Load;Antibodies, Neutralizing;Immunoglobulin G","This study aimed to compare the humoral responses to mRNA COVID-19 vaccination in people living with HIV (PWH) and HIV-negative individuals. We included PWH with an undetectable viral load under ART and HIV-negative participants from the French nationwide ANRS COV-POPART cohort who had received two doses of vaccine as a primary vaccination. We compared humoral response between controls and PWH, stratified by CD4 cell count (<200/mm  and ≥200/mm  CD4 cell counts) at 1, 6, and 12 months after primary vaccination. A total of 1776 participants were included in this analysis, 684 PWH (99% were on ART, median CD4 counts 673 cells/mm ) and 1092 controls. At 1 month, after adjustment on age, sex, and BMI, PWH had lower seroneutralization titers than controls, and PWH with <200 CD4 cell/mm  had lower anti-Spike SARS-CoV-2 IgG antibodies. Same results were found at 6 months. However, in participants who received a booster dose between 6 and 12 months postprimary vaccination, we did not observe differences between PWH and controls at 12 months. PWH had high responses to primary mRNA COVID-19 vaccination. In those who received a booster dose after 6 months, the humoral response at 12 months increased to similar levels to controls, even in those with low CD4 counts at baseline.","INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France; INSERM U1047 - Université de Montpellier, Nîmes;Vaccine Research Institute, INSERM et APHP, Hôpital H. Mondor, Créteil, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France.;Service d'infectiologie, CHU de Saint-Etienne, Saint-Étienne, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Groupement Hospitalier Nord, Lyon, France, Lyon, France; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France.;Département de Médecine Infectiologique, Hôpital de L'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, France.;Service des maladies infectieuses et tropicales, CHU d'Angers, Angers, France.;Centre d'Investigation Clinique 1415, AP-HM, Marseille, France.;INSERM CIC 1411, Centre Hospitalier Universitaire de Montpellier, Hôpital Saint-Eloi, Montpellier, France.;Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux, INSERM, BPH, Bordeaux, France.;Inserm Centre d'Investigation Clinique 1406, Centre Hospitalier Grenoble-Alpes, Grenoble, France.;Service des Maladies Infectieuses et Tropicales, Brest, France.;Sorbonne Université, Inserm IPLESP, Service de maladies infectieuses et tropicales Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.;Université de Rennes, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de maladies infectieuses et tropicales, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.;Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale CIC 1415, Tours, France.;Département des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Montpellier & Université de Montpellier, Montpellier, France.;Hospices civils de Lyon, Centre Investigation Clinique, Bron, France.;Service de Maladies Infectieuses et tropicales, Hôpital de la Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université de Paris Sorbonne, Paris, France; Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.;Le Trait d'Union, Centre de Soins de l'Infection par le VIH, NHC, Hôpitaux Universitaires, Strasbourg, France.;Réseau Ville-Hôpital, Service de Médecine Interne, Hôpital Foch, Suresnes, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France.;ANRS Emerging Infectious Diseases, Paris, France.;Service d'Immunologie biologique, Hôpital européen Georges Pompidou/APHP, Paris, France.;Unité des Virus Emergents, Aix-Marseille Université, Institut de Recherche pour le Développement 190, Marseille, France.;INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Paris, France; Université de Paris, Paris, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France; INRIA SISTM Team, Talence, France; CHU de Bordeaux, Service d'information médicale, INSERM, Bordeaux, France.","NA",0,"1878-3511","Int J Infect Dis","Int J Infect Dis",2024,"2024","146","10.1016/j.ijid.2024.107110","107110","","","38825164","38825164","PUBMED","INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Service des Maladies Infectieuses et Tropicales, CHU de Nîmes, Nîmes, France; INSERM U1047 - Université de Montpellier, Nîmes;Vaccine Research Institute, INSERM et APHP, Hôpital H. Mondor, Créteil, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France.;Service d'infectiologie, CHU de Saint-Etienne, Saint-Étienne, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Groupement Hospitalier Nord, Lyon, France, Lyon, France; Université Claude Bernard Lyon 1, Centre International de Recherche en Infectiologie, Lyon, France.;Département de Médecine Infectiologique, Hôpital de L'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, Nice, France.;Service des maladies infectieuses et tropicales, CHU d'Angers, Angers, France.;Centre d'Investigation Clinique 1415, AP-HM, Marseille, France.;INSERM CIC 1411, Centre Hospitalier Universitaire de Montpellier, Hôpital Saint-Eloi, Montpellier, France.;Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint André, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux, INSERM, BPH, Bordeaux, France.;Inserm Centre d'Investigation Clinique 1406, Centre Hospitalier Grenoble-Alpes, Grenoble, France.;Service des Maladies Infectieuses et Tropicales, Brest, France.;Sorbonne Université, Inserm IPLESP, Service de maladies infectieuses et tropicales Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.;Université de Rennes, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de maladies infectieuses et tropicales, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes, France.;Centre Hospitalier Régional Universitaire Tours, Institut National de la Santé et de la Recherche Médicale CIC 1415, Tours, France.;Département des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Montpellier & Université de Montpellier, Montpellier, France.;Hospices civils de Lyon, Centre Investigation Clinique, Bron, France.;Service de Maladies Infectieuses et tropicales, Hôpital de la Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université de Paris Sorbonne, Paris, France; Sorbonne Université, Inserm, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France.;Le Trait d'Union, Centre de Soins de l'Infection par le VIH, NHC, Hôpitaux Universitaires, Strasbourg, France.;Réseau Ville-Hôpital, Service de Médecine Interne, Hôpital Foch, Suresnes, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France.;ANRS Emerging Infectious Diseases, Paris, France.;Service d'Immunologie biologique, Hôpital européen Georges Pompidou/APHP, Paris, France.;Unité des Virus Emergents, Aix-Marseille Université, Institut de Recherche pour le Développement 190, Marseille, France.;INSERM, F-CRIN, Reseau Innovative Clinical Research in Vaccinology (IREIVAC), Paris, France; Centre d'Investigation Clinique Cochin Pasteur, Paris, France; Université de Paris, Paris, France.;Univ. Bordeaux, INSERM, MART, Bordeaux, France; INRIA SISTM Team, Talence, France; CHU de Bordeaux, Service d'information médicale, INSERM, Bordeaux, France."
"68","Cutrì E;Morel-Corlu E;Rolland Y;Saint-Jalmes H;Eliat PA;Garin E;Bezy-Wendling J","Cutrì, Elena;Morel-Corlu, Ewan;Rolland, Yan;Saint-Jalmes, Hervé;Eliat, Pierre-Antoine;Garin, Etienne;Bezy-Wendling, Johanne","A microscopic model of the dose distribution in hepatocellular carcinoma after selective internal radiation therapy.","Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)","Italy","eng","Journal Article","Dosimetry evaluation;Hepatocellular carcinoma;Microscopic model;Selective internal radiation therapy","Liver Neoplasms;Carcinoma, Hepatocellular;Humans;Microspheres;Radiotherapy Dosage;Yttrium Radioisotopes;Models, Biological;Tomography, X-Ray Computed;Radiation Dosage;Microscopy","Liver Neoplasms;Carcinoma, Hepatocellular;Humans;Microspheres;Radiotherapy Dosage;Yttrium Radioisotopes;Models, Biological;Tomography, X-Ray Computed;Radiation Dosage;Microscopy","The dosimetry evaluation for the selective internal radiation therapy is currently performed assuming a uniform activity distribution, which is in contrast with literature findings. A 2D microscopic model of the perfused liver was developed to evaluate the effect of two different  Y microspheres distributions: i) homogeneous partitioning with the microspheres equally distributed in the perfused liver, and ii) tumor-clustered partitioning where the microspheres distribution is inferred from the patient specific images. Two subjects diagnosed with liver cancer were included in this study. For each subject, abdominal CT scans acquired prior to the SIRT and post-treatment  Y positron emission tomography were considered. Two microspheres partitionings were simulated namely homogeneous and tumor-clustered partitioning. The homogeneous and tumor-clustered partitionings were derived starting from CT images. The microspheres radiation is simulated by means of Russell's law. In homogenous simulations, the dose delivery is uniform in the whole liver while in the tumor-clustered simulations a heterogeneous distribution of the delivered dose is visible with higher values in the tumor regions. In addition, in the tumor-clustered simulation, the delivered dose is higher in the viable tumor than in the necrotic tumor, for all patients. In the tumor-clustered case, the dose delivered in the non-tumoral tissue (NTT) was considerably lower than in the perfused liver. The model proposed here represents a proof-of-concept for personalized dosimetry assessment based on preoperative CT images.","Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France; Université de technologie de Compiègne, CNRS, Biomechanics and Bioengineering, 60203 Compiègne Cedex, France; Inria, Saclay Ile-de-France, Palaiseau, 91120;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;INRAE, INSERM, Univ Rennes, Nutrition Metabolisms and Cancer, NuMeCan, St Gilles, Rennes, France; CNRS, INSERM, Biosit UAR 3480 US_S 018, PRISM, Univ Rennes, Rennes, France.;INRAE, INSERM, Univ Rennes, Nutrition Metabolisms and Cancer, NuMeCan, St Gilles, Rennes, France; Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.","NA",0,"1724-191X","Phys Med","Phys Med",2023,"2024","122","10.1016/j.ejmp.2024.103384","103384","","","38824827","38824827","PUBMED","Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France; Université de technologie de Compiègne, CNRS, Biomechanics and Bioengineering, 60203 Compiègne Cedex, France; Inria, Saclay Ile-de-France, Palaiseau, 91120;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France.;INRAE, INSERM, Univ Rennes, Nutrition Metabolisms and Cancer, NuMeCan, St Gilles, Rennes, France; CNRS, INSERM, Biosit UAR 3480 US_S 018, PRISM, Univ Rennes, Rennes, France.;INRAE, INSERM, Univ Rennes, Nutrition Metabolisms and Cancer, NuMeCan, St Gilles, Rennes, France; Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, F-35000, Rennes, France."
"69","Bémer P;Aubry A;Schramm F;Koebel C;Revillet H;Baltes V;Le Brun C;Chazerain P;Zeller V;Hamdad F;Morand PC;Guillouzouic A;Piau C;Roux AL;Soueges S;Martin C;Gaudart A;Hüssler S;Fihman V;Carricajo A;Caruba CG;Bador J;Dauchy FA;Dutronc H;Vignals C;Peuchant O","Bémer, Pascale;Aubry, Alexandra;Schramm, Frédéric;Koebel, Christelle;Revillet, Hélène;Baltes, Virginie;Le Brun, Cécile;Chazerain, Pascal;Zeller, Valérie;Hamdad, Farida;Morand, Philippe C;Guillouzouic, Aurélie;Piau, Caroline;Roux, Anne-Laure;Soueges, Sarah;Martin, Christian;Gaudart, Alice;Hüssler, Sophie;Fihman, Vincent;Carricajo, Anne;Caruba, Christelle Guillet;Bador, Julien;Dauchy, Frédéric-Antoine;Dutronc, Hervé;Vignals, Carole;Peuchant, Olivia","Clinical features and treatment outcomes of bone and joint nontuberculous mycobacterial infections according to immune status: a 9-year retrospective observational cohort.","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","Canada","eng","Journal Article","Bone and joint infection;Clinical characteristics;Immune status;Non-tuberculous mycobacteria;Outcomes","Humans;Mycobacterium Infections, Nontuberculous;Retrospective Studies;Male;Female;Aged;Middle Aged;Nontuberculous Mycobacteria;Treatment Outcome;Anti-Bacterial Agents;France;Immunocompromised Host;Aged, 80 and over;Adult;Arthritis, Infectious","Humans;Mycobacterium Infections, Nontuberculous;Retrospective Studies;Male;Female;Aged;Middle Aged;Nontuberculous Mycobacteria;Treatment Outcome;Anti-Bacterial Agents;France;Immunocompromised Host;Aged, 80 and over;Adult;Arthritis, Infectious","Nontuberculous mycobacteria (NTM) bone and joint infections (BJIs) are uncommon. We evaluated the characteristics of BJIs and identified differences according to immune status. We performed a multicenter retrospective study in France involving patients with documented NTM BJI over a 9-year period. We collected the clinical and microbiological characteristics, management, and clinical outcomes of the patients. Overall, 95 patients were included, of whom 50.5% (48/95) were immunosuppressed. Tenosynovitis was more frequent in the immunocompetent group, and native arthritis more common in the immunosuppressed group. Mycobacerium marinum and M. abscessus complex were significantly more frequent in the immunocompetent group, and M. avium and M. xenopi were significantly more frequent in the immunosuppressed group. The combination of antibiotherapy with surgery tended to be more frequent in the immunocompetent than the immunosuppressed group (63.8% (30/47) vs 47.8% (22/46), respectively); of the latter, 45.7% (21/46) received antimicrobial therapy alone, a higher frequency than in the immunocompetent group (23.4%, 11/47). The median duration of antimicrobial treatment was similar in the two groups (11 months). Mortality was significantly higher in the immunosuppressed group. Although the clinical presentations and the NTM species involved in BJI differed according to immune status, most recovered completely after treatment.","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France.;Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service d'infectiologie, AP-HP, Hôpital Cochin, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de rhumatologie, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France; Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAc), Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAc), Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Laboratoire de Microbiologie, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France; Service de Bactériologie, AP-HP, Hôpital Cochin, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Bactériologie-Hygiène Hospitalière, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de microbiologie, AP-HP, Hôpital Ambroise Paré, Boulogne, France.;Service de Maladies Infectieuses et Tropicales de l'Hôpital de la Croix-Rousse, Centre de Référence des Infections Ostéo-Articulaires Complexes de Lyon (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.;Laboratoire de Bactériologie, Virologie, Hygiène, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nice, Nice, France.;Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Laboratoire des agents infectieux et Hygiène, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Service de Bactériologie et Hygiène, AH-HP, Hôpital Antoine Béclère, Clamart, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux","NA",0,"1878-3511","Int J Infect Dis","Int J Infect Dis",2024,"2024","146","10.1016/j.ijid.2024.107122","107122","","","38823623","38823623","PUBMED","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Sorbonne Université, INSERM, Centre d'Immunologie et des Maladies Infectieuses, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France.;Laboratoire de Bactériologie-Hygiène, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service d'infectiologie, AP-HP, Hôpital Cochin, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de rhumatologie, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France; Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAc), Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes (CRIOAc), Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Laboratoire de Microbiologie, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Université Paris Cité, CNRS, Inserm, Institut Cochin, Paris, France; Service de Bactériologie, AP-HP, Hôpital Cochin, Paris, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Bactériologie-Hygiène Hospitalière, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de microbiologie, AP-HP, Hôpital Ambroise Paré, Boulogne, France.;Service de Maladies Infectieuses et Tropicales de l'Hôpital de la Croix-Rousse, Centre de Référence des Infections Ostéo-Articulaires Complexes de Lyon (CRIOAc Lyon), Hospices Civils de Lyon, Lyon, France.;Laboratoire de Bactériologie, Virologie, Hygiène, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Nice, Nice, France.;Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Unité de Bactériologie, Département de Prévention, Diagnostic et Traitement des Infections, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Laboratoire des agents infectieux et Hygiène, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Service de Bactériologie et Hygiène, AH-HP, Hôpital Antoine Béclère, Clamart, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service des Maladies Infectieuses et Tropicales, Centre de Référence CRIOAc GSO, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux"
"70","Goutard M;Tawa P;Berkane Y;Andrews AR;Pendexter CA;de Vries RJ;Pozzo V;Romano G;Lancia HH;Filz von Reiterdank I;Bertheuil N;Rosales IA;How IDAL;Randolph MA;Lellouch AG;Cetrulo CL;Uygun K","Goutard, Marion;Tawa, Pierre;Berkane, Yanis;Andrews, Alec R;Pendexter, Casie A;de Vries, Reinier J;Pozzo, Victor;Romano, Golda;Lancia, Hyshem H;Filz von Reiterdank, Irina;Bertheuil, Nicolas;Rosales, Ivy A;How, Ira Doressa Anne L;Randolph, Mark A;Lellouch, Alexandre G;Cetrulo, Curtis L;Uygun, Korkut","Machine Perfusion Enables 24-h Preservation of Vascularized Composite Allografts in a Swine Model of Allotransplantation.","Transplant international : official journal of the European Society for Organ Transplantation","Switzerland","eng","Journal Article","VCA;ischemia-reperfusion injuries;machine perfusion;organ preservation;vascularized composite allotransplantation","Animals;Organ Preservation;Perfusion;Swine;Vascularized Composite Allotransplantation;Graft Survival;Hindlimb;Composite Tissue Allografts;Models, Animal;Transplantation, Homologous;Allografts","Animals;Organ Preservation;Perfusion;Swine;Vascularized Composite Allotransplantation;Graft Survival;Hindlimb;Composite Tissue Allografts;Models, Animal;Transplantation, Homologous;Allografts","The current gold standard for preserving vascularized composite allografts (VCA) is 4°C static cold storage (SCS), albeit muscle vulnerability to ischemia can be described as early as after 2 h of SCS. Alternatively, machine perfusion (MP) is growing in the world of organ preservation. Herein, we investigated the outcomes of oxygenated acellular subnormothermic machine perfusion (SNMP) for 24-h VCA preservation before allotransplantation in a swine model. Six partial hindlimbs were procured on adult pigs and preserved   for 24 h with either SNMP (  = 3) or SCS (  = 3) before heterotopic allotransplantation. Recipient animals received immunosuppression and were followed up for 14 days. Clinical monitoring was carried out twice daily, and graft biopsies and blood samples were regularly collected. Two blinded pathologists assessed skin and muscle samples. Overall survival was higher in the SNMP group. Early euthanasia of 2 animals in the SCS group was linked to significant graft degeneration. Analyses of the grafts showed massive muscle degeneration in the SCS group and a normal aspect in the SNMP group 2 weeks after allotransplantation. Therefore, this 24-h SNMP protocol using a modified Steen solution generated better clinical and histological outcomes in allotransplantation when compared to time-matched SCS.","Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Suivi Immunologique des Thérapeutiques Innovantes Laboratory, INSERM U1236, University of Rennes 1, Rennes, France.;Department of Plastic, Reconstructive, and Aesthetic Surgery, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;Department of Surgery, Amsterdam University Medical Centers-Location AMC, University of Amsterdam, Amsterdam, Netherlands.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.;Suivi Immunologique des Thérapeutiques Innovantes Laboratory, INSERM U1236, University of Rennes 1, Rennes, France.;Department of Plastic, Reconstructive, and Aesthetic Surgery, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Immunopathology Research Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.;Department of Pathology, Harvard Medical School, Boston, MA, United States.;Immunopathology Research Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.;Department of Pathology, Harvard Medical School, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.","NA",0,"1432-2277","Transpl Int","Transpl Int",2023,"2024","37","10.3389/ti.2024.12338","12338","","","38813393","38813393","PUBMED","Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Suivi Immunologique des Thérapeutiques Innovantes Laboratory, INSERM U1236, University of Rennes 1, Rennes, France.;Department of Plastic, Reconstructive, and Aesthetic Surgery, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;Department of Surgery, Amsterdam University Medical Centers-Location AMC, University of Amsterdam, Amsterdam, Netherlands.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States.;University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.;Suivi Immunologique des Thérapeutiques Innovantes Laboratory, INSERM U1236, University of Rennes 1, Rennes, France.;Department of Plastic, Reconstructive, and Aesthetic Surgery, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Immunopathology Research Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.;Department of Pathology, Harvard Medical School, Boston, MA, United States.;Immunopathology Research Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, United States.;Department of Pathology, Harvard Medical School, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, MA, United States."
"71","Guegan B;Drouineau M;Common H;Robert H","Guegan, Baptiste;Drouineau, Michel;Common, Harold;Robert, Henri","All the menisco-ligamentary structures of the medial plane play a significant role in controlling anterior tibial translation and tibial rotation of the knee. Cadaveric study of 29 knees with the Dyneelax® laximeter.","Journal of experimental orthopaedics","United States","eng","Journal Article","Dyneelax®;anterior cruciate ligament;medial meniscus;medial side structures","","","This study aimed to determine the respective roles of the anterior cruciate ligament (ACL) and the different components of the medial plane in the control of anterior tibial translation and internal and external tibial rotation. Twenty-nine fresh lower limbs, disarticulated at the hip, were tested in the anatomy laboratory. The following structures were isolated: the ACL, the anteromedial retinaculum (AMR), the medial collateral ligament (superficial and deep MCL), the posterior medial capsule (PMC) and the posterior horn of the medial meniscus (PHMM). The lower limb was positioned at 30° of flexion on the Dyneelax® laximeter (0.1 mm and 0.1° accuracies) and underwent anterior loads up to 200 N and internal and external tibial rotations sectioned from front to back. and the knee was then retested. The results were presented as relative gains in translation and rotations for each structure. Student's   test and Wilcoxon tests were used. The relative gains in translation for the ACL, AMR, superficial MCL, deep MCL, PMC and PHMM, respectively, were 42.9%, 6.7%, 7.4%, 6%, 7.5% and 11.6%. The relative gains in internal rotation for ACL, AMR, superficial MCL, deep MCL, PMC and PHMM, respectively, were 13%, 6.9%, 4.6%, 3.9%, 13% and 8%. The relative gains in external rotation for ACL, AMR, superficial MCL, deep MCL, PMC and medial meniscus, respectively, were 8.9%, 6%, 9.7%, 13.8%,11.2% and 8.5%. All the relative gains in translation, internal and external rotations were significant at each step of transection (  < 0.01). The ligamentous structures of the medial plane constitute a functional unit in which each component has a specific passive contribution. This study highlights the importance of recognising the extent of the medial ligament tears and performing a medial side anatomic and individual reconstruction and a suture of a ramp lesion, in addition to an ACL surgery.","CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;Centre Hospitalier du Haut Anjou Château-Gontier-Sur-Mayenne France.","NA",0,"2197-1153","J Exp Orthop","J Exp Orthop",2023,"2024","11","10.1002/jeo2.12038","e12038","","","38807638","38807638","PUBMED","CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;CHU Rennes: Centre Hospitalier Universitaire de Rennes Rennes France.;Centre Hospitalier du Haut Anjou Château-Gontier-Sur-Mayenne France."
"72","Clavreul A;Guette C;Lasla H;Rousseau A;Blanchet O;Henry C;Boissard A;Cherel M;Jézéquel P;Guillonneau F;Menei P;Lemée JM","Clavreul, Anne;Guette, Catherine;Lasla, Hamza;Rousseau, Audrey;Blanchet, Odile;Henry, Cécile;Boissard, Alice;Cherel, Mathilde;Jézéquel, Pascal;Guillonneau, François;Menei, Philippe;Lemée, Jean-Michel","Proteomics of tumor and serum samples from isocitrate dehydrogenase-wildtype glioblastoma patients: is the detoxification of reactive oxygen species associated with shorter survival?","Molecular oncology","United States","eng","Journal Article","IDH‐wildtype;glioblastoma;metabolism;prognosis;proteomics;reactive oxygen species","Humans;Glioblastoma;Isocitrate Dehydrogenase;Reactive Oxygen Species;Proteomics;Male;Female;Middle Aged;Brain Neoplasms;Aged;Adult;Biomarkers, Tumor;Prognosis","Humans;Glioblastoma;Isocitrate Dehydrogenase;Reactive Oxygen Species;Proteomics;Male;Female;Middle Aged;Brain Neoplasms;Aged;Adult;Biomarkers, Tumor;Prognosis","Proteomics has been little used for the identification of novel prognostic and/or therapeutic markers in isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GB). In this study, we analyzed 50 tumor and 30 serum samples from short- and long-term survivors of IDH-wildtype GB (STS and LTS, respectively) by data-independent acquisition mass spectrometry (DIA-MS)-based proteomics, with the aim of identifying such markers. DIA-MS identified 5422 and 826 normalized proteins in tumor and serum samples, respectively, with only three tumor proteins and 26 serum proteins displaying significant differential expression between the STS and LTS groups. These dysregulated proteins were principally associated with the detoxification of reactive oxygen species (ROS). In particular, GB patients in the STS group had high serum levels of malate dehydrogenase 1 (MDH1) and ribonuclease inhibitor 1 (RNH1) and low tumor levels of fatty acid-binding protein 7 (FABP7), which may have enabled them to maintain low ROS levels, counteracting the effects of the first-line treatment with radiotherapy plus concomitant and adjuvant temozolomide. A blood score built on the levels of MDH1 and RNH1 expression was found to be an independent prognostic factor for survival based on the serum proteome data for a cohort of 96 IDH-wildtype GB patients. This study highlights the utility of circulating MDH1 and RNH1 biomarkers for determining the prognosis of patients with IDH-wildtype GB. Furthermore, the pathways driven by these biomarkers, and the tumor FABP7 pathway, may constitute promising therapeutic targets for blocking ROS detoxification to overcome resistance to chemoradiotherapy in potential GB STS.","Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Omics Data Science Unit, Institut de Cancérologie de l'Ouest (ICO), Nantes, France.;SIRIC ILIAD, Institut de Recherche en Santé, Université de Nantes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Département de Pathologie, CHU d'Angers, France.;Centre de Ressources Biologiques, BB-0033-00038, CHU d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Département de Biologie Médicale, Centre Eugène Marquis, Unicancer, Rennes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Omics Data Science Unit, Institut de Cancérologie de l'Ouest (ICO), Nantes, France.;SIRIC ILIAD, Institut de Recherche en Santé, Université de Nantes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.","NA",0,"1878-0261","Mol Oncol","Mol Oncol",2024,"2024","18","10.1002/1878-0261.13668","2783-2800","","Association en avant la vie","38803161","38803161","PUBMED","Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Omics Data Science Unit, Institut de Cancérologie de l'Ouest (ICO), Nantes, France.;SIRIC ILIAD, Institut de Recherche en Santé, Université de Nantes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Département de Pathologie, CHU d'Angers, France.;Centre de Ressources Biologiques, BB-0033-00038, CHU d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Département de Biologie Médicale, Centre Eugène Marquis, Unicancer, Rennes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Omics Data Science Unit, Institut de Cancérologie de l'Ouest (ICO), Nantes, France.;SIRIC ILIAD, Institut de Recherche en Santé, Université de Nantes, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;PROT'ICO - Plateforme Oncoprotéomique, Institut de Cancérologie de l'Ouest (ICO), Angers, France.;Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France.;Département de Neurochirurgie, CHU d'Angers, France.;Inserm UMR 1307, CNRS UMR 6075, Université de Nantes, CRCI2NA, Université d'Angers, France."
"73","Petit T;Hajjaji N;Antoine EC;Benderra MA;Gozy M;Foa C;Mouysset JL;Grenier J;Mousseau M;Mailliez A;Saghatchian M;Lachaier E;Desmoulins I;Hennequin A;Maes P;Loirat D;Ricci F;Diéras V;Berton D;Tiong FL;Teixeira L;Dohollou N;Lévy C;Bachelot T;Pierga JY","Petit, Thierry;Hajjaji, Nawale;Antoine, Eric-Charles;Benderra, Marc-Antoine;Gozy, Michel;Foa, Cyril;Mouysset, Jean-Loup;Grenier, Julien;Mousseau, Mireille;Mailliez, Audrey;Saghatchian, Mahasti;Lachaier, Emma;Desmoulins, Isabelle;Hennequin, Audrey;Maes, Patricia;Loirat, Delphine;Ricci, Francesco;Diéras, Véronique;Berton, Dominique;Tiong, Florence Lai;Teixeira, Luis;Dohollou, Nadine;Lévy, Christelle;Bachelot, Thomas;Pierga, Jean-Yves","Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France.","Cancer medicine","United States","eng","Journal Article","HER2‐positive;breast cancer;early‐access program;metastatic cancer;trastuzumab deruxtecan","Humans;Female;Breast Neoplasms;Trastuzumab;Middle Aged;France;Receptor, ErbB-2;Aged;Adult;Camptothecin;Immunoconjugates;Antineoplastic Agents, Immunological;Aged, 80 and over;Treatment Outcome","Humans;Female;Breast Neoplasms;Trastuzumab;Middle Aged;France;Receptor, ErbB-2;Aged;Adult;Camptothecin;Immunoconjugates;Antineoplastic Agents, Immunological;Aged, 80 and over;Treatment Outcome","Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T-DXd) in France based on DESTINY-Breast01 trial which demonstrated its efficacy and safety in HER2-positive metastatic/unresectable breast cancer after ≥2 anti-HER2-based regimens received at metastatic stage. This multicenter real-world early access program included HER2-positive metastatic/unresectable breast patients pretreated with at least two lines of anti-HER2 regimens who received T-DXd 5.4 mg/kg intravenously in monotherapy every 3 weeks. Four hundred and fifty-nine patients (median age, 58 years; hormone receptor-positive, 67%; brain metastases, 28.1%) received T-DXd. Before inclusion, 81.7% of patients had radiation therapy and 76.5% had undergone surgery. Median number of prior metastatic treatment lines was four (range, 2-22); 99.8% patients had received trastuzumab, 94.8% trastuzumab emtansine and 79.3% pertuzumab. Follow-up was performed from September 30, 2020 to March 30, 2021; when the early access program stopped, the median duration of T-DXd treatment was 3.4 (range, 0-7.8) months. In 160 patients with available tumor assessment, objective response rate was 56.7% and 12.1% had progression. In 57 patients with available brain tumor assessment, complete or partial intracranial response was reported for 35.7% patients and 5.4% had progression. A total of 17 (3.7%) patients with interstitial lung disease (ILD) was reported with no cases of ILD-related death. In this early access program in patients with heavily pretreated HER2-positive metastatic/unresectable breast cancer, T-DXd had antitumor activity with a similar response to that reported in previous clinical studies. T-DXd was well tolerated and no new safety signals were observed.","Département d'Oncologie Médicale, Centre Paul Strauss, Strasbourg, France.;Département de Cancérologie Sénologique, Centre Oscar Lambret, INSERM U1192, Laboratoire PRISM, Lille, France.;Département d'Oncologie Médicale, Clinique Hartmann, Neuilly-sur-Seine, France.;Département d'Oncologie Médicale, Hôpital Tenon, Paris, France.;Département de Radiothérapie-Oncologie, Clinique de l'Europe, Amiens, France.;Département d'Oncologie Médicale, Hôpital Saint-Joseph, Marseille, France.;Département de Cancérologie, Hôpital Privé de Provence, Aix-en-Provence, France.;Unité Oncologie Sein-Gynécologie, Institut Sainte-Catherine, Avignon, France.;Département d'Oncologie Médicale, CHU Grenoble, Grenoble, France.;Département de Cancérologie Sénologique, Centre Oscar Lambret, INSERM U1192, Laboratoire PRISM, Lille, France.;Département d'Oncologie Médicale, Hôpital Américain de Paris, Neuilly-sur-Seine, France.;Département d'Oncologie Médicale, CHU Amiens, Amiens, France.;Département d'Oncologie Médicale, Centre Georges François Leclerc, Dijon, France.;Département d'Oncologie Médicale, Centre Georges François Leclerc, Dijon, France.;Département d'Oncologie, Hôpital Privé Le Bois, Lille, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Département d'Oncologie Médicale, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Département d'Hémato-Oncologie, CHU Sud Réunion, Saint-Pierre, France.;Breast Disease Unit, APHP, Hôpital Saint-Louis, Pathophysiology of Breast Cancer Team, Université de Paris, INSERM U976, HIPI, Paris, France.;Service d'Oncologie Médicale, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Département d'Oncologie Médicale, Centre François Baclesse, Caen, France.;Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Université Paris Cité, Paris, France.","NA",0,"2045-7634","Cancer Med","Cancer Med",2023,"2024","13","10.1002/cam4.7168","e7168","","AstraZeneca France;Daiichi-Sankyo","38733172","38733172","PUBMED","Département d'Oncologie Médicale, Centre Paul Strauss, Strasbourg, France.;Département de Cancérologie Sénologique, Centre Oscar Lambret, INSERM U1192, Laboratoire PRISM, Lille, France.;Département d'Oncologie Médicale, Clinique Hartmann, Neuilly-sur-Seine, France.;Département d'Oncologie Médicale, Hôpital Tenon, Paris, France.;Département de Radiothérapie-Oncologie, Clinique de l'Europe, Amiens, France.;Département d'Oncologie Médicale, Hôpital Saint-Joseph, Marseille, France.;Département de Cancérologie, Hôpital Privé de Provence, Aix-en-Provence, France.;Unité Oncologie Sein-Gynécologie, Institut Sainte-Catherine, Avignon, France.;Département d'Oncologie Médicale, CHU Grenoble, Grenoble, France.;Département de Cancérologie Sénologique, Centre Oscar Lambret, INSERM U1192, Laboratoire PRISM, Lille, France.;Département d'Oncologie Médicale, Hôpital Américain de Paris, Neuilly-sur-Seine, France.;Département d'Oncologie Médicale, CHU Amiens, Amiens, France.;Département d'Oncologie Médicale, Centre Georges François Leclerc, Dijon, France.;Département d'Oncologie Médicale, Centre Georges François Leclerc, Dijon, France.;Département d'Oncologie, Hôpital Privé Le Bois, Lille, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Département d'Oncologie Médicale, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Département d'Hémato-Oncologie, CHU Sud Réunion, Saint-Pierre, France.;Breast Disease Unit, APHP, Hôpital Saint-Louis, Pathophysiology of Breast Cancer Team, Université de Paris, INSERM U976, HIPI, Paris, France.;Service d'Oncologie Médicale, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Département d'Oncologie Médicale, Centre François Baclesse, Caen, France.;Département d'Oncologie Médicale, Centre Léon Bérard, Lyon, France.;Département d'Oncologie Médicale, Institut Curie, Paris, France.;Université Paris Cité, Paris, France."
"74","Epaillard N;Lusque A;Jacot W;Mailliez A;Bachelot T;Arnedos M;Le Du F;Brain E;Ferrero JM;Massard V;Desmoulins I;Mouret-Reynier MA;Levy C;Gonçalves A;Leheurteur M;Petit T;Filleron T;Bosquet L;Pistilli B;Frenel JS","Epaillard, N;Lusque, A;Jacot, W;Mailliez, A;Bachelot, T;Arnedos, M;Le Du, F;Brain, E;Ferrero, J M;Massard, V;Desmoulins, I;Mouret-Reynier, M A;Levy, C;Gonçalves, A;Leheurteur, M;Petit, T;Filleron, T;Bosquet, L;Pistilli, B;Frenel, J S","Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort.","ESMO open","England","eng","Journal Article","HER2-low;HER2-positive;brain metastases;breast cancer;metastasis","Humans;Breast Neoplasms;Female;Middle Aged;France;Brain Neoplasms;Incidence;Receptor, ErbB-2;Meningeal Neoplasms;Aged;Cohort Studies;Adult","Humans;Breast Neoplasms;Female;Middle Aged;France;Brain Neoplasms;Incidence;Receptor, ErbB-2;Meningeal Neoplasms;Aged;Cohort Studies;Adult","Breast cancer (BC) is the second most common cancer that metastasizes to the brain. Particularly up to half of patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (mBC) may develop brain metastases over the course of the disease. Nevertheless, little is known about the prevalence and the outcome of brain and leptomeningeal metastases (BLMM) in HER2-low BC. We compared the cumulative incidence of BLMM and associated outcomes among patients with HER2-low, HER2-negative (HER2-) and HER2+ mBC. This cohort study was conducted from the Epidemiological Strategy and Medical Economics (ESME) mBC database and included patients treated for mBC between 2012 and 2020 across 18 French comprehensive cancer centers and with known HER2 and hormone receptor (HR) status. The cumulative incidence of BLMM after metastatic diagnosis was estimated using a competing risk methodology with death defined as a competing event. 19 585 patients were included with 6118 (31.2%), 9943 (50.8%) and 3524 (18.0%) being HER2-low, HER2- and HER2+ mBC, respectively. After a median follow-up of 48.6 months [95% confidence interval (CI) 47.7-49.3 months], BLMM were reported in 4727 patients: 1192 (25.2%) were diagnosed with BLMM at first metastatic diagnosis and 3535 (74.8%) after metastatic diagnosis. Multivariable analysis adjusted for age, histological grade, metastases-free interval and HR status showed that the risk of BLMM at metastatic diagnosis was similar in patients with HER2- compared to HER2-low mBC [odds ratio (OR) (95% CI) 1.00 (0.86-1.17)] and higher in those with HER2+ compared to HER2-low [OR (95% CI) 2.23 (1.87-2.66)]. Similar results were found after metastatic diagnosis; the risk of BLMM was similar in HER2- compared to HER2-low [subdistribution hazard ratio (sHR) (95% CI) 1.07 (0.98-1.16)] and higher in the HER2+ group [sHR (95% CI) 1.56 (1.41-1.73)]. The prevalence and evolution of BLMM in HER2-low mBC are similar to those in patients with HER2- tumors. In contrast to patients with HER2+ mBC, the prognosis of BLMM remains dismal in this population.","Department of Medical Oncology, Gustave Roussy;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Department of Medical Oncology, Institut régional du Cancer, Montpellier.;Department of Medical Oncology, Centre Oscar Lambret, Lille.;Department of Medical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Institut Bergonié, Bordeaux.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, Institut Curie, Saint-Cloud.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand.;Department of Medical Oncology, Centre François Baclesse, Caen.;Department of Medical Oncology, Institut Paoli Calmette, Marseille.;Department of Medical Oncology, Centre Henri Becquerel, Rouen.;Department of Medical Oncology, Centre Paul Strauss ICANS, Strasbourg.;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Health Data and Partnership Department, Unicancer, Paris.;Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U1279, Gustave Roussy, Villejuif.;Department of Medical Oncology, Institut de Cancerologie de L'Ouest, Saint-Herblain, France.","NA",0,"2059-7029","ESMO Open","ESMO Open",2024,"2024","9","10.1016/j.esmoop.2024.103447","103447","","","38703431","38703431","PUBMED","Department of Medical Oncology, Gustave Roussy;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Department of Medical Oncology, Institut régional du Cancer, Montpellier.;Department of Medical Oncology, Centre Oscar Lambret, Lille.;Department of Medical Oncology, Centre Léon Bérard, Lyon.;Department of Medical Oncology, Institut Bergonié, Bordeaux.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, Institut Curie, Saint-Cloud.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand.;Department of Medical Oncology, Centre François Baclesse, Caen.;Department of Medical Oncology, Institut Paoli Calmette, Marseille.;Department of Medical Oncology, Centre Henri Becquerel, Rouen.;Department of Medical Oncology, Centre Paul Strauss ICANS, Strasbourg.;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT Oncopole, Toulouse.;Health Data and Partnership Department, Unicancer, Paris.;Department of Medical Oncology, Gustave Roussy, Villejuif; INSERM U1279, Gustave Roussy, Villejuif.;Department of Medical Oncology, Institut de Cancerologie de L'Ouest, Saint-Herblain, France."
"75","Hurvitz SA;Bardia A;Punie K;Kalinsky K;Carey LA;Rugo HS;Diéras V;Phan S;Delaney R;Zhu Y;Tolaney SM","Hurvitz, Sara A;Bardia, Aditya;Punie, Kevin;Kalinsky, Kevin;Carey, Lisa A;Rugo, Hope S;Diéras, Véronique;Phan, See;Delaney, Rosemary;Zhu, Yanni;Tolaney, Sara M","Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.","NPJ breast cancer","United States","eng","Journal Article","","","","In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients with mTNBC refractory to/relapsing after ≥2 prior chemotherapies (≥1 in the metastatic setting) were randomized 1:1 to receive SG or treatment of physician's choice (TPC) until unacceptable toxicity/progression. The primary endpoint was progression-free survival (PFS) per RECIST 1.1 by central review in patients without brain metastases. Patients with brain metastases were allowed if metastases were stable ≥4 weeks. In the intention-to-treat (ITT) population, 19% of patients were age ≥65 years; 12% were Black, and 12% had brain metastases. SG improved PFS and overall survival (OS), respectively, vs TPC in patients age ≥65 years (7.1 vs 2.4 months and 14.7 vs 8.9 months), or of Black race (5.4 vs 2.2 months and 13.8 vs 8.5 months), consistent with outcomes in the ITT population. Patients with brain metastases had numerically higher median PFS with SG vs TPC, but median OS was similar between treatment groups. SG was well tolerated and had a manageable safety profile consistent with the full safety population across all subgroups; neutropenia and diarrhea were the most common treatment-emergent adverse events. These findings confirm the meaningful clinical benefit of SG vs standard chemotherapy in patient subgroups with high unmet needs. SG should be considered an effective and safe treatment option for patients with mTNBC eligible for second-line or later therapy. ClinicalTrials.gov Number: NCT02574455.","Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA;Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Centre Eugène Marquis, Rennes, France.;Gilead Sciences Inc., Foster City, CA, USA.;Gilead Sciences Inc., Foster City, CA, USA.;Gilead Sciences Inc., Foster City, CA, USA.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.","NA",0,"2374-4677","NPJ Breast Cancer","NPJ Breast Cancer",2023,"2024","10","10.1038/s41523-024-00635-5","33","","","38664404","38664404","PUBMED","Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA;Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute and University Hospitals Leuven, Leuven, Belgium.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Centre Eugène Marquis, Rennes, France.;Gilead Sciences Inc., Foster City, CA, USA.;Gilead Sciences Inc., Foster City, CA, USA.;Gilead Sciences Inc., Foster City, CA, USA.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA."
"76","Carril-Ajuria L;Lavaud P;Dalban C;Negrier S;Gravis G;Motzer RJ;Chevreau C;Tannir NM;Oudard S;McDermott DF;Laguerre B;Hammers HJ;Barthelemy P;Plimack ER;Borchiellini D;Gross-Goupil M;Jiang R;Lee CW;de Silva H;Rini BI;Escudier B;Albigès L","Carril-Ajuria, Lucia;Lavaud, Pernelle;Dalban, Cecile;Negrier, Sylvie;Gravis, Gwénaëlle;Motzer, Robert J;Chevreau, Christine;Tannir, Nizar M;Oudard, Stéphane;McDermott, David F;Laguerre, Brigitte;Hammers, Hans J;Barthelemy, Philippe;Plimack, Elizabeth R;Borchiellini, Delphine;Gross-Goupil, Marine;Jiang, Ruiyun;Lee, Chung-Wei;de Silva, Heshani;Rini, Brian I;Escudier, Bernard;Albigès, Laurence","Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Antiangiogenics;Biomarkers;LIPI;Prognosis;Renal cell carcinoma;immune checkpoint inhibitors","Humans;Carcinoma, Renal Cell;Kidney Neoplasms;Male;Female;Middle Aged;Aged;Prognosis;Lung Neoplasms;Prospective Studies;Biomarkers, Tumor;Sunitinib;Immune Checkpoint Inhibitors;Nivolumab;Progression-Free Survival;Adult","Humans;Carcinoma, Renal Cell;Kidney Neoplasms;Male;Female;Middle Aged;Aged;Prognosis;Lung Neoplasms;Prospective Studies;Biomarkers, Tumor;Sunitinib;Immune Checkpoint Inhibitors;Nivolumab;Progression-Free Survival;Adult","The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or predictive role of LIPI in metastatic renal cell carcinoma (mRCC) are still scarce. The aim of this study was to evaluate whether LIPI could be predictive of survival in mRCC patients. We used patient level data from three different prospective studies (NIVOREN trial: nivolumab; TORAVA trial: VEGF/VEGFR-targeted therapy (TT); CheckMate 214: nivolumab-ipilimumab vs sunitinib). LIPI was calculated based on a derived neutrophils/(leukocyte-neutrophil) ratio > 3 and lactate-dehydrogenase >upper limit of normal, classifying patients into three groups (LIPI good, 0 factors;LIPI intermediate (int), 1 factor;LIPI poor, 2 factors) and/or into two groups (LIPI good, 0 factors;LIPI int/poor, 1-2 factors) according to trial sample size. Primary and secondary endpoints were overall survival (OS) and progression-free survival (PFS). In the Nivolumab dataset (n = 619), LIPI was significantly associated with OS (LIPI-good 30.1 vs 13.8 months in the LIPI int/poor; HR= 0.47) and PFS (HR=0.74). In the VEGF/VEGFR-TT dataset (n = 159), only a correlation with PFS was observed. In the CheckMate214 dataset (n = 1084), LIPI was significantly associated with OS (nivolumab-ipilimumab OS LIPI good vs int/poor: HR=0.55, p < 0.0001; sunitinib: OS LIPI good vs int/poor: 0.38, p < 0.0001) in both treatment groups in univariate and multivariate analysis. Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.","Gustave Roussy, Villejuif;Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Leon Bernard, Lyon, France.;Université de Lyon, Centre Leon Bernard, Lyon, France.;Institut Paoli-Calmettes, Aix-Marseille, France.;Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Européen Georges Pompidou, Oncology department, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.;Dana-Farber/Harvard Cancer Center, Boston, MA, USA.;Centre Eugene Marquis, Rennes, France.;UT Southwestern Kidney Cancer Program, Dallas, TX, USA.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Fox Chase Cancer Center, Philadelphia, PA, USA.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Vanderbilt-Ingram Cancer Center, Nashville, USA.;Gustave Roussy, Villejuif, France.;Gustave Roussy, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2024,"2024","204","10.1016/j.ejca.2024.114048","114048","","","38653033","38653033","PUBMED","Gustave Roussy, Villejuif;Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Leon Bernard, Lyon, France.;Université de Lyon, Centre Leon Bernard, Lyon, France.;Institut Paoli-Calmettes, Aix-Marseille, France.;Memorial Sloan Kettering Cancer Center, New York, NY, USA.;Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Européen Georges Pompidou, Oncology department, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.;Dana-Farber/Harvard Cancer Center, Boston, MA, USA.;Centre Eugene Marquis, Rennes, France.;UT Southwestern Kidney Cancer Program, Dallas, TX, USA.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Fox Chase Cancer Center, Philadelphia, PA, USA.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Bristol Myers Squibb, Princeton, USA.;Vanderbilt-Ingram Cancer Center, Nashville, USA.;Gustave Roussy, Villejuif, France.;Gustave Roussy, Villejuif"
"77","Alaterre E;Ovejero S;Bret C;Dutrieux L;Sika D;Fernandez Perez R;Espéli M;Fest T;Cogné M;Martin-Subero JI;Milpied P;Cavalli G;Moreaux J","Alaterre, Elina;Ovejero, Sara;Bret, Caroline;Dutrieux, Laure;Sika, Dassou;Fernandez Perez, Raul;Espéli, Marion;Fest, Thierry;Cogné, Michel;Martin-Subero, José Ignacio;Milpied, Pierre;Cavalli, Giacomo;Moreaux, Jérôme","Integrative single-cell chromatin and transcriptome analysis of human plasma cell differentiation.","Blood","United States","eng","Journal Article","","Humans;Cell Differentiation;Plasma Cells;Single-Cell Analysis;Chromatin;Gene Expression Profiling;Transcriptome;Epigenesis, Genetic;Cells, Cultured","Humans;Cell Differentiation;Plasma Cells;Single-Cell Analysis;Chromatin;Gene Expression Profiling;Transcriptome;Epigenesis, Genetic;Cells, Cultured","Plasma cells (PCs) are highly specialized cells representing the end stage of B-cell differentiation. We have shown that PC differentiation can be reproduced in vitro using elaborate culture systems. The molecular changes occurring during PC differentiation are recapitulated in this in vitro differentiation model. However, a major challenge exists to decipher the spatiotemporal epigenetic and transcriptional programs that drive the early stages of PC differentiation. We combined single cell (sc) RNA sequencing (RNA-seq) and assay for transposase-accessible chromatin with high throughput sequencing (scATAC-seq) to decipher the trajectories involved in PC differentiation. ScRNA-seq experiments revealed a strong heterogeneity of the preplasmablastic and plasmablastic stages. Among genes that were commonly identified using scATAC-seq and scRNA-seq, we identified several transcription factors with significant stage specific potential importance in PC differentiation. Interestingly, differentially accessible peaks characterizing the preplasmablastic stage were enriched in motifs of BATF3, FOS and BATF, belonging to activating protein 1 (AP-1) transcription factor family that may represent key transcriptional nodes involved in PC differentiation. Integration of transcriptomic and epigenetic data at the single cell level revealed that a population of preplasmablasts had already undergone epigenetic remodeling related to PC profile together with unfolded protein response activation and are committed to differentiate in PC. These results and the supporting data generated with our in vitro PC differentiation model provide a unique resource for the identification of molecular circuits that are crucial for early and mature PC maturation and biological functions. These data thus provide critical insights into epigenetic- and transcription-mediated reprogramming events that sustain PC differentiation.","Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.;INSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France.;Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, Team B_DEVIL, UMR_S1236, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Rennes, France.;Institut National de La Santé et de La Recherche Médicale, Unité Mixte de Recherche U1236, Université de Rennes, Etablissement Français Du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Suivi Immunologique des Thérapies Innovantes, Pôle Biologie, Rennes, France.;Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.;Departament de Fonaments Clínics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.;Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.;Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;University of Montpellier, UFR Medicine, Montpellier, France.;Institut Universitaire de France, Paris, France.","NA",0,"1528-0020","Blood","Blood",2023,"2024","144","10.1182/blood.2023023237","496-509","","","38643512","38643512","PUBMED","Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.;INSERM U1160 EMiLy, Institut de Recherche Saint-Louis, Université Paris-Cité, Paris, France.;Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, Team B_DEVIL, UMR_S1236, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire, Rennes, France.;Institut National de La Santé et de La Recherche Médicale, Unité Mixte de Recherche U1236, Université de Rennes, Etablissement Français Du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Suivi Immunologique des Thérapies Innovantes, Pôle Biologie, Rennes, France.;Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.;Departament de Fonaments Clínics, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.;Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.;Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Institute of Human Genetics, Unité Mixte de Recherche, Centre National de la Recherche Scientifique, Université Montpellier, Montpellier, France.;Department of Biological Hematology, CHU Montpellier, Montpellier, France.;University of Montpellier, UFR Medicine, Montpellier, France.;Institut Universitaire de France, Paris, France."
"78","Rayar M;Levi Sandri GB","Rayar, Michel;Levi Sandri, Giovanni Battista","The importance of preoperative imaging in living-donor hepatectomy.","Hepatobiliary surgery and nutrition","China (Republic : 1949- )","eng","Editorial","Liver transplant;hepatic artery;preoperative;robotic;three-dimensional imaging (3D imaging)","","","NA","Service de Chirurgie Hépatobiliaire et Digestif, Centre Hospitalier Universitaire de Rennes, Rennes, France.;NuMeCan Institute (Nutrition, Metabolisms and Cancer), Inserm, INRAE, Univ Rennes 1, Rennes, France.;Digestive Surgery Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS di Roma, Rome, Italy.","NA",0,"2304-3881","Hepatobiliary Surg Nutr","Hepatobiliary Surg Nutr",2024,"2024","13","10.21037/hbsn-24-29","356-358","","","38617489","38617489","PUBMED","Service de Chirurgie Hépatobiliaire et Digestif, Centre Hospitalier Universitaire de Rennes, Rennes, France.;NuMeCan Institute (Nutrition, Metabolisms and Cancer), Inserm, INRAE, Univ Rennes 1, Rennes, France.;Digestive Surgery Unit, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS di Roma, Rome, Italy."
"79","Le Guévelou J;Selleret L;Laas E;Lecuru F;Kissel M","Le Guévelou, Jennifer;Selleret, Lise;Laas, Enora;Lecuru, Fabrice;Kissel, Manon","Cervical Cancer Associated with Pregnancy: Current Challenges and Future Strategies.","Cancers","Switzerland","eng","Journal Article","cervical cancer;chemotherapy;fetal outcome;pregnancy;radiation therapy","","","Cancer during pregnancy is defined as a tumor diagnosed in a pregnant woman or up to 1-year post-partum. While being a rare disease, cervical cancer is probably one of the most challenging medical conditions, with the dual stake of treating the cancer without compromising its chances for cure, while preserving the pregnancy and the health of the fetus and child. To date, guidelines for gynecological cancers are provided through international consensus meetings with expert panels, giving insights on both diagnosis, treatment, and obstetrical care. However, these expert guidelines do not discuss the various approaches than can be found within the literature, such as alternative staging modalities or innovative surgical approaches. Also, the obstetrical care of women diagnosed with cervical cancer during pregnancy requires specific considerations that are not provided within our current standard of care. This systematic review aims to fill the gap on current issues with regards to the management of cervical cancer during pregnancy and provide future directions within this evolving landscape.","Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.;Department of Radiation Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University, 75005 Paris, France.;Cancer Associé à La Grossesse (CALG), French CALG Network, 75005 Paris, France.;Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, 75005 Paris, France.;Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, 75005 Paris, France.;Université de Paris, 75006 Paris, France.;Department of Radiation Oncology, Institut Curie, 75005 Paris, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2024,"2024","16","10.3390/cancers16071341",NA,"","","38611019","38611019","PUBMED","Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.;Department of Radiation Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Gynaecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Sorbonne University, 75005 Paris, France.;Cancer Associé à La Grossesse (CALG), French CALG Network, 75005 Paris, France.;Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, 75005 Paris, France.;Breast, Gynecology and Reconstructive Surgery Unit, Institut Curie, 75005 Paris, France.;Université de Paris, 75006 Paris, France.;Department of Radiation Oncology, Institut Curie, 75005 Paris, France."
"80","Astruc A;Roux L;Robin F;Sall NR;Dion L;Lavoué V;Legendre G;Leveque J;Bessede T;Bertrand M;Odimba Mpoy J;Nzau-Ngoma E;Morandi X;Chedotal A;Le Lous M;Nyangoh Timoh K","Astruc, Audrey;Roux, Léa;Robin, Fabien;Sall, Ndeye Racky;Dion, Ludivine;Lavoué, Vincent;Legendre, Guillaume;Leveque, Jean;Bessede, Thomas;Bertrand, Martin;Odimba Mpoy, Jules;Nzau-Ngoma, Emmanuel;Morandi, Xavier;Chedotal, Alain;Le Lous, Maela;Nyangoh Timoh, Krystel","Advanced Insights into Human Uterine Innervation: Implications for Endometriosis and Pelvic Pain.","Journal of clinical medicine","Switzerland","eng","Journal Article","anatomy;endometriosis;innervation;pelvic pain","","","(1)  : Understanding uterine innervation, an essential aspect of female reproductive biology, has often been overlooked. Nevertheless, the complex architecture of uterine innervation plays a significant role in conditions such as endometriosis. Recently, advances in histological techniques have provided unprecedented details about uterine innervation, highlighting its intricate structure, distribution, and density. The intricate nature of uterine innervation and its influence on pathologies such as endometriosis has garnered increasing attention. (2)  : This review aims to compile, analyze, and summarize the existing research on uterine innervation, and investigate its implications for the pathogenesis of endometriosis and associated pain. (3)  : A systematic review was conducted in line with PRISMA guidelines. Using the PubMed database, we searched relevant keywords such as ""uterine innervation"", ""endometriosis"", and ""pain association"". (4)  : The initial literature search yielded a total of 3300 potential studies. Of these, 45 studies met our inclusion criteria and were included in the final review. The analyzed studies consistently demonstrated that the majority of studies focused on macroscopic dissection of uterine innervation for surgical purposes. Fewer studies focused on micro-innervation for uterine innervation. For endometriosis, few studies focused on neural pain pathways whereas many studies underlined an increase in nerve fiber density within ectopic endometrial tissue. This heightened innervation is suggested as a key contributor to the chronic pain experienced by endometriosis patients. (5)  : The understanding of uterine innervation, and its alterations in endometriosis, offer promising avenues for research and potential treatment.","Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Angers University Hospital, 49100 Angers, France.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;H2P2 Histopathology Laboratory, Rennes 1 University, 35000 Rennes, France.;Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes 1 University, 35000 Rennes, France.;INSERM U1242, Chemistry Oncogenesis Stress Signaling, Rennes 1 University, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, IRSET-UMR_S 1085, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, IRSET-UMR_S 1085, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Angers University Hospital, 49100 Angers, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;Urology Department, APHP, Université Paris-Saclay, 94270 Le Kremlin-Bicetre, France.;Surgery Department, Nîmes University Hospital, University of Montpellier, 30900 Nîmes, France.;Department of Obstetrics and Gynecology, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.;Department of Obstetrics and Gynecology, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;INSERM, CNRS, Institut de la Vision, Sorbonne Université, 75012 Paris, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.","NA",0,"2077-0383","J Clin Med","J Clin Med",2023,"2024","13","10.3390/jcm13051433",NA,"","","38592287","38592287","PUBMED","Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Angers University Hospital, 49100 Angers, France.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;H2P2 Histopathology Laboratory, Rennes 1 University, 35000 Rennes, France.;Department of Hepatobiliary and Digestive Surgery, University Hospital, Rennes 1 University, 35000 Rennes, France.;INSERM U1242, Chemistry Oncogenesis Stress Signaling, Rennes 1 University, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, IRSET-UMR_S 1085, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, IRSET-UMR_S 1085, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Angers University Hospital, 49100 Angers, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;Urology Department, APHP, Université Paris-Saclay, 94270 Le Kremlin-Bicetre, France.;Surgery Department, Nîmes University Hospital, University of Montpellier, 30900 Nîmes, France.;Department of Obstetrics and Gynecology, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.;Department of Obstetrics and Gynecology, University Hospital of Kinshasa, Kinshasa, Democratic Republic of the Congo.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;INSERM, CNRS, Institut de la Vision, Sorbonne Université, 75012 Paris, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France.;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Obstetrics and Gynecology, Rennes University Hospital, 35000 Rennes, France.;INSERM, LTSI-UMR 1099, Rennes 1 University, 35000 Rennes, France."
"81","Mekkan-Bouv Hez M;Derbey L;de Mestier L;Lorenzo D;Walter T;Perrier M;Cadiot G;Goichot B;Pracht M;Lièvre A;Coriat R;Valancot S;Guimbaud R;Carrere N;Bacoeur-Ouzillou O;Belleannée G;Smith D;Laboureau S;Hescot S;Julie C;Teissier MP;Thereaux J;Ferru A;Evrard C;Mathonnet M;Christou N","Mekkan-Bouv Hez, M;Derbey, L;de Mestier, L;Lorenzo, D;Walter, T;Perrier, M;Cadiot, G;Goichot, B;Pracht, M;Lièvre, A;Coriat, R;Valancot, S;Guimbaud, R;Carrere, N;Bacoeur-Ouzillou, O;Belleannée, G;Smith, Denis;Laboureau, S;Hescot, Sophie;Julie, Catherine;Teissier, M P;Thereaux, J;Ferru, A;Evrard, C;Mathonnet, M;Christou, N","Survival of patients managed in France for duodenal neuroendocrine tumors (D-NET): a 20-year multicenter cohort study from the GTE group: a cohort study.","International journal of surgery (London, England)","United States","eng","Journal Article","","Humans;Female;Male;France;Neuroendocrine Tumors;Middle Aged;Duodenal Neoplasms;Aged;Adult;Cohort Studies;Registries","Humans;Female;Male;France;Neuroendocrine Tumors;Middle Aged;Duodenal Neoplasms;Aged;Adult;Cohort Studies;Registries","Duodenal neuroendocrine tumours (D-NETs) have a low incidence; however, their diagnosis has been increasing. Features such as tumour location, size, type, histological grade, and stage were used to adapt the treatment to either endoscopic (ER) or surgical (SR) resections. There is no consensus regarding the definitive treatment. The authors' study aimed to describe the management of non-metastatic, well-differentiated D-NETs in France and its impact on patient survival. A registry-based multicenter study using prospectively collected data between 2000 and 2019, including all patients managed for non-metastatic G1 and G2 D-NETs, was conducted in the GTE group. A total of 153 patients were included. Fifty-eight benefited from an ER, and 95 had an SR. No difference in recurrence-free survival (RFS) was observed regardless of treatment type. There was no significant difference between the two groups (ER vs. SR) in terms of location, size, grade, or lymphadenopathy, regardless of the type of incomplete resection performed or regarding the pre-therapeutic assessment of lymph node invasion in imaging. The surgery allowed for significantly more complete resection (patients with R1 resection in the SR group: 9 vs. 14 in the ER group, P <0.001). Among the 51 patients with positive lymph node dissection after SR, tumour size was less than or equal to 1 cm in 25 cases. Surgical complications were more numerous ( P =0.001). In the sub-group analysis of G1-G2 D-NETs between 11 and 19 mm, there was no significant difference in grade ( P =0.977) and location ( P =0.617) between the two groups (ER vs. SR). No significant difference was found in both morphological and functional imaging, focusing on the pre-therapeutic assessment of lymph node invasion ( P =0.387). Regardless of the resection type (ER or SR) of G1-G2 non-metastatic D-NETs, as well as the type of management of incomplete resection, which was greater in the ER group, long-term survival results were similar between ER and SR. Organ preservation seems to be the best choice owing to the slow evolution of these tumours.","Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex.;Gastro-entérologie, hépatologie et oncologie médicale, Hôpital Édouard-Herriot, Hospices civils de Lyon, Lyon.;Université de Paris, Department of Pancreatology and Digestive Oncology, Hospital Beaujon (APHP.Nord), Clichy.;Université de Paris, Department of Pancreatology and Digestive Oncology, Hospital Beaujon (APHP.Nord), Clichy.;Gastro-entérologie, hépatologie et oncologie médicale, Hôpital Édouard-Herriot, Hospices civils de Lyon, Lyon.;Hépatogastro-entérologie et oncologie digestive, CHU de Reims.;Hépatogastro-entérologie et oncologie digestive, CHU de Reims.;Service de Médecine interne, Endocrinologie et Nutrition, Pôle MIRNED, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Avenue Molière, Strasbourg Cedex.;Oncologie médicale, Centre Eugène Marquis, 5 Rue Bataille Flandres-Dunkerque.;Gastro-entérologie, CHU Pontchaillou, Université Rennes, Inserm U1242, COSS (Chemistry Oncogenesis Stress Signaling), Rennes.;Gastro-entérologie et hépatologie. CHU Cochin, AP-HP.;Département de Chirurgie Digestive, CHU Toulouse.;Oncologie médicale digestive gynecologique, CHU Toulouse.;Département de Chirurgie Digestive, CHU Toulouse.;Chirurgie viscérale et digestive, CHU Clermont-Ferrand, Clermont-Ferrand.;Service de Pathologie, CHU de Bordeaux, Bordeaux.;Oncologie Digestive, CHU de Bordeaux, Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévèque, Avenue Magellan, 33604 PESSAC cedex.;Département d'endocrinologie-diabétologie et nutrition, CHU Angers.;Endocrinologie et Métabolismes, Institut Curie, 26, Rue d'Ulm, Paris.;EA4340 Université Versailles- Saint-Quentin-en-Yvelines, Anatomie Pathologique, Hôpital Ambroise Paré, APHP.;Endocrinologie-Diabète-Maladies métaboliques-CHU de Limoges.;Chirurgie Digestive, CHU de Brest.;Cancérologie médicale, CHU de Poitiers, France.;Cancérologie médicale, CHU de Poitiers, France.;Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex.;Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex.","NA",0,"1743-9159","Int J Surg","Int J Surg",2023,"2024","110","10.1097/JS9.0000000000001382","4259-4265","","","38573078","38573078","PUBMED","Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex.;Gastro-entérologie, hépatologie et oncologie médicale, Hôpital Édouard-Herriot, Hospices civils de Lyon, Lyon.;Université de Paris, Department of Pancreatology and Digestive Oncology, Hospital Beaujon (APHP.Nord), Clichy.;Université de Paris, Department of Pancreatology and Digestive Oncology, Hospital Beaujon (APHP.Nord), Clichy.;Gastro-entérologie, hépatologie et oncologie médicale, Hôpital Édouard-Herriot, Hospices civils de Lyon, Lyon.;Hépatogastro-entérologie et oncologie digestive, CHU de Reims.;Hépatogastro-entérologie et oncologie digestive, CHU de Reims.;Service de Médecine interne, Endocrinologie et Nutrition, Pôle MIRNED, Hôpitaux Universitaires de Strasbourg, Hôpital de Hautepierre, Avenue Molière, Strasbourg Cedex.;Oncologie médicale, Centre Eugène Marquis, 5 Rue Bataille Flandres-Dunkerque.;Gastro-entérologie, CHU Pontchaillou, Université Rennes, Inserm U1242, COSS (Chemistry Oncogenesis Stress Signaling), Rennes.;Gastro-entérologie et hépatologie. CHU Cochin, AP-HP.;Département de Chirurgie Digestive, CHU Toulouse.;Oncologie médicale digestive gynecologique, CHU Toulouse.;Département de Chirurgie Digestive, CHU Toulouse.;Chirurgie viscérale et digestive, CHU Clermont-Ferrand, Clermont-Ferrand.;Service de Pathologie, CHU de Bordeaux, Bordeaux.;Oncologie Digestive, CHU de Bordeaux, Service d'Hépato-Gastroentérologie et d'Oncologie Digestive, Centre Médico-Chirurgical Magellan, Hôpital Haut-Lévèque, Avenue Magellan, 33604 PESSAC cedex.;Département d'endocrinologie-diabétologie et nutrition, CHU Angers.;Endocrinologie et Métabolismes, Institut Curie, 26, Rue d'Ulm, Paris.;EA4340 Université Versailles- Saint-Quentin-en-Yvelines, Anatomie Pathologique, Hôpital Ambroise Paré, APHP.;Endocrinologie-Diabète-Maladies métaboliques-CHU de Limoges.;Chirurgie Digestive, CHU de Brest.;Cancérologie médicale, CHU de Poitiers, France.;Cancérologie médicale, CHU de Poitiers, France.;Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex.;Service de Chirurgie Digestive, Endocrinienne et Générale, CHU de Limoges, Avenue Martin Luther King, Limoges Cedex."
"82","Frenel JS;Zeghondy J;Guérin-Charbonnel C;Mailliez A;Volant E;Poumeaud F;Patsouris A;Arnedos M;Bailleux C;Cabal J;Galland L;de Nonneville A;Guiu S;Dalenc F;Pistilli B;Bachelot T;Pierga JY;Le Du F;Bocquet F;Larrouquere L;Loirat D","Frenel, Jean-Sebastien;Zeghondy, Jean;Guérin-Charbonnel, Catherine;Mailliez, Audrey;Volant, Elsa;Poumeaud, François;Patsouris, Anne;Arnedos, Monica;Bailleux, Caroline;Cabal, Julie;Galland, Loick;de Nonneville, Alexandre;Guiu, Séverine;Dalenc, Florence;Pistilli, Barbara;Bachelot, Thomas;Pierga, Jean-Yves;Le Du, Fanny;Bocquet, François;Larrouquere, Louis;Loirat, Delphine","Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.","JAMA network open","United States","eng","Journal Article","","Humans;Middle Aged;Female;Breast Neoplasms;Capecitabine;Cohort Studies;Prospective Studies;Trastuzumab;Brain Neoplasms;Disease Progression;Receptor, ErbB-2;Oxazoles;Pyridines;Quinazolines","Humans;Middle Aged;Female;Breast Neoplasms;Capecitabine;Cohort Studies;Prospective Studies;Trastuzumab;Brain Neoplasms;Disease Progression;Receptor, ErbB-2;Oxazoles;Pyridines;Quinazolines","Little is known regarding the outcomes associated with tucatinib combined with trastuzumab and capecitabine (TTC) after trastuzumab-deruxtecan exposure among patients with ERBB2 (previously HER2)-positive metastatic breast cancer (MBC). To investigate outcomes following TTC treatment in patients with ERBB2-positive MBC who had previously received trastuzumab-deruxtecan. This cohort study included all patients with MBC who were treated in 12 French comprehensive cancer centers between August 1, 2020, and December 31, 2022. Tucatinib combined with trastuzumab and capecitabine administered at the recommended dose. Clinical end points included progression-free survival (PFS), time to next treatment (TTNT), overall survival (OS), and overall response rate (ORR). A total of 101 patients with MBC were included (median age, 56 [range, 31-85] years). The median number of prior treatment lines for metastatic disease at TTC treatment initiation was 4 (range, 2-15), including 82 patients (81.2%) with previous trastuzumab and/or pertuzumab and 94 (93.1%) with previous ado-trastuzumab-emtansine) exposure. The median duration of trastuzumab-deruxtecan treatment was 8.9 (range, 1.4-25.8) months, and 82 patients (81.2%) had disease progression during trastuzumab-deruxtecan treatment, whereas 18 (17.8%) had stopped trastuzumab-deruxtecan for toxic effects and 1 (1.0%) for other reasons. Tucatinib combined with trastuzumab and capecitabine was provided as a third- or fourth-line treatment in 37 patients (36.6%) and was the immediate treatment after trastuzumab-deruxtecan in 86 (85.1%). With a median follow-up of 11.6 (95% CI, 10.5-13.4) months, 76 of 101 patients (75.2%) stopped TTC treatment due to disease progression. The median PFS was 4.7 (95% CI, 3.9-5.6) months; median TTNT, 5.2 (95% CI, 4.5-7.0) months; and median OS, 13.4 (95% CI, 11.1 to not reached [NR]) months. Patients who received TTC immediately after trastuzumab-deruxtecan had a median PFS of 5.0 (95% CI, 4.2-6.0) months; median TTNT of 5.5 (95% CI, 4.8-7.2) months, and median OS of 13.4 (95% CI, 11.9-NR) months. Those who received TTC due to trastuzumab-deruxtecan toxicity-related discontinuation had a median PFS of 7.3 (95% CI, 3.0-NR) months. Best ORR was 29 of 89 patients (32.6%). Sixteen patients with active brain metastasis had a median PFS of 4.7 (95% CI, 3.0-7.3) months, median TTNT of 5.6 (95% CI, 4.4 to NR), and median OS of 12.4 (95% CI, 8.3-NR) months. In this study, TTC therapy was associated with clinically meaningful outcomes in patients with ERBB2-positive MBC after previous trastuzumab-deruxtecan treatment, including those with brain metastases. Prospective data on optimal drug sequencing in this rapidly changing therapeutic landscape are needed.","Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Data Factory, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2024,"2024","7","10.1001/jamanetworkopen.2024.4435","e244435","","","38568692","38568692","PUBMED","Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Biostatistics and Analytics, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oscar Lambret Comprehensive Cancer Center, Lille, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of Medical Oncology Bordeaux, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Montpellier Cancer Institute, Montpellier, France.;Department of Medical Oncology, Oncopôle, Toulouse, France.;Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Data Factory, Institut de Cancerologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris, France."
"83","Davies AA;Adekoya AO;Balogun OJ;Osaigbovo II;Nwosu A;Gbaja-Biamila T;Osinupebi O;Gangneux JP;Oladele RO","Davies, Adeyinka A;Adekoya, Abiola O;Balogun, Oluwaseyi J;Osaigbovo, Iriagbonse I;Nwosu, Augustina;Gbaja-Biamila, Titilola;Osinupebi, Olubunmi;Gangneux, Jean-Pierre;Oladele, Rita O","Prevalence of Chronic Pulmonary Aspergillosis in Two (2) Tuberculosis Treatment Clinics in Lagos, Nigeria: A Prospective Longitudinal Study.","Open forum infectious diseases","United States","eng","Journal Article","Nigeria;aspergillus IgG;chronic pulmonary aspergillosis;lung disease;pulmonary tuberculosis","","","Chronic pulmonary aspergillosis (CPA) is an underrecognized but common complication of pulmonary tuberculosis. In Nigeria, a tuberculosis-endemic country, there is currently no provision to monitor the development of CPA in patients treated for tuberculosis. This study determined the prevalence and incidence of CPA in Lagos, Nigeria. A prospective longitudinal study of patients with previously managed tuberculosis was conducted between June 2021 and May 2022. The study cohorts were assessed at 3-month intervals, and the following were collected: sociodemographic data, chest radiographic findings, sputum samples for fungal culture, and venous blood samples for   immunoglobulin G estimation. CPA cases were determined using the case definition for resource-constrained countries. Descriptive and inferential statistics were used, and significance was set at a probability of 5% (  < .05). Of the 141 patients recruited, 79 (56.0%) were in the retreatment and 62 (44.0%) in the posttreatment tuberculosis group. The median age (interquartile range) was 40 (30-52) years, with a male-to-female ratio of 1.1:1. Ninety-seven patients (69%) had a GeneXpert test done, of whom 63 (64.9%) were GeneXpert negative. Cough was the most common symptom, with 15 (11%) patients having hemoptysis. The rate of CPA increased steadily as the study progressed: 44 (31.2%) at commencement, 45 (34.9%) at 3 months, 49 (42.6%) at 6 months, and 51 (54.3%) at 9 months. Thus, the overall prevalence of CPA was 49.7%, and the incidence was 6.1%. CPA is common in Nigeria and its true burden may still be underestimated. Increased awareness of CPA as a posttuberculosis lung disease is advocated. Evaluation for CPA should be incorporated in patients' work-up for tuberculosis.","Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Radiology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Department of Biomedical Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology, School of Medicine, University of Benin, Benin City, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Central Research Laboratory, College of Medicine University of Lagos, Lagos, Nigeria.;Clinical Sciences Division, Nigeria Institute of Medical Research, Yaba, Lagos, Nigeria.;College of Public Health and Social Justice, Saint Louis University College of Public Health and Social Justice, Missouri, USA.;Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Laboratoire de Parasitologie et Mycologie, European Excellence Center in Medical Mycology, French National Reference Center for Chronic Aspergillosis, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Centre Hospitalier Universitaire de Rennes, Inserm, EHESP, IRSET (Institut de Recherché en Santé, Environnement et Travail) (UMR_S 1085), Rennes, France.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria.","NA",0,"2328-8957","Open Forum Infect Dis","Open Forum Infect Dis",2023,"2024","11","10.1093/ofid/ofae090","ofae090","","","38567195","38567195","PUBMED","Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Radiology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Department of Biomedical Engineering, University of Lagos, Lagos, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology, School of Medicine, University of Benin, Benin City, Nigeria.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Central Research Laboratory, College of Medicine University of Lagos, Lagos, Nigeria.;Clinical Sciences Division, Nigeria Institute of Medical Research, Yaba, Lagos, Nigeria.;College of Public Health and Social Justice, Saint Louis University College of Public Health and Social Justice, Missouri, USA.;Department of Medical Microbiology and Parasitology, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria.;Laboratoire de Parasitologie et Mycologie, European Excellence Center in Medical Mycology, French National Reference Center for Chronic Aspergillosis, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, Centre Hospitalier Universitaire de Rennes, Inserm, EHESP, IRSET (Institut de Recherché en Santé, Environnement et Travail) (UMR_S 1085), Rennes, France.;Medical Mycology Society of Nigeria, Lagos, Nigeria.;Department of Medical Microbiology and Parasitology, Lagos University Teaching Hospital, Idi-Araba, Lagos, Nigeria."
"84","Roussot N;Constantin G;Desmoulins I;Bergeron A;Arnould L;Beltjens F;Mayeur D;Kaderbhai C;Hennequin A;Jankowski C;Padeano MM;Costaz H;Jacinto S;Michel E;Amet A;Coutant C;Costa B;Jouannaud C;Deblock M;Levy C;Ferrero JM;Kerbrat P;Brain E;Mouret-Reynier MA;Coudert B;Bertaut A;Ladoire S","Roussot, Nicolas;Constantin, Guillaume;Desmoulins, Isabelle;Bergeron, Anthony;Arnould, Laurent;Beltjens, Françoise;Mayeur, Didier;Kaderbhai, Courèche;Hennequin, Audrey;Jankowski, Clémentine;Padeano, Marie Martine;Costaz, Hélène;Jacinto, Sarah;Michel, Eloise;Amet, Alix;Coutant, Charles;Costa, Brigitte;Jouannaud, Christelle;Deblock, Mathilde;Levy, Christelle;Ferrero, Jean-Marc;Kerbrat, Pierre;Brain, Etienne;Mouret-Reynier, Marie-Ange;Coudert, Bruno;Bertaut, Aurélie;Ladoire, Sylvain","Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Breast cancer;CPS+EG;HER2 low;HER2 zero;Neoadjuvant chemotherapy;Prognostic;Stratification;Survival","Humans;Female;Prognosis;Breast Neoplasms;Neoadjuvant Therapy;Retrospective Studies;Neoplasm Staging;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols;Chemotherapy, Adjuvant;Disease-Free Survival","Humans;Female;Prognosis;Breast Neoplasms;Neoadjuvant Therapy;Retrospective Studies;Neoplasm Staging;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols;Chemotherapy, Adjuvant;Disease-Free Survival","The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype. Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score. We compared the prognostic stratification abilities of the CPS+EG in HER2-low and HER2-0 eBC, analyzing ER+ and ER- tumors separately. In ER+ eBC, the CPS+EG scoring system seems to retain a prognostic value, both in HER2-low and HER2-0 tumors, by distinguishing populations with significantly different outcomes (good: score 0-1, poor: score 2-3, and very poor: score 4-5). Using C-indices for DFS and OS, CPS+EG provided the highest prognostic information in ER+ eBC, especially in HER2-0 tumors. In contrast, in ER- eBC, the CPS+EG does not appear to be able to distinguish different outcome groups, either in HER2-low or HER2-0 tumors. In ER- eBC, C-indices for DFS and OS were highest for pathological stage, reflecting the predominant prognostic importance of residual disease in this subtype. HER2-low status does not influence the prognostic performance of the CPS+EG score. Our results confirm the usefulness of the CPS+EG score in stratifying the prognosis of ER+ eBC after NAC, for both HER2-0 and HER2-low tumors. For ER- eBC, HER2-low status does not influence the performance of the CPS+EG score, which was lower than that of the pathological stage alone.","Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; INSERM U1231, 21000 Dijon, France.;Unit of Methodology and Biostatistics, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; University of Burgundy-Franche Comté, 21000 Dijon, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Curie, Centre René Huguenin, Saint-Cloud, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Unit of Methodology and Biostatistics, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; University of Burgundy-Franche Comté, 21000 Dijon, France; INSERM U1231, 21000 Dijon","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","202","10.1016/j.ejca.2024.114037","114037","","","38554542","38554542","PUBMED","Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; INSERM U1231, 21000 Dijon, France.;Unit of Methodology and Biostatistics, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Biology and Pathology of tumors, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Surgical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; University of Burgundy-Franche Comté, 21000 Dijon, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Curie, Centre René Huguenin, Saint-Cloud, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France.;Unit of Methodology and Biostatistics, Georges Francois Leclerc Cancer Centre, Dijon, France.;Department of Medical Oncology, Georges Francois Leclerc Cancer Centre, Dijon, France; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center, Dijon, France; University of Burgundy-Franche Comté, 21000 Dijon, France; INSERM U1231, 21000 Dijon"
"85","Lavoue V;Favier A;Franck S;Boutet G;Azuar AS;Brousse S;Golfier F;Uzan C;Vaysse C;Molière S;Boisserie-Lacroix M;Kermarrec E;Seror JY;Delpech Y;Luporsi É;Maugard CM;Taris N;Chabbert-Buffet N;Sabah J;Alghamdi K;Fritel X;Mathelin C","Lavoue, Vincent;Favier, Amélia;Franck, Sophie;Boutet, Gérard;Azuar, Anne-Sophie;Brousse, Susie;Golfier, François;Uzan, Catherine;Vaysse, Charlotte;Molière, Sébastien;Boisserie-Lacroix, Martine;Kermarrec, Edith;Seror, Jean-Yves;Delpech, Yann;Luporsi, Élisabeth;Maugard, Christine M;Taris, Nicolas;Chabbert-Buffet, Nathalie;Sabah, Jonathan;Alghamdi, Khalid;Fritel, Xavier;Mathelin, Carole","French college of gynecologists and obstetricians (CNGOF) recommendations for clinical practice: Place of breast self-examination in screening strategies.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Breast cancer;Breast self-examination;Clinical examination;Palpation;Screening","Humans;Female;Breast Self-Examination;Breast Neoplasms;Aged;Middle Aged;Early Detection of Cancer;France;Adult;Gynecology;Obstetrics;Gynecologists;Obstetricians","Humans;Female;Breast Self-Examination;Breast Neoplasms;Aged;Middle Aged;Early Detection of Cancer;France;Adult;Gynecology;Obstetrics;Gynecologists;Obstetricians","Breast cancer is the most common female cancer in the world. Numerous studies have shown that the risk of metastatic disease increases with tumor volume. In this context, it is useful to assess whether the regular practice of formal breast self-examination (BSE) as opposed to breast awareness has an impact on the number of cancers diagnosed, their stage, the treatments used and mortality. The Commission of Senology (CS) of the Collège National de Gynécologie et Obstétrique Français (CNGOF) respected and followed the Grading of Recommendations Assessment, Development and Evaluation method to assess the quality of the evidence on which the recommendations were based. The CS studied 16 questions individualizing four groups of women (general population, women aged over 75, high-risk women, and women previously treated for breast cancer). For each situation, it was determined whether the practice of BSE versus abstention from this examination led to detection of more breast cancers and/or recurrences and/or reduced treatment and/or increased survival. BSE should not be recommended for women in the general population, who otherwise benefit from clinical breast examination by practitioners from the age of 25, and from organized screening from 50 to 74 (strong recommendation). In the absence of data on the benefits of BSE in patients aged over 75, for those at high risk and those previously treated for breast cancer, the CS was unable to issue recommendations. Thus, if women in these categories wish to undergo BSE, information on the benefits and risks observed in the general population must be given, notably that BSE is associated with a higher number of referrals, biopsies, and a reduced quality of life.","CHU Service de Gynécologie, 16 Boulevard de Bulgarie, 35200, Rennes, France.;Gynécologie-obstétrique et Médecine de La Reproduction, Maternité Hôpital Tenon, 4 Rue de La Chine, 75020, Paris, France.;Institut Curie, 26 Rue D'Ulm, 75248, Paris Cedex 05, France.;AGREGA, Service de Chirurgie Gynécologique et Médecine de La Reproduction, Centre Aliénor D'Aquitaine, Centre Hospitalier Universitaire de Bordeaux, Groupe Hospitalier Pellegrin, Place Amélie-Raba-Léon, 33000, Bordeaux, France.;Centre Hospitalier Clavary, Chemin de Clavary, 06130, Grasse, France.;Service D'oncologie Chirurgicale, Centre Eugène Marquis, Unicancer, Rennes, France.;Service de Chirurgie Gynécologique et Cancérologique - Obstétrique, Hospices Civils de Lyon, CHU Lyon Sud, Lyon, France.;Hôpital Pitié Salpetrière, 47 Bld de L'Hôpital, 75013, Paris, France.;Service de Chirurgie Oncologique, CHU Toulouse, Institut Universitaire Du Cancer de Toulouse-Oncopole, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.;Imagerie Du Sein, CHRU, Avenue Molière, 67200, Strasbourg, France.;Unité de Radiologie-sénologie. Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.;Hôpital Tenon Service de Radiologie, 4 Rue de La Chine, 75020, Paris, France.;Imagerie Duroc, 9 Ter Boulevard Montparnasse 75006 Paris, France.;Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189, Nice, France.;Oncologie Médicale et Oncogénétique, CHR Metz-Thionville, Hôpital de Mercy, 1 Allée Du Château, 57085, Metz, France.;Service de Génétique Oncologique Clinique et Unité de Génétique Oncologique Moléculaire, Hôpitaux Universitaires de Strasbourg, 1 Avenue Molière, 67200, Strasbourg, France.;Service de Génétique Oncologique, ICANS, 17 Rue Calmette, 67200, Strasbourg, France, France.;Hôpital Tenon Service de Gynécologie-obstétrique, 4 Rue de La Chine, 75020, Paris, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex, France.;Centre Hospitalo-universitaire de Poitiers, 2 Rue de La Milétrie, 86021, Poitiers, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex","NA",0,"1532-3080","Breast","Breast",2023,"2024","75","10.1016/j.breast.2023.103619","103619","","","38547580","38547580","PUBMED","CHU Service de Gynécologie, 16 Boulevard de Bulgarie, 35200, Rennes, France.;Gynécologie-obstétrique et Médecine de La Reproduction, Maternité Hôpital Tenon, 4 Rue de La Chine, 75020, Paris, France.;Institut Curie, 26 Rue D'Ulm, 75248, Paris Cedex 05, France.;AGREGA, Service de Chirurgie Gynécologique et Médecine de La Reproduction, Centre Aliénor D'Aquitaine, Centre Hospitalier Universitaire de Bordeaux, Groupe Hospitalier Pellegrin, Place Amélie-Raba-Léon, 33000, Bordeaux, France.;Centre Hospitalier Clavary, Chemin de Clavary, 06130, Grasse, France.;Service D'oncologie Chirurgicale, Centre Eugène Marquis, Unicancer, Rennes, France.;Service de Chirurgie Gynécologique et Cancérologique - Obstétrique, Hospices Civils de Lyon, CHU Lyon Sud, Lyon, France.;Hôpital Pitié Salpetrière, 47 Bld de L'Hôpital, 75013, Paris, France.;Service de Chirurgie Oncologique, CHU Toulouse, Institut Universitaire Du Cancer de Toulouse-Oncopole, 1 Avenue Irène Joliot Curie, 31059, Toulouse, France.;Imagerie Du Sein, CHRU, Avenue Molière, 67200, Strasbourg, France.;Unité de Radiologie-sénologie. Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.;Hôpital Tenon Service de Radiologie, 4 Rue de La Chine, 75020, Paris, France.;Imagerie Duroc, 9 Ter Boulevard Montparnasse 75006 Paris, France.;Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189, Nice, France.;Oncologie Médicale et Oncogénétique, CHR Metz-Thionville, Hôpital de Mercy, 1 Allée Du Château, 57085, Metz, France.;Service de Génétique Oncologique Clinique et Unité de Génétique Oncologique Moléculaire, Hôpitaux Universitaires de Strasbourg, 1 Avenue Molière, 67200, Strasbourg, France.;Service de Génétique Oncologique, ICANS, 17 Rue Calmette, 67200, Strasbourg, France, France.;Hôpital Tenon Service de Gynécologie-obstétrique, 4 Rue de La Chine, 75020, Paris, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex, France.;Centre Hospitalo-universitaire de Poitiers, 2 Rue de La Milétrie, 86021, Poitiers, France.;CHRU Avenue Molière, 67200, Strasbourg et ICANS, 17 Rue Albert Calmette, 67033, Strasbourg,Cedex"
"86","Cosson C;Riou R;Patoli D;Niu T;Rey A;Groslambert M;De Rosny C;Chatre E;Allatif O;Henry T;Venet F;Milhavet F;Boursier G;Belot A;Jamilloux Y;Merlin E;Duquesne A;Grateau G;Savey L;Jacques Maria AT;Pagnier A;Poutrel S;Lambotte O;Mallebranche C;Ardois S;Richer O;Lemelle I;Rieux-Laucat F;Bader-Meunier B;Amoura Z;Melki I;Cuisset L;Touitou I;Geyer M;Georgin-Lavialle S;Py BF","Cosson, Camille;Riou, Romane;Patoli, Danish;Niu, Tingting;Rey, Amaury;Groslambert, Marine;De Rosny, Charlotte;Chatre, Elodie;Allatif, Omran;Henry, Thomas;Venet, Fabienne;Milhavet, Florian;Boursier, Guilaine;Belot, Alexandre;Jamilloux, Yvan;Merlin, Etienne;Duquesne, Agnès;Grateau, Gilles;Savey, Léa;Jacques Maria, Alexandre Thibault;Pagnier, Anne;Poutrel, Solène;Lambotte, Olivier;Mallebranche, Coralie;Ardois, Samuel;Richer, Olivier;Lemelle, Irène;Rieux-Laucat, Frédéric;Bader-Meunier, Brigitte;Amoura, Zahir;Melki, Isabelle;Cuisset, Laurence;Touitou, Isabelle;Geyer, Matthias;Georgin-Lavialle, Sophie;Py, Bénédicte F","Functional diversity of NLRP3 gain-of-function mutants associated with CAPS autoinflammation.","The Journal of experimental medicine","United States","eng","Journal Article","","Humans;NLR Family, Pyrin Domain-Containing 3 Protein;Gain of Function Mutation;Inflammasomes;Drug Development;Syndrome","Humans;NLR Family, Pyrin Domain-Containing 3 Protein;Gain of Function Mutation;Inflammasomes;Drug Development;Syndrome","NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization of most NLRP3 variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while NLRP3 is controlled by priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 NLRP3 variants in vitro, evaluating their activity upon induction, priming, and/or activation signals, and their sensitivity to four inhibitors. We highlight the functional diversity of the gain-of-function mutants and describe four groups based on the signals governing their activation, correlating partly with the symptom severity. We identify a new group of NLRP3 mutants responding to the activation signal without priming, associated with frequent misdiagnoses. Our results identify key NLRP3 residues controlling inflammasome activity and sensitivity to inhibitors, and antagonistic mechanisms with broader efficacy for therapeutic strategies. They provide new insights into NLRP3 activation, an explanatory mechanism for NLRP3-AID heterogeneity, and original tools for NLRP3-AID diagnosis and drug development.","CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University , Shanghai, China.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Univ Lyon, ENS de Lyon, Inserm, CNRS SFR Biosciences US8 UAR3444, Université Claude Bernard Lyon 1 , Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.;Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France.;Service de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon , Lyon, France.;Department of Pediatrics, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;Internal Medicine and Onco-Immunology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University , Montpellier, France.;Centre Hospitalier Universitaire Grenoble Alpes, Immunologie Clinique, Immuno-Hémato-Oncologie (IHO), Hôpital Couple-Enfant , Grenoble, France.;Service de Médecine Interne, Hospices Civils de Lyon, Edouard Herriot Hospital , Lyon, France.;Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Universitaire Paris Saclay, Hôpital Bicêtre , Le Kremlin-Bicêtre, France.;Université Paris Saclay, Inserm UMR, 1184, CEA , Le Kremlin-Bicêtre, France.;Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France.;Centre Hospitalier Universitaire d'Angers, Pediatric Immuno-Hemato-Oncology Unit, France.;Médecine Interne et Immunologie Clinique , Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France.;Department of Pediatric Onco-hematology, Children Hospital, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.;Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France.;Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France.;Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP)-Sorbonne Université, Hopital Pitié-Salpétrière, Institut E3M, Service de Médecine Interne 2, Centre National de Référence Lupus et Syndrome des Anticorps Antiphospholipides, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris, France.;Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France.;General Pediatrics, Infectious Disease and Internal Medicine Department, Hôpital Robert Debre, Assistance Publique-Hôpitaux de Paris (AP-HP), Reference Center for Rheumatic, AutoImmune and Systemic Diseases in Children (RAISE), Paris, France.;Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute , Paris, France.;Université Paris Cité, Service de Médecine Génomique des Maladies de Système et D'Organe, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris , Paris, France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Institute of Structural Biology, University of Bonn , Bonn, Germany.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.","NA",0,"1540-9538","J Exp Med","J Exp Med",2023,"2024","221","10.1084/jem.20231200",NA,"ERC-2013-CoG_616986","European Research Council","38530241","38530241","PUBMED","CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University , Shanghai, China.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Univ Lyon, ENS de Lyon, Inserm, CNRS SFR Biosciences US8 UAR3444, Université Claude Bernard Lyon 1 , Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.;Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Lyon Immunopathology Federation (LIFE), Université Claude Bernard Lyon 1 , Lyon, France.;Service de Médecine Interne, Hôpital de la Croix-Rousse, Hospices Civils de Lyon , Lyon, France.;Department of Pediatrics, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Pediatric Nephrology, Rheumatology, Dermatology Department, National Referee Centre for Rheumatic and Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;Internal Medicine and Onco-Immunology (MedI2O), Institute for Regenerative Medicine and Biotherapy (IRMB), Saint Eloi Hospital, Montpellier University , Montpellier, France.;Centre Hospitalier Universitaire Grenoble Alpes, Immunologie Clinique, Immuno-Hémato-Oncologie (IHO), Hôpital Couple-Enfant , Grenoble, France.;Service de Médecine Interne, Hospices Civils de Lyon, Edouard Herriot Hospital , Lyon, France.;Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne et Immunologie Clinique, Groupe Hospitalier Universitaire Paris Saclay, Hôpital Bicêtre , Le Kremlin-Bicêtre, France.;Université Paris Saclay, Inserm UMR, 1184, CEA , Le Kremlin-Bicêtre, France.;Université d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT, Angers, France.;Centre Hospitalier Universitaire d'Angers, Pediatric Immuno-Hemato-Oncology Unit, France.;Médecine Interne et Immunologie Clinique , Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France.;Department of Pediatric Onco-hematology, Children Hospital, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.;Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France.;Université Paris Cité, Institut Imagine, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Inserm UMR 1163 , Paris, France.;Pediatric Immunology, Hematology and Rheumatology Department, Hôpital Necker, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP)-Sorbonne Université, Hopital Pitié-Salpétrière, Institut E3M, Service de Médecine Interne 2, Centre National de Référence Lupus et Syndrome des Anticorps Antiphospholipides, Centre d'Immunologie et des Maladies Infectieuses (CIMI), Paris, France.;Paediatric, Rheumatology and Paediatric Internal Medicine, Reference Center for Rheumatic, Autoimmune and Systemic Diseases in Children (RAISE), Children's Hospital , Bordeaux, France.;General Pediatrics, Infectious Disease and Internal Medicine Department, Hôpital Robert Debre, Assistance Publique-Hôpitaux de Paris (AP-HP), Reference Center for Rheumatic, AutoImmune and Systemic Diseases in Children (RAISE), Paris, France.;Laboratory of Neurogenetics and Neuroinflammation, Imagine Institute , Paris, France.;Université Paris Cité, Service de Médecine Génomique des Maladies de Système et D'Organe, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris , Paris, France.;Institute for Regenerative Medicine and Biotherapy, Inserm, U1183, University of Montpellier , Montpellier, France.;Department of Molecular Genetics, Medical Genetics of Rare and Autoinflammatory Disease Unit, Montpellier University Hospital, Montpellier, France.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Institute of Structural Biology, University of Bonn , Bonn, Germany.;Centre de Référence des Maladies Autoinflammatoires et des Amyloses Inflammatoires, CEREMAIA , France.;Sorbonne Université, Department of Internal Medicine, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Tenon Hospital, Assistance Publique-Hôpitaux de Paris , Paris, France.;CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308 , ENS de Lyon, Lyon, France."
"87","Sappey-Marinier E;Fernandez A;Shatrov J;Batailler C;Servien E;Huten D;Lustig S","Sappey-Marinier, Elliot;Fernandez, Andréa;Shatrov, Jobe;Batailler, Cécile;Servien, Elvire;Huten, Denis;Lustig, Sébastien","Management of fixed flexion contracture in primary total knee arthroplasty: recent systematic review.","SICOT-J","France","eng","Journal Article","Distal femoral cuts;Fixed flexion contracture;Posterior capsule release;Postoperative rehabilitation;Total knee arthroplasty","","","This study aimed to systematically review the literature and identify the surgical management strategy for fixed flexion contracture in primary total knee arthroplasty (TKA) surgery, pre-, intra-, and post-operatively. Secondary endpoints were etiologies and factors favoring flexion contracture. Searches were carried out in November 2023 in several databases (Pubmed, Scopus, Cochrane, and Google Scholar) using the following keywords: ""flexion contracture AND TKA"", ""fixed flexion deformity AND TKA"", ""posterior capsular release AND TKA"", ""posterior capsulotomy in TKA"", ""distal femoral resection AND TKA"". Study quality was assessed using the STROBE checklist and the Downs and Black score. Data concerning factors or strategies leading to the development or prevention of flexion contracture after TKA were extracted from the text, figures, and tables of the included references. The effect of each predictive factor on flexion contracture after TKA was recorded. Thirty-one studies were identified to meet the inclusion and exclusion criteria. These studies described a variety of preoperative and intraoperative factors that contribute to the development or correction of postoperative flexion contracture. The only clearly identified predictor of postoperative flexion contracture was preoperative flexion contracture. Intraoperative steps described to correct flexion contracture were: soft-tissue balancing (in posterior and medial compartments), distal femoral resection, flexion of the femoral component, and posterior condylar resection. However, no study has investigated these factors in a global model. This review identified various pre-, intra-, and post-operative factors predictive of post-operative flexion contracture. In practice, these factors are likely to interact, and it is therefore crucial to further investigate them in a comprehensive model to develop an algorithm for the management of flexion contracture. IV.","Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France.;Service de chirurgie Orthopédique, Centre chirurgical Emile Gallé, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - LIBM - EA 7424, Interuniversity Laboratory of Biology of Mobility, Université Claude Bernard Lyon 1, Lyon, France.;Chirurgie Orthopédique, Réparatrice et Traumatologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France.","NA",0,"2426-8887","SICOT J","SICOT J",2024,"2024","10","10.1051/sicotj/2024007","11","","","38530205","38530205","PUBMED","Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France.;Service de chirurgie Orthopédique, Centre chirurgical Emile Gallé, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - LIBM - EA 7424, Interuniversity Laboratory of Biology of Mobility, Université Claude Bernard Lyon 1, Lyon, France.;Chirurgie Orthopédique, Réparatrice et Traumatologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de chirurgie orthopédique et de médecine du sport, FIFA medical center of excellence, Hôpital de la Croix-Rousse, Centre Hospitalier Universitaire de Lyon, Lyon, France - Univ Lyon, Université Claude Bernard Lyon 1, IFSTTAR, LBMC UMR_T9406, Lyon, France."
"88","Seidel D;Wurster S;Jenks JD;Sati H;Gangneux JP;Egger M;Alastruey-Izquierdo A;Ford NP;Chowdhary A;Sprute R;Cornely O;Thompson GR;Hoenigl M;Kontoyiannis DP","Seidel, Danila;Wurster, Sebastian;Jenks, Jeffrey D;Sati, Hatim;Gangneux, Jean-Pierre;Egger, Matthias;Alastruey-Izquierdo, Ana;Ford, Nathan P;Chowdhary, Anuradha;Sprute, Rosanne;Cornely, Oliver;Thompson, George R;Hoenigl, Martin;Kontoyiannis, Dimitrios P","Impact of climate change and natural disasters on fungal infections.","The Lancet. Microbe","England","eng","Journal Article","","Climate Change;Humans;Fungi;Mycoses;Natural Disasters;Temperature;Ecosystem","Climate Change;Humans;Fungi;Mycoses;Natural Disasters;Temperature;Ecosystem","The effects of climate change and natural disasters on fungal pathogens and the risks for fungal diseases remain incompletely understood. In this literature review, we examined how fungi are adapting to an increase in the Earth's temperature and are becoming more thermotolerant, which is enhancing fungal fitness and virulence. Climate change is creating conditions conducive to the emergence of new fungal pathogens and is priming fungi to adapt to previously inhospitable environments, such as polluted habitats and urban areas, leading to the geographical spread of some fungi to traditionally non-endemic areas. Climate change is also contributing to increases in the frequency and severity of natural disasters, which can trigger outbreaks of fungal diseases and increase the spread of fungal pathogens. The populations mostly affected are the socially vulnerable. More awareness, research, funding, and policies on the part of key stakeholders are needed to mitigate the effects of climate change and disaster-related fungal diseases.","Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;ECMM Excellence Center for Medical Mycology, Division of Internal Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.;Durham County Department of Public Health, Durham, NC, USA; Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA.;Department of Global Coordination and Partnership on Antimicrobial Resistance, WHO, Geneva, Switzerland.;Centre National de Référence des Mycoses et Antifongiques LA-AspC Aspergilloses Chroniques, ECMM Excellence Center for Medical Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France; University of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) - UMR_S 1085, Rennes, France.;Division of Infectious Diseases, ECMM Excellence Center for Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.;Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.;Department of HIV/AIDS and Global Hepatitis Programme, WHO, Geneva, Switzerland.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India; National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.;Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Koln), University of Cologne, Cologne, Germany.;University of California Davis Center for Valley Fever, University of California Davis, Sacramento, CA, USA; Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, USA; Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA.;Division of Infectious Diseases, ECMM Excellence Center for Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; BioTechMed, Graz;ECMM Excellence Center for Medical Mycology, Division of Internal Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.","NA",0,"2666-5247","Lancet Microbe","Lancet Microbe",2023,"2024","5","10.1016/S2666-5247(24)00039-9","e594-e605","001","World Health Organization","38518791","38518791","PUBMED","Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;ECMM Excellence Center for Medical Mycology, Division of Internal Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.;Durham County Department of Public Health, Durham, NC, USA; Division of Infectious Diseases, Department of Medicine, Duke University, Durham, NC, USA.;Department of Global Coordination and Partnership on Antimicrobial Resistance, WHO, Geneva, Switzerland.;Centre National de Référence des Mycoses et Antifongiques LA-AspC Aspergilloses Chroniques, ECMM Excellence Center for Medical Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France; University of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) - UMR_S 1085, Rennes, France.;Division of Infectious Diseases, ECMM Excellence Center for Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.;Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.;Department of HIV/AIDS and Global Hepatitis Programme, WHO, Geneva, Switzerland.;Medical Mycology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India; National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.;Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;Faculty of Medicine and University Hospital Cologne, University of Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center of Medical Mycology (ECMM), Cologne, Germany; German Centre of Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Koln), University of Cologne, Cologne, Germany.;University of California Davis Center for Valley Fever, University of California Davis, Sacramento, CA, USA; Department of Internal Medicine, Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA, USA; Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA.;Division of Infectious Diseases, ECMM Excellence Center for Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; BioTechMed, Graz;ECMM Excellence Center for Medical Mycology, Division of Internal Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX, USA."
"89","Roth GS;Verlingue L;Sarabi M;Blanc JF;Boleslawski E;Boudjema K;Bretagne-Bignon AL;Camus-Duboc M;Coriat R;Créhange G;De Baere T;de la Fouchardière C;Dromain C;Edeline J;Gelli M;Guiu B;Horn S;Laurent-Croise V;Lepage C;Lièvre A;Lopez A;Manfredi S;Meilleroux J;Neuzillet C;Paradis V;Prat F;Ronot M;Rosmorduc O;Cunha AS;Soubrane O;Turpin A;Louvet C;Bouché O;Malka D","Roth, Gael S;Verlingue, Loic;Sarabi, Matthieu;Blanc, Jean-Frédéric;Boleslawski, Emmanuel;Boudjema, Karim;Bretagne-Bignon, Anne-Laure;Camus-Duboc, Marine;Coriat, Romain;Créhange, Gilles;De Baere, Thierry;de la Fouchardière, Christelle;Dromain, Clarisse;Edeline, Julien;Gelli, Maximiliano;Guiu, Boris;Horn, Samy;Laurent-Croise, Valérie;Lepage, Côme;Lièvre, Astrid;Lopez, Anthony;Manfredi, Sylvain;Meilleroux, Julie;Neuzillet, Cindy;Paradis, Valérie;Prat, Frédéric;Ronot, Maxime;Rosmorduc, Olivier;Cunha, Antonio Sa;Soubrane, Olivier;Turpin, Anthony;Louvet, Christophe;Bouché, Olivier;Malka, David","Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Biliary tract cancer;Chemotherapy;Cholangiocarcinoma;Clinical practice guidelines;Gallbladder carcinoma;Immunotherapy;Surgery;Targeted therapy","Humans;Follow-Up Studies;Biliary Tract Neoplasms;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Endopeptidases","Humans;Follow-Up Studies;Biliary Tract Neoplasms;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Endopeptidases","This document is a summary of the French intergroup guidelines of the management of biliary tract cancers (BTC) (intrahepatic, perihilar and distal cholangiocarcinomas, and gallbladder carcinomas) published in September 2023, available on the website of the French Society of Gastroenterology (SNFGE) (www.tncd.org). This collaborative work was conducted under the auspices of French medical and surgical societies involved in the management of BTC. Recommendations were graded in three categories (A, B and C) according to the level of scientific evidence until August 2023. BTC diagnosis and staging is mainly based on enhanced computed tomography, magnetic resonance imaging and (endoscopic) ultrasound-guided biopsy. Treatment strategy depends on BTC subtype and disease stage. Surgery followed by adjuvant capecitabine is recommended for localised disease. No neoadjuvant treatment is validated to date. Cisplatin-gemcitabine chemotherapy combined to the anti-PD-L1 inhibitor durvalumab is the first-line standard of care for advanced disease. Early systematic tumour molecular profiling is recommended to screen for actionable alterations (IDH1 mutations, FGFR2 rearrangements, HER2 amplification, BRAF  mutation, MSI/dMMR status, etc.) and guide subsequent lines of treatment. In the absence of actionable alterations, FOLFOX chemotherapy is the only second-line standard-of-care. No third-line chemotherapy standard is validated to date. These guidelines are intended to provide a personalised therapeutic strategy for daily clinical practice. Each individual BTC case should be discussed by a multidisciplinary team.","Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.;Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon, France.;Gastroenterology Department, Hopital privé Jean Mermoz, 69008 Lyon, France.;Digestive Oncology Unit, CHU Bordeaux, Bordeaux, France.;Univ. Lille, INSERM U1189, CHU Lille, Service de Chirurgie Digestive et Transplantations, Lille, France.;Département de chirurgie viscérale hépatobiliaire, CHU de Rennes, Rennes, France.;Hepatogastroenterology, CHU Caen, France.;Endoscopie digestive, Hôpital Saint-Antoine, AP-HP/Sorbonne Université, Paris France.;Service de gastroentérologie, d'endoscopie et d'oncologie digestive, Hôpital Cochin, APHP, Paris, France.;Radiation Oncology Department. Paris/Saint-Cloud/Orsay, Institut Curie. PSL Research University, Paris, France.;Département de Radiologie Interventionnelle, Gustave Roussy, 94805 Villejuif, France.;Medical Oncology Department, Institut Paoli Calmette, Marseille, France.;Service de radiodiagnostic et radiologie interventionnelle, Centre Hospitalier Universitaire Vaudois, Switzerland.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Département de Chirurgie Viscérale, Gustave Roussy, 94805 Villejuif, France.;Department of Radiology, St-Eloi University Hospital - Montpellier School of Medicine, Montpellier, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.;Department of Radiology, Centre Hospitalier Universitaire de Nancy, Hôpital de Brabois, 54500 Vandœuvre-lès-Nancy, France.;Université de Bourgogne, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, 14 rue Paul Gaffarel, 21079 Dijon, France.;Department of Gastroenterology, Rennes University Hospital, University of Rennes 1, INSERM Unité 1242, Rennes, France.;INSERM U1256, NGERE, Faculty of Medicine, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France; Department of Hepatology and Gastroenterology, Nancy University Hospital, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France, NGERE, Faculty of Medicine, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France.;Université de Bourgogne, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, 14 rue Paul Gaffarel, 21079 Dijon, France.;Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole, Toulouse Cedex 9, France.;GI Oncology, Department of Medical Oncology, Institut Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud, France.;Université Paris Cité, APHP.Nord Sce d'Anatomie Pathologique Hôpital Beaujon, Clichy, INSERM UMR 1149, France.;Endoscopie digestive, Hôpital Beaujon, Clichy, France.;Department of Medical Imaging, Beaujon University Hospital, Clichy, France.;AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM U1193, Université Paris-Saclay, FHU Hépatinov, France.;AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM U1193, Université Paris-Saclay, FHU Hépatinov, France.;Department of Digestive Surgery, Institut Mutualiste Montsouris, Paris, France.;Department of Medical Oncology, CNRS UMR9020, Inserm UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CHU Lille, Lille; GERCOR, Paris, France.;Department of Medical Oncology, Institute Mutualiste Montsouris, Paris, France.;Gastroenterology and Digestive Oncology Department, Robert-Debré University Hospital, Reims, France.;Department of Medical Oncology, Institute Mutualiste Montsouris, Paris","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","202","10.1016/j.ejca.2024.114000","114000","","","38493667","38493667","PUBMED","Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble, France.;Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon, France.;Gastroenterology Department, Hopital privé Jean Mermoz, 69008 Lyon, France.;Digestive Oncology Unit, CHU Bordeaux, Bordeaux, France.;Univ. Lille, INSERM U1189, CHU Lille, Service de Chirurgie Digestive et Transplantations, Lille, France.;Département de chirurgie viscérale hépatobiliaire, CHU de Rennes, Rennes, France.;Hepatogastroenterology, CHU Caen, France.;Endoscopie digestive, Hôpital Saint-Antoine, AP-HP/Sorbonne Université, Paris France.;Service de gastroentérologie, d'endoscopie et d'oncologie digestive, Hôpital Cochin, APHP, Paris, France.;Radiation Oncology Department. Paris/Saint-Cloud/Orsay, Institut Curie. PSL Research University, Paris, France.;Département de Radiologie Interventionnelle, Gustave Roussy, 94805 Villejuif, France.;Medical Oncology Department, Institut Paoli Calmette, Marseille, France.;Service de radiodiagnostic et radiologie interventionnelle, Centre Hospitalier Universitaire Vaudois, Switzerland.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Département de Chirurgie Viscérale, Gustave Roussy, 94805 Villejuif, France.;Department of Radiology, St-Eloi University Hospital - Montpellier School of Medicine, Montpellier, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France.;Department of Radiology, Centre Hospitalier Universitaire de Nancy, Hôpital de Brabois, 54500 Vandœuvre-lès-Nancy, France.;Université de Bourgogne, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, 14 rue Paul Gaffarel, 21079 Dijon, France.;Department of Gastroenterology, Rennes University Hospital, University of Rennes 1, INSERM Unité 1242, Rennes, France.;INSERM U1256, NGERE, Faculty of Medicine, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France; Department of Hepatology and Gastroenterology, Nancy University Hospital, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France, NGERE, Faculty of Medicine, University of Lorraine, 54500 Vandœuvre-lès-Nancy, France.;Université de Bourgogne, CHU Dijon-Bourgogne, INSERM U1231. BP 87 900, 14 rue Paul Gaffarel, 21079 Dijon, France.;Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole, Toulouse Cedex 9, France.;GI Oncology, Department of Medical Oncology, Institut Curie - Site Saint Cloud, Versailles Saint-Quentin University, Paris Saclay University, Saint-Cloud, France.;Université Paris Cité, APHP.Nord Sce d'Anatomie Pathologique Hôpital Beaujon, Clichy, INSERM UMR 1149, France.;Endoscopie digestive, Hôpital Beaujon, Clichy, France.;Department of Medical Imaging, Beaujon University Hospital, Clichy, France.;AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM U1193, Université Paris-Saclay, FHU Hépatinov, France.;AP-HP Hôpital Paul-Brousse, Centre Hépato-Biliaire, INSERM U1193, Université Paris-Saclay, FHU Hépatinov, France.;Department of Digestive Surgery, Institut Mutualiste Montsouris, Paris, France.;Department of Medical Oncology, CNRS UMR9020, Inserm UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University Lille, CHU Lille, Lille; GERCOR, Paris, France.;Department of Medical Oncology, Institute Mutualiste Montsouris, Paris, France.;Gastroenterology and Digestive Oncology Department, Robert-Debré University Hospital, Reims, France.;Department of Medical Oncology, Institute Mutualiste Montsouris, Paris"
"90","D'Agostino J;Souki A;Lohse A;Carvajal Alegria G;Dernis E;Richez C;Truchetet ME;Wendling D;Toussirot E;Perdriger A;Gottenberg JE;Felten R;Fautrel B;Chiche L;Hilliquin P;Le Henaff C;Dervieux B;Direz G;Chary-Valckenaere I;Cornec D;Guellec D;Marhadour T;Nowak E;Saraux A;Devauchelle-Pensec V","D'Agostino, Justine;Souki, Aghiles;Lohse, Anne;Carvajal Alegria, Guillermo;Dernis, Emanuelle;Richez, Christophe;Truchetet, Marie-Elise;Wendling, Daniel;Toussirot, Eric;Perdriger, Aleth;Gottenberg, Jacques-Eric;Felten, Renaud;Fautrel, Bruno;Chiche, Laurent;Hilliquin, Pascal;Le Henaff, Catherine;Dervieux, Benjamin;Direz, Guillaume;Chary-Valckenaere, Isabelle;Cornec, Divi;Guellec, Dewi;Marhadour, Thierry;Nowak, Emmanuel;Saraux, Alain;Devauchelle-Pensec, Valérie","Concordance and agreement between different activity scores in polymyalgia rheumatica.","RMD open","England","eng","Randomized Controlled Trial","biological therapy;inflammation;polymyalgia rheumatica","Humans;Polymyalgia Rheumatica;Giant Cell Arteritis;Glucocorticoids;C-Reactive Protein;Blood Sedimentation","Humans;Polymyalgia Rheumatica;Giant Cell Arteritis;Glucocorticoids;C-Reactive Protein;Blood Sedimentation","The C reactive protein polymyalgia rheumatica activity score (CRP-PMR-AS) is a composite index that includes CRP levels and was developed specifically for PMR. As treatments such as interleukin-6 antagonists can normalise CRP levels, the erythrocyte sedimentation rate (ESR) of PMR-AS, the clinical (clin)-PMR-AS and the imputed-CRP (imp-CRP)-PMR-AS have been developed to avoid such bias. Our primary objective was to measure the correlation of these activity scores. Our secondary objective was to evaluate the concordance between different cutoffs of the PMR-ASs. Data from the Safety and Efficacy of tocilizumab versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence (SEMAPHORE) trial, a superiority randomised double-blind placebo-controlled trial, were subjected to post hoc analysis to compare the efficacy of tocilizumab versus placebo in patients with active PMR. The CRP-PMR-AS, ESR-PMR-AS, clin-PMR-AS and imp-CRP-PMR-AS were measured at every visit. The concordance and correlation between these scores were evaluated using kappa correlation coefficients, Bland-Altman correlations, intraclass correlation coefficients (ICCs) and scatter plots. A total of 101 patients were included in the SEMAPHORE trial, and 100 were analysed in this study. The correlation between the PMR-ASs was excellent, as the ICC and kappa were >0.85 from week 4 until week 24 (CRP-PMR-AS ≤10 or >10). Bland-Altman plots revealed that the differences between the CRP-PMR-AS and the other threescores were low. The cut-off values for the clin-PMR-AS were similar to those for the CRP-PMR-AS 86% of the time. The correlation between all the PMR-ASs was excellent, reflecting the low weight of CRP. In clinical trials using drugs that have an impact on CRP, the derived activity scores can be used. NTC02908217.","Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest;Public Agency for Clinical Research and Innovation (DRCI), Brest University Hospital, Centre Hospitalier Universitaire de Brest, Brest, France.;Hopital Nord Franche-Comte-Site de Belfort, Belfort, France.;Rheumatology and EA6295 NMNS, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Department of Rheumatology, Centre Hospitalier Le Mans, Le Mans, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France.;UMR CNRS 5164, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France.;Rheumatology and EA4266 Franche-Comté University, Centre Hospitalier Universitaire de Besancon, Besancon, France.;INSERM Clinical Investigation Center 1431, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Department of Rheumatology, Assistance Publique-Hopitaux de Paris, Paris, France.;INSERM UMR-S 1136, Pierre Louis Epidemiology and Public Health Research Institute, Paris, France.;Internal Medicine, Marseille Public University Hospital System, Marseille, France.;Department of Rhumatology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Department of Rheumatology, Pays de Morlaix Hospital Centre, Morlaix, France.;Department of Rhuamtology, GHR Mulhouse Sud Alsace, Mulhouse, France.;Department of Rheumatology, Centre Hospitalier Le Mans, Le Mans, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM Clinical Investigations Centre 1412, Centre Hospitalier Universitaire de Brest, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;Public Agency for Clinical Research and Innovation (DRCI), Brest University Hospital, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire de Brest, Brest, INSERM Clinical Investigations Centre (CIC) 1412, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France.","NA",0,"2056-5933","RMD Open","RMD Open",2023,"2024","10","10.1136/rmdopen-2023-003741",NA,"","","38490696","38490696","PUBMED","Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest;Public Agency for Clinical Research and Innovation (DRCI), Brest University Hospital, Centre Hospitalier Universitaire de Brest, Brest, France.;Hopital Nord Franche-Comte-Site de Belfort, Belfort, France.;Rheumatology and EA6295 NMNS, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Department of Rheumatology, Centre Hospitalier Le Mans, Le Mans, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France.;UMR CNRS 5164, Université de Bordeaux Collège Sciences de la Santé, Bordeaux, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin, Bordeaux, France.;Rheumatology and EA4266 Franche-Comté University, Centre Hospitalier Universitaire de Besancon, Besancon, France.;INSERM Clinical Investigation Center 1431, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Department of Rheumatology, Assistance Publique-Hopitaux de Paris, Paris, France.;INSERM UMR-S 1136, Pierre Louis Epidemiology and Public Health Research Institute, Paris, France.;Internal Medicine, Marseille Public University Hospital System, Marseille, France.;Department of Rhumatology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Department of Rheumatology, Pays de Morlaix Hospital Centre, Morlaix, France.;Department of Rhuamtology, GHR Mulhouse Sud Alsace, Mulhouse, France.;Department of Rheumatology, Centre Hospitalier Le Mans, Le Mans, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM Clinical Investigations Centre 1412, Centre Hospitalier Universitaire de Brest, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;Public Agency for Clinical Research and Innovation (DRCI), Brest University Hospital, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire de Brest, Brest, INSERM Clinical Investigations Centre (CIC) 1412, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France.;Department of Rheumatology, Centre Hospitalier Universitaire de Brest, Brest, France.;INSERM 1227, Université de Bretagne Occidentale, Brest, France."
"91","de Hoog S;Walsh TJ;Ahmed SA;Alastruey-Izquierdo A;Alexander BD;Arendrup MC;Babady E;Bai F-Y;Balada-Llasat J-M;Borman A;Chowdhary A;Clark A;Colgrove RC;Cornely OA;Dingle TC;Dufresne PJ;Fuller J;Gangneux J-P;Gibas C;Glasgow H;Graser Y;Guillot J;Groll AH;Haase G;Hanson K;Harrington A;Hawksworth DL;Hayden RT;Hoenigl M;Hubka V;Johnson K;Kus JV;Li R;Meis JF;Lackner M;Lanternier F;Leal SM;Lee F;Lockhart SR;Luethy P;Martin I;Kwon-Chung KJ;Meyer W;Nguyen MH;Ostrosky-Zeichner L;Palavecino E;Pancholi P;Pappas PG;Procop GW;Redhead SA;Rhoads DD;Riedel S;Stevens B;Sullivan KO;Vergidis P;Roilides E;Seyedmousavi A;Tao L;Vicente VA;Vitale RG;Wang Q-M;Wengenack NL;Westblade L;Wiederhold N;White L;Wojewoda CM;Zhang SX","de Hoog, Sybren;Walsh, Thomas J;Ahmed, Sarah A;Alastruey-Izquierdo, Ana;Alexander, Barbara D;Arendrup, Maiken Cavling;Babady, Esther;Bai, Feng-Yan;Balada-Llasat, Joan-Miquel;Borman, Andrew;Chowdhary, Anuradha;Clark, Andrew;Colgrove, Robert C;Cornely, Oliver A;Dingle, Tanis C;Dufresne, Philippe J;Fuller, Jeff;Gangneux, Jean-Pierre;Gibas, Connie;Glasgow, Heather;Graser, Yvonne;Guillot, Jacques;Groll, Andreas H;Haase, Gerhard;Hanson, Kimberly;Harrington, Amanda;Hawksworth, David L;Hayden, Randall T;Hoenigl, Martin;Hubka, Vit;Johnson, Kristie;Kus, Julianne V;Li, Ruoyu;Meis, Jacques F;Lackner, Michaela;Lanternier, Fanny;Leal, Sixto M;Lee, Francesca;Lockhart, Shawn R;Luethy, Paul;Martin, Isabella;Kwon-Chung, Kyung J;Meyer, Wieland;Nguyen, M Hong;Ostrosky-Zeichner, Luis;Palavecino, Elizabeth;Pancholi, Preeti;Pappas, Peter G;Procop, Gary W;Redhead, Scott A;Rhoads, Daniel D;Riedel, Stefan;Stevens, Bryan;Sullivan, Kaede Ota;Vergidis, Paschalis;Roilides, Emmanuel;Seyedmousavi, Amir;Tao, Lili;Vicente, Vania A;Vitale, Roxana G;Wang, Qi-Ming;Wengenack, Nancy L;Westblade, Lars;Wiederhold, Nathan;White, Lewis;Wojewoda, Christina M;Zhang, Sean X","Reply to Kidd et al., ""Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion"".","Journal of clinical microbiology","United States","eng","Letter","","","","NA","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Research Center for Medical Mycology, Peking University, Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Medical Mycological Society of the Americas (MMSA).;Departments of Medicine and Pathology, Duke University, Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.;Mycology Committee of Chinese Society for Microbiology, Beijing, China.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences, Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia PacificSociety for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital, Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA), Arlington, Virginia, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Mycology, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Texas Health Science Center, San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University, Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique, Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, Center for Bone Marrow Transplantation, University Children's Hospital, Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Utah School of Medicine, Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Loyola University Health System, Loyola University Chicago, Maywood, Illinois, USA.;Royal Botanic Gardens, Kew, Richmond, Surrey, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Department of Botany, Charles University, Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Public Health Ontario, Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto, Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Research Center for Medical Mycology, Peking University, Beijing, China.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Institut Pasteur, Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Dartmouth Health, Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Texas Health Science Center at Houston, Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;The American Board of Pathology, Tampa, Florida, USA.;American Board of Pathology (ABP), Chicago, Illinois, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada, Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Hippokration Hospital, Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Department of Laboratory Medicine, Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicasy Tecnológicas (CONICET), Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía, Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University, Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center, San Antonio, Texas, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2024,"2024","62","10.1128/jcm.01625-23","e0162523","","","38441056","38441056","PUBMED","Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Research Center for Medical Mycology, Peking University, Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Center for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.;University of Maryland School of Medicine, Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi, Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Mycology Reference Laboratory, Spanish National Centre for Microbiology, Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Medical Mycological Society of the Americas (MMSA).;Departments of Medicine and Pathology, Duke University, Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark.;Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Clinical Microbiology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.;Mycology Committee of Chinese Society for Microbiology, Beijing, China.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences, Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia PacificSociety for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England, Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital, Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA), Arlington, Virginia, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Alberta Precision Laboratories, Public Health Laboratory, Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Mycology, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue, Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, London Health Sciences Center, London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Department of Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Texas Health Science Center, San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University, Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique, Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Department of Pediatric Hematology and Oncology, Infectious Disease Research Program, Center for Bone Marrow Transplantation, University Children's Hospital, Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital, Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Utah School of Medicine, Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Loyola University Health System, Loyola University Chicago, Maywood, Illinois, USA.;Royal Botanic Gardens, Kew, Richmond, Surrey, United Kingdom.;Natural History Museum, London, United Kingdom.;University of Southampton, Southampton, United Kingdom.;Jilin Agricultural University, Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Department of Pathology, Clinical and Molecular Microbiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Department of Botany, Charles University, Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Public Health Ontario, Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto, Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.;Research Center for Medical Mycology, Peking University, Beijing, China.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics, Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology, Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;Institut Pasteur, Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Texas Southwestern Medical Center, Dallas, Texas, USA.;Radboudumc-CWZ Centre of Expertise for Mycology, Nijmegen, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;European Hematology Association, Specialized Working Group for Infections in Hematology, The Hague, the Netherlands.;Centers for Disease Control and Prevention, Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Dartmouth Health, Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;Westerdijk Fungal Biodiversity Institute, Utrecht, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Texas Health Science Center at Houston, Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical Microbiology at The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;University of Alabama at Birmingham, Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;The American Board of Pathology, Tampa, Florida, USA.;American Board of Pathology (ABP), Chicago, Illinois, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA), Exeter, United Kingdom.;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada, Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;European Confederation of Medical Mycology (ECMM), 's-Hertogenbosch, the Netherlands.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;Hippokration Hospital, Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID), Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health, 's-Hertogenbosch, the Netherlands.;Department of Laboratory Medicine, Microbiology Service, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicasy Tecnológicas (CONICET), Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía, Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University, Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mayo Clinic, Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC), Pittsburgh, Pennsylvania, USA.;Clinical and Laboratory Standards Institute (CLSI), Pittsburgh, Pennsylvania, USA.;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center, San Antonio, Texas, USA.;Public Health Wales Microbiology, Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature, 's-Hertogenbosch, the Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC), Baltimore, Maryland, USA.;Johns Hopkins University School of Medicine, Baltimore, Maryland, USA."
"92","Bardia A;Rugo HS;Tolaney SM;Loirat D;Punie K;Oliveira M;Brufsky A;Kalinsky K;Cortés J;Shaughnessy JO;Diéras V;Carey LA;Gianni L;Piccart-Gebhart M;Loibl S;Yoon OK;Pan Y;Hofsess S;Phan SC;Hurvitz SA","Bardia, Aditya;Rugo, Hope S;Tolaney, Sara M;Loirat, Delphine;Punie, Kevin;Oliveira, Mafalda;Brufsky, Adam;Kalinsky, Kevin;Cortés, Javier;Shaughnessy, Joyce O';Diéras, Véronique;Carey, Lisa A;Gianni, Luca;Piccart-Gebhart, Martine;Loibl, Sibylle;Yoon, Oh Kyu;Pan, Yang;Hofsess, Scott;Phan, See-Chun;Hurvitz, Sara A","Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Journal Article","","Humans;Triple Negative Breast Neoplasms;Female;Middle Aged;Antigens, Neoplasm;Adult;Receptor, ErbB-2;Antibodies, Monoclonal, Humanized;Cell Adhesion Molecules;Aged;Immunoconjugates;Camptothecin;Progression-Free Survival;Neoplasm Metastasis","Humans;Triple Negative Breast Neoplasms;Female;Middle Aged;Antigens, Neoplasm;Adult;Receptor, ErbB-2;Antibodies, Monoclonal, Humanized;Cell Adhesion Molecules;Aged;Immunoconjugates;Camptothecin;Progression-Free Survival;Neoplasm Metastasis"," JCO  Sacituzumab govitecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician's choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the international, multicenter, phase III ASCENT study.Patients were randomly assigned 1:1 to receive SG or TPC until unacceptable toxicity/progression. Final efficacy secondary end point analyses and post hoc analyses of outcomes stratified by Trop-2 expression and human epidermal growth factor receptor 2 status are reported. Updated safety analyses are provided.In this final analysis, SG (n = 267) improved median progression-free survival (PFS; 4.8   1.7 months; hazard ratio (HR), 0.41 [95% CI, 0.33 to 0.52]) and median overall survival (OS; 11.8   6.9 months; HR, 0.51 [95% CI, 0.42 to 0.63]) over TPC (n = 262). SG improved PFS over TPC in each Trop-2 expression quartile (n = 168); a trend was observed for improved OS across quartiles. Overall, SG had a manageable safety profile, with ≤5% of treatment-related discontinuations because of adverse events and no treatment-related deaths. The safety profile was consistent across all subgroups.These data confirm the clinical benefit of SG over chemotherapy, reinforcing SG as an effective treatment option in patients with mTNBC in the second line or later.","Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.;Institut Curie, Paris, France.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA.;Winship Cancer Institute, Emory University, Atlanta, GA.;International Breast Cancer Center, Quiron Group, Barcelona, Spain.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.;Gianni Bonadonna Foundation, Milan, Italy.;Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.;Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Gilead Sciences, Inc, Foster City, CA.;Gilead Sciences, Inc, Foster City, CA.;Gilead Sciences, Inc, Morris Plains, NJ.;Gilead Sciences, Inc, Foster City, CA.;Division of Hematology and Oncology, Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2024,"2024","42","10.1200/JCO.23.01409","1738-1744","","","38422473","38422473","PUBMED","Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.;Institut Curie, Paris, France.;Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA.;Winship Cancer Institute, Emory University, Atlanta, GA.;International Breast Cancer Center, Quiron Group, Barcelona, Spain.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC.;Gianni Bonadonna Foundation, Milan, Italy.;Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.;Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Gilead Sciences, Inc, Foster City, CA.;Gilead Sciences, Inc, Foster City, CA.;Gilead Sciences, Inc, Morris Plains, NJ.;Gilead Sciences, Inc, Foster City, CA.;Division of Hematology and Oncology, Clinical Research Division, Department of Medicine, UW Medicine, Fred Hutchinson Cancer Center, Seattle, WA."
"93","Mourey L;Rainho LT;Dalban C;Carril-Ajuria L;Negrier S;Chevreau C;Gravis G;Thibault C;Laguerre B;Barthelemy P;Borchiellini D;Gross-Goupil M;Geoffrois L;Rolland F;Thiery-Vuillemin A;Tantot F;Chaput N;Naigeon M;Teixeira M;Escudier B;Flippot R;Albiges L","Mourey, Loïc;Rainho, Larissa Tames;Dalban, Cécile;Carril-Ajuria, Lucía;Negrier, Sylvie;Chevreau, Christine;Gravis, Gwenaëlle;Thibault, Constance;Laguerre, Brigitte;Barthelemy, Philippe;Borchiellini, Delphine;Gross-Goupil, Marine;Geoffrois, Lionnel;Rolland, Frederic;Thiery-Vuillemin, Antoine;Tantot, Florence;Chaput, Nathalie;Naigeon, Marie;Teixeira, Marcus;Escudier, Bernard;Flippot, Ronan;Albiges, Laurence","Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Biomarkers;Cytokines;Elderly;Immune checkpoint inhibitors;Nivolumab;Outcomes;Renal cell carcinoma","Humans;Aged;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Progression-Free Survival","Humans;Aged;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Progression-Free Survival","Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses. Patients with mRCC were treated with nivolumab after at least one antiangiogenic therapy. The main endpoint of this analysis was safety in patients ≥ 70 years old (y.o), as per the rate of treatment-related grade 3-5 events (TRAE). Secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival. Exploration of candidate biomarkers associated with aging included baseline circulating cytokines involved in inflammation, adhesion, immune checkpoints, angiogenesis (IL6, IL7, IL8, BAFF, CXCL13, VCAM-1, 4-1BB, VEGF). Of 720 patients, 515 were < 70 y.o and 205 ≥ 70 y.o. Patients ≥ 70 y.o exhibited numerically less IMDC poor risk disease (21.0% vs 26.9%), sarcomatoid component (4.9% vs 9.8%) or brain metastases (5.9% vs. 14.7%), but more previous treatment lines (≥ 2 in 54.1% vs 48.5%). TRAE were higher in patients ≥ 70 y.o (24.9% vs. 17.9%, p = 0.033). Respective ORR (19.2% vs. 22.1%) and median PFS (4.5 versus 3.0 months, HR 0.97 [95%CI 0.81-1.15]) were similar. Overall survival was shorter in patients ≥ 70 y.o (19.3 versus 26.9 months, HR 1.26 [95%CI 1.04-1.51]), but not significantly in a competitive risk model. Only V-CAM1 and 4-1BB were found to be increased in patients ≥ 70 y.o. Nivolumab displayed higher grade 3/4 TRAE but manageable toxicity in elderly patients, with sustained activity. Elderly patients did not display specific inflammatory or angiogenic circulating profiles.","IUCT-Oncopole Claudius Regaud, Toulouse, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Leon Berard Center, University Lyon I, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Leon Berard Center, University Lyon I, Lyon, France.;IUCT-Oncopole Claudius Regaud, Toulouse, France.;Institut Paoli-Calmettes, Department of Medical Oncology, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.;Hopital Européen Georges Pompidou, Paris, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;University Hospital Jean Minjoz, Besançon, France.;UNICANCER, Kremlin Bicetre, France.;Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France; Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France; Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","201","10.1016/j.ejca.2024.113589","113589","","","38382153","38382153","PUBMED","IUCT-Oncopole Claudius Regaud, Toulouse, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Leon Berard Center, University Lyon I, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Leon Berard Center, University Lyon I, Lyon, France.;IUCT-Oncopole Claudius Regaud, Toulouse, France.;Institut Paoli-Calmettes, Department of Medical Oncology, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.;Hopital Européen Georges Pompidou, Paris, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;University Hospital Jean Minjoz, Besançon, France.;UNICANCER, Kremlin Bicetre, France.;Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France; Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, Paris Saclay University, Villejuif, France; Immunomonitoring Laboratory, UMS CNRS3655 & INSERM US23, Gustave Roussy, Paris Saclay University, Villejuif"
"94","François E;Magné N;Boulahssass R;Ronchin P;Huguenet V;De Lavigerie B;Nouhaud E;Cattenoz C;Martel-Lafay I;Terret C;Artru P;Clavere P;Tchalla A;Vendrely V;Duc S;Boige V;De Sousa Carvalho N;Gal J;De Bari B","François, Eric;Magné, Nicolas;Boulahssass, Rabia;Ronchin, Philippe;Huguenet, Virginie;De Lavigerie, Blandine;Nouhaud, Elodie;Cattenoz, Catherine;Martel-Lafay, Isabelle;Terret, Catherine;Artru, Pascal;Clavere, Pierre;Tchalla, Achille;Vendrely, Véronique;Duc, Sophie;Boige, Valérie;De Sousa Carvalho, Nicolas;Gal, Jocelyn;De Bari, Berardino","Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","Comprehensive geriatric assessment;Elderly;Neoadjuvant radiotherapy;Quality of life;Rectal cancer","Aged;Humans;Quality of Life;Geriatric Assessment;Neoadjuvant Therapy;Chemoradiotherapy;Rectal Neoplasms;Neoplasms, Second Primary;Neoplasm Staging","Aged;Humans;Quality of Life;Geriatric Assessment;Neoadjuvant Therapy;Chemoradiotherapy;Rectal Neoplasms;Neoplasms, Second Primary;Neoplasm Staging","The results of the PRODIGE 42/GERICO 12 study showed that short course radiotherapy had a better tolerance profile than radiochemotherapy, with comparable oncological results. We have included Quality of Life analyses and oncogeriatric evaluations in this study. In all, 101 patients ≥75 years of age with resectable T3-T4 rectal adenocarcinoma less than 12 cm from the anal margin received short course radiotherapy (5X5 Gy in one week) or radiochemotherapy (50 Gy, 2 y/f and capecitabine 800 mg/m , 5 days/week) with delayed surgery (7 weeks ± 1) in both groups. The Quality of Life analyses (EORTC QLQ C-30 et ELD14) were conducted upon inclusion, pre-operatively, at 3, 6 and 12 months post-op, together with the oncogeriatric evaluations, including an evaluation of the IADL and ADL scores, walking speed, GDS15, MMSE, MNA. We did not highlight any statistical difference for the global EORTC QLQ-C30 score; several factors are statistically in favor of the short course radiotherapy group at 3 months post-op (cognitive functions, fatigue, appetite). In the case of the ELD14 score, the disease burden is perceived as more negative at 3, 6 and 12 months postop in the radiochemotherapy group. The IADL score deteriorated in 44.8 % of the radiochemotherapy group and 14.8 % of the radiotherapy group (p = 0.032); similarly, the GDS15 depression score was better preserved in the short course radiotherapy group (p = 0.05). An analysis of the other scores: ADL, walking speed, MNA, MMSE did not highlight any statistical difference. Short course radiotherapy achieves better results in terms of Quality of Life and preservation of autonomy in patients aged ≥75 treated for locally advanced rectal cancer.","Centre Antoine-Lacassagne, Nice;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France.;Centre Antoine-Lacassagne, Nice, France; Centre Azuréen de Cancérologie, Mougins, France.;Centre Azuréen de Cancérologie, Mougins, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France.;Centre Eugène Marquis, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon-Berard, Lyon, France.;Centre Léon-Berard, Lyon, France.;Hôpital Privé Jean Mermoz, Lyon, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Gustave Roussy, Villejuif, France.;UNICANCER, Kremlin-Bicêtre, France.;Centre Antoine-Lacassagne, Nice, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2023,"2024","193","10.1016/j.radonc.2024.110144","110144","","","38341097","38341097","PUBMED","Centre Antoine-Lacassagne, Nice;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France.;Centre Antoine-Lacassagne, Nice, France; Centre Azuréen de Cancérologie, Mougins, France.;Centre Azuréen de Cancérologie, Mougins, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France.;Centre Eugène Marquis, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon-Berard, Lyon, France.;Centre Léon-Berard, Lyon, France.;Hôpital Privé Jean Mermoz, Lyon, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Gustave Roussy, Villejuif, France.;UNICANCER, Kremlin-Bicêtre, France.;Centre Antoine-Lacassagne, Nice, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France."
"95","Parisi A;Delaunay B;Pinterpe G;Hollebecque A;Blanc JF;Bouattour M;Assenat E;Ben Abdelghani M;Sarabi M;Niger M;Vivaldi C;Mandalà M;Palloni A;Bensi M;Garattini SK;Tougeron D;Combe P;Salati M;Rimini M;Cella CA;Tucci M;Diana A;Mori E;Longarini R;Artru P;Roth G;Evesque L;Vienne A;Turpin A;Hiret S;Bourgeois V;Herve C;Paulon R;Stacoffe M;Malka D;Neuzillet C;Edeline J;Lievre A;Guimbaud R;Chapda MCP;Rimassa L;Giampieri R;Valle J;Berardi R;Fares N","Parisi, Alessandro;Delaunay, Blandine;Pinterpe, Giada;Hollebecque, Antoine;Blanc, Jean Frederic;Bouattour, Mohamed;Assenat, Eric;Ben Abdelghani, Meher;Sarabi, Matthieu;Niger, Monica;Vivaldi, Caterina;Mandalà, Mario;Palloni, Andrea;Bensi, Maria;Garattini, Silvio Ken;Tougeron, David;Combe, Pierre;Salati, Massimiliano;Rimini, Margherita;Cella, Chiara Alessandra;Tucci, Marco;Diana, Anna;Mori, Elena;Longarini, Raffaella;Artru, Pascal;Roth, Gael;Evesque, Ludovic;Vienne, Agathe;Turpin, Anthony;Hiret, Sandrine;Bourgeois, Vincent;Herve, Camille;Paulon, Rodolphe;Stacoffe, Marion;Malka, David;Neuzillet, Cindy;Edeline, Julien;Lievre, Astrid;Guimbaud, Rosine;Chapda, Marie Christelle Pajiep;Rimassa, Lorenza;Giampieri, Riccardo;Valle, Juan;Berardi, Rossana;Fares, Nadim","Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","BTC;FGFR2 fusions/rearrangements;Intrahepatic cholangiocarcinoma;Real-world data;Systemic treatment;Targeted therapy","Humans;Female;Middle Aged;Male;Retrospective Studies;Cholangiocarcinoma;Cohort Studies;Bile Ducts, Intrahepatic;Bile Duct Neoplasms;Receptor, Fibroblast Growth Factor, Type 2;Morpholines;Pyrimidines;Pyrroles","Humans;Female;Middle Aged;Male;Retrospective Studies;Cholangiocarcinoma;Cohort Studies;Bile Ducts, Intrahepatic;Bile Duct Neoplasms;Receptor, Fibroblast Growth Factor, Type 2;Morpholines;Pyrimidines;Pyrroles","Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected by CCA and treated with pemigatinib as second- or further line of systemic treatment in clinical practice, within or outside the European Expanded Access Program, were included. Between July 2020 and September 2022, 72 patients were treated with pemigatinib in 14 Italian and 25 French Centres. Patients had a median age of 57 years, 76% were female, 81% had ECOG-PS 0-1, 99% had intrahepatic CCA, 74% had ≥ 2 metastatic sites, 67% had metastatic disease at diagnosis, while 38.8% received ≥ 2 previous lines of systemic treatment. At data cut-off analysis (April 2023), ORR and DCR were 45.8% and 84.7%, respectively. Median DoR was 7 months (IQR: 5.8-9.3). Over a median follow-up time of 19.5 months, median PFS and 1-year PFS rate were 8.7 months and 32.8%. Median OS and 1-year OS rate were 17.1 months and 60.6%. Fatigue (69.4%), ocular toxicity (68%), nail toxicities (61.1%), dermatologic toxicity (41.6%) hyperphosphataemia (55.6%), stomatitis (48.6%), and diarrhea (36.1%) were the most frequent, mainly G1-G2 AEs. Overall incidence of G3 AEs was 22.2%, while no patient experienced G4 AE. Dose reduction and temporary discontinuation were needed in 33.3% and 40.3% of cases, with 1 permanent discontinuation due to AEs. These results confirm the effectiveness and safety of pemigatinib in a real-world setting.","Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy; Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Département d'Innovation Thérapeutique et Essais précoces (DITEP), Gustave Roussy, Villejuif Cedex, France.;Oncology Digestive Unit, Hôpital haut-Lévêque, CHU Bordeaux France, France.;Liver Oncology and Therapeutic Innovation Functional Unit, Beaujon Hospital APHP, Clichy, France.;Medical oncology, ICM - Institut du Cancer de Montpellier, Montpellier Cedex, France.;Oncology Department, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Medical Oncology, Centre Léon Bérard, Lyon, GI Oncology Department, France; GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133 Milan, Italy.;Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.;Unit of Medical Oncology, University of Perugia, Perugia, Italy.;Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.;Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Italy; Università Cattolica del Sacro Cuore, Roma, Italy.;Department of Oncology, Academic Hospital of Udine ASUFC, Piazzale Santa Maria della Misericordia 15, Udine, UD 33100, Italy.;Université de Poitiers, Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Medical Oncology, CORT37, Pôle Santé Léonard de Vinci, Chambray-lès-Tours, France.;Division of Oncology, Department of Oncology and Hematology, University Hospital Modena, Modena Cancer Centre, Via del Pozzo 71, 41125 Modena, Italy; Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.;Vita-Salute University San Raffaele, Milan, Italy; Department of Oncology, IRCCS San Raffaele Hospital, via Olgettina N. 60, Milan 20132, Italy.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, Milan, Italy.;Department of Interdisciplinary Medicine, Oncology Unit, University of Bari ""Aldo Moro"", P.za Giulio Cesare, 11, 70124, Bari, Italy.;UOC Oncologia - Ospedale del Mare, Naples.;Department of Medical Oncology, New Hospital of Prato S. Stefano, 59100 Prato, Italy.;Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.;Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM, U1209, France.;Medical Oncology Department, Centre Antoine-Lacassagne, Nice, France.;Oncology Department, CHU Sud Réunion, Saint Pierre, France.;Medical Oncology Department, Hopital Claude Huriez, Lille, France.;Oncology Department, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Digestive Oncology, Hopital duchenne Boulogne-sur-Mer, France.;Digestive Oncology, Groupe Hospitalier Mutualiste, Grenoble.;Medical Oncology, Clinique du Sidobre, Castres, France.;Medical Oncology, CHRU Hopitaux de Tours - Hopital Bretonneau, Tours Cedex, France.;Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;GI Oncology, Medical Oncology Department, Curie Institute, Paris, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Department of Gastroenterology, CHU de Rennes - Hopital Pontchaillou, Rennes Cedex, France.;Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.;MeDatas, CIC (Centre d'Investigation Clinique), CHU Toulouse, Toulouse, France.;Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Cholangiocarcinoma Foundation, Salt Lake City, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","200","10.1016/j.ejca.2024.113587","113587","","","38340384","38340384","PUBMED","Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy; Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Département d'Innovation Thérapeutique et Essais précoces (DITEP), Gustave Roussy, Villejuif Cedex, France.;Oncology Digestive Unit, Hôpital haut-Lévêque, CHU Bordeaux France, France.;Liver Oncology and Therapeutic Innovation Functional Unit, Beaujon Hospital APHP, Clichy, France.;Medical oncology, ICM - Institut du Cancer de Montpellier, Montpellier Cedex, France.;Oncology Department, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Medical Oncology, Centre Léon Bérard, Lyon, GI Oncology Department, France; GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Via Venezian 1, 20133 Milan, Italy.;Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.;Unit of Medical Oncology, University of Perugia, Perugia, Italy.;Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.;Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Italy; Università Cattolica del Sacro Cuore, Roma, Italy.;Department of Oncology, Academic Hospital of Udine ASUFC, Piazzale Santa Maria della Misericordia 15, Udine, UD 33100, Italy.;Université de Poitiers, Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Medical Oncology, CORT37, Pôle Santé Léonard de Vinci, Chambray-lès-Tours, France.;Division of Oncology, Department of Oncology and Hematology, University Hospital Modena, Modena Cancer Centre, Via del Pozzo 71, 41125 Modena, Italy; Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.;Vita-Salute University San Raffaele, Milan, Italy; Department of Oncology, IRCCS San Raffaele Hospital, via Olgettina N. 60, Milan 20132, Italy.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO IRCCS, Via Ripamonti 435, Milan, Italy.;Department of Interdisciplinary Medicine, Oncology Unit, University of Bari ""Aldo Moro"", P.za Giulio Cesare, 11, 70124, Bari, Italy.;UOC Oncologia - Ospedale del Mare, Naples.;Department of Medical Oncology, New Hospital of Prato S. Stefano, 59100 Prato, Italy.;Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.;GI Oncology Department, Hôpital privé Jean Mermoz, Lyon, France.;Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM, U1209, France.;Medical Oncology Department, Centre Antoine-Lacassagne, Nice, France.;Oncology Department, CHU Sud Réunion, Saint Pierre, France.;Medical Oncology Department, Hopital Claude Huriez, Lille, France.;Oncology Department, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Digestive Oncology, Hopital duchenne Boulogne-sur-Mer, France.;Digestive Oncology, Groupe Hospitalier Mutualiste, Grenoble.;Medical Oncology, Clinique du Sidobre, Castres, France.;Medical Oncology, CHRU Hopitaux de Tours - Hopital Bretonneau, Tours Cedex, France.;Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;GI Oncology, Medical Oncology Department, Curie Institute, Paris, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Department of Gastroenterology, CHU de Rennes - Hopital Pontchaillou, Rennes Cedex, France.;Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France.;MeDatas, CIC (Centre d'Investigation Clinique), CHU Toulouse, Toulouse, France.;Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, 20089 Rozzano, Milan, Italy.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Cholangiocarcinoma Foundation, Salt Lake City, Utah, USA; Division of Cancer Sciences, University of Manchester, Manchester, UK.;Clinica Oncologica e Centro Regionale di Genetica Oncologica, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria delle Marche, Via Conca 71, 60126 Ancona, Italy.;Digestive Oncology Department, Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, France."
"96","Terricabras M;Martins RP;Peinado R;Derejko P;Mont L;Ernst S;Herranz D;Bailleul C;Verma A","Terricabras, Maria;Martins, Raphael P;Peinado, Rafael;Derejko, Paweł;Mont, Lluís;Ernst, Sabine;Herranz, David;Bailleul, Christophe;Verma, Atul","Cardiac Pulsed Field Ablation Lesion Durability Assessed by Polarization-Sensitive Optical Coherence Reflectometry.","Circulation. Arrhythmia and electrophysiology","United States","eng","Journal Article","atrial fibrillation;birefringence;myocytes, cardiac;phrenic nerve;pulmonary veins","Swine;Animals;Atrial Fibrillation;Catheter Ablation;Vena Cava, Superior;Thorax;Pulmonary Veins;Fibrosis;Treatment Outcome","Swine;Animals;Atrial Fibrillation;Catheter Ablation;Vena Cava, Superior;Thorax;Pulmonary Veins;Fibrosis;Treatment Outcome","Pulsed field ablation uses electrical fields to cause nonthermal cell death over several hours. Polarization-sensitive optical coherence reflectometry is an optical imaging technique that can detect changes in the tissue ultrastructure in real time, which occurs when muscular tissue is damaged. The objective of this study was to evaluate the ability of a polarization-sensitive optical coherence reflectometry system to predict the development of chronic lesions based on acute changes in tissue birefringence during pulsed field ablation. Superior vena cava isolation was performed in 30 swine using a biphasic, bipolar pulsed field ablation system delivered with a nonirrigated focal tip catheter. Acute changes in tissue birefringence and voltage abatement were analyzed for each individual lesion. A high-resolution electroanatomical map was performed at baseline and 4 to 12 weeks after ablation to locate electrical gaps in the ablated area. A total of 141 lesions were delivered and included in the analysis. Acute electrical isolation based on the electroanatomical map was achieved in 96% of the animals, but chronic isolation was only seen in 14 animals (46%). The mean voltage abatement of lesions that showed recovery was 82.8%±14.6% versus 84.4%±17.4% for those that showed fibrosis ( =0.7). The mean acute reduction in tissue birefringence in points demonstrating fibrosis was 63.8%±11.3% versus 9.1%±0.1% in the points that resulted in electrical gaps. A threshold of acute reduction of birefringence of ≥20% could predict chronic lesion formation with a sensitivity of 96% and a specificity of 83%. Acute tissue birefringence changes assessed with polarization-sensitive optical coherence reflectometry during pulsed field ablation can predict chronic lesion formation and guide the ablation procedure although limited by the tissue thickness.","Sunnybrook Research Institute, University of Toronto, ON, Canada (M.T.).;Centre Hospitalier Universitaire de Rennes, Centres d'Investigation Clinique - Innovation Technologique (CIC-IT), Laboratoire Traitement du Signal et de l'Image Institut National de la Santé et de la Recherche Médicale (LTSI INSERM) 1099, University of Rennes, France (R.P.M.).;University Hospital La Paz, Autonomous University of Madrid, Spain (R.P.).;Medicover Hospital, Warsaw, Poland (P.D.).;Hospital Clínic, Universitat de Barcelona, Spain (L.M.).;Instituto de Investigaciones Biomèdicas August Pi i Sunyer, Barcelona, Spain (L.M.).;Centro de Investigación en Red Cardiovascular, Madrid, Spain (L.M.).;Royal Brompton Hospital, Imperial College London, United Kingdom (S.E.).;MedLumics S.L., Tres Cantos, Spain (D.H., C.B.).;MedLumics S.L., Tres Cantos, Spain (D.H., C.B.).;McGill University Health Centre, McGill University, Montreal, QC, Canada (A.V.).","NA",0,"1941-3084","Circ Arrhythm Electrophysiol","Circ Arrhythm Electrophysiol",2024,"2024","17","10.1161/CIRCEP.123.012255","e012255","","","38318720","38318720","PUBMED","Sunnybrook Research Institute, University of Toronto, ON, Canada (M.T.).;Centre Hospitalier Universitaire de Rennes, Centres d'Investigation Clinique - Innovation Technologique (CIC-IT), Laboratoire Traitement du Signal et de l'Image Institut National de la Santé et de la Recherche Médicale (LTSI INSERM) 1099, University of Rennes, France (R.P.M.).;University Hospital La Paz, Autonomous University of Madrid, Spain (R.P.).;Medicover Hospital, Warsaw, Poland (P.D.).;Hospital Clínic, Universitat de Barcelona, Spain (L.M.).;Instituto de Investigaciones Biomèdicas August Pi i Sunyer, Barcelona, Spain (L.M.).;Centro de Investigación en Red Cardiovascular, Madrid, Spain (L.M.).;Royal Brompton Hospital, Imperial College London, United Kingdom (S.E.).;MedLumics S.L., Tres Cantos, Spain (D.H., C.B.).;MedLumics S.L., Tres Cantos, Spain (D.H., C.B.).;McGill University Health Centre, McGill University, Montreal, QC, Canada (A.V.)."
"97","Perrier L;Balusson F;Morelle M;Castelli J;Thariat J;Benezery K;Hasbini A;Gery B;Berger A;Liem X;Guihard S;Chapet S;Thureau S;Auberdiac P;Pommier P;Ruffier A;Devillers A;Oger E;Campillo-Gimenez B;de Crevoisier R","Perrier, Lionel;Balusson, Frédéric;Morelle, Magali;Castelli, Joël;Thariat, Juliette;Benezery, Karen;Hasbini, Ali;Gery, Bernard;Berger, Antoine;Liem, Xavier;Guihard, Sébastien;Chapet, Sophie;Thureau, Sébastien;Auberdiac, Pierre;Pommier, Pascal;Ruffier, Amandine;Devillers, Anne;Oger, Emmanuel;Campillo-Gimenez, Boris;de Crevoisier, Renaud","Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","Adaptive radiotherapy;Cost-effectiveness;Head and neck cancer;Xerostomia","Humans;Cost-Effectiveness Analysis;Radiotherapy, Intensity-Modulated;Cost-Benefit Analysis;Head and Neck Neoplasms;Xerostomia;Parotid Gland;Radiotherapy Dosage","Humans;Cost-Effectiveness Analysis;Radiotherapy, Intensity-Modulated;Cost-Benefit Analysis;Head and Neck Neoplasms;Xerostomia;Parotid Gland;Radiotherapy Dosage","We performed a cost-effectiveness analysis (CEA) comparing an adaptive radiotherapy (ART) strategy, based on weekly replanning, aiming to correct the parotid gland overdose during treatment and expecting therefore to decrease xerostomia, when compared to a standard IMRT. We conducted the ARTIX trial, a randomized, parallel-group, multicentric study comparing a systematic weekly replanning ART to a standard IMRT. The primary endpoint was the frequency of xerostomia at 12 months, measured by stimulating salivary flow with paraffin. The CEA was designed alongside the ARTIX trial which was linked to the French national health data system (SNDS). For each patient, healthcare consumptions and costs were provided by the SNDS. The reference case analysis was based on the primary endpoint of the trial. Sensitivity and scenario analyses were performed. Of the 129 patients randomly assigned between 2013 and 2018, only 2 records were not linked to the SNDS, which provides a linkage proportion of 98.4%. All of the other 127 records were linked with good to very good robustness. On the intent-to-treat population at 12 months, mean total costs per patient were €41,564 (SD 23,624) and €33,063 (SD 16,886) for ART and standard IMRT arms, respectively (p = 0.033). Incremental cost effectiveness ratio (ICER) was €162,444 per xerostomia avoided. At 24 months, ICER was €194,521 per xerostomia avoided. For both progression-free and overall survival, ART was dominated by standard IMRT. The ART strategy was deemed to be not cost-effective compared with standard IMRT for patients with locally advanced oropharyngeal cancer.","Univ Lyon, Leon Berard Cancer Center, GATE UMR 5824, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon, France; Human and Social Science Department, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon;Pharmacovigilance and Pharmacoepidemiology, CHU Rennes, Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.;Univ Lyon, Leon Berard Cancer Center, GATE UMR 5824, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon, France.;Department of Radiotherapy, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, IN2P3/ENISAEN-CNRS, Normandie Université, Caen, France.;Department of Radiotherapy, Centre Antoine Lacassagne, Avenue de Valombrose F06000, Nice, France.;Radiotherapy, Clinique Pasteur-Lanroze, 32 Rue Auguste Kervern F29200, Brest, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, IN2P3/ENISAEN-CNRS, Normandie Université, Caen, France.;Department of Radiotherapy, CHU Poitiers, 2 Rue de la Milétrie F86000, Poitiers, France.;Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Center, Lille, France.;Department of Radiotherapy, ICANS, 17 rue Albert Calmette F67033, Strasbourg, France.;Department of Radiotherapy, Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré F-72000, Le Mans, France.;Department of Radiotherapy, Centre Henri Becquerel, 1 Rue d'Amiens F76038, Rouen, France; Quantif LITIS EA 4108, University of Rouen, 22, Boulevard Gambetta F-76183, Rouen Cedex 1, France.;Radiotherapy, Clinique Claude Bernard, 1 rue du Père Colombier F81000, Albi, France.;Department of Radiotherapy, ICO-Angers, 15, rue André Boquel 49055, Angers cedex 02, France.;Department of Radiotherapy, Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré F-72000, Le Mans, France.;Department of Nuclear Medicine, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France.;Pharmacovigilance and Pharmacoepidemiology, CHU Rennes, Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.;Department of Clinical Research, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France; Inserm, LTSI-UMR 1099, University of Rennes, F-35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France.","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2023,"2024","193","10.1016/j.radonc.2024.110116","110116","","","38316193","38316193","PUBMED","Univ Lyon, Leon Berard Cancer Center, GATE UMR 5824, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon, France; Human and Social Science Department, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon;Pharmacovigilance and Pharmacoepidemiology, CHU Rennes, Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.;Univ Lyon, Leon Berard Cancer Center, GATE UMR 5824, 28 Prom. Léa et Napoléon Bullukian F-69008, Lyon, France.;Department of Radiotherapy, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, IN2P3/ENISAEN-CNRS, Normandie Université, Caen, France.;Department of Radiotherapy, Centre Antoine Lacassagne, Avenue de Valombrose F06000, Nice, France.;Radiotherapy, Clinique Pasteur-Lanroze, 32 Rue Auguste Kervern F29200, Brest, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, IN2P3/ENISAEN-CNRS, Normandie Université, Caen, France.;Department of Radiotherapy, CHU Poitiers, 2 Rue de la Milétrie F86000, Poitiers, France.;Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Center, Lille, France.;Department of Radiotherapy, ICANS, 17 rue Albert Calmette F67033, Strasbourg, France.;Department of Radiotherapy, Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré F-72000, Le Mans, France.;Department of Radiotherapy, Centre Henri Becquerel, 1 Rue d'Amiens F76038, Rouen, France; Quantif LITIS EA 4108, University of Rouen, 22, Boulevard Gambetta F-76183, Rouen Cedex 1, France.;Radiotherapy, Clinique Claude Bernard, 1 rue du Père Colombier F81000, Albi, France.;Department of Radiotherapy, ICO-Angers, 15, rue André Boquel 49055, Angers cedex 02, France.;Department of Radiotherapy, Centre Jean-Bernard, institut inter-régional de cancérologie (ILC), CCS, 64, rue de Degré F-72000, Le Mans, France.;Department of Nuclear Medicine, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France.;Pharmacovigilance and Pharmacoepidemiology, CHU Rennes, Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000, Rennes, France.;Department of Clinical Research, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France; Inserm, LTSI-UMR 1099, University of Rennes, F-35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, Avenue Bataille Flandres Dunkerques F35000, Rennes, France."
"98","Diéras V;Han HS;Wildiers H;Friedlander M;Ayoub JP;Puhalla SL;Loirat D;Ratajczak C;Adamu H;Girardi V;Arun BK","Diéras, Véronique;Han, Hyo S;Wildiers, Hans;Friedlander, Michael;Ayoub, Jean-Pierre;Puhalla, Shannon L;Loirat, Delphine;Ratajczak, Christine;Adamu, Hephzibah;Girardi, Vincent;Arun, Banu K","Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): Final overall survival results from a randomized phase 3 trial.","European journal of cancer (Oxford, England : 1990)","England","eng","Randomized Controlled Trial","BRCA1;BRCA2;BROCADE3;Breast cancer;HER2-negative;Overall survival;Progression-free survival;Veliparib","Humans;Female;Breast Neoplasms;Carboplatin;Paclitaxel;BRCA1 Protein;BRCA2 Protein;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles","Humans;Female;Breast Neoplasms;Carboplatin;Paclitaxel;BRCA1 Protein;BRCA2 Protein;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles","In the BROCADE3 study, the addition of veliparib to carboplatin plus paclitaxel resulted in a significant improvement in progression-free survival (PFS) compared with placebo plus carboplatin and paclitaxel, in patients with germline BRCA1 or BRCA2 (BRCA1/2)-mutated, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. We now report final overall survival (OS) data. BROCADE3 is a randomized phase 3 study that enrolled patients with BRCA1/2-mutated, HER2-negative advanced breast cancer who received ≤ 2 prior lines of chemotherapy for metastatic disease. Patients were randomized 2:1 to carboplatin and paclitaxel, dosed with either veliparib or matching placebo. OS was a secondary endpoint. In the intention-to-treat population (N = 509), 337 patients were randomized to receive veliparib and 172 to placebo. Median OS was 32.4 months vs 28.2 months (hazard ratio, 0.916; 95% CI, 0.736-1.140; P = .434). The updated safety data for veliparib are consistent with those reported in the primary analysis; the addition of veliparib was generally well tolerated. Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. The long survival times observed in both arms suggest that combination therapy with paclitaxel and carboplatin provides clinical benefit in the population of patients with BRCA1/2-mutated metastatic breast cancer.","Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France; Medical Oncology Department, Centre Eugène Marquis, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000 Rennes;Moffitt Cancer Center, 12920 McKinley Drive, Tampa, FL 33612, USA.;Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, O&N4 box 818, 3000 Leuven, Belgium.;School of Clinical Medicine, UNSW Sydney, Cnr High St & Botany St., Sydney NSW 2052, Australia; Department of Medical Oncology, The Prince of Wales Hospital, Barker Street, Randwick, NSW 2031 Australia.;Centre Hospitalier de l'Université de Montréal, 1000 rue Saint-Denis, Montréal, QC H2X 0C1, Canada.;UPMC Hillman Cancer Center, 9100 Babcock Blvd Ste G600, Pittsburgh, PA 15237, USA.;Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030, USA.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","200","10.1016/j.ejca.2024.113580","113580","","","38309017","38309017","PUBMED","Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France; Medical Oncology Department, Centre Eugène Marquis, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000 Rennes;Moffitt Cancer Center, 12920 McKinley Drive, Tampa, FL 33612, USA.;Department of General Medical Oncology, University Hospitals Leuven, Herestraat 49, O&N4 box 818, 3000 Leuven, Belgium.;School of Clinical Medicine, UNSW Sydney, Cnr High St & Botany St., Sydney NSW 2052, Australia; Department of Medical Oncology, The Prince of Wales Hospital, Barker Street, Randwick, NSW 2031 Australia.;Centre Hospitalier de l'Université de Montréal, 1000 rue Saint-Denis, Montréal, QC H2X 0C1, Canada.;UPMC Hillman Cancer Center, 9100 Babcock Blvd Ste G600, Pittsburgh, PA 15237, USA.;Medical Oncology Department, Institut Curie, 26 rue d'Ulm, 75005, Paris, France.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;AbbVie, 1 N Waukegan Rd, North Chicago, IL 60044, USA.;The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Houston, TX 77030, USA."
"99","Corné J;Quillien V;Godey F;Cherel M;Cochet A;Le Du F;Robert L;Bourien H;Brunot A;Crouzet L;Perrin C;Lefeuvre-Plesse C;Diéras V;De la Motte Rouge T","Corné, Julien;Quillien, Véronique;Godey, Florence;Cherel, Mathilde;Cochet, Agathe;Le Du, Fanny;Robert, Lucie;Bourien, Héloïse;Brunot, Angélique;Crouzet, Laurence;Perrin, Christophe;Lefeuvre-Plesse, Claudia;Diéras, Véronique;De la Motte Rouge, Thibault","Plasma-based analysis of ERBB2 mutational status by multiplex digital PCR in a large series of patients with metastatic breast cancer.","Molecular oncology","United States","eng","Journal Article","ERBB2;circulating tumor DNA;liquid biopsies;metastatic breast cancer;multiplex digital PCR;plasma","Humans;Receptor, ErbB-2;Female;Breast Neoplasms;Mutation;Middle Aged;Neoplasm Metastasis;Multiplex Polymerase Chain Reaction;Aged;Adult;DNA Mutational Analysis;Circulating Tumor DNA;Aged, 80 and over","Humans;Receptor, ErbB-2;Female;Breast Neoplasms;Mutation;Middle Aged;Neoplasm Metastasis;Multiplex Polymerase Chain Reaction;Aged;Adult;DNA Mutational Analysis;Circulating Tumor DNA;Aged, 80 and over","Erb-b2 receptor tyrosine kinase 2 (ERBB2)-activating mutations are therapeutically actionable alterations found in various cancers, including metastatic breast cancer (MBC). We developed multiplex digital PCR assays to detect and quantify ERBB2 mutations in circulating tumor DNA from liquid biopsies. We studied the plasma from 272 patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) MBC to detect 17 ERBB2 mutations using a screening assay. The assay was developed on the three-color Crystal dPCR™ naica® platform with a two-step strategy for precise mutation identification. We found that nine patients (3.3%) harbored at least one ERBB2 mutation. The mutation rate was higher in patients with lobular histology (5.9%) compared to invasive breast carcinoma of no special type (2.6%). A total of 12 mutations were found with the following frequencies: L755S (25.00%), V777L (25.00%), S310Y (16.67%), L869R (16.67%), S310F (8.33%), and D769H (8.33%). Matched tumor samples from six patients identified the same mutations with an 83% concordance rate. In summary, our highly sensitive multiplex digital PCR assays are well suited for plasma-based monitoring of ERBB2 mutational status in patients with MBC.","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.","NA",0,"1878-0261","Mol Oncol","Mol Oncol",2023,"2024","18","10.1002/1878-0261.13592","2714-2729","","Seagen","38287892","38287892","PUBMED","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France."
"100","Demoor-Goldschmidt C;Veillon P;Esvan M;Leonard M;Chauvet S;Bertrand A;Carausu L;Delehaye F;Lejeune J;Rouger J;Schneider P;Thomas C;Millot F;Claude L;Leseur J;Missohou F;Supiot S;Bihannic N;Debroise I;Jeanneaud C;Lebreton E;Roumy M;Aguerris L;Chrétien JM;Gandemer V;Pellier I","Demoor-Goldschmidt, Charlotte;Veillon, Pascal;Esvan, Maxime;Leonard, Mathilde;Chauvet, Sophie;Bertrand, Amandine;Carausu, Liana;Delehaye, Fanny;Lejeune, Julien;Rouger, Jérémie;Schneider, Pascale;Thomas, Caroline;Millot, Frédéric;Claude, Line;Leseur, Julie;Missohou, Fernand;Supiot, Stéphane;Bihannic, Nathalie;Debroise, Isabelle;Jeanneaud, Carole;Lebreton, Esther;Roumy, Marianne;Aguerris, Les;Chrétien, Jean-Marie;Gandemer, Virginie;Pellier, Isabelle","A software tool to support follow-up care in a French childhood cancer cohort: construction and feasibility.","BMC cancer","England","eng","Journal Article","Adolescent cancer;Chemotherapy;Childhood cancer;Database;Medical tool;Personalized survivorship care plan;Radiotherapy;Survivorship","Child;Humans;Adolescent;Aftercare;Feasibility Studies;Quality of Life;Retrospective Studies;Neoplasms;Software","Child;Humans;Adolescent;Aftercare;Feasibility Studies;Quality of Life;Retrospective Studies;Neoplasms;Software","Treatment summaries and a personalized survivorship care plans based on internationally approved, organ-specific follow-up care recommendations are essential in preserving the health and quality of life for cancer survivors. Cohorts made up of survivors of childhood cancer have made significant contributions to the understanding of early mortality, somatic late complications, and psychosocial outcomes among former patients. New treatment protocols are needed to enhance survival and reduce the potential risk and severity of late effects, and working with treatment databases is crucial in doing so. In the GOCE (Grand Ouest Cancer de l'Enfant [Western Region Childhood Cancer]) network, in a participative approach, we developed the LOG-after medical tool, on which health data are registered and can be extracted for analysis. Its name emphasizes the tool's goal, referring to 'logiciel' (the French word for software) that focuses on the period ""after"" the acute phase. This tool is hosted on a certified health data server. Several interfaces have been developed that can be used depending on the user's profile. Here we present this innovative co-constructed tool that takes national aspects into account, including the results of the feasibility/satisfaction study and its perspective. The database contains data relating to 2558 patients, with samples from 1702 of these (66.54%) being held in a tumor bank. The average year in which treatment started was 2015 (ranging from December 1967 to November 2022: 118 patients were treated before 2012 and registered retrospectively when seen in long-term follow-up consultations or for another cancer since November 2021). A short questionnaire was distributed to healthcare professionals using the tool (physicians and research associates or technicians, n = 14), of whom 11 answered and were all satisfied. Access to the patient interface is currently open to 124 former patients. This was initially offered to 30 former patients who were over 15 years old, affected by the disease within the last 5 years, and had agreed to test it. Their opinions were collected by their doctor by e-mail, telephone, or during a consultation in an open-ended question and a non-directive interview. All patients were satisfied with the tool, with interest in testing it in the long term. Some former patients found that the tool provided them with some ease of mind; one, for instance, commented: ""I feel lighter. I allow myself to forget. I know I will get a notification when the time comes."" Freely available to all users, LOG-after: (1) provides help with determining personalized survivorship care plans for follow-up; (2) builds links with general practitioners; (3) empowers the patient; and (4) enables health data to be exported for analysis. Database URL for presentation: https://youtu.be/2Ga64iausJE.","Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen;Department of Supportive Care, Centre François Baclesse, University of Caen, Caen;Inserm U 1018, Epidemiology of Radiation, Gustave Roussy, Villejuif;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, IHope, Lyon, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Rouen, Rouen, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Poitiers, Poitiers, France.;Department of Radiotherapy, Centre Leon Berard, Lyon, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen, France.;Department of Radiotherapy, Institut de Cancérologie de L'Ouest, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Association Les Aguerris, Paris, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Association Les Aguerris, Paris, France.;Data Science Department, Clinical and Innovation Direction, CHU Angers, Angers, France.;Department of Oncohematopediatrics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2023,"2024","24","10.1186/s12885-024-11857-y","130","","","38267891","38267891","PUBMED","Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen;Department of Supportive Care, Centre François Baclesse, University of Caen, Caen;Inserm U 1018, Epidemiology of Radiation, Gustave Roussy, Villejuif;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Biostatitics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, IHope, Lyon, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Rouen, Rouen, France.;Department of Oncohematopediatrics, University Hospital of Nantes, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Poitiers, Poitiers, France.;Department of Radiotherapy, Centre Leon Berard, Lyon, France.;Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Centre François Baclesse, University of Caen, Caen, France.;Department of Radiotherapy, Institut de Cancérologie de L'Ouest, Nantes, France.;Department of Oncohematopediatrics, University Hospital of Brest, Brest, France.;Association Les Aguerris, Paris, France.;Department of Oncohematopediatrics, University Hospital of Tours, Tours, France.;Department of Oncohematopediatrics, University Hospital of Caen, Caen, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France.;Association Les Aguerris, Paris, France.;Data Science Department, Clinical and Innovation Direction, CHU Angers, Angers, France.;Department of Oncohematopediatrics, University Hospital of Rennes, Rennes, France.;Department of Oncohematopediatrics, University Hospital of Angers, University of Angers, Angers, France."
"101","Arkhis S;Rouges C;Dahane N;Guegan H;Yéra H;Robert-Gangneux F","Arkhis, Safya;Rouges, Celia;Dahane, Naïma;Guegan, Hélène;Yéra, Hélène;Robert-Gangneux, Florence","Could PLATELIA Toxo IgM be the new gold standard for the serological diagnosis of congenital toxoplasmosis: a French multicenter study.","Journal of clinical microbiology","United States","eng","Multicenter Study","IgM;Toxoplasma gondii;congenital toxoplasmosis;neonatal diagnosis;serology","Infant;Pregnancy;Female;Humans;Infant, Newborn;Toxoplasmosis, Congenital;Toxoplasmosis;Antibodies, Protozoan;Toxoplasma;Immunoglobulin M","Infant;Pregnancy;Female;Humans;Infant, Newborn;Toxoplasmosis, Congenital;Toxoplasmosis;Antibodies, Protozoan;Toxoplasma;Immunoglobulin M","To assess the performance of PLATELIA Toxo IgM (Bio-Rad) and Toxo ISAGA (BioMérieux) to detect anti-  IgM in infants at risk of congenital toxoplasmosis, a retrospective multicenter study was conducted comparing serological results obtained in the framework of routine diagnosis work-up for congenital toxoplasmosis. All infants born to mothers infected with   during pregnancy from 2010 to 2020 with at least 6 months of serological follow-up were included (  = 1,010). One thousand ten cases were included, of which 250 infants (24.75%) had congenital toxoplasmosis. A total of 1039 sera were included. The concordance between the two techniques was 96%, with kappa coefficient of 0.87, showing an almost perfect agreement between ISAGA and PLATELIA. Cumulative sensitivity and specificity were 73.2% and 99.5.% and 74.8% and 100% for ISAGA and PLATELIA, respectively. The mean time to detect IgM using ISAGA and PLATELIA tests was 6.9 ± 20.1 days and 5.6 ± 14.7 days, respectively not significant (ns). Finally, the sensitivity of ISAGA and PLATELIA to detect IgM antibodies in infected neonates at 5 days of life was 62% and 64%, respectively. Performances of PLATELIA Toxo IgM assay were comparable to the gold standard ISAGA. This enzyme-linked immunosorbent assay is suitable for routine serology for the diagnosis of congenital toxoplasmosis in newborns. IMPORTANCE This study will help clinical microbiologists to chose an alternative serological method for the neonatal diagnosis of congenital toxoplasmosis, once the gold standard technique ISAGA will be withdrawn next year.","Laboratory of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) , Rennes, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Department of Parasitology and Mycology, Dupuytren University Hospital , Limoges, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) , Rennes, France.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2024,"2024","62","10.1128/jcm.01222-23","e0122223","","","38259072","38259072","PUBMED","Laboratory of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) , Rennes, France.;Department of Parasitology and Mycology, Cochin University Hospital, AP-HP , Paris, France.;Department of Parasitology and Mycology, Dupuytren University Hospital , Limoges, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé Environnement Travail) , Rennes, France."
"102","Slamon DJ;Diéras V;Rugo HS;Harbeck N;Im SA;Gelmon KA;Lipatov ON;Walshe JM;Martin M;Chavez-MacGregor M;Bananis E;Gauthier E;Lu DR;Kim S;Finn RS","Slamon, Dennis J;Diéras, Véronique;Rugo, Hope S;Harbeck, Nadia;Im, Seock-Ah;Gelmon, Karen A;Lipatov, Oleg N;Walshe, Janice M;Martin, Miguel;Chavez-MacGregor, Mariana;Bananis, Eustratios;Gauthier, Eric;Lu, Dongrui R;Kim, Sindy;Finn, Richard S","Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Randomized Controlled Trial","","Humans;Female;Letrozole;Breast Neoplasms;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols;Piperazines;Pyridines","Humans;Female;Letrozole;Breast Neoplasms;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols;Piperazines;Pyridines"," JCO  PALOMA-2 demonstrated statistically and clinically significant improvement in progression-free survival with palbociclib plus letrozole versus placebo plus letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (ABC). Here, we report results for the secondary end point overall survival (OS). Postmenopausal women (N = 666) with ER+/HER2- ABC without previous systemic therapy for ABC were randomly assigned 2:1 to palbociclib plus letrozole or placebo plus letrozole. After a median follow-up of 90.1 months, 405 deaths were observed and 155 patients were known to be alive. The median OS was 53.9 months (95% CI, 49.8 to 60.8) with palbociclib plus letrozole versus 51.2 months (95% CI, 43.7 to 58.9) with placebo plus letrozole (hazard ratio [HR], 0.96 [95% CI, 0.78 to 1.18]; stratified one-sided   = .34). An imbalance in the number of patients with unknown survival outcome between the treatment arms (13.3%   21.2%, respectively) limited interpretation of OS results. With recovered survival data, the median OS was 53.8 (95% CI, 49.8 to 59.2) versus 49.8 months (95% CI, 42.3 to 56.4), respectively (HR, 0.92 [95% CI, 0.76 to 1.12]; one-sided   = .21). OS was not significantly improved with palbociclib plus letrozole compared with placebo plus letrozole.","David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA.;Centre Eugène Marquis, Rennes Cedex, France.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.;Brustzentrum, Frauenklinik and CCC Munich, LMU University Hospital, Munich, Germany.;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.;BC Cancer, Vancouver, BC, Canada.;SAHI Republican Clinical Oncology Dispensary under the MoH of Russia, Ufa, Russia.;Cancer Trials Ireland, St Vincent's University Hospital, Dublin, Ireland.;Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, GEICAM, Madrid, Spain.;The University of Texas MD Anderson Cancer Center, Houston, TX.;Pfizer Inc, New York, NY.;Pfizer Inc, San Francisco, CA.;Pfizer Inc, San Diego, CA.;Pfizer Inc, San Diego, CA.;David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2024,"2024","42","10.1200/JCO.23.00137","994-1000","","","38252901","38252901","PUBMED","David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA.;Centre Eugène Marquis, Rennes Cedex, France.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.;Brustzentrum, Frauenklinik and CCC Munich, LMU University Hospital, Munich, Germany.;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.;BC Cancer, Vancouver, BC, Canada.;SAHI Republican Clinical Oncology Dispensary under the MoH of Russia, Ufa, Russia.;Cancer Trials Ireland, St Vincent's University Hospital, Dublin, Ireland.;Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, GEICAM, Madrid, Spain.;The University of Texas MD Anderson Cancer Center, Houston, TX.;Pfizer Inc, New York, NY.;Pfizer Inc, San Francisco, CA.;Pfizer Inc, San Diego, CA.;Pfizer Inc, San Diego, CA.;David Geffen School of Medicine at University of California Los Angeles, Santa Monica, CA."
"103","Boissière C;Bacle A;Pelletier R;Le Bouedec D;Gicquel T;Lurton Y;Le Daré B","Boissière, Camille;Bacle, Astrid;Pelletier, Romain;Le Bouedec, Diane;Gicquel, Thomas;Lurton, Yves;Le Daré, Brendan","In vitro assessment of isopropanol leakage from antiseptic barrier caps into commonly used needleless connectors.","Infection control and hospital epidemiology","United States","eng","Journal Article","","Infant, Newborn;Humans;Child;2-Propanol;Catheters, Indwelling;Equipment Contamination;Anti-Infective Agents, Local","Infant, Newborn;Humans;Child;2-Propanol;Catheters, Indwelling;Equipment Contamination;Anti-Infective Agents, Local","Needleless connectors (NCs) can be disinfected using antiseptic barrier caps (ABCs) to reduce the risk of catheter-related bloodstream infections. However, recent evidence suggests that isopropanol can leak from the ABC into the NC, posing concern about their safe use. We sought to determine in vitro which ABC and NC parameters influence the leakage of isopropanol through the infusion circuit. We assessed 13 NCs and 4 ABCs available in the European market. In vitro circuits consisting of an isopropanol cap, a NC, and an 11-cm catheter line were created. The circuits were left in place for 1 to 7 days at room temperature to assess the kinetics of isopropanol leakage. Isopropanol content in ABC and in circuit flushing solutions (5 mL NaCl 0.9%) after exposure to the cap were measured using gas chromatography with a flame ionization detector. The leakage of isopropanol from the cap to the NC was dependent on the NC, but not the cap. The NC mechanism did not predict the leakage of isopropanol. The Q-Syte NC exhibited the most isopropanol leakage (7.01±1.03 mg and 28.32±2.62 mg at 24 hours and 7 days, respectively), whereas the Caresite NC had the lowest isopropanol leakage at 7 days (1.69±0.01 mg). The use of isopropanol ABCs can cause isopropanol leakage into the catheter circuit according to NC parameters. Caution should be exercised when using these devices, especially in the pediatric and neonatal population.","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail), Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.","NA",0,"1559-6834","Infect Control Hosp Epidemiol","Infect Control Hosp Epidemiol",2024,"2024","45","10.1017/ice.2023.285","576-582","","","38213184","38213184","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé, environnement et travail), Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;Laboratoire de Toxicologie biologique et médico-légale, CHU Pontchaillou, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, Rennes, France.;University of Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes, France."
"104","Vaugier L;Martin-Mervoyer E;Ah-Thiane L;Langé M;Ollivier L;Perennec T;Supiot S;Duvergé L;Lucia F;Trémolières P;Movassaghi R;Fresse-Warin K;Moignier A;Thillays F","Vaugier, Loig;Martin-Mervoyer, Elvire;Ah-Thiane, Loic;Langé, Martin;Ollivier, Luc;Perennec, Tanguy;Supiot, Stéphane;Duvergé, Loig;Lucia, François;Trémolières, Pierre;Movassaghi, Roshanack;Fresse-Warin, Karine;Moignier, Alexandra;Thillays, Francois","How to contour the different heart subregions for future deep-learning modeling of the heart: A practical pictorial proposal for radiation oncologists.","Clinical and translational radiation oncology","Ireland","eng","Journal Article","Automatic modeling;Delineation;Heart subregions;Radio-induced cardiotoxicity;Radiotherapy","","","There are currently no accurate rules for manually delineating the subregions of the heart (cavities, vessels, aortic/mitral valves, Planning organ at Risk Volumes for coronary arteries) with the perspective of deep-learning based modeling. Our objective was to present a practical pictorial view for radiation oncologists, based on the RTOG atlas and anatomical complementary considerations for the cases where the RTOG guidelines are missing.","Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Cardiology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Laboratoire US2B, Unité en Sciences Biologiques et Biotechnologies, UMR CNRS 6286, UFR Sciences et Techniques, 2, rue de la Houssinière, 44322 Nantes, France.;Department of Radiation Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Radiation Oncology, Centre Hospitalo-Universitaire (CHU), 29200 Brest, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 49000 Angers, France.;Department of Radiology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiology - Non-invasive Cardiovascular Imaging, Centre Hospitalo-Universitaire (CHU), 44000 Nantes, France.;Department of Medical Physics, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.","NA",0,"2405-6308","Clin Transl Radiat Oncol","Clin Transl Radiat Oncol",2023,"2024","45","10.1016/j.ctro.2023.100718","100718","","","38204729","38204729","PUBMED","Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Cardiology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Laboratoire US2B, Unité en Sciences Biologiques et Biotechnologies, UMR CNRS 6286, UFR Sciences et Techniques, 2, rue de la Houssinière, 44322 Nantes, France.;Department of Radiation Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Radiation Oncology, Centre Hospitalo-Universitaire (CHU), 29200 Brest, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 49000 Angers, France.;Department of Radiology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiology - Non-invasive Cardiovascular Imaging, Centre Hospitalo-Universitaire (CHU), 44000 Nantes, France.;Department of Medical Physics, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France."
"105","Grimaldi J;Masgnaux LJ;Lupu A;Wallenhorst T;Rivory J;Jacques J;Pioche M","Grimaldi, Jean;Masgnaux, Louis-Jean;Lupu, Alexandru;Wallenhorst, Timothée;Rivory, Jérôme;Jacques, Jérémie;Pioche, Mathieu","Endoscopic submucosal dissection of Barrett's neoplasia using adaptive multipolar traction combined with line: report of two cases.","Endoscopy","Germany","eng","Case Reports","","Humans;Endoscopic Mucosal Resection;Traction","Humans;Endoscopic Mucosal Resection;Traction","NA","Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Endoscopy and Gastroenterology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Hepatogastroenterology, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.","NA",0,"1438-8812","Endoscopy","Endoscopy",2024,"2024","56","10.1055/a-2217-3544","E15-E16","","","38194982","38194982","PUBMED","Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Endoscopy and Gastroenterology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France.;Hepatogastroenterology, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Gastroenterology and Endoscopy Unit, Hopital Edouard Herriot, Lyon, France."
"106","Lacan C;Lambert J;Forcade E;Robin M;Chevallier P;Loron S;Bulabois CÉ;Orvain C;Ceballos P;Daguindau E;Charbonnier A;Chalandon Y;Bernard M;Simand C;Rubio MT;Turlure P;Maertens J;Huynh A;Loschi M;Bay JO;Guillerm G;Alani M;Castilla-Llorente C;Poiré X;Chantepie S;Maillard N;Beguin Y;Marçais A;Cornillon J;Malfuson JV;Maury S;Meuleman N;Villate A;Bekadja MA;Walter-Petrich A;Jacque N;Srour M;Devillier R;Nguyen S","Lacan, Claire;Lambert, Jérôme;Forcade, Edouard;Robin, Marie;Chevallier, Patrice;Loron, Sandrine;Bulabois, Claude-Éric;Orvain, Corentin;Ceballos, Patrice;Daguindau, Etienne;Charbonnier, Amandine;Chalandon, Yves;Bernard, Marc;Simand, Célestine;Rubio, Marie-Thérèse;Turlure, Pascal;Maertens, Johan;Huynh, Anne;Loschi, Michael;Bay, Jacques-Olivier;Guillerm, Gaëlle;Alani, Mustafa;Castilla-Llorente, Cristina;Poiré, Xavier;Chantepie, Sylvain;Maillard, Natacha;Beguin, Yves;Marçais, Ambroise;Cornillon, Jérôme;Malfuson, Jean-Valère;Maury, Sébastien;Meuleman, Nathalie;Villate, Alban;Bekadja, Mohammed-Amine;Walter-Petrich, Anouk;Jacque, Nathalie;Srour, Micha;Devillier, Raynier;Nguyen, Stéphanie","Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.","Journal of hematology & oncology","England","eng","Letter","Anti-thymoglobulin;Bone marrow;Graft source;Haploidentical hematopoietic stem cell transplantation;Peripheral stem cell","Adult;Humans;Bone Marrow;Retrospective Studies;Hematopoietic Stem Cell Transplantation;Cyclophosphamide;Graft vs Host Disease;Recurrence;Hematopoietic Stem Cells","Adult;Humans;Bone Marrow;Retrospective Studies;Hematopoietic Stem Cell Transplantation;Cyclophosphamide;Graft vs Host Disease;Recurrence;Hematopoietic Stem Cells","The use of peripheral blood (PB) or bone marrow (BM) stem cells graft in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis remains controversial. Moreover, the value of adding anti-thymoglobulin (ATG) to PTCy is unknown. A total of 1344 adult patients received an unmanipulated haploidentical transplant at 37 centers from 2012 to 2019 for hematologic malignancy. We compared the outcomes of patients according to the type of graft, using a propensity score analysis. In total population, grade II-IV and III-IV acute GVHD (aGVHD) were lower with BM than with PB. Grade III-IV aGVHD was lower with BM than with PB + ATG. All outcomes were similar in PB and PB + ATG groups. Then, in total population, adding ATG does not benefit the procedure. In acute leukemia, myelodysplastic syndrome and myeloproliferative syndrome (AL-MDS-MPS) subgroup receiving non-myeloablative conditioning, risk of relapse was twice greater with BM than with PB (51 vs. 22%, respectively). Conversely, risk of aGVHD was greater with PB (38% for aGVHD II-IV; 16% for aGVHD III-IV) than with BM (28% for aGVHD II-IV; 8% for aGVHD III-IV). In this subgroup with intensified conditioning regimen, risk of relapse became similar with PB and BM but risk of aGVHD III-IV remained higher with PB than with BM graft (HR = 2.0; range [1.17-3.43], p = 0.012).","Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France.;Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France.;Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Clinical Hematology Unit, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Clinical Hematology Unit, Hôpital Lyon Sud, HCL, Lyon, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire d'Angers, Angers, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Clinical Hematology Unit, Hôpitaux Universitaires de Genève, Geneva, Switzerland.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Clinical Hematology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Department of Hematology, UZ Leuven, Leuven, Belgium.;Clinical Hematology Unit, Oncopôle, Toulouse, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nice, Nice, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Brest, Brest, France.;Clinical Hematology Unit, Centre Henri Becquerel, Rouen, France.;Clinical Hematology Unit, Institut Gustave Roussy, Villejuif, France.;Clinical Hematology Unit, Clinique Universitaire Saint Luc, Leuven, Belgium.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Caen, Caen, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Liège and University of Liège, Liège, Belgium.;Clinical Hematology Unit, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.;Clinical Hematology Unit, Hôpitaux d'Instruction des Armées Percy, Clamart, France.;Clinical Hematology Unit, Hôpital Henri Mondor, APHP, Créteil, France.;Clinical Hematology Unit, Institut Jules Bordet, Brussels, Belgium.;Clinical Hematology Unit, Hôpital Bretonneau, Tours, France.;Clinical Hematology Unit, Clinic of Hematology and Cell Therapy, EHU 1St November, Oran, Algeria.;Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France.;Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Lille, Lille, France.;Clinical Hematology Unit, Institut Paoli Calmette, Marseille, France.;Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris","NA",0,"1756-8722","J Hematol Oncol","J Hematol Oncol",2023,"2024","17","10.1186/s13045-023-01515-4","2","","","38185663","38185663","PUBMED","Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France.;Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France.;Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Clinical Hematology Unit, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Clinical Hematology Unit, Hôpital Lyon Sud, HCL, Lyon, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire d'Angers, Angers, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Clinical Hematology Unit, Hôpitaux Universitaires de Genève, Geneva, Switzerland.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Clinical Hematology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nancy, Nancy, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire Dupuytren, Limoges, France.;Department of Hematology, UZ Leuven, Leuven, Belgium.;Clinical Hematology Unit, Oncopôle, Toulouse, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Nice, Nice, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Brest, Brest, France.;Clinical Hematology Unit, Centre Henri Becquerel, Rouen, France.;Clinical Hematology Unit, Institut Gustave Roussy, Villejuif, France.;Clinical Hematology Unit, Clinique Universitaire Saint Luc, Leuven, Belgium.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Caen, Caen, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Liège and University of Liège, Liège, Belgium.;Clinical Hematology Unit, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.;Clinical Hematology Unit, Hôpitaux d'Instruction des Armées Percy, Clamart, France.;Clinical Hematology Unit, Hôpital Henri Mondor, APHP, Créteil, France.;Clinical Hematology Unit, Institut Jules Bordet, Brussels, Belgium.;Clinical Hematology Unit, Hôpital Bretonneau, Tours, France.;Clinical Hematology Unit, Clinic of Hematology and Cell Therapy, EHU 1St November, Oran, Algeria.;Institut national de la santé et de la recherche médicale (INSERM), U1153 CRESS, Paris, France.;Service de Biostatistique et Information Médicale, Hôpital Saint Louis, APHP, Paris, France.;Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris, France.;Clinical Hematology Unit, Centre Hospitalier Universitaire de Lille, Lille, France.;Clinical Hematology Unit, Institut Paoli Calmette, Marseille, France.;Clinical Hematology Unit, Groupe Hospitalier Pitié-Salpêtrière, APHP, 47-83 Bd de l'Hôpital, 75013, Paris"
"107","Gauchery J;Rieul G;Painvin B;Canet E;Renault A;Jonas M;Kergoat P;Grillet G;Frerou A;Egreteau PY;Seguin P;Fedun Y;Delbove A","Gauchery, J;Rieul, G;Painvin, B;Canet, E;Renault, A;Jonas, M;Kergoat, P;Grillet, G;Frerou, A;Egreteau, P-Y;Seguin, P;Fedun, Y;Delbove, A","Psychological impact of medical evacuation for ICU saturation in Covid-19-related ARDS patients.","Journal of psychiatric research","England","eng","Journal Article","ARDS;Covid-19;Medical evacuation;Post traumatic stress disorder","Humans;Male;Middle Aged;Aged;Female;Retrospective Studies;COVID-19;Depression;Stress Disorders, Post-Traumatic;Anxiety;Intensive Care Units;Respiratory Distress Syndrome;Sorbitol","Humans;Male;Middle Aged;Aged;Female;Retrospective Studies;COVID-19;Depression;Stress Disorders, Post-Traumatic;Anxiety;Intensive Care Units;Respiratory Distress Syndrome;Sorbitol","Psychological impact of Medical Evacuation (MEDEVAC) in Covid-19 patients is undetermined. The objectives were to evaluate: Post-traumatic Stress Disorder (PTSD) in MEDEVAC patients hospitalized in ICU for Covid-19-related acute respiratory distress syndrome (ARDS) compared to control group; anxiety, depression rates and outcomes in patients and PTSD in relatives. This is a retrospective multicentric 1/1 paired cohort performed in 10 ICUs in the West of France. Evaluation was performed 18 months after discharge. Patients and closest relatives performed IES-R (Impact and Event Scale-Revised) and/or HADS (Hospital Anxiety and Depression Scale) scales. Twenty-six patients were included in each group. Patients were 64 ± 11 years old, with 83% male. We report 12 vs 20% of PTSD in control vs MEDEVAC groups (p = 0.7). Anxiety disorder affected 43.5 vs 28.0% (p = 0.26) and depression 12.5 vs 14.3% (p > 0.99) in control vs MEDEVAC groups. PTSD affects 33.3 vs 42.1% of closest relatives (p = 0.55). Ways of communication were adapted: video calls were more frequent in MEDEVAC patients (8.7 vs 60.9%, p < 0.01) whereas physical visits concerned more control group (45.8 vs 13.0%, p = 0.01). PTSD rate were similar between groups. Adaptive ways of communication, restricted visits and global uncertainties could explain the absence of differences.","Service d'Anesthésie-Réanimation, CHU Rennes, Rennes, France.;Réanimation polyvalente, CHBA Vannes, Vannes, France.;Service de Réanimation Médicale et des Maladies infectieuses, Centre hospitalier Universitaire de Rennes, Rennes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Médecine Intensive Réanimation, Centre hospitalier de St Nazaire, St Nazaire, France.;Réanimation polyvalente, Centre hospitalier de Cornouaille, Quimper, France.;Réanimation polyvalente, Centre hospitalier Bretagne Sud, Lorient, France.;Réanimation polyvalente, Centre hospitalier St Malo, St Malo, France.;Réanimation polyvalente, Centre hospitalier des Pays de Morlaix, Morlaix, France.;Réanimation chirurgicale, CHU Rennes, Rennes, France.;Réanimation polyvalente, CHBA Vannes, Vannes, France.;Réanimation polyvalente, CHBA Vannes, Vannes","NA",0,"1879-1379","J Psychiatr Res","J Psychiatr Res",2022,"2024","170","10.1016/j.jpsychires.2023.12.015","283-289","","","38185073","38185073","PUBMED","Service d'Anesthésie-Réanimation, CHU Rennes, Rennes, France.;Réanimation polyvalente, CHBA Vannes, Vannes, France.;Service de Réanimation Médicale et des Maladies infectieuses, Centre hospitalier Universitaire de Rennes, Rennes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Médecine Intensive Réanimation, Centre hospitalier de St Nazaire, St Nazaire, France.;Réanimation polyvalente, Centre hospitalier de Cornouaille, Quimper, France.;Réanimation polyvalente, Centre hospitalier Bretagne Sud, Lorient, France.;Réanimation polyvalente, Centre hospitalier St Malo, St Malo, France.;Réanimation polyvalente, Centre hospitalier des Pays de Morlaix, Morlaix, France.;Réanimation chirurgicale, CHU Rennes, Rennes, France.;Réanimation polyvalente, CHBA Vannes, Vannes, France.;Réanimation polyvalente, CHBA Vannes, Vannes"
"108","Oluwole OO;Forcade E;Muñoz J;de Guibert S;Vose JM;Bartlett NL;Lin Y;Deol A;McSweeney P;Goy AH;Kersten MJ;Jacobson CA;Farooq U;Minnema MC;Thieblemont C;Timmerman JM;Stiff P;Avivi I;Tzachanis D;Zheng Y;Vardhanabhuti S;Nater J;Shen RR;Miao H;Kim JJ;van Meerten T","Oluwole, Olalekan O;Forcade, Edouard;Muñoz, Javier;de Guibert, Sophie;Vose, Julie M;Bartlett, Nancy L;Lin, Yi;Deol, Abhinav;McSweeney, Peter;Goy, Andre H;Kersten, Marie José;Jacobson, Caron A;Farooq, Umar;Minnema, Monique C;Thieblemont, Catherine;Timmerman, John M;Stiff, Patrick;Avivi, Irit;Tzachanis, Dimitrios;Zheng, Yan;Vardhanabhuti, Saran;Nater, Jenny;Shen, Rhine R;Miao, Harry;Kim, Jenny J;van Meerten, Tom","Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.","Bone marrow transplantation","England","eng","Journal Article","","Humans;Lymphoma, Large B-Cell, Diffuse;Adrenal Cortex Hormones;Biological Products;Cytokine Release Syndrome;Leukoencephalopathies;Immunotherapy, Adoptive;Antigens, CD19","Humans;Lymphoma, Large B-Cell, Diffuse;Adrenal Cortex Hormones;Biological Products;Cytokine Release Syndrome;Leukoencephalopathies;Immunotherapy, Adoptive;Antigens, CD19","ZUMA-1 safety management cohort 6 investigated the impact of prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab on the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs) following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Prior analyses of cohort 6 with limited follow-up demonstrated no Grade ≥3 CRS, a low rate of NEs, and high response rates, without negatively impacting axi-cel pharmacokinetics. Herein, long-term outcomes of cohort 6 (N = 40) are reported (median follow-up, 26.9 months). Since the 1-year analysis (Oluwole, et al. Blood. 2022;138[suppl 1]:2832), no new CRS was reported. Two new NEs occurred in two patients (Grade 2 dementia unrelated to axi-cel; Grade 5 axi-cel-related leukoencephalopathy). Six new infections and eight deaths (five progressive disease; one leukoencephalopathy; two COVID-19) occurred. Objective and complete response rates remained at 95% and 80%, respectively. Median duration of response and progression-free survival were reached at 25.9 and 26.8 months, respectively. Median overall survival has not yet been reached. Eighteen patients (45%) remained in ongoing response at data cutoff. With ≥2 years of follow-up, prophylactic corticosteroids and earlier corticosteroids and/or tocilizumab continued to demonstrate CRS improvement without compromising efficacy outcomes, which remained high and durable.","Vanderbilt University Medical Cancer Center, Nashville, TN;Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France.;Banner MD Anderson Cancer Center, Gilbert, AZ, USA.;Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Nebraska Medical Center, Omaha, NE, USA.;Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA.;Mayo Clinic, Rochester, MN, USA.;Karmanos Cancer Center, Wayne State University, Detroit, MI, USA.;Colorado Blood Cancer Institute, Denver, CO, USA.;John Theurer Cancer Center, Hackensack, NJ, USA.;Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands.;Dana-Farber Cancer Institute, Boston, MA, USA.;University of Iowa, Iowa City, IA, USA.;University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands.;Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France.;University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.;Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.;Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;University of California San Diego, La Jolla, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands.","NA",0,"1476-5365","Bone Marrow Transplant","Bone Marrow Transplant",2023,"2024","59","10.1038/s41409-023-02169-z","366-372","","","38177222","38177222","PUBMED","Vanderbilt University Medical Cancer Center, Nashville, TN;Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France.;Banner MD Anderson Cancer Center, Gilbert, AZ, USA.;Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Nebraska Medical Center, Omaha, NE, USA.;Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA.;Mayo Clinic, Rochester, MN, USA.;Karmanos Cancer Center, Wayne State University, Detroit, MI, USA.;Colorado Blood Cancer Institute, Denver, CO, USA.;John Theurer Cancer Center, Hackensack, NJ, USA.;Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands.;Dana-Farber Cancer Institute, Boston, MA, USA.;University of Iowa, Iowa City, IA, USA.;University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands.;Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France.;University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA.;Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.;Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;University of California San Diego, La Jolla, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;Kite, a Gilead Company, Santa Monica, CA, USA.;University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands."
"109","Obacz J;Archambeau J;Lafont E;Nivet M;Martin S;Aubry M;Voutetakis K;Pineau R;Boniface R;Sicari D;Pelizzari-Raymundo D;Ghukasyan G;McGrath E;Vlachavas EI;Le Gallo M;Le Reste PJ;Barroso K;Fainsod-Levi T;Obiedat A;Granot Z;Tirosh B;Samal J;Pandit A;Négroni L;Soriano N;Monnier A;Mosser J;Chatziioannou A;Quillien V;Chevet E;Avril T","Obacz, Joanna;Archambeau, Jérôme;Lafont, Elodie;Nivet, Manon;Martin, Sophie;Aubry, Marc;Voutetakis, Konstantinos;Pineau, Raphael;Boniface, Rachel;Sicari, Daria;Pelizzari-Raymundo, Diana;Ghukasyan, Gevorg;McGrath, Eoghan;Vlachavas, Efstathios-Iason;Le Gallo, Matthieu;Le Reste, Pierre Jean;Barroso, Kim;Fainsod-Levi, Tanya;Obiedat, Akram;Granot, Zvi;Tirosh, Boaz;Samal, Juhi;Pandit, Abhay;Négroni, Luc;Soriano, Nicolas;Monnier, Annabelle;Mosser, Jean;Chatziioannou, Aristotelis;Quillien, Véronique;Chevet, Eric;Avril, Tony","IRE1 endoribonuclease signaling promotes myeloid cell infiltration in glioblastoma.","Neuro-oncology","England","eng","Journal Article","ER stress;IRE1;chemokines;glioblastoma;inflammation","Glioblastoma;Humans;Mice;Endoribonucleases;Animals;Protein Serine-Threonine Kinases;Signal Transduction;Brain Neoplasms;Myeloid Cells;Unfolded Protein Response;Tumor Microenvironment;Tumor Cells, Cultured;Endoplasmic Reticulum Stress","Glioblastoma;Humans;Mice;Endoribonucleases;Animals;Protein Serine-Threonine Kinases;Signal Transduction;Brain Neoplasms;Myeloid Cells;Unfolded Protein Response;Tumor Microenvironment;Tumor Cells, Cultured;Endoplasmic Reticulum Stress","Intrinsic or environmental stresses trigger the accumulation of improperly folded proteins in the endoplasmic reticulum (ER), leading to ER stress. To cope with this, cells have evolved an adaptive mechanism named the unfolded protein response (UPR) which is hijacked by tumor cells to develop malignant features. Glioblastoma (GB), the most aggressive and lethal primary brain tumor, relies on UPR to sustain growth. We recently showed that IRE1 alpha (referred to IRE1 hereafter), 1 of the UPR transducers, promotes GB invasion, angiogenesis, and infiltration by macrophage. Hence, high tumor IRE1 activity in tumor cells predicts a worse outcome. Herein, we characterized the IRE1-dependent signaling that shapes the immune microenvironment toward monocytes/macrophages and neutrophils. We used human and mouse cellular models in which IRE1 was genetically or pharmacologically invalidated and which were tested in vivo. Publicly available datasets from GB patients were also analyzed to confirm our findings. We showed that IRE1 signaling, through both the transcription factor XBP1s and the regulated IRE1-dependent decay controls the expression of the ubiquitin-conjugating E2 enzyme UBE2D3. In turn, UBE2D3 activates the NFκB pathway, resulting in chemokine production and myeloid infiltration in tumors. Our work identifies a novel IRE1/UBE2D3 proinflammatory axis that plays an instrumental role in GB immune regulation.","INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Department of Biochemistry and Biotechnology, Larissa, Greece.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Biosit H2P2, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Hospital of St Malo, France.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;CÚRAM, Ireland.;CÚRAM, Ireland.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;INSERM U1242, Rennes, France.;CNRS UMR6290, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.","NA",0,"1523-5866","Neuro Oncol","Neuro Oncol",2023,"2024","26","10.1093/neuonc/noad256","858-871","EU H2020 MSCA ITN-675448;MSCA RISE-734749","la Ligue Contre le Cancer;INSERM;INCR;INSERM;Institut National du Cancer;Région Bretagne;Rennes Métropole;Fondation pour la recherche Médicale;la Ligue Contre le Cancer Comités d'Ille-et-Vilaine;des Côtes d'Armor et du Morbihan;European Regional Development Fund","38153426","38153426","PUBMED","INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Department of Biochemistry and Biotechnology, Larissa, Greece.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Biosit H2P2, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Hospital of St Malo, France.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;Department of Developmental Biology and Cancer Research, Hebrew University of Jerusalem, Israel.;IDR, Hebrew University of Jerusalem, Israel.;CÚRAM, Ireland.;CÚRAM, Ireland.;IGBMC, Illkirch, France.;CNRS UMR7104, Illkirch, France.;INSERM U1258, Illkirch, France.;INSERM U1242, Rennes, France.;CNRS UMR6290, Rennes, France.;INSERM U1242, Rennes, France.;INSERM U1242, Rennes, France.;ICB, NHRF, Athens, Greece.;Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, Rennes, France.;Centre Eugène Marquis, Rennes, France."
"110","Ducray F;Ramirez C;Robert M;Fontanilles M;Bronnimann C;Chinot O;Estrade F;Durando X;Cartalat S;Bastid J;Bienayme H;Lemarchand C","Ducray, François;Ramirez, Carole;Robert, Marie;Fontanilles, Maxime;Bronnimann, Charlotte;Chinot, Olivier;Estrade, Florian;Durando, Xavier;Cartalat, Stéphanie;Bastid, Jeremy;Bienayme, Hugues;Lemarchand, Caroline","A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.","Pharmaceutics","Switzerland","eng","Journal Article","bioequivalence;oral suspension;pediatric formulation;temozolomide","","","Temozolomide (TMZ) oral suspension (Ped-TMZ, KIZFIZO ) is being developed for the treatment of relapsed or refractory neuroblastoma, a rare cancer affecting infants and young children. The study assessed the safety and the bioequivalence of this novel pediatric formulation with existing TMZ oral capsules. In vitro dissolution profiles and the bioequivalence were evaluated following the European Medicines Agency ""Guidelines on the investigation of Bioequivalence"". The phase I, multicenter, randomized, open-label, crossover, single-dose bioequivalence study enrolled 36 adult patients with glioblastoma multiforme or lower-grade glioma. Each patient received 200 mg/m  Ped-TMZ suspension and TMZ capsules (Temodal ) on 2 consecutive days, with the order being randomly assigned. Fourteen blood samples were collected up to 10 h post-dosing. Bioequivalence was assessed by comparing the 90% confidence interval for the ratio of the geometric means of maximum TMZ plasma concentration (C ) and the area under the curve (AUCt). Other endpoints included further pharmacokinetic parameters and safety. Both formulations exhibited a fast in vitro dissolution profile with more than 85% of TMZ dissolved within 15 min. For the bioequivalence study, thirty patients completed the trial as per the protocol. The ratio of Ped-TMZ/TMZ capsule geometric means (90% CI) for AUCt and C  were 97.18% (95.05-99.35%) and 107.62% (98.07-118.09%), respectively, i.e., within the 80-125% bioequivalence limits. No buccal toxicity was associated with Ped-TMZ liquid formulation. This study showed that Ped-TMZ oral suspension and TMZ oral capsule treatment are immediate release and bioequivalent medicines. There were also no unexpected safety signals or local toxicity (funded by ORPHELIA Pharma; ClinicalTrials.gov number, NCT04467346).","Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Services de Neurologie et D'oncologie Médicale, CHU et ICHUSE de Saint-Etienne, 42055 Saint-Etienne, France.;Institut de Cancérologie de l'Ouest, Medical Oncology, 44800 Saint Herblain, France.;INSERM U1245 Unit, Cancer Centre Henri Becquerel, Université Rouen Normandie, 76038 Rouen, France.;Le Havre Hospital Group, 76083 Le Havre, France.;CHU de Bordeaux, Service D'oncologie Médicale, Hôpital Saint André, 33075 Bordeaux, France.;Aix-Marseille Université, Neuro-Oncology Department, APHM, CNRS, Institut de Neurophysiopathologie, CHU Timone, Service de Neuro-Oncologie, 13385 Marseille, France.;Centre Eugène Marquis, 35042 Rennes, France.;INSERM U1240 IMoST, University of Clermont Auvergne, 63001 Clermont-Ferrand, France.;UMR 501, Clinical Investigation Centre, 63011 Clermont-Ferrand, France.;Clinical Research and Innovation Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Oncology Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.","NA",0,"1999-4923","Pharmaceutics","Pharmaceutics",2023,"2023","15","10.3390/pharmaceutics15122664",NA,"N/A","Orphelia Pharma (France)","38140005","38140005","PUBMED","Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Services de Neurologie et D'oncologie Médicale, CHU et ICHUSE de Saint-Etienne, 42055 Saint-Etienne, France.;Institut de Cancérologie de l'Ouest, Medical Oncology, 44800 Saint Herblain, France.;INSERM U1245 Unit, Cancer Centre Henri Becquerel, Université Rouen Normandie, 76038 Rouen, France.;Le Havre Hospital Group, 76083 Le Havre, France.;CHU de Bordeaux, Service D'oncologie Médicale, Hôpital Saint André, 33075 Bordeaux, France.;Aix-Marseille Université, Neuro-Oncology Department, APHM, CNRS, Institut de Neurophysiopathologie, CHU Timone, Service de Neuro-Oncologie, 13385 Marseille, France.;Centre Eugène Marquis, 35042 Rennes, France.;INSERM U1240 IMoST, University of Clermont Auvergne, 63001 Clermont-Ferrand, France.;UMR 501, Clinical Investigation Centre, 63011 Clermont-Ferrand, France.;Clinical Research and Innovation Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Oncology Department, Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Service de Neuro-Oncologie, Hôpital Neurologique, Hospices Civils de Lyon, Centre de Recherche en Cancérologie UMR INSERM 1052 CNRS 5286, Université Claude Bernard Lyon 1, 69008 Lyon, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France.;ORPHELIA Pharma, 75005 Paris, France."
"111","Sgreccia A;Desilles JP;Costalat V;Dargazanli C;Bourcier R;Tessier G;Rouchaud A;Saleme S;Spelle L;Caroff J;Marnat G;Barreau X;Clarençon F;Shotar E;Eugene F;Houdart E;Gory B;Zhu F;Labreuche J;Piotin M;Lapergue B;Consoli A","Sgreccia, Alessandro;Desilles, Jean-Philippe;Costalat, Vincent;Dargazanli, Cyril;Bourcier, Romain;Tessier, Guillaume;Rouchaud, Aymeric;Saleme, Suzana;Spelle, Laurent;Caroff, Jildaz;Marnat, Gaultier;Barreau, Xavier;Clarençon, Frédéric;Shotar, Eimad;Eugene, François;Houdart, Emmanuel;Gory, Benjamin;Zhu, François;Labreuche, Julien;Piotin, Michel;Lapergue, Bertrand;Consoli, Arturo","Combined Technique for Internal Carotid Artery Terminus or Middle Cerebral Artery Occlusions in the ASTER2 Trial.","Stroke","United States","eng","Clinical Trial","endovascular procedures;humans;ischemic stroke;middle cerebral artery;retrospective studies","Humans;Arterial Occlusive Diseases;Brain Ischemia;Carotid Artery Diseases;Carotid Artery, Internal;Endovascular Procedures;Infarction, Middle Cerebral Artery;Ischemic Stroke;Middle Cerebral Artery;Stents;Stroke;Thrombectomy;Treatment Outcome","Humans;Arterial Occlusive Diseases;Brain Ischemia;Carotid Artery Diseases;Carotid Artery, Internal;Endovascular Procedures;Infarction, Middle Cerebral Artery;Ischemic Stroke;Middle Cerebral Artery;Stents;Stroke;Thrombectomy;Treatment Outcome","The aim of this study was to report the results of a subgroup analysis of the ASTER2 trial (Effect of Thrombectomy With Combined Contact Aspiration and Stent Retriever vs Stent Retriever Alone on Revascularization in Patients With Acute Ischemic Stroke and Large Vessel Occlusion) comparing the safety and efficacy of the combined technique (CoT) and stent retriever as a first-line approach in internal carotid artery (ICA) terminus±M1-middle cerebral artery (M1-MCA) and isolated M1-MCA occlusions. Patients enrolled in the ASTER2 trial with ICA terminus±M1-MCA and isolated M1-MCA occlusions were included in this subgroup analysis. The effect of first-line CoT versus stent retriever according to the occlusion site was assessed on angiographic (first-pass effect, expanded Treatment in Cerebral Infarction score ≥2b50, and expanded Treatment in Cerebral Infarction score ≥2c grades at the end of the first-line strategy and at the end of the procedure) and clinicoradiological outcomes (24-hour National Institutes of Health Stroke Scale, ECASS-III [European Cooperative Acute Stroke Study] grades, and 3-month modified Rankin Scale). Three hundred sixty-two patients were included in the postsubgroup analysis according to the occlusion site: 299 were treated for isolated M1-MCA occlusion (150 with first-line CoT) and 63 were treated for ICA terminus±M1-MCA occlusion (30 with first-line CoT). Expanded Treatment in Cerebral Infarction score ≥2b50 (odds ratio, 11.83 [95% CI, 2.32-60.12]) and expanded Treatment in Cerebral Infarction score ≥2c (odds ratio, 4.09 [95% CI, 1.39-11.94]) were significantly higher in first-line CoT compared with first-line stent retriever in patients with ICA terminus±M1-MCA occlusion but not in patients with isolated M1-MCA. First-line CoT was associated with higher reperfusion grades in patients with ICA terminus±M1-MCA at the end of the procedure. URL: https://www.clinicaltrials.gov; Unique identifier: NCT03290885.","Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.).;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France (J.-P.D., M.P.).;Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier University Medical Center, France (V.C., C.D.).;Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier University Medical Center, France (V.C., C.D.).;Department of Diagnostic and Interventional Neuroradiology, University Hospital of Nantes, France (R.B., G.T.).;Department of Diagnostic and Interventional Neuroradiology, University Hospital of Nantes, France (R.B., G.T.).;Interventional Neuroradiology Department, Centre Hospitalier Universitaire Limoges, France (A.R., S.S.).;Interventional Neuroradiology Department, Centre Hospitalier Universitaire Limoges, France (A.R., S.S.).;Interventional Neuroradiology Department, Kremlin Bicêtre Hospital, France (L.S., J.C.).;Interventional Neuroradiology Department, Kremlin Bicêtre Hospital, France (L.S., J.C.).;Interventional Neuroradiology Department, Centre Hospitalier Régional Universitaire Bordeaux, France (G.M., X.B.).;Interventional Neuroradiology Department, Centre Hospitalier Régional Universitaire Bordeaux, France (G.M., X.B.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (F.C., E.S.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (F.C., E.S.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (F.E.).;Department of Neuroradiology, Lariboisière Hospital, Paris, France (E.H.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (B.G., F.Z.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (B.G., F.Z.).;Department of Biostatistics, Centre Hospitalier Universitaire Lille, Equipe d'accueil 2694 Santé Publique: Epidémiologie et Qualité des Soins, University Lille, France (J.L.).;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France (J.-P.D., M.P.).;Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.).;Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.).","NA",0,"1524-4628","Stroke","Stroke",2023,"2024","55","10.1161/STROKEAHA.123.045227","376-384","","","38126181","38126181","PUBMED","Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.).;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France (J.-P.D., M.P.).;Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier University Medical Center, France (V.C., C.D.).;Department of Neuroradiology, Hôpital Gui de Chauliac, Montpellier University Medical Center, France (V.C., C.D.).;Department of Diagnostic and Interventional Neuroradiology, University Hospital of Nantes, France (R.B., G.T.).;Department of Diagnostic and Interventional Neuroradiology, University Hospital of Nantes, France (R.B., G.T.).;Interventional Neuroradiology Department, Centre Hospitalier Universitaire Limoges, France (A.R., S.S.).;Interventional Neuroradiology Department, Centre Hospitalier Universitaire Limoges, France (A.R., S.S.).;Interventional Neuroradiology Department, Kremlin Bicêtre Hospital, France (L.S., J.C.).;Interventional Neuroradiology Department, Kremlin Bicêtre Hospital, France (L.S., J.C.).;Interventional Neuroradiology Department, Centre Hospitalier Régional Universitaire Bordeaux, France (G.M., X.B.).;Interventional Neuroradiology Department, Centre Hospitalier Régional Universitaire Bordeaux, France (G.M., X.B.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (F.C., E.S.).;Department of Neuroradiology, Pitié-Salpêtrière Hospital, Paris, France (F.C., E.S.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (F.E.).;Department of Neuroradiology, Lariboisière Hospital, Paris, France (E.H.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (B.G., F.Z.).;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, France (B.G., F.Z.).;Department of Biostatistics, Centre Hospitalier Universitaire Lille, Equipe d'accueil 2694 Santé Publique: Epidémiologie et Qualité des Soins, University Lille, France (J.L.).;Department of Interventional Neuroradiology, Rothschild Foundation Hospital, Paris, France (J.-P.D., M.P.).;Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.).;Diagnostic and Interventional Neuroradiology, Foch Hospital, Suresnes, France (A.S., B.L., A.C.)."
"112","Masson I;Larriviere L;Mahé MA;Azria D;Pommier P;Mesgouez-Nebout N;Giraud P;Peiffert D;Chauvet B;Dudouet P;Salem N;Noël G;Khalifa J;Latorzeff I;Guérin-Charbonnel C;Supiot S","Masson, Ingrid;Larriviere, Laurène;Mahé, Marc-André;Azria, David;Pommier, Pascal;Mesgouez-Nebout, Nathalie;Giraud, Philippe;Peiffert, Didier;Chauvet, Bruno;Dudouet, Philippe;Salem, Naji;Noël, Georges;Khalifa, Jonathan;Latorzeff, Igor;Guérin-Charbonnel, Catherine;Supiot, Stéphane","Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancer.","Clinical and translational radiation oncology","Ireland","eng","Journal Article","","","","High-risk (HR) prostate cancer patients usually receive high-dose radiotherapy (RT) using a two-phase sequential technique, but data on a simultaneous integrated boost (SIB) technique are lacking. We prospectively evaluated the long-term results of urinary (GU) and digestive (GI) toxicity and survival data for high-dose RT using a SIB technique in HR and very high-risk (VHR) prostate cancer. Patients were treated using an SIB technique in 34 fractions, at a dose of 54.4 Gy to the pelvis and seminal vesicles and 74.8 Gy to the prostate, combined with 36 months of androgen-depriving therapy in a prospective multicenter study. Acute and late GU and GI toxicity data were collected. Overall survival (OS), biochemical-relapse-free survival (bRFS), loco-regional-relapse-free survival (LRRFS), metastasis-free-survival (MFS) and disease-free-survival (DFS) were assessed. We recruited 114 patients. After a median follow-up of 62 months, very few patients experienced acute (M0-M3) (G3-4 GU = 3.7 %; G3-4 GI = 0.9 %) or late (M6-M60) severe toxicity (G3-4 GU = 5.6 %; G3-4 GI = 2.8 %). The occurrence of acute G2 + GU or GI toxicity was significantly related to the consequential late G2 + toxicity (p < 0.01 for both GU and GI). Medians of OS, bRFS, LRRFS, MFS and DFS were not reached. At 60 months, OS, bRFS, LRRFS, MFS and DFS were 88.2 % [82.1; 94.7], 86.0 % [79.4 %;93.2 %], 95.8 % [91.8 %;99.9 %], 87.2 % [80.9 %;94.0 %] and 84.1 % [77.2 %;91.6 %] respectively. SIB RT at a dose of 54.4 Gy to the pelvis and 74.8 Gy to the prostate is feasible, leading to satisfying tumor control and reasonable toxicity in HR and VHR prostate cancer.","Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiataion oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiation Oncology, François Baclesse Cancer Center, Caen, France.;Fédération Universitaire d'Oncologie Radiothérapie FOROM, ICM, Institut régional du Cancer Montpellier, Université de Montpellier, IRCM, Montpellier, France.;Department of Radiation Oncology, Léon Bérard Center, Lyon, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.;Department of Radiation Oncology, Georges Pompidou European Hospital, Paris, France.;Department of Radiation Oncology, Lorraine Cancer Institute, Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Sainte Catherine Institute, Avignon, France.;Department of Radiation Oncology, Pont de chaume Clinic, Montauban, France.;Department of Radiation Oncology, Paoli-Calmettes Institute, Marseille, France.;Department of Radiation Oncology, ICANS (Cancerology Institute of Strasbourg-Europe), Strasbourg, France.;Department of Radiation Oncology, IUCT Oncopole, Toulouse, France.;Department of Radiation Oncology, Pasteur Clinic, Toulouse, France.;Clinical Trial Sponsor Unit/Biometry, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Nantes Université, CNRS US2B, Nantes, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.","NA",0,"2405-6308","Clin Transl Radiat Oncol","Clin Transl Radiat Oncol",2023,"2024","44","10.1016/j.ctro.2023.100702","100702","","","38111609","38111609","PUBMED","Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiataion oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Department of Radiation Oncology, François Baclesse Cancer Center, Caen, France.;Fédération Universitaire d'Oncologie Radiothérapie FOROM, ICM, Institut régional du Cancer Montpellier, Université de Montpellier, IRCM, Montpellier, France.;Department of Radiation Oncology, Léon Bérard Center, Lyon, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest Paul Papin, Angers, France.;Department of Radiation Oncology, Georges Pompidou European Hospital, Paris, France.;Department of Radiation Oncology, Lorraine Cancer Institute, Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Sainte Catherine Institute, Avignon, France.;Department of Radiation Oncology, Pont de chaume Clinic, Montauban, France.;Department of Radiation Oncology, Paoli-Calmettes Institute, Marseille, France.;Department of Radiation Oncology, ICANS (Cancerology Institute of Strasbourg-Europe), Strasbourg, France.;Department of Radiation Oncology, IUCT Oncopole, Toulouse, France.;Department of Radiation Oncology, Pasteur Clinic, Toulouse, France.;Clinical Trial Sponsor Unit/Biometry, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France.;Nantes Université, CNRS US2B, Nantes, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest René Gauducheau, Saint-Herblain, France."
"113","Donal E;Sitges M;Panis V;Schueler R;Lapp H;Moellmann H;Nickenig G;Bekeredjian R;Estevez-Loureiro R;Atmowihardjo I;Trusty P;Lurz P","Donal, Erwan;Sitges, Marta;Panis, Vasileios;Schueler, Robert;Lapp, Harald;Moellmann, Helge;Nickenig, Georg;Bekeredjian, Raffi;Estevez-Loureiro, Rodrigo;Atmowihardjo, Iskandar;Trusty, Phillip;Lurz, Philipp","Characterization of Tricuspid Valve Anatomy and Coaptation Gap in Subjects Receiving Tricuspid Transcatheter Edge-To-Edge Repair: Observations From the bRIGHT TriClip Study.","Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography","United States","eng","Multicenter Study","Coaptation gap;Edge-to-edge repair;TriClip;Tricuspid regurgitation","Humans;Tricuspid Valve;Prospective Studies;Heart Valve Prosthesis Implantation;Treatment Outcome;Cardiac Catheterization;Tricuspid Valve Insufficiency","Humans;Tricuspid Valve;Prospective Studies;Heart Valve Prosthesis Implantation;Treatment Outcome;Cardiac Catheterization;Tricuspid Valve Insufficiency","Transcatheter edge-to-edge repair (TEER) for the treatment of tricuspid regurgitation (TR) has experienced fast adoption following commercial approval. Defining the appropriate target population for TEER therapy is important to guide patient selection. The aim of this study was to characterize tricuspid valve anatomy and coaptation gap in subjects receiving TEER for the treatment of TR in a contemporary postmarket setting. The bRIGHT study is a prospective, multicenter, single-arm, postmarket study evaluating the safety and effectiveness of the TriClip device. Procedural outcomes included implant success, acute procedural success, TR severity, major adverse events, single-leaflet device attachment, and embolization through 30 postprocedure days. Tricuspid valve characteristics, including morphology, annulus size, and leaflet mobility, were assessed via two-dimensional transesophageal echocardiography from the screening visit by an independent echo core lab to characterize subject variability. Coaptation gap measurements were taken in both the transgastric short-axis (TG SAX) and RV inflow/outflow views. The independent echo core lab performed a detailed assessment of the tricuspid valve on 135 consecutive subjects with available TG SAX views from 24 sites. Tricuspid valve morphologies included 2 to 5 leaflets, with a non-trileaflet valve in 28% of subjects and ≥4 leaflets in 21% of subjects. The etiology of TR was functional in 91% (96/105), mixed in 7% (7/105), and lead induced in 2% (2/105) of subjects. Leaflet mobility was mildly restricted in 69% (78/113) and moderately restricted in 7% (8/113) of subjects. Annulus diameter averaged 4.7 ± 0.7 cm with a range of 2.5 to 6.2 cm. From the TG SAX view, the coaptation gap measured 8.1 ± 3.1 and 5.2 ± 2.3 mm in the central and mid regions of the anterior-septal coaptation line and 6.6 ± 3.2 and 3.8 ± 2.1 mm in the central and mid regions of the septal-posterior coaptation line, respectively. From the right ventricular inflow/outflow view, the coaptation gap measured 4.7 ± 2.4, 5.2 ± 2.4, and 4.6 ± 3.0 mm in the anterior, mid, and posterior regions of the tricuspid valve, respectively. Thirty-day TR reduction (by number of grades) was similar among subjects with coaptation gaps of <7 mm, 7 to 10 mm, and >10 mm. A broad range of anatomies was observed in this postmarket population. Characterization of the tricuspid valve and coaptation gap will help to better understand and better define the target patient population for tricuspid TEER therapy.","Centre Hospitalier Universitaire de Rennes, Rennes;Centro de investigación Biomedicaen RedEnfermedades Cardiovasculares, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Elisabeth-Krankenhaus Essen GmbH, Essen, Germany.;Zentralklinik Bad Berka GmbH, Bad Berka, Germany.;St.-Johannes-Hospital, Dortmund, Germany.;Universitätsklinikum Bonn AdöR, Bonn, Germany.;Robert-Bosch-Krankenhaus, Stuttgart, Germany.;Department of Interventional Cardiology, Hospital Alvaro Cunqueiro, Vigo, Spain; Instituto de Investigación Galicia Sur, Servizo Galego de Saude, Vigo, Spain.;DRK Kliniken Berlin Köpenick, Berlin, Germany.;Abbott Structural Heart, Santa Clara, California.;Herzzentrum Leipzig GmbH, Leipzig, Germany.","NA",0,"1097-6795","J Am Soc Echocardiogr","J Am Soc Echocardiogr",2023,"2024","37","10.1016/j.echo.2023.12.002","397-404","","","38072288","38072288","PUBMED","Centre Hospitalier Universitaire de Rennes, Rennes;Centro de investigación Biomedicaen RedEnfermedades Cardiovasculares, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Barcelona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Elisabeth-Krankenhaus Essen GmbH, Essen, Germany.;Zentralklinik Bad Berka GmbH, Bad Berka, Germany.;St.-Johannes-Hospital, Dortmund, Germany.;Universitätsklinikum Bonn AdöR, Bonn, Germany.;Robert-Bosch-Krankenhaus, Stuttgart, Germany.;Department of Interventional Cardiology, Hospital Alvaro Cunqueiro, Vigo, Spain; Instituto de Investigación Galicia Sur, Servizo Galego de Saude, Vigo, Spain.;DRK Kliniken Berlin Köpenick, Berlin, Germany.;Abbott Structural Heart, Santa Clara, California.;Herzzentrum Leipzig GmbH, Leipzig, Germany."
"114","Llovet JM;Kudo M;Merle P;Meyer T;Qin S;Ikeda M;Xu R;Edeline J;Ryoo BY;Ren Z;Masi G;Kwiatkowski M;Lim HY;Kim JH;Breder V;Kumada H;Cheng AL;Galle PR;Kaneko S;Wang A;Mody K;Dutcus C;Dubrovsky L;Siegel AB;Finn RS","Llovet, Josep M;Kudo, Masatoshi;Merle, Philippe;Meyer, Tim;Qin, Shukui;Ikeda, Masafumi;Xu, Ruocai;Edeline, Julien;Ryoo, Baek-Yeol;Ren, Zhenggang;Masi, Gianluca;Kwiatkowski, Mariusz;Lim, Ho Yeong;Kim, Jee Hyun;Breder, Valeriy;Kumada, Hiromitsu;Cheng, Ann-Lii;Galle, Peter R;Kaneko, Shuichi;Wang, Anran;Mody, Kalgi;Dutcus, Corina;Dubrovsky, Leonid;Siegel, Abby B;Finn, Richard S","Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.","The Lancet. Oncology","England","eng","Randomized Controlled Trial","","Aged;Female;Humans;Male;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Hepatocellular;Double-Blind Method;Gastrointestinal Hemorrhage;Hepatorenal Syndrome;Liver Neoplasms;Middle Aged","Aged;Female;Humans;Male;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Hepatocellular;Double-Blind Method;Gastrointestinal Hemorrhage;Hepatorenal Syndrome;Liver Neoplasms;Middle Aged","Systemic therapies have improved the management of hepatocellular carcinoma, but there is still a need to further enhance overall survival in first-line advanced stages. This study aimed to evaluate the addition of pembrolizumab to lenvatinib versus lenvatinib plus placebo in the first-line setting for unresectable hepatocellular carcinoma. In this global, randomised, double-blind, phase 3 study (LEAP-002), patients aged 18 years or older with unresectable hepatocellular carcinoma, Child Pugh class A liver disease, an Eastern Cooperative Oncology Group performance status of 0 or 1, and no previous systemic treatment were enrolled at 172 global sites. Patients were randomly assigned (1:1) with a central interactive voice-response system (block size of 4) to receive lenvatinib (bodyweight <60 kg, 8 mg/day; bodyweight ≥60 kg, 12 mg/day) plus pembrolizumab (200 mg every 3 weeks) or lenvatinib plus placebo. Randomisation was stratified by geographical region, macrovascular portal vein invasion or extrahepatic spread or both, α-fetoprotein concentration, and Eastern Cooperative Oncology Group performance status. Dual primary endpoints were overall survival (superiority threshold at final overall survival analysis, one-sided p=0·019; final analysis to occur after 532 events) and progression-free survival (superiority threshold one-sided p=0·002; final analysis to occur after 571 events) in the intention-to-treat population. Results from the final analysis are reported. This study is registered with ClinicalTrials.gov, NCT03713593, and is active but not recruiting. Between Jan 17, 2019, and April 28, 2020, of 1309 patients assessed, 794 were randomly assigned to lenvatinib plus pembrolizumab (n=395) or lenvatinib plus placebo (n=399). Median age was 66·0 years (IQR 57·0-72·0), 644 (81%) of 794 were male, 150 (19%) were female, 345 (43%) were Asian, 345 (43%) were White, 22 (3%) were multiple races, 21 (3%) were American Indian or Alaska Native, 21 (3%) were Native Hawaiian or other Pacific Islander, 13 (2%) were Black or African American, and 46 (6%) did not have available race data. Median follow up as of data cutoff for the final analysis (June 21, 2022) was 32·1 months (IQR 29·4-35·3). Median overall survival was 21·2 months (95% CI 19·0-23·6; 252 [64%] of 395 died) with lenvatinib plus pembrolizumab versus 19·0 months (17·2-21·7; 282 [71%] of 399 died) with lenvatinib plus placebo (hazard ratio [HR] 0·84; 95% CI 0·71-1·00; stratified log-rank p=0·023). As of data cutoff for the progression-free survival final analysis (April 5, 2021), median progression-free survival was 8·2 months (95% CI 6·4-8·4; 270 events occurred [42 deaths; 228 progressions]) with lenvatinib plus pembrolizumab versus 8·0 months (6·3-8·2; 301 events occurred [36 deaths; 265 progressions]) with lenvatinib plus placebo (HR 0·87; 95% CI 0·73-1·02; stratified log-rank p=0·047). The most common treatment-related grade 3-4 adverse events were hypertension (69 [17%] of 395 patients in the lenvatinib plus pembrolizumab group vs 68 [17%] of 395 patients) in the lenvatinib plus placebo group), increased aspartate aminotransferase (27 [7%] vs 17 [4%]), and diarrhoea (25 [6%] vs 15 [4%]). Treatment-related deaths occurred in four (1%) patients in the lenvatinib plus pembrolizumab group (due to gastrointestinal haemorrhage and hepatorenal syndrome [n=1 each] and hepatic encephalopathy [n=2]) and in three (1%) patients in the lenvatinib plus placebo group (due to gastrointestinal haemorrhage, hepatorenal syndrome, and cerebrovascular accident [n=1 each]). In earlier studies, the addition of pembrolizumab to lenvatinib as first-line therapy for advanced hepatocellular carcinoma has shown promising clinical activity; however, lenvatinib plus pembrolizumab did not meet prespecified significance for improved overall survival and progression-free survival versus lenvatinib plus placebo. Our findings do not support a change in clinical practice. Eisai US, and Merck Sharp & Dohme, a subsidiary of Merck.","Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; August Pi i Sunyer Biomedical Research Institute, University of Barcelona Hospital Clinic Barcelona, Barcelona;Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.;Hepatology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Royal Free London NHS Foundation Trust, London, UK; University College London Cancer Institute, University College London, London, UK.;GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.;National Cancer Center Hospital East, Kashiwa, Japan.;Hunan Cancer Hospital, Changsha, Hunan, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Zhongshan Hospital, Fudan University, Shanghai, China.;Department of Translational Research and New Technologies in Medicine and Surgery, Division of Medical Oncology, Pisa University Hospital, Pisa, Italy.;Nicolaus Copernicus Provincial Hospital, Koszalin, Poland.;Samsung Medical Center, Seoul, South Korea.;Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.;N N Blokhin Russian Cancer Research Center, Moscow, Russia.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.;University Medical Center Mainz, Mainz, Germany.;Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.;Merck, Rahway, NJ, USA.;Eisai, Nutley, NJ, USA.;Eisai, Nutley, NJ, USA.;Merck, Rahway, NJ, USA.;Merck, Rahway, NJ, USA.;Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2023","24","10.1016/S1470-2045(23)00469-2","1399-1410","26813","Cancer Research UK","38039993","38039993","PUBMED","Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; August Pi i Sunyer Biomedical Research Institute, University of Barcelona Hospital Clinic Barcelona, Barcelona;Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.;Hepatology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France.;Royal Free London NHS Foundation Trust, London, UK; University College London Cancer Institute, University College London, London, UK.;GI Cancer Center, Nanjing Tianyinshan Hospital, Nanjing, China.;National Cancer Center Hospital East, Kashiwa, Japan.;Hunan Cancer Hospital, Changsha, Hunan, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Zhongshan Hospital, Fudan University, Shanghai, China.;Department of Translational Research and New Technologies in Medicine and Surgery, Division of Medical Oncology, Pisa University Hospital, Pisa, Italy.;Nicolaus Copernicus Provincial Hospital, Koszalin, Poland.;Samsung Medical Center, Seoul, South Korea.;Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.;N N Blokhin Russian Cancer Research Center, Moscow, Russia.;Department of Hepatology, Toranomon Hospital, Tokyo, Japan.;National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.;University Medical Center Mainz, Mainz, Germany.;Department of Gastroenterology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.;Merck, Rahway, NJ, USA.;Eisai, Nutley, NJ, USA.;Eisai, Nutley, NJ, USA.;Merck, Rahway, NJ, USA.;Merck, Rahway, NJ, USA.;Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA."
"115","Freund Y;Viglino D;Cachanado M;Cassard C;Montassier E;Douay B;Guenezan J;Le Borgne P;Yordanov Y;Severin A;Roussel M;Daniel M;Marteau A;Peschanski N;Teissandier D;Macrez R;Morere J;Chouihed T;Roux D;Adnet F;Bloom B;Chauvin A;Simon T","Freund, Yonathan;Viglino, Damien;Cachanado, Marine;Cassard, Clémentine;Montassier, Emmanuel;Douay, Bénedicte;Guenezan, Jérémy;Le Borgne, Pierrick;Yordanov, Youri;Severin, Armelle;Roussel, Mélanie;Daniel, Matthieu;Marteau, Adrien;Peschanski, Nicolas;Teissandier, Dorian;Macrez, Richard;Morere, Julia;Chouihed, Tahar;Roux, Damien;Adnet, Frédéric;Bloom, Ben;Chauvin, Anthony;Simon, Tabassome","Effect of Noninvasive Airway Management of Comatose Patients With Acute Poisoning: A Randomized Clinical Trial.","JAMA","United States","eng","Journal Article","","Humans;Female;Adult;Male;Coma;Hospital Mortality;Intubation, Intratracheal;Emergency Service, Hospital;Pneumonia","Humans;Female;Adult;Male;Coma;Hospital Mortality;Intubation, Intratracheal;Emergency Service, Hospital;Pneumonia","Tracheal intubation is recommended for coma patients and those with severe brain injury, but its use in patients with decreased levels of consciousness from acute poisoning is uncertain. To determine the effect of intubation withholding vs routine practice on clinical outcomes of comatose patients with acute poisoning and a Glasgow Coma Scale score less than 9. This was a multicenter, randomized trial conducted in 20 emergency departments and 1 intensive care unit (ICU) that included comatose patients with suspected acute poisoning and a Glasgow Coma Scale score less than 9 in France between May 16, 2021, and April 12, 2023, and followed up until May 12, 2023. Patients were randomized to undergo conservative airway strategy of intubation withholding vs routine practice. The primary outcome was a hierarchical composite end point of in-hospital death, length of ICU stay, and length of hospital stay. Key secondary outcomes included adverse events resulting from intubation as well as pneumonia within 48 hours. Among the 225 included patients (mean age, 33 years; 38% female), 116 were in the intervention group and 109 in the control group, with respective proportions of intubations of 16% and 58%. No patients died during the in-hospital stay. There was a significant clinical benefit for the primary end point in the intervention group, with a win ratio of 1.85 (95% CI, 1.33 to 2.58). In the intervention group, there was a lower proportion with any adverse event (6% vs 14.7%; absolute risk difference, 8.6% [95% CI, -16.6% to -0.7%]) compared with the control group, and pneumonia occurred in 8 (6.9%) and 16 (14.7%) patients, respectively (absolute risk difference, -7.8% [95% CI, -15.9% to 0.3%]). Among comatose patients with suspected acute poisoning, a conservative strategy of withholding intubation was associated with a greater clinical benefit for the composite end point of in-hospital death, length of ICU stay, and length of hospital stay. ClinicalTrials.gov Identifier: NCT04653597.","Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation (SMUR), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Emergency Department, Grenoble-Alpes University Hospital, and University Grenoble-Alpes, HP2 Laboratory INSERM U 1300, Grenoble, France.;Department of Clinical Pharmacology and Clinical Research Platform Paris-East, AP-HP, Sorbonne University, St Antoine Hospital, Paris, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation (SMUR), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Emergency Department and SMUR, Nantes Université, CHU Nantes, INSERM UMR 1064, Nantes, France.;Emergency Department and SMUR, Hôpital Beaujon AP-HP, Clichy, France.;Emergency Department, University Hospital of Poitiers, Poitiers, France.;Emergency Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France and INSERM UMR 1260, Regenerative NanoMedicine, Fédération de Médecine Translationnelle, University of Strasbourg, Strasbourg, France.;Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Emergency Department, Hôpital Saint Antoine AP-HP, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, Paris, France.;SAMU 92-SMUR Raymond Poincaré, Raymond Poincaré Hospital, AP-HP, Paris, France.;Emergency Department, Univ Rouen Normandie, CHU Rouen, Rouen, France.;Emergency Department, SAMU-SMUR et Secours en Milieu Périlleux, CHU de La Réunion Site Nord Félix Guyon, La Réunion, France.;Emergency Department, Centre Hospitalier Universitaire Sud Réunion, Saint Pierre, La Réunion, France.;Emergency Department and SAMU35-SMUR, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université de Rennes, Rennes, France.;Emergency Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, UNH, Clermont-Ferrand, France.;Emergency Department, University hospital of Caen, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, GIP Cyceron, Institut Blood and Brain Normandie University, Caen, France.;Emergency Department and SMUR, Hôpital Edouard Herriot, Lyon, France.;Emergency Department, University Hospital of Nancy, INSERM, UMR_S 1116, University Hospital of Nancy, Nancy, France.;Université Paris Cité, AP-HP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, Colombes, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation SMUR, Hôpital Avicenne, AP-HP, Bobigny, France.;Emergency Department, Royal London Hospital, London, United Kingdom.;Emergency Department, Hôpital Lariboisiere AP-HP, Paris, France and INSERM U942 MASCOT, University of Paris, Paris, France.;Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Department of Clinical Pharmacology and Clinical Research Platform Paris-East, AP-HP, Sorbonne University, St Antoine Hospital, Paris, France.","NA",0,"1538-3598","JAMA","JAMA",2023,"2023","330","10.1001/jama.2023.24391","2267-2274","","","38019968","38019968","PUBMED","Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation (SMUR), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Emergency Department, Grenoble-Alpes University Hospital, and University Grenoble-Alpes, HP2 Laboratory INSERM U 1300, Grenoble, France.;Department of Clinical Pharmacology and Clinical Research Platform Paris-East, AP-HP, Sorbonne University, St Antoine Hospital, Paris, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation (SMUR), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Emergency Department and SMUR, Nantes Université, CHU Nantes, INSERM UMR 1064, Nantes, France.;Emergency Department and SMUR, Hôpital Beaujon AP-HP, Clichy, France.;Emergency Department, University Hospital of Poitiers, Poitiers, France.;Emergency Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France and INSERM UMR 1260, Regenerative NanoMedicine, Fédération de Médecine Translationnelle, University of Strasbourg, Strasbourg, France.;Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Emergency Department, Hôpital Saint Antoine AP-HP, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR-S 1136, Paris, France.;SAMU 92-SMUR Raymond Poincaré, Raymond Poincaré Hospital, AP-HP, Paris, France.;Emergency Department, Univ Rouen Normandie, CHU Rouen, Rouen, France.;Emergency Department, SAMU-SMUR et Secours en Milieu Périlleux, CHU de La Réunion Site Nord Félix Guyon, La Réunion, France.;Emergency Department, Centre Hospitalier Universitaire Sud Réunion, Saint Pierre, La Réunion, France.;Emergency Department and SAMU35-SMUR, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université de Rennes, Rennes, France.;Emergency Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, UNH, Clermont-Ferrand, France.;Emergency Department, University hospital of Caen, UNICAEN, INSERM UMR-S U1237, Physiopathology and Imaging of Neurological Disorders, GIP Cyceron, Institut Blood and Brain Normandie University, Caen, France.;Emergency Department and SMUR, Hôpital Edouard Herriot, Lyon, France.;Emergency Department, University Hospital of Nancy, INSERM, UMR_S 1116, University Hospital of Nancy, Nancy, France.;Université Paris Cité, AP-HP, Hôpital Louis Mourier, DMU ESPRIT, Service de Médecine Intensive Réanimation, Colombes, France.;Emergency Department and Service Mobile d'Urgence et de Réanimation SMUR, Hôpital Avicenne, AP-HP, Bobigny, France.;Emergency Department, Royal London Hospital, London, United Kingdom.;Emergency Department, Hôpital Lariboisiere AP-HP, Paris, France and INSERM U942 MASCOT, University of Paris, Paris, France.;Sorbonne Université, IMProving Emergency Care FHU, Paris, France.;Department of Clinical Pharmacology and Clinical Research Platform Paris-East, AP-HP, Sorbonne University, St Antoine Hospital, Paris, France."
"116","Rached L;Geraud A;Frelaut M;Ap Thomas Z;Goldschmidt V;Beraud-Chaulet G;Nagera-Lazarovici C;Danlos FX;Henon C;Parisi C;Gazzah A;Bahleda R;Postel Vinay S;Smolenschi C;Hollebecque A;Michot JM;Ribrag V;Loriot Y;Champiat S;Ouali K;Massard C;Ponce Aix S;Bringuier M;Baldini C","Rached, Layal;Geraud, Arthur;Frelaut, Maxime;Ap Thomas, Zoe;Goldschmidt, Vincent;Beraud-Chaulet, Geoffroy;Nagera-Lazarovici, Celine;Danlos, Francois-Xavier;Henon, Clemence;Parisi, Claudia;Gazzah, Anas;Bahleda, Rastilav;Postel Vinay, Sophie;Smolenschi, Cristina;Hollebecque, Antoine;Michot, Jean-Marie;Ribrag, Vincent;Loriot, Yohann;Champiat, Stephane;Ouali, Kaissa;Massard, Christophe;Ponce Aix, Santiago;Bringuier, Michael;Baldini, Capucine","Antibody drug conjugates in older patients: State of the art.","Critical reviews in oncology/hematology","Netherlands","eng","Journal Article","Antibody-drug conjugates;Cancer;Clinical trials;Elderly;Geriatric patients;Older;Pharmacokinetics","Humans;Aged;Immunoconjugates;Quality of Life","Humans;Aged;Immunoconjugates;Quality of Life","More than half of cancer cases occur in patients aged 65 years or older. The efficacy and safety of antibody drug conjugates (ADCs) in older patients remains an unclear subject as available evidence is limited. Geriatric population is underrepresented in clinical trials. Consequently, most of our knowledge regarding innovative therapeutics was studied on a younger population. In this review of published literature, we report the available information on efficacy, safety and pharmacokinetics of FDA approved ADCs for hematologic malignancies and solid tumors in the geriatric population. We explore the results of clinical trials dedicated for older individuals as well as subgroup analyses of the geriatric population in major trials evaluating these drugs. Available data suggest a similar efficacy in older adults as compared to general population. However, older patients might be prone to a higher rate of adverse events in incidence with a potential impact on quality of life. We lack data to support primary dose reductions or schedule modifications in this category of patients. No pharmacokinetic differences were reported between age groups. It is crucial to encourage the development of clinical trials dedicated to older patients with geriatric parameters (G8 score, G-CODE…) so that results can be more representative of this population outside of clinical trials.","Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Centre Eugène Marquis, Department of Medical Oncology, 35000 Rennes;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Institut Curie, PSL Research University, Department of Medical Oncology and Department of Supportive Care, UCOG Paris Ouest, F-92210 Saint-Cloud;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif","NA",0,"1879-0461","Crit Rev Oncol Hematol","Crit Rev Oncol Hematol",2023,"2024","193","10.1016/j.critrevonc.2023.104212","104212","","","38007063","38007063","PUBMED","Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Medical Oncology , 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Centre Eugène Marquis, Department of Medical Oncology, 35000 Rennes;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif;Institut Curie, PSL Research University, Department of Medical Oncology and Department of Supportive Care, UCOG Paris Ouest, F-92210 Saint-Cloud;Gustave Roussy, Department of Therapeutic Innovation and Early Phase Trials, 94805 Villejuif"
"117","Galvin A;Courtinard C;Bouteiller F;Gourgou S;Dalenc F;Jacot W;Arnedos M;Bailleux C;Dieras V;Petit T;Emile G;Dubray-Longeras P;Frenel JS;Bachelot T;Mailliez A;Brain E;Desmoulins I;Massard V;Patsouris A;Goncalves A;Grinda T;Delaloge S;Bellera C","Galvin, Angéline;Courtinard, Coralie;Bouteiller, Fanny;Gourgou, Sophie;Dalenc, Florence;Jacot, William;Arnedos, Monica;Bailleux, Caroline;Dieras, Véronique;Petit, Thierry;Emile, George;Dubray-Longeras, Pascale;Frenel, Jean-Sébastien;Bachelot, Thomas;Mailliez, Audrey;Brain, Etienne;Desmoulins, Isabelle;Massard, Vincent;Patsouris, Anne;Goncalves, Anthony;Grinda, Thomas;Delaloge, Suzette;Bellera, Carine","First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.","European journal of cancer (Oxford, England : 1990)","England","eng","Multicenter Study","Metastatic breast cancer;Real-word data;Survival endpoints","Adult;Female;Humans;Breast Neoplasms;Databases, Factual;Progression-Free Survival;Receptor, ErbB-2;Retrospective Studies;Triple Negative Breast Neoplasms;Middle Aged;Aged","Adult;Female;Humans;Breast Neoplasms;Databases, Factual;Progression-Free Survival;Receptor, ErbB-2;Retrospective Studies;Triple Negative Breast Neoplasms;Middle Aged;Aged","To describe first-line treatment patterns, overall survival (OS) and real-world progression-free survival (rwPFS) in young women (<40) with metastatic breast cancer (mBC), as compared to women aged 40-69. Data on adult women diagnosed with mBC (2008-2017) were extracted from the ESME mBC database (NCT03275311) which includes consecutive patients starting first-line metastatic treatment in one of the 18 French Comprehensive cancer centers. We reported first-line therapeutic strategy and prognostic factors of OS and rwPFS for women aged < 40 and 40-69. In total, 14,897 mBC women were included (1512 aged <40). HR+ /HER2- mBC was the most frequent subtype. First-line treatment differed between young patients and older ones for HR+ /HER2- and Triple Negative (TN) mBC. Median OS for women aged < 40 and 40-69, respectively, was 46.9 and 46.2 months for HR+ /HER2- mBC; 13.5 and 15.2 for TN mBC; and, 60.7 and 55.1 for HER2 + mBC. Median rwPFS under first line treatment was 11.6 and 11.9 months for HR+ /HER2- in women aged < 40 and 40-69, respectively; 5.5 and 5.9 for TN, and, 13.3 and 12.9 for HER2 + . Factors associated with shorter OS and rwPFS were similar for both women aged < 40 and 40-69 and included ≥ 3 metastatic sites, visceral metastases, and longer MFI, with time-varying effects observed for several prognostic factors. Young women presented more frequently with TN and HER2 + subtypes and aggressive mBC than women aged 40-69 did. Prognostic factors of OS and rwPFS were quite similar between age groups and mBC subtypes.","University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Unicancer, Data and Partnership Department, 101 Rue de Tolbiac, 75654 Paris, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France.;Biometrics unit, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France; University of Montpellier, 34000 Montpellier, France.;Department of Medical Oncology, Oncopole Claudius Regaud - IUCT, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Boulevard Jacques Monod, 44805 Nantes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, 21079 Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, 15 rue André Boquel, 49055 Angers, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2024","196","10.1016/j.ejca.2023.113422","113422","","","37977105","37977105","PUBMED","University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Unicancer, Data and Partnership Department, 101 Rue de Tolbiac, 75654 Paris, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France.;Biometrics unit, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France; University of Montpellier, 34000 Montpellier, France.;Department of Medical Oncology, Oncopole Claudius Regaud - IUCT, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Boulevard Jacques Monod, 44805 Nantes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris, France.;Department of Medical Oncology, Centre Georges-François Leclerc, 21079 Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, 15 rue André Boquel, 49055 Angers, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, 33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000 Bordeaux, France."
"118","Kabirian R;Franzoi MA;Havas J;Coutant C;Tredan O;Levy C;Cottu P;Dhaini Mérimèche A;Guillermet S;Ferrero JM;Giacchetti S;Petit T;Dalenc F;Rouanet P;Everhard S;Martin AL;Pistilli B;Lambertini M;Vaz-Luis I;Di Meglio A","Kabirian, Rayan;Franzoi, Maria Alice;Havas, Julie;Coutant, Charles;Tredan, Olivier;Levy, Christelle;Cottu, Paul;Dhaini Mérimèche, Asma;Guillermet, Sophie;Ferrero, Jean-Marc;Giacchetti, Sylvie;Petit, Thierry;Dalenc, Florence;Rouanet, Philippe;Everhard, Sibille;Martin, Anne-Laure;Pistilli, Barbara;Lambertini, Matteo;Vaz-Luis, Ines;Di Meglio, Antonio","Chemotherapy-Related Amenorrhea and Quality of Life Among Premenopausal Women With Breast Cancer.","JAMA network open","United States","eng","Multicenter Study","","Female;Humans;Breast Neoplasms;Quality of Life;Amenorrhea;Cohort Studies;Prospective Studies","Female;Humans;Breast Neoplasms;Quality of Life;Amenorrhea;Cohort Studies;Prospective Studies","Younger survivors of breast cancer frequently report more treatment-related symptoms, mostly related to the menopausal transition. To assess factors associated with chemotherapy-related amenorrhea (CRA) and to evaluate its association with long-term quality of life (QOL). The prospective, longitudinal Cancer Toxicities Study, a multicenter French cohort study, includes women with a diagnosis of stage I to III breast cancer and collects data approximately yearly after diagnosis. The current study reports outcomes up to 4 years after diagnosis for participants enrolled from 2012 to 2017. Participants included premenopausal women younger than 50 years treated with chemotherapy and not receiving adjuvant ovarian function suppression. Data analysis was performed from September 2021 to June 2023. Clinical, socioeconomic, tumor, and treatment characteristics assessed at diagnosis (for the analysis of factors associated with CRA) and persistent CRA (for the QOL analysis). The main outcome of interest was CRA at year 1 (Y1), year 2 (Y2), and year 4 (Y4) after diagnosis. Generalized estimating equations assessed associations of exposure variables with CRA. In the QOL analysis, QOL at Y4 (assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires C30 and BR23) was the outcome of interest. Multivariable random-effect mixed models assessed the association of persistent CRA (ie, never recovering menses after treatment) with QOL. Among 1636 women, the mean (SD) age at diagnosis was 42.2 (5.6) years. Overall, 1242 of 1497 women (83.0%) reported CRA at Y1, 959 of 1323 women (72.5%) reported it at Y2, and 599 of 906 women (66.1%) reported it at Y4. Older age vs 18 to 34 years (adjusted odds ratio [OR] for 35 to 39 years, 1.84 [95% CI, 1.32 to 2.56]; adjusted OR for 40 to 44 years, 5.90 [95% CI, 4.23 to 8.24]; and adjusted OR for ≥45 years, 21.29 [95% CI, 14.34 to 31.61]) and receipt of adjuvant tamoxifen (adjusted OR, 1.97 [95% CI, 1.53 to 2.53]) were associated with higher likelihood of CRA. In the QOL analysis, 416 of 729 women (57.1%) had persistent CRA. However, late menses recovery among women aged 18 to 34 years with no menses at Y2 were reported by 11 of 21 women (52.4%) between Y2 and Y4. Persistent CRA was associated with worse insomnia (mean difference vs recovery at any time, 9.9 points [95% CI, 3.2 to 16.5 points]; P = .004), systemic therapy-related adverse effects (mean difference, 3.0 points [95% CI, 0.2 to 5.8 points]; P = .04), and sexual functioning (mean difference, -9.2 points [95% CI, -14.3 to -4.1 points]; P < .001) at Y4. In this cohort study of premenopausal women with breast cancer, persistent CRA was common, although some women recovered menses late, and was associated with worse long-term QOL. This study can help inform risk communication, personalized counseling, and early supportive care referrals for such patients.","Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Sorbonne Université, Paris, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Centre Georges François Leclerc, Dijon, France.;Centre Léon Bérard, Lyon, France.;Centre François Baclesse, Caen, France.;Institut Curie, Paris, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France.;Now with Centre Hospitalier de Lunéville-Ghemm, Pôle Mère-Enfant, Lunéville, France.;Centre Eugene-Marquis, Rennes, France.;Centre Antoine Lacassagne, Nice, France.;Hopital Saint Louis, Paris, France.;Centre Paul Strauss Centre de Lutte Contre le Cancer, Strasbourg, France.;Institut Claudius-Regaud, IUCT-Oncopole, Toulouse, France.;CRLC Val d'Aurelle, Montpellier, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Internal Medicine and Medical Specialties, School of Medicine University of Genova, Genova, Italy.;Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2023,"2023","6","10.1001/jamanetworkopen.2023.43910","e2343910","","","37971739","37971739","PUBMED","Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Sorbonne Université, Paris, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Centre Georges François Leclerc, Dijon, France.;Centre Léon Bérard, Lyon, France.;Centre François Baclesse, Caen, France.;Institut Curie, Paris, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandœuvre-lès-Nancy, France.;Now with Centre Hospitalier de Lunéville-Ghemm, Pôle Mère-Enfant, Lunéville, France.;Centre Eugene-Marquis, Rennes, France.;Centre Antoine Lacassagne, Nice, France.;Hopital Saint Louis, Paris, France.;Centre Paul Strauss Centre de Lutte Contre le Cancer, Strasbourg, France.;Institut Claudius-Regaud, IUCT-Oncopole, Toulouse, France.;CRLC Val d'Aurelle, Montpellier, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Internal Medicine and Medical Specialties, School of Medicine University of Genova, Genova, Italy.;Department of Medical Oncology, UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France."
"119","Lamarca A;Ostios L;McNamara MG;Garzon C;Gleeson JP;Edeline J;Herrero A;Hubner RA;Moreno V;Valle JW","Lamarca, Angela;Ostios, Lorena;McNamara, Mairéad G;Garzon, Carlos;Gleeson, Jack P;Edeline, Julien;Herrero, Ana;Hubner, Richard A;Moreno, Victor;Valle, Juan W","Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma.","Cancer treatment reviews","Netherlands","eng","Journal Article","Cholangiocarcinoma;FGFR;FGFR inhibitor;Fusion;Primary;Resistance;Secondary","Humans;Receptors, Fibroblast Growth Factor;Receptor, Fibroblast Growth Factor, Type 2;Cholangiocarcinoma;Protein Kinase Inhibitors;Disease Progression;Bile Ducts, Intrahepatic;Bile Duct Neoplasms","Humans;Receptors, Fibroblast Growth Factor;Receptor, Fibroblast Growth Factor, Type 2;Cholangiocarcinoma;Protein Kinase Inhibitors;Disease Progression;Bile Ducts, Intrahepatic;Bile Duct Neoplasms","Precision medicine is a major achievement that has impacted on management of patients diagnosed with advanced cholangiocarcinoma (CCA) over the last decade. Molecular profiling of CCA has identified targetable alterations, such as fibroblast growth factor receptor-2 (FGFR-2) fusions, and has thus led to the development of a wide spectrum of compounds. Despite favourable response rates, especially with the latest generation FGFRi, there are still a proportion of patients who will not achieve a radiological response to treatment, or who will have disease progression as the best response. In addition, for patients who do respond to treatment, secondary resistance frequently develops and mechanisms of such resistance are not fully understood. This review will summarise the current state of development of FGFR inhibitors in CCA, their mechanism of action, activity, and the hypothesised mechanisms of resistance.","Department of Medical Oncology - OncoHealth Institute - Instituto de Investigaciones Sanitarias FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester;START-FJD Phase I Unit, Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.;Department of Medical Oncology, Infanta Elena University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, University College Cork, Cork, Ireland.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Villalba University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.;START-FJD Phase I Unit, Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.","NA",0,"1532-1967","Cancer Treat Rev","Cancer Treat Rev",2023,"2023","121","10.1016/j.ctrv.2023.102627","102627","","","37925878","37925878","PUBMED","Department of Medical Oncology - OncoHealth Institute - Instituto de Investigaciones Sanitarias FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester;START-FJD Phase I Unit, Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.;Department of Medical Oncology, Infanta Elena University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, University College Cork, Cork, Ireland.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Villalba University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom.;START-FJD Phase I Unit, Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom."
"120","Malka D;Verret B;Faron M;Guimbaud R;Caramella C;Edeline J;Galais MP;Bengrine-Lefevre L;Smith D;Dupont-Bierre E;De Baere T;Goéré D;Dartigues P;Lacroix L;Boige V;Gelli M;Pignon JP;Ducreux M","Malka, David;Verret, Benjamin;Faron, Matthieu;Guimbaud, Rosine;Caramella, Caroline;Edeline, Julien;Galais, Marie-Pierre;Bengrine-Lefevre, Leïla;Smith, Denis;Dupont-Bierre, Eric;De Baere, Thierry;Goéré, Diane;Dartigues, Peggy;Lacroix, Ludovic;Boige, Valérie;Gelli, Maximiliano;Pignon, Jean-Pierre;Ducreux, Michel","Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.","European journal of cancer (Oxford, England : 1990)","England","eng","Multicenter Study","5-fluorouracil;Cetuximab;Hepatic arterial infusion chemotherapy;Liver metastases;Metastatic colorectal cancer;Oxaliplatin","Humans;Oxaliplatin;Cetuximab;Colorectal Neoplasms;Infusions, Intra-Arterial;Fluorouracil;Liver Neoplasms;Leucovorin;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome","Humans;Oxaliplatin;Cetuximab;Colorectal Neoplasms;Infusions, Intra-Arterial;Fluorouracil;Liver Neoplasms;Leucovorin;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome","The efficacy and tolerability of hepatic arterial infusion (HAI) oxaliplatin plus systemic 5-fluorouracil and cetuximab as frontline treatment in patients with colorectal liver metastases (CRLM) are unknown. In this multicenter, single-arm phase II study, patients with CRLM not amenable to curative-intent resection or requiring complex/major liver resection, and no prior chemotherapy for metastatic disease, received HAI oxaliplatin and intravenous 5-fluorouracil, leucovorin and cetuximab, every two weeks until disease progression, limiting toxicity or at least 3 months after complete response or curative-intent resection/ablation. The primary endpoint was overall response rate (ORR). 35 patients, mostly with bilateral (89%), multiple CRLM (>4, 86%; >10, 46%) were enrolled in eight centers. The ORR was 88% (95% CI, 71%-96%) among evaluable patients (n = 32), and 95% (95% CI 70-100%) among the 22 wild-type RAS/BRAF evaluable patients. After a median follow-up of 8.8 years (95% CI, 8.7-not reached), median progression-free survival was 17.9 months (95% CI, 15-23) and median overall survival (OS) was 46.3 months (95% CI, 40.0-not reached). 23 of the 35 patients (66%), including 22 (79%) of the 25 patients with wild-type RAS tumor, underwent curative-intent surgical resection and/or ablation of CRLM. HAI catheter remained patent in 86% of patients, allowing for a median of eight oxaliplatin infusions (range, 1-19). Treatment toxicity was manageable, without toxic death. HAI oxaliplatin plus systemic 5-fluorouracil and cetuximab appears highly effective in the frontline treatment of patients with unresectable CRLM and should be investigated further.","Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Département d'Oncologie Médicale, Institut Mutualiste Montsouris, Paris;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Biostatistique et Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France; Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Centre Hospitalier Universitaire, Toulouse, France.;Département d'Imagerie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Centre Eugène Marquis, Rennes, France.;Département d'Oncologie Médicale, Centre François Baclesse, Caen, France.;Centre Georges-François Leclerc, Dijon, France.;Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Centre Hospitalier Privé, Saint-Grégoire, France.;Département d'Imagerie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Pathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Biologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Biostatistique et Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France.;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Centre Hospitalier Universitaire Paul Brousse, Villejuif, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2023","195","10.1016/j.ejca.2023.113400","113400","","","37922632","37922632","PUBMED","Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Département d'Oncologie Médicale, Institut Mutualiste Montsouris, Paris;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Biostatistique et Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France; Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Centre Hospitalier Universitaire, Toulouse, France.;Département d'Imagerie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Centre Eugène Marquis, Rennes, France.;Département d'Oncologie Médicale, Centre François Baclesse, Caen, France.;Centre Georges-François Leclerc, Dijon, France.;Centre Hospitalier Universitaire Saint-André, Bordeaux, France.;Centre Hospitalier Privé, Saint-Grégoire, France.;Département d'Imagerie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Pathologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Biologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Département de Chirurgie Générale et Digestive, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Biostatistique et Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France.;Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Centre Hospitalier Universitaire Paul Brousse, Villejuif, France."
"121","Delestre F;Charles P;Karras A;Pagnoux C;Néel A;Cohen P;Aumaître O;Faguer S;Gobert P;Maurier F;Samson M;Godmer P;Bonnotte B;Cottin V;Hanrotel-Saliou C;Le Gallou T;Carron PL;Desmurs-Clavel H;Direz G;Jourde-Chiche N;Lifermann F;Martin-Silva N;Pugnet G;Quéméneur T;Matignon M;Benhamou Y;Daugas E;Lazaro E;Limal N;Ducret M;Huart A;Viallard JF;Hachulla E;Perrodeau E;Puechal X;Guillevin L;Porcher R;Terrier B","Delestre, Florence;Charles, Pierre;Karras, Alexandre;Pagnoux, Christian;Néel, Antoine;Cohen, Pascal;Aumaître, Olivier;Faguer, Stanislas;Gobert, Pierre;Maurier, François;Samson, Maxime;Godmer, Pascal;Bonnotte, Bernard;Cottin, Vincent;Hanrotel-Saliou, Catherine;Le Gallou, Thomas;Carron, Pierre-Louis;Desmurs-Clavel, Hélène;Direz, Guillaume;Jourde-Chiche, Noémie;Lifermann, Francois;Martin-Silva, Nicolas;Pugnet, Grégory;Quéméneur, Thomas;Matignon, Marie;Benhamou, Ygal;Daugas, Eric;Lazaro, Estibaliz;Limal, Nicolas;Ducret, Maïzé;Huart, Antoine;Viallard, Jean-François;Hachulla, Eric;Perrodeau, Elodie;Puechal, Xavier;Guillevin, Loïc;Porcher, Raphaël;Terrier, Benjamin","Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.","Annals of the rheumatic diseases","England","eng","Journal Article","Autoimmune Diseases;Rituximab;Systemic vasculitis","Humans;Rituximab;Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;Azathioprine;Antibodies, Antineutrophil Cytoplasmic;Recurrence;Remission Induction;Treatment Outcome;Immunosuppressive Agents","Humans;Rituximab;Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;Azathioprine;Antibodies, Antineutrophil Cytoplasmic;Recurrence;Remission Induction;Treatment Outcome;Immunosuppressive Agents","To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achieved a complete remission after induction therapy. Patients treated with 36-month RTX received either a fixed or a tailored regimen for the first 18 months and a fixed regimen for the last 18 months (36-month fixed/fixed RTX and 36-month tailored/fixed RTX, respectively). The Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis (MAINRITSAN) trials sequentially compared: 18-month fixed-schedule RTX versus AZA (MAINRITSAN); 18-month fixed-schedule RTX versus 18-month tailored-RTX (MAINRITSAN2); and extended therapy to 36 months with four additional RTX infusions after MAINRITSAN2 versus placebo (MAINRITSAN3). Patients were then followed prospectively through month 84 and their data were pooled to analyse relapses and adverse events. The primary endpoint was relapse-free survival at month 84. 277 patients were enrolled and divided in 5 groups: AZA (n=58), 18-month fixed-schedule RTX (n=97), 18-month tailored-RTX (n=40), 36-month tailored/fixed RTX (n=42), 36-month fixed/fixed RTX (n=41). After adjustment for prognostic factors, 18-month fixed-schedule RTX was superior to AZA in preventing major relapses at month 84 (HR 0.38, 95% CI 0.20 to 0.71). The 18-month tailored-RTX regimen was associated with an increased risk of major relapse compared with fixed-schedule regimen (HR 2.92, 95% CI 1.43 to 5.96). The risk of major relapse was similar between 36-month fixed/fixed and 18-month fixed-RTX (HR 0.69, 95% CI 0.38 to 1.25). According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.","Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Université Paris Cité, Paris, France.;Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France.;Université Paris Cité, Paris, France.;Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France.;University of Toronto, Toronto, Ontario, Canada.;Vasculitis clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.;Department of Internal Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Department of Internal Medicine, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Département de Néphrologie et Transplantation d'Organes, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Département de médecine, Hopital Général Henri-Duffaut, Avignon, France.;Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Département de Hématologie Immunologie, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.;Department of Nephrology, Centre Hospitalier Universitaire de Brest, Hôpital la Cavale Blanche, Brest, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de néphrologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France.;Rheumatology Department, Le Mans General Hospital, Le Mans, France.;Centre de Néphrologie et Transplantation Rénale, Hôpital de La Conception, Aix-Marseille Université, Marseille, France.;Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Département de Néphrologie et de Médecine Interne, Centre Hospitalier de Valenciennes, Valenciennes, France.;Nephrology and Renal Transplantation Department, Hopitaux Universitaires Henri Mondor, Créteil, France.;Department of Internal Medicine, Centre Hospitalier Universitaire Charles Nicolle, Rouen, France.;Department of Nephrology, Hopital Bichat - Claude-Bernard, Paris, France.;Department of Internal Medicine, Bordeaux University Hospital, Pessac, France.;Department of Internal Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Department of Nephrology, Annecy Hospital, Annecy, France.;Department of Nephrology, Hospital Rangueil, Toulouse, France.;Department of Internal Medicine, Bordeaux University Hospital, Pessac, France.;Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest (CERAINO), Centre Hospitalier Universitaire de Lille, Lille, France.;Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Université Paris Cité, Paris, France.;Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris;Université Paris Cité, Paris, France.","NA",0,"1468-2060","Ann Rheum Dis","Ann Rheum Dis",2023,"2024","83","10.1136/ard-2023-224623","233-241","","","37918894","37918894","PUBMED","Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Université Paris Cité, Paris, France.;Department of Internal Medicine, Institut Mutualiste Montsouris, Paris, France.;Université Paris Cité, Paris, France.;Department of Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France.;University of Toronto, Toronto, Ontario, Canada.;Vasculitis clinic, Mount Sinai Hospital, Toronto, Ontario, Canada.;Department of Internal Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Department of Internal Medicine, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Département de Néphrologie et Transplantation d'Organes, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Département de médecine, Hopital Général Henri-Duffaut, Avignon, France.;Department of Internal Medicine, Hôpitaux Privés de Metz, Metz, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Département de Hématologie Immunologie, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.;Department of Nephrology, Centre Hospitalier Universitaire de Brest, Hôpital la Cavale Blanche, Brest, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de néphrologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France.;Rheumatology Department, Le Mans General Hospital, Le Mans, France.;Centre de Néphrologie et Transplantation Rénale, Hôpital de La Conception, Aix-Marseille Université, Marseille, France.;Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Caen, Caen, France.;Department of Internal Medicine, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Département de Néphrologie et de Médecine Interne, Centre Hospitalier de Valenciennes, Valenciennes, France.;Nephrology and Renal Transplantation Department, Hopitaux Universitaires Henri Mondor, Créteil, France.;Department of Internal Medicine, Centre Hospitalier Universitaire Charles Nicolle, Rouen, France.;Department of Nephrology, Hopital Bichat - Claude-Bernard, Paris, France.;Department of Internal Medicine, Bordeaux University Hospital, Pessac, France.;Department of Internal Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Department of Nephrology, Annecy Hospital, Annecy, France.;Department of Nephrology, Hospital Rangueil, Toulouse, France.;Department of Internal Medicine, Bordeaux University Hospital, Pessac, France.;Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest (CERAINO), Centre Hospitalier Universitaire de Lille, Lille, France.;Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris, France.;Université Paris Cité, Paris, France.;Université Paris Cité, Paris, France.;Center of Research in Epidemiology and Statistics Sorbonne Paris Cité, Paris, France.;Department of Internal Medicine, National Reference Center for Rare Systemic Autoimmune Diseases, AP-HP.Centre, Hospital Cochin, Paris;Université Paris Cité, Paris, France."
"122","Duffaud F;Blay JY;Le Cesne A;Chevreau C;Boudou-Rouquette P;Kalbacher E;Penel N;Perrin C;Laurence V;Bompas E;Saada-Bouzid E;Delcambre C;Bertucci F;Cancel M;Schiffler C;Monard L;Bouvier C;Vidal V;Gaspar N;Chabaud S","Duffaud, Florence;Blay, Jean-Yves;Le Cesne, Axel;Chevreau, Christine;Boudou-Rouquette, Pascaline;Kalbacher, Elsa;Penel, Nicolas;Perrin, Christophe;Laurence, Valérie;Bompas, Emmanuelle;Saada-Bouzid, Esma;Delcambre, Corinne;Bertucci, François;Cancel, Mathilde;Schiffler, Camille;Monard, Laure;Bouvier, Corinne;Vidal, Vincent;Gaspar, Nathalie;Chabaud, Sylvie","Regorafenib in patients with advanced Ewing sarcoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre Phase II study.","British journal of cancer","England","eng","Randomized Controlled Trial","","Humans;Sarcoma, Ewing;Cohort Studies;Sarcoma;Phenylurea Compounds;Double-Blind Method","Humans;Sarcoma, Ewing;Cohort Studies;Sarcoma;Phenylurea Compounds;Double-Blind Method","The REGOBONE multi-cohort study explored the efficacy and safety of regorafenib for patients with advanced bone sarcomas; this report details the Ewing sarcoma (ES) cohort. Patients with relapsed ES progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progression. The primary endpoint was the progression-free rate at 8 weeks. With one-sided α of 0.05, and 80% power, at least 14/24 progression-free patients at 8 weeks were needed for success. From September 2014 to November 2019, 41 patients were accrued. 36 patients were evaluable for efficacy: 23 on regorafenib and 13 on placebo. Thirteen patients (56%; one-sided 95% CI [37.5%-[)) were progression-free at 8 weeks on regorafenib vs. 1 (7.7%; 95% CI [0.4%-[) on placebo. Median PFS was 11.4 weeks on regorafenib, and 3.9 weeks on placebo. Ten placebo patients crossed over to receive regorafenib after progression. The most common grade ≥3 regorafenib-related adverse events were pain (22%), asthenia (17%), thrombocytopenia (13%) and diarrhoea (13%). Although the primary endpoint was not met statistically in this randomised cohort, there is evidence to suggest that regorafenib might modestly delay tumour progression in relapsed ES after failure of prior chemotherapy.","APHM Hopital La Timone, Medical Oncology Unit, and Aix-Marseille University (AMU), Marseille;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, CHU J Minjoz, Besançon, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Centre René Gauduchau, Saint Herblain, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Unicancer, Paris, France.;APHM Hopital La Timone, Pathology Department, and Aix-Marseille University, Marseille, France.;APHM Hopital La Timone, Radiology Department, and Aix-Marseille University Marseille, Marseille, France.;Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2022,"2023","129","10.1038/s41416-023-02413-9","1940-1948","","","37914801","37914801","PUBMED","APHM Hopital La Timone, Medical Oncology Unit, and Aix-Marseille University (AMU), Marseille;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, CHU J Minjoz, Besançon, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Centre René Gauduchau, Saint Herblain, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Unicancer, Paris, France.;APHM Hopital La Timone, Pathology Department, and Aix-Marseille University, Marseille, France.;APHM Hopital La Timone, Radiology Department, and Aix-Marseille University Marseille, Marseille, France.;Department of Oncology for Child and Adolescent, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Statistics, Centre Léon Bérard, Lyon, France."
"123","Schortgen F;Tabra Osorio C;Carpentier D;Henry M;Beuret P;Lacave G;Simon G;Blanchard PY;Gobe T;Guillon A;Bitker L;Duhommet G;Quenot JP;Le Meur M;Jochmans S;Dubouloz F;Mainguy N;Saletes J;Creutin T;Nicolas P;Senay J;Berthelot AL;Rizk D;Tran Van D;Riviere A;Heili-Frades SB;Nunes J;Robquin N;Lhotellier S;Ledochowski S;Guénégou-Arnoux A;Constan A","Schortgen, Frédérique;Tabra Osorio, Cécilia;Carpentier, Dorothée;Henry, Matthieu;Beuret, Pascal;Lacave, Guillaume;Simon, Georges;Blanchard, Pierre-Yves;Gobe, Tiphanie;Guillon, Antoine;Bitker, Laurent;Duhommet, Guillaume;Quenot, Jean-Pierre;Le Meur, Matthieu;Jochmans, Sébastien;Dubouloz, Fabrice;Mainguy, Nolwenn;Saletes, Josselin;Creutin, Thibault;Nicolas, Pierre;Senay, Julien;Berthelot, Anne-Lise;Rizk, Delphine;Tran Van, David;Riviere, Audrey;Heili-Frades, Sarah Beatrice;Nunes, Justine;Robquin, Nadine;Lhotellier, Sylvie;Ledochowski, Stanislas;Guénégou-Arnoux, Armelle;Constan, Adrien","Fluid Intake in Critically Ill Patients: The ""Save Useless Fluids For Intensive Resuscitation"" Multicenter Prospective Cohort Study.","Critical care medicine","United States","eng","Multicenter Study","","Humans;Prospective Studies;Critical Illness;Cohort Studies;Fluid Therapy;Crystalloid Solutions;Resuscitation","Humans;Prospective Studies;Critical Illness;Cohort Studies;Fluid Therapy;Crystalloid Solutions;Resuscitation","Patients at risk of adverse effects related to positive fluid balance could benefit from fluid intake optimization. Less attention is paid to nonresuscitation fluids. We aim to evaluate the heterogeneity of fluid intake at the initial phase of resuscitation. Prospective multicenter cohort study. Thirty ICUs across France and one in Spain. Patients requiring vasopressors and/or invasive mechanical ventilation. None. All fluids administered by vascular or enteral lines were recorded over 24 hours following admission and were classified in four main groups according to their predefined indication: fluids having a well-documented homeostasis goal (resuscitation fluids, rehydration, blood products, and nutrition), drug carriers, maintenance fluids, and fluids for technical needs. Models of regression were constructed to determine fluid intake predicted by patient characteristics. Centers were classified according to tertiles of fluid intake. The cohort included 296 patients. The median total volume of fluids was 3546 mL (interquartile range, 2441-4955 mL), with fluids indisputably required for body fluid homeostasis representing 36% of this total. Saline, glucose-containing high chloride crystalloids, and balanced crystalloids represented 43%, 27%, and 16% of total volume, respectively. Whatever the class of fluids, center of inclusion was the strongest factor associated with volumes. Compared with the first tertile, the difference between the volume predicted by patient characteristics and the volume given was +1.2 ± 2.0 L in tertile 2 and +3.0 ± 2.8 L in tertile 3. Fluids indisputably required for body fluid homeostasis represent the minority of fluid intake during the 24 hours after ICU admission. Center effect is the strongest factor associated with the volume of fluids. Heterogeneity in practices suggests that optimal strategies for volume and goals of common fluids administration need to be developed.","Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France.;Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France.;Department of Medical Intensive Care, Rouen University Hospital, Rouen, France.;Médecine Intensive Réanimation, Centre hospitalier départemental Vendée, La Roche-sur-Yon, France.;Réanimation et Soins continus, Centre Hospitalier, Roanne, France.;Réanimation médico-chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Réanimation polyvalente, Centre hospitalier, Troyes, France.;Médecine Intensive et Réanimation, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Paris, France.;Réanimation médicale, Centre Hospitalier Universitaire de Rennes-Hôpital Pontchaillou, Rennes, France.;Intensive Care Unit, Tours University Hospital, Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France.;Médecine Intensive-Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.;Université Claude Bernard Lyon 1, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, Inserm, CREATIS UMR 5220, U1294, Villeurbanne, France.;Unité Réanimation Polyvalente, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.;Department of Intensive Care, Burgundy University Hospital, Dijon, France.;Lipness Team, INSERM Research Center LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France.;INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France.;Service de Réanimation, Groupe Hospitalier Nord Essonne, Longjumeau, France.;Service de Médecine Intensive-Réanimation et Unité de Recherche Clinique, Groupe Hospitalier Sud Ile-de-France, Melun, France.;Réanimation des urgences, Hôpitaux universitaires de Marseille Timone, Marseille, France.;Réanimation polyvalente, Centre hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Médico-Chirurgicale et USC, Centre hospitalier, Le Mans, France.;Service de médecine intensive-réanimation, Hôpitaux Universitaires APHP-Paris-Saclay, Le Kremlin-Bicêtre, France.;Médecine Intensive Réanimation, CHU Grenoble-Alpes, La Tronche, France.;Service de réanimation polyvalente, Hôpital Foch, Suresnes, France.;Service de réanimation polyvalente, Centre hospitalier, Cholet, France.;Service de Médecine Intensive-Réanimation, Groupe Hospitalier Pitié Salpêtrière APHP-Sorbonne Université, Paris, France.;Réanimation polyvalente, Hôpital d'Instruction des Armées Robert Picqué, Villenave d'Ornon, France.;Réanimation Polyvalente, CHU de La Réunion, Saint Pierre, France.;Intermediate Respiratory Care Unit, University Hospital Jiménez Díaz Quirón Health Foundation of Madrid, Madrid, Spain.;Réanimation adultes, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Médecine Intensive Réanimation, Centre hospitalier intercommunal, Villeneuve St Georges, France.;Réanimation-Hôpitaux universitaires, Strasbourg, France.;Réanimation polyvalente, Groupe hospitalier nord Dauphiné, Bourgoin-Jallieu, France.;Université Paris Cité, AP-HP, Hôpital européen Georges Pompidou, Unité de Recherche Clinique, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, INSERM, Inria, HeKA, Paris, France.;Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France.","NA",0,"1530-0293","Crit Care Med","Crit Care Med",2023,"2024","52","10.1097/CCM.0000000000006091","258-267","","","37909832","37909832","PUBMED","Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France.;Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France.;Department of Medical Intensive Care, Rouen University Hospital, Rouen, France.;Médecine Intensive Réanimation, Centre hospitalier départemental Vendée, La Roche-sur-Yon, France.;Réanimation et Soins continus, Centre Hospitalier, Roanne, France.;Réanimation médico-chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Réanimation polyvalente, Centre hospitalier, Troyes, France.;Médecine Intensive et Réanimation, Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Paris, France.;Réanimation médicale, Centre Hospitalier Universitaire de Rennes-Hôpital Pontchaillou, Rennes, France.;Intensive Care Unit, Tours University Hospital, Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France.;Médecine Intensive-Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.;Université Claude Bernard Lyon 1, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, CNRS, Inserm, CREATIS UMR 5220, U1294, Villeurbanne, France.;Unité Réanimation Polyvalente, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France.;Department of Intensive Care, Burgundy University Hospital, Dijon, France.;Lipness Team, INSERM Research Center LNC-UMR1231 and LabEx LipSTIC, University of Burgundy, Dijon, France.;INSERM CIC 1432, Clinical Epidemiology, University of Burgundy, Dijon, France.;Service de Réanimation, Groupe Hospitalier Nord Essonne, Longjumeau, France.;Service de Médecine Intensive-Réanimation et Unité de Recherche Clinique, Groupe Hospitalier Sud Ile-de-France, Melun, France.;Réanimation des urgences, Hôpitaux universitaires de Marseille Timone, Marseille, France.;Réanimation polyvalente, Centre hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Médico-Chirurgicale et USC, Centre hospitalier, Le Mans, France.;Service de médecine intensive-réanimation, Hôpitaux Universitaires APHP-Paris-Saclay, Le Kremlin-Bicêtre, France.;Médecine Intensive Réanimation, CHU Grenoble-Alpes, La Tronche, France.;Service de réanimation polyvalente, Hôpital Foch, Suresnes, France.;Service de réanimation polyvalente, Centre hospitalier, Cholet, France.;Service de Médecine Intensive-Réanimation, Groupe Hospitalier Pitié Salpêtrière APHP-Sorbonne Université, Paris, France.;Réanimation polyvalente, Hôpital d'Instruction des Armées Robert Picqué, Villenave d'Ornon, France.;Réanimation Polyvalente, CHU de La Réunion, Saint Pierre, France.;Intermediate Respiratory Care Unit, University Hospital Jiménez Díaz Quirón Health Foundation of Madrid, Madrid, Spain.;Réanimation adultes, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Médecine Intensive Réanimation, Centre hospitalier intercommunal, Villeneuve St Georges, France.;Réanimation-Hôpitaux universitaires, Strasbourg, France.;Réanimation polyvalente, Groupe hospitalier nord Dauphiné, Bourgoin-Jallieu, France.;Université Paris Cité, AP-HP, Hôpital européen Georges Pompidou, Unité de Recherche Clinique, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, INSERM, Inria, HeKA, Paris, France.;Réanimation et surveillance continue adulte, Centre hospitalier intercommunal, Créteil, France."
"124","Jones RH;Fizazi K;James ND;Tammela TL;Matsubara N;Priou F;Beuzeboc P;Lesimple T;Bono P;Kataja V;Garcia JA;Protheroe A;Shore N;Aspegren J;Joensuu H;Kuss I;Fiala-Buskies S;Vjaters E","Jones, Robert Hugh;Fizazi, Karim;James, Nicholas D;Tammela, Teuvo L;Matsubara, Nobuaki;Priou, Frank;Beuzeboc, Philippe;Lesimple, Thierry;Bono, Petri;Kataja, Vesa;Garcia, Jorge A;Protheroe, Andrew;Shore, Neal;Aspegren, John;Joensuu, Heikki;Kuss, Iris;Fiala-Buskies, Sabine;Vjaters, Egils","Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.","Prostate cancer and prostatic diseases","England","eng","Journal Article","","Humans;Male;Prostatic Neoplasms, Castration-Resistant;Aged;Middle Aged;Pyrazoles;Neoplasm Metastasis;Aged, 80 and over;Treatment Outcome;Sulfonamides;Androgen Receptor Antagonists;Antineoplastic Agents","Humans;Male;Prostatic Neoplasms, Castration-Resistant;Aged;Middle Aged;Pyrazoles;Neoplasm Metastasis;Aged, 80 and over;Treatment Outcome;Sulfonamides;Androgen Receptor Antagonists;Antineoplastic Agents","In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. Treatment-emergent adverse events (TEAEs) for patients receiving darolutamide for a median of 38 months (n = 13) are described in this pooled analysis of individual patient data from phase 1/2 studies. All patients reported TEAEs (mostly grade 1/2). The most common TEAEs were diarrhea, abdominal pain, and nausea. Serious TEAEs were reported in six patients (none related to darolutamide). All treatment-related TEAEs (n = 5) were grade 1. Long-term darolutamide treatment was well tolerated; no new safety signals observed. In patients with mCRPC, long-term darolutamide treatment was well tolerated and no new safety signals were observed. These findings are consistent with previous reports, demonstrating a favorable safety and tolerability profile of darolutamide.","Cardiff University and Velindre Cancer Centre, Cardiff;Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.;The Institute of Cancer Research, London, UK.;Tampere University Hospital, Tampere, Finland.;National Cancer Center Hospital East, Chiba, Japan.;Centre Hospitalier Départemental Vendée, La Roche-Sur-Yon, France.;Curie Institute, Paris, France.;Centre Eugène Marquis, Rennes, France.;Terveystalo Finland and University of Helsinki, Helsinki, Finland.;Kuopio University Hospital, Kuopio, Finland.;University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.;Oxford University Hospitals NHS Foundation Trust, Oxford, UK.;Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.;Orion Corporation, Espoo, Finland.;Orion Corporation, Espoo, Finland.;Bayer AG, Berlin, Germany.;Bayer AG, Wuppertal, Germany.;P. Stradins Clinical University Hospital, Riga, Latvia.","NA",0,"1476-5608","Prostate Cancer Prostatic Dis","Prostate Cancer Prostatic Dis",2023,"2024","27","10.1038/s41391-023-00740-9","786-789","","","37884613","37884613","PUBMED","Cardiff University and Velindre Cancer Centre, Cardiff;Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.;The Institute of Cancer Research, London, UK.;Tampere University Hospital, Tampere, Finland.;National Cancer Center Hospital East, Chiba, Japan.;Centre Hospitalier Départemental Vendée, La Roche-Sur-Yon, France.;Curie Institute, Paris, France.;Centre Eugène Marquis, Rennes, France.;Terveystalo Finland and University of Helsinki, Helsinki, Finland.;Kuopio University Hospital, Kuopio, Finland.;University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.;Oxford University Hospitals NHS Foundation Trust, Oxford, UK.;Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA.;Orion Corporation, Espoo, Finland.;Orion Corporation, Espoo, Finland.;Bayer AG, Berlin, Germany.;Bayer AG, Wuppertal, Germany.;P. Stradins Clinical University Hospital, Riga, Latvia."
"125","de Hoog S;Walsh TJ;Ahmed SA;Alastruey-Izquierdo A;Alexander BD;Arendrup MC;Babady E;Bai F-Y;Balada-Llasat J-M;Borman A;Chowdhary A;Clark A;Colgrove RC;Cornely OA;Dingle TC;Dufresne PJ;Fuller J;Gangneux J-P;Gibas C;Glasgow H;Gräser Y;Guillot J;Groll AH;Haase G;Hanson K;Harrington A;Hawksworth DL;Hayden RT;Hoenigl M;Hubka V;Johnson K;Kus JV;Li R;Meis JF;Lackner M;Lanternier F;Leal SM;Lee F;Lockhart SR;Luethy P;Martin I;Kwon-Chung KJ;Meyer W;Nguyen MH;Ostrosky-Zeichner L;Palavecino E;Pancholi P;Pappas PG;Procop GW;Redhead SA;Rhoads DD;Riedel S;Stevens B;Sullivan KO;Vergidis P;Roilides E;Seyedmousavi A;Tao L;Vicente VA;Vitale RG;Wang Q-M;Wengenack NL;Westblade L;Wiederhold N;White L;Wojewoda CM;Zhang SX","de Hoog, Sybren;Walsh, Thomas J;Ahmed, Sarah A;Alastruey-Izquierdo, Ana;Alexander, Barbara D;Arendrup, Maiken Cavling;Babady, Esther;Bai, Feng-Yan;Balada-Llasat, Joan-Miquel;Borman, Andrew;Chowdhary, Anuradha;Clark, Andrew;Colgrove, Robert C;Cornely, Oliver A;Dingle, Tanis C;Dufresne, Philippe J;Fuller, Jeff;Gangneux, Jean-Pierre;Gibas, Connie;Glasgow, Heather;Gräser, Yvonne;Guillot, Jacques;Groll, Andreas H;Haase, Gerhard;Hanson, Kimberly;Harrington, Amanda;Hawksworth, David L;Hayden, Randall T;Hoenigl, Martin;Hubka, Vit;Johnson, Kristie;Kus, Julianne V;Li, Ruoyu;Meis, Jacques F;Lackner, Michaela;Lanternier, Fanny;Leal, Sixto M;Lee, Francesca;Lockhart, Shawn R;Luethy, Paul;Martin, Isabella;Kwon-Chung, Kyung J;Meyer, Wieland;Nguyen, M Hong;Ostrosky-Zeichner, Luis;Palavecino, Elizabeth;Pancholi, Preeti;Pappas, Peter G;Procop, Gary W;Redhead, Scott A;Rhoads, Daniel D;Riedel, Stefan;Stevens, Bryan;Sullivan, Kaede Ota;Vergidis, Paschalis;Roilides, Emmanuel;Seyedmousavi, Amir;Tao, Lili;Vicente, Vania A;Vitale, Roxana G;Wang, Qi-Ming;Wengenack, Nancy L;Westblade, Lars;Wiederhold, Nathan;White, Lewis;Wojewoda, Christina M;Zhang, Sean X","A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC.","Journal of clinical microbiology","United States","eng","Journal Article","fungi;nomenclature;taxonomy","Humans;Phylogeny;Databases, Factual;Fungi","Humans;Phylogeny;Databases, Factual;Fungi","The rapid pace of name changes of medically important fungi is creating challenges for clinical laboratories and clinicians involved in patient care. We describe two sources of name change which have different drivers, at the species versus the genus level. Some suggestions are made here to reduce the number of name changes. We urge taxonomists to provide diagnostic markers of taxonomic novelties. Given the instability of phylogenetic trees due to variable taxon sampling, we advocate to maintain genera at the largest possible size. Reporting of identified species in complexes or series should where possible comprise both the name of the overarching species and that of the molecular sibling, often cryptic species. Because the use of different names for the same species will be unavoidable for many years to come, an open access online database of the names of all medically important fungi, with proper nomenclatural designation and synonymy, is essential. We further recommend that while taxonomic discovery continues, the adaptation of new name changes by clinical laboratories and clinicians be reviewed routinely by a standing committee for validation and stability over time, with reference to an open access database, wherein reasons for changes are listed in a transparent way.","Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi , Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital , Beijing, China.;Department of Basic Pathology, Federal University of Paraná , Curitiba, Brazil.;Research Center for Medical Mycology, Peking University , Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Center for Innovative Therapeutics and Diagnostics , Richmond, Virginia, USA.;University of Maryland School of Medicine , Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA).;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;European Confederation of Medical Mycology (ECMM).;Clinical and Laboratory Standards Institute (CLSI).;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics.;Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi , Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Mycology Reference Laboratory, Spanish National Centre for Microbiology , Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC).;Departments of Medicine and Pathology, Duke University , Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet , Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, USA.;Mycology Committee of Chinese Society for Microbiology.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences , Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia Pacific Society for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology at The Ohio State University Wexner Medical Center , Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England , Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi , Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Texas Southwestern Medical Center , Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital , Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA).;European Confederation of Medical Mycology (ECMM).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases , Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology , Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Alberta Precision Laboratories, Public Health Laboratory , Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Mycology Department, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue , Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC).;Department of Pathology and Laboratory Medicine, London Health Sciences Center , London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM).;Department of Mycology, Centre Hospitalier Universitaire de Rennes , Rennes, France.;University of Texas Health Science Center , San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Molecular Microbiology, Department of Pathology, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University , Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique , Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology and Center for Bone Marrow Transplantation, University Children's Hospital , Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital , Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Utah School of Medicine , Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Loyola University Health System, Loyola University Chicago , Maywood, Illinois, USA.;Royal Botanic Gardens, Kew , Richmond, Surrey, United Kingdom.;Natural History Museum , London, United Kingdom.;University of Southampton , Southampton, United Kingdom.;Jilin Agricultural University , Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Clinical and Molecular Microbiology, Department of Pathology, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;European Confederation of Medical Mycology (ECMM).;Division of Infectious Diseases, Medical University of Graz , Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz , Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology , The Hague, the Netherlands.;Department of Botany, Charles University , Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine , Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Public Health Ontario , Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto , Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital , Beijing, China.;Research Center for Medical Mycology, Peking University , Beijing, China.;ISHAM Working Group on Diagnostics.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases , Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology , Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck , Innsbruck, Austria.;Institut Pasteur , Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Clinical and Laboratory Standards Institute (CLSI).;University of Alabama at Birmingham , Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Texas Southwestern Medical Center , Dallas, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Centers for Disease Control and Prevention , Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine , Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Dartmouth Health , Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA).;Westerdijk Fungal Biodiversity Institute , Utrecht, The Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;University of Texas Health Science Center at Houston , Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center , Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology at The Ohio State University Wexner Medical Center , Columbus, Ohio, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;University of Alabama at Birmingham , Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;The American Board of Pathology , Tampa, Florida, USA.;American Board of Pathology (ABP).;Nomenclature Committee for Fungi, International Mycological Association (IMA).;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada , Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic , Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic , Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Beth Israel Deaconess Medical Center , Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mayo Clinic , Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;European Confederation of Medical Mycology (ECMM).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Hippokration Hospital , Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health.;Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health , Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Vanderbilt University Medical Center , Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná , Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET) , Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía , Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University , Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mayo Clinic , Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College , New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Clinical and Laboratory Standards Institute (CLSI).;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center , San Antonio, Texas, USA.;Public Health Wales Microbiology , Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center , Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Fungal Diagnostics Laboratory Consortium (FDLC).;Johns Hopkins University School of Medicine , Baltimore, Maryland, USA.","NA",0,"1098-660X","J Clin Microbiol","J Clin Microbiol",2023,"2023","61","10.1128/jcm.00873-23","e0087323","","","37882528","37882528","PUBMED","Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi , Hilversum, the Netherlands.;Department of Dermatology and Venereology, Peking University First Hospital , Beijing, China.;Department of Basic Pathology, Federal University of Paraná , Curitiba, Brazil.;Research Center for Medical Mycology, Peking University , Beijing, China.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Center for Innovative Therapeutics and Diagnostics , Richmond, Virginia, USA.;University of Maryland School of Medicine , Baltimore, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA).;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;European Confederation of Medical Mycology (ECMM).;Clinical and Laboratory Standards Institute (CLSI).;Medical Mycological Society of the Americas (MMSA).;ISHAM Working Group on Diagnostics.;Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;Foundation Atlas of Clinical Fungi , Hilversum, the Netherlands.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Mycology Reference Laboratory, Spanish National Centre for Microbiology , Madrid, Spain.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Fungal Diagnostics Laboratory Consortium (FDLC).;Departments of Medicine and Pathology, Duke University , Durham, North Carolina, USA.;Department of Microbiology and Infection Control, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Microbiology, Copenhagen University Hospital Rigshospitalet , Copenhagen, Denmark.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center , New York, USA.;Mycology Committee of Chinese Society for Microbiology.;Institute of Microbiology, State Key Laboratory of Mycology, Chinese Academy of Sciences , Beijing, China.;Medical Mycology Society of Chinese Medicine and Education Association.;Asia Pacific Society for Medical Mycology.;ISHAM Working Group Veterinary Mycology and One Health.;Mycological Society of China (MSC).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology at The Ohio State University Wexner Medical Center , Columbus, Ohio, USA.;National Mycology Reference Laboratory, Public Health England , Bristol, United Kingdom.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Department of Microbiology, National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Medical Mycology Unit, Vallabhbhai Patel Chest Institute, University of Delhi , Delhi, India.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Texas Southwestern Medical Center , Dallas, Texas, USA.;Division of Infectious Diseases, Mount Auburn Hospital , Cambridge, Massachusetts, USA.;Infectious Diseases Society of America (ISDA).;European Confederation of Medical Mycology (ECMM).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases , Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology , Cologne, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Alberta Precision Laboratories, Public Health Laboratory , Calgary, Alberta, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Mycology Department, Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec (INSPQ), Sainte-Anne-de-Bellevue , Québec, Canada.;Fungal Diagnostics Laboratory Consortium (FDLC).;Department of Pathology and Laboratory Medicine, London Health Sciences Center , London, Ontario, Canada.;European Confederation of Medical Mycology (ECMM).;Department of Mycology, Centre Hospitalier Universitaire de Rennes , Rennes, France.;University of Texas Health Science Center , San Antonio, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Molecular Microbiology, Department of Pathology, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.;Department of Parasitology (Charité), Institute of Microbiology and Hygiene, Humboldt University , Berlin, Germany.;ISHAM Working Group Veterinary Mycology and One Health.;Onoris, École Nationale Vétérinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique , Nantes, France.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Infectious Disease Research Program, Department of Pediatric Hematology and Oncology and Center for Bone Marrow Transplantation, University Children's Hospital , Münster, Germany.;Laboratory Diagnostic Center, RWTH Aachen University Hospital , Aachen, Germany.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Utah School of Medicine , Salt Lake City, Utah, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Loyola University Health System, Loyola University Chicago , Maywood, Illinois, USA.;Royal Botanic Gardens, Kew , Richmond, Surrey, United Kingdom.;Natural History Museum , London, United Kingdom.;University of Southampton , Southampton, United Kingdom.;Jilin Agricultural University , Chanchung, China.;General Committee for Nomenclature, International Botanical Congress (IBC).;Advisory Board of International Commission on the Taxonomy of Fungi (ICTF).;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;Clinical and Molecular Microbiology, Department of Pathology, St. Jude Children's Research Hospital , Memphis, Tennessee, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;European Confederation of Medical Mycology (ECMM).;Division of Infectious Diseases, Medical University of Graz , Graz, Austria.;Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz , Graz, Austria.;European Hematology Association, Specialized Working Group for Infections in Hematology , The Hague, the Netherlands.;Department of Botany, Charles University , Prague, Czechia.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine , Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Public Health Ontario , Toronto, Ontario, Canada.;Department of Laboratory Medicine and Pathobiology, Canada and University of Toronto , Toronto, Ontario, Canada.;Department of Dermatology and Venereology, Peking University First Hospital , Beijing, China.;Research Center for Medical Mycology, Peking University , Beijing, China.;ISHAM Working Group on Diagnostics.;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Antifungal Susceptibility Testing Subcommittee of European Committee of Antimicrobial Susceptibility Testing (EUCAST-AFST).;Medical Mycology Society of Chinese Medicine and Education Association.;Radboudumc-CWZ Centre of Expertise for Mycology , Nijmegen, the Netherlands.;ISHAM Working Group on Diagnostics.;University of Cologne, Faculty of Medicine, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases , Cologne, Germany.;Department I of Internal Medicine, University of Cologne, Excellence Center for Medical Mycology , Cologne, Germany.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck , Innsbruck, Austria.;Institut Pasteur , Paris, France.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Clinical and Laboratory Standards Institute (CLSI).;University of Alabama at Birmingham , Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Texas Southwestern Medical Center , Dallas, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Centers for Disease Control and Prevention , Atlanta, Georgia, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, UMMC Laboratories of Pathology, University of Maryland School of Medicine , Baltimore, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Dartmouth Health , Lebanon, New Hampshire, USA.;National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland, USA.;Nomenclature Committee for Fungi, International Mycological Association (IMA).;Westerdijk Fungal Biodiversity Institute , Utrecht, The Netherlands.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Medical Mycological Society of the Americas (MMSA).;University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;University of Texas Health Science Center at Houston , Houston, Texas, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology Laboratory, Wake Forest Baptist Medical Center , Winston-Salem, North Carolina, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical Microbiology at The Ohio State University Wexner Medical Center , Columbus, Ohio, USA.;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;University of Alabama at Birmingham , Birmingham, Alabama, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Clinical and Laboratory Standards Institute (CLSI).;The American Board of Pathology , Tampa, Florida, USA.;American Board of Pathology (ABP).;Nomenclature Committee for Fungi, International Mycological Association (IMA).;National Mycological Herbarium, Ottawa Research and Development Centre, Science and Technology Branch, Agriculture & Agri-Food Canada , Ottawa, Ontario, Canada.;Cleveland Clinic Lerner College of Medicine, Case Western Reserve University , Cleveland, Ohio, USA.;Department of Laboratory Medicine, Cleveland Clinic , Cleveland, Ohio, USA.;Infection Biology Program, Lerner Research Institute, Cleveland Clinic , Cleveland, Ohio, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Beth Israel Deaconess Medical Center , Boston, Massachusetts, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Lewis Katz School of Medicine, Temple University , Philadelphia, Pennsylvania, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mayo Clinic , Rochester, Minnesota, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;European Confederation of Medical Mycology (ECMM).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;Hippokration Hospital , Thessaloniki, Greece.;Fungal Diagnostics Laboratory Consortium (FDLC).;Fungal Infection Study Group, European Society of Clinical Microbiology and Infectious Diseases (EFISG/ESCMID) , Basel, Switzerland.;ISHAM Working Group Veterinary Mycology and One Health.;Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health , Bethesda, Maryland, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Vanderbilt University Medical Center , Nashville, Tennessee, USA.;Department of Basic Pathology, Federal University of Paraná , Curitiba, Brazil.;Consejo Nacional de Investigaciones Científicas y Tecnológicas (CONICET) , Buenos Aires, Argentina.;Unidad de Parasitología, Sector Micología, Hospital J.M. Ramos Mejía , Buenos Aires, Argentina.;Engineering Laboratory of Microbial Breeding and Preservation of Hebei Province, School of Life Sciences, Institute of Life Sciences and Green Development, Hebei University , Baoding, China.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mayo Clinic , Rochester, Minnesota, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Department of Pathology and Laboratory Medicine, Weill Cornell Medical College , New York, USA.;Fungal Diagnostics Laboratory Consortium (FDLC).;Mycoses Study Group, Education and Research Consortium (MSG-ERC).;Clinical and Laboratory Standards Institute (CLSI).;Medical Mycological Society of the Americas (MMSA).;University of Texas Health Science Center , San Antonio, Texas, USA.;Public Health Wales Microbiology , Cardiff, United Kingdom.;Department of Pathology and Laboratory Medicine, University of Vermont Medical Center , Burlington, Vermont, USA.;International Society for Human and Animal Mycology (ISHAM), Working Group Nomenclature.;Fungal Diagnostics Laboratory Consortium (FDLC).;Johns Hopkins University School of Medicine , Baltimore, Maryland, USA."
"126","von Bardeleben RS;Mahoney P;Morse MA;Price MJ;Denti P;Maisano F;Rogers JH;Rinaldi M;De Marco F;Rollefson W;Chehab B;Williams M;Leurent G;Asch FM;Rodriguez E","von Bardeleben, Ralph Stephan;Mahoney, Paul;Morse, M Andrew;Price, Matthew J;Denti, Paolo;Maisano, Francesco;Rogers, Jason H;Rinaldi, Michael;De Marco, Federico;Rollefson, William;Chehab, Bassem;Williams, Mathew;Leurent, Guillaume;Asch, Federico M;Rodriguez, Evelio","1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study.","JACC. Cardiovascular interventions","United States","eng","Multicenter Study","MitraClip G4;TEER;mitral regurgitation;mitral valve repair;transcatheter edge-to-edge repair","Humans;Mitral Valve;Heart Valve Prosthesis Implantation;Quality of Life;Prospective Studies;Treatment Outcome;Mitral Valve Insufficiency;Heart Failure;Cardiomyopathies","Humans;Mitral Valve;Heart Valve Prosthesis Implantation;Quality of Life;Prospective Studies;Treatment Outcome;Mitral Valve Insufficiency;Heart Failure;Cardiomyopathies","The fourth-generation mitral transcatheter edge-to-edge repair (M-TEER) device introduced an improved clip deployment sequence, independent leaflet grasping, and 2 wider clip sizes to tailor the treatment of patients with mitral regurgitation (MR) for a broad range of anatomies. The 30-day safety and effectiveness of the fourth-generation M-TEER device were previously demonstrated. The aim of this study was to evaluate 1-year outcomes in a contemporary, real-world cohort of subjects treated with the MitraClip G4 system. EXPAND G4 is an ongoing prospective, multicenter, international, single-arm study that enrolled subjects with primary and secondary MR. One-year outcomes included MR severity (echocardiographic core laboratory assessed), heart failure hospitalization, all-cause mortality, functional capacity (NYHA functional class), and quality of life (Kansas City Cardiomyopathy Questionnaire). A total of 1,164 subjects underwent M-TEER from 2020 to 2022. At 1 year, there was a durable reduction in MR to mild or less in 92.6% and to none or trace in 44.2% (P < 0.0001 vs baseline). Few subjects had major adverse events through 1 year (<2% for myocardial infarction, surgical reintervention, or single-leaflet device attachment). The 1-year Kaplan-Meier estimates for all-cause mortality and heart failure hospitalization were 12.3% and 16.9%. Significant improvements in functional capacity (NYHA functional class I or II in 82%; P < 0.0001 vs baseline) and quality of life (18.5-point Kansas City Cardiomyopathy Questionnaire overall summary score improvement; P < 0.0001) were observed. M-TEER with the fourth-generation M-TEER device was safe and effective at 1 year, with durable reductions in MR severity to ≤1+ in more than 90% of patients and concomitant improvements in functional status and quality of life.","Department of Cardiology, University Medical Center of Mainz, Mainz;University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania, USA.;Ascension Saint Thomas, Nashville, Tennessee, USA.;Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;University of California Davis Medical Center, Sacramento, California, USA.;Sanger Heart and Vascular Institute of Cardiothoracic Surgery, Charlotte, North Carolina, USA.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi, Wichita, Kansas, USA.;Heart Valve Center, New York University Langone Health, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Ascension Saint Thomas, Nashville, Tennessee, USA.","NA",0,"1876-7605","JACC Cardiovasc Interv","JACC Cardiovasc Interv",2023,"2023","16","10.1016/j.jcin.2023.09.029","2600-2610","","","37877913","37877913","PUBMED","Department of Cardiology, University Medical Center of Mainz, Mainz;University of Pittsburgh Medical Center Heart and Vascular Institute, Pittsburgh, Pennsylvania, USA.;Ascension Saint Thomas, Nashville, Tennessee, USA.;Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;University of California Davis Medical Center, Sacramento, California, USA.;Sanger Heart and Vascular Institute of Cardiothoracic Surgery, Charlotte, North Carolina, USA.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi, Wichita, Kansas, USA.;Heart Valve Center, New York University Langone Health, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Ascension Saint Thomas, Nashville, Tennessee, USA."
"127","Ghesquières H;Cherblanc F;Belot A;Micon S;Bouabdallah KK;Esnault C;Fornecker LM;Thokagevistk K;Bonjour M;Bijou F;Haioun C;Morineau N;Ysebaert L;Damaj G;Tessoulin B;Guidez S;Morschhauser F;Thiéblemont C;Chauchet A;Gressin R;Jardin F;Fruchart C;Labouré G;Fouillet L;Lionne-Huyghe P;Bonnet A;Lebras L;Amorim S;Leyronnas C;Olivier G;Guieze R;Houot R;Launay V;Drénou B;Fitoussi O;Detourmignies L;Abraham J;Soussain C;Lachenal F;Pica GM;Fogarty P;Cony-Makhoul P;Bernier A;Le Guyader-Peyrou S;Monnereau A;Boissard F;Rossi C;Camus V","Ghesquières, Hervé;Cherblanc, Fanny;Belot, Aurélien;Micon, Sophie;Bouabdallah, Krimo K;Esnault, Cyril;Fornecker, Luc-Matthieu;Thokagevistk, Katia;Bonjour, Maxime;Bijou, Fontanet;Haioun, Corinne;Morineau, Nadine;Ysebaert, Loïc;Damaj, Gandhi;Tessoulin, Benoit;Guidez, Stéphanie;Morschhauser, Franck;Thiéblemont, Catherine;Chauchet, Adrien;Gressin, Rémy;Jardin, Fabrice;Fruchart, Christophe;Labouré, Gaëlle;Fouillet, Ludovic;Lionne-Huyghe, Pauline;Bonnet, Antoine;Lebras, Laure;Amorim, Sandy;Leyronnas, Cécile;Olivier, Gaelle;Guieze, Romain;Houot, Roch;Launay, Vincent;Drénou, Bernard;Fitoussi, Olivier;Detourmignies, Laurence;Abraham, Julie;Soussain, Carole;Lachenal, Florence;Pica, Gian Matteo;Fogarty, Patrick;Cony-Makhoul, Pascale;Bernier, Adeline;Le Guyader-Peyrou, Sandra;Monnereau, Alain;Boissard, Frédéric;Rossi, Cédric;Camus, Vincent","Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.","Blood advances","United States","eng","Journal Article","","Adult;Humans;Aged;Prospective Studies;Antineoplastic Combined Chemotherapy Protocols;Retrospective Studies;Rituximab;Lymphoma, Large B-Cell, Diffuse;Cyclophosphamide;Prednisone;Vincristine;Doxorubicin","Adult;Humans;Aged;Prospective Studies;Antineoplastic Combined Chemotherapy Protocols;Retrospective Studies;Rituximab;Lymphoma, Large B-Cell, Diffuse;Cyclophosphamide;Prednisone;Vincristine;Doxorubicin","Real-world data (RWD) are essential to complement clinical trial (CT) data, but major challenges remain, such as data quality. REal world dAta in LYmphoma and Survival in Adults (REALYSA) is a prospective noninterventional multicentric cohort started in 2018 that included patients newly diagnosed with lymphoma in France. Herein is a proof-of-concept analysis on patients with first-line diffuse large B-cell lymphoma (DLBCL) to (1) evaluate the capacity of the cohort to provide robust data through a multistep validation process; (2) assess the consistency of the results; and (3) conduct an exploratory transportability assessment of 2 recent phase 3 CTs (POLARIX and SENIOR). The analysis population comprised 645 patients with DLBCL included before 31 March 2021 who received immunochemotherapy and for whom 3589 queries were generated, resulting in high data completeness (<4% missing data). Median age was 66 years, with mostly advanced-stage disease and high international prognostic index (IPI) score. Treatments were mostly rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP 75%) and reduced dose R-CHOP (13%). Estimated 1-year event-free survival (EFS) and overall survival rates were 77.9% and 90.0%, respectively (median follow-up, 9.9 months). Regarding transportability, when applying the CT's main inclusion criteria (age, performance status, and IPI), outcomes seemed comparable between patients in REALYSA and standard arms of POLARIX (1-year progression-free survival 79.8% vs 79.8%) and SENIOR (1-year EFS, 64.5% vs 60.0%). With its rigorous data validation process, REALYSA provides high-quality RWD, thus constituting a platform for numerous scientific purposes. The REALYSA study was registered at www.clinicaltrials.gov as #NCT03869619.","Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Roche SAS, Boulogne-Billancourt, France.;Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.;Roche SAS, Boulogne-Billancourt, France.;Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.;Roche SAS, Boulogne-Billancourt, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Department of Hematology, Institut Bergonie, Bordeaux, France.;Lymphoid Malignancies Unit, Assistante Publique Hôpitaux de Paris APHP, Hopital Henri Mondor, Creteil, France.;Department of Hematology, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Hematology Institute of Basse Normandie, Centre Hospitalier Universitaire de Caen, Caen, France.;Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.;Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France.;Department of Clinical Hematology, INSERM U1245 Unit, Centre Henri Becquerel, Rouen, France.;Department of Hematology, Centre Hospitalier de Dunkerque, Dunkirk, France.;Deparment of Hematology, Centre Hospitalier de Libourne, Libourne, France.;Department of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.;Department of Hematology, Centre Hospitalier d'Arras, Arras, France.;Department of Hematology, Centre Hospitalier de Bretagne Atlantique, Vannes, France.;Department of Hematology, Leon Berard Cancer Center, Lyon, France.;Department of Hematology, Hopital Saint Vincent de Paul, Lille, France.;Department of Hematology, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France.;Department of Hematology, Centre Hospitalier de Niort, Niort, France.;Department of Hematology, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier de Saint Brieuc, Saint Brieuc, France.;Department Hematology, Groupe Hospitalier Mulhouse Sud Alsace, Mulhouse, France.;Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Department of Hematology, Centre Hospitalier de Roubaix, Roubaix, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Hematology, Institut Curie, Saint-Cloud, France.;Department of Hematology, Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France.;Department of Hematology, Centre Hospitalier Metropole Savoie, Chambery, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.;Department of Clinical Hematology, INSERM U1245 Unit, Centre Henri Becquerel, Rouen, France.","NA",0,"2473-9537","Blood Adv","Blood Adv",2023,"2024","8","10.1182/bloodadvances.2023010798","296-308","","","37874913","37874913","PUBMED","Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Roche SAS, Boulogne-Billancourt, France.;Hematology and Cell Therapy Department, University Hospital of Bordeaux, Bordeaux, France.;Roche SAS, Boulogne-Billancourt, France.;Institut de Cancérologie Strasbourg Europe (ICANS) and University of Strasbourg, Strasbourg, France.;Roche SAS, Boulogne-Billancourt, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Department of Hematology, Institut Bergonie, Bordeaux, France.;Lymphoid Malignancies Unit, Assistante Publique Hôpitaux de Paris APHP, Hopital Henri Mondor, Creteil, France.;Department of Hematology, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France.;Hematology Institute of Basse Normandie, Centre Hospitalier Universitaire de Caen, Caen, France.;Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Hematology, Universite de Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.;Université Paris Cité, Assistante Publique Hôpitaux de Paris, Hôpital Saint-Louis, Service d'Hémato-Oncologie, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Institute for Advanced Biosciences, INSERM U1209/CNRS UMR 5309/Grenoble Alpes University, Grenoble, France.;Department of Clinical Hematology, INSERM U1245 Unit, Centre Henri Becquerel, Rouen, France.;Department of Hematology, Centre Hospitalier de Dunkerque, Dunkirk, France.;Deparment of Hematology, Centre Hospitalier de Libourne, Libourne, France.;Department of Hematology, Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France.;Department of Hematology, Centre Hospitalier d'Arras, Arras, France.;Department of Hematology, Centre Hospitalier de Bretagne Atlantique, Vannes, France.;Department of Hematology, Leon Berard Cancer Center, Lyon, France.;Department of Hematology, Hopital Saint Vincent de Paul, Lille, France.;Department of Hematology, Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France.;Department of Hematology, Centre Hospitalier de Niort, Niort, France.;Department of Hematology, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier de Saint Brieuc, Saint Brieuc, France.;Department Hematology, Groupe Hospitalier Mulhouse Sud Alsace, Mulhouse, France.;Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Department of Hematology, Centre Hospitalier de Roubaix, Roubaix, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Hematology, Institut Curie, Saint-Cloud, France.;Department of Hematology, Centre Hospitalier Pierre Oudot, Bourgoin-Jallieu, France.;Department of Hematology, Centre Hospitalier Metropole Savoie, Chambery, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Lymphoma Academic Research Organisation, Hopital Lyon Sud, Pierre Benite, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France.;Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, Bordeaux, France.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France.;Department of Clinical Hematology, INSERM U1245 Unit, Centre Henri Becquerel, Rouen, France."
"128","Siefker-Radtke AO;Matsubara N;Park SH;Huddart RA;Burgess EF;Özgüroğlu M;Valderrama BP;Laguerre B;Basso U;Triantos S;Akapame S;Kean Y;Deprince K;Mukhopadhyay S;Loriot Y","Siefker-Radtke, A O;Matsubara, N;Park, S H;Huddart, R A;Burgess, E F;Özgüroğlu, M;Valderrama, B P;Laguerre, B;Basso, U;Triantos, S;Akapame, S;Kean, Y;Deprince, K;Mukhopadhyay, S;Loriot, Y","Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Randomized Controlled Trial","FGFR;erdafitinib;metastatic urothelial cancer;overall survival;pembrolizumab;safety","Humans;Carcinoma, Transitional Cell;Urinary Bladder Neoplasms;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Pyrazoles;Quinoxalines","Humans;Carcinoma, Transitional Cell;Urinary Bladder Neoplasms;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Pyrazoles;Quinoxalines","Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor approved to treat locally advanced/metastatic urothelial carcinoma (mUC) in patients with susceptible FGFR3/2 alterations (FGFRalt) who progressed after platinum-containing chemotherapy. FGFR-altered tumours are enriched in luminal 1 subtype and may have limited clinical benefit from anti-programmed death-(ligand) 1 [PD-(L)1] treatment. This cohort in the randomized, open-label phase III THOR study assessed erdafitinib versus pembrolizumab in anti-PD-(L)1-naive patients with mUC. Patients ≥18 years with unresectable advanced/mUC, with select FGFRalt, disease progression on one prior treatment, and who were anti-PD-(L)1-naive were randomized 1 : 1 to receive erdafitinib 8 mg once daily with pharmacodynamically guided uptitration to 9 mg or pembrolizumab 200 mg every 3 weeks. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The intent-to-treat population (median follow-up 33 months) comprised 175 and 176 patients in the erdafitinib and pembrolizumab arms, respectively. There was no statistically significant difference in OS between erdafitinib and pembrolizumab [median 10.9 versus 11.1 months, respectively; hazard ratio (HR) 1.18; 95% confidence interval (CI) 0.92-1.51; P = 0.18]. Median PFS for erdafitinib and pembrolizumab was 4.4 and 2.7 months, respectively (HR 0.88; 95% CI 0.70-1.10). ORR was 40.0% and 21.6% (relative risk 1.85; 95% CI 1.32-2.59) and median duration of response was 4.3 and 14.4 months for erdafitinib and pembrolizumab, respectively. 64.7% and 50.9% of patients in the erdafitinib and pembrolizumab arms had ≥1 grade 3-4 adverse events (AEs); 5 (2.9%) and 12 (6.9%) patients, respectively, had AEs that led to death. Erdafitinib and pembrolizumab had similar median OS in this anti-PD-(L)1-naive, FGFR-altered mUC population. Outcomes with pembrolizumab were better than assumed and aligned with previous reports in non- FGFR-altered populations. Safety results were consistent with the known profiles for erdafitinib and pembrolizumab in this patient population.","Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston;Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.;Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA.;Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.;Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Beerse, Belgium.;Janssen Research & Development, Raritan, USA.;Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2023,"2024","35","10.1016/j.annonc.2023.10.003","107-117","","","37871702","37871702","PUBMED","Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston;Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK.;Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, USA.;Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.;Oncology Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Spring House, USA.;Janssen Research & Development, Beerse, Belgium.;Janssen Research & Development, Raritan, USA.;Department of Cancer Medicine, INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France."
"129","Mahé D;Bourgeau S;da Silva J;Schlederer J;Satie A-P;Kuassivi N;Mathieu R;Guillou Y-M;Le Tortorec A;Guivel-Benhassine F;Schwartz O;Plotton I;Dejucq-Rainsford N","Mahé, Dominique;Bourgeau, Salomé;da Silva, Janaina;Schlederer, Julie;Satie, Anne-Pascale;Kuassivi, Nadège;Mathieu, Romain;Guillou, Yves-Marie;Le Tortorec, Anna;Guivel-Benhassine, Florence;Schwartz, Olivier;Plotton, Ingrid;Dejucq-Rainsford, Nathalie",NA,"Journal of virology","United States","eng","Journal Article","SARS-CoV-2;ex vivo model;innate response;pathogenesis;target cells;testis","Humans;Male;SARS-CoV-2;Testis;Virus Replication;Leydig Cells;Sertoli Cells","Humans;Male;SARS-CoV-2;Testis;Virus Replication;Leydig Cells;Sertoli Cells","SARS-CoV-2 is a new virus responsible for the Covid-19 pandemic. Although SARS-CoV-2 primarily affects the lungs, other organs are infected. Alterations of testosteronemia and spermatozoa motility in infected men have raised questions about testicular infection, along with high level in the testis of ACE2, the main receptor used by SARS-CoV-2 to enter host cells. Using an organotypic culture of human testis, we found that SARS-CoV-2 replicated with slow kinetics in the testis. The virus first targeted testosterone-producing Leydig cells and then germ-cell nursing Sertoli cells. After a peak followed by the upregulation of antiviral effectors, viral replication in the testis decreased and did not induce any major damage to the tissue. Altogether, our data show that SARS-CoV-2 replicates in the human testis to a limited extent and suggest that testicular damages in infected patients are more likely to result from systemic infection and inflammation than from viral replication in the testis.","Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;University of CAS , Beijing, China.;CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS , Shanghai, China.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Service de Coordination des prélèvements, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, CNRS UMR3569 , Paris, France.;Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, CNRS UMR3569 , Paris, France.;Institut National de la Santé et de la Recherche Médicale, Institut Cellules Souche et Cerveau (SBRI), UMR_S1208 , Bron, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.","NA",0,"1098-5514","J Virol","J Virol",2023,"2023","97","10.1128/jvi.01104-23","e0110423","Covid-Urgent;Covid-urgent;INNATESTIS","ANRS-MIE;MSD International;Fondation pour la Recherche Médicale (FRM);Agence Nationale de la Recherche (ANR)","37830818","37830818","PUBMED","Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;University of CAS , Beijing, China.;CAS Key Laboratory of Molecular Virology & Immunology, Institut Pasteur of Shanghai CAS , Shanghai, China.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Service de Coordination des prélèvements, Centre Hospitalier Universitaire de Rennes , Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France.;Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, CNRS UMR3569 , Paris, France.;Virus and Immunity Unit, Institut Pasteur, Université de Paris Cité, CNRS UMR3569 , Paris, France.;Institut National de la Santé et de la Recherche Médicale, Institut Cellules Souche et Cerveau (SBRI), UMR_S1208 , Bron, France.;Institut National de la Santé et de la Recherche Médicale, Ecole des Hautes Etudes en Santé Publique, Institut de recherche en santé, environnement et travail, Université de Rennes, UMR_S1085 , Rennes, France."
"130","Modesto A;Tougeron D;Tremolières P;Ronchin P;Jouve AD;Leignel DA;Vendrely V;Riou O;Martin-Babau J;Le Sourd S;Mirabel X;Leroy T;Huguet F;Montaigne L;Baumgaertner I;Deslandres M;Moyal E;Seva C;Selves J;Otal P;Pezzella V;Guimbaud R;Filleron T;Quéro L","Modesto, Anouchka;Tougeron, David;Tremolières, Pierre;Ronchin, Philippe;Jouve, Ariane Darut;Leignel, Delphine Argo;Vendrely, Véronique;Riou, Olivier;Martin-Babau, Jérôme;Le Sourd, Samuel;Mirabel, Xavier;Leroy, Thomas;Huguet, Florence;Montaigne, Lucile;Baumgaertner, Isabelle;Deslandres, Marion;Moyal, Elizabeth;Seva, Catherine;Selves, Janick;Otal, Philippe;Pezzella, Veronica;Guimbaud, Rosine;Filleron, Thomas;Quéro, Laurent","Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.","BMC cancer","England","eng","Clinical Trial Protocol","Anti-PD-L1;Chemo-radiotherapy;Esophagus carcinoma;Immunotherapy;Phase II;Randomized trial","Humans;Proteomics;Antineoplastic Combined Chemotherapy Protocols;Chemoradiotherapy;Carcinoma;Esophageal Neoplasms;Immunotherapy;Randomized Controlled Trials as Topic;Multicenter Studies as Topic;Clinical Trials, Phase II as Topic","Humans;Proteomics;Antineoplastic Combined Chemotherapy Protocols;Chemoradiotherapy;Carcinoma;Esophageal Neoplasms;Immunotherapy;Randomized Controlled Trials as Topic;Multicenter Studies as Topic;Clinical Trials, Phase II as Topic","In case of locally advanced and/or non-metastatic unresectable esophageal cancer, definitive chemoradiotherapy (CRT) delivering 50 Gy in 25 daily fractions in combination with platinum-based regimen remains the standard of care resulting in a 2-year disease-free survival of 25% which deserves to be associated with new systemic strategies. In recent years, several immune checkpoint inhibitors (anti-PD1/anti-PD-L1, anti-Program-Death 1/anti-Program-Death ligand 1) have been approved for the treatment of various solid malignancies including metastatic esophageal cancer. As such, we hypothesized that the addition of an anti-PD-L1 to CRT would provide clinical benefit for patients with locally advanced oesophageal cancer. To assess the efficacy of the anti-PD-L1 durvalumab in combination with CRT and then as maintenance therapy we designed the randomized phase II ARION (Association of Radiochemotherapy with Immunotherapy in unresectable Oesophageal carciNoma- UCGI 33/PRODIGE 67). ARION is a multicenter, open-label, randomized, comparative phase II trial. Patients are randomly assigned in a 1:1 ratio in each arm with a stratification according to tumor stage, histology and centre. Experimental arm relies on CRT with 50 Gy in 25 daily fractions in combination with FOLFOX regimen administrated during and after radiotherapy every two weeks for a total of 6 cycles and durvalumab starting with CRT for a total of 12 infusions. Standard arm is CRT alone. Use of Intensity Modulated radiotherapy is mandatory. The primary endpoint is to increase progression-free survival at 12 months from 50 to 68% (HR = 0.55) (power 90%; one-sided alpha-risk, 10%). Progression will be defined with central external review of imaging. PD-L1 Combined Positivity Score on carcinoma cells and stromal immune cells of diagnostic biopsy specimen will be correlated to disease free survival. The study of gut microbiota will aim to determine if baseline intestinal bacteria correlates with tumor response. Proteomic analysis on blood samples will compare long-term responder after CRT with durvalumab to non-responder to identify biomarkers. Results of the present study will be of great importance to evaluate the impact of immunotherapy in combination with CRT and decipher immune response in this unmet need clinical situation. ClinicalTrials.gov, NCT: 03777813.Trial registration date: 5  December 2018.","Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse;Service d'hépato-Gastro-Entérologie, Centre Hospitalier Universitaire de Poitiers, 86000, Poitiers, France.;Institut de Cancérologie de L'Ouest: Angers Et Saint Herblain, Saint-herblain, France.;Hôpital Privé Arnault Tzanck- Centre Azuréen de Cancérologie, Mougins, France.;Institut de Cancérologie de Bourgogne, Dijon, France.;Groupe Hospitalier Bretagne Sud, Lorient, France.;CHU de Bordeaux, Bordeaux, France.;Centre Val d'Aurelle, Montpellier, France.;Centre Armoricain d'Oncologie CARIO, Plérin, France.;Centre Eugène Marquis, Renne, France.;Centre Oscar Lambret, Lille, France.;Nouvelle Clinique Des Dentellières, Valenciennes, France.;Radiation Oncology Department, Tenon Hospital, AP-HP,, Sorbonne University, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Hospitalo Universitaire Henri Mondor APHP, Créteil, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Pathology department, Centre Hospitalo Universitaire IUCT-Oncopole, Toulouse, France.;Imaging Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;UNICANCER, Paris, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Biostatistics Departement Institut Claudius Regaud Institut, Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Radiation Oncology Department, Saint Louis Hospital, AP-HP, Paris, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2022,"2023","23","10.1186/s12885-023-11227-0","966","","","37828434","37828434","PUBMED","Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse;Service d'hépato-Gastro-Entérologie, Centre Hospitalier Universitaire de Poitiers, 86000, Poitiers, France.;Institut de Cancérologie de L'Ouest: Angers Et Saint Herblain, Saint-herblain, France.;Hôpital Privé Arnault Tzanck- Centre Azuréen de Cancérologie, Mougins, France.;Institut de Cancérologie de Bourgogne, Dijon, France.;Groupe Hospitalier Bretagne Sud, Lorient, France.;CHU de Bordeaux, Bordeaux, France.;Centre Val d'Aurelle, Montpellier, France.;Centre Armoricain d'Oncologie CARIO, Plérin, France.;Centre Eugène Marquis, Renne, France.;Centre Oscar Lambret, Lille, France.;Nouvelle Clinique Des Dentellières, Valenciennes, France.;Radiation Oncology Department, Tenon Hospital, AP-HP,, Sorbonne University, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Hospitalo Universitaire Henri Mondor APHP, Créteil, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Radiation Oncology Department Institut Claudius Regaud at Institut, Universitaire du Cancer de Toulouse-Oncopole, 1 Rue Irene Joliot Curie, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Inserm Team 11 RadOpt CRCT 1, Avenue Hubert Curien, 31059, Toulouse, France.;Pathology department, Centre Hospitalo Universitaire IUCT-Oncopole, Toulouse, France.;Imaging Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;UNICANCER, Paris, France.;GI Oncology Department Centre Hospitalo, Universitaire Rangueil, Toulouse, France.;Biostatistics Departement Institut Claudius Regaud Institut, Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Radiation Oncology Department, Saint Louis Hospital, AP-HP, Paris, France."
"131","d'Abrigeon C;McNamara MG;Le Sourd S;Lamarca A;Lièvre A;Bourien H;Peinoit A;Uguen T;Hubner RA;Valle JW;Edeline J","d'Abrigeon, Constance;McNamara, Mairéad G;Le Sourd, Samuel;Lamarca, Angela;Lièvre, Astrid;Bourien, Héloïse;Peinoit, Alexandre;Uguen, Thomas;Hubner, Richard A;Valle, Juan W;Edeline, Julien","Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy.","British journal of cancer","England","eng","Journal Article","","Humans;Retrospective Studies;Cholangiocarcinoma;Liver;Bile Ducts, Intrahepatic;Bile Duct Neoplasms;Prognosis","Humans;Retrospective Studies;Cholangiocarcinoma;Liver;Bile Ducts, Intrahepatic;Bile Duct Neoplasms;Prognosis","Cirrhosis is a risk factor for intrahepatic cholangiocarcinoma (iCC). However, its exact prevalence is uncertain and its impact on the management of advanced disease is not established. Retrospective analysis of patients treated with systemic chemotherapy for advanced iCC in the 1st-line setting at 2 tertiary cancer referral centres. Cirrhosis was diagnosed based on at least one element prior to any treatment: pathological diagnosis, baseline platelets <150 × 10 /L, portal hypertension and/or dysmorphic liver on imaging. In the cohort of patients (n = 287), 82 (28.6%) had cirrhosis (45 based on pathological diagnosis). Patients with cirrhosis experienced more grade 3/4 haematologic toxicity (44% vs 22%, respectively, P = 0.001), and more grade 3/4 non-haematologic toxicity (34% vs 14%, respectively, P = 0.001) than those without. The overall survival (OS) was significantly shorter in patients with cirrhosis: median 9.1 vs 13.1 months for those without (HR = 1.56 [95% CI: 1.19-2.05]); P = 0.002), confirmed on multivariable analysis (HR = 1.48 [95% CI: 1.04-2.60]; P = 0.028). Cirrhosis was relatively common in patients with advanced iCC and was associated with increased chemotherapy-induced toxicity and shorter OS. Formal assessment and consideration of cirrhosis in therapeutic management is recommended.","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Division of Cancer Sciences, University of Manchester/Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation, Manchester/Division of Cancer Sciences, University of Manchester, Manchester, UK.;Department of Gastroenterology, CHU Pontchaillou, Inserm U1242, COSS (Chemistry Oncogenesis Stress Signaling), Rennes 1 University, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation, Manchester/Division of Cancer Sciences, University of Manchester, Manchester, UK.;Division of Cancer Sciences, University of Manchester/Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2023,"2023","129","10.1038/s41416-023-02460-2","1766-1772","","","37813958","37813958","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Division of Cancer Sciences, University of Manchester/Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation, Manchester/Division of Cancer Sciences, University of Manchester, Manchester, UK.;Department of Gastroenterology, CHU Pontchaillou, Inserm U1242, COSS (Chemistry Oncogenesis Stress Signaling), Rennes 1 University, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation, Manchester/Division of Cancer Sciences, University of Manchester, Manchester, UK.;Division of Cancer Sciences, University of Manchester/Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK.;Department of Medical Oncology, Centre Eugène Marquis, Rennes"
"132","Blay JY;Penel N;Duffaud F;Bompas E;Massard C;Chevret S","Blay, Jean-Yves;Penel, Nicolas;Duffaud, Florence;Bompas, Emmanuelle;Massard, Christophe;Chevret, Sylvie","Pembrolizumab monotherapy for advanced chordoma - Authors' reply.","The Lancet. Oncology","England","eng","Letter","","Humans;Chordoma;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological","Humans;Chordoma;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological","NA","Centre Léon Bérard & Université Claude Bernard, 69373 Lyon;Centre Oscar Lambret, Lille, France.;Departement Oncologie, Hopital la Timone, Marseille, France.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;Service de Biostatistique, Hôpital Saint Louis, Université Paris Cité, Paris, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2023","24","10.1016/S1470-2045(23)00454-0","e400","","","37797638","37797638","PUBMED","Centre Léon Bérard & Université Claude Bernard, 69373 Lyon;Centre Oscar Lambret, Lille, France.;Departement Oncologie, Hopital la Timone, Marseille, France.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;Service de Biostatistique, Hôpital Saint Louis, Université Paris Cité, Paris, France."
"133","Foy V;McNamara MG;Valle JW;Lamarca A;Edeline J;Hubner RA","Foy, Victoria;McNamara, Mairéad G;Valle, Juan W;Lamarca, Angela;Edeline, Julien;Hubner, Richard A","Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma.","Current oncology (Toronto, Ont.)","Switzerland","eng","Journal Article","HCC;ICI;PD-1;PD-L1;biomarkers;immunotherapy","","","The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiogenic therapy or dual ICI, as preferred first-line therapy for eligible patients with aHCC. Numerous other combination regimens involving ICI are under investigation with the aim of improving the tumour response and survival of patients with all stages of HCC. This review will explore the current evidence for ICI in patients with advanced HCC and discuss future directions, including the unmet clinical need for predictive biomarkers to facilitate patient selection, the effects of cirrhosis aetiology on response to ICI, and the safety of its use in patients with impaired liver function.","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Avenida de los Reyes Catolicos 2, 28040 Madrid, Spain.;Centre Eugène Marquis, Av. de la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.","NA",0,"1718-7729","Curr Oncol","Curr Oncol",2023,"2023","30","10.3390/curroncol30090628","8665-8685","","","37754543","37754543","PUBMED","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Avenida de los Reyes Catolicos 2, 28040 Madrid, Spain.;Centre Eugène Marquis, Av. de la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK."
"134","Collard MK;Bardin J;Marquet B;Laurin M;Ogier-Denis É","Collard, Maxime K;Bardin, Jérémie;Marquet, Bertille;Laurin, Michel;Ogier-Denis, Éric","Correlation between the presence of a cecal appendix and reduced diarrhea severity in primates: new insights into the presumed function of the appendix.","Scientific reports","England","eng","Journal Article","","Animals;Humans;Appendix;Retrospective Studies;Primates;Diarrhea;Appendectomy;Mammals","Animals;Humans;Appendix;Retrospective Studies;Primates;Diarrhea;Appendectomy;Mammals","Increased severity or recurrence risk of some specific infectious diarrhea, such a salmonellosis or Clostridium difficile colitis, have been reported after an appendectomy in human patients. While several other mammals also possess an appendix, the suspected protective function against diarrhea conferred by this structure is known only in humans. From a retrospective collection of veterinary records of 1251 primates attributed to 45 species, including 13 species with an appendix and 32 without, we identified 2855 episodes of diarrhea, 13% of which were classified as severe diarrhea requiring a therapeutic medication or associated with a fatal issue. We identified a lower risk of severe diarrhea among primate species with an appendix, especially in the early part of life when the risk of diarrhea is maximal. Moreover, we observed a delayed onset of diarrhea and of severe diarrhea in species possessing an appendix. Interestingly, none of the primates with an appendix were diagnosed, treated or died of an acute appendicitis during the 20 years of veterinarian follow-up. These results clarify the function of the appendix among primates, as protection against diarrhea. This supports its presumed function in humans and is congruent with the existence of a selective advantage conferred by this structure.","Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Team Gut Inflammation, Université de Paris, BP 416, 75018, Paris;Department of Colorectal Surgery, Saint-Antoine Hospital, 184 Rue du Faubourg Saint-Antoine, 75012, Paris;CR2P (Centre de Recherche en Paléontologie - Paris; UMR 7207), CNRS/MNHN/Sorbonne Université, Muséum National d'Histoire Naturelle, Paris, France.;La Vallée des Singes, Zoological Park, Le Gureau, France.;CR2P (Centre de Recherche en Paléontologie - Paris; UMR 7207), CNRS/MNHN/Sorbonne Université, Muséum National d'Histoire Naturelle, Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Team Gut Inflammation, Université de Paris, BP 416, 75018, Paris, France.;INSERM U1242, Centre Eugène Marquis, Université de Rennes 1, Rennes, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2023,"2023","13","10.1038/s41598-023-43070-5","15897","","","37741857","37741857","PUBMED","Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Team Gut Inflammation, Université de Paris, BP 416, 75018, Paris;Department of Colorectal Surgery, Saint-Antoine Hospital, 184 Rue du Faubourg Saint-Antoine, 75012, Paris;CR2P (Centre de Recherche en Paléontologie - Paris; UMR 7207), CNRS/MNHN/Sorbonne Université, Muséum National d'Histoire Naturelle, Paris, France.;La Vallée des Singes, Zoological Park, Le Gureau, France.;CR2P (Centre de Recherche en Paléontologie - Paris; UMR 7207), CNRS/MNHN/Sorbonne Université, Muséum National d'Histoire Naturelle, Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Team Gut Inflammation, Université de Paris, BP 416, 75018, Paris, France.;INSERM U1242, Centre Eugène Marquis, Université de Rennes 1, Rennes, France."
"135","Bourien H;Pircher CC;Guiu B;Lamarca A;Valle JW;Niger M;Edeline J","Bourien, Héloïse;Pircher, Chiara Carlotta;Guiu, Boris;Lamarca, Angela;Valle, Juan W;Niger, Monica;Edeline, Julien","Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?","Cancers","Switzerland","eng","Journal Article","cholangiocarcinoma;locoregional treatment","","","For unresectable intrahepatic cholangiocarcinoma (iCC), different locoregional treatments (LRT) could be proposed to patients, including radiofrequency ablation (RFA) and microwave ablation (MWA), external beam radiotherapy (EBRT) or transarterial treatments, depending on patient and tumor characteristics and local expertise. These different techniques of LRT have not been compared in a randomized clinical trial; most of the relevant studies are retrospective and not comparative. The aim of this narrative review is to help clinicians in their everyday practice discuss the pros and cons of each LRT, depending on the individual characteristics of their patients.","Medical Oncology Department, Centre Eugène Marquis, 35000 Rennes, France.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.;Interventional Radiology Department, CHU de Montpellier, 34090 Montpellier, France.;Oncology Department, Fundación Jiménez Díaz University Hospital, 28022 Madrid, Spain.;Medical Oncology Department, Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.;The Christie NHS Foundation Trust, Manchester M20 4BX, UK.;Medical Oncology Department, Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.;The Christie NHS Foundation Trust, Manchester M20 4BX, UK.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.;Medical Oncology Department, Centre Eugène Marquis, 35000 Rennes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2023,"2023","15","10.3390/cancers15174217",NA,"","","37686493","37686493","PUBMED","Medical Oncology Department, Centre Eugène Marquis, 35000 Rennes, France.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.;Interventional Radiology Department, CHU de Montpellier, 34090 Montpellier, France.;Oncology Department, Fundación Jiménez Díaz University Hospital, 28022 Madrid, Spain.;Medical Oncology Department, Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.;The Christie NHS Foundation Trust, Manchester M20 4BX, UK.;Medical Oncology Department, Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.;The Christie NHS Foundation Trust, Manchester M20 4BX, UK.;Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.;Medical Oncology Department, Centre Eugène Marquis, 35000 Rennes, France."
"136","van Ewijk R;Chatziantoniou C;Adams M;Bertolini P;Bisogno G;Bouhamama A;Caro-Dominguez P;Charon V;Coma A;Dandis R;Devalck C;De Donno G;Ferrari A;Fiocco M;Gallego S;Giraudo C;Glosli H;Ter Horst SAJ;Jenney M;Klein WM;Leemans A;Leseur J;Mandeville HC;McHugh K;Merks JHM;Minard-Colin V;Moalla S;Morosi C;Orbach D;Ording Muller LS;Pace E;Di Paolo PL;Perruccio K;Quaglietta L;Renard M;van Rijn RR;Ruggiero A;Sirvent SI;De Luca A;Schoot RA","van Ewijk, Roelof;Chatziantoniou, Cyrano;Adams, Madeleine;Bertolini, Patrizia;Bisogno, Gianni;Bouhamama, Amine;Caro-Dominguez, Pablo;Charon, Valerie;Coma, Ana;Dandis, Rana;Devalck, Christine;De Donno, Giulia;Ferrari, Andrea;Fiocco, Marta;Gallego, Soledad;Giraudo, Chiara;Glosli, Heidi;Ter Horst, Simone A J;Jenney, Meriel;Klein, Willemijn M;Leemans, Alexander;Leseur, Julie;Mandeville, Henry C;McHugh, Kieran;Merks, Johannes H M;Minard-Colin, Veronique;Moalla, Salma;Morosi, Carlo;Orbach, Daniel;Ording Muller, Lil-Sofie;Pace, Erika;Di Paolo, Pier Luigi;Perruccio, Katia;Quaglietta, Lucia;Renard, Marleen;van Rijn, Rick R;Ruggiero, Antonio;Sirvent, Sara I;De Luca, Alberto;Schoot, Reineke A","Quantitative diffusion-weighted MRI response assessment in rhabdomyosarcoma: an international retrospective study on behalf of the European paediatric Soft tissue sarcoma Study Group Imaging Committee.","Pediatric radiology","Germany","eng","Multicenter Study","Biomarker;Diffusion magnetic resonance imaging;Rhabdomyosarcoma;Sarcoma;Surrogate marker","Adolescent;Young Adult;Humans;Child;Diffusion Magnetic Resonance Imaging;Retrospective Studies;Sarcoma;Rhabdomyosarcoma","Adolescent;Young Adult;Humans;Child;Diffusion Magnetic Resonance Imaging;Retrospective Studies;Sarcoma;Rhabdomyosarcoma","To investigate the feasibility of diffusion-weighted magnetic resonance imaging (DW-MRI) as a predictive imaging marker after neoadjuvant chemotherapy in patients with rhabdomyosarcoma. We performed a multicenter retrospective study including pediatric, adolescent and young adult patients with rhabdomyosarcoma, Intergroup Rhabdomyosarcoma Study group III/IV, treated according to the European paediatric Soft tissue sarcoma Study Group (EpSSG) RMS2005 or MTS2008 studies. DW-MRI was performed according to institutional protocols. We performed two-dimensional single-slice tumor delineation. Areas of necrosis or hemorrhage were delineated to be excluded in the primary analysis. Mean, median and 5th and 95th apparent diffusion coefficient (ADC) were extracted. Of 134 included patients, 82 had measurable tumor at diagnosis and response and DW-MRI scans of adequate quality and were included in the analysis. Technical heterogeneity in scan acquisition protocols and scanners was observed. Mean ADC at diagnosis was 1.1 (95% confidence interval [CI]: 1.1-1.2) (all ADC expressed in * 10  mm /s), versus 1.6 (1.5-1.6) at response assessment. The 5th percentile ADC was 0.8 (0.7-0.9) at diagnosis and 1.1 (1.0-1.2) at response. Absolute change in mean ADC after neoadjuvant chemotherapy was 0.4 (0.3-0.5). Exploratory analyses for association between ADC and clinical parameters showed a significant difference in mean ADC at diagnosis for alveolar versus embryonal histology. Landmark analysis at nine weeks after the date of diagnosis showed no significant association (hazard ratio 1.3 [0.6-3.2]) between the mean ADC change and event-free survival. A significant change in the 5th percentile and the mean ADC after chemotherapy was observed. Strong heterogeneity was identified in DW-MRI acquisition protocols between centers and in individual patients.","Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Department of Paediatric Oncology, Children's Hospital for Wales, University Hospital, Cardiff, UK.;Pediatric Hematology-Oncology Unit University-Hospital of Parma, Parma, Italy.;Department of Women's and Children's Health, University of Padua, Padua, Italy.;Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.;Service de Radiologie Interventionnelle Oncologique, Centre Léon Bérard, Lyon, France.;Pediatric Radiology Unit, Department of Radiology, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot S/N, Seville, Spain.;Radiology Department, CHU Rennes, Rennes, France.;Paediatric Radiology Unit, Vall d´Hebron Hospital Campus, Barcelona, Spain.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Department of Hemato-Oncology, HUB, ULB, HUDERF, Brussels, Belgium.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Mathematical Institute, Leiden University, Leiden, The Netherlands.;Pediatric Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain.;Unit of Advanced Clinical and Translational Imaging, Department of Medicine-DIMED, University of Padova, 35122, Padua, Italy.;Department of Paediatric Research, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.;Department of Radiology and Nuclear Medicine, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, The Netherlands.;Paediatric Oncology, Cardiff and Vale UHB, Cardiff, UK.;Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Service de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.;Department of Radiology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Imaging, Institut Gustave Roussy, Villejuif, France.;Diagnostic and Interventional Radiology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Institut Curie, PSL Research University, Paris, France.;Department of Radiology and Intervention Unit for Paediatric Radiology, Oslo University Hospital, Ullevål, Norway.;Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.;Department of Radiology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.;Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria, Ospedale Santa Maria Della Misericordia, Perugia, Italy.;Neuro-Oncology Unit, Department of Paediatric Oncology, Santobono-Pausilipon Children's Hospital, Naples, Italy.;Department of Paediatric Hemato-Oncology, University Hospital Leuven, Louvain, Belgium.;Department of Radiology and Nuclear Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;Pediatric Radiology Department, Hospital Niño Jesús, Madrid, Spain.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Department of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.","NA",0,"1432-1998","Pediatr Radiol","Pediatr Radiol",2023,"2023","53","10.1007/s00247-023-05745-z","2539-2551","Children Cancer-free - 357","Stichting Kinderen Kankervrij","37682330","37682330","PUBMED","Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Department of Paediatric Oncology, Children's Hospital for Wales, University Hospital, Cardiff, UK.;Pediatric Hematology-Oncology Unit University-Hospital of Parma, Parma, Italy.;Department of Women's and Children's Health, University of Padua, Padua, Italy.;Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.;Service de Radiologie Interventionnelle Oncologique, Centre Léon Bérard, Lyon, France.;Pediatric Radiology Unit, Department of Radiology, Hospital Universitario Virgen del Rocío, Avenida Manuel Siurot S/N, Seville, Spain.;Radiology Department, CHU Rennes, Rennes, France.;Paediatric Radiology Unit, Vall d´Hebron Hospital Campus, Barcelona, Spain.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Department of Hemato-Oncology, HUB, ULB, HUDERF, Brussels, Belgium.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Mathematical Institute, Leiden University, Leiden, The Netherlands.;Pediatric Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain.;Unit of Advanced Clinical and Translational Imaging, Department of Medicine-DIMED, University of Padova, 35122, Padua, Italy.;Department of Paediatric Research, Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.;Department of Radiology and Nuclear Medicine, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, The Netherlands.;Paediatric Oncology, Cardiff and Vale UHB, Cardiff, UK.;Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Service de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.;Department of Radiology, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.;Division of Imaging and Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.;Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Imaging, Institut Gustave Roussy, Villejuif, France.;Diagnostic and Interventional Radiology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA With Cancer), Institut Curie, PSL Research University, Paris, France.;Department of Radiology and Intervention Unit for Paediatric Radiology, Oslo University Hospital, Ullevål, Norway.;Department of Radiology, The Royal Marsden NHS Foundation Trust, London, UK.;Department of Radiology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.;Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria, Ospedale Santa Maria Della Misericordia, Perugia, Italy.;Neuro-Oncology Unit, Department of Paediatric Oncology, Santobono-Pausilipon Children's Hospital, Naples, Italy.;Department of Paediatric Hemato-Oncology, University Hospital Leuven, Louvain, Belgium.;Department of Radiology and Nuclear Medicine, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.;Pediatric Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.;Pediatric Radiology Department, Hospital Niño Jesús, Madrid, Spain.;Image Sciences Institute, UMC Utrecht, Utrecht, The Netherlands.;Department of Neurology, UMC Utrecht Brain Center, UMC Utrecht, Utrecht, The Netherlands.;Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands."
"137","Ponce S;Cedrés S;Ricordel C;Isambert N;Viteri S;Herrera-Juarez M;Martinez-Marti A;Navarro A;Lederlin M;Serres X;Zugazagoitia J;Vetrhus S;Jaderberg M;Hansen TB;Levitsky V;Paz-Ares L","Ponce, Santiago;Cedrés, Susana;Ricordel, Charles;Isambert, Nicolas;Viteri, Santiago;Herrera-Juarez, Mercedes;Martinez-Marti, Alex;Navarro, Alejandro;Lederlin, Mathieu;Serres, Xavier;Zugazagoitia, Jon;Vetrhus, Sylvia;Jaderberg, Magnus;Hansen, Thomas Birkballe;Levitsky, Victor;Paz-Ares, Luis","ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.","Journal for immunotherapy of cancer","England","eng","Randomized Controlled Trial","T-lymphocytes;immunomodulation;oncolytic viruses;therapies, investigational;tumor microenvironment","Humans;Pemetrexed;Platinum;Mesothelioma, Malignant;Cisplatin;Tumor Microenvironment;Carboplatin","Humans;Pemetrexed;Platinum;Mesothelioma, Malignant;Cisplatin;Tumor Microenvironment;Carboplatin","ONCOS-102, an oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor, can alter the tumor microenvironment to an immunostimulatory state. Combining ONCOS-102 with standard-of-care chemotherapy for malignant pleural mesothelioma (MPM) may improve treatment outcomes. In this open-label, randomized study, patients with unresectable MPM received intratumoral ONCOS-102 (3×10  virus particles on days 1, 4, 8, 36, 78, and 120) and pemetrexed plus cisplatin/carboplatin (from day 22), or pemetrexed plus cisplatin/carboplatin alone. The primary endpoint was safety. Overall survival (OS), progression-free survival, objective response rate, and tumor immunologic activation (baseline and day 36 biopsies) were also assessed. In total, 31 patients (safety lead-in: n=6, randomized: n=25) were enrolled. Anemia (15.0% and 27.3%) and neutropenia (40.0% and 45.5%) were the most frequent grade ≥3 adverse events (AEs) in the ONCOS-102 (n=20) and chemotherapy-alone (n=11) cohorts. No patients discontinued ONCOS-102 due to AEs. No statistically significant difference in efficacy endpoints was observed. There was a numerical improvement in OS (30-month OS rate 34.1% vs 0; median OS 20.3 vs 13.5 months) with ONCOS-102 versus chemotherapy alone in chemotherapy-naïve patients (n=17). By day 36, ONCOS-102 was associated with increased T-cell infiltration and immune-related gene expression that was not observed in the control cohort. Substantial immune activation in the tumor microenvironment was associated with survival at month 18 in the ONCOS-102 cohort. ONCOS-102 plus pemetrexed and cisplatin/carboplatin was well tolerated by patients with MPM. In injected tumors, ONCOS-102 promoted a proinflammatory environment, including T-cell infiltration, which showed association with survival at month 18.","Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Pulmonology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Instituto Oncológico Rosell, Grupo Quironsalud, Hospital Universitario Dexeus, Barcelona, Spain.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Radiology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;H12O-CNIO Lung Cancer Research Unit, Madrid, Spain.;Department of Medicine, Complutense University of Madrid, Madrid, Spain.;Research and Development, Circio Holding ASA, Oslo, Norway.;Research and Development, Circio Holding ASA, Oslo, Norway.;Research and Development, Circio Holding ASA, Oslo;Research and Development, Circio Holding ASA, Oslo, Norway.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;H12O-CNIO Lung Cancer Research Unit, Madrid, Spain.;Department of Medicine, Complutense University of Madrid, Madrid, Spain.","NA",0,"2051-1426","J Immunother Cancer","J Immunother Cancer",2023,"2023","11","10.1136/jitc-2023-007552",NA,"","","37661097","37661097","PUBMED","Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Pulmonology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Instituto Oncológico Rosell, Grupo Quironsalud, Hospital Universitario Dexeus, Barcelona, Spain.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Radiology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;H12O-CNIO Lung Cancer Research Unit, Madrid, Spain.;Department of Medicine, Complutense University of Madrid, Madrid, Spain.;Research and Development, Circio Holding ASA, Oslo, Norway.;Research and Development, Circio Holding ASA, Oslo, Norway.;Research and Development, Circio Holding ASA, Oslo;Research and Development, Circio Holding ASA, Oslo, Norway.;Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.;H12O-CNIO Lung Cancer Research Unit, Madrid, Spain.;Department of Medicine, Complutense University of Madrid, Madrid, Spain."
"138","Guilhem-Ducléon G;Dalban C;Negrier S;Gravis G;Laguerre B;Chevreau C;Oudard S;Barthelemy P;Ladoire S;Boughalem E;Borchiellini D;Linassier C;Nenan S;Flippot R;Albiges L;Goupil MG","Guilhem-Ducléon, Guillemette;Dalban, Cécile;Negrier, Sylvie;Gravis, Gwenaelle;Laguerre, Brigitte;Chevreau, Christine;Oudard, Stéphane;Barthelemy, Philippe;Ladoire, Sylvain;Boughalem, Elouen;Borchiellini, Delphine;Linassier, Claude;Nenan, Soazig;Flippot, Ronan;Albiges, Laurence;Goupil, Marine Gross","Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.","Clinical genitourinary cancer","United States","eng","Journal Article","Advanced Renal Cell Carcinoma;Immune Checkpoint Inhibitor;Response;Survival analyses;Tyrosine Kinase Inhibitor","Humans;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Duration of Therapy;Vascular Endothelial Growth Factor A;Protein Kinase Inhibitors;Receptors, Vascular Endothelial Growth Factor;Cytokines;Retrospective Studies","Humans;Carcinoma, Renal Cell;Nivolumab;Kidney Neoplasms;Duration of Therapy;Vascular Endothelial Growth Factor A;Protein Kinase Inhibitors;Receptors, Vascular Endothelial Growth Factor;Cytokines;Retrospective Studies","In metastatic renal clear cell carcinoma (ccRCC), vascular endothelial growth factor receptor (VEGFR) and immune checkpoint are 2 main therapeutic targets. We investigated the impact of duration exposure to antiangiogenic on immunotherapy clinical outcomes in metastatic ccRCC. Patients from NIVOREN trial who received nivolumab after only 1 prior antiangiogenic therapy were included. Response rate, clinical benefit, progression free survival (PFS) and overall survival (OS) were prospectively analyzed depending on the duration of the first line (< 6 months, ≥6 months) and exploratory in patients with long first line exposure (≥18 months). The circulating levels of 8 plasma proteins and cytokines at baseline were collected and compared according to first line antiangiogenic duration. Among 354 patients, 127 (36%) and 227 (64%) patients had received first line antiangiogenic for < 6months and ≥ 6months respectively. Respective duration of first line therapy was not associated with objective response to nivolumab (20.5% vs. 23.9%, P = .50), or PFS (HR 0.92; P = .421). Median OS was respectively 16.6 and 31.3 months in the <6 and ≥6 months subgroups respectively. Adjusted on international metastatic renal cell carcinoma database consortium risk, age and metastatic site, OS was longer in patients with longer treatment duration in the first line setting (HR 0.73; P = .017). Duration of first line VEGFR TKI was independent from circulating levels of 8 proteins and cytokines at nivolumab baseline. Nivolumab activity in second line is independent from first-line duration of VEGFR TKI. However, first line VEGFR TKI duration ≥ 6 months is associated with longer OS.","Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.;Department of Clinical Research and Innovation, Centre de Lutte Contre Le Cancer, Centre Léon Bérard, Lyon, France.;University Lyon I, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, CHU Bretonneau et Université de Tours, Tours, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux","NA",0,"1938-0682","Clin Genitourin Cancer","Clin Genitourin Cancer",2023,"2023","21","10.1016/j.clgc.2023.07.008","643-652","","","37635052","37635052","PUBMED","Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France.;Department of Clinical Research and Innovation, Centre de Lutte Contre Le Cancer, Centre Léon Bérard, Lyon, France.;University Lyon I, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, CHU Bretonneau et Université de Tours, Tours, France.;Unicancer, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.;Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux"
"139","Rabilloud N;Allaume P;Acosta O;De Crevoisier R;Bourgade R;Loussouarn D;Rioux-Leclercq N;Khene ZE;Mathieu R;Bensalah K;Pecot T;Kammerer-Jacquet SF","Rabilloud, Noémie;Allaume, Pierre;Acosta, Oscar;De Crevoisier, Renaud;Bourgade, Raphael;Loussouarn, Delphine;Rioux-Leclercq, Nathalie;Khene, Zine-Eddine;Mathieu, Romain;Bensalah, Karim;Pecot, Thierry;Kammerer-Jacquet, Solene-Florence","Deep Learning Methodologies Applied to Digital Pathology in Prostate Cancer: A Systematic Review.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","Gleason grading;artificial intelligence;convolutional neural networks;deep learning;digital pathology;prostate cancer","","","Deep learning (DL), often called artificial intelligence (AI), has been increasingly used in Pathology thanks to the use of scanners to digitize slides which allow us to visualize them on monitors and process them with AI algorithms. Many articles have focused on DL applied to prostate cancer (PCa). This systematic review explains the DL applications and their performances for PCa in digital pathology. Article research was performed using PubMed and Embase to collect relevant articles. A Risk of Bias (RoB) was assessed with an adaptation of the QUADAS-2 tool. Out of the 77 included studies, eight focused on pre-processing tasks such as quality assessment or staining normalization. Most articles (  = 53) focused on diagnosis tasks like cancer detection or Gleason grading. Fifteen articles focused on prediction tasks, such as recurrence prediction or genomic correlations. Best performances were reached for cancer detection with an Area Under the Curve (AUC) up to 0.99 with algorithms already available for routine diagnosis. A few biases outlined by the RoB analysis are often found in these articles, such as the lack of external validation. This review was registered on PROSPERO under CRD42023418661.","Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology, Nantes University Hospital, 44000 Nantes, France.;Department of Pathology, Nantes University Hospital, 44000 Nantes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Facility for Artificial Intelligence and Image Analysis (FAIIA), Biosit UAR 3480 CNRS-US18 INSERM, Rennes University, 2 Avenue du Professeur Léon Bernard, 35042 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2023,"2023","13","10.3390/diagnostics13162676",NA,"","","37627935","37627935","PUBMED","Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology, Nantes University Hospital, 44000 Nantes, France.;Department of Pathology, Nantes University Hospital, 44000 Nantes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Urology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Facility for Artificial Intelligence and Image Analysis (FAIIA), Biosit UAR 3480 CNRS-US18 INSERM, Rennes University, 2 Avenue du Professeur Léon Bernard, 35042 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes University, 35033 Rennes, France.;Department of Pathology, Rennes University Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France."
"140","de Moura A;Vuagnat P;Renouf B;Pierga JY;Loirat D;Vaflard P;Lafayolle de la Bruyère C;Chaumard-Billotey N;Hajjaji N;Ladoire S;Dabakuyo S;Patsouris A;Frenel JS;Nicolai V;Alexandre M;Dohollou N;Grenier J;Bourien H;Bidard FC","de Moura, Alexandre;Vuagnat, Perrine;Renouf, Benjamin;Pierga, Jean-Yves;Loirat, Delphine;Vaflard, Pauline;Lafayolle de la Bruyère, Charline;Chaumard-Billotey, Natacha;Hajjaji, Nawale;Ladoire, Sylvain;Dabakuyo, Sandrine;Patsouris, Anne;Frenel, Jean Sébastien;Nicolai, Vincent;Alexandre, Marie;Dohollou, Nadine;Grenier, Julien;Bourien, Heloïse;Bidard, François-Clément","Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.","Scientific reports","England","eng","Journal Article","","Humans;Paclitaxel;Triple Negative Breast Neoplasms;B7-H1 Antigen;Retrospective Studies","Humans;Paclitaxel;Triple Negative Breast Neoplasms;B7-H1 Antigen;Retrospective Studies","Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued when the IMpassion131 trial read out with negative results. We performed a retrospective multicentric analysis in patients who were prospectively enrolled in the French EAP. Efficacy and toxicity data were obtained on 64 patients treated from August 2019 to August 2020 in 10 French cancer centers. Median progression-free survival (PFS) and overall survival (OS) were 4.1 months (95% CI [3.0-5.8]) and 17.9 months (95% CI [12.4-NR]), respectively. The 6-months PFS rate was 28% (95% CI [16-40%]) (N = 18/64), while N = 33/64 patients (52%, 95% CI [38-63%]) experienced a tumor response. Exploratory subgroup analyses retrieved that corticosteroid use at inclusion in the EAP, before treatment initiation, was the only independent unfavorable prognostic factor for PFS (HR 2.7, 95% CI [1.3-5.6]). No new safety signal was observed. This real-life study, unique by its setting (EAP granted by anticipation and later withdrawn), suggests atezolizumab and paclitaxel has a limited efficacy in PD-L1-positive aTNBC, especially in patients receiving corticosteroids as comedication before treatment start.","Department of Medical Oncology, Institut Curie, Paris & Saint Cloud;UVSQ, Université Paris-Saclay, Saint Cloud;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;UVSQ, Université Paris-Saclay, Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Clinical Pharmacy, Centre Léon Bérard, Lyon, France.;Department of Breast Cancer Oncology, Centre Oscar Lambret, Lille, France.;Inserm, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Univ. Lille, Lille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers & Nantes/Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers & Nantes/Saint-Herblain, France.;Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Department of Medical Oncology, Institut Sainte-Catherine, Avignon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;UVSQ, Université Paris-Saclay, Saint Cloud, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2023,"2023","13","10.1038/s41598-023-40569-9","13427","","","37596388","37596388","PUBMED","Department of Medical Oncology, Institut Curie, Paris & Saint Cloud;UVSQ, Université Paris-Saclay, Saint Cloud;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;UVSQ, Université Paris-Saclay, Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Université Paris Cité, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Clinical Pharmacy, Centre Léon Bérard, Lyon, France.;Department of Breast Cancer Oncology, Centre Oscar Lambret, Lille, France.;Inserm, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), Univ. Lille, Lille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers & Nantes/Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers & Nantes/Saint-Herblain, France.;Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.;Department of Medical Oncology, Institut Sainte-Catherine, Avignon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Curie, Paris & Saint Cloud, France.;UVSQ, Université Paris-Saclay, Saint Cloud, France."
"141","Le Du F;Carton M;Bachelot T;Saghatchian M;Pistilli B;Brain E;Loirat D;Vanlemmens L;Vermeulin T;Emile G;Gonçalves A;Ung M;Robert M;Jaffre A;Desmoulins I;Jouannaud C;Uwer L;Marc Ferrero J;Mouret-Reynier MA;Jacot W;Chevrot M;Delaloge S;Diéras V","Le Du, Fanny;Carton, Matthieu;Bachelot, Thomas;Saghatchian, Mahasti;Pistilli, Barbara;Brain, Etienne;Loirat, Delphine;Vanlemmens, Laurence;Vermeulin, Thomas;Emile, George;Gonçalves, Anthony;Ung, Mony;Robert, Marie;Jaffre, Anne;Desmoulins, Isabelle;Jouannaud, Christelle;Uwer, Lionel;Marc Ferrero, Jean;Mouret-Reynier, Marie-Ange;Jacot, William;Chevrot, Michaël;Delaloge, Suzette;Diéras, Véronique","Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.","The oncologist","England","eng","Journal Article","HER2 positive;anti-HER2-targeted agents;breast cancer;de novo metastatic;pertuzumab;trastuzumab","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Disease-Free Survival;Progression-Free Survival;Receptor, ErbB-2;Trastuzumab;Chemotherapy, Adjuvant","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Disease-Free Survival;Progression-Free Survival;Receptor, ErbB-2;Trastuzumab;Chemotherapy, Adjuvant","Although adjuvant cancer treatments increase cure rates, they may induce clonal selection and tumor resistance. Information still lacks as whether (neo)adjuvant anti-HER2 treatments impact the patterns of recurrence and outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC). We aimed to assess this in the large multicenter ESME real-world database. We examined the characteristics and outcomes (overall survival (OS) and progression-free survival under first-line treatment (PFS1)) of HER2+ patients with MBC from the French ESME program with recurrent disease, as a function of the previous receipt of adjuvant trastuzumab. Multivariable analyses used Cox models adjusted for baseline demographic, prognostic factors, adjuvant treatment received, and disease-free interval. Two thousand one hundred and forty-three patients who entered the ESME cohort between 2008 and 2017 had a recurrent HER2+ MBC. Among them, 56% had received (neo)adjuvant trastuzumab and 2.5% another anti-HER2 in this setting. Patients pre-exposed to trastuzumab were younger, had a lower disease-free interval, more HR-negative disease and more metastatic sites. While the crude median OS appeared inferior in patients exposed to adjuvant trastuzumab, as compared to those who did not (37.2 (95%CI 34.4-40.3) versus 53.5 months (95% CI: 47.6-60.1)), this difference disappeared in the multivariable model (HR = 1.05, 95%CI 0.91-1.22). The same figures were observed for PFS1. Among patients with relapsed HER2+ MBC, the receipt of adjuvant trastuzumab did not independently predict for worse outcomes when adjusted to other prognostic factors.","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Américain, Paris, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Curie/Saint Cloud, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Anne jaffré Department of Medical Information, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Jean-Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Godinot, Reims, France.;Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Clermont-Ferrand, France.;Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.","NA",0,"1549-490X","Oncologist","Oncologist",2023,"2023","28","10.1093/oncolo/oyad137","e867-e876","","","37589218","37589218","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Américain, Paris, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Curie/Saint Cloud, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Anne jaffré Department of Medical Information, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Jean-Francois Leclerc, Dijon, France.;Department of Medical Oncology, Institut Godinot, Reims, France.;Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Clermont-Ferrand, France.;Department of Medical Oncology, Institut du cancer de Montpellier, Montpellier, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France."
"142","Pichot O;Diard A;Bosc JY;Abbadie F;Franco G;Mahé G;Sadaghianloo N","Pichot, Olivier;Diard, Antoine;Bosc, Jean-Yves;Abbadie, Fabrice;Franco, Gilbert;Mahé, Guillaume;Sadaghianloo, Nirvana","Standardized Methodology for Duplex Ultrasound Examination of Arteriovenous Access for Hemodialysis: A Proposal of the French Society of Vascular Medicine and the French-Speaking Society of Vascular Access.","Ultrasound in medicine & biology","England","eng","Journal Article","Arteriovenous access;Duplex ultrasound;Hemodialysis;Methods;Ultrasonography","Humans;Arteriovenous Shunt, Surgical;Renal Dialysis;Ultrasonography, Doppler, Duplex;Veins;Cardiology","Humans;Arteriovenous Shunt, Surgical;Renal Dialysis;Ultrasonography, Doppler, Duplex;Veins;Cardiology","Duplex ultrasound (DUS) is an essential tool for characterizing and monitoring arteriovenous (AV) access for hemodialysis. The aim of the work described here, requested by the French Society of Vascular Medicine in collaboration with the French-Speaking Vascular Access Society, is to propose a standardized methodology for performing and documenting DUS, taking into account the variety of AV access techniques and the problems routinely encountered. A steering committee reviewed the literature and selected the relevant references. A draft was prepared, and all items with missing or conflicting data were submitted to a Delphi consensus. The final document was discussed and approved by all participants. The principles of DUS evaluation of AV access consist of examination of the afferent artery, the anastomosis and the entire venous drainage system. DUS uses B-mode ultrasound, color flow, pulsed wave and power Doppler analysis. DUS can be used in a variety of clinical situations, which can directly influence the methodology of the examination and the interpretation of the results. Blood flow should be assessed as it correlates with the risk of thrombosis. The measurement should be adapted to the different anatomical and hemodynamic conditions encountered. Characterization of stenosis should take into account the residual diameter of the drainage vein and its hemodynamic consequences. Other complications can be assessed with a standardized DUS examination. When performed according to a rigorous methodology, DUS of the AV access allows a comprehensive assessment of its functionality and eliminates the need for further invasive diagnostic procedures.","Department of Vascular Medicine, Groupement Hospitalier Mutualiste, Grenoble;Department of Vascular Medicine, Centre Hospitalier Universitaire Bordeaux, France.;Renal Disease Clinics, AIDER Santé, Hôpital Lapeyronie, Montpellier, France.;Department of Vascular Medicine, Centre Hospitalier de Vichy, Vichy, France.;Centre d'Explorations Vasculaires, Paris, France.;Department of Vascular Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France.","NA",0,"1879-291X","Ultrasound Med Biol","Ultrasound Med Biol",2023,"2023","49","10.1016/j.ultrasmedbio.2023.07.007","2213-2220","","","37544830","37544830","PUBMED","Department of Vascular Medicine, Groupement Hospitalier Mutualiste, Grenoble;Department of Vascular Medicine, Centre Hospitalier Universitaire Bordeaux, France.;Renal Disease Clinics, AIDER Santé, Hôpital Lapeyronie, Montpellier, France.;Department of Vascular Medicine, Centre Hospitalier de Vichy, Vichy, France.;Centre d'Explorations Vasculaires, Paris, France.;Department of Vascular Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Vascular Surgery, Centre Hospitalier Universitaire de Nice, Nice, France."
"143","Tzedakis S;Sebai A;Jeddou H;Garin E;Rolland Y;Bourien H;Uguen T;Sulpice L;Robin F;Edeline J;Boudjema K","Tzedakis, Stylianos;Sebai, Amine;Jeddou, Heithem;Garin, Etienne;Rolland, Yan;Bourien, Heloise;Uguen, Thomas;Sulpice, Laurent;Robin, Fabien;Edeline, Julien;Boudjema, Karim","Resection Postradioembolization in Patients With Single Large Hepatocellular Carcinoma.","Annals of surgery","United States","eng","Journal Article","","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Retrospective Studies;Yttrium Radioisotopes","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Retrospective Studies;Yttrium Radioisotopes","The aim of this study was to evaluate the efficacy of yttrium-90 transarterial radioembolization (TARE) to convert to resection initially unresectable, single, large (≥5 cm) hepatocellular carcinoma (HCC). TARE can downsize cholangiocarcinoma to resection but its role in HCC resectability remains debatable. All consecutive patients with a single large HCC treated between 2015 and 2020 in a single tertiary center were reviewed. When indicated, patients were either readily resected (upfront surgery) or underwent TARE. TARE patients were converted to resection (TARE surgery) or not (TARE-only). To further assess the effect of TARE on the long-term and short-term outcomes, a propensity score matching analysis was performed. Among 216 patients, 144 (66.7%) underwent upfront surgery. Among 72 TARE patients, 20 (27.7%) were converted to resection. TARE-surgery patients received a higher mean yttrium-90 dose that the 52 remaining TARE-only patients (211.89±107.98 vs 128.7±36.52 Gy, P <0.001). Postoperative outcomes between upfront-surgery and TARE-surgery patients were similar. In the unmatched population, overall survival at 1, 3, and 5 years was similar between upfront-surgery and TARE-surgery patients (83.0%, 60.0%, 47% vs 94.0%, 86.0%, 55.0%, P =0.43) and compared favorably with TARE-only patients (61.0%, 16.0% and 9.0%, P <0.0001). After propensity score matching, TARE-surgery patients had significantly better overall survival than upfront-surgery patients ( P =0.021), while disease-free survival was similar ( P =0.29). TARE may be a useful downstaging treatment for unresectable localized single large HCC providing comparable short-term and long-term outcomes with readily resectable tumors.","Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Interventional Radiology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.","NA",0,"1528-1140","Ann Surg","Ann Surg",2023,"2023","278","10.1097/SLA.0000000000006061","756-762","","","37539588","37539588","PUBMED","Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Interventional Radiology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatobiliary and Digestive Surgery, Pontchaillou University Hospital, University of Rennes 1, Rennes, France."
"144","Bernet L;Hardisson D;Rodrigo M;Córdoba A;Sancho M;Peg V;Ruiz I;Godey F;Sánchez-Méndez JI;Prat A","Bernet, L;Hardisson, D;Rodrigo, M;Córdoba, A;Sancho, M;Peg, V;Ruiz, I;Godey, F;Sánchez-Méndez, J I;Prat, A","OSNA Total Tumor Load for the Prediction of Axillary Involvement in Breast Cancer Patients: Should We use Different Thresholds According to the Intrinsic Molecular Subtype? MOTTO Study.","Clinical pathology (Thousand Oaks, Ventura County, Calif.)","United States","eng","Journal Article","Breast cancer;molecular subtype;total Tumor load","","","To assess the impact of the molecular subtype (MS) on the total number of CK19 mRNA copies in all positive SLN (TTL) threshold, to predict non-SLN affectation, and to compare 5 years progression-free survival (PFS) according to the risk of recurrence (ROR) group by PAM50. Cohort with infiltrating breast cancer with intra-operative metastatic SLN detected by one-step nucleic acid amplification (OSNA) assay who underwent subsequent ALND. Logistic regression was used to assess a possible interaction between TTL and MS(Triple Negative, Her-2-Enriched, Luminal A, or Luminal B), or hormone receptors (HR: positive or negative) by immunohistochemistry (IMH). Cox regression was used to compare PFS and OS in the 3 ROR groups (high, medium, or low). TTL was predictive of non-SLN affectation in both univariate (OR [95% CI]: 1.72 [1.43, 2.05],   < .001) and multivariate (1.55 [95% CI: 1.04, 2.32],   = .030) models, but MS-IMH or HR-IMH, and their interactions with TTL were not (best multivariate model: HR + main effect OR 1.16 [95% CI: 0.18, 7.64],   = .874; interaction OR: 1.04 [0.7, 1.55],   = .835; univariate model: HR + main effect OR: 1.44 [95% CI: 0.85, 2.44],   = .180). PFS was lower in the high-risk ROR group (81.1%) than in the low-risk group (93.9%) (HR: 3.68 [95 CI: 1.70, 7.94],   < .001). our results do not provide evidence to support the utilization of subtype-specific thresholds for TTL values to make therapeutic decisions on the axilla. The ROR group was predictive of 5 years-PFS.","Department of Pathology, Hospital Universitario del Vinalopó, Elche, Spain.;Department of Pathology, Hospital Universitario La Paz, Madrid.;Hospital La Paz Institute for health Research (IdiPAZ), Universidad Autónoma de Madrid.;Department of Pathology, Hospital Universitario de Burgos, Burgos, Spain.;Department of Pathology, Hospital Universitario de Navarra, Navarra, Spain.;Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain.;Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.;Universidad Autónoma de Barcelona, Barcelona, Spain.;Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.;Department of Pathology, Hospital Universitario de Donostia, Donostia, Spain.;Department of Pathology, Centre Eugène Marquis, Rennes, France.;Department of Ginecology and Obstetrics, Hospital Universitario La Paz, Madrid.;Hospital La Paz Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid.;Medical Oncology department, Hospital Clínic de Barcelona, Barcelona, Spain.","NA",0,"2632-010X","Clin Pathol","Clin Pathol",2022,"2023","16","10.1177/2632010X231183693","2632010X231183693","","","37534372","37534372","PUBMED","Department of Pathology, Hospital Universitario del Vinalopó, Elche, Spain.;Department of Pathology, Hospital Universitario La Paz, Madrid.;Hospital La Paz Institute for health Research (IdiPAZ), Universidad Autónoma de Madrid.;Department of Pathology, Hospital Universitario de Burgos, Burgos, Spain.;Department of Pathology, Hospital Universitario de Navarra, Navarra, Spain.;Department of Pathology, Hospital Universitario de Salamanca, Salamanca, Spain.;Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain.;Universidad Autónoma de Barcelona, Barcelona, Spain.;Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain.;Department of Pathology, Hospital Universitario de Donostia, Donostia, Spain.;Department of Pathology, Centre Eugène Marquis, Rennes, France.;Department of Ginecology and Obstetrics, Hospital Universitario La Paz, Madrid.;Hospital La Paz Institute for Health Research (IdiPAZ), Universidad Autónoma de Madrid.;Medical Oncology department, Hospital Clínic de Barcelona, Barcelona, Spain."
"145","Ferrant J;Pontis A;Zimmermann F;Dingli F;Poullet P;Loew D;Tarte K;Dumontet E","Ferrant, Juliette;Pontis, Adeline;Zimmermann, François;Dingli, Florent;Poullet, Patrick;Loew, Damarys;Tarte, Karin;Dumontet, Erwan","Phenotypic and proteomic analysis of plasma extracellular vesicles highlights them as potential biomarkers of primary Sjögren syndrome.","Frontiers in immunology","Switzerland","eng","Journal Article","Sjögren syndrome;biomarker;extracellular vesicles;proteomic;systemic lupus erythematosus","Humans;Sjogren's Syndrome;Proteomics;Biomarkers;Extracellular Vesicles;Lupus Erythematosus, Systemic;Lymphoma","Humans;Sjogren's Syndrome;Proteomics;Biomarkers;Extracellular Vesicles;Lupus Erythematosus, Systemic;Lymphoma","Sjögren syndrome (SjS) is an autoimmune disease characterized by the destruction of the exocrine gland epithelia, causing a dryness of mucosa called sicca symptoms, and whose main life-threatening complication is lymphoma. There is a need for new biomarkers in this disease, notably diagnostic biomarkers for patients with genuine sicca symptoms that do not meet current criteria, and prognostic biomarkers for patients at risk of lymphoma. Plasma extracellular vesicles (EVs) are promising biomarker candidates in several diseases, but their potential has not yet been explored in SjS. In this proof-of-concept study, we characterized EVs from primary SjS patients (pSS, n=12) at the phenotypic and proteomic levels, compared to EVs from healthy donor (HD, n=8) and systemic lupus erythematosus patients (SLE, n=12). Specific plasma EVs subpopulations, derived from neutrophils, endothelial, and epithelial cells, were found increased in pSS. We also identified a pSS proteomic signature in plasma EVs, including neutrophil-, epithelial-, and endothelial-related proteins, such as integrin alpha M (ITGAM), olfactomedin-4 (OLFM4), Ras-related protein RAB10, and CD36. Overall, our results support the relevance of plasma EVs as biomarkers in SjS.","Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France.;Institut Curie, PSL Research University, INSERM, Mines Paris Tech, Bioinformatics core facility (CUBIC), Paris, France.;Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France.","NA",0,"1664-3224","Front Immunol","Front Immunol",2023,"2023","14","10.3389/fimmu.2023.1207545","1207545","","","37529039","37529039","PUBMED","Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Médecine Interne et Immunologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France.;Institut Curie, PSL Research University, INSERM, Mines Paris Tech, Bioinformatics core facility (CUBIC), Paris, France.;Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;UMR, Université Rennes, INSERM, Établissement Français du Sang, Rennes, France."
"146","Lasocki S;Capdevila X;Vielle B;Bijok B;Lahlou-Casulli M;Collange V;Grillot N;Danguy des Deserts M;Duchalais A;Delannoy B;Drugeon B;Bouzat P;David JS;Rony L;Loupec T;Léger M;Rineau E","Lasocki, Sigismond;Capdevila, Xavier;Vielle, Bruno;Bijok, Benjamin;Lahlou-Casulli, Maria;Collange, Vincent;Grillot, Nicolas;Danguy des Deserts, Marc;Duchalais, Alexis;Delannoy, Bertrand;Drugeon, Bertrand;Bouzat, Pierre;David, Jean-Stéphane;Rony, Louis;Loupec, Thibault;Léger, Maxime;Rineau, Emmanuel","Ferric derisomaltose and tranexamic acid, combined or alone, for reducing blood transfusion in patients with hip fracture (the HiFIT trial): a multicentre, 2 × 2 factorial, randomised, double-blind, controlled trial.","The Lancet. Haematology","England","eng","Randomized Controlled Trial","","Male;Adult;Humans;Female;Middle Aged;Aged;Aged, 80 and over;Tranexamic Acid;Hip Fractures;Blood Transfusion;Iron;Anemia;Hemoglobins;Double-Blind Method;Treatment Outcome","Male;Adult;Humans;Female;Middle Aged;Aged;Aged, 80 and over;Tranexamic Acid;Hip Fractures;Blood Transfusion;Iron;Anemia;Hemoglobins;Double-Blind Method;Treatment Outcome","Anaemia and blood transfusion are associated with poor outcomes after hip fracture. We evaluated the efficacy of intravenous iron and tranexamic acid in reducing blood transfusions after hip fracture surgery. In this double-blind, randomised, 2 × 2 factorial trial, we recruited adults hospitalised for hip fractures in 12 medical centres in France who had preoperative haemoglobin concentrations between 9·5 and 13·0 g/dL. We randomly allocated participants (1:1:1:1), via a secure web-based service, to ferric derisomaltose (20 mg/kg intravenously) and tranexamic acid (1 g bolus followed by 1 g over 8 h intravenously at inclusion and 3 g topically during surgery), iron plus placebo (normal saline), tranexamic acid plus placebo, or double placebo. Unmasked nurses administered study drugs; participants and other clinical and research staff remained masked to treatment allocation. The primary outcome was the percentage of patients transfused during hospitalisation (or by day 30). The primary analysis included all randomised patients. This study is registered on ClinicalTrials.gov (NCT02972294) and is closed to new participants. Of 413 patients (51-104 years old, median [IQR] 86 [78-91], 312 [76%] women, 101 [24%] men), 104 received iron plus tranexamic acid, 103 iron plus placebo, 103 tranexamic acid plus placebo, and 103 double placebo between March 31, 2017 and June 18, 2021 (study stopped early for efficacy after the planned interim analysis done on the first 390 patients included on May 25, 2021). Data for the primary outcome were available for all participants. Among patients on double placebo, 31 (30%) were transfused versus 16 (15%) on both drugs (relative risk 0·51 [98·3% CI 0·27-0·97]; p=0·012). 27 (26%) participants on iron (0·81 [0·50-1·29]; p=0·28) and 28 (27%) on tranexamic acid (0·85 [0·54-1·33]; p=0·39) were transfused. 487 adverse events were reported with similar event rates among the groups; among prespecified safety endpoints, severe postoperative anaemia (haemoglobin <8 g/dL) was more frequent in the double placebo group. Main common adverse event were sepsis, pneumonia, and urinary infection, with similar rates among all groups. In patients hospitalised for hip fracture surgery with a haemoglobin concentration 9·5-13·0 g/dL, preoperative infusion of ferric derisomaltose plus tranexamic acid reduced the risk of blood transfusion by 50%. Our results suggest that combining treatments from two different pillars improves patient blood-management programmes. Either treatment alone did not reduce transfusion rates, but we might not have had the power to detect it. French Ministry of Health, HiFIT trial.","Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département de Biostatistiques, Centre Hospitalier Universitaire d'Angers, Angers, France.;Centre Hospitalier Universitaire de Lille, Pôle d'anesthésie-réanimation, Lille, France.;Department of Anesthesiology, Critical Care Medicine and Perioperative Medicine, Rennes University Hospital and School of Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anesthesiology, Médipole Lyon Villeurbanne, Lyon, France.;Nantes Université, Centre Hospitalier Universitaire de Nantes, Service d'Anesthésie Réanimation Chirurgicale, Immunologie et Infectiologie, Nantes, France.;Pôle Bloc Anesthésie Réanimation Urgences, Hôpital d'Instruction des Armées Clermont-Tonnerre, INSERM, Université de Bretagne Occidentale, Brest, France.;Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.;Department of Anesthesiology and Intensive Care Medicine, Ramsay Sante, Sauvegarde Clinic, Lyon, France.;Service des Urgences-SAMU-SMUR, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Université Grenoble Alpes, Inserm, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.;Service d'Anesthésie Réanimation, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre Bénite and Research on Healthcare Performance, Inserm, University Claude Bernard Lyon, Lyon, France.;Département de Chirurgie osseuse, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.","NA",0,"2352-3026","Lancet Haematol","Lancet Haematol",2023,"2023","10","10.1016/S2352-3026(23)00163-1","e747-e755","","","37524101","37524101","PUBMED","Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département de Biostatistiques, Centre Hospitalier Universitaire d'Angers, Angers, France.;Centre Hospitalier Universitaire de Lille, Pôle d'anesthésie-réanimation, Lille, France.;Department of Anesthesiology, Critical Care Medicine and Perioperative Medicine, Rennes University Hospital and School of Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anesthesiology, Médipole Lyon Villeurbanne, Lyon, France.;Nantes Université, Centre Hospitalier Universitaire de Nantes, Service d'Anesthésie Réanimation Chirurgicale, Immunologie et Infectiologie, Nantes, France.;Pôle Bloc Anesthésie Réanimation Urgences, Hôpital d'Instruction des Armées Clermont-Tonnerre, INSERM, Université de Bretagne Occidentale, Brest, France.;Centre Hospitalier Départemental Vendée, La Roche sur Yon, France.;Department of Anesthesiology and Intensive Care Medicine, Ramsay Sante, Sauvegarde Clinic, Lyon, France.;Service des Urgences-SAMU-SMUR, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Université Grenoble Alpes, Inserm, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.;Service d'Anesthésie Réanimation, Groupe Hospitalier Sud, Hospices Civils de Lyon, Pierre Bénite and Research on Healthcare Performance, Inserm, University Claude Bernard Lyon, Lyon, France.;Département de Chirurgie osseuse, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Anesthesiology and Intensive Care Medicine, Lapeyronie University Hospital, Montpellier, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Département Anesthésie-Réanimation, Pôle Anesthésie Samu Urgences Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France."
"147","Mosele F;Deluche E;Lusque A;Le Bescond L;Filleron T;Pradat Y;Ducoulombier A;Pistilli B;Bachelot T;Viret F;Levy C;Signolle N;Alfaro A;Tran DTN;Garberis IJ;Talbot H;Christodoulidis S;Vakalopoulou M;Droin N;Stourm A;Kobayashi M;Kakegawa T;Lacroix L;Saulnier P;Job B;Deloger M;Jimenez M;Mahier C;Baris V;Laplante P;Kannouche P;Marty V;Lacroix-Triki M;Diéras V;André F","Mosele, Fernanda;Deluche, Elise;Lusque, Amelie;Le Bescond, Loïc;Filleron, Thomas;Pradat, Yoann;Ducoulombier, Agnes;Pistilli, Barbara;Bachelot, Thomas;Viret, Frederic;Levy, Christelle;Signolle, Nicolas;Alfaro, Alexia;Tran, Diep T N;Garberis, Ingrid Judith;Talbot, Hugues;Christodoulidis, Stergios;Vakalopoulou, Maria;Droin, Nathalie;Stourm, Aurelie;Kobayashi, Maki;Kakegawa, Tomoya;Lacroix, Ludovic;Saulnier, Patrick;Job, Bastien;Deloger, Marc;Jimenez, Marta;Mahier, Celine;Baris, Vianney;Laplante, Pierre;Kannouche, Patricia;Marty, Virginie;Lacroix-Triki, Magali;Diéras, Veronique;André, Fabrice","Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.","Nature medicine","United States","eng","Clinical Trial, Phase II","","Humans;Female;Breast Neoplasms;Trastuzumab;Receptor, ErbB-2;Immunoconjugates;Camptothecin","Humans;Female;Breast Neoplasms;Trastuzumab;Receptor, ErbB-2;Immunoconjugates;Camptothecin","The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2-drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2 non-expressing (n = 40, cohort 3) metastatic breast cancer. In the full analysis set population (n = 177), the confirmed objective response rate (primary endpoint) was 70.6% (95% confidence interval (CI) 58.3-81) in cohort 1, 37.5% (95% CI 26.4-49.7) in cohort 2 and 29.7% (95% CI 15.9-47) in cohort 3. The primary endpoint was met in cohorts 1 and 2. Secondary endpoints included safety. No new safety signals were observed. During treatment, HER2-expressing tumors (n = 4) presented strong T-DXd staining. Conversely, HER2 immunohistochemistry 0 samples (n = 3) presented no or very few T-DXd staining (Pearson correlation coefficient r = 0.75, P = 0.053). Among patients with HER2 immunohistochemistry 0 metastatic breast cancer, 5 of 14 (35.7%, 95% CI 12.8-64.9) with ERBB2 expression below the median presented a confirmed objective response as compared to 3 of 10 (30%, 95% CI 6.7-65.2) with ERBB2 expression above the median. Although HER2 expression is a determinant of T-DXd efficacy, our study suggests that additional mechanisms may also be involved. (ClinicalTrials.gov identifier NCT04132960 .).","INSERM U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Dupuytren, Limoges, France.;Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.;INSERM U981, Gustave Roussy, Villejuif, France.;CVN Lab, CentraleSupélec,Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Imaging and Cytometry Platform, Gustave Roussy, UAR 23/3655, Université Paris-Saclay, Villejuif, France.;INSERM U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;CVN Lab, CentraleSupélec,Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Translational Research Department, Daiichi Sankyo RD Novare, Tokyo, Japan.;Translational Research Department, Daiichi Sankyo RD Novare, Tokyo, Japan.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;R&D Department, Unicancer, Paris, France.;R&D Department, Unicancer, Paris, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM U981, Gustave Roussy, Villejuif;Department of Medical Oncology, Gustave Roussy, Villejuif;Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre","NA",0,"1546-170X","Nat Med","Nat Med",2022,"2023","29","10.1038/s41591-023-02478-2","2110-2120","","","37488289","37488289","PUBMED","INSERM U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Dupuytren, Limoges, France.;Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.;INSERM U981, Gustave Roussy, Villejuif, France.;CVN Lab, CentraleSupélec,Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;Department of Biostatistics, Institut Claudius-Regaud, IUCT Oncopole, Toulouse, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Imaging and Cytometry Platform, Gustave Roussy, UAR 23/3655, Université Paris-Saclay, Villejuif, France.;INSERM U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;CVN Lab, CentraleSupélec,Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;OPIS, Inria, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;MICS Lab, CentraleSupélec, Université Paris-Saclay, Gif-Sur-Yvette, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Translational Research Department, Daiichi Sankyo RD Novare, Tokyo, Japan.;Translational Research Department, Daiichi Sankyo RD Novare, Tokyo, Japan.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;R&D Department, Unicancer, Paris, France.;R&D Department, Unicancer, Paris, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;UMR9019, CNRS, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;AMMICa Platform, INSERM US23, CNRS UAR 3655, AMMICa, Villejuif, France.;Department of Medical Biology and Pathology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM U981, Gustave Roussy, Villejuif;Department of Medical Oncology, Gustave Roussy, Villejuif;Faculty of Medicine, Université Paris-Saclay, Kremlin Bicêtre"
"148","Belicard F;Belhomme N;Bouzy S;Saillard C;Nedelec F;Mear JB;Ardois S;Pastoret C;Reizine F;Camus C;Painvin B","Belicard, Félicie;Belhomme, Nicolas;Bouzy, Simon;Saillard, Clémence;Nedelec, Fabienne;Mear, Jean-Baptiste;Ardois, Samuel;Pastoret, Cedric;Reizine, Florian;Camus, Christophe;Painvin, Benoit","Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome in the intensive care unit: a case report.","Journal of medical case reports","England","eng","Case Reports","Autoinflammatory disease;Cardiac arrest;ICU;Sweet’s syndrome;VEXAS syndrome;Vacuoles","Humans;Male;Aged;Sweet Syndrome;Vacuoles;Hospitalization;Exanthema;Fever;Heart Arrest;Venous Thrombosis","Humans;Male;Aged;Sweet Syndrome;Vacuoles;Hospitalization;Exanthema;Fever;Heart Arrest;Venous Thrombosis","Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome is a newly discovered inflammatory disease affecting male subjects, for which few data exist in the literature. Here, we describe the case of a patient with known Sweet's syndrome admitted to the intensive care unit and for whom a vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome was diagnosed, allowing for appropriate treatment and the patient's discharge and recovery. A 70-year-old male White patient was hospitalized in the intensive care unit following an intrahospital cardiac arrest. History started a year before with repeated deep vein thrombosis and episodes of skin eruption compatible with Sweet's syndrome. After a course of oral steroids, fever and inflammatory syndrome relapsed with onset of polychondritis, episcleritis along with neurological symptoms and pulmonary infiltrates. Intrahospital hypoxic cardiac arrest happened during patient's new investigations, and he was admitted in a critical state. During the intensive care unit stay, he presented with livedoid skin lesions on both feet. Vasculitis was not proven; however, cryoglobulinemia screening came back positive. Onset of pancytopenia was explored with a myelogram aspirate. It showed signs of dysmyelopoiesis and vacuoles in erythroid and myeloid precursors. Of note, new deep vein thrombosis developed, despite being treated with heparin leading to the diagnosis of heparin-induced thrombocytopenia. The course of symptoms were overlapping multiple entities, and so a multidisciplinary team discussion was implemented. Screening for UBA1-mutation in the blood came back positive, confirming the vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome. Corticosteroids and anti-IL1 infusion were started with satisfactory results supporting patient's discharge from intensive care unit to the internal medicine ward. Vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome should be suspected in male patients presenting with inflammatory symptoms, such as fever, skin eruption, chondritis, venous thromboembolism, and vacuoles in bone marrow precursors. Patients with undiagnosed vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic syndrome may present with organ failure requiring hospitalization in intensive care unit, where screening for UBA1 mutation should be performed when medical history is evocative. Multidisciplinary team involvement is highly recommended for patient management, notably to start appropriate immunosuppressive treatments.","Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Internal Medicine Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Dermatology Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hemostasis Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Internal Medicine Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9","NA",0,"1752-1947","J Med Case Rep","J Med Case Rep",2021,"2023","17","10.1186/s13256-023-04034-5","314","","","37480098","37480098","PUBMED","Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Internal Medicine Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Dermatology Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hemostasis Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Internal Medicine Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Hematology Laboratory Department, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9"
"149","Faron M;Cheugoua-Zanetsie M;Tierney J;Thirion P;Nankivell M;Winter K;Yang H;Shapiro J;Vernerey D;Smithers BM;Walsh T;Piessen G;Nilsson M;Boonstra J;Ychou M;Law S;Cunningham D;de Vathaire F;Stahl M;Urba S;Valmasoni M;Williaume D;Thomas J;Lordick F;Tepper J;Roth J;Gebski V;Burmeister B;Paoletti X;van Sandick J;Fu J;Pignon JP;Ducreux M;Michiels S","Faron, Matthieu;Cheugoua-Zanetsie, Maurice;Tierney, Jayne;Thirion, Pierre;Nankivell, Matthew;Winter, Kathryn;Yang, Hong;Shapiro, Joel;Vernerey, Dewi;Smithers, B Mark;Walsh, Thomas;Piessen, Guillaume;Nilsson, Magnus;Boonstra, Jurjen;Ychou, Marc;Law, Simon;Cunningham, David;de Vathaire, Florent;Stahl, Michael;Urba, Susan;Valmasoni, Michele;Williaume, Danièle;Thomas, Janine;Lordick, Florian;Tepper, Joel;Roth, Jack;Gebski, Val;Burmeister, Bryan;Paoletti, Xavier;van Sandick, Johanna;Fu, Jianhua;Pignon, Jean-Pierre;Ducreux, Michel;Michiels, Stefan","Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Meta-Analysis","","Female;Humans;Carcinoma;Chemoradiotherapy;Chemotherapy, Adjuvant;Esophageal Neoplasms;Esophagogastric Junction;Neoadjuvant Therapy;Randomized Controlled Trials as Topic;Male","Female;Humans;Carcinoma;Chemoradiotherapy;Chemotherapy, Adjuvant;Esophageal Neoplasms;Esophagogastric Junction;Neoadjuvant Therapy;Randomized Controlled Trials as Topic;Male","The optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus (TE) or gastroesophageal junction (GEJ) remains a matter of debate. We performed an individual participant data (IPD) network meta-analysis (NMA) of randomized controlled trials (RCTs) to study the effect of chemotherapy or chemoradiotherapy, with a focus on tumor location and histology subgroups. All, published or unpublished, RCTs closed to accrual before December 31, 2015 and having compared at least two of the following strategies were eligible: upfront surgery (S), chemotherapy followed by surgery (CS), and chemoradiotherapy followed by surgery (CRS). All analyses were conducted on IPD obtained from investigators. The primary end point was overall survival (OS). The IPD-NMA was analyzed by a one-step mixed-effect Cox model adjusted for age, sex, tumor location, and histology. The NMA was registered in PROSPERO (CRD42018107158). IPD were obtained for 26 of 35 RCTs (4,985 of 5,807 patients) corresponding to 12 comparisons for CS-S, 12 for CRS-S, and four for CRS-CS. CS and CRS led to increased OS when compared with S with hazard ratio (HR) = 0.86 (0.75 to 0.99),   = .03 and HR = 0.77 (0.68 to 0.87),   < .001 respectively. The NMA comparison of CRS versus CS for OS gave a HR of 0.90 (0.74 to 1.09),   = .27 (consistency   = .26, heterogeneity   = .0038). For CS versus S, a larger effect on OS was observed for GEJ versus TE tumors (  = .036). For the CRS versus S and CRS versus CS, a larger effect on OS was observed for women (  = .003, .012, respectively). Neoadjuvant chemotherapy and chemoradiotherapy were consistently better than S alone across histology, but with some variation in the magnitude of treatment effect by sex for CRS and tumor location for CS. A strong OS difference between CS and CRS was not identified.","Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;St Luke Hospital, Dublin, Ireland.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Erasmus University Medical Center, Rotterdam, the Netherlands.;CHRU Jean Minjoz, Besançon, France.;University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.;Connolly Hospital Blanchardstown, Dublin, Ireland.;CHU de Lille, Lille, France.;Division of Surgery, Department of Clinical Science, Intervention and Technoglogy, Karolinska Institutet, Stockholm, Sweden.;Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.;Leiden University Medical Center, Leiden, the Netherlands.;Val d'Aurelles, Montpellier, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, United Kingdom.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Evang. Kliniken Essen-Mitte, Essen, Germany.;University of Michigan, Ann Arbor, MI.;Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Center for Esophageal Diseases, Padova, Italy.;Centre Eugène Marquis, Rennes, France.;Princess Alexandra Hospital, Woolloongabba, Australia.;University of Leipzig, Leipzig, Germany.;University of North Carolina School of Medicine, Chapel Hill, NC.;MD Anderson, Houston, TX.;NHMRC, Sydney, Australia.;Princess Alexandra Hospital, Woolloongabba, Australia.;Institut Curie, Paris, France.;The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Departement d'Oncologie Médicale, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2023,"2023","41","10.1200/JCO.22.02279","4535-4547","MC_UU_00004/06;MC_UU_12023/20","Medical Research Council;Medical Research Council","37467395","37467395","PUBMED","Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;St Luke Hospital, Dublin, Ireland.;MRC Clinical Trial Unit at UCL, London, United Kingdom.;NRG Oncology Statistics and Data Management Center, Philadelphia, PA.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Erasmus University Medical Center, Rotterdam, the Netherlands.;CHRU Jean Minjoz, Besançon, France.;University of Queensland, Princess Alexandra Hospital, Brisbane, Australia.;Connolly Hospital Blanchardstown, Dublin, Ireland.;CHU de Lille, Lille, France.;Division of Surgery, Department of Clinical Science, Intervention and Technoglogy, Karolinska Institutet, Stockholm, Sweden.;Department of Upper Abdominal Diseases, Karolinska University Hospital, Stockholm, Sweden.;Leiden University Medical Center, Leiden, the Netherlands.;Val d'Aurelles, Montpellier, France.;Department of Surgery, School of Clinical Medicine, The University of Hong Kong, Hong Kong SAR, China.;National Institute for Health Research, Biomedical Research Centres, Royal Marsden, London, United Kingdom.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Evang. Kliniken Essen-Mitte, Essen, Germany.;University of Michigan, Ann Arbor, MI.;Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Center for Esophageal Diseases, Padova, Italy.;Centre Eugène Marquis, Rennes, France.;Princess Alexandra Hospital, Woolloongabba, Australia.;University of Leipzig, Leipzig, Germany.;University of North Carolina School of Medicine, Chapel Hill, NC.;MD Anderson, Houston, TX.;NHMRC, Sydney, Australia.;Princess Alexandra Hospital, Woolloongabba, Australia.;Institut Curie, Paris, France.;The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.;Sun Yat-Sen University Cancer Center, Guangzhou, China.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.;Departement d'Oncologie Médicale, Gustave Roussy, Villejuif, France.;Oncostat, CESP, Inserm U1018, University Paris-Saclay, labeled Ligue Contre le Cancer, Gustave Roussy, Villejuif, France."
"150","de Jong D;Desperito E;Al Feghali KA;Dercle L;Seban RD;Das JP;Ma H;Sajan A;Braumuller B;Prendergast C;Liou C;Deng A;Roa T;Yeh R;Girard A;Salvatore MM;Capaccione KM","de Jong, Dorine;Desperito, Elise;Al Feghali, Karine A;Dercle, Laurent;Seban, Romain-David;Das, Jeeban P;Ma, Hong;Sajan, Abin;Braumuller, Brian;Prendergast, Conor;Liou, Connie;Deng, Aileen;Roa, Tina;Yeh, Randy;Girard, Antoine;Salvatore, Mary M;Capaccione, Kathleen M","Advances in PET/CT Imaging for Breast Cancer.","Journal of clinical medicine","Switzerland","eng","Journal Article","18F-FDG;PET radiotracers;breast cancer;triple negative breast cancer (TNBC)","","","One out of eight women will be affected by breast cancer during her lifetime. Imaging plays a key role in breast cancer detection and management, providing physicians with information about tumor location, heterogeneity, and dissemination. In this review, we describe the latest advances in PET/CT imaging of breast cancer, including novel applications of  F-FDG PET/CT and the development and testing of new agents for primary and metastatic breast tumor imaging and therapy. Ultimately, these radiopharmaceuticals may guide personalized approaches to optimize treatment based on the patient's specific tumor profile, and may become a new standard of care. In addition, they may enhance the assessment of treatment efficacy and lead to improved outcomes for patients with a breast cancer diagnosis.","Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;RefleXion Medical, Inc., Hayward, CA 94545, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.;Laboratory of Translational Imaging in Oncology, Paris Sciences et Lettres (PSL) Research University, Institut Curie, 91401 Orsay, France.;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Hematology and Oncology, Novant Health, 170 Medical Park Road, Mooresville, NC 28117, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.","NA",0,"2077-0383","J Clin Med","J Clin Med",2023,"2023","12","10.3390/jcm12134537",NA,"P30 CA008748","NCI NIH HHS","37445572","37445572","PUBMED","Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;RefleXion Medical, Inc., Hayward, CA 94545, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 92210 Saint-Cloud, France.;Laboratory of Translational Imaging in Oncology, Paris Sciences et Lettres (PSL) Research University, Institut Curie, 91401 Orsay, France.;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Hematology and Oncology, Novant Health, 170 Medical Park Road, Mooresville, NC 28117, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA.;Department of Radiology, Columbia University Irving Medical Center, New York, NY 10032, USA."
"151","Lefort F;Dalban C;Gross-Goupil M;Laguerre B;Chabaud S;Escudier B;Albiges L","Lefort, Félix;Dalban, Cécile;Gross-Goupil, Marine;Laguerre, Brigitte;Chabaud, Sylvie;Escudier, Bernard;Albiges, Laurence","Association of Corticosteroids With Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab.","JAMA oncology","United States","eng","Journal Article","","Humans;Nivolumab;Carcinoma, Renal Cell;Kidney Neoplasms;Antineoplastic Agents, Immunological;Adrenal Cortex Hormones;Retrospective Studies","Humans;Nivolumab;Carcinoma, Renal Cell;Kidney Neoplasms;Antineoplastic Agents, Immunological;Adrenal Cortex Hormones;Retrospective Studies","NA","Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.;Clinical Research, Centre Léon Bérard, Lyon, France.;Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Clinical Research, Centre Léon Bérard, Lyon, France.;Medical Oncology, Gustave Roussy-Cancer Campus, Villejuif, France.;Medical Oncology, Gustave Roussy-Cancer Campus, Villejuif, France.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2023,"2023","9","10.1001/jamaoncol.2023.2296","1295-1298","","","37440214","37440214","PUBMED","Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.;Clinical Research, Centre Léon Bérard, Lyon, France.;Medical Oncology, CHU Bordeaux-Hopital St André, Bordeaux, France.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Clinical Research, Centre Léon Bérard, Lyon, France.;Medical Oncology, Gustave Roussy-Cancer Campus, Villejuif, France.;Medical Oncology, Gustave Roussy-Cancer Campus, Villejuif, France."
"152","Blay JY;Chevret S;Le Cesne A;Brahmi M;Penel N;Cousin S;Bertucci F;Bompas E;Ryckewaert T;Soibinet P;Boudou-Rouquette P;Saada Bouzid E;Soulie P;Valentin T;Lotz JP;Tosi D;Neviere Z;Cancel M;Ray-Coquard I;Gambotti L;Legrand F;Lamrani-Ghaouti A;Simon C;Even C;Massard C","Blay, Jean-Yves;Chevret, Sylvie;Le Cesne, Axel;Brahmi, Mehdi;Penel, Nicolas;Cousin, Sophie;Bertucci, Francois;Bompas, Emmanuelle;Ryckewaert, Thomas;Soibinet, Pauline;Boudou-Rouquette, Pascaline;Saada Bouzid, Esma;Soulie, Patrick;Valentin, Thibaud;Lotz, Jean-Pierre;Tosi, Diego;Neviere, Zoé;Cancel, Mathilde;Ray-Coquard, Isabelle;Gambotti, Laetitia;Legrand, Frédéric;Lamrani-Ghaouti, Assia;Simon, Clotilde;Even, Caroline;Massard, Christophe","Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase II","","Humans;Male;Female;Middle Aged;Adolescent;Antibodies, Monoclonal, Humanized;Soft Tissue Neoplasms;Sarcoma, Alveolar Soft Part;Response Evaluation Criteria in Solid Tumors;Antineoplastic Combined Chemotherapy Protocols;DNA Helicases;Nuclear Proteins;Transcription Factors","Humans;Male;Female;Middle Aged;Adolescent;Antibodies, Monoclonal, Humanized;Soft Tissue Neoplasms;Sarcoma, Alveolar Soft Part;Response Evaluation Criteria in Solid Tumors;Antineoplastic Combined Chemotherapy Protocols;DNA Helicases;Nuclear Proteins;Transcription Factors","Sarcoma is a heterogeneous group of diseases with few treatment options. Immunotherapy has shown little activity in studies including unselected sarcomas, but immune checkpoint blockers have shown activity in specific histotypes. We evaluated the activity of pembrolizumab in rare and ultra-rare sarcomas. AcSé Pembrolizumab is an ongoing phase 2, basket, multitumour study investigating the activity of pembrolizumab monotherapy in rare cancers. Here, we report the results obtained in patients with selected histotypes of rare sarcomas (incidence of less than one case per 1 000 000 people per year) recruited at 24 French hospitals. Key inclusion criteria were age 15 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and advanced disease that was untreated and resistant to treatment. Patients were given pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months. The primary endpoint was objective response rate at week 12 using Response Evaluation Criteria in Solid Tumours version 1.1, assessed by local investigators. The primary endpoint and safety were analysed in the intention-to-treat population. The AcSé Pembrolizumab study is registered with ClinicalTrials.gov, NCT03012620. Between Sept 4, 2017, and Dec 29, 2020, 98 patients were enrolled, of whom 97 received treatment and were included in analyses (median age 51 years [IQR 35-65]; 53 [55%] were male; 44 [45%] were female; no data were collected on race or ethnicity). 34 (35%) patients had chordomas, 14 (14%) had alveolar soft part sarcomas, 12 (12%) had SMARCA4-deficient sarcomas or malignant rhabdoid tumours, eight (8%) had desmoplastic small round cell tumours, six (6%) had epithelioid sarcomas, four (4%) had dendritic cell sarcomas, three (3%) each had clear cell sarcomas, solitary fibrous tumours, and myxoid liposarcomas, and ten (10%) had other ultra-rare histotypes. As of data cutoff (April 11, 2022), median follow-up was 13·1 months (range 0·1-52·8; IQR 4·3-19·7). At week 12, objective response rate was 6·2% (95% CI 2·3-13·0), with no complete responses and six partial responses in the 97 patients. The most common grade 3-4 adverse events were anaemia (eight [8%] of 97), alanine aminotransferase and aspartate aminotransferase increase (six [6%]), and dyspnoea (five [5%]). 86 serious adverse events were reported in 37 patients. Five deaths due to adverse events were reported, none of which were determined to be related to treatment (two due to disease progression, two due to cancer, and one due to unknown cause). Our data show the activity and manageable toxicity of pembrolizumab in some rare and ultra-rare sarcoma histotypes, and support the PD-1/PD-L1 pathway as a potential therapeutic target in selected histotypes. The completion of the basket study will provide further evidence regarding the activity and toxicity of pembrolizumab in identified rare types of cancer. The Ligue contre le cancer, INCa, MSD. For the French translation of the abstract see Supplementary Materials section.","Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon;Service de Biostatistique, Hôpital Saint Louis (AP-HP), Université Paris Cité, Paris, France.;Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France.;Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon, France.;Centre Oscar Lambret, Lille, France.;Institut Bergonié, Bordeaux, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France.;Centre Oscar Lambret, Lille, France.;Centre J Godinot, Reims, France.;Hôpital Cochin Saint Vincent de Paul, Paris, France.;Centre Antoine-Lacassagne, Nice, France.;Institut de Cancérologie de l'Ouest, Centre Paul Papin, Angers, France.;Institut Claudius Regaud, IUCT, Oncopole, Toulouse, France.;Hôpital Tenon, Paris, France.;Institut Régional du Cancer de Montpellier, Centre Val d'Aurelle, Montpellier, France.;Centre Francois Baclesse, Caen, France.;CHU Bretonneau, Tours, France.;Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon, France.;Institut National du Cancer, Boulogne, France.;Institut National du Cancer, Boulogne, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France.;Centre Eugene Marquis, Rennes, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2023,"2023","24","10.1016/S1470-2045(23)00282-6","892-902","","","37429302","37429302","PUBMED","Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon;Service de Biostatistique, Hôpital Saint Louis (AP-HP), Université Paris Cité, Paris, France.;Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France.;Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon, France.;Centre Oscar Lambret, Lille, France.;Institut Bergonié, Bordeaux, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest, Centre René Gauducheau, Nantes, France.;Centre Oscar Lambret, Lille, France.;Centre J Godinot, Reims, France.;Hôpital Cochin Saint Vincent de Paul, Paris, France.;Centre Antoine-Lacassagne, Nice, France.;Institut de Cancérologie de l'Ouest, Centre Paul Papin, Angers, France.;Institut Claudius Regaud, IUCT, Oncopole, Toulouse, France.;Hôpital Tenon, Paris, France.;Institut Régional du Cancer de Montpellier, Centre Val d'Aurelle, Montpellier, France.;Centre Francois Baclesse, Caen, France.;CHU Bretonneau, Tours, France.;Centre Léon Bérard & Université Claude Bernard Lyon 1, Lyon, France.;Institut National du Cancer, Boulogne, France.;Institut National du Cancer, Boulogne, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France.;Centre Eugene Marquis, Rennes, France."
"153","Turban A;Gaubert S;Luque-Paz D;René C;Collet N;Pawlowski M;Bendavid C;Lefèvre CR","Turban, Adrien;Gaubert, Sophie;Luque-Paz, David;René, Céline;Collet, Nicolas;Pawlowski, Maxime;Bendavid, Claude;Lefèvre, Charles R","Validation of a short turnaround time automated method for the 24/7 determination of plasma d-lactate on Roche Cobas c502.","Practical laboratory medicine","Netherlands","eng","Journal Article","","","","NA","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.","NA",0,"2352-5517","Pract Lab Med","Pract Lab Med",2022,"2023","36","10.1016/j.plabm.2023.e00317","e00317","","","37425622","37425622","PUBMED","Laboratoire de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France.;Laboratoire de Biochimie-Toxicologie, Centre Hospitalier Universitaire de Rennes, F-35033, Rennes, France."
"154","Mafi S;Essig M;Rerolle JP;Lagathu G;Crochette R;Brodard V;Schvartz B;Gouarin S;Bouvier N;Engelmann I;Garstka A;Bressollette-Bodin C;Cantarovitch D;Germi R;Janbon B;Archimbaut C;Heng AE;Garnier F;Gomes-Mayeras M;Labrunie A;Hantz S;Alain S","Mafi, Sarah;Essig, Marie;Rerolle, Jean-Philippe;Lagathu, Gisèle;Crochette, Romain;Brodard, Véronique;Schvartz, Betoul;Gouarin, Stephanie;Bouvier, Nicolas;Engelmann, Ilka;Garstka, Antoine;Bressollette-Bodin, Céline;Cantarovitch, Diego;Germi, Raphaële;Janbon, Benedicte;Archimbaut, Christine;Heng, Anne-Elizabeth;Garnier, Françoise;Gomes-Mayeras, Melissa;Labrunie, Anaïs;Hantz, Sébastien;Alain, Sophie",NA,"Frontiers in medicine","Switzerland","eng","Journal Article","CMV-seropositive recipients;QuantiFERON® CMV;Torquetenovirus;cytomegalovirus;kidney transplantation","","","Cytomegalovirus (CMV) is the most frequent infectious complication following solid organ transplantation. Torque teno viruses (TTV) viremia has been proposed as a biomarker of functional immunity in the management of kidney transplant recipients (KTR). The QuantiFERON -CMV (QF-CMV) is a commercially available assay that allows the assessment of CD8  T-cell responses in routine diagnostic laboratories. In a prospective national multicenter cohort of 64 CMV-seropositive (R+) KTR, we analyzed the value of TTV load and the two markers of the QF-CMV assay [QF-Ag (CMV-specific T-cell responses) and QF-Mg (overall T-cell responses)], alone and in combination, in prediction of CMV reactivation (≥3 log  IU/ ml) in the first post-transplant year. We compared previously published cut-offs and specific cut-offs optimized from ROC curves for our population. Using the conventional cut-off (3.45 log  copies/ml), TTV load at D0 [inclusion visit on the day of transplantation before induction (D0)], or at M1 (1-month post-transplant visit) perform better in predicting CMV viremia control than CMV reactivation. Survival analyses suggest a better performance of our optimized TTV cut-offs (3.78 log  copies/ml at D0 and 4.23 log  copies/ml at M1) for risk stratification of CMV reactivation in our R+ KTR cohort. The QF-CMV (QF-Ag = 0.2 IU/ml, and QF-Mg = 0.5 IU/ml) also appears to better predict CMV viremia control than CMV reactivation. Moreover, survival analyses suggest that the QF-Mg would perform better than the QF-Ag in stratifying the risk of CMV reactivation. The use of our optimized QF-Mg cut-off (1.27 IU/ml) at M1 further improved risk stratification of CMV reactivation. Using conventional cut-offs, the combination of TTV load and QF-Ag or TTV load and QF-Mg did not improve prediction of CMV viremia control compared to separate analysis of each marker but resulted in an increase of positive predictive values. The use of our cut-offs slightly improved risk prediction of CMV reactivation. The combination of TTV load and QF-Ag or TTV load and QF-Mg could be useful in stratifying the risk of CMV reactivation in R+ KTR during the first post-transplant year and thereby have an impact on the duration of prophylaxis in these patients. ClinicalTrials.gov registry, identifier NCT02064699.","French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Virology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Virology Department, Centre Hospitalier Universitaire de Reims, Reims, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Reims, Reims, France.;Virology Department, Centre Hospitalier Universitaire de Caen, Caen, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Caen, Caen, France.;Virology Department, Centre Hospitalier Universitaire de Lille, Lille, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Lille, Lille, France.;Virology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Virology Department, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Virology Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;Biostatistics Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.","NA",0,"2296-858X","Front Med (Lausanne)","Front Med (Lausanne)",2023,"2023","10","10.3389/fmed.2023.1180769","1180769","","","37425298","37425298","PUBMED","French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Virology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Virology Department, Centre Hospitalier Universitaire de Reims, Reims, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Reims, Reims, France.;Virology Department, Centre Hospitalier Universitaire de Caen, Caen, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Caen, Caen, France.;Virology Department, Centre Hospitalier Universitaire de Lille, Lille, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Lille, Lille, France.;Virology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Virology Department, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Grenoble, Grenoble, France.;Virology Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Nephrology and Transplantation Department, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;Biostatistics Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France.;French National Reference Center for Herpesviruses, Bacteriology, Virology, Hygiene Department, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Inserm, RESINFIT, U1092, Université de Limoges, Limoges, France."
"155","Sapoval M;Thiounn N;Descazeaud A;Déan C;Ruffion A;Pagnoux G;Duarte RC;Robert G;Petitpierre F;Karsenty G;Vidal V;Murez T;Vernhet-Kovacsik H;de la Taille A;Kobeiter H;Mathieu R;Heautot JF;Droupy S;Frandon J;Barry Delongchamps N;Korb-Savoldelli V;Durand-Zaleski I;Pereira H;Chatellier G","Sapoval, Marc;Thiounn, Nicolas;Descazeaud, Aurélien;Déan, Carole;Ruffion, Alain;Pagnoux, Gaële;Duarte, Ricardo Codas;Robert, Grégoire;Petitpierre, Francois;Karsenty, Gilles;Vidal, Vincent;Murez, Thibaut;Vernhet-Kovacsik, Hélène;de la Taille, Alexandre;Kobeiter, Hicham;Mathieu, Romain;Heautot, Jean-Francois;Droupy, Stéphane;Frandon, Julien;Barry Delongchamps, Nicolas;Korb-Savoldelli, Virginie;Durand-Zaleski, Isabelle;Pereira, Helena;Chatellier, Gilles","Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial.","The Lancet regional health. Europe","England","eng","Journal Article","5- alpha-reductase inhibitors;Alpha-blockers;Benign prostatic hyperplasia;Cost;Economics;Erectile function;International prostatic symptom score;Lower urinary tract symptoms;Prostatic artery embolisation","","","Prostatic artery embolisation (PAE) is a minimally invasive treatment of symptomatic benign prostatic hyperplasia (BPH). Our aim was to compare patient's symptoms improvement after PAE and medical treatment. A randomised, open-label, superiority trial was set in 10 French hospitals. Patients with bothersome lower urinary tract symptoms (LUTS) defined by International Prostatic Symptom Score (IPSS) > 11 and quality of life (QoL) > 3, and BPH ≥50 ml resistant to alpha-blocker monotherapy were randomly assigned (1:1) to PAE or Combined Therapy ([CT], oral dutasteride 0.5 mg/tamsulosin hydrochloride 0.4 mg per day). Randomisation was stratified by centre, IPSS and prostate volume with a minimisation procedure. The primary outcome was the 9-month IPSS change. Primary and safety analysis were done according to the intention-to-treat (ITT) principle among patients with an evaluable primary outcome. ClinicalTrials.gov Identifier: NCT02869971. Ninety patients were randomised from September 2016 to February 2020, and 44 and 43 patients assessed for primary endpoint in PAE and CT groups, respectively. The 9-month change of IPSS was -10.0 (95% confidence interval [CI]: -11.8 to -8.3) and -5.7 (95% CI: -7.5 to -3.8) in the PAE and CT groups, respectively. This reduction was significantly greater in the PAE group than in the CT group (-4.4 [95% CI: -6.9 to -1.9], p = 0.0008). The IIEF-15 score change was 8.2 (95% CI: 2.9-13.5) and -2.8 (95% CI: -8.4 to 2.8) in the PAE and CT groups, respectively. No treatment-related AE or hospitalisation was noticed. After 9 months, 5 and 18 patients had invasive prostate re-treatment in the PAE and CT group, respectively. In patients with BPH ≥50 ml and bothersome LUTS resistant to alpha-blocker monotherapy, PAE provides more urinary and sexual symptoms benefit than CT up to 24 months. French Ministry of Health and a complementary grant from Merit Medical.","Université de Paris Cité, PARCC - INSERM Unité-970, Paris, France.;Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Centre Hospitalier Universitaire de Limoges, Department of Urology, Limoges, France.;Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.;Université Lyon 1, Faculté de médecine Lyon Sud, Equipe 2 - Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Lyon, France.;Department of Uroradiology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Department of Urology and Transplantation, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Centre Hospitalier Universitaire de Bordeaux, Department of Urology, Université de Bordeaux, Bordeaux, France.;Centre Hospitalier Universitaire de Bordeaux, Department of Diagnostic and Therapeutic Imaging, Bordeaux, France.;Department of Urology and Renal Transplantation, Assistance publique-Hôpitaux de Marseille, Hôpital de la Conception, Aix-Marseille Université, Marseille, France.;Centre Hospitalier Universitaire de la Timone, Interventional Radiology Section, Department of Medical Imaging, Assistance publique-Hôpitaux de Marseille, Marseille, France.;Aix-Marseille Université, LiiE, CERIMED, Marseille, France.;Centre Hospitalier Universitaire de Montpellier, Department of Urology and Renal Transplantation, Montpellier, France.;Centre Hospitalier Universitaire de Montpellier, Department of Diagnostic and Interventional Radiology, Hôpital Arnaud-de-Villeneuve, Montpellier, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Department of Diagnostic and Interventional Medical Imaging, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Université Paris Est, Créteil, France.;Centre Hospitalier Universitaire de Rennes, Department of Urology, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Vascular Medicine Unit, Department of Radiology, Hôpital Pontchaillou, Rennes, France.;Centre Hospitalier Universitaire De Nîmes, Department of Urology and Andrology, Université de Montpellier, Nîmes, France.;Centre Hospitalier Universitaire De Nîmes, Department of Medical Imaging, Université de Montpellier, Nîmes, France.;Medical Imaging Group Nîmes, IMAGINE, Nîmes, France.;Université de Paris Cité, Inserm Unit U1151, Paris, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.;Department of Pharmacy, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Clinical Pharmacy, Université Paris-Saclay, Faculté de Pharmacie, Chatenay-Malabry, France.;Université de Paris Cité, CRESS, INSERM UMR1153, INRA, Paris, France.;Assistance Publique-Hôpitaux de Paris, Hôpital de l'Hôtel Dieu, Université Paris Est Créteil, URCEco, Paris, France.;INSERM, Centre d'investigation Clinique 1418 Épidémiologie Clinique, Paris, France.;Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.;INSERM, Centre d'investigation Clinique 1418 Épidémiologie Clinique, Paris, France.;Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.","NA",0,"2666-7762","Lancet Reg Health Eur","Lancet Reg Health Eur",2023,"2023","31","10.1016/j.lanepe.2023.100672","100672","","","37415648","37415648","PUBMED","Université de Paris Cité, PARCC - INSERM Unité-970, Paris, France.;Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Centre Hospitalier Universitaire de Limoges, Department of Urology, Limoges, France.;Department of Vascular and Oncological Interventional Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.;Université Lyon 1, Faculté de médecine Lyon Sud, Equipe 2 - Centre d'Innovation en Cancérologie de Lyon (EA 3738 CICLY), Lyon, France.;Department of Uroradiology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Department of Urology and Transplantation, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Centre Hospitalier Universitaire de Bordeaux, Department of Urology, Université de Bordeaux, Bordeaux, France.;Centre Hospitalier Universitaire de Bordeaux, Department of Diagnostic and Therapeutic Imaging, Bordeaux, France.;Department of Urology and Renal Transplantation, Assistance publique-Hôpitaux de Marseille, Hôpital de la Conception, Aix-Marseille Université, Marseille, France.;Centre Hospitalier Universitaire de la Timone, Interventional Radiology Section, Department of Medical Imaging, Assistance publique-Hôpitaux de Marseille, Marseille, France.;Aix-Marseille Université, LiiE, CERIMED, Marseille, France.;Centre Hospitalier Universitaire de Montpellier, Department of Urology and Renal Transplantation, Montpellier, France.;Centre Hospitalier Universitaire de Montpellier, Department of Diagnostic and Interventional Radiology, Hôpital Arnaud-de-Villeneuve, Montpellier, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Department of Diagnostic and Interventional Medical Imaging, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Henri Mondor, Université Paris Est, Créteil, France.;Centre Hospitalier Universitaire de Rennes, Department of Urology, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Vascular Medicine Unit, Department of Radiology, Hôpital Pontchaillou, Rennes, France.;Centre Hospitalier Universitaire De Nîmes, Department of Urology and Andrology, Université de Montpellier, Nîmes, France.;Centre Hospitalier Universitaire De Nîmes, Department of Medical Imaging, Université de Montpellier, Nîmes, France.;Medical Imaging Group Nîmes, IMAGINE, Nîmes, France.;Université de Paris Cité, Inserm Unit U1151, Paris, France.;Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.;Department of Pharmacy, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Clinical Pharmacy, Université Paris-Saclay, Faculté de Pharmacie, Chatenay-Malabry, France.;Université de Paris Cité, CRESS, INSERM UMR1153, INRA, Paris, France.;Assistance Publique-Hôpitaux de Paris, Hôpital de l'Hôtel Dieu, Université Paris Est Créteil, URCEco, Paris, France.;INSERM, Centre d'investigation Clinique 1418 Épidémiologie Clinique, Paris, France.;Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.;INSERM, Centre d'investigation Clinique 1418 Épidémiologie Clinique, Paris, France.;Clinical Research Unit, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France."
"156","Grinda T;Antoine A;Jacot W;Cottu PH;de la Motte Rouge T;Frenel JS;Mailliez A;Dalenc F;Goncalves A;Clatot F;Mouret Reynier MA;Levy C;Ferrero JM;Desmoulins I;Uwer L;Petit T;Jouannaud C;Arnedos M;Chevrot M;Courtinard C;Tredan O;Brain E;Pérol D;Pistilli B;Delaloge S","Grinda, Thomas;Antoine, Alison;Jacot, William;Cottu, Paul-Henri;de la Motte Rouge, Thibault;Frenel, Jean-Sébastien;Mailliez, Audrey;Dalenc, Florence;Goncalves, Anthony;Clatot, Florian;Mouret Reynier, Marie-Ange;Levy, Christelle;Ferrero, Jean-Marc;Desmoulins, Isabelle;Uwer, Lionel;Petit, Thierry;Jouannaud, Christelle;Arnedos, Monica;Chevrot, Michaël;Courtinard, Coralie;Tredan, Olivier;Brain, Etienne;Pérol, David;Pistilli, Barbara;Delaloge, Suzette","Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Breast cancer;ESME cohort;Overall survival;Real-world data;Triple-negative breast cancer","Female;Humans;Antibiotics, Antineoplastic;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chronic Disease;Neoplasm Recurrence, Local;Prognosis;Progression-Free Survival;Triple Negative Breast Neoplasms","Female;Humans;Antibiotics, Antineoplastic;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Chronic Disease;Neoplasm Recurrence, Local;Prognosis;Progression-Free Survival;Triple Negative Breast Neoplasms","Early metastatic relapse of triple-negative breast cancer (mTNBC) after anthracyclins and/or taxanes based (A/T) primary treatment represents a highly aggressive cancer situation requiring urgent characterisation and handling. Epidemio-Strategy-Medico-Economical-Metastatic Breast Cancer (ESME-MBC) database, a multicenter, national, observational cohort (NCT03275311) provides recent data on this entity. All ESME patients diagnosed between 2008 and 2020 with mTNBC occurring as a relapse after a systemic neoadjuvant/adjuvant taxane and/or anthracycline-based chemotherapy were included. Early relapses were defined by a metastatic diagnosis up to 12 months of the end of neo/adjuvant A/T chemotherapy. We assessed overall survival (OS) and progression-free-survival under first-line treatment (PFS1) by early versus late relapse (≥12 months). Patients with early relapse (N = 881, 46%) were younger and had a larger tumour burden at primary diagnosis than those with late relapses (N = 1045). Early relapse rates appeared stable over time. Median OS was 10.1 months (95% CI 9.3-10.9) in patients with early relapse versus 17.1 months (95% CI 15.7-18.2) in those with late relapse (adjusted hazard-ratio (aHR): 1.92 (95% CI 1.73-2.13); p < 0.001). The median PFS1 was respectively 3.1 months (95% CI 2.9-3.4) and 5.3 months (95% CI 5.1-5.8); (aHR: 1.66; [95% CI 1.50-1.83]; p < 0.001). Among early relapsed patients, a higher number of metastatic sites, visceral disease but not treatment types, were independently associated with a poorer OS. These real-world data provide strong evidence on the dismal prognosis, higher treatment resistance and major unmet medical need associated with early relapsed mTNBC. Database registration: clinicaltrials.gov Identifier NCT032753.","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Sorbonne University, Medicine, 21 rue de l'École de médecine, 75006 Paris;Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, 15 rue André Boquel, 49055 Angers, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 06000 Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079 Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000 Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2023","189","10.1016/j.ejca.2023.05.023","112935","","","37385070","37385070","PUBMED","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; Sorbonne University, Medicine, 21 rue de l'École de médecine, 75006 Paris;Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM U1194, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, 15 rue André Boquel, 49055 Angers, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 06000 Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079 Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000 Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000 Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Biostatistics, DRCI, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France."
"157","Rogers JH;Asch F;Sorajja P;Mahoney P;Price MJ;Maisano F;Denti P;Morse MA;Rinaldi M;Bedogni F;De Marco F;Rollefson W;Chehab B;Williams MR;Leurent G;Morikawa T;Asgar AW;Rodriguez E;von Bardeleben RS;Kar S","Rogers, Jason H;Asch, Federico;Sorajja, Paul;Mahoney, Paul;Price, Matthew J;Maisano, Francesco;Denti, Paolo;Morse, Michael A;Rinaldi, Michael;Bedogni, Francesco;De Marco, Federico;Rollefson, William;Chehab, Bassem;Williams, Mathew R;Leurent, Guillaume;Morikawa, Takao;Asgar, Anita W;Rodriguez, Evelio;von Bardeleben, Ralph Stephan;Kar, Saibal","Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study.","JACC. Cardiovascular interventions","United States","eng","Multicenter Study","MitraClip system;TEER;mitral regurgitation;mitral valve repair;transcatheter edge-to-edge repair","Humans;Prospective Studies;Quality of Life;Reactive Oxygen Species;Treatment Outcome;Constriction, Pathologic;Mitral Valve Insufficiency;Cardiomyopathies","Humans;Prospective Studies;Quality of Life;Reactive Oxygen Species;Treatment Outcome;Constriction, Pathologic;Mitral Valve Insufficiency;Cardiomyopathies","Anatomical and clinical criteria to define mitral transcatheter edge-to-edge repair (TEER) ""unsuitability"" have been proposed on the basis of a Heart Valve Collaboratory consensus opinion from physician experience with early-generation TEER devices but lacked an evidence-based approach. The aim of this study was to explore the spectrum of TEER suitability using echocardiographic and clinical outcomes from the EXPAND G4 real-world postapproval study. EXPAND G4 is a global, prospective, multicenter, single-arm study that enrolled 1,164 subjects with mitral regurgitation (MR) treated with the MitraClip G4 System. Three groups were defined using the Heart Valve Collaboratory TEER unsuitability criteria: 1) risk of stenosis (RoS); 2) risk of inadequate MR reduction (RoIR); and 3) subjects with baseline moderate or less MR (MMR). A TEER-suitable (TS) group was defined by the absence of these characteristics. Endpoints included independent core laboratory-assessed echocardiographic characteristics, procedural outcomes, MR reduction, NYHA functional class, Kansas City Cardiomyopathy Questionnaire score, and major adverse events through 30 days. Subjects in the RoS (n = 56), RoIR (n = 54), MMR (n = 326), and TS (n = 303) groups had high 30-day MR reduction rates (≤1+: RoS 97%, MMR 93%, and TS 91%; ≤2+: RoIR 94%). Thirty-day improvements in functional capacity (NYHA functional class I or II at 30 days vs baseline: RoS 94% vs 29%, RoIR 88% vs 30%, MMR 79% vs 26%, and TS 83% vs 33%) and quality of life (change in Kansas City Cardiomyopathy Questionnaire score: RoS +27 ± 26, RoIR +16 ± 26, MMR +19 ± 26, and TS +19 ± 24) were safely achieved in all groups, with low major adverse events (<3%) and all-cause mortality (RoS 1.8%, RoIR 0%, MMR 1.5%, and TS 1.3%). Patients previously deemed TEER unsuitable can be safely and effectively treated with the mitral TEER fourth-generation device.","University of California Davis Medical Center, Sacramento, California;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Sentara Heart and Valve and Structural Disease Center, Norfolk, Virginia, USA.;Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;Carolinas Medical Center, Charlotte, North Carolina, USA.;IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi Hospital, University of Kansas, Wichita, Kansas, USA.;NYU Langone Medical Center, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;The Sakakibara Heart Institute of Okayama, Okayama, Japan.;Institut de Cardiologie de Montréal, Montreal, Quebec, Canada.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;University Medical Center of Mainz, Mainz, Germany.;Los Robles Regional Medical Center, Thousand Oaks, California, USA.","NA",0,"1876-7605","JACC Cardiovasc Interv","JACC Cardiovasc Interv",2023,"2023","16","10.1016/j.jcin.2023.05.014","1474-1485","","","37380229","37380229","PUBMED","University of California Davis Medical Center, Sacramento, California;Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, District of Columbia, USA.;Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.;Sentara Heart and Valve and Structural Disease Center, Norfolk, Virginia, USA.;Scripps Clinic, La Jolla, California, USA.;San Raffaele University Hospital, Milan, Italy.;San Raffaele University Hospital, Milan, Italy.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;Carolinas Medical Center, Charlotte, North Carolina, USA.;IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.;Centro Cardiologico Monzino IRCCS, Milan, Italy.;Arkansas Heart Hospital, Little Rock, Arkansas, USA.;Ascension Via Christi Hospital, University of Kansas, Wichita, Kansas, USA.;NYU Langone Medical Center, New York, New York, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;The Sakakibara Heart Institute of Okayama, Okayama, Japan.;Institut de Cardiologie de Montréal, Montreal, Quebec, Canada.;Ascension Saint Thomas Hospital, Nashville, Tennessee, USA.;University Medical Center of Mainz, Mainz, Germany.;Los Robles Regional Medical Center, Thousand Oaks, California, USA."
"158","Rousseau N;Lebreton O;Masse H;Maucourant Y;Pipelart V;Clement M;Le Lez ML;Khanna RK;Pepin M;Eude Y;Le Meur G;Weber M;Ducloyer JB","Rousseau, Nicolas;Lebreton, Olivier;Masse, Hélène;Maucourant, Yann;Pipelart, Valentin;Clement, Manon;Le Lez, Marie-Laure;Khanna, Raoul Kanav;Pepin, Maxime;Eude, Yannick;Le Meur, Guylène;Weber, Michel;Ducloyer, Jean-Baptiste","Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study.","Ophthalmology and therapy","England","eng","Journal Article","Corticosteroid implant;DME;Dexamethasone;Diabetes complications;Diabetic macular oedema;Fluocinolone acetonide;Intravitreal injection;Retinal diseases","","","The aim of this study was to assess the efficacy and safety of fluocinolone acetonide implant (FAci) injected 1 month after the last dexamethasone intravitreal implant (DEXi) in chronic diabetic macular oedema (DME) patients. Retrospective multicentric study conducted in pseudophakic patients with chronic DME frequently treated with dexamethasone intravitreal implant (DEXi; time to DME recurrence ≤ 6 months), receiving FAci 1 month after the last DEXi, with at least a 6-month follow-up. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure (IOP) and additional treatments were assessed on the day of FAci injection (M0), 1 (M1) and 3 months (M3) later and then every 3 months. A total of 41 eyes from 34 patients were included. At M0, patients' mean age was 68.7 ± 9.8 years, the mean DME duration was 63.9 ± 22.9 months, the mean interval between two DEXi was 14.2 ± 3.3 weeks. M12 data were available for 71% of patients. At baseline, the mean BCVA, CMT and IOP were 63.2 ± 16.6 letters, 299.4 ± 103.3 µm, and 16.2 ± 4.5 mmHg, respectively, and remained stable during the follow-up. At M12, 14% of patients required additional intravitreal treatments. In pseudophakic patients with chronic DME showing good response to DEXi but requiring repeated injections every < 6 months, switching to FAci 1 month after the last DEXi was effective and safe. Further prospective randomized controlled studies are needed to confirm these findings, and to determine the best interval between the last DEXi and the first FAci.","Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'ophtalmologie, Rennes, France.;Centre Hospitalier Le Mans, Service d'ophtalmologie, Le Mans, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, Tours, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, UMR 1253, iBrain, Tours, France.;Centre Hospitalier Universitaire d'Angers, Service d'ophtalmologie, Angers, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes","NA",0,"2193-8245","Ophthalmol Ther","Ophthalmol Ther",2023,"2023","12","10.1007/s40123-023-00749-2","2781-2792","No award number. Horus Pharma© only funded the publication fees. Horus did not fund the study, only the English proofreading of the manuscript.","Horus Pharma","37369907","37369907","PUBMED","Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'ophtalmologie, Rennes, France.;Centre Hospitalier Le Mans, Service d'ophtalmologie, Le Mans, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, Tours, France.;Hôpital Universitaire Bretonneau, Service d'ophtalmologie, UMR 1253, iBrain, Tours, France.;Centre Hospitalier Universitaire d'Angers, Service d'ophtalmologie, Angers, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes, France.;Nantes Université, CHU Nantes, Service d'ophtalmologie, 1 Place Alexis Ricordeau, 44093, Nantes"
"159","Nigon E;Lefeuvre-Plesse C;Martinez A;Chauleur C;Lortholary A;Favier L;Bats AS;Guille A;AdélaÏde J;Finetti P;de Casteljac V;Provansal M;Mamessier E;Bertucci F;Ray-Coquard I;Sabatier R","Nigon, Elsa;Lefeuvre-Plesse, Claudia;Martinez, Alejandra;Chauleur, Céline;Lortholary, Alain;Favier, Laure;Bats, Anne-Sophie;Guille, Arnaud;AdélaÏde, José;Finetti, Pascal;de Casteljac, Victoire;Provansal, Magali;Mamessier, Emilie;Bertucci, François;Ray-Coquard, Isabelle;Sabatier, Renaud","Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.","Journal of translational medicine","England","eng","Multicenter Study","Clear cell carcinoma;Gene expression profiling;Genomics;Tissue micro-array;Uterine cancer","Humans;Female;Young Adult;Adult;Middle Aged;Aged;Aged, 80 and over;Retrospective Studies;Neoplasm Staging;Phosphatidylinositol 3-Kinases;Comparative Genomic Hybridization;Uterine Neoplasms;Carcinoma;Hormones","Humans;Female;Young Adult;Adult;Middle Aged;Aged;Aged, 80 and over;Retrospective Studies;Neoplasm Staging;Phosphatidylinositol 3-Kinases;Comparative Genomic Hybridization;Uterine Neoplasms;Carcinoma;Hormones","Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular features of these rare tumors was conducted. This multicenter retrospective national study was performed within the French TMRG (Rare Gynecologic Malignant Tumors) network. Clinical data and, when available, FFPE blocks were collected. Clinical features, treatments, and outcome (progression-free survival (PFS) and overall survival (OS)) were analyzed and correlated to the protein (tissue micro-array), RNA (Nanostring nCounter  technology), and DNA (array-Comparative Genomic hybridization and target-next generation sequencing) levels using the tumor samples available. Sixty-eight patients with uterine CCC were enrolled, 61 from endometrial localization and 5 with cervix localization. Median age at diagnosis was 68.9 years old (range 19-89.7). Most tumors were diagnosed at an early stage (78% FIGO stage I-II). Hysterectomy (performed in 90%) and lymph node dissection (80%) were the most frequent surgical treatment. More than 70% of patients received external beam radiotherapy and 57% received brachytherapy. Nearly half (46%) of the patients received chemotherapy. After a median follow-up of 24.7 months, median PFS was 64.8 months (95 CI [5.3-124.4]) and median OS was 79.7 (IC95 [31.0-128.4]). Low hormone receptor expression (13% estrogen-receptor positive), frequent PI3K pathway alterations (58% PTEN loss, 50% PIK3CA mutations), and P53 abnormalities (41%) were observed. Mismatch repair deficiency was identified in 20%. P16 expression was associated with shorter PFS (HR = 5.88, 95 CI [1.56-25], p = 0.009). Transcriptomic analyzes revealed a specific transcriptomic profile notably with a high expression of immune response-associated genes in uterine CCC displaying a very good overall prognosis. Uterine CCC reported to be potentially MSI high, hormone receptors negative, and sometimes TP53 mutated. However, some patients with immune response-associated features and better prognosis may be candidate to treatment de-escalation and immunotherapy.","Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de la Loire, Saint Etienne, France.;Hôpital privé du Confluent, Institut de Cancérologie Catherine de Sienne, Nantes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Surgical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon 1, Lyon, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille","NA",0,"1479-5876","J Transl Med","J Transl Med",2023,"2023","21","10.1186/s12967-023-04264-7","408","","","37353806","37353806","PUBMED","Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de la Loire, Saint Etienne, France.;Hôpital privé du Confluent, Institut de Cancérologie Catherine de Sienne, Nantes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Surgical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille, France.;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, University Claude Bernard Lyon 1, Lyon, France.;Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, Marseille;CRCM, Predictive Oncology laboratory, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille"
"160","Valette CA;Filleron T;Debieuvre D;Lena H;Pérol M;Chouaid C;Simon G;Quantin X;Girard N","Valette, Clarisse Audigier;Filleron, Thomas;Debieuvre, Didier;Lena, Hervé;Pérol, Maurice;Chouaid, Christos;Simon, Gaëtane;Quantin, Xavier;Girard, Nicolas","Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy.","Respiratory medicine and research","France","eng","Journal Article","Chemotherapy;Immunotherapy;Small cell lung cancer;Targeted therapy","Humans;Male;Aged;Female;Small Cell Lung Carcinoma;Lung Neoplasms;Cisplatin;Carboplatin;Etoposide;Retrospective Studies;Immunotherapy","Humans;Male;Aged;Female;Small Cell Lung Carcinoma;Lung Neoplasms;Cisplatin;Carboplatin;Etoposide;Retrospective Studies;Immunotherapy","Small cell lung cancer (SCLC) is a highly aggressive entity of lung cancer with tendency toward early recurrence after first-line treatment. As per recently updated European Society for Medical Oncology recommendations, first-line treatment with up to 4 cycles of platinum-etoposide combined with immune checkpoint inhibitor (ICIs)-targeting PD-L1, is now the standard of care. The purpose of the current analysis is to identify current patient profiles and treatment strategies in real life clinical practice, and report outcomes in Extensive Stage (ES)-SCLC. Non-interventional, retrospective, multicentre, comparative study was carried out to describe the outcome of ES-SCLC patients included in the Epidémiologie Stratégie Médico-Economique (ESME) data platform for advanced and metastatic lung cancer. Patients were selected from 34 health care facilities between January 2015 and December 2017, before the era of immunotherapy. 1315 patients were identified, including 64% male and 78% under 70 year-old; 24% had at least 3 metastatic sites, mainly liver metastases (43%), bone metastases (36%), brain metastases (32%). 49% received only one line of systemic treatment; 30% and 21% received 2 and 3 lines or more, respectively. Carboplatin was more frequently used than cisplatin (71% and 29%, respectively). Prophylactic cranial irradiation was infrequent (4% of patients), but 16% of patients received thoracic radiation therapy, mainly after the completion of first-line chemotherapy (72% of patients); such strategies were more frequently applied in cisplatin/etoposide than carboplatin/etoposide patients (p = 0.006 and p = 0.015, respectively). After a median follow-up time of 21.8 (95% CI: 20.9-23.3) months, median real-world Progression-Free Survival (rw-PFS) was 6.2 (95% CI: 5.7; 6.9) and 6.1 (95% CI: 5.8; 6.3) months for cisplatin/etoposide and carboplatin/etoposide doublet regimens, respectively; 24-month rwPFS and Overall Survival were 3.2% (95% CI: 2.3; 4;2) and 22.2% (95% CI: 19.4; 25.1) in the whole population, respectively. Our data provide with landmark reference findings on ES-SCLC before the immunotherapy era, and cover many aspects of the treatment strategy, while highlighting on the role of radiotherapy, subsequent lines of therapy, and the outcomes of patients. Generation of real-world data focusing on patients who received platinum-based chemotherapy combined with immune checkpoint inhibitors is under way.","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Toulon, France.;Institut Claudius Regaud IUCT, Toulouse, France.;Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Léon Bérard, Lyon, France.;Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Unicancer, Paris, France.;Institut régional du Cancer de Montpellier, Montpellier, France.;Institut du Thorax Curie Montsouris, Institut Curie, Paris, France et Université Versailles Saint Quentin, Paris Saclay Campus, Versailles","NA",0,"2590-0412","Respir Med Res","Respir Med Res",2022,"2023","84","10.1016/j.resmer.2023.101012","101012","","","37307617","37307617","PUBMED","Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Toulon, France.;Institut Claudius Regaud IUCT, Toulouse, France.;Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Léon Bérard, Lyon, France.;Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Unicancer, Paris, France.;Institut régional du Cancer de Montpellier, Montpellier, France.;Institut du Thorax Curie Montsouris, Institut Curie, Paris, France et Université Versailles Saint Quentin, Paris Saclay Campus, Versailles"
"161","Gray S;Letissier O;d'Abrigeon C;Shah D;Wardell S;Faluyi O;Lamarca A;Hubner RA;Edeline J;Valle JW;McNamara MG","Gray, Simon;Letissier, Octave;d'Abrigeon, Constance;Shah, Dinakshi;Wardell, Stephen;Faluyi, Olusola;Lamarca, Angela;Hubner, Richard A;Edeline, Julien;Valle, Juan W;McNamara, Mairéad G","Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes.","Cancers","Switzerland","eng","Journal Article","ampulla of Vater;biliary tract;chemotherapy;cholangiocarcinoma;gallbladder;systemic therapy;targeted therapy;third-line","","","Phase 3 trials have established standard first-line (1L) and 2L systemic therapy options for patients with advanced biliary cancer (ABC). However, a standard 3L treatment remains undefined. Clinical practice and outcomes for 3L systemic therapy in patients with ABC were therefore evaluated from three academic centres. Included patients were identified using institutional registries; demographics, staging, treatment history, and clinical outcomes were collected. Kaplan-Meier methods were used to assess progression-free survival (PFS) and overall survival (OS). Ninety-seven patients, treated between 2006 and 2022, were included; 61.9% had intrahepatic cholangiocarcinoma. At the time of analysis, there had been 91 deaths. Median PFS from initiating 3L palliative systemic therapy (mPFS3) was 3.1 months (95%CI 2.0-4.1), while mOS3 was 6.4 months (95%CI 5.5-7.3); mOS1 was 26.9 months (95%CI 23.6-30.2). Among patients with a therapy-targeted molecular aberration (10.3%; n = 10; all received in 3L), mOS3 was significantly improved versus all other included patients (12.5 vs. 5.9 months;   = 0.02). No differences in OS1 were demonstrated between anatomical subtypes. Fourth-line systemic therapy was received by 19.6% of patients (n = 19). This international multicentre analysis documents systemic therapy use in this select patient group, and provides a benchmark of outcomes for future trial design.","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Molecular and Clinical Cancer Medicine, Faculty of Health and Life Sciences, University of Liverpool, Ashton St., Liverpool L69 3GB, UK.;Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Pl, Liverpool L7 8YA, UK.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Pl, Liverpool L7 8YA, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Oncology, Oncohealth Institute, Jimémez Díaz University Hospital, Av. de los Reyes Catolicos 2, 28040 Madrid, Spain.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2023,"2023","15","10.3390/cancers15113047",NA,"","","37297009","37297009","PUBMED","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Molecular and Clinical Cancer Medicine, Faculty of Health and Life Sciences, University of Liverpool, Ashton St., Liverpool L69 3GB, UK.;Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Pl, Liverpool L7 8YA, UK.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Medical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Pembroke Pl, Liverpool L7 8YA, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Department of Oncology, Oncohealth Institute, Jimémez Díaz University Hospital, Av. de los Reyes Catolicos 2, 28040 Madrid, Spain.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Centre Eugène Marquis, Av. De la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd., Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd., Manchester M13 9PL, UK."
"162","Orlando V;Drubay D;Lavaud P;Faivre L;Lesaunier F;Delva R;Gravis G;Rolland F;Priou F;Ferrero JM;Houede N;Mourey L;Theodore C;Krakowski I;Berdah JF;Baciuchka M;Laguerre B;Fléchon A;Grosse-Goupil M;Cojean-Zelek I;Oudard S;Labourey JL;Chinet-Charrot P;Legouffe E;Lagrange JL;Linassier C;Deplanque G;Beuzeboc P;Davin JL;Martin AL;Brihoum M;Culine S;Teuff GL;Fizazi K","Orlando, Valentina;Drubay, Damien;Lavaud, Pernelle;Faivre, Laura;Lesaunier, François;Delva, Remy;Gravis, Gwenaëlle;Rolland, Frédéric;Priou, Frank;Ferrero, Jean-Marc;Houede, Nadine;Mourey, Loic;Theodore, Christine;Krakowski, Ivan;Berdah, Jean-François;Baciuchka, Marjorie;Laguerre, Brigitte;Fléchon, Aude;Grosse-Goupil, Marine;Cojean-Zelek, Isabelle;Oudard, Stéphane;Labourey, Jean-Luc;Chinet-Charrot, Paule;Legouffe, Eric;Lagrange, Jean-Léon;Linassier, Claude;Deplanque, Gaël;Beuzeboc, Philippe;Davin, Jean-Louis;Martin, Anne-Laure;Brihoum, Meryem;Culine, Stéphane;Teuff, Gwénaël Le;Fizazi, Karim","Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.","Clinical genitourinary cancer","United States","eng","Randomized Controlled Trial","Docetaxel;Flexible modeling;Functional form;High-risk prostate cancer;Prostate specific antigen","Male;Humans;Prostatic Neoplasms;Prostate-Specific Antigen;Androgen Antagonists;Treatment Outcome;Neoplasm Recurrence, Local;Docetaxel;Estramustine","Male;Humans;Prostatic Neoplasms;Prostate-Specific Antigen;Androgen Antagonists;Treatment Outcome;Neoplasm Recurrence, Local;Docetaxel;Estramustine","Serum prostate specific antigen (PSA) is a well-known prognostic parameter in men with prostate cancer. The treatment of men with very high PSA values and apparently no detectable metastases is not fully established. Ancillary analysis from the GETUG 12 phase 3 trial. Patients with non-metastatic high-risk prostate cancer by bone and computerized tomography (CT) scan were randomly assigned to receive androgen deprivation therapy (ADT) and docetaxel plus estramustine or ADT alone. Relapse-free survival (RFS), clinical RFS, metastases-free survival (MFS), overall survival (OS), and prostate cancer-specific survival (PCSS) were estimated using the Kaplan-Meier method for different levels of PSA (50 ng/mL, 75 ng/mL, and 100 ng/mL). The relationship between PSA and outcomes was studied using residual-based approaches and spline functions. The median follow-up was 12 years (range: 0-15.3). Baseline PSA (<50 ng/mL, n = 328; ≥50ng/mL, n = 85) was associated with improved RFS (P = .0005), cRFS (P = .0024), and MFS (P = .0068). The 12-year RFS rate was 46.33% (CI 40.59-51.86), 33.59% (CI 22.55-44.97), and 11.76% (1.96-31.20) in men with PSA values <50 ng/mL (n = 328), 50-100 ng/mL (n = 68), and ≥100 ng/mL (n = 17), respectively. Exploratory analyses revealed no deviation from the linear relationship assumption between PSA and the log hazard of events. Men with apparently localized prostate cancer and a high baseline PSA value have a reasonable chance of being long-term disease-free when treated with curative intent combining systemic and local therapy.","Department of Oncology, Ospedale Maggiore, Trieste;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.;Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Département Médico-technique, Centre François Baclesse, Caen, France.;Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Hospitalier Départemental, La Roche-sur-Yon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Hospitalier de Nimes, Nimes, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Hôpital Foch, Paris, France.;Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France.;Department of Medical Oncology, Castelluccio Hospital, Ajaccio, France.;Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Saint-André, Bordeaux, France.;Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France.;Department of Oncology, Hôpital de Carcassonne, Carcasonne, France.;Department of Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Clinique Valdegour, Nîmes, France.;Department of Radiation Oncology, Hopital Henri Mondor, Université Paris Est Creteil, Créteil, France.;Department of Medical Oncology, Hôpital Bretonneau, Tours, France.;Department of Oncology, Lausanne University Hospital, Lausanne, Swiss.;Oncology and Supportive Care Department, Foch Hospital, Suresnes, France.;Clinique Sainte-Catherine, Avignon, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.;Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.","NA",0,"1938-0682","Clin Genitourin Cancer","Clin Genitourin Cancer",2023,"2023","21","10.1016/j.clgc.2023.05.003","615.e1-615.e8","","","37263910","37263910","PUBMED","Department of Oncology, Ospedale Maggiore, Trieste;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.;Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Département Médico-technique, Centre François Baclesse, Caen, France.;Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Hospitalier Départemental, La Roche-sur-Yon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Hospitalier de Nimes, Nimes, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Hôpital Foch, Paris, France.;Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France.;Department of Medical Oncology, Castelluccio Hospital, Ajaccio, France.;Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Saint-André, Bordeaux, France.;Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France.;Department of Oncology, Hôpital de Carcassonne, Carcasonne, France.;Department of Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Clinique Valdegour, Nîmes, France.;Department of Radiation Oncology, Hopital Henri Mondor, Université Paris Est Creteil, Créteil, France.;Department of Medical Oncology, Hôpital Bretonneau, Tours, France.;Department of Oncology, Lausanne University Hospital, Lausanne, Swiss.;Oncology and Supportive Care Department, Foch Hospital, Suresnes, France.;Clinique Sainte-Catherine, Avignon, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, labeled Ligue Contre le Cancer, Villejuif, France.;Department of cancer medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France."
"163","Castelli J;Thariat J;Benezery K;Hasbini A;Gery B;Berger A;Liem X;Guihard S;Chapet S;Thureau S;Auberdiac P;Pommier P;Ruffier A;Perrier L;Devillers A;Campillo-Gimenez B;de Crevoisier R","Castelli, Joël;Thariat, Juliette;Benezery, Karen;Hasbini, Ali;Gery, Bernard;Berger, Antoine;Liem, Xavier;Guihard, Sébastien;Chapet, Sophie;Thureau, Sébastien;Auberdiac, Pierre;Pommier, Pascal;Ruffier, Amandine;Perrier, Lionel;Devillers, Anne;Campillo-Gimenez, Boris;de Crevoisier, Renaud","Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial.","JAMA oncology","United States","eng","Journal Article","","Humans;Male;Female;Radiotherapy, Intensity-Modulated;Paraffin;Head and Neck Neoplasms;Xerostomia;Parotid Gland;Oropharyngeal Neoplasms","Humans;Male;Female;Radiotherapy, Intensity-Modulated;Paraffin;Head and Neck Neoplasms;Xerostomia;Parotid Gland;Oropharyngeal Neoplasms","Xerostomia is a major toxic effect associated with intensity-modulated radiotherapy (IMRT) for oropharyngeal cancers. To assess whether adaptive radiotherapy (ART) improves salivary function compared with IMRT in patients with head and neck cancer. This phase 3 randomized clinical trial was conducted in 11 French centers. Patients aged 18 to 75 years with stage III-IVB squamous cell oropharyngeal cancer treated with chemoradiotherapy were enrolled between July 5, 2013, and October 1, 2018. Data were analyzed from November 2021 to May 2022. The patients were randomly assigned (1:1) to receive standard IMRT (without replanning) or ART (systematic weekly replanning). The primary end point was the frequency of xerostomia, measured by stimulating salivary flow with paraffin. Secondary end points included salivary gland excretory function measured using technetium-99m pertechnetate scintigraphy, patient-reported outcomes (Eisbruch xerostomia-specific questionnaire and the MD Anderson Symptom Inventory for Head and Neck Cancer questionnaire), early and late toxic effects, disease control, and overall and cancer-specific survival. A total of 132 patients were randomized, and after 1 exclusion in the ART arm, 131 were analyzed: 66 in the ART arm (mean [SD] age at inclusion, 60 [8] years; 57 [86.4%] male) and 65 in the standard IMRT arm (mean [SD] age at inclusion, 60 [8] years; 57 [87.7%] male). The median follow-up was 26.4 months (IQR, 1.2-31.3 months). The mean (SD) salivary flow (paraffin) at 12 months was 630 (450) mg/min in the ART arm and 584 (464) mg/min in the standard arm (P = .64). The mean (SD) excretory function of the parotid gland at 12 months, measured by scintigraphy, improved in the ART arm (48% [17%]) compared with the standard arm (41% [17%]) (P = .02). The 2-year-overall survival was 76.9% (95% CI, 64.7%-85.4%) in both arms. This randomized clinical trial did not demonstrate a benefit of ART in decreasing xerostomia compared with standard IMRT. No significant differences were found in secondary end points except for parotid gland excretory function, as assessed by scintigraphy, or in survival rates. ClinicalTrials.gov Identifier: NCT01874587.","University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France.;Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France.;Radiotherapy, Clinique Pasteur-Lanroze, Brest, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France.;Department of Radiotherapy, CHU Poitiers, Poitiers, France.;Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Center, Lille, France.;Department of Radiotherapy, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Radiotherapy, CHU Tours, Tours, France.;Department of Radiotherapy, Centre Henri Becquerel, Rouen, France.;Radiotherapy, Clinique Claude Bernard, Albi, France.;Department of Radiotherapy, Centre Léon Bérard, Lyon, France.;Department of Radiotherapy, CHU Tours, Tours, France.;University Lyon, Léon Bérard Cancer Centre, Lyon, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France.;University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2023,"2023","9","10.1001/jamaoncol.2023.1352","1056-1064","","","37261806","37261806","PUBMED","University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France.;Department of Radiotherapy, Centre Antoine Lacassagne, Nice, France.;Radiotherapy, Clinique Pasteur-Lanroze, Brest, France.;Department of Radiation Oncology, Centre François Baclesse, Laboratoire de Physique Corpusculaire, Normandie Universite, Caen, France.;Department of Radiotherapy, CHU Poitiers, Poitiers, France.;Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Center, Lille, France.;Department of Radiotherapy, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Radiotherapy, CHU Tours, Tours, France.;Department of Radiotherapy, Centre Henri Becquerel, Rouen, France.;Radiotherapy, Clinique Claude Bernard, Albi, France.;Department of Radiotherapy, Centre Léon Bérard, Lyon, France.;Department of Radiotherapy, CHU Tours, Tours, France.;University Lyon, Léon Bérard Cancer Centre, Lyon, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France.;University of Rennes, CLCC Eugène Marquis, Inserm, LTSI-UMR 1099, Rennes, France."
"164","Mélou C;Pellen-Mussi P;Novello S;Brézulier D;Novella A;Tricot S;Bellaud P;Chauvel-Lebret D","Mélou, Caroline;Pellen-Mussi, Pascal;Novello, Solen;Brézulier, Damien;Novella, Agnès;Tricot, Sylvie;Bellaud, Pascale;Chauvel-Lebret, Dominique","Spheroid Culture System, a Promising Method for Chondrogenic Differentiation of Dental Mesenchymal Stem Cells.","Biomedicines","Switzerland","eng","Journal Article","cellular spheroid;chondrocyte;chondrogenic differentiation;mesenchymal stem cells;tridimensional cell culture","","","The objective of the present work was to develop a three-dimensional culture model to evaluate, in a short period of time, cartilage tissue engineering protocols. The spheroids were compared with the gold standard pellet culture. The dental mesenchymal stem cell lines were from pulp and periodontal ligament. The evaluation used RT-qPCR and Alcian Blue staining of the cartilage matrix. This study showed that the spheroid model allowed for obtaining greater fluctuations of the chondrogenesis markers than for the pellet one. The two cell lines, although originating from the same organ, led to different biological responses. Finally, biological changes were detectable for short periods of time. In summary, this work demonstrated that the spheroid model is a valuable tool for studying chondrogenesis and the mechanisms of osteoarthritis, and evaluating cartilage tissue engineering protocols.","CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, Inserm UMS Biosit, France BioImaging, Core Facility H2P2, University of Rennes, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France.","NA",0,"2227-9059","Biomedicines","Biomedicines",2023,"2023","11","10.3390/biomedicines11051314",NA,"","","37238984","37238984","PUBMED","CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;CNRS, Inserm UMS Biosit, France BioImaging, Core Facility H2P2, University of Rennes, 35000 Rennes, France.;CNRS, ISCR (Institut des Sciences Chimiques de Rennes), University of Rennes, UMR 6226, 35000 Rennes, France.;Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;UFR Odontologie, University of Rennes, 35043 Rennes, France."
"165","Allaume P;Rabilloud N;Turlin B;Bardou-Jacquet E;Loréal O;Calderaro J;Khene ZE;Acosta O;De Crevoisier R;Rioux-Leclercq N;Pecot T;Kammerer-Jacquet SF","Allaume, Pierre;Rabilloud, Noémie;Turlin, Bruno;Bardou-Jacquet, Edouard;Loréal, Olivier;Calderaro, Julien;Khene, Zine-Eddine;Acosta, Oscar;De Crevoisier, Renaud;Rioux-Leclercq, Nathalie;Pecot, Thierry;Kammerer-Jacquet, Solène-Florence","Artificial Intelligence-Based Opportunities in Liver Pathology-A Systematic Review.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","artificial intelligence;deep learning;digital pathology;hepatology;liver;performance metrics","","","Artificial Intelligence (AI)-based Deep Neural Networks (DNNs) can handle a wide range of applications in image analysis, ranging from automated segmentation to diagnostic and prediction. As such, they have revolutionized healthcare, including in the liver pathology field. The present study aims to provide a systematic review of applications and performances provided by DNN algorithms in liver pathology throughout the Pubmed and Embase databases up to December 2022, for tumoral, metabolic and inflammatory fields. 42 articles were selected and fully reviewed. Each article was evaluated through the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool, highlighting their risks of bias. DNN-based models are well represented in the field of liver pathology, and their applications are diverse. Most studies, however, presented at least one domain with a high risk of bias according to the QUADAS-2 tool. Hence, DNN models in liver pathology present future opportunities and persistent limitations. To our knowledge, this review is the first one solely focused on DNN-based applications in liver pathology, and to evaluate their bias through the lens of the QUADAS2 tool.","Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Liver Diseases CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Assistance Publique-Hôpitaux de Paris, Department of Pathology Henri Mondor, 94000 Créteil, France.;INSERM U955, Team Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers, 94000 Créteil, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Urology, CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Biosit Platform UAR 3480 CNRS US18 INSERM U955, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2023,"2023","13","10.3390/diagnostics13101799",NA,"","","37238283","37238283","PUBMED","Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Department of Liver Diseases CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Research Unit n°UMR1341 NuMeCan-Nutrition, Métabolismes et Cancer, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Assistance Publique-Hôpitaux de Paris, Department of Pathology Henri Mondor, 94000 Créteil, France.;INSERM U955, Team Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers, 94000 Créteil, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Urology, CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Radiotherapy, Centre Eugène Marquis, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Biosit Platform UAR 3480 CNRS US18 INSERM U955, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France.;Department of Pathology CHU de Rennes, Rennes 1 University, Pontchaillou Hospital, 2 rue Henri Le Guilloux, CEDEX 09, 35033 Rennes, France.;Impact TEAM, Laboratoire Traitement du Signal et de l'Image (LTSI) INSERM, Rennes 1 University, Pontchaillou Hospital, 35033 Rennes, France."
"166","Ray-Coquard I;Leary A;Pignata S;Cropet C;González-Martín A;Marth C;Nagao S;Vergote I;Colombo N;Mäenpää J;Selle F;Sehouli J;Lorusso D;Guerra Alia EM;Bogner G;Yoshida H;Lefeuvre-Plesse C;Buderath P;Mosconi AM;Lortholary A;Burges A;Medioni J;El-Balat A;Rodrigues M;Park-Simon TW;Dubot C;Denschlag D;You B;Pujade-Lauraine E;Harter P","Ray-Coquard, I;Leary, A;Pignata, S;Cropet, C;González-Martín, A;Marth, C;Nagao, S;Vergote, I;Colombo, N;Mäenpää, J;Selle, F;Sehouli, J;Lorusso, D;Guerra Alia, E M;Bogner, G;Yoshida, H;Lefeuvre-Plesse, C;Buderath, P;Mosconi, A M;Lortholary, A;Burges, A;Medioni, J;El-Balat, A;Rodrigues, M;Park-Simon, T-W;Dubot, C;Denschlag, D;You, B;Pujade-Lauraine, E;Harter, P","Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Randomized Controlled Trial","advanced ovarian cancer;bevacizumab;olaparib;overall survival","Humans;Female;Bevacizumab;Ovarian Neoplasms;Antineoplastic Agents;Phthalazines;Poly(ADP-ribose) Polymerase Inhibitors;Maintenance Chemotherapy","Humans;Female;Bevacizumab;Ovarian Neoplasms;Antineoplastic Agents;Phthalazines;Poly(ADP-ribose) Polymerase Inhibitors;Maintenance Chemotherapy","In the PAOLA-1/ENGOT-ov25 primary analysis, maintenance olaparib plus bevacizumab demonstrated a significant progression-free survival (PFS) benefit in newly diagnosed advanced ovarian cancer patients in clinical response after first-line platinum-based chemotherapy plus bevacizumab, irrespective of surgical status. Prespecified, exploratory analyses by molecular biomarker status showed substantial benefit in patients with a BRCA1/BRCA2 mutation (BRCAm) or homologous recombination deficiency (HRD; BRCAm and/or genomic instability). We report the prespecified final overall survival (OS) analysis, including analyses by HRD status. Patients were randomized 2 : 1 to olaparib (300 mg twice daily; up to 24 months) plus bevacizumab (15 mg/kg every 3 weeks; 15 months total) or placebo plus bevacizumab. Analysis of OS, a key secondary endpoint in hierarchical testing, was planned for ∼60% maturity or 3 years after the primary analysis. After median follow-up of 61.7 and 61.9 months in the olaparib and placebo arms, respectively, median OS was 56.5 versus 51.6 months in the intention-to-treat population [hazard ratio (HR) 0.92, 95% confidence interval (CI) 0.76-1.12; P = 0.4118]. Subsequent poly(ADP-ribose) polymerase inhibitor therapy was received by 105 (19.6%) olaparib patients versus 123 (45.7%) placebo patients. In the HRD-positive population, OS was longer with olaparib plus bevacizumab (HR 0.62, 95% CI 0.45-0.85; 5-year OS rate, 65.5% versus 48.4%); at 5 years, updated PFS also showed a higher proportion of olaparib plus bevacizumab patients without relapse (HR 0.41, 95% CI 0.32-0.54; 5-year PFS rate, 46.1% versus 19.2%). Myelodysplastic syndrome, acute myeloid leukemia, aplastic anemia, and new primary malignancy incidence remained low and balanced between arms. Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer. These prespecified exploratory analyses demonstrated improvement despite a high proportion of patients in the placebo arm receiving poly(ADP-ribose) polymerase inhibitors after progression, confirming the combination as one of the standards of care in this setting with the potential to enhance cure.","Department of Medical Oncology, Centre Léon Bernard, Lyon, France; GINECO;GINECO, France; Gynecological Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif France.;Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy; MITO, Italy.;GINECO, France; Department of Biostatistics Centre Léon BERARD, Lyon, France.;Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, Spain; GEICO, Spain.;Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; AGO Austria, Austria.;Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan; GOTIC, Japan.;Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; BGOG, Belgium, European Union.;University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy; MANGO, Italy.;Department of Obstetrics and Gynecology and Cancer Center, Tampere University and University Hospital, Tampere, Finland; NSGO, Nordics.;GINECO, France; Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Charité - Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, Germany; AGO, Germany.;MITO, Italy; Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome Italy.;GEICO, Spain; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.;AGO Austria, Austria; Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria.;GOTIC, Japan; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.;GINECO, France; Department of Medical Oncology, Centre Eugène Marquis, Rennes France.;AGO, Germany; Universitätsklinikum Essen, University Hospital Essen, West German Cancer Center, Department of Gynecology and Obstetrics, Essen, Germany.;MITO, Italy; S.C. di Oncologia Medica Osp. S. Maria della Misericordia - AO di Perugia, Perugia, Italy.;GINECO, France; Centre Catherine de Sienne Hopital Privé du Confluent, Nantes, France.;AGO, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.;GINECO, France; Hôpital Européen Georges Pompidou, Universite de Paris Cite, Paris, France.;AGO, Germany; Spital Uster, Frauenklinik, Uster, Switzerland; Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany.;GINECO, France; Department of Medical Oncology, Institut Curie, Hopital Claudius Régaud, PSL Research University, Paris, France.;AGO, Germany; Department of Gynaecology and Obstetrics, Hannover Medical School, Hanover, Germany.;GINECO, France; Oncologie Médicale, Institut Curie, Hôpital René Huguenin, Saint Cloud, Paris, France.;AGO, Germany; Hochtaunuskliniken, Bad Homburg, Germany.;GINECO, France; HCL - Hospices Civils de Lyon IC-HCL, CITOHL, Université Claude Bernard Lyon 1, CICLY, Lyon, France.;Medical Oncology Department, ARCAGY Research, Paris, France.;AGO, Germany; Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2023,"2023","34","10.1016/j.annonc.2023.05.005","681-692","","","37211045","37211045","PUBMED","Department of Medical Oncology, Centre Léon Bernard, Lyon, France; GINECO;GINECO, France; Gynecological Cancer Unit, Department of Medicine, Institut Gustave Roussy, Villejuif France.;Department of Urology and Gynecology, Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Naples, Italy; MITO, Italy.;GINECO, France; Department of Biostatistics Centre Léon BERARD, Lyon, France.;Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, Spain; GEICO, Spain.;Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria; AGO Austria, Austria.;Department of Gynecologic Oncology, Hyogo Cancer Center, Akashi, Japan; GOTIC, Japan.;Department of Obstetrics and Gynaecology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium; BGOG, Belgium, European Union.;University of Milan-Bicocca and Istituto Europeo di Oncologia IRCCS, Milan, Italy; MANGO, Italy.;Department of Obstetrics and Gynecology and Cancer Center, Tampere University and University Hospital, Tampere, Finland; NSGO, Nordics.;GINECO, France; Department of Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Charité - Department of Gynecology with Center of Oncological Surgery, Universitätsmedizin Berlin, Berlin, Germany; AGO, Germany.;MITO, Italy; Gynecologic Oncology Unit, Catholic University of Sacred Heart and Fondazione Policlinico Gemelli IRCCS, Rome Italy.;GEICO, Spain; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.;AGO Austria, Austria; Department of Obstetrics and Gynecology, Paracelsus Medical University Salzburg, Salzburg, Austria.;GOTIC, Japan; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.;GINECO, France; Department of Medical Oncology, Centre Eugène Marquis, Rennes France.;AGO, Germany; Universitätsklinikum Essen, University Hospital Essen, West German Cancer Center, Department of Gynecology and Obstetrics, Essen, Germany.;MITO, Italy; S.C. di Oncologia Medica Osp. S. Maria della Misericordia - AO di Perugia, Perugia, Italy.;GINECO, France; Centre Catherine de Sienne Hopital Privé du Confluent, Nantes, France.;AGO, Germany; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.;GINECO, France; Hôpital Européen Georges Pompidou, Universite de Paris Cite, Paris, France.;AGO, Germany; Spital Uster, Frauenklinik, Uster, Switzerland; Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany.;GINECO, France; Department of Medical Oncology, Institut Curie, Hopital Claudius Régaud, PSL Research University, Paris, France.;AGO, Germany; Department of Gynaecology and Obstetrics, Hannover Medical School, Hanover, Germany.;GINECO, France; Oncologie Médicale, Institut Curie, Hôpital René Huguenin, Saint Cloud, Paris, France.;AGO, Germany; Hochtaunuskliniken, Bad Homburg, Germany.;GINECO, France; HCL - Hospices Civils de Lyon IC-HCL, CITOHL, Université Claude Bernard Lyon 1, CICLY, Lyon, France.;Medical Oncology Department, ARCAGY Research, Paris, France.;AGO, Germany; Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany."
"167","Hanvic B;Lecuru F;Vanacker H;Pautier P;Narducci F;Cherifi F;Floquet A;Angeles MA;Berton D;Pomel C;Kalbacher E;Provansal M;Fernandez Y;Rouge TM;Roméo C;Laas E;Morice P;Hudry D;Meriaux E;Guyon F;Illac-Vauquelin C;Selle F;Meeus P;Genestie C;Salleron J;Ray-Coquard I","Hanvic, Brunhilde;Lecuru, Fabrice;Vanacker, Hélène;Pautier, Patricia;Narducci, Fabrice;Cherifi, François;Floquet, Anne;Angeles, Martina Aida;Berton, Dominique;Pomel, Christophe;Kalbacher, Elsa;Provansal, Magali;Fernandez, Yolanda;Rouge, Thibault De La Motte;Roméo, Clémence;Laas, Enora;Morice, Philippe;Hudry, Delphine;Meriaux, Emeline;Guyon, Frédéric;Illac-Vauquelin, Claire;Selle, Frédéric;Meeus, Pierre;Genestie, Catherine;Salleron, Julia;Ray-Coquard, Isabelle","Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.","Gynecologic oncology","United States","eng","Journal Article","Adult granulosa cell tumor;Chemotherapy;Rare ovarian cancer;Sex cord stromal tumor","Adult;Female;Humans;Aged;Retrospective Studies;Neoplasm Recurrence, Local;Ovarian Neoplasms;Sex Cord-Gonadal Stromal Tumors;Granulosa Cell Tumor;Chemotherapy, Adjuvant;Neoplasm Staging","Adult;Female;Humans;Aged;Retrospective Studies;Neoplasm Recurrence, Local;Ovarian Neoplasms;Sex Cord-Gonadal Stromal Tumors;Granulosa Cell Tumor;Chemotherapy, Adjuvant;Neoplasm Staging","Identifying prognostic factors and evaluating the impact of adjuvant chemotherapy in patients with sex cord stromal tumors (SCST) is crucial. In this study, we aimed to address these challenges. We conducted a retrospective analysis of data from 13 centers of the French Rare malignant gynecological tumors (TMRG) network. We enrolled 469 adult patients with malignant SCST who received upfront surgery since 2011 to July 2015. 75% were diagnosed with adult Granulosa cell tumors, and 23% had another subtype. With a median follow-up of 6.4 years, 154 patients (33%) developed a first recurrence, 82 (17%) two recurrences, and 49 (10%) three recurrences. Adjuvant chemotherapy was administered in 14.7% of patients at initial diagnosis. In relapse, perioperative chemotherapy was administered in 58.5%, 28.2%, and 23.8% of patients, respectively, in the first, second, and third relapse. In the first-line therapy, age under 70 years, FIGO stage, and complete surgery were associated with longer progression-free survival (PFS). Chemotherapy had no impact on PFS in early-stage disease (FIGO I-II). The PFS was similar using BEP or other chemotherapy regimens (HR 0.88 [0.43; 1.81]) in the first-line therapy. In case of recurrence, PFS was statistically prolonged by complete surgery, but perioperative chemotherapy use did not impact PFS. Chemotherapy use did not impact survival in the first-line or relapse setting in SCST. Only surgery and its quality demonstrated benefit for PFS in ovarian SCST in any lines of treatment.","Medical Oncology, Centre Léon Bérard, Lyon;Surgery, Institut Curie, Paris, France.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Medical Oncology Derpartment, Gustave Roussy, Villejuif, France.;Surgery, Centre Oscar Lambret, Lille, France.;Medical Oncology, Centre François Baclesse, Caen, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Surgery, Institut Universitaire du Cancer Toulouse, Toulouse, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, site René Gauducheau, Nantes, France.;Surgery, Centre Jean Perrin, Clermont-Ferrand, France.;Medical Oncology CHU de Besançon, Hôpital Jean Minjoz, Besançon, France.;Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Surgery, Institut Curie, Paris, France.;Surgery, Gustave Roussy, Villejuif, France.;Surgery, Centre Oscar Lambret, Lille, France.;Medical Oncology, Centre François Baclesse, Caen, France.;Surgery, Institut Bergonié, Bordeaux, France.;Pathology, Institut Universitaire du Cancer Toulouse, Toulouse, France.;Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint Simon, Hôpital de la Croix Saint Simon, Paris, France.;Surgery, Centre Léon Bérard, Lyon, France.;Pathology, Gustave Roussy, Villejuif, France.;Biostatistics, Institut de Cancérologie de Lorraine, Nancy, France.;Medical Oncology, Centre Léon Bérard, Lyon","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2022,"2023","174","10.1016/j.ygyno.2023.05.014","190-199","","","37210929","37210929","PUBMED","Medical Oncology, Centre Léon Bérard, Lyon;Surgery, Institut Curie, Paris, France.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Medical Oncology Derpartment, Gustave Roussy, Villejuif, France.;Surgery, Centre Oscar Lambret, Lille, France.;Medical Oncology, Centre François Baclesse, Caen, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Surgery, Institut Universitaire du Cancer Toulouse, Toulouse, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, site René Gauducheau, Nantes, France.;Surgery, Centre Jean Perrin, Clermont-Ferrand, France.;Medical Oncology CHU de Besançon, Hôpital Jean Minjoz, Besançon, France.;Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Léon Bérard, Lyon, France.;Surgery, Institut Curie, Paris, France.;Surgery, Gustave Roussy, Villejuif, France.;Surgery, Centre Oscar Lambret, Lille, France.;Medical Oncology, Centre François Baclesse, Caen, France.;Surgery, Institut Bergonié, Bordeaux, France.;Pathology, Institut Universitaire du Cancer Toulouse, Toulouse, France.;Medical Oncology, Groupe Hospitalier Diaconesses Croix Saint Simon, Hôpital de la Croix Saint Simon, Paris, France.;Surgery, Centre Léon Bérard, Lyon, France.;Pathology, Gustave Roussy, Villejuif, France.;Biostatistics, Institut de Cancérologie de Lorraine, Nancy, France.;Medical Oncology, Centre Léon Bérard, Lyon"
"168","Nyangoh Timoh K;Huaulme A;Cleary K;Zaheer MA;Lavoué V;Donoho D;Jannin P","Nyangoh Timoh, Krystel;Huaulme, Arnaud;Cleary, Kevin;Zaheer, Myra A;Lavoué, Vincent;Donoho, Dan;Jannin, Pierre","A systematic review of annotation for surgical process model analysis in minimally invasive surgery based on video.","Surgical endoscopy","Germany","eng","Systematic Review","Annotation;Minimally invasive surgery;Ontology;Surgical data science;Surgical process model;Surgical video","Humans;Female;Minimally Invasive Surgical Procedures;Gynecologic Surgical Procedures","Humans;Female;Minimally Invasive Surgical Procedures;Gynecologic Surgical Procedures","Annotated data are foundational to applications of supervised machine learning. However, there seems to be a lack of common language used in the field of surgical data science. The aim of this study is to review the process of annotation and semantics used in the creation of SPM for minimally invasive surgery videos. For this systematic review, we reviewed articles indexed in the MEDLINE database from January 2000 until March 2022. We selected articles using surgical video annotations to describe a surgical process model in the field of minimally invasive surgery. We excluded studies focusing on instrument detection or recognition of anatomical areas only. The risk of bias was evaluated with the Newcastle Ottawa Quality assessment tool. Data from the studies were visually presented in table using the SPIDER tool. Of the 2806 articles identified, 34 were selected for review. Twenty-two were in the field of digestive surgery, six in ophthalmologic surgery only, one in neurosurgery, three in gynecologic surgery, and two in mixed fields. Thirty-one studies (88.2%) were dedicated to phase, step, or action recognition and mainly relied on a very simple formalization (29, 85.2%). Clinical information in the datasets was lacking for studies using available public datasets. The process of annotation for surgical process model was lacking and poorly described, and description of the surgical procedures was highly variable between studies. Surgical video annotation lacks a rigorous and reproducible framework. This leads to difficulties in sharing videos between institutions and hospitals because of the different languages used. There is a need to develop and use common ontology to improve libraries of annotated surgical videos.","Department of Gynecology and Obstetrics and Human Reproduction, CHU Rennes, Rennes;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 2 Avenue du Professeur Léon Bernard, 35043, Rennes Cedex;Department of Obstetrics and Gynecology, Rennes Hospital, Rennes;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes, France.;Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, 20010, USA.;George Washington University School of Medicine and Health Sciences, Washington, DC, USA.;Department of Gynecology and Obstetrics and Human Reproduction, CHU Rennes, Rennes, France.;Division of Neurosurgery, Center for Neuroscience, Children's National Hospital, Washington, DC, 20010, USA.;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes, France.","NA",0,"1432-2218","Surg Endosc","Surg Endosc",2022,"2023","37","10.1007/s00464-023-10041-w","4298-4314","K23 EB034110","NIBIB NIH HHS","37157035","37157035","PUBMED","Department of Gynecology and Obstetrics and Human Reproduction, CHU Rennes, Rennes;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes;Laboratoire d'Anatomie et d'Organogenèse, Faculté de Médecine, Centre Hospitalier Universitaire de Rennes, 2 Avenue du Professeur Léon Bernard, 35043, Rennes Cedex;Department of Obstetrics and Gynecology, Rennes Hospital, Rennes;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes, France.;Sheikh Zayed Institute for Pediatric Surgical Innovation, Children's National Hospital, Washington, DC, 20010, USA.;George Washington University School of Medicine and Health Sciences, Washington, DC, USA.;Department of Gynecology and Obstetrics and Human Reproduction, CHU Rennes, Rennes, France.;Division of Neurosurgery, Center for Neuroscience, Children's National Hospital, Washington, DC, 20010, USA.;INSERM, LTSI - UMR 1099, University Rennes 1, Rennes, France."
"169","Lebret C;Le Daré B;Laval F;Vigneau C;Bacle A","Lebret, Clara;Le Daré, Brendan;Laval, Florian;Vigneau, Cécile;Bacle, Astrid","Assessing health literacy in transplant patients to better tailor the content of their therapeutic education: an observational study.","European journal of hospital pharmacy : science and practice","England","eng","Journal Article","CLINICAL MEDICINE;EDUCATION, PHARMACY;PUBLIC HEALTH;TRANSPLANTATION;education","Humans;Health Literacy;Middle Aged;Male;Female;Patient Education as Topic;Aged;Surveys and Questionnaires;Health Knowledge, Attitudes, Practice;Organ Transplantation;Adult","Humans;Health Literacy;Middle Aged;Male;Female;Patient Education as Topic;Aged;Surveys and Questionnaires;Health Knowledge, Attitudes, Practice;Organ Transplantation;Adult","Evaluate health literacy in transplant patients to better tailor the content of their continuing therapeutic education. A 20-item questionnaire divided into five themes (sport/recreation, dietary measures, hygiene measures, recognition of the signs of graft rejection and medication management) was sent to transplant patient associations. Participants' responses (a score out of 20 points), were analysed according to demographic characteristics, transplanted organ (kidney, liver or heart), type of donor (living or deceased), participation in a therapeutic patient education (TPE) programme, management of end-stage renal disease (with or without dialysis) and the date of transplant. 327 individuals completed the questionnaires (mean age 63.3±12.7 years, mean time post-transplant 13.1±12.1 years). From 2 years after transplantation, the patients' score decreases significantly compared with the score obtained at hospital discharge. Patients who received TPE had significantly higher scores than patients who did not receive it, but only in the first 2 years post-transplant. The scores were different depending on the organs transplanted. Patients' knowledge varied according to the theme; the percentage of errors being higher for questions related to hygienic and dietary rules. These findings highlight the importance of the role of the clinical pharmacist in maintaining the transplant recipient's health literacy level over time to increase graft life. We show the topics on which pharmacists must acquire solid knowledge to best meet the needs of transplant patients.","Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;INSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Université de Rennes 1, Rennes, France, NuMeCan, Rennes, France, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Faculté de Pharmacie, Université de Rennes 1, Laboratoire de Biopharmacie et Pharmacie Clinique, Rennes Cedex, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Faculté de Pharmacie, Université de Rennes 1, Laboratoire de Biopharmacie et Pharmacie Clinique, Rennes Cedex, France.","NA",0,"2047-9956","Eur J Hosp Pharm","Eur J Hosp Pharm",2022,"2024","31","10.1136/ejhpharm-2022-003553","537-542","","","37142387","37142387","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;INSERM, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Université de Rennes 1, Rennes, France, NuMeCan, Rennes, France, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Faculté de Pharmacie, Université de Rennes 1, Laboratoire de Biopharmacie et Pharmacie Clinique, Rennes Cedex, France.;Centre Hospitalier Universitaire de Rennes, Service Hospitalo-Universitaire de Pharmacie, Rennes;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Faculté de Pharmacie, Université de Rennes 1, Laboratoire de Biopharmacie et Pharmacie Clinique, Rennes Cedex, France."
"170","Corné J;Quillien V;Callens C;Portois P;Bidard FC;Jeannot E;Godey F;Le Du F;Robert L;Bourien H;Brunot A;Crouzet L;Perrin C;Lefeuvre-Plesse C;Diéras V;de la Motte Rouge T","Corné, Julien;Quillien, Véronique;Callens, Céline;Portois, Pascal;Bidard, François-Clément;Jeannot, Emmanuelle;Godey, Florence;Le Du, Fanny;Robert, Lucie;Bourien, Héloïse;Brunot, Angélique;Crouzet, Laurence;Perrin, Christophe;Lefeuvre-Plesse, Claudia;Diéras, Véronique;de la Motte Rouge, Thibault","Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.","Clinica chimica acta; international journal of clinical chemistry","Netherlands","eng","Randomized Controlled Trial","ESR1;Liquid biopsy;Metastatic breast cancer;Multiplex digital PCR;Plasma;cfDNA","Humans;Female;Breast Neoplasms;Mutation;Circulating Tumor DNA;Cell-Free Nucleic Acids;Multiplex Polymerase Chain Reaction","Humans;Female;Breast Neoplasms;Mutation;Circulating Tumor DNA;Cell-Free Nucleic Acids;Multiplex Polymerase Chain Reaction","Early detection of ESR1 mutations is a key element for better personalization of the management of patients with HR+/HER2- Metastatic Breast Cancer (MBC). Analysis of circulating tumor DNA from liquid biopsies is a particularly well-suited strategy for longitudinal monitoring of such patients. Using the naica® three-color digital PCR platform, we developed a screening assay allowing the detection of 11 ESR1 mutations and designed a sequential strategy for precise mutation identification. We then applied this strategy in the analysis of plasma circulating cell-free DNA from 109 HR+/HER2- MBC patients and performed a double-blind comparison study on a subset of patients with the multiplex assay used at the Institut Curie (IC) for the PADA-1 study. Thirty-one patients (28.4%) harboured at least one ESR1 mutation, with the following frequencies: D538G (41.03%), Y537S (25.64%), E380Q (10.26%), Y537N (10.26%), ""(536-540)"" (7.69%), Y537C (2.56%), and L536R (2.56%). The presence of ESR1 mutation(s) was significantly associated with liver metastases (p = 0.0091). A very good agreement (91%) was observed with the IC assay. Our assays have proven to be robust and highly sensitive and are very well-suited for monitoring ESR1 mutations in the plasma of MBC patients.","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France; INSERM U1242, University of Rennes, Rennes, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France; Department of Pathology, Institut Curie, Paris and Saint-Cloud, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France; INSERM U1242, University of Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.","NA",0,"1873-3492","Clin Chim Acta","Clin Chim Acta",2022,"2023","545","10.1016/j.cca.2023.117366","117366","","","37105452","37105452","PUBMED","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France; INSERM U1242, University of Rennes, Rennes, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.;Department of Genetics, Institut Curie, Paris and Saint-Cloud, France; Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France; Department of Pathology, Institut Curie, Paris and Saint-Cloud, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France; Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France; INSERM U1242, University of Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France."
"171","de Masson A;Beylot-Barry M;Ram-Wolff C;Mear JB;Dalle S;d'Incan M;Ingen-Housz-Oro S;Orvain C;Abraham J;Dereure O;Charbonnier A;Cornillon J;Longvert C;Barete S;Boulinguez S;Wierzbicka-Hainaut E;Aubin F;Rubio MT;Bernard M;Schmidt-Tanguy A;Houot R;Pham-Ledard A;Michonneau D;Brice P;Labussière-Wallet H;Bouaziz JD;Grange F;Moins-Teisserenc H;Jondeau K;Michel L;Mourah S;Battistella M;Daguindau E;Loschi M;Picard A;Franck N;Maillard N;Huynh A;Nguyen S;Marçais A;Chaby G;Ceballos P;Le Corre Y;Maury S;Bay JO;Adamski H;Bachy E;Forcade E;Socié G;Bagot M;Chevret S;Peffault de Latour R","de Masson, Adèle;Beylot-Barry, Marie;Ram-Wolff, Caroline;Mear, Jean-Baptiste;Dalle, Stéphane;d'Incan, Michel;Ingen-Housz-Oro, Saskia;Orvain, Corentin;Abraham, Julie;Dereure, Olivier;Charbonnier, Amandine;Cornillon, Jérôme;Longvert, Christine;Barete, Stéphane;Boulinguez, Serge;Wierzbicka-Hainaut, Ewa;Aubin, François;Rubio, Marie-Thérèse;Bernard, Marc;Schmidt-Tanguy, Aline;Houot, Roch;Pham-Ledard, Anne;Michonneau, David;Brice, Pauline;Labussière-Wallet, Hélène;Bouaziz, Jean-David;Grange, Florent;Moins-Teisserenc, Hélène;Jondeau, Katayoun;Michel, Laurence;Mourah, Samia;Battistella, Maxime;Daguindau, Etienne;Loschi, Michael;Picard, Alexandra;Franck, Nathalie;Maillard, Natacha;Huynh, Anne;Nguyen, Stéphanie;Marçais, Ambroise;Chaby, Guillaume;Ceballos, Patrice;Le Corre, Yannick;Maury, Sébastien;Bay, Jacques-Olivier;Adamski, Henri;Bachy, Emmanuel;Forcade, Edouard;Socié, Gérard;Bagot, Martine;Chevret, Sylvie;Peffault de Latour, Régis","Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.","Lancet (London, England)","England","eng","Journal Article","","Humans;Prospective Studies;Sezary Syndrome;Propensity Score;Lymphoma, T-Cell, Cutaneous;Transplantation, Homologous;Hematopoietic Stem Cell Transplantation;Mycosis Fungoides;Skin Neoplasms","Humans;Prospective Studies;Sezary Syndrome;Propensity Score;Lymphoma, T-Cell, Cutaneous;Transplantation, Homologous;Hematopoietic Stem Cell Transplantation;Mycosis Fungoides;Skin Neoplasms","Advanced-stage cutaneous T-cell lymphomas (CTCLs) are rare, usually refractory, and fatal diseases. Case series have suggested that allogeneic haematopoietic stem cell transplantation (HSCT) might improve the prognosis of advanced-stage CTCLs. The objective of this study was to investigate the effect of allogeneic HSCT compared with non-HSCT therapy on the outcome of individuals with advanced-stage CTCLs. In this prospective, multicentre, matched controlled trial, conducted at 30 hospitals, participants with advanced CTCLs were allocated treatment: if they had an available compatible related donor they were assigned to allogeneic HSCT, or if not they were allocated to non-allogeneic HSCT therapy. Key inclusion criteria were participants aged 18-70 years, with advanced stage mycosis fungoides or Sézary syndrome, and at least one poor prognostic criteria. Participants were excluded if they were not in complete or partial remission of the disease. Propensity score 1:1 matching with replacement (ie, that each participant treated with HSCT was matched to the participant with the closest propensity score treated with non-HSCT therapy, even if they had already been matched) was used to handle confounding factors, with the balance of covariate distribution between HSCT and non-HSCT groups assessed using standardised mean differences. The primary endpoint was progression-free survival in the matched intention-to-treat population. This trial is registered with ClinicalTrials.gov (NCT02520908), and is currently active but not recruiting. From June 1, 2016, to March 3, 2022, total of 99 participants were enrolled at 17 centres in France. Participants with a sibling or matched unrelated donor were assigned to allogeneic HSCT (HSCT group, n=55 [56%]) and participants without a donor were assigned to non-allogeneic HSCT treatment (non-HSCT group, n=44 [44%]). The median follow-up among survivors was 12·6 months (IQR 11·0-35·2). In the HSCT group, 51 participants (93%) were 1:1 matched to participants from the non-HSCT group. In the intention-to-treat analysis, median progression-free survival was significantly longer in the HSCT group (9·0 months [95% CI 6·6-30·5]) than in the non-HSCT group (3·0 months [2·0-6·3]), with a hazard ratio of 0·38 (95% CI 0·21-0·69; p<0·0001). In the per-protocol population, 40 participants (78%) in the HSCT group had 101 serious events and 29 participants (67%) in the non-HSCT group had 70 serious adverse events. The most common serious adverse event other than graft-versus-host disease in both groups was infections, occurring in 30 participants (59%) in the HSCT group and in 19 participants (44%) in the non-HSCT group. Allogeneic HSCT was associated with significantly longer progression-free survival in participants with advanced-stage CTCLs. These results indicate that allogeneic HSCT treatment should be made available to individuals with high-risk, advanced-stage mycosis fungoides or Sézary syndrome who achieve pre-transplant disease remission. French Ministry of Health, National Cancer Institute, Programme Hospitalier de Recherche Clinique en Cancérologie.","Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris;Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Dermatology, Hôpital Lyon-Sud, Lyon, France.;Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France.;Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France; Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, Angers, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1307, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6075, Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université d'Angers, Angers, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Dermatology and Institut National de la Santé et de la Recherche Médicale U1058 Pathogenesis and Control of Chronic and Emergent Infections, University of Montpellier, Montpellier, France.;Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Department of Dermatology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.;Department of Dermatology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France.;Department of Dermatology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Dermatology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Hôpital Brabois, Centre Hospitalier Régional Universitaire Nancy, Nancy, France; Centre National de la Recherche Scientifique Unité Mixte de Recherche 7365, Ingéniérie Moléculaire et Physiopathologie Articulaire, Biopole, University of Lorraine, Nancy, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France; Institut National de la Santé et de la Recherche Médicale U1236, Rennes, France.;Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Hospital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Dermatology, Centre Hospitalier de Valence, Valence, France.;Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.;Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Pathology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Hôpital L'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France.;Department of Dermatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Hematology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.;Department of Hematology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Dermatology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Department of Dermatology, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Hematology, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France.;Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Dermatology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Biostatistics, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France; Institut National de la Santé et de la Recherche Médicale U1153, Paris, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris","NA",0,"1474-547X","Lancet","Lancet",2022,"2023","401","10.1016/S0140-6736(23)00329-X","1941-1950","","","37105210","37105210","PUBMED","Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris;Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Dermatology, Hôpital Lyon-Sud, Lyon, France.;Department of Dermatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Henri Mondor, University Paris-Est Créteil, Créteil, France.;Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France; Fédération Hospitalo-Universitaire Grand-Ouest Acute Leukemia, Angers, France; Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1307, Centre National de la Recherche Scientifique Unité Mixte de Recherche 6075, Nantes Université, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Université d'Angers, Angers, France.;Department of Hematology, Centre Hospitalier Universitaire de Limoges, Limoges, France.;Department of Dermatology and Institut National de la Santé et de la Recherche Médicale U1058 Pathogenesis and Control of Chronic and Emergent Infections, University of Montpellier, Montpellier, France.;Department of Hematology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Department of Dermatology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.;Department of Dermatology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Dermatology, Centre Hospitalier Universitaire Toulouse, Toulouse, France.;Department of Dermatology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Dermatology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Hôpital Brabois, Centre Hospitalier Régional Universitaire Nancy, Nancy, France; Centre National de la Recherche Scientifique Unité Mixte de Recherche 7365, Ingéniérie Moléculaire et Physiopathologie Articulaire, Biopole, University of Lorraine, Nancy, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Hematology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France; Institut National de la Santé et de la Recherche Médicale U1236, Rennes, France.;Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Institut National de la Santé et de la Recherche Médicale U1312, Bordeaux Institute of Oncology, Team 5, University of Bordeaux, Bordeaux, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.;Hospital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Dermatology, Centre Hospitalier de Valence, Valence, France.;Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne-Billancourt, France.;Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Tumor Genomics and Pharmacology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Pathology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Department of Hematology, Hôpital L'Archet, Centre Hospitalier Universitaire de Nice, Nice, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France.;Department of Dermatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Hematology, Centre Hospitalier Universitaire, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.;Department of Hematology, Centre Hospitalier Universitaire Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Hematology, Centre Hospitalier Universitaire Necker, Assistance Publique-Hôpitaux de Paris, Paris, France.;Department of Dermatology, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Department of Dermatology, Centre Hospitalier Universitaire d'Angers, Angers, France.;Department of Hematology, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France.;Department of Hematology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Department of Dermatology, L'Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Department of Clinical Hematology and Cellular Therapy, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Dermatology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Institut National de la Santé et de la Recherche Médicale U976 Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, Paris, France; Université Paris Cité, Paris, France.;Department of Biostatistics, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris, France; Institut National de la Santé et de la Recherche Médicale U1153, Paris, France.;Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université Paris Cité, Paris"
"172","Lamouche-Wilquin P;Perrin L;Pere M;Raymond M;Asfar P;Darreau C;Reizine F;Colin G;Delbove A;Auchabie J;Hourmant B;Frérou A;Combe B;Morin J;Kergoat P;Lorber J;Egreteau PY;Souchard J;Canet E;Lascarrou JB","Lamouche-Wilquin, Pauline;Perrin, Léa;Pere, Morgane;Raymond, Matthieu;Asfar, Pierre;Darreau, Cedric;Reizine, Florian;Colin, Gwenhaël;Delbove, Agathe;Auchabie, Johann;Hourmant, Baptiste;Frérou, Aurélien;Combe, Béatrice La;Morin, Jean;Kergoat, Pierre;Lorber, Julien;Egreteau, Pierre-Yves;Souchard, Jérome;Canet, Emmanuel;Lascarrou, Jean-Baptiste","Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study.","Thrombosis journal","England","eng","Journal Article","Anticoagulation strategies;COVID-19;Deep vein thrombosis;Intensive care unit;Pulmonary embolism;Venous thromboembolism","","","Patients with critical illness due to COVID-19 exhibit increased coagulability associated with a high risk of venous thrombo-embolism (VTE). Data on prophylactic anticoagulation for these patients are limited and conflicting. The purpose of this study was to evaluate whether intermediate-dose prophylactic anticoagulation in patients with COVID-19 requiring ICU admission was associated with better outcomes compared to standard-dose prophylactic anticoagulation. We retrospectively included adults admitted with severe COVID-19 to any of 15 ICUs, in 2020 or 2021. We compared the groups given intermediate-dose vs. standard-dose prophylactic anticoagulation. The primary outcome was all-cause day-90 mortality. Secondary outcomes were VTE (pulmonary embolism or deep vein thrombosis), ICU stay length, and adverse effects of anticoagulation. Of 1174 included patients (mean age, 63 years), 399 received standard-dose and 775 intermediate-dose prophylactic anticoagulation. Of the 211 patients who died within 90 days, 86 (21%) received intermediate and 125 (16%) standard doses. After adjustment on early corticosteroid therapy and critical illness severity, there were no significant between-group differences in day-90 mortality (hazard ratio [HR], 0.73; 95%CI, 0.52-1.04; p = 0.09) or ICU stay length (HR, 0.93; 95%CI, 0.79-1.10; p = 0.38). Intermediate-dose anticoagulation was significantly associated with fewer VTE events (HR, 0.55; 95%CI, 0.38-0.80; p < 0.001). Bleeding events occurred in similar proportions of patients in the two groups (odds ratio, 0.86; 95%CI, 0.50-1.47; p = 0.57). Mortality on day 90 did not differ between the groups given standard-dose and intermediate-dose prophylactic anticoagulation, despite a higher incidence of VTE in the standard-dose group.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Le Mans, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Sud, Lorient, France.;Service de Soins Intensifs de Pneumologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cornouaille, Quimper, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Morlaix, Morlaix, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093","NA",0,"1477-9560","Thromb J","Thromb J",2022,"2023","21","10.1186/s12959-023-00491-6","42","","","37072788","37072788","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Le Mans, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Sud, Lorient, France.;Service de Soins Intensifs de Pneumologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cornouaille, Quimper, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Morlaix, Morlaix, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 30 Bd Jean Monet, Nantes Cedex 9, 44093"
"173","Gangneux JP;Brun S;Menotti J;Botterel F","Gangneux, Jean-Pierre;Brun, Sophie;Menotti, Jean;Botterel, Françoise","Role of the mycological diagnosis in the management of tinea capitis: French recommendations in the post-griseofulvin era.","Journal de mycologie medicale","France","eng","Editorial","","Humans;Griseofulvin;Tinea Capitis;Antifungal Agents","Humans;Griseofulvin;Tinea Capitis;Antifungal Agents","NA","Laboratoire de Parasitologie et Mycologie Médicale, LA-AspC Centre National de Référence des Mycoses et Antifongiques, European Excellence Center for Medical Mycology (ECMM), Centre hospitalier Universitaire de Rennes, Rennes F-35000, France; CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé environnement et Travail), UMRS 1085, Université de Rennes, Rennes F-35000, France.;Service de Parasitologie-Mycologie, Hôpital Avicenne, AP-HP, Bobigny 93009, France; Faculté de Médecine, Université Sorbonne Paris Nord, Bobigny 93009, France.;Service de Parasitologie-Mycologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon 69004, France.;President of French Society of Medical MycologyDépartement de Prévention, Diagnostic et Traitement des Infections, Unité de Parasitologie-Mycologie, CHU Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), France; UR DYNAMYC 7380, Faculté de Santé, Univ Paris-Est Créteil (UPEC), Enva, USC ANSES, Créteil","NA",0,"1773-0449","J Mycol Med","J Mycol Med",2023,"2023","33","10.1016/j.mycmed.2023.101379","101379","","","37060851","37060851","PUBMED","Laboratoire de Parasitologie et Mycologie Médicale, LA-AspC Centre National de Référence des Mycoses et Antifongiques, European Excellence Center for Medical Mycology (ECMM), Centre hospitalier Universitaire de Rennes, Rennes F-35000, France; CHU Rennes, INSERM, EHESP, IRSET (Institut de recherche en santé environnement et Travail), UMRS 1085, Université de Rennes, Rennes F-35000, France.;Service de Parasitologie-Mycologie, Hôpital Avicenne, AP-HP, Bobigny 93009, France; Faculté de Médecine, Université Sorbonne Paris Nord, Bobigny 93009, France.;Service de Parasitologie-Mycologie, Institut des Agents Infectieux, Hospices Civils de Lyon, Lyon 69004, France.;President of French Society of Medical MycologyDépartement de Prévention, Diagnostic et Traitement des Infections, Unité de Parasitologie-Mycologie, CHU Henri Mondor, Assistance Publique des Hôpitaux de Paris (APHP), France; UR DYNAMYC 7380, Faculté de Santé, Univ Paris-Est Créteil (UPEC), Enva, USC ANSES, Créteil"
"174","Thibault C;Fléchon A;Albiges L;Joly C;Barthelemy P;Gross-Goupil M;Chevreau C;Coquan E;Rolland F;Laguerre B;Gravis G;Pécuchet N;Elaidi RT;Timsit MO;Brihoum M;Auclin E;de Reyniès A;Allory Y;Oudard S","Thibault, Constance;Fléchon, Aude;Albiges, Laurence;Joly, Charlotte;Barthelemy, Philippe;Gross-Goupil, Marine;Chevreau, Christine;Coquan, Elodie;Rolland, Frédéric;Laguerre, Brigitte;Gravis, Gwenaelle;Pécuchet, Nicolas;Elaidi, Réza-Thierry;Timsit, Marc-Olivier;Brihoum, Meryem;Auclin, Edouard;de Reyniès, Aurélien;Allory, Yves;Oudard, Stéphane","Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).","European journal of cancer (Oxford, England : 1990)","England","eng","Clinical Trial, Phase II","Adult;Bevacizumab;Chemotherapy;Collecting duct carcinoma;Rare tumours;Renal medullary carcinoma (RMC)","Humans;Bevacizumab;Gemcitabine;Carcinoma, Medullary;Platinum;Prospective Studies;Retrospective Studies;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Renal Cell;Kidney Neoplasms;Hypertension;Kidney","Humans;Bevacizumab;Gemcitabine;Carcinoma, Medullary;Platinum;Prospective Studies;Retrospective Studies;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Renal Cell;Kidney Neoplasms;Hypertension;Kidney","Renal medullary carcinoma (RMC) and collecting duct carcinoma (CDC) are rare entities with a poor outcome. First-line metastatic treatment is based on gemcitabine + platinum chemotherapy (GC) regimen but retrospective data suggest enhanced anti-tumour activity with the addition of bevacizumab. Therefore, we performed a prospective assessment of the safety and efficacy of GC + bevacizumab in metastatic RMC/CDC. We conducted a phase 2 open-label trial in 18 centres in France in patients with metastatic RMC/CDC and no prior systemic treatment. Patients received bevacizumab plus GC up to 6 cycles followed, for non-progressive disease, by maintenance therapy with bevacizumab until progression or unacceptable toxicity. The co-primary end-points were objective response rates (ORRs) and progression-free survival (PFS) at 6 months (ORR-6; PFS-6). PFS, overall survival (OS) and safety were secondary end-points. At interim analysis, the trial was closed due to toxicity and lack of efficacy. From 2015 to 2019, 34 of the 41 planned patients have been enroled. After a median follow-up of 25 months, ORR-6 and PFS-6 were 29.4% and 47.1%, respectively. Median OS was 11.1 months (95% confidence interval [CI]: 7.6-24.2). Seven patients (20.6%) discontinued bevacizumab because of toxicities (hypertension, proteinuria, colonic perforation). Grade 3-4 toxicities were reported in 82% patients, the most common being haematologic toxicities and hypertension. Two patients experienced grade 5 toxicity (subdural haematoma related to bevacizumab and encephalopathy of unknown origin). Our study showed no benefit for bevacizumab added to chemotherapy in metastatic RMC and CDC with higher than expected toxicity. Consequently, GC regimen remains a therapeutic option for RMC/CDC patients.","Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Université Paris Cité, AP-HP, Centre de Recherche des Cordeliers INSERM UMR-S 1138, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Hôpital Henri Mondor, Créteil, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre hospitalo-Universitaire, Bordeaux, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre René Gauducheau, Saint-Herblin, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Hôpital d'Instruction des Armées Bégin, Saint Mandé F-94160, France.;ARTIC: Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Department of Urology, Hôpital Européen Georges Pompidou, APHP-Centre, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Université Paris Cité, AP-HP, laboratoire SeQOIA, Centre de Recherche des Cordeliers INSERM UMR-S 1138, Paris, France.;Department of Anatomopathology, Institut Curie, Université Paris Saclay, Saint-Cloud, France; Institut Curie, CNRS, UMR 144, Paris 75248, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Université Paris Cité, PARCC, INSERM U970, Paris","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2023,"2023","186","10.1016/j.ejca.2023.03.018","83-90","","","37054556","37054556","PUBMED","Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Université Paris Cité, AP-HP, Centre de Recherche des Cordeliers INSERM UMR-S 1138, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Hôpital Henri Mondor, Créteil, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre hospitalo-Universitaire, Bordeaux, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre René Gauducheau, Saint-Herblin, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Hôpital d'Instruction des Armées Bégin, Saint Mandé F-94160, France.;ARTIC: Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Department of Urology, Hôpital Européen Georges Pompidou, APHP-Centre, France.;UNICANCER, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France.;Université Paris Cité, AP-HP, laboratoire SeQOIA, Centre de Recherche des Cordeliers INSERM UMR-S 1138, Paris, France.;Department of Anatomopathology, Institut Curie, Université Paris Saclay, Saint-Cloud, France; Institut Curie, CNRS, UMR 144, Paris 75248, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Paris, France; Université Paris Cité, PARCC, INSERM U970, Paris"
"175","Legriel S;Badenes R;Engrand N;Mendoza-Trujillo R;Soulier P;Benghanem S;Pizzi M;Maciel C;Chelly J;Zuber B;Labruyere M;Plantefeve G;Jacq G;Galbois A;Launey Y;Argaud L;Lesieur O;Ferre A;Paul M;Guillon A;Bailly P;Beuret P;de-Carne MC;Siami S;Benzekri D;Colin G;Gaviria L;Aldana JL;Bruel C;Stoclin A;Sedillot N;Geri G;Samano D;Sobczak E;Swafford E;O'Phelan K;Meffert A;Holleville M;Silva S;Alves da Costa MJ;Mejia J;Alkhachroum A","Legriel, Stephane;Badenes, Rafael;Engrand, Nicolas;Mendoza-Trujillo, Rocio;Soulier, Pauline;Benghanem, Sarah;Pizzi, Michael;Maciel, Carolina;Chelly, Jonathan;Zuber, Benjamin;Labruyere, Marie;Plantefeve, Gaetan;Jacq, Gwenaëlle;Galbois, Arnaud;Launey, Yoann;Argaud, Laurent;Lesieur, Olivier;Ferre, Alexis;Paul, Marine;Guillon, Antoine;Bailly, Pierre;Beuret, Pascal;de-Carne, Marie-Charlotte;Siami, Shidasp;Benzekri, Dalila;Colin, Gwenhael;Gaviria, Leidy;Aldana, Jose Luis;Bruel, Cedric;Stoclin, Annabelle;Sedillot, Nicholas;Geri, Guillaume;Samano, Daniel;Sobczak, Evie;Swafford, Emily;O'Phelan, Kristine;Meffert, Arnaud;Holleville, Mathilde;Silva, Stein;Alves da Costa, Manoel José;Mejia, Jorge;Alkhachroum, Ayham","Outcomes in Patients With COVID-19 With Acute Encephalopathy and Coma: An International Prospective Study.","Neurology","United States","eng","Observational Study","","Adult;Humans;Aged;COVID-19;Coma;Prospective Studies;Posterior Leukoencephalopathy Syndrome;Intensive Care Units;Delirium","Adult;Humans;Aged;COVID-19;Coma;Prospective Studies;Posterior Leukoencephalopathy Syndrome;Intensive Care Units;Delirium","To report the prevalence of acute encephalopathy and outcomes in patients with severe coronavirus disease 2019 (COVID-19) and to identify determinants of 90-day outcomes. Data from adults with severe COVID-19 and acute encephalopathy were prospectively collected for patients requiring intensive care unit management in 31 university or university-affiliated intensive care units in 6 countries (France, United States, Colombia, Spain, Mexico, and Brazil) between March and September of 2020. Acute encephalopathy was defined, as recently recommended, as subsyndromal delirium or delirium or as a comatose state in case of severely decreased level of consciousness. Logistic multivariable regression was performed to identify factors associated with 90-day outcomes. A Glasgow Outcome Scale-Extended (GOS-E) score of 1-4 was considered a poor outcome (indicating death, vegetative state, or severe disability). Of 4,060 patients admitted with COVID-19, 374 (9.2%) experienced acute encephalopathy at or before the intensive care unit (ICU) admission. A total of 199/345 (57.7%) patients had a poor outcome at 90-day follow-up as evaluated by the GOS-E (29 patients were lost to follow-up). On multivariable analysis, age older than 70 years (odds ratio [OR] 4.01, 95% CI 2.25-7.15), presumed fatal comorbidity (OR 3.98, 95% CI 1.68-9.44), Glasgow coma scale score <9 before/at ICU admission (OR 2.20, 95% CI 1.22-3.98), vasopressor/inotrope support during ICU stay (OR 3.91, 95% CI 1.97-7.76), renal replacement therapy during ICU stay (OR 2.31, 95% CI 1.21-4.50), and CNS ischemic or hemorrhagic complications as acute encephalopathy etiology (OR 3.22, 95% CI 1.41-7.82) were independently associated with higher odds of poor 90-day outcome. Status epilepticus, posterior reversible encephalopathy syndrome, and reversible cerebral vasoconstriction syndrome were associated with lower odds of poor 90-day outcome (OR 0.15, 95% CI 0.03-0.83). In this observational study, we found a low prevalence of acute encephalopathy at ICU admission in patients with COVID-19. More than half of patients with COVID-19 presenting with acute encephalopathy had poor outcomes as evaluated by GOS-E. Determinants of poor 90-day outcome were dominated by older age, comorbidities, degree of impairment of consciousness before/at ICU admission, association with other organ failures, and acute encephalopathy etiology. The study is registered with ClinicalTrials.gov, number NCT04320472.","From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.","NA",0,"1526-632X","Neurology","Neurology",2022,"2023","100","10.1212/WNL.0000000000207263","e2247-e2258","","","37041081","37041081","PUBMED","From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil.;From the Intensive Care Unit (S.L., G.J., A.F., M. Paul, M.-C.d.-C.), Centre Hospitalier de Versailles-Site André Mignot, Le Chesnay; University Paris-Saclay (S.L., G.J.), UVSQ, INSERM, CESP, Team « PsyDev », Villejuif; IctalGroup (S.L., P.S., J.C., M.L., G.P., G.J., A. Galbois, O.L., P. Bailly, P. Beuret, C.B., A.S., A.M.), Le Chesnay, France; Anesthesiology and Surgical-Trauma Intensive Care (R.B.), University Clinic Hospital, Valencia; Department of Surgery (R.B.), University of Valencia, Spain; Neuro-Intensive Care Unit (N.E.), Rothschild Foundation Hospital, Paris, France; Anesthesiology and Intensive Care (R.M.-T.), Hospital Regional de Alta Especilidad del Bajío, Leon, Mexico; Intensive Care Unit (P.S.), Groupe Hospitalier Sud Ile de France, Melun; Medical ICU (S.B.), Cochin Hospital, AP-HP, Paris, France; Departments of Neurology and Neurosurgery (M. Pizzi, C.M.), University of Florida College of Medicine, Gainesville; Department of Neurology (C.M.), Yale University School of Medicine, New Haven, CT; Department of Neurology (C.M.), University of Utah, Salt Lake City; Intensive Care Unit (J.C.), Centre Hospitalier Intercommunal Toulon La Seyne sur Mer; Intensive Care Unit (B.Z.), Hôpital Foch, Suresnes; Réanimation Médicale (M.L.), CHU Dijon; Service de Médecine Intensive Réanimation (G.P.), Centre Hospitalier d'Argenteuil; Intensive Care Unit (A. Galbois), Claude Galien Private Hospital, Quincy-sous-Senart, Île-de-France; Réanimation Chirurgicale (Y.L.), Département d'Anesthésie-Réanimation, Centre Hospitalier Universitaire de Rennes; Hospices Civils de Lyon (L.A.), Hôpital Edouard Herriot, Service de Médecine Intensive-Réanimation; Université de Lyon (L.A.), Université Claude Bernard Lyon 1, Faculté de Médecine Lyon-Est; Service de Réanimation (O.L.), Centre Hospitalier de la Rochelle, Nouvelle-Aquitaine; Intensive Care Unit (A. Guillon), Tours University Hospital; INSERM UMR 1100 (Research Center for Respiratory Diseases) (A. Guillon), University of Tours; Médecine Intensive Réanimation (P. Bailly), CHU de Brest; Service de Réanimation et Soins Continus (P. Beuret), Centre Hospitalier de Roanne, Rhône-Alpes; Polyvalent ICU (S. Siami), Centre Hospitalier Sud Essonne Dourdan-Etampes, Paris; Médecine Intensive Réanimation (D.B.), Centre Hospitalier Régional d'Orléans; Médecine Intensive Réanimation (G.C.), District Hospital Center, La Roche-sur-Yon, France; Centro de Investigación Clínica (L.G.), and Adult Intensive Care Unit (J.L.A., J.M.), Fundación Valle del Lili, University Hospital, Cali, Colombia; Service de Réanimation (C.B.), Groupe Hospitalier Paris Saint Joseph; Service de Réanimation (A.S.), Institut Gustave Roussy, Villejuif, France; Service de Réanimation (N.S.), Hôpital Fleyriat, Bourg en Bresse; Service de Médecine Intensive Réanimation (G.G.), Hôpital Universitaire Ambroise-Paré, APHP, Boulogne-Billancourt, France; Department of Neurology (D.S., Evie Sobczak, Emily Swafford, K.O.P., A.A.), University of Miami, FL; Service d'Anesthésie Réanimation Chirurgicale (A.M.), Hôpital Henri Mondor, Creteil, Île-de-France; Department of Anesthesiology and Critical Care (M.H.), Beaujon Hospital, DMU Parabol, AP-HP. Nord, Paris; Critical Care Unit (S. Silva), University Teaching Hospital of Purpan, Toulouse Cedex 9; Toulouse NeuroImaging Center (S. Silva), Toulouse University, UMR INSERM/UPS 1214, UPS, France; and Intensive Care Unit (M.J.A.d.C.), Hospital Nossa Senhora de Lourdes (Antigo Hospital Alfa), Recife, Pernambuco, Brazil."
"176","Tollenaere Q;Métairie A;Le Pabic E;Le Faucheur A;Mahé G","Tollenaere, Quentin;Métairie, Antoine;Le Pabic, Estelle;Le Faucheur, Alexis;Mahé, Guillaume","Use of the Walking Impairment Questionnaire and Walking Estimated-Limitation Calculated by History questionnaire to detect maximal walking distance equal to or lower than 250 m in patients with lower extremity arterial disease.","Frontiers in cardiovascular medicine","Switzerland","eng","Journal Article","intermittent claudication;lower extremity artery disease;peripheral artery disease;questionnaire;treadmill test;walking distance assessment","","","The objective was to assess the accuracy and optimal threshold of the Walking Impairment Questionnaire (WIQ) and the Walking Estimated-Limitation Calculated by History (WELCH) questionnaire in identifying patients with a maximal walking distance (MWD) below or equal to 250 m. This retrospective study screened 388 consecutive patients with suspected symptomatic lower extremity arterial disease (LEAD). Collected data included the patient's history, resting ankle-brachial index, WIQ, and WELCH. MWD was assessed with a treadmill test at 2 mph (3.2 km/h) with a 10% grade. An optimized threshold for detection of MWD ≤ 250 m was determined for each questionnaire   receiver operating characteristic (ROC) curves. Subsequently, multivariate analysis was performed to build a new simple score to detect MWD ≤ 250 m. The study included 297 patients (63 ± 10 years old). With a threshold of ≤ 64%, the WIQ predicted MWD ≤ 250 m with an accuracy of 71.4% (66.2, 76.5%). With a threshold of ≤ 22, the WELCH predicted a treadmill walking distance of ≤ 250 m with an accuracy of 68.7% (63.4, 74.0%). A new score with only four ""yes or no"" questions had an accuracy of 71.4% (66.3, 76.6%). Items on this new score consisted of the level of difficulty of walking 1 block, declared maximum walking distance, usual walking speed, and maximum duration of slow walking. A WIQ score ≤ 64% and a WELCH score ≤ 22 help to predict a walking distance of ≤ 250 m in a treadmill test at 2 mph (3.2 km/h) with a 10% grade. A 4-item score could be used for rapid evaluation of walking distance among patients with LEAD, but the validity of this 4-item score requires further confirmation studies.","Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;CHU Rennes, Inserm, CIC 1414 (Clinical Investigation Center), Rennes, France.;Univ Rennes, M2S - EA 7470, Rennes, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, M2S - EA 7470, Rennes, France.","NA",0,"2297-055X","Front Cardiovasc Med","Front Cardiovasc Med",2022,"2023","10","10.3389/fcvm.2023.968213","968213","","","37025694","37025694","PUBMED","Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;CHU Rennes, Inserm, CIC 1414 (Clinical Investigation Center), Rennes, France.;Univ Rennes, M2S - EA 7470, Rennes, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, M2S - EA 7470, Rennes, France."
"177","Delaby N;Barateau A;Chiavassa S;Biston MC;Chartier P;Graulières E;Guinement L;Huger S;Lacornerie T;Millardet-Martin C;Sottiaux A;Caron J;Gensanne D;Pointreau Y;Coutte A;Biau J;Serre AA;Castelli J;Tomsej M;Garcia R;Khamphan C;Badey A","Delaby, Nolwenn;Barateau, Anaïs;Chiavassa, Sophie;Biston, Marie-Claude;Chartier, Philippe;Graulières, Eliane;Guinement, Lucie;Huger, Sandrine;Lacornerie, Thomas;Millardet-Martin, Corinne;Sottiaux, Alain;Caron, Jérôme;Gensanne, David;Pointreau, Yoann;Coutte, Alexandre;Biau, Julian;Serre, Anne-Agathe;Castelli, Joel;Tomsej, Milan;Garcia, Robin;Khamphan, Catherine;Badey, Aurélien","Practical and technical key challenges in head and neck adaptive radiotherapy: The GORTEC point of view.","Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)","Italy","eng","Journal Article","Adaptive radiotherapy;Automatic segmentation;Dose accumulation;Head and neck cancer;Image registration;Quality assurance;Workflow","Humans;Radiotherapy Dosage;Radiotherapy Planning, Computer-Assisted;Neck;Head;Radiotherapy, Image-Guided;Head and Neck Neoplasms","Humans;Radiotherapy Dosage;Radiotherapy Planning, Computer-Assisted;Neck;Head;Radiotherapy, Image-Guided;Head and Neck Neoplasms","Anatomical variations occur during head and neck (H&N) radiotherapy (RT) treatment. These variations may result in underdosage to the target volume or overdosage to the organ at risk. Replanning during the treatment course can be triggered to overcome this issue. Due to technological, methodological and clinical evolutions, tools for adaptive RT (ART) are becoming increasingly sophisticated. The aim of this paper is to give an overview of the key steps of an H&N ART workflow and tools from the point of view of a group of French-speaking medical physicists and physicians (from GORTEC). Focuses are made on image registration, segmentation, estimation of the delivered dose of the day, workflow and quality assurance for an implementation of H&N offline and online ART. Practical recommendations are given to assist physicians and medical physicists in a clinical workflow.","Centre Eugène Marquis, Unité de Physique Médicale, rue de La Bataille Flandres Dunkerque - CS 44229, 35042 Rennes Cedex, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France.;Institut de cancérologie de l'Ouest (ICO) Centre René-Gauducheau, Service de physique médicale, 44805 Saint-Herblain, France.;Centre Léon Bérard, 69373, LYON Cedex 08; CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, 69100 Villeurbanne, France.;Centre Hospitalier Universitaire Grenoble Alpes, Département de Radiothérapie, BP217, 38043 Grenoble, Cedex 9, France.;Institut Universitaire du Cancer de Toulouse Oncopole, Département de Physique Médicale, 31000 Toulouse, France.;Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Département de radiothérapie, 54000 Vandoeuvre les Nancy, France.;Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Département de radiothérapie, 54000 Vandoeuvre les Nancy, France.;Centre Oscar Lambret, Service de Physique Médicale, 59000 Lille, France.;Centre Jean Perrin, Département de Physique Médicale, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France.;CHU de Charleroi, Département de Radiothérapie, B-6110 Charleroi, Belgique.;Institut Bergonié, Département de radiothérapie, 33000 Bordeaux, France.;Centre Henri Becquerel, Département de radiothérapie, 76000 Rouen, France; QuantIF-LITIS EA4108, Université de Rouen Normandie, Rouen, France.;Centre Jean Bernard, Institut inter-régionaL de Cancérologie (ILC), Centre de Cancérologie de la Sarthe (CCS), 72000 Le Mans, France.;CHU Amiens Picardie, Département de radiothérapie, 80054 Amiens, France.;Centre Jean Perrin, Département de Radiothérapie, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France; INSERM U1240 IMoST, Université de Clermont Auvergne, 63000 Clermont-Ferrand, France.;Centre Léon Bérard, 69373, LYON Cedex 08.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France.;CHU de Charleroi, Département de Radiothérapie, B-6110 Charleroi, Belgique.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9, France.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9, France.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9","NA",0,"1724-191X","Phys Med","Phys Med",2022,"2023","109","10.1016/j.ejmp.2023.102568","102568","","","37015168","37015168","PUBMED","Centre Eugène Marquis, Unité de Physique Médicale, rue de La Bataille Flandres Dunkerque - CS 44229, 35042 Rennes Cedex, France.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France.;Institut de cancérologie de l'Ouest (ICO) Centre René-Gauducheau, Service de physique médicale, 44805 Saint-Herblain, France.;Centre Léon Bérard, 69373, LYON Cedex 08; CREATIS, CNRS UMR5220, Inserm U1044, INSA-Lyon, Université Lyon 1, 69100 Villeurbanne, France.;Centre Hospitalier Universitaire Grenoble Alpes, Département de Radiothérapie, BP217, 38043 Grenoble, Cedex 9, France.;Institut Universitaire du Cancer de Toulouse Oncopole, Département de Physique Médicale, 31000 Toulouse, France.;Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Département de radiothérapie, 54000 Vandoeuvre les Nancy, France.;Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Département de radiothérapie, 54000 Vandoeuvre les Nancy, France.;Centre Oscar Lambret, Service de Physique Médicale, 59000 Lille, France.;Centre Jean Perrin, Département de Physique Médicale, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France.;CHU de Charleroi, Département de Radiothérapie, B-6110 Charleroi, Belgique.;Institut Bergonié, Département de radiothérapie, 33000 Bordeaux, France.;Centre Henri Becquerel, Département de radiothérapie, 76000 Rouen, France; QuantIF-LITIS EA4108, Université de Rouen Normandie, Rouen, France.;Centre Jean Bernard, Institut inter-régionaL de Cancérologie (ILC), Centre de Cancérologie de la Sarthe (CCS), 72000 Le Mans, France.;CHU Amiens Picardie, Département de radiothérapie, 80054 Amiens, France.;Centre Jean Perrin, Département de Radiothérapie, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand Cedex 1, France; INSERM U1240 IMoST, Université de Clermont Auvergne, 63000 Clermont-Ferrand, France.;Centre Léon Bérard, 69373, LYON Cedex 08.;Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099, 35000 Rennes, France.;CHU de Charleroi, Département de Radiothérapie, B-6110 Charleroi, Belgique.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9, France.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9, France.;Sainte-Catherine Institut du Cancer d'Avignon Provence, Département de physique médicale, 250, chemin de Baigne-Pieds, 84918 Avignon cedex 9"
"178","Frenel JS;Lusque A;Delaloge S;Ferrero JM;Bachelot T;Desmoulins I;Levy C;Eymard JC;Gonçalves A;Patsouris A;Reynier MAM;Thery MJ;Petit T;Cabel L;Uwer L;Debled M;Chevrot M;Mailliez A;Jacot W;de La Motte Rouge T","Frenel, J-S;Lusque, A;Delaloge, S;Ferrero, J-M;Bachelot, T;Desmoulins, I;Levy, C;Eymard, J-C;Gonçalves, A;Patsouris, A;Reynier, M A Mouret;Thery, M J-C;Petit, T;Cabel, L;Uwer, L;Debled, M;Chevrot, M;Mailliez, A;Jacot, W;de La Motte Rouge, T","Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation.","British journal of cancer","England","eng","Journal Article","","Humans;Female;Breast Neoplasms;BRCA1 Protein;Receptor, ErbB-2;BRCA2 Protein;Germ Cells;Mutation;Antineoplastic Combined Chemotherapy Protocols","Humans;Female;Breast Neoplasms;BRCA1 Protein;Receptor, ErbB-2;BRCA2 Protein;Germ Cells;Mutation;Antineoplastic Combined Chemotherapy Protocols","Efficacy of endocrine therapy in HR+/HER2- metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation. The ESME metastatic breast cancer platform (NCT03275311) is a French real world database. Multivariable models including a time-varying approach and landmark analyses assessed the association between time-dependent gBRCA status (categorised as gBRCAm, gBRCAwt (wild type), and untested), overall survival (OS), and first-line progression-free survival (PFS1). A total of 170 patients were gBRCAm carriers, 676 gBRCAwt, and 12,930 were untested at baseline. In the multivariable analysis, gBRCAm carriers overall had a lower OS compared to gBRCAwt (adjusted HR [95% CI] 1.26 [1.03-1.55]). gBRCAm patients treated with front-line endocrine therapy had lower adjusted OS (adjusted HR [95% CI] = 1.54 [1.03-2.32]) and PFS1 (adjusted HR [95% CI] 1.58 [1.17-2.12]) compared to gBRCAwt patients. However, for patients who received frontline chemotherapy, neither OS nor PFS1 differed between gBRCAm carriers and the other groups (HR versus gBRCAwt for OS: 1.12 [0.88-1.41], p = 0.350; PFS1: 1.09 [0.90-1.31], p = 0.379). In this large cohort of HR+/HER2- MBC patients treated in a pre-CDK4/6 inhibitors era, gBRCAm status was associated with a lower OS and lower PFS following first-line endocrine therapy, but not following first-line chemotherapy.","Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.;Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon, France.;Medical Oncology, Centre Francois Baclesse, Caen, France.;Medical Oncology, Institut Jean Godinot, Reims, France.;Medical Oncology Department, Institute Paoli Calmettes, Marseille, France.;Medical Oncology Department, ICO - Institut de cancerologie de l'Ouest - Site Paul Papin, Angers, France.;Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France.;Medical Oncology, Centre Henri Becquerel, Rouen, France.;Bas-Rhin, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology, Hôpital René Huguenin - Institut Curie, Saint-Cloud, France.;Medical Oncology, Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Real World Data, UNICANCER, Paris, France.;Medical Oncology, Centre Oscar Lambret, Lille, France.;Medical Oncology Department, ICM Regional Cancer Institute of Montpellier, Montpellier University, INSERM U1194, Montpellier, France.;Medical Oncology, Centre Eugene - Marquis, Rennes, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2022,"2023","128","10.1038/s41416-023-02248-4","2072-2080","","","37012318","37012318","PUBMED","Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain;Biostatistics & Health Data Science Unit, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Department of Cancer Medicine, Institut Gustave Roussy, Villejuif, France.;Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon, France.;Medical Oncology, Centre Francois Baclesse, Caen, France.;Medical Oncology, Institut Jean Godinot, Reims, France.;Medical Oncology Department, Institute Paoli Calmettes, Marseille, France.;Medical Oncology Department, ICO - Institut de cancerologie de l'Ouest - Site Paul Papin, Angers, France.;Medical Oncology, Jean Perrin Center, Clermont-Ferrand, France.;Medical Oncology, Centre Henri Becquerel, Rouen, France.;Bas-Rhin, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology, Hôpital René Huguenin - Institut Curie, Saint-Cloud, France.;Medical Oncology, Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Real World Data, UNICANCER, Paris, France.;Medical Oncology, Centre Oscar Lambret, Lille, France.;Medical Oncology Department, ICM Regional Cancer Institute of Montpellier, Montpellier University, INSERM U1194, Montpellier, France.;Medical Oncology, Centre Eugene - Marquis, Rennes, France."
"179","Muzellec L;Campion L;Bachet JB;Taieb J;Fremont E;Senellart H;Moreau J;Bouché O;Garric M;Guimbaud R;Greilsamer C;Bodère A;Lièvre A;Girot P;Edeline J;Tougeron D;Bennouna J;Touchefeu Y","Muzellec, Léa;Campion, Loïc;Bachet, Jean-Baptiste;Taieb, Julien;Fremont, Elodie;Senellart, Hélène;Moreau, Johanna;Bouché, Olivier;Garric, Marie;Guimbaud, Rosine;Greilsamer, Charlotte;Bodère, Anaïs;Lièvre, Astrid;Girot, Paul;Edeline, Julien;Tougeron, David;Bennouna, Jaafar;Touchefeu, Yann","Prognostic score for synchronous metastatic rectal cancer: A real-world study.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Netherlands","eng","Journal Article","Metastatic;Multivariate analysis;Prognosis;Rectal neoplasm;Score","Humans;Prognosis;Retrospective Studies;Rectal Neoplasms;Antineoplastic Agents;Lung Neoplasms","Humans;Prognosis;Retrospective Studies;Rectal Neoplasms;Antineoplastic Agents;Lung Neoplasms","Prognostic factors of metastatic rectal cancer are not well known. The objective of this study was to identify prognostic factors of overall survival (OS) in a cohort of patients with non-resectable synchronous metastatic rectal cancer. Patients were retrospectively enrolled from 18 French centres. Univariate and multivariate analyses were performed to identify prognostic factors for OS. A simple score was derived from this a development cohort RESULTS: A total of 243 patients with metastatic rectal cancer were included in the study. Median OS was 24.4 months, 95% CI [19.4-27.2]. Among patients with non-resected metastases (n=141), six independent prognostic factors associated with better OS were identified in multivariate analysis: primary tumour surgery, WHO score 0-1, middle or upper rectal tumour, lung metastases only, systemic chemotherapy and targeted agent in first line. A prognostic score individualized three groups, each factor counting for one point in the score (<3, = 3 et > 3). Their median OS were respectively 27.9 months, 95% CI [21.7-35.1], 17.1 months [11.9-19.7] (HR =2.08, 95%, CI [1.31-3.30], p =0.002) and 9.1 months [4.9-11.7] (HR =2.32, 95% CI [1.38-3.92], p =0.001). A prognostic score for non-resectable synchronous metastatic rectal cancer can be proposed to classify patients in three prognostic groups.","Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes, France.;Biometrics, Institut de Cancérologie de l'Ouest, Saint Herblain 44800, France; CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, 44000 Nantes, France.;Department of Gastroenterology and Digestive Oncology, Assistance publique-Hôpitaux de Paris, Groupe hospitalier Pitié Salpêtrière, France.;Department of Gastroenterology and Digestive Oncology, Université Paris Descartes, Hopital Européen Georges Pompidou, Paris, France.;Department of Gastroenterology, Centre Hospitalier Universitaire de Poitiers, France.;Medical Oncology department, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, France.;Oncologie Médicale Digestive, CHU de Toulouse, Toulouse, France.;Oncologie Médicale Digestive, CHU de Toulouse, Toulouse, France.;Medical Oncology department, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Rennes, France.;Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Rennes, France.;Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes, France.;Medical Oncology department, Centre Eugène Marquis, Rennes, France.;Department of Gastroenterology, Centre Hospitalier Universitaire de Poitiers, France.;Department of Medical Oncology, Hospital Foch, F-92150 Suresnes, France.;Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes","NA",0,"1878-3562","Dig Liver Dis","Dig Liver Dis",2021,"2023","55","10.1016/j.dld.2023.03.004","1411-1416","","","37005173","37005173","PUBMED","Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes, France.;Biometrics, Institut de Cancérologie de l'Ouest, Saint Herblain 44800, France; CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, 44000 Nantes, France.;Department of Gastroenterology and Digestive Oncology, Assistance publique-Hôpitaux de Paris, Groupe hospitalier Pitié Salpêtrière, France.;Department of Gastroenterology and Digestive Oncology, Université Paris Descartes, Hopital Européen Georges Pompidou, Paris, France.;Department of Gastroenterology, Centre Hospitalier Universitaire de Poitiers, France.;Medical Oncology department, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Robert Debré, CHU Reims, France.;Oncologie Médicale Digestive, CHU de Toulouse, Toulouse, France.;Oncologie Médicale Digestive, CHU de Toulouse, Toulouse, France.;Medical Oncology department, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Rennes, France.;Department of Gastroenterology and Digestive Oncology, Centre Hospitalier Universitaire de Rennes, France.;Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes, France.;Medical Oncology department, Centre Eugène Marquis, Rennes, France.;Department of Gastroenterology, Centre Hospitalier Universitaire de Poitiers, France.;Department of Medical Oncology, Hospital Foch, F-92150 Suresnes, France.;Nantes Université, CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, F-44000 Nantes"
"180","Le Guevelou J;Zilli T","Le Guevelou, Jennifer;Zilli, Thomas","Prostate cancer radiotherapy and incidental testicular irradiation: Impact on gonadal function.","Clinical and translational radiation oncology","Ireland","eng","Journal Article","Hypogonadism;Prostate cancer;Radiotherapy;Sexual toxicity;Testicles;Testosterone levels","","","Incidental testicular irradiation during prostate cancer radiotherapy is rarely documented in literature and the long-term impact on gonadal function largely underreported. Here we present an overview of available data on incidental testicular irradiation and radiation-induced hypogonadism during prostate cancer radiotherapy and discuss future technical developments to minimize testis irradiation.","Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Università della Svizzera Italiana, Lugano, Switzerland.","NA",0,"2405-6308","Clin Transl Radiat Oncol","Clin Transl Radiat Oncol",2023,"2023","40","10.1016/j.ctro.2023.100611","100611","","","36942089","36942089","PUBMED","Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Radiation Oncology, Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland.;Università della Svizzera Italiana, Lugano, Switzerland."
"181","Féray C;Campion L;Mathurin P;Archambreaud I;Mirabel X;Bronowicki JP;Rio E;Perret C;Mineur L;Oberti F;Touchefeu Y;Gournay J;Regnault H;Edeline J;Rode A;Hillion P;Blanc JF;Khac EN;Azoulay D;Luciani A;Preglisasco AG;Faurel-Paul E;Auble H;Mornex F;Merle P","Féray, Cyrille;Campion, Loic;Mathurin, Philippe;Archambreaud, Isabelle;Mirabel, Xavier;Bronowicki, Jean Pierre;Rio, Emmanuel;Perret, Christophe;Mineur, Laurent;Oberti, Frédéric;Touchefeu, Yann;Gournay, Jérôme;Regnault, Hélène;Edeline, Julien;Rode, Agnès;Hillion, Patrick;Blanc, Jean Frédéric;Khac, Eric Nguyen;Azoulay, Daniel;Luciani, Alain;Preglisasco, Athena Galetto;Faurel-Paul, Elodie;Auble, Hélène;Mornex, Françoise;Merle, Philippe",NA,"JHEP reports : innovation in hepatology","Netherlands","eng","Journal Article","3-DCRT, three-dimensional conformal radiotherapy;AE, adverse event;ALBI, albumin–bilirubin;BCLC, Barcelona Clinic Liver Cancer;CRT, conformal radiotherapy;CT, computed tomography;CTV, clinical tumour volume;Conformal external radiotherapy;ECOG, Eastern Cooperative Oncology Group;HCC, hepatocellular carcinoma;HR, hazard ratio;Hepatocellular carcinoma;ITT, intention-to-treat;OS, overall survival;PFS, progression-free survival;PS, propensity score;RILD, radio-induced liver disease;SBRT, stereotaxic body radiation therapy;TACE, transcatheter arterial chemoembolisation;TTP, time to tumour progression;mRECIST, modified Response Evaluation Criteria in Solid Tumour","","","Transcatheter arterial chemoembolisation (TACE) is recommended for patients with hepatocellular carcinoma devoid of macrovascular invasion or extrahepatic spread but not eligible for curative therapies. We compared the efficacy and safety of the combination of a single TACE and external conformal radiotherapy (CRT)  . classical TACE. TACERTE was an open-labelled, randomised controlled trial with a 1:1 allocation rate to two or three TACE (arm A) or one TACE + CRT (arm B). Participants had a mean age of 70 years, and 86% were male. The aetiology was alcohol in 85%. The primary endpoint was liver progression-free survival (PFS) in the intention-to-treat population. The typical CRT schedule was 54 Gy in 18 sessions of 3 Gy. Of the 120 participants randomised, 64 were in arm A and 56 in arm B; 100 participants underwent the planned schedule and defined the 'per-protocol' group. In intention-to-treat participants, the liver PFS at 12 and 18 months were 59% and 19% in arm A and 61% and 36% in arm B (hazard ratio [HR] 0.69; 95% CI 0.40-1.18;   = 0.17), respectively. In the per-protocol population, treated liver PFS tended to be better in arm B (HR 0.61; 95% CI 0.34-1.06;   = 0.081) than in arm A. Liver-related grade III-IV adverse events were more frequent in arm B than in arm A. Median overall survival reached 30 months (95% CI 23-35) in arm A and 22 months (95% CI 15.7-26.2) in arm B. Although TACE + CRT tended to improve local control, this first Western randomised controlled trial showed that the combined strategy failed to increase PFS or overall survival and led more frequently to liver-related adverse effects. Hepatocellular carcinoma is frequently treated by arterial embolisation of the tumour and more recently by external radiotherapy. We tried to determine whether combination of the two treatments (irradiation after embolisation) might produce interesting results. Our results in this prospective randomised study were not able to demonstrate a beneficial effect of combining embolisation and irradiation in these patients. On the contrary, we observed more adverse effects with the combined treatment. NCT01300143.","Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Department of Biostatistics, Institut de Cancérologie de l'Ouest, Université Nantes, INSERM U307, Nantes, France.;Service des Maladies de l'Appareil Digestif, Hôpital Huriez, Université Lille, INSERM 1286, Lille, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Hepatology, CHU Nancy-Brabois, Nancy, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Radiology Department, Hôtel-Dieu, Nantes, France.;Digestive Oncology, Institut Sainte Catherine, Avignon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Angers, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Gastroenterology and Hepatology, Hôpital Henri Mondor, APHP, Université Paris Est, Creteil, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Radiology Department, Hôpital de la Croix-Rousse, Hospice Civil de Lyon; Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Dijon, France.;Department of Gastroenterology and Hepatology, Hôpital Sud Haut-Lévêque, Bordeaux, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Université Amiens, Amiens, France.;Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon, EMR 3738, Lyon, France.;Hepatology and Gastroenterology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard, INSERM U1052, Lyon, France.","NA",0,"2589-5559","JHEP Rep","JHEP Rep",2022,"2023","5","10.1016/j.jhepr.2023.100689","100689","","","36937990","36937990","PUBMED","Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Department of Biostatistics, Institut de Cancérologie de l'Ouest, Université Nantes, INSERM U307, Nantes, France.;Service des Maladies de l'Appareil Digestif, Hôpital Huriez, Université Lille, INSERM 1286, Lille, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Gastroenterology and Hepatology, CHU Nancy-Brabois, Nancy, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Radiology Department, Hôtel-Dieu, Nantes, France.;Digestive Oncology, Institut Sainte Catherine, Avignon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Angers, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Institut des Maladies de l'Appareil Digestif, Hôtel-Dieu, Nantes, France.;Department of Gastroenterology and Hepatology, Hôpital Henri Mondor, APHP, Université Paris Est, Creteil, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Radiology Department, Hôpital de la Croix-Rousse, Hospice Civil de Lyon; Lyon, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Dijon, France.;Department of Gastroenterology and Hepatology, Hôpital Sud Haut-Lévêque, Bordeaux, France.;Department of Gastroenterology and Hepatology, Centre Hospitalo-universitaire, Université Amiens, Amiens, France.;Centre Hepato-Biliaire, Hôpital Paul Brousse, APHP, Université Paris-Saclay, INSERM 1193, Villejuif, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Radiology Department, Hôpital Henri Mondor, APHP, Créteil, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Direction de la Recherche Medicale, Hôtel-Dieu, Nantes, France.;Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon, EMR 3738, Lyon, France.;Hepatology and Gastroenterology Unit, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard, INSERM U1052, Lyon, France."
"182","Etienne H;Fournel L;Mordant P;Delatour BR;Pfeuty K;Frey G;Seguin-Givelet A;Fourdrain A;Lancelin C;Berna P;Legras A;Alifano M;Bagan P;Assouad J","Etienne, Harry;Fournel, Ludovic;Mordant, Pierre;Delatour, Bertrand Richard;Pfeuty, Karel;Frey, Gil;Seguin-Givelet, Agathe;Fourdrain, Alex;Lancelin, Christophe;Berna, Pascal;Legras, Antoine;Alifano, Marco;Bagan, Patrick;Assouad, Jalal","Anatomic lung resection after immune checkpoint inhibitors for initially unresectable advanced-staged non-small cell lung cancer: a retrospective cohort analysis.","Journal of thoracic disease","China","eng","Journal Article","Non-small cell lung cancers (NSCLCs);anatomic lung resection;immune checkpoint inhibitors (ICIs)","","","Patients with initially unresectable advanced non-small cell lung cancer (NSCLC) might experience prolonged responses under immune checkpoint inhibitors (ICIs). In this setting, Multidisciplinary Tumor Board (MTB) seldomly suggest surgical resection of the primary tumor with the ultimate goal to eradicate macroscopic residual disease. Our objective was to report the perioperative outcomes of patients who underwent anatomic lung resection in these infrequent circumstances. We set a retrospective multicentric single arm study, including all patients with advanced-staged initially unresectable NSCLC (stage IIIB to IVB) who received systemic therapy including ICIs and eventually anatomical resection of the primary tumor in 10 French thoracic surgery units from January 2016 to December 2020. Coprimary endpoints were in-hospital mortality and morbidity. Secondary endpoints were the rate of complete resection of the pulmonary disease, major pathologic response, risk factors associated with post-operative complications, and overall survival. Twenty-one patients (median age 64, female 62%) were included. Eighteen patients (86%) progressed after first line chemotherapy and received second line ICI. The median time between diagnosis and surgery was 22 months [interquartile range (IQR) 18-35 months]. Minimally-invasive approach was used in 10 cases (48%), with half of these requiring conversion to open thoracotomy. Nine patients (43%) presented early post-operative complications, and one patient died from broncho-pleural fistula one month after surgery. Rates of complete resection of the pulmonary disease and major pathologic response were 100% and 43%, respectively. In univariable analysis, diffusing capacity for carbon monoxide (DLCO) was the only factor associated with the occurrence of postoperative complications (P=0.027). After a median follow-up of 16.0 months after surgery (IQR, 12.0-30.0 months), 19 patients (90%) were still alive. Anatomic lung resections appear to be a reasonable option for initially unresectable advanced NSCLC experiencing prolonged response under ICIs. Nonetheless, minimally invasive techniques have a low applicability and post-operative complications remains higher in patients who had lower DLCO values. The late timing of surgery may also contribute to complications.","AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Nord-Université de Paris, site Bichat-Claude Bernard, Service de Chirurgie Thoracique et Vasculaire, Paris, France.;Centre Hospitalier Universitaire de Rennes, Service de Chirurgie Cardiaque et Thoracique, Rennes, France.;Centre Hospitalier Général de Saint-Brieuc, Service de Chirurgie Thoracique, Saint-Brieuc, France.;Centre Hospitalier Universitaire de Grenoble, Service de Chirurgie Thoracique, Grenoble, France.;Institut Mutualiste Montsouris, Service de Chirurgie Thoracique, Paris, France.;Centre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.;Clinique du Grand Large, Service de Chirurgie Thoracique, Brest, France.;Centre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.;Centre Hospitalier Universitaire de Tours, Service de Chirurgie Thoracique et Vasculaire, Tours, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.;Centre Hospitalier Général d'Argenteuil, Service de Chirurgie Thoracique et Vasculaire, Argenteuil, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France.","NA",0,"2072-1439","J Thorac Dis","J Thorac Dis",2022,"2023","15","10.21037/jtd-22-704","270-280","","","36910122","36910122","PUBMED","AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Nord-Université de Paris, site Bichat-Claude Bernard, Service de Chirurgie Thoracique et Vasculaire, Paris, France.;Centre Hospitalier Universitaire de Rennes, Service de Chirurgie Cardiaque et Thoracique, Rennes, France.;Centre Hospitalier Général de Saint-Brieuc, Service de Chirurgie Thoracique, Saint-Brieuc, France.;Centre Hospitalier Universitaire de Grenoble, Service de Chirurgie Thoracique, Grenoble, France.;Institut Mutualiste Montsouris, Service de Chirurgie Thoracique, Paris, France.;Centre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.;Clinique du Grand Large, Service de Chirurgie Thoracique, Brest, France.;Centre Hospitalier Universitaire de Amiens, Service de Chirurgie Thoracique, Amiens, France.;Centre Hospitalier Universitaire de Tours, Service de Chirurgie Thoracique et Vasculaire, Tours, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Université Descartes, site Cochin, Service de Chirurgie Thoracique, Paris, France.;Centre Hospitalier Général d'Argenteuil, Service de Chirurgie Thoracique et Vasculaire, Argenteuil, France.;AP-HP, Groupe Hospitalier Universitaire APHP-Sorbonne Université, site Tenon, Service de Chirurgie Thoracique et Vasculaire, Paris, France."
"183","Shahim A;Hourqueig M;Lund LH;Savarese G;Oger E;Venkateshvaran A;Benson L;Daubert JC;Linde C;Donal E;Hage C","Shahim, Angiza;Hourqueig, Marion;Lund, Lars H;Savarese, Gianluigi;Oger, Emmanuel;Venkateshvaran, Ashwin;Benson, Lina;Daubert, Jean-Claude;Linde, Cecilia;Donal, Erwan;Hage, Camilla","Long-term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non-cardiac mortality.","ESC heart failure","England","eng","Journal Article","Cardiovascular mortality;Diastolic heart failure;Heart failure with preserved ejection fraction;Non-cardiovascular mortality;Outcome;Prognosis","Humans;Female;Aged;Male;Heart Failure;Stroke Volume;Tricuspid Valve Insufficiency;Prognosis;Kidney Diseases;Stroke;Sodium","Humans;Female;Aged;Male;Heart Failure;Stroke Volume;Tricuspid Valve Insufficiency;Prognosis;Kidney Diseases;Stroke;Sodium","Heart failure (HF) with preserved ejection fraction (HFpEF) is associated with cardiovascular (CV) and non-CV events, but long-term risk is poorly studied. We assessed incidence and predictors of the long-term CV and non-CV events. Patients presenting with acute HF, EF ≥ 45%, and N-terminal pro-brain natriuretic peptide > 300 ng/L were enrolled in the Karolinska-Rennes study in 2007-11 and were reassessed after 4-8 weeks in a stable state. Long-term follow-up was conducted in 2018. The Fine-Gray sub-distribution hazard regression was used to detect predictors of CV and non-CV deaths, investigated separately from baseline acute presentation (demographic data only) and from the 4-8 week outpatient visit (including echocardiographic data). Of 539 patients enrolled [median age 78 (interquartile range: 72-84) years; 52% female], 397 patients were available for the long-term follow-up. Over a median follow-up time from acute presentation of 5.4 (2.1-7.9) years, 269 (68%) patients died, 128 (47%) from CV and 120 (45%) from non-CV causes. Incidence rates per 1000 patient-years were 62 [95% confidence interval (CI) 52-74] for CV and 58 (95% CI 48-69) for non-CV death. Higher age and coronary artery disease (CAD) were independent predictors of CV death, and anaemia, stroke, kidney disease, and lower body mass index (BMI) and sodium concentrations of non-CV death. From the stable 4-8 week visit, anaemia, CAD, and tricuspid regurgitation (>3.1 m/s) were independent predictors of CV death, and higher age of non-CV death. In patients with acute decompensated HFpEF, over 5 years of follow-up, nearly two-thirds of patients died, half from CV and the other half from non-CV causes. CAD and tricuspid regurgitation were associated with CV death. Stroke, kidney disease, lower BMI, and lower sodium were associated with non-CV death. Anaemia and higher age were associated with both outcomes. [Correction added on 24 March 2023, after first online publication: In the first sentence of the Conclusions, 'two-thirds' has been inserted before 'of patients died...' in this version.].","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Département de Pharmacologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Faculté de Médecine, Universitaire de Rennes 1, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Faculté de Médecine, Universitaire de Rennes 1, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2022,"2023","10","10.1002/ehf2.14302","1835-1846","","","36896796","36896796","PUBMED","Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Département de Pharmacologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Faculté de Médecine, Universitaire de Rennes 1, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.;Faculté de Médecine, Universitaire de Rennes 1, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden."
"184","Chen JW;Jacot W;Cortés J;Krop IE;Dent S;Harbeck N;De Laurentiis M;Diéras V;Im YH;Stout TJ;Schimmoller F;Savage HM;Hutchinson KE;Wilson TR","Chen, Jessica W;Jacot, William;Cortés, Javier;Krop, Ian E;Dent, Susan;Harbeck, Nadia;De Laurentiis, Michelino;Diéras, Véronique;Im, Young-Hyuck;Stout, Thomas J;Schimmoller, Frauke;Savage, Heidi M;Hutchinson, Katherine E;Wilson, Timothy R","ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.","Molecular oncology","United States","eng","Journal Article","PIK3CA;SANDPIPER;breast cancer;circulating tumour DNA;taselisib","Humans;Female;Breast Neoplasms;Fulvestrant;Receptors, Estrogen;Tumor Suppressor Protein p53;Phosphatidylinositol 3-Kinases;Genomics;Class I Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols","Humans;Female;Breast Neoplasms;Fulvestrant;Receptors, Estrogen;Tumor Suppressor Protein p53;Phosphatidylinositol 3-Kinases;Genomics;Class I Phosphatidylinositol 3-Kinases;Receptor, ErbB-2;Antineoplastic Combined Chemotherapy Protocols","Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with response to PI3K inhibition, we analysed circulating tumour DNA (ctDNA) from participants enrolled in the SANDPIPER trial. Participants were designated as either PIK3CAmut or PIK3CA no mutation was detected (NMD) per baseline ctDNA. The top mutated genes and tumour fraction estimates identified were analysed for their association with outcomes. In participants with PIK3CAmut ctDNA treated with taselisib + fulvestrant, tumour protein p53 (TP53; encoding p53) and fibroblast growth factor receptor 1 (FGFR1) alterations were associated with shorter progression-free survival (PFS) compared to participants with NMD in these genes. Conversely, participants with PIK3CAmut ctDNA harbouring a neurofibromin 1 (NF1) alteration or high baseline tumour fraction estimate experienced improved PFS upon treatment with taselisib + fulvestrant compared to placebo + fulvestrant. Broadly, alterations in oestrogen receptor (ER), PI3K and p53 pathway genes were associated with resistance to taselisib + fulvestrant in participants with PIK3CAmut ctDNA. Altogether, we demonstrated the impact of genomic (co-)alterations on outcomes with one of the largest clinico-genomic datasets of ER+, HER2-, PIK3CAmut breast cancer patients treated with a PI3K inhibitor.","Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, France.;International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid, Spain.;International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.;Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.;Yale Cancer Center, New Haven, CT, USA.;Duke Cancer Institute, Duke University, Durham, NC, USA.;Breast Center, Department Gynecology and Obstetrics and Comprehensive Cancer Center (CCC) Munich, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.;Istituto Nazionale Tumori IRCCS ""Fondazione Pascale"", Napoli, Italy.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.;Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.;Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.","NA",0,"1878-0261","Mol Oncol","Mol Oncol",2022,"2023","17","10.1002/1878-0261.13416","2000-2016","","","36892268","36892268","PUBMED","Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, INSERM U1194, France.;International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid, Spain.;International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain.;Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain.;Yale Cancer Center, New Haven, CT, USA.;Duke Cancer Institute, Duke University, Durham, NC, USA.;Breast Center, Department Gynecology and Obstetrics and Comprehensive Cancer Center (CCC) Munich, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.;Istituto Nazionale Tumori IRCCS ""Fondazione Pascale"", Napoli, Italy.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.;Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.;Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA.;Oncology Biomarker Development, Genentech, Inc., South San Francisco, CA, USA."
"185","Courtinard C;Gourgou S;Jacot W;Carton M;Guérin O;Vacher L;Bertaut A;Le Deley MC;Pérol D;Marino P;Levy C;Uwer L;Perrocheau G;Schiappa R;Bachelot F;Parent D;Breton M;Petit T;Filleron T;Loeb A;Mathoulin-Pélissier S;Robain M;Delaloge S;Bellera C","Courtinard, Coralie;Gourgou, Sophie;Jacot, William;Carton, Matthieu;Guérin, Olivier;Vacher, Laure;Bertaut, Aurélie;Le Deley, Marie-Cécile;Pérol, David;Marino, Patricia;Levy, Christelle;Uwer, Lionel;Perrocheau, Geneviève;Schiappa, Renaud;Bachelot, Florence;Parent, Damien;Breton, Mathias;Petit, Thierry;Filleron, Thomas;Loeb, Agnès;Mathoulin-Pélissier, Simone;Robain, Mathieu;Delaloge, Suzette;Bellera, Carine","Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.","BMC medicine","England","eng","Journal Article","Association;Breast cancer;Overall survival;Progression-free survival;Real-word data;Surrogacy","Adult;Female;Humans;Middle Aged;Breast Neoplasms;Progression-Free Survival;Databases, Factual;Gene Expression","Adult;Female;Humans;Middle Aged;Breast Neoplasms;Progression-Free Survival;Databases, Factual;Gene Expression","Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an intermediate endpoint. Evidence remains scarce regarding the degree of association between PFS and OS. Our study aimed to describe the individual-level association between real-world PFS (rwPFS) and OS according to first-line treatment in female patients with mBC managed in real-world setting for each BC subtype (defined by status for both hormone-receptor [HR] expression and HER2 protein expression/gene amplification). We extracted data from the ESME mBC database (NCT03275311) which gathers deidentified data from consecutive patients managed in 18 French Comprehensive Cancer Centers. Adult women diagnosed with mBC between 2008 and 2017 were included. Endpoints (PFS, OS) were described using the Kaplan-Meier method. Individual-level associations between rwPFS and OS were estimated using the Spearman's correlation coefficient. Analyses were conducted by tumor subtype. 20,033 women were eligible. Median age was 60.0 years. Median follow-up duration was 62.3 months. Median rwPFS ranged from 6.0 months (95% CI 5.8-6.2) for HR-/HER2 - subtype to 13.3 months (36% CI 12.7-14.3) for HR + /HER2 + subtype. Correlation coefficients were highly variable across subtypes and first-line (L1) treatments. Among patients with HR - /HER2 - mBC, correlation coefficients ranged from 0.73 to 0.81, suggesting a strong rwPFS/OS association. For HR + /HER2 + mBC patients, the individual-level associations were weak to strong with coefficients ranging from 0.33 to 0.43 for monotherapy and from 0.67 to 0.78 for combined therapies. Our study provides comprehensive information on individual-level association between rwPFS and OS for L1 treatments in mBC women managed in real-life practice. Our results could be used as a basis for future research dedicated to surrogate endpoint candidates.","University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux, France.;Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Biometrics Unit, Institut du Cancer de Montpellier, 208 Rue Des Apothicaires, 34298, Montpellier, France.;University of Montpellier, 163 Rue Auguste Broussonnet, 34090, Montpellier, France.;University of Montpellier, 163 Rue Auguste Broussonnet, 34090, Montpellier, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue Des Apothicaires, 34298, Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194, 208 Rue Des Apothicaires, 34298, Montpellier, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Information, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Biometry, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Biometry, Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, Lyon, 69008, France.;Institut Paoli-Calmettes, SESSTIM UMR912, 232, Boulevard Sainte-Marguerite, 13009, Marseille, France.;Aix-Marseille Université, Inserm, IRD, SESSTIM Sciences Économiques Et Sociales de La Santé Et Traitement de L'information Médicale, 13009, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Pharmacy, Institut de Cancérologie de L'Ouest Nantes, Bd Professeur Jacques Monod, 44800, Saint-Herblain, France.;Department of Biometry, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Information, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Pharmacy, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Information, Centre Eugène Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200, Strasbourg, France.;Department of Biometry, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Medical Information, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000, Bordeaux, France.;Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000, Bordeaux","NA",0,"1741-7015","BMC Med","BMC Med",2022,"2023","21","10.1186/s12916-023-02754-5","87","","","36882736","36882736","PUBMED","University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux, France.;Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Biometrics Unit, Institut du Cancer de Montpellier, 208 Rue Des Apothicaires, 34298, Montpellier, France.;University of Montpellier, 163 Rue Auguste Broussonnet, 34090, Montpellier, France.;University of Montpellier, 163 Rue Auguste Broussonnet, 34090, Montpellier, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue Des Apothicaires, 34298, Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194, 208 Rue Des Apothicaires, 34298, Montpellier, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Information, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Biometry, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Biometry, Centre Léon Bérard, 28 Prom. Léa Et Napoléon Bullukian, Lyon, 69008, France.;Institut Paoli-Calmettes, SESSTIM UMR912, 232, Boulevard Sainte-Marguerite, 13009, Marseille, France.;Aix-Marseille Université, Inserm, IRD, SESSTIM Sciences Économiques Et Sociales de La Santé Et Traitement de L'information Médicale, 13009, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Pharmacy, Institut de Cancérologie de L'Ouest Nantes, Bd Professeur Jacques Monod, 44800, Saint-Herblain, France.;Department of Biometry, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Information, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Pharmacy, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Information, Centre Eugène Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), 17 Rue Albert Calmette, 67200, Strasbourg, France.;Department of Biometry, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Medical Information, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux, France.;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000, Bordeaux, France.;Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, 33000, Bordeaux;Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33000, Bordeaux"
"186","Ren Z;Ducreux M;Abou-Alfa GK;Merle P;Fang W;Edeline J;Li Z;Wu L;Assenat E;Hu S;Rimassa L;Zhang T;Blanc JF;Pan H;Ross P;Yen CJ;Tran A;Shao G;Bouattour M;Chen Y;Meyer T;Hou J;Tougeron D;Bai Y;Hou MM;Meng Z;Wu J;Li V;Chica-Duque S;Cheng AL","Ren, Zhenggang;Ducreux, Michel;Abou-Alfa, Ghassan K;Merle, Philippe;Fang, Weijia;Edeline, Julien;Li, Zhiwei;Wu, Lihua;Assenat, Eric;Hu, Sheng;Rimassa, Lorenza;Zhang, Tao;Blanc, Jean-Frédéric;Pan, Hongming;Ross, Paul;Yen, Chia-Jui;Tran, Albert;Shao, Guoliang;Bouattour, Mohamed;Chen, Yajin;Meyer, Tim;Hou, Jinlin;Tougeron, David;Bai, Yuxian;Hou, Ming-Mo;Meng, Zhiqiang;Wu, John;Li, Vincent;Chica-Duque, Sandra;Cheng, Ann-Lii","Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.","Liver cancer","Switzerland","eng","Journal Article","Hepatocellular carcinoma;Immunotherapy;Pretreated patient population;Tislelizumab","","","Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. The multiregional phase 2 study RATIONALE-208 examined single-agent tislelizumab (200 mg intravenously every 3 weeks) in patients with advanced HCC with Child-Pugh A, Barcelona Clinic Liver Cancer stage B or C, and who had received one or more prior lines of systemic therapy. The primary endpoint was objective response rate (ORR), radiologically confirmed per Response Evaluation Criteria in Solid Tumors version 1.1 by the Independent Review Committee. Safety was assessed in patients who received ≥1 dose of tislelizumab. Between April 9, 2018, and February 27, 2019, 249 eligible patients were enrolled and treated. After a median study follow-up of 12.7 months, ORR was 13% (  = 32/249; 95% confidence interval [CI], 9-18), including five complete and 27 partial responses. The number of prior lines of therapy did not impact ORR (one prior line, 13% [95% CI, 8-20]; two or more prior lines, 13% [95% CI, 7-20]). Median duration of response was not reached. The disease control rate was 53%, and median overall survival was 13.2 months. Of the 249 total patients, grade ≥3 treatment-related adverse events were reported in 38 (15%) patients; the most common was liver transaminase elevations in 10 (4%) patients. Treatment-related adverse events led to treatment discontinuation in 13 (5%) patients or dose delay in 46 (19%) patients. No deaths were attributed to the treatment per investigator assessment. Tislelizumab demonstrated durable objective responses, regardless of the number of prior lines of therapy, and acceptable tolerability in patients with previously treated advanced HCC.","Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.;Medical Oncology Department, Gustave Roussy, INSERM U1279, Paris-Saclay University, Villejuif, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College at Cornell University, New York, New York, USA.;Department of Hepatology, Hospital La Croix-Rousse, Lyon, France.;Department of Medical Oncology, The First Affiliated Hospital Zhejiang University, Hangzhou, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Department of Oncology, CHRU Saint Eloi, Montpellier, France.;Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China.;Medical Oncology and Hematology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.;Abdominal Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Service Hépato-Gastroentérologie et Oncologie Digestive, Groupe Hospitalier Sud - Hôpital Haut Lévêque, Bordeaux, France.;Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.;Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust and Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.;Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Département Digestif, Université Côte d'Azur, Nice, France, and Centre Hospitalier Universitaire de Nice, Nice, France, and Centre Méditerranéen de Médecine Moléculaire, INSERUM U1065, Université Côte d'Azur, Nice, France.;Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.;Department of Digestive Oncology, APHP Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.;Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.;Academic Department of Oncology, Royal Free Hospital NHS Trust, Pond Street, London, UK.;State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Gastroenterology and Hepatology Department, University of Poitiers and Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.;Department of Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.;Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.;Biostatistics, BeiGene USA, Inc., Ridgefield Park, New Jersey, USA.;Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.;Clinical Development, BeiGene USA, Inc., San Mateo, California, USA.;Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.","NA",0,"2235-1795","Liver Cancer","Liver Cancer",2022,"2023","12","10.1159/000527175","72-84","P30 CA008748","NCI NIH HHS","36872927","36872927","PUBMED","Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China.;Medical Oncology Department, Gustave Roussy, INSERM U1279, Paris-Saclay University, Villejuif, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Medical College at Cornell University, New York, New York, USA.;Department of Hepatology, Hospital La Croix-Rousse, Lyon, France.;Department of Medical Oncology, The First Affiliated Hospital Zhejiang University, Hangzhou, China.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.;Department of Oncology, CHRU Saint Eloi, Montpellier, France.;Department of Internal Medicine-Oncology, Hubei Cancer Hospital, Wuhan, China.;Medical Oncology and Hematology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.;Abdominal Oncology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.;Service Hépato-Gastroentérologie et Oncologie Digestive, Groupe Hospitalier Sud - Hôpital Haut Lévêque, Bordeaux, France.;Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China.;Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust and Department of Oncology, King's College Hospital NHS Foundation Trust, London, UK.;Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan.;Département Digestif, Université Côte d'Azur, Nice, France, and Centre Hospitalier Universitaire de Nice, Nice, France, and Centre Méditerranéen de Médecine Moléculaire, INSERUM U1065, Université Côte d'Azur, Nice, France.;Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, China.;Department of Digestive Oncology, APHP Hôpitaux Universitaires Paris Nord Val de Seine, Hôpital Beaujon, Clichy, France.;Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.;Academic Department of Oncology, Royal Free Hospital NHS Trust, Pond Street, London, UK.;State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.;Gastroenterology and Hepatology Department, University of Poitiers and Department of Gastroenterology and Hepatology, Poitiers University Hospital, Poitiers, France.;Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.;Department of Oncology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.;Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.;Biostatistics, BeiGene USA, Inc., Ridgefield Park, New Jersey, USA.;Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.;Clinical Development, BeiGene USA, Inc., San Mateo, California, USA.;Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan."
"187","Pascal V;Dupont M;de Rouault P;Rizzo D;Rossille D;Jeannet R;Daix T;François B;Genebrier S;Cornic M;Monneret G;Venet F;Ferrant J;Roussel M;Reizine F;Le Souhaitier M;Tadié JM;Tarte K;Feuillard J;Cogné M","Pascal, Virginie;Dupont, Marine;de Rouault, Paco;Rizzo, David;Rossille, Delphine;Jeannet, Robin;Daix, Thomas;François, Bruno;Genebrier, Steve;Cornic, Marie;Monneret, Guillaume;Venet, Fabienne;Ferrant, Juliette;Roussel, Mikael;Reizine, Florian;Le Souhaitier, Mathieu;Tadié, Jean-Marc;Tarte, Karin;Feuillard, Jean;Cogné, Michel","Demultiplexing Ig repertoires by parallel mRNA/DNA sequencing shows major differential alterations in severe COVID-19.","iScience","United States","eng","Journal Article","Immunology;Respiratory medicine","","","To understand the fine differential elements that can lead to or prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients, it is crucial to investigate the immune response architecture. We herein dissected the multiple layers of B cell responses by flow cytometry and Ig repertoire analysis from acute phase to recovery. Flow cytometry with FlowSOM analysis showed major changes associated with COVID-19 inflammation such as an increase of double-negative B-cells and ongoing plasma cell differentiation. This paralleled COVID-19-driven expansion of two disconnected B-cell repertoires. Demultiplexing successive DNA and RNA Ig repertoire patterns characterized an early expansion of IgG1 clonotypes with atypically long and uncharged CDR3, the abundance of this inflammatory repertoire being correlated with ARDS and likely pejorative. A superimposed convergent response included convergent anti-SARS-CoV-2 clonotypes. It featured progressively increasing somatic hypermutation together with normal-length or short CDR3 and it persisted until a quiescent memory B-cell stage after recovery.","CNRS UMR-7276, INSERM U1262, Team 3 BioPIC of CRIBL, University of Limoges, and Immunology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Department of BioInformatics of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.","NA",0,"2589-0042","iScience","iScience",2022,"2023","26","10.1016/j.isci.2023.106260","106260","","","36845033","36845033","PUBMED","CNRS UMR-7276, INSERM U1262, Team 3 BioPIC of CRIBL, University of Limoges, and Immunology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Department of BioInformatics of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Inserm CIC 1435, UMR 1092, Faculty of Medicine, University of Limoges, and Réanimation Polyvalente, CHU Dupuytren, 2, 87042 Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Lyon, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;CNRS UMR-7276, INSERM U1262, Team 1 2MB2C of CRIBL, University of Limoges, and Hematology Laboratory of Dupuytren Hospital University Center (CHU) of Limoges, Limoges, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France."
"188","François-Martin H;Lardy-Cléaud A;Pistilli B;Levy C;Diéras V;Frenel JS;Guiu S;Mouret-Reynier MA;Mailliez A;Eymard JC;Petit T;Ung M;Desmoulins I;Augereau P;Bachelot T;Uwer L;Debled M;Ferrero JM;Clatot F;Goncalves A;Chevrot M;Chabaud S;Cottu P","François-Martin, Hélène;Lardy-Cléaud, Audrey;Pistilli, Barbara;Levy, Christelle;Diéras, Véronique;Frenel, Jean-Sébastien;Guiu, Séverine;Mouret-Reynier, Marie-Ange;Mailliez, Audrey;Eymard, Jean-Christophe;Petit, Thierry;Ung, Mony;Desmoulins, Isabelle;Augereau, Paule;Bachelot, Thomas;Uwer, Lionel;Debled, Marc;Ferrero, Jean-Marc;Clatot, Florian;Goncalves, Anthony;Chevrot, Michael;Chabaud, Sylvie;Cottu, Paul","Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study.","Cancers","Switzerland","eng","Journal Article","advanced luminal breast cancer;everolimus;overall survival;real-world data","","","Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2- breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. We compared 1693 patients having received everolimus to 5928 patients not exposed to everolimus in the same period. Overall survival was evaluated according to treatment line, and a propensity score with the inverse probability of treatment weighting method was built to adjust for differences between groups. Crude and landmark overall survival analyses were all compatible with a benefit from everolimus-based therapy. Adjusted hazard ratios for overall survival were 0.34 (95% CI: 0.16-0.72,   = 0.0054), 0.34 (95% CI: 0.22-0.52,   < 0.0001), and 0.23 (95% CI: 0.14-0.36,   < 0.0001) for patients treated with everolimus in line 1, 2, and 3 and beyond, respectively. No clinically relevant benefit on progression-free survival was observed. Causes for everolimus discontinuation were progressive disease (56.2%), adverse events (27.7%), and other miscellaneous reasons. Despite the limitations inherent to such retrospective studies, these results suggest that adding everolimus-based therapy to the therapeutic sequences in patients with advanced HR+/HER2- breast cancer may favorably affect overall survival.","Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.;Centre Léon Bérard, Department of Biostatistics, 69008 Lyon, France.;Gustave Roussy Cancer Campus, Department of Medical Oncology, 94805 Villejuif, France.;Centre François Baclesse, Department of Medical Oncology, 14000 Caen, France.;Centre Eugène Marquis, Department of Medical Oncology, 35000 Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de la Méditerranée, 34090 Montpellier, France.;Centre Jean Perrin, Department of Medical Oncology, 63011 Clermont Ferrand, France.;Centre Oscar Lambret, Department of Medical Oncology, 59000 Lille, France.;Department of Medical Oncology, Institut Godinot, 51100 Reims, France.;Centre Paul Strauss, Department of Medical Oncology, 67200 Strasbourg, France.;Department of Medical Oncology, Institut Claudius Regaud, 31100 Toulouse, France.;Centre Georges Francois Leclerc, Department of Medical Oncology, 21000 Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Centre Léon Bérard, Department of Medical Oncology, 69008 Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54519 Nancy, France.;Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France.;Centre Antoine Lacassagne, Department of Medical Oncology, 06100 Nice, France.;Centre Henri Becquerel, Department of Medical Oncology, 76038 Rouen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 13009 Marseille, France.;Unicancer, Direction des Data, 75013 Paris, France.;Centre Léon Bérard, Department of Biostatistics, 69008 Lyon, France.;Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2023","15","10.3390/cancers15041191",NA,"","","36831532","36831532","PUBMED","Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.;Centre Léon Bérard, Department of Biostatistics, 69008 Lyon, France.;Gustave Roussy Cancer Campus, Department of Medical Oncology, 94805 Villejuif, France.;Centre François Baclesse, Department of Medical Oncology, 14000 Caen, France.;Centre Eugène Marquis, Department of Medical Oncology, 35000 Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de la Méditerranée, 34090 Montpellier, France.;Centre Jean Perrin, Department of Medical Oncology, 63011 Clermont Ferrand, France.;Centre Oscar Lambret, Department of Medical Oncology, 59000 Lille, France.;Department of Medical Oncology, Institut Godinot, 51100 Reims, France.;Centre Paul Strauss, Department of Medical Oncology, 67200 Strasbourg, France.;Department of Medical Oncology, Institut Claudius Regaud, 31100 Toulouse, France.;Centre Georges Francois Leclerc, Department of Medical Oncology, 21000 Dijon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 49055 Angers, France.;Centre Léon Bérard, Department of Medical Oncology, 69008 Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54519 Nancy, France.;Department of Medical Oncology, Institut Bergonié, 33076 Bordeaux, France.;Centre Antoine Lacassagne, Department of Medical Oncology, 06100 Nice, France.;Centre Henri Becquerel, Department of Medical Oncology, 76038 Rouen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 13009 Marseille, France.;Unicancer, Direction des Data, 75013 Paris, France.;Centre Léon Bérard, Department of Biostatistics, 69008 Lyon, France.;Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75005 Paris, France."
"189","Andrade E;Quinlan LR;Harte R;Reid-McDermott B;Kirrane F;Fallon E;Kelly M;Hall T;Scully M;Laffey J;Pladys P;Ryan E;Byrne D;ÓLaighin G","Andrade, Evismar;Quinlan, Leo R;Harte, Richard;Reid-McDermott, Bronwyn;Kirrane, Frank;Fallon, Enda;Kelly, Martina;Hall, Tony;Scully, Michael;Laffey, John;Pladys, Patrick;Ryan, Ethel;Byrne, Dara;ÓLaighin, Gearóid","The development and preliminary evaluation of a clinician e-learning training platform for a neonatal sepsis risk monitor for use in ICU settings.","Applied ergonomics","England","eng","Journal Article","E-learning;Human factors;Medical equipment;Patient monitoring system;Sepsis;Training;Usability","Infant, Newborn;Humans;Neonatal Sepsis;Computer-Assisted Instruction;Learning;Surveys and Questionnaires;Intensive Care Units","Infant, Newborn;Humans;Neonatal Sepsis;Computer-Assisted Instruction;Learning;Surveys and Questionnaires;Intensive Care Units","Training clinicians on the use of hospital-based patient monitoring systems (PMS) is vital to mitigate the risk of use errors and of frustration using these devices, especially when used in ICU settings. PMS training is typically delivered through face-to-face training sessions in the hospital. However, it is not always feasible to deliver training in this format to all clinical staff given some constraints (e.g., availability of staff and trainers to attend in-person training sessions and the costs associated with face-to-face training). The literature indicates that E-learning has the potential to mitigate barriers associated with time restrictions for trainers and trainees and evidence shows it to be more flexible, and convenient for learners in healthcare settings. This study aimed to develop and carry out a preliminary evaluation via a case study of an e-learning training platform designed for a novel neonatal sepsis risk monitor system (Digi-NewB). A multi-modal qualitative research case study approach was used, including the analysis of three qualitative data sources: (i) audio/video recordings of simulation sessions in which participants were asked to operate the system as intended (e.g., update the clinical observations and monitor the sepsis risk), (ii) interviews with the simulation participants and an attending key opinion leader (KOL), who observed all simulation sessions, and (iii) post-simulation survey. After receiving ethical approval for the study, nine neonatal intensive care unit (NICU) nurses completed the online training and participated in the simulation and follow-up interview sessions. The KOL was also interviewed, and seven out of the nine NICU nurses answered the post-simulation survey. The video/audio analysis of the simulations revealed that participants were able to use and interpret the Digi-NewB interface. Interviews with simulation participants and the KOL, and feedback extracted from the survey, revealed that participants were overall satisfied with the training platform and perceived it as an efficient and effective method to deliver medical device training. This study developed an online training platform to train clinicians in the use of a critical care medical device and carried out a preliminary evaluation of the platform via a case study. The e-learning platform was designed to supplement and enhance other training approaches. Further research is required to evaluate the effectiveness of this approach.","Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway, Ireland.;Physiology, School of Medicine, University of Galway, University Road, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Medical Physics and Clinical Engineering, University Hospital Galway, Galway, IE, Ireland.;Mechanical Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland.;Mechanical Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland.;School of Education, University of Galway, Galway, Ireland.;Anaesthesia, School of Medicine, Galway University Hospitals, Galway, IE, Ireland; Department of Anaesthesia & Intensive Care Medicine, Galway, IE, Ireland.;Anaesthesia, School of Medicine, Galway University Hospitals, Galway, IE, Ireland; Department of Anaesthesia & Intensive Care Medicine, Galway, IE, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France; Faculté de Médicine de l'Université de Rennes, Rennes, France.;Department of Paediatrics, University Hospital Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway","NA",0,"1872-9126","Appl Ergon","Appl Ergon",2022,"2023","109","10.1016/j.apergo.2023.103990","103990","","","36791557","36791557","PUBMED","Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway, Ireland.;Physiology, School of Medicine, University of Galway, University Road, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Medical Physics and Clinical Engineering, University Hospital Galway, Galway, IE, Ireland.;Mechanical Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland.;Mechanical Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland.;School of Education, University of Galway, Galway, Ireland.;Anaesthesia, School of Medicine, Galway University Hospitals, Galway, IE, Ireland; Department of Anaesthesia & Intensive Care Medicine, Galway, IE, Ireland.;Anaesthesia, School of Medicine, Galway University Hospitals, Galway, IE, Ireland; Department of Anaesthesia & Intensive Care Medicine, Galway, IE, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France; Faculté de Médicine de l'Université de Rennes, Rennes, France.;Department of Paediatrics, University Hospital Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, University of Galway, University Road, Galway, Ireland; Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, University of, Galway, University Road, Galway"
"190","de Langen AJ;Johnson ML;Mazieres J;Dingemans AC;Mountzios G;Pless M;Wolf J;Schuler M;Lena H;Skoulidis F;Yoneshima Y;Kim SW;Linardou H;Novello S;van der Wekken AJ;Chen Y;Peters S;Felip E;Solomon BJ;Ramalingam SS;Dooms C;Lindsay CR;Ferreira CG;Blais N;Obiozor CC;Wang Y;Mehta B;Varrieur T;Ngarmchamnanrith G;Stollenwerk B;Waterhouse D;Paz-Ares L","de Langen, Adrianus Johannes;Johnson, Melissa L;Mazieres, Julien;Dingemans, Anne-Marie C;Mountzios, Giannis;Pless, Miklos;Wolf, Jürgen;Schuler, Martin;Lena, Hervé;Skoulidis, Ferdinandos;Yoneshima, Yasuto;Kim, Sang-We;Linardou, Helena;Novello, Silvia;van der Wekken, Anthonie J;Chen, Yuanbin;Peters, Solange;Felip, Enriqueta;Solomon, Benjamin J;Ramalingam, Suresh S;Dooms, Christophe;Lindsay, Colin R;Ferreira, Carlos Gil;Blais, Normand;Obiozor, Cynthia C;Wang, Yang;Mehta, Bhakti;Varrieur, Tracy;Ngarmchamnanrith, Gataree;Stollenwerk, Björn;Waterhouse, David;Paz-Ares, Luis",NA,"Lancet (London, England)","England","eng","Randomized Controlled Trial","","Humans;Adolescent;Adult;Carcinoma, Non-Small-Cell Lung;Docetaxel;Proto-Oncogene Proteins p21(ras);Lung Neoplasms;Antineoplastic Agents;Mutation;Antineoplastic Combined Chemotherapy Protocols;Disease-Free Survival","Humans;Adolescent;Adult;Carcinoma, Non-Small-Cell Lung;Docetaxel;Proto-Oncogene Proteins p21(ras);Lung Neoplasms;Antineoplastic Agents;Mutation;Antineoplastic Combined Chemotherapy Protocols;Disease-Free Survival","Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS . We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS  mutation who had been previously treated with other anticancer drugs. We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRAS -mutated advanced NSCLC, who progressed after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRAS  for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRAS  inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m  once every 3 weeks) in an open-label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression-free survival, which was assessed by a blinded, independent central review in the intention-to-treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting. Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow-up of 17·7 months (IQR 16·4-20·1), the study met its primary endpoint of a statistically significant increase in the progression-free survival for sotorasib, compared with docetaxel (median progression-free survival 5·6 months [95% CI 4·3-7·8] vs 4·5 months [3·0-5·7]; hazard ratio 0·66 [0·51-0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment-related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment-related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]). Sotorasib significantly increased progression-free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRAS  mutation and who had been previously treated with other anticancer drugs. Amgen.","Netherlands Cancer Institute, Amsterdam, Netherlands.;Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA.;Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands.;Henry Dunant Hospital Center, Athens, Greece.;Department of Medical Oncology, Cancer Center Kantonsspital Winterthur, Winterthur, Switzerland.;Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;West German Cancer Center, University Hospital Essen, Essen, Germany.;Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou, Rennes, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Kyushu University Hospital, Fukuoka, Japan.;Asan Medical Center, Seoul, South Korea.;Metropolitan Hospital, Athens, Greece.;Department of Oncology, Università Degli Studi Di Torino-San Luigi Hospital Orbassano, Italy.;Department of Pulmonology and Tuberculosis, University of Groningen, Medical Centre Groningen, Groningen, Netherlands.;Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA.;Oncology Department-CHUV, Lausanne University, Lausanne, Switzerland.;Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.;Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.;Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.;Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium.;Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.;Oncoclinicas, Rio De Janeiro, Brazil.;Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen (Europe), Rotkreuz, Switzerland.;Oncology Hematology Care, Cincinnati, OH, USA.;Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University and Ciberonc, Madrid","NA",0,"1474-547X","Lancet","Lancet",2022,"2023","401","10.1016/S0140-6736(23)00221-0","733-746","","","36764316","36764316","PUBMED","Netherlands Cancer Institute, Amsterdam, Netherlands.;Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA.;Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands.;Henry Dunant Hospital Center, Athens, Greece.;Department of Medical Oncology, Cancer Center Kantonsspital Winterthur, Winterthur, Switzerland.;Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;West German Cancer Center, University Hospital Essen, Essen, Germany.;Centre Hospitalier Universitaire de Rennes-Hopital Pontchaillou, Rennes, France.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Kyushu University Hospital, Fukuoka, Japan.;Asan Medical Center, Seoul, South Korea.;Metropolitan Hospital, Athens, Greece.;Department of Oncology, Università Degli Studi Di Torino-San Luigi Hospital Orbassano, Italy.;Department of Pulmonology and Tuberculosis, University of Groningen, Medical Centre Groningen, Groningen, Netherlands.;Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA.;Oncology Department-CHUV, Lausanne University, Lausanne, Switzerland.;Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.;Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.;Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA.;Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium.;Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK.;Oncoclinicas, Rio De Janeiro, Brazil.;Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen, Thousand Oaks, CA, USA.;Amgen (Europe), Rotkreuz, Switzerland.;Oncology Hematology Care, Cincinnati, OH, USA.;Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Complutense University and Ciberonc, Madrid"
"191","Raoul JL;Moreau-Bachelard C;Gilabert M;Edeline J;Frénel JS","Raoul, J L;Moreau-Bachelard, C;Gilabert, M;Edeline, J;Frénel, J S","Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.","ESMO open","England","eng","Journal Article","chemotherapy drugs;drug–drug interactions;efficacy;immune checkpoint inhibitors;proton pump inhibitors;tyrosine kinase inhibitors","Humans;Proton Pump Inhibitors;Neoplasms;Treatment Failure;Antineoplastic Agents;Drug Interactions","Humans;Proton Pump Inhibitors;Neoplasms;Treatment Failure;Antineoplastic Agents;Drug Interactions","New concepts and drugs have revolutionized medical treatment for cancers. These drugs, which are very expensive and usually well tolerated, have dramatically improved cancer prognosis. We must use them wisely for patients to fully benefit. Gastric acid antisecretory drugs and particularly proton pump inhibitors (PPIs) revolutionized the treatment of gastroduodenal ulcers and severe gastroesophageal reflux, but are frequently overused for symptomatic treatment of epigastric pain or heartburn. Long-term acid suppression may alter the efficacy of many anticancer drugs, such as tyrosine kinase inhibitors (TKIs), cyclin-dependent kinase (CDK) 4/6 inhibitors and immune checkpoint inhibitors (ICIs), by either decreasing gastric acid secretion and thus drug absorption, or by modifying the gut microbiome that modulates the response to ICIs. Oncologists thus need to pay particular attention to the concomitant use of PPIs and anticancer drugs. These interactions translate into major clinical impacts, with demonstrated loss of efficacy for some TKIs (erlotinib, gefitinib, pazopanib), and conflicting results with many other oral drugs, including capecitabine and CDK 4/6 inhibitors. Furthermore, the profound changes in the gut microbiome due to using PPIs have shown that the benefit of using ICIs may be suppressed in patients treated with PPIs. As the use of PPIs is not essential, we must apply the precautionary principle. The first sentence of a recent Comment in Nature was ""Every day, millions of people are taking medications that will not help them"". We fear that every day millions of cancer patients are taking medications that harm them. While this may well be only association and not causation, there is enough to make us pause until we reach a clear answer. All these data should encourage medical oncologists to refrain from prescribing PPIs, explaining to patients the risks of interaction in order to prevent inappropriate prescription by another physician.","Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.","NA",0,"2059-7029","ESMO Open","ESMO Open",2022,"2023","8","10.1016/j.esmoop.2023.100880","100880","","","36764092","36764092","PUBMED","Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France."
"192","Poizeau F;Balusson F;Lemaitre F;Tron C;Pracht M;Russo D;Dinulescu M;Lesimple T;Oger E;Dupuy A","Poizeau, Florence;Balusson, Frédéric;Lemaitre, Florian;Tron, Camille;Pracht, Marc;Russo, David;Dinulescu, Monica;Lesimple, Thierry;Oger, Emmanuel;Dupuy, Alain","The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.","The British journal of dermatology","England","eng","Journal Article","","Humans;Proton Pump Inhibitors;Proto-Oncogene Proteins B-raf;Antineoplastic Combined Chemotherapy Protocols;Melanoma;Protein Kinase Inhibitors;Mitogen-Activated Protein Kinase Kinases","Humans;Proton Pump Inhibitors;Proto-Oncogene Proteins B-raf;Antineoplastic Combined Chemotherapy Protocols;Melanoma;Protein Kinase Inhibitors;Mitogen-Activated Protein Kinase Kinases","Proton-pump inhibitors (PPIs) are commonly used by patients with cancer, although they could reduce the absorption of oral anticancer targeted therapies. The US Food and Drug Administration states that the effect of PPIs on the efficacy of dabrafenib use by patients with metastatic melanoma is unknown. As a precautionary measure, the European Society for Medical Oncology recommends avoiding PPIs for patients receiving dabrafenib. To determine the effect of the concomitant use of PPIs and BRAF/MEK inhibitors in patients with metastatic melanoma. Patients with advanced melanoma receiving BRAF/MEK inhibitors as first-line treatments between 2015 and 2017 in France were selected using the French National Health Insurance database. We compared time-to-treatment discontinuation (TTD) and overall survival (OS) according to concomitant PPI exposure. We balanced the baseline characteristics of patients exposed and nonexposed to PPIs using an overlap weighting method based on a propensity score. The metastatic melanoma cohort comprised 1028 patients receiving BRAF/MEK inhibitors, including 361 (35.1%) patients using PPIs. PPI users had more comorbidities and a more severe metastatic disease. After having equally distributed metastatic sites and comorbidities across patients exposed and nonexposed to PPIs, concomitant PPI use was not associated with shorter TTD [weighted hazard ratio (wHR) 1.03, 95% confidence interval (CI) 0.86-1.24] or OS (wHR 1.11, 95% CI 0.88-1.39). Consistent results were observed when restricting the population to patients receiving dabrafenib, or when narrowing exposure to PPIs with stronger inhibition of cytochromes. In a population-based cohort of patients with advanced melanoma, the concomitant use of PPIs and BRAF/MEK inhibitors was not associated with worse outcome.","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Dermatology, CHU Rennes, Rennes, France.;Department of Dermatology, CHU Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France.","NA",0,"1365-2133","Br J Dermatol","Br J Dermatol",2022,"2023","188","10.1093/bjd/ljac085","482-490","","Ligue Contre le Cancer","36760148","36760148","PUBMED","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Dermatology, CHU Rennes, Rennes, France.;Department of Dermatology, CHU Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Dermatology, Univ Rennes, CHU Rennes, Rennes, France."
"193","Gangneux JP;Hoenigl M;Papon N","Gangneux, Jean-Pierre;Hoenigl, Martin;Papon, Nicolas","How to lose resistance to Aspergillus infections.","Trends in microbiology","England","eng","Journal Article","","Humans;Aspergillosis;Aspergillus;Neutrophils;Risk Factors;Aspergillus fumigatus","Humans;Aspergillosis;Aspergillus;Neutrophils;Risk Factors;Aspergillus fumigatus","The distinct risk factors to deadly infections by Aspergillus fumigatus (Af) in intensive care unit (ICU) patients are well known; however, so far, the mechanistic link between these predisposing conditions has been unknown. Sarden et al. recently unraveled a shared B1a lymphocyte-natural antibody-neutrophil defense pathway to Af, opening new perspectives in diagnostics and therapeutics.","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, F-35000 Rennes, France; Laboratoire de Parasitologie et Mycologie Médicale, LA-AspC Centre National de Référence des Mycoses et Antifongiques, European Excellence Center for Medical Mycology (ECMM), Centre hospitalier Universitaire de Rennes, F-35000 Rennes;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria; Translational Medical Mycology Research Unit, European Confederation of Medical Mycology (ECMM) Excellence Center, Medical University of Graz, Graz, Austria.;Univ Angers, Univ Brest, IRF, SFR ICAT, F-49000 Angers, France.","NA",0,"1878-4380","Trends Microbiol","Trends Microbiol",2023,"2023","31","10.1016/j.tim.2023.01.008","222-224","","","36754763","36754763","PUBMED","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, F-35000 Rennes, France; Laboratoire de Parasitologie et Mycologie Médicale, LA-AspC Centre National de Référence des Mycoses et Antifongiques, European Excellence Center for Medical Mycology (ECMM), Centre hospitalier Universitaire de Rennes, F-35000 Rennes;Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria; Translational Medical Mycology Research Unit, European Confederation of Medical Mycology (ECMM) Excellence Center, Medical University of Graz, Graz, Austria.;Univ Angers, Univ Brest, IRF, SFR ICAT, F-49000 Angers, France."
"194","Velev M;Dalban C;Chevreau C;Gravis G;Negrier S;Laguerre B;Gross-Goupil M;Ladoire S;Borchiellini D;Geoffrois L;Joly F;Priou F;Barthelemy P;Laramas M;Narciso B;Thiery-Vuillemin A;Berdah JF;Ferrari V;Dominique Thomas Q;Mione C;Curcio H;Oudard S;Tantot F;Escudier B;Chabaud S;Albiges L;Thibault C","Velev, Maud;Dalban, Cécile;Chevreau, Christine;Gravis, Gwenaelle;Negrier, Sylvie;Laguerre, Brigitte;Gross-Goupil, Marine;Ladoire, Sylvain;Borchiellini, Delphine;Geoffrois, Lionnel;Joly, Florence;Priou, Frank;Barthelemy, Philippe;Laramas, Mathieu;Narciso, Berangère;Thiery-Vuillemin, Antoine;Berdah, Jean-François;Ferrari, Victoria;Dominique Thomas, Quentin;Mione, Cécile;Curcio, Hubert;Oudard, Stephane;Tantot, Florence;Escudier, Bernard;Chabaud, Sylvie;Albiges, Laurence;Thibault, Constance","Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.","European journal of cancer (Oxford, England : 1990)","England","eng","Clinical Trial, Phase II","Bone metastases;Bone-targeting agent;Denosumab;Immune checkpoint inhibitors;Metastatic renal cell carcinoma;Nivolumab;Skeletal-related events;Survival analyses","Humans;Nivolumab;Carcinoma, Renal Cell;Retrospective Studies;Angiogenesis Inhibitors;Prospective Studies;Antineoplastic Agents, Immunological;Bone Neoplasms;Kidney Neoplasms","Humans;Nivolumab;Carcinoma, Renal Cell;Retrospective Studies;Angiogenesis Inhibitors;Prospective Studies;Antineoplastic Agents, Immunological;Bone Neoplasms;Kidney Neoplasms","Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone metastatic RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial. All patients with BM at inclusion were included in our study. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE). Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The median follow-up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post-hoc analysis evaluating the impact of bone-targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895]). Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE.","Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Service d'oncologie médicale, Université Paris Cité, 20 rue Leblanc, 75015, Paris;Centre Léon Bérard Direction de la Recherche Clinique et de l'Innovation, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon;Institut Universitaire du Cancer Toulouse-Oncopole, Service d'oncologie médicale, 1 Av. Irène Joliot-Curie, 31100, Toulouse;Institut Paoli Calmettes, Service d'oncologie médicale, 232 Bd de Sainte-Marguerite, 13009, Marseille;Centre Léon Bérard, université Lyon I, Service oncologie médicale, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon;Centre Eugene Marquis, Service d'oncologie médicale, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000, Rennes;Bordeaux University Hospital, Service d'oncologie medicale, Hôpital Pellegrin, Pl. Amélie Raba Léon, 33000, Bordeaux;Centre Georges François Leclerc, Service d'oncologie médicale, 1 Rue du Professeur Marion, 21000, Dijon;Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice;Institut de Cancérologie de Lorraine, Service d'oncologie médicale, 6 Av. de Bourgogne, Institut de Cancérologie de Lorraine, 54519, Vandoeuvre-lès-Nancy;Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen;Centre Hospitalier de Vendée, Service d'oncologie médicale, Bd Stéphane Moreau, 85000, La Roche sur Yon;Institut de Cancérologie Strasbourg Europe, Service d'oncologie médicale, 17 Rue Albert Calmette, 67200, Strasbourg;Grenoble Alpes University Hospital, Grenoble, Service d'oncologie médicale, Av. des Maquis du Grésivaudan, 38700 La Tronche;Tours University Hospital, Service d'oncologie médicale, 2 Bd Tonnellé, 37000, Tours;Hôpital Jean-Minjoz, Service d'oncologie médicale, 3 Bd Alexandre Fleming, 25000, Besançon;Centre Hospitalier de Hyères, Service d'oncologie médicale, Centre hospitalier d'Ajaccio, 27 Av. Impératrice Eugénie, 20000 Ajaccio;Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice;Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Service d'oncologie médicale, Parc Euromédecine, 208 Av. des Apothicaires, 34090, Montpellier;Université Clermont-Ferrand, 28 Pl. Henri Dunant, 63000, Clermont-Ferrand;Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen, France.;Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris;GETUG Group, Unicancer, 101 rue de Tolbiac, Paris;Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif;Centre Léon Bérard, Lyon, France.;Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif;Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2023","182","10.1016/j.ejca.2022.12.028","66-76","","","36746010","36746010","PUBMED","Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Service d'oncologie médicale, Université Paris Cité, 20 rue Leblanc, 75015, Paris;Centre Léon Bérard Direction de la Recherche Clinique et de l'Innovation, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon;Institut Universitaire du Cancer Toulouse-Oncopole, Service d'oncologie médicale, 1 Av. Irène Joliot-Curie, 31100, Toulouse;Institut Paoli Calmettes, Service d'oncologie médicale, 232 Bd de Sainte-Marguerite, 13009, Marseille;Centre Léon Bérard, université Lyon I, Service oncologie médicale, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon;Centre Eugene Marquis, Service d'oncologie médicale, Av. de la Bataille Flandres-Dunkerque CS 44229, 35000, Rennes;Bordeaux University Hospital, Service d'oncologie medicale, Hôpital Pellegrin, Pl. Amélie Raba Léon, 33000, Bordeaux;Centre Georges François Leclerc, Service d'oncologie médicale, 1 Rue du Professeur Marion, 21000, Dijon;Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice;Institut de Cancérologie de Lorraine, Service d'oncologie médicale, 6 Av. de Bourgogne, Institut de Cancérologie de Lorraine, 54519, Vandoeuvre-lès-Nancy;Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen;Centre Hospitalier de Vendée, Service d'oncologie médicale, Bd Stéphane Moreau, 85000, La Roche sur Yon;Institut de Cancérologie Strasbourg Europe, Service d'oncologie médicale, 17 Rue Albert Calmette, 67200, Strasbourg;Grenoble Alpes University Hospital, Grenoble, Service d'oncologie médicale, Av. des Maquis du Grésivaudan, 38700 La Tronche;Tours University Hospital, Service d'oncologie médicale, 2 Bd Tonnellé, 37000, Tours;Hôpital Jean-Minjoz, Service d'oncologie médicale, 3 Bd Alexandre Fleming, 25000, Besançon;Centre Hospitalier de Hyères, Service d'oncologie médicale, Centre hospitalier d'Ajaccio, 27 Av. Impératrice Eugénie, 20000 Ajaccio;Centre Antoine Lacassagne, Université Côte d'Azur, Service d'oncologie médicale, 33 Av. de Valombrose, 06100, Nice;Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Service d'oncologie médicale, Parc Euromédecine, 208 Av. des Apothicaires, 34090, Montpellier;Université Clermont-Ferrand, 28 Pl. Henri Dunant, 63000, Clermont-Ferrand;Centre François Baclesse, Service d'oncologie médicale, 3 Av. du Général Harris, 14000, Caen, France.;Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris;GETUG Group, Unicancer, 101 rue de Tolbiac, Paris;Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif;Centre Léon Bérard, Lyon, France.;Gustave Roussy Cancer Campus, Université Paris-Saclay, Service d'oncologie médicale, 114 Rue Edouard Vaillant, 94805, Villejuif;Departement of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, APHP-Centre, Université Paris Cité, Service d'oncologie médicale, 20 rue Leblanc, 75015, Paris"
"195","Guerin M;Miran C;Colomba E;Cabart M;Herrmann T;Pericart S;Maillet D;Neuzillet Y;Deleuze A;Coquan E;Laramas M;Thibault C;Abbar B;Mesnard B;Borchiellini D;Dumont C;Boughalem E;Deville JL;Cancel M;Saldana C;Khalil A;Baciarello G;Flechon A;Walz J;Gravis G","Guerin, M;Miran, C;Colomba, E;Cabart, M;Herrmann, T;Pericart, S;Maillet, D;Neuzillet, Y;Deleuze, A;Coquan, E;Laramas, M;Thibault, C;Abbar, B;Mesnard, B;Borchiellini, D;Dumont, C;Boughalem, E;Deville, J L;Cancel, M;Saldana, C;Khalil, A;Baciarello, G;Flechon, A;Walz, J;Gravis, G","Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group.","Frontiers in oncology","Switzerland","eng","Journal Article","multicentric;rare disease;retrospective;urachal cancer;urachus","","","Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome, the most common histological subtype of UrC is adenocarcinoma. UrC develops from an embryonic remnant, and is frequently diagnosed in advanced stage with poor prognosis. The treatment is not standardized, and based only on case reports and small series. This large retrospective multicentric study was conducted by the French Genito-Urinary Tumor Group to gain a better understanding of UrC. data has been collected retrospectively on 97 patients treated at 22 French Cancer Centers between 1996 and 2020. The median follow-up was 59 months (range 44-96). The median age at diagnosis was 53 years (range 20-86), 45% were females and 23% had tobacco exposure. For patients with localized disease (Mayo I-II, n=46) and with lymph-node invasion (Mayo III, n=13) median progression-free-survival (mPFS) was 31 months (95% CI: 20-67) and 7 months (95% CI: 6-not reached (NR)), and median overall survival (mOS) was 73 months (95% CI: 57-NR) and 22 months (95% CI: 21-NR) respectively. For 45 patients with Mayo I-III had secondary metastatic progression, and 20 patients were metastatic at diagnosis. Metastatic localization was peritoneal for 54% of patients. Most patients with localized tumor were treated with partial cystectomy, with mPFS of 20 months (95% CI: 14-49), and only 12 patients received adjuvant therapy. Metastatic patients (Mayo IV) had a mOS of 23 months (95% CI: 19-33) and 69% received a platin-fluorouracil combination treatment. UrC is a rare tumor of the bladder where patients are younger with a higher number of females, and a lower tobacco exposure than in standard urothelial carcinoma. For localized tumor, partial cystectomy is recommended. The mOS and mPFS were low, notably for patients with lymph node invasion. For metastatic patients the prognosis is poor and standard therapy is not well-defined. Further clinical and biological knowledge are needed.","Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Leon-Berard, Lyon, France.;Department of Cancer Medicine, Institut Gustave-Roussy, University of Paris Saclay, Villejuif, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Jean-Perrin, Clermont-Ferrand, France.;Department of Anatomo-pathology, Institut Universitaire du Cancer, Centre Hospital-Universitaire de Toulouse, Toulouse, France.;Department of Medical Oncology, Centre hospitalo-Universitaire Hospices civils, Lyon, France.;Department of Urology, Hopital Foch, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire, Grenoble, France.;Department of Medical Oncology, Hopital Europeen Georges Pompidou, Paris, France.;Department of Medical Oncology, Hopital Pitié-Salpetriere, Paris, France.;Department of Urology, Centre Hospitalo-Universitaire, Nantes, France.;Department of Medical Oncology, Centre Lacassagne, Nice, France.;Department of Medical Oncology, Hopital Saint-Louis, Paris, France.;Department of Medical Oncology, Centre Paul Papin, Angers, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire Timone, Marseille, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire Bretonneau, Tours, France.;Department of Medical Oncology, Hopital Henri Mondor, Paris, France.;Department of Medical Oncology, Hopital tenon, Paris, France.;Department of Cancer Medicine, Institut Gustave-Roussy, University of Paris Saclay, Villejuif, France.;Department of Medical Oncology, Centre Leon-Berard, Lyon, France.;Department of Urology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2022,"2023","13","10.3389/fonc.2023.1110003","1110003","","","36741023","36741023","PUBMED","Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Leon-Berard, Lyon, France.;Department of Cancer Medicine, Institut Gustave-Roussy, University of Paris Saclay, Villejuif, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Jean-Perrin, Clermont-Ferrand, France.;Department of Anatomo-pathology, Institut Universitaire du Cancer, Centre Hospital-Universitaire de Toulouse, Toulouse, France.;Department of Medical Oncology, Centre hospitalo-Universitaire Hospices civils, Lyon, France.;Department of Urology, Hopital Foch, Paris, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire, Grenoble, France.;Department of Medical Oncology, Hopital Europeen Georges Pompidou, Paris, France.;Department of Medical Oncology, Hopital Pitié-Salpetriere, Paris, France.;Department of Urology, Centre Hospitalo-Universitaire, Nantes, France.;Department of Medical Oncology, Centre Lacassagne, Nice, France.;Department of Medical Oncology, Hopital Saint-Louis, Paris, France.;Department of Medical Oncology, Centre Paul Papin, Angers, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire Timone, Marseille, France.;Department of Medical Oncology, Centre Hospitalo-Universitaire Bretonneau, Tours, France.;Department of Medical Oncology, Hopital Henri Mondor, Paris, France.;Department of Medical Oncology, Hopital tenon, Paris, France.;Department of Cancer Medicine, Institut Gustave-Roussy, University of Paris Saclay, Villejuif, France.;Department of Medical Oncology, Centre Leon-Berard, Lyon, France.;Department of Urology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France."
"196","Kubicek P;Cesne AL;Lervat C;Toulmonde M;Chevreau C;Duffaud F;Le Nail LR;Morelle M;Gaspar N;Vérité C;Castex MP;Penel N;Saada E;Causeret S;Bertucci F;Perrin C;Bompas E;Orbach D;Laurence V;Piperno-Neumann S;Anract P;Rios M;Gentet JC;Mascard É;Pannier S;Blouin P;Carrère S;Chaigneau L;Soibinet-Oudot P;Corradini N;Boudou-Rouquette P;Ruzic JC;Lebrun-Ly V;Dubray-Longeras P;Varatharajah S;Lebbe C;Ropars M;Kurtz JE;Guillemet C;Lotz JP;Berchoud J;Cherrier G;Ducimetière F;Chemin C;Italiano A;Honoré C;Desandes E;Blay JY;Gouin F;Marec-Bérard P","Kubicek, Pierre;Cesne, Axel Le;Lervat, Cyril;Toulmonde, Maud;Chevreau, Christine;Duffaud, Florence;Le Nail, Louis-Romée;Morelle, Magali;Gaspar, Nathalie;Vérité, Cécile;Castex, Marie-Pierre;Penel, Nicolas;Saada, Esma;Causeret, Sylvain;Bertucci, François;Perrin, Christophe;Bompas, Emmanuelle;Orbach, Daniel;Laurence, Valérie;Piperno-Neumann, Sophie;Anract, Philippe;Rios, Maria;Gentet, Jean-Claude;Mascard, Éric;Pannier, Stéphanie;Blouin, Pascale;Carrère, Sébastien;Chaigneau, Loïc;Soibinet-Oudot, Pauline;Corradini, Nadège;Boudou-Rouquette, Pascaline;Ruzic, Jean-Christophe;Lebrun-Ly, Valérie;Dubray-Longeras, Pascale;Varatharajah, Sharmini;Lebbe, Céleste;Ropars, Mickaël;Kurtz, Jean-Emmanuel;Guillemet, Cécile;Lotz, Jean-Pierre;Berchoud, Juliane;Cherrier, Grégory;Ducimetière, Françoise;Chemin, Claire;Italiano, Antoine;Honoré, Charles;Desandes, Emmanuel;Blay, Jean-Yves;Gouin, François;Marec-Bérard, Perrine","Management and outcomes of adolescent and young adult sarcoma patients: results from the French nationwide database NETSARC.","BMC cancer","England","eng","Journal Article","AYAs;Adolescents and young adults;Management;Multidisciplinary tumor board;NETSARC;Reference centers;Sarcoma;Survival","Humans;Adolescent;Young Adult;Child;Prospective Studies;Sarcoma;Soft Tissue Neoplasms;Databases, Factual;Progression-Free Survival","Humans;Adolescent;Young Adult;Child;Prospective Studies;Sarcoma;Soft Tissue Neoplasms;Databases, Factual;Progression-Free Survival","The initial management of patients with sarcoma is a critical issue. We used the nationwide French National Cancer Institute-funded prospective sarcoma database NETSARC to report the management and oncologic outcomes in adolescents and young adults (AYAs) patients with sarcoma at the national level. NETSARC database gathers regularly monitored and updated data from patients with sarcoma. NETSARC was queried for patients (15-30 years) with sarcoma diagnosed from 2010 to 2017 for whom tumor resection had been performed. We reported management, locoregional recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) in AYA treated in French reference sarcoma centers (RSC) and outside RSC (non-RSC) and conducted multivariable survival analyses adjusted for classical prognostic factors. Among 3,227 patients aged 15-30 years with sarcoma diagnosed between 2010 and 2017, the study included 2,227 patients with surgery data available, among whom 1,290 AYAs had been operated in RSC, and 937 AYAs in non-RSC. Significant differences in compliance to guidelines were observed including pre-treatment biopsy (RSC: 85.9%; non-RSC 48.1%), pre-treatment imaging (RSC: 86.8%; non-RSC: 56.5%) and R0 margins (RSC 57.6%; non-RSC: 20.2%) (p < 0.001). 3y-OS rates were 81.1% (95%CI 78.3-83.6) in AYA in RSC and 82.7% (95%CI 79.4-85.5) in AYA in non-RSC, respectively. Whereas no significant differences in OS was observed in AYAs treated in RSC and in non-RSC, LRFS and PFS were improved in AYAs treated in RSC compared to AYAs treated in non-RSC (Hazard Ratios (HR): 0.58 and 0.83, respectively). This study highlights the importance for AYA patients with sarcoma to be managed in national sarcoma reference centers involving multidisciplinary medical teams with paediatric and adult oncologists.","Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers;Centre Léon Bérard, Lyon;Gustave Roussy, Villejuif, France.;Centre Oscar Lambret, Lille, France.;Institut Bergonié, Bordeaux, France.;Institut Claudius Régaud IUCT Toulouse, Toulouse, France.;CHU Timone, Marseille, France.;CHU Tours, Tours, France.;Centre Léon Bérard, Lyon, France.;Gustave Roussy, Villejuif, France.;Institut Bergonié, Bordeaux, France.;CHU Toulouse, Toulouse, France.;Centre Oscar Lambret, Lille, France.;Centre Antoine Lacassagne, Nice, France.;Centre Georges François Leclerc, Dijon, France.;Institut Paoli-Calmettes, Marseille, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;Hôpital Cochin, Paris, France.;Institut de Cancérologie de Lorraine, Nancy, France.;CHU Timone, Marseille, France.;Hôpital Necker, Paris, France.;Hôpital Necker, Paris, France.;CHU Tours, Tours, France.;Centre Val d'Aurelle ICM, Montpellier, France.;CHU Besançon, Besançon, France.;Institut Jean Godinot, Reims, France.;Institute of Pediatric Hematology and Oncology, Lyon, France.;Hôpital Cochin, Paris, France.;CHU La Réunion Mayotte, Saint-Pierre, France.;CHU Limoges, Limoges, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Centre François Baclesse, Caen, France.;Hôpital Saint-Louis, Paris, France.;CHU Rennes, Rennes, France.;Institut de Cancérologie Strasbourg-Europe ICANS, Strasbourg, France.;Centre Henri Becquerel, Rouen, France.;Hôpital Tenon, Paris, France.;CHU Nantes, Nantes, France.;CHU Tours, Tours, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Gustave Roussy, Villejuif, France.;Institut Bergonié, Bordeaux, France.;Gustave Roussy, Villejuif, France.;CHRU Nancy, Centre de Recherche en Epidémiologie et en Statistique Sorbonne-Paris Cité (CRESS), UMR 1153, INSERM, Université de Paris-Descartes, Paris, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;CHU Nantes, Nantes, France.;Centre Léon Bérard, Lyon, France.;Institute of Pediatric Hematology and Oncology, Lyon, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2022,"2023","23","10.1186/s12885-023-10556-4","69","","","36670431","36670431","PUBMED","Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers;Centre Léon Bérard, Lyon;Gustave Roussy, Villejuif, France.;Centre Oscar Lambret, Lille, France.;Institut Bergonié, Bordeaux, France.;Institut Claudius Régaud IUCT Toulouse, Toulouse, France.;CHU Timone, Marseille, France.;CHU Tours, Tours, France.;Centre Léon Bérard, Lyon, France.;Gustave Roussy, Villejuif, France.;Institut Bergonié, Bordeaux, France.;CHU Toulouse, Toulouse, France.;Centre Oscar Lambret, Lille, France.;Centre Antoine Lacassagne, Nice, France.;Centre Georges François Leclerc, Dijon, France.;Institut Paoli-Calmettes, Marseille, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancérologie de l'Ouest, Nantes, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;Hôpital Cochin, Paris, France.;Institut de Cancérologie de Lorraine, Nancy, France.;CHU Timone, Marseille, France.;Hôpital Necker, Paris, France.;Hôpital Necker, Paris, France.;CHU Tours, Tours, France.;Centre Val d'Aurelle ICM, Montpellier, France.;CHU Besançon, Besançon, France.;Institut Jean Godinot, Reims, France.;Institute of Pediatric Hematology and Oncology, Lyon, France.;Hôpital Cochin, Paris, France.;CHU La Réunion Mayotte, Saint-Pierre, France.;CHU Limoges, Limoges, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Centre François Baclesse, Caen, France.;Hôpital Saint-Louis, Paris, France.;CHU Rennes, Rennes, France.;Institut de Cancérologie Strasbourg-Europe ICANS, Strasbourg, France.;Centre Henri Becquerel, Rouen, France.;Hôpital Tenon, Paris, France.;CHU Nantes, Nantes, France.;CHU Tours, Tours, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Gustave Roussy, Villejuif, France.;Institut Bergonié, Bordeaux, France.;Gustave Roussy, Villejuif, France.;CHRU Nancy, Centre de Recherche en Epidémiologie et en Statistique Sorbonne-Paris Cité (CRESS), UMR 1153, INSERM, Université de Paris-Descartes, Paris, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;CHU Nantes, Nantes, France.;Centre Léon Bérard, Lyon, France.;Institute of Pediatric Hematology and Oncology, Lyon, France."
"197","Cinotti R;Roquilly A;Chopin A;Martin FP;Morato Y;Lerebourg C;Moyer JD;Huet O;Lasocki S;Cohen B;Dahyot-Fizelier C;Chalard K;Seguin P;Chenet A;Perrouin-Verbe B;Sinha D;Asehnoune K;Feuillet F;Sébille V","Cinotti, Raphaël;Roquilly, Antoine;Chopin, Alice;Martin, Florian Pierre;Morato, Yoanna;Lerebourg, Céline;Moyer, Jean Denis;Huet, Olivier;Lasocki, Sigismond;Cohen, Benjamin;Dahyot-Fizelier, Claire;Chalard, Kevin;Seguin, Philippe;Chenet, Amandine;Perrouin-Verbe, Brigitte;Sinha, Debajyoti;Asehnoune, Karim;Feuillet, Fanny;Sébille, Véronique","Relationship between health-related quality-of-life and functional outcome 6 months after moderate to severe TBI.","Annals of physical and rehabilitation medicine","Netherlands","eng","Letter","Functional outcome;GOS-extended;Health-related quality of life;Post-intensive care syndrome;SF-36;Traumatic brain injury","Humans;Brain Injuries, Traumatic;Quality of Life","Humans;Brain Injuries, Traumatic;Quality of Life","NA","CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris.;Centre Hospitalier Universitaire de Brest, Anaesthesia and Intensive Care Unit, Brest, France.;Centre Hospitalier Universitaire d'Angers, Anaesthesia and Intensive Care Unit, Angers, France.;Centre Hospitalier Universitaire de Tours, Anaesthesia and Intensive Care Unit, Tours, France.;Centre Hospitalier Universitaire de Potiers, Anaesthesia and Intensive Care Unit, Poitiers, France.;Centre Hospitalier Universitaire de Montpellier, Anaesthesia and Intensive Care Unit, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Anaesthesia and Intensive Care Unit, Rennes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Plateforme de Méthodologie et Biostatistique, Direction Recherche et Innovation, CHU Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.","NA",0,"1877-0665","Ann Phys Rehabil Med","Ann Phys Rehabil Med",2022,"2023","66","10.1016/j.rehab.2022.101715","101715","","","36652785","36652785","PUBMED","CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France.;Department of Anesthesiology and Critical Care, Beaujon Hospital, DMU Parabol, AP-HP Nord, Paris.;Centre Hospitalier Universitaire de Brest, Anaesthesia and Intensive Care Unit, Brest, France.;Centre Hospitalier Universitaire d'Angers, Anaesthesia and Intensive Care Unit, Angers, France.;Centre Hospitalier Universitaire de Tours, Anaesthesia and Intensive Care Unit, Tours, France.;Centre Hospitalier Universitaire de Potiers, Anaesthesia and Intensive Care Unit, Poitiers, France.;Centre Hospitalier Universitaire de Montpellier, Anaesthesia and Intensive Care Unit, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Anaesthesia and Intensive Care Unit, Rennes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Rehabilitation, Hôpital Saint-Jacques, F-44000 Nantes, France.;Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;CHU Nantes, Nantes Université, Department of Anaesthesia and critical care, Hôtel Dieu, F-44000 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Plateforme de Méthodologie et Biostatistique, Direction Recherche et Innovation, CHU Nantes, France.;UMR 1246 SPHERE ""MethodS in Patients-centered outcomes and HEalth Research"", University of Nantes, University of Tours, INSERM, IRS2 22 Boulevard Benoni Goulin, 44200 Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France."
"198","Brouillard-Saby F;Saint-Martin C;Ray-Coquard I;Gladieff L;Pomel C;Colombo PE;Classe JM;Chevrier M;Joly F;De la Motte Rouge T;Floquet A;Sabatier R;Barranger E;Costaz H;Leblanc E;Marchal F;Pautier P;Bosquet L;Rodrigues M","Brouillard-Saby, Flora;Saint-Martin, Caroline;Ray-Coquard, Isabelle;Gladieff, Laurence;Pomel, Christophe;Colombo, Pierre-Emmanuel;Classe, Jean-Marc;Chevrier, Marion;Joly, Florence;De la Motte Rouge, Thibault;Floquet, Anne;Sabatier, Renaud;Barranger, Emmanuel;Costaz, Hélène;Leblanc, Eric;Marchal, Frédéric;Pautier, Patricia;Bosquet, Lise;Rodrigues, Manuel",NA,"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","England","eng","Multicenter Study","BRCA1 Protein;Cystadenocarcinoma, Serous;Gynecology;Neoplasm Recurrence, Local;Ovarian Cancer","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Carboplatin;Deoxycytidine;Doxorubicin;Neoplasm Recurrence, Local;Ovarian Neoplasms;Paclitaxel;Platinum;Polyethylene Glycols;Retrospective Studies;Tumor Suppressor Proteins","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Carboplatin;Deoxycytidine;Doxorubicin;Neoplasm Recurrence, Local;Ovarian Neoplasms;Paclitaxel;Platinum;Polyethylene Glycols;Retrospective Studies;Tumor Suppressor Proteins","Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to   data,   mutated patients are sensitive to replicative stress agents but   status is not yet used for the choice of chemotherapy at relapse. Our aim was to assess these doublets according to   status in first platinum-sensitive relapse. The ESME ovarian cancer database comprises a multicenter retrospective cohort of patients with ovarian cancer treated in French cancer centers between January 2011 and December 2017. Patients with high-grade serous ovarian cancers at first platinum-sensitive relapse who received one of these doublets were included. The objective was to compare progression-free survival of each chemotherapy doublet according to   status. Among the 10 263 patients in the database, 1539 patients had a first platinum-sensitive relapse: 825   wild type patients (53.6%) and 304   mutated patients (19.8%) (7 patients had a homologous recombination mutation and   status was unkown for 403 patients). Median progression-free survival was longer in   mutated patients than in   wild type patients when receiving carboplatin/pegylated liposomal doxorubicin without maintenance treatment (15.8 vs 11.8 months; p<0.001). In contrast, we observed no difference in patients treated with carboplatin/paclitaxel (14.6 vs 14.3 months, respectively; p=0.70) or in those treated with carboplatin/gemcitabine (12.0 vs 9.8 months, respectively; p=0.18). In   wild type patients without maintenance, better progression-free survival occurred with carboplatin/paclitaxel (median progression-free survival 14.3 months) than with carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin (9.8 and 11.8 months, respectively; p=0.017). In   mutated patients without maintenance, there was no difference between the three doublets (median progression-free survival of 14.6, 12.0, and 15.8 months with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin, respectively; p=0.40). While treatment with carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin shows comparable efficacy in   mutated patients, treatment with carboplatin/paclitaxel appears to be more effective than carboplatin/gemcitabine and carboplatin/pegylated liposomal doxorubicin in   wild type patients with high-grade serous ovarian cancers at first platinum-sensitive relapse.","Medical Oncology, Institut Curie, Paris, France.;Biostatistics, Institut Curie, Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Hesper Lab, Université Claude Bernard Lyon 1, Villeurbanne, France.;Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Surgical Oncology, Institut Jean Perrin, Clermont-Ferrand, France.;Surgical Oncology, Institut régional du Cancer de Montpellier, Montpellier, France.;Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Biostatistics, Institut Curie, Paris, France.;Medical Oncology, Centre Francois Baclesse, Caen, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Medical Oncology, Paoli-Calmettes Institute, Marseille, France.;SESSTIM, Marseille, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, France.;Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Surgical Oncology, Centre Oscar Lambret, Lille, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, Lorraine, France.;Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;Medical Oncology, Institut Curie, Paris;INSERM U830, Institut Curie, Paris, France.","NA",0,"1525-1438","Int J Gynecol Cancer","Int J Gynecol Cancer",2023,"2023","33","10.1136/ijgc-2022-003993","577-584","","","36631150","36631150","PUBMED","Medical Oncology, Institut Curie, Paris, France.;Biostatistics, Institut Curie, Paris, France.;Medical Oncology, Centre Leon Berard, Lyon, France.;Hesper Lab, Université Claude Bernard Lyon 1, Villeurbanne, France.;Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Surgical Oncology, Institut Jean Perrin, Clermont-Ferrand, France.;Surgical Oncology, Institut régional du Cancer de Montpellier, Montpellier, France.;Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Biostatistics, Institut Curie, Paris, France.;Medical Oncology, Centre Francois Baclesse, Caen, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Institut Bergonié, Bordeaux, France.;Medical Oncology, Paoli-Calmettes Institute, Marseille, France.;SESSTIM, Marseille, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, France.;Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Surgical Oncology, Centre Oscar Lambret, Lille, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, Lorraine, France.;Medical Oncology, Gustave Roussy, Villejuif, France.;UNICANCER, Paris, France.;Medical Oncology, Institut Curie, Paris;INSERM U830, Institut Curie, Paris, France."
"199","Bellier C;Gladieff L;Le Du F;Berton D;Bonnard C;Suau D;Richard AC;Brenner O;Lahouegue A;Freyer G;Floquet A;Frank S;Kfoury M","Bellier, Charlotte;Gladieff, Laurence;Le Du, Fanny;Berton, Dominique;Bonnard, Charlotte;Suau, Delphine;Richard, Anne-Céline;Brenner, Ophélie;Lahouegue, Amir;Freyer, Gilles;Floquet, Anne;Frank, Sophie;Kfoury, Maria","Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.","Drugs - real world outcomes","Switzerland","eng","Journal Article","","","","Olaparib, a poly(ADP-ribose) polymerase inhibitor, was approved by the European Commission in June 2019, following the results of the SOLO-1/GOG 3004 trial as maintenance monotherapy in adult patients with BRCA-mutated epithelial ovarian cancer. This study aimed to provide a descriptive analysis of the first real-world data from patients with BRCA-mutated ovarian cancer who received olaparib as first-line maintenance monotherapy in the French cohort Temporary Authorisation for Use (Autorisation Temporaire d'Utilisation de cohorte, ATUc) programme from 11 March, 2019 to 16 January, 2020. Eligible patients were aged 18 years and over with confirmed epithelial ovarian, primary peritoneal or Fallopian tube cancer and a deleterious or suspected deleterious germline or somatic BRCA 1/2 mutation. Patients were in complete or partial clinical response at the end of first-line platinum-based chemotherapy. Olaparib maintenance therapy was initiated within 8 weeks of the patients' last dose of chemotherapy. Real-world data were collected through treatment access request forms completed by physicians. Clinical and safety data were collected monthly until the end of the ATUc programme. A total of 107 centres in metropolitan France and the French Overseas Departments and Territories requested the inclusion for 238 patients, of whom 194 received maintenance olaparib. In total, 87.6% of the primary tumour locations were ovary, the most common histology was high-grade serous (93.0%) and the most common International Federation of Gynaecology and Obstetrics (Fédération Internationale de Gynécologie et d'Obstétrique) stage was IIIC (56.8%). BRCA testing was performed in routine practice, prior to inclusion into the ATUc programme. All patients had a BRCA mutation: 52.5% had a somatic mutation, 38.4% had a germinal mutation and 9.1% had germinal and somatic mutations. Twenty-four (12%) patients experienced serious adverse drug reactions at the last safety follow-up (17 February, 2020). The most common were anaemia (12 [6%] patients), neutropenia (3 [2%] patients) and thrombocytopenia (3 [2%] patients). The rapid enrolment into the ATUc programme highlighted the strong unmet need for patients with ovarian cancer and a BRCA mutation in first-line maintenance treatment. Olaparib was well tolerated and no new safety signals were observed in this real-world patient population.","Centre Oscar Lambret, Lille;IUCT Oncopôle, Institut Claudius Regaud, Toulouse, France.;Centre Eugène-Marquis, Rennes, France.;Institut de Cancérologie de l'ouest, Saint-Herblain, France.;AstraZeneca Medical Affairs, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;Hôpital Lyon Sud HCL, Pierre-Bénite, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Gustave Roussy, Villejuif, France.","NA",0,"2199-1154","Drugs Real World Outcomes","Drugs Real World Outcomes",2022,"2023","10","10.1007/s40801-022-00349-9","207-213","","","36630055","36630055","PUBMED","Centre Oscar Lambret, Lille;IUCT Oncopôle, Institut Claudius Regaud, Toulouse, France.;Centre Eugène-Marquis, Rennes, France.;Institut de Cancérologie de l'ouest, Saint-Herblain, France.;AstraZeneca Medical Affairs, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;AstraZeneca Pharmaceutical Pole, Courbevoie, France.;Hôpital Lyon Sud HCL, Pierre-Bénite, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Gustave Roussy, Villejuif, France."
"200","Leclerc D;Goujon L;Jaillard S;Nouyou B;Cluzeau L;Damaj L;Dubourg C;Etcheverry A;Levade T;Froissart R;Dréano S;Guillory X;Eriksson LA;Launay E;Mouriaux F;Belaud-Rotureau MA;Odent S;Gilot D","Leclerc, Delphine;Goujon, Louise;Jaillard, Sylvie;Nouyou, Bénédicte;Cluzeau, Laurence;Damaj, Léna;Dubourg, Christèle;Etcheverry, Amandine;Levade, Thierry;Froissart, Roseline;Dréano, Stéphane;Guillory, Xavier;Eriksson, Leif A;Launay, Erika;Mouriaux, Frédéric;Belaud-Rotureau, Marc-Antoine;Odent, Sylvie;Gilot, David",NA,"The CRISPR journal","United States","eng","Journal Article","","Humans;Gangliosidosis, GM1;beta-Galactosidase;Gene Editing;CRISPR-Cas Systems;Alleles","Humans;Gangliosidosis, GM1;beta-Galactosidase;Gene Editing;CRISPR-Cas Systems;Alleles","Ganglioside-monosialic acid (GM1) gangliosidosis, a rare autosomal recessive disorder, is frequently caused by deleterious single nucleotide variants (SNVs) in   gene. These variants result in reduced β-galactosidase (β-gal) activity, leading to neurodegeneration associated with premature death. Currently, no effective therapy for GM1 gangliosidosis is available. Three ongoing clinical trials aim to deliver a functional copy of the   gene to stop disease progression. In this study, we show that 41% of   pathogenic SNVs can be replaced by adenine base editors (ABEs). Our results demonstrate that ABE efficiently corrects the pathogenic allele in patient-derived fibroblasts, restoring therapeutic levels of β-gal activity. Off-target DNA analysis did not detect off-target editing activity in treated patient's cells, except a bystander edit without consequences on β-gal activity based on 3D structure bioinformatics predictions. Altogether, our results suggest that gene editing might be an alternative strategy to cure GM1 gangliosidosis.","INSERM U1242, OSS, Univ Rennes, Rennes, France.;CHU Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, FHU GenOMEDS, ERN ITHACA, Hôpital Sud, Rennes, France.;INSERM, EHESP, IRSET-UMR_S, 1085, Université Rennes 1, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Department of Pediatrics, Competence Center of Inherited Metabolic Disorders, Rennes Hospital, Rennes, France.;Laboratoire de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;Laboratoire de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biochimie, CHU de Toulouse, Pôle biologie, Institut Fédératif de Biologie, Toulouse, France.;CHU Lyon HCL, LBMMS-Service Biochimie et Biologie Moléculaire, UM Pathologies Héréditaires du Métabolisme et du Globule Rouge, Bron, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Rennes, France.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Department of Ophthalmology, CHU Rennes, Univ Rennes, Rennes, France.;INSERM, EHESP, IRSET-UMR_S, 1085, Université Rennes 1, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;CHU Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, FHU GenOMEDS, ERN ITHACA, Hôpital Sud, Rennes, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.","NA",0,"2573-1602","CRISPR J","CRISPR J",2023,"2023","6","10.1089/crispr.2022.0045","17-31","","","36629845","36629845","PUBMED","INSERM U1242, OSS, Univ Rennes, Rennes, France.;CHU Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, FHU GenOMEDS, ERN ITHACA, Hôpital Sud, Rennes, France.;INSERM, EHESP, IRSET-UMR_S, 1085, Université Rennes 1, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;Department of Pediatrics, Competence Center of Inherited Metabolic Disorders, Rennes Hospital, Rennes, France.;Laboratoire de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;Laboratoire de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biochimie, CHU de Toulouse, Pôle biologie, Institut Fédératif de Biologie, Toulouse, France.;CHU Lyon HCL, LBMMS-Service Biochimie et Biologie Moléculaire, UM Pathologies Héréditaires du Métabolisme et du Globule Rouge, Bron, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Rennes, France.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Department of Ophthalmology, CHU Rennes, Univ Rennes, Rennes, France.;INSERM, EHESP, IRSET-UMR_S, 1085, Université Rennes 1, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France.;CHU Rennes, Service de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, FHU GenOMEDS, ERN ITHACA, Hôpital Sud, Rennes, France.;Univ Rennes, CNRS, IGDR (Institut de Génétique et Développement de Rennes), UMR 6290, ERL U1305, Rennes, France.;INSERM U1242, OSS, Univ Rennes, Rennes, France.;Service de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, France."
"201","Goudot G;Berkane Y;de Clermont-Tonnerre E;Guinier C;Filz von Reiterdank I;van Kampen A;Uygun K;Cetrulo CL;Uygun BE;Dua A;Lellouch AG","Goudot, Guillaume;Berkane, Yanis;de Clermont-Tonnerre, Eloi;Guinier, Claire;Filz von Reiterdank, Irina;van Kampen, Antonia;Uygun, Korkut;Cetrulo, Curtis L;Uygun, Basak E;Dua, Anahita;Lellouch, Alexandre G","Microvascular assessment of fascio-cutaneous flaps by ultrasound: A large animal study.","Frontiers in physiology","Switzerland","eng","Journal Article","MV-Flow;Microvascular flow imaging;flap surgery;microcirculation;microvascularization;pig;vascularity index","",""," Blood perfusion quality of a flap is the main prognostic factor for success. Microvascular evaluation remains mostly inaccessible. We aimed to evaluate the microflow imaging mode, MV-Flow, in assessing flap microvascularization in a pig model of the fascio-cutaneous flap.   On five pigs, bilateral saphenous fascio-cutaneous flaps were procured on the superficial femoral vessels. A conventional ultrasound evaluation in pulsed Doppler and color Doppler was conducted on the ten flaps allowing for the calculation of the saphenous artery flow rate. The MV-Flow mode was then applied: for qualitative analysis, with identification of saphenous artery collaterals; then quantitative, with repeated measurements of the Vascularity Index (VI), percentage of pixels where flow is detected relative to the total ultrasound view area. The measurements were then repeated after increasing arterial flow by clamping the distal femoral artery.   The MV-Flow mode allowed a better follow-up of the saphenous artery's collaterals and detected microflows not seen with the color Doppler. The VI was correlated to the saphenous artery flow rate (Spearman rho of 0.64;   = 0.002) and allowed to monitor the flap perfusion variations.   Ultrasound imaging of microvascularization by MV-Flow mode and its quantification by VI provides valuable information in evaluating the microvascularization of flaps.","Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Cité, Paris, France.;Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Cité, Paris, France.;Shriners Children's Boston, Boston, MA, United States.;Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.;Shriners Children's Boston, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Department of Plastic, Reconstructive and Aesthetic Surgery, Groupe Almaviva Santé, Clinique de l'Alma, IAOPC, Paris, France.","NA",0,"1664-042X","Front Physiol","Front Physiol",2022,"2022","13","10.3389/fphys.2022.1063240","1063240","","","36589429","36589429","PUBMED","Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Cité, Paris, France.;Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Cité, Paris, France.;Shriners Children's Boston, Boston, MA, United States.;Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany.;Shriners Children's Boston, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Cardiac Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.;Shriners Children's Boston, Boston, MA, United States.;Division of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation Laboratory Center for Transplantation Sciences, Massachusetts General Hospital Harvard Medical School, Boston, MA, United States.;Department of Plastic, Reconstructive and Aesthetic Surgery, Groupe Almaviva Santé, Clinique de l'Alma, IAOPC, Paris, France."
"202","Pelletier R;Le Daré B;Le Bouëdec D;Kernalléguen A;Ferron PJ;Morel I;Gicquel T","Pelletier, Romain;Le Daré, Brendan;Le Bouëdec, Diane;Kernalléguen, Angéline;Ferron, Pierre-Jean;Morel, Isabelle;Gicquel, Thomas","Arylcyclohexylamine Derivatives: Pharmacokinetic, Pharmacodynamic, Clinical and Forensic Aspects.","International journal of molecular sciences","Switzerland","eng","Journal Article","NPS;arylcyclohexylamines;ketamine;phencyclidine;review","Ketamine;Phencyclidine;Receptors, N-Methyl-D-Aspartate;Asia;Europe","Ketamine;Phencyclidine;Receptors, N-Methyl-D-Aspartate;Asia;Europe","Since the 2000s, an increasing number of new psychoactive substances (NPS) have appeared on the drug market. Arylcyclohexylamine (ACH) compounds such as ketamine, phencyclidine and eticyclidine derivatives are of particular concern, given their rapidly increasing use and the absence of detailed toxicity data. First used mainly for their pharmacological properties in anesthesia, their recreational use is increasing. ACH derivatives have an antagonistic activity against the N-methyl-D-aspartate receptor, which leads to dissociative effects (dissociation of body and mind). Synthetic ketamine derivatives produced in Asia are now arriving in Europe, where most are not listed as narcotics and are, thus, legal. These structural derivatives have pharmacokinetic and pharmacodynamic properties that are sometimes very different from ketamine. Here, we describe the pharmacology, epidemiology, chemistry and metabolism of ACH derivatives, and we review the case reports on intoxication.","Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.","NA",0,"1422-0067","Int J Mol Sci","Int J Mol Sci",2022,"2022","23","10.3390/ijms232415574",NA,"Direction de la Recherche et de l'Innovation ; CHU de Rennes - Hôpital Pontchaillou - 2, rue Henri Le Guilloux, 35033 Rennes 352 Cedex 9","Centre Hospitalier Universitaire de Rennes","36555217","36555217","PUBMED","Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolisme et Cancer), F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Toxicologie Biologique et Medico-Légale, CHU Pontchaillou, 2 Rue Henri Le Guilloux, F-35000 Rennes, France."
"203","Brahmi M;Gaspar N;Gantzer J;Toulmonde M;Boudou-Rouquette P;Bompas E;Firmin N;Valentin T;Cancel M;Duffaud F;Bertucci F;Perrin C;Dufresne A;Marec-Bérard P;Jean-Denis M;Ray-Coquard I;Le Loarer F;Pierron G;Tirode F;Blay JY;Watson S","Brahmi, Mehdi;Gaspar, Nathalie;Gantzer, Justine;Toulmonde, Maud;Boudou-Rouquette, Pascaline;Bompas, Emmanuelle;Firmin, Nelly;Valentin, Thibaud;Cancel, Mathilde;Duffaud, Florence;Bertucci, Francois;Perrin, Christophe;Dufresne, Armelle;Marec-Bérard, Perrine;Jean-Denis, Myriam;Ray-Coquard, Isabelle;Le Loarer, Francois;Pierron, Gaille;Tirode, Franck;Blay, Jean-Yves;Watson, Sarah","Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.","Cancer medicine","United States","eng","Journal Article","CIC-rearranged sarcomas;CIC::DUX4 sarcomas;Ewing-like sarcoma.;Ultra-rare sarcoma;Undifferentiated round cell sarcoma","Adult;Humans;Male;Female;Child;Child, Preschool;Adolescent;Young Adult;Middle Aged;Aged;Aged, 80 and over;Sarcoma, Ewing;Retrospective Studies;Sarcoma, Small Cell;Sarcoma;Bone Neoplasms;Soft Tissue Neoplasms;Skin Neoplasms;Death;Oncogene Proteins, Fusion;Biomarkers, Tumor","Adult;Humans;Male;Female;Child;Child, Preschool;Adolescent;Young Adult;Middle Aged;Aged;Aged, 80 and over;Sarcoma, Ewing;Retrospective Studies;Sarcoma, Small Cell;Sarcoma;Bone Neoplasms;Soft Tissue Neoplasms;Skin Neoplasms;Death;Oncogene Proteins, Fusion;Biomarkers, Tumor","CIC-rearranged sarcomas (CIC-RS) represent the most frequent subset of ""Ewing-like"" undifferentiated small round cell sarcomas. These tumors tend to be more aggressive than Ewing sarcomas. Moreover, treatment strategy can differ according to teams. The primary aim of this retrospective study was to describe the characteristics, treatments, and outcome for patients with CIC-RS included in the French NETSARC+ database. Pediatric and adult patients from 13 French centers with a diagnosis of CIC-RS were registered from October 2008 to March 2021. Patients and tumors characteristics were collected from the national network NETSARC+ database (http://netsarc.sarcomabcb.org). CIC-RS diagnosis was pathologically and molecularly confirmed with a central review by expert pathologists. Two groups of patients were studied: those treated as classical Ewing sarcomas (cohort EwS) and those treated as high-grade soft tissue sarcomas (cohort STS) according to ESMO and/or EpSSG guidelines. Survival was calculated using the Kaplan-Meier method and the log-rank test was used to compare survival. Among 79 patients, the male/female sex ratio was 0.7 and the median age at diagnosis was 27 years (range 2-87). With a median follow-up of 37 months, 39 patients died of the disease. Median overall survival from diagnosis was 18 months, with no significant difference between both cohorts (p = 0.9). Nevertheless, when focusing on patients with metastatic disease at diagnosis (N = 21), all patients from cohort STS died of disease while some patients from cohort EwS were still alive and in complete remission. FSG experience confirms the aggressive clinical course of CDS patients regardless of chemotherapy regimen.","Centre Léon Bérard, Lyon, France.;Gustave Roussy Cancer Campus, Villejuif, France.;ICANS, Strabourg, France.;Institut Bergonié, Bordeaux, France.;Hopital Cochin Saint Vincent de Paul, Paris, France.;ICO, Angers, France.;ICM, Montpellier, France.;Institut Claudius Regaud, Toulouse, France.;CHU Bretonneau, Tours, France.;CHU Timone, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Institut Curie, Paris, France.","NA",0,"2045-7634","Cancer Med","Cancer Med",2022,"2023","12","10.1002/cam4.5539","7801-7807","","","36537582","36537582","PUBMED","Centre Léon Bérard, Lyon, France.;Gustave Roussy Cancer Campus, Villejuif, France.;ICANS, Strabourg, France.;Institut Bergonié, Bordeaux, France.;Hopital Cochin Saint Vincent de Paul, Paris, France.;ICO, Angers, France.;ICM, Montpellier, France.;Institut Claudius Regaud, Toulouse, France.;CHU Bretonneau, Tours, France.;CHU Timone, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Centre Léon Bérard, Lyon, France.;Centre Léon Bérard, Lyon, France.;Institut Curie, Paris, France."
"204","François E;De Bari B;Ronchin P;Nouhaud E;Martel-Lafay I;Artru P;Clavere P;Vendrely V;Boige V;Gargot D;Lemanski C;De Sousa Carvalho N;Gal J;Pernot M;Magné N","François, Eric;De Bari, Berardino;Ronchin, Philippe;Nouhaud, Elodie;Martel-Lafay, Isabelle;Artru, Pascal;Clavere, Pierre;Vendrely, Veronique;Boige, Valerie;Gargot, Deny;Lemanski, Claire;De Sousa Carvalho, Nicolas;Gal, Jocelyn;Pernot, Mandy;Magné, Nicolas","Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.","European journal of cancer (Oxford, England : 1990)","England","eng","Randomized Controlled Trial","Elderly;Geriatric assessment;Rectal cancer;Short course radiotherapy","Humans;Aged;Rectum;Activities of Daily Living;Neoplasm Staging;Chemoradiotherapy;Capecitabine;Rectal Neoplasms;Neoadjuvant Therapy;Fluorouracil;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome","Humans;Aged;Rectum;Activities of Daily Living;Neoplasm Staging;Chemoradiotherapy;Capecitabine;Rectal Neoplasms;Neoadjuvant Therapy;Fluorouracil;Antineoplastic Combined Chemotherapy Protocols;Treatment Outcome","There is no specific guideline for the treatment of locally advanced rectal cancers in the elderly. Here we compared R0 resection rate and degradation of autonomy based on the instrumental activities of daily living score between neoadjuvant, short course radiotherapy and chemoradiotherapy in this specific population. Patients ≥75 years with resectable T3-T4 rectal adenocarcinoma within 12 cm of the anal verge or T2 of the very low rectum were randomised between short course radiotherapy (5 × 5 Gy in one week) and chemoradiotherapy (50 Gy, 2 Gy/f, 5 weeks with capecitabine: 800 mg/m  twice daily, 5 days per week), with delayed surgery 7 ± 1 weeks for the two arms. One hundred and three eligible patients were enrolled between January 2016 and December 2019 when the trial was closed due to poor accrual. The R0 resection rate (first co-primary objective) was 84.3%; confidence interval 95% [73.26-94.18] in the short course group and 88%; confidence interval 95% [77.77-96.60] in the chemoradiotherapy group (non-inferiority p = 0.28). The deterioration of the instrumental activities of daily living score was not different during the pre-operative phase, it was significantly more deteriorated in the chemoradiotherapy group at 3 months post-operative (44.8% versus 14.8%; p = 0.032) but was not different at 12 months post-operative (second co-primary objective). During pre-operative phase, 9.8% of patients in short course group and 22% of patients in chemoradiotherapy group presented a serious adverse event, but we observed no difference during the post-operative phase between the two groups. Although the main objectives of the study were not achieved, the short course radiotherapy followed by delayed surgery could represent a preferred treatment option in patients ≥75 years with locally advanced rectal cancer; a new study must be performed to confirm the improvement in overall and specific survival results.","Centre Antoine-Lacassagne, Nice;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Centre Azuréen de Cancérologie, Mougins, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon-Bérard, Lyon, France.;Clinique Mermoz, Lyon, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Gustave Roussy, Villejuif, France.;Centre Hospitalier Blois, Blois, France.;Institut de Cancérologie de Montpellier, Montpellier, France.;UNICANCER, Kremlin-Bicêtre, France.;Centre Antoine-Lacassagne, Nice, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2023","180","10.1016/j.ejca.2022.11.020","62-70","","","36535196","36535196","PUBMED","Centre Antoine-Lacassagne, Nice;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Centre Azuréen de Cancérologie, Mougins, France.;Centre Eugène Marquis, Rennes, France.;Centre Léon-Bérard, Lyon, France.;Clinique Mermoz, Lyon, France.;Centre Hospitalier Régional Universitaire Dupuytren 1, Limoges, France.;Centre Hospitalier Régional Universitaire Bordeaux, Bordeaux, France.;Gustave Roussy, Villejuif, France.;Centre Hospitalier Blois, Blois, France.;Institut de Cancérologie de Montpellier, Montpellier, France.;UNICANCER, Kremlin-Bicêtre, France.;Centre Antoine-Lacassagne, Nice, France.;Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz, Besançon, France.;Institut de Cancérologie Lucien-Neuwrith, Saint-Priest-en-Jarez, France."
"205","Tao Y;Biau J;Sun XS;Sire C;Martin L;Alfonsi M;Prevost JB;Modesto A;Lafond C;Tourani JM;Miroir J;Kaminsky MC;Coutte A;Liem X;Chautard E;Vauleon E;Drouet F;Ruffier A;Ramee JF;Waksi G;Péchery A;Wanneveich M;Guigay J;Aupérin A;Bourhis J","Tao, Y;Biau, J;Sun, X S;Sire, C;Martin, L;Alfonsi, M;Prevost, J B;Modesto, A;Lafond, C;Tourani, J M;Miroir, J;Kaminsky, M C;Coutte, A;Liem, X;Chautard, E;Vauleon, E;Drouet, F;Ruffier, A;Ramee, J F;Waksi, G;Péchery, A;Wanneveich, M;Guigay, J;Aupérin, A;Bourhis, J","Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Randomized Controlled Trial","PD-1;concurrent radiotherapy;head and neck cancer;pembrolizumab","Aged;Humans;Middle Aged;Cetuximab;Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Squamous Cell Carcinoma of Head and Neck","Aged;Humans;Middle Aged;Cetuximab;Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Squamous Cell Carcinoma of Head and Neck","To evaluate potential synergistic effect of pembrolizumab with radiotherapy (RT) compared with a standard-of-care (SOC) cetuximab-RT in patients with locally advanced-squamous cell carcinoma of head and neck (LA-SCCHN). Patients with nonoperated stage III-IV SCC of oral cavity, oropharynx, hypopharynx, and larynx and unfit for receiving high-dose cisplatin were enrolled. Patients received once-daily RT up to 69.96 Gy in 33 fractions with weekly cetuximab (cetuximab-RT arm) or 200 mg Q3W pembrolizumab during RT (pembrolizumab-RT arm). The primary endpoint was locoregional control (LRC) rate 15 months after RT. To detect a difference between arms of 60%-80% in 15-month LRC, inclusion of 66 patients per arm was required to achieve a power of at least 0.85 at two-sided significance level of 0.20. Between May 2016 and October 2017, 133 patients were randomized to cetuximab-RT (n = 66) and pembrolizumab-RT (n = 67). Two patients (one in each arm) were not included in the analysis (a consent withdrawal and a progression before treatment start). The median age was 65 years (interquartile range 60-70 years), 92% were smokers, 60% were oropharynx (46% of oropharynx with p16+) and 75% were stage IV. Median follow-up was 25 months in both arms. The 15-month LRC rate was 59% with cetuximab-RT and 60% with pembrolizumab-RT ]odds ratio 1.05, 95% confidence interval (CI) 0.43-2.59; P = 0.91]. There was no significant difference between arms for progression-free survival (hazard ratio 0.85, 95% CI 0.55-1.32; P = 0.47) and for overall survival (hazard ratio 0.83, 95% CI 0.49-1.40; P = 0.49). Toxicity was lower in the pembrolizumab-RT arm than in the cetuximab-RT arm: 74% versus 92% patients with at least one grade ≥3 adverse events (P = 0.006), mainly due to mucositis, radiodermatitis, and rash. Compared with the SOC cetuximab-RT, pembrolizumab concomitant with RT did not improve the tumor control and survival but appeared less toxic in unfit patients with LA-SCCHN.","Gustave-Roussy Institute, Villejuif, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hôpital Nord Franche-Comté, Montbéliard and CHU Besançon, Montbéliard, France.;Centre Hospitalier de Bretagne Sud, Lorient, France.;Clinique des Ormeaux, Le Havre, France.;Clinique Sainte Catherine, Avignon, France.;Centre Pierre Curie, Beuvry, France.;Institut Claudius Regaud, Toulouse, France.;Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France.;Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Centre Jean Perrin, Clermont Ferrand, France.;Institut de Cancérologie de Lorraine, Nancy, France.;Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Centre Oscar Lambret, Lille, France.;Centre Jean Perrin, Clermont Ferrand, France.;Centre Eugène Marquis, Rennes, France.;Clinique Mutualiste de l'estuaire, Saint-Nazaire, France.;Gustave-Roussy Institute, Villejuif, France; Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France.;Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France.;GORTEC, Tours, France.;GORTEC, Tours, France.;GORTEC, Tours, France.;Centre Antoine Lacassagne, FHU OncoAge, University Côte d'Azur, Nice, France.;Unit of Biostatistics and Epidemiology, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France.;Centre Hospitalier Universitaire Vaudois, Lausanne","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2022,"2023","34","10.1016/j.annonc.2022.10.006","101-110","","","36522816","36522816","PUBMED","Gustave-Roussy Institute, Villejuif, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hôpital Nord Franche-Comté, Montbéliard and CHU Besançon, Montbéliard, France.;Centre Hospitalier de Bretagne Sud, Lorient, France.;Clinique des Ormeaux, Le Havre, France.;Clinique Sainte Catherine, Avignon, France.;Centre Pierre Curie, Beuvry, France.;Institut Claudius Regaud, Toulouse, France.;Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France.;Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Centre Jean Perrin, Clermont Ferrand, France.;Institut de Cancérologie de Lorraine, Nancy, France.;Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Centre Oscar Lambret, Lille, France.;Centre Jean Perrin, Clermont Ferrand, France.;Centre Eugène Marquis, Rennes, France.;Clinique Mutualiste de l'estuaire, Saint-Nazaire, France.;Gustave-Roussy Institute, Villejuif, France; Clinique Victor Hugo-Centre Jean Bernard, Le Mans, France.;Centre Hospitalier Départemental de Vendée, La Roche sur Yon, France.;GORTEC, Tours, France.;GORTEC, Tours, France.;GORTEC, Tours, France.;Centre Antoine Lacassagne, FHU OncoAge, University Côte d'Azur, Nice, France.;Unit of Biostatistics and Epidemiology, Gustave Roussy, Oncostat 1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif, France.;Centre Hospitalier Universitaire Vaudois, Lausanne"
"206","Carausu M;Carton M;Diéras V;Petit T;Guiu S;Gonçalves A;Augereau P;Ferrero JM;Levy C;Ung M;Desmoulins I;Debled M;Bachelot T;Pistilli B;Frenel JS;Mailliez A;Chevrot M;Cabel L","Carausu, Marcela;Carton, Matthieu;Diéras, Véronique;Petit, Thierry;Guiu, Séverine;Gonçalves, Anthony;Augereau, Paule;Ferrero, Jean Marc;Levy, Christelle;Ung, Mony;Desmoulins, Isabelle;Debled, Marc;Bachelot, Thomas;Pistilli, Barbara;Frenel, Jean-Sébastien;Mailliez, Audrey;Chevrot, Michaël;Cabel, Luc","Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.","JAMA network open","United States","eng","Journal Article","","Humans;Female;Middle Aged;Breast Neoplasms;Cohort Studies;Antineoplastic Combined Chemotherapy Protocols;Trastuzumab","Humans;Female;Middle Aged;Breast Neoplasms;Cohort Studies;Antineoplastic Combined Chemotherapy Protocols;Trastuzumab","Evidence suggests that patients with human epidermal growth factor receptor 2-positive (ERBB2+ [formerly HER2+]) metastatic breast cancer (MBC) have different clinical characteristics and outcomes according to their hormone receptor (HR) status. The place of endocrine therapy (ET) for patients with HR+/ERBB2+ is still not clearly defined in this setting. To evaluate the association of HR status and first-line inclusion of ET with outcomes among patients with ERBB2+ MBC. This cohort study was an analysis of clinical data from the French clinical Epidemiological Strategy and Medical Economics (ESME) cohort, including patients with MBC who started treatment between 2008 and 2017. The last date of follow-up was June 18, 2020. Data were analyzed from May 2021 to May 2022. Patients were treated with first-line ERBB2-targeted therapy and either chemotherapy (CT) with or without ET or ET alone. For the study of the association of maintenance ET with outcomes, we included patients treated with first-line ERBB2-targeted therapy with CT and with or without maintenance ET. Median overall survival (OS) and median first-line progression-free survival (PFS) were reported using the Kaplan-Meier method. Cox proportional hazards models and a propensity score were constructed to report and adjust for prognostic factors. Multivariable analysis included age at MBC, time to MBC, number of metastatic sites, type of metastases, and Eastern Cooperative Oncology Group performance status. Among 4145 women with ERBB2+ MBC, 2696 patients had HR+ (median [IQR] age, 58.0 [47.0-67.0] years) and 1449 patients had HR- (56.0 [47.0-64.0] years) tumors. The median OS for patients with HR+ vs HR- tumors was 55.9 months (95% CI, 53.7-59.4 months) vs 42.0 months (95% CI, 38.8-45.2 months), confirmed in multivariable analysis (hazard ratio, 1.40; 95% CI, 1.26-1.56; P < .001). The median PFS for patients with HR+ vs HR- tumors was 12.2 months (95% CI, 11.5-12.9 months) vs 9.8 months (95% CI, 9.2-11.0 months; P = .01), and the HR was 1.15 (95% CI, 1.06-1.26; P < .001). In multivariable analysis, no significant difference was found in OS or PFS for 1520 patients treated with ERBB2-targeted therapy with CT and with or without ET vs 203 patients receiving ERBB2-targeted therapy with ET, regardless of type of ERBB2-targeted therapy (trastuzumab or trastuzumab with pertuzumab). This result was confirmed by matching patients using a propensity score. Using the time-dependent ET variable among patients with ERBB2-targeted therapy with CT, those with maintenance ET had significantly better PFS (hazard ratio, 0.70; 95% CI, 0.60-0.82; P < .001) and OS (hazard ratio, 0.47; 95% CI, 0.39-0.57; P < .001). These results suggest that ET-containing first-line regimens may be associated with benefits among a subgroup of patients with HR+/ERBB2+ MBC.","Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss/ICANS, Strasbourg, France.;Department of Medical Oncology, Institut régional du Cancer Montpellier, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2022,"2022","5","10.1001/jamanetworkopen.2022.47154","e2247154","","","36520434","36520434","PUBMED","Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss/ICANS, Strasbourg, France.;Department of Medical Oncology, Institut régional du Cancer Montpellier, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France."
"207","Francis PA;Fleming GF;Láng I;Ciruelos EM;Bonnefoi HR;Bellet M;Bernardo A;Climent MA;Martino S;Bermejo B;Burstein HJ;Davidson NE;Geyer CE;Walley BA;Ingle JN;Coleman RE;Müller B;Le Du F;Loibl S;Winer EP;Ruepp B;Loi S;Colleoni M;Coates AS;Gelber RD;Goldhirsch A;Regan MM","Francis, Prudence A;Fleming, Gini F;Láng, István;Ciruelos, Eva M;Bonnefoi, Hervé R;Bellet, Meritxell;Bernardo, Antonio;Climent, Miguel A;Martino, Silvana;Bermejo, Begoña;Burstein, Harold J;Davidson, Nancy E;Geyer, Charles E;Walley, Barbara A;Ingle, James N;Coleman, Robert E;Müller, Bettina;Le Du, Fanny;Loibl, Sibylle;Winer, Eric P;Ruepp, Barbara;Loi, Sherene;Colleoni, Marco;Coates, Alan S;Gelber, Richard D;Goldhirsch, Aron;Regan, Meredith M","Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Randomized Controlled Trial","","Female;Humans;Breast Neoplasms;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Tamoxifen;Combined Modality Therapy;Disease-Free Survival;Antineoplastic Combined Chemotherapy Protocols;Adjuvants, Immunologic;Premenopause","Female;Humans;Breast Neoplasms;Antineoplastic Agents, Hormonal;Chemotherapy, Adjuvant;Tamoxifen;Combined Modality Therapy;Disease-Free Survival;Antineoplastic Combined Chemotherapy Protocols;Adjuvants, Immunologic;Premenopause"," JCO  The Suppression of Ovarian Function Trial (SOFT; ClinicalTrials.gov identifier: NCT00066690) randomly assigned premenopausal women with hormone receptor-positive breast cancer to 5 years of adjuvant tamoxifen, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. The primary analysis compared disease-free survival (DFS) between tamoxifen plus OFS versus tamoxifen alone; exemestane plus OFS versus tamoxifen was a secondary objective. After 8 years, SOFT reported a significant reduction in recurrence and improved overall survival (OS) with adjuvant tamoxifen plus OFS versus tamoxifen alone. Here, we report outcomes after median follow-up of 12 years. DFS remained significantly improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.82; 95% CI, 0.69 to 0.98) with a 12-year DFS of 71.9% with tamoxifen, 76.1% with tamoxifen plus OFS, and 79.0% with exemestane plus OFS. OS was improved with tamoxifen plus OFS versus tamoxifen (hazard ratio, 0.78; 95% CI, 0.60 to 1.01) and was 86.8% with tamoxifen, 89.0% with tamoxifen plus OFS, and 89.4% with exemestane plus OFS at 12 years. Among those who received prior chemotherapy for human epidermal growth factor receptor-2-negative tumors, OS was 78.8% with tamoxifen, 81.1% with tamoxifen plus OFS, and 84.4% with exemestane plus OFS. In conclusion, after 12 years, there remains a benefit from including OFS in adjuvant endocrine therapy, with an absolute improvement in OS more apparent with higher baseline risk of recurrence.[Media: see text].","Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.;Breast Cancer Trials Australia & New Zealand, University of Newcastle, Callaghan, Newcastle, Australia.;International Breast Cancer Study Group, Bern, Switzerland.;The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL.;Clinexpert-Research, Budapest, Hungary.;National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.;Medical Oncology Department, University Hospital and SOLTI Breast Cancer Research Cooperative Group, Madrid, Spain.;Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC), Bordeaux, France.;Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.;Medical Oncology Unit, ICS Maugeri-IRCCS, Pavia, Italy.;Instituto Valenciano de Oncologia, Valencia and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.;The Angeles Clinic and Research Institute and SWOG, Santa Monica, CA.;Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Incliva, Barcelona, Spain.;Medicine Department Universidad de Valencia, Valencia and SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.;Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.;Fred Hutchinson Cancer Center, University of Washington and ECOG-ACRIN, Seattle, WA.;University of Pittsburgh Medical Center Hillman Cancer Center and NRG Oncology, Pittsburgh, PA.;University of Calgary and Canadian Cancer Trials Group, Calgary, Alberta, Canada.;Mayo Clinic and Alliance for Clinical Trials in Oncology, Rochester, MN.;Weston Park Hospital, Sheffield, United Kingdom.;NCRI Breast Cancer Clinical Studies Group, London, United Kingdom.;ICR-CTSU, London, United Kingdom.;Chilean Cooperative Group for Oncological Research (GOCCHI), Santiago, Chile.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;German Breast Group, Neu-Isenburg, Germany.;Goethe University of Frankfurt, Frankfurt, Germany.;Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.;Yale Cancer Center, Yale School of Medicine, New Haven, CT.;Smilow Cancer Hospital, New Haven, CT.;International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.;International Breast Cancer Study Group and Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.;Division of Medical Senology, IEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.;International Breast Cancer Study Group and University of Sydney, Sydney, Australia.;International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA.;IEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.;International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2022,"2023","41","10.1200/JCO.22.01065","1370-1375","UG1 CA189867;UG1 CA233329;U10 CA180821;UG1 CA233160;U10 CA180863;CRUKE/03/023;U24 CA075362;U10 CA180820;U10 CA180794;CRUKE/03/022;U10 CA180888;U10 CA180868;C1491/A15955;U10 CA180822;UG1 CA233328","NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;NCI NIH HHS;NCI NIH HHS","36493334","36493334","PUBMED","Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.;Breast Cancer Trials Australia & New Zealand, University of Newcastle, Callaghan, Newcastle, Australia.;International Breast Cancer Study Group, Bern, Switzerland.;The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL.;Clinexpert-Research, Budapest, Hungary.;National Institute of Oncology and International Breast Cancer Study Group, Budapest, Hungary.;Medical Oncology Department, University Hospital and SOLTI Breast Cancer Research Cooperative Group, Madrid, Spain.;Institut Bergonié Comprehensive Cancer Centre, Université de Bordeaux, INSERM U1312, and European Organisation for Research and Treatment of Cancer (EORTC), Bordeaux, France.;Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.;Medical Oncology Unit, ICS Maugeri-IRCCS, Pavia, Italy.;Instituto Valenciano de Oncologia, Valencia and SOLTI Breast Cancer Research Cooperative Group, Barcelona, Spain.;The Angeles Clinic and Research Institute and SWOG, Santa Monica, CA.;Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Incliva, Barcelona, Spain.;Medicine Department Universidad de Valencia, Valencia and SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.;Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.;Fred Hutchinson Cancer Center, University of Washington and ECOG-ACRIN, Seattle, WA.;University of Pittsburgh Medical Center Hillman Cancer Center and NRG Oncology, Pittsburgh, PA.;University of Calgary and Canadian Cancer Trials Group, Calgary, Alberta, Canada.;Mayo Clinic and Alliance for Clinical Trials in Oncology, Rochester, MN.;Weston Park Hospital, Sheffield, United Kingdom.;NCRI Breast Cancer Clinical Studies Group, London, United Kingdom.;ICR-CTSU, London, United Kingdom.;Chilean Cooperative Group for Oncological Research (GOCCHI), Santiago, Chile.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;German Breast Group, Neu-Isenburg, Germany.;Goethe University of Frankfurt, Frankfurt, Germany.;Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, Harvard Medical School and Alliance for Clinical Trials in Oncology, Boston, MA.;Yale Cancer Center, Yale School of Medicine, New Haven, CT.;Smilow Cancer Hospital, New Haven, CT.;International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.;International Breast Cancer Study Group and Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Victoria, Australia.;Division of Medical Senology, IEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.;International Breast Cancer Study Group and University of Sydney, Sydney, Australia.;International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard TH Chan School of Public Health, Frontier Science Foundation, Boston, MA.;IEO, European Institute of Oncology, IRCCS and International Breast Cancer Study Group, Milan, Italy.;International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA."
"208","Rugo HS;Im SA;Joy AA;Shparyk Y;Walshe JM;Sleckman B;Loi S;Theall KP;Kim S;Huang X;Bananis E;Mahtani R;Finn RS;Diéras V","Rugo, Hope S;Im, Seock-Ah;Joy, Anil A;Shparyk, Yaroslav;Walshe, Janice M;Sleckman, Bethany;Loi, Sherene;Theall, Kathy Puyana;Kim, Sindy;Huang, Xin;Bananis, Eustratios;Mahtani, Reshma;Finn, Richard S;Diéras, Véronique","Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.","Breast (Edinburgh, Scotland)","Netherlands","eng","Randomized Controlled Trial","Advanced breast cancer;Chemotherapy;Palbociclib;Progression-free survival;Safety","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Fulvestrant;Receptor, ErbB-2","Female;Humans;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Fulvestrant;Receptor, ErbB-2","Previous analyses from the PALOMA-2 and PALOMA-3 studies showed that palbociclib (PAL) plus endocrine therapy (ET) prolongs time to first subsequent chemotherapy (TTC) versus placebo (PBO) plus ET in the overall population of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative (HR+/HER2-) advanced breast cancer (ABC). Here, we evaluated TTC in relevant patient subgroups. These post hoc analyses evaluated TTC by subgroup using data from 2 randomized, phase 3 studies of women with HR+/HER2- ABC. In PALOMA-2, postmenopausal patients previously untreated for ABC were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus letrozole (LET; 2.5 mg/day; n = 444) or PBO plus LET (n = 222). In PALOMA-3, premenopausal or postmenopausal patients whose disease had progressed after prior ET were randomized 2:1 to receive PAL (125 mg/day, 3/1-week schedule) plus fulvestrant (FUL; 500 mg; n = 347) or PBO plus FUL (n = 174). First subsequent chemotherapy was received by 35.5% and 56.2% in PALOMA-2 and PALOMA-3 after progression on palbociclib plus ET or placebo plus ET. Across all subgroups analyzed, the median progression-free survival (PFS) was longer in the PAL plus ET arm than the PBO plus ET arm. TTC was longer with PAL plus ET versus PBO plus ET across the same patient subgroups in both studies. Across all subgroups, PAL plus ET versus PBO plus ET had longer median PFS and resulted in prolonged TTC in both the PALOMA-2 and PALOMA-3 studies. Pfizer Inc (NCT01740427, NCT01942135).","University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Department of Medicine (Hematology/Oncology), 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, 101 Daehak-ro, Jonro-gu, Seoul 03080;Cross Cancer Institute, University of Alberta, 11560 University Ave NW, Edmonton, AB T6G1Z2;Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv;Cancer Trials Ireland, St Vincent's University Hospital, Elm Park, Dublin 4;Mercy Hospital St. Louis, 607 S New Ballas Road, Suite 3300, St. Louis, MO, 63141;Peter MacCallum Cancer Centre, University of Melbourne;Pfizer Oncology, 300 Technology Square, Cambridge, MA 02139;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 235 E 42nd St, New York, NY, 10017;Miami Cancer Institute, Baptist Health South Florida, Member, Memorial Sloan Kettering Cancer Alliance, 1228 South Pine Island Road, Plantation, FL, 33324;David Geffen School of Medicine, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404;Unicancer Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex","NA",0,"1532-3080","Breast","Breast",2022,"2022","66","10.1016/j.breast.2022.11.005","324-331","","","36463643","36463643","PUBMED","University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Department of Medicine (Hematology/Oncology), 1825 4th Street, 3rd Floor, Box 1710, San Francisco, CA, 94158;Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, 101 Daehak-ro, Jonro-gu, Seoul 03080;Cross Cancer Institute, University of Alberta, 11560 University Ave NW, Edmonton, AB T6G1Z2;Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv;Cancer Trials Ireland, St Vincent's University Hospital, Elm Park, Dublin 4;Mercy Hospital St. Louis, 607 S New Ballas Road, Suite 3300, St. Louis, MO, 63141;Peter MacCallum Cancer Centre, University of Melbourne;Pfizer Oncology, 300 Technology Square, Cambridge, MA 02139;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 10555 Science Center Dr, San Diego, CA 92121;Pfizer Inc, 235 E 42nd St, New York, NY, 10017;Miami Cancer Institute, Baptist Health South Florida, Member, Memorial Sloan Kettering Cancer Alliance, 1228 South Pine Island Road, Plantation, FL, 33324;David Geffen School of Medicine, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404;Unicancer Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex"
"209","Roth GS;Neuzillet C;Sarabi M;Edeline J;Malka D;Lièvre A","Roth, Gael S;Neuzillet, Cindy;Sarabi, Matthieu;Edeline, Julien;Malka, David;Lièvre, Astrid","Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Bile tract cancer;Cholangiocarcinoma;FGFR2 fusion;HER2 amplification;IDH1 mutation;Molecular profiling;Personnalized medicine","Humans;Precision Medicine;Cholangiocarcinoma;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Fluorouracil","Humans;Precision Medicine;Cholangiocarcinoma;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Fluorouracil","Cholangiocarcinoma is a deadly cancer comprising very heterogenous subtypes with a limited therapeutic arsenal in all comers. However, recent significant advances were made with immunotherapy in the first-line treatment of advanced cholangiocarcinoma, with the addition of durvalumab to cisplatin-gemcitabine chemotherapy showing a survival benefit. In the second line setting, only FOLFOX (5FU/folinic acid-oxaliplatin) is validated by a phase 3 trial, yet with a very modest benefit on survival; new options using 5FU with nanoliposomal-irinotecan may emerge in the next few years. The advent of molecular profiling in advanced cholangiocarcinoma in the last decade revealed frequent targetable alterations such as IDH1 mutations, FGFR2 fusions or rearrangements, HER2 amplification, BRAF V600E mutation and others. This strategy opened the way to personalised medicine for patients which are still fit after first-line treatment and the use of targeted inhibitors in first line constitutes a huge challenge with many ongoing trials to improve patients' care. This review exposes the recent clinical trial findings in non-molecularly selected advanced cholangiocarcinoma, offers a focus on how systematic molecular screening should be structured to allow patients to access to personalised medicine, and details which are the therapeutic options accessible in case of actionable alteration.","Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble;Institut Curie, Versailles Saint-Quentin University - Paris Saclay University, Saint-Cloud, France.;Medical Oncology Department, Centre Léon Bérard, 28 Rue Laennec, Lyon 69008, France; Tumor Escape, Resistance and Immunity Department, Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Lyon, France.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Department of Gastroenterology, Rennes University Hospital, University of Rennes 1, INSERM Unité 1242, Rennes, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2023","179","10.1016/j.ejca.2022.11.006","1-14","","","36463640","36463640","PUBMED","Univ. Grenoble Alpes / Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes / Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Grenoble;Institut Curie, Versailles Saint-Quentin University - Paris Saclay University, Saint-Cloud, France.;Medical Oncology Department, Centre Léon Bérard, 28 Rue Laennec, Lyon 69008, France; Tumor Escape, Resistance and Immunity Department, Centre de Recherche en Cancérologie de Lyon, INSERM 1052, CNRS 5286, Lyon, France.;Medical Oncology, Centre Eugene Marquis, Rennes, France.;Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Department of Gastroenterology, Rennes University Hospital, University of Rennes 1, INSERM Unité 1242, Rennes, France."
"210","Yoann L;Clément M;François E;Elise B;Hubert S;Jean-Christophe F;Philippe S;Jean-Yves G","Yoann, Launey;Clément, Mycinski;François, Eugène;Elise, Bellec;Hubert, Serpolay;Jean-Christophe, Ferré;Philippe, Seguin;Jean-Yves, Gauvrit","Implementation of portable head CT imaging in patients with severe acute brain injury in a French ICU: a prospective before-after design pilot study.","Scientific reports","England","eng","Journal Article","","Humans;Pilot Projects;Prospective Studies;Tomography, X-Ray Computed;Intensive Care Units;Brain Injuries","Humans;Pilot Projects;Prospective Studies;Tomography, X-Ray Computed;Intensive Care Units;Brain Injuries","Head-CT-scanning is a cornerstone procedure during the management of patients admitted for acute brain injury (ABI) in intensive care unit (ICU). But intrahospital transfer for these procedure is known to increase the rate of severe adverse events potentially worsening the brain injuries. Portable head-CT (pCTH) may facilitate pCTH performance in safer conditions for the patients avoiding transfer out of the ICU. To evaluate the safety and the time duration required to use a portable head CT (pCTH) scanner in the intensive care unit (ICU) in the French healthcare system in ICU patients admitted for acute brain injury, we prospectively included all ICU-patients admitted for severe ABI over a 2-year period following before-after design. As the main outcome, we compared the time required to perform a scan with pCTH to that with conventional head CT (cCTH) and reported adverse events and reactions. In total, forty-six patients were included and finally, 41 patients were analyzed (21 in the pCTH group and 20 in the cCTH group). The median (interquartile) time required to perform a scan with pCTH was 28 (23-48) minutes compared to 30 (25-36) minutes with cCTH (p = 0.825). The duration time required to perform a pCTH was similar to that with cCTH in an ICU of the French healthcare system without significant difference in adverse events reactions.","Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes;Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Radiation Protection Unit, Department of Biomedical Engineering, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Head office of the Department of Biomedical Engineering, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2022,"2022","12","10.1038/s41598-022-25263-6","20846","","","36460751","36460751","PUBMED","Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes;Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Radiation Protection Unit, Department of Biomedical Engineering, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Head office of the Department of Biomedical Engineering, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;Critical Care Unit, Department of Anaesthesia, Critical Care and Perioperative Medicine, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;University of Rennes, 2, Rue Henri Le Guilloux, 35033, Rennes, France.;Department of Neuroradiology, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri Le Guilloux, 35033, Rennes, France."
"211","Theysohn JM;Demircioglu A;Kleditzsch M;Ludwig JM;Weber M;Umutlu L;Li Y;Kircher M;Lapa C;Buck A;Koehler M;Wildgruber M;Lange CM;Palard X;Garin E;Herrmann K;Forsting M;Nensa F","Theysohn, Jens M;Demircioglu, Aydin;Kleditzsch, Malte;Ludwig, Johannes M;Weber, Manuel;Umutlu, Lale;Li, Yan;Kircher, Malte;Lapa, Constantin;Buck, Andreas;Koehler, Michael;Wildgruber, Moritz;Lange, Christian M;Palard, Xavier;Garin, Etienne;Herrmann, Ken;Forsting, Michael;Nensa, Felix","Prediction of left lobe hypertrophy after right lobe radioembolization of the liver using a clinical data model with external validation.","Scientific reports","England","eng","Journal Article","","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Hypertrophy;Brachytherapy","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Hypertrophy;Brachytherapy","In cirrhotic patients with hepatocellular carcinoma (HCC), right-sided radioembolization (RE) with Yttrium-90-loaded microspheres is an established palliative therapy and can be considered a ""curative intention"" treatment when aiming for sequential tumor resection. To become surgical candidate, hypertrophy of the left liver lobe to > 40% (future liver remnant, FLR) is mandatory, which can develop after RE. The amount of radiation-induced shrinkage of the right lobe and compensatory hypertrophy of the left lobe is difficult for clinicians to predict. This study aimed to utilize machine learning to predict left lobe liver hypertrophy in patients with HCC and cirrhosis scheduled for right lobe RE, with external validation. The results revealed that machine learning can accurately predict relative and absolute volume changes of the left liver lobe after right lobe RE. This prediction algorithm could help to estimate the chances of conversion from palliative RE to curative major hepatectomy following significant FLR hypertrophy.","Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06510, USA.;Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.;Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.;Clinic for Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.;Radiology, University Hospital Muenster, Muenster, Germany.;Department for Radiology, University Hospital, LMU, Munich, Germany.;Clinic for Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Institute for Artificial Intelligence in Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.","NA",0,"2045-2322","Sci Rep","Sci Rep",2021,"2022","12","10.1038/s41598-022-25077-6","20718","","","36456637","36456637","PUBMED","Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Division of Interventional Radiology, Department of Radiology and Biomedical Imaging, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06510, USA.;Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.;Nuclear Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany.;Clinic for Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.;Radiology, University Hospital Muenster, Muenster, Germany.;Department for Radiology, University Hospital, LMU, Munich, Germany.;Clinic for Gastroenterology and Hepatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122, Essen, Germany.;Institute for Artificial Intelligence in Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany."
"212","Codoni G;Kirchner T;Engel B;Villamil AM;Efe C;Stättermayer AF;Weltzsch JP;Sebode M;Bernsmeier C;Lleo A;Gevers TJ;Kupčinskas L;Castiella A;Pinazo J;De Martin E;Bobis I;Sandahl TD;Pedica F;Invernizzi F;Del Poggio P;Bruns T;Kolev M;Semmo N;Bessone F;Giguet B;Poggi G;Ueno M;Jang H;Elpek GÖ;Soylu NK;Cerny A;Wedemeyer H;Vergani D;Mieli-Vergani G;Lucena MI;Andrade RJ;Zen Y;Taubert R;Terziroli Beretta-Piccoli B","Codoni, Greta;Kirchner, Theresa;Engel, Bastian;Villamil, Alejandra Maria;Efe, Cumali;Stättermayer, Albert Friedrich;Weltzsch, Jan Philipp;Sebode, Marcial;Bernsmeier, Christine;Lleo, Ana;Gevers, Tom Jg;Kupčinskas, Limas;Castiella, Agustin;Pinazo, Jose;De Martin, Eleonora;Bobis, Ingrid;Sandahl, Thomas Damgaard;Pedica, Federica;Invernizzi, Federica;Del Poggio, Paolo;Bruns, Tony;Kolev, Mirjam;Semmo, Nasser;Bessone, Fernando;Giguet, Baptiste;Poggi, Guido;Ueno, Masayuki;Jang, Helena;Elpek, Gülsüm Özlem;Soylu, Neşe Karadağ;Cerny, Andreas;Wedemeyer, Heiner;Vergani, Diego;Mieli-Vergani, Giorgina;Lucena, M Isabel;Andrade, Raul J;Zen, Yoh;Taubert, Richard;Terziroli Beretta-Piccoli, Benedetta","Histological and serological features of acute liver injury after SARS-CoV-2 vaccination.","JHEP reports : innovation in hepatology","Netherlands","eng","Journal Article","AIH, autoimmune hepatitis;ALP, alkaline phosphatase;ALT, alanine aminotransferase;AMA, anti-mitochondrial antibody;ANA, anti-nuclear antibody;AST, aspartate aminotransferase;COVID-19, coronavirus disease 2019;DILI, drug-induced liver injury;IAIHG, International Autoimmune Hepatitis Group;IFT, indirect immunofluorescence;LKM, liver kidney microsomal;LT, liver transplantation;PCA, parietal cell antigen;SARS-CoV-2 vaccines;SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2;SLA, soluble liver antigen;SMA, anti-smooth muscle antibody;ULN, upper limit of normal;acute liver injury;autoimmune liver serology;liver histology;pIgG, polyreactive IgG","","","Liver injury with autoimmune features after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is increasingly reported. We investigated a large international cohort of individuals with acute hepatitis arising after SARS-CoV-2 vaccination, focusing on histological and serological features. Individuals without known pre-existing liver diseases and transaminase levels ≥5x the upper limit of normal within 3 months after any anti-SARS-CoV-2 vaccine, and available liver biopsy were included. Fifty-nine patients were recruited; 35 females; median age 54 years. They were exposed to various combinations of mRNA, vectorial, inactivated and protein-based vaccines. Liver histology showed predominantly lobular hepatitis in 45 (76%), predominantly portal hepatitis in 10 (17%), and other patterns in four (7%) cases; seven had fibrosis Ishak stage ≥3, associated with more severe interface hepatitis. Autoimmune serology, centrally tested in 31 cases, showed anti-antinuclear antibody in 23 (74%), anti-smooth muscle antibody in 19 (61%), anti-gastric parietal cells in eight (26%), anti-liver kidney microsomal antibody in four (13%), and anti-mitochondrial antibody in four (13%) cases. Ninety-one percent were treated with steroids ± azathioprine. Serum transaminase levels improved in all cases and were normal in 24/58 (41%) after 3 months, and in 30/46 (65%) after 6 months. One patient required liver transplantation. Of 15 patients re-exposed to SARS-CoV-2 vaccines, three relapsed. Acute liver injury arising after SARS-CoV-2 vaccination is frequently associated with lobular hepatitis and positive autoantibodies. Whether there is a causal relationship between liver damage and SARS-CoV-2 vaccines remains to be established. A close follow-up is warranted to assess the long-term outcomes of this condition. Cases of liver injury after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) have been published. We investigated a large international cohort of individuals with acute hepatitis after SARS-CoV-2 vaccination, focusing on liver biopsy findings and autoantibodies: liver biopsy frequently shows inflammation of the lobule, which is typical of recent injury, and autoantibodies are frequently positive. Whether there is a causal relationship between liver damage and SARS-CoV-2 vaccines remains to be established. Close follow-up is warranted to assess the long-term outcome of this condition.","Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;HIBA, Buenos Aires, Argentina.;Harran University, Şanlıurfa, Turkey.;Medical University of Vienna, Wien, Austria.;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.;IRCCS Humanitas Research Hospital Milan, Milan, Italy.;Humanitas University, Pieve Emanuele, Milan, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Maastricht University Medical Center, Maastricht, Netherlands.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Lithuanian University of Health Sciences, Kaunas, Lituania.;Donostia University Hospital, Donostia, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Hépatologie et Transplantation Hépatique, Hôpital Paul Brousse, Villejuif, France.;Städtisches Krankenhaus Kiel, Kiel, Germany.;Aarhus University Hospital, Aarhus, Denmark.;Ospedale San Raffaele, Milano, Italy.;Ospedale San Raffaele, Milano, Italy.;Policlinico San Marco, Zingonia, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Hospital RWTH Aachen, Aachen, Germany.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;University of Rosario School of Medicine, Rosario, Argentina.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Istituti Clinici Pavia-Vigevano UO Epatologia Oncologica, Vigevano, Italy.;Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.;Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.;Department of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Australia.;Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Turkey.;Department of Pathology, Inonu University Faculty of Medicine, Malatya 44280, Turkey.;Epatocentro Ticino, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Epatocentro Ticino, Lugano, Switzerland.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.","NA",0,"2589-5559","JHEP Rep","JHEP Rep",2022,"2023","5","10.1016/j.jhepr.2022.100605","100605","","","36440259","36440259","PUBMED","Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;HIBA, Buenos Aires, Argentina.;Harran University, Şanlıurfa, Turkey.;Medical University of Vienna, Wien, Austria.;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Centre for Gastrointestinal and Liver Diseases, Basel, Switzerland.;IRCCS Humanitas Research Hospital Milan, Milan, Italy.;Humanitas University, Pieve Emanuele, Milan, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Maastricht University Medical Center, Maastricht, Netherlands.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Lithuanian University of Health Sciences, Kaunas, Lituania.;Donostia University Hospital, Donostia, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Hépatologie et Transplantation Hépatique, Hôpital Paul Brousse, Villejuif, France.;Städtisches Krankenhaus Kiel, Kiel, Germany.;Aarhus University Hospital, Aarhus, Denmark.;Ospedale San Raffaele, Milano, Italy.;Ospedale San Raffaele, Milano, Italy.;Policlinico San Marco, Zingonia, Italy.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;University Hospital RWTH Aachen, Aachen, Germany.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital Bern, University of Bern, Bern, Switzerland.;University of Rosario School of Medicine, Rosario, Argentina.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Istituti Clinici Pavia-Vigevano UO Epatologia Oncologica, Vigevano, Italy.;Department of Gastroenterology and Hepatology, Kurashiki Central Hospital, Kurashiki, Japan.;Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.;Department of Clinical Immunology and Allergy, Royal North Shore Hospital, St Leonards, Australia.;Department of Pathology, Akdeniz University Faculty of Medicine, Antalya, Turkey.;Department of Pathology, Inonu University Faculty of Medicine, Malatya 44280, Turkey.;Epatocentro Ticino, Lugano, Switzerland.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;Servicios de Ap Digestivo y Farmacologia Clínica, Hospital Universitario Virgen de la Victoria, IBIMA, Universidad de Málaga, Malaga, Spain.;Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK.;Dept. Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.;European Reference Network on Hepatological Diseases (ERN RARE-LIVER).;Università della Svizzera Italiana, Facoltà di Scienze Biomediche, Lugano, Switzerland.;Epatocentro Ticino, Lugano, Switzerland.;MowatLabs, Faculty of Life Sciences & Medicine, King's College London, King's College Hospital, London, UK."
"213","Racadot S;Thennevet I;Ouldbey Y;Kaminsky MC;Bosset M;Martin L;Tao Y;Sire C;de Raucourt D;Alfonsi M;Malaurie E;Tourani JM;Fournel P;Vauleon E;Modesto A;Rolland F;Metzger S;Pommier P;Chabaud S;Dussart S","Racadot, Séverine;Thennevet, Isabelle;Ouldbey, Yaelle;Kaminsky, Marie-Christine;Bosset, Mathieu;Martin, Laurent;Tao, Yungan;Sire, Christian;de Raucourt, Dominique;Alfonsi, Marc;Malaurie, Emmanuelle;Tourani, Jean-Marc;Fournel, Pierre;Vauleon, Elodie;Modesto, Anouchka;Rolland, Frédéric;Metzger, Séverine;Pommier, Pascal;Chabaud, Sylvie;Dussart, Sophie","Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).","European journal of cancer (Oxford, England : 1990)","England","eng","Randomized Controlled Trial","Cancer;Head and neck;Outcome;Post-operative chemoradiotherapy;Squamous cell carcinoma;Treatment-related toxicity","Adult;Humans;Squamous Cell Carcinoma of Head and Neck;Afatinib;Head and Neck Neoplasms;Carcinoma, Squamous Cell;Chemoradiotherapy;Double-Blind Method;Treatment Outcome","Adult;Humans;Squamous Cell Carcinoma of Head and Neck;Afatinib;Head and Neck Neoplasms;Carcinoma, Squamous Cell;Chemoradiotherapy;Double-Blind Method;Treatment Outcome","We investigated the efficacy and safety of afatinib maintenance therapy in patients with head and neck squamous cell carcinoma (HNSCC) with macroscopically complete resection and adjuvant radiochemotherapy (RCT). This French multicentric randomised phase III double-blind placebo-controlled study included adult patients with ECOG-PS≤2, normal haematological, hepatic and renal functions, and non-metastatic, histologically confirmed HNSCC of the oral cavity, oropharynx, larynx or hypopharynx, with macroscopically complete resection and adjuvant RCT (≥2 cycles of cisplatin 100 mg/m2 J1, J22, J43 and 66Gy (2Gy/fraction, 5 fractions/week, conventional or intensity modulated radiotherapy ≥60Gy). Randomised patients were planned to receive either afatinib (afa arm) or placebo (control arm (C)) as maintenance therapy for one year. Primary endpoint was disease free survival (DFS). A 15% improvement in DFS was expected at 2 years with afatinib (from 55 to 70%). Among the 167 patients with resected HNSCC included in 19 cancer centres and hospitals from Dec 2011, 134 patients were randomised to receive one-year maintenance afatinib or placebo (afa:67; C:67). Benefit/risk ratio was below assumptions and independent advisory committee recommended to stop the study in Feb 2017, the sponsor decided premature study discontinuation, with a 2-year follow-up for the last randomised patient. 2y-DFS was 61% (95% CI 0.48-0.72) in the afatinib group and 64% (95% CI 0.51-0.74) in the placebo group (HR 1.12, 95% CI 0.70-1.80). Maintenance therapy with afatinib compared with placebo following post-operative RCT in patients with HNSCC did not significantly improve 2y-DFS and should not be recommended in this setting outside clinical trials. gov identifier NCT01427478.","Department of Radiotherapy, Leon Berard Cancer Center, Lyon;Department of Oncology, Centre Henri Becquerel, Rouen, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Oncology, Institut de Cancérologie de Lorraine, Vandroeuve les Nancy, France.;Department of Radiotherapy, Centre de radiothérapie Marie Curie, Hopital privé Drôme Ardèche, Valence, France.;Department of Radiotherapy, Centre Guillaume le Conquérant, Le Havre, France.;Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.;Department of Radiotherapy, Centre Hospitalier de Bretagne Sud, Hôpital du Scorff, Lorient, France.;Department of Surgery, Centre François Baclesse, Caen, France.;Department of Radiotherapy, Institut Sainte Catherine, Avignon, France.;Department of Radiotherapy, Centre Hospitalier Intercommunal, Créteil, France.;Department of Oncology, CHU Poitiers, France.;Department of Radiotherapy, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France.;Department of Oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Institut Claudius Régaud, Toulouse Oncopôle, Toulouse, France.;Department of Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Radiotherapy, Leon Berard Cancer Center, Lyon, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2023","178","10.1016/j.ejca.2022.10.023","114-127","","","36434888","36434888","PUBMED","Department of Radiotherapy, Leon Berard Cancer Center, Lyon;Department of Oncology, Centre Henri Becquerel, Rouen, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Oncology, Institut de Cancérologie de Lorraine, Vandroeuve les Nancy, France.;Department of Radiotherapy, Centre de radiothérapie Marie Curie, Hopital privé Drôme Ardèche, Valence, France.;Department of Radiotherapy, Centre Guillaume le Conquérant, Le Havre, France.;Department of Radiotherapy, Institut Gustave Roussy, Villejuif, France.;Department of Radiotherapy, Centre Hospitalier de Bretagne Sud, Hôpital du Scorff, Lorient, France.;Department of Surgery, Centre François Baclesse, Caen, France.;Department of Radiotherapy, Institut Sainte Catherine, Avignon, France.;Department of Radiotherapy, Centre Hospitalier Intercommunal, Créteil, France.;Department of Oncology, CHU Poitiers, France.;Department of Radiotherapy, Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France.;Department of Oncology, Centre Eugène Marquis, Rennes, France.;Department of Radiotherapy, Institut Claudius Régaud, Toulouse Oncopôle, Toulouse, France.;Department of Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Radiotherapy, Leon Berard Cancer Center, Lyon, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France.;Department of Clinical Research and Innovation, Leon Berard Cancer Center, Lyon, France."
"214","Montégut C;Guillamo JS;Ducray F;Dehais C;Cohen-Jonathan Moyal E;Desenclos C;Petit A;Seizeur R;Bekaert L;Gaultier C;Motuo Fotso MJ;Blonski M;Frenel JS;Vauléon E;Langlois O;Noel G;Carpentier AF;Di Stefano AL;Bronnimann C;Figarella-Branger D;Chinot O;Tabouret E","Montégut, Coline;Guillamo, Jean-Sébastien;Ducray, François;Dehais, Caroline;Cohen-Jonathan Moyal, Elisabeth;Desenclos, Christine;Petit, Antoine;Seizeur, Romuald;Bekaert, Lien;Gaultier, Claude;Motuo Fotso, Marie Jeannette;Blonski, Marie;Frenel, Jean-Sébastien;Vauléon, Elodie;Langlois, Olivier;Noel, Georges;Carpentier, Antoine F;Di Stefano, Anna Luisa;Bronnimann, Charlotte;Figarella-Branger, Dominique;Chinot, Olivier;Tabouret, Emeline",NA,"Cancers","Switzerland","eng","Journal Article","IDH mutation;elderly;geriatric assessment;high grade glioma","","","Background: Describe the characteristics, patterns of care, and predictive geriatric factors of elderly patients with IDHm high-grade glioma (HGG) included in the French POLA network. Material and Methods: The characteristics of elderly (≥70 years) patients IDHm HGG were compared to those of younger patients IDHm HGG (<70 years) and of elderly patients IDHwt HGG. Geriatric features were collected. Results: Out of 1433 HGG patients included, 119 (8.3%) were ≥70 years. Among them, 39 presented with IDHm HGG. The main characteristics of elderly IDHm HGG were different from those of elderly IDHwt HGG but similar to those of younger IDHm HGG. In contrast, their therapeutic management was different from those of younger IDHm HGG with less frequent gross total resection and radiotherapy. The median progression-free survival (PFS) and overall survival (OS) were longer for elderly patients IDHm HGG (29.3 months and 62.1 months) than elderly patients IDHwt HGG (8.3 months and 13.3 months) but shorter than those of younger patients IDHm HGG (69.1 months and not reached). Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, body mass index, and autonomy. Geriatric factors associated with PFS and OS were mobility, neuropsychological disorders, and body mass index, and autonomy. Conclusion: the outcome of IDHm HGG in elderly patients is better than that of IDHwt HGG. Geriatric assessment may be particularly important to optimally manage these patients.","Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;Nîmes, Centre Hospitalier Universitaire de Nîmes Caremeau, Service de Neurologie, 30000 Nimes, France.;Neuro-Oncology Department, Hospices Civils de Lyon, Université Lyon 1, CRCL, UMR Inserm 1052_CNRS 5286, 69000 Lyon, France.;Service Neurology 2, Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, 75013 Paris, France.;Département de Radiothérapie, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Neurosurgery Department, Hôpital Nord, Centre Hospitalo-Universitaire Amiens, 80000 Amiens, France.;Neurosurgery Department, Hôpital Jean Minjoz, Centre Hospitalo-Universitaire Besançon, 25000 Besançon, France.;Neurosurgery Department, Hôpital de la Cavale Blanche, Centre Hospitalo-Universitaire Brest, 29200 Brest, France.;Neurology Department, Centre Hospitalo-Universitaire de Caen, 14000 Caen, France.;Neurology Department, Centre Hospitalier Colmar, 68000 Colmar, France.;Neurosurgery Department, Hôpital Nord, Centre Hospitalo-Universitaire Saint-Étienne, 42270 Saint-Priest en Jarez, France.;Service de Neurologie, Hopital Central, Centre Hospitalier Régional Universitaire, 54000 Nancy, France.;Medical Oncology Department, Institut de Cancérologie de l'Ouest, 11 Boulevard Jacques Monod, 44800 Saint-Herblain, France.;Medical Oncology Department, Centre Eugene Marquis, INSERMU1242, University of Rennes, 35000 Rennes, France.;Neurosurgery Department, Centre Hospitalo-Universitaire Charles Nicolle, 76000 Rouen, France.;Radiotherapy Department, Centre Paul Strauss, 76000 Strasbourg, France.;Neurology Department, Hôpital Saint-Louis, 75010 Paris, France.;Service de Neurologie, Hôpital Foch, 92150 Suresnes, France.;Hôpital Saint-André Bordeaux, Centre Hospitalier Universitaire, Service d'Oncologie, 33000 Bordeaux, France.;Service d'Anatomie Pathologique et de Neuropathologie, Centre Hospitalo-Universitaire Timone, APHM, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France.;Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France.;Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14225509",NA,"","","36428602","36428602","PUBMED","Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;Nîmes, Centre Hospitalier Universitaire de Nîmes Caremeau, Service de Neurologie, 30000 Nimes, France.;Neuro-Oncology Department, Hospices Civils de Lyon, Université Lyon 1, CRCL, UMR Inserm 1052_CNRS 5286, 69000 Lyon, France.;Service Neurology 2, Mazarin, Assistance Public-Hôpitaux de Paris, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Sorbonne University, 75013 Paris, France.;Département de Radiothérapie, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Neurosurgery Department, Hôpital Nord, Centre Hospitalo-Universitaire Amiens, 80000 Amiens, France.;Neurosurgery Department, Hôpital Jean Minjoz, Centre Hospitalo-Universitaire Besançon, 25000 Besançon, France.;Neurosurgery Department, Hôpital de la Cavale Blanche, Centre Hospitalo-Universitaire Brest, 29200 Brest, France.;Neurology Department, Centre Hospitalo-Universitaire de Caen, 14000 Caen, France.;Neurology Department, Centre Hospitalier Colmar, 68000 Colmar, France.;Neurosurgery Department, Hôpital Nord, Centre Hospitalo-Universitaire Saint-Étienne, 42270 Saint-Priest en Jarez, France.;Service de Neurologie, Hopital Central, Centre Hospitalier Régional Universitaire, 54000 Nancy, France.;Medical Oncology Department, Institut de Cancérologie de l'Ouest, 11 Boulevard Jacques Monod, 44800 Saint-Herblain, France.;Medical Oncology Department, Centre Eugene Marquis, INSERMU1242, University of Rennes, 35000 Rennes, France.;Neurosurgery Department, Centre Hospitalo-Universitaire Charles Nicolle, 76000 Rouen, France.;Radiotherapy Department, Centre Paul Strauss, 76000 Strasbourg, France.;Neurology Department, Hôpital Saint-Louis, 75010 Paris, France.;Service de Neurologie, Hôpital Foch, 92150 Suresnes, France.;Hôpital Saint-André Bordeaux, Centre Hospitalier Universitaire, Service d'Oncologie, 33000 Bordeaux, France.;Service d'Anatomie Pathologique et de Neuropathologie, Centre Hospitalo-Universitaire Timone, APHM, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France.;Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France.;Neuro-Oncology Department, University Hospital La Timone, 264 Rue Saint Pierre, 13005 Marseille, France.;GlioME Team, Institute of Neurophysiopathology, Aix-Marseille University 27 Bd Jean Moulin, 13005 Marseille, France."
"215","Batail JM;Corouge I;Combès B;Conan C;Guillery-Sollier M;Vérin M;Sauleau P;Le Jeune F;Gauvrit JY;Robert G;Barillot C;Ferre JC;Drapier D","Batail, J M;Corouge, I;Combès, B;Conan, C;Guillery-Sollier, M;Vérin, M;Sauleau, P;Le Jeune, F;Gauvrit, J Y;Robert, G;Barillot, C;Ferre, J C;Drapier, D","Apathy in depression: An arterial spin labeling perfusion MRI study.","Journal of psychiatric research","England","eng","Journal Article","Apathy;Arterial spin labeling;Depressive disorder;Neuroimaging;Perfusion MRI","Depression;Apathy;Prospective Studies;Magnetic Resonance Imaging;Perfusion;Cerebrovascular Circulation","Depression;Apathy;Prospective Studies;Magnetic Resonance Imaging;Perfusion;Cerebrovascular Circulation","Apathy, as defined as a deficit in goal-directed behaviors, is a critical clinical dimension in depression associated with chronic impairment. Little is known about its cerebral perfusion specificities in depression. To explore neurovascular mechanisms underpinning apathy in depression by pseudo-continuous arterial spin labeling (pCASL) magnetic resonance imaging (MRI). Perfusion imaging analysis was performed on 90 depressed patients included in a prospective study between November 2014 and February 2017. Imaging data included anatomical 3D T1-weighted and perfusion pCASL sequences. A multiple regression analysis relating the quantified cerebral blood flow (CBF) in different regions of interest defined from the FreeSurfer atlas, to the Apathy Evaluation Scale (AES) total score was conducted. After confound adjustment (demographics, disease and clinical characteristics) and correction for multiple comparisons, we observed a strong negative relationship between the CBF in the left anterior cingulate cortex (ACC) and the AES score (standardized beta = -0.74, corrected p value = 0.0008). Our results emphasized the left ACC as a key region involved in apathy severity in a population of depressed participants. Perfusion correlates of apathy in depression evidenced in this study may contribute to characterize different phenotypes of depression.","Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Univ Rennes, LP3C (Laboratoire de Psychologie: Cognition, Comportement, Communication) - EA 1285, CC5000, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurophysiology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Centre Eugène Marquis, Department of Nuclear Medicine, F-35062, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.","NA",0,"1879-1379","J Psychiatr Res","J Psychiatr Res",2021,"2023","157","10.1016/j.jpsychires.2022.11.015","7-16","","","36427413","36427413","PUBMED","Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Univ Rennes, LP3C (Laboratoire de Psychologie: Cognition, Comportement, Communication) - EA 1285, CC5000, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; CHU Rennes, Department of Neurophysiology, F-35033, Rennes, France.;Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France; Centre Eugène Marquis, Department of Nuclear Medicine, F-35062, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France.;Univ Rennes, Inria, CNRS, IRISA, INSERM, Empenn U1228 ERL, F-35042, Rennes, France; CHU Rennes, Department of Radiology, F-35033, Rennes, France.;Centre Hospitalier Guillaume Régnier, Pôle Hospitalo-Universitaire de Psychiatrie Adulte, F-35703, Rennes, France; Univ Rennes, ""Comportement et noyaux gris centraux"" Research Unit (EA 4712), F-35000, Rennes, France."
"216","Mata-Garrido J;Xiang Y;Chang-Marchand Y;Reisacher C;Ageron E;Guerrera IC;Casafont I;Bruneau A;Cherbuy C;Treton X;Dumay A;Ogier-Denis E;Batsché E;Costallat M;Revêchon G;Eriksson M;Muchardt C;Arbibe L","Mata-Garrido, Jorge;Xiang, Yao;Chang-Marchand, Yunhua;Reisacher, Caroline;Ageron, Elisabeth;Guerrera, Ida Chiara;Casafont, Iñigo;Bruneau, Aurelia;Cherbuy, Claire;Treton, Xavier;Dumay, Anne;Ogier-Denis, Eric;Batsché, Eric;Costallat, Mickael;Revêchon, Gwladys;Eriksson, Maria;Muchardt, Christian;Arbibe, Laurence","The Heterochromatin protein 1 is a regulator in RNA splicing precision deficient in ulcerative colitis.","Nature communications","England","eng","Journal Article","","Humans;Mice;Animals;Chromobox Protein Homolog 5;Colitis, Ulcerative;RNA Splicing;Progeria;Inflammation","Humans;Mice;Animals;Chromobox Protein Homolog 5;Colitis, Ulcerative;RNA Splicing;Progeria;Inflammation","Defects in RNA splicing have been linked to human disorders, but remain poorly explored in inflammatory bowel disease (IBD). Here, we report that expression of the chromatin and alternative splicing regulator HP1γ is reduced in ulcerative colitis (UC). Accordingly, HP1γ gene inactivation in the mouse gut epithelium triggers IBD-like traits, including inflammation and dysbiosis. In parallel, we find that its loss of function broadly increases splicing noise, favoring the usage of cryptic splice sites at numerous genes with functions in gut biology. This results in the production of progerin, a toxic splice variant of prelamin A mRNA, responsible for the Hutchinson-Gilford Progeria Syndrome of premature aging. Splicing noise is also extensively detected in UC patients in association with inflammation, with progerin transcripts accumulating in the colon mucosa. We propose that monitoring HP1γ activity and RNA splicing precision can help in the management of IBD and, more generally, of accelerated aging.","Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Proteomics platform Necker, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, 75015, Paris, France.;The Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011, Santander, Spain.;Anatomy & Cell Biology Department, Faculty of Medicine, University of Cantabria, 39011, Santander, Spain.;Micalis Institute, Institut National de Recherche pour L'agriculture, L'alimentation et L'environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350, Jouy-en-Josas, France.;Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571, Paris, France.;Micalis Institute, Institut National de Recherche pour L'agriculture, L'alimentation et L'environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350, Jouy-en-Josas, France.;Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571, Paris, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;Paris IBD Center, Centre hospitalier privé Ambroise Pare-Hartmann, Neuilly, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;INSERM 1242 and Centre Eugène Marquis, Rennes, France.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Department of Biosciences and Nutrition, Center for Innovative Medicine, Karolinska Institutet, SE-141 57, Huddinge, Sweden.;Department of Biosciences and Nutrition, Center for Innovative Medicine, Karolinska Institutet, SE-141 57, Huddinge, Sweden.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris","NA",0,"2041-1723","Nat Commun","Nat Commun",2022,"2022","13","10.1038/s41467-022-34556-3","6834","","","36400769","36400769","PUBMED","Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris, France.;Proteomics platform Necker, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UAR3633, 75015, Paris, France.;The Nanomedicine Group, Institute Valdecilla-IDIVAL, 39011, Santander, Spain.;Anatomy & Cell Biology Department, Faculty of Medicine, University of Cantabria, 39011, Santander, Spain.;Micalis Institute, Institut National de Recherche pour L'agriculture, L'alimentation et L'environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350, Jouy-en-Josas, France.;Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571, Paris, France.;Micalis Institute, Institut National de Recherche pour L'agriculture, L'alimentation et L'environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350, Jouy-en-Josas, France.;Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571, Paris, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;Paris IBD Center, Centre hospitalier privé Ambroise Pare-Hartmann, Neuilly, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;UMR-S 1149, Université Paris Cité, Inserm, Centre de recherche sur l'inflammation, équipe Inflammation intestinale, F-75018, Paris, France.;INSERM 1242 and Centre Eugène Marquis, Rennes, France.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Department of Biosciences and Nutrition, Center for Innovative Medicine, Karolinska Institutet, SE-141 57, Huddinge, Sweden.;Department of Biosciences and Nutrition, Center for Innovative Medicine, Karolinska Institutet, SE-141 57, Huddinge, Sweden.;Sorbonne Université, Institut de Biologie Paris-Seine (IBPS), CNRS Unit of Biological Adaptation and Ageing (B2A), Epigenetics and RNA metabolism in human diseases, 75005, Paris, France.;Université Paris Cité, INSERM, CNRS, Institut Necker Enfants Malades, F-75015, Paris"
"217","Loibl S;Loirat D;Tolaney SM;Punie K;Oliveira M;Rugo HS;Bardia A;Hurvitz SA;Brufsky AM;Kalinsky K;Cortés J;O'Shaughnessy JA;Dieras V;Carey LA;Gianni L;Gharaibeh M;Preger L;Phan S;Chang L;Shi L;Piccart MJ","Loibl, Sibylle;Loirat, Delphine;Tolaney, Sara M;Punie, Kevin;Oliveira, Mafalda;Rugo, Hope S;Bardia, Aditya;Hurvitz, Sara A;Brufsky, Adam M;Kalinsky, Kevin;Cortés, Javier;O'Shaughnessy, Joyce A;Dieras, Véronique;Carey, Lisa A;Gianni, Luca;Gharaibeh, Mahdi;Preger, Luciana;Phan, See;Chang, Lawrence;Shi, Ling;Piccart, Martine J","Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer.","European journal of cancer (Oxford, England : 1990)","England","eng","Randomized Controlled Trial","Antibody–drug conjugate;Clinical trial;EORTC QLQ-C30;Phase III;Quality of life;Sacituzumab govitecan;Triple-negative breast neoplasms","Adult;Humans;Quality of Life;Triple Negative Breast Neoplasms;Immunoconjugates;Fatigue;Pain","Adult;Humans;Quality of Life;Triple Negative Breast Neoplasms;Immunoconjugates;Fatigue;Pain","The antibody-drug conjugate sacituzumab govitecan (SG) prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, we investigated its effect on health-related quality of life (HRQoL). This analysis was based on the open-label phase III ASCENT trial (NCT02574455). Adults with refractory/relapsed mTNBC who had received ≥2 prior systemic therapies (≥1 in the metastatic setting) were randomised 1:1 to SG or treatment of physician's choice (TPC; capecitabine, eribulin, vinorelbine, or gemcitabine). HRQoL was assessed on day 1 of each treatment cycle using the EORTC QLQ-C30. Score changes from baseline were analysed using linear mixed-effect models for repeated measures. Stratified Cox regressions evaluated time to first clinically meaningful change of HRQoL. The analysis population comprised 236 patients randomised to SG and 183 to TPC. For global health status (GHS)/QoL, physical functioning, fatigue, and pain, changes from baseline were superior for SG versus TPC. Compared with TPC, SG was inferior regarding changes from baseline for nausea/vomiting and diarrhoea but non-inferior for other QLQ-C30 domains. Median time to first clinically meaningful worsening was longer for SG than for TPC for physical functioning (22.1 versus 12.1 weeks, P < 0.001), role functioning (11.4 versus 7.1 weeks, P < 0.001), fatigue (7.7 versus 6.0 weeks, P < 0.05), and pain (21.6 versus 9.9 weeks, P < 0.001). SG was generally associated with greater improvements and delayed worsening of HRQoL scores compared with TPC. This supports the favourable profile of SG as an mTNBC treatment.","Hämatologisch-Onkologische Gemeinschaftspraxis Am Bethanien-Krankenhaus, Frankfurt;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of Medicine, Division of Hematology/Medical Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Division of Hematology/Oncology, Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.;Department of Medicine, Columbia University Irving Medical Center, New York, USA; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA.;Oncology Department, International Breast Cancer Center (BCC), Pangaea Oncology, Quirónsalud, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain.;Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medicine - Hematology/Oncology Division, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Medical Oncology, Gianni Bonadonna Foundation, Milano, Italy.;Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Medical Affairs, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.;Evidence Synthesis, Modeling & Communication (EMC), Evidera PPD, Waltham, MA, USA.;Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2023","178","10.1016/j.ejca.2022.10.003","23-33","P30 CA047904","NCI NIH HHS","36379186","36379186","PUBMED","Hämatologisch-Onkologische Gemeinschaftspraxis Am Bethanien-Krankenhaus, Frankfurt;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of Medicine, Division of Hematology/Medical Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Division of Hematology/Oncology, Magee-Womens Hospital and the Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.;Department of Medicine, Columbia University Irving Medical Center, New York, USA; Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA.;Oncology Department, International Breast Cancer Center (BCC), Pangaea Oncology, Quirónsalud, Barcelona, Spain; Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid, Madrid, Spain.;Medical Oncology, Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medicine - Hematology/Oncology Division, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Medical Oncology, Gianni Bonadonna Foundation, Milano, Italy.;Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Medical Affairs, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Clinical Development, Gilead Sciences, Inc., Foster City, CA, USA.;Department of Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.;Evidence Synthesis, Modeling & Communication (EMC), Evidera PPD, Waltham, MA, USA.;Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium."
"218","Plainvert C;Varon E;Viriot D;Kempf M","Plainvert, C;Varon, E;Viriot, D;Kempf, M","Invasive pneumococcal infections in France: Changes from 2009 to 2021 in antibiotic resistance and serotype distribution of Streptococcus pneumoniae based on data from the French Regional Pneumococcal Observatories network.","Infectious diseases now","France","eng","Journal Article","Antimicrobial resistance;French Regional Pneumococcal Observatories;Invasive infection;Serotype;Streptococcus pneumoniae","Child;Adult;Humans;Streptococcus pneumoniae;Serogroup;Anti-Bacterial Agents;Pneumococcal Infections;Drug Resistance, Microbial;Cefotaxime;Penicillins;Amoxicillin;France","Child;Adult;Humans;Streptococcus pneumoniae;Serogroup;Anti-Bacterial Agents;Pneumococcal Infections;Drug Resistance, Microbial;Cefotaxime;Penicillins;Amoxicillin;France","The 23 French Regional Pneumococcal Observatories (ORPs) analyzed antibiotic resistance and serotypes of Streptococcus pneumoniae strains isolated from invasive infections in France over a 12-year period. Between 2009 and 2021, the ORPs analyzed 19,319 strains, including 1,965 in children and 17,354 in adults. Strains were assessed for their resistance to penicillin G, amoxicillin and cefotaxime. Serotypes were identified in collaboration with the National Reference Centre. During this period, the number of strains collected yearly decreased significantly. The decrease was particularly pronounced up until 2013, especially in children (-61.0%). However, penicillin non-susceptible strains (PNSPs) increased in children (24.7% in 2009 vs 45.0% in 2021, p < 0.0001) and in adults (27.1% in 2009 vs 31.3% in 2021, p < 0.05), as well as resistance (I + R) to amoxicillin (children: 12.5% in 2009 vs 19.4% in 2021, p < 0.05; adults: 13.4% in 2009 vs 14.5% in 2021, NS) and resistance (I + R) to cefotaxime (children: 8.0% in 2009 vs 13.1% in 2021, p < 0.05; adults: 7.1% in 2009 vs 11.9% in 2021, p < 0.0001). All in all, the proportion of strains belonging to serotypes present in the PCV13 vaccine has fallen sharply, from 64.8% in 2009 to 23.6 % in 2021. At the same time, serotypes such as 8, 10A, 11A, 15B/C and 9N, not included in PCV13, were increasing. During the study period, data collected by the network highlighted an increase of invasive PNSPs in children and non-vaccine serotypes. Surveillance of resistance and serotypes remains instrumental, particularly to monitor the evolution of vaccine efficacy.","Observatoire Régional du Pneumocoque Île-de-France Ouest, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Service de Bactériologie, Paris, France.;Centre National de Référence des Pneumocoques (CNRP), Centre de Recherche Clinique et Biologique, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Santé Publique France, Saint Maurice, France.;Observatoire Régional du Pneumocoque Pays-de-la-Loire, Centre Hospitalier Universitaire d'Angers, Département de Biologie des Agents Infectieux, Laboratoire de Bactériologie, Angers, France; Nantes Université, Angers Université, INSERM, CNRS, INCIT, UMR 1302/EMR6001, équipe ATOMycA","NA",0,"2666-9919","Infect Dis Now","Infect Dis Now",2022,"2023","53","10.1016/j.idnow.2022.11.001","104632","","","36375765","36375765","PUBMED","Observatoire Régional du Pneumocoque Île-de-France Ouest, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Service de Bactériologie, Paris, France.;Centre National de Référence des Pneumocoques (CNRP), Centre de Recherche Clinique et Biologique, Centre Hospitalier Intercommunal de Créteil, Créteil, France.;Santé Publique France, Saint Maurice, France.;Observatoire Régional du Pneumocoque Pays-de-la-Loire, Centre Hospitalier Universitaire d'Angers, Département de Biologie des Agents Infectieux, Laboratoire de Bactériologie, Angers, France; Nantes Université, Angers Université, INSERM, CNRS, INCIT, UMR 1302/EMR6001, équipe ATOMycA"
"219","Deharo P;Leroux L;Theron A;Ferrara J;Vaillier A;Jaussaud N;Porto A;Morera P;Gariboldi V;Iung B;Lefevre T;Commeau P;Gouysse M;du Chayla F;Glatt N;Cayla G;Le Breton H;Benamer H;Beurtheret S;Verhoye JP;Eltchaninoff H;Gilard M;Collet JP;Dumonteil N;Collart F;Modine T;Cuisset T","Deharo, Pierre;Leroux, Lionel;Theron, Alexis;Ferrara, Jérome;Vaillier, Antoine;Jaussaud, Nicolas;Porto, Alizée;Morera, Pierre;Gariboldi, Vlad;Iung, Bernard;Lefevre, Thierry;Commeau, Philippe;Gouysse, Margaux;du Chayla, Florence;Glatt, Nicolas;Cayla, Guillaume;Le Breton, Herve;Benamer, Hakim;Beurtheret, Sylvain;Verhoye, Jean Philippe;Eltchaninoff, Helene;Gilard, Martine;Collet, Jean Philippe;Dumonteil, Nicolas;Collart, Frederic;Modine, Thomas;Cuisset, Thomas","Long-Term Prognosis Value of Paravalvular Leak and Patient-Prosthesis Mismatch following Transcatheter Aortic Valve Implantation: Insight from the France-TAVI Registry.","Journal of clinical medicine","Switzerland","eng","Journal Article","TAVI;mismatch;paravalvular leak","","","Transcatheter aortic valve implantation (TAVI) is the preferred treatment for symptomatic severe aortic stenosis (AS) in a majority of patients across all surgical risks. Paravalvular leak (PVL) and patient-prosthesis mismatch (PPM) are two frequent complications of TAVI. Therefore, based on the large France-TAVI registry, we planned to report the incidence of both complications following TAVI, evaluate their respective risk factors, and study their respective impacts on long-term clinical outcomes, including mortality. We identified 47,494 patients in the database who underwent a TAVI in France between 1 January 2010 and 31 December 2019. Within this population, 17,742 patients had information regarding PPM status (5138 with moderate-to-severe PPM, 29.0%) and 20,878 had information regarding PVL (4056 with PVL ≥ 2, 19.4%). After adjustment, the risk factors for PVL ≥ 2 were a lower body mass index (BMI), a high baseline mean aortic gradient, a higher body surface area, a lower ejection fraction, a smaller diameter of TAVI, and a self-expandable TAVI device, while for moderate-to-severe PPM we identified a younger age, a lower BMI, a larger body surface area, a low aortic annulus area, a low ejection fraction, and a smaller diameter TAVI device (OR 0.85; 95% CI, 0.83-0.86) as predictors. At 6.5 years, PVL ≥ 2 was an independent predictor of mortality and was associated with higher mortality risk. PPM was not associated with increased risk of mortality. Our analysis from the France-TAVI registry showed that both moderate-to-severe PPM and PVL ≥ 2 continue to be frequently observed after the TAVI procedure. Different risk factors, mostly related to the patient's anatomy and TAVI device selection, for both complications have been identified. Only PVL ≥ 2 was associated with higher mortality during follow-up.","Département de Cardiologie, CHU Timone, 13385 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;AP-HP, Cardiology Department, Bichat Hospital, Université Paris Cité, INSERM 1148, 46 rue Henri Huchard, 75018 Paris, France.;Hopital Privé Jacques Cartier, 6 Av. Noyer Lambert, 91300 Massy, France.;Cardiologie Interventionnelle, Polyclinique Les Fleurs, Groupe ELSAN, 83190 Ollioules, France.;Clinityx, 78620 Acheres, France.;Clinityx, 78620 Acheres, France.;Clinityx, 78620 Acheres, France.;Department of Cardiology, CHU Nîmes, 30029 Nimes, France.;Service de Cardiologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Hopital Privé Jacques Cartier, 6 Av. Noyer Lambert, 91300 Massy, France.;Saint-Joseph Hospital, 13000 Marseille, France.;Rennes University Hospital, 35033 Rennes, France.;Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, 76000 Rouen, France.;Department of Cardiology, CHRU Brest, 29200 Brest, France.;Department of Cardiology, Sorbonne Université, INSERM UMRS_1166, Pitié Salpêtrière (AP-HP), 75000 Paris, France.;Groupe CardioVasculaire Interventionnel, Clinique Pasteur, 31300 Toulouse, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.","NA",0,"2077-0383","J Clin Med","J Clin Med",2022,"2022","11","10.3390/jcm11206117",NA,"","","36294438","36294438","PUBMED","Département de Cardiologie, CHU Timone, 13385 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Chirurgie Cardiaque, CHU Timone, 13005 Marseille, France.;AP-HP, Cardiology Department, Bichat Hospital, Université Paris Cité, INSERM 1148, 46 rue Henri Huchard, 75018 Paris, France.;Hopital Privé Jacques Cartier, 6 Av. Noyer Lambert, 91300 Massy, France.;Cardiologie Interventionnelle, Polyclinique Les Fleurs, Groupe ELSAN, 83190 Ollioules, France.;Clinityx, 78620 Acheres, France.;Clinityx, 78620 Acheres, France.;Clinityx, 78620 Acheres, France.;Department of Cardiology, CHU Nîmes, 30029 Nimes, France.;Service de Cardiologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Hopital Privé Jacques Cartier, 6 Av. Noyer Lambert, 91300 Massy, France.;Saint-Joseph Hospital, 13000 Marseille, France.;Rennes University Hospital, 35033 Rennes, France.;Department of Cardiology, Normandie University, UNIROUEN, U1096, CHU Rouen, 76000 Rouen, France.;Department of Cardiology, CHRU Brest, 29200 Brest, France.;Department of Cardiology, Sorbonne Université, INSERM UMRS_1166, Pitié Salpêtrière (AP-HP), 75000 Paris, France.;Groupe CardioVasculaire Interventionnel, Clinique Pasteur, 31300 Toulouse, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Cardiologie, CHU Bordeaux, 33075 Bordeaux, France.;Département de Cardiologie, CHU Timone, 13385 Marseille, France.;INSERM, Inra, C2VN, Aix Marseille La Timone University, 13005 Marseille, France.;Faculté de Médecine, Aix-Marseille Université, 13005 Marseille, France."
"220","Kenji SF;Kurma K;Collet B;Oblet C;Debure L;Di Primo C;Minder L;Vérité F;Danger Y;Jean M;Penna A;Levoin N;Legembre P","Kenji, Shoji F;Kurma, Keerthi;Collet, Brigitte;Oblet, Christelle;Debure, Laure;Di Primo, Carmelo;Minder, Laëtitia;Vérité, Franck;Danger, Yannic;Jean, Mickael;Penna, Aubin;Levoin, Nicolas;Legembre, Patrick","MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathways.","Cell death & disease","England","eng","Journal Article","","fas Receptor;Matrix Metalloproteinase 7;Apoptosis;Leucine;Phosphatidylinositol 3-Kinases;Protein Sorting Signals;Arginine","fas Receptor;Matrix Metalloproteinase 7;Apoptosis;Leucine;Phosphatidylinositol 3-Kinases;Protein Sorting Signals;Arginine","CD95 is a death receptor that can promote oncogenesis through molecular mechanisms that are not fully elucidated. Although the mature CD95 membrane receptor is considered to start with the arginine at position 17 after elimination of the signal peptide, this receptor can also be cleaved by MMP7 upstream of its leucine at position 37. This post-translational modification occurs in cancer cells but also in normal cells such as peripheral blood leukocytes. The non-cleaved CD95 amino-terminal region consists in a disordered domain and its in silico reconstitution suggests that it might contribute to receptor aggregation and thereby, regulate the downstream death signaling pathways. In agreement with this molecular modeling analysis, the comparison of CD95-deficient cells reconstituted with full-length or N-terminally truncated CD95 reveals that the loss of the amino-terminal region of CD95 impairs the initial steps of the apoptotic signal while favoring the induction of pro-survival signals, including the PI3K and MAPK pathways.","IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;Université de Rennes-1, INSERM U1242, rue bataille Flandres Dunkerque, 35042, Rennes, France.;University Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, F-33000, Bordeaux, France.;University Bordeaux, CNRS, INSERM, UAR 3033, US001, IECB, F-33000, Bordeaux, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;Université de Rennes 1, Institut des Sciences Chimiques de Rennes - UMR CNRS 6226 Equipe COrInt, F-35000, Rennes, France.;IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;4CS, CNRS UMR6041, Université de Poitiers, 86073, Poitiers, France.;Bioprojet Biotech, rue du Chesnay Beauregard, 35760, Saint-Grégoire, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges","NA",0,"2041-4889","Cell Death Dis","Cell Death Dis",2022,"2022","13","10.1038/s41419-022-05352-0","895","","","36274061","36274061","PUBMED","IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, 35042, Rennes, France.;Université de Rennes-1, INSERM U1242, rue bataille Flandres Dunkerque, 35042, Rennes, France.;University Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, IECB, F-33000, Bordeaux, France.;University Bordeaux, CNRS, INSERM, UAR 3033, US001, IECB, F-33000, Bordeaux, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;EFS Rennes, Rue Pierre Jean Gineste, 35016, Rennes Cedex, France.;Université de Rennes 1, Institut des Sciences Chimiques de Rennes - UMR CNRS 6226 Equipe COrInt, F-35000, Rennes, France.;IRSET, INSERM U1085, Université de Rennes 1, 36043, Rennes, France.;4CS, CNRS UMR6041, Université de Poitiers, 86073, Poitiers, France.;Bioprojet Biotech, rue du Chesnay Beauregard, 35760, Saint-Grégoire, France.;INSERM U1262, Université de Limoges, 2, Rue Marcland, 87025, Limoges"
"221","Corniola MV;Roche PH;Bruneau M;Cavallo LM;Daniel RT;Messerer M;Froelich S;Gardner PA;Gentili F;Kawase T;Paraskevopoulos D;Régis J;Schroeder HWS;Schwartz TH;Sindou M;Cornelius JF;Tatagiba M;Meling TR","Corniola, Marco V;Roche, Pierre-Hugues;Bruneau, Michaël;Cavallo, Luigi M;Daniel, Roy T;Messerer, Mahmoud;Froelich, Sebastien;Gardner, Paul A;Gentili, Fred;Kawase, Takeshi;Paraskevopoulos, Dimitrios;Régis, Jean;Schroeder, Henry W S;Schwartz, Theodore H;Sindou, Marc;Cornelius, Jan F;Tatagiba, Marcos;Meling, Torstein R","Management of cavernous sinus meningiomas: Consensus statement on behalf of the EANS skull base section.","Brain & spine","Netherlands","eng","Journal Article","Cavernous sinus;Consensus statement;Cranial nerves;Gammaknife;Gross total resection;Intracranial meningiomas;Meningioma;Microsurgery;Neurosurgery;Pituitary;Radiosurgery;Radiotherapy","","","The evolution of cavernous sinus meningiomas (CSMs) might be unpredictable and the efficacy of their treatments is challenging due to their indolent evolution, variations and fluctuations of symptoms, heterogeneity of classifications and lack of randomized controlled trials. Here, a dedicated task force provides a consensus statement on the overall management of CSMs. To determine the best overall management of CSMs, depending on their clinical presentation, size, and evolution as well as patient characteristics. Using the PRISMA 2020 guidelines, we included literature from January 2000 to December 2020. A total of 400 abstracts and 77 titles were kept for full-paper screening. The task force formulated 8 recommendations (Level C evidence). CSMs should be managed by a highly specialized multidisciplinary team. The initial evaluation of patients includes clinical, ophthalmological, endocrinological and radiological assessment. Treatment of CSM should involve experienced skull-base neurosurgeons or neuro-radiosurgeons, radiation oncologists, radiologists, ophthalmologists, and endocrinologists. Radiosurgery is preferred as first-line treatment in small, enclosed, pauci-symptomatic lesions/in elderly patients, while large CSMs not amenable to resection or WHO grade II-III are candidates for radiotherapy. Microsurgery is an option in aggressive/rapidly progressing lesions in young patients presenting with oculomotor/visual/endocrinological impairment. Whenever surgery is offered, open cranial approaches are the current standard. There is limited experience reported about endoscopic endonasal approach for CSMs and the main indication is decompression of the cavernous sinus to improve symptoms. Whenever surgery is indicated, the current trend is to offer decompression followed by radiosurgery.","Department of Neurosurgery, Centre Hospitalier Universitaire de Rennes/Pontchaillou, Rennes, France.;Faculty of Medicine, University of Rennes, Rennes, France.;MediCIS Research Group, INSERM UR1, UMR 1099 LTSI, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Service de Neurochirurgie, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France.;Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium.;Department of Neurological Sciences, Division of Neurosurgery, Università Degli Studi di Napoli Federico II, Naples, Italy.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service de Neurochirurgie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, APHP Nord, Paris, France.;Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.;Department of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.;Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan.;Department of Neurosurgery, Barts Health NHS Trust, St. Bartholomew's and the Royal London Hospital, London, United Kingdom.;Department of Functional and Stereotactic Neurosurgery and Radiosurgery, Timone University Hospital, Marseille, France.;Department of Neurosurgery, Ernst Moritz Arndt University, Greifswald, Germany.;Department of Neurosurgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, USA.;University of Lyon, France.;IRR Flavigny, UGECAM Nord-Est, Nancy, France.;Pediatric Neurosurgery Department, Centre Hospitalier Régional de Nancy, Nancy, France.;Department of Neurosurgery, Heinrich Heine Universität, Düsseldorf, Germany.;Department of Neurosurgery, Uniklinik Tübingen, Tübingen, Germany.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland.","NA",0,"2772-5294","Brain Spine","Brain Spine",2021,"2022","2","10.1016/j.bas.2022.100864","100864","","","36248124","36248124","PUBMED","Department of Neurosurgery, Centre Hospitalier Universitaire de Rennes/Pontchaillou, Rennes, France.;Faculty of Medicine, University of Rennes, Rennes, France.;MediCIS Research Group, INSERM UR1, UMR 1099 LTSI, France.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Service de Neurochirurgie, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France.;Department of Neurosurgery, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan, Brussels, Belgium.;Department of Neurological Sciences, Division of Neurosurgery, Università Degli Studi di Napoli Federico II, Naples, Italy.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Department of Neurosurgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Service de Neurochirurgie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, APHP Nord, Paris, France.;Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA.;Department of Neurosurgery, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.;Department of Neurosurgery, School of Medicine, Keio University, Tokyo, Japan.;Department of Neurosurgery, Barts Health NHS Trust, St. Bartholomew's and the Royal London Hospital, London, United Kingdom.;Department of Functional and Stereotactic Neurosurgery and Radiosurgery, Timone University Hospital, Marseille, France.;Department of Neurosurgery, Ernst Moritz Arndt University, Greifswald, Germany.;Department of Neurosurgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, USA.;University of Lyon, France.;IRR Flavigny, UGECAM Nord-Est, Nancy, France.;Pediatric Neurosurgery Department, Centre Hospitalier Régional de Nancy, Nancy, France.;Department of Neurosurgery, Heinrich Heine Universität, Düsseldorf, Germany.;Department of Neurosurgery, Uniklinik Tübingen, Tübingen, Germany.;Faculty of Medicine, University of Geneva, Geneva, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, Geneva, Switzerland."
"222","Lamaison C;Ferrant J;Gravelle P;Traverse-Glehen A;Ghesquières H;Tosolini M;Rossi C;Ysebaert L;Brousset P;Laurent C;Syrykh C","Lamaison, Claire;Ferrant, Juliette;Gravelle, Pauline;Traverse-Glehen, Alexandra;Ghesquières, Hervé;Tosolini, Marie;Rossi, Cédric;Ysebaert, Loic;Brousset, Pierre;Laurent, Camille;Syrykh, Charlotte","Histological Subtypes Drive Distinct Prognostic Immune Signatures in Classical Hodgkin Lymphoma.","Cancers","Switzerland","eng","Journal Article","Hodgkin lymphoma;gene expression profiling;histological subtypes;immune prognosis signature","","","Despite the success of standard front-line chemotherapy, 20% of classical Hodgkin lymphoma (cHL) patients still relapse or have refractory disease (r/r), and a subset of them die due to disease progression. There is a critical lack of predictive factors for early identification of those r/r patients who may benefit from new therapeutic strategies. This study aimed to evaluate the dynamic expression of 586 immune-related genes in a cohort of 42 cHL patients including 30 r/r cHL after first-line chemotherapy. Gene expression profiling (GEP) using NanoString technology identified a 19-gene immune signature at diagnosis predictive of cHL relapse, but dependent on histological subtypes. Genes related to tumor survival were found upregulated while genes related to B-lineage were downregulated at diagnosis in r/r nodular sclerosis cHL. In contrast to the mixed-cellularity subtype, comparative GEP analyses between paired diagnosis/relapse biopsies of nodular sclerosis cHL showed 118 differentially expressed genes, supporting an immune contexture switch at relapse with upregulation of immunosuppressive cytokines, such as   and  , and downregulation of the T-cell co-stimulatory receptor  . These results indicate that the predictive value of immune signature in cHL is strongly influenced by histological subtype which should be considered when assessing new immunotherapy target strategies.","Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France.;Institut National de la Santé et de la Recherche Médicale, INSERM, Unité Mixte de Recherche U1236, Université Rennes 1, Établissement Français du Sang Bretagne, 35000 Rennes, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Lyon-Sud, 69495 Lyon, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Lyon-Sud, Université Claude Bernard Lyon-1, Pierre-Bénite, 69495 Lyon, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Hématologie, Centre Hospitalier Universitaire Dijon, Hôpital François Mitterrand, 21000 Dijon, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14194893",NA,"","","36230815","36230815","PUBMED","Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 35033 Rennes, France.;Institut National de la Santé et de la Recherche Médicale, INSERM, Unité Mixte de Recherche U1236, Université Rennes 1, Établissement Français du Sang Bretagne, 35000 Rennes, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Lyon-Sud, 69495 Lyon, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Lyon-Sud, Université Claude Bernard Lyon-1, Pierre-Bénite, 69495 Lyon, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Hématologie, Centre Hospitalier Universitaire Dijon, Hôpital François Mitterrand, 21000 Dijon, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Laboratoire d'Excellence TOUCAN, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France.;Service d'Anatomopathologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, 31059 Toulouse, France.;Centre de Recherches en Cancérologie de Toulouse, INSERM, U1037, 31037 Toulouse, France.;Université de Toulouse III Paul Sabatier, 31062 Toulouse, France."
"223","Jacot W;Lusque A;Vicier C;Mailliez A;de La Motte Rouge T;Cabel L;Levy C;Patsouris A;Desmoulins I;Uwer L;Thery JC;Robain M;Caron O;Tredan O;Filleron T;Frenel JS;Delaloge S","Jacot, William;Lusque, Amélie;Vicier, Cécile;Mailliez, Audrey;de La Motte Rouge, Thibault;Cabel, Luc;Levy, Christelle;Patsouris, Anne;Desmoulins, Isabelle;Uwer, Lionel;Thery, Jean-Christophe;Robain, Mathieu;Caron, Olivier;Tredan, Olivier;Filleron, Thomas;Frenel, Jean-Sébastien;Delaloge, Suzette","Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.","British journal of cancer","England","eng","Clinical Trial","","Female;Humans;Antineoplastic Agents;BRCA1 Protein;Breast Neoplasms;Germ Cells;Mutation;Platinum","Female;Humans;Antineoplastic Agents;BRCA1 Protein;Breast Neoplasms;Germ Cells;Mutation;Platinum","The efficacy and added benefit of platinum-based chemotherapy (PtCT) for metastatic breast cancer (MBC) remain unclear in patients with and without germline BRCA1 or BRCA2 mutations (gBRCA1/2m and gBRCA1/2wt, respectively). We selected from the French national real-world multicentre ESME cohort (2008-2016) all patients with HER2-negative MBC with known gBRCA1/2 status at first-line chemotherapy initiation. Using multivariable Cox models, we compared the outcome (progression-free (PFS) and overall survival (OS)) of first-line PtCT and non-PtCT regimens based on the patients' gBRCA1/2 status and tumour subtype. Patients who received PtCT had more aggressive tumour features. In the multivariable analysis, first-line PtCT was associated with better adjusted PFS and OS in gBRCA1/2m carriers (N = 300), compared with non-PtCT (HR 0.54, 95% CI 0.4-0.73, P < 0.001, and HR 0.70, 95% CI 0.49-0.99, P = 0.047, respectively). Conversely, outcomes were similar in gBRCA1/2wt patients (N = 922) treated with PtCT and non-PtCT, whatever the tumour subtype. Landmark analyses at months 3 and 6 post treatment initiation supported these results. In this pre-PARP inhibitor real-world cohort, PFS and OS were better after PtCT than non-PtCT in patients with gBRCA1/2m, but not in those with gBRCA1/2wt. These results emphasise the need of early gBRCA1/2 testing in patients with MBC. NCT03275311.","Institut du Cancer de Montpellier (ICM), INSERM U1194, Montpellier University, Montpellier, 34298;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre Oscar Lambret, Lille, France.;Centre Eugène Marquis, Rennes, France.;Institut Curie-UMR 144-CNRS, Paris, France.;Centre François Baclesse, Caen, France.;Institut de Cancérologie de l'Ouest, Pays de Loire, Angers, France.;Centre Georges François Leclerc, Dijon, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Henri Becquerel, Rouen, France.;UNICANCER, Paris, France.;Gustave Roussy, Villejuif, France.;Centre Léon Berard, Lyon, France.;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Gustave Roussy, Villejuif, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2022,"2022","127","10.1038/s41416-022-02003-1","1963-1973","","","36207609","36207609","PUBMED","Institut du Cancer de Montpellier (ICM), INSERM U1194, Montpellier University, Montpellier, 34298;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Centre Oscar Lambret, Lille, France.;Centre Eugène Marquis, Rennes, France.;Institut Curie-UMR 144-CNRS, Paris, France.;Centre François Baclesse, Caen, France.;Institut de Cancérologie de l'Ouest, Pays de Loire, Angers, France.;Centre Georges François Leclerc, Dijon, France.;Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France.;Centre Henri Becquerel, Rouen, France.;UNICANCER, Paris, France.;Gustave Roussy, Villejuif, France.;Centre Léon Berard, Lyon, France.;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Institut de Cancérologie de l'Ouest, Saint Herblain, France.;Gustave Roussy, Villejuif, France."
"224","Bidard FC;Hardy-Bessard AC;Dalenc F;Bachelot T;Pierga JY;de la Motte Rouge T;Sabatier R;Dubot C;Frenel JS;Ferrero JM;Ladoire S;Levy C;Mouret-Reynier MA;Lortholary A;Grenier J;Chakiba C;Stefani L;Plaza JE;Clatot F;Teixeira L;D'Hondt V;Vegas H;Derbel O;Garnier-Tixidre C;Canon JL;Pistilli B;André F;Arnould L;Pradines A;Bièche I;Callens C;Lemonnier J;Berger F;Delaloge S","Bidard, François-Clément;Hardy-Bessard, Anne-Claire;Dalenc, Florence;Bachelot, Thomas;Pierga, Jean-Yves;de la Motte Rouge, Thibault;Sabatier, Renaud;Dubot, Coraline;Frenel, Jean-Sébastien;Ferrero, Jean Marc;Ladoire, Sylvain;Levy, Christelle;Mouret-Reynier, Marie-Ange;Lortholary, Alain;Grenier, Julien;Chakiba, Camille;Stefani, Laetitia;Plaza, Jérôme Edouard;Clatot, Florian;Teixeira, Luis;D'Hondt, Véronique;Vegas, Hélène;Derbel, Olfa;Garnier-Tixidre, Claire;Canon, Jean-Luc;Pistilli, Barbara;André, Fabrice;Arnould, Laurent;Pradines, Anne;Bièche, Ivan;Callens, Céline;Lemonnier, Jérôme;Berger, Frédérique;Delaloge, Suzette","Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.","The Lancet. Oncology","England","eng","Randomized Controlled Trial","","Humans;Female;Adolescent;Adult;Fulvestrant;Aromatase Inhibitors;Breast Neoplasms;Receptors, Estrogen;Receptor, ErbB-2;Prospective Studies;Antineoplastic Combined Chemotherapy Protocols;Mutation;Neutropenia;Lymphopenia;Disease-Free Survival","Humans;Female;Adolescent;Adult;Fulvestrant;Aromatase Inhibitors;Breast Neoplasms;Receptors, Estrogen;Receptor, ErbB-2;Prospective Studies;Antineoplastic Combined Chemotherapy Protocols;Mutation;Neutropenia;Lymphopenia;Disease-Free Survival","In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones, which might be sensitive to fulvestrant. The PADA-1 trial aimed to show the efficacy of an early change in therapy on the basis of a rising ESR1 mutation in blood (bESR1 ), while assessing the global safety of combination fulvestrant and palbociclib. We did a randomised, open-label, phase 3 trial in 83 hospitals in France. Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1  during first-line aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1-21 of a 28-day cycle) therapy. Patients with newly present or increased bESR1  in circulating tumour DNA and no synchronous disease progression were randomly assigned (1:1) to continue with the same therapy or to switch to fulvestrant (500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1) and palbociclib (dosing unchanged). The randomisation sequence was generated within an interactive web response system using a minimisation method (with an 80% random factor); patients were stratified according to visceral involvement (present or absent) and the time from inclusion to bESR1  detection (<12 months or ≥12 months). The co-primary endpoints were investigator-assessed progression-free survival from random assignment, analysed in the intention-to-treat population (ie, all randomly assigned patients), and grade 3 or worse haematological adverse events in all patients. The trial is registered with Clinicaltrials.gov (NCT03079011), and is now complete. From March 22, 2017, to Jan 31, 2019, 1017 patients were included, of whom 279 (27%) developed a rising bESR1  and 172 (17%) were randomly assigned to treatment: 88 to switching to fulvestrant and palbociclib and 84 patients to continuing aromatase inhibitor and palbociclib. At database lock on July 31, 2021, randomly assigned patients had a median follow-up of 35·3 months (IQR 29·2-41·4) from inclusion and 26·0 months (13·8-34·3) from random assignment. Median progression-free survival from random assignment was 11·9 months (95% CI 9·1-13·6) in the fulvestrant and palbociclib group versus 5·7 months (3·9-7·5) in the aromatase inhibitor and palbociclib group (stratified HR 0·61, 0·43-0·86; p=0·0040). The most frequent grade 3 or worse haematological adverse events were neutropenia (715 [70·3%] of 1017 patients), lymphopenia (66 [6·5%]), and thrombocytopenia (20 [2·0%]). The most common grade 3 or worse adverse events in step 2 were neutropenia (35 [41·7%] of 84 patients in the aromatase inhibitor and palbociclib group vs 39 [44·3%] of 88 patients in the fulvestrant and palbociclib group) and lymphopenia (three [3·6%] vs four [4·5%]). 31 (3·1%) patients had grade 3 or worse serious adverse events related to treatment in the overall population. Three (1·7%) of 172 patients randomly assigned had one serious adverse event in step 2: one (1·2%) grade 4 neutropenia and one (1·2%) grade 3 fatigue among 84 patients in the aromatase inhibitor and palbociclib group, and one (1·1%) grade 4 neutropenia among 88 patients in the fulvestrant and palbociclib group. One death by pulmonary embolism in step 1 was declared as being treatment related. PADA-1 is the first prospective randomised trial showing that the early therapeutic targeting of bESR1  results in significant clinical benefit. Additionally, the original design explored in PADA-1 might help with tackling acquired resistance with new drugs in future trials. Pfizer.","Department of Medical Oncology, Institut Curie, Université Versailles Saint-Quentin, Université Paris-Saclay, Saint-Cloud, France; Circulating Tumour Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, Paris;Department of Medical Oncology, Centre Armoricaind'Oncologie, Plérin, France.;Department of Medical Oncology, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Circulating Tumour Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie and Université de Paris, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.;Department of Medical Oncology, Institut Curie, Université Versailles Saint-Quentin, Université Paris-Saclay, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Hopital Privé du Confluent, Nantes, France.;Department of Medical Oncology, Institut Sainte Catherine, Avignon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Hospitalier Annecy Genvoi, Pringy-Metz-Tessy, France.;Department of Medical Oncology, UNEOS Site Hôpital Robert Schuman, Vantoux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Hôpital Saint Louis, Paris, France.;Department of Medical Oncology, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France.;Department of Medical Oncology, Centre Hospitalier de Tours, Hôpital Bretonneau, Tours, France.;Department of Medical Oncology, Hôpital Privé Jean Mermoz, Lyon, France.;Department of Medical Oncology, Institut Daniel Hollard, G H Mutualiste de Grenoble, Grenoble, France.;Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgique.;Breast Oncology Department, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Pathology, Centre Georges François Leclerc, Dijon, France.;INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, Toulouse, France; Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute, Toulouse, France.;Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Research and Development Department, UNICANCER, Paris, France.;Biometry Unit, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Breast Oncology Department, Gustave Roussy, Villejuif, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2022,"2022","23","10.1016/S1470-2045(22)00555-1","1367-1377","","","36183733","36183733","PUBMED","Department of Medical Oncology, Institut Curie, Université Versailles Saint-Quentin, Université Paris-Saclay, Saint-Cloud, France; Circulating Tumour Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, Paris;Department of Medical Oncology, Centre Armoricaind'Oncologie, Plérin, France.;Department of Medical Oncology, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Circulating Tumour Biomarkers Laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie and Université de Paris, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.;Department of Medical Oncology, Institut Curie, Université Versailles Saint-Quentin, Université Paris-Saclay, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Hopital Privé du Confluent, Nantes, France.;Department of Medical Oncology, Institut Sainte Catherine, Avignon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Hospitalier Annecy Genvoi, Pringy-Metz-Tessy, France.;Department of Medical Oncology, UNEOS Site Hôpital Robert Schuman, Vantoux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Hôpital Saint Louis, Paris, France.;Department of Medical Oncology, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier, France.;Department of Medical Oncology, Centre Hospitalier de Tours, Hôpital Bretonneau, Tours, France.;Department of Medical Oncology, Hôpital Privé Jean Mermoz, Lyon, France.;Department of Medical Oncology, Institut Daniel Hollard, G H Mutualiste de Grenoble, Grenoble, France.;Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgique.;Breast Oncology Department, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Pathology, Centre Georges François Leclerc, Dijon, France.;INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, Toulouse, France; Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute, Toulouse, France.;Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Pharmacogenomic Unit, Genetics Laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Research and Development Department, UNICANCER, Paris, France.;Biometry Unit, Institut Curie, PSL University, Saint-Cloud, Paris, France.;Breast Oncology Department, Gustave Roussy, Villejuif, France."
"225","Coste G;Robin F;Chemouny J;Tron C;Le Priol J;Bouvet R;Le Vée M;Houssel-Debry P;Rayar M;Verdier MC;Roussel M;Galibert MD;Bardou-Jacquet E;Fardel O;Vigneau C;Boudjema K;Laviolle B;Lemaitre F","Coste, Gwendal;Robin, Fabien;Chemouny, Jonathan;Tron, Camille;Le Priol, Jérôme;Bouvet, Régis;Le Vée, Marc;Houssel-Debry, Pauline;Rayar, Michel;Verdier, Marie-Clémence;Roussel, Mikael;Galibert, Marie-Dominique;Bardou-Jacquet, Edouard;Fardel, Olivier;Vigneau, Cécile;Boudjema, Karim;Laviolle, Bruno;Lemaitre, Florian","Drug transporters are implicated in the diffusion of tacrolimus into the T lymphocyte in kidney and liver transplant recipients: Genetic, mRNA, protein expression, and functionality.","Drug metabolism and pharmacokinetics","England","eng","Journal Article","Drug transporter;Personalized medicine;Pharmacokinetics;Solid organ transplantation;Tacrolimus;Therapeutic drug monitoring","Humans;Tacrolimus;Leukocytes, Mononuclear;Liver Transplantation;RNA, Messenger;Cytochrome P-450 CYP3A;T-Lymphocytes;Immunosuppressive Agents;Kidney","Humans;Tacrolimus;Leukocytes, Mononuclear;Liver Transplantation;RNA, Messenger;Cytochrome P-450 CYP3A;T-Lymphocytes;Immunosuppressive Agents;Kidney","Because of a narrow therapeutic index and a wide inter- and intra-patient variability, therapeutic drug monitoring of the immunosuppressant drug tacrolimus (TAC) based on whole-blood concentrations (C ) is mandatory in solid organ transplant recipients. Using peripheral blood mononuclear cells concentrations (C ) could improve patient outcomes. The poor correlation between C  and C  makes hypothesize that drug transporters are implicated in the intracellular accumulation of TAC. The aim of this work was therefore to clinically study: i) the role of genetic variants and ii) the effect of mRNA and protein expression of 4 drug transporters on the TAC C  ratio. In addition, functional in vitro experiments were performed to mechanistically validate the clinical observations. Genetic variants of ABCB1/P-gp and SLC28A3/CNT3 did not influence TAC C  in liver transplant recipients (LTR). ABCC2/MRP2 at the mRNA level; ABCB1/P-gp, SLC28A3/CNT3 and SLC29A1/ENT1 at the protein level; correlated with the C  in kidney and LTR. In vitro results suing transporter-expressing cells confirmed that TAC is substrate of P-gp but not MRP2, whereas experiments remained inconclusive for CNT3 and ENT1. In conclusion, the genetic-transcription-protein-functional approach presented in this work provides new insights in the understanding of TAC transport at the T lymphocyte plasma membrane.","Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes;Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de néphrologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire de génétique moléculaire et génomique médicale, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France; Université de Rennes, Établissement Français du Sang (EFS) de Bretagne, Inserm, MICMAC-UMR_S1236, Rennes, France.;Laboratoire de génétique moléculaire et génomique médicale, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France; Université Rennes, CNRS, IGDR, UMR, 6290, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; Service de néphrologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.","NA",0,"1880-0920","Drug Metab Pharmacokinet","Drug Metab Pharmacokinet",2022,"2022","47","10.1016/j.dmpk.2022.100473","100473","","","36166890","36166890","PUBMED","Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes;Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de néphrologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire de génétique moléculaire et génomique médicale, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France; Université de Rennes, Établissement Français du Sang (EFS) de Bretagne, Inserm, MICMAC-UMR_S1236, Rennes, France.;Laboratoire de génétique moléculaire et génomique médicale, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France; Université Rennes, CNRS, IGDR, UMR, 6290, Rennes, France.;INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; Service de néphrologie, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de chirurgie hépato-biliaire et digestive, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes, Université Rennes 1, F-35000, Rennes, France; INSERM, Centre d'Investigation Clinique 1414, F-35000, Rennes, France; Service de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France."
"226","Gigante E;Hobeika C;Le Bail B;Paradis V;Tougeron D;Lequoy M;Bouattour M;Blanc JF;Ganne-Carrié N;Tran H;Hollande C;Allaire M;Amaddeo G;Regnault H;Vigneron P;Ronot M;Elkrief L;Verset G;Trepo E;Zaanan A;Ziol M;Ningarhari M;Calderaro J;Edeline J;Nault JC","Gigante, Elia;Hobeika, Christian;Le Bail, Brigitte;Paradis, Valérie;Tougeron, David;Lequoy, Marie;Bouattour, Mohamed;Blanc, Jean-Frederic;Ganne-Carrié, Nathalie;Tran, Henri;Hollande, Clémence;Allaire, Manon;Amaddeo, Giuliana;Regnault, Hélène;Vigneron, Paul;Ronot, Maxime;Elkrief, Laure;Verset, Gontran;Trepo, Eric;Zaanan, Aziz;Ziol, Marianne;Ningarhari, Massih;Calderaro, Julien;Edeline, Julien;Nault, Jean-Charles","Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.","Liver cancer","Switzerland","eng","Journal Article","Cholangiocarcinoma;Hepatocellular carcinoma;Hepatocholangiocarcinoma;Platinum;Systemic treatment;Tyrosine kinase inhibitors","","","Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA. Patients with histological diagnosis of unresectable or metastatic cHCC-CCA confirmed by a centralized review (WHO classification 2019) and who received systemic treatment from 2009 to 2020 were included retrospectively in 11 centers. The outcomes of patients with cHCC-CCA were compared with patients with hepatocellular carcinoma (HCC) treated by sorafenib (  = 117) and with intrahepatic cholangiocarcinoma (iCCA,   = 94) treated mainly by platinum-based chemotherapy using a frailty Cox model. The efficacy of TKIs and platinum-based chemotherapies in patients with cHCC-CCA was assessed using a doubly robust estimator. A total of 83 patients with cHCC-CCA were included and were predominantly male (72%) with underlying cirrhosis (55%). 67% of patients had extrahepatic metastases and 31% macrovascular tumor invasion. cHCC-CCAs were more often developed on cirrhosis (55.4%) than iCCA (26.6%) but less frequently than HCC (80.2%) (  < 0.001). Both HCC (36.8% and cHCC-CCA (66.2%) had less frequent extrahepatic metastases than iCCA (81%) (  < 0.001). Unadjusted overall survival (OS) was better in iCCA (13 months) compared to cHCC-CCA (12 months) and HCC (11 months) (  = 0.130). In multivariable analysis, after adjustment by a Cox frailty model, patients with cHCC-CCA had the same survival as HCC and iCCA (HR = 0.67, 95% CI: 0.37-1.22,   = 0.189 and HR = 0.66, 95% CI: 0.43-1.02,   = 0.064, respectively). ALBI score (HR = 2.15; 95% CI: 1.23-3.76;   = 0.009), ascites (HR = 3.45, 95% CI: 1.31-9.03,   = 0.013), and tobacco use (HR = 2.29, 95% CI: 1.08-4.87,   = 0.032) were independently associated with OS in patients with cHCC-CCA. Among patients with cHCC-CCA, 25 patients treated with TKI were compared with 54 patients who received platinum-based chemotherapies. Patients treated with TKI had a median OS of 8.3 months compared to 11.9 months for patients treated with platinum-based chemotherapy (  = 0.86). After a robust doubly adjustment on tumor number and size, vascular invasion, ALBI, MELD, and cirrhosis, the type of treatment did not impact OS (HR = 0.92, 95% CI: 0.27-3.15,   = 0.88) or progression-free survival (HR = 1.24, 95% CI: 0.44-3.49,   = 0.67). First-line systemic treatments with TKIs or platinum-based chemotherapies have similar efficacy in patients with unresectable/metastatic cHCC-CCA. The ALBI score predicts OS.","Service d'Hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.;Service d'Anatomo-Pathologie, Hôpital Beaujon, AP-HP, Clichy, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers, France.;Service d'Hépatologie, Hôpital Saint-Antoine, AP-HP, Paris, France.;Unité Oncologie Hépatique, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie et d'Oncologie digestive, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac: INSERM U1053, Université de Bordeaux, Bordeaux, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Cochin, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Radiologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépatologie HC, UMUH 1, CHRU Tours, Tours, France.;Department of Gastroenterology and Digestive Oncology, Erasme Hospital, Brussels, Belgium.;Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.;Service Hépato-gastro-entérologie et Oncologie digestive, Hôpital Européen Georges-Pompidou, Université de Paris, AP-HP centre, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France.;Service des Maladies de l'appareil digestif et nutrition-Hépatologie, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Service d'Anatomo-Pathologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Oncologie, Centre Eugène Marquis, Rennes, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.","NA",0,"2235-1795","Liver Cancer","Liver Cancer",2021,"2022","11","10.1159/000525488","460-473","","","36158591","36158591","PUBMED","Service d'Hépatologie, Hôpital Avicenne, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bobigny, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Chirurgie Digestive, Hépato-Bilio-Pancréatique et Transplantation Hépatique, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Pellegrin, CHU Bordeaux, Bordeaux, France.;Service d'Anatomo-Pathologie, Hôpital Beaujon, AP-HP, Clichy, France et Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers, France.;Service d'Hépatologie, Hôpital Saint-Antoine, AP-HP, Paris, France.;Unité Oncologie Hépatique, Service d'Hépatologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie et d'Oncologie digestive, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac: INSERM U1053, Université de Bordeaux, Bordeaux, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France.;Service d'Hépatologie, Hôpital Cochin, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital de la Pitié Salpêtrière, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Hépatologie, Hôpital Mondor, AP-HP, Paris, France.;Centre de recherche sur l'inflammation, Inserm, Université de Paris, INSERM UMR 1149, De l'inflammation au cancer, Paris, France.;Service de Radiologie, Hôpital Beaujon, AP-HP, Paris, France.;Service d'Hépatologie HC, UMUH 1, CHRU Tours, Tours, France.;Department of Gastroenterology and Digestive Oncology, Erasme Hospital, Brussels, Belgium.;Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Hôpital Erasme, Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.;Service Hépato-gastro-entérologie et Oncologie digestive, Hôpital Européen Georges-Pompidou, Université de Paris, AP-HP centre, Paris, France.;Service d'Anatomo-Pathologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France.;Service des Maladies de l'appareil digestif et nutrition-Hépatologie, CHRU de Lille-Hôpital Claude Huriez, Lille, France.;Service d'Anatomo-Pathologie, Hôpital Mondor, AP-HP, Paris, France.;Service d'Oncologie, Centre Eugène Marquis, Rennes, France.;Service d'Hépatologie, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, Paris, France.;Centre de Recherche des Cordeliers, Université de Paris, INSERM UMR 1138, Paris, France."
"227","de Calbiac O;Lusque A;Mailliez A;Bachelot T;Uwer L;Mouret-Reynier MA;Emile G;Jouannaud C;Gonçalves A;Patsouris A;Diéras V;Leheurteur M;Petit T;Cottu P;Ferrero JM;D'Hondt V;Desmoulins I;Mourato-Ribeiro J;Martin AL;Frenel JS","de Calbiac, Ombline;Lusque, Amélie;Mailliez, Audrey;Bachelot, Thomas;Uwer, Lionel;Mouret-Reynier, Marie-Ange;Emile, George;Jouannaud, Christelle;Gonçalves, Anthony;Patsouris, Anne;Diéras, Véronique;Leheurteur, Marianne;Petit, Thierry;Cottu, Paul;Ferrero, Jean-Marc;D'Hondt, Véronique;Desmoulins, Isabelle;Mourato-Ribeiro, Joana;Martin, Anne-Laure;Frenel, Jean-Sébastien","Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.","JAMA network open","United States","eng","Comparative Study","","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cohort Studies;Female;Hormones;Humans;Middle Aged;Prognosis;Receptor, ErbB-2;Retrospective Studies;Young Adult","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Cohort Studies;Female;Hormones;Humans;Middle Aged;Prognosis;Receptor, ErbB-2;Retrospective Studies;Young Adult","ERBB2-low (ie, ERBB2 immunohistochemistry score of 1+ or 2+ in the absence of ERBB2 gene amplification) breast cancer (BC) is a new entity, with emerging dedicated treatments. Little is known about its prognosis and response to conventional therapy compared with ERBB2-zero breast tumors (ie, those with an immunohistochemistry score of 0). To compare the outcomes for patients with ERBB2-low metastatic BC (MBC) with those of patients with ERBB2-zero MBC. This cohort study was conducted from the Epidemiological Strategy and Medical Economics MBC platform and included patients with MBC treated between 2008 and 2016 in 18 French comprehensive cancer centers. The data analysis was conducted from July 16, 2020, to April 1, 2022. The main outcome was overall survival (OS), and the secondary outcome was progression-free survival under first-line treatments (PFS1). The median (range) age was 60.0 (22.0-103.0) years. Among 15 054 patients with MBC, 4671 (31%) had ERBB2-low MBC and 10 383 (69%) had ERBB2-zero MBC. The proportion of ERBB2-low cancers was higher among patients with hormone receptor-positive MBC than those with hormone receptor-negative disease (4083 patients [33.0%] vs 588 patients [21.0%]). With a median follow-up of 49.5 months (95% CI, 48.6-50.4 months), the median OS of the ERBB2-low group was 38.0 months (95% CI, 36.4-40.5 months) compared with 33.9 months (95% CI, 32.9-34.9 months) for the ERBB2-zero group (P < .001). After adjustment for age, visceral metastases, number of metastatic sites, de novo disease, period of care, and hormone receptor status, patients with ERBB2-low MBC had slightly better OS compared with patients with ERBB2-zero MBC (adjusted hazard ratio, 0.95; 95% CI, 0.91-0.99; P = .02). In contrast, PFS1 did not differ by ERBB2 status (adjusted hazard ratio, 0.99; 95% CI, 0.95-1.02; P = .45). No significant differences in OS and PFS1 were observed in multivariate analyses by hormone receptor status and types of frontline treatment. In this large cohort study, patients with ERBB2-low MBC had a slightly better OS than those with completely ERBB2-zero tumors, but identical PFS1, which could help guide treatment selection.","Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Saint-Herblain, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Angers, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Health Data and Partnerships Department, Unicancer, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Saint-Herblain, France.","NA",0,"2574-3805","JAMA Netw Open","JAMA Netw Open",2022,"2022","5","10.1001/jamanetworkopen.2022.31170","e2231170","","","36107428","36107428","PUBMED","Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Saint-Herblain, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Angers, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut Curie, Paris and Saint-Cloud, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Health Data and Partnerships Department, Unicancer, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes and Angers, Saint-Herblain, France."
"228","Heddar A;Ogur C;Da Costa S;Braham I;Billaud-Rist L;Findikli N;Beneteau C;Reynaud R;Mahmoud K;Legrand S;Marchand M;Cedrin-Durnerin I;Cantalloube A;Peigne M;Bretault M;Dagher-Hayeck B;Perol S;Droumaguet C;Cavkaytar S;Nicolas-Bonne C;Elloumi H;Khrouf M;Rougier-LeMasle C;Fradin M;Le Boette E;Luigi P;Guerrot AM;Ginglinger E;Zampa A;Fauconnier A;Auger N;Paris F;Brischoux-Boucher E;Cabrol C;Brun A;Guyon L;Berard M;Riviere A;Gruchy N;Odent S;Gilbert-Dussardier B;Isidor B;Piard J;Lambert L;Hamamah S;Guedj AM;Brac de la Perriere A;Fernandez H;Raffin-Sanson ML;Polak M;Letur H;Epelboin S;Plu-Bureau G;Wołczyński S;Hieronimus S;Aittomaki K;Catteau-Jonard S;Misrahi M","Heddar, Abdelkader;Ogur, Cagri;Da Costa, Sabrina;Braham, Inès;Billaud-Rist, Line;Findikli, Necati;Beneteau, Claire;Reynaud, Rachel;Mahmoud, Khaled;Legrand, Stéphanie;Marchand, Maud;Cedrin-Durnerin, Isabelle;Cantalloube, Adèle;Peigne, Maeliss;Bretault, Marion;Dagher-Hayeck, Benedicte;Perol, Sandrine;Droumaguet, Celine;Cavkaytar, Sabri;Nicolas-Bonne, Carole;Elloumi, Hanen;Khrouf, Mohamed;Rougier-LeMasle, Charlotte;Fradin, Melanie;Le Boette, Elsa;Luigi, Perrine;Guerrot, Anne-Marie;Ginglinger, Emmanuelle;Zampa, Amandine;Fauconnier, Anais;Auger, Nathalie;Paris, Françoise;Brischoux-Boucher, Elise;Cabrol, Christelle;Brun, Aurore;Guyon, Laura;Berard, Melanie;Riviere, Axelle;Gruchy, Nicolas;Odent, Sylvie;Gilbert-Dussardier, Brigitte;Isidor, Bertrand;Piard, Juliette;Lambert, Laetitia;Hamamah, Samir;Guedj, Anne Marie;Brac de la Perriere, Aude;Fernandez, Hervé;Raffin-Sanson, Marie-Laure;Polak, Michel;Letur, Hélène;Epelboin, Sylvie;Plu-Bureau, Genevieve;Wołczyński, Sławomir;Hieronimus, Sylvie;Aittomaki, Kristiina;Catteau-Jonard, Sophie;Misrahi, Micheline","Genetic landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized medicine.","EBioMedicine","Netherlands","eng","Journal Article","Meiosis/DNA repair genes;Mitophagy;NF-KB;Personalized medicine;Post - translational regulation;Primary ovarian insufficiency","Female;Humans;Infertility;Mitomycins;NF-kappa B;Precision Medicine;Primary Ovarian Insufficiency","Female;Humans;Infertility;Mitomycins;NF-kappa B;Precision Medicine;Primary Ovarian Insufficiency","Primary Ovarian Insufficiency (POI), a public health problem, affects 1-3.7% of women under 40 yielding infertility and a shorter lifespan. Most causes are unknown. Recently, genetic causes were identified, mostly in single families. We studied an unprecedented large cohort of POI to unravel its molecular pathophysiology. 375 patients with 70 families were studied using targeted (88 genes) or whole exome sequencing with pathogenic/likely-pathogenic variant selection. Mitomycin-induced chromosome breakages were studied in patients' lymphocytes if necessary. A high-yield of 29.3% supports a clinical genetic diagnosis of POI. In addition, we found strong evidence of pathogenicity for nine genes not previously related to a Mendelian phenotype or POI: ELAVL2, NLRP11, CENPE, SPATA33, CCDC150, CCDC185, including DNA repair genes: C17orf53(HROB), HELQ, SWI5 yielding high chromosomal fragility. We confirmed the causal role of BRCA2, FANCM, BNC1, ERCC6, MSH4, BMPR1A, BMPR1B, BMPR2, ESR2, CAV1, SPIDR, RCBTB1 and ATG7 previously reported in isolated patients/families. In 8.5% of cases, POI is the only symptom of a multi-organ genetic disease. New pathways were identified: NF-kB, post-translational regulation, and mitophagy (mitochondrial autophagy), providing future therapeutic targets. Three new genes have been shown to affect the age of natural menopause supporting a genetic link. We have developed high-performance genetic diagnostic of POI, dissecting the molecular pathogenesis of POI and enabling personalized medicine to i) prevent/cure comorbidities for tumour/cancer susceptibility genes that could affect life-expectancy (37.4% of cases), or for genetically-revealed syndromic POI (8.5% of cases), ii) predict residual ovarian reserve (60.5% of cases). Genetic diagnosis could help to identify patients who may benefit from the promising in vitro activation-IVA technique in the near future, greatly improving its success in treating infertility. Université Paris Saclay, Agence Nationale de Biomédecine.","Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif, France.;Igenomix Turkey, İstanbul, Turkey; Institute of Science, Department of Bioengineering Yildiz Technical University, İstanbul, Turkey.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service d'Endocrinologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin/Port-Royal, 75005, Paris, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Faculty of Engineering and Architecture, Department of Biomedical Engineering, Beykent University, İstanbul, Turkey.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Aix Marseille Université, Assistance-Publique des Hôpitaux de Marseille (AP-HM), Service de Pédiatrie multidisciplinaire Hôpital de la Timone Enfants, 13385, Marseille Cedex 05, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre de Fertilité - Clinique de l'Atlantique La Rochelle, 17000, La Rochelle, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Üsküdar University, Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey.;Service de Gynécologie et d'Obstétrique, Centre Hospitalier Alpes Léman, 74130, Contamine-Sur-Arve, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France; Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service d'Endocrinologie-Diabétologie, Centre Hospitalier Antibes Juan Les Pins, 06600, Antibes, France.;Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics and reference center for developmental disorders, FHU G4 Génomique, F-76000 Rouen, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service d'Endocrinologie, Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Saint-Etienne, 42270, Saint-Priest-en-Jarez, France.;Service de génétique des tumeurs. Institut Gustave Roussy, 94805, Villejuif, France.;Département de Pédiatrie, Unité d'Endocrinologie-Gynécologie Pédiatrique, Hôpital A.-de-Villeneuve, Centre Hospitalier Universitaire Montpellier et Université Montpellier, 34090, Montpellier, France; Constitutif Sud, Centre de Référence Maladies Rares du Développement Génital, Hôpital Lapeyronie, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, 34090 Montpellier, France; INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, EA 7450 BioTARGen, FHU G4 Genomics, Caen, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France; Centre Hospitalier Universitaire de Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Université de Montpellier, Montpellier, France.;Service d'Endocrinologie et de Maladies Métaboliques, Centre Hospitalier Universitaire Nîmes, Université de Montpellier, 30029, Nîmes, France.;Fédération d'Endocrinologie, Centre de Référence des Maladies Rares du Développement Génital, Groupement Hospitalier Est, Hôpital Louis Pradel, 69002, Lyon, France.;Service de Gynecologie et d'Obstétrique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Faculté de médicine, Université Paris-Saclay, 94270 Le Kremlin Bicêtre, France; UVSQ, Inserm, CESP, Université Paris-Saclay, 94807 Villejuif, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Foch, 40 rue Worth 92 150 Suresnes, France; Service de Médecine de la Reproduction et Préservation de la Fertilité, Polyclinique de Navarre, 8, boulevard Hauterive, 64000 Pau, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.;Service de gynécologie médicale, orthogénie et sexologie, Centre Hospitalier Universitaire de Lille, Université de Lille, 59000 Lille, France.;Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif","NA",0,"2352-3964","EBioMedicine","EBioMedicine",2022,"2022","84","10.1016/j.ebiom.2022.104246","104246","","","36099812","36099812","PUBMED","Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif, France.;Igenomix Turkey, İstanbul, Turkey; Institute of Science, Department of Bioengineering Yildiz Technical University, İstanbul, Turkey.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service d'Endocrinologie, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin/Port-Royal, 75005, Paris, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Faculty of Engineering and Architecture, Department of Biomedical Engineering, Beykent University, İstanbul, Turkey.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Aix Marseille Université, Assistance-Publique des Hôpitaux de Marseille (AP-HM), Service de Pédiatrie multidisciplinaire Hôpital de la Timone Enfants, 13385, Marseille Cedex 05, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre de Fertilité - Clinique de l'Atlantique La Rochelle, 17000, La Rochelle, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service de Médecine de la Reproduction et Préservation de la Fertilité, hôpital Jean-Verdier, Assistance Publique-Hôpitaux de Paris, 93143 Bondy, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Service de Médecine Interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris, 94000 Créteil, France.;Bahçeci Umut IVF Centre, Altunizade, İstanbul, Turkey; Üsküdar University, Faculty of Medicine, Department of Obstetrics and Gynecology, İstanbul, Turkey.;Service de Gynécologie et d'Obstétrique, Centre Hospitalier Alpes Léman, 74130, Contamine-Sur-Arve, France.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Centre FERTILLIA de Médecine de la Reproduction- Clinique la ROSE, Tunis, Tunisie.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France; Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service de Génétique Médicale, Centre Hospitalier de Saint Brieuc, 22000, Saint-Brieuc, France.;Service d'Endocrinologie-Diabétologie, Centre Hospitalier Antibes Juan Les Pins, 06600, Antibes, France.;Normandie Univ, UNIROUEN, Inserm U1245, CHU Rouen, Department of Genetics and reference center for developmental disorders, FHU G4 Génomique, F-76000 Rouen, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service de Génétique, Centre Hospitalier de Mulhouse, 68100, Mulhouse, France.;Service d'Endocrinologie, Diabète et Maladies Métaboliques, Centre Hospitalier Universitaire de Saint-Etienne, 42270, Saint-Priest-en-Jarez, France.;Service de génétique des tumeurs. Institut Gustave Roussy, 94805, Villejuif, France.;Département de Pédiatrie, Unité d'Endocrinologie-Gynécologie Pédiatrique, Hôpital A.-de-Villeneuve, Centre Hospitalier Universitaire Montpellier et Université Montpellier, 34090, Montpellier, France; Constitutif Sud, Centre de Référence Maladies Rares du Développement Génital, Hôpital Lapeyronie, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, 34090 Montpellier, France; INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;Normandy University, UNICAEN, Caen University Hospital, Department of Genetics, EA 7450 BioTARGen, FHU G4 Genomics, Caen, France.;Service de Génétique Clinique, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Univ Rennes, CNRS IGDR UMR 6290, Centre de référence Anomalies du développement CLAD-Ouest, ERN ITHACA, 35203, Rennes, France.;Service de Génétique, Centre Hospitalier Universitaire de Poitiers, Université de Poitiers, 86021, Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire Nantes, 44000, Nantes, France.;Centre de Génétique Humaine, Université de Franche-Comté, Centre Hospitalier Universitaire de Besançon, 25000, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, F-54000, Nancy, France.;INSERM 1203, Développement Embryonnaire Fertilité Environnement, Université de Montpellier, 34090, Montpellier, France; Centre Hospitalier Universitaire de Montpellier, Département de Biologie de la Reproduction, Biologie de la Reproduction/DPI et CECOS, Université de Montpellier, Montpellier, France.;Service d'Endocrinologie et de Maladies Métaboliques, Centre Hospitalier Universitaire Nîmes, Université de Montpellier, 30029, Nîmes, France.;Fédération d'Endocrinologie, Centre de Référence des Maladies Rares du Développement Génital, Groupement Hospitalier Est, Hôpital Louis Pradel, 69002, Lyon, France.;Service de Gynecologie et d'Obstétrique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Faculté de médicine, Université Paris-Saclay, 94270 Le Kremlin Bicêtre, France; UVSQ, Inserm, CESP, Université Paris-Saclay, 94807 Villejuif, France.;Service d'Endocrinologie, Hôpital Ambroise Paré, Assistance Publique-Hôpitaux de Paris, 92100, Boulogne Billancourt, France.;Service d'Endocrinologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, CNR pathologies gynécologiques rares, 75015, Paris, France.;Service de Gynécologie Obstétrique et Médecine de la Reproduction, Hôpital Foch, 40 rue Worth 92 150 Suresnes, France; Service de Médecine de la Reproduction et Préservation de la Fertilité, Polyclinique de Navarre, 8, boulevard Hauterive, 64000 Pau, France.;Service de Gynécologie et d'Obstétrique, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, AP-HP. Faculté de Médecine Pierre et Marie Curie. Université de la Sorbonne, Paris, France.;Unité de gynécologie médicale, APHP, Hôpital Port-Royal Cochin, 27 Rue du Faubourg Saint-Jacques, Paris 75014, France.;Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Bialystok, Poland.;Service d'Endocrinologie et de Médicine de la Reproduction, Hôpital Universitaire de Nice, 06200, Nice, France.;Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.;Service de gynécologie médicale, orthogénie et sexologie, Centre Hospitalier Universitaire de Lille, Université de Lille, 59000 Lille, France.;Université Paris Saclay, Faculté de Médecine. Unité de Génétique Moléculaire des Maladies Métaboliques et de la Reproduction, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, AP-HP, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France; UMR-S 1193, INSERM, Université Paris Saclay, Faculté de Médecine, Hôpital Paul Brousse, Villejuif"
"229","Meynard L;Dinart D;Delaunay B;Fléchon A;Saldana C;Lefort F;Gravis G;Thiery-Vuillemin A;Cancel M;Coquan E;Ladoire S;Maillet D;Rolland F;Boughalem E;Martin S;Laramas M;Crouzet L;Abbar B;Falkowski S;Pouessel D;Roubaud G","Meynard, Lucie;Dinart, Derek;Delaunay, Blandine;Fléchon, Aude;Saldana, Carolina;Lefort, Félix;Gravis, Gwenaëlle;Thiery-Vuillemin, Antoine;Cancel, Mathilde;Coquan, Elodie;Ladoire, Sylvain;Maillet, Denis;Rolland, Frédéric;Boughalem, Elouen;Martin, Sophie;Laramas, Mathieu;Crouzet, Laurence;Abbar, Baptiste;Falkowski, Sabrina;Pouessel, Damien;Roubaud, Guilhem","Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Chemotherapy;Immune checkpoint inhibitor;Urothelial carcinoma","Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Transitional Cell;Humans;Immune Checkpoint Inhibitors;Retrospective Studies;Taxoids;Treatment Outcome;Urinary Bladder Neoplasms","Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Transitional Cell;Humans;Immune Checkpoint Inhibitors;Retrospective Studies;Taxoids;Treatment Outcome;Urinary Bladder Neoplasms","Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy re-challenge after ICI, compared with second-line chemotherapy without previous ICI in patients with locally advanced or metastatic urothelial carcinoma (la/mUC). In this multicentre retrospective study, we included all patients with la/mUC initiating second or third-line chemotherapy from January 2015 to June 2020. We compared patients treated with second-line chemotherapy without previous ICI (CT2) and patients treated with third-line chemotherapy after ICI (CT3). The primary end-point was objective response rate (ORR) in CT3 compared with CT2. Secondary end-points included progression-free survival (PFS) and toxicities. Overall, 553 patients were included. ORRs were 31.0% (95% CI, 26.5 to 35.5) and 29.2% (95% CI, 21.9 to 36.6), respectively, in CT2 and CT3, with no statistically significant differences (P = 0.62). In subgroup analyses, no differences in ORR were observed by Bellmunt risk group, type of chemotherapy (platinum or taxanes), duration of response to first-platinum-based chemotherapy (&lt; or ≥ 12 months) or FGFR-status. Median PFS was 4.6 months (95% CI, 3.9 to 5.1) and 4.9 months (95% CI, 4.1 to 5.5) in CT2 and CT3, respectively, and grade 3-4 hematologic toxicity occurred in 35.0% and 22.4% of patients. This large multicentre retrospective study provides clinically relevant real-world data. Chemotherapy re-challenge after ICI in la/mUC achieves ORR and PFS comparable with those obtained in CT2 with an acceptable safety profile. These updated results offer more promising outcomes than historically reported with second-line chemotherapy data.","Department of Medical Oncology, Institut Bergonié, Bordeaux;University Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France.;Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;AP-HP, Hopital Henri Mondor, Service d'Oncologie, Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France.;Department of Medical Oncology, University Hospital, Bordeaux, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France.;Department of Medical Oncology, University Hospital, Tours, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, University Hospital, Grenoble, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Medical Oncology, Institute Universitaire de Cancérologie, CLIP(2) Galilée, Paris, France.;Department of Medical Oncology, Clinique François Chénieux, Limoges, France.;Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2022","175","10.1016/j.ejca.2022.08.014","43-53","","","36088671","36088671","PUBMED","Department of Medical Oncology, Institut Bergonié, Bordeaux;University Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, F-33000 Bordeaux, France; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France.;Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;AP-HP, Hopital Henri Mondor, Service d'Oncologie, Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France.;Department of Medical Oncology, University Hospital, Bordeaux, France.;Department of Medical Oncology, Institut Paoli Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital Jean Minjoz, Besançon, France.;Department of Medical Oncology, University Hospital, Tours, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Lyon, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, University Hospital, Grenoble, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié Salpêtrière Hospital, Department of Medical Oncology, Institute Universitaire de Cancérologie, CLIP(2) Galilée, Paris, France.;Department of Medical Oncology, Clinique François Chénieux, Limoges, France.;Department of Medical Oncology, Institut Claudius Régaud, IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France."
"230","Cousin I;Basmaison C;Cousin E;Lebonvallet N;Germouty I;Leven C;De Vries P","Cousin, Ianis;Basmaison, Camille;Cousin, Elie;Lebonvallet, Nicolas;Germouty, Isabelle;Leven, Cyril;De Vries, Philine","Complication rates of proximal hypospadias: meta-analyses of four surgical repairs.","Journal of pediatric urology","England","eng","Meta-Analysis","Hypospadias;Meta analyses;Surgical repairs","Male;Humans;Systematic Reviews as Topic;Hypospadias;Urethra;Surgical Flaps;Constriction, Pathologic;Urologic Surgical Procedures, Male","Male;Humans;Systematic Reviews as Topic;Hypospadias;Urethra;Surgical Flaps;Constriction, Pathologic;Urologic Surgical Procedures, Male","Proximal hypospadias surgery is impacted by a high complication rate. The goal of this work was to assess the overall composite complication rate, fistula rate and stenosis rate following proximal hypospadias surgery realized according to onlay urethroplasty, Duckett, Koyanagi and Bracka techniques. The databases MEDLINE, EMBASE, SCOPUS, Cochrane Library, the Cochrane Database of Systematic Reviews and the Cochrane Central Register of Controlled Trials (CENTRAL) and Sciencedirect were searched. Studies had to report data about the mean age of population, the average duration of patient follow-up and the number of procedures required for surgical treatment of primary and proximal hypospadias. Two independent including one urologist reviewers screened all the articles and selected the articles to be included. Overall composite complication rates were 32%, 34%, 49%, and 43%, for Onlay urethroplasty, Duckett's tubularized flaps urethroplasty, Koyanagi repair and Bracka 2 stages repair, respectively. Fistula rates were 13%, 18%, 21% and 23% respectively. The heterogeneity of complication rates reported in the different studies was not moderated by age, country, or patient's continent origin. The classifications of complications used in articles were disparate and make comparisons between techniques difficult. The report of post-surgical complications in the literature is often poorly coded and follow-up times were often too short. This meta-analysis attempts to determine to the extent possible, given the serious weaknesses in the hypospadias literature, plausible estimates of complication rates after skin flap urethroplasty. The patched onlay skin flap, the Duckett's tubularized skin flap technique, the Koyanagi's technique, and the Bracka's two-stage urethroplasty procedure lead to very high complication rates. Reported complication rates are comparable across techniques.","Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France; Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest;Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France.;Department of Pediatry, Centre Hospitalier Universitaire de Rennes, 16 Boulevard de Bulgarie 35200 Rennes, France.;Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France.;Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France.;Department of Pharmacology, Centre Hospitalier Régional Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest, France.;Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France; Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France.","NA",0,"1873-4898","J Pediatr Urol","J Pediatr Urol",2022,"2022","18","10.1016/j.jpurol.2022.08.005","587-597","","","36058812","36058812","PUBMED","Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France; Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest;Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France.;Department of Pediatry, Centre Hospitalier Universitaire de Rennes, 16 Boulevard de Bulgarie 35200 Rennes, France.;Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France.;Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France.;Department of Pharmacology, Centre Hospitalier Régional Universitaire de Brest, Hôpital de la Cavale Blanche, Boulevard Tanguy Prigent, 29200 Brest, France.;Department of Pediatric Surgery, Centre Hospitalier Régional Universitaire de Brest, Hôpital Augustin Morvan, 4 Avenue Foch, 29200 Brest, France; Laboratoire Intéraction épithéliums Neurones, Université de Bretagne Occidentale, 6 Rue Colbert, 29200 Brest, France."
"231","Vilotte F;Pasquier D;Blanchard P;Supiot S;Khalifa J;Schick U;Lacornerie T;Vieillevigne L;Marre D;Chapet O;Latorzeff I;Magne N;Meyer E;Cao K;Belkacemi Y;Bibault JE;Berge-Lefranc M;Faivre JC;Gnep K;Guimas V;Hasbini A;Langrand-Escure J;Hennequin C;Graff P","Vilotte, F;Pasquier, D;Blanchard, P;Supiot, S;Khalifa, J;Schick, U;Lacornerie, T;Vieillevigne, L;Marre, D;Chapet, O;Latorzeff, I;Magne, N;Meyer, E;Cao, K;Belkacemi, Y;Bibault, J E;Berge-Lefranc, M;Faivre, J C;Gnep, K;Guimas, V;Hasbini, A;Langrand-Escure, J;Hennequin, C;Graff, P","Recommendations for stereotactic body radiation therapy for spine and non-spine bone metastases. A GETUG (French society of urological radiation oncolgists) consensus using a national two-round modified Delphi survey.","Clinical and translational radiation oncology","Ireland","eng","Journal Article","Metastasis-directed;Non-spine bone metastasis;Oligometastatic;Spine bone metastasis;Stereotactic radiation therapy;Stereotaxy","","","The relevance of metastasis-directed stereotactic body radiation therapy (SBRT) remains to be demonstrated through phase III trials. Multiple SBRT procedures have been published potentially resulting in a disparity of practices. Therefore, the french society of urological radiation oncolgists (GETUG) recognized the need for joint expert consensus guidelines for metastasis-directed SBRT in order to standardize practice in trials carried out by the group. After a comprehensive literature review, 97 recommendation statements were created regarding planning and delivery of spine bone (SBM) and non-spine bone metastases (NSBM) SBRT. These statements were then submitted to a national online two-round modified Delphi survey among main GETUG investigators. Consensus was achieved if a statement received ≥ 75 % agreements, a trend to consensus being defined as 65-74 % agreements. Any statement without consensus at round one was re-submitted in round two. Twenty-one out of 29 (72.4%) surveyed experts responded to both rounds. Seventy-five statements achieved consensus at round one leaving 22 statements needing a revote of which 16 achieved consensus and 5 a trend to consensus. The final rate of consensus was 91/97 (93.8%). Statements with no consensus concerned patient selection (3/19), dose and fractionation (1/11), prescription and dose objectives (1/9) and organs at risk delineation (1/15). The voting resulted in the writing of step-by-step consensus guidelines. Consensus guidelines for SBM and NSBM SBRT were agreed upon using a validated modified Delphi approach. These guidelines will be used as per-protocole recommendations in ongoing and further GETUG clinical trials.","Department of Radiation Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux, France.;Department of Radiation Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Radiation Oncology, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France.;Department of Radiation Oncology, Institut de Cancérologie de L'Ouest, Boulevard Professeur Jacques Monod, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, 1 AV Irène Joliot Curie, 31059 Toulouse, France.;Department of Radiation Oncology, CHU de Brest, Hôpital Morvan, avenue Foch, 29200 Brest, France.;Division of Radiation Medical Physics, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Division of Radiation Medical Physics, Institut Universitaire du Cancer de Toulouse-Oncopole, 1 AV Irène Joliot Curie, 31059 Toulouse, France.;Division of Radiation Medical Physics, Groupe ONCORAD Garonne, Clinique Pasteur, Bât Atrium, 1 rue de la petite vitesse, 31300 Toulouse, France.;Department of Radiation Oncology, CH Lyon Sud 165 Chemin Du Grand Revoyet, 69310 Pierre-bénite, France.;Department of Radiation Oncology, Groupe ONCORAD Garonne, Clinique Pasteur, Bât Atrium, 1 rue de la petite vitesse, 31300 Toulouse, France.;Department of Radiation Oncology, Institut de cancérologie Lucien Neuwirth, 108 bis AV Albert Raimond, 42270 Saint Priest en Jarez, France.;Department of Radiation Oncology, Centre François Baclesse, 3 Av. du Général Harris, 14000 Caen, France.;Department of Radiation Oncology, Institut Curie Paris, 26 rue d'Ulm, 75005 Paris, France.;Department of Radiation Oncology, Hôpital Henri-Mondor, 1 rue Gustave Eiffel, 94000 Créteil, France.;Department of Radiation Oncology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.;Department of Radiation Oncology, Centre Saint Michel, rue du Docteur Schweitzer, 17000 La Rochelle, France.;Department of Radiation Oncology, Institut de Cancérologie de Lorraine, 6 Av. de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Centre Eugène Marquis, AV de la Bataille Flandres Dunkerque, 35000 Rennes, France.;Department of Radiation Oncology, Institut de Cancérologie de L'Ouest, Boulevard Professeur Jacques Monod, 44800 Saint Herblain, France.;Department of Radiation Oncology, Clinique Pasteur, 32 r Auguste Kervern, 29200 Brest, France.;Department of Radiation Oncology, Institut de cancérologie Lucien Neuwirth, 108 bis AV Albert Raimond, 42270 Saint Priest en Jarez, France.;Department of Radiation Oncology, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France.;Department of Radiation Oncology, Institut Curie Saint Cloud, 35 rue Dailly, 92210 Saint Cloud, France.","NA",0,"2405-6308","Clin Transl Radiat Oncol","Clin Transl Radiat Oncol",2022,"2022","37","10.1016/j.ctro.2022.08.006","33-40","","","36052019","36052019","PUBMED","Department of Radiation Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33076 Bordeaux, France.;Department of Radiation Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Radiation Oncology, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France.;Department of Radiation Oncology, Institut de Cancérologie de L'Ouest, Boulevard Professeur Jacques Monod, 44800 Saint Herblain, France.;Department of Radiation Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, 1 AV Irène Joliot Curie, 31059 Toulouse, France.;Department of Radiation Oncology, CHU de Brest, Hôpital Morvan, avenue Foch, 29200 Brest, France.;Division of Radiation Medical Physics, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Division of Radiation Medical Physics, Institut Universitaire du Cancer de Toulouse-Oncopole, 1 AV Irène Joliot Curie, 31059 Toulouse, France.;Division of Radiation Medical Physics, Groupe ONCORAD Garonne, Clinique Pasteur, Bât Atrium, 1 rue de la petite vitesse, 31300 Toulouse, France.;Department of Radiation Oncology, CH Lyon Sud 165 Chemin Du Grand Revoyet, 69310 Pierre-bénite, France.;Department of Radiation Oncology, Groupe ONCORAD Garonne, Clinique Pasteur, Bât Atrium, 1 rue de la petite vitesse, 31300 Toulouse, France.;Department of Radiation Oncology, Institut de cancérologie Lucien Neuwirth, 108 bis AV Albert Raimond, 42270 Saint Priest en Jarez, France.;Department of Radiation Oncology, Centre François Baclesse, 3 Av. du Général Harris, 14000 Caen, France.;Department of Radiation Oncology, Institut Curie Paris, 26 rue d'Ulm, 75005 Paris, France.;Department of Radiation Oncology, Hôpital Henri-Mondor, 1 rue Gustave Eiffel, 94000 Créteil, France.;Department of Radiation Oncology, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.;Department of Radiation Oncology, Centre Saint Michel, rue du Docteur Schweitzer, 17000 La Rochelle, France.;Department of Radiation Oncology, Institut de Cancérologie de Lorraine, 6 Av. de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Centre Eugène Marquis, AV de la Bataille Flandres Dunkerque, 35000 Rennes, France.;Department of Radiation Oncology, Institut de Cancérologie de L'Ouest, Boulevard Professeur Jacques Monod, 44800 Saint Herblain, France.;Department of Radiation Oncology, Clinique Pasteur, 32 r Auguste Kervern, 29200 Brest, France.;Department of Radiation Oncology, Institut de cancérologie Lucien Neuwirth, 108 bis AV Albert Raimond, 42270 Saint Priest en Jarez, France.;Department of Radiation Oncology, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France.;Department of Radiation Oncology, Institut Curie Saint Cloud, 35 rue Dailly, 92210 Saint Cloud, France."
"232","Rugo HS;Tolaney SM;Loirat D;Punie K;Bardia A;Hurvitz SA;O'Shaughnessy J;Cortés J;Diéras V;Carey LA;Gianni L;Piccart MJ;Loibl S;Goldenberg DM;Hong Q;Olivo M;Itri LM;Kalinsky K","Rugo, Hope S;Tolaney, Sara M;Loirat, Delphine;Punie, Kevin;Bardia, Aditya;Hurvitz, Sara A;O'Shaughnessy, Joyce;Cortés, Javier;Diéras, Véronique;Carey, Lisa A;Gianni, Luca;Piccart, Martine J;Loibl, Sibylle;Goldenberg, David M;Hong, Quan;Olivo, Martin;Itri, Loretta M;Kalinsky, Kevin","Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.","NPJ breast cancer","United States","eng","Journal Article","","","","Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload. In the ASCENT study, patients with metastatic triple-negative breast cancer (mTNBC) relapsed/refractory to ≥2 prior chemotherapy regimens (≥1 in the metastatic setting), received SG or single-agent treatment of physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine). This ASCENT safety analysis includes the impact of age and UGT1A1 polymorphisms, which hinder SN-38 detoxification. SG demonstrated a manageable safety profile in patients with mTNBC, including those ≥65 years; neutropenia/diarrhea are key adverse events (AE). Patients with UGT1A1 *28/*28 genotype versus those with 1/*28 and *1/*1 genotypes had higher rates of grade ≥3 SG-related neutropenia (59% vs 47% and 53%), febrile neutropenia (18% vs 5% and 3%), anemia (15% vs 6% and 4%), and diarrhea (15% vs 9% and 10%), respectively. Individuals with UGT1A1 *28/*28 genotype should be monitored closely; active monitoring and routine AE management allow optimal therapeutic exposure of SG.","Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Medical Oncology and D3i, Institut Curie, Paris, France.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Medical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.;International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, Spain.;Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Gianni Bonadonna Foundation, Milano, Italy.;Medical Oncology, Institute Jules Bordet, Brussels, Belgium.;Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Columbia University Irving Medical Center, New York, NY, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.","NA",0,"2374-4677","NPJ Breast Cancer","NPJ Breast Cancer",2022,"2022","8","10.1038/s41523-022-00467-1","98","","","36038616","36038616","PUBMED","Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.;Department of Medical Oncology and D3i, Institut Curie, Paris, France.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Medical Oncology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.;International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Barcelona, Spain.;Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Gianni Bonadonna Foundation, Milano, Italy.;Medical Oncology, Institute Jules Bordet, Brussels, Belgium.;Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Department of Clinical Development, Immunomedics, Inc., Morris Plains, NJ, USA.;Columbia University Irving Medical Center, New York, NY, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA."
"233","De Bari B;Lefevre L;Henriques J;Gatta R;Falcoz A;Mathieu P;Borg C;Dinapoli N;Boulahdour H;Boldrini L;Valentini V;Vernerey D","De Bari, Berardino;Lefevre, Loriane;Henriques, Julie;Gatta, Roberto;Falcoz, Antoine;Mathieu, Pierre;Borg, Christophe;Dinapoli, Nicola;Boulahdour, Hatem;Boldrini, Luca;Valentini, Vincenzo;Vernerey, Dewi","Could 18-FDG PET-CT Radiomic Features Predict the Locoregional Progression-Free Survival in Inoperable or Unresectable Oesophageal Cancer?","Cancers","Switzerland","eng","Journal Article","18-FDG PET-CT;chemoradiotherapy;neoadjuvant treatment;oesophageal cancer;predictive factors;radiomics","","","Background: We evaluated the value of pre-treatment positron-emission tomography−computed tomography (PET-CT)-based radiomic features in predicting the locoregional progression-free survival (LR-PFS) of patients with inoperable or unresectable oesophageal cancer. Material and Methods: Forty-six patients were included and 230 radiomic parameters were extracted. After a principal component analysis (PCA), we identified the more robust radiomic parameters, and we used them to develop a heatmap. Finally, we correlated these radiomic features with LR-PFS. Results: The median follow-up time was 17 months. The two-year LR-PFS and PFS rates were 35.9% (95% CI: 18.9−53.3) and 21.6% (95%CI: 10.0−36.2), respectively. After the correlation analysis, we identified 55 radiomic parameters that were included in the heatmap. According to the results of the hierarchical clustering, we identified two groups of patients presenting statistically different median LR-PFSs (22.8 months vs. 9.9 months; HR = 2.64; 95% CI 0.97−7.15; p = 0.0573). We also identified two radiomic features (“F_rlm_rl_entr_per” and “F_rlm_2_5D_rl_entr”) significantly associated with LR-PFS. Patients expressing a “F_rlm_2_5D_rl_entr” of <3.3 had a better median LR- PFS (29.4 months vs. 8.2 months; p = 0.0343). Patients presenting a “F_rlm_rl_entr_per” of <4.7 had a better median LR-PFS (50.4 months vs. 9.9 months; p = 0.0132). Conclusion: We identified two radiomic signatures associated with a lower risk of locoregional relapse after CRT.","Radiation Oncology Department, Neuchâtel Hospital Network, CH-2300 La Chaux-de-Fonds, Switzerland.;Radiation Oncology Department, University Hospital of Besançon, F-25000 Besancon, France.;Radiation Oncology Department, University Hospital of Besançon, F-25000 Besancon, France.;Radiation Oncology Department, Centre Eugène Marquis, F-35042 Rennes, France.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, I-25123 Brescia, Italy.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Department of Digestive Surgery and Liver Transplantation, University Hospital of Besançon, F-25000 Besancon, France.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Department of Medical Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;EA 4662-""Nanomedicine Lab, Imagery and Therapeutics"", Nuclear Medicine Department, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14164043",NA,"","","36011035","36011035","PUBMED","Radiation Oncology Department, Neuchâtel Hospital Network, CH-2300 La Chaux-de-Fonds, Switzerland.;Radiation Oncology Department, University Hospital of Besançon, F-25000 Besancon, France.;Radiation Oncology Department, University Hospital of Besançon, F-25000 Besancon, France.;Radiation Oncology Department, Centre Eugène Marquis, F-35042 Rennes, France.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Scienze Cliniche e Sperimentali, Università degli Studi di Brescia, I-25123 Brescia, Italy.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Department of Digestive Surgery and Liver Transplantation, University Hospital of Besançon, F-25000 Besancon, France.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Department of Medical Oncology, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;EA 4662-""Nanomedicine Lab, Imagery and Therapeutics"", Nuclear Medicine Department, University Hospital of Besançon, F-25000 Besancon, France.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario ""A. Gemelli"" IRCCS, I-00100 Rome, Italy.;INSERM, Établissement Français du Sang Bourgogne Franche-Comté, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Bourgogne Franche-Comté University, F-25000 Besancon, France.;Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, F-25000 Besancon, France."
"234","Bini M;Quesada S;Meeus P;Rodrigues M;Leblanc E;Floquet A;Pautier P;Marchal F;Provansal M;Campion L;Causeret S;Gourgou S;Ray-Coquard I;Classe JM;Pomel C;De La Motte Rouge T;Barranger E;Savoye AM;Guillemet C;Gladieff L;Demarchi M;Rouzier R;Courtinard C;Romeo C;Joly F","Bini, Marta;Quesada, Stanislas;Meeus, Pierre;Rodrigues, Manuel;Leblanc, Eric;Floquet, Anne;Pautier, Patricia;Marchal, Frédéric;Provansal, Magali;Campion, Loïc;Causeret, Sylvain;Gourgou, Sophie;Ray-Coquard, Isabelle;Classe, Jean-Marc;Pomel, Christophe;De La Motte Rouge, Thibault;Barranger, Emmanuel;Savoye, Aude Marie;Guillemet, Cécile;Gladieff, Laurence;Demarchi, Martin;Rouzier, Roman;Courtinard, C;Romeo, Clémence;Joly, Florence",NA,"Cancers","Switzerland","eng","Journal Article","BRCA1;BRCA2;epidemiological strategy and medical economics database;epidemiology;high-grade epithelial ovarian cancer;overall survival;platinum-based chemotherapy;progression-free survival;real-world data;treatment patterns","","","In spite of the frequency and clinical impact of   alterations in high-grade epithelial ovarian cancer (HGEOC), real-world information based on robust data warehouse has been scarce to date. Consecutive patients with  -mutated HGEOC treated between 2011 and 2016 within French comprehensive cancer centers from the Unicancer network were extracted from the ESME database. The main objective of the study was the assessment of clinicopathological and treatments parameters. Out of the 8021 patients included in the ESME database, 266 patients matching the selection criteria were included.   mutation was found in 191 (71.8%) patients, while 75 (28.2%) had a   mutation only; 95.5% of patients received a cytoreductive surgery. All patients received a taxane/platinum-based chemotherapy (median = six cycles). Complete and partial response were obtained in 53.3% and 20.4% of the cases, respectively. Maintenance therapy was administered in 55.3% of the cases, bevacizumab being the most common agent. After a median follow up of 51.7 months, a median progression-free survival of 28.6 months (95% confidence interval (CI) [26.5; 32.7]) and an estimated 5-year median overall survival of 69.2% (95% CI [61.6; 70.3]) were reported. Notably,  - and  -mutated cases exhibited a trend towards different median progression-free survivals, with 28.0 (95% CI [24.4; 32.3]) and 33.3 months (95% CI [26.7; 46.1]), respectively ( -value = 0.053). Furthermore, five-year OS for  -mutated patients was 64.5% (95% CI [59.7; 69.2]), while it was 82.5% (95% CI [76.6; 88.5]) for  -mutated ones ( -value = 0.029). This study reports the largest French multicenter cohort of  -mutated HGEOCs based on robust data from the ESME, exhibiting relevant real-world data regarding this specific population.","Centre Léon Bérard, 69008 Lyon, France.;Instituto Nazionale dei Tumori, 20133 Milano, Italy.;Centre Léon Bérard, 69008 Lyon, France.;Institut Régional du Cancer de Montpellier, 34298 Montpellier, France.;Centre Léon Bérard, 69008 Lyon, France.;Institut Curie, 75005 Paris, France.;Centre Oscar Lambret, 59000 Lille, France.;Institut Bergonié, 33076 Bordeaux, France.;Gustave Roussy, 94805 Villejuif, France.;Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France.;Institut Paoli Calmettes, 13009 Marseille, France.;Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Centre Georges Francois Leclerc, 21000 Dijon, France.;Institut Régional du Cancer de Montpellier, 34298 Montpellier, France.;Centre Léon Bérard, 69008 Lyon, France.;Department of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.;Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Centre Eugene Marquis, 35000 Rennes, France.;Centre Antoine Lacassagne, 06100 Nice, France.;Institut Godinot, 51726 Reims, France.;Centre Henri Becquerel, 76038 Rouen, France.;Institut Claudius Regaud, IUCT Oncopole, 31059 Toulouse, France.;Institut de Cancérologie Strasbourg ICANS, 67200 Strasbourg, France.;Centre François Baclesse, 14000 Caen, France.;Unicancer, 75654 Paris, France.;Centre Léon Bérard, 69008 Lyon, France.;Centre François Baclesse, 14000 Caen, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14164040",NA,"","","36011033","36011033","PUBMED","Centre Léon Bérard, 69008 Lyon, France.;Instituto Nazionale dei Tumori, 20133 Milano, Italy.;Centre Léon Bérard, 69008 Lyon, France.;Institut Régional du Cancer de Montpellier, 34298 Montpellier, France.;Centre Léon Bérard, 69008 Lyon, France.;Institut Curie, 75005 Paris, France.;Centre Oscar Lambret, 59000 Lille, France.;Institut Bergonié, 33076 Bordeaux, France.;Gustave Roussy, 94805 Villejuif, France.;Institut de Cancérologie de Lorraine, 54519 Vandœuvre-lès-Nancy, France.;Institut Paoli Calmettes, 13009 Marseille, France.;Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Centre Georges Francois Leclerc, 21000 Dijon, France.;Institut Régional du Cancer de Montpellier, 34298 Montpellier, France.;Centre Léon Bérard, 69008 Lyon, France.;Department of Surgery, Institut de Cancerologie de l'Ouest, Boulevard Professor Monod, 44805 Saint Herblain, France.;Centre Jean Perrin, 63011 Clermont-Ferrand, France.;Centre Eugene Marquis, 35000 Rennes, France.;Centre Antoine Lacassagne, 06100 Nice, France.;Institut Godinot, 51726 Reims, France.;Centre Henri Becquerel, 76038 Rouen, France.;Institut Claudius Regaud, IUCT Oncopole, 31059 Toulouse, France.;Institut de Cancérologie Strasbourg ICANS, 67200 Strasbourg, France.;Centre François Baclesse, 14000 Caen, France.;Unicancer, 75654 Paris, France.;Centre Léon Bérard, 69008 Lyon, France.;Centre François Baclesse, 14000 Caen, France."
"235","Corniola MV;Meling TR","Corniola, Marco Vincenzo;Meling, Torstein R","Management of Recurrent Meningiomas: State of the Art and Perspectives.","Cancers","Switzerland","eng","Journal Article","meningioma;overall survival;progression-free survival;recurrence;retreatment","","","While meningiomas often recur over time, the natural history of repeated recurrences and their management are not well described. Should recurrence occur, repeat surgery and/or use of adjuvant therapeutic options may be necessary. Here, we summarize current practice when it comes to meningioma recurrence after initial surgical management. A total of N = 89 articles were screened. N = 41 articles met the inclusion criteria and N = 16 articles failed to assess management of meningioma recurrence. Finally, N = 24 articles were included in our review. The articles were distributed as follows: studies on chemotherapy (N = 14), radiotherapy, protontherapy, and stereotaxic radiosurgery (N = 6), boron-neutron capture therapy (N = 2) and surgery (N = 3). No study seems to provide serious alternatives to surgery in terms of progression-free and overall survival. Recurrence can occur long after the initial surgery and also affects WHO grade 1 meningiomas, even after initial gross total resection at first surgery, emphasizing the need for a long-term and comprehensive follow-up. Surgery still seems to be the state-of-the-art management when it comes to meningioma recurrence, since none of the non-surgical alternatives show promising results in terms of progression-free and overall survival.","Service de Neurochirurgie, Pôle des Neurosciences, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Faculté de Médecine, Université de Rennes 1, 35000 Rennes, France.;Faculté de Médecine, Université de Genève, 1205 Geneve, Switzerland.;Laboratoire du Traitement de Signal, Unité Médicis, INSERM UMR 1099 LTSI, Université de Rennes 1, 35000 Rennes, France.;Faculté de Médecine, Université de Genève, 1205 Geneve, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, 1205 Geneva, Switzerland.;Besta NeuroSim Center, Fondazione IRCCS, Istituto Neurologico Carlo Basta, 20133 Milano, Italy.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14163995",NA,"","","36010988","36010988","PUBMED","Service de Neurochirurgie, Pôle des Neurosciences, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Faculté de Médecine, Université de Rennes 1, 35000 Rennes, France.;Faculté de Médecine, Université de Genève, 1205 Geneve, Switzerland.;Laboratoire du Traitement de Signal, Unité Médicis, INSERM UMR 1099 LTSI, Université de Rennes 1, 35000 Rennes, France.;Faculté de Médecine, Université de Genève, 1205 Geneve, Switzerland.;Department of Neurosurgery, Geneva University Hospitals, 1205 Geneva, Switzerland.;Besta NeuroSim Center, Fondazione IRCCS, Istituto Neurologico Carlo Basta, 20133 Milano, Italy."
"236","Marcé D;Le Vilain-Abraham F;Bridou M;Quéreux G;Dupuy A;Lesimple T;Le Corre Y;Wierzbicka-Hainaut E;Legoupil D;Célérier P;Maillard H;Machet L;Caille A","Marcé, Diane;Le Vilain-Abraham, Floriane;Bridou, Morgiane;Quéreux, Gaelle;Dupuy, Alain;Lesimple, Thierry;Le Corre, Yannick;Wierzbicka-Hainaut, Ewa;Legoupil, Delphine;Célérier, Philippe;Maillard, Hervé;Machet, Laurent;Caille, Agnès","Impact of Distribution of a Tip Sheet to Increase Early Detection and Prevention Behavior among First-Degree Relatives of Melanoma Patients: A Randomized Cluster Trial.","Cancers","Switzerland","eng","Journal Article","cluster randomized trial;familial;first-degree relatives;high-risk population;intervention;medical skin examination;melanoma;prevention;screening;sun-related behaviors","","","First-degree relatives (FDRs, defined as parents, children, and siblings) of melanoma patients are at a two-to-fivefold increased risk of developing melanoma themselves. FDRs are advised to perform self-skin examination (SSE) and annual medical total cutaneous examination (TCE) performed either by a dermatologist or a general practitioner, and to change their sun-related behavior. This advice is given orally to melanoma patients who are asked to relay the information to their FDRs. Our aim was to determine the impact of providing a tip sheet to melanoma patients intended to their first-degree relatives (FDRs) on early detection and sun-related behaviors in this group at increased risk of melanoma. A superiority, cluster-randomized trial was conducted at nine hospital centers. In the intervention group, dermatologists were asked to deliver to melanoma patients (index cases) the tip sheet and oral advice intended to their FDRs. The control group were asked to deliver the usual oral advice alone. The primary outcome was early detection of melanoma in FDRs with a medical TCE performed within one year after the first visit of the index case. Secondary outcomes were SSE and sun-related behaviors in FDRs. A total of 48 index cases and 114 FDRS in the control group, 60 index cases and 166 FDRS in the intervention group were recruited. In the intervention group, 36.1% of FDRs performed a medical TCE as compared to 39.5% of FDRs in the control group (OR 0.9 [95% CI 0.5 to 1.5],   = 0.63). We did not find a between-group difference in SSE and sun-related behaviors. A tip sheet added to the usual oral advice did not increase medical TCE among FDRs of melanoma patients. Overall, the rate of TCE among FDRs was low. Research on other strategies is needed to increase melanoma detection in this population.","Service de Dermatologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.;INSERM, Université de Tours, Université de Nantes, SPHERE U1246, 37044 Tours, France.;Laboratoire de Psychopathologie et Neuropsychologie, Université Paris 8, 93200 Paris, France.;Dermatology Department, Nantes University Hospital, Université de Nantes, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, 44000 Nantes, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service d'Oncologie Médicale, Centre Anticancéreux de Rennes, 35033 Rennes, France.;Service de Dermatologie, Centre Hospitalier Universitaire d'Angers, 49100 Angers, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Brest, 29200 Brest, France.;Service de Dermatologie, Centre Hospitalier de La Rochelle, 17000 La Rochelle, France.;Service de Dermatologie, Centre Hospitalier du Mans, 72037 Le Mans, France.;Service de Dermatologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.;INSERM, Université de Tours, iBrain U1253, 37044 Tours, France.;INSERM, Université de Tours, Université de Nantes, SPHERE U1246, 37044 Tours, France.;INSERM CIC1415, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14163864",NA,"INCA_8186","Institut National contre le Cancer","36010858","36010858","PUBMED","Service de Dermatologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.;INSERM, Université de Tours, Université de Nantes, SPHERE U1246, 37044 Tours, France.;Laboratoire de Psychopathologie et Neuropsychologie, Université Paris 8, 93200 Paris, France.;Dermatology Department, Nantes University Hospital, Université de Nantes, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, 44000 Nantes, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service d'Oncologie Médicale, Centre Anticancéreux de Rennes, 35033 Rennes, France.;Service de Dermatologie, Centre Hospitalier Universitaire d'Angers, 49100 Angers, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Dermatologie, Centre Hospitalier Universitaire de Brest, 29200 Brest, France.;Service de Dermatologie, Centre Hospitalier de La Rochelle, 17000 La Rochelle, France.;Service de Dermatologie, Centre Hospitalier du Mans, 72037 Le Mans, France.;Service de Dermatologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.;INSERM, Université de Tours, iBrain U1253, 37044 Tours, France.;INSERM, Université de Tours, Université de Nantes, SPHERE U1246, 37044 Tours, France.;INSERM CIC1415, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France."
"237","Coste G;Chabanne C;Tron C;Lelong B;Verdier MC;Roussel M;Le Gall F;Turlin B;Desille-Dugast M;Flécher E;Laviolle B;Lemaitre F","Coste, Gwendal;Chabanne, Céline;Tron, Camille;Lelong, Bernard;Verdier, Marie-Clémence;Roussel, Mikael;Le Gall, François;Turlin, Bruno;Desille-Dugast, Mireille;Flécher, Erwan;Laviolle, Bruno;Lemaitre, Florian","Blood, Cellular, and Tissular Calcineurin Inhibitors Pharmacokinetic-Pharmacodynamic Relationship in Heart Transplant Recipients: The INTRACAR Study.","Therapeutic drug monitoring","United States","eng","Journal Article","","Humans;Calcineurin Inhibitors;Cyclosporine;Leukocytes, Mononuclear;Immunosuppressive Agents;Heart Transplantation;Graft Rejection","Humans;Calcineurin Inhibitors;Cyclosporine;Leukocytes, Mononuclear;Immunosuppressive Agents;Heart Transplantation;Graft Rejection","After heart transplantation, calcineurin inhibitors (CNI) (cyclosporin A and tacrolimus) are key immunosuppressive drugs to prevent graft rejection. Whole-blood concentration (C blood )-guided therapeutic drug monitoring (TDM) is systematically performed to improve graft outcomes. However, some patients will still experience graft rejection and/or adverse events despite CNI C blood within the therapeutic range. Other pharmacokinetic parameters, such as the intragraft, or intracellular concentration at the CNI site of action could refine their TDM. Nonetheless, these remain to be explored. The objective of the INTRACAR study was to describe the relationship between whole blood, intragraft, and intracellular CNI concentrations as well as their efficacy in heart transplant recipients (HTR). In a cohort of HTR, protocol endomyocardial biopsies (EMB) were collected to assess rejection by anatomopathological analysis. Part of the EMB was used to measure the intragraft concentrations of CNI (C EMB ). C blood and the concentration inside peripheral blood mononuclear cells, (C PBMC ), a cellular fraction enriched with lymphocytes, were also monitored. Concentrations in the 3 matrices were compared between patients with and without biopsy-proven acute rejection (BPAR). Thirty-four HTR were included, representing nearly 100 pharmacokinetic (PK) samples for each CNI. C blood , C EMB , and C PBMC correlated for both CNI. BPAR was observed in 74 biopsies (39.6%) from 26 patients (76.5%), all except one was of low grade. None of the PK parameters (C blood , C EMB , C PBMC , C EMB/blood , and C PBMC/blood ) was associated with BPAR. In this cohort of well-immunosuppressed patients, no association was observed for any of the PK parameters, including C blood , with the occurrence of BPAR. However, a trend was noticed for the C EMB and C EMB/blood of cyclosporin A. Further studies in higher-risk patients may help optimize the use of C EMB and C PBMC for CNI TDM in HTR.","Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes.;Université de Rennes, Établissement Français du Sang (EFS) de Bretagne, Inserm, MICMAC-UMR_S1236.;Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes.;Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes.;Centre de Ressources Biologiques (CRB) Santé de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes.;Centre de Ressources Biologiques (CRB) Santé de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes.;INSERM, Centre d'Investigation Clinique.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Laboratoire Traitement du Signal et de l'Image (LTSI) unité mixte 1099 INSERM; and.;FHU SUPORT, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;FHU SUPORT, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;FHU SUPORT, Rennes, France.","NA",0,"1536-3694","Ther Drug Monit","Ther Drug Monit",2022,"2023","45","10.1097/FTD.0000000000001025","229-235","","","36006706","36006706","PUBMED","Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;Laboratoire d'hématologie, Centre Hospitalier Universitaire de Rennes.;Université de Rennes, Établissement Français du Sang (EFS) de Bretagne, Inserm, MICMAC-UMR_S1236.;Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes.;Laboratoire d'anatomie et cytologie pathologiques, Centre Hospitalier Universitaire de Rennes.;Centre de Ressources Biologiques (CRB) Santé de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes.;Centre de Ressources Biologiques (CRB) Santé de Rennes BB-0033-00056, Centre Hospitalier Universitaire de Rennes.;INSERM, Centre d'Investigation Clinique.;Service de chirurgie cardio-thoracique et vasculaire, Centre Hospitalier Universitaire de Rennes.;Laboratoire Traitement du Signal et de l'Image (LTSI) unité mixte 1099 INSERM; and.;FHU SUPORT, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;FHU SUPORT, Rennes, France.;Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR S 1085, EHESP, Inserm, CHU Rennes.;INSERM, Centre d'Investigation Clinique.;Laboratoire de pharmacologie biologique, Centre Hospitalier Universitaire de Rennes.;FHU SUPORT, Rennes, France."
"238","Kfoury M;Najean M;Lappara A;Voisin AL;Champiat S;Michot JM;Laghouati S;Robert C;Besse B;Soria JC;Lambotte O;Massard C;Marabelle A;Texier M","Kfoury, Maria;Najean, Marie;Lappara, Ariane;Voisin, Anne-Laure;Champiat, Stéphane;Michot, Jean-Marie;Laghouati, Salim;Robert, Caroline;Besse, Benjamin;Soria, Jean-Charles;Lambotte, Olivier;Massard, Christophe;Marabelle, Aurélien;Texier, Matthieu","Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.","Cancer treatment reviews","Netherlands","eng","Journal Article","Immortal-time bias;Immune-checkpoint blockers;Immune-related adverse events;Melanoma;Non-small cell lung cancer","Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Drug-Related Side Effects and Adverse Reactions;Humans;Immune Checkpoint Inhibitors;Lung Neoplasms;Melanoma;Nivolumab;Retrospective Studies","Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Drug-Related Side Effects and Adverse Reactions;Humans;Immune Checkpoint Inhibitors;Lung Neoplasms;Melanoma;Nivolumab;Retrospective Studies","Numerous retrospective studies and reviews have reported a positive association between immune-related adverse events (irAEs) and survival in non-small cell lung cancer (NSCLC) and melanoma patients treated with immune checkpoint blockers (ICBs). However, some results are controversial and the studies, whose results converge, should be interpreted cautiously because most of them do not deal appropriately with the immortal-time bias. Here, we report an observational real-life study of the association between prospectively collected irAEs and survival of patients treated with ICBs while dealing with the immortal-time bias. Data from patients treated at Gustave Roussy from June 2014 to October 2017 with anti-PD-(L)1 antibodies for a melanoma or NSCLC have been prospectively collected in the REISAMIC database, a pharmacovigilance registry dedicated to irAEs. Adverse events of grade 2 and higher were collected prospectively. To study the association between the occurrence of irAEs and survival, we used both a landmark analysis and a Cox regression model with time-dependent covariate. 577 patients were treated with anti-PD-(L)1 antibodies for melanoma (60.3 %) or NSCLC (39.7 %). The occurrence of an irAE was significantly associated with improved overall survival (OS): HR 0.56, 95 % CI [0.41; 0.75], p = 0.0001 and progression-free survival (PFS): HR 0.63, 95 % CI [0.47; 0.83], p = 0.001 using a Cox regression model with time-dependent covariate. In a 12-week landmark analysis, median OS was 21.2 months (95 % CI, 12.2 to 35.7) and 16.4 months (95 % CI, 12.4 to 21.3) p = 0.26 and median PFS was 14.3 months (95 % CI, 9.5 to 24.6) and 13.4 months (95 % CI, 10.2 to 18.3) p = 0.66, for patients with and without irAEs, respectively. In our real-life study of patients with melanoma and NSCLC treated with anti-PD-(L)1 antibodies, we confirm that irAEs are associated with improved survival using a time-varying Cox regression model. Analysis with a landmark method showed no difference in OS or PFS between patients who experienced irAE during the first 12 weeks of treatment and those who did not. Retrospective analysis and reviews including studies that do not deal with the immortal-time bias and studies insufficiently powered for a landmark analysis should be interpreted with caution.","Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département d'Oncologie Médicale, Gustave Roussy, Villejuif;Département d'Epidémiologie et de Biostatistiques, Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département interdisciplinaire du parcours patient (DIOPP), Gustave Roussy, Villejuif, France.;Unité de Pharmacovigilance, Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.;Unité de Pharmacovigilance, Gustave Roussy, Villejuif, France.;Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département de Médecine Interne et Immunologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; INSERM U1184, Immunologie des infections virales et maladies auto-immunes, F-94276 Le Kremlin Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France.;Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France; Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département de Médecine Interne et Immunologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; INSERM U1015 & CIC1428, Villejuif, France.;Département d'Epidémiologie et de Biostatistiques, Gustave Roussy, Villejuif, France.","NA",0,"1532-1967","Cancer Treat Rev","Cancer Treat Rev",2022,"2022","110","10.1016/j.ctrv.2022.102452","102452","","","35998515","35998515","PUBMED","Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département d'Oncologie Médicale, Gustave Roussy, Villejuif;Département d'Epidémiologie et de Biostatistiques, Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département interdisciplinaire du parcours patient (DIOPP), Gustave Roussy, Villejuif, France.;Unité de Pharmacovigilance, Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France.;Unité de Pharmacovigilance, Gustave Roussy, Villejuif, France.;Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France.;Département de Médecine Interne et Immunologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; INSERM U1184, Immunologie des infections virales et maladies auto-immunes, F-94276 Le Kremlin Bicêtre, France; CEA, DSV/iMETI, IDMIT, F-92265 Fontenay-aux-Roses, France.;Université Paris Saclay, F-94276 Le Kremlin Bicêtre, France; Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Villejuif, France; Département de Médecine Interne et Immunologie clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Bicêtre, F-94275 Le Kremlin Bicêtre, France; INSERM U1015 & CIC1428, Villejuif, France.;Département d'Epidémiologie et de Biostatistiques, Gustave Roussy, Villejuif, France."
"239","Péju E;Belicard F;Silva S;Hraiech S;Painvin B;Kamel T;Thille AW;Goury A;Grimaldi D;Jung B;Piagnerelli M;Winiszewski H;Jourdain M;Jozwiak M","Péju, Edwige;Belicard, Félicie;Silva, Stein;Hraiech, Sami;Painvin, Benoît;Kamel, Toufik;Thille, Arnaud W;Goury, Antoine;Grimaldi, David;Jung, Boris;Piagnerelli, Michael;Winiszewski, Hadrien;Jourdain, Merce;Jozwiak, Mathieu","Management and outcomes of pregnant women admitted to intensive care unit for severe pneumonia related to SARS-CoV-2 infection: the multicenter and international COVIDPREG study.","Intensive care medicine","United States","eng","Journal Article","Acute respiratory distress syndrome;COVID-19;Mechanical ventilation;Neonates;Oxygenation;Pregnancy;Prognosis;Prone positioning","Adult;COVID-19;Female;Humans;Infant, Newborn;Intensive Care Units;Pregnancy;Pregnancy Complications, Infectious;Pregnant People;SARS-CoV-2","Adult;COVID-19;Female;Humans;Infant, Newborn;Intensive Care Units;Pregnancy;Pregnancy Complications, Infectious;Pregnant People;SARS-CoV-2","Management and outcomes of pregnant women with coronavirus disease 2019 (COVID-19) admitted to intensive care unit (ICU) remain to be investigated. A retrospective multicenter study conducted in 32 ICUs in France, Belgium and Switzerland. Maternal management as well as maternal and neonatal outcomes were reported. Among the 187 pregnant women with COVID-19 (33 ± 6 years old and 28 ± 7 weeks' gestation), 76 (41%) were obese, 12 (6%) had diabetes mellitus and 66 (35%) had pregnancy-related complications. Standard oxygenation, high-flow nasal oxygen therapy (HFNO) and non-invasive ventilation (NIV) were used as the only oxygenation technique in 41 (22%), 55 (29%) and 18 (10%) patients, respectively, and 73 (39%) were intubated. Overall, 72 (39%) patients required several oxygenation techniques and 15 (8%) required venovenous extracorporeal membrane oxygenation. Corticosteroids and tocilizumab were administered in 157 (84%) and 25 (13%) patients, respectively. Awake prone positioning or prone positioning was performed in 49 (26%) patients. In multivariate analysis, risk factors for intubation were obesity (cause-specific hazard ratio (CSH) 2.00, 95% CI (1.05-3.80), p = 0.03), term of pregnancy (CSH 1.07, 95% CI (1.02-1.10), per + 1 week gestation, p = 0.01), extent of computed tomography (CT) scan abnormalities > 50% (CSH 2.69, 95% CI (1.30-5.60), p < 0.01) and NIV use (CSH 2.06, 95% CI (1.09-3.90), p = 0.03). Delivery was required during ICU stay in 70 (37%) patients, mainly due to maternal respiratory worsening, and improved the driving pressure and oxygenation. Maternal and fetal/neonatal mortality rates were 1% and 4%, respectively. The rate of maternal and/or neonatal complications increased with the invasiveness of maternal respiratory support. In ICU, corticosteroids, tocilizumab and prone positioning were used in few pregnant women with COVID-19. Over a third of patients were intubated and delivery improved the driving pressure.","Service de Médecine Intensive et Réanimation, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27 rue du faubourg Saint Jacques, 75014, Paris, France.;Université de Paris, Paris, France.;Institut Cochin, INSERM U1016, CNRS UMR8104, 75006, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27 rue du faubourg Saint Jacques, 75014, Paris, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire Purpan, 31300, Toulouse, France.;Service de Médecine Intensive et Réanimation, AP-HM, Hôpital Nord, Marseille, France.;Aix-Marseille Université, Health Service Research and Quality of Life Center (CEReSS), Marseille, France.;Service de réanimation médicale, service des maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Régional d'Orléans, Orléans, France.;Service de Médecine Intensive et Réanimation, CHU de Poitiers, Poitiers, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de soins intensifs CUB-Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.;Service de Médecine Intensive et Réanimation, CHU de Lapeyronie, Montpellier, France.;PhyMedExp, Université de Montpellier, Montpellier, France.;Intensive Care, CHU-Charleroi, Université Libre de Bruxelles, 140, chaussée de Bruxelles, 6042, Charleroi, Belgium.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Pôle de Médecine Intensive et Réanimation, Hôpital Roger Salengro, CHU Lille, Lille, France.;Inserm U1190, Université de Lille, 59000, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet 1, 151 rue saint Antoine de Ginestière, 06200, Nice;Équipe 2 CARRES, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice","NA",0,"1432-1238","Intensive Care Med","Intensive Care Med",2022,"2022","48","10.1007/s00134-022-06833-8","1185-1196","","","35978137","35978137","PUBMED","Service de Médecine Intensive et Réanimation, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27 rue du faubourg Saint Jacques, 75014, Paris, France.;Université de Paris, Paris, France.;Institut Cochin, INSERM U1016, CNRS UMR8104, 75006, Paris, France.;Service de Médecine Intensive et Réanimation, Hôpitaux Universitaires Paris Centre, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 27 rue du faubourg Saint Jacques, 75014, Paris, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire Purpan, 31300, Toulouse, France.;Service de Médecine Intensive et Réanimation, AP-HM, Hôpital Nord, Marseille, France.;Aix-Marseille Université, Health Service Research and Quality of Life Center (CEReSS), Marseille, France.;Service de réanimation médicale, service des maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Régional d'Orléans, Orléans, France.;Service de Médecine Intensive et Réanimation, CHU de Poitiers, Poitiers, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de soins intensifs CUB-Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.;Service de Médecine Intensive et Réanimation, CHU de Lapeyronie, Montpellier, France.;PhyMedExp, Université de Montpellier, Montpellier, France.;Intensive Care, CHU-Charleroi, Université Libre de Bruxelles, 140, chaussée de Bruxelles, 6042, Charleroi, Belgium.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Pôle de Médecine Intensive et Réanimation, Hôpital Roger Salengro, CHU Lille, Lille, France.;Inserm U1190, Université de Lille, 59000, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet 1, 151 rue saint Antoine de Ginestière, 06200, Nice;Équipe 2 CARRES, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Côte d'Azur, Nice"
"240","Zhu Z;Turner NC;Loi S;André F;Martin M;Diéras V;Gelmon KA;Harbeck N;Zhang C;Cao JQ;Yan Z;Lu DR;Wei P;VanArsdale TL;Rejto PA;Huang X;Rugo HS;Loibl S;Cristofanilli M;Finn RS;Liu Y","Zhu, Zhou;Turner, Nicholas C;Loi, Sherene;André, Fabrice;Martin, Miguel;Diéras, Véronique;Gelmon, Karen A;Harbeck, Nadia;Zhang, Cathy;Cao, Joan Q;Yan, Zhengming;Lu, Dongrui R;Wei, Ping;VanArsdale, Todd L;Rejto, Paul A;Huang, Xin;Rugo, Hope S;Loibl, Sibylle;Cristofanilli, Massimo;Finn, Richard S;Liu, Yuan","Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.","NPJ precision oncology","England","eng","Journal Article","","","","While cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, combined with endocrine therapy (ET), are becoming the standard-of-care for hormone receptor-positive/human epidermal growth factor receptor 2‒negative metastatic breast cancer, further mechanistic insights are needed to maximize benefit from the treatment regimen. Herein, we conducted a systematic comparative analysis of gene expression/progression-free survival relationship from two phase 3 trials (PALOMA-2 [first-line] and PALOMA-3 [≥second-line]). In the ET-only arm, there was no inter-therapy line correlation. However, adding palbociclib resulted in concordant biomarkers independent of initial ET responsiveness, with shared sensitivity genes enriched in estrogen response and resistance genes over-represented by mTORC1 signaling and G2/M checkpoint. Biomarker patterns from the combination arm resembled patterns observed in ET in advanced treatment-naive patients, especially patients likely to be endocrine-responsive. Our findings suggest palbociclib may recondition endocrine-resistant tumors to ET, and may guide optimal therapeutic sequencing by partnering CDK4/6 inhibitors with different ETs. Pfizer (NCT01740427; NCT01942135).","Pfizer Inc, La Jolla, CA, USA.;Royal Marsden Hospital and Institute of Cancer Research, London;Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.;Institut Gustave Roussy, INSERM and Université Paris Saclay, Villejuif, France.;Instituto para la Investigación Sanitaria Gregorio Marañón, Ciberonc, Universidad Complutense, Madrid, Spain.;Centre Eugène Marquis, Rennes Cedex, France.;British Columbia Cancer, Vancouver, BC, Canada.;Brustzentrum der Universität München (LMU), München, Germany.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;University of California San Francisco Helen Diller Comprehensive Center, San Francisco, CA, USA.;German Breast Group, Neu-Isenburg, Germany.;Weill Cornell Medicine, New York, NY, USA.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Pfizer Inc, La Jolla, CA, USA.","NA",0,"2397-768X","NPJ Precis Oncol","NPJ Precis Oncol",2021,"2022","6","10.1038/s41698-022-00297-1","56","N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A;N/A","Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.);Pfizer (Pfizer Inc.)","35974168","35974168","PUBMED","Pfizer Inc, La Jolla, CA, USA.;Royal Marsden Hospital and Institute of Cancer Research, London;Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.;Institut Gustave Roussy, INSERM and Université Paris Saclay, Villejuif, France.;Instituto para la Investigación Sanitaria Gregorio Marañón, Ciberonc, Universidad Complutense, Madrid, Spain.;Centre Eugène Marquis, Rennes Cedex, France.;British Columbia Cancer, Vancouver, BC, Canada.;Brustzentrum der Universität München (LMU), München, Germany.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;Pfizer Inc, La Jolla, CA, USA.;University of California San Francisco Helen Diller Comprehensive Center, San Francisco, CA, USA.;German Breast Group, Neu-Isenburg, Germany.;Weill Cornell Medicine, New York, NY, USA.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Pfizer Inc, La Jolla, CA, USA."
"241","Thomas QD;Boussere A;Classe JM;Pomel C;Costaz H;Rodrigues M;Ray-Coquard I;Gladieff L;Rouzier R;Rouge TM;Gouy S;Barranger E;Sabatier R;Floquet A;Marchal F;Guillemet C;Polivka V;Martin AL;Colombo PE;Fiteni F","Thomas, Quentin Dominique;Boussere, Amal;Classe, Jean-Marc;Pomel, Christophe;Costaz, Hélène;Rodrigues, Manuel;Ray-Coquard, Isabelle;Gladieff, Laurence;Rouzier, Roman;Rouge, Thibault De La Motte;Gouy, Sébastien;Barranger, Emmanuel;Sabatier, Renaud;Floquet, Anne;Marchal, Frédéric;Guillemet, Cécile;Polivka, Valentine;Martin, Anne-Laure;Colombo, Pierre-Emmanuel;Fiteni, Frédéric","Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.","Gynecologic oncology","United States","eng","Journal Article","Cytoreduction;Neoadjuvant;Prognosis;Propensity score;Survival","Carcinoma, Ovarian Epithelial;Chemotherapy, Adjuvant;Cytoreduction Surgical Procedures;Female;Humans;Neoadjuvant Therapy;Neoplasm Staging;Ovarian Neoplasms;Retrospective Studies","Carcinoma, Ovarian Epithelial;Chemotherapy, Adjuvant;Cytoreduction Surgical Procedures;Female;Humans;Neoadjuvant Therapy;Neoplasm Staging;Ovarian Neoplasms;Retrospective Studies","Interval debulking surgery is recommended after 3-4 cycles (standard IDS) of neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer (EOC) not able to received upfront complete debulking surgery. However, real world practices frequently report performing IDS after ≥5 NAC cycles (delayed IDS). The aim of this work was to evaluate the impact on survival of the number of NACT cycles before IDS. We identified from a French national database, women with newly diagnosed EOC who underwent IDS from January 2011 to December 2016. Progression free survival (PFS) and overall survival (OS) were compared using Cox model with adjustments for confounding factors provided by two propensity score methods: inverse probability of treatment weighting (IPTW) and matched-pair analysis. 928 patients treated by IDS for which our propensity score could be applied were identified. After a median follow-up of 49.0 months (95% CI [46.0;52.9]); from the IPTW analysis, median PFS was 17.6 months and 11.5 months (HR = 1.42; CI 95% [1.22-1.67]; p < 0.0001); median OS was 51.2 months and 44.3 months (HR = 1.29; CI 95% [1.06-1.56]; p = 0.0095) for the standard and delayed IDS groups. From the matched-pair analysis (comparing 352 patients for each group), standard IDS was associated with better PFS (HR = 0,77; CI 95% [0.65-0.90]; p = 0.018) but not significantly associated with better OS (HR = 0,84; CI 95% [0.68-1,03]; p = 0.0947). Carrying IDS after ≥5 NACT cycles seems to have a negative effect on patients survival. The goal of IDS surgery is complete resection and should not be performed after >3-4 NACT cycles.","Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier;Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint Herblain, France.;Department of Surgical Oncology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR INSERM-UCA, Clermont-Ferrand, France.;Department of Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Claudius Régaud IUCT-O, Toulouse, France.;Department of Surgical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgery, Gustave Roussy, Villejuif, France.;Departement of Surgery, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Departement of Surgery, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Departement of Surgery, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Departement of Medical Oncology, University Hospital of Nîmes, University of Montpellier, UMR UA11 INSERM, IDESP Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France.","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2022,"2022","167","10.1016/j.ygyno.2022.08.005","11-21","","","35970603","35970603","PUBMED","Departement of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier;Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint Herblain, France.;Department of Surgical Oncology, Centre de Lutte Contre le Cancer Jean Perrin, Imagerie Moléculaire et Stratégies Théranostiques, Université Clermont Auvergne, UMR INSERM-UCA, Clermont-Ferrand, France.;Department of Surgical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Claudius Régaud IUCT-O, Toulouse, France.;Department of Surgical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgery, Gustave Roussy, Villejuif, France.;Departement of Surgery, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Departement of Surgery, Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Biometry, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Health Data and Partnership Department, Unicancer, Paris, France.;Departement of Surgery, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.;Departement of Medical Oncology, University Hospital of Nîmes, University of Montpellier, UMR UA11 INSERM, IDESP Institut Desbrest d'Epidémiologie et de Santé Publique, Montpellier, France."
"242","Mahdizadeh SJ;Pålsson E;Carlesso A;Chevet E;Eriksson LA","Mahdizadeh, Sayyed Jalil;Pålsson, Emil;Carlesso, Antonio;Chevet, Eric;Eriksson, Leif A","QM/MM Well-Tempered Metadynamics Study of the Mechanism of XBP1 mRNA Cleavage by Inositol Requiring Enzyme 1α RNase.","Journal of chemical information and modeling","United States","eng","Journal Article","","Endoribonucleases;Inositol;Molecular Docking Simulation;Protein Serine-Threonine Kinases;RNA, Messenger;Ribonucleases","Endoribonucleases;Inositol;Molecular Docking Simulation;Protein Serine-Threonine Kinases;RNA, Messenger;Ribonucleases","A range of   methodologies were herein employed to study the unconventional XBP1 mRNA cleavage mechanism performed by the unfolded protein response (UPR) mediator Inositol Requiring Enzyme 1α (IRE1). Using Protein-RNA molecular docking along with a series of extensive restrained/unrestrained atomistic molecular dynamics (MD) simulations, the dynamical behavior of the system was evaluated and a reliable model of the IRE1/XBP1 mRNA complex was constructed. From a series of well-converged quantum mechanics molecular mechanics well-tempered metadynamics (QM/MM WT-MetaD) simulations using the Grimme dispersion interaction corrected semiempirical parametrization method 6 level of theory (PM6-D3) and the AMBER14SB-OL3 force field, the free energy profile of the cleavage mechanism was determined, along with intermediates and transition state structures. The results show two distinct reaction paths based on general acid-general base type mechanisms, with different activation energies that perfectly match observations from experimental mutagenesis data. The study brings unique atomistic insights into the cleavage mechanism of XBP1 mRNA by IRE1 and clarifies the roles of the catalytic residues H910 and Y892. Increased understanding of the details in UPR signaling can assist in the development of new therapeutic agents for its modulation.","Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Faculty of Biomedical Sciences, Euler Institute, Università della Svizzera Italiana (USI),, Lugano 6904, Switzerland.;Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, 405 30 Göteborg, Sweden.;INSERM U1242, University of Rennes 1, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.","NA",0,"1549-960X","J Chem Inf Model","J Chem Inf Model",2022,"2022","62","10.1021/acs.jcim.2c00735","4247-4260","","","35960929","35960929","PUBMED","Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden.;Faculty of Biomedical Sciences, Euler Institute, Università della Svizzera Italiana (USI),, Lugano 6904, Switzerland.;Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, 405 30 Göteborg, Sweden.;INSERM U1242, University of Rennes 1, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Chemistry and Molecular Biology, University of Gothenburg, 405 30 Göteborg, Sweden."
"243","Cazelles A;Collard MK;Lalatonne Y;Doblas S;Zappa M;Labiad C;Cazals-Hatem D;Maggiori L;Treton X;Panis Y;Jarry U;Desvallées T;Eliat PA;Pineau R;Motte L;Letourneur D;Simon-Yarza T;Ogier-Denis E","Cazelles, Antoine;Collard, Maxime K;Lalatonne, Yoann;Doblas, Sabrina;Zappa, Magaly;Labiad, Camélia;Cazals-Hatem, Dominique;Maggiori, Léon;Treton, Xavier;Panis, Yves;Jarry, Ulrich;Desvallées, Thomas;Eliat, Pierre-Antoine;Pineau, Raphaël;Motte, Laurence;Letourneur, Didier;Simon-Yarza, Teresa;Ogier-Denis, Eric","A Preclinical Validation of Iron Oxide Nanoparticles for Treatment of Perianal Fistulizing Crohn's Disease.","International journal of molecular sciences","Switzerland","eng","Journal Article","Crohn’s disease;fistula treatment;iron oxide nanoparticles;perianal fistula;preclinical model","Animals;Male;Rats;Crohn Disease;Magnetic Iron Oxide Nanoparticles;Neoplasm Recurrence, Local;Quality of Life;Rats, Sprague-Dawley;Rectal Fistula;Treatment Outcome","Animals;Male;Rats;Crohn Disease;Magnetic Iron Oxide Nanoparticles;Neoplasm Recurrence, Local;Quality of Life;Rats, Sprague-Dawley;Rectal Fistula;Treatment Outcome","Fistulizing anoperineal lesions are severe complications of Crohn's disease (CD) that affect quality of life with a long-term risk of anal sphincter destruction, incontinence, permanent stoma, and anal cancer. Despite several surgical procedures, they relapse in about two-thirds of patients, mandating innovative treatments. Ultrasmall particles of iron oxide (USPIO) have been described to achieve in vivo rapid healing of deep wounds in the skin and liver of rats thanks to their nanobridging capability that could be adapted to fistula treatment. Our main purpose was to highlight preclinical data with USPIO for the treatment of perianal fistulizing CD. Twenty male Sprague Dawley rats with severe 2,4,6-trinitrobenzenesulfonic acid solution (TNBS)-induced proctitis were operated to generate two perianal fistulas per rat. At day 35, two inflammatory fistulas were obtained per rat and perineal magnetic resonance imaging (MRI) was performed. After a baseline MRI, a fistula tract was randomly drawn and topically treated either with saline or with USPIO for 1 min (  = 17 for each). The rats underwent a perineal MRI on postoperative days (POD) 1, 4, and 7 and were sacrificed for pathological examination. The primary outcome was the filling or closure of the fistula tract, including the external or internal openings. USPIO treatment allowed the closure and/or filling of all the treated fistulas from its application until POD 7 in comparison with the control fistulas (23%). The treatment with USPIO was safe, permanently closed the fistula along its entire length, including internal and external orifices, and paved new avenues for the treatment of perianal fistulizing Crohn's disease.","Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Départements of Biochimie and de Médecine Nucléaire, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, 93009 Bobigny, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Laboratory of Imaging Biomarkers, Université Paris Cité, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Laboratory of Imaging Biomarkers, Université Paris Cité, BP 416, 75018 Paris, France.;Département of Radiologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département of Pathologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département Gastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, 35000 Rennes, France.;Biotrial Pharmacology, Unité De Pharmacologie Préclinique, 35000 Rennes, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, 35000 Rennes, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, PRISM, 35000 Rennes, France.;INRAE, INSERM, Institute NUMECAN, UMR_A 1341, Université Rennes, UMR_S 1241, 35000 Rennes, France.;INSERM, CLCC Eugène Marquis, Oncogenesis, Stress Signaling, Université Rennes, UMR_S 1242, 35000 Rennes, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;INSERM, CLCC Eugène Marquis, Oncogenesis, Stress Signaling, Université Rennes, UMR_S 1242, 35000 Rennes, France.;INSERM U1242, Centre Eugène Marquis, Rue de la Bataille de Flandres-Dunkerque, 35042 Rennes, France.","NA",0,"1422-0067","Int J Mol Sci","Int J Mol Sci",2022,"2022","23","10.3390/ijms23158324",NA,"","","35955465","35955465","PUBMED","Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Départements of Biochimie and de Médecine Nucléaire, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, 93009 Bobigny, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Laboratory of Imaging Biomarkers, Université Paris Cité, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Laboratory of Imaging Biomarkers, Université Paris Cité, BP 416, 75018 Paris, France.;Département of Radiologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département of Pathologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Département Gastroentérologie, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Département of Chirurgie Colorectale, Assistance Publique Hôpitaux de Paris, Hôpital Beaujon, CEDEX, 92110 Clichy, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, 35000 Rennes, France.;Biotrial Pharmacology, Unité De Pharmacologie Préclinique, 35000 Rennes, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, Oncotrial, 35000 Rennes, France.;Université Rennes, CNRS, INSERM, BIOSIT UAR 3480, US_S 018, PRISM, 35000 Rennes, France.;INRAE, INSERM, Institute NUMECAN, UMR_A 1341, Université Rennes, UMR_S 1241, 35000 Rennes, France.;INSERM, CLCC Eugène Marquis, Oncogenesis, Stress Signaling, Université Rennes, UMR_S 1242, 35000 Rennes, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Laboratory for Vascular Translational Science, Université Paris Cité, Université Sorbonne Paris Nord, LVTS, INSERM, UMR 1148, 75018 Paris, France.;Centre de Recherche sur l'Inflammation, INSERM, U1149, CNRS, ERL8252, Université Paris Cité, Team Gut Inflammation, BP 416, 75018 Paris, France.;INSERM, CLCC Eugène Marquis, Oncogenesis, Stress Signaling, Université Rennes, UMR_S 1242, 35000 Rennes, France.;INSERM U1242, Centre Eugène Marquis, Rue de la Bataille de Flandres-Dunkerque, 35042 Rennes, France."
"244","Vasseur A;Carton M;Guiu S;Augereau P;Uwer L;Mouret-Reynier MA;Levy C;Eymard JC;Ferrero JM;Leheurteur M;Goncalves A;Robert M;De La Motte Rouge T;Bachelot T;Petit T;Debled M;Grinda T;Desmoulins I;Vanlemmens L;Nicolaï V;Simon G;Cabel L","Vasseur, Antoine;Carton, Matthieu;Guiu, Severine;Augereau, Paule;Uwer, Lionel;Mouret-Reynier, Marie-Ange;Levy, Christelle;Eymard, Jean-Christophe;Ferrero, Jean-Marc;Leheurteur, Marianne;Goncalves, Anthony;Robert, Marie;De La Motte Rouge, Thibault;Bachelot, Thomas;Petit, Thierry;Debled, Marc;Grinda, Thomas;Desmoulins, Isabelle;Vanlemmens, Laurence;Nicolaï, Vincent;Simon, Gaëtane;Cabel, Luc","Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Early relapse;Metastatic breast cancer;Rechallenge;Taxanes","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Breast Neoplasms;Carboplatin;Female;Humans;Neoplasm Metastasis;Neoplasm Recurrence, Local;Receptor, ErbB-2;Retrospective Studies;Taxoids;Treatment Outcome;Triple Negative Breast Neoplasms","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Breast Neoplasms;Carboplatin;Female;Humans;Neoplasm Metastasis;Neoplasm Recurrence, Local;Receptor, ErbB-2;Retrospective Studies;Taxoids;Treatment Outcome;Triple Negative Breast Neoplasms","Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant setting. Our study aimed to analyse the efficacy of taxane rechallenge in case of early metastatic relapse in a multicentre retrospective observational study compared with other chemotherapies. We analysed the French national ESME metastatic BC (MBC) database and selected HER2- MBC patients who received CT in first-line treatment for a metastatic relapse occurring 3-24 months after previous (neo)adjuvant taxanes treatment. Of 23,501 female patients with MBC in ESME, 1057 met the selection criteria. 58.4% received a taxane-based regimen (75.4% concomitant bevacizumab) and 41.6% received other CT. In hormone-receptor positive (HR+)/HER2- MBC, multivariate analysis showed no difference in OS between taxanes without bevacizumab compared to other CT (HZR = 1.3 [0.97; 1.74], but taxanes was significantly associated with worse PFS (HZR = 1.48 [1.14; 1.93]). In TNBC, taxanes without bevacizumab and carboplatin/gemcitabine were not superior to other CT for OS (HZR = 1.07 [0.79; 1.44] and HZR = 0.81 [0.58; 1.13], respectively), while for PFS, taxanes was inferior (HZR = 1.33 [1.06-1.67]) and carboplatin plus gemcitabine was superior to other CT (HZR = 0.63 [0.46; 0.87]). For both subtypes, the worse outcome observed with paclitaxel was no longer observed with the addition of bevacizumab. With the limitation of retrospective design, taxanes rechallenge in early metastatic relapse of BC may result in a worse PFS in TNBC and HR+/HER2- MBC, which was not observed with the addition of bevacizumab.","Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Biostatistics, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, Boulevard Professeur Jacques Monod, 44800, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33, avenue de Valombrose, 06100, Nice, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000, Strasbourg, France.;Department of Medical Oncology, Institut Bergonié, Cours de l'Argonne, 33000, Bordeaux, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue Professeur Marion, 21000, Dijon, France.;Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Real World Data, Data Office of Unicancer, 101 rue de Tolbiac, 75013, Paris, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud","NA",0,"1532-3080","Breast","Breast",2022,"2022","65","10.1016/j.breast.2022.07.014","136-144","","","35944353","35944353","PUBMED","Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Biostatistics, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, Boulevard Professeur Jacques Monod, 44800, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33, avenue de Valombrose, 06100, Nice, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000, Strasbourg, France.;Department of Medical Oncology, Institut Bergonié, Cours de l'Argonne, 33000, Bordeaux, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Medical Oncology, Centre Georges-François Leclerc, 1 rue Professeur Marion, 21000, Dijon, France.;Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Real World Data, Data Office of Unicancer, 101 rue de Tolbiac, 75013, Paris, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud"
"245","Drillet G;Lhomme F;De Guibert S;Manson G;Houot R","Drillet, Gaëlle;Lhomme, Faustine;De Guibert, Sophie;Manson, Guillaume;Houot, Roch","Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists.","Blood advances","United States","eng","Journal Article","","Humans;Receptors, Thrombopoietin;Immunotherapy, Adoptive;Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic;Anemia","Humans;Receptors, Thrombopoietin;Immunotherapy, Adoptive;Thrombocytopenia;Purpura, Thrombocytopenic, Idiopathic;Anemia","NA","Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;INSERM U1236, Rennes, France.","NA",0,"2473-9537","Blood Adv","Blood Adv",2022,"2023","7","10.1182/bloodadvances.2022008066","537-540","","","35930692","35930692","PUBMED","Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Department of Hematology, Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;INSERM U1236, Rennes, France."
"246","Jaïs X;Brenot P;Bouvaist H;Jevnikar M;Canuet M;Chabanne C;Chaouat A;Cottin V;De Groote P;Favrolt N;Horeau-Langlard D;Magro P;Savale L;Prévot G;Renard S;Sitbon O;Parent F;Trésorier R;Tromeur C;Piedvache C;Grimaldi L;Fadel E;Montani D;Humbert M;Simonneau G","Jaïs, Xavier;Brenot, Philippe;Bouvaist, Hélène;Jevnikar, Mitja;Canuet, Matthieu;Chabanne, Céline;Chaouat, Ari;Cottin, Vincent;De Groote, Pascal;Favrolt, Nicolas;Horeau-Langlard, Delphine;Magro, Pascal;Savale, Laurent;Prévot, Grégoire;Renard, Sébastien;Sitbon, Olivier;Parent, Florence;Trésorier, Romain;Tromeur, Cécile;Piedvache, Céline;Grimaldi, Lamiae;Fadel, Elie;Montani, David;Humbert, Marc;Simonneau, Gérald","Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.","The Lancet. Respiratory medicine","England","eng","Clinical Trial, Phase III","","Angioplasty;Angioplasty, Balloon;Chronic Disease;Follow-Up Studies;Humans;Hypertension, Pulmonary;Pulmonary Embolism;Pyrazoles;Pyrimidines;Randomized Controlled Trials as Topic;Treatment Outcome","Angioplasty;Angioplasty, Balloon;Chronic Disease;Follow-Up Studies;Humans;Hypertension, Pulmonary;Pulmonary Embolism;Pyrazoles;Pyrimidines;Randomized Controlled Trials as Topic;Treatment Outcome","Riociguat and balloon pulmonary angioplasty (BPA) are treatment options for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). However, randomised controlled trials comparing these treatments are lacking. We aimed to evaluate the efficacy and safety of BPA versus riociguat in patients with inoperable CTEPH. In this phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension, we enrolled treatment-naive patients aged 18-80 years with newly diagnosed, inoperable CTEPH and pulmonary vascular resistance of more than 320 dyn·s/cm . Patients were randomly assigned (1:1) to BPA or riociguat via a web-based randomisation system, with block randomisation (block sizes of two or four patients) without stratification. The primary endpoint was change in pulmonary vascular resistance at week 26, expressed as percentage of baseline pulmonary vascular resistance in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of riociguat or had at least one BPA session. Patients who completed the RACE trial continued into an ancillary 26-week follow-up during which symptomatic patients with pulmonary vascular resistance of more than 320 dyn·s/cm  benefited from add-on riociguat after BPA or add-on BPA after riociguat. This trial is registered at ClinicalTrials.gov, NCT02634203, and is completed. Between Jan 19, 2016, and Jan 18, 2019, 105 patients were randomly assigned to riociguat (n=53) or BPA (n=52). At week 26, the geometric mean pulmonary vascular resistance decreased to 39·9% (95% CI 36·2-44·0) of baseline pulmonary vascular resistance in the BPA group and 66·7% (60·5-73·5) of baseline pulmonary vascular resistance in the riociguat group (ratio of geometric means 0·60, 95% CI 0·52-0·69; p<0·0001). Treatment-related serious adverse events occurred in 22 (42%) of 52 patients in the BPA group and five (9%) of 53 patients in the riociguat group. The most frequent treatment-related serious adverse events were lung injury (18 [35%] of 52 patients) in the BPA group and severe hypotension with syncope (two [4%] of 53 patients) in the riociguat group. There were no treatment-related deaths. At week 52, a similar reduction in pulmonary vascular resistance was observed in patients treated with first-line riociguat or first-line BPA (ratio of geometric means 0·91, 95% CI 0·79-1·04). The incidence of BPA-related serious adverse events was lower in patients who were pretreated with riociguat (five [14%] of 36 patients vs 22 [42%] of 52 patients). At week 26, pulmonary vascular resistance reduction was more pronounced with BPA than with riociguat, but treatment-related serious adverse events were more common with BPA. The finding of fewer BPA-related serious adverse events among patients who were pretreated with riociguat in the follow-up study compared with those who received BPA as first-line treatment points to the potential benefits of a multimodality approach to treatment in patients with inoperable CTEPH. Further studies are needed to explore the effects of sequential treatment combining one or two medications and BPA in patients with inoperable CTEPH. Programme Hospitalier de Recherche Clinique of the French Ministry of Health and Bayer HealthCare. For the French translation of the abstract see Supplementary Materials section.","Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Radiologie, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Grenoble-Alpes, Service de Cardiologie, Grenoble, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Hôpitaux Universitaires de Strasbourg, Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, France.;Centre Hospitalier Régional Universitaire de Nancy-Brabois, Département de Pneumologie, Vandœuvre-lès-Nancy, France.;Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Pneumologie-Centre de Référence des Maladies Pulmonaires Rares, Lyon, France.;Centre Hospitalier Régional Universitaire de Lille, Service de Cardiologie, Lille, France.;Centre Hospitalier Universitaire de Dijon, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France.;Centre Hospitalier Universitaire de Nantes, Service de Pneumologie, Hôpital Laënnec, Nantes, France.;Centre Hospitalier Régional Universitaire de Tours, Service de Pneumologie, Hôpital Bretonneau, Tours, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Toulouse, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;Assistance Publique-Hôpitaux de Marseille (APHM), Service de Cardiologie, Hôpital de la Timone, Marseille, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Régional Universitaire de Brest, Département de Médecine Interne et Pneumologie, Hôpital de la Cavale Blanche, Brest, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Faculté de Médecine Simone Veil, Université Versailles Saint Quentin-Université Paris-Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.","NA",0,"2213-2619","Lancet Respir Med","Lancet Respir Med",2022,"2022","10","10.1016/S2213-2600(22)00214-4","961-971","","","35926542","35926542","PUBMED","Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Radiologie, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Grenoble-Alpes, Service de Cardiologie, Grenoble, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Hôpitaux Universitaires de Strasbourg, Service de Pneumologie, Nouvel Hôpital Civil, Strasbourg, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Rennes, France.;Centre Hospitalier Régional Universitaire de Nancy-Brabois, Département de Pneumologie, Vandœuvre-lès-Nancy, France.;Hospices Civils de Lyon, Groupe Hospitalier Est, Service de Pneumologie-Centre de Référence des Maladies Pulmonaires Rares, Lyon, France.;Centre Hospitalier Régional Universitaire de Lille, Service de Cardiologie, Lille, France.;Centre Hospitalier Universitaire de Dijon, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France.;Centre Hospitalier Universitaire de Nantes, Service de Pneumologie, Hôpital Laënnec, Nantes, France.;Centre Hospitalier Régional Universitaire de Tours, Service de Pneumologie, Hôpital Bretonneau, Tours, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Toulouse, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;Assistance Publique-Hôpitaux de Marseille (APHM), Service de Cardiologie, Hôpital de la Timone, Marseille, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Régional Universitaire de Brest, Département de Médecine Interne et Pneumologie, Hôpital de la Cavale Blanche, Brest, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Unité de Recherche Clinique Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Faculté de Médecine Simone Veil, Université Versailles Saint Quentin-Université Paris-Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, Montigny-Le-Bretonneux, France.;Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France; Service de Chirurgie Thoracique, Vasculaire et Transplantation Cardio-pulmonaire, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris (APHP), Service de Pneumologie et Soins Intensifs Respiratoires, Centre de Référence de l'Hypertension Pulmonaire, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France; INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis-Robinson, France."
"247","Lamouche-Wilquin P;Souchard J;Pere M;Raymond M;Asfar P;Darreau C;Reizine F;Hourmant B;Colin G;Rieul G;Kergoat P;Frérou A;Lorber J;Auchabie J;La Combe B;Seguin P;Egreteau PY;Morin J;Fedun Y;Canet E;Lascarrou JB;Delbove A","Lamouche-Wilquin, Pauline;Souchard, Jérôme;Pere, Morgane;Raymond, Matthieu;Asfar, Pierre;Darreau, Cédric;Reizine, Florian;Hourmant, Baptiste;Colin, Gwenhaël;Rieul, Guillaume;Kergoat, Pierre;Frérou, Aurélien;Lorber, Julien;Auchabie, Johann;La Combe, Béatrice;Seguin, Philippe;Egreteau, Pierre-Yves;Morin, Jean;Fedun, Yannick;Canet, Emmanuel;Lascarrou, Jean-Baptiste;Delbove, Agathe","Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS.","Critical care (London, England)","England","eng","Journal Article","Dexamethasone;Mechanical ventilation;Methylprednisolone;Nosocomial pneumonia;SARS-CoV-19","Adrenal Cortex Hormones;Adult;Aged;COVID-19;Humans;Intensive Care Units;Pneumonia, Ventilator-Associated;Respiration, Artificial;Respiratory Distress Syndrome;Retrospective Studies;Steroids","Adrenal Cortex Hormones;Adult;Aged;COVID-19;Humans;Intensive Care Units;Pneumonia, Ventilator-Associated;Respiration, Artificial;Respiratory Distress Syndrome;Retrospective Studies;Steroids","Early corticosteroid treatment is used to treat COVID-19-related acute respiratory distress syndrome (ARDS). Infection is a well-documented adverse effect of corticosteroid therapy. To determine whether early corticosteroid therapy to treat COVID-19 ARDS was associated with ventilator-associated pneumonia (VAP). We retrospectively included adults with COVID-19-ARDS requiring invasive mechanical ventilation (MV) for ≥ 48 h at any of 15 intensive care units in 2020. We divided the patients into two groups based on whether they did or did not receive corticosteroids within 24 h. The primary outcome was VAP incidence, with death and extubation as competing events. Secondary outcomes were day 90-mortality, MV duration, other organ dysfunctions, and VAP characteristics. Of 670 patients (mean age, 65 years), 369 did and 301 did not receive early corticosteroids. The cumulative VAP incidence was higher with early corticosteroids (adjusted hazard ratio [aHR] 1.29; 95% confidence interval [95% CI] 1.05-1.58; P = 0.016). Antibiotic resistance of VAP bacteria was not different between the two groups (odds ratio 0.94, 95% CI 0.58-1.53; P = 0.81). 90-day mortality was 30.9% with and 24.3% without early corticosteroids, a nonsignificant difference after adjustment on age, SOFA score, and VAP occurrence (aHR 1.15; 95% CI 0.83-1.60; P = 0.411). VAP was associated with higher 90-day mortality (aHR 1.86; 95% CI 1.33-2.61; P = 0.0003). Early corticosteroid treatment was associated with VAP in patients with COVID-19-ARDS. Although VAP was associated with higher 90-day mortality, early corticosteroid treatment was not. Longitudinal randomized controlled trials of early corticosteroids in COVID-19-ARDS requiring MV are warranted.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Polyvalente, Centre Hospitalier du Mans, Le Mans, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cornouaille, Quimper, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Sud, Lorient, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Morlaix, Morlaix, France.;Service de Soins Intensifs de Pneumologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.","NA",0,"1466-609X","Crit Care","Crit Care",2022,"2022","26","10.1186/s13054-022-04097-8","233","","","35918776","35918776","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Polyvalente, Centre Hospitalier du Mans, Le Mans, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cornouaille, Quimper, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Nazaire, Saint-Nazaire, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Sud, Lorient, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Morlaix, Morlaix, France.;Service de Soins Intensifs de Pneumologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 1 Place Alexis Ricordeau, 44093, Nantes Cedex 01;Service de Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France."
"248","Garret C;Douillard M;David A;Péré M;Quenehervé L;Legros L;Archambeaud I;Douane F;Lerhun M;Regenet N;Gournay J;Coron E;Frampas E;Reignier J","Garret, Charlotte;Douillard, Marion;David, Arthur;Péré, Morgane;Quenehervé, Lucille;Legros, Ludivine;Archambeaud, Isabelle;Douane, Frédéric;Lerhun, Marc;Regenet, Nicolas;Gournay, Jerome;Coron, Emmanuel;Frampas, Eric;Reignier, Jean","Infected pancreatic necrosis complicating severe acute pancreatitis in critically ill patients: predicting catheter drainage failure and need for necrosectomy.","Annals of intensive care","Germany","eng","Journal Article","Acute pancreatitis;Catheter drainage;Infected necrosis;Intensive care;Necrosectomy;Organ failure","","","Recent guidelines advocate a step-up approach for managing suspected infected pancreatic necrosis (IPN) during acute pancreatitis. Nearly half the patients require secondary necrosectomy after catheter drainage. Our primary objective was to assess the external validity of a previously reported nomogram for catheter drainage, based on four predictors of failure. Our secondary objectives were to identify other potential predictors of catheter-drainage failure. We retrospectively studied consecutive patients admitted to the intensive care units (ICUs) of three university hospitals in France between 2012 and 2016, for severe acute pancreatitis with suspected IPN requiring catheter drainage. We assessed drainage success and failure rates in 72 patients, with success defined as survival without subsequent necrosectomy and failure as death and/or subsequent necrosectomy required by inadequate improvement. We plotted the receiver operating characteristics (ROC) curve for the nomogram and computed the area under the curve (AUROC). Catheter drainage alone was successful in 32 (44.4%) patients. The nomogram predicted catheter-drainage failure with an AUROC of 0.71. By multivariate analysis, catheter-drainage failure was independently associated with a higher body mass index [odds ratio (OR), 1.12; 95% confidence interval (95% CI), 1.00-1.24; P = 0.048], heterogeneous collection (OR, 16.7; 95% CI, 1.83-152.46; P = 0.01), and respiratory failure onset within 24 h before catheter drainage (OR, 18.34; 95% CI, 2.18-154.3; P = 0.007). Over half the patients required necrosectomy after failed catheter drainage. Newly identified predictors of catheter-drainage failure were heterogeneous collection and respiratory failure. Adding these predictors to the nomogram might help to identify patients at high risk of catheter-drainage failure. gov number: NCT03234166.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Plateforme de Méthodologie et Biostatistique, Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Brest, 29200, Brest, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Rennes, 35203, Rennes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2021,"2022","12","10.1186/s13613-022-01039-z","71","","","35916981","35916981","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Plateforme de Méthodologie et Biostatistique, Direction de la Recherche, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Brest, 29200, Brest, France.;Service d'Hépatogastroentérologie, Centre Hospitalier Universitaire de Rennes, 35203, Rennes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Institut des Maladies de L'Appareil Digestif, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France.;Radiologie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, 44000, Nantes, France."
"249","Coutzac C;Bibeau F;Ben Abdelghani M;Aparicio T;Cohen R;Coquan E;Dubreuil O;Evesque L;Ghiringhelli F;Kim S;Lesourd S;Neuzillet C;Phelip JM;Piessen G;Rochigneux P;Samalin E;Soularue E;Touchefeu Y;Tougeron D;Zaanan A;de la Fouchardière C","Coutzac, Clélia;Bibeau, Frederic;Ben Abdelghani, Meher;Aparicio, Thomas;Cohen, Romain;Coquan, Elodie;Dubreuil, Olivier;Evesque, Ludovic;Ghiringhelli, François;Kim, Stefano;Lesourd, Samuel;Neuzillet, Cindy;Phelip, Jean-Marc;Piessen, Guillaume;Rochigneux, Philippe;Samalin, Emmanuelle;Soularue, Emilie;Touchefeu, Yann;Tougeron, David;Zaanan, Aziz;de la Fouchardière, Christelle","Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Netherlands","eng","Clinical Trial, Phase II","Colorectal cancer;Endometrial cancer;Gastric cancer;Immune checkpoint inhibitor;MSI/dMMR;Perioperative immunotherapy","Antineoplastic Agents, Immunological;Colorectal Neoplasms;DNA Mismatch Repair;Humans;Immune Checkpoint Inhibitors;Immunologic Factors;Immunotherapy;Microsatellite Instability;Neoplasms;Prospective Studies","Antineoplastic Agents, Immunological;Colorectal Neoplasms;DNA Mismatch Repair;Humans;Immune Checkpoint Inhibitors;Immunologic Factors;Immunotherapy;Microsatellite Instability;Neoplasms;Prospective Studies","Immune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The MSI/dMMR status predicts clinical response to ICI. The promising results evaluating ICI in localized MSI/dMMR tumors in neoadjuvant setting need to be confirmed in MSI/dMMR solid tumors. The aim of the IMHOTEP trial is to assess the efficacy of neoadjuvant anti-PD-1 treatment in MSI/dMMR tumors regarding the pathological complete response rate. This study is a prospective, multicenter, phase II study including 120 patients with localized MSI/dMMR carcinomas suitable for curative surgery. A single dose of pembrolizumab will be administered before the surgery planned 6 weeks later. Primary objective is to evaluate the efficacy of neoadjuvant pembrolizumab according to pathological complete tumor response. Secondary objectives are to assess safety, recurrence-free survival and overall survival. Ancillary studies will assess molecular and immunological biomarkers predicting response/resistance to ICI. First patient was enrolled in December 2021. The IMHOTEP trial will be one of the first clinical trial investigating perioperative ICI in localized MSI/dMMR in a tumor agnostic setting. Assessing neoadjuvant anti-PD-1 is mandatory to improve MSI/dMMR patient's outcomes. The translational program will explore potential biomarker to improve our understanding of immune escape and response in this ICI neoadjuvant setting.","Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France.;Department of pathology, Besançon University Hospital, Besançon, France.;Department of Medical Oncology, Paul Strauss Center, Strasbourg, France.;AP-HP, Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, Paris, France.;AP-HP, INSERM, Sorbonne University, Saint-Antoine Hospital, Unité Mixte de Recherche Scientifique 938, Paris 75012, France.;Department of Medical Oncology, Center François Baclesse, Caen, France.;Department of Digestive Oncology, Groupe hospitalier Diaconesses Croix Saint Simon, Paris, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Georges François Leclerc, Dijon, France.;Department of Medical Oncology, University Hospital of Besançon, Besançon 25000, France.;Medical Oncology, Centre Eugène Marquis, Rennes 35000, France.;Department of Medical Oncology, Curie Institute, Versailles Saint-Quentin University (UVSQ) - Paris Saclay University, Saint-Cloud, France.;Centre Hospitalier Universitaire St Etienne, St Etienne, France.;Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille F-59000, France.;Medical Oncology Department, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.;Department of medical Oncology, Institut régional du Cancer de Montpellier (ICM), Université Montpellier, Montpellier, France.;Department of Oncology, Institute Mutualiste Montsouris, Paris 75014, France.;CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes Université, Nantes F-44000, France.;Department of Hepato-gastroenterology, Centre Hospitalo-Universitaire Poitiers, Poitiers 86000, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris University, Assistance Publique-Hôpitaux de Paris, Paris, France.;Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon","NA",0,"1878-3562","Dig Liver Dis","Dig Liver Dis",2022,"2022","54","10.1016/j.dld.2022.07.008","1335-1341","","","35907691","35907691","PUBMED","Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon, France.;Department of pathology, Besançon University Hospital, Besançon, France.;Department of Medical Oncology, Paul Strauss Center, Strasbourg, France.;AP-HP, Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, Paris, France.;AP-HP, INSERM, Sorbonne University, Saint-Antoine Hospital, Unité Mixte de Recherche Scientifique 938, Paris 75012, France.;Department of Medical Oncology, Center François Baclesse, Caen, France.;Department of Digestive Oncology, Groupe hospitalier Diaconesses Croix Saint Simon, Paris, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Georges François Leclerc, Dijon, France.;Department of Medical Oncology, University Hospital of Besançon, Besançon 25000, France.;Medical Oncology, Centre Eugène Marquis, Rennes 35000, France.;Department of Medical Oncology, Curie Institute, Versailles Saint-Quentin University (UVSQ) - Paris Saclay University, Saint-Cloud, France.;Centre Hospitalier Universitaire St Etienne, St Etienne, France.;Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille F-59000, France.;Medical Oncology Department, Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France.;Department of medical Oncology, Institut régional du Cancer de Montpellier (ICM), Université Montpellier, Montpellier, France.;Department of Oncology, Institute Mutualiste Montsouris, Paris 75014, France.;CHU Nantes, Institut des Maladies de l'Appareil Digestif (IMAD), Hépato-Gastroentérologie, Inserm CIC 1413, Nantes Université, Nantes F-44000, France.;Department of Hepato-gastroenterology, Centre Hospitalo-Universitaire Poitiers, Poitiers 86000, France.;Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris University, Assistance Publique-Hôpitaux de Paris, Paris, France.;Medical Oncology Department, Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France; Cancer Research Center of Lyon (CRCL), UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, Lyon"
"250","Saint-Ghislain M;Derrien AC;Geoffrois L;Gastaud L;Lesimple T;Negrier S;Penel N;Kurtz JE;Le Corre Y;Dutriaux C;Gardrat S;Barnhill R;Matet A;Cassoux N;Houy A;Ramtohul T;Servois V;Mariani P;Piperno-Neumann S;Stern MH;Rodrigues M","Saint-Ghislain, Mathilde;Derrien, Anne-Céline;Geoffrois, Lionnel;Gastaud, Lauris;Lesimple, Thierry;Negrier, Sylvie;Penel, Nicolas;Kurtz, Jean-Emmanuel;Le Corre, Yannick;Dutriaux, Caroline;Gardrat, Sophie;Barnhill, Raymond;Matet, Alexandre;Cassoux, Nathalie;Houy, Alexandre;Ramtohul, Toulsie;Servois, Vincent;Mariani, Pascale;Piperno-Neumann, Sophie;Stern, Marc-Henri;Rodrigues, Manuel","MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Hypermutation;Immune checkpoint inhibitor;MBD4;Mutational process;PD-1;PD-L1;Predictive biomarker","Endodeoxyribonucleases;Humans;Immune Checkpoint Inhibitors;Melanoma;Neoplasm Metastasis;Retrospective Studies;Uveal Neoplasms;Uveal Melanoma","Endodeoxyribonucleases;Humans;Immune Checkpoint Inhibitors;Melanoma;Neoplasm Metastasis;Retrospective Studies;Uveal Neoplasms;Uveal Melanoma","MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant to immune checkpoint inhibitors (ICI), the first reported MBD4-mutated (MBD4m) patient responded to ICI, suggesting that MBD4 mutation may predict response to ICI. Retrospective cohort of mUM patients treated with ICI. MBD4 was sequenced in a subset of these patients. Three hundred mUM patients were included. Median follow-up was 17.3 months. Ten patients with an objective response and 20 cases with stable disease for &gt;12 months were observed, corresponding to an objective response rate of 3.3% and a clinical benefit (i.e., responder patients and stable disease) rate of 10%. Of the 131 tumors sequenced for MBD4, five (3.8%) were mutated. MBD4 mutation was associated with a better objective response rate as three out of five MBD4m versus 4% of MBD4 wild-type patients responded (p &lt; 0.001). Of these five responders, three presented progressive disease at 2.8, 13.9, and 22.3 months. Median PFS was 4.0 months in MBD4 wild-type and 22.3 months in MBD4m patients (HR = 0.22; p = 0.01). Median OS in MBD4def patients was unreached as compared to 16.6 months in MBD4pro (HR = 0.11; 95% CI: 0.02-0.86; log-rank p-test = 0.04; Fig. 2e). In mUM patients, MBD4 mutation is highly predictive for the response, PFS, and overall survival benefit to ICI. MBD4 could be a tissue-agnostic biomarker and should be sequenced in mUM, and other tumor types where MBD4 mutations are reported.","Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin Cancer, Nancy;Department of Medical Oncology, Antoine Lacassagne Cancer Centre, 06000 Nice;Department of Medical Oncology, Centre Eugène Marquis, Rennes;Université de Lyon, Centre Léon Bérard, Lyon;Department of Medical Oncology, Centre Oscar Lambret, Lille University, Lille;Department of Medical Oncology, Strasbourg University Hospital, Strasbourg;Department of Dermatology, Angers University Hospital, UNAM;Dermatology Department, CHU de Bordeaux, Hôpital Saint André, Bordeaux;Department of Biopathology, Institut Curie, PSL Research University, Paris;Department of Biopathology, Institut Curie, PSL Research University, Paris, France; Faculty of Medicine, Université de Paris, Paris;Department of Ocular Oncology, Institut Curie, PSL Research University, Paris, France; Université de Paris, Paris;Department of Ocular Oncology, Institut Curie, PSL Research University, Paris, France; Université de Paris, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;Department of Radiology, Institut Curie, PSL Research University, Paris;Department of Radiology, Institut Curie, PSL Research University, Paris;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut Curie, PSL Research University, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris, France; Department of Genetics, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2022,"2022","173","10.1016/j.ejca.2022.06.033","105-112","","","35863105","35863105","PUBMED","Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin Cancer, Nancy;Department of Medical Oncology, Antoine Lacassagne Cancer Centre, 06000 Nice;Department of Medical Oncology, Centre Eugène Marquis, Rennes;Université de Lyon, Centre Léon Bérard, Lyon;Department of Medical Oncology, Centre Oscar Lambret, Lille University, Lille;Department of Medical Oncology, Strasbourg University Hospital, Strasbourg;Department of Dermatology, Angers University Hospital, UNAM;Dermatology Department, CHU de Bordeaux, Hôpital Saint André, Bordeaux;Department of Biopathology, Institut Curie, PSL Research University, Paris;Department of Biopathology, Institut Curie, PSL Research University, Paris, France; Faculty of Medicine, Université de Paris, Paris;Department of Ocular Oncology, Institut Curie, PSL Research University, Paris, France; Université de Paris, Paris;Department of Ocular Oncology, Institut Curie, PSL Research University, Paris, France; Université de Paris, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris;Department of Radiology, Institut Curie, PSL Research University, Paris;Department of Radiology, Institut Curie, PSL Research University, Paris;Department of Surgical Oncology, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut Curie, PSL Research University, Paris;INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris, France; Department of Genetics, Institut Curie, PSL Research University, Paris;Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France; INSERM U830, DNA Repair and Uveal Melanoma (D.R.U.M.), Equipe Labellisée Par La Ligue Nationale Contre le Cancer, Institut Curie, PSL Research University, Paris"
"251","Bhave P;Ahmed T;Lo SN;Shoushtari A;Zaremba A;Versluis JM;Mangana J;Weichenthal M;Si L;Lesimple T;Robert C;Trojanello C;Wicky A;Heywood R;Tran L;Batty K;Dimitriou F;Stansfeld A;Allayous C;Schwarze JK;Mooradian MJ;Klein O;Mehmi I;Roberts-Thomson R;Maurichi A;Yeoh HL;Khattak A;Zimmer L;Blank CU;Ramelyte E;Kähler KC;Roy S;Ascierto PA;Michielin O;Lorigan PC;Johnson DB;Plummer R;Lebbe C;Neyns B;Sullivan R;Hamid O;Santinami M;McArthur GA;Haydon AM;Long GV;Menzies AM;Carlino MS","Bhave, Prachi;Ahmed, Tasnia;Lo, Serigne N;Shoushtari, Alexander;Zaremba, Anne;Versluis, Judith M;Mangana, Joanna;Weichenthal, Michael;Si, Lu;Lesimple, Thierry;Robert, Caroline;Trojanello, Claudia;Wicky, Alexandre;Heywood, Richard;Tran, Lena;Batty, Kathleen;Dimitriou, Florentia;Stansfeld, Anna;Allayous, Clara;Schwarze, Julia K;Mooradian, Meghan J;Klein, Oliver;Mehmi, Inderjit;Roberts-Thomson, Rachel;Maurichi, Andrea;Yeoh, Hui-Ling;Khattak, Adnan;Zimmer, Lisa;Blank, Christian U;Ramelyte, Egle;Kähler, Katharina C;Roy, Severine;Ascierto, Paolo A;Michielin, Olivier;Lorigan, Paul C;Johnson, Douglas B;Plummer, Ruth;Lebbe, Celeste;Neyns, Bart;Sullivan, Ryan;Hamid, Omid;Santinami, Mario;McArthur, Grant A;Haydon, Andrew M;Long, Georgina V;Menzies, Alexander M;Carlino, Matteo S","Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.","Journal for immunotherapy of cancer","England","eng","Journal Article","CTLA-4 Antigen;Immunotherapy;Melanoma;Programmed Cell Death 1 Receptor","Humans;Ipilimumab;Melanoma;Prospective Studies;Retrospective Studies;Skin Neoplasms;Melanoma, Cutaneous Malignant","Humans;Ipilimumab;Melanoma;Prospective Studies;Retrospective Studies;Skin Neoplasms;Melanoma, Cutaneous Malignant","Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated with differences in TMB. However the impact of this on the effectiveness of immune CPIs is unknown. We examined the efficacy of CPIs in acral melanoma, including by primary site. Patients with unresectable stage III/IV acral melanoma treated with CPI (anti-PD-1 and/or ipilimumab) were studied. Multivariable logistic and Cox regression analyses were conducted. Primary outcome was objective response rate (ORR); secondary outcomes were progression-free survival (PFS) and overall survival (OS). In total, 325 patients were included: 234 (72%) plantar, 69 (21%) subungual and 22 (7%) palmar primary sites. First CPI included: 184 (57%) anti-PD-1, 59 (18%) anti-PD-1/ipilimumab combination and 82 (25%) ipilimumab. ORR was significantly higher with initial anti-PD-1/ipilimumab compared with anti-PD-1 (43% vs 26%, HR 2.14, p=0.0004) and significantly lower with ipilimumab (15% vs 26%, HR 0.49, p=0.0016). Landmark PFS at 1 year was highest for anti-PD-1/ipilimumab at 34% (95% CI 24% to 49%), compared with 26% (95% CI 20% to 33%) with anti-PD-1 and 10% (95% CI 5% to 19%) with ipilimumab. Despite a trend for increased PFS, anti-PD-1/ipilimumab combination did not significantly improve PFS (HR 0.85, p=0.35) or OS over anti-PD-1 (HR 1.30, p=0.16), potentially due to subsequent therapies and high rates of acquired resistance. No outcome differences were found between primary sites. While the ORR to anti-PD-1/ipilimumab was significantly higher than anti-PD-1 and PFS numerically higher, in this retrospective cohort this benefit did not translate to improved OS. Future trials should specifically include patients with acral melanoma, to help determine the optimal management of this important melanoma subtype.","Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.;Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Medicine, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.;Dermatology, University Hospital Essen, Essen, Germany.;Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany.;Melanoma and Sarcoma, Peking University Cancer Hospital, Beijing, China.;Research and Medical Oncology, Centre Eugène Marquis, Rennes, France.;Dermatology, Gustave Roussy, Villejuif, France.;Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.;Oncology, Lausanne University Hospital, Lausanne, Switzerland.;Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK.;Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.;Dermatology, Saint-Louis hospital, INSERM U976, AP-HP, Paris, France.;Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium.;Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.;Medical Oncology, Olivia Newton John Cancer Centre, Austin Health, Melbourne, Victoria, Australia.;Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria, Australia.;Medical Oncology, Peninsula Health, Melbourne, Victoria, Australia.;The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA.;Medical Oncology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.;Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.;Medical Oncology, Fiona Stanley Hospital & Edith Cowan Univserity, Perth, Western Australia, Australia.;Dermatology, University Hospital Essen, Essen, Germany.;Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany.;Dermatology, Gustave Roussy, Villejuif, France.;Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.;Oncology, Lausanne University Hospital, Lausanne, Switzerland.;Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK.;Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.;Université de Paris, AP-HP Department of Dermatology, Hôpital Saint-Louis, Paris, France.;Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium.;Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.;The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA.;Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.;Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.;Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales;Melanoma Institute Australia, North Sydney, New South Wales, Australia.","NA",0,"2051-1426","J Immunother Cancer","J Immunother Cancer",2022,"2022","10","10.1136/jitc-2022-004668",NA,"P30 CA008748","NCI NIH HHS","35793872","35793872","PUBMED","Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.;Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Medicine, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.;Dermatology, University Hospital Essen, Essen, Germany.;Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany.;Melanoma and Sarcoma, Peking University Cancer Hospital, Beijing, China.;Research and Medical Oncology, Centre Eugène Marquis, Rennes, France.;Dermatology, Gustave Roussy, Villejuif, France.;Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.;Oncology, Lausanne University Hospital, Lausanne, Switzerland.;Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK.;Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.;Dermatology, Saint-Louis hospital, INSERM U976, AP-HP, Paris, France.;Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium.;Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.;Medical Oncology, Olivia Newton John Cancer Centre, Austin Health, Melbourne, Victoria, Australia.;Medical Oncology, Warrnambool Hospital, Warrnambool, Victoria, Australia.;Medical Oncology, Peninsula Health, Melbourne, Victoria, Australia.;The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA.;Medical Oncology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.;Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.;Medical Oncology, Fiona Stanley Hospital & Edith Cowan Univserity, Perth, Western Australia, Australia.;Dermatology, University Hospital Essen, Essen, Germany.;Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.;Dermatology, University Hospital Zürich, Zurich, Switzerland.;Dermatology, University Hospital Schleswig-Holstein - Campus Kiel, Kiel, Germany.;Dermatology, Gustave Roussy, Villejuif, France.;Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione ""G.Pascale"", Napoli, Italy.;Oncology, Lausanne University Hospital, Lausanne, Switzerland.;Christie NHS Foundation Trust and Division of Cancer Services, University of Manchester, Manchester, UK.;Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.;Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK.;Université de Paris, AP-HP Department of Dermatology, Hôpital Saint-Louis, Paris, France.;Medical Oncology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel, Brussel, Belgium.;Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.;The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, California, USA.;Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;Sir Peter MacCallum Cancer Centre Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.;Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.;Melanoma Institute Australia, North Sydney, New South Wales, Australia.;Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.;Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.;Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales;Melanoma Institute Australia, North Sydney, New South Wales, Australia."
"252","Plaçais L;Dalle S;Dereure O;Trabelsi S;Dalac S;Legoupil D;Montaudié H;Arnault JP;De Quatrebarbes J;Saiag P;Brunet-Possenti F;Lesimple T;Maubec E;Aubin F;Granel-Brocard F;Grob JJ;Stoebner PE;Allayous C;Oriano B;Dutriaux C;Mortier L;Lebbe C","Plaçais, Léo;Dalle, Stéphane;Dereure, Olivier;Trabelsi, Sabiha;Dalac, Sophie;Legoupil, Delphine;Montaudié, Henri;Arnault, Jean-Philippe;De Quatrebarbes, Julie;Saiag, Philippe;Brunet-Possenti, Florence;Lesimple, Thierry;Maubec, Eve;Aubin, François;Granel-Brocard, Florence;Grob, Jean-Jacques;Stoebner, Pierre-Emmanuel;Allayous, Clara;Oriano, Bastien;Dutriaux, Caroline;Mortier, Laurent;Lebbe, Céleste","Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study.","Annals of the rheumatic diseases","England","eng","Journal Article","autoimmunity;immune system diseases;therapeutics","Antineoplastic Agents, Immunological;Autoimmune Diseases;Case-Control Studies;Humans;Immune Checkpoint Inhibitors;Immune System Diseases;Melanoma;Prospective Studies;Retrospective Studies","Antineoplastic Agents, Immunological;Autoimmune Diseases;Case-Control Studies;Humans;Immune Checkpoint Inhibitors;Immune System Diseases;Melanoma;Prospective Studies;Retrospective Studies","To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma. Case-control study performed on a French multicentric prospective cohort of patients with melanoma, matched for irAE risk factors and oncological staging. Risk of irAE was assessed by logistic regression. 110 patients with pAID were included and matched with 330 controls, from March 2013 to October 2020. Over a median follow-up period of 7.2 months for cases and 6.9 months for controls, the ORs of developing all-grade and grade ≥3 irAEs among cases compared with controls were 1.91 (95% CI (1.56 to 2.27)) and 1.44 (95% CI (1.08 to 1.82)), respectively. Patients with pAID had an increased risk of multiple irAEs (OR 1.46, 95% CI (1.15 to 2.67)) and a shorter time to irAE onset. In contrast, there were no difference in irAE-related mortality nor in the rate of treatment discontinuation, and a landmark analysis revealed a better survival at 24 months among cases (p=0.02). Thirty per cent of cases experienced a pAID flare during follow-up, and baseline immunosuppression did not prevent irAE occurrence. Last, we report associations between the pAID clinical subsets and organ-specific irAEs. In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy.","Internal Medicine and Clinical Immunology, Hopital Bicêtre, Le Kremlin-Bicêtre, Île-de-France;Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Dermatology, CHU Montpellier, Montpellier, Languedoc-Roussillon, France.;Dermatology, CHU Grenoble Alpes, Grenoble, Auvergne-Rhone-Alpes, France.;Dermatology, CHU Dijon, Dijon, Bourgogne, France.;Dermatology, CHU Brest, Brest, Bretagne, France.;Dermatology, University Hospital, Nice, France.;Dermatology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, Hauts-de-France, France.;Dermatology, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Dermatology, Hôpital Ambroise Paré, Neuilly-sur-Seine, Île-de-France, France.;Oncodermatology, Hopital Bichat - Claude-Bernard, Paris, France.;Oncology, Centre Eugene Marquis, Rennes, France.;Dermatology, Hopital Avicenne, Bobigny, France.;Dermatology, CHU Besancon, Besancon, France.;Dermatology, CHU de Nancy, Nancy, Lorraine, France.;Dermatology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azu, France.;Dermatology, CHU Nimes, Nimes, Languedoc-Roussillon, France.;Dermatology, CHU Saint-Louis, Paris, Île-de-France, France.;Dermatology, CHU Saint-Louis, Paris, Île-de-France, France.;Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Dermatology, CHU Lille, Lille, Hauts-de-France, France.;Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France.","NA",0,"1468-2060","Ann Rheum Dis","Ann Rheum Dis",2022,"2022","81","10.1136/ard-2022-222186","1445-1452","","","35788496","35788496","PUBMED","Internal Medicine and Clinical Immunology, Hopital Bicêtre, Le Kremlin-Bicêtre, Île-de-France;Dermatology, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Dermatology, CHU Montpellier, Montpellier, Languedoc-Roussillon, France.;Dermatology, CHU Grenoble Alpes, Grenoble, Auvergne-Rhone-Alpes, France.;Dermatology, CHU Dijon, Dijon, Bourgogne, France.;Dermatology, CHU Brest, Brest, Bretagne, France.;Dermatology, University Hospital, Nice, France.;Dermatology, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, Hauts-de-France, France.;Dermatology, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Dermatology, Hôpital Ambroise Paré, Neuilly-sur-Seine, Île-de-France, France.;Oncodermatology, Hopital Bichat - Claude-Bernard, Paris, France.;Oncology, Centre Eugene Marquis, Rennes, France.;Dermatology, Hopital Avicenne, Bobigny, France.;Dermatology, CHU Besancon, Besancon, France.;Dermatology, CHU de Nancy, Nancy, Lorraine, France.;Dermatology, Hôpital de la Timone, Marseille, Provence-Alpes-Côte d'Azu, France.;Dermatology, CHU Nimes, Nimes, Languedoc-Roussillon, France.;Dermatology, CHU Saint-Louis, Paris, Île-de-France, France.;Dermatology, CHU Saint-Louis, Paris, Île-de-France, France.;Dermatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Dermatology, CHU Lille, Lille, Hauts-de-France, France.;Dermatology, Hopital Saint-Louis, Paris, Île-de-France, France."
"253","Edeline J;Malka D","Edeline, Julien;Malka, David","Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Letter","","Humans;Capecitabine;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Antineoplastic Combined Chemotherapy Protocols","Humans;Capecitabine;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Antineoplastic Combined Chemotherapy Protocols","NA","Julien Edeline, MD, PhD, Medical Oncology, Centre Eugène Marquis, Rennes, France; and David Malka, MD, Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Julien Edeline, MD, PhD, Medical Oncology, Centre Eugène Marquis, Rennes, France; and David Malka, MD, Medical Oncology, Institut Mutualiste Montsouris, Paris, France.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2022,"2022","40","10.1200/JCO.22.01213","3667-3668","","","35786978","35786978","PUBMED","Julien Edeline, MD, PhD, Medical Oncology, Centre Eugène Marquis, Rennes, France; and David Malka, MD, Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Julien Edeline, MD, PhD, Medical Oncology, Centre Eugène Marquis, Rennes, France; and David Malka, MD, Medical Oncology, Institut Mutualiste Montsouris, Paris, France."
"254","Kuassivi ON;Abiven H;Satie AP;Cartron M;Mahé D;Aubry F;Mathieu R;Rebours V;Le Tortorec A;Dejucq-Rainsford N","Kuassivi, Ohiniba Nadège;Abiven, Hervé;Satie, Anne-Pascale;Cartron, Matéo;Mahé, Dominique;Aubry, Florence;Mathieu, Romain;Rebours, Valérie;Le Tortorec, Anna;Dejucq-Rainsford, Nathalie","Human Testicular Germ Cells, a Reservoir for Zika Virus, Lack Antiviral Response Upon Zika or Poly(I:C) Exposure.","Frontiers in immunology","Switzerland","eng","Journal Article","IRF3;Poly(I:C);RNA viruses;Zika virus persistence;human testis innate immunity;interferon and antiviral effectors;pathogen recognition receptor (PRR);testicular germ cells","Antiviral Agents;Germ Cells;Humans;Male;Poly I-C;Testis;Zika Virus;Zika Virus Infection","Antiviral Agents;Germ Cells;Humans;Male;Poly I-C;Testis;Zika Virus;Zika Virus Infection","Zika virus (ZIKV) is an emerging teratogenic arbovirus that persists in semen and is sexually transmitted. We previously demonstrated that ZIKV infects the human testis and persists in testicular germ cells (TGCs) for several months after patients' recovery. To decipher the mechanisms underlying prolonged ZIKV replication in TGCs, we compared the innate immune response of human testis explants and isolated TGCs to ZIKV and to Poly(I:C), a viral RNA analog. Our results demonstrate the weak innate responses of human testis to both ZIKV and Poly(I:C) as compared with other tissues or species. TGCs failed to up-regulate antiviral effectors and type I IFN upon ZIKV or Poly(I:C) stimulation, which might be due to a tight control of PRR signaling, as evidenced by the absence of activation of the downstream effector IRF3 and elevated expression of repressors. Importantly, exogenous IFNβ boosted the innate immunity of TGCs and inhibited ZIKV replication in the testis  , raising hopes for the prevention of ZIKV infection and persistence in this organ.","Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de Coordination Hospitalière des Prélèvements d'Organes et de Tissus, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.","NA",0,"1664-3224","Front Immunol","Front Immunol",2022,"2022","13","10.3389/fimmu.2022.909341","909341","","","35784373","35784373","PUBMED","Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de Coordination Hospitalière des Prélèvements d'Organes et de Tissus, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, INSERM, Ecole des Hautes Etudes en Santé Publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France."
"255","Painvin B;Ehrmann S;Thille AW;Tadié JM","Painvin, Benoit;Ehrmann, Stephan;Thille, Arnaud W;Tadié, Jean-Marc","Intensive care unit-to-unit capacity transfers are associated with increased mortality: no hasty conclusions in the event of a crisis.","Annals of intensive care","Germany","eng","Letter","","","","NA","Service des Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes;Service de Médecine Intensive Et Réanimation, CRICS- Triggersep Research Network, Centre Hospitalier Régional Universitaire de Tours, CIC INSERM 1415Hôpital Bretonneau 2, boulevard Tonnellé, 27044, Tours, France.;Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive Et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, 90577 86000, Poitiers, France.;Service des Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2022,"2022","12","10.1186/s13613-022-01031-7","60","","","35779148","35779148","PUBMED","Service des Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes;Service de Médecine Intensive Et Réanimation, CRICS- Triggersep Research Network, Centre Hospitalier Régional Universitaire de Tours, CIC INSERM 1415Hôpital Bretonneau 2, boulevard Tonnellé, 27044, Tours, France.;Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive Et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, 90577 86000, Poitiers, France.;Service des Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes"
"256","Tardieu L;Divard G;Lortholary O;Scemla A;Rondeau É;Accoceberry I;Agbonon R;Alanio A;Angoulvant A;Albano L;Attias P;Bellanger AP;Bertrand D;Bonhomme J;Botterel F;Bouvier N;Buchler M;Chouaki T;Crépin T;Durieux MF;Desoubeaux G;Doppelt G;Favennec L;Fekkar A;Fourdinier O;Frimat M;Gangneux JP;Garandeau C;Hasseine L;Hennequin C;Iriart X;Kamar N;Kaminski H;Kormann R;Lachaud L;Legendre C;Le Quintrec Donnette M;Leroy J;Levi C;Machouart M;Marx D;Menotti J;Moal V;Morio F;Mrozek N;Nicolas M;Poirier P;Peraldi MN;Poussot B;Ranque S;Rerolle JP;Sendid B;Snanoudj R;Tourret J;Vasse M;Vigneau C;Villard O;Mesnard L;Lanternier F;Rafat C","Tardieu, Laurène;Divard, Gillian;Lortholary, Olivier;Scemla, Anne;Rondeau, Éric;Accoceberry, Isabelle;Agbonon, Rémi;Alanio, Alexandre;Angoulvant, Adela;Albano, Laetitia;Attias, Philippe;Bellanger, Anne Pauline;Bertrand, Dominique;Bonhomme, Julie;Botterel, Françoise;Bouvier, Nicolas;Buchler, Matthias;Chouaki, Taieb;Crépin, Thomas;Durieux, Marie-Fleur;Desoubeaux, Guillaume;Doppelt, Gary;Favennec, Loïc;Fekkar, Arnaud;Fourdinier, Ophélie;Frimat, Marie;Gangneux, Jean-Pierre;Garandeau, Claire;Hasseine, Lilia;Hennequin, Christophe;Iriart, Xavier;Kamar, Nassim;Kaminski, Hannah;Kormann, Raphael;Lachaud, Laurence;Legendre, Christophe;Le Quintrec Donnette, Moglie;Leroy, Jordan;Levi, Charlène;Machouart, Marie;Marx, David;Menotti, Jean;Moal, Valérie;Morio, Florent;Mrozek, Natacha;Nicolas, Muriel;Poirier, Philippe;Peraldi, Marie-Noelle;Poussot, Benjamin;Ranque, Stéphane;Rerolle, Jean-Philippe;Sendid, Boualem;Snanoudj, Renaud;Tourret, Jérôme;Vasse, Marc;Vigneau, Cécile;Villard, Odile;Mesnard, Laurent;Lanternier, Fanny;Rafat, Cédric","Cryptococcal Meningitis in Kidney Transplant Recipients: A Two-Decade Cohort Study in France.","Pathogens (Basel, Switzerland)","Switzerland","eng","Journal Article","cryptococcal meningitis;cryptococcosis;graft outcome;opportunistic infection;renal transplantation;transplant associated diseases","","","Cryptococcosis is the third most common cause of invasive fungal infection in solid organ transplant recipients and cryptococcal meningitis (CM) its main clinical presentation. CM outcomes, as well as its clinical features and radiological characteristics, have not yet been considered on a large scale in the context of kidney transplantation (KT). We performed a nationwide retrospective study of adult patients diagnosed with cryptococcosis after KT between 2002 and 2020 across 30 clinical centers in France. We sought to describe overall and graft survival based on whether KT patients with cryptococcosis developed CM or not. Clinical indicators of CNS involvement and brain radiological characteristics were assessed. Eighty-eight cases of cryptococcosis were diagnosed during the study period, with 61 (69.3%) cases of CM. Mortality was high (32.8%) at 12 months (M12) but not significantly different whether or not patients presented with CM. Baseline hyponatremia and at least one neurological symptom were independently associated with CM (p < 0.001). Positive serum cryptococcal antigen at diagnosis was also significantly associated with CM (p < 0.001). On magnetic resonance imaging (MRI), three patterns of brain injury were identified: parenchymal, meningeal, and vascular lesions. Although CM does not affect graft function directly, it entails a grim prognosis.","Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM U970, Université de Paris, 75015 Paris, France.;Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, 75015 Paris, France.;Centre d'Infectiologie Necker-Pasteur, Université de Paris Cité, Hôpital Necker-Enfant Malades, AP-HP, 75015 Paris, France.;Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, Université Paris Cité, CNRS UMR20000, 75015 Paris, France.;Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, 75015 Paris, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Laboratory of Parasitology-Mycology, Pellegrin University Hospital, 33000 Bordeaux, France.;Department of Radiology, Tenon Hospital, 75020 Paris, France.;Laboratory of Parasitology-Mycology, Saint-Louis Hospital, AP-HP, 75010 Paris, France.;Service de Maladies infectieuses et Tropicale, APHP-Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France.;Department of Nephrology and Transplantation, 06000 CHU Nice, France.;Nephrology and Renal Transplantation Department, APHP, Groupe Hospitalier Henri-Mondor, 94010 Créteil, France.;Parasitology Mycology Department, University Hospital, 25000 Besancon, France.;Department of Nephrology and Transplantation, University of Rouen, 76000 Rouen, France.;Laboratory of Parasitology-Mycology, CHU Caen, 14033 Caen, France.;Laboratory of Mycology, AP-HP (Assistance Publique-Hôpitaux de Paris), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France.;Department of Nephrology and Transplantation, University of Caen, 14033 Caen, France.;Service de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, Hôpital Bretonneau et Hôpital Clocheville, 37000 Tours, France.;Service de Parasitologie et Mycologie Médicales, CHU d'Amiens, 80000 Amiens, France.;Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, 25000 Besançon, France.;Laboratoire de Parasitologie-Mycologie, CHU de Limoges, 87000 Limoges, France.;Department of Parasitology-Mycology Service, Tropical Medicine Program, University Hospital of Tours, 37000 Tours, France.;Department of Radiology, André Rosemon, Hôpital de Cayenne, Université des Antilles et de la Guyane Française, 97139 Pointe à Pitre, France.;Department of Parasitology/Mycology, Rouen University Hospital, 76000 Rouen, France.;Service de Parasitologie Mycologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.;Department of Nephrology, Dialysis and Transplantation, CHU Amiens, 80000 Amiens, France.;Nephrology Department, University Lille, CHU Lille, 59000 Lille, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Rennes, France INSERM U1085, IRSET (Institut de Recherche en Santé Environnement Travail), Université Rennes 1, 35000 Rennes, France.;Department of Nephrology and Immunology, Institut de Transplantation Urologie Néphrologie (ITUN), 44000 Nantes, France.;Centre Méditerranéen de Médecine Moléculaire, Université de Nice-Sophia Antipolis, 06000 Nice, France.;Centre de Recherche Saint-Antoine, CRSA, Inserm, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Sorbonne Université, 75012 Paris, France.;Department of Parasitology-Mycology, Toulouse University Hospital Toulouse, 31400 Toulouse, France.;Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Paul Sabatier University, 31400 Toulouse, France.;Department of Nephrology, Transplantation, Dialysis and Apheresis, Pellegrin University Hospital, 33000 Bordeaux, France.;Department of Nephrology, University of Lorrain, CHRU-Nancy, 54511 Vandoeuvre, France.;CHU Montpellier, Laboratoire de parasitologie-mycologie, Centre national de référence Leishmaniose, Université de Montpellier, UMR MiVEGEC, 34090 Montpellier, France.;Service de Néphrologie et Transplantation Rénale, Hôpital Kremlin Bicêtre, 94270 Le Kremlin-Bicêtre, France.;Department of Nephrology, Université de Montpellier, CHU de Montpellier, 34090 Montpellier, France.;INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, 59000 Lille, France.;Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie Mycologie, CHU Lille, 59000 Lille, France.;Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot University Hospital, 69003 Lyon, France.;Laboratory of Parasitology-Mycology, University of Lorrain, 54511 Nancy, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France.;Hospices Civils de Lyon, Institut des Agents Infectieux, Service de Parasitologie et Mycologie Médicale, Hôpital de la Croix-Rousse, 69004 Lyon, France.;Institut pour la Recherche et pour le Développement, Microbes, Evolution, Phylogénie et Infection, Institut Hospitalo Universitaire-Méditerranée Infection, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, 13005 Marseille, France.;Cibles et Médicaments des Infections et de L'immunité, IICiMed, UR1155, CHU de Nantes, Nantes Université, 44000 Nantes, France.;Service de Néphrologie Réanimation Médicale, Pole REUNNIRH, 63000 Clermont-Ferrand, France.;Laboratoire de Microbiologie, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, 97189 Guadeloupe, France.;Service de Parasitologie-Mycologie, CHU Clermont-Ferrand, 3iHP, INSERM, Université Clermont Auvergne, 63000 Clermont Ferrand, France.;Department of Nephrology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, 75010 Paris, France.;Centre Hospitalier Bordeaux, Department of Radiology, 33400 Bordeaux, France.;Assistance Publique-Hôpitaux de Marseille, Institut Hospitalo-Universitaire Méditerranée Infection, Institut de Recherche Pour le Développement, Aix-Marseille Université, Service de Santé des Armées, VITROME, 19-21 Boulevard Jean-Moulin, 13005 Marseille, France.;Department of Nephrology and Kidney Transplantation, CHU de Limoges, 87000 Limoges, France.;INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, 59000 Lille, France.;Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie Mycologie, CHU Lille, 59000 Lille, France.;Service de Néphrologie-Transplantation Rénale, Hôpital Foch, 92150 Suresnes, France.;AP-HP, Service de Néphrologie, Groupe Hospitalier Pitié Salpétrière Charles Foix, 75013 Paris, France.;Service de Biologie Clinique and UMR-S 1176, Hôpital Foch, 92150 Suresnes, France.;Department of Nephrology, Centre Hospitalier Universitaire Pontchaillou, 35000 Rennes, France.;CHU Strasbourg, Laboratoire de Parasitologie-Mycologie, 67000 Strasbourg, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Centre d'Infectiologie Necker-Pasteur, Université de Paris Cité, Hôpital Necker-Enfant Malades, AP-HP, 75015 Paris, France.;Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, Université Paris Cité, CNRS UMR20000, 75015 Paris, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.","NA",0,"2076-0817","Pathogens","Pathogens",2022,"2022","11","10.3390/pathogens11060699",NA,"","","35745553","35745553","PUBMED","Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Paris Translational Research Centre for Organ Transplantation, PARCC, INSERM U970, Université de Paris, 75015 Paris, France.;Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, 75015 Paris, France.;Centre d'Infectiologie Necker-Pasteur, Université de Paris Cité, Hôpital Necker-Enfant Malades, AP-HP, 75015 Paris, France.;Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, Université Paris Cité, CNRS UMR20000, 75015 Paris, France.;Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes Sorbonne Paris Cité, 75015 Paris, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Laboratory of Parasitology-Mycology, Pellegrin University Hospital, 33000 Bordeaux, France.;Department of Radiology, Tenon Hospital, 75020 Paris, France.;Laboratory of Parasitology-Mycology, Saint-Louis Hospital, AP-HP, 75010 Paris, France.;Service de Maladies infectieuses et Tropicale, APHP-Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, France.;Department of Nephrology and Transplantation, 06000 CHU Nice, France.;Nephrology and Renal Transplantation Department, APHP, Groupe Hospitalier Henri-Mondor, 94010 Créteil, France.;Parasitology Mycology Department, University Hospital, 25000 Besancon, France.;Department of Nephrology and Transplantation, University of Rouen, 76000 Rouen, France.;Laboratory of Parasitology-Mycology, CHU Caen, 14033 Caen, France.;Laboratory of Mycology, AP-HP (Assistance Publique-Hôpitaux de Paris), Hôpitaux Universitaires Henri Mondor, 94010 Créteil, France.;Department of Nephrology and Transplantation, University of Caen, 14033 Caen, France.;Service de Néphrologie-Hypertension, Dialyses, Transplantation Rénale, Hôpital Bretonneau et Hôpital Clocheville, 37000 Tours, France.;Service de Parasitologie et Mycologie Médicales, CHU d'Amiens, 80000 Amiens, France.;Department of Nephrology, Dialysis, and Renal Transplantation, CHU Besançon, 25000 Besançon, France.;Laboratoire de Parasitologie-Mycologie, CHU de Limoges, 87000 Limoges, France.;Department of Parasitology-Mycology Service, Tropical Medicine Program, University Hospital of Tours, 37000 Tours, France.;Department of Radiology, André Rosemon, Hôpital de Cayenne, Université des Antilles et de la Guyane Française, 97139 Pointe à Pitre, France.;Department of Parasitology/Mycology, Rouen University Hospital, 76000 Rouen, France.;Service de Parasitologie Mycologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Pitié-Salpêtrière, 75013 Paris, France.;Department of Nephrology, Dialysis and Transplantation, CHU Amiens, 80000 Amiens, France.;Nephrology Department, University Lille, CHU Lille, 59000 Lille, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie-Mycologie, Rennes, France INSERM U1085, IRSET (Institut de Recherche en Santé Environnement Travail), Université Rennes 1, 35000 Rennes, France.;Department of Nephrology and Immunology, Institut de Transplantation Urologie Néphrologie (ITUN), 44000 Nantes, France.;Centre Méditerranéen de Médecine Moléculaire, Université de Nice-Sophia Antipolis, 06000 Nice, France.;Centre de Recherche Saint-Antoine, CRSA, Inserm, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Sorbonne Université, 75012 Paris, France.;Department of Parasitology-Mycology, Toulouse University Hospital Toulouse, 31400 Toulouse, France.;Department of Nephrology and Organs Transplantation, Toulouse Rangueil University Hospital, INSERM UMR 1291, Toulouse Institute for Infectious and Inflammatory Disease (Infinity), Paul Sabatier University, 31400 Toulouse, France.;Department of Nephrology, Transplantation, Dialysis and Apheresis, Pellegrin University Hospital, 33000 Bordeaux, France.;Department of Nephrology, University of Lorrain, CHRU-Nancy, 54511 Vandoeuvre, France.;CHU Montpellier, Laboratoire de parasitologie-mycologie, Centre national de référence Leishmaniose, Université de Montpellier, UMR MiVEGEC, 34090 Montpellier, France.;Service de Néphrologie et Transplantation Rénale, Hôpital Kremlin Bicêtre, 94270 Le Kremlin-Bicêtre, France.;Department of Nephrology, Université de Montpellier, CHU de Montpellier, 34090 Montpellier, France.;INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, 59000 Lille, France.;Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie Mycologie, CHU Lille, 59000 Lille, France.;Department of Transplantation, Nephrology and Clinical Immunology, Edouard Herriot University Hospital, 69003 Lyon, France.;Laboratory of Parasitology-Mycology, University of Lorrain, 54511 Nancy, France.;Department of Nephrology and Transplantation, Strasbourg University Hospital, 67000 Strasbourg, France.;Hospices Civils de Lyon, Institut des Agents Infectieux, Service de Parasitologie et Mycologie Médicale, Hôpital de la Croix-Rousse, 69004 Lyon, France.;Institut pour la Recherche et pour le Développement, Microbes, Evolution, Phylogénie et Infection, Institut Hospitalo Universitaire-Méditerranée Infection, Hôpital Conception, Centre de Néphrologie et Transplantation Rénale, Assistance Publique Hôpitaux de Marseille, Aix Marseille Université, 13005 Marseille, France.;Cibles et Médicaments des Infections et de L'immunité, IICiMed, UR1155, CHU de Nantes, Nantes Université, 44000 Nantes, France.;Service de Néphrologie Réanimation Médicale, Pole REUNNIRH, 63000 Clermont-Ferrand, France.;Laboratoire de Microbiologie, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, 97189 Guadeloupe, France.;Service de Parasitologie-Mycologie, CHU Clermont-Ferrand, 3iHP, INSERM, Université Clermont Auvergne, 63000 Clermont Ferrand, France.;Department of Nephrology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, 75010 Paris, France.;Centre Hospitalier Bordeaux, Department of Radiology, 33400 Bordeaux, France.;Assistance Publique-Hôpitaux de Marseille, Institut Hospitalo-Universitaire Méditerranée Infection, Institut de Recherche Pour le Développement, Aix-Marseille Université, Service de Santé des Armées, VITROME, 19-21 Boulevard Jean-Moulin, 13005 Marseille, France.;Department of Nephrology and Kidney Transplantation, CHU de Limoges, 87000 Limoges, France.;INSERM U1285, CNRS UMR 8576, Glycobiology in Fungal Pathogenesis and Clinical Applications, Université de Lille, 59000 Lille, France.;Pôle de Biologie-Pathologie-Génétique, Institut de Microbiologie, Service de Parasitologie Mycologie, CHU Lille, 59000 Lille, France.;Service de Néphrologie-Transplantation Rénale, Hôpital Foch, 92150 Suresnes, France.;AP-HP, Service de Néphrologie, Groupe Hospitalier Pitié Salpétrière Charles Foix, 75013 Paris, France.;Service de Biologie Clinique and UMR-S 1176, Hôpital Foch, 92150 Suresnes, France.;Department of Nephrology, Centre Hospitalier Universitaire Pontchaillou, 35000 Rennes, France.;CHU Strasbourg, Laboratoire de Parasitologie-Mycologie, 67000 Strasbourg, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France.;Centre d'Infectiologie Necker-Pasteur, Université de Paris Cité, Hôpital Necker-Enfant Malades, AP-HP, 75015 Paris, France.;Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, Université Paris Cité, CNRS UMR20000, 75015 Paris, France.;Service de Soins Intensifs Néphrologiques et Rein Aigu, French Intensive Renal Network, Hôpital Tenon, 75020 Paris, France."
"257","Bonnet I;Haddad E;Guglielmetti L;Bémer P;Bernard L;Bourgoin A;Brault R;Catho G;Caumes E;Escaut L;Fourniols E;Fréchet-Jachym M;Gaudart A;Guillot H;Lafon-Desmurs B;Lanoix JP;Lanotte P;Lemaignen A;Lemaire B;Lemaitre N;Michau C;Morand P;Mougari F;Marigot-Outtandy D;Patrat-Delon S;Perpoint T;Piau C;Pourcher V;Zarrouk V;Zeller V;Veziris N;Jauréguiberry S;Aubry A","Bonnet, Isabelle;Haddad, Elie;Guglielmetti, Lorenzo;Bémer, Pascale;Bernard, Louis;Bourgoin, Anne;Brault, Rachel;Catho, Gaud;Caumes, Eric;Escaut, Lélia;Fourniols, Eric;Fréchet-Jachym, Mathilde;Gaudart, Alice;Guillot, Hélène;Lafon-Desmurs, Barthélémy;Lanoix, Jean-Philippe;Lanotte, Philippe;Lemaignen, Adrien;Lemaire, Bénédicte;Lemaitre, Nadine;Michau, Christophe;Morand, Philippe;Mougari, Faiza;Marigot-Outtandy, Dhiba;Patrat-Delon, Solène;Perpoint, Thomas;Piau, Caroline;Pourcher, Valérie;Zarrouk, Virginie;Zeller, Valérie;Veziris, Nicolas;Jauréguiberry, Stéphane;Aubry, Alexandra","Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France.","Microorganisms","Switzerland","eng","Journal Article","MDR-TB;XDR-TB;bone;spinal","","","The optimal treatment for osteoarticular infection due to multidrug-resistant tuberculosis strains (MDR-OATB) remains unclear. This study aims to evaluate the diagnosis, management and outcome of MDR-OATB in France. We present a case series of MDR-OATB patients reviewed at the French National Reference Center for Mycobacteria between 2007 and 2018. Medical history and clinical, microbiological, treatment and outcome data were collected. Twenty-three MDR-OATB cases were reported, representing 3% of all concurrent MDR-TB cases in France. Overall, 17 were male, and the median age was 32 years. Six patients were previously treated for TB, including four with first-line drugs. The most frequently affected site was the spine (  = 16). Bone and joint surgery were required in 12 patients. Twenty-one patients (91%) successfully completed the treatment with a regimen containing a mean of four drugs (range, 2-6) for a mean duration of 20 months (range, 13-27). Overall, high rates of treatment success were achieved following WHO MDR-TB treatment guidelines and individualized patient management recommendations by the French National TB Consilium. However, the optimal combination of drugs, duration of treatment and role of surgery in the management of MDR-OATB remains to be determined.","Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Department of Bacteriology, University Hospital, CHU Nantes, 44000 Nantes, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France.;Service de Virologie et Mycobactériologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Rhumatologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France.;Service de Chirurgie Orthopédique, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne-Université, 75013 Paris, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.;Service de Médecine Interne, Hôpital Robert Ballanger, 93600 Aulnay-sous-Bois, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d'Amiens-Picardie, 80054 Amiens, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Tours, 37000 Tours, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Bactériologie, Centre Hospitalier Universitaire d'Amiens-Picardie, 59200 Tourcoing, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Saint-Nazaire, 44606 Saint-Nazaire, France.;Service de Bactériologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France.;Service de Bactériologie, Hôpital Lariboisière, AP-HP, Nord-Université de Paris, 75018 Paris, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Médecine Interne, Hôpital Beaujon, AP-HP, Nord-Université de Paris, 92110 Clichy, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Service de Bactériologie, Hôpitaux Saint-Antoine, Tenon, Trousseau, Rothschild, AP-HP, 75012 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France.","NA",0,"2076-2607","Microorganisms","Microorganisms",2022,"2022","10","10.3390/microorganisms10061215",NA,"","","35744731","35744731","PUBMED","Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Department of Bacteriology, University Hospital, CHU Nantes, 44000 Nantes, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France.;Service de Virologie et Mycobactériologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Rhumatologie, Centre Hospitalier Universitaire de Poitiers, 86000 Poitiers, France.;Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France.;Service de Chirurgie Orthopédique, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne-Université, 75013 Paris, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Nice, 06000 Nice, France.;Service de Médecine Interne, Hôpital Robert Ballanger, 93600 Aulnay-sous-Bois, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Tourcoing, 59200 Tourcoing, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire d'Amiens-Picardie, 80054 Amiens, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Tours, 37000 Tours, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, 37000 Tours, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Bactériologie, Centre Hospitalier Universitaire d'Amiens-Picardie, 59200 Tourcoing, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier de Saint-Nazaire, 44606 Saint-Nazaire, France.;Service de Bactériologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 75014 Paris, France.;Service de Bactériologie, Hôpital Lariboisière, AP-HP, Nord-Université de Paris, 75018 Paris, France.;Sanatorium, Centre Hospitalier de Bligny, 91640 Briis-sous-Forges, France.;Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service de Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, 69002 Lyon, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Médecine Interne, Hôpital Beaujon, AP-HP, Nord-Université de Paris, 92110 Clichy, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Groupe Hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Service de Bactériologie, Hôpitaux Saint-Antoine, Tenon, Trousseau, Rothschild, AP-HP, 75012 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, AP-HP, INSERM 1136, Sorbonne-Université, 75013 Paris, France.;Service de Maladies Infectieuses et Tropicales, Hôpital Bicêtre, AP-HP, Université Paris Saclay, 94270 Le Kremlin-Bicêtre, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France.;Cimi-Paris, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Sorbonne Université, 75013 Paris, France.;Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne-Université, 75013 Paris, France.;TB Consilium of the National Reference Center for Mycobacteria, 75013 Paris, France.;Centre de Référence des Infections Ostéo-Articulaires Complexes, Hôpital Pitié-Salpêtrière, AP-HP, 75013 Paris, France."
"258","Presti D;Havas J;Soldato D;Lapidari P;Martin E;Pistilli B;Jouannaud C;Emile G;Rigal O;Fournier M;Soulie P;Mouret-Reynier MA;Tarpin C;Campone M;Guillermet S;Martin AL;Everhard S;Di Meglio A","Presti, D;Havas, J;Soldato, D;Lapidari, P;Martin, E;Pistilli, B;Jouannaud, C;Emile, G;Rigal, O;Fournier, M;Soulie, P;Mouret-Reynier, M-A;Tarpin, C;Campone, M;Guillermet, S;Martin, A-L;Everhard, S;Di Meglio, A","Factors associated with enrolment in clinical trials among women with early-stage breast cancer.","ESMO open","England","eng","Journal Article","breast neoplasms;clinical trial;quality of life;survivorship","Breast Neoplasms;Female;Humans;Prospective Studies;Quality of Life;Surveys and Questionnaires","Breast Neoplasms;Female;Humans;Prospective Studies;Quality of Life;Surveys and Questionnaires","Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer. We included 9516 patients with stage I-III breast cancer from the multicenter, prospective CANTO study (NCT01993498), followed-up until year 4 (Y4) post-diagnosis. We assessed factors associated with enrolment using multivariable logistic regression. In exploratory, propensity score matched analyses, we used multiple linear regression to evaluate the relationship of enrolment in clinical trials with the European Organisation for Research and Treatment of Cancer Quality Of Life (QoL) questionnaire (EORTC QLQ-C30) Summary Score and described clinical outcomes (distant disease event, invasive disease event, and death by any cause) according to enrolment. Overall, 1716 patients (18%) were enrolled in a clinical trial until Y4 post-diagnosis of breast cancer. Socioeconomic factors were not associated with enrolment. Centres of intermediate volume were most likely to enrol patients in clinical trials [versus low volume, odds ratio 1.45 (95% confidence interval (CI) 1.08-1.95), P = 0.0124]. Among 2118 propensity score matched patients, enrolment was associated with better QoL at Y4 (adjusted mean difference versus not enrolled 1.37, 95% CI 0.03-2.71, P = 0.0458), and clinical outcomes (enrolled versus not enrolled, distant disease event 7.3% versus 10.1%, P = 0.0206; invasive disease event 8.2% versus 10.5%, P = 0.0732; death by any cause 2.8% versus 3.7%, P = 0.2707). In this large study, one in five patients enrolled on a clinical trial until Y4 after diagnosis of early breast cancer. Geographical and centre-related factors were significantly associated with enrolment in clinical trials. Inclusion in clinical trials seemed associated with improved QoL and clinical outcomes. Access to innovation for early-stage breast cancer patients should be encouraged and facilitated by overcoming organizational and geographical barriers to recruitment.","INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Institut Jean Godinot, Reims, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologie de L'ouest -Paul Papin, Angers, France.;Centre Jean-Perrin, Clermont Ferrand, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif","NA",0,"2059-7029","ESMO Open","ESMO Open",2022,"2022","7","10.1016/j.esmoop.2022.100513","100513","","","35724624","35724624","PUBMED","INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genoa, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France; Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Institut Jean Godinot, Reims, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Institut Bergonié, Bordeaux, France.;Institut de Cancérologie de L'ouest -Paul Papin, Angers, France.;Centre Jean-Perrin, Clermont Ferrand, France.;Institut Paoli Calmettes, Marseille, France.;Institut de Cancérologie de l'Ouest - Site de Nantes - Centre René Gauducheau, Nantes, France.;Centre Eugene Marquis, Rennes, France.;UNICANCER, Paris, France.;UNICANCER, Paris, France.;INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif"
"259","Martin-Blondel G;Lescure FX;Assoumou L;Charpentier C;Chapplain JM;Perpoint T;Grouteau G;Cordel H;Pialoux G;Pacanowski J;Thy M;Bauvois A;Laureillard D;Hamrouni F;Algarte-Genin M;Poissy J;Descamps D;Costagliola D","Martin-Blondel, Guillaume;Lescure, François-Xavier;Assoumou, Lambert;Charpentier, Charlotte;Chapplain, Jean-Marc;Perpoint, Thomas;Grouteau, Gaspard;Cordel, Hugues;Pialoux, Gilles;Pacanowski, Jérome;Thy, Michael;Bauvois, Adeline;Laureillard, Didier;Hamrouni, Fadia;Algarte-Genin, Michèle;Poissy, Julien;Descamps, Diane;Costagliola, Dominique","Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.","BMC infectious diseases","England","eng","Journal Article","COVID-19;SARS-CoV-2;Severity;Variant of concern Alpha","Aged;COVID-19;Cohort Studies;Female;Hospitalization;Humans;Male;Retrospective Studies;SARS-CoV-2","Aged;COVID-19;Cohort Studies;Female;Hospitalization;Humans;Male;Retrospective Studies;SARS-CoV-2","The impact of the variant of concern (VOC) Alpha on the severity of COVID-19 has been debated. We report our analysis in France. We conducted an exposed/unexposed cohort study with retrospective data collection, comparing patients infected by VOC Alpha to contemporaneous patients infected by historical lineages. Participants were matched on age (± 2.5 years), sex and region of hospitalization. The primary endpoint was the proportion of hospitalized participants with severe COVID-19, defined as a WHO-scale > 5 or by the need of a non-rebreather mask, occurring up to day 29 after admission. We used a logistic regression model stratified on each matched pair and accounting for factors known to be associated with the severity of the disease. We included 650 pairs of patients hospitalized between Jan 1, 2021, and Feb 28, 2021, in 47 hospitals. Median age was 70 years and 61.3% of participants were male. The proportion of participants with comorbidities was high in both groups (85.0% vs 90%, p = 0.004). Infection by VOC Alpha was associated with a higher odds of severe COVID-19 (41.7% vs 38.5%-aOR = 1.33 95% CI [1.03-1.72]). Infection by the VOC Alpha was associated with a higher odds of severe COVID-19.","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse;Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Service de Médecine Interne, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;University of Lille, Inserm U1285, CHU Lille, Pôle de Médecine Intensive Réanimation, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.","NA",0,"1471-2334","BMC Infect Dis","BMC Infect Dis",2021,"2022","22","10.1186/s12879-022-07508-x","540","","","35698029","35698029","PUBMED","Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse;Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Tropicales, Hospices Civils de Lyon, Lyon, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Avicenne, AP-HP, Bobigny, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Tenon, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, APHP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude-Bernard, APHP, Paris, France.;Service de Médecine Interne, Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France.;University of Lille, Inserm U1285, CHU Lille, Pôle de Médecine Intensive Réanimation, CNRS, UMR 8576, UGSF, Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Service de Virologie, Université de Paris, INSERM, IAME, UMR 1137, AP-HP, Hôpital Bichat-Claude Bernard, 75018, Paris, France.;Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP), Paris, France."
"260","Carey LA;Loirat D;Punie K;Bardia A;Diéras V;Dalenc F;Diamond JR;Fontaine C;Wang G;Rugo HS;Hurvitz SA;Kalinsky K;O'Shaughnessy J;Loibl S;Gianni L;Piccart M;Zhu Y;Delaney R;Phan S;Cortés J","Carey, Lisa A;Loirat, Delphine;Punie, Kevin;Bardia, Aditya;Diéras, Véronique;Dalenc, Florence;Diamond, Jennifer R;Fontaine, Christel;Wang, Grace;Rugo, Hope S;Hurvitz, Sara A;Kalinsky, Kevin;O'Shaughnessy, Joyce;Loibl, Sibylle;Gianni, Luca;Piccart, Martine;Zhu, Yanni;Delaney, Rosemary;Phan, See;Cortés, Javier","Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.","NPJ breast cancer","United States","eng","Journal Article","","","","Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.","University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;Medical Oncology Department, Oncologisch Centrum, UZ Brussel, Brussels, Belgium.;Miami Cancer Institute, Miami, FL, USA.;Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.;Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Medical Oncology, Gianni Bonadonna Foundation, Milan, Italy.;Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.;Department of Biostatistics, Gilead Sciences, Inc, Foster City, CA, USA.;Department of Clinical Research, Gilead Sciences, Inc, Morris Plains, NJ, USA.;Department of Clinical Development, Gilead Sciences Inc, Foster City, CA, USA.;International Breast Cancer Center, Quirón Group, Barcelona, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.","NA",0,"2374-4677","NPJ Breast Cancer","NPJ Breast Cancer",2021,"2022","8","10.1038/s41523-022-00439-5","72","P50 CA058223","NCI NIH HHS","35680967","35680967","PUBMED","University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;Medical Oncology Department, Oncologisch Centrum, UZ Brussel, Brussels, Belgium.;Miami Cancer Institute, Miami, FL, USA.;Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA.;Department of Medicine and Research, Hämatologisch-Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany.;Medical Oncology, Gianni Bonadonna Foundation, Milan, Italy.;Medical Oncology Department, Institut Jules Bordet and l'Université Libre de Bruxelles, Brussels, Belgium.;Department of Biostatistics, Gilead Sciences, Inc, Foster City, CA, USA.;Department of Clinical Research, Gilead Sciences, Inc, Morris Plains, NJ, USA.;Department of Clinical Development, Gilead Sciences Inc, Foster City, CA, USA.;International Breast Cancer Center, Quirón Group, Barcelona, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain."
"261","Driemeyer C;Falci DR;Oladele RO;Bongomin F;Ocansey BK;Govender NP;Hoenigl M;Gangneux JP;Lass-Flörl C;Cornely OA;Alanio A;Guinea J;Morrissey CO;Rautemaa-Richardson R;Chakrabarti A;Meis JF;Bruns C;Stemler J;Pasqualotto AC","Driemeyer, Cândida;Falci, Diego R;Oladele, Rita O;Bongomin, Felix;Ocansey, Bright K;Govender, Nelesh P;Hoenigl, Martin;Gangneux, Jean Pierre;Lass-Flörl, Cornelia;Cornely, Oliver A;Alanio, Alexandre;Guinea, Jesus;Morrissey, C Orla;Rautemaa-Richardson, Riina;Chakrabarti, Arunaloke;Meis, Jacques F;Bruns, Caroline;Stemler, Jannik;Pasqualotto, Alessandro C","The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey.","The Lancet. Microbe","England","eng","Journal Article","","Animals;Antifungal Agents;Fungi;Humans;Mycology;Mycoses;Nigeria","Animals;Antifungal Agents;Fungi;Humans;Mycology;Mycoses;Nigeria","Africa, although not unique in this context, is a favourable environment for fungal infections, given the high burden of risk factors. An online survey was developed asking about laboratory infrastructure and antifungal drug availability. We received 40 responses (24·4% response rate) of 164 researchers contacted from 21 African countries. Only five institutions (12·5%) of 40 located in Cameroon, Kenya, Nigeria, Sudan, and Uganda potentially fulfilled the minimum laboratory requirements for European Confederation of Medical Mycology Excellence Centre blue status. Difficulties included low access to susceptibility testing for both yeasts and moulds (available in only 30% of institutions) and Aspergillus spp antigen detection (available in only 47·5% of institutions as an in-house or outsourced test), as well as access to mould-active antifungal drugs such as amphotericin B deoxycholate (available for 52·5% of institutions), itraconazole (52·5%), voriconazole (35·0%), and posaconazole (5·0%). United and targeted efforts are crucial to face the growing challenges in clinical mycology.","Post-graduation Programme in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil; Molecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil.;Infectious Diseases Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.;Department of Medical Microbiology & Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria.;Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.;Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK.;National Institute for Communicable Diseases, A Division of the National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.;Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Centre Hospitalier Universitaire de Rennes, University of Rennes, Institut National de la Santé et de la Recherche Médicale, Institut de Recherche en Santé, Environnement et Travail, Rennes, France.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne, Cologne, Germany.;Université de Paris, Paris, France; Laboratoire de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France; Institut Pasteur, Centre National de la Recherche Scientifique, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.;Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red, Enfermedades Respiratorias, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.;Department of Infectious Diseases, Alfred Health & Monash University, Melbourne, VIC, Australia.;Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK; National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Mycology Reference Centre Manchester, Excellence Center for Medical Mycology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.;Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Medical Microbiology and Infectious Diseases and Centre of Expertise in Mycology Radboudumc/Canisius Wilhelmina Hospital, Excellence Center for Medical Mycology, Nijmegen, Netherlands.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;Post-graduation Programme in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil; Molecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre","NA",0,"2666-5247","Lancet Microbe","Lancet Microbe",2021,"2022","3","10.1016/S2666-5247(21)00190-7","e464-e470","","","35659908","35659908","PUBMED","Post-graduation Programme in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil; Molecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil.;Infectious Diseases Unit, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.;Department of Medical Microbiology & Parasitology, College of Medicine, University of Lagos, Lagos, Nigeria.;Department of Medical Microbiology and Immunology, Faculty of Medicine, Gulu University, Gulu, Uganda.;Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK.;National Institute for Communicable Diseases, A Division of the National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.;Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA; Division of Infectious Diseases, Medical University of Graz, Graz, Austria.;Centre Hospitalier Universitaire de Rennes, University of Rennes, Institut National de la Santé et de la Recherche Médicale, Institut de Recherche en Santé, Environnement et Travail, Rennes, France.;Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne, Cologne, Germany.;Université de Paris, Paris, France; Laboratoire de Parasitologie-Mycologie, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand-Widal, Paris, France; Institut Pasteur, Centre National de la Recherche Scientifique, Unité de Mycologie Moléculaire, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.;Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Centro de Investigación Biomédica en Red, Enfermedades Respiratorias, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain.;Department of Infectious Diseases, Alfred Health & Monash University, Melbourne, VIC, Australia.;Division of Infection, Immunity, and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK; National Aspergillosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Mycology Reference Centre Manchester, Excellence Center for Medical Mycology, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK.;Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Department of Medical Microbiology and Infectious Diseases and Centre of Expertise in Mycology Radboudumc/Canisius Wilhelmina Hospital, Excellence Center for Medical Mycology, Nijmegen, Netherlands.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology, Cologne, Germany; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany.;Post-graduation Programme in Pathology, Federal University of Health Sciences of Porto Alegre, Porto Alegre, Brazil; Molecular Biology Laboratory, Santa Casa de Misericordia de Porto Alegre, Porto Alegre"
"262","Chan SL;Schuler M;Kang YK;Yen CJ;Edeline J;Choo SP;Lin CC;Okusaka T;Weiss KH;Macarulla T;Cattan S;Blanc JF;Lee KH;Maur M;Pant S;Kudo M;Assenat E;Zhu AX;Yau T;Lim HY;Bruix J;Geier A;Guillén-Ponce C;Fasolo A;Finn RS;Fan J;Vogel A;Qin S;Riester M;Katsanou V;Chaudhari M;Kakizume T;Gu Y;Porta DG;Myers A;Delord JP","Chan, Stephen L;Schuler, Martin;Kang, Yoon-Koo;Yen, Chia-Jui;Edeline, Julien;Choo, Su Pin;Lin, Chia-Chi;Okusaka, Takuji;Weiss, Karl-Heinz;Macarulla, Teresa;Cattan, Stéphane;Blanc, Jean-Frederic;Lee, Kyung-Hun;Maur, Michela;Pant, Shubham;Kudo, Masatoshi;Assenat, Eric;Zhu, Andrew X;Yau, Thomas;Lim, Ho Yeong;Bruix, Jordi;Geier, Andreas;Guillén-Ponce, Carmen;Fasolo, Angelica;Finn, Richard S;Fan, Jia;Vogel, Arndt;Qin, Shukui;Riester, Markus;Katsanou, Vasiliki;Chaudhari, Monica;Kakizume, Tomoyuki;Gu, Yi;Porta, Diana Graus;Myers, Andrea;Delord, Jean-Pierre","A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.","Journal of experimental & clinical cancer research : CR","England","eng","Clinical Trial, Phase I","FGF19;FGFR4;Hepatocellular carcinoma;Immune checkpoint inhibitors;KLB;PD-1;PD-L1;Phase 1","Antibodies, Monoclonal, Humanized;Bayes Theorem;Biomarkers;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Piperazines;Pyridines","Antibodies, Monoclonal, Humanized;Bayes Theorem;Biomarkers;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Piperazines;Pyridines","Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclinical models. This study was designed to determine the recommended phase 2 dose (RP2D), characterize PK/PD, and evaluate the safety and efficacy of FGF401 alone and combined with the anti-PD-1 antibody, spartalizumab. Patients with HCC or other FGFR4/KLB expressing tumors were enrolled. Dose-escalation was guided by a Bayesian model. Phase 2 dose-expansion enrolled patients with HCC from Asian countries (group1), non-Asian countries (group2), and patients with other solid tumors expressing FGFR4 and KLB (group3). FGF401 and spartalizumab combination was evaluated in patients with HCC. Seventy-four patients were treated in the phase I with single-agent FGF401 at 50 to 150 mg. FGF401 displayed favorable PK characteristics and no food effect when dosed with low-fat meals. The RP2D was established as 120 mg qd. Six of 70 patients experienced grade 3 dose-limiting toxicities: increase in transaminases (n = 4) or blood bilirubin (n = 2). In phase 2, 30 patients in group 1, 36 in group 2, and 20 in group 3 received FGF401. In total, 8 patients experienced objective responses (1 CR, 7 PR; 4 each in phase I and phase II, respectively). Frequent adverse events (AEs) were diarrhea (73.8%), increased AST (47.5%), and ALT (43.8%). Increase in levels of C4, total bile acid, and circulating FGF19, confirmed effective FGFR4 inhibition. Twelve patients received FGF401 plus spartalizumab. RP2D was established as FGF401 120 mg qd and spartalizumab 300 mg Q3W; 2 patients reported PR. At biologically active doses, FGF401 alone or combined with spartalizumab was safe in patients with FGFR4/KLB-positive tumors including HCC. Preliminary clinical efficacy was observed. Further clinical evaluation of FGF401 using a refined biomarker strategy is warranted. NCT02325739 .","State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong;West German Cancer Center, University Hospital Essen, Germany & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Centre Eugène Marquis, Rennes, France and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;National Cancer Centre, Singapore, Singapore.;National Taiwan University Hospital, Taipei, Taiwan.;National Cancer Centre Hospital, Tokyo, Japan.;Salem Medical Center, Internal Medicine, Heidelberg, Germany.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quirón, Barcelona, Spain.;Chru de Lille, Lille, France.;CHU de Bordeaux Pessac, Bordeaux, France.;Seoul National University Hospital, Seoul, South Korea.;University Hospital of Modena, Modena, Italy.;MD Anderson Cancer Center, Houston, TX, USA.;Kindai University Hospital, Osaka, Japan.;Hôpital Saint-Eloi Montpellier, Montpellier, France.;Massachusetts General Hospital, Boston, MA, USA.;Jiahui International Cancer Center, Jiahui Health, Shanghai, China.;Queen Mary Hospital, Hong Kong, China.;Samsung Medical Center, Seoul, South Korea.;Barcelona clinic liver cancer (BCLC) Group, Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.;University Hospital Würzburg, Würzburg, Germany.;Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.;San Raffaele Hospital, Milan, Italy.;University of California, Los Angeles, California, USA.;Zhongshan Hospital, Fudan University, Shanghai, China.;Hannover Medical School, Hanover, Germany.;No. 81th PLA Hospital Nanjing, Jiangsu, China.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;IQVIA, Durham, North Carolina, USA.;Novartis Pharma K.K, Tokyo, Japan.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;IUCT Oncopole - Institut Claudius Regaud, Toulouse, France.","NA",0,"1756-9966","J Exp Clin Cancer Res","J Exp Clin Cancer Res",2022,"2022","41","10.1186/s13046-022-02383-5","189","","","35655320","35655320","PUBMED","State Key Laboratory of Translational Oncology, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong;West German Cancer Center, University Hospital Essen, Germany & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany.;Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.;Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.;Centre Eugène Marquis, Rennes, France and ARPEGO (Accès à La Recherche Précoce Dans Le Grand-Ouest) Network, Rennes, France.;National Cancer Centre, Singapore, Singapore.;National Taiwan University Hospital, Taipei, Taiwan.;National Cancer Centre Hospital, Tokyo, Japan.;Salem Medical Center, Internal Medicine, Heidelberg, Germany.;Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quirón, Barcelona, Spain.;Chru de Lille, Lille, France.;CHU de Bordeaux Pessac, Bordeaux, France.;Seoul National University Hospital, Seoul, South Korea.;University Hospital of Modena, Modena, Italy.;MD Anderson Cancer Center, Houston, TX, USA.;Kindai University Hospital, Osaka, Japan.;Hôpital Saint-Eloi Montpellier, Montpellier, France.;Massachusetts General Hospital, Boston, MA, USA.;Jiahui International Cancer Center, Jiahui Health, Shanghai, China.;Queen Mary Hospital, Hong Kong, China.;Samsung Medical Center, Seoul, South Korea.;Barcelona clinic liver cancer (BCLC) Group, Liver Unit, Hospital Clínic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain.;University Hospital Würzburg, Würzburg, Germany.;Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.;San Raffaele Hospital, Milan, Italy.;University of California, Los Angeles, California, USA.;Zhongshan Hospital, Fudan University, Shanghai, China.;Hannover Medical School, Hanover, Germany.;No. 81th PLA Hospital Nanjing, Jiangsu, China.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;IQVIA, Durham, North Carolina, USA.;Novartis Pharma K.K, Tokyo, Japan.;Novartis Institutes for BioMedical Research, Cambridge, MA, USA.;Novartis Institutes for BioMedical Research, Basel, Switzerland.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;IUCT Oncopole - Institut Claudius Regaud, Toulouse, France."
"263","Lefort M;Sharmin S;Andersen JB;Vukusic S;Casey R;Debouverie M;Edan G;Ciron J;Ruet A;De Sèze J;Maillart E;Zephir H;Labauge P;Defer G;Lebrun-Frenay C;Moreau T;Berger E;Clavelou P;Pelletier J;Stankoff B;Gout O;Thouvenot E;Heinzlef O;Al-Khedr A;Bourre B;Casez O;Cabre P;Montcuquet A;Wahab A;Camdessanché JP;Maurousset A;Ben Nasr H;Hankiewicz K;Pottier C;Maubeuge N;Dimitri-Boulos D;Nifle C;Laplaud DA;Horakova D;Havrdova EK;Alroughani R;Izquierdo G;Eichau S;Ozakbas S;Patti F;Onofrj M;Lugaresi A;Terzi M;Grammond P;Grand'Maison F;Yamout B;Prat A;Girard M;Duquette P;Boz C;Trojano M;McCombe P;Slee M;Lechner-Scott J;Turkoglu R;Sola P;Ferraro D;Granella F;Shaygannejad V;Prevost J;Maimone D;Skibina O;Buzzard K;Van der Walt A;Karabudak R;Van Wijmeersch B;Csepany T;Spitaleri D;Vucic S;Koch-Henriksen N;Sellebjerg F;Soerensen PS;Hilt Christensen CC;Rasmussen PV;Jensen MB;Frederiksen JL;Bramow S;Mathiesen HK;Schreiber KI;Butzkueven H;Magyari M;Kalincik T;Leray E","Lefort, M;Sharmin, S;Andersen, J B;Vukusic, S;Casey, R;Debouverie, M;Edan, G;Ciron, J;Ruet, A;De Sèze, J;Maillart, E;Zephir, H;Labauge, P;Defer, G;Lebrun-Frenay, C;Moreau, T;Berger, E;Clavelou, P;Pelletier, J;Stankoff, B;Gout, O;Thouvenot, E;Heinzlef, O;Al-Khedr, A;Bourre, B;Casez, O;Cabre, P;Montcuquet, A;Wahab, A;Camdessanché, J P;Maurousset, A;Ben Nasr, H;Hankiewicz, K;Pottier, C;Maubeuge, N;Dimitri-Boulos, D;Nifle, C;Laplaud, D A;Horakova, D;Havrdova, E K;Alroughani, R;Izquierdo, G;Eichau, S;Ozakbas, S;Patti, F;Onofrj, M;Lugaresi, A;Terzi, M;Grammond, P;Grand'Maison, F;Yamout, B;Prat, A;Girard, M;Duquette, P;Boz, C;Trojano, M;McCombe, P;Slee, M;Lechner-Scott, J;Turkoglu, R;Sola, P;Ferraro, D;Granella, F;Shaygannejad, V;Prevost, J;Maimone, D;Skibina, O;Buzzard, K;Van der Walt, A;Karabudak, R;Van Wijmeersch, B;Csepany, T;Spitaleri, D;Vucic, S;Koch-Henriksen, N;Sellebjerg, F;Soerensen, P S;Hilt Christensen, C C;Rasmussen, P V;Jensen, M B;Frederiksen, J L;Bramow, S;Mathiesen, H K;Schreiber, K I;Butzkueven, H;Magyari, M;Kalincik, T;Leray, E","Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.","BMC medical research methodology","England","eng","Journal Article","Causal contrasts;Censoring;Effectiveness;Indication bias;Multiple sclerosis;Positivity assumption;Propensity score","Fingolimod Hydrochloride;Humans;Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Natalizumab;Treatment Outcome","Fingolimod Hydrochloride;Humans;Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting;Natalizumab;Treatment Outcome","Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment indication bias and manage censoring. The objective of this empirical study was to elucidate the impact of methods of causal inference on the results of comparative effectiveness studies. Data from three observational multiple sclerosis registries (MSBase, the Danish MS Registry and French OFSEP registry) were combined. Four clinical outcomes were studied. Propensity scores were used to match or weigh the compared groups, allowing for estimating average treatment effect for treated or average treatment effect for the entire population. Analyses were conducted both in intention-to-treat and per-protocol frameworks. The impact of the positivity assumption was also assessed. Overall, 5,148 relapsing-remitting multiple sclerosis patients were included. In this well-powered sample, the 95% confidence intervals of the estimates overlapped widely. Propensity scores weighting and propensity scores matching procedures led to consistent results. Some differences were observed between average treatment effect for the entire population and average treatment effect for treated estimates. Intention-to-treat analyses were more conservative than per-protocol analyses. The most pronounced irregularities in outcomes and propensity scores were introduced by violation of the positivity assumption. This applied study elucidates the influence of methodological decisions on the results of comparative effectiveness studies of treatments for multiple sclerosis. According to our results, there are no material differences between conclusions obtained with propensity scores matching or propensity scores weighting given that a study is sufficiently powered, models are correctly specified and positivity assumption is fulfilled.","Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France.;Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes, France.;Department of Medicine, University of Melbourne, Melbourne, Australia.;Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet Glostrup, Denmark.;Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.;Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.;Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France.;Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.;Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.;Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France.;Eugene Devic EDMUS Foundation, 69677, Lyon/Bron, France.;Centre Hospitalier Régional Universitaire de Nancy, Hôpital Central, Service de neurologie, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, Rennes, France.;Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, CRC-SEP, Département de neurologie, Toulouse, France.;Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Service de neurologie, Bordeaux, France.;Service des maladies inflammatoires du système nerveux - neurologie, centre d'investigation clinique de Strasbourg, Hôpitaux Universitaire de Strasbourg, Hôpital de Hautepierre, INSERM 1434, Strasbourg, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital de La Pitié-Salpêtrière, Service de neurologie, Paris, France.;Centre Hospitalier Universitaire de Lille, Hôpital Salengro, Service de neurologie D, Lille, France.;Centre Hospitalier Universitaire de Montpellier, Hôpital Gui de Chauliac, Service de neurologie, Montpellier, France.;Centre Hospitalier Universitaire de Caen Normandie, Hôpital Côte de Nacre, Service de neurologie, Caen, France.;Centre Hospitalier Universitaire de Nice, UR2CA-URRIS,, Université Nice Côte d'Azur, Hôpital, Pasteur 2, Service de neurologie, Nice, France.;Centre Hospitalier Universitaire Dijon Bourgogne, Hôpital François Mitterrand, Maladies Inflammatoires du Système Nerveux Et Neurologie Générale, Service de neurologie, Dijon, France.;Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz, Service de neurologie, Besançon, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel-Montpied, Service de neurologie, Clermont-Ferrand, France.;Service de Neurologie, Aix Marseille Univ, APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, 13005, Marseille, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Saint-Antoine, Service de neurologie, Paris, France.;Fondation Adolphe de Rothschild de L'œil Et du Cerveau, Service de neurologie, Paris, France.;Centre Hospitalier Universitaire de Nîmes, Hôpital Carémeau, Service de neurologie, Nîmes, France.;Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye, Service de neurologie, Poissy, France.;Centre Hospitalier Universitaire d'Amiens Picardie, Site sud, Service de neurologie, Amiens, France.;Rouen University Hospital, 76000, Rouen, France.;Centre Hospitalier Universitaire Grenoble-Alpes, Site nord, Service de neurologie, Grenoble/La Tronche, France.;Centre Hospitalier Universitaire de Martinique, Hôpital Pierre Zobda-Quitman, Service de neurologie, Fort-de-France, France.;Centre Hospitalier Universitaire Limoges, Hôpital Dupuytren, Service de neurologie, Limoges, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Henri Mondor, Service de neurologie, Créteil, France.;Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Service de neurologie, Saint-Étienne, France.;Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, Service de neurologie, Tours, France.;Centre Hospitalier Sud Francilien, Service de neurologie, Corbeil-Essonnes, France.;Centre Hospitalier de Saint-Denis, Hôpital Casanova, Service de neurologie, Saint-Denis, France.;Centre Hospitalier de Pontoise, Service de neurologie, Pontoise, France.;Centre Hospitalier Universitaire de Poitiers, Site de La Milétrie, Service de neurologie, Poitiers, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Bicêtre, Service de neurologie, Le Kremlin-Bicêtre, France.;Centre Hospitalier de Versailles, Hôpital André-Mignot, Service de neurologie, Le Chesnay, France.;CHU de Nantes, Service de Neurologie & CIC015 INSERM, 44093, Nantes, France.;INSERM CR1064, 44000, Nantes, France.;Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.;Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.;Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.;Hospital Universitario Virgen Macarena, Seville, Spain.;Hospital Universitario Virgen Macarena, Seville, Spain.;Dokuz Eylul University, Konak/Izmir, Turkey.;GF Ingrassia Department, University of Catania, Catania, Italy.;Policlinico G Rodolico, Catania, Italy.;Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy.;Dipartimento Di Scienze Biomediche E Neuromotorie, Università Di Bologna, Bologna, Italy.;IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy.;Medical Faculty, 19 Mayis University, Samsun, Turkey.;CISSS Chaudiere-Appalache, Levis, Canada.;Neuro Rive-Sud, Longueuil, QC, Canada.;Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.;Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.;University of Queensland, Brisbane, Australia.;Royal Brisbane and Women's Hospital, Herston, Australia.;Flinders University, Adelaide, Australia.;School of Medicine and Public Health, University Newcastle, Newcastle, Australia.;Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia.;Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.;Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.;Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.;Department of Medicine and Surgery, University of Parma, Parma, Italy.;Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy.;Isfahan University of Medical Sciences, Isfahan, Iran.;CSSS Saint-Jérôme, Saint-Jerome, Canada.;Garibaldi Hospital, Catania, Italy.;Monash University, Melbourne, Australia.;Monash University, Melbourne, Australia.;Monash University, Melbourne, Australia.;Hacettepe University, Ankara, Turkey.;Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium.;Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.;Azienda Ospedaliera Di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.;Westmead Hospital, Sydney, Australia.;Department of Clinical Epidemiology, Aarhus University Hospital Aarhus, Aarhus, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Neurology, Aalborg University Hospital, Multiple Sclerosis Unit, Aalborg, Denmark.;Aarhus University Hospital, Neurology, PJJ Boulevard, DK-8200, Aarhus N, Denmark.;Department of Neurology, University Hospital of Northern Sealand, Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Neurology, Copenhagen University Hospital Herlev, Copenhagen, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Central Clinical School, Monash University, Melbourne, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Australia.;Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.;Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Medicine, University of Melbourne, Melbourne;Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes;Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes","NA",0,"1471-2288","BMC Med Res Methodol","BMC Med Res Methodol",2022,"2022","22","10.1186/s12874-022-01623-8","155","","","35637426","35637426","PUBMED","Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes, France.;Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes, France.;Department of Medicine, University of Melbourne, Melbourne, Australia.;Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.;Department of Neurology, The Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet Glostrup, Denmark.;Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.;Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.;Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France.;Service de Neurologie, Sclérose en Plaques, Pathologies de La Myéline Et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, 69677, Lyon/Bron, France.;Centre Des Neurosciences de Lyon, UMR5292, Observatoire Français de La Sclérose en Plaques, INSERM, 1028 et CNRS, 69003, Lyon, France.;Université, Claude Bernard Lyon 1, Faculté de médecine Lyon Est, 69000, Lyon, France.;Eugene Devic EDMUS Foundation, 69677, Lyon/Bron, France.;Centre Hospitalier Régional Universitaire de Nancy, Hôpital Central, Service de neurologie, Nancy, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Service de neurologie, Rennes, France.;Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, CRC-SEP, Département de neurologie, Toulouse, France.;Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Service de neurologie, Bordeaux, France.;Service des maladies inflammatoires du système nerveux - neurologie, centre d'investigation clinique de Strasbourg, Hôpitaux Universitaire de Strasbourg, Hôpital de Hautepierre, INSERM 1434, Strasbourg, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital de La Pitié-Salpêtrière, Service de neurologie, Paris, France.;Centre Hospitalier Universitaire de Lille, Hôpital Salengro, Service de neurologie D, Lille, France.;Centre Hospitalier Universitaire de Montpellier, Hôpital Gui de Chauliac, Service de neurologie, Montpellier, France.;Centre Hospitalier Universitaire de Caen Normandie, Hôpital Côte de Nacre, Service de neurologie, Caen, France.;Centre Hospitalier Universitaire de Nice, UR2CA-URRIS,, Université Nice Côte d'Azur, Hôpital, Pasteur 2, Service de neurologie, Nice, France.;Centre Hospitalier Universitaire Dijon Bourgogne, Hôpital François Mitterrand, Maladies Inflammatoires du Système Nerveux Et Neurologie Générale, Service de neurologie, Dijon, France.;Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz, Service de neurologie, Besançon, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel-Montpied, Service de neurologie, Clermont-Ferrand, France.;Service de Neurologie, Aix Marseille Univ, APHM, Hôpital de La Timone, Pôle de Neurosciences Cliniques, 13005, Marseille, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Saint-Antoine, Service de neurologie, Paris, France.;Fondation Adolphe de Rothschild de L'œil Et du Cerveau, Service de neurologie, Paris, France.;Centre Hospitalier Universitaire de Nîmes, Hôpital Carémeau, Service de neurologie, Nîmes, France.;Centre Hospitalier Intercommunal de Poissy Saint-Germain-en-Laye, Service de neurologie, Poissy, France.;Centre Hospitalier Universitaire d'Amiens Picardie, Site sud, Service de neurologie, Amiens, France.;Rouen University Hospital, 76000, Rouen, France.;Centre Hospitalier Universitaire Grenoble-Alpes, Site nord, Service de neurologie, Grenoble/La Tronche, France.;Centre Hospitalier Universitaire de Martinique, Hôpital Pierre Zobda-Quitman, Service de neurologie, Fort-de-France, France.;Centre Hospitalier Universitaire Limoges, Hôpital Dupuytren, Service de neurologie, Limoges, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Henri Mondor, Service de neurologie, Créteil, France.;Centre Hospitalier Universitaire de Saint-Étienne, Hôpital Nord, Service de neurologie, Saint-Étienne, France.;Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, Service de neurologie, Tours, France.;Centre Hospitalier Sud Francilien, Service de neurologie, Corbeil-Essonnes, France.;Centre Hospitalier de Saint-Denis, Hôpital Casanova, Service de neurologie, Saint-Denis, France.;Centre Hospitalier de Pontoise, Service de neurologie, Pontoise, France.;Centre Hospitalier Universitaire de Poitiers, Site de La Milétrie, Service de neurologie, Poitiers, France.;Assistance Publique Des Hôpitaux de Paris, Hôpital Bicêtre, Service de neurologie, Le Kremlin-Bicêtre, France.;Centre Hospitalier de Versailles, Hôpital André-Mignot, Service de neurologie, Le Chesnay, France.;CHU de Nantes, Service de Neurologie & CIC015 INSERM, 44093, Nantes, France.;INSERM CR1064, 44000, Nantes, France.;Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.;Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic.;Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.;Hospital Universitario Virgen Macarena, Seville, Spain.;Hospital Universitario Virgen Macarena, Seville, Spain.;Dokuz Eylul University, Konak/Izmir, Turkey.;GF Ingrassia Department, University of Catania, Catania, Italy.;Policlinico G Rodolico, Catania, Italy.;Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy.;Dipartimento Di Scienze Biomediche E Neuromotorie, Università Di Bologna, Bologna, Italy.;IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy.;Medical Faculty, 19 Mayis University, Samsun, Turkey.;CISSS Chaudiere-Appalache, Levis, Canada.;Neuro Rive-Sud, Longueuil, QC, Canada.;Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;Hopital Notre Dame, Montreal, Canada.;CHUM and Universite de Montreal, Montreal, Canada.;KTU Medical Faculty Farabi Hospital, Trabzon, Turkey.;Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Bari, Italy.;University of Queensland, Brisbane, Australia.;Royal Brisbane and Women's Hospital, Herston, Australia.;Flinders University, Adelaide, Australia.;School of Medicine and Public Health, University Newcastle, Newcastle, Australia.;Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, Australia.;Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.;Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.;Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.;Department of Medicine and Surgery, University of Parma, Parma, Italy.;Department of Emergency and General Medicine, Parma University Hospital, Parma, Italy.;Isfahan University of Medical Sciences, Isfahan, Iran.;CSSS Saint-Jérôme, Saint-Jerome, Canada.;Garibaldi Hospital, Catania, Italy.;Monash University, Melbourne, Australia.;Monash University, Melbourne, Australia.;Monash University, Melbourne, Australia.;Hacettepe University, Ankara, Turkey.;Rehabilitation and MS-Centre Overpelt and Hasselt University, Hasselt, Belgium.;Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.;Azienda Ospedaliera Di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.;Westmead Hospital, Sydney, Australia.;Department of Clinical Epidemiology, Aarhus University Hospital Aarhus, Aarhus, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Neurology, Aalborg University Hospital, Multiple Sclerosis Unit, Aalborg, Denmark.;Aarhus University Hospital, Neurology, PJJ Boulevard, DK-8200, Aarhus N, Denmark.;Department of Neurology, University Hospital of Northern Sealand, Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Neurology, Copenhagen University Hospital Herlev, Copenhagen, Denmark.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Central Clinical School, Monash University, Melbourne, Australia.;Department of Neurology, The Alfred Hospital, Melbourne, Australia.;Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia.;Melbourne MS Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.;Danish Multiple Sclerosis Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet Glostrup, 2600, Glostrup, Denmark.;Department of Medicine, University of Melbourne, Melbourne;Arènes - UMR 6051, RSMS (Recherche sur les Services et Management en Santé) - U 1309, Univ Rennes, EHESP, CNRS, Inserm, Rennes;Univ Rennes, CHU Rennes, Investigation Clinique de Rennes)], CIC 1414 [(Centre d, 35000, InsermRennes"
"264","Randrian V;Pernot S;Le Malicot K;Catena V;Baumgaertner I;Tacher V;Forestier J;Hautefeuille V;Tabouret-Viaud C;Gagnaire A;Mitry E;Guiu B;Aparicio T;Smith D;Dhomps A;Tasu JP;Perdrisot R;Edeline J;Capron C;Cheze-Le Rest C;Emile JF;Laurent-Puig P;Bejan-Angoulvant T;Sokol H;Lepage C;Taieb J;Tougeron D","Randrian, Violaine;Pernot, Simon;Le Malicot, Karine;Catena, Vittorio;Baumgaertner, Isabelle;Tacher, Vania;Forestier, Julien;Hautefeuille, Vincent;Tabouret-Viaud, Claire;Gagnaire, Alice;Mitry, Emmanuel;Guiu, Boris;Aparicio, Thomas;Smith, Denis;Dhomps, Anthony;Tasu, Jean-Pierre;Perdrisot, Rémy;Edeline, Julien;Capron, Claude;Cheze-Le Rest, Catherine;Emile, Jean-François;Laurent-Puig, Pierre;Bejan-Angoulvant, Theodora;Sokol, Harry;Lepage, Come;Taieb, Julien;Tougeron, David","FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Netherlands","eng","Clinical Trial, Phase II","Colorectal cancer;Immune checkpoint inhibitor;Liver metastases;Selective internal radiation therapy","Humans;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Colonic Neoplasms;Colorectal Neoplasms;Liver Neoplasms;Prospective Studies;Rectal Neoplasms","Humans;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Colonic Neoplasms;Colorectal Neoplasms;Liver Neoplasms;Prospective Studies;Rectal Neoplasms","Immune checkpoint inhibitors (ICI) have high efficacy in metastatic colorectal cancer (mCRC) with microsatellite instability (MSI) but not in microsatellite stable (MSS) tumour due to the low tumour mutational burden. Selective internal radiation therapy (SIRT) could enhance neoantigen production thus triggering systemic anti-tumoral immune response (abscopal effect). In addition, Oxalipatin can induce immunogenic cell death and Bevacizumab can decrease the exhaustion of tumour infiltrating lymphocyte. In combination, these treatments could act synergistically to sensitize MSS mCRCs to ICI SIRTCI is a prospective, multicentre, open-label, phase II, non-comparative single-arm study evaluating the efficacy and safety of SIRT plus Xelox, Bevacizumab and Atezolizumab (anti-programmed death-ligand 1) in patients with liver-dominant MSS mCRC. The primary objective is progression-free survival at 9 months. The main inclusion criteria are patients with MSS mCRC with liver-dominant disease, initially unresectable disease and with no prior oncologic treatment for metastatic disease. The trial started in November 2020 and has included 10 out of the 52 planned patients.","Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers 86021, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Fédération Francophone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.;Department of Radiology, Institut Bergonié, Bordeaux, France.;Department of Clinical Oncology, Henri-Mondor University Hospital, Créteil, France.;University of Paris Est Créteil, Unité INSERM 955, Equipe 18, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil F-94010, France.;Department of Medical Oncology, Hôpital Edouard Herriot, Lyon Cedex 03 69437, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Amiens University Hospital, Amiens, France.;Department of Nuclear Medicine, Unicancer-Georges François Leclerc Cancer Center, Dijon, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Dijon University Hospital, BP 87900 21079 Dijon, EPICAD LNC-UMR1231, Burgundy and Franche-Comte University, Dijon, France.;Medical Oncology Department, Paoli-Calmettes Institut, Marseille, France.;Hôpital St-Eloi (CHU Montpellier), Université de Montpellier, Montpellier, France.;AP-HP, Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, 1 avenue Claude Vellefaux, Université de Paris, Paris F-75010, France.;Service d'Oncologie médicale, Haut-Lévèque Hospital, CHU Bordeaux, Bordeaux, France.;Nuclear Medicine, University Hospital of Lyon, Pierre Bénite, France.;Radiology Department, University Hospital Centre Poitiers, Poitiers, France; LATIM, INSERM UMR 1101, Université de Brest, CHU Morvan, 2 avenue FOCH, 29 609 Brest cedex, France.;Nuclear Medicine, Poitiers University Hospital, Poitiers France.;Medical Oncology, Centre Eugène Marquis, Rennes 35000, France.;Service d'immunologie, AP-HP, Hôpital Ambroise Paré, Paris, France.;LATIM, INSERM UMR 1101, Université de Brest, CHU Morvan, 2 avenue FOCH, 29 609 Brest cedex, France; Nuclear Medicine, Poitiers University Hospital, Poitiers France.;Department of Pathology, APHP-Hôpital Ambroise Paré, Boulogne-Billancourt, France.;Department of Biology, Georges Pompidou Hospital, APHP, Université de Paris, Paris, France.;Department of Medical Pharmacology, CHRU de Tours, Tours, France.;Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Gastroentérologie, Paris, Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas and Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Dijon University Hospital, BP 87900 21079 Dijon, EPICAD LNC-UMR1231, Burgundy and Franche-Comte University, Dijon, France.;Service de Gastroentérologie et d'Oncologie Digestive, Hôpital Européen George Pompidou, Université de Paris, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers 86021","NA",0,"1878-3562","Dig Liver Dis","Dig Liver Dis",2022,"2022","54","10.1016/j.dld.2022.04.024","857-863","","","35610167","35610167","PUBMED","Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers 86021, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Fédération Francophone de Cancérologie Digestive, EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.;Department of Radiology, Institut Bergonié, Bordeaux, France.;Department of Clinical Oncology, Henri-Mondor University Hospital, Créteil, France.;University of Paris Est Créteil, Unité INSERM 955, Equipe 18, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil F-94010, France.;Department of Medical Oncology, Hôpital Edouard Herriot, Lyon Cedex 03 69437, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Amiens University Hospital, Amiens, France.;Department of Nuclear Medicine, Unicancer-Georges François Leclerc Cancer Center, Dijon, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Dijon University Hospital, BP 87900 21079 Dijon, EPICAD LNC-UMR1231, Burgundy and Franche-Comte University, Dijon, France.;Medical Oncology Department, Paoli-Calmettes Institut, Marseille, France.;Hôpital St-Eloi (CHU Montpellier), Université de Montpellier, Montpellier, France.;AP-HP, Gastroenterology and Digestive Oncology Department, Saint Louis Hospital, 1 avenue Claude Vellefaux, Université de Paris, Paris F-75010, France.;Service d'Oncologie médicale, Haut-Lévèque Hospital, CHU Bordeaux, Bordeaux, France.;Nuclear Medicine, University Hospital of Lyon, Pierre Bénite, France.;Radiology Department, University Hospital Centre Poitiers, Poitiers, France; LATIM, INSERM UMR 1101, Université de Brest, CHU Morvan, 2 avenue FOCH, 29 609 Brest cedex, France.;Nuclear Medicine, Poitiers University Hospital, Poitiers France.;Medical Oncology, Centre Eugène Marquis, Rennes 35000, France.;Service d'immunologie, AP-HP, Hôpital Ambroise Paré, Paris, France.;LATIM, INSERM UMR 1101, Université de Brest, CHU Morvan, 2 avenue FOCH, 29 609 Brest cedex, France; Nuclear Medicine, Poitiers University Hospital, Poitiers France.;Department of Pathology, APHP-Hôpital Ambroise Paré, Boulogne-Billancourt, France.;Department of Biology, Georges Pompidou Hospital, APHP, Université de Paris, Paris, France.;Department of Medical Pharmacology, CHRU de Tours, Tours, France.;Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Gastroentérologie, Paris, Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, Jouy-en-Josas and Center for Microbiome Medicine (PaCeMM) FHU, Paris, France.;Department of Hepato-Gastroenterology and Digestive Oncology, Dijon University Hospital, BP 87900 21079 Dijon, EPICAD LNC-UMR1231, Burgundy and Franche-Comte University, Dijon, France.;Service de Gastroentérologie et d'Oncologie Digestive, Hôpital Européen George Pompidou, Université de Paris, AP-HP, Paris, France.;Service d'Hépato-gastroentérologie, CHU de Poitiers et Université de Poitiers, Poitiers 86021"
"265","Bourgon N;Garde A;Bruel AL;Lefebvre M;Mau-Them FT;Moutton S;Sorlin A;Nambot S;Delanne J;Chevarin M;Pöe C;Thevenon J;Lehalle D;Jean-Marçais N;Kuentz P;Lambert L;El Chehadeh S;Schaefer E;Willems M;Laffargue F;Francannet C;Fradin M;Gaillard D;Blesson S;Goldenberg A;Capri Y;Sagot P;Rousseau T;Simon E;Binquet C;Ascencio ML;Duffourd Y;Philippe C;Faivre L;Vitobello A;Thauvin-Robinet C","Bourgon, Nicolas;Garde, Aurore;Bruel, Ange-Line;Lefebvre, Mathilde;Mau-Them, Frederic Tran;Moutton, Sebastien;Sorlin, Arthur;Nambot, Sophie;Delanne, Julian;Chevarin, Martin;Pöe, Charlotte;Thevenon, Julien;Lehalle, Daphné;Jean-Marçais, Nolween;Kuentz, Paul;Lambert, Laetitia;El Chehadeh, Salima;Schaefer, Elise;Willems, Marjolaine;Laffargue, Fanny;Francannet, Christine;Fradin, Mélanie;Gaillard, Dominique;Blesson, Sophie;Goldenberg, Alice;Capri, Yline;Sagot, Paul;Rousseau, Thierry;Simon, Emmanuel;Binquet, Christine;Ascencio, Marie-Laure;Duffourd, Yannis;Philippe, Christophe;Faivre, Laurence;Vitobello, Antonio;Thauvin-Robinet, Christel","Same performance of exome sequencing before and after fetal autopsy for congenital abnormalities: toward a paradigm shift in prenatal diagnosis?","European journal of human genetics : EJHG","England","eng","Journal Article","","Abnormalities, Multiple;Autopsy;Congenital Abnormalities;Exome;Female;Fetus;Humans;Pregnancy;Prenatal Diagnosis;Ultrasonography, Prenatal;Exome Sequencing","Abnormalities, Multiple;Autopsy;Congenital Abnormalities;Exome;Female;Fetus;Humans;Pregnancy;Prenatal Diagnosis;Ultrasonography, Prenatal;Exome Sequencing","Prenatal exome sequencing could be complex because of limited phenotypical data compared to postnatal/portmortem phenotype in fetuses affected by multiple congenital abnormalities (MCA). Here, we investigated limits of prenatal phenotype for ES interpretation thanks to a blindly reanalysis of postmortem ES data using prenatal data only in fetuses affected by MCA and harboring a (likely)pathogenic variant or a variant of unknown significance (VUS). Prenatal ES identified all causative variant previously reported by postmortem ES (22/24 (92%) and 2/24 (8%) using solo-ES and trio-ES respectively). Prenatal ES identified 5 VUS (in four fetuses). Two of them have been previously reported by postmortem ES. Prenatal ES were negative for four fetuses for which a VUS were diagnosed after autopsy. Our study suggests that prenatal phenotype is not a limitation for implementing pES in the prenatal assessment of unsolved MCA to personalize fetal medicine and could influence indication of postmortem examination.","INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Département Génétique Médicale, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de génétique, Unité de Génétique Clinique, Centre Hospitalier Régional Universitaire de Rouen, Rouen, France.;Département de génétique, Hôpital Robert Debré, APHP, Paris, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon","NA",0,"1476-5438","Eur J Hum Genet","Eur J Hum Genet",2021,"2022","30","10.1038/s41431-022-01117-7","967-975","","","35577939","35577939","PUBMED","INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Oncobiologie Génétique Bioinformatique, PCBio, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Génétique Clinique, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Département Génétique Médicale, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de génétique clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de génétique médicale, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de génétique, Unité de Génétique Clinique, Centre Hospitalier Régional Universitaire de Rouen, Rouen, France.;Département de génétique, Hôpital Robert Debré, APHP, Paris, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Service de Gynécologie Obstétrique, Médecine Fœtale et Stérilité Conjugale, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;Centre d'Investigation Clinique CIC-EC Inserm CIC1432, UFR des Sciences de Santé, Université de Bourgogne-Franche-Comté, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon, France.;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon, France.;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon, France.;INSERM UMR 1231, Génétique des Anomalies du Développement, Université́ de Bourgogne Franche-Comté́, Dijon;FHU-TRANSLAD, Fédération Hospitalo-Universitaire Médecine Transrationnelle et Anomalies du Développement, CHU Dijon Bourgogne, Dijon;Centre de Génétique et Centre de Référence ""Anomalies du Développement et Syndromes Malformatifs de l'Inter-région Est"", CHU Dijon Bourgogne, Dijon;UF Innovation en Diagnostic Génomique des Maladies Rares, CHU Dijon Bourgogne, Dijon"
"266","Bonsang-Kitzis H;Panchbhaya N;Bats AS;Pujade-Lauraine E;Pautier P;Ngô C;Le Frère-Belda MA;Kalbacher E;Floquet A;Berton-Rigaud D;Lefeuvre-Plesse C;Fabbro M;Ray-Coquard I;Lécuru F","Bonsang-Kitzis, Hélène;Panchbhaya, Nabilah;Bats, Anne-Sophie;Pujade-Lauraine, Eric;Pautier, Patricia;Ngô, Charlotte;Le Frère-Belda, Marie-Aude;Kalbacher, Elsa;Floquet, Anne;Berton-Rigaud, Dominique;Lefeuvre-Plesse, Claudia;Fabbro, Michel;Ray-Coquard, Isabelle;Lécuru, Fabrice","Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network.","Cancers","Switzerland","eng","Journal Article","advanced stage;low-grade serous ovarian cancer;neoadjuvant chemotherapy;surgery;survival","","","The surgical specificities of advanced low-grade serous ovarian carcinoma (LGSOC) have been little investigated. Our objective was to describe surgical procedures/complications in primary (PDS) compared to interval debulking surgery (neoadjuvant chemotherapy and interval debulking surgery, NACT-IDS) and to assess the survival (progression-free (PFS) and overall survival (OS)) in patients with advanced LGSOC. We retrospectively analyzed advanced LGSOC from a nationwide registry (January 2000 to July 2017). A total of 127 patients were included (48% PDS and 35% NACT-IDS). Peritoneal carcinomatosis was more severe (  = 0.01 to 0.0001, according to sites), surgery more complex (  = 0.03) and late postoperative morbidity more frequent (  = 0.03) and more severe in the NACT-IDS group. PFS and OS were similar in patients with CC0 and CC1 residual disease after PDS or IDS. Prognosis was poorest for NACT-IDS patients with CC2/CC3 resection (PFS: HR = 2.31, IC95% (1.3-4.58);   = 0.005; OS: HR = 4.98, IC95% (1.59-15.61);   = 0.006). NACT has no benefit in terms of surgical outputs in patients with advanced LGSOC. Patients with complete resection or minimal residual disease (CC0 and CC1) have similar prognoses. On the other hand, patients with CC2 and more residual disease have similar survival rates compared to nonoperated patients. Primary cytoreduction with complete or with minimal residuals should be preferred when feasible.","Gynecological and Breast Surgery and Cancerology Center, RAMSAY-Générale de Santé, Hôpital Privé des Peupliers, 75013 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Obsterics and Gynecology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, 75020 Paris, France.;Department of Breast and Gynecological Surgical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.;School of Medicine, Université de Paris, 75005 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;School of Medicine, Université de Paris, 75005 Paris, France.;Women Cancer Center and Clinical Research, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 75006 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Gustave Roussy, 94000 Villejuif, France.;Gynecological and Breast Surgery and Cancerology Center, RAMSAY-Générale de Santé, Hôpital Privé des Peupliers, 75013 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Pathology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Hôpital Jean Minjoz, 25000 Besançon, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, 44000 Saint Herblain, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Régional du Cancer de Montpellier, 33000 Montpellier, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Centre Léon Bérard, 69000 Lyon, France.;School of Medicine, Claude Bernard University, 69000 Lyon, France.;GINECO/TMRG Network, 75008 Paris, France.;Women Cancer Center and Clinical Research, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 75006 Paris, France.;Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005 Paris, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14092345",NA,"","","35565475","35565475","PUBMED","Gynecological and Breast Surgery and Cancerology Center, RAMSAY-Générale de Santé, Hôpital Privé des Peupliers, 75013 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Obsterics and Gynecology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, 75020 Paris, France.;Department of Breast and Gynecological Surgical Oncology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.;School of Medicine, Université de Paris, 75005 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;School of Medicine, Université de Paris, 75005 Paris, France.;Women Cancer Center and Clinical Research, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 75006 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Gustave Roussy, 94000 Villejuif, France.;Gynecological and Breast Surgery and Cancerology Center, RAMSAY-Générale de Santé, Hôpital Privé des Peupliers, 75013 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Pathology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Hôpital Jean Minjoz, 25000 Besançon, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Bergonié, 33000 Bordeaux, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, 44000 Saint Herblain, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Institut Régional du Cancer de Montpellier, 33000 Montpellier, France.;GINECO/TMRG Network, 75008 Paris, France.;Department of Medical Oncology, Centre Léon Bérard, 69000 Lyon, France.;School of Medicine, Claude Bernard University, 69000 Lyon, France.;GINECO/TMRG Network, 75008 Paris, France.;Women Cancer Center and Clinical Research, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 75006 Paris, France.;Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005 Paris, France."
"267","Tripathy D;Tolaney SM;Seidman AD;Anders CK;Ibrahim N;Rugo HS;Twelves C;Diéras V;Müller V;Du Y;Currie SL;Hoch U;Tagliaferri M;Hannah AL;Cortés J","Tripathy, Debu;Tolaney, Sara M;Seidman, Andrew D;Anders, Carey K;Ibrahim, Nuhad;Rugo, Hope S;Twelves, Chris;Diéras, Véronique;Müller, Volkmar;Du, Yining;Currie, Sue L;Hoch, Ute;Tagliaferri, Mary;Hannah, Alison L;Cortés, Javier","Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial.","JAMA oncology","United States","eng","Clinical Trial, Phase III","","Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Breast Neoplasms;Female;Heterocyclic Compounds, 4 or More Rings;Humans;Middle Aged;Polyethylene Glycols","Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Breast Neoplasms;Female;Heterocyclic Compounds, 4 or More Rings;Humans;Middle Aged;Polyethylene Glycols","Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end point, treatment with etirinotecan pegol vs chemotherapy of the physician's choice for patients with advanced breast cancer demonstrated a significant improvement in overall survival (OS) for the prespecified patient subgroup with preexisting, pretreated, and nonprogressive BM. To compare clinical outcomes in patients with BM treated with etirinotecan pegol vs chemotherapy of the physician's choice in a confirmatory trial. This study was a phase 3, open-label, randomized clinical trial (ATTAIN) in patients with metastatic breast cancer and a history of stable pretreated BM who experienced disease progression while receiving chemotherapy in the metastatic setting. The trial took place at 47 sites in 10 countries, and patients were enrolled between March 7, 2017, and November 6, 2019. Patients were randomized to receive etirinotecan pegol, 145 mg/m2, every 21 days or chemotherapy (eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel). The primary end point was OS. Key secondary end points included progression-free survival, objective response rate, duration of response, and the clinical benefit rate. A total of 178 female patients (9 [5.1%] Asian, 8 [4.5%] Black or African American, and 123 [69.1] White individuals) were randomized to receive treatment with etirinotecan pegol (92 [51.7%]; median [range] age, 53 [27-79] years) or chemotherapy (86 [48.3%]; median [range] age, 52 [24-77] years). Median OS was similar in both groups (etirinotecan pegol, 7.8 months; chemotherapy, 7.5 months; hazard ratio [HR], 0.90; 95% CI, 0.61-1.33; P = .60). Median progression-free survival for non-central nervous system metastases per blinded independent central review for etirinotecan pegol vs chemotherapy was 2.8 and 1.9 months (HR, 0.72; 95% CI, 0.45-1.16; P = .18) and 3.9 vs 3.3 months, respectively, for central nervous system metastases (HR, 0.59; 95% CI, 0.33-1.05; P = .07). Safety profiles between the groups were largely comparable. The results of the ATTAIN randomized clinical trial found no statistically significant difference in outcomes between treatment with etirinotecan pegol and chemotherapy in patients with BM. However, this study represents one of the largest published trials dedicated to patients with breast cancer and BM and may help to inform further research. ClinicalTrials.gov Identifier: NCT02915744.","The University of Texas MD Anderson Cancer Center, Houston.;Dana-Farber Cancer Institute, Boston, Massachusetts.;Memorial Sloan Kettering Cancer Center, New York, New York.;Duke Cancer Institute, Durham, North Carolina.;The University of Texas MD Anderson Cancer Center, Houston.;University of California, San Francisco.;University of Leeds and Leeds Teaching Hospitals Trust, Leeds, England.;Centre Eugène Marquis, Rennes, France.;University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;International Breast Cancer Center, Quironsalud Group, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2022,"2022","8","10.1001/jamaoncol.2022.0514","1047-1052","P30 CA008748;P30 CA014236;P30 CA016672","NCI NIH HHS;NCI NIH HHS;NCI NIH HHS","35552364","35552364","PUBMED","The University of Texas MD Anderson Cancer Center, Houston.;Dana-Farber Cancer Institute, Boston, Massachusetts.;Memorial Sloan Kettering Cancer Center, New York, New York.;Duke Cancer Institute, Durham, North Carolina.;The University of Texas MD Anderson Cancer Center, Houston.;University of California, San Francisco.;University of Leeds and Leeds Teaching Hospitals Trust, Leeds, England.;Centre Eugène Marquis, Rennes, France.;University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;Nektar Therapeutics, San Francisco, California.;International Breast Cancer Center, Quironsalud Group, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain."
"268","Léger M;Frasca D;Roquilly A;Seguin P;Cinotti R;Dahyot-Fizelier C;Asehnoune K;Le Borgne F;Gaillard T;Foucher Y;Lasocki S","Léger, Maxime;Frasca, Denis;Roquilly, Antoine;Seguin, Philippe;Cinotti, Raphaël;Dahyot-Fizelier, Claire;Asehnoune, Karim;Le Borgne, Florent;Gaillard, Thomas;Foucher, Yohann;Lasocki, Sigismond","Early use of barbiturates is associated with increased mortality in traumatic brain injury patients from a propensity score-based analysis of a prospective cohort.","PloS one","United States","eng","Journal Article","","Barbiturates;Brain Injuries, Traumatic;Glasgow Coma Scale;Humans;Intracranial Hypertension;Pneumonia, Ventilator-Associated;Propensity Score;Prospective Studies","Barbiturates;Brain Injuries, Traumatic;Glasgow Coma Scale;Humans;Intracranial Hypertension;Pneumonia, Ventilator-Associated;Propensity Score;Prospective Studies","Barbiturates are proposed as a second/third line treatment for intracranial hypertension in traumatic brain injury (TBI) patients, but the literature remains uncertain regarding their benefit/risk balance. We aimed to evaluate the impact of barbiturates therapy in TBI patients with early intracranial hypertension on the intensive care unit (ICU) survival, the occurrence of ventilator-associated pneumonia (VAP), and the patient's functional status at three months. We used the French AtlanREA prospective cohort of trauma patients. Using a propensity score-based methodology (inverse probability of treatment weighting), we compared patients having received barbiturates within the first 24 hours of admission (barbiturates group) and those who did not (control group). We used cause-specific Cox models for ICU survival and risk of VAP, and logistic regression for the 3-month Glasgow Outcome Scale (GOS) evaluation. Among the 1396 patients with severe trauma, 383 had intracranial hypertension on admission and were analyzed. Among them, 96 (25.1%) received barbiturates. The early use of barbiturates was significantly associated with increased ICU mortality (HR = 1.85, 95%CI 1.03-3.33). However, barbiturates treatment was not significantly associated with VAP (HR = 1.02, 95%CI 0.75-1.41) or 3-month GOS (OR = 1.67, 95%CI 0.84-3.33). Regarding the absence of relevant clinical trials, our results suggest that each early prescription of barbiturates requires a careful assessment of the benefit/risk ratio.","Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;IDBC-A2COM, Pacé, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.","NA",0,"1932-6203","PLoS One","PLoS One",2020,"2022","17","10.1371/journal.pone.0268013","e0268013","","","35507627","35507627","PUBMED","Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;IDBC-A2COM, Pacé, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;INSERM UMR 1246-SPHERE, Nantes University, Tours University, Nantes, France.;Centre Hospitalier Universitaire de Nantes, Nantes, France.;Département d'Anesthésie Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France."
"269","Mahfoudhi E;Ricordel C;Lecuyer G;Mouric C;Lena H;Pedeux R","Mahfoudhi, Emna;Ricordel, Charles;Lecuyer, Gwendoline;Mouric, Cécile;Lena, Hervé;Pedeux, Rémy","Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.","Frontiers in oncology","Switzerland","eng","Journal Article","3rd G EGFR-TKI;lung cancer;osimertinib;preclinical models;resistance mechanism","","","Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are currently recommended as first-line treatment for advanced non-small-cell lung cancer (NSCLC) with  -activating mutations. Third-generation (3rd G) EGFR-TKIs, including osimertinib, offer an effective treatment option for patients with NSCLC resistant 1st and 2nd EGFR-TKIs. However, the efficacy of 3rd G EGFR-TKIs is limited by acquired resistance that has become a growing clinical challenge. Several clinical and preclinical studies are being carried out to better understand the mechanisms of resistance to 3rd G EGFR-TKIs and have revealed various genetic aberrations associated with molecular heterogeneity of cancer cells. Studies focusing on epigenetic events are limited despite several indications of their involvement in the development of resistance. Preclinical models, established in most cases in a similar manner, have shown different prevalence of resistance mechanisms from clinical samples. Clinically identified mechanisms include EGFR mutations that were not identified in preclinical models. Thus, NRAS genetic alterations were not observed in patients but have been described in cell lines resistant to 3rd G EGFR-TKI. Mainly, resistance to 3rd G EGFR-TKI in preclinical models is related to the activation of alternative signaling pathways through tyrosine kinase receptor (TKR) activation or to histological and phenotypic transformations. Yet, preclinical models have provided some insight into the complex network between dominant drivers and associated events that lead to the emergence of resistance and consequently have identified new therapeutic targets. This review provides an overview of preclinical studies developed to investigate the mechanisms of acquired resistance to 3rd G EGFR-TKIs, including osimertinib and rociletinib, across all lines of therapy. In fact, some of the models described were first generated to be resistant to first- and second-generation EGFR-TKIs and often carried the T790M mutation, while others had never been exposed to TKIs. The review further describes the therapeutic opportunities to overcome resistance, based on preclinical studies.","Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2022,"2022","12","10.3389/fonc.2022.853501","853501","","","35463360","35463360","PUBMED","Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, Université de Rennes 1, Rennes, France.;Univ Rennes, Institut Nationale de la Santé et de la Recherche Médicale (INSERM), COSS (Chemistry Oncogenesis Stress Signaling), UMR_S 1242, Centre de Lutte Contre le Cancer (CLOC) Eugène Marquis, Rennes, France."
"270","Novello S;Tricot-Doleux S;Novella A;Pellen-Mussi P;Jeanne S","Novello, Solen;Tricot-Doleux, Sylvie;Novella, Agnès;Pellen-Mussi, Pascal;Jeanne, Sylvie","Influence of Periodontal Ligament Stem Cell-Derived Conditioned Medium on Osteoblasts.","Pharmaceutics","Switzerland","eng","Journal Article","bone regeneration;conditioned medium;exosomes;mesenchymal stem cells;osteoblasts;periodontal regeneration","","","Mesenchymal stem cells (MSC) are involved in the regeneration of various missing or compromised periodontal tissues, including bone. MSC-derived conditioned medium (CM) has recently been explored as a favorable surrogate for stem cell therapy, as it is capable of producing comparable therapeutic effects. This study aimed to evaluate the influence of periodontal ligament stem cells (PDLSC)-CM on osteoblasts (OB) and its potential as a therapeutic tool for periodontal regeneration. Human PDLSC were isolated and characterized, and CM from these cells was collected. The presence of exosomes in the culture supernatant was observed by immunofluorescence and by transmission electron microscopy. CM was added to a cultured osteoblastic cell line (Saos-2 cells) and viability (MTT assay) and gene expression analysis (real-time PCR) were examined. A cell line derived from the periodontal ligament and showing all the characteristics of MSC was successfully isolated and characterized. The addition of PDLSC-CM to Saos-2 cells led to an enhancement of their proliferation and an increased expression of some osteoblastic differentiation markers, but this differentiation was not complete. Saos-2 cells were involved in the initial inflammation process by releasing IL-6 and activating COX2. The effects of PDLSC-CM on Saos-2 appear to arise from a cumulative effect of different effective components rather than a few factors present at high levels.","ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.","NA",0,"1999-4923","Pharmaceutics","Pharmaceutics",2022,"2022","14","10.3390/pharmaceutics14040729",NA,"","","35456563","35456563","PUBMED","ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;ISCR (Institut des Sciences Chimiques de Rennes)-UMR 6226, Université de Rennes, 35000 Rennes, France.;Unité de Formation et de Recherche d'Odontologie, Université de Rennes, 35000 Rennes, France.;UF Parodontologie, Pôle d'Odontologie, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France."
"271","Harriswangler C;Caneda-Martínez L;Rousseaux O;Esteban-Gómez D;Fougère O;Pujales-Paradela R;Valencia L;Fernández MI;Lepareur N;Platas-Iglesias C","Harriswangler, Charlene;Caneda-Martínez, Laura;Rousseaux, Olivier;Esteban-Gómez, David;Fougère, Olivier;Pujales-Paradela, Rosa;Valencia, Laura;Fernández, M Isabel;Lepareur, Nicolas;Platas-Iglesias, Carlos",NA,"Inorganic chemistry","United States","eng","Journal Article","","Humans;Ions;Lanthanoid Series Elements;Ligands;Nitrogen;Radiopharmaceuticals;Water;Yttrium","Humans;Ions;Lanthanoid Series Elements;Ligands;Nitrogen;Radiopharmaceuticals;Water;Yttrium","We report a macrocyclic ligand (H ) based on a 3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane platform containing three acetate pendant arms and a benzyl group attached to the fourth nitrogen atom of the macrocycle. The X-ray structures of the Y  and Tb  complexes reveal nine coordination of the ligand to the metal ions through the six nitrogen atoms of the macrocycle and three oxygen atoms of the carboxylate pendants. A combination of NMR spectroscopic studies ( H,  C, and  Y) and DFT calculations indicated that the structure of the Y  complex in the solid state is maintained in an aqueous solution. The detailed study of the emission spectra of the Eu  and Tb  complexes revealed Ln -centered emission with quantum yields of 7.0 and 60%, respectively. Emission lifetime measurements indicate that the ligand offers good protection of the metal ions from surrounding water molecules, preventing the coordination of water molecules. The Y  complex is remarkably inert with respect to complex dissociation, with a lifetime of 1.7 h in 1 M HCl. On the other hand, complex formation is fast (∼1 min at pH 5.4, 2 × 10  M). Studies using the  Y-nuclide confirmed fast radiolabeling since [ Y]Y  is nearly quantitatively formed (radiochemical yield (RCY) > 95) in a short time over a broad range of pH values from ca. 2.4 to 9.0. Challenging experiments in the presence of excess ethylenediaminetetraacetic acid (EDTA) and in human serum revealed good stability of the [ Y]Y  complex. All of these experiments combined suggest the potential application of H  derivatives as Y-based radiopharmaceuticals.","Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, BP 57400, 95943 Roissy CdG Cedex, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, BP 57400, 95943 Roissy CdG Cedex, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Departamento de Química Inorgánica, Facultad de Ciencias, Universidade de Vigo, As Lagoas, Marcosende, 36310 Pontevedra, Spain.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Univ Rennes, Centre Eugène Marquis, Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer)─UMR_A 1341, UMR_S 1241, F-35000 Rennes, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.","NA",0,"1520-510X","Inorg Chem","Inorg Chem",2022,"2022","61","10.1021/acs.inorgchem.2c00378","6209-6222","","","35418232","35418232","PUBMED","Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, BP 57400, 95943 Roissy CdG Cedex, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Groupe Guerbet, Centre de Recherche d'Aulnay-sous-Bois, BP 57400, 95943 Roissy CdG Cedex, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Departamento de Química Inorgánica, Facultad de Ciencias, Universidade de Vigo, As Lagoas, Marcosende, 36310 Pontevedra, Spain.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain.;Univ Rennes, Centre Eugène Marquis, Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer)─UMR_A 1341, UMR_S 1241, F-35000 Rennes, France.;Centro de Investigacións Científicas Avanzadas (CICA) and Departamento de Química, Facultade de Ciencias, Universidade da Coruña, 15071 Galicia, A Coruña, Spain."
"272","Gray S;Lamarca A;Edeline J;Klümpen HJ;Hubner RA;McNamara MG;Valle JW","Gray, Simon;Lamarca, Angela;Edeline, Julien;Klümpen, Heinz-Josef;Hubner, Richard A;McNamara, Mairéad G;Valle, Juan W","Targeted Therapies for Perihilar Cholangiocarcinoma.","Cancers","Switzerland","eng","Journal Article","biliary tract cancer;cholangiocarcinoma;extrahepatic;pCCA;perihilar;targeted therapy","","","Perihilar cholangiocarcinoma (pCCA) is the anatomical sub-group of biliary tract cancer (BTC) arising between the second-order intrahepatic bile ducts and the cystic duct. Together with distal and intrahepatic cholangiocarcinoma (dCCA and iCCA; originating distal to, and proximal to this, respectively), gallbladder cancer (GBC) and ampulla of Vater carcinoma (AVC), these clinicopathologically and molecularly distinct entities comprise biliary tract cancer (BTC). Most pCCAs are unresectable at diagnosis, and for those with resectable disease, surgery is extensive, and recurrence is common. Therefore, the majority of patients with pCCA will require systemic treatment for advanced disease. The prognosis with cytotoxic chemotherapy remains poor, driving interest in therapies targeted to the molecular nature of a given patient's cancer. In recent years, the search for efficacious targeted therapies has been fuelled both by whole-genome and epigenomic studies, looking to uncover the molecular landscape of CCA, and by specifically testing for aberrations where established therapies exist in other indications. This review aims to provide a focus on the current molecular characterisation of pCCA, targeted therapies applicable to pCCA, and future directions in applying personalised medicine to this difficult-to-treat malignancy.","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Centre Eugène Marquis, Av. de la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, Amsterdam University Medical Center, P.O. Box 7057, 1081 HV Amsterdam, The Netherlands.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14071789",NA,"","","35406560","35406560","PUBMED","Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Centre Eugène Marquis, Av. de la Bataille Flandres Dunkerque-CS 44229, CEDEX, 35042 Rennes, France.;Department of Medical Oncology, Amsterdam University Medical Center, P.O. Box 7057, 1081 HV Amsterdam, The Netherlands.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester M20 4BX, UK.;Division of Cancer Sciences, University of Manchester, Oxford Rd, Manchester M13 9PL, UK."
"273","Bonnet C;Dupuis J;Tilly H;Lamy T;Fruchart C;le Gouill S;Thieblemont C;Morschhauser F;Casasnovas O;Bouabdallah K;Ghesquieres H;Van Den Neste E;André M;Cartron G;Salles G","Bonnet, Christophe;Dupuis, Jehan;Tilly, Hervé;Lamy, Thierry;Fruchart, Christophe;le Gouill, Steven;Thieblemont, Catherine;Morschhauser, Franck;Casasnovas, Olivier;Bouabdallah, Krimo;Ghesquieres, Hervé;Van Den Neste, Eric;André, Marc;Cartron, Guillaume;Salles, Gilles","Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.","Cancers","Switzerland","eng","Journal Article","R-DHAOx;R-DHAP;ibrutinib;relapsed/refractory non-Hodgkin B-cell lymphoma;safety","","","In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous stem cell transplantation, with the quality of the response to salvage predicting survival. The Bruton tyrosine kinase inhibitor ibrutinib, given as monotherapy or combined with other molecules, has proven effective in numerous B-cell lymphomas. To evaluate the safety of the combination of ibrutinib, rituximab, dexamethasone, and cytarabine with either cisplatin (R-DHAP) or oxaliplatin (R-DHAOx), we conducted a multicenter Phase 1b-II study in transplant-eligible R/R B-NHL patients, with ibrutinib given using a 3-by-3 dose-escalation design. The combination of R-DHAP and ibrutinib (given from Day 1 to Day 21 of each cycle) was associated with dose-limiting hematological, infectious, and renal toxicities, while we were unable to reach a dose to recommend for Phase II. R-DHAOx could only be combined with a daily dosage of 280 mg ibrutinib when administered continuously. R-DHAP combined with intermittent ibrutinib administration (from Day 5 to Day 18) was found to be highly toxic. On the other hand, when this administration schedule was combined with R-DHAOx, ibrutinib dosing could be increased up to 560 mg but with relevant toxicities. Despite a strong rationale for combining ibrutinib and R-DHAP/R-DHAOx, as both target lymphoma B-cells by different mechanisms, this approach was limited by significant toxicities.","Clinical Hematology Unit, Centre Hospitalier Universitaire de Liège, Liège Université, B35, Campus Universitaire du Sart-Tilman, 4000 Liège, Belgium.;Lymphoid Malignancies Unit, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, CEDEX, 94000 Créteil, France.;Hematology Department Henri Becquerel, Rue d'Amiens, CEDEX, 76000 Rouen, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, 35033 Rennes, France.;Institut National de la Recherche Médicale, Unité Mixte de Recherche U1236, Université de Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Hematology Unit, Centre Hospitalier de Dunkerque, 130, Avenue Louis Herbeaux, CS 76 367, CEDEX 1, 59385 Dunkerque, France.;Institut Curie, 26 Rue d'Ulm, 75005 Paris, France.;Hemato-Oncology Department, Hôpital Saint Louis, 1 Av. Claude Vellefaux, 75010 Paris, France.;Hematology Unit, Centre Hospitalier de Lille, 2, Avenue Oscar Lambret, 59037 Lille, France.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne and INSERM 1231, 14 Rue Paul Gaffarel, 21000 Dijon, France.;Hematology Department, Centre Hospitalier de Bordeaux, 12, Rue Dubernat, 33000 Bordeaux, France.;Hematology Unit, Hopital Lyon Sud, Pierre-Benite, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France.;Hematology Unit, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200 Bruxelles, Belgium.;Department of Hematology, Centre Hospitalier Universaitaire, Université Catholique de Louvain Namur, Université Catholique de Louvain, 1 Rue Dr Gaston Therasse, 5530 Yvoir, Belgium.;Department of Hematology, Centre Hospitalier Universtaire de Montpellier, UMR-CNRS 5535, 34090 Montpellier, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 530 East 74th Street, New York, NY 10065, USA.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14071761",NA,"P30 CA008748","NCI NIH HHS","35406532","35406532","PUBMED","Clinical Hematology Unit, Centre Hospitalier Universitaire de Liège, Liège Université, B35, Campus Universitaire du Sart-Tilman, 4000 Liège, Belgium.;Lymphoid Malignancies Unit, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, CEDEX, 94000 Créteil, France.;Hematology Department Henri Becquerel, Rue d'Amiens, CEDEX, 76000 Rouen, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, 35033 Rennes, France.;Institut National de la Recherche Médicale, Unité Mixte de Recherche U1236, Université de Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Hematology Unit, Centre Hospitalier de Dunkerque, 130, Avenue Louis Herbeaux, CS 76 367, CEDEX 1, 59385 Dunkerque, France.;Institut Curie, 26 Rue d'Ulm, 75005 Paris, France.;Hemato-Oncology Department, Hôpital Saint Louis, 1 Av. Claude Vellefaux, 75010 Paris, France.;Hematology Unit, Centre Hospitalier de Lille, 2, Avenue Oscar Lambret, 59037 Lille, France.;Department of Hematology, Centre Hospitalier Universitaire de Dijon Bourgogne and INSERM 1231, 14 Rue Paul Gaffarel, 21000 Dijon, France.;Hematology Department, Centre Hospitalier de Bordeaux, 12, Rue Dubernat, 33000 Bordeaux, France.;Hematology Unit, Hopital Lyon Sud, Pierre-Benite, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France.;Hematology Unit, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200 Bruxelles, Belgium.;Department of Hematology, Centre Hospitalier Universaitaire, Université Catholique de Louvain Namur, Université Catholique de Louvain, 1 Rue Dr Gaston Therasse, 5530 Yvoir, Belgium.;Department of Hematology, Centre Hospitalier Universtaire de Montpellier, UMR-CNRS 5535, 34090 Montpellier, France.;Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, 530 East 74th Street, New York, NY 10065, USA."
"274","Guillaume Z;Colomba E;Thouvenin J;Saldana C;Campedel L;Dumont C;Laguerre B;Maillet D;Vicier C;Rolland F;Borchiellini D;Barthelemy P;Albiges L;Auclin E;Roulleaux Dugage M;Oudard S;Thibault C","Guillaume, Zoé;Colomba, Emeline;Thouvenin, Jonathan;Saldana, Carolina;Campedel, Luca;Dumont, Clément;Laguerre, Brigitte;Maillet, Denis;Vicier, Cécile;Rolland, Frédéric;Borchiellini, Delphine;Barthelemy, Philippe;Albiges, Laurence;Auclin, Edouard;Roulleaux Dugage, Matthieu;Oudard, Stéphane;Thibault, Constance","Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.","Cancers","Switzerland","eng","Journal Article","Bellini carcinoma;collecting duct carcinoma;immune checkpoint inhibitors;metastatic renal medullary;tyrosine kinase inhibitors","","","Collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are two rare subtypes of kidney cancer with a poor prognosis in the metastatic setting. Beyond first-line treatment, there are no standard-of-care therapies. This retrospective study assessed the efficacy of treatments after first-line chemotherapy in 57 patients with metastatic (m) CDC (n = 35) or RMC (n = 22) treated between 2010 and 2019 at 11 French centers. The median age was 53 years; overall, 60% (n = 34) of patients were metastatic at diagnosis. After a median follow-up of 13 months, the median overall survival was 12 (95% CI, 11−16) months. All patients received first-line platinum chemotherapy ± bevacizumab, with a median time to progression of 7.27 (95% CI, 7−100 months and an objective response rate (ORR) of 39% (95% CI, 26−52%). Patients received a median of two (1−5) treatment lines. Subsequent treatments included tyrosine kinase inhibitors (n = 12), chemotherapy (n = 34), and checkpoint inhibitors (n = 20), with ORR ranging 10−15% and disease control rates ranging 24−50%. The duration of response for all treatments was ~2 months. Notably, nine patients with CDC were still alive > two years after metastatic diagnosis. Beyond first-line therapy, treatments showed very low antitumor activity in mCDC/RMC. A better understanding of the biology of those rare tumors is urgently needed in order to identify potential targets.","Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, Gustave Roussy Institute, Université Paris-Saclay, 94805 Villejuif, France.;Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.;Medical Oncology, Hopital Henri-Mondor, 94010 Créteil, France.;Medical Oncology, Pitié Salpêtrière Hospital, Sorbonne Université, 75013 Paris, France.;Medical Oncology, Hôpital Saint Louis, Oncology Unit, 1 Avenue Claude Vellefaux, 75010 Paris, France.;Medical Oncology, Centre Eugene-Marquis, 35000 Rennes, France.;Medical Oncology, Centre Hospitalier Lyon Sud, 69310 Pierre Bénite, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Medical Oncology Department, Centre Antoine Lacassagne, Université Côte d'Azur, 06100 Nice, France.;Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.;Medical Oncology, Gustave Roussy Institute, Université Paris-Saclay, 94805 Villejuif, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14071678",NA,"","","35406448","35406448","PUBMED","Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, Gustave Roussy Institute, Université Paris-Saclay, 94805 Villejuif, France.;Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.;Medical Oncology, Hopital Henri-Mondor, 94010 Créteil, France.;Medical Oncology, Pitié Salpêtrière Hospital, Sorbonne Université, 75013 Paris, France.;Medical Oncology, Hôpital Saint Louis, Oncology Unit, 1 Avenue Claude Vellefaux, 75010 Paris, France.;Medical Oncology, Centre Eugene-Marquis, 35000 Rennes, France.;Medical Oncology, Centre Hospitalier Lyon Sud, 69310 Pierre Bénite, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Medical Oncology, Institut de Cancérologie de l'Ouest, 44805 Saint-Herblain, France.;Medical Oncology Department, Centre Antoine Lacassagne, Université Côte d'Azur, 06100 Nice, France.;Medical Oncology, Institut de Cancérologie Strasbourg Europe, 67200 Strasbourg, France.;Medical Oncology, Gustave Roussy Institute, Université Paris-Saclay, 94805 Villejuif, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France.;Medical Oncology, European Georges Pompidou Hospital, Université Paris Cité, 75006 Paris, France."
"275","Thibaud V;Billy C;Prud'homm J;Garin J;Hue B;Cattenoz C;Somme D;Corvol A","Thibaud, Vincent;Billy, Claire;Prud'homm, Joaquim;Garin, Jeanne;Hue, Benoit;Cattenoz, Catherine;Somme, Dominique;Corvol, Aline","Inside the Black Box: A Narrative Review on Comprehensive Geriatric Assessment-Driven Interventions in Older Adults with Cancer.","Cancers","Switzerland","eng","Journal Article","CGA;cancer;comprehensive geriatric assessment;malignant hemopathies;older patients","","","There is a consensus that the use of comprehensive geriatric assessment (CGA) is good clinical practice for older patients with solid tumors or hematological malignancies. To be complete, a CGA must include a geriatric assessment and an intervention plan. According to the SIOG consensus, a CGA should assess several domains: functional status, comorbidity, cognition, mental health status, fatigue, social status and support, nutrition, and the presence of geriatric syndromes. Progress has been made in the definition of the best way to detect problems, but the benefits are mostly based on prognosis stratification and on the adaptation of cancer treatment. The present review aims to evaluate the level of evidence regarding geriatric interventions proposed following the detection of a problem in cancer patients in each domain mentioned in the SIOG consensus. An online search of the PubMed database was performed using predefined search algorithms specific for each domain of the CGA. Eligible articles had to have well-defined interventions targeting specific domains of the CGA. We screened 1864 articles, but only a few trials on single-domain interventions were found, and often, these studies involved small groups of patients. This review highlights the scarcity of published studies on this topic. The specific impacts of CGA-based interventions have not yet been demonstrated. Multi-domain interventions seem promising, especially when they are based on global assessments. However, standardization seems difficult considering the lack of evidence for each domain. New studies are necessary in multiple care contexts, and innovative designs must be used to balance internal and external validity. An accurate description of the intervention and what ""usual care"" means will improve the external validity of such studies.","Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Hematology, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Hematology, Hôpital Saint-Vincent, Université Catholique de Lille, 59000 Lille, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Laboratoire Traitement du Signal et de l'Image (INSERM LTSI-UMR 1099), CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Pharmacy, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Centre Eugène Marquis, Department of Medical Oncology, Université Rennes 1, 35000 Rennes, France.;Laboratoire Arènes(CNRS UMR 6051), CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Laboratoire Arènes(CNRS UMR 6051), CHU Rennes, Université Rennes 1, 35000 Rennes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2022,"2022","14","10.3390/cancers14071642",NA,"","","35406414","35406414","PUBMED","Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Hematology, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Hematology, Hôpital Saint-Vincent, Université Catholique de Lille, 59000 Lille, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Laboratoire Traitement du Signal et de l'Image (INSERM LTSI-UMR 1099), CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Pharmacy, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Department of Geriatrics, CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Centre Eugène Marquis, Department of Medical Oncology, Université Rennes 1, 35000 Rennes, France.;Laboratoire Arènes(CNRS UMR 6051), CHU Rennes, Université Rennes 1, 35000 Rennes, France.;Laboratoire Arènes(CNRS UMR 6051), CHU Rennes, Université Rennes 1, 35000 Rennes, France."
"276","Fizazi K;Foulon S;Carles J;Roubaud G;McDermott R;Fléchon A;Tombal B;Supiot S;Berthold D;Ronchin P;Kacso G;Gravis G;Calabro F;Berdah JF;Hasbini A;Silva M;Thiery-Vuillemin A;Latorzeff I;Mourey L;Laguerre B;Abadie-Lacourtoisie S;Martin E;El Kouri C;Escande A;Rosello A;Magne N;Schlurmann F;Priou F;Chand-Fouche ME;Freixa SV;Jamaluddin M;Rieger I;Bossi A","Fizazi, Karim;Foulon, Stéphanie;Carles, Joan;Roubaud, Guilhem;McDermott, Ray;Fléchon, Aude;Tombal, Bertrand;Supiot, Stéphane;Berthold, Dominik;Ronchin, Philippe;Kacso, Gabriel;Gravis, Gwenaëlle;Calabro, Fabio;Berdah, Jean-François;Hasbini, Ali;Silva, Marlon;Thiery-Vuillemin, Antoine;Latorzeff, Igor;Mourey, Loïc;Laguerre, Brigitte;Abadie-Lacourtoisie, Sophie;Martin, Etienne;El Kouri, Claude;Escande, Anne;Rosello, Alvar;Magne, Nicolas;Schlurmann, Friederike;Priou, Frank;Chand-Fouche, Marie-Eve;Freixa, Salvador Villà;Jamaluddin, Muhammad;Rieger, Isabelle;Bossi, Alberto","Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.","Lancet (London, England)","England","eng","Clinical Trial, Phase III","","Androgen Antagonists;Androgens;Androstenes;Antineoplastic Combined Chemotherapy Protocols;Castration;Docetaxel;Humans;Hypertension;Male;Prednisone;Prostatic Neoplasms","Androgen Antagonists;Androgens;Androstenes;Antineoplastic Combined Chemotherapy Protocols;Castration;Docetaxel;Humans;Hypertension;Male;Prednisone;Prostatic Neoplasms","Current standard of care for metastatic castration-sensitive prostate cancer supplements androgen deprivation therapy with either docetaxel, second-generation hormonal therapy, or radiotherapy. We aimed to evaluate the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care. We conducted an open-label, randomised, phase 3 study with a 2 × 2 factorial design (PEACE-1) at 77 hospitals across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland. Eligible patients were male, aged 18 years or older, with histologically confirmed or cytologically confirmed de novo metastatic prostate adenocarcinoma, and an Eastern Cooperative Oncology Group performance status of 0-1 (or 2 due to bone pain). Participants were randomly assigned (1:1:1:1) to standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/m  once every 3 weeks), standard of care plus radiotherapy, standard of care plus abiraterone (oral 1000 mg abiraterone once daily plus oral 5 mg prednisone twice daily), or standard of care plus radiotherapy plus abiraterone. Neither the investigators nor the patients were masked to treatment allocation. The coprimary endpoints were radiographic progression-free survival and overall survival. Abiraterone efficacy was first assessed in the overall population and then in the population who received androgen deprivation therapy with docetaxel as standard of care (population of interest). This study is ongoing and is registered with ClinicalTrials.gov, NCT01957436. Between Nov 27, 2013, and Dec 20, 2018, 1173 patients were enrolled (one patient subsequently withdrew consent for analysis of his data) and assigned to receive standard of care (n=296), standard of care plus radiotherapy (n=293), standard of care plus abiraterone (n=292), or standard of care plus radiotherapy plus abiraterone (n=291). Median follow-up was 3·5 years (IQR 2·8-4·6) for radiographic progression-free survival and 4·4 years (3·5-5·4) for overall survival. Adjusted Cox regression modelling revealed no interaction between abiraterone and radiotherapy, enabling the pooled analysis of abiraterone efficacy. In the overall population, patients assigned to receive abiraterone (n=583) had longer radiographic progression-free survival (hazard ratio [HR] 0·54, 99·9% CI 0·41-0·71; p<0·0001) and overall survival (0·82, 95·1% CI 0·69-0·98; p=0·030) than patients who did not receive abiraterone (n=589). In the androgen deprivation therapy with docetaxel population (n=355 in both with abiraterone and without abiraterone groups), the HRs were consistent (radiographic progression-free survival 0·50, 99·9% CI 0·34-0·71; p<0·0001; overall survival 0·75, 95·1% CI 0·59-0·95; p=0·017). In the androgen deprivation therapy with docetaxel population, grade 3 or worse adverse events occurred in 217 (63%) of 347 patients who received abiraterone and 181 (52%) of 350 who did not; hypertension had the largest difference in occurrence (76 [22%] patients and 45 [13%], respectively). Addition of abiraterone to androgen deprivation therapy plus docetaxel did not increase the rates of neutropenia, febrile neutropenia, fatigue, or neuropathy compared with androgen deprivation therapy plus docetaxel alone. Combining androgen deprivation therapy, docetaxel, and abiraterone in de novo metastatic castration-sensitive prostate cancer improved overall survival and radiographic progression-free survival with a modest increase in toxicity, mostly hypertension. This triplet therapy could become a standard of care for these patients. Janssen-Cilag, Ipsen, Sanofi, and the French Government.","Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif;Department of Biostatistics and Epidemiology, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, Ligue Contre le Cancer, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.;Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Institut Bergonié 229 cours de l'Argonne, Bordeaux, France.;Cancer Trials Ireland, St Vincent's University Hospital, Dublin, Ireland.;Centre Léon Bérard, Lyon, France.;Clinique Universitaire St Luc, Brussels, Belgium.;Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France.;Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Centre Azureen de Cancerologie, Mougins, France.;Amethyst Radiotherapy Center, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.;Institut Paoli-Calmettes, Aix-Marseille Université, CRCM, Marseille, France.;San Camillo Forlanini Hospitals, Rome, Italy.;Clinique Sainte Marguerite, Hyeres, France.;Clinique Pasteur, Brest, France.;Centre François Baclesse, Caen, France.;CHU Jean Minjoz, Besancon, France.;Clinique Pasteur, Toulouse, France.;IUCT-Oncopole, Toulouse, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancerologie de l'Ouest, Angers, France.;Centre Georges-François Leclerc, Dijon, France.;Centre Catherine de Sienne, Nantes, France.;Strasbourg Oncologie Libérale, Strasbourg, France.;Institut Català d'Oncologia, Hospital Universitari Josep Trueta, Girona, Spain.;Institut de Cancérologie Lucien Neuwirth, St Priest en Jarez, France.;CHIC Quimper, Quimper, France.;CHD Vendée, La Roche sur Yon, France.;Centre Antoine Lacassagne, Nice, France.;Institut Català d'Oncologia, Cap de Servei Oncologia Radioteràpica, Hospital Universitari Germans Trias, Badalona, Catalunya, Spain.;Cork University Hospital, Cork, Ireland.;Unicancer, Paris, France.;Department of Radiotherapy, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.","NA",0,"1474-547X","Lancet","Lancet",2022,"2022","399","10.1016/S0140-6736(22)00367-1","1695-1707","","","35405085","35405085","PUBMED","Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif;Department of Biostatistics and Epidemiology, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France; Oncostat U1018, Inserm, Ligue Contre le Cancer, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.;Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.;Institut Bergonié 229 cours de l'Argonne, Bordeaux, France.;Cancer Trials Ireland, St Vincent's University Hospital, Dublin, Ireland.;Centre Léon Bérard, Lyon, France.;Clinique Universitaire St Luc, Brussels, Belgium.;Institut de Cancérologie de l'Ouest, René Gauducheau, Saint-Herblain, France.;Centre Pluridisciplinaire d'Oncologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.;Centre Azureen de Cancerologie, Mougins, France.;Amethyst Radiotherapy Center, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.;Institut Paoli-Calmettes, Aix-Marseille Université, CRCM, Marseille, France.;San Camillo Forlanini Hospitals, Rome, Italy.;Clinique Sainte Marguerite, Hyeres, France.;Clinique Pasteur, Brest, France.;Centre François Baclesse, Caen, France.;CHU Jean Minjoz, Besancon, France.;Clinique Pasteur, Toulouse, France.;IUCT-Oncopole, Toulouse, France.;Centre Eugène Marquis, Rennes, France.;Institut de Cancerologie de l'Ouest, Angers, France.;Centre Georges-François Leclerc, Dijon, France.;Centre Catherine de Sienne, Nantes, France.;Strasbourg Oncologie Libérale, Strasbourg, France.;Institut Català d'Oncologia, Hospital Universitari Josep Trueta, Girona, Spain.;Institut de Cancérologie Lucien Neuwirth, St Priest en Jarez, France.;CHIC Quimper, Quimper, France.;CHD Vendée, La Roche sur Yon, France.;Centre Antoine Lacassagne, Nice, France.;Institut Català d'Oncologia, Cap de Servei Oncologia Radioteràpica, Hospital Universitari Germans Trias, Badalona, Catalunya, Spain.;Cork University Hospital, Cork, Ireland.;Unicancer, Paris, France.;Department of Radiotherapy, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France."
"277","Gargadennec T;Oilleau JF;Rozec B;Nesseler N;Lasocki S;Futier E;Amour J;Durand M;Bougle A;Kerforne T;Consigny M;Eddi D;Huet O","Gargadennec, Thomas;Oilleau, Jean-Ferréol;Rozec, Bertrand;Nesseler, Nicolas;Lasocki, Sigismond;Futier, Emmanuel;Amour, Julien;Durand, Michel;Bougle, Adrien;Kerforne, Thomas;Consigny, Maëlys;Eddi, Dauphou;Huet, Olivier","Dexmedetomidine after Cardiac Surgery for Prevention of Delirium (EXACTUM) trial protocol: a multicentre randomised, double-blind, placebo-controlled trial.","BMJ open","England","eng","Clinical Trial Protocol","Cardiac surgery;Delirium;Dexmedetomidine;Intensive care","Aged;Cardiac Surgical Procedures;Delirium;Dexmedetomidine;Double-Blind Method;Humans;Multicenter Studies as Topic;Quality of Life;Randomized Controlled Trials as Topic","Aged;Cardiac Surgical Procedures;Delirium;Dexmedetomidine;Double-Blind Method;Humans;Multicenter Studies as Topic;Quality of Life;Randomized Controlled Trials as Topic","Incidence of delirium after cardiac surgery remains high and delirium has a significant burden on short-term and long-term outcomes. Multiple causes can trigger delirium occurence, and it has been hypothesised that sleep disturbances can be one of them. Preserving the circadian rhythm with overnight infusion of low-dose dexmedetomidine has been shown to lower the occurrence of delirium in older patients after non-cardiac surgery. However, these results remain controversial. The aim of this study was to demonstrate the usefulness of sleep induction by overnight infusion of dexmedetomidine to prevent delirium after cardiac surgery. Dexmedetomidine after Cardiac Surgery for Prevention of Delirium is an investigator-initiated, randomised, placebo-controlled, parallel, multicentre, double-blinded trial. Nine centres in France will participate in the study. Patients aged 65 years or older and undergoing cardiac surgery will be enrolled in the study. The intervention starts on day 0 (the day of surgery) until intensive care unit (ICU) discharge; the treatment is administered from 20:00 to 08:00 on the next day. Infusion rate is modified by the treating nurse or the clinician with an objective of Richmond Agitation and Sedation Scale score from -1 to +1. The primary outcome is delirium occurrence evaluated with confusion assessment method for the ICU two times per day during 7 days following surgery. Secondary outcomes include incidence of agitation related events, self-evaluated quality of sleep, cognitive evaluation 3 months after surgery and quality of life 3 months after surgery. The sample size is 348. The study was approved for all participating centers by the French Central Ethics Committee (Comité de Protection des Personnes Ile de France VI, registration number 2018-000850-22). The results will be submitted for publication in peer-reviewed journals. NCT03477344.","Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest;Université de Bretagne Occidentale, Brest, France.;Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest, France.;Université de Bretagne Occidentale, Brest, France.;Intensive Care Unit, Anesthesia and Critical Care Department, Hôpital Laennec, University Hospital Centre Nantes, Nantes, France.;CNRS, INSERM, l'institut du thorax, Université de Nantes, Nantes, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département Anesthésie Réanimation, CHU Angers, Angers, France.;Université Angers Faculté des Sciences, Angers, France.;Département de Médecine Périopératoire, Anesthésie Réanimation, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CNRS, Inserm U-1103, Université Clermont Auvergne, Clermont-Ferrand, France.;Institute of Perfusion, Critical Care Medicine and Anesthesiology in Cardiothoracic Surgery (IPRA), Jacques Cartier Private Hospital, Massy, France.;Pôle Anesthésie-Réanimation, CHU Grenoble Alpes, Grenoble, France.;Sorbonne Universite, Paris, France.;Department of Anesthesiology and Critical Care Medicine, Institute of Cardiology, GRC 29, Pitié-Salpêtrière Hospital, APHP, Paris, France.;Faculté de Médecine, INSERM U1082, Ischémie Reperfusion en Transplantation Modélisation et Innovations Thérapeutiques, Université de Poitiers, Poitiers, France.;Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU Poitiers, Poitiers, France.;Direction de la Recherche Clinique et de l'Innovation (DRCI), CHU Brest, Brest, France.;Direction de la Recherche Clinique et de l'Innovation (DRCI), CHU Brest, Brest, France.;Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest, France.;Université de Bretagne Occidentale, Brest, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2022,"2022","12","10.1136/bmjopen-2021-058968","e058968","","","35396310","35396310","PUBMED","Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest;Université de Bretagne Occidentale, Brest, France.;Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest, France.;Université de Bretagne Occidentale, Brest, France.;Intensive Care Unit, Anesthesia and Critical Care Department, Hôpital Laennec, University Hospital Centre Nantes, Nantes, France.;CNRS, INSERM, l'institut du thorax, Université de Nantes, Nantes, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département Anesthésie Réanimation, CHU Angers, Angers, France.;Université Angers Faculté des Sciences, Angers, France.;Département de Médecine Périopératoire, Anesthésie Réanimation, Hôpital Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CNRS, Inserm U-1103, Université Clermont Auvergne, Clermont-Ferrand, France.;Institute of Perfusion, Critical Care Medicine and Anesthesiology in Cardiothoracic Surgery (IPRA), Jacques Cartier Private Hospital, Massy, France.;Pôle Anesthésie-Réanimation, CHU Grenoble Alpes, Grenoble, France.;Sorbonne Universite, Paris, France.;Department of Anesthesiology and Critical Care Medicine, Institute of Cardiology, GRC 29, Pitié-Salpêtrière Hospital, APHP, Paris, France.;Faculté de Médecine, INSERM U1082, Ischémie Reperfusion en Transplantation Modélisation et Innovations Thérapeutiques, Université de Poitiers, Poitiers, France.;Service d'Anesthésie, Réanimation et Médecine Péri-Opératoire, CHU Poitiers, Poitiers, France.;Direction de la Recherche Clinique et de l'Innovation (DRCI), CHU Brest, Brest, France.;Direction de la Recherche Clinique et de l'Innovation (DRCI), CHU Brest, Brest, France.;Département d'Anesthésie et Réanimation Chirurgicale, CHU Brest, Brest, France.;Université de Bretagne Occidentale, Brest, France."
"278","Henno S;Jeanne C;Rouge TM;Genestie C;Treilleux I;Croce S;Just PA;Le Frere-Belda MA;Guinaudeau E;Penault-Llorca F;Arnould L;Mery-Lamarche E;Leroux A;Lemaire AS;Averous G;Renaud O;Charafe-Jauffret E;Bonneau C;Leaha C;Ray-Coquard I;Devouassoux-Shisheboran M","Henno, S;Jeanne, C;Rouge, T De La Motte;Genestie, C;Treilleux, I;Croce, S;Just, P A;Le Frere-Belda, M A;Guinaudeau, E;Penault-Llorca, F;Arnould, L;Mery-Lamarche, E;Leroux, A;Lemaire, A S;Averous, G;Renaud, O;Charafe-Jauffret, E;Bonneau, C;Leaha, C;Ray-Coquard, I;Devouassoux-Shisheboran, M","Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG).","Gynecologic oncology","United States","eng","Journal Article","Concordance evaluation;Network;Ovarian tumor;Pathological discordance;Pathological review;Rare ovarian tumor","Female;Humans;Ovarian Neoplasms;Referral and Consultation;Sex Cord-Gonadal Stromal Tumors","Female;Humans;Ovarian Neoplasms;Referral and Consultation;Sex Cord-Gonadal Stromal Tumors","Since 2010, the network of rare malignant tumors of the ovary (TMRG) was developed to optimize the management of patients, also allowing a histological second opinion of rare ovarian tumors. The aim of this work was to study the contribution of second opinion to improve histological diagnostic accuracy on ovarian rare malignant tumors included in the TMRG database. Histological data of patients diagnosed with a rare ovarian tumor included in TMRG network over a one-year period (2018) were collected. Initial diagnoses were compared with second opinion from national gynecological pathologist experts. The modalities of histological second opinion requests were studied, as well as the histological characteristics of the tumors. The discordances were classified as minor (if the modification of histological diagnosis did not change patient management) and major (if the patient management can be modified). Of 1185 included patients, 937 matched the inclusion criteria. Full concordance between primary diagnosis and expert second opinion was reached in 611 cases (65,3%), minor discordance was seen in 114 (12,2%) and major discordance in 209 (22,3%) of cases. In systematic review requested by the network, 26% (n = 137) of cases were reported with a change in histological diagnosis, while the change concerned 44% (n = 186) of cases for a second opinion spontaneously requested by the initial pathologist. The discrepancies concerned all categories of ovarian tumors, with a majority of mucinous tumors (43% of major discordances), followed by stromal and sex-cord tumors (13.8% of major discordances) and clear cell tumors (12,4% of major discordances). This analysis confirms the diagnostic difficulty of ovarian tumors, due to their rarity and morphological heterogeneity. French pathologists are aware of these difficulties and spontaneously refer ovarian tumors with unusual histology for a second opinion and collaborate with rare tumor networks for systematic review.","Service d'Anatomie Pathologique, CHU Pontchaillou, Rennes;Service d'Anatomie Pathologique, Centre François Baclesse, Caen, France.;Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Service d'Anatomie Pathologique, Institut Gustave Roussy, Villejuif, France.;Service d'Anatomie Pathologique, Centre Léon Bérard, Lyon, France.;Service d'Anatomie Pathologique, Centre Jean Perrin, Clermont-Ferrand, France.;Service d'Anatomie Pathologique, Hôpital Cochin, Paris, France.;Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou, Paris, France.;Institut d'Histopathologie - IHP, Nantes, France.;Service d'Anatomie Pathologique, Centre Jean Perrin, Clermont-Ferrand.;Service d'Anatomie Pathologique, Centre Georges François Leclerc, Dijon, France.;Service d'Anatomie Pathologique, Institut Claudius Rigaud, Toulouse, France.;Service d'Anatomie Pathologique, Institut de cancérologie de Lorraine, Nancy, France.;Service d'Anatomie Pathologique, Centre Oscar Lambret, Lille, France.;Service d'Anatomie Pathologique, CHU, Strasbourg, France.;Service d'Anatomie Pathologique, CHU, Poitiers, France.;Service d'Anatomie Pathologique, Institut Paoli-Calmettes, Marseille, France.;Service d'Anatomie Pathologique, Centre hospitalier, Orléans, France.;Service d'Anatomie Pathologique, Centre Val d'Aurelles, Montpellier, France.;Département d'Oncologie, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.;Service d'Anatomie Pathologique, CHU Lyon Sud & Université Claude Bernard Lyon I, Lyon, France.","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2022,"2022","165","10.1016/j.ygyno.2022.03.019","637-641","","","35393217","35393217","PUBMED","Service d'Anatomie Pathologique, CHU Pontchaillou, Rennes;Service d'Anatomie Pathologique, Centre François Baclesse, Caen, France.;Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Service d'Anatomie Pathologique, Institut Gustave Roussy, Villejuif, France.;Service d'Anatomie Pathologique, Centre Léon Bérard, Lyon, France.;Service d'Anatomie Pathologique, Centre Jean Perrin, Clermont-Ferrand, France.;Service d'Anatomie Pathologique, Hôpital Cochin, Paris, France.;Service d'Anatomie Pathologique, Hôpital Européen Georges Pompidou, Paris, France.;Institut d'Histopathologie - IHP, Nantes, France.;Service d'Anatomie Pathologique, Centre Jean Perrin, Clermont-Ferrand.;Service d'Anatomie Pathologique, Centre Georges François Leclerc, Dijon, France.;Service d'Anatomie Pathologique, Institut Claudius Rigaud, Toulouse, France.;Service d'Anatomie Pathologique, Institut de cancérologie de Lorraine, Nancy, France.;Service d'Anatomie Pathologique, Centre Oscar Lambret, Lille, France.;Service d'Anatomie Pathologique, CHU, Strasbourg, France.;Service d'Anatomie Pathologique, CHU, Poitiers, France.;Service d'Anatomie Pathologique, Institut Paoli-Calmettes, Marseille, France.;Service d'Anatomie Pathologique, Centre hospitalier, Orléans, France.;Service d'Anatomie Pathologique, Centre Val d'Aurelles, Montpellier, France.;Département d'Oncologie, Centre Léon Bérard & Université Claude Bernard Lyon I, Lyon, France.;Service d'Anatomie Pathologique, CHU Lyon Sud & Université Claude Bernard Lyon I, Lyon, France."
"279","Vano YA;Elaidi R;Bennamoun M;Chevreau C;Borchiellini D;Pannier D;Maillet D;Gross-Goupil M;Tournigand C;Laguerre B;Barthélémy P;Coquan E;Gravis G;Houede N;Cancel M;Huillard O;Beuzeboc P;Fournier L;Méjean A;Cathelineau X;Doumerc N;Paparel P;Bernhard JC;de la Taille A;Bensalah K;Tricard T;Waeckel T;Pignot G;Braychenko E;Caruso S;Sun CM;Verkarre V;Lacroix G;Moreira M;Meylan M;Bougouïn A;Phan L;Thibault-Carpentier C;Zucman-Rossi J;Fridman WH;Sautès-Fridman C;Oudard S","Vano, Yann-Alexandre;Elaidi, Réza;Bennamoun, Mostefa;Chevreau, Christine;Borchiellini, Delphine;Pannier, Diane;Maillet, Denis;Gross-Goupil, Marine;Tournigand, Christophe;Laguerre, Brigitte;Barthélémy, Philippe;Coquan, Elodie;Gravis, Gwenaëlle;Houede, Nadine;Cancel, Mathilde;Huillard, Olivier;Beuzeboc, Philippe;Fournier, Laure;Méjean, Arnaud;Cathelineau, Xavier;Doumerc, Nicolas;Paparel, Philippe;Bernhard, Jean-Christophe;de la Taille, Alexandre;Bensalah, Karim;Tricard, Thibault;Waeckel, Thibaut;Pignot, Géraldine;Braychenko, Elena;Caruso, Stefano;Sun, Cheng-Ming;Verkarre, Virginie;Lacroix, Guillaume;Moreira, Marco;Meylan, Maxime;Bougouïn, Antoine;Phan, Letuan;Thibault-Carpentier, Christelle;Zucman-Rossi, Jessica;Fridman, Wolf Herman;Sautès-Fridman, Catherine;Oudard, Stéphane","Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase II","","Angiogenesis Inhibitors;Antineoplastic Combined Chemotherapy Protocols;Biomarkers;Carcinoma, Renal Cell;Female;Humans;Ipilimumab;Lipase;Male;Neoplasm Staging;Nivolumab;Prospective Studies;Protein Kinase Inhibitors;Sunitinib;Tumor Microenvironment","Angiogenesis Inhibitors;Antineoplastic Combined Chemotherapy Protocols;Biomarkers;Carcinoma, Renal Cell;Female;Humans;Ipilimumab;Lipase;Male;Neoplasm Staging;Nivolumab;Prospective Studies;Protein Kinase Inhibitors;Sunitinib;Tumor Microenvironment","We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic clear-cell renal cell carcinoma. Efficacy profiles might differ with nivolumab and nivolumab-ipilimumab. We therefore aimed to evaluate treatment efficacy and tolerability of nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors (VEGFR-TKIs) in patients according to tumour molecular groups. This biomarker-driven, open-label, non-comparative, randomised, phase 2 trial included patients from 15 university hospitals or expert cancer centres in France. Eligible patients were aged 18 years or older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had previously untreated metastatic clear-cell renal cell carcinoma. Patients were randomly assigned (1:1) using permuted blocks of varying sizes to receive either nivolumab or nivolumab-ipilimumab (ccrcc1 and ccrcc4 groups), or either a VEGFR-TKI or nivolumab-ipilimumab (ccrcc2 and ccrcc3 groups). Patients assigned to nivolumab-ipilimumab received intravenous nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses followed by intravenous nivolumab 240 mg every 2 weeks. Patients assigned to nivolumab received intravenous nivolumab 240 mg every 2 weeks. Patients assigned to VEGFR-TKIs received oral sunitinib (50 mg/day for 4 weeks every 6 weeks) or oral pazopanib (800 mg daily continuously). The primary endpoint was the objective response rate by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1. The primary endpoint and safety were assessed in the population who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT02960906, and with the EU Clinical Trials Register, EudraCT 2016-003099-28, and is closed to enrolment. Between June 28, 2017, and July 18, 2019, 303 patients were screened for eligibility, 202 of whom were randomly assigned to treatment (61 to nivolumab, 101 to nivolumab-ipilimumab, 40 to a VEGFR-TKI). In the nivolumab group, two patients were excluded due to a serious adverse event before the first study dose and one patient was excluded from analyses due to incorrect diagnosis. Median follow-up was 18·0 months (IQR 17·6-18·4). In the ccrcc1 group, objective responses were seen in 12 (29%; 95% CI 16-45) of 42 patients with nivolumab and 16 (39%; 24-55) of 41 patients with nivolumab-ipilimumab (odds ratio [OR] 0·63 [95% CI 0·25-1·56]). In the ccrcc4 group, objective responses were seen in seven (44%; 95% CI 20-70) of 16 patients with nivolumab and nine (50% 26-74) of 18 patients with nivolumab-ipilimumab (OR 0·78 [95% CI 0·20-3·01]). In the ccrcc2 group, objective responses were seen in 18 (50%; 95% CI 33-67) of 36 patients with a VEGFR-TKI and 19 (51%; 34-68) of 37 patients with nivolumab-ipilimumab (OR 0·95 [95% CI 0·38-2·37]). In the ccrcc3 group, no objective responses were seen in the four patients who received a VEGFR-TKI, and in one (20%; 95% CI 1-72) of five patients who received nivolumab-ipilimumab. The most common treatment-related grade 3-4 adverse events were hepatic failure and lipase increase (two [3%] of 58 for both) with nivolumab, lipase increase and hepatobiliary disorders (six [6%] of 101 for both) with nivolumab-ipilimumab, and hypertension (six [15%] of 40) with a VEGFR-TKI. Serious treatment-related adverse events occurred in two (3%) patients in the nivolumab group, 38 (38%) in the nivolumab-ipilimumab group, and ten (25%) patients in the VEGFR-TKI group. Three deaths were treatment-related: one due to fulminant hepatitis with nivolumab-ipilimumab, one death from heart failure with sunitinib, and one due to thrombotic microangiopathy with sunitinib. We demonstrate the feasibility and positive effect of a prospective patient selection based on tumour molecular phenotype to choose the most efficacious treatment between nivolumab with or without ipilimumab and a VEGFR-TKI in the first-line treatment of metastatic clear-cell renal cell carcinoma. Bristol Myers Squibb, ARTIC.","Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Department of MedicalOncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux, France.;INSERM, IMRB, F-94010 Creteil, France; Department of Medical Oncology, Hôpital Henri-Mondor, AP-HP Université de Paris Est, Créteil France.;Department of Medical Oncology, Centre Eugene-Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre de Lutte Contre le Cancer François Baclesse, Caen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.;Department of Medical Oncology, Institut de cancérologie du Gard, Nimes, Montpellier University, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Bretonneau, Tours, France.;Department of Medical Oncology, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Medical Oncology, Hôpital Foch, Suresnes, France.;Department of Radiology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Urology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Urology, Institut Mutualiste Montsouris, Paris, France.;Urology and Transplantation Department, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France.;Department of Urology, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint-André, Bordeaux, France.;Department of Urology, Hôpital Henri-Mondor, AP-HP Université de Paris Est, Créteil France.;Department of Urology, Centre Eugene-Marquis, Rennes, France.;Department of Surgical Oncology, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Urology and Transplantation Department, CHU de Caen, Avenue de Côte de Nacre, Caen, France.;Department of Surgical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Department of Pathology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;IGBMC-CNRS UMR 7104-Inserm U 1258, Université de Strasbourg, Illkirch, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; INSERM U970, PARCC, Paris, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2022,"2022","23","10.1016/S1470-2045(22)00128-0","612-624","","","35390339","35390339","PUBMED","Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France.;Department of MedicalOncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, IMMUCARE, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux, France.;INSERM, IMRB, F-94010 Creteil, France; Department of Medical Oncology, Hôpital Henri-Mondor, AP-HP Université de Paris Est, Créteil France.;Department of Medical Oncology, Centre Eugene-Marquis, Rennes, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, Centre de Lutte Contre le Cancer François Baclesse, Caen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.;Department of Medical Oncology, Institut de cancérologie du Gard, Nimes, Montpellier University, France.;Department of Medical Oncology, Centre Hospitalier Universitaire Bretonneau, Tours, France.;Department of Medical Oncology, Hôpital Cochin, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Medical Oncology, Hôpital Foch, Suresnes, France.;Department of Radiology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Urology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Department of Urology, Institut Mutualiste Montsouris, Paris, France.;Urology and Transplantation Department, Centre Hospitalier Universitaire de Toulouse, Hôpital Rangueil, Toulouse, France.;Department of Urology, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices de Lyon, Pierre-Bénite, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux - Hôpital Saint-André, Bordeaux, France.;Department of Urology, Hôpital Henri-Mondor, AP-HP Université de Paris Est, Créteil France.;Department of Urology, Centre Eugene-Marquis, Rennes, France.;Department of Surgical Oncology, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Urology and Transplantation Department, CHU de Caen, Avenue de Côte de Nacre, Caen, France.;Department of Surgical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, CRCM, Marseille, France.;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Department of Pathology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;ARTIC-Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.;IGBMC-CNRS UMR 7104-Inserm U 1258, Université de Strasbourg, Illkirch, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris Cité, Sorbonne Université, Paris, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France; INSERM U970, PARCC, Paris, France."
"280","Kudo M;Finn RS;Edeline J;Cattan S;Ogasawara S;Palmer DH;Verslype C;Zagonel V;Fartoux L;Vogel A;Sarker D;Verset G;Chan SL;Knox J;Daniele B;Yau T;Gurary EB;Siegel AB;Wang A;Cheng AL;Zhu AX","Kudo, Masatoshi;Finn, Richard S;Edeline, Julien;Cattan, Stéphane;Ogasawara, Sadahisa;Palmer, Daniel H;Verslype, Chris;Zagonel, Vittorina;Fartoux, Laetitia;Vogel, Arndt;Sarker, Debashis;Verset, Gontran;Chan, Stephen L;Knox, Jennifer;Daniele, Bruno;Yau, Thomas;Gurary, Ellen B;Siegel, Abby B;Wang, Anran;Cheng, Ann-Lii;Zhu, Andrew X","Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.","European journal of cancer (Oxford, England : 1990)","England","eng","Clinical Trial, Phase II","Advanced hepatocellular carcinoma;Anti-PD-1;Long-term treatment;Pembrolizumab","Adult;Antibodies, Monoclonal, Humanized;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Sorafenib","Adult;Antibodies, Monoclonal, Humanized;Carcinoma, Hepatocellular;Humans;Liver Neoplasms;Sorafenib","Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE-224. Longer-term efficacy and safety after ∼2.5 years of additional follow-up are reported. Adults with confirmed hepatocellular carcinoma who experienced progression after or intolerance to sorafenib treatment received pembrolizumab 200 mg every 3 weeks for ≤35 cycles or until confirmed progression, unacceptable toxicity, withdrawal of consent or investigator decision. The primary end-point was objective response rate assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumours v1.1. The secondary end-points included duration of response, disease control rate, time to progression, progression-free survival, overall survival and adverse events. Efficacy and safety were assessed in 104 patients. The median time from first dose to data cutoff was 45.1 months (range, 41.3-49.3). Objective response rate was 18.3% (95% CI: 11.4-27.1), and median duration of response was 21.0 months (range, 3.1 to 39.5+). Disease control rate was 61.5%, and median time to progression was 4.8 months (95% CI: 3.9-7.0). Median progression-free survival was 4.9 months (95% CI: 3.5-6.7) and median overall survival was 13.2 months (95% CI: 9.7-15.3). Of 104 patients, 76 (73.1%) patients reported treatment-related adverse events; most were low grade in severity (grade 3-4, n = 26 [25.0%]; grade 5, n = 1 [1.0%]). Immune-mediated hepatitis occurred in 3 patients (all grade 3). No viral-induced hepatitis flares occurred. After ∼2.5 years of additional follow-up, pembrolizumab continued to provide durable anti-tumour activity and no new safety concerns were identified. NCT02702414.","Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka;University of California, 10833 Le Conte Avenue, Los Angeles, CA;Centre Eugene Marquis, Avenue de la Bataille Flandres-Dunkerque, Rennes;Hôpital Huriez, 2, Oscar Lambret Avenue, Lille;Chiba University Graduate School of Medicine, Inohana Campus 1-8-1, Inohana, Chuo-ku, Chiba;CR UK Liverpool Experimental Cancer Medicine Centre, 5 Pembroke Place, Liverpool, UK; Clatterbridge Cancer Centre, Liverpool;University Hospitals Leuven, Herestraat 49, Leuven;Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata, 64, Padua;The Hospital Group Saint Joseph, 47-83 Boulevard de l'Hôpital, Paris;Medizinische Hochschule, Carl-Neuberg-Strasse 1, Hannover;King's College London, Strand, London;Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels;State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Shatin, LG, LKS Specialist Clinic (North Wing), Hong Kong;Princess Margaret Cancer Centre and University of Toronto, 610 University Avenue, Toronto, Ontario;Ospedale del Mare, Via Enrico Russo, Napoli;University of Hong Kong, Queen Mary Hospital, Hong Kong, 102 Pok Fu Lam Rd, Hong Kong;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;National Taiwan University Cancer Center, No. 57, Lane 155, Keelung 3rd Road, Taipei;Massachusetts General Hospital Cancer Center and Harvard Medical School, 55 Fruit Street, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","167","10.1016/j.ejca.2022.02.009","1-12","","","35364421","35364421","PUBMED","Kindai University Faculty of Medicine, 377-2, Ohno-Higashi, Osaka-Sayama, Osaka;University of California, 10833 Le Conte Avenue, Los Angeles, CA;Centre Eugene Marquis, Avenue de la Bataille Flandres-Dunkerque, Rennes;Hôpital Huriez, 2, Oscar Lambret Avenue, Lille;Chiba University Graduate School of Medicine, Inohana Campus 1-8-1, Inohana, Chuo-ku, Chiba;CR UK Liverpool Experimental Cancer Medicine Centre, 5 Pembroke Place, Liverpool, UK; Clatterbridge Cancer Centre, Liverpool;University Hospitals Leuven, Herestraat 49, Leuven;Istituto Oncologico Veneto IOV-IRCCS, Via Gattamelata, 64, Padua;The Hospital Group Saint Joseph, 47-83 Boulevard de l'Hôpital, Paris;Medizinische Hochschule, Carl-Neuberg-Strasse 1, Hannover;King's College London, Strand, London;Erasme Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels;State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Shatin, LG, LKS Specialist Clinic (North Wing), Hong Kong;Princess Margaret Cancer Centre and University of Toronto, 610 University Avenue, Toronto, Ontario;Ospedale del Mare, Via Enrico Russo, Napoli;University of Hong Kong, Queen Mary Hospital, Hong Kong, 102 Pok Fu Lam Rd, Hong Kong;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ;National Taiwan University Cancer Center, No. 57, Lane 155, Keelung 3rd Road, Taipei;Massachusetts General Hospital Cancer Center and Harvard Medical School, 55 Fruit Street, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai"
"281","Brulé N;Canet E;Péré M;Feuillet F;Hourmant M;Asehnoune K;Rozec B;Duveau A;Dube L;Pierrot M;Humbert S;Tirot P;Boyer JM;Martin-Lefevre L;Labadie F;Robert R;Benard T;Kerforne T;Thierry A;Lesieur O;Vincent JF;Lesouhaitier M;Larmet R;Vigneau C;Goepp A;Bouju P;Quentin C;Egreteau PY;Huet O;Renault A;Le Meur Y;Venhard JC;Buchler M;Michel O;Voellmy MH;Herve F;Schnell D;Courte A;Glotz D;Amrouche L;Hazzan M;Kamar N;Moal V;Bourenne J;Le Quintrec-Donnette M;Morelon E;Boulain T;Grimbert P;Heng AE;Merville P;Garin A;Hiesse C;Fermier B;Mousson C;Guyot-Colosio C;Bouvier N;Rerolle JP;Durrbach A;Drouin S;Caillard S;Frimat L;Girerd S;Albano L;Rostaing L;Bertrand D;Hertig A;Westeel PF;Montini F;Delpierre E;Dorez D;Alamartine E;Ouisse C;Sebille V;Reignier J","Brulé, Noëlle;Canet, Emmanuel;Péré, Morgane;Feuillet, Fanny;Hourmant, Maryvonne;Asehnoune, Karim;Rozec, Bertrand;Duveau, Agnes;Dube, Laurent;Pierrot, Marc;Humbert, Stanislas;Tirot, Patrice;Boyer, Jean-Marc;Martin-Lefevre, Laurent;Labadie, François;Robert, René;Benard, Thierry;Kerforne, Thomas;Thierry, Antoine;Lesieur, Olivier;Vincent, Jean-François;Lesouhaitier, Mathieu;Larmet, Raphaelle;Vigneau, Cecile;Goepp, Angelique;Bouju, Pierre;Quentin, Charlotte;Egreteau, Pierre-Yves;Huet, Olivier;Renault, Anne;Le Meur, Yannick;Venhard, Jean-Christophe;Buchler, Mathias;Michel, Olivier;Voellmy, Marie-Hélène;Herve, Fabien;Schnell, David;Courte, Anne;Glotz, Denis;Amrouche, Lucile;Hazzan, Marc;Kamar, Nassim;Moal, Valerie;Bourenne, Jeremy;Le Quintrec-Donnette, Moglie;Morelon, Emmanuel;Boulain, Thierry;Grimbert, Philippe;Heng, Anne Elisabeth;Merville, Pierre;Garin, Aude;Hiesse, Christian;Fermier, Brice;Mousson, Christiane;Guyot-Colosio, Charlotte;Bouvier, Nicolas;Rerolle, Jean-Philippe;Durrbach, Antoine;Drouin, Sarah;Caillard, Sophie;Frimat, Luc;Girerd, Sophie;Albano, Laetitia;Rostaing, Lionel;Bertrand, Dominique;Hertig, Alexandre;Westeel, Pierre-Francois;Montini, Florent;Delpierre, Eric;Dorez, Dider;Alamartine, Eric;Ouisse, Carole;Sebille, Veronique;Reignier, Jean","Impact of targeted hypothermia in expanded-criteria organ donors on recipient kidney-graft function: study protocol for a multicentre randomised controlled trial (HYPOREME).","BMJ open","England","eng","Clinical Trial Protocol","dialysis;intensive & critical care;renal transplantation","Graft Survival;Humans;Hypothermia;Kidney;Kidney Transplantation;Multicenter Studies as Topic;Randomized Controlled Trials as Topic;Tissue Donors;Transplants","Graft Survival;Humans;Hypothermia;Kidney;Kidney Transplantation;Multicenter Studies as Topic;Randomized Controlled Trials as Topic;Tissue Donors;Transplants","Expanded-criteria donors (ECDs) are used to reduce the shortage of kidneys for transplantation. However, kidneys from ECDs are associated with an increased risk of delayed graft function (DGF), a risk factor for allograft loss and mortality. HYPOREME will be a multicentre randomised controlled trial (RCT) comparing targeted hypothermia to normothermia in ECDs, in a country where the use of machine perfusion for organ storage is the standard of care. We hypothesise that hypothermia will decrease the incidence of DGF. HYPOREME is a multicentre RCT comparing the effect on kidney function in recipients of targeted hypothermia (34°C-35°C) and normothermia (36.5°C-37.5°C) in the ECDs. The temperature intervention starts from randomisation and is maintained until aortic clamping in the operating room. We aim to enrol 289 ECDs in order to analyse the kidney function of 516 recipients in the 53 participating centres. The primary outcome is the occurrence of DGF in kidney recipients, defined as a requirement for renal replacement therapy within 7 days after transplantation (not counting a single session for hyperkalemia during the first 24 hours). Secondary outcomes include the proportion of patients with individual organs transplanted in each group; the number of organs transplanted from each ECD and the vital status and kidney function of the recipients 7 days, 28 days, 3 months and 1 year after transplantation. An interim analysis is planned after the enrolment of 258 kidney recipients. The trial was approved by the ethics committee of the French Intensive Care Society (CE-SRLF-16-07) on 26 April 2016 and by the competent French authorities on 20 April 2016 (Comité de Protection des Personnes-TOURS-Région Centre-Ouest 1, registration #2016-S3). Findings will be published in peer-reviewed journals and presented during national and international scientific meetings. NCT03098706.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;INSERM SPHERE U1246 Methods for Patient-centered Outcomes and Health Research, Université de Nantes, Université de Tours, Nantes, PAYS-DE-LA-LOIRE, France.;Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation en Chirurgie Cardio-thoracique et Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Néphrologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Coordination des prélèvements d'organe, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier de Laval, Laval, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Departemental Les Oudairies, La Roche-sur-Yon, Pays de la Loire, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint Nazaire, Saint Nazaire, Pays de la Loire, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE Research Group, INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service de Réanimation Neurochirurgicale, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service d'Anesthésie-Réanimation Cardio-Thoracique, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service de Réanimation, Centre Hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation, Centre Hospitalier de Saintes, Saintes, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Réanimation, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France.;Service de Réanimation, Centre Hospitalier de Bretagne Sud, Lorient, Lorient, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, Bretagne, France.;Service de Réanimation Polyvalente, Centre Hospitalier des Pays de Morlaix, Morlaix, France.;Service de Réanimation Chirurgicale, Hôpital La Cavale Blanche, CHU de Brest, Brest, France.;Service de Médecine Intensive Réanimation, CHRU de Brest, Brest, Bretagne, France.;Service de Néphrologie, Hôpital La Cavale Blanche, CHU de Brest, Brest, France.;Coordination des prélèvements d'organes et de tissus, Pôle Anesthésie Réanimations, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Néphrologie, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Jacques Cœur, Bourges, Centre-Val de Loire, France.;Service de Coordination des prélèvements, Centre Hospitalier Jacques Cœur, Bourges, Centre-Val de Loire, France.;Service de Réanimation Polyvalente, Centre Hospitalier Intercommunal de Cornouaille, Quimper, France.;Service de Réanimation Polyvalente, Centre Hospitalier d'Angoulême, Angouleme, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint Brieuc, Saint Brieuc, Bretagne, France.;Service de Néphrologie, Hôpital Saint-Louis, Université de Paris, Assistance Publique -Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Hôpital Necker, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.;University of Lille, Inserm, CHU Lille, U1286-Infinite-Institute for Translational Research in Inflammation, CHRU de Lille, Lille, Hauts-de-France, France.;Département de Néphrologie et Transplantation d'organes, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Centre de Physiopathologie Toulouse Purpan, Inserm UMR 1043- CNRS 5282, Toulouse, France, Toulouse, Midi-Pyrénées, France.;Centre de Néphrologie et Transplantation Rénale, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hôpital Conception, Marseille, France.;Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, CHU La Timone 2, Marseille, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France.;Service d'Urologie et de Chirurgie de la Transplantation, Pôle Chirurgie, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orléans Hôpital de La Source, Orléans, France.;Service de Néphrologie et Transplantation, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, Créteil, France.;Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Nephrologie Transplantation Dialyse Aphérèses, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine-Limousin-Poitou, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Dreux, Dreux, France.;Service de Néphrologie, Hôpital Foch, Suresnes, Suresnes, France.;Service de Réanimation, Centre Hospitalier de Blois, Blois, Centre-Val de Loire, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Reims, Reims, Champagne-Ardenne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Service de Néphrologie, Hôpital Kremlin-Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.;Service Médico-Chirurgical de Transplantation Rénale, APHP Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, Île-de-France, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Nephrology Department, CHRU Nancy, Université de Lorraine, Nancy, France.;Service de Néphrologie et Transplantation, Hôpital Brabois, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble Alpes, Grenoble, Rhône-Alpes, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Service de Néphrologie, Hôpital Tenon, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Service de Réanimation, Centre Hospitalier Henri Duffaut, Avignon, France.;Service de Réanimation, Grand Hôpital de l'Est Francilien, Marne La vallée, France.;Service de Réanimation Polyvalente, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Néphrologie Dialyse et Transplantation Rénale, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, Rhône-Alpes, France.;Service de Médecine Intensive Réanimation, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;INSERM SPHERE U1246 Methods for Patient-centered Outcomes and Health Research, Université de Nantes, Université de Tours, Nantes, PAYS-DE-LA-LOIRE, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2022,"2022","12","10.1136/bmjopen-2021-052845","e052845","","","35351701","35351701","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;INSERM SPHERE U1246 Methods for Patient-centered Outcomes and Health Research, Université de Nantes, Université de Tours, Nantes, PAYS-DE-LA-LOIRE, France.;Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Réanimation en Chirurgie Cardio-thoracique et Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Néphrologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Coordination des prélèvements d'organe, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Cholet, Cholet, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier de Laval, Laval, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Departemental Les Oudairies, La Roche-sur-Yon, Pays de la Loire, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint Nazaire, Saint Nazaire, Pays de la Loire, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE Research Group, INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service de Réanimation Neurochirurgicale, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service d'Anesthésie-Réanimation Cardio-Thoracique, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Service de Réanimation, Centre Hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation, Centre Hospitalier de Saintes, Saintes, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service de Réanimation, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France.;Service de Réanimation, Centre Hospitalier de Bretagne Sud, Lorient, Lorient, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint-Malo, Saint-Malo, Bretagne, France.;Service de Réanimation Polyvalente, Centre Hospitalier des Pays de Morlaix, Morlaix, France.;Service de Réanimation Chirurgicale, Hôpital La Cavale Blanche, CHU de Brest, Brest, France.;Service de Médecine Intensive Réanimation, CHRU de Brest, Brest, Bretagne, France.;Service de Néphrologie, Hôpital La Cavale Blanche, CHU de Brest, Brest, France.;Coordination des prélèvements d'organes et de tissus, Pôle Anesthésie Réanimations, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Néphrologie, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Jacques Cœur, Bourges, Centre-Val de Loire, France.;Service de Coordination des prélèvements, Centre Hospitalier Jacques Cœur, Bourges, Centre-Val de Loire, France.;Service de Réanimation Polyvalente, Centre Hospitalier Intercommunal de Cornouaille, Quimper, France.;Service de Réanimation Polyvalente, Centre Hospitalier d'Angoulême, Angouleme, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Saint Brieuc, Saint Brieuc, Bretagne, France.;Service de Néphrologie, Hôpital Saint-Louis, Université de Paris, Assistance Publique -Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Hôpital Necker, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.;University of Lille, Inserm, CHU Lille, U1286-Infinite-Institute for Translational Research in Inflammation, CHRU de Lille, Lille, Hauts-de-France, France.;Département de Néphrologie et Transplantation d'organes, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Centre de Physiopathologie Toulouse Purpan, Inserm UMR 1043- CNRS 5282, Toulouse, France, Toulouse, Midi-Pyrénées, France.;Centre de Néphrologie et Transplantation Rénale, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hôpital Conception, Marseille, France.;Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, CHU La Timone 2, Marseille, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France.;Service d'Urologie et de Chirurgie de la Transplantation, Pôle Chirurgie, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orléans Hôpital de La Source, Orléans, France.;Service de Néphrologie et Transplantation, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, Créteil, France.;Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Nephrologie Transplantation Dialyse Aphérèses, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine-Limousin-Poitou, France.;Service de Réanimation Polyvalente, Centre Hospitalier de Dreux, Dreux, France.;Service de Néphrologie, Hôpital Foch, Suresnes, Suresnes, France.;Service de Réanimation, Centre Hospitalier de Blois, Blois, Centre-Val de Loire, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Reims, Reims, Champagne-Ardenne, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Caen, Caen, Basse-Normandie, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Service de Néphrologie, Hôpital Kremlin-Bicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre, France.;Service Médico-Chirurgical de Transplantation Rénale, APHP Sorbonne-Université, Hôpital Pitié-Salpêtrière, Paris, Île-de-France, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, Alsace, France.;Nephrology Department, CHRU Nancy, Université de Lorraine, Nancy, France.;Service de Néphrologie et Transplantation, Hôpital Brabois, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Service de Néphrologie et Transplantation, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Service de Néphrologie, Hémodialyse, Aphérèses et Transplantation Rénale, CHU Grenoble Alpes, Grenoble, Rhône-Alpes, France.;Service de Néphrologie, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Service de Néphrologie, Hôpital Tenon, Université de Paris, Assistance Publique-Hôpitaux de Paris, Paris, France.;Service de Néphrologie, Centre Hospitalier Universitaire d'Amiens, Amiens, France.;Service de Réanimation, Centre Hospitalier Henri Duffaut, Avignon, France.;Service de Réanimation, Grand Hôpital de l'Est Francilien, Marne La vallée, France.;Service de Réanimation Polyvalente, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Néphrologie Dialyse et Transplantation Rénale, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, Rhône-Alpes, France.;Service de Médecine Intensive Réanimation, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Direction de la Recherche, Plateforme de Méthodologie et Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;INSERM SPHERE U1246 Methods for Patient-centered Outcomes and Health Research, Université de Nantes, Université de Tours, Nantes, PAYS-DE-LA-LOIRE, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France."
"282","Louarn M;Chatonnet F;Garnier X;Fest T;Siegel A;Faron C;Dameron O","Louarn, Marine;Chatonnet, Fabrice;Garnier, Xavier;Fest, Thierry;Siegel, Anne;Faron, Catherine;Dameron, Olivier","Improving reusability along the data life cycle: a regulatory circuits case study.","Journal of biomedical semantics","England","eng","Journal Article","Bioinformatics;Dataset architecture;Linked Open Data;RDF named graphs;Reusability;SPARQL","Animals;Biological Science Disciplines;Databases, Factual;Humans;Life Cycle Stages;Metadata","Animals;Biological Science Disciplines;Databases, Factual;Humans;Life Cycle Stages;Metadata","In life sciences, there has been a long-standing effort of standardization and integration of reference datasets and databases. Despite these efforts, many studies data are provided using specific and non-standard formats. This hampers the capacity to reuse the studies data in other pipelines, the capacity to reuse the pipelines results in other studies, and the capacity to enrich the data with additional information. The Regulatory Circuits project is one of the largest efforts for integrating human cell genomics data to predict tissue-specific transcription factor-genes interaction networks. In spite of its success, it exhibits the usual shortcomings limiting its update, its reuse (as a whole or partially), and its extension with new data samples. To address these limitations, the resource has previously been integrated in an RDF triplestore so that TF-gene interaction networks could be generated with two SPARQL queries. However, this triplestore did not store the computed networks and did not integrate metadata about tissues and samples, therefore limiting the reuse of this dataset. In particular, it does not enable to reuse only a portion of Regulatory Circuits if a study focuses on a subset of the tissues, nor to combine the samples described in the datasets with samples from other studies. Overall, these limitations advocate for the design of a complete, flexible and reusable representation of the Regulatory Circuits dataset based on Semantic Web technologies. We provide a modular RDF representation of the Regulatory Circuits, called Linked Extended Regulatory Circuits (LERC). It consists in (i) descriptions of biological and experimental context mapped to the references databases, (ii) annotations about TF-gene interactions at the sample level for 808 samples, (iii) annotations about TF-gene interactions at the tissue level for 394 tissues, (iv) metadata connecting the knowledge graphs cited above. LERC is based on a modular organisation into 1,205 RDF named graphs for representing the biological data, the sample-specific and the tissue-specific networks, and the corresponding metadata. In total it contains 3,910,794,050 triples and is available as a SPARQL endpoint. The flexible and modular architecture of LERC supports biologically-relevant SPARQL queries. It allows an easy and fast querying of the resources related to the initial Regulatory Circuits datasets and facilitates its reuse in other studies. ASSOCIATED WEBSITE: https://regulatorycircuits-lod.genouest.org.","Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000, France.;Laboratoire d'Hématologie, Pôle de Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000, France.;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000, France.;Laboratoire d'Hématologie, Pôle de Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000, France.;Université Côte d'Azur, Inria, CNRS, I3S, Sophia-Antipolis, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000","NA",0,"2041-1480","J Biomed Semantics","J Biomed Semantics",2021,"2022","13","10.1186/s13326-022-00266-4","11","","","35346379","35346379","PUBMED","Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000, France.;Laboratoire d'Hématologie, Pôle de Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000, France.;UMR_S1236, Université Rennes 1, INSERM, Etablissement Français du Sang, Rennes, 35000, France.;Laboratoire d'Hématologie, Pôle de Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, 35033, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000, France.;Université Côte d'Azur, Inria, CNRS, I3S, Sophia-Antipolis, France.;Univ Rennes, CNRS, Inria, IRISA, UMR 6074, Rennes, F-35000"
"283","Moinard-Butot F;Saint-Martin C;Pflumio C;Carton M;Jacot W;Cottu PH;Diéras V;Dalenc F;Goncalves A;Debled M;Patsouris A;Mouret-Reynier MA;Vanlemmens L;Leheurteur M;Emile G;Ferrero JM;Desmoulins I;Uwer L;Eymard JC;Cheaib B;Courtinard C;Bachelot T;Chevrot M;Petit T","Moinard-Butot, Fabien;Saint-Martin, Caroline;Pflumio, Carole;Carton, Matthieu;Jacot, William;Cottu, Paul-Henri;Diéras, Véronique;Dalenc, Florence;Goncalves, Anthony;Debled, Marc;Patsouris, Anne;Mouret-Reynier, Marie-Ange;Vanlemmens, Laurence;Leheurteur, Marianne;Emile, George;Ferrero, Jean-Marc;Desmoulins, Isabelle;Uwer, Lionel;Eymard, Jean-Christophe;Cheaib, Bianca;Courtinard, Coralie;Bachelot, Thomas;Chevrot, Michaël;Petit, Thierry","Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Dual HER2 blockade;Lapatinib;Metastatic breast cancer;Overall survival;Progression-free survival;T-DM1","Ado-Trastuzumab Emtansine;Adolescent;Adult;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Lapatinib;Receptor, ErbB-2;Retrospective Studies;Taxoids;Trastuzumab","Ado-Trastuzumab Emtansine;Adolescent;Adult;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Lapatinib;Receptor, ErbB-2;Retrospective Studies;Taxoids;Trastuzumab","Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and lapatinib plus capecitabine beyond, without formal evaluation of these strategies. ESME Data Platform (NCT03275311) included individual data from all patients aged ≥18 years, in whom first-line treatment for metastatic breast cancer (MBC) was initiated between January 1, 2008 and December 31, 2016 in one of the 18 French Comprehensive Cancer Centers. The efficacy of T-DM1 and lapatinib plus capecitabine combination, following double blockade associating trastuzumab and pertuzumab were evaluated in this national real-life database. Eligibility criteria were: female, MBC, HER2+ tumor, first-line taxane-based chemotherapy and dual HER2-blockage by trastuzumab plus pertuzumab. Cohort A received second-line T-DM1, and Cohort B second-line T-DM1 and third or fourth-line lapatinib plus capecitabine. Cohort A comprised 233 patients, and Cohort B 47 patients. Median progression-free survival (PFS) was 7.1 months in Cohort A and 4.6 months in Cohort B. Median overall survival were 36.7 months and 12.9 months, respectively. PFS was significantly dependent on the preceding treatment line's duration. In cohort A, HER2 expression status was a significant predictive factor of PFS. First-line trastuzumab plus pertuzumab do not markedly diminish T-DM1's efficacy in second-line. Similarly, sequential treatment with trastuzumab plus pertuzumab then T-DM1 does not noticeably modify the efficacy of lapatinib plus capecitabine.","Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.","NA",0,"1532-3080","Breast","Breast",2021,"2022","63","10.1016/j.breast.2022.03.004","54-60","","","35299035","35299035","PUBMED","Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.;Department of Biostatistics, Institut Curie, 35 Rue Dailly, 92210, Saint-Cloud, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, 21079, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Unicancer, Data Office, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France."
"284","Beauvais C;Fayet F;Rousseau A;Sordet C;Pouplin S;Maugars Y;Poilverd RM;Savel C;Ségard V;Godon B;L'amour C;Perdriger A;Brin F;Peyrard P;Chalier F;Pallot-Prades B;Tuffet S;Griffoul I;Gossec L","Beauvais, Catherine;Fayet, Françoise;Rousseau, Alexandra;Sordet, Christelle;Pouplin, Sophie;Maugars, Yves;Poilverd, Rose Marie;Savel, Carine;Ségard, Véronique;Godon, Béatrice;L'amour, Christian;Perdriger, Aleth;Brin, Fabienne;Peyrard, Patricia;Chalier, Fabienne;Pallot-Prades, Béatrice;Tuffet, Sophie;Griffoul, Isabelle;Gossec, Laure","Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial.","RMD open","England","eng","Journal Article","arthritis;biological therapy;nursing;patient care team","Antirheumatic Agents;Arthritis, Rheumatoid;Biological Products;Humans;Nurse's Role;Patient Education as Topic","Antirheumatic Agents;Arthritis, Rheumatoid;Biological Products;Humans;Nurse's Role;Patient Education as Topic","To evaluate the effect of a nurse-led patient education on safety skills of patients with inflammatory arthritis treated with biologic disease-modifying antirheumatic drugs (bDMARDs). This is a multicentre, open-labelled, randomised controlled trial comparing an intervention group (face-to-face education by a nurse at baseline and 3 months later) with a control group (usual care) at the introduction of a first subcutaneous bDMARD. The primary outcome was score on the BioSecure questionnaire at 6 months (0-100 scale), a validated questionnaire assessing competencies in dealing with fever, infections, vaccination and daily situations. The secondary outcomes were disease activity, coping, psychological well-being, beliefs about medication, self-efficacy and severe infection rate. 129 patients with rheumatoid arthritis and spondyloarthritis were enrolled in nine rheumatology departments; 122 completed the study; 127 were analysed; and 64 received the intervention (mean duration: 65 min at baseline and 44 min at 3 months). The primary outcome was met: the BioSecure score was 81.2±13.1 and 75.6±13.0 in the education and usual care groups (difference: +6.2, 95% CI 1.3 to 11.1, p=0.015), demonstrating higher safety skills in the education group. Exploratory analyses showed better skills regarding infections, greater willingness for vaccinations and greater adherence-related behaviours in the education group. Coping was significantly more improved by education; other secondary outcomes were improved in both groups, with no difference. Educating patients was effective in promoting patient behaviours for preventing adverse events with bDMARDs. An education session delivered to patients starting a first bDMARD can be useful to help them self-manage safety issues. NCT02855320.","Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine,Sorbonne Université, APHP, Paris;Rheumatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Pharmacologie Clinique et Plateforme de Recherche Clinique de l'Est Parisien, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Rhumatologie, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Rheumatology, Centre Hospitalier Universitaire de Nantes Hôpital Saint Jacques, Nantes, France.;Medical Faculty, Universite de Nantes Pole Sante, Nantes, France.;Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Rheumatology Department, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Rheumatology Department, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université, APHP, Paris, France.;Rhumatologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Rheumatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Rheumatology Department, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Rheumatology Department, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Rheumatology Department, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.;APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France.","NA",0,"2056-5933","RMD Open","RMD Open",2021,"2022","8","10.1136/rmdopen-2021-001828",NA,"","","35296528","35296528","PUBMED","Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine,Sorbonne Université, APHP, Paris;Rheumatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Pharmacologie Clinique et Plateforme de Recherche Clinique de l'Est Parisien, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Rhumatologie, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Rheumatology, Centre Hospitalier Universitaire de Nantes Hôpital Saint Jacques, Nantes, France.;Medical Faculty, Universite de Nantes Pole Sante, Nantes, France.;Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Rheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Rheumatology Department, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Rheumatology Department, Centre Hospitalier Universitaire Pitié Salpétrière, Sorbonne Université, APHP, Paris, France.;Rhumatologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Rheumatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Rheumatology Department, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Rheumatology Department, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Rheumatology Department, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Rheumatology Department, Centre Hospitalier Universitaire Saint Antoine, Sorbonne Université, APHP, Paris, France.;Rheumatology, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Universite, Paris, France.;APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France."
"285","van Leeuwaarde RS;González-Clavijo AM;Pracht M;Emelianova G;Cheung WY;Thirlwell C;Öberg K;Spada F","van Leeuwaarde, Rachel S;González-Clavijo, Angélica M;Pracht, Marc;Emelianova, Galina;Cheung, Winson Y;Thirlwell, Christina;Öberg, Kjell;Spada, Francesca","A Multinational Pilot Study on Patients' Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires.","Journal of clinical medicine","Switzerland","eng","Journal Article","EORTC QLQ-C30;EORTC QLQ-G.I.NET21;NETs;neuroendocrine tumors;quality of life","","","Among the available neuroendocrine neoplasm (NEN)-specific HR-QoL scales, only the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires have been validated in several languages. We aim to assess patients' perceptions of these questionnaires. A cross-sectional qualitative pilot study was conducted among 65 adults from four countries with well-differentiated advanced gastro-entero-pancreatic (GEP) or unknown primary NENs. Patients completed the EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires and then a survey containing statements concerning the questionnaires. The majority of patients had a small intestine NET (52%). Most tumors were functioning (55%) and grade 2 NET (52%). Almost half of the patients identified limitations in the questionnaires, with nine (14%) patients scoring the questionnaires as poor and 16 (25%) patients as moderate. Overall, 37 (57%) patients were positive towards the questionnaires. Approximately a quarter of patients considered the questionnaires not suitable for all ages, missing some of their complaints, not representative of their overall HR-QoL regarding the treatment of their NET and too superficial. The current validated EORTC QLQ-C30 and EORTC QLQ-G.I.NET21 questionnaires may show some limitations in the design of questions and the patients' final satisfaction reporting of the questionnaire. Large-scale, high-quality prospective studies are required in HR-QoL assessment regarding NETs.","Department of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.;Department of Physiological Sciences, School of Medicine, Universidad Nacional de Colombia, Bogota 111321, Colombia.;Instituto Nacional de Cancerología, Bogota 111321, Colombia.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Oncology, National Medical Research Center N.N. Blokhin, 115191 Moscow, Russia.;Department of Medicine and Dentistry, A.I. Yevdokimov Moscow State University, 127473 Moscow, Russia.;Department of Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.;Cancer Institute, University College London, London WC1E 6DD, UK.;Department of Medicine and Health, University of Exeter School, Exeter EX4 4PY, UK.;Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden.;Department of Medical Sciences, Uppsala University, 75236 Uppsala, Sweden.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico, 20141 Milan, Italy.","NA",0,"2077-0383","J Clin Med","J Clin Med",2022,"2022","11","10.3390/jcm11051271",NA,"","","35268362","35268362","PUBMED","Department of Endocrine Oncology, University Medical Center Utrecht, 3584 Utrecht, The Netherlands.;Department of Physiological Sciences, School of Medicine, Universidad Nacional de Colombia, Bogota 111321, Colombia.;Instituto Nacional de Cancerología, Bogota 111321, Colombia.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Oncology, National Medical Research Center N.N. Blokhin, 115191 Moscow, Russia.;Department of Medicine and Dentistry, A.I. Yevdokimov Moscow State University, 127473 Moscow, Russia.;Department of Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, AB T2N 4N2, Canada.;Cancer Institute, University College London, London WC1E 6DD, UK.;Department of Medicine and Health, University of Exeter School, Exeter EX4 4PY, UK.;Department of Endocrine Oncology, Uppsala University Hospital, 75185 Uppsala, Sweden.;Department of Medical Sciences, Uppsala University, 75236 Uppsala, Sweden.;Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico, 20141 Milan, Italy."
"286","Le Deroff C;Berger L;Bellec J;Boissonnat G;Chesneau H;Chiavassa S;Desrousseaux J;Gempp S;Henry O;Jarril J;Lazaro D;Lefeuvre R;Passal V;Solinhac F;Lafond C;Delpon G","Le Deroff, Coralie;Berger, Lucie;Bellec, Julien;Boissonnat, Guillaume;Chesneau, Héléna;Chiavassa, Sophie;Desrousseaux, Julie;Gempp, Stéphanie;Henry, Olivier;Jarril, Jimmy;Lazaro, Delphine;Lefeuvre, Ronan;Passal, Vincent;Solinhac, Fanny;Lafond, Caroline;Delpon, Gregory","Monte Carlo-based software for 3D personalized dose calculations in image-guided radiotherapy.","Physics and imaging in radiation oncology","Netherlands","eng","Journal Article","Breast;CBCT, Cone Beam Computed Tomography;Head-and-neck;IGRT;IGRT, Image Guided Radiotherapy;MC, Monte Carlo;Monte Carlo dose calculation;Personalized dose;Prostate","","","Image-guided radiotherapy (IGRT) involves frequent in-room imaging sessions contributing to additional patient irradiation. The present work provided patient-specific dosimetric data related to different imaging protocols and anatomical sites. We developed a Monte Carlo based software able to calculate 3D personalized dose distributions for five imaging devices delivering kV-CBCT (Elekta and Varian linacs), MV-CT (Tomotherapy machines) and 2D-kV stereoscopic images from BrainLab and Accuray. Our study reported the dose distributions calculated for pelvis, head and neck and breast cases based on dose volume histograms for several organs at risk. 2D-kV imaging provided the minimum dose with less than 1 mGy per image pair. For a single kV-CBCT and MV-CT, median dose to organs were respectively around 30 mGy and 15 mGy for the pelvis, around 7 mGy and 10 mGy for the head and neck and around 5 mGy and 15 mGy for the breast. While MV-CT dose varied sparsely with tissues, dose from kV imaging was around 1.7 times higher in bones than in soft tissue. Daily kV-CBCT along 40 sessions of prostate radiotherapy delivered up to 3.5 Gy to the femoral heads. The dose level for head and neck and breast appeared to be lower than 0.4 Gy for every organ in case of a daily imaging session. This study showed the dosimetric impact of IGRT procedures. Acquisition parameters should therefore be chosen wisely depending on the clinical purposes and tailored to morphology. Indeed, imaging dose could be reduced up to a factor 10 with optimized protocols.","Centre Eugène Marquis (Unicancer), Rennes, France.;Centre Jean Perrin (Unicancer), Clermont Ferrand, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Université Paris-Saclay, CEA, List, F-91120 Palaiseau, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Centre Jean Perrin (Unicancer), Clermont Ferrand, France.;Université Paris-Saclay, CEA, List, F-91120 Palaiseau, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Université de Rennes, Inserm, LTSI - UMR 1099, Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France.","NA",0,"2405-6316","Phys Imaging Radiat Oncol","Phys Imaging Radiat Oncol",2021,"2022","21","10.1016/j.phro.2022.02.004","108-114","","","35243041","35243041","PUBMED","Centre Eugène Marquis (Unicancer), Rennes, France.;Centre Jean Perrin (Unicancer), Clermont Ferrand, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Université Paris-Saclay, CEA, List, F-91120 Palaiseau, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Centre Jean Perrin (Unicancer), Clermont Ferrand, France.;Université Paris-Saclay, CEA, List, F-91120 Palaiseau, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France.;Assistance Publique - Hôpitaux de Marseille, Marseille, France.;Centre Eugène Marquis (Unicancer), Rennes, France.;Université de Rennes, Inserm, LTSI - UMR 1099, Rennes, France.;Institut de Cancérologie de l'Ouest (Unicancer), Saint-Herblain, France."
"287","Berger F;Marce M;Delaloge S;Hardy-Bessard AC;Bachelot T;Bièche I;Pradines A;De La Motte Rouge T;Canon JL;André F;Arnould L;Clatot F;Lemonnier J;Marques S;Bidard FC","Berger, Frédérique;Marce, Margaux;Delaloge, Suzette;Hardy-Bessard, Anne-Claire;Bachelot, Thomas;Bièche, Ivan;Pradines, Anne;De La Motte Rouge, Thibault;Canon, Jean-Luc;André, Fabrice;Arnould, Laurent;Clatot, Florian;Lemonnier, Jérôme;Marques, Sandrine;Bidard, François-Clement","Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.","BMJ open","England","eng","Clinical Trial, Phase III","breast tumours;clinical trials;oncology","Antineoplastic Combined Chemotherapy Protocols;Aromatase Inhibitors;Breast Neoplasms;Circulating Tumor DNA;Female;Fulvestrant;Humans;Mutation;Piperazines;Pyridines;Receptor, ErbB-2;Receptors, Estrogen","Antineoplastic Combined Chemotherapy Protocols;Aromatase Inhibitors;Breast Neoplasms;Circulating Tumor DNA;Female;Fulvestrant;Humans;Mutation;Piperazines;Pyridines;Receptor, ErbB-2;Receptors, Estrogen","The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2-) advanced breast cancer. However, most patients receiving this combination will ultimately progress and require further therapies.Several studies have demonstrated that the onset of a   gene mutation lead to AIs resistance in the advanced setting.   mutations can be detected in circulating tumour DNA (ctDNA) using a digital PCR assay. Our study aims to prove the clinical efficacy of periodic monitoring for emerging or rise of   mutations in ctDNA to trigger an early change from AI plus palbociclib to fulvestrant plus palbociclib treatment while assessing global safety. PADA-1 is a randomised, open-label, multicentric, phase III trial conducted in patients receiving AI and palbociclib as first line therapy for metastatic ER +HER2- breast cancer. 1000 patients will be included and treated with palbociclib in combination with an AI. Patients will be screened for circulating blood   mutation detection at regular intervals. Patients for whom a rising circulating   mutation is detected without tumour progression (up to N=200) will be randomised (1:1) between (1) Arm A: no modification of therapy; and (2) Arm B: palbociclib in combination with fulvestrant, a selective ER down-regulator. At tumour progression, an optional crossover will be offered to patients randomised in arm A. The coprimary endpoints are (1) Grade ≥3 haematological toxicities and their associations with baseline characteristics and (2) progression-free survival in randomised patients. The study has been approved by the French medicines agency (ANSM) and by an ethics committee (ref 01/17_1 CPP Ouest-IV Nantes) in January 2017. The trial results will be published in academic conference presentations and international peer-reviewed journals. EudraCT: 2016-004360-18; NCT03079011.","Biometry Unit, Institut Curie, PSL Research University, Paris and Saint-Cloud, France.;Biometry Unit, Data Center, Institut Régional du Cancer de Montpellier, Montpellier, France.;Breast Oncology Department, Gustave Roussy, Villejuif, France.;Dapartment of Medical Oncology, Centre Armoricaind'Oncologie, Plérin, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Pharmacogenomic Unit, Genetics laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, Paris, France.;INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, Toulouse, France.;Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgique.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Pathology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Research and Development Department, UNICANCER, Paris, France.;Research and Development Department, UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ/Paris Saclay University, Saint Cloud;Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2022,"2022","12","10.1136/bmjopen-2021-055821","e055821","","","35241469","35241469","PUBMED","Biometry Unit, Institut Curie, PSL Research University, Paris and Saint-Cloud, France.;Biometry Unit, Data Center, Institut Régional du Cancer de Montpellier, Montpellier, France.;Breast Oncology Department, Gustave Roussy, Villejuif, France.;Dapartment of Medical Oncology, Centre Armoricaind'Oncologie, Plérin, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Pharmacogenomic Unit, Genetics laboratory, Department of Diagnostic and Theranostic Medicine, Institut Curie and PSL University, Paris, France.;INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, Toulouse, France.;Prospective Biology Unit, Medical Laboratory, Claudius Regaud Institute, Toulouse University Cancer Institute (IUCT-O), Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Grand Hôpital de Charleroi, Charleroi, Belgique.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Pathology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Research and Development Department, UNICANCER, Paris, France.;Research and Development Department, UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ/Paris Saclay University, Saint Cloud;Circulating Tumor Biomarkers laboratory, Inserm CIC-BT 1428, Institut Curie, Paris, France."
"288","Tiffney EA;Coombes JL;Legembre P;Flynn RJ","Tiffney, Ellen A;Coombes, Janine L;Legembre, Patrick;Flynn, Robin J","Cleaved CD95L perturbs in vitro macrophages responses to Toxoplasma gondii.","Microbes and infection","France","eng","Journal Article","Arginase;CD95L;Cleaved CD95L;JAK/STAT;Macrophage;Toxoplasma gondii","Arginase;Fas Ligand Protein;Humans;Janus Kinases;Macrophages;Toxoplasma","Arginase;Fas Ligand Protein;Humans;Janus Kinases;Macrophages;Toxoplasma","Toxoplasma gondii infects approximately 1-2 billion people, and manipulation of the macrophage response is critical to host and parasite survival. A cleaved (cl)-CD95L form can promote cellular migration and we have previously shown that cl-CD95L aggravates inflammation and pathology in systemic lupus erythematosus (SLE). Findings have shown that CD95L is upregulated during human infection, therefore we examined the effect of cl-CD95L on the macrophage response to T. gondii. . We find that cl-CD95L promotes parasite replication in macrophages, associated with increased arginase-1 levels, mediated by signal transducer and activator of transcription (STAT)6. Inhibition of both arginase-1 and STAT6 reversed the effects of cl-CD95L. Phospho-kinase array showed that cl-CD95L alters Janus Kinases (JAK)/STAT, mammalian target of rapamycin (mTOR), and Src kinase signals. By triggering changes in JAK/STAT cl-CD95L may limit anti-parasite effectors.","Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Centre Eugène Marquis, Université Rennes-1, INSERM U1242, Rennes, France.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK; Graduate Studies Office, Department of Research, Innovation and Graduate Studies, Waterford Institute of Technology, X91 K0EK","NA",0,"1769-714X","Microbes Infect","Microbes Infect",2021,"2022","24","10.1016/j.micinf.2022.104952","104952","","Wellcome Trust","35240289","35240289","PUBMED","Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK.;Centre Eugène Marquis, Université Rennes-1, INSERM U1242, Rennes, France.;Dept. Infection Biology, Institute of Infection and Global Health, University of Liverpool, L3 5RF, UK; Graduate Studies Office, Department of Research, Innovation and Graduate Studies, Waterford Institute of Technology, X91 K0EK"
"289","Carausu M;Carton M;Cabel L;Patsouris A;Levy C;Verret B;Pasquier D;Debled M;Gonçalves A;Desmoulins I;Lecouillard I;Bachelot T;Ferrero JM;Eymard JC;Mouret-Reynier MA;Chevrot M;De Maio E;Uwer L;Frenel JS;Leheurteur M;Petit T;Darlix A;Bozec L","Carausu, Marcela;Carton, Matthieu;Cabel, Luc;Patsouris, Anne;Levy, Christelle;Verret, Benjamin;Pasquier, David;Debled, Marc;Gonçalves, Anthony;Desmoulins, Isabelle;Lecouillard, Isabelle;Bachelot, Thomas;Ferrero, Jean-Marc;Eymard, Jean-Christophe;Mouret-Reynier, Marie-Ange;Chevrot, Michaël;De Maio, Eleonora;Uwer, Lionel;Frenel, Jean-Sébastien;Leheurteur, Marianne;Petit, Thierry;Darlix, Amélie;Bozec, Laurence","Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.","Therapeutic advances in medical oncology","England","eng","Journal Article","CNS metastases;breast cancer;real-world data","","","As a result of progress in diagnosis and treatment, there is a growing prevalence of metastatic breast cancer (MBC) with isolated CNS metastases. This study describes the largest-to-date real-life cohort of this clinical setting and compares it to other clinical presentations. We retrospectively analysed the French Epidemiological Strategy and Medical Economics (ESME) MBC database including patients who initiated treatment for MBC between 2008 and 2016. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Descriptive statistics and multivariate Cox model were used. Of 22,266 patients, 647 (2.9%) and 929 (4.2%) patients had isolated first-site CNS metastases or combined with extra-CNS metastases, with longer OS for the group with isolated CNS metastases (16.9   13.9 months, adjusted HR = 1.69 (95% CI: 1.50-1.91),   < 0.001). Among the 541 (2.4%) patients with isolated CNS metastases and no intrathecal therapy (excluding leptomeningeal metastases), HER2+ cases were preponderant over TN or HR+ /HER2- cases (41.6%   26.1%   28.5%, respectively,   < 0.01). The treatment strategy consisted of a combination of local treatment and systemic therapy (49.2%), local treatment only (35.5%) or systemic therapy only (11.4%), or symptomatic therapy only (3.9%). Median PFS was 6.1 months (95% CI: 5.7-6.8). Median OS was 20.7 months (95% CI: 17.3-24.3), reaching 37.9 months (95% CI: 25.9-47.6) in the HR+ /HER2+ subgroup. Older age, TN subtype, MBC-free interval of 6-12 months, lower performance status, and WBRT were associated with poorer survival. Patients who received systemic therapy within 3 months from MBC diagnosis had longer OS (24.1   16.1 months,   = 0.031), but this was not significant on multivariate analysis [HR = 1.0 (95% CI: 0.7-1.3),   = 0.806]. Patients with isolated CNS metastases at MBC diagnosis represent a distinct population for which the role of systemic therapy needs to be further investigated in prospective studies.","Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Radiation Oncology, Centre Oscar Lambret, CRIStAL UMR CNRS 9189, Lille University, Lille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Unicancer, Paris, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Institut de Génomique Fonctionnelle, INSERM U1191-CNRS UMR 5203, Université de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Curie, 35 rue Dailly, 92210 Saint-Cloud, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2021,"2022","14","10.1177/17588359221077082","17588359221077082","","","35237352","35237352","PUBMED","Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Radiation Oncology, Centre Oscar Lambret, CRIStAL UMR CNRS 9189, Lille University, Lille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Radiation Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Unicancer, Paris, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), Institut de Génomique Fonctionnelle, INSERM U1191-CNRS UMR 5203, Université de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Curie, 35 rue Dailly, 92210 Saint-Cloud, France."
"290","Van Braeckel E;Page I;Davidsen JR;Laursen CB;Agarwal R;Alastruey-Izquierdo A;Barac A;Cadranel J;Chakrabarti A;Cornely OA;Denning DW;Flick H;Gangneux JP;Godet C;Hayashi Y;Hennequin C;Hoenigl M;Irfan M;Izumikawa K;Koh WJ;Kosmidis C;Lange C;Lamprecht B;Laurent F;Munteanu O;Oladele R;Patterson TF;Watanabe A;Salzer HJF","Van Braeckel, Eva;Page, Iain;Davidsen, Jesper Rømhild;Laursen, Christian B;Agarwal, Ritesh;Alastruey-Izquierdo, Ana;Barac, Aleksandra;Cadranel, Jacques;Chakrabarti, Arunaloke;Cornely, Oliver A;Denning, David W;Flick, Holger;Gangneux, Jean-Pierre;Godet, Cendrine;Hayashi, Yuta;Hennequin, Christophe;Hoenigl, Martin;Irfan, Muhammed;Izumikawa, Koichi;Koh, Won-Jun;Kosmidis, Chris;Lange, Christoph;Lamprecht, Bernd;Laurent, Francois;Munteanu, Oxana;Oladele, Rita;Patterson, Thomas F;Watanabe, Akira;Salzer, Helmut J F","Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement.","The European respiratory journal","England","eng","Letter","","Consensus;Humans;Persistent Infection;Pulmonary Aspergillosis;Treatment Outcome","Consensus;Humans;Persistent Infection;Pulmonary Aspergillosis;Treatment Outcome","NA","Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.;Dept of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.;Regional Infectious Diseases Unit, NHS Lothian, Western General Hospital, Edinburgh, UK.;Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.;Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.;Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.;Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.;Dept of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.;Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia.;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.;Dept of Pulmonology and Thoracic Oncology, APHP Hôpital Tenon and Sorbonne University, Paris, France.;Dept of Medical Microbiology; Center of Advanced Research in Medical Mycology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.;German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;Manchester Fungal Infection Group, University of Manchester, Manchester, UK.;Division of Pulmonology, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.;Dept of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Dept of Pulmonology, AP-HP, Hôpital Bichat, Paris, France.;Dept of Respiratory Medicine, Higashinagoya National Hospital, Nagoya, Japan.;Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.;Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.;Division of Infectious Diseases, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.;Section of Pulmonary and Critical Care Medicine, Dept of Medicine, Aga Khan University, Karachi, Pakistan.;Dept of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.;Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.;Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Manchester Fungal Infection Group, University of Manchester, Manchester, UK.;National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.;Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.;German Center for Infection Research (DZIF), DZIF Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.;International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.;Dept of Medicine, Karolinska Institute, Stockholm, Sweden.;Dept of Pulmonology, Kepler University Hospital, Linz, Austria.;Dept of Cardiothoracic Imaging, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France.;Division of Pneumology and Allergology, Dept of Internal Medicine, State University of Medicine and Pharmacy ""Nicolae Testemitanu"", Chisinau, Republic of Moldova.;Dept of Microbiology, College of Medicine, University of Lagos, Lagos, Nigeria.;San Antonio Center for Medical Mycology, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, TX, USA.;Medical Mycology Research Center, Chiba University, Chiba, Japan.;Dept of Pulmonology, Kepler University Hospital, Linz","NA",0,"1399-3003","Eur Respir J","Eur Respir J",2021,"2022","59","10.1183/13993003.02950-2021",NA,"","","35236726","35236726","PUBMED","Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.;Dept of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.;Regional Infectious Diseases Unit, NHS Lothian, Western General Hospital, Edinburgh, UK.;Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.;Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.;Pulmonary Aspergillosis Centre Denmark (PACD), Dept of Respiratory Medicine, Odense University Hospital, Odense, Denmark.;Odense Respiratory Research Unit (ODIN), Dept of Clinical Research, University of Southern Denmark, Odense, Denmark.;Dept of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.;Clinic for Infectious and Tropical Diseases, University Clinical Centre of Serbia, Belgrade, Serbia.;Faculty of Medicine, University of Belgrade, Belgrade, Serbia.;Dept of Pulmonology and Thoracic Oncology, APHP Hôpital Tenon and Sorbonne University, Paris, France.;Dept of Medical Microbiology; Center of Advanced Research in Medical Mycology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Dept I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.;University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.;German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.;Manchester Fungal Infection Group, University of Manchester, Manchester, UK.;Division of Pulmonology, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.;Dept of Parasitology and Mycology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Dept of Pulmonology, AP-HP, Hôpital Bichat, Paris, France.;Dept of Respiratory Medicine, Higashinagoya National Hospital, Nagoya, Japan.;Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Hôpital Saint-Antoine, Service de Parasitologie-Mycologie, Paris, France.;Division of Infectious Diseases and Global Health, University of California San Diego, La Jolla, CA, USA.;Division of Infectious Diseases, Dept of Internal Medicine, Medical University of Graz, Graz, Austria.;Section of Pulmonary and Critical Care Medicine, Dept of Medicine, Aga Khan University, Karachi, Pakistan.;Dept of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.;Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan.;Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.;Manchester Fungal Infection Group, University of Manchester, Manchester, UK.;National Aspergillosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.;Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.;German Center for Infection Research (DZIF), DZIF Partner Site, Hamburg-Lübeck-Borstel-Riems, Germany.;International Health/Infectious Diseases, University of Lübeck, Lübeck, Germany.;Dept of Medicine, Karolinska Institute, Stockholm, Sweden.;Dept of Pulmonology, Kepler University Hospital, Linz, Austria.;Dept of Cardiothoracic Imaging, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France.;Division of Pneumology and Allergology, Dept of Internal Medicine, State University of Medicine and Pharmacy ""Nicolae Testemitanu"", Chisinau, Republic of Moldova.;Dept of Microbiology, College of Medicine, University of Lagos, Lagos, Nigeria.;San Antonio Center for Medical Mycology, Division of Infectious Diseases, The University of Texas Health Science Center, San Antonio, TX, USA.;Medical Mycology Research Center, Chiba University, Chiba, Japan.;Dept of Pulmonology, Kepler University Hospital, Linz"
"291","Vauchier C;Auclin E;Barthélémy P;Carril-Ajuria L;Ryckewaert T;Borchiellini D;Castel-Ajgal Z;Bennamoun M;Campedel L;Thiery-Vuillemin A;Coquan E;Crouzet L;Berdah JF;Chevreau C;Ratta R;Fléchon A;Lefort F;Albiges L;Gross-Goupil M;Vano YA;Thibault C;Oudard S","Vauchier, Charles;Auclin, Edouard;Barthélémy, Philippe;Carril-Ajuria, Lucia;Ryckewaert, Thomas;Borchiellini, Delphine;Castel-Ajgal, Zahra;Bennamoun, Mostefa;Campedel, Luca;Thiery-Vuillemin, Antoine;Coquan, Elodie;Crouzet, Laurence;Berdah, Jean-François;Chevreau, Christine;Ratta, Raffaele;Fléchon, Aude;Lefort, Felix;Albiges, Laurence;Gross-Goupil, Marine;Vano, Yann-Alexandre;Thibault, Constance;Oudard, Stéphane","REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.","Journal of oncology","Egypt","eng","Journal Article","","","","Immune checkpoint inhibitors (ICI) have been approved for front-line therapy in metastatic renal cell carcinoma (mRCC). However, progressive disease often occurs and subsequent therapies are needed. ICI rechallenge may be an option, but there is a lack of data regarding efficacy and prognostic factors. We assessed efficacy of ICI rechallenge and factors associated with better outcomes.  . This ambispective multicenter study included 45 mRCC patients rechallenged with nivolumab ± ipilimumab between 2014 and 2020. Primary endpoint was investigator-assessed best objective response rate (ORR) for ICI rechallenge (ICI-2). Factors associated with ICI-2 progression-free survival (PFS) were evaluated with multivariate Cox models. ORR was 51% (  = 23) at first ICI therapy (ICI-1) and 16% (  = 7) for ICI-2. Median PFS was 11.4 months (95% CI, 9.8-23.5) and 3.5 months (95% CI, 2.8-9.7), and median overall survival was not reached (NR) (95% CI, 37.8-NR) and 24 months (95% CI, 9.9-NR) for ICI-1 and ICI-2, respectively. Factors associated with poorer ICI-2 PFS were a high number of metastatic sites, presence of liver metastases, use of an intervening treatment between ICI regimens, Eastern Cooperative Oncology Group performance status ≥2, and poor International Metastatic RCC Database Consortium score at ICI-2 start. Conversely, ICI-1 PFS >6 months was associated with better ICI-2 PFS. In multivariate analysis, there were only statistical trends toward better ICI-2 PFS in patients with ICI-1 PFS >6 months ( =0.07) and toward poorer ICI-2 PFS in patients who received a treatment between ICI regimens ( =0.07). Rechallenge with nivolumab-based ICI has some efficacy in mRCC. We identified various prognostic factors in univariate analysis but only statistical trends in multivariate analysis. Our findings bring new evidence on ICI rechallenge and preliminary but unique data that may help clinicians to select patients who will benefit from this strategy.","Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France.;Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille 59000, France.;Department of Medical Oncology, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice 06100, France.;Medical Oncology Department, Hôpital Cochin-Port Royal, AP-HP, Paris75014, France.;Department of Medical Oncology, Institut Mutualiste Montsouris, Paris 75014, France.;Department of Oncology, Hôpital Pitié Salpêtrière, AP-HP, Paris 75013, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon 25000, France.;Medical Oncology Department, Centre François Baclesse, Caen 14000, France.;Oncology Department, Centre Eugène Marquis, Rennes 35000, France.;Oncology Department, Clinique Sainte-Marguerite, Hyères 83400, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse 31100, France.;Oncology and Supportive Care Department, Hôpital Foch, Suresnes 92150, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon 69008, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.;Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris 75006, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Université de Paris, PARCC, INSERM U970, Paris 75006, France.","NA",0,"1687-8450","J Oncol","J Oncol",2021,"2022","2022","10.1155/2022/3449660","3449660","","","35222642","35222642","PUBMED","Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Medical Oncology Unit, Institut de Cancérologie Strasbourg Europe, Strasbourg 67200, France.;Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille 59000, France.;Department of Medical Oncology, Centre Antoine-Lacassagne, Université Côte d'Azur, Nice 06100, France.;Medical Oncology Department, Hôpital Cochin-Port Royal, AP-HP, Paris75014, France.;Department of Medical Oncology, Institut Mutualiste Montsouris, Paris 75014, France.;Department of Oncology, Hôpital Pitié Salpêtrière, AP-HP, Paris 75013, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon 25000, France.;Medical Oncology Department, Centre François Baclesse, Caen 14000, France.;Oncology Department, Centre Eugène Marquis, Rennes 35000, France.;Oncology Department, Clinique Sainte-Marguerite, Hyères 83400, France.;Department of Medical Oncology, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse 31100, France.;Oncology and Supportive Care Department, Hôpital Foch, Suresnes 92150, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon 69008, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.;Oncology Department, Institut Gustave Roussy, Université Paris-Saclay, Villejuif 94076, France.;Department of Medical Oncology, Centre Hospitalier Universitaire de Bordeaux-Hôpital Saint-André, Bordeaux 33000, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris 75006, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, Paris 75015, France.;Université de Paris, PARCC, INSERM U970, Paris 75006, France."
"292","Zhang-Yin JT;Girard A;Bertaux M","Zhang-Yin, Jules Tianyu;Girard, Antoine;Bertaux, Marc","What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review.","Cancers","Switzerland","eng","Journal Article","PCNSL;[18F]FDG;[18F]FDOPA;[18F]FET;[68Ga]Ga-DOTA-SSTR;brain metastases;glioma;meningioma","","","PET imaging is being increasingly used to supplement MRI in the clinical management of brain tumors. The main radiotracers implemented in clinical practice include [ F]FDG, radiolabeled amino acids ([ C]MET, [ F]FDOPA, [ F]FET) and [ Ga]Ga-DOTA-SSTR, targeting glucose metabolism, L-amino-acid transport and somatostatin receptors expression, respectively. This review aims at addressing the current place and perspectives of brain PET imaging for patients who suffer from primary or secondary brain tumors, at diagnosis and during follow-up. A special focus is given to the following: radiolabeled amino acids PET imaging for tumor characterization and follow-up in gliomas; the role of amino acid PET and [ F]FDG PET for detecting brain metastases recurrence; [ Ga]Ga-DOTA-SSTR PET for guiding treatment in meningioma and particularly before targeted radiotherapy.","Department of Nuclear Medicine, Clinique Sud Luxembourg, 486762 Arlon, Belgium.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2021,"2022","14","10.3390/cancers14040879",NA,"","","35205625","35205625","PUBMED","Department of Nuclear Medicine, Clinique Sud Luxembourg, 486762 Arlon, Belgium.;Department of Nuclear Medicine, Centre Eugène Marquis, Université Rennes 1, 35000 Rennes, France.;Department of Nuclear Medicine, Foch Hospital, 92150 Suresnes, France."
"293","Moreau-Bachelard C;Campion L;Toulmonde M;Le Cesne A;Brahmi M;Italiano A;Mir O;Piperno-Neumann S;Laurence V;Firmin N;Penel N;Duffaud F;Chevreau C;Bertucci F;Narciso B;Dubray-Longeras P;Delcambre C;Saada-Bouzid E;Boudou-Rouquette P;Soulie P;Perrin C;Blay JY;Bompas E","Moreau-Bachelard, C;Campion, L;Toulmonde, M;Le Cesne, A;Brahmi, M;Italiano, A;Mir, O;Piperno-Neumann, S;Laurence, V;Firmin, N;Penel, N;Duffaud, F;Chevreau, C;Bertucci, F;Narciso, B;Dubray-Longeras, P;Delcambre, C;Saada-Bouzid, E;Boudou-Rouquette, P;Soulie, P;Perrin, C;Blay, J Y;Bompas, E","Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).","ESMO open","England","eng","Journal Article","metastatic synovial sarcoma","Adolescent;Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Child;Doxorubicin;Humans;Ifosfamide;Middle Aged;Sarcoma;Sarcoma, Synovial;Young Adult","Adolescent;Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Child;Doxorubicin;Humans;Ifosfamide;Middle Aged;Sarcoma;Sarcoma, Synovial;Young Adult","Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort. All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group database. Data were collected from the national database https://conticabase.sarcomabcb.org/ up to March 2020. Descriptive and comparative analyses were conducted using SAS 9.4 and Stata Special Edition 16.1 software. Between January 1981 and December 2019, 417 patients with metastatic SS from 17 French sarcoma centers were included, including 64 (15.3%) under the age of 26 years. Median age was 42.5 years (range 9-87 years). The metastases were synchronous (cohort 1) or metachronous (cohort 2) in 18.9% (N = 79) and 81.1% (N = 338) patients, respectively. Median overall survival (OS) from the date of metastasis was 22.3 months (95% confidence interval 19.7-24.1 months). First-line chemotherapy without ifosfamide and/or doxorubicin was unfavorable for progression-free survival and OS (P < 0.001). Concerning cohort 1, young age, surgery of the primary tumor, and single metastatic site were independent favorable prognostic factors for OS. In cohort 2, surgery within an expert French Sarcoma Group center, absence of chemotherapy in the perioperative setting, the lungs as a single metastatic site, time to first metastasis >12 months, local therapy, and ifosfamide in the first metastatic line were independent favorable prognostic factors. The outcome of patients with metastatic SS is influenced by local treatment, management in reference centers, and cytotoxic treatments given in the perioperative and metastatic setting.","ICO Centre René Gauducheau, Oncology, Nantes, France.;ICO Centre René Gauducheau, Oncology, Nantes, France; CNRS, Inserm, CRCINA, Nantes, France.;Institut Bergonié, Medical Oncology, Bordeaux, France.;Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France.;Centre Leon Berard, Medical Oncology, Lyon, France.;Institut Bergonié, Medical Oncology, Bordeaux, France.;Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France.;Institut Curie, Medical Oncology, Paris, France.;Institut Curie, Medical Oncology, Paris, France.;Department of Medical Oncology, ICM, INSERM U1194, IRCM, Université Montpellier, Montpellier, France.;Centre Oscar Lambret, Medical Oncology, Lille, France.;Hôpital De La Timone, Medical Oncology, Marseille, Aix Marseille Université, Marseille, France.;IUCT Oncopole, Oncology, Medical Toulouse, Toulouse, France.;Institut Paoli-Calmettes (IPC), Medical Oncology, Marseille, France.;CHRU Bretonneau, Medical Oncology, Tours, France.;Centre Jean Perrin, Medical Oncology, Clermont-Ferrand, France.;Centre François Baclesse, Medical Oncology, Caen, France.;Centre Antoine Lacassagne, Medical Oncology, Nice, France.;Hopital Cochin APHP, Medical Oncology, Paris, France.;ICO Centre Paul Pain, Medical Oncology, Angers, France.;Centre Eugène Marquis, Medical Oncology, Rennes, France.;Centre Leon Berard, Medical Oncology, Lyon, France.;ICO Centre René Gauducheau, Oncology, Nantes","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2022","7","10.1016/j.esmoop.2022.100402","100402","","","35202953","35202953","PUBMED","ICO Centre René Gauducheau, Oncology, Nantes, France.;ICO Centre René Gauducheau, Oncology, Nantes, France; CNRS, Inserm, CRCINA, Nantes, France.;Institut Bergonié, Medical Oncology, Bordeaux, France.;Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France.;Centre Leon Berard, Medical Oncology, Lyon, France.;Institut Bergonié, Medical Oncology, Bordeaux, France.;Department of Ambulatory Cancer Care & Sarcoma Group, Gustave Roussy, Villejuif, France.;Institut Curie, Medical Oncology, Paris, France.;Institut Curie, Medical Oncology, Paris, France.;Department of Medical Oncology, ICM, INSERM U1194, IRCM, Université Montpellier, Montpellier, France.;Centre Oscar Lambret, Medical Oncology, Lille, France.;Hôpital De La Timone, Medical Oncology, Marseille, Aix Marseille Université, Marseille, France.;IUCT Oncopole, Oncology, Medical Toulouse, Toulouse, France.;Institut Paoli-Calmettes (IPC), Medical Oncology, Marseille, France.;CHRU Bretonneau, Medical Oncology, Tours, France.;Centre Jean Perrin, Medical Oncology, Clermont-Ferrand, France.;Centre François Baclesse, Medical Oncology, Caen, France.;Centre Antoine Lacassagne, Medical Oncology, Nice, France.;Hopital Cochin APHP, Medical Oncology, Paris, France.;ICO Centre Paul Pain, Medical Oncology, Angers, France.;Centre Eugène Marquis, Medical Oncology, Rennes, France.;Centre Leon Berard, Medical Oncology, Lyon, France.;ICO Centre René Gauducheau, Oncology, Nantes"
"294","Papaioannou A;Centonze F;Metais A;Maurel M;Negroni L;Gonzalez-Quiroz M;Mahdizadeh SJ;Svensson G;Zare E;Blondel A;Koong AC;Hetz C;Pedeux R;Tremblay ML;Eriksson LA;Chevet E","Papaioannou, Alexandra;Centonze, Federica;Metais, Alice;Maurel, Marion;Negroni, Luc;Gonzalez-Quiroz, Matías;Mahdizadeh, Sayyed Jalil;Svensson, Gabriella;Zare, Ensieh;Blondel, Alice;Koong, Albert C;Hetz, Claudio;Pedeux, Rémy;Tremblay, Michel L;Eriksson, Leif A;Chevet, Eric","Stress-induced tyrosine phosphorylation of RtcB modulates IRE1 activity and signaling outputs.","Life science alliance","United States","eng","Journal Article","","Endoribonucleases;Phosphorylation;Protein Serine-Threonine Kinases;RNA, Messenger;Ribonucleases;Tyrosine;X-Box Binding Protein 1","Endoribonucleases;Phosphorylation;Protein Serine-Threonine Kinases;RNA, Messenger;Ribonucleases;Tyrosine;X-Box Binding Protein 1","ER stress is mediated by three sensors and the most evolutionary conserved IRE1α signals through its cytosolic kinase and endoribonuclease (RNase) activities. IRE1α RNase activity can either catalyze the initial step of XBP1 mRNA unconventional splicing or degrade a number of RNAs through regulated IRE1-dependent decay. Until now, the biochemical and biological outputs of IRE1α RNase activity have been well documented; however, the precise mechanisms controlling whether IRE1α signaling is adaptive or pro-death (terminal) remain unclear. We investigated those mechanisms and hypothesized that XBP1 mRNA splicing and regulated IRE1-dependent decay activity could be co-regulated by the IRE1α RNase regulatory network. We identified that RtcB, the tRNA ligase responsible for XBP1 mRNA splicing, is tyrosine-phosphorylated by c-Abl and dephosphorylated by PTP1B. Moreover, we show that the phosphorylation of RtcB at Y306 perturbs RtcB interaction with IRE1α, thereby attenuating XBP1 mRNA splicing. Our results demonstrate that the IRE1α RNase regulatory network is dynamically fine-tuned by tyrosine kinases and phosphatases upon various stresses and that the extent of RtcB tyrosine phosphorylation determines cell adaptive or death outputs.","INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.;Institut National de la Santé et de la Recherche Médicale, U1258, Illkirch, France.;Université de Strasbourg, Illkirch, France.;INSERM U1242, University of Rennes, Rennes, France.;Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.;Center for Geroscience, Brain Health and Metabolism (GERO), Santiago, Chile.;Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.;Center for Geroscience, Brain Health and Metabolism (GERO), Santiago, Chile.;Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Goodman Cancer Research Centre, McGill University, Montreal, Canada.;Department of Biochemistry, McGill University, Montreal, Canada.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg;INSERM U1242, University of Rennes, Rennes;Centre Eugène Marquis, Rennes, France.","NA",0,"2575-1077","Life Sci Alliance","Life Sci Alliance",2022,"2022","5","10.26508/lsa.202201379",NA,"","","35193953","35193953","PUBMED","INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Centre National de la Recherche Scientifique, UMR7104, Illkirch, France.;Institut National de la Santé et de la Recherche Médicale, U1258, Illkirch, France.;Université de Strasbourg, Illkirch, France.;INSERM U1242, University of Rennes, Rennes, France.;Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.;Center for Geroscience, Brain Health and Metabolism (GERO), Santiago, Chile.;Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg, Sweden.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Biomedical Neuroscience Institute, Faculty of Medicine, University of Chile, Santiago, Chile.;Center for Geroscience, Brain Health and Metabolism (GERO), Santiago, Chile.;Program of Cellular and Molecular Biology, Institute of Biomedical Sciences, University of Chile, Santiago, Chile.;INSERM U1242, University of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Goodman Cancer Research Centre, McGill University, Montreal, Canada.;Department of Biochemistry, McGill University, Montreal, Canada.;Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg;INSERM U1242, University of Rennes, Rennes;Centre Eugène Marquis, Rennes, France."
"295","Machavoine R;Helfre S;Bernier V;Bolle S;Leseur J;Corradini N;Rome A;Defachelles AS;Deneuve S;Bernard S;Fayoux P;Nicollas R;Mondain M;Luscan R;Denoyelle F;Simon F;Kadlub N;Kolb F;Honart JF;Orbach D;Minard-Colin V;Moya-Plana A;Couloigner V","Machavoine, Roxane;Helfre, Sylvie;Bernier, Valérie;Bolle, Stéphanie;Leseur, Julie;Corradini, Nadège;Rome, Angélique;Defachelles, Anne-Sophie;Deneuve, Sophie;Bernard, Sophie;Fayoux, Pierre;Nicollas, Richard;Mondain, Michel;Luscan, Romain;Denoyelle, Françoise;Simon, François;Kadlub, Natacha;Kolb, Fréderic;Honart, Jean-François;Orbach, Daniel;Minard-Colin, Véronique;Moya-Plana, Antoine;Couloigner, Vincent","Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma-The French Experience.","Frontiers in pediatrics","Switzerland","eng","Journal Article","alveolar rhabdomyosarcoma (ARMS);children;head and neck neoplasm;neck dissection;survival","","","The head and neck (HN) are the most frequent sites of pediatric rhabdomyosarcoma (RMS). Alveolar RMS (ARMS) represents ~20% of all RMS cases and frequently spread to lymph nodes (LNs). The aim was to report locoregional control, event-free survival (EFS), and overall survival (OS), according to clinical and pathological features, LN staging, and treatment modalities. The study included all patients prospectively enrolled in EpSSG RMS 2005 study under 21 years of age with localized HN ARMS and diagnosed between 2005 and 2016 in France. Medical data including imaging, surgical report, and radiation therapy planes were analyzed. Forty-eight patients (median age 6 years; range 4 months-21 years), corresponding to 30 parameningeal and 18 non-parameningeal ARMS, were included. There were 33 boys (69%). Tumor locations included the following: orbit (  = 7) among which four cases had bone erosion, paranasal sinuses and nasal cavity (  = 16), deep facial spaces (  = 10), nasolabial fold (  = 8), and other non-parameningeal HN sites (  = 7). A fusion transcript of PAX3-FOXO1 or PAX7-FOXO1 was expressed in 33 of the 45 cases (73%) with molecular analysis. At diagnosis, 10 patients had primary resection of the primary tumor (PRPT) (none with microscopic complete resection) and 9 had LN staging. After induction chemotherapy, 26 patients (54%) had secondary resection of the primary tumor (SRPT) and 13 patients (27%) had cervical LN dissection. A total of 43 patients (90%) were treated with radiation therapy.With a median follow-up of 7 years (range 2-13 years), 5-year OS and EFS were 78% (95% CI, 63-88%) and 66% (95% CI, 51-78%), respectively. We observed 16 events (10 deaths): 4 local, 4 regional, 1 local and regional, and 7 metastatic. In univariate analysis, OS was only superior for patients under 10 years of age (  = 0.002), while  -negative ARMS, SRPT for parameningeal ARMS, and LN surgery were associated with significantly better EFS. Our study confirms a better outcome for fusion-negative ARMS and ARMS in children under 10 years. Moreover, LN surgery and SRPT of parameningeal tumor may improve EFS of ARMS. Larger studies are needed to confirm our findings.","Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Radiation Oncology, Institut Curie, Paris, France.;Département Universitaire de Radiothérapie-Curiethérapie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Service d'Oncologie Pédiatrique, Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon, France.;Pediatric Oncology Department, Hôpitaux Universitaires de Marseille Timone, AP-HM, Marseille, France.;Department of Pediatric Oncology, Centre Oscar Lambret, Lille, France.;Service d'Oto-Rhino-Laryngologie, Centre Léon Bérard, Lyon, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Robert Debré, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Jeanne de Flandre, CHRU Lille, Lille, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpitaux Universitaires de Marseille Timone, AP-HM, Marseille, France.;Service d'Oto-Rhino-Laryngologie, CHU Montpellier, Montpellier, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Maxillo-Facial and Plastic Surgery, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Plastic Surgery Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Plastic Surgery Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;Department of Pediatric and Adolescent Oncology, INSERM 1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Department of Oto-Rhino-Laryngology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.","NA",0,"2296-2360","Front Pediatr","Front Pediatr",2021,"2021","9","10.3389/fped.2021.783754","783754","","","35186818","35186818","PUBMED","Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Radiation Oncology, Institut Curie, Paris, France.;Département Universitaire de Radiothérapie-Curiethérapie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Service de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Service d'Oncologie Pédiatrique, Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civils de Lyon, Lyon, France.;Pediatric Oncology Department, Hôpitaux Universitaires de Marseille Timone, AP-HM, Marseille, France.;Department of Pediatric Oncology, Centre Oscar Lambret, Lille, France.;Service d'Oto-Rhino-Laryngologie, Centre Léon Bérard, Lyon, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Robert Debré, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Jeanne de Flandre, CHRU Lille, Lille, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpitaux Universitaires de Marseille Timone, AP-HM, Marseille, France.;Service d'Oto-Rhino-Laryngologie, CHU Montpellier, Montpellier, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Department of Pediatric Maxillo-Facial and Plastic Surgery, Hôpital Necker-Enfants Malades, APHP, Paris, France.;Plastic Surgery Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Plastic Surgery Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), PSL Research University, Institut Curie, Paris, France.;Department of Pediatric and Adolescent Oncology, INSERM 1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Department of Oto-Rhino-Laryngology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.;Department of Pediatric Oto-Rhino-Laryngology, Hôpital Necker-Enfants Malades, APHP, Paris, France."
"296","Edeline J;Hirano S;Bertaut A;Konishi M;Benabdelghani M;Uesaka K;Watelet J;Ohtsuka M;Hammel P;Kaneoka Y;Joly JP;Yamamoto M;Monard L;Ambo Y;Louvet C;Ando M;Malka D;Nagino M;Phelip JM;Ebata T","Edeline, Julien;Hirano, Satoshi;Bertaut, Aurélie;Konishi, Masaru;Benabdelghani, Meher;Uesaka, Katsuhiko;Watelet, Jérôme;Ohtsuka, Masayuki;Hammel, Pascal;Kaneoka, Yuji;Joly, Jean-Paul;Yamamoto, Masakazu;Monard, Laure;Ambo, Yoshiyasu;Louvet, Christophe;Ando, Masahiko;Malka, David;Nagino, Masato;Phelip, Jean-Marc;Ebata, Tomoki","Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Adjuvant treatment;Biliary tract cancer;Chemotherapy;Cholangiocarcinoma;Gemcitabine","Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Deoxycytidine;Humans;Neoplasm Recurrence, Local;Randomized Controlled Trials as Topic;Gemcitabine","Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Deoxycytidine;Humans;Neoplasm Recurrence, Local;Randomized Controlled Trials as Topic;Gemcitabine","Although gemcitabine-based chemotherapy is the standard of care for advanced biliary tract cancers (BTCs), adjuvant phase III studies (BCAT in Japan, PRODIGE 12 in France) failed to show benefit, possibly owing to fewer patients (n = 225 and n = 194) compared with the adjuvant capecitabine BILCAP trial (n = 447). We performed a combined analysis of both gemcitabine-based chemotherapy adjuvant studies. We performed individual patient data meta-analysis of all patients included in BCAT and PRODIGE 12. BCAT study randomised patients with extrahepatic cholangiocarcinoma to single-agent gemcitabine or observation. PRODIGE 12 randomised patients with all BTC subtypes to gemcitabine-oxaliplatin combination or observation. Combined analysis was performed using Kaplan-Meier curves and a Cox regression model stratified on the trial. Two hundred and twelve versus 207 patients were randomised in the gemcitabine-based chemotherapy versus observation arms. Baseline characteristics were balanced between arms. The median follow-up was 5.5 years. After 258 relapse-free survival (RFS) events, there was no difference in RFS (log-rank p = 0.45; hazard ratio [HR] = 0.91 [95% confidence interval [CI] 0.71-1.16]; p = 0.46). RFS rates at five years were 40.8% (95%CI: 33.9%-47.5%) for gemcitabine-based chemotherapy versus 36.6% (95%CI: 29.8%-43.4%) for observation. After 201 deaths, there was no difference in overall survival (OS) (log-rank p = 0.83; HR = 1.03 [95%CI: 0.78-1.35]; p = 0.85). OS rates at five years were 50.5% (95%CI: 43.1%-57.4%) for gemcitabine-based chemotherapy versus 49.3% (95%CI: 41.6%-56.5%) for observation. With 419 patients included, this analysis did not show significant improvement in RFS and no trend in improvement in OS. Gemcitabine-based chemotherapy should not be used as an adjuvant treatment for BTC.","Medical Oncology, Centre Eugène Marquis, av de la bataille Flandres-Dunkerque, 35042 Rennes;Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo;Methodology and Biostatistics Unit, Centre Georges-François Leclerc, Dijon;Department of Hepatobiliary-Pancreatic Surgery, National Cancer Centre Hospital East, Kashiwa;Centre Paul Strauss, Strasbourg;Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, Shizuoka;CHU Brabois, Vondoeuvre les Nancy;Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba;AP-HP hôpital Beaujon, Clichy;Department of Surgery, Ogaki Municipal Hospital, Ogaki;CHU Nord, Amiens;Department of Surgery, Institute of Gastroenterology, TokyoWomen's Medical University, Tokyo;Unicancer, Paris;Department of Surgery, Teine-Keijinkai Hospital, Sapporo;Institut Mutualiste Montsouris, Paris;Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya;Gustave Roussy, Villejuif;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine;CHU St Etienne, St Etienne;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","164","10.1016/j.ejca.2022.01.009","80-87","","","35182925","35182925","PUBMED","Medical Oncology, Centre Eugène Marquis, av de la bataille Flandres-Dunkerque, 35042 Rennes;Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo;Methodology and Biostatistics Unit, Centre Georges-François Leclerc, Dijon;Department of Hepatobiliary-Pancreatic Surgery, National Cancer Centre Hospital East, Kashiwa;Centre Paul Strauss, Strasbourg;Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, Shizuoka;CHU Brabois, Vondoeuvre les Nancy;Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba;AP-HP hôpital Beaujon, Clichy;Department of Surgery, Ogaki Municipal Hospital, Ogaki;CHU Nord, Amiens;Department of Surgery, Institute of Gastroenterology, TokyoWomen's Medical University, Tokyo;Unicancer, Paris;Department of Surgery, Teine-Keijinkai Hospital, Sapporo;Institut Mutualiste Montsouris, Paris;Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya;Gustave Roussy, Villejuif;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine;CHU St Etienne, St Etienne;Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine"
"297","Drillet G;Pastoret C;Moignet A;Lamy T;Marchand T","Drillet, Gaëlle;Pastoret, Cédric;Moignet, Aline;Lamy, Thierry;Marchand, Tony","Toward a Better Classification System for NK-LGL Disorders.","Frontiers in oncology","Switzerland","eng","Journal Article","KIR phenotype;NK cells;STAT3;chronic lymphoproliferative disorders of NK cells;large granular lymphocyte leukemia","","","Large granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by a clonal expansion of T-lineage lymphocyte or natural killer (NK) cells in 85 and 15% of cases respectively. T and NK large granular leukemia share common pathophysiology, clinical and biological presentation. The disease is characterized by cytopenia and a frequent association with autoimmune manifestations. Despite an indolent course allowing a watch and wait attitude in the majority of patients at diagnosis, two third of the patient will eventually need a treatment during the course of the disease. Unlike T lymphocyte, NK cells do not express T cell receptor making the proof of clonality difficult. Indeed, the distinction between clonal and reactive NK-cell expansion observed in several situations such as autoimmune diseases and viral infections is challenging. Advances in our understanding of the pathogenesis with the recent identification of recurrent mutations provide new tools to prove the clonality. In this review, we will discuss the pathophysiology of NK large granular leukemia, the recent advances in the diagnosis and therapeutic strategies.","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;CIC 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2021,"2022","12","10.3389/fonc.2022.821382","821382","","","35178350","35178350","PUBMED","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;CIC 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France."
"298","Dalenc F;Lusque A;De La Motte Rouge T;Pistilli B;Brain E;Pasquier D;Debled M;Thery JC;Gonçalves A;Desmoulins I;Levy C;Uwer L;Ferrero JM;Eymard JC;Mouret-Reynier MA;Patsouris A;Frenel JS;Petit T;Chevrot M;Bachelot T;Guiu S","Dalenc, Florence;Lusque, Amélie;De La Motte Rouge, Thibault;Pistilli, Barbara;Brain, Etienne;Pasquier, David;Debled, Marc;Thery, Jean-Christophe;Gonçalves, Anthony;Desmoulins, Isabelle;Levy, Christelle;Uwer, Lionel;Ferrero, Jean-Marc;Eymard, Jean-Christophe;Mouret-Reynier, Marie-Ange;Patsouris, Anne;Frenel, Jean-Sébastien;Petit, Thierry;Chevrot, Michael;Bachelot, Thomas;Guiu, Séverine","Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Invasive ductal carcinoma;Invasive lobular carcinoma;Metastatic breast cancer;Overall survival","Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Prognosis;Retrospective Studies","Breast Neoplasms;Carcinoma, Ductal, Breast;Carcinoma, Lobular;Female;Humans;Prognosis;Retrospective Studies","The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics. Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20-1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07-1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64-0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08-1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67-1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.","Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Saint-Cloud and Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-Paul Papin, Angers, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-René Gauducheau, Nantes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real Worl Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","164","10.1016/j.ejca.2021.12.031","70-79","","","35176614","35176614","PUBMED","Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Biostatistics, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Saint-Cloud and Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-Paul Papin, Angers, France.;Department of MedicalOncology, Institut de Cancérologie de L'Ouest-René Gauducheau, Nantes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real Worl Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier"
"299","Reizine F;Grégoire M;Lesouhaitier M;Coirier V;Gauthier J;Delaloy C;Dessauge E;Creusat F;Uhel F;Gacouin A;Dessauge F;Le Naoures C;Moreau C;Bendavid C;Daniel Y;Petitjean K;Bordeau V;Lamaison C;Piau C;Cattoir V;Roussel M;Fromenty B;Michelet C;Le Tulzo Y;Zmijewski J;Thibault R;Cogné M;Tarte K;Tadié JM","Reizine, Florian;Grégoire, Murielle;Lesouhaitier, Mathieu;Coirier, Valentin;Gauthier, Juliette;Delaloy, Céline;Dessauge, Elise;Creusat, Florent;Uhel, Fabrice;Gacouin, Arnaud;Dessauge, Frédéric;Le Naoures, Cécile;Moreau, Caroline;Bendavid, Claude;Daniel, Yoann;Petitjean, Kilian;Bordeau, Valérie;Lamaison, Claire;Piau, Caroline;Cattoir, Vincent;Roussel, Mikael;Fromenty, Bernard;Michelet, Christian;Le Tulzo, Yves;Zmijewski, Jaroslaw;Thibault, Ronan;Cogné, Michel;Tarte, Karin;Tadié, Jean-Marc","Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction.","Proceedings of the National Academy of Sciences of the United States of America","United States","eng","Journal Article","T cell;citrulline;mitochondria;sepsis","Animals;Arginine;Biological Availability;Citrulline;Cytokines;Disease Models, Animal;Female;Immune Tolerance;Immunosuppression Therapy;Lymphocyte Activation;Mice;Mice, Inbred C57BL;Mitochondria;Myeloid-Derived Suppressor Cells;Sepsis;T-Lymphocytes;T-Lymphocytes, Regulatory","Animals;Arginine;Biological Availability;Citrulline;Cytokines;Disease Models, Animal;Female;Immune Tolerance;Immunosuppression Therapy;Lymphocyte Activation;Mice;Mice, Inbred C57BL;Mitochondria;Myeloid-Derived Suppressor Cells;Sepsis;T-Lymphocytes;T-Lymphocytes, Regulatory","Severe sepsis induces a sustained immune dysfunction associated with poor clinical behavior. In particular, lymphopenia along with increased lymphocyte apoptosis and decreased lymphocyte proliferation, enhanced circulating regulatory T cells (Treg), and the emergence of myeloid-derived suppressor cells (MDSCs) have all been associated with persistent organ dysfunction, secondary infections, and late mortality. The mechanisms involved in MDSC-mediated T cell dysfunction during sepsis share some features with those described in malignancies such as arginine deprivation. We hypothesized that increasing arginine availability would restore T cell function and decrease sepsis-induced immunosuppression. Using a mouse model of sepsis based on cecal ligation and puncture and secondary pneumonia triggered by methicillin-resistant   inoculation, we demonstrated that citrulline administration was more efficient than arginine in increasing arginine plasma levels and restoring T cell mitochondrial function and proliferation while reducing sepsis-induced Treg and MDSC expansion. Because there is no specific therapeutic strategy to restore immune function after sepsis, we believe that our study provides evidence for developing citrulline-based clinical studies in sepsis.","Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;PEGASE, INRAE, Institut Agro, 35590 Saint Gilles, France.;Laboratoire d'anatomie pathologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Centre National de Référence de la Résistance aux Antibiotique (laboratoire associé ""Entérocoques""), Centre Hospitalier Universitaire de Rennes, F-35043 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.;INSERM, Service d'Endocrinologie, Diabétologie et Nutrition, Institut National de Recherche Agronomoque, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.","NA",0,"1091-6490","Proc Natl Acad Sci U S A","Proc Natl Acad Sci U S A",2021,"2022","119","10.1073/pnas.2115139119",NA,"","","35173051","35173051","PUBMED","Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;PEGASE, INRAE, Institut Agro, 35590 Saint Gilles, France.;Laboratoire d'anatomie pathologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Laboratoire de Biochimie, Pôle Biologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;BACTERIAL REGULATORY RNAS AND MEDICINE-UMR_S 1230, INSERM, Université de Rennes 2, F-35000 Rennes, France.;Service de Bactériologie, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;Centre National de Référence de la Résistance aux Antibiotique (laboratoire associé ""Entérocoques""), Centre Hospitalier Universitaire de Rennes, F-35043 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;UMR_A 1341, UMR_S 1241, INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Université de Rennes 2, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294.;INSERM, Service d'Endocrinologie, Diabétologie et Nutrition, Institut National de Recherche Agronomoque, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Institut de Nutrition, Métabolismes et Cancer, Institut National de Recherche Agronomique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes, France.;INSERM, Microenvironment, Cell Differentiation, Immunology, and Cancer-UMR_S1236, Établissement française du sang Bretagne, Université de Rennes 2, F-35000 Rennes;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, F-35033 Rennes, France.;INSERM, Centre d'Investigation Clinique de Rennes, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France."
"300","Pham F;Boespflug A;Duru G;Phan A;Poulalhon N;Weiler L;Tanaka M;Lallas A;Ogata D;Davaine AC;Bahadoran P;Balguerie X;Kamińska-Winciorek G;Tromme I;Correia O;Kim MB;Marghoob AA;Linda Martin P;Guitera M;Meziane J;Miquel JH;Mun G;Argenziano D;Bessis J;Bourke Z;Mijuskovic C;Chiaverini C;Corven-Benoit C;Droitcourt F;Skowron M;Marque I;Zalaudek C;Rosendahl D;Moreno-Ramirez P;Vabres H;Haenssle J;Malvehy S;Puig C;Robert TR;Schopf A;Scope S;Dalle L;Thomas F","Pham, Félix;Boespflug, Amélie;Duru, Gérard;Phan, Alice;Poulalhon, Nicolas;Weiler, Laura;Tanaka, Masaru;Lallas, Aimilios;Ogata, Dai;Davaine, Anne Céline;Bahadoran, Philippe;Balguerie, Xavier;Kamińska-Winciorek, Grażyna;Tromme, Isabelle;Correia, Osvaldo;Kim, Moon-Bum;Marghoob, Ashfaq A;Linda Martin, Pascale;Guitera, Mariame;Meziane, Juliette;Miquel, Je-Ho;Mun, Giuseppe;Argenziano, Didier;Bessis, Johnny;Bourke, Zeljko;Mijuskovic, Christine;Chiaverini, Cloé;Corven-Benoit, Catherine;Droitcourt, François;Skowron, Myriam;Marque, Iris;Zalaudek, Cliff;Rosendahl, David;Moreno-Ramirez, Pierre;Vabres, Holger;Haenssle, Josep;Malvehy, Susana;Puig, Caroline;Robert, Thomas R;Schopf, Alon;Scope, Stéphane;Dalle, Luc;Thomas, Félix","Dermatoscopic and clinical features of congenital or congenital-type nail matrix nevi: A multicenter prospective cohort study by the International Dermoscopy Society.","Journal of the American Academy of Dermatology","United States","eng","Journal Article","children;congenital;congenital nail matrix nevus;dermatoscopy;longitudinal melanonychia;melanonychia striata;nevus of the nail unit;pediatric;subungual melanoma","Adult;Child;Child, Preschool;Dermoscopy;Diagnosis, Differential;Humans;Infant, Newborn;Melanoma;Nail Diseases;Nevus;Prospective Studies;Skin Neoplasms","Adult;Child;Child, Preschool;Dermoscopy;Diagnosis, Differential;Humans;Infant, Newborn;Melanoma;Nail Diseases;Nevus;Prospective Studies;Skin Neoplasms","Congenital nail matrix nevi (NMN) are difficult to diagnose because they feature clinical characteristics suggestive of adult subungual melanoma. Nail matrix biopsy is difficult to perform, especially in children. To describe the initial clinical and dermatoscopic features of NMN appearing at birth (congenital) or after birth but before the age of 5 years (congenital-type). We conducted a prospective, international, and consecutive data collection in 102 hospitals or private medical offices across 30 countries from 2009 to 2019. There were 69 congenital and 161 congenital-type NMNs. Congenital and congenital-type NMN predominantly displayed an irregular pattern of longitudinal microlines (n = 146, 64%), reminiscent of subungual melanoma in adults. The distal fibrillar (""brush-like"") pattern, present in 63 patients (27.8%), was more frequently encountered in congenital NMN than in congenital-type NMN (P = .012). Moreover, congenital NMN more frequently displayed a periungual pigmentation (P = .029) and Hutchinson's sign (P = .027) than did congenital-type NMN. Lack of systematic biopsy-proven diagnosis and heterogeneity of clinical and dermatoscopic photographs. Congenital and congenital-type NMN showed worrisome clinical and dermatoscopic features similar to those observed in adulthood subungual melanoma. The distal fibrillar (""brush-like"") pattern is a suggestive feature of congenital and congenital-type NMN.","Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Cyklad Group, Lyon, France.;Nephrology-Rheumatology-Dermatology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Department of Dermatology, Saitama Medical University, Japan.;First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.;Department of Dermatologic oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.;Dermatologist, private practice, Morlaix, France.;Centre Hospitalier Universitaire Nice, Department of Dermatology, Université Nice Côte d'Azur, Nice, France.;Department of Dermatology, Rouen University Medical Center, Rouen, France.;Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and the Institute of Oncology, Gliwice Branch, Poland.;Dermatology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.;Centro Dermatologia Epidermis, Instituto CUF and Faculty of Medicine of University of Porto, Porto, Portugal.;Department of Dermatology, School of Medicine, Pusan National University Medical Research Institute, Pusan National University, Busan, Korea.;Memorial Sloan Kettering Skin Cancer Center, Hauppauge, New York, USA.;Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.;Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.;Department of Dermatology, Ibn Sina University Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V university, Rabat, Morocco.;Unit of Pediatric Dermatology, Saint-Pierre University Hospital, Saint-Pierre, la Réunion, France.;Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.;Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Napoli, Italy.;Service de Dermatologie, Hôpital Saint-Eloi et Hôpital Universitaire de Montpellier, Montpellier, France.;Dermatology Department, South Infirmary-Victoria University Hospital, Cork, Ireland.;Department of Dermatology and Venereology,School of Medicine, Military Medical Academy, Belgrade, Serbia.;Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France.;Dermatologist, private practice, Joué-lès-Tours, Joué-lès-Tours, France.;Department of Dermatology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de dermatologie, Hôpitaux Drôme Nord, Romans sur Isère, Romans sur Isère, France.;Department of Dermatology, Caremeau Hospital, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Department of Dermatology, Medical University of Trieste, Trieste, Italy.;Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.;Dermatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.;Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Universitäts-Hautklinik Heidelberg, Ruprecht-Karl Universität, Heidelberg, Germany.;Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.;Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.;Department of Medicine, Dermatology Service, Gustave Roussy and Paris-Saclay University, INSERM U981, Villejuif, France.;Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway.;The Kittner Skin Cancer Screening and Research Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon","NA",0,"1097-6787","J Am Acad Dermatol","J Am Acad Dermatol",2021,"2022","87","10.1016/j.jaad.2022.01.028","551-558","P30 CA008748","NCI NIH HHS","35104588","35104588","PUBMED","Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Cyklad Group, Lyon, France.;Nephrology-Rheumatology-Dermatology Department, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.;Department of Dermatology, Saitama Medical University, Japan.;First Department of Dermatology, School of Medicine, Faculty of Health Sciences, Aristotle University, Thessaloniki, Greece.;Department of Dermatologic oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.;Dermatologist, private practice, Morlaix, France.;Centre Hospitalier Universitaire Nice, Department of Dermatology, Université Nice Côte d'Azur, Nice, France.;Department of Dermatology, Rouen University Medical Center, Rouen, France.;Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and the Institute of Oncology, Gliwice Branch, Poland.;Dermatology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.;Centro Dermatologia Epidermis, Instituto CUF and Faculty of Medicine of University of Porto, Porto, Portugal.;Department of Dermatology, School of Medicine, Pusan National University Medical Research Institute, Pusan National University, Busan, Korea.;Memorial Sloan Kettering Skin Cancer Center, Hauppauge, New York, USA.;Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.;Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.;Department of Dermatology, Ibn Sina University Hospital, Rabat, Morocco; Faculty of Medicine and Pharmacy, Mohammed V university, Rabat, Morocco.;Unit of Pediatric Dermatology, Saint-Pierre University Hospital, Saint-Pierre, la Réunion, France.;Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.;Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Napoli, Italy.;Service de Dermatologie, Hôpital Saint-Eloi et Hôpital Universitaire de Montpellier, Montpellier, France.;Dermatology Department, South Infirmary-Victoria University Hospital, Cork, Ireland.;Department of Dermatology and Venereology,School of Medicine, Military Medical Academy, Belgrade, Serbia.;Department of Dermatology, Centre Hospitalier Universitaire de Nice, Nice, France.;Dermatologist, private practice, Joué-lès-Tours, Joué-lès-Tours, France.;Department of Dermatology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de dermatologie, Hôpitaux Drôme Nord, Romans sur Isère, Romans sur Isère, France.;Department of Dermatology, Caremeau Hospital, Centre Hospitalier Universitaire de Nîmes, Nîmes, France.;Department of Dermatology, Medical University of Trieste, Trieste, Italy.;Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.;Dermatology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.;Centre de Référence MAGEC, Service de Dermatologie, Centre Hospitalier Universitaire Dijon Bourgogne, Dijon, France.;Universitäts-Hautklinik Heidelberg, Ruprecht-Karl Universität, Heidelberg, Germany.;Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.;Melanoma Unit, Department of Dermatology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.;Department of Medicine, Dermatology Service, Gustave Roussy and Paris-Saclay University, INSERM U981, Villejuif, France.;Norwegian Centre for E-health Research, University Hospital of North Norway, Tromsø, Norway.;The Kittner Skin Cancer Screening and Research Institute, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon, France.;Service de Dermatologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université Claude-Bernard-Lyon Lyon, Lyon"
"301","Zaibet S;Hautefeuille V;Auclin E;Lièvre A;Tougeron D;Sarabi M;Gilabert M;Wasselin J;Edeline J;Artru P;Bechade D;Morin C;Ducoulombier A;Taieb J;Pernot S","Zaibet, Sonia;Hautefeuille, Vincent;Auclin, Edouard;Lièvre, Astrid;Tougeron, David;Sarabi, Mathieu;Gilabert, Marine;Wasselin, Julie;Edeline, Julien;Artru, Pascal;Bechade, Dominique;Morin, Clémence;Ducoulombier, Agnes;Taieb, Julien;Pernot, Simon","Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.","British journal of cancer","England","eng","Journal Article","","Adenocarcinoma;Albumins;Antineoplastic Combined Chemotherapy Protocols;Deoxycytidine;Fluorouracil;Humans;Irinotecan;Leucovorin;Oxaliplatin;Paclitaxel;Pancreatic Neoplasms;Retrospective Studies;Gemcitabine","Adenocarcinoma;Albumins;Antineoplastic Combined Chemotherapy Protocols;Deoxycytidine;Fluorouracil;Humans;Irinotecan;Leucovorin;Oxaliplatin;Paclitaxel;Pancreatic Neoplasms;Retrospective Studies;Gemcitabine","Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist. This study evaluates the efficacy and safety of adding Nab-paclitaxel to Gem for mPA after FFX failure. In this retrospective real-world multicenter study, from 2011 to 2019, patients with mPA receiving Gem-Nab (Gem 1000 mg/m² + Nab 125 mg/m², 3 out of 4 weeks) or Gem alone were included after progression on FFX. A total of 427 patients were included. Patients receiving Gem-Nab had more metastatic sites, peritoneal disease and less PS 2 (24% vs. 35%). After median follow-up of 22 months, Gem-Nab was associated with better disease control rate (DCR) (56% vs. 32%; P < 0.001), progression-free survival (PFS) (3.5 vs. 2.3 months; 95% CI: 0.43-0.65) and overall survival (OS) (7.1 vs. 4.7 months; 95% CI: 0.53-0.86). After multivariate analysis, Gem-Nab and PS 0/1 were associated with better OS and PFS. Grade 3/4 toxicity was more frequent with Gem-Nab (44% vs. 29%). In this study, Gem-Nab was associated with better DCR, PFS and OS compared with Gem alone in patients with mPA after FFX failure, at the cost of higher toxicity.","Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.;Department of Gastroenterology, CHU Rennes, INSERM U1242, Rennes, France.;Department of Hepato-Gastroenterology, CHU Poitiers, Poitiers, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepato-Gastroenterology, Hôpital Privé Jean Mermoz, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2021,"2022","126","10.1038/s41416-022-01713-w","1394-1400","","","35094032","35094032","PUBMED","Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France.;Department of Medical Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers, Université de Paris, Paris, France.;Department of Gastroenterology, CHU Rennes, INSERM U1242, Rennes, France.;Department of Hepato-Gastroenterology, CHU Poitiers, Poitiers, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, CHU Amiens Picardie, Amiens, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepato-Gastroenterology, Hôpital Privé Jean Mermoz, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Hepato-Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou, Université de Paris, SIRIC CARPEM Comprehensive Cancer Center, Paris, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux"
"302","Mallet A;Lusque A;Levy C;Pistilli B;Brain E;Pasquier D;Debled M;Thery JC;Gonçalves A;Desmoulins I;De La Motte Rouge T;Faure C;Ferrero JM;Eymard JC;Mouret-Reynier MA;Patsouris A;Cottu P;Dalenc F;Petit T;Payen O;Uwer L;Guiu S;Frenel JS","Mallet, Amélie;Lusque, Amélie;Levy, Christelle;Pistilli, Barbara;Brain, Etienne;Pasquier, David;Debled, Marc;Thery, Jean Christophe;Gonçalves, Anthony;Desmoulins, Isabelle;De La Motte Rouge, Thibault;Faure, Christelle;Ferrero, Jean Marc;Eymard, Jean Christophe;Mouret-Reynier, Marie Ange;Patsouris, Anne;Cottu, Paul;Dalenc, Florence;Petit, Thierry;Payen, Olivier;Uwer, Lionel;Guiu, Séverine;Frenel, Jean Sébastien",NA,"Therapeutic advances in medical oncology","England","eng","Journal Article","de novo;metastatic breast cancer;prognosis;real-life;young women","","","Breast cancer (BC) in young women merits a specific approach given the associated fertility, genetic and psychosocial issues.   metastatic breast cancer (MBC) in young women is an even more serious condition, with limited data available. We evaluated management of women aged ⩽40 years with   MBC in a real-life national multicentre cohort of 22,463 patients treated between 2008 and 2016 (NCT0327531). Our primary objective was to compare overall survival (OS) in young women   women aged 41-69 years. The secondary objectives were to compare first-line progression-free survival (PFS1) and to describe treatment patterns. Of the 4524 women included, 598 (13%) were ⩽40 years. Median age at MBC diagnosis was 36 years (range = 20-40). Compared with women aged 41-69 years, young women had more grade III tumours (49%   35.7%,   < 0.0001), human epidermal growth factor receptor 2 amplified (HER2+) disease (34.6%   26.4%,   < 0.0001) and HR-/HER2- disease known as ""triple negative breast cancer"" (TNBC) (17.1%   12.7%,   < 0.0001). BRCA testing was performed for 260 young women, with a BRCA1/2 mutation in 44 (17% of those tested) In young HR+/HER2- patients, chemotherapy (CT) was given as the frontline treatment more frequently compared with older ones (89.6%   68.8%, respectively,   < 0.0001). After median follow-up of 49.7 months (95% confidence interval, CI = 48.0-51.7), the median OS of young women was 58.5 months, 20.7 months and not attained in HR+/HER2-, TNBC and HER2+ subgroups, respectively. After adjustment for histological subtype, tumour grade, and number and type of metastasis, young women had significantly better OS compared with older ones, except for the TNBC subgroup, for which the outcome was similar. PFS1 was statistically different only in the TNBC subgroup, with 7.8 months for young women and 6.3 months for older women (  = 0.0015).  MBC affects a significant proportion of young women. A subgroup of these patients achieves long OS and merits multidisciplinary care.","Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Department of Biostatistics, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgery Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Etablissement Hospitalier Institut Curie, Paris, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real World Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2021,"2022","14","10.1177/17588359211070362","17588359211070362","","","35082924","35082924","PUBMED","Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Department of Biostatistics, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Surgery Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Etablissement Hospitalier Institut Curie, Paris, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Real World Data, Data Unit, Unicancer, Paris, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - René Gauducheau, Boulevard Jacques Monod, 44805 Saint-Herblain, France."
"303","Hossain SI;de Goër de Herve J;Hassan MS;Martineau D;Petrosyan E;Corbin V;Beytout J;Lebert I;Durand J;Carravieri I;Brun-Jacob A;Frey-Klett P;Baux E;Cazorla C;Eldin C;Hansmann Y;Patrat-Delon S;Prazuck T;Raffetin A;Tattevin P;Vourc'h G;Lesens O;Nguifo EM","Hossain, Sk Imran;de Goër de Herve, Jocelyn;Hassan, Md Shahriar;Martineau, Delphine;Petrosyan, Evelina;Corbin, Violaine;Beytout, Jean;Lebert, Isabelle;Durand, Jonas;Carravieri, Irene;Brun-Jacob, Annick;Frey-Klett, Pascale;Baux, Elisabeth;Cazorla, Céline;Eldin, Carole;Hansmann, Yves;Patrat-Delon, Solene;Prazuck, Thierry;Raffetin, Alice;Tattevin, Pierre;Vourc'h, Gwenaël;Lesens, Olivier;Nguifo, Engelbert Mephu","Exploring convolutional neural networks with transfer learning for diagnosing Lyme disease from skin lesion images.","Computer methods and programs in biomedicine","Ireland","eng","Journal Article","CNN;Erythema migrans;Explainability;Lyme disease;Transfer learning","France;Humans;Lyme Disease;Machine Learning;Neural Networks, Computer;Skin Diseases","France;Humans;Lyme Disease;Machine Learning;Neural Networks, Computer;Skin Diseases","Lyme disease which is one of the most common infectious vector-borne diseases manifests itself in most cases with erythema migrans (EM) skin lesions. Recent studies show that convolutional neural networks (CNNs) perform well to identify skin lesions from images. Lightweight CNN based pre-scanner applications for resource-constrained mobile devices can help users with early diagnosis of Lyme disease and prevent the transition to a severe late form thanks to appropriate antibiotic therapy. Also, resource-intensive CNN based robust computer applications can assist non-expert practitioners with an accurate diagnosis. The main objective of this study is to extensively analyze the effectiveness of CNNs for diagnosing Lyme disease from images and to find out the best CNN architectures considering resource constraints. First, we created an EM dataset with the help of expert dermatologists from Clermont-Ferrand University Hospital Center of France. Second, we benchmarked this dataset for twenty-three CNN architectures customized from VGG, ResNet, DenseNet, MobileNet, Xception, NASNet, and EfficientNet architectures in terms of predictive performance, computational complexity, and statistical significance. Third, to improve the performance of the CNNs, we used custom transfer learning from ImageNet pre-trained models as well as pre-trained the CNNs with the skin lesion dataset HAM10000. Fourth, for model explainability, we utilized Gradient-weighted Class Activation Mapping to visualize the regions of input that are significant to the CNNs for making predictions. Fifth, we provided guidelines for model selection based on predictive performance and computational complexity. Customized ResNet50 architecture gave the best classification accuracy of 84.42% ±1.36, AUC of 0.9189±0.0115, precision of 83.1%±2.49, sensitivity of 87.93%±1.47, and specificity of 80.65%±3.59. A lightweight model customized from EfficientNetB0 also performed well with an accuracy of 83.13%±1.2, AUC of 0.9094±0.0129, precision of 82.83%±1.75, sensitivity of 85.21% ±3.91, and specificity of 80.89%±2.95. All the trained models are publicly available at https://dappem.limos.fr/download.html, which can be used by others for transfer learning and building pre-scanners for Lyme disease. Our study confirmed the effectiveness of even some lightweight CNNs for building Lyme disease pre-scanner mobile applications to assist people with an initial self-assessment and referring them to expert dermatologist for further diagnosis.","Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Inserm, Neuro-Dol, CNRS 6023 Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;CPIE Champenoux, F-54280 Champenoux, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;INRAE, US 1371 Laboratory of Excellence ARBRE, Centre INRAE Grand Est-Nancy, Champenoux F-54280, France.;Infectious Diseases Department, University Hospital of Nancy, Nancy, France.;Infectious Disease Department, University Hospital of Saint Etienne, Saint-Etienne, France.;IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires, 67000 Strasbourg, France.;Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Tick-Borne Diseases Reference Center, North region, Department of Infectious Diseases, Hospital of Villeneuve-Saint-Georges, 40 allée de la Source, 94190 Villeneuve-Saint-Georges; ESGBOR, European Study Group for Lyme Borreliosis.;Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Infectious and Tropical Diseases Department, CRIOA, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6023, Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand","NA",0,"1872-7565","Comput Methods Programs Biomed","Comput Methods Programs Biomed",2021,"2022","215","10.1016/j.cmpb.2022.106624","106624","","","35051835","35051835","PUBMED","Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;Infectious and Tropical Diseases Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.;CHU Clermont-Ferrand, Inserm, Neuro-Dol, CNRS 6023 Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;CPIE Champenoux, F-54280 Champenoux, France.;Tous Chercheurs Laboratory, UMR 1136 'Interactions Arbres Micro-Organismes', INRAE, Centre INRAE Grand Est-Nancy, F-54280 Champenoux, France.;INRAE, US 1371 Laboratory of Excellence ARBRE, Centre INRAE Grand Est-Nancy, Champenoux F-54280, France.;Infectious Diseases Department, University Hospital of Nancy, Nancy, France.;Infectious Disease Department, University Hospital of Saint Etienne, Saint-Etienne, France.;IHU-Méditerranée Infection, Marseille, France; Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.;Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires, 67000 Strasbourg, France.;Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Tick-Borne Diseases Reference Center, North region, Department of Infectious Diseases, Hospital of Villeneuve-Saint-Georges, 40 allée de la Source, 94190 Villeneuve-Saint-Georges; ESGBOR, European Study Group for Lyme Borreliosis.;Department of Infectious Diseases and Intensive Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Université Clermont Auvergne, INRAE, VetAgro Sup, UMR EPIA, 63122 Saint-Genès-Champanelle, France; Université de Lyon, INRAE, VetAgro Sup, UMR EPIA, F-69280 Marcy l'Etoile, France.;Infectious and Tropical Diseases Department, CRIOA, CHU Clermont-Ferrand, Clermont-Ferrand, France; UMR CNRS 6023, Laboratoire Microorganismes: Génome Environnement (LMGE), Université Clermont Auvergne, Clermont-Ferrand, France.;Université Clermont Auvergne, CNRS, ENSMSE, LIMOS, F-63000 Clermont-Ferrand"
"304","Brüggenwirth IMA;Lantinga VA;Rayar M;van den Berg AP;Blokzijl H;Reyntjens KMEM;Porte RJ;de Meijer VE","Brüggenwirth, Isabel M A;Lantinga, Veerle A;Rayar, Michel;van den Berg, Aad P;Blokzijl, Hans;Reyntjens, Koen M E M;Porte, Robert J;de Meijer, Vincent E","Prolonged dual hypothermic oxygenated machine preservation (DHOPE-PRO) in liver transplantation: study protocol for a stage 2, prospective, dual-arm, safety and feasibility clinical trial.","BMJ open gastroenterology","England","eng","Clinical Trial","clinical trials;liver;liver transplantation","Feasibility Studies;Humans;Liver Transplantation;Living Donors;Organ Preservation;Prospective Studies","Feasibility Studies;Humans;Liver Transplantation;Living Donors;Organ Preservation;Prospective Studies","End-ischaemic preservation of a donor liver by dual hypothermic oxygenated machine perfusion (DHOPE) for 2 hours prior to transplantation is sufficient to mitigate ischaemia-reperfusion damage and fully restore cellular energy levels. Clinical studies have shown beneficial outcomes after transplantation of liver grafts preserved by DHOPE compared with static cold storage. In addition to graft reconditioning, DHOPE may also be used to prolong preservation time, which could facilitate logistics for allocation and transplantation globally. This is a prospective, pseudo-randomised, dual-arm, IDEAL-D (Idea, Development, Exploration, Assessment, Long term study-Framework for Devices) stage 2 clinical device trial designed to determine safety and feasibility of prolonged DHOPE (DHOPE-PRO). The end-time of the donor hepatectomy will determine whether the graft will be assigned to the intervention (16:00-3:59 hour) or to the control arm (4:00-15:59 hour). In total, 36 livers will be included in the study. Livers in the intervention group (n=18) will undergo DHOPE-PRO (≥4 hours) until implantation the following morning, whereas livers in the control group (n=18) will undergo regular DHOPE (2 hours) prior to implantation. The primary endpoint of this study is a composite of the occurrence of all (serious) adverse events during DHOPE and up to 30 days after liver transplantation. The protocol was approved by the Medical Ethical Committee of Groningen, METc2020.126 in June 2020, and the study was registered in the Netherlands National Trial Registry (https://www.trialregister.nl/) prior to initiation. NL8740.","Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Organ Preservation and Resuscitation Unit, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Anesthesiology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen","NA",0,"2054-4774","BMJ Open Gastroenterol","BMJ Open Gastroenterol",2021,"2022","9","10.1136/bmjgast-2021-000842",NA,"","","35039326","35039326","PUBMED","Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Organ Preservation and Resuscitation Unit, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Anesthesiology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.;Hepato-Pancreato-Biliary Surgery and Liver Transplantation, University of Groningen and University Medical Center Groningen, Groningen"
"305","Lamarca A;Edeline J;Goyal L","Lamarca, A;Edeline, J;Goyal, L","How I treat biliary tract cancer.","ESMO open","England","eng","Journal Article","ampullary cancer;biliary tract cancer;chemotherapy;cholangiocarcinoma;gallbladder cancer;surgery;targeted;treatment","Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Cholangiocarcinoma;Humans;Neoplasm Recurrence, Local","Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Biliary Tract Neoplasms;Cholangiocarcinoma;Humans;Neoplasm Recurrence, Local","Management of biliary tract cancers (BTCs) is rapidly evolving. Curative management relies on surgical resection followed by adjuvant capecitabine for cholangiocarcinoma and gallbladder cancers. Unfortunately relapse rate remains high, and better adjuvant strategies are urgently required. A majority of patients are diagnosed with advanced disease, when chemotherapy with cisplatin and gemcitabine followed by second-line 5-FU and oxaliplatin /irinotecan is the cornerstone of treatment for most patients in the absence of targetable alterations. Targeted therapies, including therapies for tumours with fibroblast growth factor receptor-2 (FGFR-2) fusions, isocitrate dehydrogenase-1 (IDH-1) mutations, B-Raf proto-oncogene serine/threonine kinase (BRAF) V600E mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, Human epidermal growth factor-2 (HER-2) amplifications, and/or microsatellite instability are rapidly changing the treatment paradigm for many patients with advanced BTC, especially for patients with intrahepatic cholangiocarcinoma. Because of this, molecular profiling should be considered early on patients pathway to allow adequate planning of therapy. Ongoing research is likely to clarify the role of immunotherapy, liver-directed therapy, and liver transplant for BTCs in the future.","Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA.","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2022","7","10.1016/j.esmoop.2021.100378","100378","16281;P50 CA127003","Cancer Research UK;NCI NIH HHS","35032765","35032765","PUBMED","Department of Medical Oncology, The Christie NHS Foundation, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Mass General Cancer Center, Harvard Medical School, Boston, USA."
"306","Muzellec L;Bourien H;Edeline J","Muzellec, Léa;Bourien, Héloïse;Edeline, Julien","Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life.","Cancers","Switzerland","eng","Journal Article","PROs;hepatocellular carcinoma;quality of life;treatment management","","","Quality of life (QoL) in oncology is an outcome becoming more and more important and relevant to explore. Some studies have demonstrated its prognostic impact in different cancers, such as colorectal, breast, and prostate cancers, but also in hepatocellular carcinoma (HCC). Different tools have been developed for assessing quality of life, some general, such as EORTC QLQ-C30, but also specific tools depending on cancer origin which seem to be more pertinent for patients. Systemic treatments and specific symptoms due to cancer evolution could decrease quality of life. For approval of new systemic treatments, authorities ask for benefit in terms of efficacy but also benefit in quality of life, which is crucial for patients. This review reports data about QoL in HCC, including specific tools used, impact of systemic treatments and prognosis for QoL for HCC patients. Management of adverse events is essential to enhance compliance with treatment and quality of life. Assessing quality of life in clinical trials appears quite systematic, but its application in clinical routine requires development.","Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2021,"2021","14","10.3390/cancers14010179",NA,"","","35008343","35008343","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France."
"307","Bayle A;Italiano A;Massard C;Blay JY;Marabelle A","Bayle, Arnaud;Italiano, Antoine;Massard, Christophe;Blay, Jean-Yves;Marabelle, Aurelien","Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox.","European journal of cancer (Oxford, England : 1990)","England","eng","Letter","","Humans;Medical Oncology;Neoplasms;Technology Assessment, Biomedical","Humans;Medical Oncology;Neoplasms;Technology Assessment, Biomedical","NA","Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, Université Paris-Saclay, Équipe Labellisée Ligue Contre le Cancer, Villejuif;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Early Phase Trials and Sarcoma Units, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; University of Bordeaux, Bordeaux, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Centre Eugène Marquis, Rennes, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Department of Cancer Medicine, Léon Bérard Cancer Center, Lyon, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Société Française d'Immunotherapie des Cancers (FITC) France; INSERM U1015 & CIC1428, Universite Paris Saclay, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2022","162","10.1016/j.ejca.2021.12.008","128-129","","","34983014","34983014","PUBMED","Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, Université Paris-Saclay, Équipe Labellisée Ligue Contre le Cancer, Villejuif;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Early Phase Trials and Sarcoma Units, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; University of Bordeaux, Bordeaux, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Centre Eugène Marquis, Rennes, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Department of Cancer Medicine, Léon Bérard Cancer Center, Lyon, France; SCOPP (French Academic Association for Early Phase Trial in Oncology);Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Société Française d'Immunotherapie des Cancers (FITC) France; INSERM U1015 & CIC1428, Universite Paris Saclay, Villejuif"
"308","Deleuze A;Farce J;d'Abrigeon C;Girard A;Le Du F","Deleuze, Antoine;Farce, Julien;d'Abrigeon, Constance;Girard, Antoine;Le Du, Fanny","Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in uterine papillary serous carcinoma.","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","England","eng","Case Reports","endometrial neoplasms;paraneoplastic syndromes;uterine cancer","Adenocarcinoma, Papillary;Aged;Female;Humans;Magnetic Resonance Imaging;Paraneoplastic Cerebellar Degeneration;Uterine Neoplasms","Adenocarcinoma, Papillary;Aged;Female;Humans;Magnetic Resonance Imaging;Paraneoplastic Cerebellar Degeneration;Uterine Neoplasms","NA","Department of Medical Oncology, Centre Eugène Marquis, Rennes;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.","NA",0,"1525-1438","Int J Gynecol Cancer","Int J Gynecol Cancer",2021,"2022","32","10.1136/ijgc-2021-003077","101-104","","","34980663","34980663","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, Rennes;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France."
"309","Le Gallou S;Lhomme F;Irish JM;Mingam A;Pangault C;Monvoisin C;Ferrant J;Azzaoui I;Rossille D;Bouabdallah K;Damaj G;Cartron G;Godmer P;Le Gouill S;Casasnovas RO;Molina TJ;Houot R;Lamy T;Tarte K;Fest T;Roussel M","Le Gallou, Simon;Lhomme, Faustine;Irish, Jonathan M;Mingam, Anna;Pangault, Celine;Monvoisin, Celine;Ferrant, Juliette;Azzaoui, Imane;Rossille, Delphine;Bouabdallah, Krimo;Damaj, Gandhi;Cartron, Guillaume;Godmer, Pascal;Le Gouill, Steven;Casasnovas, René-Olivier;Molina, Thierry Jo;Houot, Roch;Lamy, Thierry;Tarte, Karin;Fest, Thierry;Roussel, Mikael","Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma.","Frontiers in immunology","Switzerland","eng","Journal Article","B cell lymphoma;DLBCL;biomarker;immune suppression;monocyte","Adult;Aged;Female;Humans;Immunophenotyping;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Monocytes","Adult;Aged;Female;Humans;Immunophenotyping;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Monocytes","Absolute count of circulating monocytes has been proposed as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, monocyte nomenclature includes various subsets with pro-, anti-inflammatory, or suppressive functions, and their clinical relevance in DLBCL has been poorly explored. Herein, we broadly assessed circulating monocyte heterogeneity in 91 DLBCL patients. Classical- (cMO, CD14  CD16 ) and intermediate- (iMO, CD14  CD16 ) monocytes accumulated in DLBCL peripheral blood and exhibited an inflammatory phenotype. On the opposite, nonclassical monocytes (ncMOSlan , CD14  CD16  Slan  and ncMOSlan , CD14  CD16 , Slan ) were decreased in peripheral blood. Tumor-conditioned monocytes presented similarities with ncMO phenotype from DLBCL and were prone to migrate in response to CCL5 and CXCL12, and presented similarities with DLBCL-infiltrated myeloid cells, as defined by mass cytometry. Finally, we demonstrated the adverse value of an accumulation of nonclassical monocytes in 2 independent cohorts of DLBCL.","Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique, Bordeaux, France.;Centre Hospitalier Universitaire de Caen, Service d'Hématologie Clinique, Caen, France.;Centre Hospitalier Universitaire de Montpellier, Service d'Hématologie Clinique, Montpellier, France.;Centre Hospitalier de Bretagne Atlantique, Unité d'Hématologie Clinique, Vannes, France.;Centre Hospitalier Universitaire de Nantes, Service d'Hématologie Clinique, Institut National de la Sante et de la Recherche Medicale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (INSERM CCRCINA) Nantes-Angers, NeXT Université de Nantes, Nantes, France.;Centre Hospitalier Universitaire de Dijon, Service d'Hématologie Clinique, Dijon, France.;Asistance Publique, Hopitaux de Paris (APHP), Necker, Service d'Anatomopathologie, Sorbonne Université, Paris, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.","NA",0,"1664-3224","Front Immunol","Front Immunol",2021,"2021","12","10.3389/fimmu.2021.755623","755623","R01 CA226833","NCI NIH HHS","34975843","34975843","PUBMED","Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique, Bordeaux, France.;Centre Hospitalier Universitaire de Caen, Service d'Hématologie Clinique, Caen, France.;Centre Hospitalier Universitaire de Montpellier, Service d'Hématologie Clinique, Montpellier, France.;Centre Hospitalier de Bretagne Atlantique, Unité d'Hématologie Clinique, Vannes, France.;Centre Hospitalier Universitaire de Nantes, Service d'Hématologie Clinique, Institut National de la Sante et de la Recherche Medicale, Centre de Recherche en Cancérologie et Immunologie Nantes Angers (INSERM CCRCINA) Nantes-Angers, NeXT Université de Nantes, Nantes, France.;Centre Hospitalier Universitaire de Dijon, Service d'Hématologie Clinique, Dijon, France.;Asistance Publique, Hopitaux de Paris (APHP), Necker, Service d'Anatomopathologie, Sorbonne Université, Paris, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie Clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Pôle Biologie, Rennes, France.;Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche U1236, Université Rennes 1, Etablissement Français du Sang Bretagne, Rennes, France."
"310","Ayoub JP;Wildiers H;Friedlander M;Arun BK;Han HS;Puhalla S;Shparyk Y;Jakobsen EH;Wu M;Bach BA;Feng D;Ratajczak CK;Maag D;Diéras V","Ayoub, Jean-Pierre;Wildiers, Hans;Friedlander, Michael;Arun, Banu K;Han, Hyo S;Puhalla, Shannon;Shparyk, Yaroslav;Jakobsen, Erik H;Wu, Meijing;Bach, Bruce A;Feng, Dai;Ratajczak, Christine K;Maag, David;Diéras, Véronique",NA,"Therapeutic advances in medical oncology","England","eng","Journal Article","BRCA;PARP inhibitor;TNBC;breast cancer;phase 3","","","To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline   (g )-associated breast cancer defined by hormone receptor (HR) and g /  mutation status. In this phase-3, double-blind, placebo-controlled trial, patients (  = 509) with advanced HER2-negative breast cancer and g  mutations were randomized 2:1 to receive veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel. Patients who discontinued chemotherapy prior to disease progression continued receiving blinded veliparib/placebo monotherapy. The primary endpoint was investigator-assessed progression-free survival (PFS). Subgroup analyses of PFS stratified by HR and g  mutation status were prespecified. In the intention-to-treat population, there were similar proportions of patients with g  g  mutations (51%   49%) and HR+ disease   triple-negative breast cancer (TNBC) (52%   48%). Median PFS was longer in the veliparib arm compared with the placebo arm for all subgroups (HR+: 13.0   12.5 months, hazard ratio (95% confidence interval (CI)): 0.69 (0.52, 0.93),   = 0.013; TNBC: 16.6   14.1 months, hazard ratio (95% CI): 0.72 (0.52, 1.00),   = 0.052; g : 14.2   12.6 months, hazard ratio (95% CI): 0.75 (0.55, 1.03),   = 0.073; g : 14.6   12.6 months, hazard ratio (95% CI): 0.69 (0.50, 0.95);   = 0.021). Benefit was durable, with improved PFS rates at 2 years (HR+, 27.5%   15.3%; TNBC, 40.4%   25.0%) and 3 years (HR+, 17.5%   8.6%; TNBC, 35.3%   13.0%) in all subgroups. g  status ( ) did not substantially affect the carboplatin/paclitaxel ± veliparib toxicity profile. Veliparib plus carboplatin/paclitaxel resulted in durable benefit in subgroups defined by HR status or by g  g  mutation. Overall, addition of veliparib to carboplatin/paclitaxel was tolerable, and there were no clinically meaningful differences in adverse events between the g  g  and HR+   TNBC subgroups. NCT02163694, https://clinicaltrials.gov/ct2/show/NCT02163694.","Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, NSW, Australia.;The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Moffitt Cancer Center, Tampa, FL, USA.;Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.;Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine.;Vejle Hospital, Lillebaelt Hospital, Vejle, Denmark.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35042 Rennes Cedex, FranceInstitut Curie, Paris, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2021,"2021","13","10.1177/17588359211059601","17588359211059601","","","34917174","34917174","PUBMED","Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.;University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, NSW, Australia.;The University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Moffitt Cancer Center, Tampa, FL, USA.;Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.;Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine.;Vejle Hospital, Lillebaelt Hospital, Vejle, Denmark.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35042 Rennes Cedex, FranceInstitut Curie, Paris, France."
"311","Le Bras A;Boustia F;Janot K;Le Pabic E;Ouvrard M;Fougerou-Leurent C;Ferre JC;Gauvrit JY;Eugene F","Le Bras, Anthony;Boustia, Fakhreddine;Janot, Kevin;Le Pabic, Estelle;Ouvrard, Mathilde;Fougerou-Leurent, Claire;Ferre, Jean-Christophe;Gauvrit, Jean-Yves;Eugene, François","Rehearsals using patient-specific 3D-printed aneurysm models for simulation of endovascular embolization of complex intracranial aneurysms: 3D SIM study.","Journal of neuroradiology = Journal de neuroradiologie","France","eng","Multicenter Study","3D-printed;Interventional neuroradiology;Intracranial aneurysm;Simulation","Humans;Intracranial Aneurysm;Retrospective Studies;Prospective Studies;Stents;Embolization, Therapeutic;Printing, Three-Dimensional;Treatment Outcome;Endovascular Procedures","Humans;Intracranial Aneurysm;Retrospective Studies;Prospective Studies;Stents;Embolization, Therapeutic;Printing, Three-Dimensional;Treatment Outcome;Endovascular Procedures","In neurovascular treatment planning, endovascular devices to manage complex intracranial aneurysms requiring intervention are often selected based on conventional measurements and interventional neuroradiologist experience. A recently developed technology allows a patient-specific 3D-printed model to mimic the navigation experience. The goal of this study was to assess the effect of pre-procedure 3D simulation on procedural and clinical outcomes for wide-neck aneurysm embolization. In this unblinded, non-randomized, prospective, multicenter study conducted from November 18 through December 20, patients with complex intracranial aneurysms (neck > 4 mm or ratio < 2 ) were treated by WEB or flow diverter stents (FDS). The primary endpoint was concordance between simulation and procedure, 3D-printed model accuracy as well as embolization outcomes including complications, procedure times, and radiation dose were also assessed. Secondary endpoint was to compare versus a retrospective WEB cohort. Twenty-one patients were treated, 76% of cases by WEB and 24% by FDS. Concordance between post-simulation and real procedure efficiency was 0.85 [0.69 - 1.00] for size device selection and 0.93 [0.79 - 1.00] for wall-apposition/aneurysm neck closure. Geometrical accuracy of the 3D-printed model showed a mean absolute shift of 0.11 mm. Two complications without major clinical impact were reported with a post-operative mRS similar to pre-procedure mRS for all patients. Rehearsal using accurate 3D-printed patient-specific aneurysm models enabled optimization of embolization strategy, resulting in reduced procedure duration and cumulative fluoroscopy time which translated to reduced radiation exposure compared to procedures performed without simulation.","Service de Radiologie, Centre Hospitalier Bretagne Atlantique, France; Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Tours, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Rennes, France.;Direction de la Recherche, Centre Hospitalier Universitaire de Rennes, France.;Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes","NA",0,"0150-9861","J Neuroradiol","J Neuroradiol",2021,"2023","50","10.1016/j.neurad.2021.11.008","86-92","","","34914933","34914933","PUBMED","Service de Radiologie, Centre Hospitalier Bretagne Atlantique, France; Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Tours, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Rennes, France.;Direction de la Recherche, Centre Hospitalier Universitaire de Rennes, France.;Service de Pharmacologie Clinique, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes, France.;Service de Radiologie, Centre Hospitalier Universitaire de Rennes"
"312","Yau T;Park JW;Finn RS;Cheng AL;Mathurin P;Edeline J;Kudo M;Harding JJ;Merle P;Rosmorduc O;Wyrwicz L;Schott E;Choo SP;Kelley RK;Sieghart W;Assenat E;Zaucha R;Furuse J;Abou-Alfa GK;El-Khoueiry AB;Melero I;Begic D;Chen G;Neely J;Wisniewski T;Tschaika M;Sangro B","Yau, Thomas;Park, Joong-Won;Finn, Richard S;Cheng, Ann-Lii;Mathurin, Philippe;Edeline, Julien;Kudo, Masatoshi;Harding, James J;Merle, Philippe;Rosmorduc, Olivier;Wyrwicz, Lucjan;Schott, Eckart;Choo, Su Pin;Kelley, Robin Kate;Sieghart, Wolfgang;Assenat, Eric;Zaucha, Renata;Furuse, Junji;Abou-Alfa, Ghassan K;El-Khoueiry, Anthony B;Melero, Ignacio;Begic, Damir;Chen, Gong;Neely, Jaclyn;Wisniewski, Tami;Tschaika, Marina;Sangro, Bruno","Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase III","","Aged;Carcinoma, Hepatocellular;Female;Humans;Liver Neoplasms;Male;Middle Aged;Nivolumab;Sorafenib","Aged;Carcinoma, Hepatocellular;Female;Humans;Liver Neoplasms;Male;Middle Aged;Nivolumab;Sorafenib","Single-agent nivolumab showed durable responses, manageable safety, and promising survival in patients with advanced hepatocellular carcinoma in the phase 1-2 CheckMate 040 study. We aimed to investigate nivolumab monotherapy compared with sorafenib monotherapy in the first-line setting for patients with advanced hepatocellular carcinoma. In this randomised, open-label, phase 3 trial done at medical centres across 22 countries and territories in Asia, Australasia, Europe, and North America, patients at least 18 years old with histologically confirmed advanced hepatocellular carcinoma not eligible for, or whose disease had progressed after, surgery or locoregional treatment; with no previous systemic therapy for hepatocellular carcinoma, with Child-Pugh class A and Eastern Cooperative Oncology Group performance status score of 0 or 1, and regardless of viral hepatitis status were randomly assigned (1:1) via an interactive voice response system to receive nivolumab (240 mg intravenously every 2 weeks) or sorafenib (400 mg orally twice daily) until disease progression or unacceptable toxicity. The primary endpoint was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study drug. This completed trial is registered with ClinicalTrials.gov, NCT02576509. Between Jan 11, 2016, and May 24, 2017, 743 patients were randomly assigned to treatment (nivolumab, n=371; sorafenib, n=372). At the primary analysis, the median follow-up for overall survival was 15·2 months (IQR 5·7-28·0) for the nivolumab group and 13·4 months (5·7-25·9) in the sorafenib group. Median overall survival was 16·4 months (95% CI 13·9-18·4) with nivolumab and 14·7 months (11·9-17·2) with sorafenib (hazard ratio 0·85 [95% CI 0·72-1·02]; p=0·075; minimum follow-up 22·8 months); the protocol-defined significance level of p=0·0419 was not reached. The most common grade 3 or worse treatment-related adverse events were palmar-plantar erythrodysaesthesia (1 [<1%] of 367 patients in the nivolumab group vs 52 [14%] of patients in the sorafenib group), aspartate aminotransferase increase (22 [6%] vs 13 [4%]), and hypertension (0 vs 26 [7%]). Serious treatment-related adverse events were reported in 43 (12%) patients receiving nivolumab and 39 (11%) patients receiving sorafenib. Four deaths in the nivolumab group and one death in the sorafenib group were assessed as treatment related. First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib, but clinical activity and a favourable safety profile were observed in patients with advanced hepatocellular carcinoma. Thus, nivolumab might be considered a therapeutic option for patients in whom tyrosine kinase inhibitors and antiangiogenic drugs are contraindicated or have substantial risks. Bristol Myers Squibb in collaboration with Ono Pharmaceutical.","Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region;Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, South Korea.;Geffen School of Medicine, University of California, Los Angeles, CA, USA.;National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.;Centre Hospitalo-Universitaire Claude Huriez, Service d'Hépatologie, Lille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Kindai University Faculty of Medicine, Osaka, Japan.;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.;Hepatology Unit, Croix-Rousse Hospital, Lyon, France.;Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière-Université Pierre et Marie Curie, Paris, France.;M Skłodowska-Curie Memorial National Cancer Research Institute, Warsaw, Poland.;Helios Klinikum Emil von Behring GmbH, Klinik für Innere Medizin II, Berlin, Germany.;National Cancer Centre Singapore, Singapore.;UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Liver Cancer (HCC) Study Group, Medical University Vienna, Vienna, Austria.;Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi Medical Oncology, Montpellier, France.;Department of Clinical Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.;Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.;University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.;Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2021,"2022","23","10.1016/S1470-2045(21)00604-5","77-90","","","34914889","34914889","PUBMED","Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region;Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, South Korea.;Geffen School of Medicine, University of California, Los Angeles, CA, USA.;National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan.;Centre Hospitalo-Universitaire Claude Huriez, Service d'Hépatologie, Lille, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Kindai University Faculty of Medicine, Osaka, Japan.;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.;Hepatology Unit, Croix-Rousse Hospital, Lyon, France.;Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpétrière-Université Pierre et Marie Curie, Paris, France.;M Skłodowska-Curie Memorial National Cancer Research Institute, Warsaw, Poland.;Helios Klinikum Emil von Behring GmbH, Klinik für Innere Medizin II, Berlin, Germany.;National Cancer Centre Singapore, Singapore.;UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.;Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Liver Cancer (HCC) Study Group, Medical University Vienna, Vienna, Austria.;Centre Hospitalier Universitaire de Montpellier, Hôpital Saint Eloi Medical Oncology, Montpellier, France.;Department of Clinical Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland.;Department of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.;Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical Center, New York, NY, USA.;University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA.;Department of Immunology and Immunotherapy, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Bristol Myers Squibb, Princeton, NJ, USA.;Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain."
"313","Goislard de Monsabert C;Touchefeu Y;Guiu B;Campillo-Gimenez B;Farges O;Tougeron D;Baumgaertner I;Ayav A;Beuzit L;Pracht M;Lièvre A;Le Sourd S;Boudjema K;Rolland Y;Garin E;Boucher E;Edeline J","Goislard de Monsabert, Camille;Touchefeu, Yann;Guiu, Boris;Campillo-Gimenez, Boris;Farges, Olivier;Tougeron, David;Baumgaertner, Isabelle;Ayav, Ahmet;Beuzit, Luc;Pracht, Marc;Lièvre, Astrid;Le Sourd, Samuel;Boudjema, Karim;Rolland, Yan;Garin, Etienne;Boucher, Eveline;Edeline, Julien","Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas.","Current oncology (Toronto, Ont.)","Switzerland","eng","Journal Article","Yttrium-90;biliary tract cancer;chemotherapy;patient-reported outcomes;radioembolization","Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Brachytherapy;Cholangiocarcinoma;Humans;Quality of Life","Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Brachytherapy;Cholangiocarcinoma;Humans;Quality of Life","In the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) single-arm phase 2 trial, concomitant chemotherapy and selective internal radiotherapy (SIRT) showed antitumor activity as a first-line treatment of unresectable intrahepatic cholangiocarcinomas (ICCs). In this sub-analysis, we aimed to evaluate one of the secondary endpoints, the health-related quality of life (QoL), evaluated with an EORTC QLQ-C30 instrument at the baseline and during treatment. The MISPHEC trial included treatment-naïve patients with an unresectable ICC between November 2013 and June 2016. Patients received concomitant first-line chemotherapy with cisplatin and gemcitabine for 8 cycles; SIRT was administered during cycle 1 (for patients with unilobar disease) or cycles 1 and 3 (for patients with bilobar disease) using glass Yttrium-90 microspheres. We evaluated the QoL-measured by the QLQ-C30 questionnaire-at the baseline, every 8 weeks during chemotherapy and follow-up, between 12 and 15 weeks after embolization and every 12 weeks after a liver resection if applicable. A total of 41 patients were included, of which 34 completed questionnaires at the baseline. No clinically significant changes in the global health score or the sub-scales of the QLQ-C30 were observed during follow-up. The physical, social and role function mean score worsened during treatment and fatigue, nausea and pain scores increased although the differences were not clinically significant. In patients undergoing subsequent surgery, the QoL was not impaired. A combination of SIRT and chemotherapy with gemcitabine and cisplatin as the first-line treatment of unresectable ICCs was found to maintain the QoL.","Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Centre Hospitalo-Universitaire Nantes, 44000 Nantes, France.;Centre Hospitalo-Universitaire Montpellier, 34000 Montpellier, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Laboratoire du Traitement du Signal et de l'Image U1099, Centre Hospitalo-Universitaire, Université Rennes 1, F-35000 Rennes, France.;Centre Hospitalo-Universitaire Beaujon, 92100 Clichy, France.;Centre Hospitalo-Universitaire Poitiers, 86000 Poitiers, France.;Centre Hospitalo-Universitaire Mondor, 94000 Créteil, France.;Centre Hospitalo-Universitaire Nancy, 54000 Nancy, France.;Radiology, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Gastroenterology, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Inserm, Centre Eugène Marquis, COSS (Chemistry Oncogenesis Stress Signaling)-UMR1242, Université Rennes, F-35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Hepatobiliary Surgery, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Radiology, Centre Eugène Marquis, 35000 Rennes, France.;Nuclear Medicine, Centre Eugène Marquis, 35000 Rennes, France.;Institut national de la rechercher médicale, Institut national de la recherche agronomique, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Université Rennes, F-35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Institut national de la rechercher médicale, Institut national de la recherche agronomique, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Université Rennes, F-35000 Rennes, France.","NA",0,"1718-7729","Curr Oncol","Curr Oncol",2021,"2021","28","10.3390/curroncol28060384","4530-4541","NA;NA","BTG;Ligue Contre le Cancer","34898592","34898592","PUBMED","Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Centre Hospitalo-Universitaire Nantes, 44000 Nantes, France.;Centre Hospitalo-Universitaire Montpellier, 34000 Montpellier, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Laboratoire du Traitement du Signal et de l'Image U1099, Centre Hospitalo-Universitaire, Université Rennes 1, F-35000 Rennes, France.;Centre Hospitalo-Universitaire Beaujon, 92100 Clichy, France.;Centre Hospitalo-Universitaire Poitiers, 86000 Poitiers, France.;Centre Hospitalo-Universitaire Mondor, 94000 Créteil, France.;Centre Hospitalo-Universitaire Nancy, 54000 Nancy, France.;Radiology, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Gastroenterology, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Inserm, Centre Eugène Marquis, COSS (Chemistry Oncogenesis Stress Signaling)-UMR1242, Université Rennes, F-35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Hepatobiliary Surgery, Centre Hospitalo-Universitaire Pontchaillou, 35000 Rennes, France.;Radiology, Centre Eugène Marquis, 35000 Rennes, France.;Nuclear Medicine, Centre Eugène Marquis, 35000 Rennes, France.;Institut national de la rechercher médicale, Institut national de la recherche agronomique, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Université Rennes, F-35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Institut national de la rechercher médicale, Institut national de la recherche agronomique, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Université Rennes, F-35000 Rennes, France."
"314","Bannay A;Bories M;Le Corre P;Riou C;Lemordant P;Van Hille P;Chazard E;Dode X;Cuggia M;Bouzillé G","Bannay, Aurélie;Bories, Mathilde;Le Corre, Pascal;Riou, Christine;Lemordant, Pierre;Van Hille, Pascal;Chazard, Emmanuel;Dode, Xavier;Cuggia, Marc;Bouzillé, Guillaume","Leveraging National Claims and Hospital Big Data: Cohort Study on a Statin-Drug Interaction Use Case.","JMIR medical informatics","Canada","eng","Journal Article","administrative claims;big data;data linking;data warehousing;drug interactions;health care;statins","","","Linking different sources of medical data is a promising approach to analyze care trajectories. The aim of the INSHARE (Integrating and Sharing Health Big Data for Research) project was to provide the blueprint for a technological platform that facilitates integration, sharing, and reuse of data from 2 sources: the clinical data warehouse (CDW) of the Rennes academic hospital, called eHOP (entrepôt Hôpital), and a data set extracted from the French national claim data warehouse (Système National des Données de Santé [SNDS]). This study aims to demonstrate how the INSHARE platform can support big data analytic tasks in the health field using a pharmacovigilance use case based on statin consumption and statin-drug interactions. A Spark distributed cluster-computing framework was used for the record linkage procedure and all analyses. A semideterministic record linkage method based on the common variables between the chosen data sources was developed to identify all patients discharged after at least one hospital stay at the Rennes academic hospital between 2015 and 2017. The use-case study focused on a cohort of patients treated with statins prescribed by their general practitioner or during their hospital stay. The whole process (record linkage procedure and use-case analyses) required 88 minutes. Of the 161,532 and 164,316 patients from the SNDS and eHOP CDW data sets, respectively, 159,495 patients were successfully linked (98.74% and 97.07% of patients from SNDS and eHOP CDW, respectively). Of the 16,806 patients with at least one statin delivery, 8293 patients started the consumption before and continued during the hospital stay, 6382 patients stopped statin consumption at hospital admission, and 2131 patients initiated statins in hospital. Statin-drug interactions occurred more frequently during hospitalization than in the community (3800/10,424, 36.45% and 3253/14,675, 22.17%, respectively; P<.001). Only 121 patients had the most severe level of statin-drug interaction. Hospital stay burden (length of stay and in-hospital mortality) was more severe in patients with statin-drug interactions during hospitalization. This study demonstrates the added value of combining and reusing clinical and claim data to provide large-scale measures of drug-drug interaction prevalence and care pathways outside hospitals. It builds a path to move the current health care system toward a Learning Health System using knowledge generated from research on real-world health data.","Université de Lorraine, Centre Hospitalier Régional Universitaire de Nancy, Centre national de la recherche scientifique, Inria, Laboratoire lorrain de recherche en informatique et ses applications, Nancy, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Inserm, Ecole des hautes études en santé publique, Institut de recherche en santé, environnement et travail, UMR_S 1085, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Centre National Hospitalier d'Information sur le Médicament, Paris, France.;Department of Pharmacy, Hospices Civils de Lyon, University Hospital, Lyon, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.","NA",0,"2291-9694","JMIR Med Inform","JMIR Med Inform",2021,"2021","9","10.2196/29286","e29286","","","34898457","34898457","PUBMED","Université de Lorraine, Centre Hospitalier Régional Universitaire de Nancy, Centre national de la recherche scientifique, Inria, Laboratoire lorrain de recherche en informatique et ses applications, Nancy, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Inserm, Ecole des hautes études en santé publique, Institut de recherche en santé, environnement et travail, UMR_S 1085, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Centre National Hospitalier d'Information sur le Médicament, Paris, France.;Department of Pharmacy, Hospices Civils de Lyon, University Hospital, Lyon, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Inserm, Laboratoire Traitement du Signal et de l'Image - UMR 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France."
"315","Brüggenwirth IMA;van der Plas WS;van Leeuwen OB;Thorne AM;Rayar M;de Meijer VE;Porte RJ","Brüggenwirth, Isabel M A;van der Plas, Willemijn S;van Leeuwen, Otto B;Thorne, Adam M;Rayar, Michel;de Meijer, Vincent E;Porte, Robert J","Oxygenated versus non-oxygenated flush out and storage of donor livers: An experimental study.","Artificial organs","United States","eng","Journal Article","ischemia-reperfusion injury;liver transplantation;organ preservation;static cold storage","Adenosine Triphosphate;Animals;Bile;Female;Liver;Liver Transplantation;Organ Preservation;Organ Preservation Solutions;Oxygen;Reperfusion;Reperfusion Injury;Sus scrofa","Adenosine Triphosphate;Animals;Bile;Female;Liver;Liver Transplantation;Organ Preservation;Organ Preservation Solutions;Oxygen;Reperfusion;Reperfusion Injury;Sus scrofa","During donor organ procurement and subsequent static cold storage (SCS), hepatic adenosine triphosphate (ATP) levels are progressively depleted, which contributes to ischemia-reperfusion injury (IRI). We sought to investigate a simple approach to prevent ATP depletion and IRI using a porcine donation after circulatory death (DCD) liver reperfusion model. After 30 min warm ischemia, porcine livers were flushed via the portal vein with cold (4°C) non-oxygenated University of Wisconsin (UW) preservation solution (n = 6, control group) or with oxygenated UW (n = 6, OxyFlush group). Livers were then subjected to 4 h SCS in non-oxygenated (control) or oxygenated (OxyFlush) UW, followed by 4 h normothermic reperfusion using whole blood. Hepatic ATP levels were compared, and hepatobiliary function and injury were assessed. At the end of SCS, ATP was higher in the OxyFlush group compared to controls (delta ATP of +0.26 vs. -0.68 µmol/g protein, p = 0.04). All livers produced bile and metabolized lactate, and there were no differences between the groups. Grafts in the OxyFlush group had lower blood glucose levels after reperfusion (p = 0.04). Biliary pH, glucose and bicarbonate were not different between the groups. Injury markers including liver transaminases, lactate dehydrogenase, malondialdehyde, cell-free DNA and flavin mononucleotide in the SCS solution and during reperfusion were also similar. Histological assessment of the parenchyma and bile ducts did not reveal differences between the groups. Oxygenated flush out and storage of DCD porcine livers prevents ATP depletion during ischemia, but this does not seem sufficient to mitigate early signs of IRI.","Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Centre Hospitalier Universitaire de Rennes, Service de Chirurgie Hépatobiliaire et Digestive, Rennes, France.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.","NA",0,"1525-1594","Artif Organs","Artif Organs",2021,"2022","46","10.1111/aor.14135","201-209","","","34866205","34866205","PUBMED","Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Centre Hospitalier Universitaire de Rennes, Service de Chirurgie Hépatobiliaire et Digestive, Rennes, France.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands.;Department of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University Medical Center Groningen, Groningen, The Netherlands."
"316","Han HS;Arun BK;Kaufman B;Wildiers H;Friedlander M;Ayoub JP;Puhalla SL;Bach BA;Kundu MG;Khandelwal N;Feng D;Bhattacharya S;Maag D;Ratajczak CK;Diéras V","Han, H S;Arun, B K;Kaufman, B;Wildiers, H;Friedlander, M;Ayoub, J P;Puhalla, S L;Bach, B A;Kundu, M G;Khandelwal, N;Feng, D;Bhattacharya, S;Maag, D;Ratajczak, C K;Diéras, V","Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Journal Article","BRCA;BROCADE3;PARP inhibitor;metastatic breast cancer;veliparib","Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Germ Cells;Humans;Paclitaxel","Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Germ Cells;Humans;Paclitaxel","In the BROCADE3 trial, addition of the poly(ADP-ribose) polymerase inhibitor, veliparib, to carboplatin/paclitaxel improved progression-free survival (PFS) (hazard ratio 0.71, 95% confidence interval 0.57-0.88; P = 0.002) in patients with advanced human epidermal growth factor receptor 2-negative, germline BRCA1/2-mutated breast cancer. A subset of patients discontinued both carboplatin and paclitaxel before progression and continued on veliparib/placebo maintenance monotherapy until progression. Analyses in this patient subgroup are reported. Patients were randomized 2 : 1 to veliparib plus carboplatin/paclitaxel or placebo plus carboplatin/paclitaxel. Veliparib (120 mg twice daily) or placebo was given on days -2 to 5, carboplatin (area under the curve 6 mg/ml) on day 1, and paclitaxel (80 mg/m ) on days 1, 8, and 15 of 21-day cycles. Patients who discontinued both carboplatin and paclitaxel before progression received blinded study drug monotherapy at an increased dose of 300-400 mg twice daily continuously. PFS was the primary endpoint. Exploratory analyses were carried out in the subgroup of patients who received blinded study drug as monotherapy. A time-varying Cox model including data from all patients was also used to evaluate treatment effect in the combination and monotherapy phases. A total of 136 of 337 patients randomized to veliparib plus carboplatin/paclitaxel and 58/172 patients randomized to placebo plus carboplatin/paclitaxel discontinued both carboplatin and paclitaxel before progression and continued on blinded veliparib or placebo monotherapy. In this blinded monotherapy subgroup, investigator-assessed median PFS from randomization was 25.7 months with veliparib versus 14.6 months with placebo. Hazard ratios from a time-varying Cox model favored veliparib during both combination therapy and monotherapy. Any-grade adverse events occurring in the monotherapy phase were primarily gastrointestinal. The most common grade ≥3 adverse events were neutropenia and anemia (4% each with veliparib; 5% and 2%, respectively, with placebo). Veliparib maintenance monotherapy had a tolerable safety profile and may extend PFS following combination chemotherapy.","Moffitt Cancer Center, Tampa;The University of Texas MD Anderson Cancer Center, Houston, USA.;Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel.;University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, Australia.;Centre Hospitalier de l'Université de Montréal, Montréal, Canada.;University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;Institut Curie, Paris, France; Centre Eugène Marquis, Rennes, France.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2021,"2022","33","10.1016/j.annonc.2021.11.018","299-309","","","34861374","34861374","PUBMED","Moffitt Cancer Center, Tampa;The University of Texas MD Anderson Cancer Center, Houston, USA.;Sheba Medical Center, Tel HaShomer, Ramat Gan, Israel.;University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School UNSW and Prince of Wales Hospital, Sydney, Australia.;Centre Hospitalier de l'Université de Montréal, Montréal, Canada.;University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;AbbVie Inc., North Chicago, USA.;Institut Curie, Paris, France; Centre Eugène Marquis, Rennes, France."
"317","Agbakou M;Mekontso-Dessap A;Pere M;Voiriot G;Picard M;Bourenne J;Ehrmann S;Canet E;Boyer A;Nseir S;Tamion F;Thille AW;Argaud L;Pontis E;Quenot JP;Schneider F;Hot A;Capellier G;Aubron C;Razazi K;Masseau A;Brule N;Reignier J;Lascarrou JB","Agbakou, Maïté;Mekontso-Dessap, Armand;Pere, Morgane;Voiriot, Guillaume;Picard, Muriel;Bourenne, Jérémy;Ehrmann, Stephan;Canet, Emmanuel;Boyer, Alexandre;Nseir, Saad;Tamion, Fabienne;Thille, Arnaud W;Argaud, Laurent;Pontis, Emmanuel;Quenot, Jean-Pierre;Schneider, Francis;Hot, Arnaud;Capellier, Gilles;Aubron, Cécile;Razazi, Keyvan;Masseau, Agathe;Brule, Noëlle;Reignier, Jean;Lascarrou, Jean-Baptiste","Nationwide retrospective study of critically ill adults with sickle cell disease in France.","Scientific reports","England","eng","Journal Article","","Acute Chest Syndrome;Adult;Anemia, Sickle Cell;Blood Pressure;Critical Care;Critical Illness;Female;France;Hospitalization;Humans;Intensive Care Units;Length of Stay;Male;Middle Aged;Multivariate Analysis;Odds Ratio;Pain;Retrospective Studies;Treatment Outcome;Young Adult","Acute Chest Syndrome;Adult;Anemia, Sickle Cell;Blood Pressure;Critical Care;Critical Illness;Female;France;Hospitalization;Humans;Intensive Care Units;Length of Stay;Male;Middle Aged;Multivariate Analysis;Odds Ratio;Pain;Retrospective Studies;Treatment Outcome;Young Adult","Little is known about patients with sickle cell disease (SCD) who require intensive care unit (ICU) admission. The goals of this study were to assess outcomes in patients admitted to the ICU for acute complications of SCD and to identify factors associated with adverse outcomes. This multicenter retrospective study included consecutive adults with SCD admitted to one of 17 participating ICUs. An adverse outcome was defined as death or a need for life-sustaining therapies (non-invasive or invasive ventilation, vasoactive drugs, renal replacement therapy, and/or extracorporeal membrane oxygenation). Factors associated with adverse outcomes were identified by mixed multivariable logistic regression. We included 488 patients admitted in 2015-2017. The main reasons for ICU admission were acute chest syndrome (47.5%) and severely painful vaso-occlusive event (21.3%). Sixteen (3.3%) patients died in the ICU, mainly of multi-organ failure following a painful vaso-occlusive event or sepsis. An adverse outcome occurred in 81 (16.6%; 95% confidence interval [95% CI], 13.3%-19.9%) patients. Independent factors associated with adverse outcomes were low mean arterial blood pressure (adjusted odds ratio [aOR], 0.98; 95% CI 0.95-0.99; p = 0.027), faster respiratory rate (aOR, 1.09; 95% CI 1.05-1.14; p < 0.0001), higher haemoglobin level (aOR, 1.22; 95% CI 1.01-1.48; p = 0.038), impaired creatinine clearance at ICU admission (aOR, 0.98; 95% CI 0.97-0.98; p < 0.0001), and red blood cell exchange before ICU admission (aOR, 5.16; 95% CI 1.16-22.94; p = 0.031). Patients with SCD have a substantial risk of adverse outcomes if they require ICU admission. Early ICU admission should be encouraged in patients who develop abnormal physiological parameters.","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.;Plateforme de methodologie et biostatistique, Direction de la Recherche de l'Innovation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Sorbonne Université, Assistance Publique Hôpitaux de Paris, Service de Médecine Intensive et Réanimation, Hôpital Tenon, Paris, France.;Réanimation Polyvalente, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU Toulouse, Toulouse, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU la Timone 2, Marseille, France.;Médecine Intensive Réanimation, INSERM CIC 1415, CRICS-TriggerSEP Research Network, Centre Hospitalier Régional Universitaire de Tours and Centre d'Etude Des Pathologies Respiratoires (CEPR) INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Médecine Intensive Réanimation, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Médecine Intensive-Réanimation, CHU de Lille; Inserm U1285, Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Médecine Intensive Réanimation, Hôpital Charles Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.;Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Médecine Intensive Réanimation, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Médecine Intensive Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France.;Réanimation Médicale, Hôpital de la Cavale Blanche, Centre Hospitalier Régional Universitaire de Bretagne Occidentale, Brest, France.;Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.;Médecine Interne, Centre Hospitalier Universitaire Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1","NA",0,"2045-2322","Sci Rep","Sci Rep",2021,"2021","11","10.1038/s41598-021-02437-2","23132","","","34848756","34848756","PUBMED","Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.;Plateforme de methodologie et biostatistique, Direction de la Recherche de l'Innovation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Sorbonne Université, Assistance Publique Hôpitaux de Paris, Service de Médecine Intensive et Réanimation, Hôpital Tenon, Paris, France.;Réanimation Polyvalente, Institut Universitaire du Cancer de Toulouse-Oncopole, CHU Toulouse, Toulouse, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU la Timone 2, Marseille, France.;Médecine Intensive Réanimation, INSERM CIC 1415, CRICS-TriggerSEP Research Network, Centre Hospitalier Régional Universitaire de Tours and Centre d'Etude Des Pathologies Respiratoires (CEPR) INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Médecine Intensive Réanimation, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Médecine Intensive-Réanimation, CHU de Lille; Inserm U1285, Univ. Lille, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, 59000, Lille, France.;Médecine Intensive Réanimation, Hôpital Charles Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France.;Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Médecine Intensive Réanimation, Hôpital de Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Médecine Intensive Réanimation, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France.;Réanimation Médicale, Hôpital de la Cavale Blanche, Centre Hospitalier Régional Universitaire de Bretagne Occidentale, Brest, France.;Médecine Intensive Réanimation, Hôpital Henri Mondor, Assistance Publique des Hôpitaux de Paris, Créteil, France.;Médecine Interne, Centre Hospitalier Universitaire Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Hôtel-Dieu, 30 Bd. Jean Monnet, 44093, Nantes Cedex 1"
"318","Qadir AS;Guégan JP;Ginestier C;Chaibi A;Bessede A;Charafe-Jauffret E;Macario M;Lavoué V;Rouge TM;Law C;Vilker J;Wang H;Stroup E;Schipma MJ;Bridgeman B;Murmann AE;Ji Z;Legembre P;Peter ME","Qadir, Abdul S;Guégan, Jean Philippe;Ginestier, Christophe;Chaibi, Assia;Bessede, Alban;Charafe-Jauffret, Emmanuelle;Macario, Manon;Lavoué, Vincent;Rouge, Thibault de la Motte;Law, Calvin;Vilker, Jacob;Wang, Hongbin;Stroup, Emily;Schipma, Matthew J;Bridgeman, Bryan;Murmann, Andrea E;Ji, Zhe;Legembre, Patrick;Peter, Marcus E","CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells.","iScience","United States","eng","Journal Article","Cancer;Cell biology;Immunology","","","The apoptosis inducing receptor CD95/Fas has multiple tumorigenic activities. In different genetically engineered mouse models tumor-expressed CD95 was shown to be critical for cell growth. Using a combination of immune-deficient and immune-competent mouse models, we now establish that loss of CD95 in metastatic triple negative breast cancer (TNBC) cells prevents tumor growth by modulating the immune landscape. CD95-deficient, but not wild-type, tumors barely grow in an immune-competent environment and show an increase in immune infiltrates into the tumor. This growth reduction is caused by infiltrating NK cells and does not involve T cells or macrophages. In contrast, in immune compromised mice CD95 k.o. cells are not growth inhibited, but they fail to form metastases. In summary, we demonstrate that in addition to its tumor and metastasis promoting activities, CD95 expression by tumor cells can exert immune suppressive activities on NK cells, providing a new target for immune therapy.","Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;Department of Gynecology, University Hospital of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, USA.;INSERM U1262, CRIBL, Université Limoges, Limoges, France.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.","NA",0,"2589-0042","iScience","iScience",2021,"2021","24","10.1016/j.isci.2021.103348","103348","R00 CA207865;R35 CA197450;R35 GM138192;T32 LM012203","NCI NIH HHS;NCI NIH HHS;NIGMS NIH HHS;NLM NIH HHS","34816102","34816102","PUBMED","Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;Explicyte, Cours de l'Argonne, 33000 Bordeaux, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;CRCM, Inserm, CNRS, Institut Paoli-Calmettes, Aix-Marseille Univ, Epithelial Stem Cells and Cancer Lab, Equipe labellisée LIGUE contre le cancer, Marseille, France.;Department of Gynecology, University Hospital of Rennes, Rennes, France.;Centre Eugène Marquis, Rennes, France.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Evanston, IL, USA.;INSERM U1262, CRIBL, Université Limoges, Limoges, France.;Division Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.;Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA."
"319","Campredon A;Battistella E;Martin C;Durieu I;Mely L;Marguet C;Belleguic C;Murris-Espin M;Chiron R;Fanton A;Bui S;Reynaud-Gaubert M;Reix P;Hoang-Thi TN;Vakalopoulou M;Revel MP;Da Silva J;Burgel PR;Chassagnon G;Mounard J;Poulet C;Rames Amiens C;Person C;Troussier F;Urban Angers T;Dalphin ML;Dalphin JC;Pernet D;Richaud-Thiriez Besançon B;Bui S;Fayon M;Macey-Caro Bordeaux J;Campbell K;Laurans Caen M;Borderon C;Heraud MC;Labbé A;Montcouquiol Clermont-Ferrand S;Bassinet L;Remus Créteil N;Fanton A;Houzel-Charavel A;Huet F;Perez-Martin Dijon S;Boldron-Ghaddar A;Scalbert Dunkerque M;Mely Giens L;Camara B;Llerena C;Pin I;Quétant Grenoble S;Cottereau A;Deschildre A;Gicquello A;Perez T;Stervinou-Wemeau L;Thumerelle C;Wallaert B;Wizla Lille N;Languepin J;Ménétrey C;Dupuy-Grasset Limoges M;Bazus L;Buchs C;Jubin V;Werck-Gallois MC;Mainguy C;Perrin T;Reix P;Toutain-Rigolet Lyon Pédiatrie A;Durieu I;Durupt S;Reynaud Q;Nove-Josserand Lyon Adultes R;Baravalle-Einaudi M;Coltey B;Dufeu N;Dubus JC;Stremler Marseille N;Caimmi D;Chiron Montpellier R;Billon Y;Derelle J;Kieffer S;Pichon AS;Schweitzer C;Tatopoulos Nancy A;Abbes S;Bihouée T;Danner-Boucher I;David V;Haloun A;Tissot Nantes A;Leroy S;Bailly-Piccini Nice C;Clément A;Corvol H;Tamalet ParisTrousseau A;Burgel PR;Honoré I;Hubert D;Kanaan R;Martin Paris Cochin C;Bailly C;Chédevergne F;De Blic J;Fauroux B;Bourgeois ML;Sermet-Gaudelus Paris Necker I;Delaisi B;Gérardin M;Munck ParisRobert Debré A;Abély M;Ravoninjatovo Reims B;Belleguic C;Desrues B;Brinchault Rennes G;Dagorne M;Deneuville E;Lefeuvre Rennes-Saint Brieuc S;Dirou A;Bihan JL;Ramel Roscoff S;Dominique S;Marguet Rouen C;Payet La Réunion A;Kessler R;Porzio M;Rosner V;Weiss Strasbourg L;Miranda S;Grenet D;Hamid A;Picard Suresnes C;Brémont F;Didier A;Labouret G;Mittaine M;Murris-Espin M;Têtu Toulouse L;Cosson L;Giraut C;Henriet AC;Mankikian J;Marchand Tours S;Hugé S;Storni Vannes V;Coirier-Duet Versailles E","Campredon, Alienor;Battistella, Enzo;Martin, Clémence;Durieu, Isabelle;Mely, Laurent;Marguet, Christophe;Belleguic, Chantal;Murris-Espin, Marlène;Chiron, Raphaël;Fanton, Annlyse;Bui, Stéphanie;Reynaud-Gaubert, Martine;Reix, Philippe;Hoang-Thi, Trieu-Nghi;Vakalopoulou, Maria;Revel, Marie-Pierre;Da Silva, Jennifer;Burgel, Pierre-Régis;Chassagnon, Guillaume;Mounard, Julie;Poulet, Claire;Rames Amiens, Cinthia;Person, Christine;Troussier, Françoise;Urban Angers, Thierry;Dalphin, Marie-Laure;Dalphin, Jean-Claude;Pernet, Didier;Richaud-Thiriez Besançon, Bénédicte;Bui, Stéphanie;Fayon, Mickael;Macey-Caro Bordeaux, Julie;Campbell, Karine;Laurans Caen, Muriel;Borderon, Corinne;Heraud, Marie-Christine;Labbé, André;Montcouquiol Clermont-Ferrand, Sylvie;Bassinet, Laurence;Remus Créteil, Natascha;Fanton, Annlyse;Houzel-Charavel, Anne;Huet, Frédéric;Perez-Martin Dijon, Stéphanie;Boldron-Ghaddar, Amale;Scalbert Dunkerque, Manuela;Mely Giens, Laurent;Camara, Boubou;Llerena, Catherine;Pin, Isabelle;Quétant Grenoble, Sébastien;Cottereau, Aurélie;Deschildre, Antoine;Gicquello, Alice;Perez, Thierry;Stervinou-Wemeau, Lidwine;Thumerelle, Caroline;Wallaert, Benoit;Wizla Lille, Nathalie;Languepin, Jane;Ménétrey, Céline;Dupuy-Grasset Limoges, Magalie;Bazus, Lucie;Buchs, Clelia;Jubin, Virginie;Werck-Gallois, Marie-Christine;Mainguy, Catherine;Perrin, Thomas;Reix, Philippe;Toutain-Rigolet Lyon Pédiatrie, Agnès;Durieu, Isabelle;Durupt, Stéphane;Reynaud, Quitterie;Nove-Josserand Lyon Adultes, Raphaele;Baravalle-Einaudi, Melisande;Coltey, Bérangère;Dufeu, Nadine;Dubus, Jean-Christophe;Stremler Marseille, Nathalie;Caimmi, Davide;Chiron Montpellier, Raphaël;Billon, Yves;Derelle, Jocelyne;Kieffer, Sébastien;Pichon, Anne-Sophie;Schweitzer, Cyril;Tatopoulos Nancy, Aurélie;Abbes, Sarah;Bihouée, Tiphaine;Danner-Boucher, Isabelle;David, Valérie;Haloun, Alain;Tissot Nantes, Adrien;Leroy, Sylvie;Bailly-Piccini Nice, Carole;Clément, Annick;Corvol, Harriet;Tamalet ParisTrousseau, Aline;Burgel, Pierre-Régis;Honoré, Isabelle;Hubert, Dominique;Kanaan, Reem;Martin Paris Cochin, Clémence;Bailly, Cécile;Chédevergne, Frédérique;De Blic, Jacques;Fauroux, Brigitte;Bourgeois, Murielle Le;Sermet-Gaudelus Paris Necker, Isabelle;Delaisi, Bertrand;Gérardin, Michèle;Munck ParisRobert Debré, Anne;Abély, Michel;Ravoninjatovo Reims, Bruno;Belleguic, Chantal;Desrues, Benoit;Brinchault Rennes, Graziella;Dagorne, Michel;Deneuville, Eric;Lefeuvre Rennes-Saint Brieuc, Sylvaine;Dirou, Anne;Bihan, Jean Le;Ramel Roscoff, Sophie;Dominique, Stéphane;Marguet Rouen, Christophe;Payet La Réunion, Annabelle;Kessler, Romain;Porzio, Michele;Rosner, Vincent;Weiss Strasbourg, Laurence;Miranda, Sandra de;Grenet, Dominique;Hamid, Abdoul;Picard Suresnes, Clément;Brémont, François;Didier, Alain;Labouret, Géraldine;Mittaine, Marie;Murris-Espin, Marlène;Têtu Toulouse, Laurent;Cosson, Laure;Giraut, Charlotte;Henriet, Anne-Cécile;Mankikian, Julie;Marchand Tours, Sophie;Hugé, Sandrine;Storni Vannes, Véronique;Coirier-Duet Versailles, Emmanuelle","Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.","The European respiratory journal","England","eng","Journal Article","","","","Lumacaftor-ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator known to improve clinical status in people with cystic fibrosis (CF). The aim of this study was to assess lung structural changes after 1 year of lumacaftor-ivacaftor treatment and to use unsupervised machine learning to identify morphological phenotypes of lung disease that are associated with response to lumacaftor-ivacaftor. Adolescents and adults with CF from a French multicentre real-world prospective observational study evaluating the first year of treatment with lumacaftor-ivacaftor were included if they had pre-therapeutic and follow-up chest computed tomography (CT) scans available. CT scans were visually scored using a modified Bhalla score. A k-means clustering method was performed based on 120 radiomics features extracted from unenhanced pre-therapeutic chest CT scans. In total, 283 patients were included. The Bhalla score significantly decreased after 1 year of lumacaftor-ivacaftor (-1.40±1.53 points compared with pre-therapeutic CT, p<0.001). This finding was related to a significant decrease in mucus plugging (-0.58±0.88 points, p<0.001), bronchial wall thickening (-0.35±0.62 points, p<0.001) and parenchymal consolidations (-0.24±0.52 points, p<0.001). Cluster analysis identified three morphological clusters. Patients from cluster C were more likely to experience an increase in per cent predicted forced expiratory volume in 1 s (FEV  % pred) ≥5% under lumacaftor-ivacaftor than those in the other clusters (54% of responders   32% and 33%; p=0.02). 1-year treatment with lumacaftor-ivacaftor was associated with a significant visual improvement of bronchial disease on chest CT. Radiomics features on pre-therapeutic CT scans may help to predict lung function response under lumacaftor-ivacaftor.","Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;Université de Paris, Paris, France.;OPIS - OPtimisation Imagerie et Santé, Inria Saclay, Palaiseau, France.;MICS - Mathématiques et Informatique pour la Complexité et les Systèmes, CentraleSupelec, Gif-sur-Yvette, France.;Université de Paris, Paris, France.;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;ERN-Lung CF Network, Frankfurt am Main, Germany.;ERN-Lung CF Network, Frankfurt am Main, Germany.;Centre de Référence Adulte de la Mucoviscidose, Service de Médecine Interne, Hospices Civils de Lyon, Pierre Bénite, France.;Research on Healthcare Performance RESHAPE, Inserm U1290, Université Claude Bernard Lyon 1, Lyon, France.;Hôpital Renée Sabran, Cystic Fibrosis Center, Giens, France.;Pediatric Respiratory Disease and Cystic Fibrosis Center, Hospital UNIROUEN, Inserm EA 2656, Rouen University Hospital, Normandie Université, Rouen, France.;Centre de Ressources et de Compétences de la Mucoviscidose Adulte, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cystic Fibrosis Center, Service de Pneumologie, Pôle des Voies Respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France.;Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Dept of Pulmonary Medicine, Cystic Fibrosis Resource and Competence Centre for Adults, Dijon University Hospital, Dijon, France.;Pediatric Respiratory Disease and Cystic Fibrosis Center and CIC 1401, CHU de Bordeaux, Bordeaux, France.;Dept of Respiratory Medicine and Lung Transplantation, Aix Marseille Universitaire, APHM, Hôpital Nord, Marseille, France.;UMR 5558 CNRS, Equipe EMET, Université Claude Bernard Lyon 1, Lyon, France.;Cystic Fibrosis Center, Hospices Civils de Lyon, Lyon, France.;Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;OPIS - OPtimisation Imagerie et Santé, Inria Saclay, Palaiseau, France.;MICS - Mathématiques et Informatique pour la Complexité et les Systèmes, CentraleSupelec, Gif-sur-Yvette, France.;Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;Université de Paris, Paris, France.;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;URC-CIC Paris Descartes Necker Cochin, AP-HP, Hôpital Cochin, Paris, France.;Université de Paris, Paris;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;ERN-Lung CF Network, Frankfurt am Main, Germany.","NA",0,"1399-3003","Eur Respir J","Eur Respir J",2021,"2022","59","10.1183/13993003.01344-2021",NA,"","","34795038","34795038","PUBMED","Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;Université de Paris, Paris, France.;OPIS - OPtimisation Imagerie et Santé, Inria Saclay, Palaiseau, France.;MICS - Mathématiques et Informatique pour la Complexité et les Systèmes, CentraleSupelec, Gif-sur-Yvette, France.;Université de Paris, Paris, France.;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;ERN-Lung CF Network, Frankfurt am Main, Germany.;ERN-Lung CF Network, Frankfurt am Main, Germany.;Centre de Référence Adulte de la Mucoviscidose, Service de Médecine Interne, Hospices Civils de Lyon, Pierre Bénite, France.;Research on Healthcare Performance RESHAPE, Inserm U1290, Université Claude Bernard Lyon 1, Lyon, France.;Hôpital Renée Sabran, Cystic Fibrosis Center, Giens, France.;Pediatric Respiratory Disease and Cystic Fibrosis Center, Hospital UNIROUEN, Inserm EA 2656, Rouen University Hospital, Normandie Université, Rouen, France.;Centre de Ressources et de Compétences de la Mucoviscidose Adulte, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cystic Fibrosis Center, Service de Pneumologie, Pôle des Voies Respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France.;Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Dept of Pulmonary Medicine, Cystic Fibrosis Resource and Competence Centre for Adults, Dijon University Hospital, Dijon, France.;Pediatric Respiratory Disease and Cystic Fibrosis Center and CIC 1401, CHU de Bordeaux, Bordeaux, France.;Dept of Respiratory Medicine and Lung Transplantation, Aix Marseille Universitaire, APHM, Hôpital Nord, Marseille, France.;UMR 5558 CNRS, Equipe EMET, Université Claude Bernard Lyon 1, Lyon, France.;Cystic Fibrosis Center, Hospices Civils de Lyon, Lyon, France.;Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;OPIS - OPtimisation Imagerie et Santé, Inria Saclay, Palaiseau, France.;MICS - Mathématiques et Informatique pour la Complexité et les Systèmes, CentraleSupelec, Gif-sur-Yvette, France.;Radiology Dept, Hôpital Cochin, AP-HP Centre Université de Paris, Paris, France.;Université de Paris, Paris, France.;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;URC-CIC Paris Descartes Necker Cochin, AP-HP, Hôpital Cochin, Paris, France.;Université de Paris, Paris;Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.;ERN-Lung CF Network, Frankfurt am Main, Germany."
"320","Aldea M;Lam L;Orillard E;Llacer Perez C;Saint-Ghislain M;Gravis G;Fléchon A;Roubaud G;Barthelemy P;Ricci F;Priou F;Neviere Z;Beaufils M;Laguerre B;Hardy AC;Helissey C;Ratta R;Borchiellini D;Pobel C;Joly F;Castro E;Thiery-Vuillemin A;Baciarello G;Fizazi K","Aldea, Mihaela;Lam, Laurent;Orillard, Emeline;Llacer Perez, Casilda;Saint-Ghislain, Mathilde;Gravis, Gwenaelle;Fléchon, Aude;Roubaud, Guilhem;Barthelemy, Philippe;Ricci, Francesco;Priou, Frank;Neviere, Zoe;Beaufils, Mathilde;Laguerre, Brigitte;Hardy, Anne-Claire;Helissey, Carole;Ratta, Raffaele;Borchiellini, Delphine;Pobel, Cedric;Joly, Florence;Castro, Elena;Thiery-Vuillemin, Antoine;Baciarello, Giulia;Fizazi, Karim","Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","BRCA;Cabazitaxel;DNA damage repair;PARP inhibitors;mCRPC","Antineoplastic Agents;DNA Repair;Humans;Male;Progression-Free Survival;Prostatic Neoplasms, Castration-Resistant;Retrospective Studies;Taxoids","Antineoplastic Agents;DNA Repair;Humans;Male;Progression-Free Survival;Prostatic Neoplasms, Castration-Resistant;Retrospective Studies;Taxoids","Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown. With the advent of poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPi) in partially overlapping indications with cabazitaxel, we aimed to determine cabazitaxel activity in men with mCRPC according to their DDR status. This is a retrospective multicenter study that enrolled patients with mCRPC treated with cabazitaxel who had undergone DDR tumour tissue profiling. Patients with at least one deleterious germline or somatic alterations were considered DDR positive (DDR+). Each DDR + patient has been matched with a DDR negative (DDR-) from the same institution who underwent the same test. An exploratory cohort of patients found to be DDR + by liquid biopsy was also included. Prostate specific antigen (PSA) decline≥50% (PSA50), PSA progression-free survival (PFS, PSA-PFS), radiographic PFS (rPFS), clinical PFS or radiographic PFS (c/rPFS) and OS were evaluated. Among 190 men (95 DDR+, 95 DDR-) with tissue sequencing, PSA50 was achieved with cabazitaxel in 29/92 (32%) and 33/92 (36%) in patients with DDR+ and DDR- (P = 0.64). The median rPFS was 5.33 months [95%CI 4.34-7.04] versus 5.75 months [95%CI 4.67-7.27] (P = 0.55). The median OS was 15.4 months [95%CI 12.16-26.6] and 11.5 months [95%CI 9.76-14.4] (P = 0.036), respectively. No PSA50 responses on cabazitaxel were observed in BRCA1/2 patients previously treated with PARPi (n = 10). Similar outcomes with cabazitaxel were observed in the liquid biopsy cohort (n = 63 DDR+). Our study suggests that cabazitaxel is active in patients with mCRPC regardless of their DDR status, although its activity in men pretreated with a PARPi may be lower.","Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Medical Oncology, Hôpital Jean Minjoz, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.;Department of Medical Oncology, Hospitales Virgen de La Victoria y Regional de Málaga, Campus de Teatinos, S/N, 29010, Málaga, Spain.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg/ICANS Strasbourg, 17 Rue Albert Calmette, 67200, Strasbourg, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Hospitalier Départemental Vendée, Boulevard Stéphane Moreau, 85000, La Roche-sur-Yon, France.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Bataille Flandres-Dunkerque Avenue, 35000, Rennes, France.;Department of Medical Oncology, Hôpital Privé des Côtes D'Armor, 10 François Jacob Street, 22190, Plérin, France.;Department of Medical Oncology, Hôpital D'Instruction des Armées Begin, 69 Paris Avenue, 94160, Saint-Mandé, France.;Department of Medical Oncology, Hôpital Foch, 40 Worth Street, 92150, Suresnes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Cote D'Azur, 33 Valombrose Avenue, 06100, Nice, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, 20 Leblanc Street, 75015, Paris, France.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Hospitales Virgen de La Victoria y Regional de Málaga, Campus de Teatinos, S/N, 29010, Málaga, Spain.;Department of Medical Oncology, Hôpital Jean Minjoz, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.;Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","159","10.1016/j.ejca.2021.09.029","87-97","","","34742160","34742160","PUBMED","Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Medical Oncology, Hôpital Jean Minjoz, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.;Department of Medical Oncology, Hospitales Virgen de La Victoria y Regional de Málaga, Campus de Teatinos, S/N, 29010, Málaga, Spain.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg/ICANS Strasbourg, 17 Rue Albert Calmette, 67200, Strasbourg, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France.;Department of Medical Oncology, Centre Hospitalier Départemental Vendée, Boulevard Stéphane Moreau, 85000, La Roche-sur-Yon, France.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut Paoli Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Eugène Marquis, Bataille Flandres-Dunkerque Avenue, 35000, Rennes, France.;Department of Medical Oncology, Hôpital Privé des Côtes D'Armor, 10 François Jacob Street, 22190, Plérin, France.;Department of Medical Oncology, Hôpital D'Instruction des Armées Begin, 69 Paris Avenue, 94160, Saint-Mandé, France.;Department of Medical Oncology, Hôpital Foch, 40 Worth Street, 92150, Suresnes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Université Cote D'Azur, 33 Valombrose Avenue, 06100, Nice, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, 20 Leblanc Street, 75015, Paris, France.;Department of Medical Oncology, Centre Francois Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Hospitales Virgen de La Victoria y Regional de Málaga, Campus de Teatinos, S/N, 29010, Málaga, Spain.;Department of Medical Oncology, Hôpital Jean Minjoz, 3 Boulevard Alexandre Fleming, 25000, Besançon, France.;Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif, France.;Department of Cancer Medicine, Gustave Roussy, University of Paris Saclay, 114 Edouard Vaillant Street, 94805, Villejuif"
"321","Marchand T;Pinho S","Marchand, Tony;Pinho, Sandra","Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.","Frontiers in immunology","Switzerland","eng","Journal Article","acute myeloid leukemia;genetic heterogeneity;leukemic stem cell (LSC);stem cell niche;therapeutic targets","Biomarkers, Tumor;Bone Marrow;Disease Management;Disease Susceptibility;Genetic Heterogeneity;Genetic Predisposition to Disease;Humans;Leukemia, Myeloid, Acute;Molecular Targeted Therapy;Neoplastic Stem Cells;Phenotype;Stem Cell Niche;Tumor Microenvironment","Biomarkers, Tumor;Bone Marrow;Disease Management;Disease Susceptibility;Genetic Heterogeneity;Genetic Predisposition to Disease;Humans;Leukemia, Myeloid, Acute;Molecular Targeted Therapy;Neoplastic Stem Cells;Phenotype;Stem Cell Niche;Tumor Microenvironment","Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. While complete remission can be obtained with intensive chemotherapy in young and fit patients, relapse is frequent and prognosis remains poor. Leukemic cells are thought to arise from a pool of leukemic stem cells (LSCs) which sit at the top of the hierarchy. Since their discovery, more than 30 years ago, LSCs have been a topic of intense research and their identification paved the way for cancer stem cell research. LSCs are defined by their ability to self-renew, to engraft into recipient mice and to give rise to leukemia. Compared to healthy hematopoietic stem cells (HSCs), LSCs display specific mutations, epigenetic modifications, and a specific metabolic profile. LSCs are usually considered resistant to chemotherapy and are therefore the drivers of relapse. Similar to their HSC counterpart, LSCs reside in a highly specialized microenvironment referred to as the ""niche"". Bidirectional interactions between leukemic cells and the microenvironment favor leukemic progression at the expense of healthy hematopoiesis. Within the niche, LSCs are thought to be protected from genotoxic insults. Improvement in our understanding of LSC gene expression profile and phenotype has led to the development of prognosis signatures and the identification of potential therapeutic targets. In this review, we will discuss LSC biology in the context of their specific microenvironment and how a better understanding of LSC niche biology could pave the way for new therapies that target AML.","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Department of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, United States.","NA",0,"1664-3224","Front Immunol","Front Immunol",2021,"2021","12","10.3389/fimmu.2021.775128","775128","","","34721441","34721441","PUBMED","Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de médecine, Université Rennes 1, Rennes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) U1236, Rennes, France.;Department of Pharmacology & Regenerative Medicine, University of Illinois at Chicago, Chicago, IL, United States."
"322","Gaillard T;Carton M;Mailliez A;Desmoulins I;Mouret-Reynier MA;Petit T;Leheurteur M;Dieras V;Ferrero JM;Uwer L;Guiu S;Gonçalves A;Levy C;Debled M;Dalenc F;Patsouris A;Bachelot T;Eymard JC;Chevrot M;Conversano A;Robain M;Hequet D","Gaillard, T;Carton, M;Mailliez, A;Desmoulins, I;Mouret-Reynier, M A;Petit, T;Leheurteur, M;Dieras, V;Ferrero, J M;Uwer, L;Guiu, S;Gonçalves, A;Levy, C;Debled, M;Dalenc, F;Patsouris, A;Bachelot, T;Eymard, J C;Chevrot, M;Conversano, A;Robain, M;Hequet, D","De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Breast cancer;Metastatic;Workup","","","The estimated rate of de novo metastatic breast cancer (dnMBC) at the time of diagnosis is between 5 to 12%. International guidelines recommend metastatic work-up (MWU) only in women with advanced breast cancer. The purpose of this study was to describe the characteristics and prognosis of patients with dnMBC diagnosed without an initial indication for MWU. We conducted a retrospective, comparative study in dnMBC patients selected from the ESME-MBC cohort. Patients were treated in France between 2008 and 2016. We compared two populations: patients in whom dnMBC was diagnosed by staging although not indicated by guidelines (non-guideline staging [NGS]) and those in whom dnMBC was diagnosed by guideline staging (GS). During the study period, 22,463 patients with MBC were included in the ESME cohort. Among them, 6698 were dnMBC patients. In 247 of these patients (6% of dnMBC and 1% of the overall population), dnMBC was diagnosed by non-guideline staging. Women in this group were significantly younger (57 vs. 59 years, p = 0.02) and had fewer metastatic sites at diagnosis than dnMBC-GS patients. The two groups were not significantly different in terms of the other characteristics. Overall survival (OS) and progression-free survival (PFS) were better in the dnMBC-NGS group than in the dnMBC-GS group. The impact on survival was confirmed by univariate and multivariate analysis (HR 1.83 [1.31-2.57], p < 0.01). This study provides the first description of a very specific population. These patients with dnMBC-NGS were younger and more likely to have oligometastatic disease with a better prognosis.","Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud;Department of Biostatistics, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, ICANS Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, IUCT-Oncopole Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers & Nantes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Real World Data Department, Unicancer Data Office, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Real World Data Department, Unicancer Data Office, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","158","10.1016/j.ejca.2021.09.021","181-188","","","34689042","34689042","PUBMED","Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud;Department of Biostatistics, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, ICANS Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, IUCT-Oncopole Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers & Nantes, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Real World Data Department, Unicancer Data Office, Paris, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Real World Data Department, Unicancer Data Office, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France."
"323","Phelip JM;Desrame J;Edeline J;Barbier E;Terrebonne E;Michel P;Perrier H;Dahan L;Bourgeois V;Akouz FK;Soularue E;Ly VL;Molin Y;Lecomte T;Ghiringhelli F;Coriat R;Louafi S;Neuzillet C;Manfredi S;Malka D","Phelip, Jean Marc;Desrame, Jérôme;Edeline, Julien;Barbier, Emilie;Terrebonne, Eric;Michel, Pierre;Perrier, Hervé;Dahan, Laetitia;Bourgeois, Vincent;Akouz, Faiza Khemissa;Soularue, Emilie;Ly, Valérie Lebrun;Molin, Yann;Lecomte, Thierry;Ghiringhelli, François;Coriat, Romain;Louafi, Samy;Neuzillet, Cindy;Manfredi, Sylvain;Malka, David","Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Clinical Trial, Phase II","","Aged;Antineoplastic Combined Chemotherapy Protocols;Biliary Tract Neoplasms;Cisplatin;Deoxycytidine;Disease Progression;Female;Fluorouracil;France;Humans;Irinotecan;Leucovorin;Male;Middle Aged;Neoplasm Metastasis;Oxaliplatin;Progression-Free Survival;Time Factors;Gemcitabine","Aged;Antineoplastic Combined Chemotherapy Protocols;Biliary Tract Neoplasms;Cisplatin;Deoxycytidine;Disease Progression;Female;Fluorouracil;France;Humans;Irinotecan;Leucovorin;Male;Middle Aged;Neoplasm Metastasis;Oxaliplatin;Progression-Free Survival;Time Factors;Gemcitabine","Whether triplet chemotherapy is superior to doublet chemotherapy in advanced biliary tract cancer (BTC) is unknown. In this open-label, randomized phase II-III study, patients with locally advanced or metastatic BTC and an Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned (1:1) to receive oxaliplatin, irinotecan, and infusional fluorouracil (mFOLFIRINOX), or cisplatin and gemcitabine (CISGEM) for a maximum of 6 months. We report the results of the phase II part, where the primary end point was the 6-month progression-free survival (PFS) rate among the patients who received at least one dose of treatment (modified intention-to-treat population) according to Response Evaluation Criteria in Solid Tumors version 1.1 (statistical assumptions: 6-month PFS rate ≥ 59%, 73% expected). A total of 191 patients (modified intention-to-treat population, 185: mFOLFIRINOX, 92; CISGEM, 93) were randomly assigned in 43 French centers. After a median follow-up of 21 months, the 6-month PFS rate was 44.6% (90% CI, 35.7 to 53.7) in the mFOLFIRINOX arm and 47.3% (90% CI, 38.4 to 56.3) in the CISGEM arm. Median PFS was 6.2 months (95% CI, 5.5 to 7.8) in the mFOLFIRINOX arm and 7.4 months (95% CI, 5.6 to 8.7) in the CISGEM arm. Median overall survival was 11.7 months (95% CI, 9.5 to 14.2) in the mFOLFIRINOX arm and 13.8 months (95% CI, 10.9 to 16.1) in the CISGEM arm. Adverse events ≥ grade 3 occurred in 72.8% of patients in the mFOLFIRINOX arm and 72.0% of patients in the CISGEM arm (toxic deaths: mFOLFIRINOX arm, two; CISGEM arm, one). mFOLFIRINOX triplet chemotherapy did not meet the primary study end point. CISGEM doublet chemotherapy remains the first-line standard in advanced BTC.","INSERM U1059, Université Jean Monnet, CHU de Saint Etienne, Hôpital Nord, Saint-Etienne, France.;Hôpital privé Jean Mermoz, Lyon, France.;Centre Eugène Marquis, Rennes, France.;FFCD, EPICAD INSERM LNC-UMR 1231, Dijon, France.;Hôpital Haut-Lévêque, Pessac, France.;CHU Charles Nicolle, Rouen, France.;Hôpital Saint Joseph, Marseille, France.;CHU la Timone, Marseille, France.;Hôpital Duchenne, Boulogne sur mer, France.;CH Perpignan, Perpignan, France.;Hôpital de Bicêtre, le Kremlin Bicêtre, France.;CHU Dupuytren, Limoges, France.;Clinique de La Sauvegarde, Lyon, France.;Hôpital Trousseau, Tours, France.;Centre Georges-François Leclerc, Dijon, France.;CHU Cochin, Paris, France.;Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Curie Institute, Saint Cloud, France.;INSERM U1231, Université Bourgogne, Franche Comté, CHU Le Bocage, Dijon, France.;Gustave Roussy, Université Paris Saclay, Villejuif, France.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2021,"2022","40","10.1200/JCO.21.00679","262-271","","","34662180","34662180","PUBMED","INSERM U1059, Université Jean Monnet, CHU de Saint Etienne, Hôpital Nord, Saint-Etienne, France.;Hôpital privé Jean Mermoz, Lyon, France.;Centre Eugène Marquis, Rennes, France.;FFCD, EPICAD INSERM LNC-UMR 1231, Dijon, France.;Hôpital Haut-Lévêque, Pessac, France.;CHU Charles Nicolle, Rouen, France.;Hôpital Saint Joseph, Marseille, France.;CHU la Timone, Marseille, France.;Hôpital Duchenne, Boulogne sur mer, France.;CH Perpignan, Perpignan, France.;Hôpital de Bicêtre, le Kremlin Bicêtre, France.;CHU Dupuytren, Limoges, France.;Clinique de La Sauvegarde, Lyon, France.;Hôpital Trousseau, Tours, France.;Centre Georges-François Leclerc, Dijon, France.;CHU Cochin, Paris, France.;Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.;Curie Institute, Saint Cloud, France.;INSERM U1231, Université Bourgogne, Franche Comté, CHU Le Bocage, Dijon, France.;Gustave Roussy, Université Paris Saclay, Villejuif, France."
"324","Farce J;Lecouillard I;Carsin Nicol B;Bretonnier M;Girard A","Farce, Julien;Lecouillard, Isabelle;Carsin Nicol, Béatrice;Bretonnier, Maxime;Girard, Antoine","Intracavernous Schwannoma Characterized With 18F-FDG, 68Ga-DOTATOC, and 18F-Choline PET.","Clinical nuclear medicine","United States","eng","Case Reports","","Aged;Choline;Fluorodeoxyglucose F18;Humans;Male;Neurilemmoma;Octreotide;Organometallic Compounds;Positron Emission Tomography Computed Tomography","Aged;Choline;Fluorodeoxyglucose F18;Humans;Male;Neurilemmoma;Octreotide;Organometallic Compounds;Positron Emission Tomography Computed Tomography","We report the case of a 75-year-old man with history of prostate cancer whose left intracavernous lesion was successfully characterized by 3 PETs performed successively with different tracers. This poorly characterized tumor was initially discovered on an MRI conducted to investigate an acute diplopia and slowly growing during follow-up. On 18F-FDG PET, the lesion showed no significant uptake, and no extracranial lesion was found nor did it have increased 68Ga-DOTATOC uptake. Finally, this tumor displayed a high 18F-choline uptake, and no extracranial lesion was revealed with this tracer. The diagnosis of schwannoma without malignancy criterion was proven by biopsy.","From the Departments of Nuclear Medicine.;Radiation Oncology, Centre Eugène Marquis, Université de Rennes 1.;Departments of Radiology.;Neurosurgery, Rennes University Hospital, Rennes, France.;From the Departments of Nuclear Medicine.","NA",0,"1536-0229","Clin Nucl Med","Clin Nucl Med",2021,"2022","47","10.1097/RLU.0000000000003929","e165-e166","","","34661554","34661554","PUBMED","From the Departments of Nuclear Medicine.;Radiation Oncology, Centre Eugène Marquis, Université de Rennes 1.;Departments of Radiology.;Neurosurgery, Rennes University Hospital, Rennes, France.;From the Departments of Nuclear Medicine."
"325","Cancel M;Fromont G;Blonz C;Chevreau C;Rioux-Leclercq N;Laguerre B;Oudard S;Gross-Goupil M;Gravis G;Goldwasser F;Rolland F;Delva R;Moise L;Emambux S;Vassal C;Zanetta S;Penel N;Fléchon A;Barthélémy P;Saldana C;Lefort F;Escudier B;Linassier C;Albiges L","Cancel, Mathilde;Fromont, Gaelle;Blonz, Cyriac;Chevreau, Christine;Rioux-Leclercq, Nathalie;Laguerre, Brigitte;Oudard, Stéphane;Gross-Goupil, Marine;Gravis, Gwenaelle;Goldwasser, François;Rolland, Frédéric;Delva, Rémy;Moise, Laura;Emambux, Sheik;Vassal, Cécile;Zanetta, Sylvie;Penel, Nicolas;Fléchon, Aude;Barthélémy, Philippe;Saldana, Carolina;Lefort, Félix;Escudier, Bernard;Linassier, Claude;Albiges, Laurence","Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Everolimus;First-line treatment;IMDC risk groups;Metastatic;Papillary renal cell carcinoma;Prognostic factors;Real world;Sunitinib","","","Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib or a mammalian target of rapamycin (mTOR) inhibitor in first- and second-line treatment, the optimal strategy remained unknown. In 23 centres of the Groupe d'Etude des Tumeurs Urogénitales group, after centralised pathological review, we analysed retrospectively progression-free survival (PFS) of patients with mpRCC treated in first-line treatment (PFS-1) with sunitinib or everolimus (primary end-point), PFS in second-line treatment (PFS-2), overall survival (OS), objective response rate, disease control rate (DCR), overall sequence and prognostic factors for OS (secondary end-points). One hundred thirty-eight patients (119 men and 19 women), median age 62.5 years, with mpRCC type 1 (n = 24) or non-type 1 (n = 114), received first-line sunitinib (n = 107) or everolimus (n = 31). With a median follow-up of 92 months, we found no significant difference between the treatment groups in terms of PFS-1 (5.5 versus 6.2 months) and DCR (69% versus 83%). Ninety-eight patients received a second-line treatment, 69% with mTOR inhibitors after sunitinib and 100% with tyrosine kinase inhibitors after everolimus, with similar DCR (64% versus 58%), median PFS-2 (3.4 versus 4.8 months) and OS (16.0 versus 20.3 months). No factor was prognostic for PFS-1, whereas leukocytosis, anaemia and the time from diagnosis to first systemic therapy < 1 year were prognostic for OS. We found no prognostic difference between both pRCC subtypes. The International Metastatic Renal Cell Database Consortium risk factors were prognostic for OS. Sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC.","Department of Medical Oncology, CHU Bretonneau Tours, France.;Department of Pathology, CHU Bretonneau, Tours, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, IUCT Oncopole - CLCC Institut Claudius Regaud, Toulouse, France.;Department of Pathology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, CHU Hôpital Européen Georges Pompidou, Paris, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, CHU Hôpital Cochin, Paris.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, CHU La Milétrie, Poitiers, France.;Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, CHU Mondor, Créteil, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Bretonneau Tours;Department of Medical Oncology, Gustave Roussy, Villejuif, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","158","10.1016/j.ejca.2021.08.046","1-11","","","34619467","34619467","PUBMED","Department of Medical Oncology, CHU Bretonneau Tours, France.;Department of Pathology, CHU Bretonneau, Tours, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, IUCT Oncopole - CLCC Institut Claudius Regaud, Toulouse, France.;Department of Pathology, CHU Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes.;Department of Medical Oncology, CHU Hôpital Européen Georges Pompidou, Paris, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, CHU Hôpital Cochin, Paris.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Saint-Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Angers, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, CHU La Milétrie, Poitiers, France.;Department of Medical Oncology, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Lille University and Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut de Cancérologie Strasbourg Europe, Strasbourg, France.;Department of Medical Oncology, CHU Mondor, Créteil, France.;Department of Medical Oncology, CHU Saint-André, Bordeaux, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, CHU Bretonneau Tours;Department of Medical Oncology, Gustave Roussy, Villejuif, France."
"326","Martin S;Heslan C;Jégou G;Eriksson LA;Le Gallo M;Thibault V;Chevet E;Godey F;Avril T","Martin, Sophie;Heslan, Christopher;Jégou, Gwénaële;Eriksson, Leif A;Le Gallo, Matthieu;Thibault, Vincent;Chevet, Eric;Godey, Florence;Avril, Tony","SARS-CoV-2 integral membrane proteins shape the serological responses of patients with COVID-19.","iScience","United States","eng","Journal Article","Immunology;Virology","","","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has elicited a unique mobilization of the scientific community to develop efficient tools to understand and combat the infection. Like other  , SARS-CoV-2 hijacks host cell secretory machinery to produce viral proteins that compose the nascent virions; including spike (S), envelope (E), and membrane (M) proteins, the most exposed transmembrane proteins to the host immune system. As antibody response is part of the anti-viral immune arsenal, we investigate the immunogenic potential of S, E, and M using a human cell-based system to mimic membrane insertion and N-glycosylation. Both S and M elicit specific Ig production in patients with SARS-CoV-2. Patients with moderate and severe diseases exhibit elevated Ig responses. Finally, reduced Ig binding was observed with spike G614 compared to D614 variant. Altogether, our assay points toward an unexpected immune response against M and represents a powerful tool to test humoral responses against actively evolving SARS-CoV-2 variants and vaccine effectiveness.","Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Virology, CHU Pontchaillou, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Chemistry & Molecular Biology, University of Gothenburg, 41390 Göteborg, Sweden.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Virology, CHU Pontchaillou, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.","NA",0,"2589-0042","iScience","iScience",2021,"2021","24","10.1016/j.isci.2021.103185","103185","","","34604721","34604721","PUBMED","Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Virology, CHU Pontchaillou, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Chemistry & Molecular Biology, University of Gothenburg, 41390 Göteborg, Sweden.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Department of Virology, CHU Pontchaillou, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France.;Inserm U1242 Oncogenesis Stress Signaling, 35000 Rennes, France.;Centre Eugène Marquis, 35000 Rennes, France."
"327","Caputo SM;Golmard L;Léone M;Damiola F;Guillaud-Bataille M;Revillion F;Rouleau E;Derive N;Buisson A;Basset N;Schwartz M;Vilquin P;Garrec C;Privat M;Gay-Bellile M;Abadie C;Abidallah K;Airaud F;Allary AS;Barouk-Simonet E;Belotti M;Benigni C;Benusiglio PR;Berthemin C;Berthet P;Bertrand O;Bézieau S;Bidart M;Bignon YJ;Birot AM;Blanluet M;Bloucard A;Bombled J;Bonadona V;Bonnet F;Bonnet-Dupeyron MN;Boulaire M;Boulouard F;Bouras A;Bourdon V;Brahimi A;Brayotel F;Bressac de Paillerets B;Bronnec N;Bubien V;Buecher B;Cabaret O;Carriere J;Chiesa J;Chieze-Valéro S;Cohen C;Cohen-Haguenauer O;Colas C;Collonge-Rame MA;Conoy AL;Coulet F;Coupier I;Crivelli L;Cusin V;De Pauw A;Dehainault C;Delhomelle H;Delnatte C;Demontety S;Denizeau P;Devulder P;Dreyfus H;d'Enghein CD;Dupré A;Durlach A;Dussart S;Fajac A;Fekairi S;Fert-Ferrer S;Fiévet A;Fouillet R;Mouret-Fourme E;Gauthier-Villars M;Gesta P;Giraud S;Gladieff L;Goldbarg V;Goussot V;Guibert V;Guillerm E;Guy C;Hardouin A;Heude C;Houdayer C;Ingster O;Jacquot-Sawka C;Jones N;Krieger S;Lacoste S;Lallaoui H;Larbre H;Laugé A;Le Guyadec G;Le Mentec M;Lecerf C;Le Gall J;Legendre B;Legrand C;Legros A;Lejeune S;Lidereau R;Lignon N;Limacher JM;Doriane Livon S;Lizard M;Longy A;Lortholary P;Macquere A;Mailliez S;Malsa H;Margot V;Mari C;Maugard C;Meira J;Menjard D;Molière V;Moncoutier J;Moretta-Serra E;Muller Z;Nevière TV;Nguyen Minh Tuan T;Noguchi C;Noguès F;Oca C;Popovici F;Prieur S;Raad JM;Rey A;Ricou L;Salle C;Saule N;Sevenet F;Simaga H;Sobol V;Suybeng I;Tennevet H;Tenreiro J;Tinat C;Toulas I;Turbiez N;Uhrhammer P;Vande Perre D;Vaur L;Venat N;Viellard MC;Villy M;Warcoin A;Yvard H;Zattara O;Caron C;Lasset A;Remenieras N;Boutry-Kryza L;Castéra D;Stoppa-Lyonnet SM","Caputo, Sandrine M;Golmard, Lisa;Léone, Mélanie;Damiola, Francesca;Guillaud-Bataille, Marine;Revillion, Françoise;Rouleau, Etienne;Derive, Nicolas;Buisson, Adrien;Basset, Noémie;Schwartz, Mathias;Vilquin, Paul;Garrec, Celine;Privat, Maud;Gay-Bellile, Mathilde;Abadie, Caroline;Abidallah, Khadija;Airaud, Fabrice;Allary, Anne-Sophie;Barouk-Simonet, Emmanuelle;Belotti, Muriel;Benigni, Charlotte;Benusiglio, Patrick R;Berthemin, Christelle;Berthet, Pascaline;Bertrand, Ophelie;Bézieau, Stéphane;Bidart, Marie;Bignon, Yves-Jean;Birot, Anne-Marie;Blanluet, Maud;Bloucard, Amelie;Bombled, Johny;Bonadona, Valerie;Bonnet, Françoise;Bonnet-Dupeyron, Marie-Noëlle;Boulaire, Manon;Boulouard, Flavie;Bouras, Ahmed;Bourdon, Violaine;Brahimi, Afane;Brayotel, Fanny;Bressac de Paillerets, Brigitte;Bronnec, Noémie;Bubien, Virginie;Buecher, Bruno;Cabaret, Odile;Carriere, Jennifer;Chiesa, Jean;Chieze-Valéro, Stephanie;Cohen, Camille;Cohen-Haguenauer, Odile;Colas, Chrystelle;Collonge-Rame, Marie-Agnès;Conoy, Anne-Laure;Coulet, Florence;Coupier, Isabelle;Crivelli, Louise;Cusin, Véronica;De Pauw, Antoine;Dehainault, Catherine;Delhomelle, Hélène;Delnatte, Capucine;Demontety, Sophie;Denizeau, Philippe;Devulder, Pierre;Dreyfus, Helene;d'Enghein, Catherine Dubois;Dupré, Anaïs;Durlach, Anne;Dussart, Sophie;Fajac, Anne;Fekairi, Samira;Fert-Ferrer, Sandra;Fiévet, Alice;Fouillet, Robin;Mouret-Fourme, Emmanuelle;Gauthier-Villars, Marion;Gesta, Paul;Giraud, Sophie;Gladieff, Laurence;Goldbarg, Veronica;Goussot, Vincent;Guibert, Virginie;Guillerm, Erell;Guy, Christophe;Hardouin, Agnès;Heude, Céline;Houdayer, Claude;Ingster, Olivier;Jacquot-Sawka, Caroline;Jones, Natalie;Krieger, Sophie;Lacoste, Sofiane;Lallaoui, Hakima;Larbre, Helene;Laugé, Anthony;Le Guyadec, Gabrielle;Le Mentec, Marine;Lecerf, Caroline;Le Gall, Jessica;Legendre, Bérengère;Legrand, Clémentine;Legros, Angélina;Lejeune, Sophie;Lidereau, Rosette;Lignon, Norbert;Limacher, Jean-Marc;Doriane Livon, Sarab;Lizard, Michel;Longy, Alain;Lortholary, Pierre;Macquere, Audrey;Mailliez, Sarah;Malsa, Henri;Margot, Véronique;Mari, Christine;Maugard, Cindy;Meira, Julie;Menjard, Diane;Molière, Virginie;Moncoutier, Jessica;Moretta-Serra, Etienne;Muller, Zoe;Nevière, Thien-Vu;Nguyen Minh Tuan, Tetsuro;Noguchi, Catherine;Noguès, Florine;Oca, Cornel;Popovici, Fabienne;Prieur, Sabine;Raad, Jean-Marc;Rey, Agathe;Ricou, Lucie;Salle, Claire;Saule, Nicolas;Sevenet, Fatoumata;Simaga, Hagay;Sobol, Voreak;Suybeng, Isabelle;Tennevet, Henrique;Tenreiro, Julie;Tinat, Christine;Toulas, Isabelle;Turbiez, Nancy;Uhrhammer, Pierre;Vande Perre, Dominique;Vaur, Laurence;Venat, Nicolas;Viellard, Marie-Charlotte;Villy, Mathilde;Warcoin, Alice;Yvard, Helene;Zattara, Olivier;Caron, Christine;Lasset, Audrey;Remenieras, Nadia;Boutry-Kryza, Laurent;Castéra, Dominique;Stoppa-Lyonnet, Sandrine M","Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.","American journal of human genetics","United States","eng","Journal Article","BRCA1;BRCA2;classification;clinical;cosegregation data;multifactorial model;variant of uncertain significance","BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;Female;Genetic Predisposition to Disease;Genetic Testing;Genetic Variation;Genotype;Humans;Ovarian Neoplasms","BRCA1 Protein;BRCA2 Protein;Breast Neoplasms;Female;Genetic Predisposition to Disease;Genetic Testing;Genetic Variation;Genotype;Humans;Ovarian Neoplasms","Up to 80% of BRCA1 and BRCA2 genetic variants remain of uncertain clinical significance (VUSs). Only variants classified as pathogenic or likely pathogenic can guide breast and ovarian cancer prevention measures and treatment by PARP inhibitors. We report the first results of the ongoing French national COVAR (cosegregation variant) study, the aim of which is to classify BRCA1/2 VUSs. The classification method was a multifactorial model combining different associations between VUSs and cancer, including cosegregation data. At this time, among the 653 variants selected, 101 (15%) distinct variants shared by 1,624 families were classified as pathogenic/likely pathogenic or benign/likely benign by the COVAR study. Sixty-six of the 101 (65%) variants classified by COVAR would have remained VUSs without cosegregation data. Of note, among the 34 variants classified as pathogenic by COVAR, 16 remained VUSs or likely pathogenic when following the ACMG/AMP variant classification guidelines. Although the initiation and organization of cosegregation analyses require a considerable effort, the growing number of available genetic tests results in an increasing number of families sharing a particular variant, and thereby increases the power of such analyses. Here we demonstrate that variant cosegregation analyses are a powerful tool for the classification of variants in the BRCA1/2 breast-ovarian cancer predisposition genes.","Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Centre Léon Bérard, Lyon 69373, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France; INSERM U1240, Université Clermont Auvergne, Clermont-Ferrand 63000, France.;Unité d'Oncogénétique, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, St Herbain-Nantes 44805, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Clinical research direction, Institut Curie, Paris 75005, France.;Hôpital d'Enfants, CHRU Nancy Hopitaux de Brabois, Vandoeuvre les Nancy 54500, France.;UF d'Oncogénétique, GH Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Laboratoire de Génétique Moléculaire: Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble 38700, France; INSERM 1209, Université Grenoble Alpes, Grenoble 38700, France.;Department of Oncogenetics, Centre Jean Perrin, UMR INSERM 1240, Université Clermont Auvergne, Clermont-Ferrand Cedex 63011, France.;Service de Génétique, Hôpital Européen Georges Pompidou, Paris 75015, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Consultations de Génétique, Centre Hospitalier de Valence, Valence 26953, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Genetics, CHU Lille, Lille 59000, France.;Oncogenetics Laboratory, Institut Godinot, Reims 51726, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Génétique Médicale, CHU Bordeaux, Bordeaux 33076, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Centre Hospitalier Régional Universitaire, Nimes 30029, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Service de Génétique, CHI de Poissy-Saint Germain En Laye, Poissy 78300, France.;Service de Génétique, CHI de Poissy-Saint Germain En Laye, Poissy 78300, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Oncobiologie Génétique Bioinformatique, CHRU Besançon, Besançon 25030, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Centre Eugène Marquis, Rennes, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France; Unité d'Oncogénétique, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, St Herbain-Nantes 44805, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Centre Hospitalo-Universitaire Rennes, Rennes 35000, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Institut Sainte Catherine, Avignon 84082, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Consultation oncogénétique, CHU Reims, Reims 51092, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon, AP-HP, Sorbonne Université, Paris 75020, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;UF Consultation de génétique, Centre Hospitalier Métropole Savoie, Chambéry 73011, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Hospices Civils de Lyon, Lyon 69229, France.;Oncogenetics Department, Institut Claudius Regaud, Toulouse 31059, France.;Gustave Roussy, Département de médecine oncologique, Villejuif 94805, France.;Département de Biologie et Pathologie des Tumeurs, Centre Georges François Leclerc, Dijon 21000, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Département de Génétique Médicale/oncogénétique, CHU Angers, Angers 49000, France.;Centre de Génétique, CHU de Dijon (hopital François Mitterand) and CLCC de Dijon (Centre Georges François Leclerc), Dijon 21000, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France.;CH La rochelle, La Rochelle 17000, France.;Oncogenetics Laboratory, Institut Godinot, Reims 51726, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Laboratoire de Génétique Moléculaire: Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble 38700, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Service de Génétique, CHU Grenoble Alpes, Grenoble 38700, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, CHU Lille, Lille 59000, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Oncogenetics Department, Institut Claudius Regaud, Toulouse 31059, France.;Génétique Oncologique Clinique, Hospices Civils de Colmar, Colmar 68000, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Department of Genetics, CHRU Nancy Hopitaux de Brabois, Vandoeuvre les Nancy 54500, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Hôpital Privé du Confluent, Nantes 44202, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Genetics, CHU de Martinique, Fort de France 97200, Martinique.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Service oncogénétique, Centre Antoine Lacassagne, Nice 06189, France.;Génétique Oncologique Moléculaire, Hôpital de Hautepierre, Strasbourg 67000, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Genetics, CHU Brest, Brest 29600, France.;Service de Génétique, Hôpital Européen Georges Pompidou, Paris 75015, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Service de Génétique, CHU St Etienne, Saint Etienne 42055, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France; Department of Oncology, Comprehensive Cancer Centre Henri Becquerel, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Génétique Médicale, CHU Bordeaux, Bordeaux 33076, France.;Oncogenetics Laboratory, Institut Claudius Regaud, Toulouse 31059, France.;Clinical research direction, Institut Curie, Paris 75005, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France; INSERM U1240, Université Clermont Auvergne, Clermont-Ferrand 63000, France.;Oncogenetics Laboratory, Institut Claudius Regaud, Toulouse 31059, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of oncology, CHU Dupuytren, Limoges 87042, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Hôpital Privé du Confluent, Nantes 44202, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Gustave Roussy, Département de médecine oncologique, Villejuif 94805, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris University, Paris 75005, France; INSERM U830, Institut Curie, Paris 75005, France.","NA",0,"1537-6605","Am J Hum Genet","Am J Hum Genet",2021,"2021","108","10.1016/j.ajhg.2021.09.003","1907-1923","","","34597585","34597585","PUBMED","Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Centre Léon Bérard, Lyon 69373, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France; INSERM U1240, Université Clermont Auvergne, Clermont-Ferrand 63000, France.;Unité d'Oncogénétique, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, St Herbain-Nantes 44805, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Clinical research direction, Institut Curie, Paris 75005, France.;Hôpital d'Enfants, CHRU Nancy Hopitaux de Brabois, Vandoeuvre les Nancy 54500, France.;UF d'Oncogénétique, GH Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Laboratoire de Génétique Moléculaire: Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble 38700, France; INSERM 1209, Université Grenoble Alpes, Grenoble 38700, France.;Department of Oncogenetics, Centre Jean Perrin, UMR INSERM 1240, Université Clermont Auvergne, Clermont-Ferrand Cedex 63011, France.;Service de Génétique, Hôpital Européen Georges Pompidou, Paris 75015, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Consultations de Génétique, Centre Hospitalier de Valence, Valence 26953, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Genetics, CHU Lille, Lille 59000, France.;Oncogenetics Laboratory, Institut Godinot, Reims 51726, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Génétique Médicale, CHU Bordeaux, Bordeaux 33076, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Centre Hospitalier Régional Universitaire, Nimes 30029, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Service de Génétique, CHI de Poissy-Saint Germain En Laye, Poissy 78300, France.;Service de Génétique, CHI de Poissy-Saint Germain En Laye, Poissy 78300, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Oncobiologie Génétique Bioinformatique, CHRU Besançon, Besançon 25030, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Centre Eugène Marquis, Rennes, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France; Unité d'Oncogénétique, Institut de Cancérologie de l'Ouest, Centre René Gauducheau, St Herbain-Nantes 44805, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Centre Hospitalo-Universitaire Rennes, Rennes 35000, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Institut Sainte Catherine, Avignon 84082, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Consultation oncogénétique, CHU Reims, Reims 51092, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Service d'Anatomie et Cytologie Pathologiques, Hôpital Tenon, AP-HP, Sorbonne Université, Paris 75020, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;UF Consultation de génétique, Centre Hospitalier Métropole Savoie, Chambéry 73011, France.;Service de Génétique des Tumeurs, Gustave Roussy, Villejuif 94806, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Hospices Civils de Lyon, Lyon 69229, France.;Oncogenetics Department, Institut Claudius Regaud, Toulouse 31059, France.;Gustave Roussy, Département de médecine oncologique, Villejuif 94805, France.;Département de Biologie et Pathologie des Tumeurs, Centre Georges François Leclerc, Dijon 21000, France.;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes 44093, France.;Département de génétique, AP-HP, Sorbonne université-Site Pitié-Salpêtrière, Paris 75013, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Département de Génétique Médicale/oncogénétique, CHU Angers, Angers 49000, France.;Centre de Génétique, CHU de Dijon (hopital François Mitterand) and CLCC de Dijon (Centre Georges François Leclerc), Dijon 21000, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France.;CH La rochelle, La Rochelle 17000, France.;Oncogenetics Laboratory, Institut Godinot, Reims 51726, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Laboratoire de Génétique Moléculaire: Maladies Héréditaires et Oncologie, CHU Grenoble Alpes, Grenoble 38700, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Service de Génétique, CHU Grenoble Alpes, Grenoble 38700, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, CHU Lille, Lille 59000, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Oncogenetics Department, Institut Claudius Regaud, Toulouse 31059, France.;Génétique Oncologique Clinique, Hospices Civils de Colmar, Colmar 68000, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Department of Genetics, CHRU Nancy Hopitaux de Brabois, Vandoeuvre les Nancy 54500, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Hôpital Privé du Confluent, Nantes 44202, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Genetics, CHU de Martinique, Fort de France 97200, Martinique.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Service oncogénétique, Centre Antoine Lacassagne, Nice 06189, France.;Génétique Oncologique Moléculaire, Hôpital de Hautepierre, Strasbourg 67000, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Genetics, CHU Brest, Brest 29600, France.;Service de Génétique, Hôpital Européen Georges Pompidou, Paris 75015, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Oncogenetic, Department of Biopathology, Comprehensive Cancer Center François Baclesse, Caen 14076, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris Sciences Lettres Research University, Paris 75005, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Clinical Cancer Genetics, Institut Paoli-Calmettes, Marseille 13273, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Service de Génétique, CHU St Etienne, Saint Etienne 42055, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Département Pathologie et Oncobiologie, CHU Montpellier, Montpellier 34070, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Service Oncogénétique Régional Poitou-Charentes, CH Georges Renon, Niort 79000, France.;Department of Genetics, Institut Curie, Saint-Cloud 92210, France.;Unité d'Oncogénétique, Institut Bergonié, Bordeaux 33076, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France; Department of Oncology, Comprehensive Cancer Centre Henri Becquerel, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Génétique Médicale, CHU Bordeaux, Bordeaux 33076, France.;Oncogenetics Laboratory, Institut Claudius Regaud, Toulouse 31059, France.;Clinical research direction, Institut Curie, Paris 75005, France.;Département d'Oncogénétique, Centre Jean Perrin, Clermont-Ferrand 63000, France; INSERM U1240, Université Clermont Auvergne, Clermont-Ferrand 63000, France.;Oncogenetics Laboratory, Institut Claudius Regaud, Toulouse 31059, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of oncology, CHU Dupuytren, Limoges 87042, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Institut Curie, Paris 75005, France.;Department of Genetics, Hôpital Privé du Confluent, Nantes 44202, France.;Department of Genetics, Centre Oscar Lambret, Lille 59000, France.;Gustave Roussy, Département de médecine oncologique, Villejuif 94805, France.;Département Prévention Santé Publique, Centre Léon Bérard, Lyon 69008, France.;Department of Cancer Biology, Laboratory of Molecular Oncogenetics, Institut Paoli Calmettes, Marseille 13273, France.;Service de Génétique, plate-forme mixte des cancers fréquents, Hospices Civils de Lyon, Bron 69229, France.;Laboratory of Cancer Biology and Genetics, Comprehensive Cancer Center François Baclesse, Caen 14076, France; Inserm U1245, Rouen University, Normandy Centre for Genomic and Personalized Medicine, Rouen 76031, France.;Department of Genetics, Institut Curie, Paris 75005, France; Paris University, Paris 75005, France; INSERM U830, Institut Curie, Paris 75005, France."
"328","Rollet Q;Bouvier V;Moutel G;Launay L;Bignon AL;Bouhier-Leporrier K;Launoy G;Lièvre A","Rollet, Quentin;Bouvier, Véronique;Moutel, Grégoire;Launay, Ludivine;Bignon, Anne-Laure;Bouhier-Leporrier, Karine;Launoy, Guy;Lièvre, Astrid","Multidisciplinary team meetings: are all patients presented and does it impact quality of care and survival - a registry-based study.","BMC health services research","England","eng","Journal Article","Disease management;Health care ethics;Health services accessibility;Multidisciplinary team meeting;Quality of health care","Aged;Colorectal Neoplasms;Humans;Neoplasms;Patient Care Team;Probability;Proportional Hazards Models;Registries","Aged;Colorectal Neoplasms;Humans;Neoplasms;Patient Care Team;Probability;Proportional Hazards Models;Registries","Multidisciplinary team meetings (MDTMs) are part of the standard cancer care process in many European countries. In France, they are a mandatory condition in the authorization system for cancer care administration, with the goal to ensure that all new patients diagnosed with cancer are presented in MDTMs. Identify the factors associated with non-presentation or unknown presentation in MDTMs, and study the impact of presentation in MDTMs on quality of care and survival in patients diagnosed with colorectal cancer (CRC). 3999 CRC patients diagnosed between 2005 and 2014 in the area covered by the ""Calvados Registry of Digestive Tumours"" were included. Multivariate multinomial logistic regression was used to assess the factors associated with presentation in MDTMs. Univariate analyses were performed to study the impact of MDTMs on quality of care. Multivariate Cox model and the Log-Rank test were used to assess the impact of MDTMs on survival. Non-presentation or unknown presentation in MDTMs were associated with higher age at diagnosis, dying within 3 months after diagnosis, unknown metastatic status, non-metastatic cancer and colon cancer. Non-presentation was associated with a diagnosis after 2010. Unknown presentation was associated with a diagnosis before 2007 and a longer travel time to the reference care centres. Presentation in MDTMs was associated with more chemotherapy administration for patients with metastatic cancer and more adjuvant chemotherapy for patients with stage III colon cancer. After excluding poor prognosis patients, lower survival was significantly associated with higher age at diagnosis, unknown metastatic status or metastatic cancer, presence of comorbidities, rectal cancer and non-presentation in MDTMs (HR = 1.5 [1.1-2.0], p < 0.001). Elderly and poor prognosis patients were less presented in MDTMs. Geriatric assessments before presentation in MDTMs were shown to improve care plan establishment. The 100% objective is not coherent if MDTMs are only to discuss diagnosis and curative cares. They could also be a place to discuss therapeutic limitations. MDTMs were associated with better treatment and longer survival. We must ensure that there is no inequity in presentation in MDTMs that could lead to a loss of chance for patients.","U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Digestive Cancer Registry of Calvados, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Espace Régional de Réflexion éthique, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Department of Gastroenterology, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;Department of Gastroenterology, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Digestive Cancer Registry of Calvados, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;Department of Gastroenterology, Rennes University Hospital 2 Rue Henri le Guilloux, 35000, Rennes, France.;U1242 ""COSS"" INSERM-University of Rennes, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, 35042, Rennes, France.","NA",0,"1472-6963","BMC Health Serv Res","BMC Health Serv Res",2021,"2021","21","10.1186/s12913-021-07022-x","1032","","","34592971","34592971","PUBMED","U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Digestive Cancer Registry of Calvados, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Espace Régional de Réflexion éthique, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Department of Gastroenterology, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;Department of Gastroenterology, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;U1086 ""ANTICIPE"" INSERM-University of Caen Normandie, U1086 ""Anticipe"" - Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen, France.;Digestive Cancer Registry of Calvados, University Hospital of Caen, Avenue de la Côte de Nacre, 14000, Caen, France.;Department of Gastroenterology, Rennes University Hospital 2 Rue Henri le Guilloux, 35000, Rennes, France.;U1242 ""COSS"" INSERM-University of Rennes, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, 35042, Rennes, France."
"329","Bizot A;Karimi M;Rassy E;Heudel PE;Levy C;Vanlemmens L;Uzan C;Deluche E;Genet D;Saghatchian M;Giacchetti S;Grenier J;Patsouris A;Dieras V;Pierga JY;Petit T;Ladoire S;Jacot W;Benderra MA;De Jesus A;Delaloge S;Lambertini M;Pistilli B","Bizot, Alexandra;Karimi, Maryam;Rassy, Elie;Heudel, Pierre Etienne;Levy, Christelle;Vanlemmens, Laurence;Uzan, Catherine;Deluche, Elise;Genet, Dominique;Saghatchian, Mahasti;Giacchetti, Sylvie;Grenier, Juline;Patsouris, Anne;Dieras, Véronique;Pierga, Jean-Yves;Petit, Thierry;Ladoire, Sylvain;Jacot, William;Benderra, Marc-Antoine;De Jesus, Anne;Delaloge, Suzette;Lambertini, Matteo;Pistilli, Barbara","Multicenter evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits during the COVID-19 pandemic.","British journal of cancer","England","eng","Journal Article","","Adult;Aged;Breast Neoplasms;COVID-19;Female;France;Humans;Italy;Medical Oncology;Middle Aged;Pandemics;Patient Satisfaction;Remote Consultation;Surveys and Questionnaires;Telemedicine","Adult;Aged;Breast Neoplasms;COVID-19;Female;France;Humans;Italy;Medical Oncology;Middle Aged;Pandemics;Patient Satisfaction;Remote Consultation;Surveys and Questionnaires;Telemedicine","During the COVID-19 pandemic, teleconsultation was implemented in clinical practice to limit patient exposure to COVID-19 while monitoring their treatment and follow-up. We sought to examine the satisfaction of patients with breast cancer (BC) who underwent teleconsultations during this period. Eighteen centres in France and Italy invited patients with BC who had at least one teleconsultation during the first wave of the COVID-19 pandemic to participate in a web-based survey that evaluated their satisfaction (EORTC OUT-PATSAT 35 and Telemedicine Satisfaction Questionnaire [TSQ] scores) with teleconsultation. Among the 1299 participants eligible for this analysis, 53% of participants were undergoing standard post-treatment follow-up while 22 and 17% were currently receiving active anticancer therapy for metastatic and localised cancers, respectively. The mean satisfaction scores were 77.4 and 73.3 for the EORTC OUT-PATSAT 35 and TSQ scores, respectively. In all, 52.6% of participants had low/no anxiety. Multivariable analysis showed that the EORTC OUT-PATSAT 35 score correlated to age, anxiety score and teleconsultation modality. The TSQ score correlated to disease status and anxiety score. Patients with BC were satisfied with oncology teleconsultations during the COVID-19 pandemic. Teleconsultation may be an acceptable alternative follow-up modality in specific circumstances.","Medical Oncology Department, Gustave Roussy, Villejui, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Institut Normand du Sein, Centre Francois Baclesse, Caen, France.;Centre Oscar Lambret, Lille, France.;Breast and Gynecologic Surgery, Assistance Publique - Hopitaux De Paris, Paris, France.;Medical Oncology Department, CHU Limoges - Hopital Dupuytren, Limoges, France.;Medical Oncology Department, Clinique Chenieux, Limoges, France.;Breast Cancer Unit, American Hospital of Paris, Neuilly-Sur-Seine, France.;Breast Cancer Unit, AP university Hospital St Louis, Paris, France.;Medical Oncology Department, Institut Ste Catherine, Avignon, France.;Medical Oncology Department, ICO - Institut de Cancérologie de l'Ouest Nantes-Angers, Angers, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Medical Oncology Department, Institut Curie & St Cloud, Université de Paris, Paris, France.;Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology Department, Centre Georges-François Leclerc (Dijon), Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM, U1194, Montpellier, France.;Medical Oncology Department, Hopital Tenon, Paris, France.;Patient Relationship Coordination, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.;Medical Oncology Department, Gustave Roussy, Villejui","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2021,"2021","125","10.1038/s41416-021-01555-y","1486-1493","","","34588616","34588616","PUBMED","Medical Oncology Department, Gustave Roussy, Villejui, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.;Institut Normand du Sein, Centre Francois Baclesse, Caen, France.;Centre Oscar Lambret, Lille, France.;Breast and Gynecologic Surgery, Assistance Publique - Hopitaux De Paris, Paris, France.;Medical Oncology Department, CHU Limoges - Hopital Dupuytren, Limoges, France.;Medical Oncology Department, Clinique Chenieux, Limoges, France.;Breast Cancer Unit, American Hospital of Paris, Neuilly-Sur-Seine, France.;Breast Cancer Unit, AP university Hospital St Louis, Paris, France.;Medical Oncology Department, Institut Ste Catherine, Avignon, France.;Medical Oncology Department, ICO - Institut de Cancérologie de l'Ouest Nantes-Angers, Angers, France.;Medical Oncology Department, Centre Eugene - Marquis, Rennes, France.;Medical Oncology Department, Institut Curie & St Cloud, Université de Paris, Paris, France.;Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, France.;Medical Oncology Department, Centre Georges-François Leclerc (Dijon), Dijon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, INSERM, U1194, Montpellier, France.;Medical Oncology Department, Hopital Tenon, Paris, France.;Patient Relationship Coordination, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Gustave Roussy, Villejui, France.;Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy.;Medical Oncology Department, Gustave Roussy, Villejui"
"330","Bourgier C;Cowen D;Castan F;Lemanski C;Gourgou S;Rivera S;Labib A;Peignaux K;Blanc-Onfroy ML;Benyoucef A;Mege A;Douadi-Gaci Z;Racadot S;Latorzeff I;Schick U;Jacquot S;Massabeau C;Guilbert P;Geffrelot J;Ellis S;Lecouillard I;Breton-Callu C;Richard-Tallet A;Boulbair F;Cretin J;Belkacémi Y;Bons F;Azria D;Fenoglietto P","Bourgier, Celine;Cowen, Didier;Castan, Florence;Lemanski, Claire;Gourgou, Sophie;Rivera, Sofia;Labib, Alain;Peignaux, Karine;Blanc-Onfroy, Magali Le;Benyoucef, Ahmed;Mege, Alice;Douadi-Gaci, Zineb;Racadot, Severine;Latorzeff, Igor;Schick, Ulrike;Jacquot, Stephane;Massabeau, Carole;Guilbert, Philippe;Geffrelot, Julien;Ellis, Stephen;Lecouillard, Isabelle;Breton-Callu, Christel;Richard-Tallet, Agnès;Boulbair, Fatiha;Cretin, Jacques;Belkacémi, Yazid;Bons, Françoise;Azria, David;Fenoglietto, Pascal","Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Journal Article","Acute toxicities;Boost;DCIS;Quality assurance;Randomized trial","Breast;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Female;Humans;Hypertrophy;Radiotherapy Planning, Computer-Assisted","Breast;Breast Neoplasms;Carcinoma, Intraductal, Noninfiltrating;Female;Humans;Hypertrophy;Radiotherapy Planning, Computer-Assisted","To describe the quality assurance (QA) program and early toxicities in the phase III randomized trial BONBIS (NCT00907868) on the role of a localized radiation boost in ductal carcinoma in situ (DCIS). From November 2008 to July 2014, 2004 patients were randomized in arm A (only whole breast radiotherapy, WBRT) and arm B (WBRT + boost). The QA program involved 44 participant centers that performed the dummy run (DR). Compliance and uniformity of clinical target volume (CTV) delineations, and dose prescription and delivery according to the BONBIS trial radiotherapy guidelines were analyzed. Acute toxicities (during and up to 3 months after radiotherapy completion, NCI-CTCAE v3.0 classification) were evaluated in 1929 patients. The differences in whole breast CTV (CTV1) and planning target volume (PTV1) were ≤10%, and the differences in boost CTV (CTV2) and PTV (PTV2) were ≥20% compared with the reference DR values; 95% of the prescribed dose encompassed 98.7% and 100% of the median CTV1 and CTV2. Grade ≥2 breast erythema (38.3% vs. 22.4% of grade 2 and 5.4% vs. 2.1% of grade 3, p < 0.001), grade ≥2 dermatitis (2.8% vs. 0.7%, p < 0.001), and grade 2 hyperpigmentation (6.9% vs. 3.6%, p = 0.005) were more frequent in arm B than arm A. No acute lung or cardiac toxicity was observed. Smoking history, large breast size, and large breast CTV were strong predictive factors of grade ≥2 acute skin toxicities. The QA program showed deviations in breast and tumor bed delineation. The boost significantly increased acute skin toxicities.","Univ Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Aix Marseille Univ, APHM, Hôpital Timone-Hôpital Nord, Département de Radiothérapie, Marseille, France.;Unité de Biométrie, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Unité de Biométrie, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Gustave Roussy, Département d'oncologie radiothérapie, Villejuif, France; Université Paris-Saclay, Inserm, U1030, Villejuif, France.;Institut Curie, Paris, France.;Département d'Oncologie Radiothérapie Centre Georges-François LECLERC, Dijon, France.;Service de Radiothérapie, ICO René Gauducheau, Saint-Herblain, France.;Département de Radiothérapie et de Physique médicale, Centre Henri Becquerel, Rouen, France.;Sainte Catherine, Institut du Cancer Avignon-Provence, Avignon, France.;Hôpital privé Le Confluent, Nantes, France.;Service de Radiothérapie, Centre Léon Bérard, Lyon, France.;Département de radiothérapie-oncologie, Clinique Pasteur, Toulouse, France.;Department of Radiation Oncology, University Hospital of Brest, UBO, LaTIM UMR 1101, Brest, France.;Centre de Cancerologie du Grand Montpellier, Montpellier, France.;Département de Radiotherapie, Institut Claudius Regaud IUCT-O, Toulouse, France.;Département de Radiothérapie, Institut Godinot, Reims, France.;Service de Radiothérapie, Centre François Baclesse, Caen, France.;Service de Radiothérapie, Centre Catalan d'Oncologie, Perpignan, France.;Département de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Pôle oncologie, centre hospitalier Brive, France.;Institut Paoli-Calmettes, département d'Oncologie Radiothérapie, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, Marseille, France.;Service d'Oncologie-Radiothérapie, CHRU Besançon, France.;Centre Médical ONCOGARD - ICG, Nîmes, France.;Department of Radiation Oncology and Henri Mondor Breast Center, AP HP - Henri Mondor University Hospital, University of Paris-Est (UPEC), INSERM Unit 955, Team 21-IMRB, Creteil, France.;Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France; Service de Radiothérapie, CHU Nîmes, France.;Univ Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2021,"2021","164","10.1016/j.radonc.2021.09.014","57-65","","","34571090","34571090","PUBMED","Univ Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Aix Marseille Univ, APHM, Hôpital Timone-Hôpital Nord, Département de Radiothérapie, Marseille, France.;Unité de Biométrie, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Unité de Biométrie, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Gustave Roussy, Département d'oncologie radiothérapie, Villejuif, France; Université Paris-Saclay, Inserm, U1030, Villejuif, France.;Institut Curie, Paris, France.;Département d'Oncologie Radiothérapie Centre Georges-François LECLERC, Dijon, France.;Service de Radiothérapie, ICO René Gauducheau, Saint-Herblain, France.;Département de Radiothérapie et de Physique médicale, Centre Henri Becquerel, Rouen, France.;Sainte Catherine, Institut du Cancer Avignon-Provence, Avignon, France.;Hôpital privé Le Confluent, Nantes, France.;Service de Radiothérapie, Centre Léon Bérard, Lyon, France.;Département de radiothérapie-oncologie, Clinique Pasteur, Toulouse, France.;Department of Radiation Oncology, University Hospital of Brest, UBO, LaTIM UMR 1101, Brest, France.;Centre de Cancerologie du Grand Montpellier, Montpellier, France.;Département de Radiotherapie, Institut Claudius Regaud IUCT-O, Toulouse, France.;Département de Radiothérapie, Institut Godinot, Reims, France.;Service de Radiothérapie, Centre François Baclesse, Caen, France.;Service de Radiothérapie, Centre Catalan d'Oncologie, Perpignan, France.;Département de Radiothérapie, Centre Eugène Marquis, Rennes, France.;Pôle oncologie, centre hospitalier Brive, France.;Institut Paoli-Calmettes, département d'Oncologie Radiothérapie, Marseille, France; Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR 1068, Marseille, France.;Service d'Oncologie-Radiothérapie, CHRU Besançon, France.;Centre Médical ONCOGARD - ICG, Nîmes, France.;Department of Radiation Oncology and Henri Mondor Breast Center, AP HP - Henri Mondor University Hospital, University of Paris-Est (UPEC), INSERM Unit 955, Team 21-IMRB, Creteil, France.;Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France; Service de Radiothérapie, CHU Nîmes, France.;Univ Montpellier, Montpellier, France; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Montpellier, France; Fédération Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée, Institut régional du Cancer Montpellier (ICM), Montpellier, France."
"331","Patterson T;Clayton T;Dodd M;Khawaja Z;Morice MC;Wilson K;Kim WK;Meneveau N;Hambrecht R;Byrne J;Carrié D;Fraser D;Roberts DH;Doshi SN;Zaman A;Banning AP;Eltchaninoff H;Le Breton H;Smith D;Cox I;Frank D;Gershlick A;de Belder M;Thomas M;Hildick-Smith D;Prendergast B;Redwood S","Patterson, Tiffany;Clayton, Tim;Dodd, Matthew;Khawaja, Zeeshan;Morice, Marie Claude;Wilson, Karen;Kim, Won-Keun;Meneveau, Nicolas;Hambrecht, Rainer;Byrne, Jonathan;Carrié, Didier;Fraser, Doug;Roberts, David H;Doshi, Sagar N;Zaman, Azfar;Banning, Adrian P;Eltchaninoff, Hélène;Le Breton, Hervé;Smith, David;Cox, Ian;Frank, Derk;Gershlick, Anthony;de Belder, Mark;Thomas, Martyn;Hildick-Smith, David;Prendergast, Bernard;Redwood, Simon","ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial.","JACC. Cardiovascular interventions","United States","eng","Journal Article","aortic stenosis;percutaneous coronary intervention;randomized control trial;transcatheter aortic valve replacement","Aortic Valve Stenosis;Canada;Humans;Percutaneous Coronary Intervention;Transcatheter Aortic Valve Replacement;Treatment Outcome","Aortic Valve Stenosis;Canada;Humans;Percutaneous Coronary Intervention;Transcatheter Aortic Valve Replacement;Treatment Outcome","This study sought to determine if percutaneous coronary intervention (PCI) prior to transcatheter aortic valve replacement (TAVR) in patients with significant coronary artery disease would produce noninferior clinical results when compared with no PCI (control arm). PCI in patients undergoing TAVR is not without risk, and there are no randomized data to inform clinical practice. Patients with severe symptomatic aortic stenosis and significant coronary artery disease with Canadian Cardiovascular Society class ≤2 angina were randomly assigned to receive PCI or no PCI prior to TAVR. The primary endpoint was a composite of all-cause death or rehospitalization at 1 year. Noninferiority testing (prespecified margin of 7.5%) was performed in the intention-to-treat population. At 17 centers, 235 patients underwent randomization. At 1 year, the primary composite endpoint occurred in 48 (41.5%) of the PCI arm and 47 (44.0%) of the no-PCI arm. The requirement for noninferiority was not met (difference: -2.5%; 1-sided upper 95% confidence limit: 8.5%; 1-sided noninferiority test P = 0.067). On analysis of the as-treated population, the difference was -3.7% (1-sided upper 95% confidence limit: 7.5%; P = 0.050). Mortality was 16 (13.4%) in the PCI arm and 14 (12.1%) in the no-PCI arm. At 1 year, there was no evidence of a difference in the rates of stroke, myocardial infarction, or acute kidney injury, with higher rates of any bleed in the PCI arm (P = 0.021). Observed rates of death and rehospitalization at 1 year were similar between PCI and no PCI prior to TAVR; however, the noninferiority margin was not met, and PCI resulted in a higher incidence of bleeding. (Assessing the Effects of Stenting in Significant Coronary Artery Disease Prior to Transcatheter Aortic Valve Implantation; ISRCTN75836930).","Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.;Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.;Cardiology Department, Lewisham and Greenwich NHS Foundation Trust, United Kingdom.;Institut Cardiovasculaire Paris Sud, Massy, France; Cardiovascular European Research Center, Massy, France.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Cardiology Department, Kerckhoff-Klinik Bad Nauheim Abteilung Kardiologie, Bad Nauheim, Germany.;Department of Cardiology, University Hospital Jean Minjoz, Besançon, France; EA3920, University of Burgundy Franche-Comté, Besançon, France.;Cardiology Department, Klinikum Links der Weser GmbH, Bremen, Germany.;Cardiothoracic Department, King's College Hospital, London, United Kingdom.;Cardiology Department, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Cardiology Department, Manchester Royal Infirmary, Manchester, United Kingdom.;Lancashire Cardiac Centre, Blackpool Victoria Hospital NHS Trust, Blackpool, United Kingdom.;Cardiology Department, Queen Elizabeth Hospital, Birmingham, United Kingdom.;Cardiology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust of the Freeman Hospital, Newcastle, United Kingdom.;Department of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom.;Cardiology Department, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Service de Cardiologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiology Department, Morriston Hospital, Swansea, United Kingdom.;Cardiology Department, Derriford Hospital, Plymouth, United Kingdom.;Cardiology Department, Oberarzt Facharzt für Innere Medizin und Kardiologie, Kiel, Germany.;Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester, Leicester, United Kingdom.;Cardiology Department, Barts Heart Centre, London, United Kingdom.;Edwards Lifesciences, Irvine, California, USA.;Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London","NA",0,"1876-7605","JACC Cardiovasc Interv","JACC Cardiovasc Interv",2021,"2021","14","10.1016/j.jcin.2021.06.041","1965-1974","","","34556269","34556269","PUBMED","Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.;Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom.;Cardiology Department, Lewisham and Greenwich NHS Foundation Trust, United Kingdom.;Institut Cardiovasculaire Paris Sud, Massy, France; Cardiovascular European Research Center, Massy, France.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Cardiology Department, Kerckhoff-Klinik Bad Nauheim Abteilung Kardiologie, Bad Nauheim, Germany.;Department of Cardiology, University Hospital Jean Minjoz, Besançon, France; EA3920, University of Burgundy Franche-Comté, Besançon, France.;Cardiology Department, Klinikum Links der Weser GmbH, Bremen, Germany.;Cardiothoracic Department, King's College Hospital, London, United Kingdom.;Cardiology Department, Hôpital Rangueil, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Cardiology Department, Manchester Royal Infirmary, Manchester, United Kingdom.;Lancashire Cardiac Centre, Blackpool Victoria Hospital NHS Trust, Blackpool, United Kingdom.;Cardiology Department, Queen Elizabeth Hospital, Birmingham, United Kingdom.;Cardiology Department, Newcastle upon Tyne Hospitals NHS Foundation Trust of the Freeman Hospital, Newcastle, United Kingdom.;Department of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom.;Cardiology Department, Hôpital Charles-Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Service de Cardiologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Cardiology Department, Morriston Hospital, Swansea, United Kingdom.;Cardiology Department, Derriford Hospital, Plymouth, United Kingdom.;Cardiology Department, Oberarzt Facharzt für Innere Medizin und Kardiologie, Kiel, Germany.;Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester, Leicester, United Kingdom.;Cardiology Department, Barts Heart Centre, London, United Kingdom.;Edwards Lifesciences, Irvine, California, USA.;Sussex Cardiac Centre, Brighton and Sussex University Hospitals, Brighton, United Kingdom.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London, United Kingdom.;Cardiovascular Department, St Thomas' Hospital, Kings College London, London"
"332","Cottin V;Larrieu S;Boussel L;Si-Mohamed S;Bazin F;Marque S;Massol J;Thivolet-Bejui F;Chalabreysse L;Maucort-Boulch D;Jouneau S;Hachulla E;Chollet J;Nasser M","Cottin, Vincent;Larrieu, Sophie;Boussel, Loic;Si-Mohamed, Salim;Bazin, Fabienne;Marque, Sébastien;Massol, Jacques;Thivolet-Bejui, Françoise;Chalabreysse, Lara;Maucort-Boulch, Delphine;Jouneau, Stéphane;Hachulla, Eric;Chollet, Julien;Nasser, Mouhamad","Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France.","Frontiers in medicine","Switzerland","eng","Journal Article","cost;epidemiology;pulmonary fibrosis;scleroderma;systemic sclerosis","",""," To investigate the clinical characteristics, epidemiology, survival estimates and healthcare resource utilization and associated costs in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in France.   The French national administrative healthcare database, the Système National des Données de Santé (SNDS), includes data on 98.8% of the French population, including data relating to ambulatory care, hospitalizations and death. In our study, claims data from the SNDS were used to identify adult patients with SSc-ILD between 2010 and 2017. We collected data on clinical features, incidence, prevalence, survival estimates, healthcare resource use and costs.   In total, 3,333 patients with SSc-ILD were identified, 76% of whom were female. Patients had a mean age [standard deviation (SD)] of 60.6 (14.4) years and a mean (SD) individual study duration of 3.9 (2.7) years. In 2016, the estimated overall incidence and prevalence were 0.69/100,000 individuals and 5.70/100,000 individuals, respectively. The overall survival estimates of patients using Kaplan-Meier estimation were 93, 82, and 55% at 1, 3, and 8 years, respectively. During the study, 98.7% of patients had ≥1 hospitalization and 22.3% of patients were hospitalized in an intensive care unit. The total annual mean healthcare cost per patient with SSc-ILD was €25,753, of which €21,539 was related to hospitalizations.   This large, real-world longitudinal study provides important insights into the epidemiology of SSc-ILD in France and shows that the disease is associated with high mortality, healthcare resource utilization and costs. SSc-ILD represents a high burden on both patients and healthcare services.  www.ClinicalTrials.gov, identifier: NCT03858842.","Hôpital Louis Pradel, Centre Coordonnateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754 INRAE and Université Claude Bernard Lyon 1, Member of ERN-LUNG, RespiFil, OrphaLung, Lyon, France.;IQVIA - RWS La Défense, Courbevoie, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS Inserm, CREATIS UMR 5220, Lyon, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS Inserm, CREATIS UMR 5220, Lyon, France.;IQVIA - RWS La Défense, Courbevoie, France.;IQVIA - RWS La Défense, Courbevoie, France.;AIXIAL - Paris, Paris, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et Bioinformatique, Lyon, France.;Université de Lyon, Lyon, France.;Université Lyon 1, Villeurbanne, France.;CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France.;Centre Hospitalier Universitaire de Rennes, Centre de Compétences pour les Maladies Pulmonaires Rares, Univ Rennes, Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et travail), RespiFil, OrphaLung, Rennes, France.;Hôpital Claude Huriez, Centre National de Référence des maladies auto-immunes systémiques rares (CeRAINO), CHU de Lille, Lille, France.;Boehringer Ingelheim France SAS, Paris, France.;Hôpital Louis Pradel, Centre Coordonnateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754 INRAE and Université Claude Bernard Lyon 1, Member of ERN-LUNG, RespiFil, OrphaLung, Lyon, France.","NA",0,"2296-858X","Front Med (Lausanne)","Front Med (Lausanne)",2021,"2021","8","10.3389/fmed.2021.699532","699532","","","34552943","34552943","PUBMED","Hôpital Louis Pradel, Centre Coordonnateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754 INRAE and Université Claude Bernard Lyon 1, Member of ERN-LUNG, RespiFil, OrphaLung, Lyon, France.;IQVIA - RWS La Défense, Courbevoie, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS Inserm, CREATIS UMR 5220, Lyon, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Université Lyon, INSA-Lyon, Université Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS Inserm, CREATIS UMR 5220, Lyon, France.;IQVIA - RWS La Défense, Courbevoie, France.;IQVIA - RWS La Défense, Courbevoie, France.;AIXIAL - Paris, Paris, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Hospices Civils de Lyon, Pôle Santé Publique, Service de Biostatistique et Bioinformatique, Lyon, France.;Université de Lyon, Lyon, France.;Université Lyon 1, Villeurbanne, France.;CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique-Santé, Villeurbanne, France.;Centre Hospitalier Universitaire de Rennes, Centre de Compétences pour les Maladies Pulmonaires Rares, Univ Rennes, Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et travail), RespiFil, OrphaLung, Rennes, France.;Hôpital Claude Huriez, Centre National de Référence des maladies auto-immunes systémiques rares (CeRAINO), CHU de Lille, Lille, France.;Boehringer Ingelheim France SAS, Paris, France.;Hôpital Louis Pradel, Centre Coordonnateur National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, UMR754 INRAE and Université Claude Bernard Lyon 1, Member of ERN-LUNG, RespiFil, OrphaLung, Lyon, France."
"333","Bordonaro R;Calvo A;Auriemma A;Hollebecque A;Rubovszky G;Saunders MP;Pápai Z;Prager G;Stein A;André T;Argilés G;Cubillo A;Dahan L;Edeline J;Leger C;Cattan V;Fougeray R;Amellal N;Tabernero J","Bordonaro, R;Calvo, A;Auriemma, A;Hollebecque, A;Rubovszky, G;Saunders, M P;Pápai, Z;Prager, G;Stein, A;André, T;Argilés, G;Cubillo, A;Dahan, L;Edeline, J;Leger, C;Cattan, V;Fougeray, R;Amellal, N;Tabernero, J","Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.","ESMO open","England","eng","Clinical Trial, Phase I","fluoropyrimidines;metastatic colorectal cancer;oxaliplatin;trifluridine/tipiracil","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Colorectal Neoplasms;Humans;Nivolumab;Oxaliplatin;Pyrrolidines;Thymine;Trifluridine","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Colorectal Neoplasms;Humans;Nivolumab;Oxaliplatin;Pyrrolidines;Thymine;Trifluridine","In preclinical studies trifluridine/tipiracil (FTD/TPI) plus oxaliplatin (Industriestrasse, Holzkirchen, Germany) sensitised microsatellite stable (MSS) metastatic colorectal cancer (mCRC) to anti-programmed cell death protein-1; the addition of oxaliplatin or bevacizumab (F Hoffmann- la ROCHE AG, Kaiseraugst, Switzerland) enhanced the antitumour effects of FTD/TPI. This study aimed to investigate the safety and efficacy of FTD/TPI plus oxaliplatin and either bevacizumab or nivolumab (Uxbridge business Park, Uxbridge, United Kingdom) in patients with mCRC who had progressed after at least one prior line of treatment. In 14-day cycles, patients received FTD/TPI 35 mg/m  (twice daily, days 1-5) plus oxaliplatin 85 mg/m  (day 1), and, on day 1, either bevacizumab 5 mg/kg (cohort A) or nivolumab 3 mg/kg (cohort B). Patients in Cohort B had confirmed MSS status. In total, 54 patients were enrolled: 37 in cohort A and 17 in cohort B. Recruitment in cohort B was stopped early due to the low response rate (RR) observed at interim analyses of efficacy. The most common adverse events (AEs) in cohort A were neutropenia/decreased neutrophils (75.7%), nausea (59.5%), vomiting (40.5%), diarrhoea (37.8%), peripheral sensory neuropathy (37.8%), fatigue (35.1%) and decreased appetite (35.1%). In cohort B, the most common AEs were neutropenia/decreased neutrophils (70.6%), diarrhoea (58.8%), nausea (47.1%), vomiting (47.1%), fatigue (47.1%), asthenia (41.2%), paraesthesia (41.2%), thrombocytopenia/decreased platelets (35.3%) and decreased appetite (35.3%). Confirmed objective RR was 17.1% in cohort A and 7.1% in cohort B; the corresponding values for median progression-free survival in the two cohorts were 6.3 and 6.0 months. FTD/TPI plus oxaliplatin and bevacizumab or nivolumab had an acceptable safety profile and demonstrated antitumour activity in previously treated patients with mCRC.","Azienda Ospedaliera ARNAS Garibaldi, Catania;Gregorio Marañon University General Hospital, Madrid, Spain.;Azienda Ospedaliera Universitaria Integrat, University of Verona, Verona, Italy.;Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology Hungary, Budapest, Hungary.;Christie NHS Foundation Trust, Manchester, UK.;Department of Medical Oncology, Duna Medical Centre, Budapest, Hungary.;Comprehensive Cancer Centre Vienna, Medical University Vienna, Austria.;UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany.;Sorbonne Université et Hôpital Saint-Antoine, Service d'Oncologie Médicale, Paris, France.;Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.;Medical Oncology, Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal, Madrid, Spain.;Aix Marseille University; Assistance Publique Hôpitaux de Marseille, Centre d'Essais Précoces en Cancérologie de Marseille CLIP, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, ARPEGO network, Rennes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain.","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2021","6","10.1016/j.esmoop.2021.100270","100270","","","34547581","34547581","PUBMED","Azienda Ospedaliera ARNAS Garibaldi, Catania;Gregorio Marañon University General Hospital, Madrid, Spain.;Azienda Ospedaliera Universitaria Integrat, University of Verona, Verona, Italy.;Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France.;Department of Medical Oncology and Clinical Pharmacology, National Institute of Oncology Hungary, Budapest, Hungary.;Christie NHS Foundation Trust, Manchester, UK.;Department of Medical Oncology, Duna Medical Centre, Budapest, Hungary.;Comprehensive Cancer Centre Vienna, Medical University Vienna, Austria.;UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany.;Sorbonne Université et Hôpital Saint-Antoine, Service d'Oncologie Médicale, Paris, France.;Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.;Medical Oncology, Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal, Madrid, Spain.;Aix Marseille University; Assistance Publique Hôpitaux de Marseille, Centre d'Essais Précoces en Cancérologie de Marseille CLIP, Marseille, France.;Department of Medical Oncology, Centre Eugene Marquis, ARPEGO network, Rennes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Institut de Recherches Internationales Servier, Suresnes, France.;Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; UVic-UCC, IOB-Quiron, Barcelona, Spain."
"334","Couloume L;Michel L","Couloume, Laura;Michel, Laure","New concepts on immunology of Multiple Sclerosis.","Presse medicale (Paris, France : 1983)","France","eng","Journal Article","","B-Lymphocytes;CD8-Positive T-Lymphocytes;Disease Progression;Gastrointestinal Microbiome;Humans;Image Cytometry;Immune System;Microglia;Multiple Sclerosis;Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis, Relapsing-Remitting;Sequence Analysis, RNA;Single-Cell Analysis","B-Lymphocytes;CD8-Positive T-Lymphocytes;Disease Progression;Gastrointestinal Microbiome;Humans;Image Cytometry;Immune System;Microglia;Multiple Sclerosis;Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis, Relapsing-Remitting;Sequence Analysis, RNA;Single-Cell Analysis","Multiple sclerosis (MS) is a chronic inflammatory and immune-driven demyelinating disease of the central nervous system (CNS). During the past decade, major advances have been made to understand the development of MS as well as its progressive stage. Here, we discuss some emerging concepts on immunology of MS, including the growing interest in the involvement of gut microbiota and the recent pathological concepts on the progression phase. Finally, we present some immuno-tools recently available that contribute to better understand diversity and function of the immune system.","Service de Neurologie, CHU Nantes, France.;Univ Rennes, CHU Rennes, Neurology, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F-35000 Rennes, France; Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France; Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes","NA",0,"2213-0276","Presse Med","Presse Med",2021,"2021","50","10.1016/j.lpm.2021.104072","104072","","","34547375","34547375","PUBMED","Service de Neurologie, CHU Nantes, France.;Univ Rennes, CHU Rennes, Neurology, Inserm, CIC 1414 (Centre d'Investigation Clinique de Rennes), F-35000 Rennes, France; Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France; Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes"
"335","Mulcahy MF;Mahvash A;Pracht M;Montazeri AH;Bandula S;Martin RCG;Herrmann K;Brown E;Zuckerman D;Wilson G;Kim TY;Weaver A;Ross P;Harris WP;Graham J;Mills J;Yubero Esteban A;Johnson MS;Sofocleous CT;Padia SA;Lewandowski RJ;Garin E;Sinclair P;Salem R","Mulcahy, Mary F;Mahvash, Armeen;Pracht, Marc;Montazeri, Amir H;Bandula, Steve;Martin, Robert C G;Herrmann, Ken;Brown, Ewan;Zuckerman, Darryl;Wilson, Gregory;Kim, Tae-You;Weaver, Andrew;Ross, Paul;Harris, William P;Graham, Janet;Mills, Jamie;Yubero Esteban, Alfonso;Johnson, Matthew S;Sofocleous, Constantinos T;Padia, Siddharth A;Lewandowski, Robert J;Garin, Etienne;Sinclair, Philip;Salem, Riad","Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.","Journal of clinical oncology : official journal of the American Society of Clinical Oncology","United States","eng","Clinical Trial, Phase III","","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Case-Control Studies;Chemoradiotherapy;Colorectal Neoplasms;Embolization, Therapeutic;Female;Follow-Up Studies;Humans;Irinotecan;Liver Neoplasms;Male;Middle Aged;Oxaliplatin;Prognosis;Survival Rate;Yttrium Radioisotopes","Antineoplastic Combined Chemotherapy Protocols;Bevacizumab;Case-Control Studies;Chemoradiotherapy;Colorectal Neoplasms;Embolization, Therapeutic;Female;Follow-Up Studies;Humans;Irinotecan;Liver Neoplasms;Male;Middle Aged;Oxaliplatin;Prognosis;Survival Rate;Yttrium Radioisotopes","To study the impact of transarterial Yttrium-90 radioembolization (TARE) in combination with second-line systemic chemotherapy for colorectal liver metastases (CLM). In this international, multicenter, open-label phase III trial, patients with CLM who progressed on oxaliplatin- or irinotecan-based first-line therapy were randomly assigned 1:1 to receive second-line chemotherapy with or without TARE. The two primary end points were progression-free survival (PFS) and hepatic PFS (hPFS), assessed by blinded independent central review. Random assignment was performed using a web- or voice-based system stratified by unilobar or bilobar disease, oxaliplatin- or irinotecan-based first-line chemotherapy, and   mutation status. Four hundred twenty-eight patients from 95 centers in North America, Europe, and Asia were randomly assigned to chemotherapy with or without TARE; this represents the intention-to-treat population and included 215 patients in the TARE plus chemotherapy group and 213 patients in the chemotherapy alone group. The hazard ratio (HR) for PFS was 0.69 (95% CI, 0.54 to 0.88; 1-sided   = .0013), with a median PFS of 8.0 (95% CI, 7.2 to 9.2) and 7.2 (95% CI, 5.7 to 7.6) months, respectively. The HR for hPFS was 0.59 (95% CI, 0.46 to 0.77; 1-sided   < .0001), with a median hPFS of 9.1 (95% CI, 7.8 to 9.7) and 7.2 (95% CI, 5.7 to 7.6) months, respectively. Objective response rates were 34.0% (95% CI, 28.0 to 40.5) and 21.1% (95% CI, 16.2 to 27.1; 1-sided   = .0019) for the TARE and chemotherapy groups, respectively. Median overall survival was 14.0 (95% CI, 11.8 to 15.5) and 14.4 months (95% CI, 12.8 to 16.4; 1-sided   = .7229) with a HR of 1.07 (95% CI, 0.86 to 1.32) for TARE and chemotherapy groups, respectively. Grade 3 adverse events were reported more frequently with TARE (68.4%   49.3%). Both groups received full chemotherapy dose intensity. The addition of TARE to systemic therapy for second-line CLM led to longer PFS and hPFS. Further subset analyses are needed to better define the ideal patient population that would benefit from TARE.","Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL.;Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX.;Centre Eugene Marquis, Medical Oncology, Rennes, France.;Clatterbridge Cancer Center NHS Foundation Trust, Liverpool, United Kingdom.;University College London Hospital, London, United Kingdom.;University of Louisville, Louisville, KY.;Universitätsklinikum Essen, Essen, Germany.;Western General Hospital, Edinburgh, Scotland.;Yale School of Medicine, New Haven, CT.;The Christie NHS Foundation Trust, Manchester, United Kingdom.;Seoul National University, Seoul, South Korea.;Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.;Guy's Hospital, London, United Kingdom.;University of Washington, Seattle, WA.;Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.;Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.;Hospital Clínico Lozano Blesa, Zaragoza, Spain.;Indiana University School of Medicine, Indianapolis, IN.;Memorial Sloan Kettering Cancer Center, New York, NY.;University of California-Los Angeles, Los Angeles, CA.;Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL.;Centre Eugene Marquis, Nuclear Medicine, Rennes, France.;Boston Scientific Corporation, Marlborough, MA.;Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL.","NA",0,"1527-7755","J Clin Oncol","J Clin Oncol",2021,"2021","39","10.1200/JCO.21.01839","3897-3907","P30 CA008748","NCI NIH HHS","34541864","34541864","PUBMED","Department of Medicine, Northwestern Feinberg School of Medicine, Chicago, IL.;Department of Interventional Radiology, MD Anderson Cancer Center, Houston, TX.;Centre Eugene Marquis, Medical Oncology, Rennes, France.;Clatterbridge Cancer Center NHS Foundation Trust, Liverpool, United Kingdom.;University College London Hospital, London, United Kingdom.;University of Louisville, Louisville, KY.;Universitätsklinikum Essen, Essen, Germany.;Western General Hospital, Edinburgh, Scotland.;Yale School of Medicine, New Haven, CT.;The Christie NHS Foundation Trust, Manchester, United Kingdom.;Seoul National University, Seoul, South Korea.;Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.;Guy's Hospital, London, United Kingdom.;University of Washington, Seattle, WA.;Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.;Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.;Hospital Clínico Lozano Blesa, Zaragoza, Spain.;Indiana University School of Medicine, Indianapolis, IN.;Memorial Sloan Kettering Cancer Center, New York, NY.;University of California-Los Angeles, Los Angeles, CA.;Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL.;Centre Eugene Marquis, Nuclear Medicine, Rennes, France.;Boston Scientific Corporation, Marlborough, MA.;Department of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL."
"336","Jakobczyk H;Jiang Y;Debaize L;Soubise B;Avner S;Sérandour AA;Rouger-Gaudichon J;Rio AG;Carroll JS;Raslova H;Gilot D;Liu Z;Demengeot J;Salbert G;Douet-Guilbert N;Corcos L;Galibert MD;Gandemer V;Troadec MB","Jakobczyk, Hélène;Jiang, Yan;Debaize, Lydie;Soubise, Benoit;Avner, Stéphane;Sérandour, Aurélien A;Rouger-Gaudichon, Jérémie;Rio, Anne-Gaëlle;Carroll, Jason S;Raslova, Hana;Gilot, David;Liu, Ziling;Demengeot, Jocelyne;Salbert, Gilles;Douet-Guilbert, Nathalie;Corcos, Laurent;Galibert, Marie-Dominique;Gandemer, Virginie;Troadec, Marie-Bérengère","ETV6-RUNX1 and RUNX1 directly regulate RAG1 expression: one more step in the understanding of childhood B-cell acute lymphoblastic leukemia leukemogenesis.","Leukemia","England","eng","Journal Article","","Cell Transformation, Neoplastic;Core Binding Factor Alpha 2 Subunit;Gene Expression Regulation, Leukemic;Homeodomain Proteins;Humans;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Tumor Cells, Cultured","Cell Transformation, Neoplastic;Core Binding Factor Alpha 2 Subunit;Gene Expression Regulation, Leukemic;Homeodomain Proteins;Humans;Oncogene Proteins, Fusion;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Tumor Cells, Cultured","ETV6-RUNX1 and RUNX1 directly promote   expression. ETV6-RUNX1 and RUNX1 preferentially bind to the −1200 bp enhancer of   and the −80 bp promoter of   gene respectively, and compete for these bindings. ETV6-RUNX1 and RUNX1 induce an excessive RAG recombinase activity. ETV6-RUNX1 participates directly in two events of the multi-hit ALL leukemogenesis: as an initiating event and as an activator of   expression.","Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Department of Hematology, The First Hospital of Jilin University, Changchun, China.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Université de Nantes, Ecole Centrale de Nantes, Inserm, CRCINA, Nantes, France.;Department of Pediatric Oncology and Hematology, University Hospital, Caen, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.;INSERM, UMR 1287, Gustave Roussy, Université Paris Saclay, Villejuif, France.;Equipe labellisée Ligue Nationale contre le Cancer, Villejuif, France.;INSERM, Université Rennes, CLCC Eugène Marquis, UMR_S 1242, Rennes, France.;Cancer Center, The First Hospital of Jilin University, Changchun, China.;Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, Oeiras, Portugal.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, Brest, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU-Rennes), Service de Génétique et Génomique Moléculaire, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU-Rennes), Department of pediatric hemato-oncology, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, Brest","NA",0,"1476-5551","Leukemia","Leukemia",2021,"2022","36","10.1038/s41375-021-01409-9","549-554","","","34535762","34535762","PUBMED","Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Department of Hematology, The First Hospital of Jilin University, Changchun, China.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Université de Nantes, Ecole Centrale de Nantes, Inserm, CRCINA, Nantes, France.;Department of Pediatric Oncology and Hematology, University Hospital, Caen, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.;INSERM, UMR 1287, Gustave Roussy, Université Paris Saclay, Villejuif, France.;Equipe labellisée Ligue Nationale contre le Cancer, Villejuif, France.;INSERM, Université Rennes, CLCC Eugène Marquis, UMR_S 1242, Rennes, France.;Cancer Center, The First Hospital of Jilin University, Changchun, China.;Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 6, Oeiras, Portugal.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, Brest, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU-Rennes), Service de Génétique et Génomique Moléculaire, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU-Rennes), Department of pediatric hemato-oncology, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, Rennes;Univ Brest, Inserm, EFS, UMR 1078, GGB, Brest;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, Brest"
"337","Noirclerc N;Huttin O;de Chillou C;Selton-Suty C;Fillipetti L;Sellal JM;Bozec E;Donal E;Lamiral Z;Kobayashi M;Ferreira JP;Rossignol P;Girerd N","Noirclerc, Nathalie;Huttin, Olivier;de Chillou, Christian;Selton-Suty, Christine;Fillipetti, Laura;Sellal, Jean Marc;Bozec, Erwan;Donal, Erwan;Lamiral, Zohra;Kobayashi, Masatake;Ferreira, João Pedro;Rossignol, Patrick;Girerd, Nicolas","Cardiac Remodeling and Diastolic Dysfunction in Paroxysmal Atrial Fibrillation.","Journal of clinical medicine","Switzerland","eng","Journal Article","atrial fibrillation;diastolic dysfunction;echocardiography;heart failure;left atrial remodeling","","","Atrial fibrillation (AF) leads to the development of cardiac remodeling/diastolic dysfunction and vice versa. We intended to determine whether cardiac remodeling/diastolic dysfunction is present at early stages of AF. We studied 175 patients with paroxysmal AF, compared with 175 matched control subjects, who had available echocardiography data to investigate the association between echocardiographic variables and AF from the STANISLAS cohort. In this study (mean age 55 years; 70.3% male), patients with paroxysmal AF had greater left ventricular mass compared to matched controls (  < 0.05). Patients with paroxysmal AF were also likely to have larger left atrial volume and a higher peak tricuspid regurgitation velocity, leading to higher prevalence (though <10% in the AF group) of diastolic dysfunction (all-  < 0.05). Multivariable conditional logistic regression models showed that paroxysmal AF was significantly associated with increased left ventricular mass and left atrial enlargement (all-  < 0.001), but not with e' and deceleration time of E wave (all-  > 0.1). Left ventricular mass and left atrial enlargement rather than diastolic dysfunction (as evaluated by echocardiography) were associated with paroxysmal AF irrespective of body mass index, blood pressure and renal function. These findings suggest that cardiac remodeling may occur very early in the natural history of AF.","Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.","NA",0,"2077-0383","J Clin Med","J Clin Med",2021,"2021","10","10.3390/jcm10173894",NA,"","","34501342","34501342","PUBMED","Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Department of Cardiology, University Hospital of Nancy, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France.;Université de Lorraine, Inserm, Centre d'Investigations Cliniques-1433 and Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT, 54000 Nancy, France."
"338","Guillot-Tantay C;Robert G;Ruffion A;Gamé X;Balanca A;Cousin T;Campello PV;Simon J;Baron M;Fleury R;Dequirez PL;Davidson S;Joussain C;Vangheluwe L;Anastay V;Léon P;Perrouin-Verbe MA;Peyronnet B;Biardeau X;Cornu JN;Karsenty G;Phé V","Guillot-Tantay, Cyrille;Robert, Grégoire;Ruffion, Alain;Gamé, Xavier;Balanca, Astrid;Cousin, Tiffany;Campello, Pierre-Vincent;Simon, Jeanne;Baron, Maximilien;Fleury, Raphael;Dequirez, Pierre-Luc;Davidson, Sypre;Joussain, Charles;Vangheluwe, Lucie;Anastay, Vassily;Léon, Priscilla;Perrouin-Verbe, Marie-Aimée;Peyronnet, Benoit;Biardeau, Xavier;Cornu, Jean-Nicolas;Karsenty, Gilles;Phé, Véronique","Impact of COVID-19 pandemic on functional urology procedures in France: a prospective study.","World journal of urology","Germany","eng","Journal Article","COVID-19;Functional urology;SARS-CoV-2;Urinary incontinence;Urology","Adult;Aged;COVID-19;Communicable Disease Control;Female;France;Humans;Male;Middle Aged;Patient Selection;Prospective Studies;Time Factors;Time-to-Treatment;Triage;Urologic Diseases;Urologic Surgical Procedures","Adult;Aged;COVID-19;Communicable Disease Control;Female;France;Humans;Male;Middle Aged;Patient Selection;Prospective Studies;Time Factors;Time-to-Treatment;Triage;Urologic Diseases;Urologic Surgical Procedures","To evaluate the impact of COVID-19 pandemic on functional urology procedures in France. A prospective study was conducted within 11 secondary and tertiary referral centers in France. Patients aged > 18 years who were diagnosed with a functional urology disease before the national lockdown (March 17th, 2020) and who required a surgery were included. Study period went from March 17th to September 30th 2020. The included interventions were listed according to the guidelines for functional urology enacted by the French Association of Urology and delay of reoperation was compared to the guidelines' delay. The primary outcome was the number of procedures left unscheduled at the end of the study period. Descriptive statistics were performed. From March 17th 2020 to September 3 rd 2020, 1246 patients with a previous diagnosis of a functional urological disease requiring a surgery were included. The mean follow-up was 140.4 days (± 53.4). Overall, 316 interventions (25.4%) were maintained whereas 74 (5.9%) were canceled, 848 (68.1%) postponed and 8 patients (0.6%) died. At the end of the follow-up, 184 patients (21.7%) were still not rescheduled. If the intervention was postponed, the mean delay between the initial and final date was 85.7 days (± 64.4). Overall, more than two thirds of interventions had to be postponed and the mean delay between the initial and final date was about three months.","Department of Urology, Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Academic Hospital, 47-83 boulevard de l'hôpital, 75013, Paris, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.;Department of Urology, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.;Department of Neuro-Urology, Assistance-Publique-Hôpitaux de Paris (AP-HP), Raymond Poincaré Academic Hospital, Garches, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.;Department of Urology, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.;Department of Urology, Nantes Academic Hospital, Hôtel Dieu, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'urologie, Rennes, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Neuro-Urology, Assistance-Publique-Hôpitaux de Paris (AP-HP), Raymond Poincaré Academic Hospital, Garches, France.;Department of Urology, Centre Hospitalier Universitaire Rouen, Rouen, France.;Department of Urology, Assistance-Publique-Hôpitaux de Marseille (AP-HM), La Conception Hospital, Marseille, France.;Urology Department, Pasteur Clinic, Paris, France.;Department of Urology, Nantes Academic Hospital, Hôtel Dieu, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'urologie, Rennes, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Urology, Centre Hospitalier Universitaire Rouen, Rouen, France.;Department of Urology, Assistance-Publique-Hôpitaux de Marseille (AP-HM), La Conception Hospital, Marseille, France.;Department of urology, Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Tenon Academic Hospital, Paris","NA",0,"1433-8726","World J Urol","World J Urol",2021,"2022","40","10.1007/s00345-021-03821-3","277-282","","","34476595","34476595","PUBMED","Department of Urology, Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Academic Hospital, 47-83 boulevard de l'hôpital, 75013, Paris, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.;Department of Urology, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.;Department of Neuro-Urology, Assistance-Publique-Hôpitaux de Paris (AP-HP), Raymond Poincaré Academic Hospital, Garches, France.;Department of Urology, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux, Bordeaux, France.;Department of Urology, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.;Department of Urology, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.;Department of Urology, Nantes Academic Hospital, Hôtel Dieu, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'urologie, Rennes, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Neuro-Urology, Assistance-Publique-Hôpitaux de Paris (AP-HP), Raymond Poincaré Academic Hospital, Garches, France.;Department of Urology, Centre Hospitalier Universitaire Rouen, Rouen, France.;Department of Urology, Assistance-Publique-Hôpitaux de Marseille (AP-HM), La Conception Hospital, Marseille, France.;Urology Department, Pasteur Clinic, Paris, France.;Department of Urology, Nantes Academic Hospital, Hôtel Dieu, Nantes, France.;Centre Hospitalier Universitaire de Rennes, Service d'urologie, Rennes, France.;Department of Urology, Lille Academic Hospital, Claude Huriez Hospital, Lille, France.;Department of Urology, Centre Hospitalier Universitaire Rouen, Rouen, France.;Department of Urology, Assistance-Publique-Hôpitaux de Marseille (AP-HM), La Conception Hospital, Marseille, France.;Department of urology, Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Tenon Academic Hospital, Paris"
"339","Le Daré B;Bacle A;Lhermitte R;Lesourd F;Lurton Y","Le Daré, Brendan;Bacle, Astrid;Lhermitte, Roxane;Lesourd, François;Lurton, Yves","Increasing vaccine supply with low dead-volume syringes and needles.","International journal of pharmaceutics","Netherlands","eng","Journal Article","COVID-19;Dead-volume;Medical device;Needle;Syringe;Vaccine","COVID-19;COVID-19 Vaccines;Humans;Needles;SARS-CoV-2;Syringes","COVID-19;COVID-19 Vaccines;Humans;Needles;SARS-CoV-2;Syringes","As global vaccine production capacity is limited, every optimization strategy must be explored to rapidly increase the number of people vaccinated. The objective of this study is to determine which medical devices allow the extraction of the maximum number of doses from different vaccine vials (Pfizer-BioNTech, AstraZeneca, Moderna and Johnson & Johnson vaccines) by analyzing all the factors involved in the preparation of the injected doses. By measuring the dead-volume of 32 syringe-needle combinations, we show that fixed-needle syringe with a dead-volume of less than 5 µL can extract up to 7 doses from Pfizer vials, 13 doses from AstraZeneca vials, 12 doses from Moderna vials and 6 doses from Johnson & Johnson vials. We found that the syringe accuracy is important, and can compromise the chances of extracting additional doses when withdrawing too large a volume. For Pfizer vaccine, particular attention must be paid to the choice of dilution syringe, which may compromise the extraction of the 7th dose. The withdrawal of extra doses from vaccine vials was not operator-dependent. In this unprecedented health context, the medical device considerations presented here could help to optimize every COVID-19 vaccine vial.","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.","NA",0,"1873-3476","Int J Pharm","Int J Pharm",2021,"2021","608","10.1016/j.ijpharm.2021.121053","121053","","","34461171","34461171","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Rennes;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, F-35000 Rennes, France."
"340","Corné J;Le Du F;Quillien V;Godey F;Robert L;Bourien H;Brunot A;Crouzet L;Perrin C;Lefeuvre-Plesse C;Diéras V;De la Motte Rouge T","Corné, Julien;Le Du, Fanny;Quillien, Véronique;Godey, Florence;Robert, Lucie;Bourien, Héloïse;Brunot, Angélique;Crouzet, Laurence;Perrin, Christophe;Lefeuvre-Plesse, Claudia;Diéras, Véronique;De la Motte Rouge, Thibault","Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.","Scientific reports","England","eng","Journal Article","","Adolescent;Base Sequence;Biomarkers, Tumor;Breast Neoplasms;Cell-Free Nucleic Acids;Child;Child, Preschool;Class I Phosphatidylinositol 3-Kinases;Female;Humans;Infant;Infant, Newborn;Mutation;Polymerase Chain Reaction;Reproducibility of Results;Young Adult","Adolescent;Base Sequence;Biomarkers, Tumor;Breast Neoplasms;Cell-Free Nucleic Acids;Child;Child, Preschool;Class I Phosphatidylinositol 3-Kinases;Female;Humans;Infant;Infant, Newborn;Mutation;Polymerase Chain Reaction;Reproducibility of Results;Young Adult","With the approval of new therapies targeting the PI3K pathway, the detection of PIK3CA mutations has become a key factor in treatment management for HR+/HER2- metastatic breast cancer (MBC). We developed multiplex digital PCR (dPCR) assays to detect and quantify PIK3CA mutations. A first screening assay allows the detection of 21 mutations, with a drop-off system targeting the 542-546 hotspot mutations combined with the simultaneous detection of N345K, C420R, H1047L and H1047R mutations. In the case of a positive result, a sequential strategy based on other assays that we have developped allows for precise mutation identification. Clinical validity was determined by analyzing plasma circulating free DNA (cfDNA) from 213 HR+/HER2- MBC samples, as well as DNA extracted from 97 available matched tumors from 89 patients. Our assays have shown reliable specificity, accuracy and reproducibility, with limits of blank of three and four droplets for the screening assay. Sixty-eight patients (32%) had at least one PIK3CA mutation detectable in their plasma, and we obtained 83.1% agreement between the cfDNA analysis and the corresponding tumors. The high sensitivity and robustness of these new dPCR assays make them well-suited for rapid and cost-effective detection of PIK3CA mutations in the plasma of MBC patients.","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2021,"2021","11","10.1038/s41598-021-96644-6","17316","","","34453076","34453076","PUBMED","Department of Biology, Centre Eugène Marquis, Unicancer, Rennes;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Department of Biology, Centre Eugène Marquis, Unicancer, Rennes, France.;INSERM U1242, University of Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Unicancer, Rennes, France."
"341","Boyer PH;Baldinger L;Degeilh B;Wirth X;Kamdem CM;Hansmann Y;Zilliox L;Boulanger N;Jaulhac B","Boyer, Pierre H;Baldinger, Lisa;Degeilh, Brigitte;Wirth, Xavier;Kamdem, Chasy Mewa;Hansmann, Yves;Zilliox, Laurence;Boulanger, Nathalie;Jaulhac, Benoît",NA,"Emerging microbes & infections","United States","eng","Journal Article","Neoehrlichia mikurensis;Neoehrlichiosis;Tick-borne diseases;post-tick bite fever;vector epidemiology","Aged;Anaplasmataceae;Anaplasmataceae Infections;Animals;Cohort Studies;Disease Vectors;Female;France;Humans;Male;Middle Aged;Prevalence;Tick-Borne Diseases;Ticks","Aged;Anaplasmataceae;Anaplasmataceae Infections;Animals;Cohort Studies;Disease Vectors;Female;France;Humans;Male;Middle Aged;Prevalence;Tick-Borne Diseases;Ticks"," is an intracellular bacterium transmitted in Europe and Asia by ticks of the   complex. Interest in this bacterium has increased since it was demonstrated to be responsible for febrile syndromes in patients. To date, most clinical cases have been reported in northern Europe, but case series have also been described in central Europe and China. Notably, thrombotic events occurred during the course of the disease. We investigated the presence of   in 10,885   nymphs in two regions of France (Alsace and Brittany) collected between 2013 and 2020 and in 934 patients suspected of human granulocytic anaplasmosis in Alsace, an endemic area for Lyme borreliosis, using a specific PCR assay.   was detected in 5.42% of the ticks from Alsace, whereas only one (0.03%) tick was found to be positive in Brittany. Spatiotemporal disparities were also noticed within the Alsace region over the four collection sites investigated, and a significant increase in the prevalence of nymphs carrying   was also observed in the last three years of collection. Four out of 934 screened patients were found to be positive for  . Two had malignancies, and the other two were apparently immunocompetent. Superficial thrombosis was noticed in one patient, and long-lasting bacteremia was noted in another patient. These four patients are the first clinical cases of neoehrlichiosis described in France. We suggest including   in the differential diagnosis of post-tick bite febrile syndromes to treat patients and prevent the occurrence of thrombotic complications.","Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes Cedex 9, France.;Laboratoire de Parasitologie Médicale Faculté de Médecine, Université de Rennes1., Rennes cedex, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.","NA",0,"2222-1751","Emerg Microbes Infect","Emerg Microbes Infect",2021,"2021","10","10.1080/22221751.2021.1973347","1731-1738","","","34432610","34432610","PUBMED","Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes Cedex 9, France.;Laboratoire de Parasitologie Médicale Faculté de Médecine, Université de Rennes1., Rennes cedex, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;Department of Infectious Disease, Strasbourg University Hospital, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France.;Institut de Bactériologie, Fédération de Médecine Translationnelle de Strasbourg, University of Strasbourg, Strasbourg, France.;French National Reference Center for Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Groupe d'Étude de la Borréliose de Lyme (GEBLY), Strasbourg, France."
"342","Lensen KDF;Escudero-Sanchez R;Cobo J;Trebše R;Gubavu C;Tedeschi S;Lomas JM;Arvieux C;Rodriguez-Pardo D;Fantoni M;Pais MJG;Jover F;Salles MJC;Sancho I;Sampedro MF;Soriano A;Wouthuyzen-Bakker M;Escmid Study Group Of Implant Associated Infections Esgiai KDF","Lensen, Karel-Jan Dag François;Escudero-Sanchez, Rosa;Cobo, Javier;Trebše, Rihard;Gubavu, Camelia;Tedeschi, Sara;Lomas, Jose M;Arvieux, Cedric;Rodriguez-Pardo, Dolors;Fantoni, Massimo;Pais, Maria Jose Garcia;Jover, Francisco;Salles, Mauro José Costa;Sancho, Ignacio;Sampedro, Marta Fernandez;Soriano, Alex;Wouthuyzen-Bakker, Marjan;Escmid Study Group Of Implant Associated Infections Esgiai, Karel-Jan Dag François","The efficacy of suppressive antibiotic treatment in patients managed non-operatively for periprosthetic joint infection and a draining sinus.","Journal of bone and joint infection","Germany","eng","Journal Article","","","",": Patients with prosthetic joint infections (PJIs) not suitable for curative surgery may benefit from suppressive antibiotic therapy (SAT). However, the usefulness of SAT in cases with a draining sinus has never been investigated.  : A multicentre, retrospective observational cohort study was performed in which patients with a PJI and a sinus tract were eligible for inclusion if managed conservatively and if sufficient follow-up data were available (i.e. at least 2 years). SAT was defined as a period of    6 months of oral antibiotic therapy.  : SAT was initiated in 63 of 72 (87.5 %) included patients. Implant retention during follow-up was the same in patients receiving SAT vs. no SAT (79.4 % vs. 88.9 %;   .68). In total, 27 % of patients using SAT experienced side effects. In addition, the occurrence of prosthetic loosening in initially fixed implants, the need for surgical debridement, or the occurrence of bacteremia during follow-up could not be fully prevented with the use of SAT, which still occurred in 42 %, 6.3 %, and 3.2 % of cases, respectively. However, the sinus tract tended to close more often (42 % vs. 13 %;   .14), and a higher resolution of pain was observed (35 % vs. 14 %;   .22) in patients receiving SAT.  : SAT is not able to fully prevent complications in patients with a draining sinus. However, it may be beneficial in a subset of patients, particularly in those with pain or the hindrance of a draining sinus. A future prospective study, including a higher number of patients not receiving SAT, is needed.","Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.;Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.;Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.;Service for Bone Infections, Valdoltra Orthopaedic Hospital, Ankaran, Slovenia.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna Policlinico di Sant Orsola, Bologna, Italy.;Department of Infectious Diseases, Virgen del Rocio University Hospital, Seville, Spain.;Department of Infectious Diseases and Intensive Care, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.;UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Infectious Diseases Unit, Hospital Universitario Lucus Augusti, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Lugo, Spain.;Unidad de Enfermedades Infecciosas, Hospital Universitario San Juan de Alicante, Alicante, Spain.;Unit of Infectious Diseases, Department of Internal Medicine, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil.;Department of Infectious Diseases, Hospital Reina Sofía de Tudela, Navarra, Spain.;Servicio de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Santander, Spain.;Department of Infectious Diseases, Hospital Clínic, IDIBAPS, Catalonia, Barcelona, Spain.;Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.;A full list of authors appears at the end of the paper.","NA",0,"2206-3552","J Bone Jt Infect","J Bone Jt Infect",2021,"2021","6","10.5194/jbji-6-313-2021","313-319","","","34422548","34422548","PUBMED","Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.;Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.;Department of Infectious Diseases, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain.;Service for Bone Infections, Valdoltra Orthopaedic Hospital, Ankaran, Slovenia.;Department of Infectious and Tropical Diseases, CHR Orléans, Orléans, France.;Infectious Diseases Unit, Department of Medical and Surgical Sciences, University of Bologna Policlinico di Sant Orsola, Bologna, Italy.;Department of Infectious Diseases, Virgen del Rocio University Hospital, Seville, Spain.;Department of Infectious Diseases and Intensive Care, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.;UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.;Infectious Diseases Unit, Hospital Universitario Lucus Augusti, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Lugo, Spain.;Unidad de Enfermedades Infecciosas, Hospital Universitario San Juan de Alicante, Alicante, Spain.;Unit of Infectious Diseases, Department of Internal Medicine, Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil.;Department of Infectious Diseases, Hospital Reina Sofía de Tudela, Navarra, Spain.;Servicio de Enfermedades Infecciosas, Hospital Universitario Marqués de Valdecilla, Santander, Spain.;Department of Infectious Diseases, Hospital Clínic, IDIBAPS, Catalonia, Barcelona, Spain.;Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.;A full list of authors appears at the end of the paper."
"343","Lescure C;Estrade F;Pedrono M;Campillo-Gimenez B;Le Sourd S;Pracht M;Palard X;Bourien H;Muzellec L;Uguen T;Rolland Y;Garin E;Edeline J","Lescure, Céline;Estrade, Florian;Pedrono, Maud;Campillo-Gimenez, Boris;Le Sourd, Samuel;Pracht, Marc;Palard, Xavier;Bourien, Héloïse;Muzellec, Léa;Uguen, Thomas;Rolland, Yan;Garin, Etienne;Edeline, Julien","ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma.","Cancers","Switzerland","eng","Journal Article","Yttrium-90;liver function;radioembolization;toxicity","","","Selective internal radiation therapy (SIRT) is an innovative treatment of hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI) score was designed to better evaluate liver functions in HCC. We studied, retrospectively, data from patients treated with SIRT for HCC. The primary endpoint was the occurrence of radioembolization-induced liver disease (REILD). The secondary endpoint was overall survival (OS). 222 patients were studied. The ALBI grade 1 patients had significantly less REILD (3.4%) after the first SIRT than ALBI grade 2 or 3 patients (16.8%,   = 0.002). Of the 207 patients with data, 77 (37.2%) had a worsening of ALBI grade after one SIRT. The baseline ALBI grade was significantly associated with OS (  = 0.001), also in the multivariable analysis. The ALBI grade after the first SIRT was significantly associated with OS (  ≤ 0.001), with median OS of 26.4 months (CI 95% 18.2-34.7) for ALBI grade 1 patients (  = 48) versus 17.3 months (CI 95% 12.9-21.8) for ALBI grade 2 patients (  = 123) and 8.1 months (CI 95% 4.1-12.1) for ALBI grade 3 patients (  = 36). The baseline ALBI grade is a strong predictor of REILD. The baseline ALBI score and variations of ALBI are prognostic after SIRT.","Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Clinical Research, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Nuclear Medicine, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;CHU Pontchaillou, Hepatology, 35043 Rennes, France.;Centre Eugène Marquis, Interventional Radiology, 35043 Rennes, France.;Centre Eugène Marquis, Nuclear Medicine, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2021,"2021","13","10.3390/cancers13153794",NA,"","","34359695","34359695","PUBMED","Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Clinical Research, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Nuclear Medicine, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France.;CHU Pontchaillou, Hepatology, 35043 Rennes, France.;Centre Eugène Marquis, Interventional Radiology, 35043 Rennes, France.;Centre Eugène Marquis, Nuclear Medicine, 35043 Rennes, France.;Centre Eugène Marquis, Medical Oncology, 35043 Rennes, France."
"344","Lesueur F;Eon-Marchais S;Bonnet-Boissinot S;Beauvallet J;Dondon MG;Golmard L;Rouleau E;Garrec C;Martinez M;Toulas C;Nguyen TD;Brayotel F;Crivelli L;Maugard CM;Bubien V;Sevenet N;Gesta P;Chieze-Valero S;Nambot S;Goussot V;Mari V;Popovici C;Prieur F;Morin-Meschin ME;Tinat J;Lortholary A;Dreyfus H;Bidart M;Collonge-Rame MA;Mozelle-Nivoix M;Gladieff L;Giraud S;Boutry-Kryza N;Chiesa J;Denizeau P;Bignon YJ;Uhrhammer N;Cohen-Haguenauer O;Vilquin P;Mailliez A;Coupier I;Rey JM;Lacaze E;Béra O;Colas C;Coulet F;Delnatte C;Houdayer C;Lasset C;Lemonnier J;Longy M;Noguès C;Stoppa-Lyonnet D;Vaur D;Andrieu N;Caron O","Lesueur, Fabienne;Eon-Marchais, Séverine;Bonnet-Boissinot, Sarah;Beauvallet, Juana;Dondon, Marie-Gabrielle;Golmard, Lisa;Rouleau, Etienne;Garrec, Céline;Martinez, Mathilde;Toulas, Christine;Nguyen, Tan Dat;Brayotel, Fanny;Crivelli, Louise;Maugard, Christine M;Bubien, Virginie;Sevenet, Nicolas;Gesta, Paul;Chieze-Valero, Stéphanie;Nambot, Sophie;Goussot, Vincent;Mari, Véronique;Popovici, Cornel;Prieur, Fabienne;Morin-Meschin, Marie-Emmanuelle;Tinat, Julie;Lortholary, Alain;Dreyfus, Hélène;Bidart, Marie;Collonge-Rame, Marie-Agnès;Mozelle-Nivoix, Monique;Gladieff, Laurence;Giraud, Sophie;Boutry-Kryza, Nadia;Chiesa, Jean;Denizeau, Philippe;Bignon, Yves-Jean;Uhrhammer, Nancy;Cohen-Haguenauer, Odile;Vilquin, Paul;Mailliez, Audrey;Coupier, Isabelle;Rey, Jean-Marc;Lacaze, Elodie;Béra, Odile;Colas, Chrystelle;Coulet, Florence;Delnatte, Capucine;Houdayer, Claude;Lasset, Christine;Lemonnier, Jérôme;Longy, Michel;Noguès, Catherine;Stoppa-Lyonnet, Dominique;Vaur, Dominique;Andrieu, Nadine;Caron, Olivier","TUMOSPEC: A Nation-Wide Study of Hereditary Breast and Ovarian Cancer Families with a Predicted Pathogenic Variant Identified through Multigene Panel Testing.","Cancers","Switzerland","eng","Journal Article","cancer risk estimate;genetic predisposition to breast and ovarian cancer;multigene panels;penetrance of pathogenic variants","","","Assessment of age-dependent cancer risk for carriers of a predicted pathogenic variant (PPV) is often hampered by biases in data collection, with a frequent under-representation of cancer-free PPV carriers. TUMOSPEC was designed to estimate the cumulative risk of cancer for carriers of a PPV in a gene that is usually tested in a hereditary breast and ovarian cancer context. Index cases are enrolled consecutively among patients who undergo genetic testing as part of their care plan in France. First- and second-degree relatives and cousins of PPV carriers are invited to participate whether they are affected by cancer or not, and genotyped for the familial PPV. Clinical, family and epidemiological data are collected, and all data including sequencing data are centralized at the coordinating centre. The three-year feasibility study included 4431 prospective index cases, with 19.1% of them carrying a PPV. When invited by the coordinating centre, 65.3% of the relatives of index cases (5.7 relatives per family, on average) accepted the invitation to participate. The study logistics were well adapted to clinical and laboratory constraints, and collaboration between partners (clinicians, biologists, coordinating centre and participants) was smooth. Hence, TUMOSPEC is being pursued, with the aim of optimizing clinical management guidelines specific to each gene.","Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Service de Génétique, Département de Biologie et Pathologie Médicales, Gustave Roussy, F-94805 Villejuif, France.;Laboratoire Génétique Moléculaire, Institut de Biologie, CHU Hôtel Dieu, F-44093 Nantes, France.;Unité de Génétique Clinique, CHU Rouen Normandie, F-76100 Rouen, France.;Laboratoire d'Oncogénétique, Institut Claudius Regaud, IUCT-Oncopole, F-31100 Toulouse, France.;Institut de Cancérologie Jean Godinot, F-51100 Reims, France.;Institut de Cancérologie Jean Godinot, F-51100 Reims, France.;Service d'Oncogénétique, Centre Eugène Marquis, F-35000 Rennes, France.;Centre Paul Strauss, Unité d'Oncogénétique, ICANS Institut de Cancérologie de Strasbourg, F-67200 Strasbourg, France.;Unité d'Oncogénétique, Département de Bio-Pathologie, Institut Bergonié, F-33000 Bordeaux, France.;Institut Bergonié, UFR des Sciences Pharmaceutiques, Collège des Sciences de la Santé Université de Bordeaux, INSERM U1218, F-33000 Bordeaux, France.;CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, F-79000 Niort, France.;CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, F-79000 Niort, France.;Institut GIMI, CHU de Dijon, Hôpital d'Enfants, F-21000 Dijon, France.;Unité de Biologie Moléculaire, Département de Biologie et Pathologie des Tumeurs, Centre Georges François Leclerc, F-21000 Dijon, France.;Service d'Oncogénétique et Recherche Clinique, Centre Antoine Lacassagne, F-06100 Nice, France.;Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, F-13009 Marseille, France.;Service de Génétique, CHU-Hôpital Nord, F-42055 Saint Etienne, France.;Service d'Oncogénétique, Institut de Cancérologie de l'Ouest, Site Paul Papin, F-49055 Angers, France.;Génétique Médicale, CHU de Bordeaux, F-33000 Bordeaux, France.;Service d'Oncologie Médicale, Centre Catherine de Sienne, Hôpital Privé du Confluent, F-44200 Nantes, France.;Clinique Sainte Catherine, F-84000 Avignon, France.;Département de Génétique, Hôpital Couple-Enfant, CHU de Grenoble, F-38700 Grenoble, France.;Laboratoire de Génétique Moléculaire: Maladies Rares et Oncologies, Institut de Biologie et Pathologie, CHU Grenoble Alpes, F-38700 Grenoble, France.;Consultation d'Oncogénétique, Oncobiologie Génétique Bioinformatique, CHRU, F-25000 Besançon, France.;Centre Hospitalier de Troyes, Hôpital S. Veil, F-10000 Troyes, France.;Service d'Oncologie Médicale, Institut Claudius Regaud-IUCT-Oncopole, F-31100 Toulouse, France.;Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier EST, F-69500 Bron, France.;Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier EST, F-69500 Bron, France.;UF de Cytogénétique et Génétique Médicale, CHRU Hôpital Caremeau, F-30900 Nîmes, France.;Service de Génétique Clinique, Hôpital Sud, F-35200 Rennes, France.;Centre Jean Perrin, Département d'Oncogénétique, Université Clermont Auvergne, UMR INSERM 1240, F-63011 Clermont Ferrand, France.;Centre Jean Perrin, LBM OncoGenAuvergne, F-63011 Clermont Ferrand, France.;Unité d'Oncogénétique Clinique AP-HP Nord-UP, DMU Icare, UFR de Médecine de l'Université de Paris, INSERM UMR-S 976, Hôpital Saint-Louis, F-75010 Paris, France.;Département de Génomique des Tumeurs Solides, Hôpital Saint-Louis, APHP, F-75010 Paris, France.;Centre Oscar Lambret, F-59000 Lille, France.;Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve, CHU Montpellier, F-34090 Montpellier, France.;INSERM 896, CRCM Val d'Aurelle, F-34090 Montpellier, France.;Laboratoire de Biopathologie Cellulaire et Tissulaire des Tumeurs, CHRU Arnaud de Villeneuve, F-34090 Montpellier, France.;Unité de Génétique Médicale, Groupe Hospitalier du Havre, F-76290 Le Havre, France.;CHU de Martinique, F-97261 Fort-de-France, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Service de Génétique, AP-HP, Hôpital Universitaire Pitié-Salpétrière, F-75013 Paris, France.;Unité d'Oncogénétique, ICO-Site René Gauducheau, F-44800 Nantes Saint Herblain, France.;Département de Génétique, Hôpital Universitaire de Rouen, Unirouen, Inserm U1245, F-76000 Rouen, France.;CNRS UMR 5558, Université Claude Bernard Lyon 1, F-69100 Villeurbanne, France.;Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, F-69008 Lyon, France.;R&D UNICANCER, Fédération Nationale des Centres de Lutte Contre le Cancer, F-75013 Paris, France.;Cancer Genetics Unit & INSERM U1218, Institut Bergonié, University of Bordeaux, F-33000 Bordeaux, France.;Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, F-13009 Marseille, France.;Institut Paoli-Calmettes & Aix Marseille University, INSERM, IRD, SESSTIM, F-13009 Marseille, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Inserm, U830, Université de Paris, F-75005 Paris, France.;Laboratoire de Biologie et de Génétique du Cancer, Centre François Baclesse, F-14000 Caen, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Département de Médecine Oncologique, Gustave Roussy, F-94805 Villejuif, France.;Centre Médical de Bligny, F-91640 Briis-Sous-Forges, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2021,"2021","13","10.3390/cancers13153659",NA,"PRT-K 15-166;PRE2019.LCC/NA;INCa-DGOS-4654","Institut National Du Cancer;Ligue Contre le Cancer;Institut National de la Santé et de la Recherche Médicale;Site de Recherche Intégrée sur le Cancer (SiRIC);GENETICANCER","34359559","34359559","PUBMED","Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Service de Génétique, Département de Biologie et Pathologie Médicales, Gustave Roussy, F-94805 Villejuif, France.;Laboratoire Génétique Moléculaire, Institut de Biologie, CHU Hôtel Dieu, F-44093 Nantes, France.;Unité de Génétique Clinique, CHU Rouen Normandie, F-76100 Rouen, France.;Laboratoire d'Oncogénétique, Institut Claudius Regaud, IUCT-Oncopole, F-31100 Toulouse, France.;Institut de Cancérologie Jean Godinot, F-51100 Reims, France.;Institut de Cancérologie Jean Godinot, F-51100 Reims, France.;Service d'Oncogénétique, Centre Eugène Marquis, F-35000 Rennes, France.;Centre Paul Strauss, Unité d'Oncogénétique, ICANS Institut de Cancérologie de Strasbourg, F-67200 Strasbourg, France.;Unité d'Oncogénétique, Département de Bio-Pathologie, Institut Bergonié, F-33000 Bordeaux, France.;Institut Bergonié, UFR des Sciences Pharmaceutiques, Collège des Sciences de la Santé Université de Bordeaux, INSERM U1218, F-33000 Bordeaux, France.;CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, F-79000 Niort, France.;CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, F-79000 Niort, France.;Institut GIMI, CHU de Dijon, Hôpital d'Enfants, F-21000 Dijon, France.;Unité de Biologie Moléculaire, Département de Biologie et Pathologie des Tumeurs, Centre Georges François Leclerc, F-21000 Dijon, France.;Service d'Oncogénétique et Recherche Clinique, Centre Antoine Lacassagne, F-06100 Nice, France.;Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, F-13009 Marseille, France.;Service de Génétique, CHU-Hôpital Nord, F-42055 Saint Etienne, France.;Service d'Oncogénétique, Institut de Cancérologie de l'Ouest, Site Paul Papin, F-49055 Angers, France.;Génétique Médicale, CHU de Bordeaux, F-33000 Bordeaux, France.;Service d'Oncologie Médicale, Centre Catherine de Sienne, Hôpital Privé du Confluent, F-44200 Nantes, France.;Clinique Sainte Catherine, F-84000 Avignon, France.;Département de Génétique, Hôpital Couple-Enfant, CHU de Grenoble, F-38700 Grenoble, France.;Laboratoire de Génétique Moléculaire: Maladies Rares et Oncologies, Institut de Biologie et Pathologie, CHU Grenoble Alpes, F-38700 Grenoble, France.;Consultation d'Oncogénétique, Oncobiologie Génétique Bioinformatique, CHRU, F-25000 Besançon, France.;Centre Hospitalier de Troyes, Hôpital S. Veil, F-10000 Troyes, France.;Service d'Oncologie Médicale, Institut Claudius Regaud-IUCT-Oncopole, F-31100 Toulouse, France.;Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier EST, F-69500 Bron, France.;Hospices Civils de Lyon, Service de Génétique, Groupement Hospitalier EST, F-69500 Bron, France.;UF de Cytogénétique et Génétique Médicale, CHRU Hôpital Caremeau, F-30900 Nîmes, France.;Service de Génétique Clinique, Hôpital Sud, F-35200 Rennes, France.;Centre Jean Perrin, Département d'Oncogénétique, Université Clermont Auvergne, UMR INSERM 1240, F-63011 Clermont Ferrand, France.;Centre Jean Perrin, LBM OncoGenAuvergne, F-63011 Clermont Ferrand, France.;Unité d'Oncogénétique Clinique AP-HP Nord-UP, DMU Icare, UFR de Médecine de l'Université de Paris, INSERM UMR-S 976, Hôpital Saint-Louis, F-75010 Paris, France.;Département de Génomique des Tumeurs Solides, Hôpital Saint-Louis, APHP, F-75010 Paris, France.;Centre Oscar Lambret, F-59000 Lille, France.;Service de Génétique Médicale et Oncogénétique, Hôpital Arnaud de Villeneuve, CHU Montpellier, F-34090 Montpellier, France.;INSERM 896, CRCM Val d'Aurelle, F-34090 Montpellier, France.;Laboratoire de Biopathologie Cellulaire et Tissulaire des Tumeurs, CHRU Arnaud de Villeneuve, F-34090 Montpellier, France.;Unité de Génétique Médicale, Groupe Hospitalier du Havre, F-76290 Le Havre, France.;CHU de Martinique, F-97261 Fort-de-France, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Service de Génétique, AP-HP, Hôpital Universitaire Pitié-Salpétrière, F-75013 Paris, France.;Unité d'Oncogénétique, ICO-Site René Gauducheau, F-44800 Nantes Saint Herblain, France.;Département de Génétique, Hôpital Universitaire de Rouen, Unirouen, Inserm U1245, F-76000 Rouen, France.;CNRS UMR 5558, Université Claude Bernard Lyon 1, F-69100 Villeurbanne, France.;Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, F-69008 Lyon, France.;R&D UNICANCER, Fédération Nationale des Centres de Lutte Contre le Cancer, F-75013 Paris, France.;Cancer Genetics Unit & INSERM U1218, Institut Bergonié, University of Bordeaux, F-33000 Bordeaux, France.;Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, Institut Paoli-Calmettes, F-13009 Marseille, France.;Institut Paoli-Calmettes & Aix Marseille University, INSERM, IRD, SESSTIM, F-13009 Marseille, France.;Service de Génétique, Institut Curie, F-75005 Paris, France.;Inserm, U830, Université de Paris, F-75005 Paris, France.;Laboratoire de Biologie et de Génétique du Cancer, Centre François Baclesse, F-14000 Caen, France.;Inserm, U900, Institut Curie, PSL Research University, Mines ParisTech, F-75005 Paris, France.;Département de Médecine Oncologique, Gustave Roussy, F-94805 Villejuif, France.;Centre Médical de Bligny, F-91640 Briis-Sous-Forges, France."
"345","Dano D;Lardy-Cleaud A;Monneur A;Quenel-Tueux N;Levy C;Mouret-Reynier MA;Coudert B;Mailliez A;Ferrero JM;Guiu S;Campone M;de La Motte Rouge T;Petit T;Pistilli B;Dalenc F;Simon G;Lerebours F;Chabaud S;Bertucci F;Gonçalves A","Dano, D;Lardy-Cleaud, A;Monneur, A;Quenel-Tueux, N;Levy, C;Mouret-Reynier, M-A;Coudert, B;Mailliez, A;Ferrero, J-M;Guiu, S;Campone, M;de La Motte Rouge, T;Petit, T;Pistilli, B;Dalenc, F;Simon, G;Lerebours, F;Chabaud, S;Bertucci, F;Gonçalves, A","Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).","ESMO open","England","eng","Journal Article","inflammatory breast cancer;metastatic breast cancer;multimodal therapy;prognostic factors;real-life study","Cohort Studies;Humans;Inflammatory Breast Neoplasms;Prognosis;Progression-Free Survival;Retrospective Studies","Cohort Studies;Humans;Inflammatory Breast Neoplasms;Prognosis;Progression-Free Survival;Retrospective Studies","Primary inflammatory breast cancer (IBC) is a rare and aggressive entity whose prognosis has been improved by multimodal therapy. However, 5-year overall survival (OS) remains poor. Given its low incidence, the prognosis of IBC at metastatic stage is poorly described. This study aimed to compare OS calculated from the diagnosis of metastatic disease between IBC patients and non-IBC patients in the Epidemiological Strategy and Medical Economics database (N = 16 702 patients). Secondary objectives included progression-free survival (PFS) after first-line metastatic treatment, identification of prognostic factors for OS and PFS, and evolution of survival during the study period. From 2008 to 2014, 7465 patients with metastatic breast cancer and known clinical status of their primary tumor (T) were identified (582 IBC and 6883 non-IBC). Compared with metastatic non-IBC, metastatic IBC was associated with less hormone receptor-positive (44% versus 65.6%), more human epidermal growth factor receptor 2-positive (30% versus 18.6%), and more triple-negative (25.9% versus 15.8%) cases, more frequent de novo M1 stage (53.3% versus 27.7%; P < 0.001), and shorter median disease-free interval (2.02 years versus 4.9 years; P < 0.001). With a median follow-up of 50.2 months, median OS was 28.4 months [95% confidence interval (CI) 24.1-33.8 months] versus 37.2 months (95% CI 36.1-38.5 months) in metastatic IBC and non-IBC cases, respectively (P < 0.0001, log-rank test). By multivariate analysis, OS was significantly shorter in the metastatic IBC group compared with the metastatic non-IBC group [hazard ratio = 1.27 (95% CI 1.1-1.4); P = 0.0001]. Survival of metastatic IBC patients improved over the study period: median OS was 24 months (95% CI 20-31.9 months), 29 months (95% CI 21.7-39.9 months), and 36 months (95% CI 27.9-not estimable months) if diagnosis of metastatic disease was carried out until 2010, between 2011 and 2012, and from 2013, respectively (P = 0.003). IBC is independently associated with adverse outcome when compared with non-IBC in the metastatic setting.","Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Biometrics Unit, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes St-Herblain Cedex, France.;Medical Oncology Department, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Data Office, Unicancer, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Biometrics Unit, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2021","6","10.1016/j.esmoop.2021.100220","100220","","","34303929","34303929","PUBMED","Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Biometrics Unit, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes St-Herblain Cedex, France.;Medical Oncology Department, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Data Office, Unicancer, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Biometrics Unit, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France; Aix-Marseille University, CNRS U7258, INSERM U1068, Institut Paoli-Calmettes, CRCM, Marseille"
"346","De Nonneville A;Zemmour C;Frank S;Joly F;Ray-Coquard I;Costaz H;Classe JM;Floquet A;De la Motte Rouge T;Colombo PE;Sauterey B;Leblanc E;Pomel C;Marchal F;Barranger E;Savoye AM;Guillemet C;Petit T;Pautier P;Rouzier R;Gladieff L;Simon G;Courtinard C;Sabatier R","De Nonneville, Alexandre;Zemmour, Christophe;Frank, Sophie;Joly, Florence;Ray-Coquard, Isabelle;Costaz, Hèlène;Classe, Jean-Marc;Floquet, Anne;De la Motte Rouge, Thibault;Colombo, Pierre-Emmanuel;Sauterey, Baptiste;Leblanc, Eric;Pomel, Christophe;Marchal, Frédéric;Barranger, Emmanuel;Savoye, Aude-Marie;Guillemet, Cécile;Petit, Thierry;Pautier, Patricia;Rouzier, Roman;Gladieff, Laurence;Simon, Gaëtane;Courtinard, Coralie;Sabatier, Renaud","Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.","Gynecologic oncology","United States","eng","Journal Article","Endometrioid;Epidemiology;Ovarian cancer;Prognostic factors;Survival","Adolescent;Adult;Aged;Aged, 80 and over;BRCA1 Protein;BRCA2 Protein;Carcinoma, Endometrioid;Carcinoma, Ovarian Epithelial;Databases, Factual;Female;Humans;Middle Aged;Mutation;Ovarian Neoplasms;Retrospective Studies;Young Adult","Adolescent;Adult;Aged;Aged, 80 and over;BRCA1 Protein;BRCA2 Protein;Carcinoma, Endometrioid;Carcinoma, Ovarian Epithelial;Databases, Factual;Female;Humans;Middle Aged;Mutation;Ovarian Neoplasms;Retrospective Studies;Young Adult","Prognostic significance of endometrioid epithelial ovarian cancer (EOC) is controversial. We compared clinical, pathological, and biological features of patients with endometrioid and serous EOC, and assessed the independent effect of histology on outcomes. We conducted a multicenter retrospective analysis of patients with EOC selected from the French Epidemiological Strategy and Medical Economics OC database between 2011 and 2016. Our main objective was to compare overall survival (OS) in endometrioid and serous tumors of all grades. Our second objectives were progression-free survival (PFS) and prognostic features. Out of 10,263 patients included, 3180 cases with a confirmed diagnosis of serous (N = 2854) or endometrioid (N = 326) EOC were selected. Patients with endometrioid histology were younger, more often diagnosed at an early stage, with lower-grade tumors, more frequently dMMR/MSI-high, and presented more personal/familial histories of Lynch syndrome-associated cancers. BRCA1/2 mutations were more frequently identified in the serous population. Endometrioid patients were less likely to receive chemotherapy, with less bevacizumab. After median follow-up of 51.7 months (95CI[50.1-53.6]), five-year OS rate was 81% (95CI[74-85]) in the endometrioid subgroup vs. 55% (95CI[53-57] in the serous subset (p < 0.001, log-rank test). In multivariate analyses including [age, ECOG-PS, FIGO, grade, and histology], the endometrioid subtype was independently associated with better OS (HR = 0.38, 95CI[0.20-0.70], p= 0.002) and PFS (HR = 0.53, 95CI[0.37-0.75], p < 0.001). Clinicopathological features at diagnosis are not the same for endometrioid and serous EOC. Endometrioid histology is an independent prognosis factor in EOC. These observations suggest the endometrioid population requires dedicated clinical trials and management.","Aix-Marseille Univ., CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Paoli-Calmettes Institute, Aix Marseille Univ., INSERM, IRD, SESSTIM, Marseille, France.;Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Surgical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079 Dijon, France.;Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Surgical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of medical Oncology, Institut de Cancérologie de l'Ouest Centre Paul Papin, 5 Rue Moll, 49000 Angers, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Surgical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Université de Lorraine, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Institut de cancérologie Strasbourg Europe, Centre Paul Strauss, 17 rue Albert Calmette, 67033 Strasbourg, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Breast and Gynecological Surgery, Institut Curie, 35, Rue Dailly, 92 210 Saint-Cloud, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Data Office, Unicancer, 101 Rue de Tolbiac, 75654 Paris, France.;Data Office, Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Aix-Marseille Univ., CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2021,"2021","163","10.1016/j.ygyno.2021.07.019","64-71","","","34294414","34294414","PUBMED","Aix-Marseille Univ., CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France.;Department of Clinical Research and Investigation, Biostatistics and Methodology Unit, Paoli-Calmettes Institute, Aix Marseille Univ., INSERM, IRD, SESSTIM, Marseille, France.;Department of Medical Oncology, Institut Curie, 26 rue d'Ulm, 75248 Paris, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Surgical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079 Dijon, France.;Department of Surgical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Boulevard Jacques Monod, 44805 Saint Herblain, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Surgical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of medical Oncology, Institut de Cancérologie de l'Ouest Centre Paul Papin, 5 Rue Moll, 49000 Angers, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Surgical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011 Clermont Ferrand, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Université de Lorraine, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Institut de cancérologie Strasbourg Europe, Centre Paul Strauss, 17 rue Albert Calmette, 67033 Strasbourg, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Department of Breast and Gynecological Surgery, Institut Curie, 35, Rue Dailly, 92 210 Saint-Cloud, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059 Toulouse, France.;Data Office, Unicancer, 101 Rue de Tolbiac, 75654 Paris, France.;Data Office, Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Aix-Marseille Univ., CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille"
"347","Emens LA;Adams S;Barrios CH;Diéras V;Iwata H;Loi S;Rugo HS;Schneeweiss A;Winer EP;Patel S;Henschel V;Swat A;Kaul M;Molinero L;Patel S;Chui SY;Schmid P","Emens, L A;Adams, S;Barrios, C H;Diéras, V;Iwata, H;Loi, S;Rugo, H S;Schneeweiss, A;Winer, E P;Patel, S;Henschel, V;Swat, A;Kaul, M;Molinero, L;Patel, S;Chui, S Y;Schmid, P","First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Journal Article","atezolizumab;first-line treatment;immune checkpoint inhibitor;metastatic;nab-paclitaxel;triple-negative breast cancer","Albumins;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Humans;Paclitaxel;Survival Analysis;Triple Negative Breast Neoplasms","Albumins;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Humans;Paclitaxel;Survival Analysis;Triple Negative Breast Neoplasms","Guidelines recommend atezolizumab plus nab-paclitaxel (A + nP) for first-line treatment of unresectable, locally advanced, or metastatic triple-negative breast cancer expressing programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (IC), based on IMpassion130. We report the final overall survival (OS) and safety of that study as per the prespecified analysis plan. Patients were randomized to nP 100 mg/m  (days 1, 8, and 15 of a 28-day cycle) with atezolizumab 840 mg (A + nP) or placebo (P + nP; days 1 and 15), until progression or unacceptable toxicity. Coprimary endpoints were progression-free survival [intention-to-treat (ITT) and PD-L1 IC-positive populations] and OS (tested hierarchically in the ITT population and, if significant, in the PD-L1 IC-positive population). Each arm comprised 451 patients; 666 (73.8%) had died by the final OS analysis cut-off (median follow-up, 18.8 months; interquartile range, 8.9-34.7 months). Median OS in the ITT population was 21.0 months [95% confidence interval (CI), 19.0-23.4 months] with A + nP, and 18.7 months (95% CI, 16.9-20.8 months) with P + nP [stratified hazard ratio (HR), 0.87; 95% CI, 0.75-1.02; P = 0.077]. Exploratory analysis in the PD-L1 IC-positive population showed a median OS of 25.4 months (95% CI, 19.6-30.7 months) with A + nP (n = 185) and 17.9 months (95% CI, 13.6-20.3 months) with P + nP (n = 184; stratified HR, 0.67; 95% CI, 0.53-0.86). Safety outcomes were consistent with previous analyses and the known toxicity profiles of each agent. Immune-mediated adverse events of special interest were reported in 58.7% and 41.6% of patients treated with A + nP and P + nP, respectively. Although the OS benefit in the ITT population was not statistically significant, precluding formal testing, clinically meaningful OS benefit was observed with A + nP in PD-L1 IC-positive patients, consistent with prior interim analyses. This combination remained safe and tolerable with longer follow-up.","University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh;New York University Langone Health, Perlmutter Cancer Center, New York, USA.;Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Aichi Cancer Center Hospital, Nagoya, Japan.;Peter MacCallum Cancer Centre, Melbourne, Australia.;University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.;Dana-Farber Cancer Institute, Boston, USA.;Genentech, Inc., South San Francisco, USA.;F. Hoffmann-La Roche Ltd., Basel, Switzerland.;Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.;Product Development Safety, Genentech, Inc., South San Francisco.;Oncology Biomarker Development, Genentech, Inc., South San Francisco.;Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Barts Cancer Institute, Queen Mary University London, London, UK.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2021,"2021","32","10.1016/j.annonc.2021.05.355","983-993","","","34272041","34272041","PUBMED","University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh;New York University Langone Health, Perlmutter Cancer Center, New York, USA.;Centro de Pesquisa Clínica, HSL, PUCRS, Porto Alegre, Brazil.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Aichi Cancer Center Hospital, Nagoya, Japan.;Peter MacCallum Cancer Centre, Melbourne, Australia.;University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.;Dana-Farber Cancer Institute, Boston, USA.;Genentech, Inc., South San Francisco, USA.;F. Hoffmann-La Roche Ltd., Basel, Switzerland.;Product Development Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.;Product Development Safety, Genentech, Inc., South San Francisco.;Oncology Biomarker Development, Genentech, Inc., South San Francisco.;Product Development Data Sciences, Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Barts Cancer Institute, Queen Mary University London, London, UK."
"348","Arun BK;Han HS;Kaufman B;Wildiers H;Friedlander M;Ayoub JP;Puhalla SL;Bell-McGuinn KM;Bach BA;Kundu MG;Ratajczak CK;Maag D;Diéras V","Arun, Banu K;Han, Hyo S;Kaufman, Bella;Wildiers, Hans;Friedlander, Michael;Ayoub, Jean-Pierre;Puhalla, Shannon L;Bell-McGuinn, Katherine M;Bach, Bruce A;Kundu, Madan G;Ratajczak, Christine K;Maag, David;Diéras, Véronique","Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","BRCA;Breast cancer;Chemotherapy;PARP inhibitor","Adult;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Genes, BRCA1;Genes, BRCA2;Germ-Line Mutation;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2","Adult;Antineoplastic Combined Chemotherapy Protocols;Benzimidazoles;Breast Neoplasms;Carboplatin;Female;Genes, BRCA1;Genes, BRCA2;Germ-Line Mutation;Humans;Middle Aged;Paclitaxel;Receptor, ErbB-2","Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and ≤2 lines of previous cytotoxic therapy for metastatic disease in BROCADE3. A pre-planned subgroup analysis evaluated efficacy and safety in patients without previous cytotoxic therapy for metastatic disease. Patients were randomised 2:1 to receive veliparib (120 mg orally BID) or placebo on days -2 to 5. Carboplatin (AUC 6) was administered on day 1, and paclitaxel (80 mg/m ) on days 1, 8 and 15 (21-day cycles). Patients discontinuing carboplatin-paclitaxel for reasons besides progression could continue veliparib/placebo monotherapy (300 mg BID, increasing to 400 mg BID if tolerated) until progression. The primary end-point was PFS assessed by investigator. Of 509 patients in the intention-to-treat population (98.6% female; mean age 47, standard deviation 11), 413 (81%) had no previous cytotoxic therapy for metastatic disease (274, veliparib; 139, placebo). In the first-line subgroup, median PFS was 16.6 months (95% confidence interval [CI] 13.4-18.7) versus 13.1 months (95% CI 11.4-14.5) for the veliparib versus control groups (hazard ratio 0.70, 95% CI 0.54-0.89, P = .004). More patients were alive and progression-free at 2 years (36% versus 23.2%) and 3 years (27.9% versus 13.3%) in the veliparib versus control group. Adverse events unrelated to progression leading to study drug discontinuation occurred in 25 (9.1%) and 8 (5.8%) patients. Veliparib with carboplatin-paclitaxel led to durable disease control among first-line patients, suggesting a benefit of this treatment approach in early lines. NCT02163694.","Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX;Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.;Department of Oncology, Breast Oncology Institute, Sheba Medical Center, Tel-Aviv, Israel.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.;Department of Hematology and Oncology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Hematology/Oncology, Department of Medicine, UPMC Cancer Centers, Pittsburgh, PA, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Department of Medical Oncology, Institut Curie, Paris, France, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","154","10.1016/j.ejca.2021.05.037","35-45","","","34243076","34243076","PUBMED","Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX;Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.;Department of Oncology, Breast Oncology Institute, Sheba Medical Center, Tel-Aviv, Israel.;Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.;Prince of Wales Clinical School, University of New South Wales, Sydney, Australia, Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia.;Department of Hematology and Oncology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.;Division of Hematology/Oncology, Department of Medicine, UPMC Cancer Centers, Pittsburgh, PA, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;AbbVie Inc., North Chicago, IL, USA.;Department of Medical Oncology, Institut Curie, Paris, France, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France."
"349","Lanéelle D;Le Brun C;Mauger C;Guillaumat J;Le Pabic E;Omarjee L;Mahé G","Lanéelle, Damien;Le Brun, Charles;Mauger, Chadi;Guillaumat, Jérôme;Le Pabic, Estelle;Omarjee, Loukman;Mahé, Guillaume","Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease.","Frontiers in cardiovascular medicine","Switzerland","eng","Journal Article","anticoagulation management;anticoagulation/administration and dosing;patient concern;patient preference (MeSH);venous thromboembolism disease (VTE disease)","",""," Anticoagulants are the recommended treatment for venous thromboembolic disease (VTE). The mode of anticoagulant administration may influence compliance, and therefore the effectiveness of the treatment. Unlike in atrial fibrillation or cancer-associated thrombosis, there is only limited data on patient preferences regarding the choice of anticoagulation in VTE. This study aims to evaluate patient preferences regarding anticoagulants in terms of administration: types (oral or injectable treatment) and number of doses or injections per day.   This is a national survey through a questionnaire sent by e-mail to 1936 French vascular physicians between February and April 2019. They recorded the responses for each patient admitted for VTE.   Three hundred and eleven (response rate of 16%) of the 1936 contacted physicians responded for 364 patients. Among these, there were 167 fully completed questionnaires. Most patients (63%) express concerns about VTE and prefer oral treatment (81.5%), justified by the ease of administration (74%) and a fear of the injections (22%). When patients were taking more than three oral treatments they statistically chose injectable treatment more often (54%) than oral treatment (25%,   = 0.002). Patients who chose injectable treatment were also older (70 ± 16 vs. 58 ± 17 years old,   = 0.001). There was no statistically difference in anticoagulation preference according to gender or to the expected duration of treatment (6 weeks, 3 months, 6 months or unlimited). When oral treatment was preferred (81%), most chose oral treatment without dose adjustment and biomonitoring (74.3%). Among them, very few (5.8%) preferred a twice-daily intake.   Patient preference in terms of anticoagulant treatment in VTE disease is in favor of oral treatment without adjustment or biomonitoring and with once-daily intake. When an injectable treatment is chosen, a prolonged duration of treatment does not seem to be a constraint for the patient.   ClinicalTrials.gov, identifier [NCT03889457].","Centre Hospitalier Universitaire Caen Normandie, Service de Médecine Vasculaire, Caen, France.;Université de Caen, COMETE, Caen, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire Caen Normandie, Service de Médecine Vasculaire, Caen, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Université de Rennes 1, Rennes, France.","NA",0,"2297-055X","Front Cardiovasc Med","Front Cardiovasc Med",2021,"2021","8","10.3389/fcvm.2021.675969","675969","","","34235186","34235186","PUBMED","Centre Hospitalier Universitaire Caen Normandie, Service de Médecine Vasculaire, Caen, France.;Université de Caen, COMETE, Caen, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire Caen Normandie, Service de Médecine Vasculaire, Caen, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Université de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Department of Vascular Medicine, Rennes, France.;Université de Rennes 1, Rennes, France."
"350","Di Perri D;Jouglar E;Blanc E;Ducassou A;Huchet A;Vigneron C;Escande A;Chapet S;Leseur J;Bernier V;Carrie C;Martin V;Claude L","Di Perri, Dario;Jouglar, Emmanuel;Blanc, Ellen;Ducassou, Anne;Huchet, Aymeri;Vigneron, Céline;Escande, Alexandre;Chapet, Sophie;Leseur, Julie;Bernier, Valérie;Carrie, Christian;Martin, Valentine;Claude, Line","Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study.","The British journal of radiology","England","eng","Journal Article","","Adolescent;Adult;Brain Neoplasms;Child;Child, Preschool;Dose Fractionation, Radiation;Female;France;Humans;Lung Neoplasms;Male;Pediatrics;Prospective Studies;Radiosurgery;Re-Irradiation;Spinal Neoplasms;Treatment Outcome;Young Adult","Adolescent;Adult;Brain Neoplasms;Child;Child, Preschool;Dose Fractionation, Radiation;Female;France;Humans;Lung Neoplasms;Male;Pediatrics;Prospective Studies;Radiosurgery;Re-Irradiation;Spinal Neoplasms;Treatment Outcome;Young Adult","While hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3-24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients. Between 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3-20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%). Acute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting. SBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions. SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future.","Department of radiation oncology, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of clinical research and innovation, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France.;Department of radiation oncology, Centre Hospitalier Universitaire, Bordeaux, France.;Department of radiation oncology, Centre Paul Strauss, Strasbourg, France.;Department of radiation oncology, Centre Oscar Lambret, Lille, France.;Department of radiation oncology, Centre Hospitalier Universitaire, Tours, France.;Department of radiation oncology, Centre Eugène Marquis, Rennes, France.;Department of radiation oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of radiation oncology, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut Gustave Roussy, Villejuif, France.;Department of radiation oncology, Centre Léon Bérard, Lyon, France.","NA",0,"1748-880X","Br J Radiol","Br J Radiol",2021,"2021","94","10.1259/bjr.20210176","20210176","","","34233469","34233469","PUBMED","Department of radiation oncology, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;Department of clinical research and innovation, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France.;Department of radiation oncology, Centre Hospitalier Universitaire, Bordeaux, France.;Department of radiation oncology, Centre Paul Strauss, Strasbourg, France.;Department of radiation oncology, Centre Oscar Lambret, Lille, France.;Department of radiation oncology, Centre Hospitalier Universitaire, Tours, France.;Department of radiation oncology, Centre Eugène Marquis, Rennes, France.;Department of radiation oncology, Institut de Cancérologie de Lorraine, Nancy, France.;Department of radiation oncology, Centre Léon Bérard, Lyon, France.;Department of radiation oncology, Institut Gustave Roussy, Villejuif, France.;Department of radiation oncology, Centre Léon Bérard, Lyon, France."
"351","Sargos P;Faye MD;Bacci M;Supiot S;Latorzeff I;Azria D;Niazi TM;Vuong T;Vendrely V;de Crevoisier R","Sargos, Paul;Faye, Mame Daro;Bacci, Manon;Supiot, Stéphane;Latorzeff, Igor;Azria, David;Niazi, Tamim M;Vuong, Te;Vendrely, Véronique;de Crevoisier, Renaud","Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review.","Frontiers in oncology","Switzerland","eng","Journal Article","anal canal;gastrointestinal toxicities;prostate cancer;radiotherapy;rectum","","","Late gastro-intestinal toxicities (LGIT) secondary to pelvic radiotherapy (RT) are well described in the literature. LGIT are mainly related to rectal or ano-rectal irradiation; however, involvement of the anal canal (AC) in the occurrence of LGIT remains poorly described and understood. The aim of this work was to explore the potential role of the AC in the development of LGIT after prostate irradiation and identify predictive factors that could be optimized in order to limit these toxicities. This narrative literature review was realized using the Pubmed database. We identified original articles published between June 1997 and July 2019, relating to LGIT after RT for localized prostate cancer and for which AC was identified independently. Articles defining the AC as part of an anorectal or rectal volume only were excluded. A history of abdominal surgery or cardio-vascular risk, anticoagulant or tobacco use, and the occurrence of acute GIT during RT increases the risk of LGIT. A dose-effect relationship was identified between dose to the AC and development of LGIT. Identification and contouring of the AC and adjacent anatomical structures (muscles or nerves) are justified to apply specific dose constraints. As a limitation, our review mainly considered on 3DCRT which is no longer the standard of care nowadays; we did not identify any reports in the literature using moderately hypofractionated RT for the prostate and AC specific dosimetry. These results suggest that the AC may have an important role in the development of LGIT after pelvic RT for prostate cancer. The individualization of the AC during planning should be recommended in prospective studies.","Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Radiation Oncology, Clinique Pasteur, Toulouse, France.;Department of Radiation Oncology, Institut de Cancérologie de Montpellier, Montpellier, France.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Bordeaux University Hospital, Bordeaux, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France.","NA",0,"2234-943X","Front Oncol","Front Oncol",2021,"2021","11","10.3389/fonc.2021.666962","666962","","","34221983","34221983","PUBMED","Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Institut Bergonié, Bordeaux Cedex, France.;Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Saint-Herblain, France.;Department of Radiation Oncology, Clinique Pasteur, Toulouse, France.;Department of Radiation Oncology, Institut de Cancérologie de Montpellier, Montpellier, France.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Jewish General Hospital, Montreal, QC, Canada.;Department of Radiation Oncology, Bordeaux University Hospital, Bordeaux, France.;Department of Radiation Oncology, Centre Eugene Marquis, Rennes, France."
"352","Zelek L;Debourdeau P;Bourgeois H;Wagner JP;Brocard F;Lefeuvre-Plesse C;Chauffert B;Leheurteur M;Bachet JB;Simon H;Mayeur D;Scotté F","Zelek, Laurent;Debourdeau, Philippe;Bourgeois, Hugues;Wagner, Jean Philippe;Brocard, Fabien;Lefeuvre-Plesse, Claudia;Chauffert, Bruno;Leheurteur, Marianne;Bachet, Jean-Baptiste;Simon, Hélène;Mayeur, Didier;Scotté, Florian","A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.","The oncologist","England","eng","Journal Article","Chemotherapy-induced nausea and vomiting • Netupitant • Palonosetron • Aprepitant • NEPA","Antibiotics, Antineoplastic;Antiemetics;Antineoplastic Agents;Aprepitant;Double-Blind Method;Humans;Isoquinolines;Nausea;Palonosetron;Prospective Studies;Quinuclidines;Vomiting","Antibiotics, Antineoplastic;Antiemetics;Antineoplastic Agents;Aprepitant;Double-Blind Method;Humans;Isoquinolines;Nausea;Palonosetron;Prospective Studies;Quinuclidines;Vomiting","Neurokinin (NK) 1 receptor antagonists (RAs), administered in combination with a 5-hydroxytryptamine-3 (5-HT  ) RA and dexamethasone (DEX), have demonstrated clear improvements in chemotherapy-induced nausea and vomiting (CINV) prevention over a 5-HT  RA plus DEX. However, studies comparing the NK  RAs in the class are lacking. A fixed combination of a highly selective NK  RA, netupitant, and the 5-HT  RA, palonosetron (NEPA), simultaneously targets two critical antiemetic pathways, thereby offering a simple convenient antiemetic with long-lasting protection from CINV. This study is the first head-to-head NK  RA comparative study in patients receiving anthracycline cyclophosphamide (AC) and non-AC moderately emetogenic chemotherapy (MEC). This was a pragmatic, multicenter, randomized, single-cycle, open-label, prospective study designed to demonstrate noninferiority of single-dose NEPA to a 3-day aprepitant regimen in preventing CINV in chemotherapy-naive patients receiving AC/non-AC MEC in a real-life setting. The primary efficacy endpoint was complete response (no emesis/no rescue) during the overall (0-120 hour) phase. Noninferiority was achieved if the lower limit of the 95% confidence interval (CI) of the difference between NEPA and the aprepitant group was greater than the noninferiority margin set at -10%. Noninferiority of NEPA versus aprepitant was demonstrated (risk difference 9.2%; 95% CI, -2.3% to 20.7%); the overall complete response rate was numerically higher for NEPA (64.9%) than aprepitant (54.1%). Secondary endpoints also revealed numerically higher rates for NEPA than aprepitant. This pragmatic study in patients with cancer receiving AC and non-AC MEC revealed that a single dose of oral NEPA plus DEX was at least as effective as a 3-day aprepitant regimen, with indication of a potential efficacy benefit for NEPA. In the absence of comparative neurokinin 1 (NK  ) receptor antagonist (RA) studies, guideline committees and clinicians consider NK  RA agents to be interchangeable and equivalent. This is the first head-to-head study comparing one NK  RA (oral netupitant/palonosetron [NEPA]) versus another (aprepitant) in patients receiving anthracycline cyclophosphamide (AC) and non-AC moderately emetogenic chemotherapy. Noninferiority of NEPA versus the aprepitant regimen was demonstrated; the overall complete response (no emesis and no rescue use) rate was numerically higher for NEPA (65%) than aprepitant (54%). As a single-dose combination antiemetic, NEPA not only simplifies dosing but may offer a potential efficacy benefit over the current standard-of-care.","Hôpital Avicenne, Bobigny, France.;Institut Sainte-Catherine, Avignon, France.;Clinique Victor Hugo, Le Mans, France.;Institut Andrée Dutreix and Clinique de Flandre, Dunkerque, France.;Polyclinique De Gentilly, Nancy, France.;Centre Eugène Marquis, Rennes Cedex, France.;Centre Hospitalier Universitaire Amiens, Amiens, France.;Centre Henri Becquerel, Rouen, France.;Hôpital La Pitié Salpêtrière, Paris, France.;Centre Hospitalier Universitaire Morvan, Brest, France.;Centre George Francois Leclerc, Dijon, France.;Interdisciplinary Cancer Course Department, Gustave Roussy Cancer Center, Villejuif, France.","NA",0,"1549-490X","Oncologist","Oncologist",2020,"2021","26","10.1002/onco.13888","e1870-e1879","","","34216177","34216177","PUBMED","Hôpital Avicenne, Bobigny, France.;Institut Sainte-Catherine, Avignon, France.;Clinique Victor Hugo, Le Mans, France.;Institut Andrée Dutreix and Clinique de Flandre, Dunkerque, France.;Polyclinique De Gentilly, Nancy, France.;Centre Eugène Marquis, Rennes Cedex, France.;Centre Hospitalier Universitaire Amiens, Amiens, France.;Centre Henri Becquerel, Rouen, France.;Hôpital La Pitié Salpêtrière, Paris, France.;Centre Hospitalier Universitaire Morvan, Brest, France.;Centre George Francois Leclerc, Dijon, France.;Interdisciplinary Cancer Course Department, Gustave Roussy Cancer Center, Villejuif, France."
"353","Le Daré B;Ferron PJ;Gicquel T","Le Daré, Brendan;Ferron, Pierre-Jean;Gicquel, Thomas","Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics.","Toxins","Switzerland","eng","Journal Article","Amanita phalloïdes;amanitin;amanitin-conjugated antibody;antidote;hepatotoxicity","Amanitins;Animals;Humans;Mushroom Poisoning","Amanitins;Animals;Humans;Mushroom Poisoning","The consumption of mushrooms has become increasingly popular, partly due to their nutritional and medicinal properties. This has increased the risk of confusion during picking, and thus of intoxication. In France, about 1300 cases of intoxication are observed each year, with deaths being mostly attributed to   poisoning. Among amatoxins, α- and β-amanitins are the most widely studied toxins. Hepatotoxicity is the hallmark of these compounds, leading to hepatocellular failure within three days of ingestion. The toxic mechanisms of action mainly include RNA polymerase II inhibition and oxidative stress generation, leading to hepatic cell apoptosis or necrosis depending on the doses ingested. Currently, there is no international consensus concerning   poisoning management. However, antidotes with antioxidant properties remain the most effective therapeutics to date suggesting the predominant role of oxidative stress in the pathophysiology. The partially elucidated mechanisms of action may reveal a suitable target for the development of an antidote. The aim of this review is to present an overview of the knowledge on amanitins, including the latest advances that could allow the proposal of new innovative and effective therapeutics.","Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, service Pharmacie, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de toxicologie biologique et médico-légale, F-35000 Rennes, France.","NA",0,"2072-6651","Toxins (Basel)","Toxins (Basel)",2021,"2021","13","10.3390/toxins13060417",NA,"","","34208167","34208167","PUBMED","Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, service Pharmacie, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Univ Rennes, INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Métabolismes et Cancer), Previtox Network, F-35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire de toxicologie biologique et médico-légale, F-35000 Rennes, France."
"354","Lanéelle D;Sauvet G;Guillaumat J;Trihan JE;Mahé G","Lanéelle, Damien;Sauvet, Gabriella;Guillaumat, Jérôme;Trihan, Jean Eudes;Mahé, Guillaume","Gender Differences in the Medical Treatment of Peripheral Artery Disease.","Journal of clinical medicine","Switzerland","eng","Journal Article","gender differences;optimal medical treatment;peripheral arterial disease","","","Peripheral arterial disease is a frequent and severe disease with high cardiovascular morbidity and mortality. However, female patients appear to be undertreated. The primary goal was to compare the prescription of optimal medical treatment (OMT) of peripheral arterial disease between women and men in primary health care. An observational retrospective study was based on the data collected from general practitioners (GP) office in Brittany. The study included 100 patients, aged 71 ± 10 years old, with 24% of women. Compared to men, women received the OMT less frequently (29.2% vs. 53.9%,   = 0.038), especially after 75 years old. Antiplatelet therapy was largely prescribed (100%), statins less frequently (70.8% women vs. 85.5% men), and prescription of renin-angiotensin-aldosterone system inhibitors was still not optimal in the two genders (41.7% women vs. 61.9% men). Active smoking is important for both women and men (33% and 30% respectively). Optimal medical treatment of peripheral artery disease is insufficiently prescribed, especially in women in this region of France.","Vascular Medicine Unit, Centre Hospitalier Universitaire de Caen Normandie, 14000 Caen, France.;COMETE Laboratory, INSERM 1075, Université de Caen, 14000 Caen, France.;Medical School, Université de Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-Le-Bretonneux, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Caen Normandie, 14000 Caen, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Poitiers, 86021 Poitiers, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;INSERM CIC 1414, Université de Rennes, 35033 Rennes, France.","NA",0,"2077-0383","J Clin Med","J Clin Med",2021,"2021","10","10.3390/jcm10132855",NA,"","","34203172","34203172","PUBMED","Vascular Medicine Unit, Centre Hospitalier Universitaire de Caen Normandie, 14000 Caen, France.;COMETE Laboratory, INSERM 1075, Université de Caen, 14000 Caen, France.;Medical School, Université de Versailles Saint-Quentin-en-Yvelines, 78180 Montigny-Le-Bretonneux, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Caen Normandie, 14000 Caen, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Poitiers, 86021 Poitiers, France.;Vascular Medicine Unit, Centre Hospitalier Universitaire de Rennes, 35033 Rennes, France.;INSERM CIC 1414, Université de Rennes, 35033 Rennes, France."
"355","Luque Paz D;Jouneau S;Tattevin P;Ricordel C","Luque Paz, David;Jouneau, Stephane;Tattevin, Pierre;Ricordel, Charles","Pneumocystis in metastatic lung cancer, a pragmatic approach in support of prophylaxis.","BMJ case reports","England","eng","Case Reports","lung cancer (oncology);pneumonia (respiratory medicine)","Aged, 80 and over;Carcinoma, Non-Small-Cell Lung;Humans;Immunocompromised Host;Lung Neoplasms;Male;Pneumocystis;Pneumocystis carinii;Pneumonia, Pneumocystis","Aged, 80 and over;Carcinoma, Non-Small-Cell Lung;Humans;Immunocompromised Host;Lung Neoplasms;Male;Pneumocystis;Pneumocystis carinii;Pneumonia, Pneumocystis","Lung cancer prognosis has improved in the last decade, including in patients with brain metastasis. However, few of these patients who receive corticosteroids have a primary prophylaxis for   pneumonia (PJP). We report the case of an 80-year-old man diagnosed with non-small cell lung cancer and concomitant symptomatic brain metastases, treated with 50 mg/day of prednisolone without any prophylaxis, who presented an acute PJP. After 72 hours of unsuccessful treatment of PJP, the patient died. In our review of this case and the existing literature, we emphasise the importance of a wide use of prophylaxis for PJP, especially in advanced lung cancer treated with corticosteroid therapy. We discuss this issue and report current evidence for primary prophylaxis by trimethoprim-sulfamethoxazole.","Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2021,"2021","14","10.1136/bcr-2019-232895",NA,"","","34183310","34183310","PUBMED","Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infectious Diseases and Intensive Care Unit, CHU Rennes, Rennes, France.;Department of Respiratory Medicine, Centre Hospitalier Universitaire de Rennes, Rennes"
"356","Thille AW;Monseau G;Coudroy R;Nay MA;Gacouin A;Decavèle M;Sonneville R;Beloncle F;Girault C;Dangers L;Lautrette A;Levrat Q;Rouzé A;Vivier E;Lascarrou JB;Ricard JD;Razazi K;Barberet G;Lebert C;Ehrmann S;Massri A;Bourenne J;Pradel G;Bailly P;Terzi N;Dellamonica J;Lacave G;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Monseau, Grégoire;Coudroy, Rémi;Nay, Mai-Anh;Gacouin, Arnaud;Decavèle, Maxens;Sonneville, Romain;Beloncle, François;Girault, Christophe;Dangers, Laurence;Lautrette, Alexandre;Levrat, Quentin;Rouzé, Anahita;Vivier, Emmanuel;Lascarrou, Jean-Baptiste;Ricard, Jean-Damien;Razazi, Keyvan;Barberet, Guillaume;Lebert, Christine;Ehrmann, Stephan;Massri, Alexandre;Bourenne, Jeremy;Pradel, Gael;Bailly, Pierre;Terzi, Nicolas;Dellamonica, Jean;Lacave, Guillaume;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","Non-invasive ventilation versus high-flow nasal oxygen for postextubation respiratory failure in ICU: a post-hoc analysis of a randomized clinical trial.","Critical care (London, England)","England","eng","Journal Article","Acute respiratory failure;Airway extubation;High-flow nasal oxygen;Noninvasive ventilation;Ventilator weaning","Aged;Aged, 80 and over;Airway Extubation;Female;Humans;Intensive Care Units;Kaplan-Meier Estimate;Length of Stay;Male;Middle Aged;Noninvasive Ventilation;Oxygen Inhalation Therapy;Respiratory Insufficiency","Aged;Aged, 80 and over;Airway Extubation;Female;Humans;Intensive Care Units;Kaplan-Meier Estimate;Length of Stay;Male;Middle Aged;Noninvasive Ventilation;Oxygen Inhalation Therapy;Respiratory Insufficiency","In intensive care units (ICUs), patients experiencing post-extubation respiratory failure have poor outcomes. The use of noninvasive ventilation (NIV) to treat post-extubation respiratory failure may increase the risk of death. This study aims at comparing mortality between patients treated with NIV alternating with high-flow nasal oxygen or high-flow nasal oxygen alone. Post-hoc analysis of a multicenter, randomized, controlled trial focusing on patients who experienced post-extubation respiratory failure within the 7 days following extubation. Patients were classified in the NIV group or the high-flow nasal oxygen group according to oxygenation strategy used after the onset of post-extubation respiratory failure. Patients reintubated within the first hour after extubation and those promptly reintubated without prior treatment were excluded. The primary outcome was mortality at day 28 after the onset of post-extubation respiratory failure. Among 651 extubated patients, 158 (25%) experienced respiratory failure and 146 were included in the analysis. Mortality at day 28 was 18% (15/84) using NIV alternating with high-flow nasal oxygen and 29% (18/62) with high flow nasal oxygen alone (difference, - 11% [95% CI, - 25 to 2]; p = 0.12). Among the 46 patients with hypercapnia at the onset of respiratory failure, mortality at day 28 was 3% (1/33) with NIV and 31% (4/13) with high-flow nasal oxygen alone (difference, - 28% [95% CI, - 54 to - 6]; p = 0.006). The proportion of patients reintubated 48 h after the onset of post-extubation respiratory failure was 44% (37/84) with NIV and 52% (32/62) with high-flow nasal oxygen alone (p = 0.21). In patients with post-extubation respiratory failure, NIV alternating with high-flow nasal oxygen might not increase the risk of death. Trial registration number The trial was registered at http://www.clinicaltrials.gov with the registration number NCT03121482 the 20th April 2017.","Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Rennes, France.;Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP 6 - Sorbonne, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat - Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de la Rochelle, Service de Réanimation, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, UMR IAME 1137, Sorbonne Paris Cité, Université Paris Diderot, Colombes, France.;Hôpitaux Universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, Service de Réanimation Médicale, Site Emile Muller, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERMU1042, HP2, Université Grenoble-Alpes, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.","NA",0,"1466-609X","Crit Care","Crit Care",2021,"2021","25","10.1186/s13054-021-03621-6","221","grant number 15-0060","Ministère des Affaires Sociales, de la Santé et des Droits des Femmes","34183053","34183053","PUBMED","Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Rennes, France.;Hôpital Pitié-Salpêtrière, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP 6 - Sorbonne, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat - Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de la Rochelle, Service de Réanimation, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, UMR IAME 1137, Sorbonne Paris Cité, Université Paris Diderot, Colombes, France.;Hôpitaux Universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, Service de Réanimation Médicale, Site Emile Muller, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERMU1042, HP2, Université Grenoble-Alpes, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Service de Médecine Intensive Réanimation, Médecine Intensive Réanimation, 2 rue la Milétrie, 86021, Poitiers Cedex, France.;Centre d'Investigation Clinique 1402 ALIVE Research Group, University of Poitiers, Poitiers, France."
"357","Sletten OJ;Aalen JM;Izci H;Duchenne J;Remme EW;Larsen CK;Hopp E;Galli E;Sirnes PA;Kongsgard E;Donal E;Voigt JU;Smiseth OA;Skulstad H","Sletten, Ole J;Aalen, John M;Izci, Hava;Duchenne, Jürgen;Remme, Espen W;Larsen, Camilla K;Hopp, Einar;Galli, Elena;Sirnes, Per A;Kongsgard, Erik;Donal, Erwan;Voigt, Jens U;Smiseth, Otto A;Skulstad, Helge","Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block.","JACC. Cardiovascular imaging","United States","eng","Journal Article","cardiac resynchronization therapy;heart failure;left bundle branch block;myocardial work;septal rebound stretch;strain","Bundle-Branch Block;Cardiac Resynchronization Therapy;Heart Failure;Humans;Predictive Value of Tests;Stroke Volume;Treatment Outcome;Ventricular Function, Left","Bundle-Branch Block;Cardiac Resynchronization Therapy;Heart Failure;Humans;Predictive Value of Tests;Stroke Volume;Treatment Outcome;Ventricular Function, Left","This study sought to investigate if contractile asymmetry between septum and left ventricular (LV) lateral wall drives heart failure development in patients with left bundle branch block (LBBB) and whether the presence of lateral wall dysfunction affects potential for recovery of LV function with cardiac resynchronization therapy (CRT). LBBB may induce or aggravate heart failure. Understanding the underlying mechanisms is important to optimize timing of CRT. In 76 nonischemic patients with LBBB and 11 controls, we measured strain using speckle-tracking echocardiography and regional work using pressure-strain analysis. Patients with LBBB were stratified according to LV ejection fraction (EF) ≥50% (EF ), 36% to 49% (EF ), and ≤35% (EF ). Sixty-four patients underwent CRT and were re-examined after 6 months. Septal work was successively reduced from controls, through EF , EF , and EF  (all p < 0.005), and showed a strong correlation to left ventricular ejection fraction (LVEF; r = 0.84; p < 0.005). In contrast, LV lateral wall work was numerically increased in EF  and EF  versus controls, and did not significantly correlate with LVEF in these groups. In EF  however, LV lateral wall work was substantially reduced (p < 0.005). There was a moderate overall correlation between LV lateral wall work and LVEF (r = 0.58; p < 0.005). In CRT recipients, LVEF was normalized (≥50%) in 54% of patients with preserved LV lateral wall work, but only in 13% of patients with reduced LV lateral wall work (p < 0.005). In early stages, LBBB-induced heart failure is associated with impaired septal function but preserved lateral wall function. The advent of LV lateral wall dysfunction may be an optimal time-point for CRT.","Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; The Intervention Center, Oslo University Hospital, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Ostlandske hjertesenter, Moss, Norway.;Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo","NA",0,"1876-7591","JACC Cardiovasc Imaging","JACC Cardiovasc Imaging",2021,"2021","14","10.1016/j.jcmg.2021.04.017","2059-2069","","","34147454","34147454","PUBMED","Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; The Intervention Center, Oslo University Hospital, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Ostlandske hjertesenter, Moss, Norway.;Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Department of Cardiology, Centre Hospitalier Universitaire de Rennes Rennes and Inserm, Laboratoire Traitement du Signal et de l'Image, University of Rennes, Rennes, France.;Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium; Department of Cardiovascular Diseases, University Hospitals Leuven, Leuven, Belgium.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.;Institute for Surgical Research, Rikshospitalet, Oslo University Hospital and University of Oslo, Oslo, Norway; Department of Cardiology, Rikshospitalet, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo"
"358","Pasquier G;Bounhiol A;Robert Gangneux F;Zahar JR;Gangneux JP;Novara A;Bougnoux ME;Dannaoui E","Pasquier, Grégoire;Bounhiol, Agathe;Robert Gangneux, Florence;Zahar, Jean-Ralph;Gangneux, Jean Pierre;Novara, Ana;Bougnoux, Marie-Elisabeth;Dannaoui, Eric","A review of significance of Aspergillus detection in airways of ICU COVID-19 patients.","Mycoses","Germany","eng","Journal Article","Aspergillus fumigatus;COVID-19;SARS-CoV-2;colonisation;intensive care unit;invasive pulmonary aspergillosis;mortality","Adult;Aged;Aged, 80 and over;Antifungal Agents;Bronchoalveolar Lavage Fluid;COVID-19;Cause of Death;Female;Humans;Intensive Care Units;Invasive Pulmonary Aspergillosis;Male;Middle Aged;SARS-CoV-2","Adult;Aged;Aged, 80 and over;Antifungal Agents;Bronchoalveolar Lavage Fluid;COVID-19;Cause of Death;Female;Humans;Intensive Care Units;Invasive Pulmonary Aspergillosis;Male;Middle Aged;SARS-CoV-2","It is now well known that patients with SARS-CoV-2 infection admitted in ICU and mechanically ventilated are at risk of developing invasive pulmonary aspergillosis (IPA). Nevertheless, symptomatology of IPA is often atypical in mechanically ventilated patients, and radiological aspects in SARS-CoV-2 pneumonia and IPA are difficult to differentiate. In this context, the significance of the presence of Aspergillus in airway specimens (detected by culture, galactomannan antigen or specific PCR) remains to be fully understood. To decipher the relevance of the detection of Aspergillus, we performed a comprehensive review of all published cases of respiratory Aspergillus colonisation and IPA in COVID-19 patients. The comparison of patients receiving or not antifungal treatment allowed us to highlight the most important criteria for the decision to treat. The comparison of surviving and non-surviving patients made it possible to unveil criteria associated with mortality that should be taken into account in the treatment decision.","Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Infection Control Unit, Avicenne Hospital, Bobigny, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Medical Intensive Care Unit, Faculty of Medicine, Paris-Descartes University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Fungal biology and Pathogenicity. Institut Pasteur, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Dynamyc EA 7380, Paris-Créteil University, Créteil, France.","NA",0,"1439-0507","Mycoses","Mycoses",2021,"2021","64","10.1111/myc.13341","980-988","","","34143533","34143533","PUBMED","Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Infection Control Unit, Avicenne Hospital, Bobigny, France.;Parasitology-Mycology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, University Rennes, Rennes, France.;Medical Intensive Care Unit, Faculty of Medicine, Paris-Descartes University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, Necker-Enfants maladies Hospital, Paris, France.;Fungal biology and Pathogenicity. Institut Pasteur, Paris, France.;Microbiology Department, Parasitology-Mycology Unit, Faculty of Medicine, Paris University, AP-HP, European Georges-Pompidou Hospital, Paris, France.;Dynamyc EA 7380, Paris-Créteil University, Créteil, France."
"359","Bardia A;Tolaney SM;Punie K;Loirat D;Oliveira M;Kalinsky K;Zelnak A;Aftimos P;Dalenc F;Sardesai S;Hamilton E;Sharma P;Recalde S;Gil EC;Traina T;O'Shaughnessy J;Cortes J;Tsai M;Vahdat L;Diéras V;Carey LA;Rugo HS;Goldenberg DM;Hong Q;Olivo M;Itri LM;Hurvitz SA","Bardia, A;Tolaney, S M;Punie, K;Loirat, D;Oliveira, M;Kalinsky, K;Zelnak, A;Aftimos, P;Dalenc, F;Sardesai, S;Hamilton, E;Sharma, P;Recalde, S;Gil, E C;Traina, T;O'Shaughnessy, J;Cortes, J;Tsai, M;Vahdat, L;Diéras, V;Carey, L A;Rugo, H S;Goldenberg, D M;Hong, Q;Olivo, M;Itri, L M;Hurvitz, S A","Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Clinical Trial, Phase III","BRCA;triple-negative breast cancer;trophoblast cell-surface antigen 2","Antibodies, Monoclonal, Humanized;Biomarkers;Camptothecin;Humans;Immunoconjugates;Triple Negative Breast Neoplasms","Antibodies, Monoclonal, Humanized;Biomarkers;Camptothecin;Humans;Immunoconjugates;Triple Negative Breast Neoplasms","The pivotal phase III ASCENT trial demonstrated improved survival outcomes associated with sacituzumab govitecan (SG), an anti-trophoblast cell-surface antigen 2 (anti-Trop-2) antibody-drug conjugate linked with the topoisomerase-inhibitor SN-38, over single-agent chemotherapy treatment of physician's choice (TPC) in previously treated metastatic triple-negative breast cancer (mTNBC). This prespecified, exploratory biomarker analysis from the ASCENT trial evaluates the association between tumor Trop-2 expression and germline BRCA1/2 mutation status with clinical outcomes. Patients with mTNBC refractory to or progressing after two or more prior chemotherapies, with one or more in the metastatic setting, were randomized to receive SG (10 mg/kg intravenously days 1 and 8, every 21 days) or TPC (capecitabine, eribulin, vinorelbine, or gemcitabine) until disease progression/unacceptable toxicity. Biopsy or surgical specimens were collected at study entry to determine Trop-2 expression level using a validated immunohistochemistry assay and histochemical scoring. Germline BRCA1/2 mutation status was collected at baseline. Of 468 assessable patients, 290 had Trop-2 expression data [64% (n = 151 SG) versus 60% (n = 139 TPC)] and 292 had known BRCA1/2 mutation status [63% (n = 149 SG) versus 61% (n = 143 TPC)]. Median progression-free survival in SG- versus TPC-treated patients was 6.9, 5.6, and 2.7 months versus 2.5, 2.2, and 1.6 months for high, medium, and low Trop-2 expression, respectively. Median overall survival (14.2, 14.9, and 9.3 months versus 6.9, 6.9, and 7.6 months) and objective response rates (44%, 38%, and 22% versus 1%, 11%, and 6%) were numerically higher with SG versus TPC in patients with high, medium, and low Trop-2 expression, respectively. Efficacy outcomes were numerically higher with SG versus TPC in patients with and without germline BRCA1/2 mutations. SG benefits patients with previously treated mTNBC expressing high/medium Trop-2 compared with standard-of-care chemotherapy and regardless of germline BRCA1/2 mutation status. The small number of patients with low Trop-2 expression precludes definitive conclusions on the benefit of SG in this subgroup.","Massachusetts General Hospital, Harvard Medical School, Boston, USA.;Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Columbia University Irving Medical Center, New York, USA; Winship Cancer Institute, Emory University, Atlanta, USA.;Northside Hospital, Atlanta, USA.;Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.;Institut Claudius Regaud, Toulouse, France.;The Ohio State University Wexner Medical Center, Columbus, USA.;Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.;University of Kansas Medical Center, Westwood, USA.;Institut Catala d'Oncologia Hospitalet, Barcelona, Spain.;Hospital Universitario 12 de Octubre, Madrid, Spain.;Memorial Sloan Kettering Cancer Center, New York, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.;International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Spain.;VPCI Oncology Research, Minneapolis, USA.;MSK-Norwalk Hospital Partnership, Norwalk, USA.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA.;University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;Immunomedics, Inc., Morris Plains, USA; Center for Molecular Medicine and Immunology, Mendham, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2021,"2021","32","10.1016/j.annonc.2021.06.002","1148-1156","","","34116144","34116144","PUBMED","Massachusetts General Hospital, Harvard Medical School, Boston, USA.;Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.;Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.;Medical Oncology Department and D3i, Institut Curie, Paris, France.;Hospital Universitari Vall d'Hebron, Barcelona, Spain.;Columbia University Irving Medical Center, New York, USA; Winship Cancer Institute, Emory University, Atlanta, USA.;Northside Hospital, Atlanta, USA.;Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.;Institut Claudius Regaud, Toulouse, France.;The Ohio State University Wexner Medical Center, Columbus, USA.;Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.;University of Kansas Medical Center, Westwood, USA.;Institut Catala d'Oncologia Hospitalet, Barcelona, Spain.;Hospital Universitario 12 de Octubre, Madrid, Spain.;Memorial Sloan Kettering Cancer Center, New York, USA.;Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.;International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, Spain.;VPCI Oncology Research, Minneapolis, USA.;MSK-Norwalk Hospital Partnership, Norwalk, USA.;Centre Eugène Marquis, Rennes, France.;University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, USA.;University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;Immunomedics, Inc., Morris Plains, USA; Center for Molecular Medicine and Immunology, Mendham, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Immunomedics, Inc., Morris Plains, USA; Department of Clinical Development, Gilead Sciences, Inc., Morris Plains, USA.;Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles"
"360","Bettuzzi T;Jourdes A;Robineau O;Alcaraz I;Manda V;Molina JM;Mehlen M;Cazanave C;Tattevin P;Mensi S;Terrier B;Régent A;Ghosn J;Charlier C;Martin-Blondel G;Dupin N","Bettuzzi, Thomas;Jourdes, Aurélie;Robineau, Olivier;Alcaraz, Isabelle;Manda, Victoria;Molina, Jean Michel;Mehlen, Maxime;Cazanave, Charles;Tattevin, Pierre;Mensi, Sami;Terrier, Benjamin;Régent, Alexis;Ghosn, Jade;Charlier, Caroline;Martin-Blondel, Guillaume;Dupin, Nicolas","Ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study.","The Lancet. Infectious diseases","United States","eng","Journal Article","","Adult;Anti-Bacterial Agents;Ceftriaxone;Female;France;Humans;Male;Middle Aged;Neurosyphilis;Penicillin G;Retrospective Studies;Treatment Outcome","Adult;Anti-Bacterial Agents;Ceftriaxone;Female;France;Humans;Male;Middle Aged;Neurosyphilis;Penicillin G;Retrospective Studies;Treatment Outcome","Intravenous benzylpenicillin is the gold-standard treatment for neurosyphilis, but it requires prolonged hospitalisation. Ceftriaxone is a possible alternative treatment, the effectiveness of which remains unclear. We aimed to assess the effectiveness of ceftriaxone compared with benzylpenicillin in the treatment of neurosyphilis. We did a retrospective multicentre study including patients with neurosyphilis who were treated at one of eight tertiary care centres in France, from Jan 1, 1997, to Dec 31, 2017. We defined neurosyphilis as positive treponemal and non-treponemal tests and at least one of otic syphilis, ocular syphilis, either neurological symptom with a positive result on cerebrospinal fluid (CSF)-VDRL or CSF-PCR tests, or more than five leukocytes in a CSF cell count. Patients with neurosyphilis were identified from the medical information department database of each centre and assigned to one of two groups on the basis of the initial treatment received (ie, benzylpenicillin group or ceftriaxone group). The primary outcome was the overall clinical response (ie, proportion of patients with a complete or partial response) 1 month after treatment initiation. The secondary endpoints were proportions of patients with a complete response at 1 month and serological response at 6 months, and length of hospital stay. Of 365 patients with a coded diagnosis of neurosyphilis in one of the eight care centres during 1997-2017, 208 were included in this study (42 in the ceftriaxone group and 166 in the benzylpenicillin group). The mean age of patients was 44·4 years (SD 13·4), and 193 (93%) were men. We observed 41 instances of overall clinical response (98%) in the ceftriaxone group versus 125 (76%) in the benzylpenicillin group (crude odds ratio [OR] 13·02 [95% CI 1·73-97·66], p=0·017). After propensity score weighting, overall clinical response rates remained different between the groups (OR 1·22 [95% CI 1·12-1·33], p<0·0001). 22 (52%) patients in the ceftriaxone group and 55 (33%) in the benzylpenicillin group had a complete response (crude OR 2·26 [95% CI 1·12-4·41], p=0·031), with no significant difference after propensity score weighting (OR 1·08 [95% CI 0·94-1·24], p=0·269). Serological response at 6 months did not differ between the groups (21 [88%] of 24 in the ceftriaxone group vs 76 [82%] of 93 in the benzylpenicillin group; crude OR 1·56 [95% CI 0·42-5·86], p=0·50), whereas hospital stay was shorter for patients in the ceftriaxone group than for those in the benzylpenicillin group (mean 13·8 days [95% CI 12·8-14·8] vs 8·9 days [5·7-12·0], p<0·0001). No major adverse effects were reported in either group. Our results suggest that ceftriaxone is similarly effective to benzylpenicillin for the treatment of neurosyphilis, potentially decreasing the length of hospital stay. Randomised, controlled trials should be done to confirm these results. None.","Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; EpiDermE, University Paris Est Créteil, Créteil, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Maladies Infectieuses, Hôpital Bichat, AP-HP, Paris, France.;Université de Paris, Paris, France; Service de Maladies Infectieuses, Hôpital Necker, AP-HP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; INSERM UMR 1291 - CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases, Université Toulouse III, Toulouse, France.;Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Centre National de Référence de la Syphilis, Institut Cochin, Unité Inserm U1016, Université de Paris, Paris","NA",0,"1474-4457","Lancet Infect Dis","Lancet Infect Dis",2020,"2021","21","10.1016/S1473-3099(20)30857-4","1441-1447","","","34051142","34051142","PUBMED","Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; EpiDermE, University Paris Est Créteil, Créteil, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Service Universitaire des Maladies Infectieuses et du Voyageur, Hôpital Dron, Tourcoing, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Département des Maladies Infectieuses, Hôpital Saint Louis et Lariboisière, AP-HP, Paris, France; Université de Paris, Paris, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Hôpital Pellegrin, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.;Service de Maladies Infectieuses, Hôpital Bichat, AP-HP, Paris, France.;Université de Paris, Paris, France; Service de Maladies Infectieuses, Hôpital Necker, AP-HP, Paris, France.;Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; INSERM UMR 1291 - CNRS UMR 5051, Toulouse Institute for Infectious and Inflammatory Diseases, Université Toulouse III, Toulouse, France.;Service de Dermatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; Centre National de Référence de la Syphilis, Institut Cochin, Unité Inserm U1016, Université de Paris, Paris"
"361","Andrade E;Quinlan L;Harte R;Byrne D;Fallon E;Kelly M;Casey S;Kirrane F;O'Connor P;O'Hora D;Scully M;Laffey J;Pladys P;Beuchée A;ÓLaighin G","Andrade, Evismar;Quinlan, Leo;Harte, Richard;Byrne, Dara;Fallon, Enda;Kelly, Martina;Casey, Siobhan;Kirrane, Frank;O'Connor, Paul;O'Hora, Denis;Scully, Michael;Laffey, John;Pladys, Patrick;Beuchée, Alain;ÓLaighin, Gearoid","Augmenting Critical Care Patient Monitoring Using Wearable Technology: Review of Usability and Human Factors.","JMIR human factors","Canada","eng","Journal Article","critical care;ergonomics;human factors;mobile phone;patient monitor;physiologic monitor;usability;user experience;wearable","","","Continuous monitoring of the vital signs of critical care patients is an essential component of critical care medicine. For this task, clinicians use a patient monitor (PM), which conveys patient vital sign data through a screen and an auditory alarm system. Some limitations with PMs have been identified in the literature, such as the need for visual contact with the PM screen, which could result in reduced focus on the patient in specific scenarios, and the amount of noise generated by the PM alarm system. With the advancement of material science and electronic technology, wearable devices have emerged as a potential solution for these problems. This review presents the findings of several studies that focused on the usability and human factors of wearable devices designed for use in critical care patient monitoring. The aim of this study is to review the current state of the art in wearable devices intended for use by clinicians to monitor vital signs of critical care patients in hospital settings, with a focus on the usability and human factors of the devices. A comprehensive literature search of relevant databases was conducted, and 20 studies were identified and critically reviewed by the authors. We identified 3 types of wearable devices: tactile, head-mounted, and smartwatch displays. In most cases, these devices were intended for use by anesthesiologists, but nurses and surgeons were also identified as potentially important users of wearable technology in critical care medicine. Although the studies investigating tactile displays revealed their potential to improve clinical monitoring, usability problems related to comfort need to be overcome before they can be considered suitable for use in clinical practice. Only a few studies investigated the usability and human factors of tactile displays by conducting user testing involving critical care professionals. The studies of head-mounted displays (HMDs) revealed that these devices could be useful in critical care medicine, particularly from an ergonomics point of view. By reducing the amount of time the user spends averting their gaze from the patient to a separate screen, HMDs enable clinicians to improve their patient focus and reduce the potential of repetitive strain injury. Researchers and designers of new wearable devices for use in critical care medicine should strive to achieve not only enhanced performance but also enhanced user experience for their users, especially in terms of comfort and ease of use. These aspects of wearable displays must be extensively tested with the intended end users in a setting that properly reflects the intended context of use before their adoption can be considered in clinical settings.","Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Physiology, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;General Practice, School of Medicine, NUI Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, NUI Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, NUI Galway, Galway, Ireland.;Intensive Care Unit, University Hospital Galway, Galway, Ireland.;Medical Physics and Clinical Engineering, University Hospital Galway, Galway, Ireland.;General Practice, School of Medicine, NUI Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;School of Psychology, NUI Galway, Galway, Ireland.;Anaesthesia, School of Medicine, NUI Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, Galway, Ireland.;Anaesthesia, School of Medicine, NUI Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, Galway, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.","NA",0,"2292-9495","JMIR Hum Factors","JMIR Hum Factors",2019,"2021","8","10.2196/16491","e16491","","","34032574","34032574","PUBMED","Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Physiology, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;General Practice, School of Medicine, NUI Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, NUI Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, NUI Galway, Galway, Ireland.;Intensive Care Unit, University Hospital Galway, Galway, Ireland.;Medical Physics and Clinical Engineering, University Hospital Galway, Galway, Ireland.;General Practice, School of Medicine, NUI Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation (ICAPSS), University Hospital Galway, Galway, Ireland.;School of Psychology, NUI Galway, Galway, Ireland.;Anaesthesia, School of Medicine, NUI Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, Galway, Ireland.;Anaesthesia, School of Medicine, NUI Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, Galway, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland."
"362","Nasser M;Larrieu S;Boussel L;Si-Mohamed S;Bazin F;Marque S;Massol J;Thivolet-Bejui F;Chalabreysse L;Maucort-Boulch D;Hachulla E;Jouneau S;Le Lay K;Cottin V","Nasser, Mouhamad;Larrieu, Sophie;Boussel, Loic;Si-Mohamed, Salim;Bazin, Fabienne;Marque, Sébastien;Massol, Jacques;Thivolet-Bejui, Françoise;Chalabreysse, Lara;Maucort-Boulch, Delphine;Hachulla, Eric;Jouneau, Stéphane;Le Lay, Katell;Cottin, Vincent","Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).","Respiratory research","England","eng","Journal Article","Algorithms;Epidemiology;Healthcare resource utilisation;Interstitial lung disease;Progressive fibrosis","Administrative Claims, Healthcare;Aged;Aged, 80 and over;Cause of Death;Cost of Illness;Databases, Factual;Disease Progression;Female;France;Hospital Costs;Humans;Incidence;Longitudinal Studies;Lung Diseases, Interstitial;Male;Middle Aged;Prevalence;Prognosis;Pulmonary Fibrosis;Retrospective Studies;Time Factors","Administrative Claims, Healthcare;Aged;Aged, 80 and over;Cause of Death;Cost of Illness;Databases, Factual;Disease Progression;Female;France;Hospital Costs;Humans;Incidence;Longitudinal Studies;Lung Diseases, Interstitial;Male;Middle Aged;Prevalence;Prognosis;Pulmonary Fibrosis;Retrospective Studies;Time Factors","There is a paucity of data on the epidemiology, survival estimates and healthcare resource utilisation and associated costs of patients with progressive fibrosing interstitial lung disease (PF-ILD) in France. An algorithm for extracting claims data was developed to indirectly identify and describe patients with PF-ILD in the French national administrative healthcare database. The French healthcare database, the Système National des Données de Santé (SNDS), includes data related to ambulatory care, hospitalisations and death for 98.8% of the population. In this study, algorithms based on age, diagnosis and healthcare consumption were created to identify adult patients with PF-ILD other than idiopathic pulmonary fibrosis between 2010 and 2017. Incidence, prevalence, survival estimates, clinical features and healthcare resource usage and costs were described among patients with PF-ILD. We identified a total of 14,413 patients with PF-ILD. Almost half of them (48.1%) were female and the mean (± standard deviation) age was 68.4 (± 15.0) years. Between 2010 and 2017, the estimated incidence of PF-ILD ranged from 4.0 to 4.7/100,000 person-years and the estimated prevalence from 6.6 to 19.4/100,000 persons. The main diagnostic categories represented were exposure-related ILD other than hypersensitivity pneumonitis (n = 3486; 24.2%), idiopathic interstitial pneumonia (n = 3113; 21.6%) and rheumatoid arthritis-associated ILD (n = 2521; 17.5%). Median overall survival using Kaplan-Meier estimation was 3.7 years from the start of progression. During the study, 95.2% of patients had ≥ 1 hospitalisation for respiratory care and 34.3% were hospitalised in an intensive care unit. The median (interquartile range) total specific cost per patient during the follow-up period was €25,613 (10,622-54,287) and the median annual cost per patient was €18,362 (6856-52,026), of which €11,784 (3003-42,097) was related to hospitalisations. Limitations included the retrospective design and identification of cases through an algorithm in the absence of chest high-resolution computed tomography scans and pulmonary function tests. This large, real-world, longitudinal study provides important insights into the characteristics, epidemiology and healthcare resource utilisation and costs associated with PF-ILD in France using a comprehensive and exhaustive database, and provides vital evidence that PF-ILD represents a high burden on both patients and healthcare services. Trial registration ClinicalTrials.gov, NCT03858842. ISRCTN, ISRCTN12345678. Registered 3 January 2019-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03858842.","Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex, France.;UMR754, INRAE, Université Claude Bernard Lyon 1, Lyon, France.;IQVIA, RWS - La Défense, Paris, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;CNRS, Inserm, CREATIS UMR 5220, Université de Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, Lyon, France.;IQVIA, RWS - La Défense, Paris, France.;IQVIA, RWS - La Défense, Paris, France.;AIXIAL, Boulogne-Billancourt, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, 69000, Lyon, France.;Université de Lyon 1, 69100, Villeurbanne, France.;Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Pôle Santé Publique, 69003, Lyon, France.;CNRS, UMR 5558, Équipe Biostatistique-Santé, Laboratoire de Biométrie et Biologie Évolutive, 69100, Villeurbanne, France.;Service de Médecine Interne et Immunologie Clinique, Hôpital Claude Huriez, Centre National de Référence des maladies auto‑immunes systémiques rare du Nord et Nord‑Ouest de France (CeRAINO), CHU de Lille, Lille, France.;Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex, France.;Centre Hospitalier Universitaire de Rennes, Centre de Compétences pour les Maladies Pulmonaires Rares, Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et travail), RespiFil, OrphaLung, Univ Rennes, Rennes, France.;Boehringer Ingelheim France SAS, Paris, France.;Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex;UMR754, INRAE, Université Claude Bernard Lyon 1, Lyon","NA",0,"1465-993X","Respir Res","Respir Res",2021,"2021","22","10.1186/s12931-021-01749-1","162","","","34030695","34030695","PUBMED","Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex, France.;UMR754, INRAE, Université Claude Bernard Lyon 1, Lyon, France.;IQVIA, RWS - La Défense, Paris, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;Département de Radiologie, Hospices Civils de Lyon, Lyon, France.;CNRS, Inserm, CREATIS UMR 5220, Université de Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, Lyon, France.;IQVIA, RWS - La Défense, Paris, France.;IQVIA, RWS - La Défense, Paris, France.;AIXIAL, Boulogne-Billancourt, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Département d'anatomo-pathologie, Hospices Civils de Lyon, Lyon, France.;Université de Lyon, 69000, Lyon, France.;Université de Lyon 1, 69100, Villeurbanne, France.;Service de Biostatistique et Bioinformatique, Hospices Civils de Lyon, Pôle Santé Publique, 69003, Lyon, France.;CNRS, UMR 5558, Équipe Biostatistique-Santé, Laboratoire de Biométrie et Biologie Évolutive, 69100, Villeurbanne, France.;Service de Médecine Interne et Immunologie Clinique, Hôpital Claude Huriez, Centre National de Référence des maladies auto‑immunes systémiques rare du Nord et Nord‑Ouest de France (CeRAINO), CHU de Lille, Lille, France.;Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex, France.;Centre Hospitalier Universitaire de Rennes, Centre de Compétences pour les Maladies Pulmonaires Rares, Inserm, EHESP, IRSET (Institut de recherche en santé, environnement et travail), RespiFil, OrphaLung, Univ Rennes, Rennes, France.;Boehringer Ingelheim France SAS, Paris, France.;Hôpital Louis Pradel, Centre National de Référence des Maladies Pulmonaires Rares, Hospices Civils de Lyon, Lyon, OrphaLung, RespiFil, ERN-LUNG, Claude Bernard University Lyon 1, 28 Avenue du Doyen Lepine, 69677, Lyon Cedex;UMR754, INRAE, Université Claude Bernard Lyon 1, Lyon"
"363","Bucci EM;Berkhof J;Gillibert A;Gopalakrishna G;Calogero RA;Bouter LM;Andreev K;Naudet F;Vlassov V","Bucci, Enrico M;Berkhof, Johannes;Gillibert, André;Gopalakrishna, Gowri;Calogero, Raffaele A;Bouter, Lex M;Andreev, Konstantin;Naudet, Florian;Vlassov, Vasiliy","Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial.","Lancet (London, England)","England","eng","Letter","","Humans;Research Report","Humans;Research Report","NA","Sbarro Institute, Temple University Department of Biology, Philadelphia, 19122 PA;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.;Department of Biostatistics, CHU Rouen, Rouen, France.;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Philosophy, Faculty of Humanities, Vrije Universiteit Amsterdam.;Department of Molecular Biosciences, Howard Hughes Medical Institute, Northwestern University, Evanston, IL, USA.;Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Higher School of Economics University, Moscow, Russia.","NA",0,"1474-547X","Lancet","Lancet",2021,"2021","397","10.1016/S0140-6736(21)00899-0","1881-1883","","","33991475","33991475","PUBMED","Sbarro Institute, Temple University Department of Biology, Philadelphia, 19122 PA;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.;Department of Biostatistics, CHU Rouen, Rouen, France.;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands.;Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.;Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, Netherlands; Department of Philosophy, Faculty of Humanities, Vrije Universiteit Amsterdam.;Department of Molecular Biosciences, Howard Hughes Medical Institute, Northwestern University, Evanston, IL, USA.;Centre Hospitalier Universitaire de Rennes, Université de Rennes, Rennes, France.;Higher School of Economics University, Moscow, Russia."
"364","Blay JY;Boucher S;Le Vu B;Cropet C;Chabaud S;Perol D;Barranger E;Campone M;Conroy T;Coutant C;De Crevoisier R;Debreuve-Theresette A;Delord JP;Fumoleau P;Gentil J;Gomez F;Guerin O;Jaffré A;Lartigau E;Lemoine C;Mahe MA;Mahon FX;Mathieu-Daude H;Merrouche Y;Penault-Llorca F;Pivot X;Soria JC;Thomas G;Vera P;Vermeulin T;Viens P;Ychou M;Beaupere S","Blay, J Y;Boucher, S;Le Vu, B;Cropet, C;Chabaud, S;Perol, D;Barranger, E;Campone, M;Conroy, T;Coutant, C;De Crevoisier, R;Debreuve-Theresette, A;Delord, J P;Fumoleau, P;Gentil, J;Gomez, F;Guerin, O;Jaffré, A;Lartigau, E;Lemoine, C;Mahe, M A;Mahon, F X;Mathieu-Daude, H;Merrouche, Y;Penault-Llorca, F;Pivot, X;Soria, J C;Thomas, G;Vera, P;Vermeulin, T;Viens, P;Ychou, M;Beaupere, S","Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.","ESMO open","England","eng","Journal Article","COVID-19;cancer;delay;diagnosis;treatment","COVID-19;Female;France;Humans;Male;Neoplasms;SARS-CoV-2","COVID-19;Female;France;Humans;Male;Neoplasms;SARS-CoV-2","The impact of the first coronavirus disease 2019 (COVID-19) wave on cancer patient management was measured within the nationwide network of the Unicancer comprehensive cancer centers in France. The number of patients diagnosed and treated within 17 of the 18 Unicancer centers was collected in 2020 and compared with that during the same periods between 2016 and 2019. Unicancer centers treat close to 20% of cancer patients in France yearly. The reduction in the number of patients attending the Unicancer centers was analyzed per regions and cancer types. The impact of delayed care on cancer-related deaths was calculated based on different hypotheses. A 6.8% decrease in patients managed within Unicancer in the first 7 months of 2020 versus 2019 was observed. This reduction reached 21% during April and May, and was not compensated in June and July, nor later until November 2020. This reduction was observed only for newly diagnosed patients, while the clinical activity for previously diagnosed patients increased by 4% similar to previous years. The reduction was more pronounced in women, in breast and prostate cancers, and for patients without metastasis. Using an estimated hazard ratio of 1.06 per month of delay in diagnosis and treatment of new patients, we calculated that the delays observed in the 5-month period from March to July 2020 may result in an excess mortality due to cancer of 1000-6000 patients in coming years. In this study, the delays in cancer patient management were observed only for newly diagnosed patients, more frequently in women, for breast cancer, prostate cancer, and nonmetastatic cancers. These delays may result is an excess risk of cancer-related deaths in the coming years.","Centre Leon Berard, Lyon;Unicancer, Paris, France.;Unicancer, Paris, France.;Centre Leon Berard, Lyon, France.;Centre Leon Berard, Lyon, France.;Centre Leon Berard, Lyon, France.;Centre Antoine Lacassagne, Nice, France.;Institut de Cancerologie de l'Ouest, Nantes et Angers, France.;Institut de Cancerologie de Lorraine, Nancy, France.;Centre George Francoise Leclerc, Dijon, France.;Centre Eugene Marquis, Rennes, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Institut Curie, Paris, France.;Centre George Francoise Leclerc, Dijon, France.;Centre Leon Berard, Lyon, France.;Institut de Cancerologie de l'Ouest, Nantes et Angers, France.;Institut Bergonié, Bordeaux.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre François Baclesse, Caen, France.;Institut Bergonié, Bordeaux.;Institut de Cancerologie de Montpellier, Montpellier, France.;Institut Jean Godinot, Reims, France.;Centre Jean Perrin, Clermont Ferrand, France.;Centre Paul Strauss/ICANS, Strasbourg, France.;Gustave Roussy, Villejuif, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Centre Henri Becquerel, Rouen, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancerologie de Montpellier, Montpellier, France.;Unicancer, Paris, France.","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2021","6","10.1016/j.esmoop.2021.100134","100134","","","33984676","33984676","PUBMED","Centre Leon Berard, Lyon;Unicancer, Paris, France.;Unicancer, Paris, France.;Centre Leon Berard, Lyon, France.;Centre Leon Berard, Lyon, France.;Centre Leon Berard, Lyon, France.;Centre Antoine Lacassagne, Nice, France.;Institut de Cancerologie de l'Ouest, Nantes et Angers, France.;Institut de Cancerologie de Lorraine, Nancy, France.;Centre George Francoise Leclerc, Dijon, France.;Centre Eugene Marquis, Rennes, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Institut Curie, Paris, France.;Centre George Francoise Leclerc, Dijon, France.;Centre Leon Berard, Lyon, France.;Institut de Cancerologie de l'Ouest, Nantes et Angers, France.;Institut Bergonié, Bordeaux.;Centre Oscar Lambret, Lille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre François Baclesse, Caen, France.;Institut Bergonié, Bordeaux.;Institut de Cancerologie de Montpellier, Montpellier, France.;Institut Jean Godinot, Reims, France.;Centre Jean Perrin, Clermont Ferrand, France.;Centre Paul Strauss/ICANS, Strasbourg, France.;Gustave Roussy, Villejuif, France.;Centre François Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Centre Henri Becquerel, Rouen, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancerologie de Montpellier, Montpellier, France.;Unicancer, Paris, France."
"365","Carausu M;Carton M;Darlix A;Pasquier D;Leheurteur M;Debled M;Mouret-Reynier MA;Goncalves A;Dalenc F;Verret B;Campone M;Augereau P;Ferrero JM;Levy C;Fumet JD;Lefeuvre-Plesse C;Petit T;Uwer L;Jouannaud C;Larrouquere L;Chevrot M;Courtinard C;Cabel L","Carausu, M;Carton, M;Darlix, A;Pasquier, D;Leheurteur, M;Debled, M;Mouret-Reynier, M A;Goncalves, A;Dalenc, F;Verret, B;Campone, M;Augereau, P;Ferrero, J M;Levy, C;Fumet, J-D;Lefeuvre-Plesse, C;Petit, T;Uwer, L;Jouannaud, C;Larrouquere, L;Chevrot, M;Courtinard, C;Cabel, L","Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.","ESMO open","England","eng","Journal Article","breast cancer;cohort study;intrathecal therapy;leptomeningeal metastasis","Breast;Breast Neoplasms;Female;Humans;Meningeal Carcinomatosis;Middle Aged;Neoplasm Recurrence, Local;Prognosis","Breast;Breast Neoplasms;Female;Humans;Meningeal Carcinomatosis;Middle Aged;Neoplasm Recurrence, Local;Prognosis","Leptomeningeal metastasis (LM) is a rare complication of metastatic breast cancer (MBC), with high morbidity/mortality rates. Our study aimed to describe the largest-to-date real-life population of MBC patients treated with intrathecal (IT) therapy and to evaluate prognostic models. The Epidemiological Strategy and Medical Economics (ESME) MBC database (NCT03275311) includes all consecutive patients who have initiated treatment for MBC since 2008. Overall survival (OS) of patients treated with IT therapy was estimated using the Kaplan-Meier method. Prognostic models were constructed using Cox proportional hazards models. Performance was evaluated using C-index and calibration plots. Of the 22 266 patients included in the database between 2008 and 2016, 312 received IT therapy and were selected for our analysis. Compared with non-IT-treated patients, IT-treated patients were younger at MBC relapse (median age: 52 years versus 61 years) and more often had lobular histology (23.4% versus 12.7%) or triple-negative subtype (24.7% versus 13.3%) (all P < 0.001). Median OS was 4.5 months [95% confidence interval (CI) 3.8-5.6] and 1-year survival rate was 25.6%. Significant prognostic factors associated with poorer outcome on multivariable analysis were triple-negative subtype (hazard ratio 1.81, 95% CI 1.32-2.47), treatment line ≥3 (hazard ratio 1.88, 95% CI 1.30-2.73), ≥3 other metastatic sites (hazard ratio 1.33, 95% CI 1.01-1.74) and IT cytarabine or thiotepa versus methotrexate (hazard ratio 1.68, 95% CI 1.28-2.22), while concomitant systemic therapy was associated with better OS (hazard ratio 0.47, 95% CI 0.35-0.62) (all P < 0.001). We validated two previously published prognostic scores, the Curie score and the Breast-graded prognostic assessment, both with C-index of 0.57. MBC patients with LM treated with IT therapy have a poor prognosis. We could identify a subgroup of patients with better prognosis, when concomitant systemic therapy and IT methotrexate were used.","Department of Medical Oncology, Institut Curie, Saint-Cloud and Paris, France.;Department of Biostatistics, Institut Curie, Saint Cloud, France.;Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.;Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Medical Oncology Department, Centre Eugéne Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Data Office, Unicancer, Paris, France.;Data Office, Unicancer, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud and Paris","NA",0,"2059-7029","ESMO Open","ESMO Open",2021,"2021","6","10.1016/j.esmoop.2021.100150","100150","","","33984675","33984675","PUBMED","Department of Medical Oncology, Institut Curie, Saint-Cloud and Paris, France.;Department of Biostatistics, Institut Curie, Saint Cloud, France.;Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM), University of Montpellier, Montpellier, France.;Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Medical Oncology Department, Centre Eugéne Marquis, Rennes, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Data Office, Unicancer, Paris, France.;Data Office, Unicancer, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud and Paris"
"366","Reignier J;Le Gouge A;Lascarrou JB;Annane D;Argaud L;Hourmant Y;Asfar P;Badie J;Nay MA;Botoc NV;Brisard L;Bui HN;Chatellier D;Chauvelot L;Combes A;Cracco C;Darmon M;Das V;Debarre M;Delbove A;Devaquet J;Voicu S;Aissaoui-Balanant N;Dumont LM;Oziel J;Gontier O;Groyer S;Guidet B;Jaber S;Lambiotte F;Leroy C;Letocart P;Madeux B;Maizel J;Martinet O;Martino F;Mercier E;Mira JP;Nseir S;Picard W;Piton G;Plantefeve G;Quenot JP;Renault A;Guérin L;Richecoeur J;Rigaud JP;Schneider F;Silva D;Sirodot M;Souweine B;Reizine F;Tamion F;Terzi N;Thévenin D;Thiéry G;Thieulot-Rolin N;Timsit JF;Tinturier F;Tirot P;Vanderlinden T;Vinatier I;Vinsonneau C;Maugars D;Giraudeau B","Reignier, Jean;Le Gouge, Amélie;Lascarrou, Jean-Baptiste;Annane, Djillali;Argaud, Laurent;Hourmant, Yannick;Asfar, Pierre;Badie, Julio;Nay, Mai-Anh;Botoc, Nicolae-Vlad;Brisard, Laurent;Bui, Hoang-Nam;Chatellier, Delphine;Chauvelot, Louis;Combes, Alain;Cracco, Christophe;Darmon, Michael;Das, Vincent;Debarre, Matthieu;Delbove, Agathe;Devaquet, Jérôme;Voicu, Sebastian;Aissaoui-Balanant, Nadia;Dumont, Louis-Marie;Oziel, Johanna;Gontier, Olivier;Groyer, Samuel;Guidet, Bertrand;Jaber, Samir;Lambiotte, Fabien;Leroy, Christophe;Letocart, Philippe;Madeux, Benjamin;Maizel, Julien;Martinet, Olivier;Martino, Frédéric;Mercier, Emmanuelle;Mira, Jean-Paul;Nseir, Saad;Picard, Walter;Piton, Gael;Plantefeve, Gaetan;Quenot, Jean-Pierre;Renault, Anne;Guérin, Laurent;Richecoeur, Jack;Rigaud, Jean Philippe;Schneider, Francis;Silva, Daniel;Sirodot, Michel;Souweine, Bertrand;Reizine, Florian;Tamion, Fabienne;Terzi, Nicolas;Thévenin, Didier;Thiéry, Guillaume;Thieulot-Rolin, Nathalie;Timsit, Jean-François;Tinturier, François;Tirot, Patrice;Vanderlinden, Thierry;Vinatier, Isabelle;Vinsonneau, Christophe;Maugars, Diane;Giraudeau, Bruno","Impact of early low-calorie low-protein versus standard-calorie standard-protein feeding on outcomes of ventilated adults with shock: design and conduct of a randomised, controlled, multicentre, open-label, parallel-group trial (NUTRIREA-3).","BMJ open","England","eng","Journal Article","adult intensive & critical care;clinical trials;nutrition & dietetics","Adult;COVID-19;Critical Illness;Diet, Protein-Restricted;Humans;Respiration, Artificial;SARS-CoV-2","Adult;COVID-19;Critical Illness;Diet, Protein-Restricted;Humans;Respiration, Artificial;SARS-CoV-2","International guidelines include early nutritional support (≤48 hour after admission), 20-25 kcal/kg/day, and 1.2-2 g/kg/day protein at the acute phase of critical illness. Recent data challenge the appropriateness of providing standard amounts of calories and protein during acute critical illness. Restricting calorie and protein intakes seemed beneficial, suggesting a role for metabolic pathways such as autophagy, a potential key mechanism in safeguarding cellular integrity, notably in the muscle, during critical illness. However, the optimal calorie and protein supply at the acute phase of severe critical illness remains unknown. NUTRIREA-3 will be the first trial to compare standard calorie and protein feeding complying with guidelines to low-calorie low-protein feeding. We hypothesised that nutritional support with calorie and protein restriction during acute critical illness decreased day 90 mortality and/or dependency on intensive care unit (ICU) management in mechanically ventilated patients receiving vasoactive amine therapy for shock, compared with standard calorie and protein targets. NUTRIREA-3 is a randomised, controlled, multicentre, open-label trial comparing two parallel groups of patients receiving invasive mechanical ventilation and vasoactive amine therapy for shock and given early nutritional support according to one of two strategies: early calorie-protein restriction (6 kcal/kg/day-0.2-0.4 g/kg/day) or standard calorie-protein targets (25 kcal/kg/day, 1.0-1.3 g/kg/day) at the acute phase defined as the first 7 days in the ICU. We will include 3044 patients in 61 French ICUs. Two primary end-points will be evaluated: day 90 mortality and time to ICU discharge readiness. The trial will be considered positive if significant between-group differences are found for one or both alternative primary endpoints. Secondary outcomes include hospital-acquired infections and nutritional, clinical and functional outcomes. The NUTRIREA-3 study has been approved by the appropriate ethics committee. Patients are included after informed consent. Results will be submitted for publication in peer-reviewed journals. NCT03573739.","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes;INSERM CIC 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Hôpital Raymond Poincaré, Garches, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Pôle Anesthésie Réanimations, Service d'Anesthésie Réanimation Chirurgicale, CHU Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Hôpital Nord Franche-Comté, Montbeliard, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service d'Anesthésie Réanimation Chirurgicale, CHU Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, CHU de Bordeaux, Bordeaux, France.;Service de Médecine Intensive Réanimation, CHU Poitiers, Poitiers, France.;Service de Médecine Intensive Réanimation, CHU Lyon, Lyon, France.;Service de Médecine Intensive Réanimation, Hôpital Universitaire Pitié Salpêtrière, Paris, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier d'Angouleme, Angouleme, France.;Service de Médecine Intensive Réanimation, Hôpital Saint-Louis, Paris, France.;Médecine Intensive Réanimation, CHI André Grégoire, Montreuil, France.;Médecine Intensive Réanimation, Centre Hospitalier de Saint Brieuc, Saint Brieuc, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Medical-Surgical Intensive Care Unit, Hôpital Foch, Suresnes, France.;Médecine Intensive Réanimation, Hopital Lariboisiere, Paris, France.;Médecine Intensive Réanimation, Hôpital Europeen Georges-Pompidou - Broussais, Paris, France.;Service de Médecine Intensive Réanimation, Hôpital Louis-Mourier, Colombes, France.;Service de Médecine Intensive Réanimation, Hôpital Avicenne, Bobigny, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Chartres, Chartres, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Montauban, Montauban, France.;Service de Médecine Intensive Réanimation, Hôpital Saint-Antoine, Paris, France.;Service de Réanimation Chirurgicale, Hôpital Saint-Eloi, Montpellier, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Valenciennes, Valenciennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Rodez, Rodez, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Bigorre, Tarbes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de La Réunion, Saint-Denis, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Pointe-à-Pitre Abymes, Pointe-a-Pitre, Guadeloupe.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Hôpital Cochin, Paris, France.;Service de Médecine Intensive Réanimation, CHU Lille, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Pau, Pau, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier d'Argenteuil, Argenteuil, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service de Médecine Intensive Réanimation, CHRU de Brest, Brest, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicetre, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Beauvais, Beauvais, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Dieppe, Dieppe, France.;Service de Médecine Intensive Réanimation, Hopitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint Denis, Saint Denis, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon, La Tronche, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Lens, Lens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Melun, Melun, France.;Service de Médecine Intensive Réanimation, Hôpital Bichat - Claude-Bernard, Paris, France.;Réanimation Chirurgicale, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier du Mans, Le Mans, France.;Service de Médecine Intensive Réanimation, Institut Catholique de Lille, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Béthune, Bethune, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM CIC 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2021,"2021","11","10.1136/bmjopen-2020-045041","e045041","","","33980526","33980526","PUBMED","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes;INSERM CIC 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Hôpital Raymond Poincaré, Garches, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Lyon, Lyon, France.;Pôle Anesthésie Réanimations, Service d'Anesthésie Réanimation Chirurgicale, CHU Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Médecine Intensive Réanimation, Hôpital Nord Franche-Comté, Montbeliard, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint-Malo, Saint-Malo, France.;Service d'Anesthésie Réanimation Chirurgicale, CHU Nantes, Nantes, France.;Service de Médecine Intensive Réanimation, CHU de Bordeaux, Bordeaux, France.;Service de Médecine Intensive Réanimation, CHU Poitiers, Poitiers, France.;Service de Médecine Intensive Réanimation, CHU Lyon, Lyon, France.;Service de Médecine Intensive Réanimation, Hôpital Universitaire Pitié Salpêtrière, Paris, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier d'Angouleme, Angouleme, France.;Service de Médecine Intensive Réanimation, Hôpital Saint-Louis, Paris, France.;Médecine Intensive Réanimation, CHI André Grégoire, Montreuil, France.;Médecine Intensive Réanimation, Centre Hospitalier de Saint Brieuc, Saint Brieuc, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, France.;Medical-Surgical Intensive Care Unit, Hôpital Foch, Suresnes, France.;Médecine Intensive Réanimation, Hopital Lariboisiere, Paris, France.;Médecine Intensive Réanimation, Hôpital Europeen Georges-Pompidou - Broussais, Paris, France.;Service de Médecine Intensive Réanimation, Hôpital Louis-Mourier, Colombes, France.;Service de Médecine Intensive Réanimation, Hôpital Avicenne, Bobigny, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Chartres, Chartres, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Montauban, Montauban, France.;Service de Médecine Intensive Réanimation, Hôpital Saint-Antoine, Paris, France.;Service de Réanimation Chirurgicale, Hôpital Saint-Eloi, Montpellier, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Valenciennes, Valenciennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Rodez, Rodez, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Bigorre, Tarbes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de La Réunion, Saint-Denis, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Pointe-à-Pitre Abymes, Pointe-a-Pitre, Guadeloupe.;Service de Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Service de Médecine Intensive Réanimation, Hôpital Cochin, Paris, France.;Service de Médecine Intensive Réanimation, CHU Lille, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Pau, Pau, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Besancon, Besancon, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier d'Argenteuil, Argenteuil, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service de Médecine Intensive Réanimation, CHRU de Brest, Brest, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicetre, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Beauvais, Beauvais, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Dieppe, Dieppe, France.;Service de Médecine Intensive Réanimation, Hopitaux Universitaires de Strasbourg, Strasbourg, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Saint Denis, Saint Denis, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes Hopital Michallon, La Tronche, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Lens, Lens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Melun, Melun, France.;Service de Médecine Intensive Réanimation, Hôpital Bichat - Claude-Bernard, Paris, France.;Réanimation Chirurgicale, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier du Mans, Le Mans, France.;Service de Médecine Intensive Réanimation, Institut Catholique de Lille, Lille, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental Vendée, La Roche-sur-Yon, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier de Béthune, Bethune, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM CIC 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, France."
"367","Roussel M;Ferrant J;Reizine F;Le Gallou S;Dulong J;Carl S;Lesouhaitier M;Gregoire M;Bescher N;Verdy C;Latour M;Bézier I;Cornic M;Vinit A;Monvoisin C;Sawitzki B;Leonard S;Paul S;Feuillard J;Jeannet R;Daix T;Tiwari VK;Tadié JM;Cogné M;Tarte K","Roussel, Mikael;Ferrant, Juliette;Reizine, Florian;Le Gallou, Simon;Dulong, Joelle;Carl, Sarah;Lesouhaitier, Matheiu;Gregoire, Murielle;Bescher, Nadège;Verdy, Clotilde;Latour, Maelle;Bézier, Isabelle;Cornic, Marie;Vinit, Angélique;Monvoisin, Céline;Sawitzki, Birgit;Leonard, Simon;Paul, Stéphane;Feuillard, Jean;Jeannet, Robin;Daix, Thomas;Tiwari, Vijay K;Tadié, Jean Marc;Cogné, Michel;Tarte, Karin","Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection.","Cell reports. Medicine","United States","eng","Journal Article","","Aged;COVID-19;Cohort Studies;Evolution, Molecular;Female;HLA-DR Antigens;Humans;Intensive Care Units;Leukocytes, Mononuclear;Lipopolysaccharide Receptors;Machine Learning;Male;Middle Aged;Monocytes;Respiratory Distress Syndrome;SARS-CoV-2;Sialic Acid Binding Ig-like Lectin 1;Th1 Cells","Aged;COVID-19;Cohort Studies;Evolution, Molecular;Female;HLA-DR Antigens;Humans;Intensive Care Units;Leukocytes, Mononuclear;Lipopolysaccharide Receptors;Machine Learning;Male;Middle Aged;Monocytes;Respiratory Distress Syndrome;SARS-CoV-2;Sialic Acid Binding Ig-like Lectin 1;Th1 Cells","Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COVID-19), requiring admission to the intensive care unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, here, we build 3 cohorts of patients categorized in COVID-19 ARDS , COVID-19 ARDS , and COVID-19 ARDS , and compare, by high-dimensional mass cytometry, their immune landscape. A cell signature associating S100A9/calprotectin-producing CD169  monocytes, plasmablasts, and Th1 cells is found in COVID-19 ARDS , unlike COVID-19 ARDS  patients. Moreover, this signature is essentially shared with COVID-19 ARDS  patients, suggesting that severe COVID-19 patients, whether or not they experience ARDS, display similar immune profiles. We show an increase in CD14 HLA-DR  and CD14 CD16  monocytes correlating to the occurrence of adverse events during the ICU stay. We demonstrate that COVID-19-associated ARDS displays a specific immune profile and may benefit from personalized therapy in addition to standard ARDS management.","Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Scailyte AG, 6210, Sursee, Switzerland.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Sorbonne Université, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, 75013 Paris, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Charité-Universitätsmedizin Berlin, Institut für Medizinische Immunologie, AG Molekulare Immunmodulation, 13353 Berlin, Germany.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Saint-Etienne, Laboratoire Immunologie, 42000 Saint-Etienne, France.;Centre Hospitalier Universitaire de Limoges, Laboratoire Hématologie, 87000 Limoges, France.;Centre Hospitalier Universitaire de Limoges, Laboratoire Hématologie, 87000 Limoges, France.;Unité Mixte de Recherche CNRS 7276 INSERM 1262, 87000 Limoges, France.;Centre d'Investigation Clinique INSERM 1435, 87000 Limoges, France.;Centre d'Investigation Clinique INSERM 1435, 87000 Limoges, France.;Unité Mixte de Recherche INSERM 1092, 87000 Limoges, France.;Centre Hospitalier Universitaire de Limoges, Service de Réanimation Médicale, 87000 Limoges, France.;Scailyte AG, 6210, Sursee, Switzerland.;Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Science, Queens University Belfast, BT9 7BL Belfast, UK.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Immunologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.","NA",0,"2666-3791","Cell Rep Med","Cell Rep Med",2020,"2021","2","10.1016/j.xcrm.2021.100291","100291","","","33977279","33977279","PUBMED","Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Scailyte AG, 6210, Sursee, Switzerland.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Sorbonne Université, UMS037, PASS, Plateforme de Cytométrie de la Pitié-Salpêtrière CyPS, 75013 Paris, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Charité-Universitätsmedizin Berlin, Institut für Medizinische Immunologie, AG Molekulare Immunmodulation, 13353 Berlin, Germany.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Saint-Etienne, Laboratoire Immunologie, 42000 Saint-Etienne, France.;Centre Hospitalier Universitaire de Limoges, Laboratoire Hématologie, 87000 Limoges, France.;Centre Hospitalier Universitaire de Limoges, Laboratoire Hématologie, 87000 Limoges, France.;Unité Mixte de Recherche CNRS 7276 INSERM 1262, 87000 Limoges, France.;Centre d'Investigation Clinique INSERM 1435, 87000 Limoges, France.;Centre d'Investigation Clinique INSERM 1435, 87000 Limoges, France.;Unité Mixte de Recherche INSERM 1092, 87000 Limoges, France.;Centre Hospitalier Universitaire de Limoges, Service de Réanimation Médicale, 87000 Limoges, France.;Scailyte AG, 6210, Sursee, Switzerland.;Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Science, Queens University Belfast, BT9 7BL Belfast, UK.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Immunologie, Pôle Biologie, 35033 Rennes, France.;Centre Hospitalier Universitaire de Rennes, SITI, Pôle Biologie, 35033 Rennes, France.;Institut national de la santé et de la recherche médicale, Unité Mixte de Recherche U1236, LabEx IGO, Université Rennes 1, Etablissement Français du Sang Bretagne, 35000 Rennes, France."
"368","Hayden PJ;Eikema DJ;de Wreede LC;Koster L;Kröger N;Einsele H;Minnema M;Dominietto A;Potter M;Passweg J;Bermúdez A;Nguyen-Quoc S;Platzbecker U;Tischer J;Ciceri F;Veelken JH;Ljungman P;Schaap N;Forcade E;Carella AM;Gandemer V;Arcese W;Bloor A;Olivieri A;Vincent L;Beksac M;Schönland S;Yakoub-Agha I","Hayden, Patrick J;Eikema, Dirk-Jan;de Wreede, Liesbeth C;Koster, Linda;Kröger, Nicolaus;Einsele, Hermann;Minnema, Monique;Dominietto, Alida;Potter, Michael;Passweg, Jacob;Bermúdez, Arancha;Nguyen-Quoc, Stephanie;Platzbecker, Uwe;Tischer, Johanna;Ciceri, Fabio;Veelken, Joan Hendrik;Ljungman, Per;Schaap, Nicolaas;Forcade, Edouard;Carella, Angelo Michele;Gandemer, Virginie;Arcese, William;Bloor, Adrian;Olivieri, Attilio;Vincent, Laure;Beksac, Meral;Schönland, Stefan;Yakoub-Agha, Ibrahim","Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.","Bone marrow transplantation","England","eng","Journal Article","","Allografts;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Multiple Myeloma;Neoplasm Recurrence, Local;Retrospective Studies;Transplantation Conditioning","Allografts;Graft vs Host Disease;Hematopoietic Stem Cell Transplantation;Humans;Multiple Myeloma;Neoplasm Recurrence, Local;Retrospective Studies;Transplantation Conditioning","The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.","Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin;EBMT Statistical Unit, Leiden, The Netherlands.;Department of Biomedical Data Sciences, LUMC, Leiden, The Netherlands.;EBMT Data Office Leiden, Leiden, The Netherlands.;University Hospital Eppendorf, Hamburg, Germany.;Universitätsklinikum Würzburg, Würzburg, Germany.;University Medical Center Utrecht, Utrecht, The Netherlands.;IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Royal Marsden Hospital, London, UK.;University Hospital, Basel, Switzerland.;Hospital Universitario Marqués de Valdecilla, Santander, Spain.;Hopital la Pitié-Salpêtrière, Paris, France.;Medical Clinic and Policinic 1, Leipzig, Germany.;Klinikum Grosshadern, Munich, Germany.;Ospedale San Raffaele s.r.l., Milano, Italy.;Leiden University Hospital, Leiden, The Netherlands.;Karolinska University Hospital, Stockholm, Sweden.;Radboud University Medical Centre, Nijmegen, The Netherlands.;CHU Bordeaux, Pessac, France.;Casa Sollievo della Sofferenza, San Giovanni, Italy.;Centre Hospitalier Universitaire de Rennes Hôpital sud, Rennes, France.;Rome Transplant Network ¨Tor Vergata¨ University of Rome, Rome, Italy.;Christie NHS Trust Hospital, Manchester, UK.;Azienda Ospedali Riuniti di Ancona, Ancona, Italy.;CHU Lapeyronie, Montpellier, France.;Ankara University Faculty of Medicine, Ankara, Turkey.;Medical Department V, University Hospital Heidelberg, Heidelberg, Germany.;Univ. Lille, CHU Lille, INSERM, Infinite, U1286, Lille, France.","NA",0,"1476-5365","Bone Marrow Transplant","Bone Marrow Transplant",2020,"2021","56","10.1038/s41409-021-01286-x","2367-2381","","","33976382","33976382","PUBMED","Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin;EBMT Statistical Unit, Leiden, The Netherlands.;Department of Biomedical Data Sciences, LUMC, Leiden, The Netherlands.;EBMT Data Office Leiden, Leiden, The Netherlands.;University Hospital Eppendorf, Hamburg, Germany.;Universitätsklinikum Würzburg, Würzburg, Germany.;University Medical Center Utrecht, Utrecht, The Netherlands.;IRCCS Ospedale Policlinico San Martino, Genova, Italy.;Royal Marsden Hospital, London, UK.;University Hospital, Basel, Switzerland.;Hospital Universitario Marqués de Valdecilla, Santander, Spain.;Hopital la Pitié-Salpêtrière, Paris, France.;Medical Clinic and Policinic 1, Leipzig, Germany.;Klinikum Grosshadern, Munich, Germany.;Ospedale San Raffaele s.r.l., Milano, Italy.;Leiden University Hospital, Leiden, The Netherlands.;Karolinska University Hospital, Stockholm, Sweden.;Radboud University Medical Centre, Nijmegen, The Netherlands.;CHU Bordeaux, Pessac, France.;Casa Sollievo della Sofferenza, San Giovanni, Italy.;Centre Hospitalier Universitaire de Rennes Hôpital sud, Rennes, France.;Rome Transplant Network ¨Tor Vergata¨ University of Rome, Rome, Italy.;Christie NHS Trust Hospital, Manchester, UK.;Azienda Ospedali Riuniti di Ancona, Ancona, Italy.;CHU Lapeyronie, Montpellier, France.;Ankara University Faculty of Medicine, Ankara, Turkey.;Medical Department V, University Hospital Heidelberg, Heidelberg, Germany.;Univ. Lille, CHU Lille, INSERM, Infinite, U1286, Lille, France."
"369","Carril-Ajuria L;Colomba E;Cerbone L;Romero-Ferreiro C;Crouzet L;Laguerre B;Thibault C;Vicier C;de Velasco G;Fléchon A;Saldana C;Benusiglio PR;Bressac-de Paillerets B;Guillaud-Bataille M;Gaignard P;Scoazec JY;Richard S;Caron O;Escudier B;Albiges L","Carril-Ajuria, Lucia;Colomba, Emeline;Cerbone, Luigi;Romero-Ferreiro, Carmen;Crouzet, Laurence;Laguerre, Brigitte;Thibault, Constance;Vicier, Cécile;de Velasco, Guillermo;Fléchon, Aude;Saldana, Carolina;Benusiglio, Patrick R;Bressac-de Paillerets, Brigitte;Guillaud-Bataille, Marine;Gaignard, Pauline;Scoazec, Jean-Yves;Richard, Stéphane;Caron, Olivier;Escudier, Bernard;Albiges, Laurence","Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.","European journal of cancer (Oxford, England : 1990)","England","eng","Comparative Study","Antiangiogenics;FH-deficient RCC;Hereditary leiomyomatosis;Immunotherapy;Non–clear cell RCC","Adult;Angiogenesis Inhibitors;Biomarkers, Tumor;Disease Progression;Female;France;Fumarate Hydratase;Genetic Predisposition to Disease;Humans;Immune Checkpoint Inhibitors;Kidney Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Phenotype;Protein Kinase Inhibitors;Retrospective Studies;Spain;TOR Serine-Threonine Kinases;Time Factors;Treatment Failure;Young Adult","Adult;Angiogenesis Inhibitors;Biomarkers, Tumor;Disease Progression;Female;France;Fumarate Hydratase;Genetic Predisposition to Disease;Humans;Immune Checkpoint Inhibitors;Kidney Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Phenotype;Protein Kinase Inhibitors;Retrospective Studies;Spain;TOR Serine-Threonine Kinases;Time Factors;Treatment Failure;Young Adult","Fumarate hydratase-deficient (FHdef) renal cell carcinoma (RCC) is a rare entity associated with the hereditary leiomyomatosis and RCC syndrome with no standard therapy approved. The aim of this retrospective study was to evaluate the efficacy of different systemic treatments in this population. We performed a multicentre retrospective analysis of Fhdef RCC patients to determine the response to systemic treatments. The endpoints were objective response rate (ORR), time-to-treatment failure (TTF), and overall survival (OS). The two latter were estimated using the Kaplan-Meier method. Twenty-four Fhdef RCC patients were identified, and 21 under systemic therapy were included in the analysis: ten received cabozantinib, 14 received sunitinib, nine received ""other antiangiogenics"" (sorafenib, pazopanib, and axitinib), three received erlotinib-bevacizumab (E-B), three received mTOR inhibitors, and 11 received immune checkpoint blockers (ICBs). ORR for treatments were 50% for cabozantinib, 43% for sunitinib, 63% for ""other antiangiogenics,"" and 30% for E-B, whereas ORR was 0% for mTOR inhibitors and 18% for ICBs. The median TTF (mTTF) was significantly higher with antiangiogenics (11.6 months) than with mTOR inhibitors (4.4 months) or ICBs (2.7 months). In the first-line setting, antiangiogenics presented a higher ORR compared with nivolumab-ipilimumab (64% versus 25%) and a significantly superior mTTF (11.0 months vs 2.5 months; p = 0.0027). The median OS from the start of the first systemic treatment was 44.0 months (95% confidence interval: 13.0-95.0). We report the first European retrospective study of Fhdef RCC patients treated with systemic therapy with a remarkably long median OS of 44.0 months. Our results suggest that antiangiogenics may be superior to ICB/mTOR inhibitors in this population.","Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;CIBERESP, Instituto i+12, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France.;Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France; Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;Biochemistry Department, Hôpital Bicêtre, APHP Université Paris-Saclay, Le Kremlin Bicêtre F-94275, France.;Department of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.;Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France; Génétique Oncologique EPHE, PSL Research University, Paris, France; UMR9019 CNRS Genome Integrity and Cancers, Institute Gustave Roussy, Villejuif, France.;Laboratory Integrative Tumor Immunology and Genetic Oncology, Institute Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","151","10.1016/j.ejca.2021.04.009","106-114","","","33975058","33975058","PUBMED","Department of Medical Oncology, Gustave Roussy, Villejuif, France; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;CIBERESP, Instituto i+12, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Hôpital Européen Georges-Pompidou, Paris, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain.;Department of Medical Oncology, Centre Léon-Bérard, Lyon, France.;Department of Medical Oncology, Hôpital Henri Mondor Créteil AP-HP, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France.;Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;UF d'Oncogénétique, Département de Génétique et Institut Universitaire de Cancérologie, GH Pitié-Salpêtrière, AP-HP Sorbonne Université F-75013 Paris, France; Service de Génétique, Molecular Genetic Department, GRCC, 94805 Villejuif, France.;Biochemistry Department, Hôpital Bicêtre, APHP Université Paris-Saclay, Le Kremlin Bicêtre F-94275, France.;Department of Pathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France.;Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France; Génétique Oncologique EPHE, PSL Research University, Paris, France; UMR9019 CNRS Genome Integrity and Cancers, Institute Gustave Roussy, Villejuif, France.;Laboratory Integrative Tumor Immunology and Genetic Oncology, Institute Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France; Réseau National de Référence pour Cancers Rares de l'Adulte PREDIR labellisé par l'INCa, Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre"
"370","Arnaud MP;Talibi S;Lejeune-Cairon S","Arnaud, Marie-Pierre;Talibi, Sarra;Lejeune-Cairon, Sophie","Knowledge and attitudes of French dentists on bone resorption inhibitors (bisphosphonates and denosumab): A cross-sectional study.","Journal of stomatology, oral and maxillofacial surgery","France","eng","Journal Article","Bone resorption inhibitor;Cross-sectional study;Dental education;Dentist;Knowledge;Osteonecrosis","Adult;Attitude;Bisphosphonate-Associated Osteonecrosis of the Jaw;Bone Density Conservation Agents;Cross-Sectional Studies;Denosumab;Dentists;Diphosphonates;Humans","Adult;Attitude;Bisphosphonate-Associated Osteonecrosis of the Jaw;Bone Density Conservation Agents;Cross-Sectional Studies;Denosumab;Dentists;Diphosphonates;Humans","A cross-sectional study by questionnaire was performed to evaluate the knowledge of French dentists about bone resorption inhibitors (BRIs) and medication-related osteonecrosis of the jaw (MRONJ). 498 digital questionnaires were collected and 358 complete responses of French dental practionners in active practice except for orthodontists were analyzed. Descriptive analysis was computed and categorical variables were compared by Z test. The independence of the compared variables was tested by χ2 test. The scores obtained to the knowledge questions were compared by Mann-Whitney's tests depending on age, gender and year of graduation. 84% of the respondents routinely record antiresorptive medication history in the medical chart. Therefore, almost all the practitioners know the importance to report in anamnesis the use of BRIs, but we noticed some contradictions: Less than half of the respondents recognized the brand names of BRIs and their indications. The combination of BRIs with other drugs like antiangiogenic or corticosteroid therapies is identified as a MRONJ systemic risk factor by respectively 46,3% and 29,7% of the respondents. Likewise, only 43,2% of the practitioners identified removable dentures as a local risk factor. We showed that practitioners under 30 years old and/or who graduated for less than 10 years reached a significantly higher score putting university as the main source of information on that subject. According to our results, it is evident that there is a lack of knowledge about BRI, the risk of MRONJ, and the methods and means of preventing this complication.","Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9, France.;Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9, France.;Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9","NA",0,"2468-7855","J Stomatol Oral Maxillofac Surg","J Stomatol Oral Maxillofac Surg",2021,"2022","123","10.1016/j.jormas.2021.04.010","163-170","","","33930600","33930600","PUBMED","Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9, France.;Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9, France.;Faculté d'odontologie de Rennes, Université de Rennes 1, 2 avenue du Professeur Léon Bernard, 35043 Rennes, France; Centre de Soins Dentaires de Rennes, Centre Hospitalier Universitaire de Rennes, 2 Rue Henri le Guilloux, 35033 Rennes cedex 9"
"371","Grinda T;Antoine A;Jacot W;Blaye C;Cottu PH;Diéras V;Dalenc F;Gonçalves A;Debled M;Patsouris A;Mouret-Reynier MA;Mailliez A;Clatot F;Levy C;Ferrero JM;Desmoulins I;Uwer L;Petit T;Jouannaud C;Lacroix-Triki M;Deluche E;Robain M;Courtinard C;Bachelot T;Brain E;Pérol D;Delaloge S","Grinda, T;Antoine, A;Jacot, W;Blaye, C;Cottu, P-H;Diéras, V;Dalenc, F;Gonçalves, A;Debled, M;Patsouris, A;Mouret-Reynier, M-A;Mailliez, A;Clatot, F;Levy, C;Ferrero, J-M;Desmoulins, I;Uwer, L;Petit, T;Jouannaud, C;Lacroix-Triki, M;Deluche, E;Robain, M;Courtinard, C;Bachelot, T;Brain, E;Pérol, D;Delaloge, S","Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.","ESMO open","England","eng","Journal Article","HER2;metastatic breast cancer;new drugs;overall survival;real-life","Cohort Studies;Epidermal Growth Factor;Humans;Receptor, ErbB-2;Retrospective Studies;Triple Negative Breast Neoplasms","Cohort Studies;Epidermal Growth Factor;Humans;Receptor, ErbB-2;Retrospective Studies;Triple Negative Breast Neoplasms","Treatment strategies for metastatic breast cancer (MBC) have made great strides over the past 10 years. Real-world data allow us to evaluate the actual benefit of new treatments. ESME (Epidemio-Strategy-Medico-Economical)-MBC, a nationwide observational cohort (NCT03275311), gathers data of all consecutive MBC patients who initiated their treatment in 18 French Cancer Centres since 2008. We evaluated overall survival (OS) in the whole cohort (N = 20 446) and among subtypes: hormone receptor positive, human epidermal growth factor 2 negative (HR+/HER2-; N = 13 590), HER2+ (N = 3919), and triple-negative breast cancer (TNBC; N = 2937). We performed multivariable analyses including year of MBC diagnosis as one of the covariates, to assess the potential OS improvement over time, and we described exposure to newly released drugs at any time during MBC history by year of diagnosis (YOD). The median follow-up of the whole cohort was 65.5 months (95% CI 64.6-66.7). Year of metastatic diagnosis appears as a strong independent prognostic factor for OS [Year 2016 HR 0.89 (95% CI 0.82-0.97); P = 0.009, using 2008 as reference]. This effect is driven by the HER2+ subcohort, where it is dramatic [Year 2016 HR 0.52 (95% CI 0.42-0.66); P < 0.001, using 2008 as reference]. YOD had, however, no sustained impact on OS among patients with TNBC [Year 2016 HR 0.93 (95% CI 0.77-1.11); P = 0.41, using 2008 as reference] nor among those with HR+/HER2- MBC [Year 2016 HR 1.02 (95% CI 0.91-1.13); P = 0.41, using 2008 as reference]. While exposure to newly released anti-HER2 therapies appeared very high (e.g. >70% of patients received pertuzumab from 2016 onwards), use of everolimus or eribulin was recorded in less than one-third of HR+/HER2- and TNBC cohorts, respectively, whatever YOD. OS has dramatically improved among HER2+ MBC patients, probably in association with the release of several major HER2-directed therapies, whose penetrance was high. This trend was not observed in the other subtypes, but the impact of CDK4/6 inhibitors cannot yet be assessed.","Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of BioPathology, Gustave Roussy, Villejuif.;Department of Medical Oncology, CHU de Limoges, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Research and Development, R&D Unicancer, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif","NA",0,"2059-7029","ESMO Open","ESMO Open",2020,"2021","6","10.1016/j.esmoop.2021.100114","100114","","","33895695","33895695","PUBMED","Department of Cancer Medicine, Gustave Roussy, Villejuif, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Pays de Loire, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Medical Oncology Department, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, Dijon, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of BioPathology, Gustave Roussy, Villejuif.;Department of Medical Oncology, CHU de Limoges, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Research and Development, R&D Unicancer, Paris, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Bordeaux, France; Université de Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, UMR 1219, Bordeaux, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Cancer Medicine, Gustave Roussy, Villejuif"
"372","Duffaud F;Italiano A;Bompas E;Rios M;Penel N;Mir O;Piperno-Neumann S;Chevreau C;Delcambre C;Bertucci F;Boudou-Rouquette P;Cancel M;Perrin C;Saada-Bouzid E;Monard L;Schiffler C;Chaigneau L;Hervieu A;Collard O;Bouvier C;Vidal V;Chabaud S;Blay JY","Duffaud, Florence;Italiano, Antoine;Bompas, Emannuelle;Rios, Maria;Penel, Nicolas;Mir, Olivier;Piperno-Neumann, Sophie;Chevreau, Christine;Delcambre, Corinne;Bertucci, François;Boudou-Rouquette, Pascaline;Cancel, Mathilde;Perrin, Christophe;Saada-Bouzid, Esma;Monard, Laure;Schiffler, Camille;Chaigneau, Loic;Hervieu, Alice;Collard, Olivier;Bouvier, Corinne;Vidal, Vincent;Chabaud, Sylvie;Blay, Jean-Yves","Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.","European journal of cancer (Oxford, England : 1990)","England","eng","Clinical Trial, Phase II","Metastatic chondrosarcoma;Progression after standard chemotherapy;Regorafenib","Adult;Aged;Antineoplastic Agents;Bone Neoplasms;Chondrosarcoma;Disease Progression;Double-Blind Method;Female;France;Humans;Male;Middle Aged;Phenylurea Compounds;Progression-Free Survival;Pyridines;Time Factors","Adult;Aged;Antineoplastic Agents;Bone Neoplasms;Chondrosarcoma;Disease Progression;Double-Blind Method;Female;France;Humans;Male;Middle Aged;Phenylurea Compounds;Progression-Free Survival;Pyridines;Time Factors","This multi-cohort trial explored the efficacy and safety of regorafenib for patients with advanced sarcomas of bone origin; this report details the cohort of patients with metastatic or locally advanced chondrosarcoma (CS), progressing after prior chemotherapy. Patients with CS, progressing despite prior standard therapy, were randomised (2:1) to receive regorafenib or placebo. Patients on placebo could crossover to receive regorafenib after centrally confirmed progressive disease. The primary endpoint was progression-free rate (PFR) at 12 weeks. With one-sided α of 0.05, and 80% power, at least 16/24 progression-free patients at 12 weeks were needed for success (P0 = 50%, P1 = 75%). From September 2014 to February 2019, 46 patients were included in the CS cohort, and 40 patients were evaluable for efficacy: 16 on placebo and 24 on regorafenib. Thirteen patients (54.2%; 95% CI [35.8%-[) were non-progressive at 12 weeks on regorafenib versus 5 (31.3%; 95% CI [13.2%-[);) on placebo. Median PFS was 19.9 weeks on regorafenib, and 8.0 on placebo. Fourteen placebo patients crossed over to regorafenib after progression. The most common grade ≥3 treatment-related adverse events on regorafenib included hypertension (12%), asthenia (8%), thrombocytopenia (8%) and diarrhoea (8%). One episode of fatal liver dysfunction occurred on regorafenib. Although the primary endpoint was not met statistically in this small randomised cohort, there is modest evidence to suggest that regorafenib might slow disease progression in patients with metastatic CS after the failure of prior chemotherapy. The trial is registered at ClinicalTrials.gov (NCT02389244).","Aix Marseille Univ, APHM Hopital La Timone, Medical Oncology Unit, Marseille;Medical Oncology Unit, Institut Bergonié, Bordeaux, France.;Medical Oncology Department, Centre René Gauducheau, Saint Herblain, France.;Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Unicancer, Paris, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Hospitalier Universitaire - Jean Minjoz Hospital, Besançon, France.;Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France.;Medical Oncology Department, Institut de Cancérologie Lucien Neuwirth, St Priest En Jarez, France.;Aix Marseille Univ, APHM Hopital La Timone, Pathology Department, Marseille, France.;Aix Marseille Univ, APHM Hopital La Timone, Radiology Department, Marseille, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","150","10.1016/j.ejca.2021.03.039","108-118","","","33895682","33895682","PUBMED","Aix Marseille Univ, APHM Hopital La Timone, Medical Oncology Unit, Marseille;Medical Oncology Unit, Institut Bergonié, Bordeaux, France.;Medical Oncology Department, Centre René Gauducheau, Saint Herblain, France.;Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.;Medical Oncology Department, Centre Oscar Lambret and Lille University Hospital, Lille, France.;Medical Oncology Department, Gustave Roussy, Villejuif, France.;Medical Oncology Department, Institut Curie, Paris, France.;Medical Oncology Department, Institut Universitaire de Cancérologie de Toulouse, Oncopole, Toulouse, France.;Medical Oncology Department, Centre François Baclesse, Caen, France.;Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France.;Medical Oncology Department, Centre Hospitalier Universitaire Cochin, APHP, Paris, France.;Medical Oncology Department, Centre Hospitalier Régional Universitaire Bretonneau, Tours, France.;Medical Oncology Unit, Centre Eugène Marquis, Rennes, France.;Medical Oncology Department, Centre Antoine Lacassagne, Nice, France.;Unicancer, Paris, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Hospitalier Universitaire - Jean Minjoz Hospital, Besançon, France.;Medical Oncology Department, Centre Georges Francois Leclerc, Dijon, France.;Medical Oncology Department, Institut de Cancérologie Lucien Neuwirth, St Priest En Jarez, France.;Aix Marseille Univ, APHM Hopital La Timone, Pathology Department, Marseille, France.;Aix Marseille Univ, APHM Hopital La Timone, Radiology Department, Marseille, France.;Department of Statistics, Centre Léon Bérard, Lyon, France.;Medical Oncology Department, Centre Léon Bérard, Lyon, France."
"373","Jeanne M;Demory H;Moutal A;Vuillaume ML;Blesson S;Thépault RA;Marouillat S;Halewa J;Maas SM;Motazacker MM;Mancini GMS;van Slegtenhorst MA;Andreou A;Cox H;Vogt J;Laufman J;Kostandyan N;Babikyan D;Hancarova M;Bendova S;Sedlacek Z;Aldinger KA;Sherr EH;Argilli E;England EM;Audebert-Bellanger S;Bonneau D;Colin E;Denommé-Pichon AS;Gilbert-Dussardier B;Isidor B;Küry S;Odent S;Redon R;Khanna R;Dobyns WB;Bézieau S;Honnorat J;Lohkamp B;Toutain A;Laumonnier F","Jeanne, Médéric;Demory, Hélène;Moutal, Aubin;Vuillaume, Marie-Laure;Blesson, Sophie;Thépault, Rose-Anne;Marouillat, Sylviane;Halewa, Judith;Maas, Saskia M;Motazacker, M Mahdi;Mancini, Grazia M S;van Slegtenhorst, Marjon A;Andreou, Avgi;Cox, Helene;Vogt, Julie;Laufman, Jason;Kostandyan, Natella;Babikyan, Davit;Hancarova, Miroslava;Bendova, Sarka;Sedlacek, Zdenek;Aldinger, Kimberly A;Sherr, Elliott H;Argilli, Emanuela;England, Eleina M;Audebert-Bellanger, Séverine;Bonneau, Dominique;Colin, Estelle;Denommé-Pichon, Anne-Sophie;Gilbert-Dussardier, Brigitte;Isidor, Bertrand;Küry, Sébastien;Odent, Sylvie;Redon, Richard;Khanna, Rajesh;Dobyns, William B;Bézieau, Stéphane;Honnorat, Jérôme;Lohkamp, Bernhard;Toutain, Annick;Laumonnier, Frédéric","Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities.","American journal of human genetics","United States","eng","Journal Article","DPYSL5;brain malformation;corpus callosum agenesis;de novo missense variants;dendrite branching;neurodevelopmental disorder;primary neuronal cultures","Adult;Agenesis of Corpus Callosum;Cerebellum;Child;Child, Preschool;Female;Humans;Hydrolases;Intellectual Disability;Male;Microtubule-Associated Proteins;Models, Molecular;Mutation, Missense;Neurodevelopmental Disorders;Tubulin;Young Adult","Adult;Agenesis of Corpus Callosum;Cerebellum;Child;Child, Preschool;Female;Humans;Hydrolases;Intellectual Disability;Male;Microtubule-Associated Proteins;Models, Molecular;Mutation, Missense;Neurodevelopmental Disorders;Tubulin;Young Adult","The collapsin response mediator protein (CRMP) family proteins are intracellular mediators of neurotrophic factors regulating neurite structure/spine formation and are essential for dendrite patterning and directional axonal pathfinding during brain developmental processes. Among this family, CRMP5/DPYSL5 plays a significant role in neuronal migration, axonal guidance, dendrite outgrowth, and synapse formation by interacting with microtubules. Here, we report the identification of missense mutations in DPYSL5 in nine individuals with brain malformations, including corpus callosum agenesis and/or posterior fossa abnormalities, associated with variable degrees of intellectual disability. A recurrent de novo p.Glu41Lys variant was found in eight unrelated patients, and a p.Gly47Arg variant was identified in one individual from the first family reported with Ritscher-Schinzel syndrome. Functional analyses of the two missense mutations revealed impaired dendritic outgrowth processes in young developing hippocampal primary neuronal cultures. We further demonstrated that these mutations, both located in the same loop on the surface of DPYSL5 monomers and oligomers, reduced the interaction of DPYSL5 with neuronal cytoskeleton-associated proteins MAP2 and βIII-tubulin. Our findings collectively indicate that the p.Glu41Lys and p.Gly47Arg variants impair DPYSL5 function on dendritic outgrowth regulation by preventing the formation of the ternary complex with MAP2 and βIII-tubulin, ultimately leading to abnormal brain development. This study adds DPYSL5 to the list of genes implicated in brain malformation and in neurodevelopmental disorders.","UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Department of Clinical Genetics, Laboratory of Genome Diagnostics, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands.;Department of Clinical Genetics, Erasmus MC University Medical Center, 30125 CN Rotterdam, the Netherlands.;Department of Clinical Genetics, Erasmus MC University Medical Center, 30125 CN Rotterdam, the Netherlands.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;Department of Clinical Genetics, Akron Children's Hospital, Akron, OH 44308-1062, USA.;Department of Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi, and Center of Medical Genetics and Primary Health Care, Yerevan 0001, Armenia.;Department of Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi, and Center of Medical Genetics and Primary Health Care, Yerevan 0001, Armenia.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.;Departments of Neurology and Pediatrics, Weill Institute of Neuroscience and Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94158, USA.;Departments of Neurology and Pediatrics, Weill Institute of Neuroscience and Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94158, USA.;Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.;Service de Génétique Médicale et de Biologie de la Reproduction, Centre Hospitalier Régional Universitaire, 29200 Brest, France.;Department of Biochemistry and Genetics, Angers University Hospital and UMR CNRS 6015-INSERM 1083, University of Angers, 49933 Angers, France.;Department of Biochemistry and Genetics, Angers University Hospital and UMR CNRS 6015-INSERM 1083, University of Angers, 49933 Angers, France.;Centre Hospitalier Universitaire de Dijon, UMR Inserm 1231, Team Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, 21070 Dijon, France.;Service de Génétique, Centre Hospitalier Universitaire, 86021 Poitiers, France; Equipe d'Accueil 3808, Université de Poitiers, 86034 Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Service de Génétique Clinique, Centre Référence Déficiences Intellectuelles de Causes Rares, Centre de Référence Anomalies du Développement, Centre Labellisé pour les Anomalies du Développement Ouest, Centre Hospitalier Universitaire de Rennes, 35203 Rennes, France; Institut de Génétique et Développement de Rennes, CNRS, UMR 6290, Université de Rennes, 35043 Rennes, France.;Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.;Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA; Department of Pediatrics, University of Washington, Seattle, WA 98015, USA.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;French Reference Center on Autoimmune Encephalitis, Hospices Civils de Lyon, Institut NeuroMyoGene, Inserm U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Division of Molecular Structural Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours","NA",0,"1537-6605","Am J Hum Genet","Am J Hum Genet",2020,"2021","108","10.1016/j.ajhg.2021.04.004","951-961","UM1 HG008900;R01 NS119263;R01 NS058721;R01 NS050375;R01 HG009141","NHGRI NIH HHS;NINDS NIH HHS;Wellcome Trust;NINDS NIH HHS;NINDS NIH HHS;NHGRI NIH HHS","33894126","33894126","PUBMED","UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France.;Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Department of Clinical Genetics, Laboratory of Genome Diagnostics, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands.;Department of Clinical Genetics, Erasmus MC University Medical Center, 30125 CN Rotterdam, the Netherlands.;Department of Clinical Genetics, Erasmus MC University Medical Center, 30125 CN Rotterdam, the Netherlands.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;West Midlands Regional Clinical Genetics Service, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK; Birmingham Health Partners, Birmingham Women's and Children's Hospital, National Health Service Foundation Trust, Birmingham BT15 2TG, UK.;Department of Clinical Genetics, Akron Children's Hospital, Akron, OH 44308-1062, USA.;Department of Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi, and Center of Medical Genetics and Primary Health Care, Yerevan 0001, Armenia.;Department of Medical Genetics, Yerevan State Medical University after Mkhitar Heratsi, and Center of Medical Genetics and Primary Health Care, Yerevan 0001, Armenia.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Department of Biology and Medical Genetics, Charles University 2(nd) Faculty of Medicine and University Hospital Motol, Charles University, Prague 15006, Czech Republic.;Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA.;Departments of Neurology and Pediatrics, Weill Institute of Neuroscience and Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94158, USA.;Departments of Neurology and Pediatrics, Weill Institute of Neuroscience and Institute of Human Genetics, University of California, San Francisco, San Francisco, CA 94158, USA.;Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.;Service de Génétique Médicale et de Biologie de la Reproduction, Centre Hospitalier Régional Universitaire, 29200 Brest, France.;Department of Biochemistry and Genetics, Angers University Hospital and UMR CNRS 6015-INSERM 1083, University of Angers, 49933 Angers, France.;Department of Biochemistry and Genetics, Angers University Hospital and UMR CNRS 6015-INSERM 1083, University of Angers, 49933 Angers, France.;Centre Hospitalier Universitaire de Dijon, UMR Inserm 1231, Team Génétique des Anomalies du Développement, Université de Bourgogne Franche-Comté, 21070 Dijon, France.;Service de Génétique, Centre Hospitalier Universitaire, 86021 Poitiers, France; Equipe d'Accueil 3808, Université de Poitiers, 86034 Poitiers, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Service de Génétique Clinique, Centre Référence Déficiences Intellectuelles de Causes Rares, Centre de Référence Anomalies du Développement, Centre Labellisé pour les Anomalies du Développement Ouest, Centre Hospitalier Universitaire de Rennes, 35203 Rennes, France; Institut de Génétique et Développement de Rennes, CNRS, UMR 6290, Université de Rennes, 35043 Rennes, France.;Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;Department of Pharmacology, College of Medicine, University of Arizona, Tucson, AZ 85724, USA.;Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA 98101, USA; Department of Pediatrics, University of Washington, Seattle, WA 98015, USA.;Service de Génétique Médicale, Centre Hospitalier Universitaire, 44093 Nantes, France; Université de Nantes, CHU Nantes, CNRS, INSERM, l'Institut du Thorax, 44007 Nantes, France.;French Reference Center on Autoimmune Encephalitis, Hospices Civils de Lyon, Institut NeuroMyoGene, Inserm U1217/CNRS UMR 5310, Université de Lyon, Université Claude Bernard Lyon 1, 69008 Lyon, France.;Division of Molecular Structural Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours, France.;UMR 1253, iBrain, Université de Tours, Inserm, 37032 Tours, France; Service de Génétique, Centre Hospitalier Universitaire, 37044 Tours"
"374","Le Daré B;Boglione-Kerrien C;Reizine F;Gangneux JP;Bacle A","Le Daré, Brendan;Boglione-Kerrien, Christelle;Reizine, Florian;Gangneux, Jean-Pierre;Bacle, Astrid","Toward the personalized and integrative management of voriconazole dosing during COVID-19-associated pulmonary aspergillosis.","Critical care (London, England)","England","eng","Journal Article","","Antifungal Agents;COVID-19;Drug Administration Schedule;Evidence-Based Medicine;Female;Humans;Male;Pulmonary Aspergillosis;Voriconazole","Antifungal Agents;COVID-19;Drug Administration Schedule;Evidence-Based Medicine;Female;Humans;Male;Pulmonary Aspergillosis;Voriconazole","NA","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes;INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Univ Rennes, Rennes;Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, 35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033, Rennes, France.;Faculté de Médecine, Biosit, Université Rennes 1, 35043, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.","NA",0,"1466-609X","Crit Care","Crit Care",2021,"2021","25","10.1186/s13054-021-03568-8","152","","","33879175","33879175","PUBMED","Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes;INSERM, INRAE, CHU Rennes, Institut NuMeCan (Nutrition, Metabolisms and Cancer), Réseau PREVITOX, Univ Rennes, Rennes;Department of Clinical and Biological Pharmacology and Pharmacovigilance, Pharmacoepidemiology and Drug Information Centre, Rennes University Hospital, 35033, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033, Rennes, France.;Faculté de Médecine, Biosit, Université Rennes 1, 35043, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Pharmacie, 35000, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, environnement et travail) - UMR_S 1085, CHU Rennes, Univ Rennes, 35000, Rennes, France."
"375","Edeline J;Houot R;Marabelle A;Alcantara M","Edeline, Julien;Houot, Roch;Marabelle, Aurélien;Alcantara, Marion","CAR-T cells and BiTEs in solid tumors: challenges and perspectives.","Journal of hematology & oncology","England","eng","Journal Article","BiTEs;Bispecific antibodies;CAR-T cells;Solid tumors","Antibodies, Bispecific;Humans;Neoplasms;Receptors, Antigen, T-Cell;T-Lymphocytes","Antibodies, Bispecific;Humans;Neoplasms;Receptors, Antigen, T-Cell;T-Lymphocytes","Chimeric antigen receptor (CAR)-modified T cells and BiTEs are both immunotherapies which redirect T cell specificity against a tumor-specific antigen through the use of antibody fragments. They demonstrated remarkable efficacy in B cell hematologic malignancies, thus paving the way for their development in solid tumors. Nonetheless, the use of such new drugs to treat solid tumors is not straightforward. So far, the results from early phase clinical trials are not as impressive as expected but many improvements are under way. In this review we present an overview of the clinical development of CAR-T cells and BiTEs targeting the main antigens expressed by solid tumors. We emphasize the most frequent hurdles encountered by either CAR-T cells or BiTEs, or both, and summarize the strategies that have been proposed to overcome these obstacles.","Medical Oncology, Centre Eugène Marquis, University of Rennes 1, Rennes, France.;Department of Hematology, CHU Rennes, INSERM U1236, University of Rennes, Rennes, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), INSERM U1015, INSERM CIC1428, Université Paris Saclay, Gustave Roussy, France.;Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris","NA",0,"1756-8722","J Hematol Oncol","J Hematol Oncol",2020,"2021","14","10.1186/s13045-021-01067-5","65","","","33874996","33874996","PUBMED","Medical Oncology, Centre Eugène Marquis, University of Rennes 1, Rennes, France.;Department of Hematology, CHU Rennes, INSERM U1236, University of Rennes, Rennes, France.;Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), INSERM U1015, INSERM CIC1428, Université Paris Saclay, Gustave Roussy, France.;Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris"
"376","Painvin B;Messet H;Rodriguez M;Lebouvier T;Chatellier D;Soulat L;Ehrmann S;Thille AW;Gacouin A;Tadie JM","Painvin, Benoit;Messet, Hélène;Rodriguez, Maeva;Lebouvier, Thomas;Chatellier, Delphine;Soulat, Louis;Ehrmann, Stephane;Thille, Arnaud W;Gacouin, Arnaud;Tadie, Jean-Marc","Inter-hospital transport of critically ill patients to manage the intensive care unit surge during the COVID-19 pandemic in France.","Annals of intensive care","Germany","eng","Journal Article","ARDS;COVID-19;Hospital transport;Intensive care unit;Mechanical ventilation;Mortality","","","The COVID-19 pandemic led authorities to evacuate via various travel modalities critically ill ventilated patients into less crowded units. However, it is not known if interhospital transport impacts COVID-19 patient's mortality in intensive care units (ICUs). A cohort from three French University Hospitals was analysed in ICUs between 15th of March and the 15th of April 2020. Patients admitted to ICU with positive COVID-19 test and mechanically ventilated were recruited. Among the 133 patients included in the study, 95 (71%) were male patients and median age was 63 years old (interquartile range: 54-71). Overall ICU mortality was 11%. Mode of transport included train (48 patients), ambulance (6 patients), and plane plus helicopter (14 patients). During their ICU stay, 7 (10%) transferred patients and 8 (12%) non-transferred patients died (p = 0.71). Median SAPS II score at admission was 33 (interquartile range: 25-46) for the transferred group and 35 (27-42) for non-transferred patients (p = 0.53). SOFA score at admission was 4 (3-6) for the transferred group versus 3 (2-5) for the non-transferred group (p = 0.25). In the transferred group, median PaO /FiO  ratio (P/F) value in the 24 h before departure was 197 mmHg (160-250) and remained 166 mmHg (125-222) in the first 24 h post arrival (p = 0.13). During the evacuation 46 (68%) and 21 (31%) of the patients, respectively, benefited from neuromuscular blocking agents and from vasopressors. Transferred and non-transferred patients had similar rate of nosocomial infections, 37/68 (54%) versus 34/65 (52%), respectively (p = 0.80). Median length of mechanical ventilation was significantly increased in the transferred group compared to the non-transferred group, 18 days (11-24) and 14 days (8-20), respectively (p = 0.007). Finally, ICU and hospital length of stay did not differ between groups. In France, inter-hospital evacuation of COVID-19 ventilated ICU patients did not appear to increase mortality and therefore could be proposed to manage ICU surges in the future.","Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Service de Médecine Intensive et Réanimation, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2, boulevard Tonnellé, 27044, Tours cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service Samu-Smur-Urgences médico-chirurgicales adultes, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, CIC INSERM 1415, CRICS-Triggersep Research Network, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2, boulevard Tonnellé, 27044, Tours cedex 9, France.;Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2021,"2021","11","10.1186/s13613-021-00841-5","54","","","33788010","33788010","PUBMED","Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Service de Médecine Intensive et Réanimation, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2, boulevard Tonnellé, 27044, Tours cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service de Réanimation Chirurgicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service Samu-Smur-Urgences médico-chirurgicales adultes, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Service de Médecine Intensive et Réanimation, CIC INSERM 1415, CRICS-Triggersep Research Network, Centre Hospitalier Régional Universitaire de Tours, Hôpital Bretonneau, 2, boulevard Tonnellé, 27044, Tours cedex 9, France.;Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Poitiers, 2 rue de la Milétrie, CS 90577, 86000, Poitiers, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes"
"377","Cuvilliers C;Palard-Novello X;Pontoizeau C;Meneret P;Devillers A;Le Jeune F;Girard A","Cuvilliers, Cécile;Palard-Novello, Xavier;Pontoizeau, Clémence;Meneret, Pierre;Devillers, Anne;Le Jeune, Florence;Girard, Antoine","The Added Value of Bloodpool SPECT/CT in Painful Non-Operated Foot and Ankle Undiagnosed With Standard Three-Phase Bone Scintigraphy.","Frontiers in medicine","Switzerland","eng","Journal Article","ankle;bloodpool SPECT;bone scintigraphy;early SPECT/CT;foot","",""," To evaluate the interest of adding a bloodpool SPECT/CT to standard three-phase bone scintigraphy (BS) for etiological diagnosis of subacute and chronic lower extremity pains.   We prospectively included patients addressed for pain of lower extremities lasting for at least 6 weeks, without previous surgery. They underwent a standard three-phase BS including late phase SPECT/CT, modified with an additional bloodpool SPECT/CT acquisition. Two independent physicians interpreted the images provided by both protocols. Diagnostic conclusion, diagnostic confidence, and interrater agreements were compared.   One hundred and eighteen lower extremities from 113 patients were analyzed (71 men, median age of 53 years). Adding bloodpool SPECT/CT to standard three-phase BS changed diagnostic conclusions in 24.6% (29/118) of lower extremities. The modified protocol revealed at least one diagnostic conclusion explaining the pain in 89% of extremities, rather than 83.1% with the standard protocol (  = 0.02). Tendinopathies were diagnosed in 12.7% of lower extremities, rather than 4.2% with standard BS (  = 0.002). Adding bloodpool SPECT/CT substantially increased overall confidence of each reader (  < 0.001). Inter-reader agreement was not significantly impacted.   Adding bloodpool SPECT/CT to standard three-phase BS impacted diagnostic conclusion in a quarter of the patients with painful lower extremities, notably by revealing significantly more tendonitis.","Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.","NA",0,"2296-858X","Front Med (Lausanne)","Front Med (Lausanne)",2020,"2021","8","10.3389/fmed.2021.634419","634419","","","33763434","33763434","PUBMED","Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France.;Nuclear Medicine Department, Centre Eugène Marquis, Rennes, France.;University of Rennes 1, Rennes, France."
"378","Jakobczyk H;Debaize L;Soubise B;Avner S;Rouger-Gaudichon J;Commet S;Jiang Y;Sérandour AA;Rio AG;Carroll JS;Wichmann C;Lie-A-Ling M;Lacaud G;Corcos L;Salbert G;Galibert MD;Gandemer V;Troadec MB","Jakobczyk, Hélène;Debaize, Lydie;Soubise, Benoit;Avner, Stéphane;Rouger-Gaudichon, Jérémie;Commet, Séverine;Jiang, Yan;Sérandour, Aurélien A;Rio, Anne-Gaëlle;Carroll, Jason S;Wichmann, Christian;Lie-A-Ling, Michael;Lacaud, Georges;Corcos, Laurent;Salbert, Gilles;Galibert, Marie-Dominique;Gandemer, Virginie;Troadec, Marie-Bérengère","Reduction of RUNX1 transcription factor activity by a CBFA2T3-mimicking peptide: application to B cell precursor acute lymphoblastic leukemia.","Journal of hematology & oncology","England","eng","Journal Article","AML1;CBFA2T3;Childhood leukemia;Driver loop;ETO2;Inhibitor;NHR2;RUNX1;Transcription factor","Antineoplastic Agents;Cell Line, Tumor;Child;Core Binding Factor Alpha 2 Subunit;Gene Expression Regulation, Leukemic;Humans;Peptides;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Protein Interaction Domains and Motifs;Protein Interaction Maps;Repressor Proteins;Transcriptional Activation","Antineoplastic Agents;Cell Line, Tumor;Child;Core Binding Factor Alpha 2 Subunit;Gene Expression Regulation, Leukemic;Humans;Peptides;Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;Protein Interaction Domains and Motifs;Protein Interaction Maps;Repressor Proteins;Transcriptional Activation","B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is the most common pediatric cancer. Identifying key players involved in proliferation of BCP-ALL cells is crucial to propose new therapeutic targets. Runt Related Transcription Factor 1 (RUNX1) and Core-Binding Factor Runt Domain Alpha Subunit 2 Translocated To 3 (CBFA2T3, ETO2, MTG16) are master regulators of hematopoiesis and are implicated in leukemia. We worked with BCP-ALL mononuclear bone marrow patients' cells and BCP-ALL cell lines, and performed Chromatin Immunoprecipitations followed by Sequencing (ChIP-Seq), co-immunoprecipitations (co-IP), proximity ligation assays (PLA), luciferase reporter assays and mouse xenograft models. We demonstrated that CBFA2T3 transcript levels correlate with RUNX1 expression in the pediatric t(12;21) ETV6-RUNX1 BCP-ALL. By ChIP-Seq in BCP-ALL patients' cells and cell lines, we found that RUNX1 is recruited on its promoter and on an enhancer of CBFA2T3 located - 2 kb upstream CBFA2T3 promoter and that, subsequently, the transcription factor RUNX1 drives both RUNX1 and CBFA2T3 expression. We demonstrated that, mechanistically, RUNX1 and CBFA2T3 can be part of the same complex allowing CBFA2T3 to strongly potentiate the activity of the transcription factor RUNX1. Finally, we characterized a CBFA2T3-mimicking peptide that inhibits the interaction between RUNX1 and CBFA2T3, abrogating the activity of this transcription complex and reducing BCP-ALL lymphoblast proliferation. Altogether, our findings reveal a novel and important activation loop between the transcription regulator CBFA2T3 and the transcription factor RUNX1 that promotes BCP-ALL proliferation, supporting the development of an innovative therapeutic approach based on the NHR2 subdomain of CBFA2T3 protein.","Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Département d'onco-hematologie pediatrique, Centre Hospitalier Universitaire de Caen Normandie, Caen, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, 22 avenue Camille Desmoulins, 29238, Brest Cedex 3, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Department of Hematology, The First Hospital of Jilin University, Changchun, China.;Université de Nantes, Ecole Centrale de Nantes, Inserm, CRCINA, Nantes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK.;Department of Transfusion Medicine, Cell Therapeutics and Haemostasis, Ludwig-Maximilians-University of Munich, Munich, Germany.;Cancer Research UK Manchester Institute, University of Manchester, Aderley Park, Macclesfield, SK10 4TG, UK.;Cancer Research UK Manchester Institute, University of Manchester, Aderley Park, Macclesfield, SK10 4TG, UK.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Service de Génétique et Génomique Moléculaire, Centre Hospitalier Universitaire de Rennes (CHU-Rennes), 35033, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Department of Pediatric Hemato-Oncology, Centre Hospitalier Universitaire de Rennes (CHU-Rennes), 35203, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, 22 avenue Camille Desmoulins, 29238, Brest Cedex 3","NA",0,"1756-8722","J Hematol Oncol","J Hematol Oncol",2020,"2021","14","10.1186/s13045-021-01051-z","47","","","33743795","33743795","PUBMED","Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Département d'onco-hematologie pediatrique, Centre Hospitalier Universitaire de Caen Normandie, Caen, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, 22 avenue Camille Desmoulins, 29238, Brest Cedex 3, France.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Department of Hematology, The First Hospital of Jilin University, Changchun, China.;Université de Nantes, Ecole Centrale de Nantes, Inserm, CRCINA, Nantes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, CB2 0RE, UK.;Department of Transfusion Medicine, Cell Therapeutics and Haemostasis, Ludwig-Maximilians-University of Munich, Munich, Germany.;Cancer Research UK Manchester Institute, University of Manchester, Aderley Park, Macclesfield, SK10 4TG, UK.;Cancer Research UK Manchester Institute, University of Manchester, Aderley Park, Macclesfield, SK10 4TG, UK.;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Service de Génétique et Génomique Moléculaire, Centre Hospitalier Universitaire de Rennes (CHU-Rennes), 35033, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes, France.;Department of Pediatric Hemato-Oncology, Centre Hospitalier Universitaire de Rennes (CHU-Rennes), 35203, Rennes, France.;Univ Rennes 1, CNRS, IGDR (Institut de génétique et développement de Rennes) - UMR 6290, 35000, Rennes;Univ Brest, Inserm, EFS, UMR 1078, GGB, 29200, Brest;CHRU Brest, Service de génétique, laboratoire de génétique chromosomique, 22 avenue Camille Desmoulins, 29238, Brest Cedex 3"
"379","Gauci ML;Coutzac C;Houot R;Marabelle A;Lebbé C","Gauci, Marie-Léa;Coutzac, Clélia;Houot, Roch;Marabelle, Aurélien;Lebbé, Céleste","SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).","European journal of cancer (Oxford, England : 1990)","England","eng","Letter","COVID- 19;Cancer;FITC;Immunotherapy;SARS-CoV-2 vaccines;mRNA-based vaccine","2019-nCoV Vaccine mRNA-1273;Antineoplastic Agents, Immunological;BNT162 Vaccine;COVID-19;COVID-19 Vaccines;ChAdOx1 nCoV-19;France;Humans;Immune Checkpoint Inhibitors;Immunotherapy, Adoptive;Neoplasms;Receptors, Chimeric Antigen;SARS-CoV-2","2019-nCoV Vaccine mRNA-1273;Antineoplastic Agents, Immunological;BNT162 Vaccine;COVID-19;COVID-19 Vaccines;ChAdOx1 nCoV-19;France;Humans;Immune Checkpoint Inhibitors;Immunotherapy, Adoptive;Neoplasms;Receptors, Chimeric Antigen;SARS-CoV-2","NA","Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris;Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Lyon, France.;Centre Hospitalier Universitaire de Rennes, Service D'Hématologie Clinique, Rennes, France.;Gustave Roussy, Université Paris-Saclay, Département D'Innovation Thérapeutique et D'Essais Précoces, Villejuif, France; Gustave-Roussy, Université Paris-Saclay, INSERM U1015 & CIC1428, Villejuif, France.;Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2021,"2021","148","10.1016/j.ejca.2021.02.003","121-123","","","33743480","33743480","PUBMED","Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris;Centre Léon Bérard, Cancer Research Center of Lyon (CRCL), Lyon, France.;Centre Hospitalier Universitaire de Rennes, Service D'Hématologie Clinique, Rennes, France.;Gustave Roussy, Université Paris-Saclay, Département D'Innovation Thérapeutique et D'Essais Précoces, Villejuif, France; Gustave-Roussy, Université Paris-Saclay, INSERM U1015 & CIC1428, Villejuif, France.;Université de Paris, AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Paris, France."
"380","le Doré S;Grinda N;Ferré E;Roussel-Robert V;Frotscher B;Chamouni P;Meunier S;Bayart S;Dolimier E;Truong-Berthoz F;de Raucourt E","le Doré, Sophie;Grinda, Nathalie;Ferré, Emmanuelle;Roussel-Robert, Valerie;Frotscher, Birgit;Chamouni, Pierre;Meunier, Sandrine;Bayart, Sophie;Dolimier, Edita;Truong-Berthoz, Francoise;de Raucourt, Emmanuelle","The Hemarthrosis-Simulating Knee Model: A Useful Tool for Individualized Education in Patients with Hemophilia (GEFACET Study).","Journal of blood medicine","New Zealand","eng","Journal Article","hemarthrosis;hemophilia;knee joint;patient education as topic;therapeutic education","","","Hemophilic arthropathy is a major complication in patients with severe hemophilia. A plastic knee model has been developed for the therapeutic education of patients to promote improved care management and self-treatment skills. The objective of this study was to evaluate the impact of this hemarthrosis-simulating artificial knee (HSAK) on patients' knowledge of their disease and its treatment. In this observational study, the impact of HSAK was assessed during individualized education in patients with severe/moderately severe hemophilia A or B at seven hemophilia treatment centers in France. Participants provided written informed consent and completed questionnaires to assess knowledge of their disease (score range: 0-7) and knowledge of their treatment (score range: 0-4). Questionnaires were completed before, immediately after and 6 months after HSAK use. The scores obtained before and after the use of the HSAK were compared. The participants comprised 32 children, 29 teenagers, and 31 adults. The mean (SD) disease knowledge score increased significantly in all age groups of patients from 4.5 (2.0) to 5.9 (1.5; p<0.001) immediately after the training and remained unchanged at 6 months. Mean (SD) treatment knowledge scores were unchanged, but Wilcoxon signed rank testing showed a significant increase after the training course that was maintained at 6 months in children and teenagers. These findings suggest that an individualized training course can enhance the understanding of hemophilia in patients of all ages, especially in children and teenagers, and that the HSAK may assist in improving patients' management of their disease.","Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France.;Regional Hemophilia Centre, Hôpital de Bicêtre (AP-HP), Kremlin-Bicêtre, France.;Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France.;Regional Hemophilia Treatment, Hôpital Cochin (AP-HP) Centre, Paris, France.;Haemophilia Treatment Centre, Hôpital de Brabois, Vandoeuvre-Les-Nancy, France.;Regional Hemophilia Treatment Centre, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Hospices Civils de Lyon - Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Bron, France.;Haemophilia Treatment Centre, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Baxalta France SAS, a Takeda Company, Paris, France.;Baxalta GmbH, a Takeda Company, Zurich, Switzerland.;Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France.","NA",0,"1179-2736","J Blood Med","J Blood Med",2020,"2021","12","10.2147/JBM.S280032","133-138","","","33727876","33727876","PUBMED","Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France.;Regional Hemophilia Centre, Hôpital de Bicêtre (AP-HP), Kremlin-Bicêtre, France.;Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France.;Regional Hemophilia Treatment, Hôpital Cochin (AP-HP) Centre, Paris, France.;Haemophilia Treatment Centre, Hôpital de Brabois, Vandoeuvre-Les-Nancy, France.;Regional Hemophilia Treatment Centre, Centre Hospitalier Universitaire de Rouen, Rouen, France.;Hospices Civils de Lyon - Unité d'Hémostase Clinique, Hôpital Cardiologique Louis Pradel, Bron, France.;Haemophilia Treatment Centre, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Baxalta France SAS, a Takeda Company, Paris, France.;Baxalta GmbH, a Takeda Company, Zurich, Switzerland.;Haemophilia Treatment Centre, Hôpital Mignot, Versailles, France."
"381","Gautron A;Bachelot L;Aubry M;Leclerc D;Quéméner AM;Corre S;Rambow F;Paris A;Tardif N;Leclair HM;Marin-Bejar O;Coulouarn C;Marine JC;Galibert MD;Gilot D","Gautron, Arthur;Bachelot, Laura;Aubry, Marc;Leclerc, Delphine;Quéméner, Anaïs M;Corre, Sébastien;Rambow, Florian;Paris, Anaïs;Tardif, Nina;Leclair, Héloïse M;Marin-Bejar, Oskar;Coulouarn, Cédric;Marine, Jean-Christophe;Galibert, Marie-Dominique;Gilot, David","CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance.","EMBO molecular medicine","Germany","eng","Journal Article","Aryl hydrocarbon Receptor;CRISPR-SAM;SMAD3;melanoma;targeted therapy resistance","Cell Line, Tumor;Cell Plasticity;Clustered Regularly Interspaced Short Palindromic Repeats;Drug Resistance, Neoplasm;Humans;Melanoma;Neoplasm Recurrence, Local;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf","Cell Line, Tumor;Cell Plasticity;Clustered Regularly Interspaced Short Palindromic Repeats;Drug Resistance, Neoplasm;Humans;Melanoma;Neoplasm Recurrence, Local;Protein Kinase Inhibitors;Proto-Oncogene Proteins B-raf","Most genetic alterations that drive melanoma development and resistance to targeted therapy have been uncovered. In contrast, and despite their increasingly recognized contribution, little is known about the non-genetic mechanisms that drive these processes. Here, we performed in vivo gain-of-function CRISPR screens and identified SMAD3, BIRC3, and SLC9A5 as key actors of BRAFi resistance. We show that their expression levels increase during acquisition of BRAFi resistance and remain high in persister cells and during relapse. The upregulation of the SMAD3 transcriptional activity (SMAD3-signature) promotes a mesenchymal-like phenotype and BRAFi resistance by acting as an upstream transcriptional regulator of potent BRAFi-resistance genes such as EGFR and AXL. This SMAD3-signature predicts resistance to both current melanoma therapies in different cohorts. Critically, chemical inhibition of SMAD3 may constitute amenable target for melanoma since it efficiently abrogates persister cells survival. Interestingly, decrease of SMAD3 activity can also be reached by inhibiting the Aryl hydrocarbon Receptor (AhR), another druggable transcription factor governing SMAD3 expression level. Our work highlights novel drug vulnerabilities that can be exploited to develop long-lasting antimelanoma therapies.","CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Plateforme GEH, CNRS, Inserm, BIOSIT - UMS 3480, US_S 018, Univ Rennes, Rennes, France.;INSERM U1242, Centre Eugène Marquis, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;INSERM U1242, Centre Eugène Marquis, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Service de Génétique Moléculaire et Génomique, CHU Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.","NA",0,"1757-4684","EMBO Mol Med","EMBO Mol Med",2020,"2021","13","10.15252/emmm.202013466","e13466","","","33724679","33724679","PUBMED","CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Plateforme GEH, CNRS, Inserm, BIOSIT - UMS 3480, US_S 018, Univ Rennes, Rennes, France.;INSERM U1242, Centre Eugène Marquis, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;INSERM U1242, Centre Eugène Marquis, Rennes, France.;Department of Oncology, KU Leuven, Leuven, Belgium.;VIB Center for Cancer Biology, VIB, Leuven, Belgium.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France.;Service de Génétique Moléculaire et Génomique, CHU Rennes, Rennes, France.;CNRS, IGDR (Institut de génétique et développement de Rennes)-UMR 6290, Univ Rennes, Rennes, France."
"382","Guegan H;Prat E;Robert-Gangneux F;Gangneux JP","Guegan, Hélène;Prat, Emilie;Robert-Gangneux, Florence;Gangneux, Jean-Pierre",NA,"Frontiers in cellular and infection microbiology","Switzerland","eng","Journal Article","Aspergillus fumigatus;azole resistance;cyp51A;cystic fibrosis;hematology;intensive care unit;invasive aspergillosis","Antifungal Agents;Aspergillus fumigatus;Azoles;Cystic Fibrosis;Drug Resistance, Fungal;Follow-Up Studies;Humans;Microbial Sensitivity Tests;Tertiary Care Centers","Antifungal Agents;Aspergillus fumigatus;Azoles;Cystic Fibrosis;Drug Resistance, Fungal;Follow-Up Studies;Humans;Microbial Sensitivity Tests;Tertiary Care Centers","Azole-resistant   (AR ) has emerged worldwide during the last decades. Drug pressure after long term treatments of chronically infected patients and the propagation of environmental clones selected under the pressure of imidazoles fungicides used in agriculture and farming both account for this emergence. The objectives of this study were to determine the rate of azole resistance in   during a 5-year period, taking into account (i) differences between underlying diseases of the patients treated, (ii) cross-resistance between azoles, and (iii) focusing on the 5-year evolution of our center's cystic fibrosis cohort. Overall, the rates of voriconazole (VRC)-resistant and itraconazole (ITC)-resistant   isolates were 4.1% (38/927) and 14.5% (95/656), respectively, corresponding to 21/426 (4.9%) and 44/308 (14.3%) patients, respectively. Regarding cross-resistance, among VRC-R isolates tested for ITC, nearly all were R (20/21;95%), compared to only 27% (20/74) of VRC-R among ITC-R isolates. The level of azole resistance remained somewhat stable over years but greatly varied according to the azole drug, patient origin, and clinical setting. Whereas azole resistance during invasive aspergillosis was very scarce, patients with cystic fibrosis were infected with multiple strains and presented the highest rate of resistance: 5% (27/539) isolates were VRC-R and 17.9% (78/436) were ITC-R. These results underline that the interpretation of the azole resistance level in   in a routine setting may consider the huge variability depending on the azole drug, the clinical setting, the patient background and the type of infection.","Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.","NA",0,"2235-2988","Front Cell Infect Microbiol","Front Cell Infect Microbiol",2020,"2020","10","10.3389/fcimb.2020.613774","613774","","","33680981","33680981","PUBMED","Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Univ Rennes, CHU, Inserm, Irset (Institut de Recherche en santé, environnement et travail) - UMR_S 1085, Rennes, France."
"383","Bertho M;Fraisse J;Patsouris A;Cottu P;Arnedos M;Pérol D;Jaffré A;Goncalves A;Lebitasy MP;D'Hondt V;Dalenc F;Ferrero JM;Levy C;Dabakuyo S;Rouzier R;Penault-Llorca F;Uwer L;Eymard JC;Breton M;Chevrot M;Thureau S;Petit T;Simon G;Frénel JS","Bertho, Marion;Fraisse, Julien;Patsouris, Anne;Cottu, Paul;Arnedos, Monica;Pérol, David;Jaffré, Anne;Goncalves, Anthony;Lebitasy, Marie-Paule;D'Hondt, Véronique;Dalenc, Florence;Ferrero, Jean-Marc;Levy, Christelle;Dabakuyo, Sandrine;Rouzier, Roman;Penault-Llorca, Frédérique;Uwer, Lionel;Eymard, Jean-Christophe;Breton, Mathias;Chevrot, Michaël;Thureau, Sébastien;Petit, Thierry;Simon, Gaëtane;Frénel, Jean-Sébastien","Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.","Therapeutic advances in medical oncology","England","eng","Journal Article","bone-only;metastatic breast cancer;outcomes;overall survival;real-life;treatments","","","Bone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far. Using the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO   non-BO MBC at diagnosis, with adjustment on main prognostic factors using a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1), describe treatment patterns, and estimate factors associated with OS. Out of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2-),   = 4 102/13,229 (31%); HER2+,   = 644/3909 (16.5%); HR-/HER2-,   = 295/2 957 (10%)]. BO MBC patients had a better adjusted OS compared with non-BO MBC [52.1 months (95% confidence interval (CI) 50.3-54.1)   34.7 months (95% CI 34.0-35.6) respectively]. The 5-year OS rate of BO MBC patients was 43.4% (95% CI 41.7-45.2). They also had a better PFS1 [13.1 months (95% CI 12.6-13.8)   8.5 months (95% CI 8.3-8.7), respectively]. This observation could be repeated in all subtypes. BO disease was an independent prognostic factor of OS [hazard ratio 0.68 (95% CI 0.65-0.72),   < 0.0001]. Results were concordant in all analyses. BO MBC patients have better outcomes compared with non-BO MBC, consistently, through all MBC subtypes.","Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Biometrics Unit, Regional Cancer Institute of Montpellier (ICM), Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;Department of Medical Information, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;National Quality of Life and Cancer Clinical Research Platform, Centre Georges François Leclerc, Dijon, France.;Department of Surgical Oncology, Institut Curie, Saint-Cloud, France.;Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Information, Centre Eugène Marquis, Rennes, France.;UNICANCER R&D, Paris, France.;Department of Radiation Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;UNICANCER R&D, Paris, France.;Department of Medical Oncology, ICO René Gauducheau, Boulevard Jacques Monod, Saint Herblain, Pays de la Loire 44805, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2020,"2021","13","10.1177/1758835920987657","1758835920987657","","","33613700","33613700","PUBMED","Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Biometrics Unit, Regional Cancer Institute of Montpellier (ICM), Montpellier, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Institut Curie, Paris, France.;Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;Department of Medical Information, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Clinical Research and Innovation Department, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;Department of Medical Oncology, Institut Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;National Quality of Life and Cancer Clinical Research Platform, Centre Georges François Leclerc, Dijon, France.;Department of Surgical Oncology, Institut Curie, Saint-Cloud, France.;Department of Pathology and Molecular Pathology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès- Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, Reims, France.;Department of Medical Information, Centre Eugène Marquis, Rennes, France.;UNICANCER R&D, Paris, France.;Department of Radiation Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;UNICANCER R&D, Paris, France.;Department of Medical Oncology, ICO René Gauducheau, Boulevard Jacques Monod, Saint Herblain, Pays de la Loire 44805, France."
"384","Bailly P;Egreteau PY;Ehrmann S;Thille AW;Guitton C;Grillet G;Reizine F;Huet O;Jaber S;Nowak E;L'her E","Bailly, Pierre;Egreteau, Pierre-Yves;Ehrmann, Stephan;Thille, Arnaud W;Guitton, Christophe;Grillet, Guillaume;Reizine, Florian;Huet, Olivier;Jaber, S;Nowak, Emmanuel;L'her, Erwan","Inased (inhaled sedation in ICU) trial protocol: a multicentre randomised open-label trial.","BMJ open","England","eng","Clinical Trial Protocol","adult anaesthesia;adult intensive & critical care;delirium & cognitive disorders","Anesthesia;Delirium;Humans;Intensive Care Units;Multicenter Studies as Topic;Prospective Studies;Randomized Controlled Trials as Topic;Respiration, Artificial","Anesthesia;Delirium;Humans;Intensive Care Units;Multicenter Studies as Topic;Prospective Studies;Randomized Controlled Trials as Topic;Respiration, Artificial","The use of sedation in intensive care units (ICUs) is necessary and ubiquitous. The impact of sedation strategy on outcome, particularly when delivered early after initiation of mechanical ventilation, is unknown. Evidence is increasing that volatile anaesthetic agents could be associated with better outcome. Their use in delirium prevention is unknown. This study is an investigator-initiated, prospective, multicentre, two-arm, randomised, control, open-trial comparing inhaled sedation strategy versus intravenous sedation strategy in mechanically ventilated patients in ICU. Two hundred and fifty patients will be randomly assigned to the intravenous sedation group or inhaled sedation group, with a 1:1 ratio in two groups according to the sedation strategy. The primary outcome is the occurrence of delirium assessed using two times a day confusion assessment method for the ICU (CAM-ICU). Secondary outcomes include cognitive and functional outcomes at 3 and 12 months. The study has been approved by the Regional Ethics Committee (CPP Ouest) and national authorities (ANSM). The results will be submitted for publication in peer-reviewed journals. NCT04341350.","Médecine Intensive et Réanimation, CHRU de Brest, Brest, Bretagne;Réanimation polyvalente, Centre Hospitalier des Pays de Morlaix, Morlaix, France.;Médecine Intensive et Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Médecine Intensive et Réanimation, CHU de Poitiers, Poitiers, France.;INSERM CIC 1402 Alive Research Group, Université de Poitiers, Poitiers, Poitou-Charentes, France.;Service de Réanimation Médico- Chirurgicale & USC, Centre Hospitalier de Mans, Le Mans, France.;Réanimation polyvalente, Centre Hospitalier de Lorient, Lorient, Bretagne, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Réanimation chirurgicale, Centre Hospitalier Régional et Universitaire de Brest, Brest, Bretagne, France.;Anesthesia and Critical Care, Montpellier Univ Hosp, Montpellier, France.;CIC INSERM 1412, CHRU de Brest, Brest, NA, France.;Médecine Intensive et Réanimation, CHRU de Brest, Brest, NA, France.;LATIM INSERM UMR 1101, Université de Bretagne Occidentale, Brest, NA, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2021,"2021","11","10.1136/bmjopen-2020-042284","e042284","","","33608400","33608400","PUBMED","Médecine Intensive et Réanimation, CHRU de Brest, Brest, Bretagne;Réanimation polyvalente, Centre Hospitalier des Pays de Morlaix, Morlaix, France.;Médecine Intensive et Réanimation, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Médecine Intensive et Réanimation, CHU de Poitiers, Poitiers, France.;INSERM CIC 1402 Alive Research Group, Université de Poitiers, Poitiers, Poitou-Charentes, France.;Service de Réanimation Médico- Chirurgicale & USC, Centre Hospitalier de Mans, Le Mans, France.;Réanimation polyvalente, Centre Hospitalier de Lorient, Lorient, Bretagne, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Réanimation chirurgicale, Centre Hospitalier Régional et Universitaire de Brest, Brest, Bretagne, France.;Anesthesia and Critical Care, Montpellier Univ Hosp, Montpellier, France.;CIC INSERM 1412, CHRU de Brest, Brest, NA, France.;Médecine Intensive et Réanimation, CHRU de Brest, Brest, NA, France.;LATIM INSERM UMR 1101, Université de Bretagne Occidentale, Brest, NA, France."
"385","Ferrant J;Lhomme F;Le Gallou S;Irish JM;Roussel M","Ferrant, Juliette;Lhomme, Faustine;Le Gallou, Simon;Irish, Jonathan M;Roussel, Mikael","Circulating Myeloid Regulatory Cells: Promising Biomarkers in B-Cell Lymphomas.","Frontiers in immunology","Switzerland","eng","Journal Article","biomarker;lymphoma;mass cytometry;monocyte;myeloid-derived suppressor cells","Aged;Aged, 80 and over;Biomarkers, Tumor;Calgranulin B;Female;Humans;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Myeloid-Derived Suppressor Cells;Tumor Microenvironment","Aged;Aged, 80 and over;Biomarkers, Tumor;Calgranulin B;Female;Humans;Lymphoma, Large B-Cell, Diffuse;Male;Middle Aged;Myeloid-Derived Suppressor Cells;Tumor Microenvironment","The monocyte/macrophage lineage has been shown to be involved in the promotion of a protumoral tumor microenvironment and resistance to treatment in B cell lymphomas. However, it is still poorly described at the single cell level, and tissue samples are not easily accessible. Thus, a detailed analysis of the circulating myeloid cell compartment in the different B lymphomas is needed to better understand the mechanisms of resistance to treatment and identify at risk patients. In this Perspective, we review current knowledge on the phenotypic and functional description of the circulating monocytic lineage in B cell lymphomas and provide first insights into the heterogeneity of these cell populations in health and lymphoma, using mass cytometry. Indeed, the monocytic compartment is a continuum more than distinct subpopulations, as demonstrated by our high-resolution approach, explaining the sometimes confusing and contradictory conclusions on the prognostic impact of the different populations, including monocytes and monocytic myeloid derived suppressor cells (M-MDSC). By identifying S100A9  monocytic cells as a potential biomarker in diffuse large B cell lymphoma (DLBCL) in this proof-of-concept preliminary study including a limited number of samples, we underline the potential of circulating myeloid regulatory cells as diagnostic and prognostic biomarkers in B-cell lymphomas.","UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Hématologie, Rennes, France.;UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.;UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, Rennes, France.","NA",0,"1664-3224","Front Immunol","Front Immunol",2020,"2020","11","10.3389/fimmu.2020.623993","623993","R01 CA226833","NCI NIH HHS","33603754","33603754","PUBMED","UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service Hématologie, Rennes, France.;UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, United States.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.;UMR_S_1236, Univ Rennes, Inserm, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire Hématologie, Pôle Biologie, Rennes, France."
"386","Demiselle J;Duval G;Hamel JF;Renault A;Bodet-Contentin L;Martin-Lefèvre L;Vivier D;Villers D;Lefèvre M;Robert R;Markowicz P;Lavoué S;Courte A;Lebas E;Chevalier S;Annweiler C;Lerolle N","Demiselle, Julien;Duval, Guillaume;Hamel, Jean-François;Renault, Anne;Bodet-Contentin, Laetitia;Martin-Lefèvre, Laurent;Vivier, Dominique;Villers, Daniel;Lefèvre, Montaine;Robert, René;Markowicz, Philippe;Lavoué, Sylvain;Courte, Anne;Lebas, Eddy;Chevalier, Stéphanie;Annweiler, Cédric;Lerolle, Nicolas","Determinants of hospital and one-year mortality among older patients admitted to intensive care units: results from the multicentric SENIOREA cohort.","Annals of intensive care","Germany","eng","Journal Article","Critical care outcomes;Mechanical ventilation;Older adults;Outcome assessment (health care)","","","Improving outcomes of older patients admitted into intensive care units (ICU) is a raising concern. This study aimed at determining which geriatric and ICU parameters were associated with in-hospital and long-term mortality in this population. We conducted a prospective multicentric observational cohort study, including patients aged 75 years and older requiring mechanical ventilation, admitted between September 2012 and December 2013 into ICU of 13 French hospitals. Comprehensive geriatric assessment at ICU admission and ICU usual parameters were registered in a standardized manner. Survival was recorded and comprehensive geriatric assessment was updated after 1 year during a dedicated home visit. 501 patients were analyzed. 108 patients (21.6%) died during the hospital stay. One-year survival rate was 53.8% (IC 95% [49.2%; 58.2%]). Factors associated with increased in-hospital mortality were higher acute illness severity score, resuscitated cardiac arrest as primary ICU diagnosis, perception of anxiety and low quality of life by the proxy, and living in a chronic care facility before ICU admission. Among patients alive at hospital discharge, factors associated with increased 1-year mortality in multivariate analysis were longer duration of mechanical ventilation, all primary ICU diagnoses other than septic shock, a Katz-activities of daily living (ADL) score below 5 and living in a chronic care facility before ICU admission. Among the 163 survivors at 1 year who received a second comprehensive geriatric assessment, the ADL score (functional abilities) showed a significant but moderate decline over time, whereas the Mini-Zarit score (family burden) improved. No significant change in patients' place of life was observed after 1 year, and quality of life was reported as happy-to-very-happy in 88% of survivors. The mortality rate remains high among older ICU patients requiring mechanical ventilation. Factors associated with short- and long-term mortality combined geriatric and ICU criteria, which should be jointly evaluated in routine care. Clinical trial registration NCT01679171.","Service de Médecine Intensive Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9, France.;Department of Geriatric Medicine, Angers University Hospital, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Maison de la Recherche, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire, Boulevard Tanguy Prigent, 29609, Brest, France.;Hôpital Bretonneau, Service de Réanimation Médicale, Centre Hospitalier Régional Universitaire de Tours, 2 Bis Boulevard Tonnellé, 37044, Tours Cedex 09, France.;Service de Réanimation Polyvalente, Centre Hospitalier Départemental Vendée-Hôpital de La-Roche-sur-Yon, Les Oudairies, 85925, La-Roche-sur-Yon Cedex 09, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 09, France.;Hôtel-Dieu, Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Nantes, 30 bd Jean Monnet, 44093, Nantes, France.;Centre Hospitalier Des Pays de Morlaix, Service de Réanimation Polyvalente, 15, Rue de Kersaint Gilly, BP 97237, 29672, Morlaix Cedex, France.;CHU de Poitiers, Service de Réanimation Médicale, 2, Rue de la Milétrie, CS 90577, 86021, Poitiers Cedex, France.;Centre Hospitalier de Cholet, Service de Réanimation Polyvalente, 1 Rue de Marengo, BP 507, 49325, Cholet Cedex, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Unité de Réanimation Médicale, 2, Rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.;Centre Hospitalier de Saint Brieuc, Service de Réanimation Polyvalente, 10, Rue Marcel Proust, BP 2367, 22027, Saint Brieux Cedex 01, France.;Centre Hospitalier Bretagne Atlantique, 20 Boulevard Général Maurice Guillaudot, BP 70555, 56017, Vannes Cedex, France.;Centre Hospitalier de Saint Malo, Service de Réanimation Polyvalente, 1, Rue de la Marne, 35403, Saint Malo Cedex, France.;Department of Geriatric Medicine, Angers University Hospital, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.;Service de Médecine Intensive Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2020,"2021","11","10.1186/s13613-021-00804-w","35","","","33595733","33595733","PUBMED","Service de Médecine Intensive Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9, France.;Department of Geriatric Medicine, Angers University Hospital, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Maison de la Recherche, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire, Boulevard Tanguy Prigent, 29609, Brest, France.;Hôpital Bretonneau, Service de Réanimation Médicale, Centre Hospitalier Régional Universitaire de Tours, 2 Bis Boulevard Tonnellé, 37044, Tours Cedex 09, France.;Service de Réanimation Polyvalente, Centre Hospitalier Départemental Vendée-Hôpital de La-Roche-sur-Yon, Les Oudairies, 85925, La-Roche-sur-Yon Cedex 09, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 09, France.;Hôtel-Dieu, Service de Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Nantes, 30 bd Jean Monnet, 44093, Nantes, France.;Centre Hospitalier Des Pays de Morlaix, Service de Réanimation Polyvalente, 15, Rue de Kersaint Gilly, BP 97237, 29672, Morlaix Cedex, France.;CHU de Poitiers, Service de Réanimation Médicale, 2, Rue de la Milétrie, CS 90577, 86021, Poitiers Cedex, France.;Centre Hospitalier de Cholet, Service de Réanimation Polyvalente, 1 Rue de Marengo, BP 507, 49325, Cholet Cedex, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, Unité de Réanimation Médicale, 2, Rue Henri Le Guilloux, 35033, Rennes Cedex 9, France.;Centre Hospitalier de Saint Brieuc, Service de Réanimation Polyvalente, 10, Rue Marcel Proust, BP 2367, 22027, Saint Brieux Cedex 01, France.;Centre Hospitalier Bretagne Atlantique, 20 Boulevard Général Maurice Guillaudot, BP 70555, 56017, Vannes Cedex, France.;Centre Hospitalier de Saint Malo, Service de Réanimation Polyvalente, 1, Rue de la Marne, 35403, Saint Malo Cedex, France.;Department of Geriatric Medicine, Angers University Hospital, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Angers University Memory Clinic, Research Center on Autonomy and Longevity, UPRES EA 4638, University of Angers, 4 rue du Larrey, 49933 cedex 9, Angers, France.;Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON, Canada.;Service de Médecine Intensive Réanimation et Médecine Hyperbare, Centre Hospitalier Universitaire, 4, Rue Larrey, 49933, Angers Cedex 9"
"387","Joste M;Dion L;Brousse S;Nyangoh Timoh K;Rousseau C;Reilhac A;Laviolle B;Lesimple T;Lavoue V;Leveque J","Joste, Marine;Dion, Ludivine;Brousse, Susie;Nyangoh Timoh, Krystel;Rousseau, Chloé;Reilhac, Astrid;Laviolle, Bruno;Lesimple, Thierry;Lavoue, Vincent;Leveque, Jean","Vulvar and vaginal melanomas: A retrospective study spanning 19 years from a tertiary center.","Journal of gynecology obstetrics and human reproduction","France","eng","Journal Article","Cancer treatment;Mucosal melanoma;Survival;Vagina;Vulva","Adult;Aged;Aged, 80 and over;Disease-Free Survival;Female;Follow-Up Studies;Humans;Lymph Node Excision;Melanoma;Middle Aged;Mucous Membrane;Neoplasm Recurrence, Local;Prognosis;Retrospective Studies;Tertiary Care Centers;Time Factors;Vaginal Neoplasms;Vulvar Neoplasms","Adult;Aged;Aged, 80 and over;Disease-Free Survival;Female;Follow-Up Studies;Humans;Lymph Node Excision;Melanoma;Middle Aged;Mucous Membrane;Neoplasm Recurrence, Local;Prognosis;Retrospective Studies;Tertiary Care Centers;Time Factors;Vaginal Neoplasms;Vulvar Neoplasms","Mucosal melanomas (MM) of the female genital tract are rare a. We aimed to study the prognostic factors of vulvar and vaginal locations of MM. A multicenter, retrospective cohort study conducted between 01/01/2000 and 01/06/2019. Of the 33 patients included 25 (75.8 %) had vulvar (VuM) and eight (24.2 %) vaginal melanomas (VaM). VaMs were deeper: median Breslow index: 17.5mm [3.5-22] versus 4.3mm [0.35-18] (p=0.013). Average follow-up was 24.0±59.8 months. Twenty-six patients (78.8 %) experienced recurrence. Disease-free survival was 52.9 % at 1year (64.7 % for VuM and 14.3 % for VaM) and 8.4 % at 3 years (11 % for VuM and 0% for VaM) (p=0.002). Median time to the first recurrence was 9.01 months [CI95 %: 2.07-56.71]. VaM recurred earlier than VuM (3.12 months [CI95 %: 2.07-12.49] versus 17.72 [CI95 %: 3.58-56.71], p=0.011). VaM had a higher risk of recurrence (HR=5.64 [CI95 %: 2.01-15.82], p=0.001) in multivariate analysis. Overall survival was 88.5 % at 1year (100 % for VuM and 50 % for VaM), and 59.4 % at 3 years (69.3 % for VuM and 25 % for VaM). Women with VaM died earlier: median specific death occurrence of 8.76 months [CI95 %: 6.54-24.72] versus 39.61 [CI95 %: 21.89-209.21], p=0.013 (HR=5.08 [CI95 %: 1.39-18.60], p=0.014). A lesion size ≥3cm was associated with an increased risk of mortality (HR=8.45 [CI95 %: 1.60-44.52], p=0.012). In multivariate analysis, vaginal location remained an independent and predictive variable of a higher risk of specific death (HR=8.56 [CI95 %: 1.95-37.64], p=0.005). A vaginal location of MM is associated with a poorer prognosis than a vulvar location.","Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Medical Oncology, CRLCC Centre Eugène Marquis, Avenue de la Bataille Flandre-Dunkerque, CS 44 229, 35042, RENNES Cedex 9, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.","NA",0,"2468-7847","J Gynecol Obstet Hum Reprod","J Gynecol Obstet Hum Reprod",2020,"2021","50","10.1016/j.jogoh.2021.102091","102091","","","33592345","33592345","PUBMED","Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Clinical Pharmacology Unit, CHU Pontchaillou, 2 rue Henri Le Guilloux, BP 35 033, RENNES Cedex 9, France.;Medical Oncology, CRLCC Centre Eugène Marquis, Avenue de la Bataille Flandre-Dunkerque, CS 44 229, 35042, RENNES Cedex 9, France.;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2;Gynecology Unit, CHU Rennes, 16 Bd de Bulgarie, BP 90 347, 35203, RENNES Cedex 2, France."
"388","Diguisto C;Le Gouge A;Arthuis C;Winer N;Parant O;Poncelet C;Chauleur C;Hannigsberg J;Ducarme G;Gallot D;Gabriel R;Desbriere R;Beucher G;Faraguet C;Isly H;Rozenberg P;Giraudeau B;Perrotin F","Diguisto, Caroline;Le Gouge, Amélie;Arthuis, Chloé;Winer, Norbert;Parant, Olivier;Poncelet, Christophe;Chauleur, Celine;Hannigsberg, Jacob;Ducarme, Guillaume;Gallot, Denis;Gabriel, Rene;Desbriere, Raoul;Beucher, Gael;Faraguet, Cyrille;Isly, Helene;Rozenberg, Patrick;Giraudeau, Bruno;Perrotin, Franck","Cervical ripening in prolonged pregnancies by silicone double balloon catheter versus vaginal dinoprostone slow release system: The MAGPOP randomised controlled trial.","PLoS medicine","United States","eng","Journal Article","","Adult;Cervical Ripening;Cesarean Section;Delivery, Obstetric;Dinoprostone;Female;Humans;Labor, Induced;Oxytocics;Pessaries;Pregnancy;Pregnancy, Prolonged;Silicones","Adult;Cervical Ripening;Cesarean Section;Delivery, Obstetric;Dinoprostone;Female;Humans;Labor, Induced;Oxytocics;Pessaries;Pregnancy;Pregnancy, Prolonged;Silicones","Prolonged pregnancies are a frequent indication for induction of labour. When the cervix is unfavourable, cervical ripening before oxytocin administration is recommended to increase the likelihood of vaginal delivery, but no particular method is currently recommended for cervical ripening of prolonged pregnancies. This trial evaluates whether the use of mechanical cervical ripening with a silicone double balloon catheter for induction of labour in prolonged pregnancies reduces the cesarean section rate for nonreassuring fetal status compared with pharmacological cervical ripening by a vaginal pessary for the slow release of dinoprostone (prostaglandin E2). This is a multicentre, superiority, open-label, parallel-group, randomised controlled trial conducted in 15 French maternity units. Women with singleton pregnancies, a vertex presentation, ≥41+0 and ≤42+0 weeks' gestation, a Bishop score <6, intact membranes, and no history of cesarean delivery for whom induction of labour was decided were randomised to either mechanical cervical ripening with a Cook Cervical Ripening Balloon or pharmacological cervical ripening by a Propess vaginal pessary serving as a prostaglandin E2 slow-release system. The primary outcome was the rate of cesarean for nonreassuring fetal status, with an independent endpoint adjudication committee determining whether the fetal heart rate was nonreassuring. Secondary outcomes included delivery (time from cervical ripening to delivery, number of patients requiring analgesics), maternal and neonatal outcomes. Between January 2017 and December 2018, 1,220 women were randomised in a 1:1 ratio, 610 allocated to a silicone double balloon catheter, and 610 to the Propess vaginal pessary for the slow release of dinoprostone. The mean age of women was 31 years old, and 80% of them were of white ethnicity. The cesarean rates for nonreassuring fetal status were 5.8% (35/607) in the mechanical ripening group and 5.3% (32/609) in the pharmacological ripening group (proportion difference: 0.5%; 95% confidence interval (CI) -2.1% to 3.1%, p = 0.70). Time from cervical ripening to delivery was shorter in the pharmacological ripening group (23 hours versus 32 hours, median difference 6.5 95% CI 5.0 to 7.9, p < 0.001), and fewer women required analgesics in the mechanical ripening group (27.5% versus 35.4%, difference in proportion -7.9%, 95% CI -13.2% to -2.7%, p = 0.003). There were no statistically significant differences between the 2 groups for other delivery, maternal, and neonatal outcomes. A limitation was a low observed rate of cesarean section. In this study, we observed no difference in the rates of cesarean deliveries for nonreassuring fetal status between mechanical ripening with a silicone double balloon catheter and pharmacological cervical ripening with a pessary for the slow release of dinoprostone. ClinicalTrials.gov NCT02907060.","Pôle de gynécologie obstétrique, médecine fœtale, médecine et biologie de la reproduction, centre Olympe de Gouges, CHRU de Tours, Tours, France.;Université de Tours, France.;Université de Paris, CRESS, INSERM, INRA, Paris, France.;INSERM CIC1415, CHRU de Tours, Tours, France.;Department of Obstetrics and Gynecology, University Hospital of Nantes, NUN, INRAE, UMR 1280, PhAN, Université de Nantes, France.;Department of Obstetrics and Gynecology, University Hospital of Nantes, NUN, INRAE, UMR 1280, PhAN, Université de Nantes, France.;Pôle de gynécologie obstétrique, hôpital Paule-de-Viguier, CHU de Toulouse, Toulouse, France.;Department of Obstetrics and Gynecology, Rene DUBOS Hospital, Cergy-Pontoise, France.;Université Paris 13, Sorbonne Paris Cité, UFR SMBH, Bobigny, France.;Department of Gynecology and Obstetrics, University Hospital of Saint-Etienne, Saint-Etienne, France.;INSERM, SAINBIOSE, U1059, Dysfonction Vasculaire et Hémostase, Université Jean-Monnet; CIC1408, Saint-Etienne, France.;CHU Brest, Hôpital Morvan, service de gynécologie-obstétrique, Brest, France.;Department of Obstetrics and Gynecology, Centre Hospitalier Departemental, La Roche sur Yon, France.;Pôle femme et enfant, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, Clermont-Ferrand, France, Team Translational approach to epithelial injury and repair, UMR6293 CNRS-Université Clermont Auvergne, U1103 Inserm, GReD, Clermont-Ferrand, France.;Service de Gynécologie-Obstétrique, Hôpital Maison Blanche, Reims Cedex, Université de Reims Champagne Ardennes, France.;Hôpital Saint Joseph, Department of Obstetrics and Gynecology, Marseille, France.;Service de gynécologie obstétrique et médecine de la reproduction, CHU de Caen, Caen, France.;Service de Gynécologie Obstétrique, Centre Hospitalier de Chartre, France.;Service de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Rennes, France.;Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Poissy, France.;Versailles St-Quentin University, research unit EA 7285. Montigny-le-Bretonneux, France.;Université de Tours, France.;INSERM CIC1415, CHRU de Tours, Tours, France.;Pôle de gynécologie obstétrique, médecine fœtale, médecine et biologie de la reproduction, centre Olympe de Gouges, CHRU de Tours, Tours, France.;Université de Tours, France.;INSERM U1253 Imaging and Brain (iBrain), Tours, France.","NA",0,"1549-1676","PLoS Med","PLoS Med",2020,"2021","18","10.1371/journal.pmed.1003448","e1003448","","","33571294","33571294","PUBMED","Pôle de gynécologie obstétrique, médecine fœtale, médecine et biologie de la reproduction, centre Olympe de Gouges, CHRU de Tours, Tours, France.;Université de Tours, France.;Université de Paris, CRESS, INSERM, INRA, Paris, France.;INSERM CIC1415, CHRU de Tours, Tours, France.;Department of Obstetrics and Gynecology, University Hospital of Nantes, NUN, INRAE, UMR 1280, PhAN, Université de Nantes, France.;Department of Obstetrics and Gynecology, University Hospital of Nantes, NUN, INRAE, UMR 1280, PhAN, Université de Nantes, France.;Pôle de gynécologie obstétrique, hôpital Paule-de-Viguier, CHU de Toulouse, Toulouse, France.;Department of Obstetrics and Gynecology, Rene DUBOS Hospital, Cergy-Pontoise, France.;Université Paris 13, Sorbonne Paris Cité, UFR SMBH, Bobigny, France.;Department of Gynecology and Obstetrics, University Hospital of Saint-Etienne, Saint-Etienne, France.;INSERM, SAINBIOSE, U1059, Dysfonction Vasculaire et Hémostase, Université Jean-Monnet; CIC1408, Saint-Etienne, France.;CHU Brest, Hôpital Morvan, service de gynécologie-obstétrique, Brest, France.;Department of Obstetrics and Gynecology, Centre Hospitalier Departemental, La Roche sur Yon, France.;Pôle femme et enfant, CHU Estaing, 1, place Lucie-et-Raymond-Aubrac, Clermont-Ferrand, France, Team Translational approach to epithelial injury and repair, UMR6293 CNRS-Université Clermont Auvergne, U1103 Inserm, GReD, Clermont-Ferrand, France.;Service de Gynécologie-Obstétrique, Hôpital Maison Blanche, Reims Cedex, Université de Reims Champagne Ardennes, France.;Hôpital Saint Joseph, Department of Obstetrics and Gynecology, Marseille, France.;Service de gynécologie obstétrique et médecine de la reproduction, CHU de Caen, Caen, France.;Service de Gynécologie Obstétrique, Centre Hospitalier de Chartre, France.;Service de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Rennes, France.;Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Poissy, France.;Versailles St-Quentin University, research unit EA 7285. Montigny-le-Bretonneux, France.;Université de Tours, France.;INSERM CIC1415, CHRU de Tours, Tours, France.;Pôle de gynécologie obstétrique, médecine fœtale, médecine et biologie de la reproduction, centre Olympe de Gouges, CHRU de Tours, Tours, France.;Université de Tours, France.;INSERM U1253 Imaging and Brain (iBrain), Tours, France."
"389","Cabel L;Carton M;Pistilli B;Dalenc F;Vanlemnens L;Levy C;Jacot W;Debled M;Loeb A;Hennequin A;De la Motte Rouge T;Laborde L;Laurent C;Chamorey E;Parent D;Petit T;Mouret-Reynier MA;Campone M;Perrocheau G;Labreveux C;Bachelot T;Robain M;Lerebours F","Cabel, Luc;Carton, Matthieu;Pistilli, Barbara;Dalenc, Florence;Vanlemnens, Laurence;Levy, Christelle;Jacot, William;Debled, Michel;Loeb, Agnes;Hennequin, Audrey;De la Motte Rouge, Thibault;Laborde, Lilian;Laurent, Carine;Chamorey, E;Parent, Damien;Petit, Thierry;Mouret-Reynier, Marie-Ange;Campone, Mario;Perrocheau, Geneviève;Labreveux, Claire;Bachelot, Thomas;Robain, Mathieu;Lerebours, Florence","Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Chemotherapy;Heavily pretreated;Metastatic breast cancer;Prognostic factors;Real-life","Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cohort Studies;Disease-Free Survival;Female;France;Humans;Middle Aged;Prognosis;Prospective Studies;Treatment Outcome;Triple Negative Breast Neoplasms","Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Cohort Studies;Disease-Free Survival;Female;France;Humans;Middle Aged;Prognosis;Prospective Studies;Treatment Outcome;Triple Negative Breast Neoplasms","Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study was to identify predictive factors of outcome after third- or fourth-line chemotherapy. The ESME-MBC database is a French prospective real-life cohort with homogeneous data collection, including patients who initiated first-line treatment for MBC (2008-2016) in 18 cancer centers. After selection of mTNBC cases, we searched for independent predictive factors (Cox proportional-hazards regression models) for overall survival (OS) on third- and fourth-line chemotherapy (OS3, OS4). We built prognostic nomograms based on the main prognostic factors identified. Of the 22,266 MBC cases in the ESME cohort, 2903 were mTNBC, 1074 (37%) and 598 (20%) of which had received at least 3 or 4 lines of chemotherapy. PFS after first- and second-line chemotherapy (PFS1, PFS2) and number of metastatic sites ≥3 at baseline were identified by multivariate analysis as prognostic factors for both OS3 (HR = 0.76 95%CI[0.66-0.88], HR = 0.55 95%CI[0.46-0.65], HR = 1.36 95%CI[1.14-1.62], respectively), and OS4 (HR = 0.76 95%CI[0.63-0.91], HR = 0.56 95%CI[0.45-0.7], HR = 1.37 95%CI[1.07-1.74]), respectively. In addition, metastasis-free interval was identified as a prognostic factor for OS3 (p = 0.01), while PFS3 influenced OS4 (HR = 0.75 95%CI[0.57-0.98]). Nomograms predicting OS3 and OS4 achieved a C-index of 0.62 and 0.61, respectively. The duration of each previous PFS is a major prognostic factor for OS in mTNBC patients receiving third- or fourth-line chemotherapy. The clinical utility of nomograms including this information was not demonstrated.","Curie, Saint Cloud;Curie, Saint Cloud, France.;Gustave Roussy, Paris, France.;Claudius Regaud IUCT, Toulouse, France.;Centre Oscar Lambret, Lille, France.;Centre Francois Baclesse, Caen, France.;ICM, Montpellier, France.;Institut Bergonie, Bordeaux, France.;Centre Henri Becquere, Rouen, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Eugene Marquis, Rennes, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie Lorraine, Vandoeuvre-les-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Paul Strauss, Strasbourg, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut de Cancérologie de L'Ouest, Angers et Nantes, France.;Institut de Cancérologie de L'Ouest, Angers et Nantes, France.;Unicancer, Paris, France.;Centre Léon Bérard, Lyon, France.;Unicancer, Paris, France.;Curie, Saint Cloud, France.","NA",0,"1532-3080","Breast","Breast",2020,"2021","56","10.1016/j.breast.2021.01.006","18-25","","","33561617","33561617","PUBMED","Curie, Saint Cloud;Curie, Saint Cloud, France.;Gustave Roussy, Paris, France.;Claudius Regaud IUCT, Toulouse, France.;Centre Oscar Lambret, Lille, France.;Centre Francois Baclesse, Caen, France.;ICM, Montpellier, France.;Institut Bergonie, Bordeaux, France.;Centre Henri Becquere, Rouen, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Eugene Marquis, Rennes, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancérologie Lorraine, Vandoeuvre-les-Nancy, France.;Centre Antoine Lacassagne, Nice, France.;Institut Jean Godinot, Reims, France.;Centre Paul Strauss, Strasbourg, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut de Cancérologie de L'Ouest, Angers et Nantes, France.;Institut de Cancérologie de L'Ouest, Angers et Nantes, France.;Unicancer, Paris, France.;Centre Léon Bérard, Lyon, France.;Unicancer, Paris, France.;Curie, Saint Cloud, France."
"390","Thille AW;Coudroy R;Nay MA;Gacouin A;Decavèle M;Sonneville R;Beloncle F;Girault C;Dangers L;Lautrette A;Levrat Q;Rouzé A;Vivier E;Lascarrou JB;Ricard JD;Razazi K;Barberet G;Lebert C;Ehrmann S;Massri A;Bourenne J;Pradel G;Bailly P;Terzi N;Dellamonica J;Lacave G;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Coudroy, Rémi;Nay, Mai-Anh;Gacouin, Arnaud;Decavèle, Maxens;Sonneville, Romain;Beloncle, François;Girault, Christophe;Dangers, Laurence;Lautrette, Alexandre;Levrat, Quentin;Rouzé, Anahita;Vivier, Emmanuel;Lascarrou, Jean-Baptiste;Ricard, Jean-Damien;Razazi, Keyvan;Barberet, Guillaume;Lebert, Christine;Ehrmann, Stephan;Massri, Alexandre;Bourenne, Jeremy;Pradel, Gael;Bailly, Pierre;Terzi, Nicolas;Dellamonica, Jean;Lacave, Guillaume;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","Non-invasive ventilation alternating with high-flow nasal oxygen versus high-flow nasal oxygen alone after extubation in COPD patients: a post hoc analysis of a randomized controlled trial.","Annals of intensive care","Germany","eng","Journal Article","Airway extubation;Chronic obstructive pulmonary disease;High-flow nasal oxygen;Non-invasive ventilation;Weaning","","","Several randomized clinical trials have shown that non-invasive ventilation (NIV) applied immediately after extubation may prevent reintubation in patients at high-risk of extubation failure. However, most of studies included patients with chronic respiratory disorders as well as patients without underlying respiratory disease. To date, no study has shown decreased risk of reintubation with prophylactic NIV after extubation among patients with chronic obstructive pulmonary disease (COPD). We hypothesized that prophylactic NIV after extubation may decrease the risk of reintubation in COPD patients as compared with high-flow nasal oxygen. We performed a post hoc subgroup analysis of COPD patients included in a multicenter, randomized, controlled trial comparing prophylactic use of NIV alternating with high-flow nasal oxygen versus high-flow nasal oxygen alone immediately after extubation. Among the 651 patients included in the original study, 150 (23%) had underlying COPD including 86 patients treated with NIV alternating with high-flow nasal oxygen and 64 patients treated with high-flow nasal oxygen alone. The reintubation rate was 13% (11 out of 86 patients) with NIV and 27% (17 out of 64 patients) with high-flow nasal oxygen alone [difference, - 14% (95% CI - 27% to - 1%); p = 0.03]. Whereas reintubation rates were significantly lower with NIV than with high-flow nasal oxygen alone at 72 h and until ICU discharge, mortality in ICU did not differ between groups: 6% (5/86) with NIV vs. 9% (6/64) with high-flow nasal oxygen alone [difference - 4% (95% CI - 14% to 5%); p = 0.40]. In COPD patients, prophylactic NIV alternating with high-flow nasal oxygen significantly decreased the risk of reintubation compared with high-flow nasal oxygen alone. Trial registration The study was registered at http://www.clinicaltrials.gov with the trial registration number NCT03121482 (20 April 2017).","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers;Service de Médecine Intensive Réanimation, CHU de Poitiers, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Rennes, France.;Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.;Hôpital Bichat, Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université de Paris, INSERM U1148, Paris, France.;Département de Médecine Intensive Réanimation, Centre Hospitalier Universitaire D'Angers, Université d'Angers, Angers, France.;Département de Réanimation Médicale, Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, EA3830-GRHV, Rouen, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint Denis de la Réunion, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Service de Réanimation, Centre Hospitalier de La Rochelle, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, 59000, Lille, France.;Réanimation Polyvalente, Centre Hospitalier Saint-Joseph Saint-Luc, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Service de Réanimation Médicale, DHU A-TVB, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Site Emile Muller, Service de Réanimation Médicale, Groupe Hospitalier Régional Mulhouse Sud Alsace, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.","NA",0,"2110-5820","Ann Intensive Care","Ann Intensive Care",2020,"2021","11","10.1186/s13613-021-00823-7","30","grant number 15-0060","Direction de l'hospitalisation et de l'offre de Soins","33559765","33559765","PUBMED","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers;Service de Médecine Intensive Réanimation, CHU de Poitiers, 2 rue la Milétrie, 86021, Poitiers Cedex;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Rennes, France.;Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.;Hôpital Bichat, Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université de Paris, INSERM U1148, Paris, France.;Département de Médecine Intensive Réanimation, Centre Hospitalier Universitaire D'Angers, Université d'Angers, Angers, France.;Département de Réanimation Médicale, Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, EA3830-GRHV, Rouen, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint Denis de la Réunion, France.;Service de Réanimation Médicale, Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Service de Réanimation, Centre Hospitalier de La Rochelle, La Rochelle, France.;Centre de Réanimation, Centre Hospitalier Universitaire de Lille, 59000, Lille, France.;Réanimation Polyvalente, Centre Hospitalier Saint-Joseph Saint-Luc, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Service de Réanimation Médicale, DHU A-TVB, AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.;Site Emile Muller, Service de Réanimation Médicale, Groupe Hospitalier Régional Mulhouse Sud Alsace, Mulhouse, France.;Service de Médecine Intensive Réanimation, Centre Hospitalier Départemental de Vendée, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, UR2CA, Université Cote d'Azur, Nice, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France."
"391","Hotton J;Lusque A;Leufflen L;Campone M;Levy C;Honart JF;Mailliez A;Debled M;Gutowski M;Leheurteur M;Goncalves A;Jankowski C;Guillermet S;Bachelot T;Ferrero JM;Eymard JC;Petit T;Pouget N;de La Lande B;Frenel JS;Villacroux O;Simon G;Pons-Tostivint E;Marchai F","Hotton, Judicaël;Lusque, Amélie;Leufflen, Léa;Campone, Mario;Levy, Christelle;Honart, Jean-Francois;Mailliez, Audrey;Debled, Marc;Gutowski, Marian;Leheurteur, Marianne;Goncalves, Anthony;Jankowski, Clementine;Guillermet, Sophie;Bachelot, Thomas;Ferrero, Jean-Marc;Eymard, Jean-Christophe;Petit, Thierry;Pouget, Nicolas;de La Lande, Brigitte;Frenel, Jean-Sébastien;Villacroux, Olivier;Simon, Gaëtane;Pons-Tostivint, Elvire;Marchai, Frédéric","Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.","Annals of surgery","United States","eng","Clinical Trial","","Female;Humans;Breast Neoplasms;Mastectomy;Progression-Free Survival;Receptor, ErbB-2;Retrospective Studies","Female;Humans;Breast Neoplasms;Mastectomy;Progression-Free Survival;Receptor, ErbB-2;Retrospective Studies","The aim was to evaluate the impact of local surgery performed during the year after MBC diagnosis on patients' outcomes from a large reallife cohort. Locoregional treatment for patients with MBC at the time of diagnosis remains debated. Women with newly diagnosed, de novo stage IV MBC and who started MBC treatment between January 2008 and December 2014 in one of the 18 French Comprehensive Cancer Centers were included (NCT03275311). The impact of local surgery performed during the first year on overall survival (OS) and progression-free survival (PFS) was evaluated by the Cox proportional hazards model in a 12 month-landmark analysis. Out of 16,703 patients in the ESME database, 1977 had stage IV MBC at diagnosis, were alive and progression-free at 12 months and eligible for this study. Among them, 530 (26.8%) had received primary breast cancer surgery within 12 months. A greater proportion of patients who received surgery had less than 3 metastatic sites than the no-surgery group (90.8% vs 78.2%, P < 0.0001). Surgery within 12 months was associated with treatment with chemotherapy, HER2-targeted therapy (89.1% vs 69.6%, P < 0.0001) and locoregional radiotherapy (81.7% vs 32.5%, P < 0.0001). Multivariable analyses showed that surgery performed within 12 months was associated with longer OS and PFS (adjusted HR [95%CI] = 0.75 [0.61-0.92] and 0.72 [0.63-0.83], respectively), which were also affected by pattern and number of metastatic sites, histological subtype, and age. In the large ESME cohort, surgery within 1 year after de novo MBC diagnosis was associated with a significantly better OS and PFS.","Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Surgical Oncology, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Biostatistics, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irene-Joliot-Curie, 31059 Toulouse, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue Andre Boquel, 49055 Angers, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Plastic and Reconstructive Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Bergonie, 229 Cours de l'Argonne, F-33000 Bordeaux, France.;Department of Surgical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille.;Department of Surgical Oncology, Centre Georges Francois Leclerc, 1 rue Professeur Marion, 21079 Dijon, France.;Department of Surgical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Surgical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Centre Antoine Lacas-sagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l,Hopital, 67000 Strasbourg, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancerologie de l,Ouest - Rene Gauducheau, Boulevard Professeur Jacques Monod, 44805 Nantes, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; and.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; and.;Department of Medical Oncology, Centre Leon Berard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irtine-Joliot-Curie, 31059 Toulouse, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.","NA",0,"1528-1140","Ann Surg","Ann Surg",2021,"2023","277","10.1097/SLA.0000000000004767","e153-e161","","","33534229","33534229","PUBMED","Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Surgical Oncology, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Biostatistics, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irene-Joliot-Curie, 31059 Toulouse, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Nantes & Angers, 15 rue Andre Boquel, 49055 Angers, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France.;Department of Plastic and Reconstructive Surgery, Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000 Lille, France.;Department of Medical Oncology, Institut Bergonie, 229 Cours de l'Argonne, F-33000 Bordeaux, France.;Department of Surgical Oncology, Institut du Cancer de Montpellier, 208 Rue des Apothicaires, 34298 Montpellier, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000 Rouen, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009 Marseille.;Department of Surgical Oncology, Centre Georges Francois Leclerc, 1 rue Professeur Marion, 21079 Dijon, France.;Department of Surgical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Surgical Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Department of Medical Oncology, Centre Antoine Lacas-sagne, 33 Avenue de Valambrose, 06189 Nice, France.;Department of Medical Oncology, Institut Godinot, 1 Rue du Général Koenig, 51100 Reims, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l,Hopital, 67000 Strasbourg, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005 Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancerologie de l,Ouest - Rene Gauducheau, Boulevard Professeur Jacques Monod, 44805 Nantes, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; and.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654 Paris, France; and.;Department of Medical Oncology, Centre Leon Berard, 28 Prom. Léa et Napoléon Bullukian, 69008 Lyon, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irtine-Joliot-Curie, 31059 Toulouse, France.;Department of Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France."
"392","Sirieix J;Fraisse J;Mathoulin-Pelissier S;Leheurteur M;Vanlemmens L;Jouannaud C;Diéras V;Lévy C;Ung M;Mouret-Reynier MA;Petit T;Coudert B;Brain E;Pistilli B;Ferrero JM;Goncalves A;Uwer L;Patsouris A;Tredan O;Courtinard C;Gourgou S;Frénel JS","Sirieix, Junien;Fraisse, Julien;Mathoulin-Pelissier, Simone;Leheurteur, Marianne;Vanlemmens, Laurence;Jouannaud, Christelle;Diéras, Véronique;Lévy, Christelle;Ung, Mony;Mouret-Reynier, Marie-Ange;Petit, Thierry;Coudert, Bruno;Brain, Etienne;Pistilli, Barbara;Ferrero, Jean-Marc;Goncalves, Anthony;Uwer, Lionel;Patsouris, Anne;Tredan, Olivier;Courtinard, Coralie;Gourgou, Sophie;Frénel, Jean-Sébastien","Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).","Therapeutic advances in medical oncology","England","eng","Journal Article","male breast cancer;metastatic breast cancer;real-life study","","","Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of male MBC characteristics, management and outcome. The Epidemiological Strategy and Medical Economics Data Platform collected data for all men and women ⩾18 years with MBC in 18 participating French Comprehensive Cancer Centers from January 2008 to November 2016. Demographic, clinical, and pathological characteristics were retrieved, as was treatment modality. Men were matched 1:1 to women with similar characteristics. Of 16,701 evaluable patients, 149 (0.89%) men were identified. These men were older (median age 69 years) and predominantly had hormone receptor HR+/HER2- disease (78.3%). Median overall survival (OS) was 41.8 months [95% confidence interval (CI: 26.9-49.7)] and similar to women. Median progression-free survival (PFS) with first-line therapy was 9.3 months [95% CI (7.4-11.5)]. In the HR+/HER2- subpopulation, endocrine therapy (ET) alone was the frontline treatment for 43% of patients, including antiestrogens (  = 19), aromatase inhibitors (  = 15) with luteinizing hormone-releasing hormone (LHRH) analogs (  = 3), and various sequential treatments. Median PFS achieved by frontline ET alone was similar in men [9.8 months, 95% CI (6.9-17.4)] and in women [13 months, 95% CI (8.4-30.9)] (  = 0.80). PFS was similar for HR+/HER2- men receiving upfront ET or chemotherapy: 9.8 months [95% CI (6.9-17.4)]   9.5 months [95% CI (7.4-11.7)] (  = 0.22), respectively. MBC management in men and women leads to similar outcomes, especially in HR+/HER2- patients for whom ET should also be a cornerstone. Unsolved questions remain and successfully recruiting trials for men are still lacking.","Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, France.;Bordeaux University, Inserm CIC1401 and Clinical and Epidemiological Research Unit, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Francois Baclesse, Caen, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, GINECO & Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-Lès-Nancy, France.;Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;R&D, Unicancer, Paris, France.;Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, France.;Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - René Gauducheau, Saint-Herblain, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2020,"2020","12","10.1177/1758835920980548","1758835920980548","","","33488779","33488779","PUBMED","Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - René Gauducheau, Saint-Herblain, France.;Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, France.;Bordeaux University, Inserm CIC1401 and Clinical and Epidemiological Research Unit, Institut Bergonie, Bordeaux, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Institut Jean Godinot, Reims, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Francois Baclesse, Caen, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, GINECO & Paul Strauss Cancer Center and University of Strasbourg, Strasbourg, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institute Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-Lès-Nancy, France.;Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - Paul Papin, Angers, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;R&D, Unicancer, Paris, France.;Biometrics Unit, ICM Regional Cancer Institute of Montpellier, Montpellier, France.;Department of Medical Oncology, ICO Institut de Cancerologie de l'Ouest - René Gauducheau, Saint-Herblain, France."
"393","Finn RS;Rugo HS;Gelmon KA;Cristofanilli M;Colleoni M;Loi S;Schnell P;Lu DR;Theall KP;Mori A;Gauthier E;Bananis E;Turner NC;Diéras V","Finn, Richard S;Rugo, Hope S;Gelmon, Karen A;Cristofanilli, Massimo;Colleoni, Marco;Loi, Sherene;Schnell, Patrick;Lu, Dongrui R;Theall, Kathy Puyana;Mori, Ave;Gauthier, Eric;Bananis, Eustratios;Turner, Nicholas C;Diéras, Véronique","Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.","The oncologist","England","eng","Journal Article","Advanced breast cancer;HR+/HER2−;Long-term safety;Palbociclib;Pooled safety","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Follow-Up Studies;Hormones;Humans;Piperazines;Pyridines;Receptor, ErbB-2","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Follow-Up Studies;Hormones;Humans;Piperazines;Pyridines;Receptor, ErbB-2","Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure. Data were pooled from three randomized studies of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC), including postmenopausal women who had not received prior systemic treatment for advanced disease (PALOMA-1/-2) and pre- and postmenopausal women who had progressed on prior ET (PALOMA-3). Updated cutoff dates were December 21, 2017 (PALOMA-1), May 31, 2017 (PALOMA-2), and April 13, 2018 (PALOMA-3). Total person-years of treatment exposure were 1,421.6 with palbociclib plus ET (n = 872) and 528.4 with ET (n = 471). Any-grade neutropenia and infections were more frequent with palbociclib plus ET (82.1% and 59.2%, respectively) than with ET (5.1% and 39.5%). The hazard ratios were 1.6 (p = .0995) for grade 3/4 infections, 1.8 (p = .4358) for grade 3/4 viral infections, 1.4 (p = .0001) for infections, and 30.8 (p < .0001) for neutropenia. Febrile neutropenia was reported in 1.4% of patients receiving palbociclib plus ET. Cumulative incidence of all-grade hematologic adverse events in both arms peaked during the first year of treatment and plateaued over the 5 subsequent years. Interstitial lung disease was reported in 13 patients receiving palbociclib plus ET and 3 receiving ET. This 5-year, long-term analysis demonstrated that palbociclib plus ET has a consistent and stable safety profile and is a safe treatment for patients with HR+/HER2- ABC. Several treatments for patients with breast cancer are associated with long-term or latent adverse events. This long-term, 5-year analysis demonstrated that palbociclib plus endocrine therapy has a consistent and stable safety profile without cumulative or delayed toxicities. These results further support palbociclib plus endocrine therapy as a safe and manageable treatment in clinical practice for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.","David Geffen School of Medicine at the University of California Los Angeles, Santa Monica, California, USA.;University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA.;British Columbia Cancer Agency, Vancouver, British Columbia, Canada.;Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA.;IEO European Institute of Oncology, IRCCS, Milan, Italy.;Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.;Pfizer Inc., New York, New York, USA.;Pfizer Inc., La Jolla, California, USA.;Pfizer Oncology, Cambridge, Massachusetts, USA.;Pfizer S.r.l., Milan, Italy.;Pfizer Inc., San Francisco, California, USA.;Pfizer Inc., New York, New York, USA.;Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.;Centre Eugène Marquis, Rennes, France.","NA",0,"1549-490X","Oncologist","Oncologist",2020,"2021","26","10.1002/onco.13684","e749-e755","","","33486783","33486783","PUBMED","David Geffen School of Medicine at the University of California Los Angeles, Santa Monica, California, USA.;University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA.;British Columbia Cancer Agency, Vancouver, British Columbia, Canada.;Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA.;IEO European Institute of Oncology, IRCCS, Milan, Italy.;Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.;Pfizer Inc., New York, New York, USA.;Pfizer Inc., La Jolla, California, USA.;Pfizer Oncology, Cambridge, Massachusetts, USA.;Pfizer S.r.l., Milan, Italy.;Pfizer Inc., San Francisco, California, USA.;Pfizer Inc., New York, New York, USA.;Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom.;Centre Eugène Marquis, Rennes, France."
"394","Gouëffic Y;Pin JL;Sabatier J;Alimi Y;Steinmetz E;Magnan PE;Marret O;Kaladji A;Chavent B;Kretz B;Jobert A;Schirr-Bonnans S;Guyomarc'h B;Riche VP;du Mont LS;Tessier P","Gouëffic, Yann;Pin, Jean L;Sabatier, Jean;Alimi, Yves;Steinmetz, Eric;Magnan, Pierre-Edouard;Marret, Olivier;Kaladji, Adrien;Chavent, Bertrand;Kretz, Benjamin;Jobert, Alexandra;Schirr-Bonnans, Solène;Guyomarc'h, Béatrice;Riche, Valéry P;du Mont, Lucie S;Tessier, Philippe","Editor's Choice - A Cost Effectiveness Analysis of Outpatient versus Inpatient Hospitalisation for Lower Extremity Arterial Disease Endovascular Revascularisation in France: A Randomised Controlled Trial.","European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery","England","eng","Comparative Study","Conventional hospitalisation;Cost effectiveness;Endovascular;Outpatient;Peripheral arterial occlusive disease","Aged;Ambulatory Care;Cost Savings;Cost-Benefit Analysis;Endovascular Procedures;Female;France;Hospital Costs;Hospitalization;Humans;Lower Extremity;Male;Middle Aged;Peripheral Arterial Disease;Prospective Studies;Quality of Life;Quality-Adjusted Life Years;Time Factors;Treatment Outcome","Aged;Ambulatory Care;Cost Savings;Cost-Benefit Analysis;Endovascular Procedures;Female;France;Hospital Costs;Hospitalization;Humans;Lower Extremity;Male;Middle Aged;Peripheral Arterial Disease;Prospective Studies;Quality of Life;Quality-Adjusted Life Years;Time Factors;Treatment Outcome","The AMBUVASC trial evaluated the cost effectiveness of outpatient vs. inpatient hospitalisation for endovascular repair of lower extremity arterial disease (LEAD). AMBUVASC was a national multicentre, prospective, randomised controlled trial conducted in nine public and two private French centres. The primary endpoint was the incremental cost effectiveness ratio (ICER), defined by cost per quality adjusted life year (QALY). Analysis was conducted from a societal perspective, excluding indirect costs, and considering a one month time horizon. From 16 February 2016 to 29 May 2017, 160 patients were randomised (80 per group). A modified intention to treat analysis was performed with 153 patients (outpatient hospitalisation: n = 76; inpatient hospitalisation: n = 77). The patients mainly presented intermittent claudication (outpatient arm: 97%; inpatient arm: 92%). Rates of peri-operative complications were 20% (15 events) and 18% (14 events) for the outpatient and inpatient arms respectively (p = .81). Overall costs (difference: €187.83; 95% confidence interval [CI] -275.68-651.34) and QALYs (difference: 0.00277; 95% CI -0.00237 - 0.00791) were higher for outpatients due to more re-admissions than the inpatient arm. The mean ICER was €67 741 per QALY gained for the base case analysis with missing data imputed using multiple imputation by predictive mean matching. The outpatient procedure was not cost effective for a willingness to pay of €50 000 per QALY and the probability of being cost effective was only 59% for a €100 000/QALY threshold. Outpatient hospitalisation is not cost effective compared with inpatient hospitalisation for endovascular repair of patients with claudication at a €50 000/QALY threshold.","Department of Vascular and Endovascular Surgery, Groupe Hôpitalier Paris St Joseph, Paris;Service de Chirurgie Vasculaire, Hôpital Privé Dijon Bourgogne, Dijon, France.;Clinique de l'Europe, Rouen, France.;Service de Chirurgie Vasculaire, Hôpital Nord, Marseille, France.;Service de Chirurgie Cardio-Thoracique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service de Chirurgie Vasculaire, Hôpital La Timone, Marseille, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Départemental Vendée-La Roche sur Yon, La Roche sur Yon, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Universitaire de St-Etienne-Hôpital Nord, Saint Etienne, France.;Service de Chirurgie Vasculaire, Hôpitaux Civils de Colmar, Colmar, France.;Département Promotion, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Institut du Thorax, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Régional Universitaire de Besançon-Hôpital Jean Minjoz, Besançon, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France; SPHERE (UMR INSERM 1246), Université de Nantes & Université de Tours, France.","NA",0,"1532-2165","Eur J Vasc Endovasc Surg","Eur J Vasc Endovasc Surg",2020,"2021","61","10.1016/j.ejvs.2020.11.030","447-455","","","33414066","33414066","PUBMED","Department of Vascular and Endovascular Surgery, Groupe Hôpitalier Paris St Joseph, Paris;Service de Chirurgie Vasculaire, Hôpital Privé Dijon Bourgogne, Dijon, France.;Clinique de l'Europe, Rouen, France.;Service de Chirurgie Vasculaire, Hôpital Nord, Marseille, France.;Service de Chirurgie Cardio-Thoracique, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service de Chirurgie Vasculaire, Hôpital La Timone, Marseille, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Départemental Vendée-La Roche sur Yon, La Roche sur Yon, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Universitaire de St-Etienne-Hôpital Nord, Saint Etienne, France.;Service de Chirurgie Vasculaire, Hôpitaux Civils de Colmar, Colmar, France.;Département Promotion, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Institut du Thorax, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France.;Service de Chirurgie Vasculaire, Centre Hospitalier Régional Universitaire de Besançon-Hôpital Jean Minjoz, Besançon, France.;Service Evaluation Economique et Développement des Produits de Santé, Département Partenariats et Innovation, Centre Hospitalier Universitaire de Nantes, Nantes Université, Nantes, France; SPHERE (UMR INSERM 1246), Université de Nantes & Université de Tours, France."
"395","Roger S;Edeline J;Campillo-Gimenez B;Ventroux E;Rouge-Bugat ME;Chapron A","Roger, Samuel;Edeline, Julien;Campillo-Gimenez, Boris;Ventroux, Elodie;Rouge-Bugat, Marie-Eve;Chapron, Anthony","Adverse events of targeted therapies reported by patients with cancer treated in primary care.","The European journal of general practice","England","eng","Journal Article","Adverse effect;ambulatory monitoring;cancer survivors;questionnaire;targeted therapies","Aged;Drug-Related Side Effects and Adverse Reactions;France;Humans;Interviews as Topic;Middle Aged;Molecular Targeted Therapy;Neoplasms;Primary Health Care;Prospective Studies;Qualitative Research;Quality of Life;Surveys and Questionnaires","Aged;Drug-Related Side Effects and Adverse Reactions;France;Humans;Interviews as Topic;Middle Aged;Molecular Targeted Therapy;Neoplasms;Primary Health Care;Prospective Studies;Qualitative Research;Quality of Life;Surveys and Questionnaires","Targeted Therapies (TT) are among the therapeutic innovations for cancer treatment in outpatient settings. TT-related Adverse Events (AEs) are a source of loss of opportunity for patients if their management is inappropriate. The objective of this study was to describe the AE frequency and severity as reported by patients with cancer who received TT in ambulatory settings. A second objective was to describe the role of the general practitioner (GP) in the management of AEs. All patients who started TT at a French Regional Cancer Centre in 2017-2018 were eligible for this 12-month prospective study. A self-administered questionnaire was distributed at inclusion and returned after three months. In the questionnaire, patients listed all AEs that occurred during this period and rated their severity. Occurrence and severity were compared with the rating by a specialised nurse. Patients also indicated the health professional they contacted first for the reported AE. Among the 247 eligible patients, 15 were excluded and 144 responded to the questionnaire. Fourteen different TTs have been prescribed. Asthenia (92.4%) and anorexia (64.6%) were the most frequent AE. Patients' AE severity rating was more severe than the nurse's rating for all drugs (  < 0.001). Patients first contacted their GP for 15.6% of AEs, whereas 20.7% of AEs were not reported to any health professional. Patients experienced an average of 4 AEs. AE severity rating was significantly different between patients and nurses. Patients do not always communicate AEs to health care professionals.","Department of General Practice, University Rennes, Rennes, France.;CHU Rennes, INSERM, CIC 1414 (Centre d'investigation clinique de Rennes), University Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM, LTSI U1099, Rennes, France.;Clinical Research Department, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of General Practice, University Toulouse, Toulouse, France.;Department of General Practice, University Rennes, Rennes, France.;CHU Rennes, INSERM, CIC 1414 (Centre d'investigation clinique de Rennes), University Rennes, Rennes, France.","NA",0,"1751-1402","Eur J Gen Pract","Eur J Gen Pract",2021,"2020","26","10.1080/13814788.2020.1846713","202-209","","","33399025","33399025","PUBMED","Department of General Practice, University Rennes, Rennes, France.;CHU Rennes, INSERM, CIC 1414 (Centre d'investigation clinique de Rennes), University Rennes, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM, LTSI U1099, Rennes, France.;Clinical Research Department, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of General Practice, University Toulouse, Toulouse, France.;Department of General Practice, University Rennes, Rennes, France.;CHU Rennes, INSERM, CIC 1414 (Centre d'investigation clinique de Rennes), University Rennes, Rennes, France."
"396","Ferrero PA;Blanc T;Binet A;Arnaud A;Abbo O;Vatta F;Bonnard A;Spampinato G;Lardy H;Fourcade L;Ballouhey Q","Ferrero, Pierre Alexandre;Blanc, Thomas;Binet, Aurélien;Arnaud, Alexis;Abbo, Olivier;Vatta, Fabrizio;Bonnard, Arnaud;Spampinato, Grazia;Lardy, Hubert;Fourcade, Laurent;Ballouhey, Quentin","The Potential and the Limitations of Esophageal Robotic Surgery in Children.","European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie","United States","eng","Journal Article","","Child;Esophagus;Heller Myotomy;Humans;Infant, Newborn;Multicenter Studies as Topic;Retrospective Studies;Robotic Surgical Procedures;Robotics","Child;Esophagus;Heller Myotomy;Humans;Infant, Newborn;Multicenter Studies as Topic;Retrospective Studies;Robotic Surgical Procedures;Robotics"," There have been numerous reports of robotic pediatric surgery in the literature, particularly regarding urological procedures for school-aged children. Thoracic procedures appear to be less common, despite the fact that encouraging results were reported more than 10 years. Our aim was to report a national experience of esophageal robotic-assisted thoracoscopic surgery (ERATS) and to discuss the most appropriate indications.  A retrospective multicenter study was conducted to compile the ERATS performed at five French surgical centers that have been involved in spearheading robotic pediatric surgery over the past 15 years. The data were supplemented by a review of the literature.  Over the study period, 68 cases of robotic thoracic surgery were performed at the five pediatric centers in question. ERATS was performed for 18 patients (mean age 7.1 years [ ± 5.6]) in four of the centers. These comprised seven esophageal duplications, four esophageal atresias, five Heller's myotomies, and two cases of esophagoplasty. A conversion was needed for two neonates (11%) due to exposure difficulties. Four other procedures for patients who weighed less than 15 kg were successfully completed without causing postoperative complications. In the past 12 years, 22 other cases of ERATS were published worldwide. The indications were the same, except for esophagoplasty, which was not found.  Aside from accessibility issues with the robotic platform, the main limitation is still very much that the low body weight of children results in incompatibility between the size of the trocars and the size of the intercostal space. ERATS is clearly a feasible procedure with technical advantages for most pediatric cases with body weights more than 15 kg. A transdiaphragmatic abdominal approach should be considered for lower esophagus surgery.","Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France.;Department of Pediatric Surgery, Hôpital Universitaire Necker-Enfants malades, Paris, Île-de-France, France.;Department of Pediatric Surgery, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Region, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;Department of Pediatric Surgery, Necker-Enfants Malades Hospitals, Paris, Île-de-France, France.;Department of Pediatric Surgery, Robert-Debré Mother-Child University Hospital, Paris, Île-de-France, France.;Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France.;Department of Pediatric Surgery, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Region, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France.","NA",0,"1439-359X","Eur J Pediatr Surg","Eur J Pediatr Surg",2020,"2022","32","10.1055/s-0040-1721770","170-176","","","33378777","33378777","PUBMED","Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France.;Department of Pediatric Surgery, Hôpital Universitaire Necker-Enfants malades, Paris, Île-de-France, France.;Department of Pediatric Surgery, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Region, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;Department of Pediatric Surgery, Necker-Enfants Malades Hospitals, Paris, Île-de-France, France.;Department of Pediatric Surgery, Robert-Debré Mother-Child University Hospital, Paris, Île-de-France, France.;Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France.;Department of Pediatric Surgery, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre Region, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Department of Pediatric Surgery, Hôpital des Enfants, Limoges, France."
"397","Estrade F;Le Du F;Crouzet L;Bourien H;Muzellec L;Edeline J","Estrade, Florian;Le Du, Fanny;Crouzet, Laurence;Bourien, Héloïse;Muzellec, Léa;Edeline, Julien","Tivozanib for hepatocellular carcinoma: not likely a new option.","Annals of translational medicine","China","eng","Editorial","","","","NA","Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.","NA",0,"2305-5839","Ann Transl Med","Ann Transl Med",2020,"2020","8","10.21037/atm-20-3389","1337","","","33313082","33313082","PUBMED","Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France.;Medical Oncology, Centre Eugène Marquis, Rennes, France."
"398","Saleh K;Carton M;Dieras V;Heudel PE;Brain E;D'Hondt V;Mailliez A;Patsouris A;Mouret-Reynier MA;Goncalves A;Ferrero JM;Petit T;Emile G;Uwer L;Debled M;Dalenc F;Jouannaud C;Ladoire S;Leheurteur M;Cottu P;Veron L;Savignoni A;Courtinard C;Robain M;Delaloge S;Deluche E","Saleh, Khalil;Carton, Matthieu;Dieras, Véronique;Heudel, Pierre-Etienne;Brain, Etienne;D'Hondt, Véronique;Mailliez, Audrey;Patsouris, Anne;Mouret-Reynier, Marie-Ange;Goncalves, Anthony;Ferrero, Jean Marc;Petit, Thierry;Emile, George;Uwer, Lionel;Debled, Marc;Dalenc, Florence;Jouannaud, Christelle;Ladoire, Sylvain;Leheurteur, Marianne;Cottu, Paul;Veron, Lucie;Savignoni, Alexia;Courtinard, Coralie;Robain, Mathieu;Delaloge, Suzette;Deluche, Elise","Impact of body mass index on overall survival in patients with metastatic breast cancer.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","BMI;Metastatic breast cancer;Obesity;Overall survival;Underweight","Body Mass Index;Breast Neoplasms;Female;Humans;Obesity;Overweight;Prognosis;Retrospective Studies;Risk Factors","Body Mass Index;Breast Neoplasms;Female;Humans;Obesity;Overweight;Prognosis;Retrospective Studies;Risk Factors","High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m  (range 12.1-66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2-48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02-1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Biostatistics, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, INSERM U1194, University of Montpellier, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, 67000, Strasbourg, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut Bergonie, 229 Cours de L'Argonne, F-33000, Bordeaux, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Georges François Leclerc, 1 Rue Professeur Marion, 21079, Dijon, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Biostatistics, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France; Department of Medical Oncology, CHU de Limoges, 2 Avenue Martin Luther King, Limoges, France.","NA",0,"1532-3080","Breast","Breast",2020,"2021","55","10.1016/j.breast.2020.11.014","16-24","","","33307392","33307392","PUBMED","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Biostatistics, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France.;Department of Medical Oncology, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, INSERM U1194, University of Montpellier, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, 67000, Strasbourg, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut Bergonie, 229 Cours de L'Argonne, F-33000, Bordeaux, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Georges François Leclerc, 1 Rue Professeur Marion, 21079, Dijon, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, 76000, Rouen, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Department of Biostatistics, Institut Curie, 26 Rue D'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France; Department of Medical Oncology, CHU de Limoges, 2 Avenue Martin Luther King, Limoges, France."
"399","Bourdel N;Huchon C;Abdel Wahab C;Azaïs H;Bendifallah S;Bolze PA;Brun JL;Canlorbe G;Chauvet P;Chereau E;Courbiere B;De La Motte Rouge T;Devouassoux-Shisheboran M;Eymerit-Morin C;Fauvet R;Gauroy E;Gauthier T;Grynberg M;Koskas M;Larouzee E;Lecointre L;Levêque J;Margueritte F;Mathieu D'argent E;Nyangoh-Timoh K;Ouldamer L;Raad J;Raimond E;Ramanah R;Rolland L;Rousset P;Rousset-Jablonski C;Thomassin-Naggara I;Uzan C;Zilliox M;Daraï E","Bourdel, N;Huchon, C;Abdel Wahab, C;Azaïs, H;Bendifallah, S;Bolze, P A;Brun, J L;Canlorbe, G;Chauvet, P;Chereau, E;Courbiere, B;De La Motte Rouge, T;Devouassoux-Shisheboran, M;Eymerit-Morin, C;Fauvet, R;Gauroy, E;Gauthier, T;Grynberg, M;Koskas, M;Larouzee, E;Lecointre, L;Levêque, J;Margueritte, F;Mathieu D'argent, E;Nyangoh-Timoh, K;Ouldamer, L;Raad, J;Raimond, E;Ramanah, R;Rolland, L;Rousset, P;Rousset-Jablonski, C;Thomassin-Naggara, I;Uzan, C;Zilliox, M;Daraï, E","Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).","European journal of obstetrics, gynecology, and reproductive biology","Ireland","eng","Editorial","Borderline ovarian tumor;Guidelines;Pregnancy;Recurrence;Restaging surgery;Surgery","CA-125 Antigen;Carcinoma, Ovarian Epithelial;Female;Humans;Hysterectomy;Neoplasm Recurrence, Local;Neoplasm Staging;Ovarian Neoplasms;Physicians","CA-125 Antigen;Carcinoma, Ovarian Epithelial;Female;Humans;Hysterectomy;Neoplasm Recurrence, Local;Neoplasm Staging;Ovarian Neoplasms;Physicians","It is recommended to classify Borderline Ovarian Tumors (BOTs) according to the WHO classification. Transvaginal and suprapubic ultrasonography are recommended for the analysis of an ovarian mass (Grade A). In case of an undetermined ovarian lesion on ultrasonography, it is recommended to perform a pelvic MRI (Grade A) with a score for malignancy (ADNEX MR/O-RADS) (Grade C) included in the report and to formulate a histological hypothesis (Grade C). Pelvic MRI is recommended to characterize a tumor suspected of being BOT (Grade C). It is recommended to evaluate serum levels of HE4 and CA125 and to use the ROMA score for the diagnosis of indeterminate ovarian mass on imaging (grade A). If there is a suspicion of a mucinous BOT on imaging, serum levels of CA 19-9 may be proposed (Grade C). For Early Stages (ES) of BOT, if surgery without risk of tumor rupture is possible, laparoscopy with protected extraction is recommended over laparotomy (Grade C). For treatment of a bilateral serous ES BOT with a strategy to preserve fertility and/or endocrine function, bilateral cystectomy is recommended where possible (Grade B). For mucinous BOTs with a treatment strategy of fertility and/or endocrine function preservation, unilateral salpingo-oophorectomy is recommended (grade C). For mucinous BOTs treated by initial cystectomy, unilateral salpingo-oophorectomy is recommended (grade C). For serous or mucinous ES BOTs, routine hysterectomy is not recommended (Grade C). For ES BOTs, lymphadenectomy is not recommended (Grade C). For ES BOTs, appendectomy is recommended only in case of a macroscopically pathological appendix (Grade C). Restaging surgery is recommended in cases of serous BOTs with micropapillary architecture and an incomplete abdominal cavity inspection during initial surgery (Grade C). Restaging surgery is recommended for mucinous BOTs after initial cystectomy or in cases where the appendix was not examined (Grade C). If restaging surgery is decided for ES BOTs, the following procedures should be performed: peritoneal washing (grade C), omentectomy (grade B), complete exploration of the abdominal cavity with peritoneal biopsies (grade C), visualization of the appendix and appendectomy in case of a pathological macroscopic appearance (grade C) as well as unilateral salpingo-oophorectomy in case of a mucinous BOT initially treated by cystectomy (grade C). In advanced stages (AS) of BOT, it is not recommended to perform a lymphadenectomy as a routine procedure (Grade C). For AS BOT in a patient with a desire to fall pregnant, conservative treatment involving preservation of the uterus and all or part of the ovary may be proposed (Grade C). Restaging surgery aimed at removing all lesions, not performed initially, is recommended for AS BOTs (Grade C). After treatment, follow-up for a duration greater than 5 years is recommended due to the median recurrence time of BOTs (Grade B). It is recommended that a systematic clinical examination be carried out during follow-up of a treated BOT (Grade B). If the determination of tumor markers is normal preoperatively, the routine dosage of tumor markers in BOT follow-up is not recommended (Grade C). In case of an initial elevation in serum CA 125 levels, it is recommended to monitor CA 125 during follow up (Grade B). In case of conservative treatment, it is recommended to use transvaginal and transabdominal ultrasound during follow up of a treated BOT (Grade B). In the event of a BOT recurrence in a woman of childbearing age, a second conservative treatment may be proposed (Grade C). A consultation with a physician specialized in Assisted Reproductive Technique (ART) should be offered in the case of BOTs in women of childbearing age (Grade C). When possible, a conservative surgical strategy is recommended to preserve fertility in women of childbearing age (Grade C). In the case of optimally treated BOT, there is no evidence to contraindicate the use of ART. The use of hormonal contraception after serous or mucinous BOT is not contraindicated (Grade C). After management of mucinous BOT, for women under 45 years, given the benefit of Hormonal Replacement Therapy (HRT) on cardiovascular and bone risks, and the lack of hormone sensitivity of mucinous BOTs, it is recommended to offer HRT (Grade C). Over 45 years of age, HRT can be prescribed in case of a climacteric syndrome after individual benefit to risk assessment (Grade C).","Service de Chirurgie Gynécologique, CHU de Clermont Ferrand, 1 Place Lucie Aubrac, 63 003 Clermont Ferrand, France.;Service de Gynécologie & Obstétrique, Hopital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France; Université de Paris, Paris;APHP.6 Service de Radiologie, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France; Faculté De Médecine UPMC, Sorbonne Université, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Service De Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France.;Service De Chirurgie Gynécologique Et Oncologique, Obstétrique, 165 Chemin du Grand Revoyet, 69310, Lyon Sud, Pierre Bénite, France; Université Lyon 1, 43 Boulevard du 11 Novembre 1918, 69100, Villeurbanne, France.;Service De Chirurgie Gynécologique, Centre Aliénor d'Aquitaine, Hôpital Pellegrin, 33076 Bordeaux, Société Française De Gynéco Pathologie, 81 Rue Verte, 76000 Rouen, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Service de Chirurgie Gynécologique, CHU de Clermont Ferrand, 1 Place Lucie Aubrac, 63 003 Clermont Ferrand, France.;Service De Gynécologie Obstétrique, Hopital Saint Joseph, Marseille, France.;Centre Clinico-Biologique d'AMP, Pôle Femmes - Parents- Enfants, AP-HM, Hôpital de La Conception, 147 Bd Baille, 13005 Marseille, France.;Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Institut De Pathologie Multi-Sites Des HOSPICES CIVILS De LYON, Centre Hospitalier Lyon Sud, Centre De Biologie Et Pathologie Sud, 165 Chemin Du Grand Revoyet, 69495 Pierre Bénite. Société Française de Gynéco Pathologie, 81 Rue Verte, 76000 Rouen, France.;Service d'Anatomie Et Cytologie Pathologiques, Hôpital Tenon, HUEP, UPMC Paris VI, Sorbonne Universities, 4 rue de la Chine, 75020 Paris, France; Institut de Pathologie de Paris, 35 boulevard Stalingrad, 92240 Malakoff, France.;Service de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Caen, Caen, France.;Service de Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Service De Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU Limoges, 8 Av Dominique Larrey 87042 Limoges, France.;Service De Médecine De La Reproduction, Hôpital Antoine Béclère, 157 Rue De La Porte De Trivaux, 92140 Clamart, France.;Service De Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Service de Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Centre Hospitalier Universitaire Hautepierre, Hôpital de Hautepierre, CHRU Strasbourg, 1 Avenue Molière, 67000 Strasbourg, France.;Département De Gynécologie Obstétrique Et Reproduction Humaine, 16, Boulevard De Bulgarie, 35000 CHU Anne De Bretagne, UFR Médecine Université de Rennes 1, Rennes, Bretagne, France.;Service De Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU Limoges, 8 Av Dominique Larrey, 87042 Limoges, France.;Service de Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France.;Département De Gynécologie Obstétrique Et Reproduction Humaine, 16, Boulevard De Bulgarie, 35000 CHU Anne De Bretagne, UFR Médecine Université de Rennes 1, Rennes, Bretagne, France.;Département De Gynécologie, Centre Hospitalier Universitaire De Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000, Tours, France.;Service De Médecine De La Reproduction, Hôpital Antoine Béclère, 157 Rue De La Porte De Trivaux, 92140 Clamart, France.;Département de Gynécologie Obstétrique, Institut Alix De Champagne, CHU Reims, Reims, France.;Pôle Mère-Femme, CHU Besançon, 3 Boulevard Fleming, 25000 Besançon, France.;Centre Clinico-Biologique d'AMP, Pôle Femmes - Parents- Enfants, AP-HM, Hôpital de La Conception, 147 Bd Baille, 13005 Marseille, France.;Service de Radiologie, Centre Hospitalier Lyon Sud, HCL, EMR 3738, 165 Chemin du Grand Revoyet, 69310, Lyon Sud, Pierre-Bénite, France; Université Lyon 1, 43 Boulevard Du 11 Novembre 1918, 69100, Villeurbanne, France.;Centre Léon Bérard, 28 Rue Laënnec, 69008, Lyon, France; Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Université Claude Bernard Lyon 1, EA 7425 Hesper, Health Service and Performance Research, Domaine Rockefeller, 8 Avenue Rockefeller, 69373, Lyon Cedex 8, France.;APHP.6 Service de Radiologie, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Centre Hospitalier Universitaire Hautepierre, Hôpital De Hautepierre, CHRU Strasbourg, 1 Avenue Molière, 67000 Strasbourg, France.;Service de Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France.","NA",0,"1872-7654","Eur J Obstet Gynecol Reprod Biol","Eur J Obstet Gynecol Reprod Biol",2020,"2021","256","10.1016/j.ejogrb.2020.11.045","492-501","","","33262005","33262005","PUBMED","Service de Chirurgie Gynécologique, CHU de Clermont Ferrand, 1 Place Lucie Aubrac, 63 003 Clermont Ferrand, France.;Service de Gynécologie & Obstétrique, Hopital Lariboisière, 2 rue Ambroise Paré, 75010 Paris, France; Université de Paris, Paris;APHP.6 Service de Radiologie, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France; Faculté De Médecine UPMC, Sorbonne Université, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Service De Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France.;Service De Chirurgie Gynécologique Et Oncologique, Obstétrique, 165 Chemin du Grand Revoyet, 69310, Lyon Sud, Pierre Bénite, France; Université Lyon 1, 43 Boulevard du 11 Novembre 1918, 69100, Villeurbanne, France.;Service De Chirurgie Gynécologique, Centre Aliénor d'Aquitaine, Hôpital Pellegrin, 33076 Bordeaux, Société Française De Gynéco Pathologie, 81 Rue Verte, 76000 Rouen, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Service de Chirurgie Gynécologique, CHU de Clermont Ferrand, 1 Place Lucie Aubrac, 63 003 Clermont Ferrand, France.;Service De Gynécologie Obstétrique, Hopital Saint Joseph, Marseille, France.;Centre Clinico-Biologique d'AMP, Pôle Femmes - Parents- Enfants, AP-HM, Hôpital de La Conception, 147 Bd Baille, 13005 Marseille, France.;Département d'Oncologie Médicale, Centre Eugène Marquis, Rennes, France.;Institut De Pathologie Multi-Sites Des HOSPICES CIVILS De LYON, Centre Hospitalier Lyon Sud, Centre De Biologie Et Pathologie Sud, 165 Chemin Du Grand Revoyet, 69495 Pierre Bénite. Société Française de Gynéco Pathologie, 81 Rue Verte, 76000 Rouen, France.;Service d'Anatomie Et Cytologie Pathologiques, Hôpital Tenon, HUEP, UPMC Paris VI, Sorbonne Universities, 4 rue de la Chine, 75020 Paris, France; Institut de Pathologie de Paris, 35 boulevard Stalingrad, 92240 Malakoff, France.;Service de Gynécologie Obstétrique, Centre Hospitalier Universitaire de Caen, Caen, France.;Service de Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Service De Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU Limoges, 8 Av Dominique Larrey 87042 Limoges, France.;Service De Médecine De La Reproduction, Hôpital Antoine Béclère, 157 Rue De La Porte De Trivaux, 92140 Clamart, France.;Service De Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Service de Gynécologie-Obstétrique, Hôpital Bichat, 46 Rue Henri Huchard, 75018 Paris, France; Université de Paris, Paris, France.;Centre Hospitalier Universitaire Hautepierre, Hôpital de Hautepierre, CHRU Strasbourg, 1 Avenue Molière, 67000 Strasbourg, France.;Département De Gynécologie Obstétrique Et Reproduction Humaine, 16, Boulevard De Bulgarie, 35000 CHU Anne De Bretagne, UFR Médecine Université de Rennes 1, Rennes, Bretagne, France.;Service De Gynécologie-Obstétrique, Hôpital Mère-Enfant, CHU Limoges, 8 Av Dominique Larrey, 87042 Limoges, France.;Service de Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France.;Département De Gynécologie Obstétrique Et Reproduction Humaine, 16, Boulevard De Bulgarie, 35000 CHU Anne De Bretagne, UFR Médecine Université de Rennes 1, Rennes, Bretagne, France.;Département De Gynécologie, Centre Hospitalier Universitaire De Tours, Hôpital Bretonneau, 2 Boulevard Tonnellé, 37000, Tours, France.;Service De Médecine De La Reproduction, Hôpital Antoine Béclère, 157 Rue De La Porte De Trivaux, 92140 Clamart, France.;Département de Gynécologie Obstétrique, Institut Alix De Champagne, CHU Reims, Reims, France.;Pôle Mère-Femme, CHU Besançon, 3 Boulevard Fleming, 25000 Besançon, France.;Centre Clinico-Biologique d'AMP, Pôle Femmes - Parents- Enfants, AP-HM, Hôpital de La Conception, 147 Bd Baille, 13005 Marseille, France.;Service de Radiologie, Centre Hospitalier Lyon Sud, HCL, EMR 3738, 165 Chemin du Grand Revoyet, 69310, Lyon Sud, Pierre-Bénite, France; Université Lyon 1, 43 Boulevard Du 11 Novembre 1918, 69100, Villeurbanne, France.;Centre Léon Bérard, 28 Rue Laënnec, 69008, Lyon, France; Centre Hospitalier Lyon Sud, Pierre-Bénite, France; Université Claude Bernard Lyon 1, EA 7425 Hesper, Health Service and Performance Research, Domaine Rockefeller, 8 Avenue Rockefeller, 69373, Lyon Cedex 8, France.;APHP.6 Service de Radiologie, Hôpital Tenon, 4 rue de la Chine, 75020, Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;AP-HP, Hôpital Pitié-Salpêtrière, Service De Chirurgie Et Oncologie Gynécologique Et Mammaire, 75013 Paris, France; Faculté de Médecine UPMC, Sorbonne Université, France.;Centre Hospitalier Universitaire Hautepierre, Hôpital De Hautepierre, CHRU Strasbourg, 1 Avenue Molière, 67000 Strasbourg, France.;Service de Gynécologie-Obstétrique Et Médecine De La Reproduction, Hôpital Tenon, Assistance Publique Des Hôpitaux De Paris (AP-HP), Institut Universitaire de Cancérologie (IUC), Centre CALG (Cancer Associé à La Grossesse), UMRS-938, Faculté de Médecine UPMC, Sorbonne Université, France."
"400","Albiges L;Fléchon A;Chevreau C;Topart D;Gravis G;Oudard S;Tourani JM;Geoffrois L;Meriaux E;Thiery-Vuillemin A;Barthélémy P;Ladoire S;Laguerre B;Perrot V;Billard A;Escudier B;Gross-Goupil M","Albiges, Laurence;Fléchon, Aude;Chevreau, Christine;Topart, Delphine;Gravis, Gwenaëlle;Oudard, Stéphane;Tourani, Jean M;Geoffrois, Lionnel;Meriaux, Emeline;Thiery-Vuillemin, Antoine;Barthélémy, Philippe;Ladoire, Sylvain;Laguerre, Brigitte;Perrot, Valérie;Billard, Anaïs;Escudier, Bernard;Gross-Goupil, Marine","Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","Cabozantinib;French Early Access Program;Nivolumab;Renal cell carcinoma;Treatment patterns","Aged;Anilides;Carcinoma, Renal Cell;Female;Humans;Male;Middle Aged;Neoplasm Metastasis;Pyridines;Receptor Protein-Tyrosine Kinases;Retrospective Studies;Treatment Outcome","Aged;Anilides;Carcinoma, Renal Cell;Female;Humans;Male;Middle Aged;Neoplasm Metastasis;Pyridines;Receptor Protein-Tyrosine Kinases;Retrospective Studies;Treatment Outcome","Real-world data on cabozantinib in metastatic renal cell carcinoma (mRCC) is limited. This study (CABOREAL) reports treatment patterns and outcomes for patients treated with cabozantinib through the French Early Access Program. This multicentre (n = 26), observational, retrospective study enrolled patients with mRCC who had received ≥1 dose of cabozantinib. Overall survival (OS) was estimated using the Kaplan-Meier method; subgroups were compared using the log-rank test. A multiple Cox regression model assessed predictive factors of OS after cabozantinib initiation. Four hundred and ten recruited patients started treatment between September 2016 and February 2018: the Eastern Cooperative Oncology Group Performance Status ≥2, 39.3%; poor International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk, 31.7%; 0-1, 2 and ≥3 previous treatment lines, 25.3%, 33.4% and 41.2%, respectively; bone metastases, 55.9%; brain metastases, 16.8%. Median (min-max) follow-up was 14.4 (0-30) months. Overall, 57.0% of patients had a dose reduction, 15.6% an alternative dose schedule. The median average daily dose was 40.0 mg. Median (quartile [Q]1-Q3) treatment duration was 7.6 (0.1-29.1) months, median OS was 14.4 months, and the 12-month OS rate was 56.5% (95% confidence interval: 51.5-61.2). Most patients (54.4%) received subsequent treatment. Predictive factors associated with longer OS were body mass index ≥25 kg/m  (p = 0.0021), prior nephrectomy (p = 0.0109), favourable or intermediate IMDC risk (p < 0.0001) and cabozantinib initiation at 60 mg/day (p = 0.0486). In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation at 60 mg/day was associated with improved outcomes. CLINICALTRIALS. NCT03744585.","Gustave Roussy, Villejuif;Centre Léon Bérard, Lyon, France.;IUCT Oncopole Institut Claudius Regaud, Toulouse, France.;Centre Hospitalier Universitaire, Montpellier, France.;Institut Paoli-Calmettes, Department of Medical Oncology, Aix-Marseille University, Inserm, CNRS, CRCM, Marseille, France.;Hôpital Européen Georges Pompidou, Paris, France.;Centre Hospitalier Universitaire, Poitiers, France.;Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Centre François Baclesse, Caen, France.;Centre Hospitalier Universitaire Jean Minjoz, Besançon, France.;Centre Hospitalier Universitaire, Strasbourg, France.;Centre Georges François Leclerc, Dijon, France.;Centre Eugène Marquis, Rennes, France.;Ipsen, Boulogne-Billancourt, France.;Ipsen, Boulogne-Billancourt, France.;Gustave Roussy, Villejuif, France.;Centre Hospitalier Universitaire Saint-André, Bordeaux, France.","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2020,"2021","142","10.1016/j.ejca.2020.09.030","102-111","","","33253997","33253997","PUBMED","Gustave Roussy, Villejuif;Centre Léon Bérard, Lyon, France.;IUCT Oncopole Institut Claudius Regaud, Toulouse, France.;Centre Hospitalier Universitaire, Montpellier, France.;Institut Paoli-Calmettes, Department of Medical Oncology, Aix-Marseille University, Inserm, CNRS, CRCM, Marseille, France.;Hôpital Européen Georges Pompidou, Paris, France.;Centre Hospitalier Universitaire, Poitiers, France.;Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Centre François Baclesse, Caen, France.;Centre Hospitalier Universitaire Jean Minjoz, Besançon, France.;Centre Hospitalier Universitaire, Strasbourg, France.;Centre Georges François Leclerc, Dijon, France.;Centre Eugène Marquis, Rennes, France.;Ipsen, Boulogne-Billancourt, France.;Ipsen, Boulogne-Billancourt, France.;Gustave Roussy, Villejuif, France.;Centre Hospitalier Universitaire Saint-André, Bordeaux, France."
"401","Saraceni F;Labopin M;Forcade E;Kröger N;Socié G;Niittyvuopio R;Cornelissen JJ;Labussière-Wallet H;Blaise D;Choi G;Byrne JL;Guillerm G;Marchand T;Esteve J;Bazarbachi A;Savani B;Olivieri A;Nagler A;Mohty M","Saraceni, Francesco;Labopin, Myriam;Forcade, Edouard;Kröger, Nicolaus;Socié, Gerard;Niittyvuopio, Riitta;Cornelissen, Jan J;Labussière-Wallet, Hélène;Blaise, Didier;Choi, Goda;Byrne, Jenny L;Guillerm, Gaelle;Marchand, Tony;Esteve, Jordi;Bazarbachi, Ali;Savani, Bipin;Olivieri, Attilio;Nagler, Arnon;Mohty, Mohamad","Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).","Cancer medicine","United States","eng","Journal Article","acute myeloid leukemia;allogeneic stem cell transplant;karnofsky performance status score;myeloablative conditioning;reduced intensity conditioning","Adult;Clinical Decision-Making;Disease Progression;Female;Graft vs Host Disease;Humans;Karnofsky Performance Status;Leukemia, Myeloid, Acute;Male;Middle Aged;Predictive Value of Tests;Progression-Free Survival;Recurrence;Registries;Retrospective Studies;Risk Assessment;Risk Factors;Stem Cell Transplantation;Time Factors;Transplantation Conditioning;Transplantation, Homologous","Adult;Clinical Decision-Making;Disease Progression;Female;Graft vs Host Disease;Humans;Karnofsky Performance Status;Leukemia, Myeloid, Acute;Male;Middle Aged;Predictive Value of Tests;Progression-Free Survival;Recurrence;Registries;Retrospective Studies;Risk Assessment;Risk Factors;Stem Cell Transplantation;Time Factors;Transplantation Conditioning;Transplantation, Homologous","Limited data are currently available on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) with a reduced performance status. We herein present the results of a registry study on 2,936 AML patients undergoing allo-SCT in first remission (CR1) with a Karnofsky Performance Status (KPS) score less than or equal to 80%. Two-year leukemia-free survival (LFS), overall survival (OS) and graft-versus-host disease (GVHD)-free, and relapse-free survival (GRFS) rates were 54%, 59%, and 41%, respectively. In multivariable analysis, patients with a KPS score = 80% had lower non-relapse mortality (NRM) and superior OS in comparison to patients with a KPS score <80% (p < 0.001). In the subgroup of patients with a KPS score =80%, a reduced-intensity conditioning (RIC) regimen was associated with an increased risk of relapse (p = 0.002) and lower GRFS (p < 0.001) compared to myeloablative conditioning (MAC). Differently, in patients with a KPS score <80%, a RIC regimen resulted in lower NRM (p < 0.001), whereas relapse incidence did not differ, thus leading to an improved GRFS (p = 0.008) as compared to MAC. A transplant from a matched sibling donor (MSD) was associated with a reduced incidence of grade III-IV acute GVHD (p < 0.01) and NRM (p < 0.01) in comparison to other donor types. In conclusion, allo-SCT appears feasible in AML patients with a jeopardized KPS score. Survival is significantly affected by the conditioning intensity, which should be adjusted according to the severity of KPS impairment.","Hematology and Stem Cell Transplant, Università Politecnica delle Marche, Ancona, Italy.;EBMT Paris Study Office, Saint Antoine Hospital, Paris, France.;CHU Bordeaux, Hôpital Haut-leveque, Pessac, France.;Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.;Department of Hematology - BMT, Hopital St. Louis, Paris, France.;HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.;Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.;Centre Hospitalier Lyon Sud, Lyon, France.;Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.;University Medical Center Groningen (UMCG), Department of Hematology, University of Groningen, Groningen, The Netherlands.;Nottingham University, Nottingham, United Kingdom.;C.H.R.U de Brest, Service Onco-Hematologie, Brest, France.;Service d`Hematologie Clinique Adulte, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hospital Clínic, Barcelona, Spain.;Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.;Vanderbilt University Medical Center, Nashville, TN, USA.;Hematology and Stem Cell Transplant, Università Politecnica delle Marche, Ancona, Italy.;Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.;EBMT Paris Study Office, Saint Antoine Hospital, Paris, France.","NA",0,"2045-7634","Cancer Med","Cancer Med",2020,"2021","10","10.1002/cam4.3593","23-33","","","33242374","33242374","PUBMED","Hematology and Stem Cell Transplant, Università Politecnica delle Marche, Ancona, Italy.;EBMT Paris Study Office, Saint Antoine Hospital, Paris, France.;CHU Bordeaux, Hôpital Haut-leveque, Pessac, France.;Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.;Department of Hematology - BMT, Hopital St. Louis, Paris, France.;HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.;Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.;Centre Hospitalier Lyon Sud, Lyon, France.;Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.;University Medical Center Groningen (UMCG), Department of Hematology, University of Groningen, Groningen, The Netherlands.;Nottingham University, Nottingham, United Kingdom.;C.H.R.U de Brest, Service Onco-Hematologie, Brest, France.;Service d`Hematologie Clinique Adulte, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hospital Clínic, Barcelona, Spain.;Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.;Vanderbilt University Medical Center, Nashville, TN, USA.;Hematology and Stem Cell Transplant, Università Politecnica delle Marche, Ancona, Italy.;Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.;EBMT Paris Study Office, Saint Antoine Hospital, Paris, France."
"402","Thille AW;Coudroy R;Gacouin A;Ehrmann S;Contou D;Dangers L;Romen A;Guitton C;Lacave G;Quenot JP;Lacombe B;Pradel G;Terzi N;Prat G;Labro G;Reignier J;Beduneau G;Dellamonica J;Nay MA;Rouze A;Delbove A;Sedillot N;Mira JP;Bourenne J;Lautrette A;Argaud L;Levrat Q;Devaquet J;Vivier E;Azais MA;Leroy C;Dres M;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Coudroy, Rémi;Gacouin, Arnaud;Ehrmann, Stephan;Contou, Damien;Dangers, Laurence;Romen, Antoine;Guitton, Christophe;Lacave, Guillaume;Quenot, Jean-Pierre;Lacombe, Béatrice;Pradel, Gael;Terzi, Nicolas;Prat, Gwenael;Labro, Guylaine;Reignier, Jean;Beduneau, Gaetan;Dellamonica, Jean;Nay, Mai-Anh;Rouze, Anahita;Delbove, Agathe;Sedillot, Nicholas;Mira, Jean-Paul;Bourenne, Jeremy;Lautrette, Alexandre;Argaud, Laurent;Levrat, Quentin;Devaquet, Jérôme;Vivier, Emmanuel;Azais, Marie-Ange;Leroy, Christophe;Dres, Martin;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","T-piece versus pressure-support ventilation for spontaneous breathing trials before extubation in patients at high risk of reintubation: protocol for a multicentre, randomised controlled trial (TIP-EX).","BMJ open","England","eng","Journal Article","adult intensive & critical care;respiratory medicine (see thoracic medicine);respiratory physiology","Airway Extubation;France;Humans;Positive-Pressure Respiration;Respiration, Artificial;Ventilator Weaning","Airway Extubation;France;Humans;Positive-Pressure Respiration;Respiration, Artificial;Ventilator Weaning","In intensive care unit (ICU), the decision of extubation is a critical time because mortality is particularly high in case of reintubation. To reduce that risk, guidelines recommend to systematically perform a spontaneous breathing trial (SBT) before extubation in order to mimic the postextubation physiological conditions. SBT is usually performed with a T-piece disconnecting the patient from the ventilator or with low levels of pressure-support ventilation (PSV). However, work of breathing is lower during PSV than during T-piece. Consequently, while PSV trial may hasten extubation, it may also increase the risk of reintubation. We hypothesise that, compared with T-piece, SBT performed using PSV may hasten extubation without increasing the risk of reintubation. This study is an investigator-initiated, multicentre randomised controlled trial comparing T-piece vs PSV for SBTs in patients at high risk of reintubation in ICUs. Nine hundred patients will be randomised with a 1:1 ratio in two groups according to the type of SBT. The primary outcome is the number of ventilator-free days at day 28, defined as the number of days alive and without invasive mechanical ventilation between the initial SBT (day 1) and day 28. Secondary outcomes include the number of days between the initial SBT and the first extubation attempt, weaning difficulty, the number of patients extubated after the initial SBT and not reintubated within the following 72 hours, the number of patients extubated within the 7 days following the initial SBT, the number of patients reintubated within the 7 days following extubation, in-ICU length of stay and mortality in ICU, at day 28 and at day 90. The study has been approved by the central ethics committee 'Ile de France V' (2019-A02151-56) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. NCT04227639.","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy d'Argenteuil, Argenteuil, Île-de-France, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint-Denis, La Réunion, Réunion.;Service de Réanimation, Centre Hospitalier de Pau, Pau, Aquitaine-Limousin-Poitou, France.;Médecine intensive réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Réanimation Polyvalente, Centre Hospitalier de Bretagne Sud, Lorient, Bretagne, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, Rhône-Alpes, France.;INSERM, U1042, HP2, Université Grenoble Alpes, Saint-Martin-d'Heres, Rhône-Alpes, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Service de Réanimation Médicale, Site Emile Muller, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, Grand Est, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Département de Réanimation Médicale, Hôpital Charles Nicolle, Normandie Université, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Réanimation Médicale Archet 1, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Cote d'Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Centre de Réanimation, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, Hauts-de-France, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, Rhône-Alpes, France.;Groupe Hospitalier Paris Centre - Cochin University Hospital - Medical Intensive Care Unit, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU La Timone 2, Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Service de Réanimation, Unicancer, Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.;Service de Réanimation, Centre hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation Polyvalente, Hopital Foch, Suresnes, Île-de-France, France.;Reanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, Auvergne, France.;Service de Pneumologie, Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2020,"2020","10","10.1136/bmjopen-2020-042619","e042619","","","33234658","33234658","PUBMED","Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Hôpital Ponchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Médecin Intensive Réanimation, CIC 1415, CRICS-TriggerSEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Centre Hospitalier Régional Universitaire de Tours, Tours, Centre, France.;Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy d'Argenteuil, Argenteuil, Île-de-France, France.;Service de Réanimation Polyvalente, Centre Hospitalier Universitaire Félix Guyon, Saint-Denis, La Réunion, Réunion.;Service de Réanimation, Centre Hospitalier de Pau, Pau, Aquitaine-Limousin-Poitou, France.;Médecine intensive réanimation, Centre Hospitalier du Mans, Le Mans, Pays de la Loire, France.;Service de Réanimation Médico-Chirurgicale, Centre Hospitalier de Versailles, Le Chesnay, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Dijon, Dijon, Bourgogne, France.;Réanimation Polyvalente, Centre Hospitalier de Bretagne Sud, Lorient, Bretagne, France.;Service de Réanimation, Centre Hospitalier Henri Mondor d'Aurillac, Aurillac, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, Rhône-Alpes, France.;INSERM, U1042, HP2, Université Grenoble Alpes, Saint-Martin-d'Heres, Rhône-Alpes, France.;Médecine Intensive et Réanimation, Centre Hospitalier Universitaire de Brest, Brest, Bretagne, France.;Service de Réanimation Médicale, Site Emile Muller, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Mulhouse, Grand Est, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Département de Réanimation Médicale, Hôpital Charles Nicolle, Normandie Université, Centre Hospitalier Universitaire de Rouen, Rouen, Normandie, France.;Réanimation Médicale Archet 1, UR2CA-Unité de Recherche Clinique Côte d'Azur, Université Cote d'Azur, Centre Hospitalier Universitaire de Nice, Nice, Provence-Alpes-Côte d'Azur, France.;Médecine Intensive Réanimation, Centre Hospitalier Régional d'Orleans Hôpital de La Source, Orleans, France.;Centre de Réanimation, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille, Hauts-de-France, France.;Réanimation Polyvalente, Centre Hospitalier Bretagne Atlantique, Vannes, Bretagne, France.;Hôpital Fleyriat, Réanimation Polyvalente, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, Rhône-Alpes, France.;Groupe Hospitalier Paris Centre - Cochin University Hospital - Medical Intensive Care Unit, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Réanimation des Urgences, CHU La Timone 2, Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille, Marseille, Provence-Alpes-Côte d'Azu, France.;Service de Réanimation, Unicancer, Centre Jean Perrin, Clermont-Ferrand, Auvergne-Rhône-Alpes, France.;Médecine Intensive Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, Auvergne-Rhône-Alpes, France.;Service de Réanimation, Centre hospitalier de la Rochelle, La Rochelle, Nouvelle-Aquitaine, France.;Service de Réanimation Polyvalente, Hopital Foch, Suresnes, Île-de-France, France.;Reanimation Polyvalente, Centre Hospitalier Saint Joseph Saint Luc, Lyon, Rhône-Alpes, France.;Service de Médecine Intensive et Réanimation, Centre Hospitalier Departmental La Roche-sur-Yon, La Roche-sur-Yon, Pays de la Loire, France.;Service de Réanimation, Centre Hospitalier Emile Roux, Le Puy en Velay, Auvergne, France.;Service de Pneumologie, Médecine Intensive et Réanimation, Hôpital Pitié-Salpêtrière, Sorbonne Université, Assistance Publique - Hopitaux de Paris, Paris, Île-de-France, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France.;Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;ALIVE research group, CIC 1402 INSERM, University of Poitiers, Poitiers, Poitou-Charentes, France."
"403","Tron C;Lemaitre F;Boisteau E;Sourd SL;Lièvre A","Tron, C;Lemaitre, F;Boisteau, Emeric;Sourd, S Le;Lièvre, A","When helping the minority of patients may hurt the majority: The case for DPD phenotyping and 5-fluorouracil therapeutic drug monitoring.","Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","Netherlands","eng","Letter","","Aged;Antimetabolites, Antineoplastic;Dihydropyrimidine Dehydrogenase Deficiency;Dihydrouracil Dehydrogenase (NADP);Drug Monitoring;Female;Fluorouracil;Gastrointestinal Neoplasms;Head and Neck Neoplasms;Humans;Male;Middle Aged;Phenotype","Aged;Antimetabolites, Antineoplastic;Dihydropyrimidine Dehydrogenase Deficiency;Dihydrouracil Dehydrogenase (NADP);Drug Monitoring;Female;Fluorouracil;Gastrointestinal Neoplasms;Head and Neck Neoplasms;Humans;Male;Middle Aged;Phenotype","NA","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes F-35000;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes F-35000, France.;Department of Gastro-Enterology, Rennes University Hospital, Rennes 1 University, INSERM U1242 ""Chemistry Oncogenesis Stress Signaling"", Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Gastro-Enterology, Rennes University Hospital, Rennes 1 University, INSERM U1242 ""Chemistry Oncogenesis Stress Signaling"", Rennes, France.","NA",0,"1878-3562","Dig Liver Dis","Dig Liver Dis",2020,"2021","53","10.1016/j.dld.2020.11.004","258-260","","","33229275","33229275","PUBMED","Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes F-35000;Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, Rennes F-35000, France.;Department of Gastro-Enterology, Rennes University Hospital, Rennes 1 University, INSERM U1242 ""Chemistry Oncogenesis Stress Signaling"", Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Gastro-Enterology, Rennes University Hospital, Rennes 1 University, INSERM U1242 ""Chemistry Oncogenesis Stress Signaling"", Rennes, France."
"404","Justet A;Klay D;Porcher R;Cottin V;Ahmad K;Molina Molina M;Nunes H;Reynaud-Gaubert M;Naccache JM;Manali E;Froidure A;Jouneau S;Wemeau L;Andrejak C;Gondouin A;Hirschi S;Blanchard E;Bondue B;Bonniaud P;Tromeur C;Prévot G;Marchand-Adam S;Funke-Chambour M;Gamez AS;Ba I;Papiris S;Grutters J;Crestani B;van Moorsel C;Kannengiesser C;Borie R","Justet, Aurélien;Klay, Dymph;Porcher, Raphaël;Cottin, Vincent;Ahmad, Kais;Molina Molina, Maria;Nunes, Hilario;Reynaud-Gaubert, Martine;Naccache, Jean Marc;Manali, Effrosyni;Froidure, Antoine;Jouneau, Stéphane;Wemeau, Lidwine;Andrejak, Claire;Gondouin, Anne;Hirschi, Sandrine;Blanchard, Elodie;Bondue, Benjamin;Bonniaud, Philippe;Tromeur, Cécile;Prévot, Grégoire;Marchand-Adam, Sylvain;Funke-Chambour, Manuela;Gamez, Anne Sophie;Ba, Ibrahima;Papiris, Spyridon;Grutters, Jan;Crestani, Bruno;van Moorsel, Coline;Kannengiesser, Caroline;Borie, Raphaël","Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation.","The European respiratory journal","England","eng","Letter","","Humans;Idiopathic Pulmonary Fibrosis;Indoles;Mutation;Pyridones;Telomere;Treatment Outcome","Humans;Idiopathic Pulmonary Fibrosis;Indoles;Mutation;Pyridones;Telomere;Treatment Outcome","NA","Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, CHU de Caen - ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité -CRESS-UMR1153, Paris, France.;OrphaLung Network, Paris, France.;National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France.;OrphaLung Network, Paris, France.;National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France.;Unit of Interstitial Lung Diseases, Dept of Pneumology, University Hospital of Bellvitge, Barcelona, Spain.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Hôpital Nord, Marseille, France.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, APHP, Service de Pneumologie, Hôpital Tenon, Paris, France.;Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.;Cliniques Universitaires Saint-Luc, Service de Pneumologie, Bruxelles, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, - IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Université de Rennes 1, Rennes, France.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, Service de Pneumologie, CHRU de Lille, Lille, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Hôpital d'Amiens, Université de Picardie Jules Verne, Amiens, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease CHU de Besançon, Service de Pneumologie, Besançon, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, CHU de Bordeaux, Service de Pneumologie, Pessac, France.;Hôpital Erasme - ULB, Brussels, Belgium.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, Service de Pneumologie, Dijon, France.;OrphaLung Network, Paris, France.;CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, CHU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France.;Service universitaire de pneumologie, Bern, Switzerland.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France.;OrphaLung Network, Paris, France.;Dept of Genetics, APHP, Hôpital Bichat, Paris, France.;Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;OrphaLung Network, Paris, France.;Dept of Genetics, APHP, Hôpital Bichat, Paris, France.;Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France.","NA",0,"1399-3003","Eur Respir J","Eur Respir J",2020,"2021","57","10.1183/13993003.03198-2020",NA,"","","33214205","33214205","PUBMED","Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, CHU de Caen - ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité -CRESS-UMR1153, Paris, France.;OrphaLung Network, Paris, France.;National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France.;OrphaLung Network, Paris, France.;National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France.;Unit of Interstitial Lung Diseases, Dept of Pneumology, University Hospital of Bellvitge, Barcelona, Spain.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Hôpital Nord, Marseille, France.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, APHP, Service de Pneumologie, Hôpital Tenon, Paris, France.;Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.;Cliniques Universitaires Saint-Luc, Service de Pneumologie, Bruxelles, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, - IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Université de Rennes 1, Rennes, France.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, Service de Pneumologie, CHRU de Lille, Lille, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Hôpital d'Amiens, Université de Picardie Jules Verne, Amiens, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease CHU de Besançon, Service de Pneumologie, Besançon, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, Service de Pneumologie, Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary disease, CHU de Bordeaux, Service de Pneumologie, Pessac, France.;Hôpital Erasme - ULB, Brussels, Belgium.;OrphaLung Network, Paris, France.;Reference center for rare pulmonary diseases, Service de Pneumologie, Dijon, France.;OrphaLung Network, Paris, France.;CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, Service de Pneumologie, Hôpital Larrey, Toulouse, France.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, CHU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France.;Service universitaire de pneumologie, Bern, Switzerland.;OrphaLung Network, Paris, France.;Center for rare pulmonary diseases, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France.;OrphaLung Network, Paris, France.;Dept of Genetics, APHP, Hôpital Bichat, Paris, France.;Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France.;Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.;OrphaLung Network, Paris, France.;Dept of Genetics, APHP, Hôpital Bichat, Paris, France.;Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.;OrphaLung Network, Paris, France."
"405","Zheng J;Yu Y;Durairaj C;Diéras V;Finn RS;Wang DD","Zheng, Jenny;Yu, Yanke;Durairaj, Chandrasekar;Diéras, Véronique;Finn, Richard S;Wang, Diane D","Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib.","Targeted oncology","France","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Drug Tapering;Female;Humans;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyridines;Treatment Outcome","Adult;Aged;Aged, 80 and over;Breast Neoplasms;Drug Tapering;Female;Humans;Middle Aged;Piperazines;Protein Kinase Inhibitors;Pyridines;Treatment Outcome","Palbociclib is indicated for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Exposure-response analyses were conducted to evaluate efficacy in Asian versus non-Asian patients and in patients with versus without dose reduction in PALOMA-2. PALOMA-2 compared palbociclib plus letrozole versus placebo plus letrozole in patients with ABC. Population pharmacokinetic analysis provided apparent palbociclib clearance (CL/F) for each patient. The time-varying exposure metric, C , was calculated using average dose intensity and CL/F at the time of each progression-free survival (PFS) event. A Cox proportional model characterized PFS and palbociclib C  relationships. Significant prognostic factors for PFS were identified by univariate analysis, which were subsequently included in multivariate analyses, in addition to the C  effect on PFS. PFS profiles in Asian/non-Asian patients and patients with/without dose reduction were simulated and compared using observed palbociclib exposures and established exposure-response relationships. Patients (n = 421) received palbociclib plus letrozole (Asian = 64, non-Asian = 357; no dose reduction = 272, dose reduction = 149). Based on univariate analyses, significant prognostic factors were Ki67 score, age, and baseline aspartate aminotransferase (BAST), tumor size, alkaline phosphatase, and albumin levels. In multivariate analysis, only Ki67 and BAST remained significant. Palbociclib exposure did not significantly affect PFS in either univariate (P = 0.12) or multivariate (P = 0.44) analyses. This analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians. NCT01740427.","Pharmacometrics, Global Product Development, Pfizer Inc, Col-D/006/D6400, 500 Arcola Rd., Collegeville, PA, 19426;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Department of Medical Oncology Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.","NA",0,"1776-260X","Target Oncol","Target Oncol",2020,"2021","16","10.1007/s11523-020-00771-5","69-76","","","33211314","33211314","PUBMED","Pharmacometrics, Global Product Development, Pfizer Inc, Col-D/006/D6400, 500 Arcola Rd., Collegeville, PA, 19426;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA.;Department of Medical Oncology Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, CA, USA."
"406","Coudert B;Pierga JY;Mouret-Reynier MA;Kerrou K;Ferrero JM;Petit T;Du FL;Dupré PF;Bachelot T;Gabelle P;Chauvet MP;Coeffic D;Barbe C;Prevost JB;Paintaud G;Thibault G;Ferhat A;Dupin J;Berriolo-Riedinger A;Arnould L","Coudert, Bruno;Pierga, Jean-Yves;Mouret-Reynier, Marie-Ange;Kerrou, Kaldoun;Ferrero, Jean-Marc;Petit, Thierry;Du, Fanny Le;Dupré, Pierre-François;Bachelot, Thomas;Gabelle, Philippe;Chauvet, Marie-Pierre;Coeffic, David;Barbe, Catherine;Prevost, Jean-Briac;Paintaud, Gilles;Thibault, Gilles;Ferhat, Abdennour;Dupin, Julien;Berriolo-Riedinger, Alina;Arnould, Laurent","Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study.","EClinicalMedicine","England","eng","Journal Article","Bevacizumab;Early pet assessment;Her-2 positive breast cancer;Long-term follow-up;Neoadjuvant;Positron emission tomography;pathological complete response;Δsuvmax","","","The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improved pathological complete response (pCR) rates (43.8% vs 24.0%). We investigated long-term study outcomes. Patients were treated in three groups. All patients initially received two cycles of standard neoadjuvant therapy with [¹⁸F]-FDG PET conducted before each cycle. Those with ≥70% change in the maximum standardised uptake value (∆SUVmax) received four further cycles of standard neoadjuvant therapy (PET responders). PET-predicted poor-responders (∆SUVmax <70%) were randomised (2:1) to neoadjuvant therapy with (Group A) or without (Group B) bevacizumab for cycles 3-6. All patients received one further cycle of trastuzumab before surgery plus adjuvant trastuzumab (11 cycles). 142 patients were randomized and treated (PET responders,   = 69; Group A,   = 48; Group B,   = 25). 5-year disease-free survival rates were 90.5% (95% CI: 80.0-95.6%) in PET responders, 90.2% (95% CI: 75.9-96.2%) in Group A, and 76.0% (95% CI: 54.2-88.4%) in Group B. However, no difference was observed between randomised arms in a sensitivity analysis. During adjuvant therapy, the incidence of Grade ≥3 (Group A: 25.6%; Group B 12.5%) and serious adverse events (Group A: 18.6%; Group B 12.5%) was higher in Group A vs Group B, but with no apparent effect on cardiac events. In patients with HER2-positive breast cancer, an intervention based on early PET assessment and improvement of pCR does not modify disease-free survival. Roche France.","Centre Georges-Francois Leclerc, Dijon, France.;Institut Curie, Université de Paris, Paris, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hopital Tenon, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Paul Strauss, Strasbourg, France.;Centre Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire Augustin-Morvan, Brest, France.;Centre Léon Berard, Lyon, France.;Institut Daniel Hollard, Grenoble, France.;Centre Oscar Lambret, Lille, France.;Polyclinique Courlancy, Institut du Cancer Courlancy Reims, France.;CHU Bretonneau, Tours, France.;Centre Pierre Curie, Beuvry, France.;Université de Tours, CHRU de Tours, Tours, France.;Université de Tours, CHRU de Tours, Tours, France.;Roche France S.A.S., Boulogne Billancourt, France.;Roche France S.A.S., Boulogne Billancourt, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Georges-Francois Leclerc, Dijon, France.","NA",0,"2589-5370","EClinicalMedicine","EClinicalMedicine",2020,"2020","28","10.1016/j.eclinm.2020.100566","100566","","","33205032","33205032","PUBMED","Centre Georges-Francois Leclerc, Dijon, France.;Institut Curie, Université de Paris, Paris, France.;Centre Jean Perrin, Clermont Ferrand, France.;Hopital Tenon, Paris, France.;Centre Antoine Lacassagne, Nice, France.;Centre Paul Strauss, Strasbourg, France.;Centre Eugène Marquis, Rennes, France.;Centre Hospitalier Universitaire Augustin-Morvan, Brest, France.;Centre Léon Berard, Lyon, France.;Institut Daniel Hollard, Grenoble, France.;Centre Oscar Lambret, Lille, France.;Polyclinique Courlancy, Institut du Cancer Courlancy Reims, France.;CHU Bretonneau, Tours, France.;Centre Pierre Curie, Beuvry, France.;Université de Tours, CHRU de Tours, Tours, France.;Université de Tours, CHRU de Tours, Tours, France.;Roche France S.A.S., Boulogne Billancourt, France.;Roche France S.A.S., Boulogne Billancourt, France.;Centre Georges-Francois Leclerc, Dijon, France.;Centre Georges-Francois Leclerc, Dijon, France."
"407","Cameli M;Miglioranza MH;Magne J;Mandoli GE;Benfari G;Ancona R;Sibilio G;Reskovic Luksic V;Dejan D;Griseli L;Van De Heyning CM;Mortelmans P;Michalski B;Kupczynska K;Di Giannuario G;Devito F;Dulgheru R;Ilardi F;Salustri A;Abushahba G;Morrone D;Fabiani I;Penicka M;Katbeh A;Sammarco G;Esposito R;Santoro C;Pastore MC;Comenale Pinto S;Kalinin A;Pičkure Ž;Ažman Juvan K;Zupan Mežnar A;Coisne A;Coppin A;Opris MM;Nistor DO;Paakkanen R;Biering-Sørensen T;Olsen FJ;Lapinskas T;Vaškelyté JJ;Galian-Gay L;Casas G;Motoc AI;Papadopoulos CH;Loizos S;Ágoston G;Szabó I;Hristova K;Tsonev SN;Galli E;Vinereanu D;Mihaila Baldea S;Muraru D;Mondillo S;Donal E;Galderisi M;Cosyns B;Edvardsen T;Popescu BA","Cameli, Matteo;Miglioranza, Marcelo Haertel;Magne, Julien;Mandoli, Giulia Elena;Benfari, Giovanni;Ancona, Roberta;Sibilio, Gerolamo;Reskovic Luksic, Vlatka;Dejan, Dosen;Griseli, Leonardo;Van De Heyning, Caroline M;Mortelmans, Philippe;Michalski, Blazej;Kupczynska, Karolina;Di Giannuario, Giovanna;Devito, Fiorella;Dulgheru, Raluca;Ilardi, Federica;Salustri, Alessandro;Abushahba, Galal;Morrone, Doralisa;Fabiani, Iacopo;Penicka, Martin;Katbeh, Asim;Sammarco, Giuseppe;Esposito, Roberta;Santoro, Ciro;Pastore, Maria Concetta;Comenale Pinto, Salvatore;Kalinin, Artem;Pičkure, Žanna;Ažman Juvan, Katja;Zupan Mežnar, Anja;Coisne, Augustine;Coppin, Amandine;Opris, Mihaela Maria;Nistor, Dan Octavian;Paakkanen, Riitta;Biering-Sørensen, Tor;Olsen, Flemming Javier;Lapinskas, Tomas;Vaškelyté, Jolanta Justina;Galian-Gay, Laura;Casas, Guillem;Motoc, Andreea Iulia;Papadopoulos, Constantinos Hristou;Loizos, Savvas;Ágoston, Gergely;Szabó, Istvan;Hristova, Krasimira;Tsonev, Svetlin Netkov;Galli, Elena;Vinereanu, Dragos;Mihaila Baldea, Sorina;Muraru, Denisa;Mondillo, Sergio;Donal, Erwan;Galderisi, Maurizio;Cosyns, Bernard;Edvardsen, Thor;Popescu, Bogdan A","Multicentric Atrial Strain COmparison between Two Different Modalities: MASCOT HIT Study.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","left atrial strain;multi-centric study;reference point;speckle tracking echocardiography;standardization","","","Two methods are currently available for left atrial (LA) strain measurement by speckle tracking echocardiography, with two different reference timings for starting the analysis: QRS (QRS-LASr) and P wave (P-LASr). The aim of MASCOT HIT study was to define which of the two was more reproducible, more feasible, and less time consuming. In 26 expert centers, LA strain was analyzed by two different echocardiographers (young vs senior) in a blinded fashion. The study population included: healthy subjects, patients with arterial hypertension or aortic stenosis (LA pressure overload, group 2) and patients with mitral regurgitation or heart failure (LA volume-pressure overload, group 3). Difference between the inter-correlation coefficient (ICC) by the two echocardiographers using the two techniques, feasibility and analysis time of both methods were analyzed. A total of 938 subjects were included: 309 controls, 333 patients in group 2, and 296 patients in group 3. The ICC was comparable between QRS-LASr (0.93) and P-LASr (0.90). The young echocardiographers calculated QRS-LASr in 90% of cases, the expert ones in 95%. The feasibility of P-LASr was 85% by young echocardiographers and 88% by senior ones. QRS-LASr young median time was 110 s (interquartile range, IR, 78-149) vs senior 110 s (IR 78-155); for P-LASr, 120 s (IR 80-165) and 120 s (IR 90-161), respectively. LA strain was feasible in the majority of patients with similar reproducibility for both methods. QRS complex guaranteed a slightly higher feasibility and a lower time wasting compared to the use of P wave as the reference.","Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Institute of Cardiology, University Foundation of Cardiology, Porto Alegre 90620-000, Brazil.;CHU Limoges, Hôpital Dupuytren, Service Cardiologie, F-87042, 87042 Limoges, France.;Cardiology Department, INSERM U1094, Faculté de médecine de Limoges, 2, rue Marcland, 87000 Limoges, France.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Section of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.;Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.;Institute of Cardiology, University Foundation of Cardiology, Porto Alegre 90620-000, Brazil.;Department of Cardiology, Antwerp University Hospital, 2650 Edegem, Belgium.;Department of Cardiology, Antwerp University Hospital, 2650 Edegem, Belgium.;Department of Cardiology, Medical University of Lodz, 91347 Lodz, Poland.;Department of Cardiology, Medical University of Lodz, 91347 Lodz, Poland.;UO Cardiologia, Ospedale Infermi di Rimini, 47923 Rimini, Italy.;Ramazzini Hospital, 41012 Carpi, Italy.;Cardiology Department-Heart Valve Clinic-University Hospital Liege, B-4000 Liege, Belgium.;Cardiology Department-Heart Valve Clinic-University Hospital Liege, B-4000 Liege, Belgium.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Non-Invasive Department, Heart Hospital-Hamad Medical Corporation, Doha 3050, Qatar.;Non-Invasive Department, Heart Hospital-Hamad Medical Corporation, Doha 3050, Qatar.;Cardiothoracic and Vascular Department, Pisa University, 56126 Pisa, Italy.;Cardiothoracic and Vascular Department, Pisa University, 56126 Pisa, Italy.;Cardiologia e Medicina Cardiovascolare-Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy.;Cardiovascular Research Center Aalst, OLV Clinic, 9300 Aalst, Belgium.;Cardiovascular Research Center Aalst, OLV Clinic, 9300 Aalst, Belgium.;Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, 35122 Padua, Italy.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;Department ""Gailezers"", Riga East Clinical University Hospital, LV-1038 Riga, Latvia.;Department ""Gailezers"", Riga East Clinical University Hospital, LV-1038 Riga, Latvia.;Department of Cardiovascular Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.;Cardiology Department, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Lille University Hospital, 59800 Lille, France.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Lille University Hospital, 59800 Lille, France.;Institute for Emergency Cardiovascular Diseases and Transplant of Targu Mures, 540136 Targu Mures, Romania.;Institute for Emergency Cardiovascular Diseases and Transplant of Targu Mures, 540136 Targu Mures, Romania.;Heart and Lung Center, Helsinki University Hospital and Helsinki University, 00100 Helsinki, Finland.;Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Copenhagen, Denmark.;Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Copenhagen, Denmark.;Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.;Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.;Department of Cardiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.;Department of Cardiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.;Centre for Cardiovascular Diseases, University Hospital of Brussels, B-1090 Brussels, Belgium.;Korgialenio Benakio-Red Cross Hospital, 115 26 Athens, Greece.;Korgialenio Benakio-Red Cross Hospital, 115 26 Athens, Greece.;Department of Family Medicine, University of Szeged, H-6725 Szeged, Hungary.;Department of Family Medicine, University of Szeged, H-6725 Szeged, Hungary.;Department of Noninvasive Functional Diagnostic and Imaging, National Heart Hospital, 1309 Sofia, Bulgaria.;Department of Noninvasive Functional Diagnostic and Imaging, National Heart Hospital, 1309 Sofia, Bulgaria.;Centre Hospitalier Universitaire de Rennes, Inserm, University of Rennes, LTSI-UMR 1099, F-35000 Rennes, France.;Department of Cardiology, University of Medicine and Pharmacy Carol Davila-Emergency and University Hospital, 050474 Bucharest, Romania.;Department of Cardiology, University of Medicine and Pharmacy Carol Davila-Emergency and University Hospital, 050474 Bucharest, Romania.;Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, 35122 Padua, Italy.;Department of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Centre Hospitalier Universitaire de Rennes, Inserm, University of Rennes, LTSI-UMR 1099, F-35000 Rennes, France.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Centre for Cardiovascular Diseases, University Hospital of Brussels, B-1090 Brussels, Belgium.;Center for Cardiological Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.;Faculty of Medicine, University of Oslo, 0315 Oslo, Norway.;Department of Cardiology, University of Medicine and Pharmacy ""Carol Davila""-Euroecolab, Emergency Institute for Cardiovascular Diseases ""Prof. Dr. C. C. Iliescu"", Sos. Fundeni 258, 022328 Bucharest, Romania.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2020,"2020","10","10.3390/diagnostics10110946",NA,"","","33202837","33202837","PUBMED","Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Institute of Cardiology, University Foundation of Cardiology, Porto Alegre 90620-000, Brazil.;CHU Limoges, Hôpital Dupuytren, Service Cardiologie, F-87042, 87042 Limoges, France.;Cardiology Department, INSERM U1094, Faculté de médecine de Limoges, 2, rue Marcland, 87000 Limoges, France.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Section of Cardiology, Department of Medicine, University of Verona, 37126 Verona, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.;Department of Cardiovascular Diseases, University Hospital Centre Zagreb, 10000 Zagreb, Croatia.;Institute of Cardiology, University Foundation of Cardiology, Porto Alegre 90620-000, Brazil.;Department of Cardiology, Antwerp University Hospital, 2650 Edegem, Belgium.;Department of Cardiology, Antwerp University Hospital, 2650 Edegem, Belgium.;Department of Cardiology, Medical University of Lodz, 91347 Lodz, Poland.;Department of Cardiology, Medical University of Lodz, 91347 Lodz, Poland.;UO Cardiologia, Ospedale Infermi di Rimini, 47923 Rimini, Italy.;Ramazzini Hospital, 41012 Carpi, Italy.;Cardiology Department-Heart Valve Clinic-University Hospital Liege, B-4000 Liege, Belgium.;Cardiology Department-Heart Valve Clinic-University Hospital Liege, B-4000 Liege, Belgium.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Non-Invasive Department, Heart Hospital-Hamad Medical Corporation, Doha 3050, Qatar.;Non-Invasive Department, Heart Hospital-Hamad Medical Corporation, Doha 3050, Qatar.;Cardiothoracic and Vascular Department, Pisa University, 56126 Pisa, Italy.;Cardiothoracic and Vascular Department, Pisa University, 56126 Pisa, Italy.;Cardiologia e Medicina Cardiovascolare-Fondazione Toscana Gabriele Monasterio, 56124 Pisa, Italy.;Cardiovascular Research Center Aalst, OLV Clinic, 9300 Aalst, Belgium.;Cardiovascular Research Center Aalst, OLV Clinic, 9300 Aalst, Belgium.;Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, 35122 Padua, Italy.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;UOC Cardiologia/UTIC-""Santa Maria delle Grazie"" Hospital Pozzuoli, 80078 Pozzuoli, Italy.;Department ""Gailezers"", Riga East Clinical University Hospital, LV-1038 Riga, Latvia.;Department ""Gailezers"", Riga East Clinical University Hospital, LV-1038 Riga, Latvia.;Department of Cardiovascular Surgery, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.;Cardiology Department, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Lille University Hospital, 59800 Lille, France.;Department of Clinical Physiology and Echocardiography-Heart Valve Clinic, Lille University Hospital, 59800 Lille, France.;Institute for Emergency Cardiovascular Diseases and Transplant of Targu Mures, 540136 Targu Mures, Romania.;Institute for Emergency Cardiovascular Diseases and Transplant of Targu Mures, 540136 Targu Mures, Romania.;Heart and Lung Center, Helsinki University Hospital and Helsinki University, 00100 Helsinki, Finland.;Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Copenhagen, Denmark.;Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Copenhagen, Denmark.;Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.;Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.;Department of Cardiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.;Department of Cardiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.;Centre for Cardiovascular Diseases, University Hospital of Brussels, B-1090 Brussels, Belgium.;Korgialenio Benakio-Red Cross Hospital, 115 26 Athens, Greece.;Korgialenio Benakio-Red Cross Hospital, 115 26 Athens, Greece.;Department of Family Medicine, University of Szeged, H-6725 Szeged, Hungary.;Department of Family Medicine, University of Szeged, H-6725 Szeged, Hungary.;Department of Noninvasive Functional Diagnostic and Imaging, National Heart Hospital, 1309 Sofia, Bulgaria.;Department of Noninvasive Functional Diagnostic and Imaging, National Heart Hospital, 1309 Sofia, Bulgaria.;Centre Hospitalier Universitaire de Rennes, Inserm, University of Rennes, LTSI-UMR 1099, F-35000 Rennes, France.;Department of Cardiology, University of Medicine and Pharmacy Carol Davila-Emergency and University Hospital, 050474 Bucharest, Romania.;Department of Cardiology, University of Medicine and Pharmacy Carol Davila-Emergency and University Hospital, 050474 Bucharest, Romania.;Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, 35122 Padua, Italy.;Department of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy.;Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy.;Centre Hospitalier Universitaire de Rennes, Inserm, University of Rennes, LTSI-UMR 1099, F-35000 Rennes, France.;Department of Advanced Biomedical Sciences, Federico II, University Hospital, 80131 Naples, Italy.;Centre for Cardiovascular Diseases, University Hospital of Brussels, B-1090 Brussels, Belgium.;Center for Cardiological Innovation, Department of Cardiology, Oslo University Hospital, Rikshospitalet, 0372 Oslo, Norway.;Faculty of Medicine, University of Oslo, 0315 Oslo, Norway.;Department of Cardiology, University of Medicine and Pharmacy ""Carol Davila""-Euroecolab, Emergency Institute for Cardiovascular Diseases ""Prof. Dr. C. C. Iliescu"", Sos. Fundeni 258, 022328 Bucharest, Romania."
"408","Gangneux JP;Padoin C;Michallet M;Saillio E;Kumichel A;Peffault de La Tour R;Ceballos P;Gastinne T;Pigneux A","Gangneux, Jean-Pierre;Padoin, Christophe;Michallet, Mauricette;Saillio, Emeline;Kumichel, Alexandra;Peffault de La Tour, Régis;Ceballos, Patrice;Gastinne, Thomas;Pigneux, Arnaud","Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study.","Journal of fungi (Basel, Switzerland)","Switzerland","eng","Journal Article","antifungal prophylaxis;haematological malignancies;invasive fungal disease;neutropenia","","","Antifungal prophylaxis (AFP) is recommended by international guidelines for patients with acute myeloid leukaemia (AML) undergoing induction chemotherapy and allogeneic hematopoietic cell transplantation. Nonetheless, treatment of breakthrough fungal infections remains challenging. This observational, prospective, multicentre, non-comparative study of patients undergoing myelosuppressive and intensive chemotherapy for AML who are at high-risk of invasive fungal diseases (IFDs), describes AFP management and outcomes for 404 patients (65.6% newly diagnosed and 73.3% chemotherapy naïve). Ongoing chemotherapy started 1.0 ± 4.5 days before inclusion and represented induction therapy for 79% of participants. In 92.3% of patients, posaconazole was initially prescribed, and 8.2% of all patients underwent at least one treatment change after 17 ± 24 days, mainly due to medical conditions influencing AFP absorption (65%). The mean AFP period was 24 ± 32 days, 66.8% stopped their prophylaxis after the high-risk period and 31.2% switched to a non-prophylactic treatment (2/3 empirical, 1/3 pre-emptive/curative). Overall, 9/404 patients (2.2%) were diagnosed with probable or proven IFDs. During the follow-up, 94.3% showed no signs of infection. Altogether, 20 patients (5%) died, and three deaths (0.7%) were IFD-related. In conclusion, AFP was frequently prescribed and well tolerated by these AML patients, breakthrough infections incidence and IFD mortality were low and very few treatment changes were required.","Mycology Department, Centre Hospitalier Universitaire de Rennes, University Rennes, INSERM, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR S_1085, 35000 Rennes, France.;Pharmacy Department, CHU Martinique Site P. Zobda Quitman, 97261 Fort de France, Martinique, France.;Clinical Haematology Department, Centre Léon Bérard (Anticancer Center), 28 Rue Laennec, 69373 Lyon, France.;Department of Medical Affairs, MSD France, 10-12 cours Michelet, 92800 Puteaux, France.;Scientific Department, ClinSearch, 110 Avenue Pierre Brossolette, 92240 Malakoff, France.;Haematology-Bone Marrow Transplant Department, Saint-Louis Hospital APHP, 1 Avenue Claude-Vellefaux, 75010 Paris, France.;Clinical Haematology Department, CHRU Lapeyronie, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.;Clinical Haematology Department, CHU Nantes, 1 Place Alexis-Ricordeau, 44093 Nantes, France.;Blood Diseases Department, Hospital Group Haut Leveque, Avenue de Magellan, 33604 Pessac, France.","NA",0,"2309-608X","J Fungi (Basel)","J Fungi (Basel)",2020,"2020","6","10.3390/jof6040281",NA,"The SAPHIR study","MSD France","33198192","33198192","PUBMED","Mycology Department, Centre Hospitalier Universitaire de Rennes, University Rennes, INSERM, Irset (Institut de Recherche en Santé, Environnement et Travail), UMR S_1085, 35000 Rennes, France.;Pharmacy Department, CHU Martinique Site P. Zobda Quitman, 97261 Fort de France, Martinique, France.;Clinical Haematology Department, Centre Léon Bérard (Anticancer Center), 28 Rue Laennec, 69373 Lyon, France.;Department of Medical Affairs, MSD France, 10-12 cours Michelet, 92800 Puteaux, France.;Scientific Department, ClinSearch, 110 Avenue Pierre Brossolette, 92240 Malakoff, France.;Haematology-Bone Marrow Transplant Department, Saint-Louis Hospital APHP, 1 Avenue Claude-Vellefaux, 75010 Paris, France.;Clinical Haematology Department, CHRU Lapeyronie, 371 Avenue Doyen Gaston Giraud, 34295 Montpellier, France.;Clinical Haematology Department, CHU Nantes, 1 Place Alexis-Ricordeau, 44093 Nantes, France.;Blood Diseases Department, Hospital Group Haut Leveque, Avenue de Magellan, 33604 Pessac, France."
"409","Dent S;Cortés J;Im YH;Diéras V;Harbeck N;Krop IE;Wilson TR;Cui N;Schimmoller F;Hsu JY;He J;De Laurentiis M;Sousa S;Drullinsky P;Jacot W","Dent, S;Cortés, J;Im, Y-H;Diéras, V;Harbeck, N;Krop, I E;Wilson, T R;Cui, N;Schimmoller, F;Hsu, J Y;He, J;De Laurentiis, M;Sousa, S;Drullinsky, P;Jacot, W","Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Clinical Trial, Phase III","PI3K inhibitors;PIK3CA mutations;advanced breast cancer;taselisib","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Class I Phosphatidylinositol 3-Kinases;Female;Fulvestrant;Humans;Imidazoles;Neoplasm Recurrence, Local;Oxazepines;Phosphatidylinositol 3-Kinases;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Class I Phosphatidylinositol 3-Kinases;Female;Fulvestrant;Humans;Imidazoles;Neoplasm Recurrence, Local;Oxazepines;Phosphatidylinositol 3-Kinases;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen","The phase III SANDPIPER study assessed taselisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, PIK3CA-mutant locally advanced or metastatic breast cancer. Postmenopausal women with disease recurrence/progression during/after an aromatase inhibitor were randomized 2 : 1 to receive taselisib (4 mg; taselisib arm) or placebo (placebo arm) plus fulvestrant (500 mg). Stratification factors were visceral disease, endocrine sensitivity, and geographic region. Patients with PIK3CA-mutant tumors (central cobas® PIK3CA Mutation Test) were randomized separately from those without detectable mutations. The primary endpoint was investigator-assessed progression-free survival (INV-PFS) in patients with PIK3CA-mutant tumors. Secondary endpoints included objective response rate, overall survival, clinical benefit rate, duration of objective response, PFS by blinded independent central review (BICR-PFS), safety, and time to deterioration in health-related quality of life. The PIK3CA-mutant intention-to-treat population comprised 516 patients (placebo arm: n = 176; taselisib arm: n = 340). INV-PFS was significantly improved in the taselisib {7.4 months [95% confidence interval (CI), 7.26-9.07]} versus placebo arm (5.4 months [95% CI, 3.68-7.29]) (stratified hazard ratio [HR] 0.70; 95% CI, 0.56-0.89; P = 0.0037) and confirmed by BICR-PFS (HR 0.66). Secondary endpoints, including objective response rate, clinical benefit rate, and duration of objective response, showed consistent improvements in the taselisib arm. Safety was assessed in all randomized patients who received at least one dose of taselisib/placebo or fulvestrant regardless of PIK3CA-mutation status (n = 629). Serious adverse events were lower in the placebo versus taselisib arm (8.9% versus 32.0%). There were more discontinuations (placebo arm: 2.3%; taselisib arm: 16.8%) and dose reductions (placebo arm: 2.3%; taselisib arm: 36.5%) in the taselisib arm. SANDPIPER met its primary endpoint; however, the combination of taselisib plus fulvestrant has no clinical utility given its safety profile and modest clinical benefit.","The Ottawa Hospital Cancer Centre, Ottawa, Canada.;IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Samsung Medical Center, Seoul, Republic of Korea.;Institut Curie, Paris, France; Centre Eugène Marquis, Rennes, France.;Breast Center, Department Gynecology and Obstetrics and CCC Munich, LMU University Hospital, Munich, Germany.;Dana-Farber Cancer Institute, Boston, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;IRCCS Istituto Nazionale Tumori ""Fondazione G. Pascale"", Naples, Italy.;Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.;Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, USA.;Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, Montpellier","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2020,"2021","32","10.1016/j.annonc.2020.10.596","197-207","P30 CA008748","NCI NIH HHS","33186740","33186740","PUBMED","The Ottawa Hospital Cancer Centre, Ottawa, Canada.;IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.;Samsung Medical Center, Seoul, Republic of Korea.;Institut Curie, Paris, France; Centre Eugène Marquis, Rennes, France.;Breast Center, Department Gynecology and Obstetrics and CCC Munich, LMU University Hospital, Munich, Germany.;Dana-Farber Cancer Institute, Boston, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;Genentech, Inc., South San Francisco, USA.;IRCCS Istituto Nazionale Tumori ""Fondazione G. Pascale"", Naples, Italy.;Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.;Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, USA.;Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, Montpellier"
"410","Hraiech S;Yoshida T;Annane D;Duggal A;Fanelli V;Gacouin A;Heunks L;Jaber S;Sottile PD;Papazian L","Hraiech, Sami;Yoshida, Takeshi;Annane, Djillali;Duggal, Abhijit;Fanelli, Vito;Gacouin, Arnaud;Heunks, Leo;Jaber, Samir;Sottile, Peter D;Papazian, Laurent","Myorelaxants in ARDS patients.","Intensive care medicine","United States","eng","Journal Article","Corticosteroids;ECMO;Muscle relaxants;PEEP;Prone positioning;Protective ventilation;Sedation","Humans;Neuromuscular Blocking Agents;Respiration, Artificial;Respiratory Distress Syndrome;Tidal Volume;Ventilator-Induced Lung Injury","Humans;Neuromuscular Blocking Agents;Respiration, Artificial;Respiratory Distress Syndrome;Tidal Volume;Ventilator-Induced Lung Injury","Neuromuscular blocking agents (NMBAs) inhibit patient-initiated active breath and the risk of high tidal volumes and consequent high transpulmonary pressure swings, and minimize patient/ ventilator asynchrony in acute respiratory distress syndrome (ARDS). Minimization of volutrauma and ventilator-induced lung injury (VILI) results in a lower incidence of barotrauma, improved oxygenation and a decrease in circulating proinflammatory markers. Recent randomized clinical trials did not reveal harmful muscular effects during a short course of NMBAs. The use of NMBAs should be considered during the early phase of severe ARDS for patients to facilitate lung protective ventilation or prone positioning only after optimising mechanical ventilation and sedation. The use of NMBAs should be integrated in a global strategy including the reduction of tidal volume, the rational use of PEEP, prone positioning and the use of a ventilatory mode allowing spontaneous ventilation as soon as possible. Partial neuromuscular blockade should be evaluated in future trials.","Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille, France.;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille, France.;The Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.;School of Medicine Simone Veil, Lab of Infection and Inflammation, U1173, RHU-RECORDS, FHU SEPSIS, INSERM, Université Paris Saclay, UVSQ, Hôpital Raymond Poincaré (APHP), 104 boulevard Raymond Poincaré, 92380, Garches, France.;Department of Critical Care, Respiratory Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, 44195, USA.;Department of Surgical Sciences, Anaesthesia and Intensive Care Medicine, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, Inserm-CIC-1414, Université Rennes I, IFR 140, F-35033, Rennes, France.;Department of Intensive Care Medicine, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands.;Réanimation Chirurgicale, Centre Hospitalier Universitaire de Montpellier, Hôpital St-Eloi, Montpellier, France.;Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.;Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille","NA",0,"1432-1238","Intensive Care Med","Intensive Care Med",2020,"2020","46","10.1007/s00134-020-06297-8","2357-2372","K23 HL145011","NHLBI NIH HHS","33159530","33159530","PUBMED","Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille, France.;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille, France.;The Department of Anesthesiology and Intensive Care Medicine, Osaka University Graduate School of Medicine, Suita, Japan.;School of Medicine Simone Veil, Lab of Infection and Inflammation, U1173, RHU-RECORDS, FHU SEPSIS, INSERM, Université Paris Saclay, UVSQ, Hôpital Raymond Poincaré (APHP), 104 boulevard Raymond Poincaré, 92380, Garches, France.;Department of Critical Care, Respiratory Institute, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, 44195, USA.;Department of Surgical Sciences, Anaesthesia and Intensive Care Medicine, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy.;Centre Hospitalier Universitaire de Rennes, Maladies Infectieuses et Réanimation Médicale, Inserm-CIC-1414, Université Rennes I, IFR 140, F-35033, Rennes, France.;Department of Intensive Care Medicine, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands.;Réanimation Chirurgicale, Centre Hospitalier Universitaire de Montpellier, Hôpital St-Eloi, Montpellier, France.;Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO, USA.;Assistance Publique - Hôpitaux de Marseille, Hôpital Nord, Médecine Intensive Réanimation, 13015, Marseille;Faculté de médecine, Groupe de recherche en Réanimation et Anesthésie de Marseille pluridisciplinaire (GRAM +), Centre d'Etudes et de Recherches sur les Services de Santé et qualité de vie EA 3279, Aix-Marseille Université, 13005, Marseille"
"411","de la Motte Rouge T;Touboul C;Lhomel C;Rouprêt M;Morère JF","de la Motte Rouge, Thibault;Touboul, Chantal;Lhomel, Christine;Rouprêt, Morgan;Morère, Jean-François","Factors associated with compliance to cervical cancer screening in France: The EDIFICE 6 survey.","Gynecologic oncology","United States","eng","Journal Article","Attitude to health;Early detection of Cancer;Mass screening;Risk factors;Socioeconomic factors;Uterine cervical neoplasms","Adult;Age Factors;Aged;Early Detection of Cancer;Female;France;Humans;Middle Aged;Papanicolaou Test;Patient Acceptance of Health Care;Social Factors;Surveys and Questionnaires;Treatment Adherence and Compliance;Uterine Cervical Neoplasms","Adult;Age Factors;Aged;Early Detection of Cancer;Female;France;Humans;Middle Aged;Papanicolaou Test;Patient Acceptance of Health Care;Social Factors;Surveys and Questionnaires;Treatment Adherence and Compliance;Uterine Cervical Neoplasms","A nationwide cervical cancer (CC) screening program was implemented in France in 2018. Asymptomatic women are invited for a cytological test once every 3 years (age, 25-29 years), and an HPV test every 5 years (age, 30-65 years). We investigated the characteristics of women who are resistant to CC screening. Since 2005, the EDIFICE survey program has assessed attitudes toward cancer screening in France. The 6th edition (2017) included 12,046 representative women (age, 18-69 years). Social vulnerability was assessed using the EPICES score. Multivariate stepwise logistic regression analysis identified factors correlated with nonuptake of CC screening. Questionnaires from 4499 women (age, 25-65 years) with no history of cancer were analyzed; 88% (N = 3960) reported at least one test in their lifetime, and 73% (N = 3262) did the test in the previous 3 years. Compared to ever-screened women, never-screened women were younger (38 ± 11 yrs. vs 44 ± 12 yrs., P < 0.05), and more likely to be single (48% vs 20%, P < 0.05) and/or socially vulnerable (59% vs 38%, P < 0.05). In multivariate analysis, items significantly (P < 0.05) associated with never screening included living alone (OR = 2.26, 95% CI [1.85-2.75]) and social vulnerability (OR = 1.95 [1.59-2.40]). Women who were not compliant with recommendations were more likely to be older (mean age, 49.2 yrs. vs. 43.2 yrs), living alone (single, widowed or divorced, 40% vs. 30%, P < 0.05), and/or socially vulnerable (55% vs. 35%, P < 0.05; OR = 1.78, 95% CI [1.49-2.12]). This analysis identified several factors associated with never screening and under-screening. Effective prevention messages should specifically target these populations.","Centre Eugène-Marquis, Rennes;Kantar, Health Division, Paris, France.;Roche, Boulogne-Billancourt, France.;Sorbonne Université, GRC n°5, Oncotype-URO, Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, 75 013, Paris, France.;Hôpital Paul Brousse, Villejuif, France.","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2020,"2021","160","10.1016/j.ygyno.2020.10.032","112-117","","","33158509","33158509","PUBMED","Centre Eugène-Marquis, Rennes;Kantar, Health Division, Paris, France.;Roche, Boulogne-Billancourt, France.;Sorbonne Université, GRC n°5, Oncotype-URO, Assistance Publique - Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, 75 013, Paris, France.;Hôpital Paul Brousse, Villejuif, France."
"412","Bidard FC;Jacot W;Kiavue N;Dureau S;Kadi A;Brain E;Bachelot T;Bourgeois H;Gonçalves A;Ladoire S;Naman H;Dalenc F;Gligorov J;Espié M;Emile G;Ferrero JM;Loirat D;Frank S;Cabel L;Diéras V;Cayrefourcq L;Simondi C;Berger F;Alix-Panabières C;Pierga JY","Bidard, François-Clément;Jacot, William;Kiavue, Nicolas;Dureau, Sylvain;Kadi, Amir;Brain, Etienne;Bachelot, Thomas;Bourgeois, Hugues;Gonçalves, Anthony;Ladoire, Sylvain;Naman, Hervé;Dalenc, Florence;Gligorov, Joseph;Espié, Marc;Emile, George;Ferrero, Jean-Marc;Loirat, Delphine;Frank, Sophie;Cabel, Luc;Diéras, Véronique;Cayrefourcq, Laure;Simondi, Cécile;Berger, Frédérique;Alix-Panabières, Catherine;Pierga, Jean-Yves","Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.","JAMA oncology","United States","eng","Journal Article","","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Neoplastic Cells, Circulating;Prognosis;Progression-Free Survival;Receptor, ErbB-2;Receptors, Estrogen","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Neoplastic Cells, Circulating;Prognosis;Progression-Free Survival;Receptor, ErbB-2;Receptors, Estrogen","The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circulating tumor cell (CTC) count (≥5 CTCs/7.5 mL) is a strong adverse prognostic factor for overall survival and progression-free survival (PFS). To compare the efficacy of a clinician-driven treatment choice vs a CTC-driven choice for first-line treatment. In the CTC arm, patients received chemotherapy or endocrine therapy according to the CTC count (chemotherapy if ≥5 CTCs/7.5 mL; endocrine therapy if <5 CTCs/7.5 mL), whereas in the control arm, the choice was left to the investigator. In the STIC CTC randomized, open-label, noninferiority phase 3 trial, participants were randomized to a clinician-driven choice of first-line treatment or a CTC count-driven first-line treatment choice. Eligible participants were premenopausal and postmenopausal women 18 years or older diagnosed with hormone receptor-positive, ERBB2-negative metastatic breast cancer. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019. The primary end point was the investigator-assessed PFS in the per-protocol population, with a noninferiority margin of 1.25 for the 90% CI of the hazard ratio. Among the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years [64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm]; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median PFS was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09). This randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor-positive, ERBB2-negative metastatic breast cancer. ClinicalTrials.gov Identifier: NCT01710605.","Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;INSERM Center of Clinical Investigations in Biotherapies of Cancer (CIC-BT) 1428, Paris, France.;Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France.;Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Aix-Marseille University, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Hôpital Tenon, Sorbonne Université, Paris, France.;Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Formerly with Department of Medical Oncology, Institut Curie, Paris, France.;Now with Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France.;Clinical Research Department, Institut Curie, PSL Research University, Paris, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2020,"2021","7","10.1001/jamaoncol.2020.5660","34-41","","","33151266","33151266","PUBMED","Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;INSERM Center of Clinical Investigations in Biotherapies of Cancer (CIC-BT) 1428, Paris, France.;Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Department of Medical Oncology, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Victor Hugo Clinic, Le Mans, France.;Department of Medical Oncology, Institut Paoli-Calmettes, CRCM, Aix-Marseille University, Marseille, France.;Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Azuréen de Cancérologie, Mougins, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Medical Oncology, Hôpital Tenon, Sorbonne Université, Paris, France.;Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France.;Department of Medical Oncology, Institut Curie, UVSQ and Paris-Saclay University, Saint-Cloud, France.;Formerly with Department of Medical Oncology, Institut Curie, Paris, France.;Now with Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France.;Clinical Research Department, Institut Curie, PSL Research University, Paris, France.;Biometry Unit, Institut Curie, PSL Research University, Paris, France.;Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, EA 2415, Montpellier University, Montpellier, France.;Department of Medical Oncology, Institut Curie, Université de Paris, Paris, France."
"413","Vrana A;Rieutord A;Hue B","Vrana, Anastasia;Rieutord, Andre;Hue, Benoit","An odyssey across Europe.","European journal of hospital pharmacy : science and practice","England","eng","Letter","clinical competence;education;hospital;organisation and administration;pharmacy;pharmacy service;professional competence","Europe;Humans;Pharmacists;Pharmacy Service, Hospital","Europe;Humans;Pharmacists;Pharmacy Service, Hospital","NA","Département de Pharmacie Clinique, Institut Gustave-Roussy, Villejuif, Île-de-France;Département de Pharmacie Clinique, Institut Gustave-Roussy, Villejuif, Île-de-France, France.;Service de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.","NA",0,"2047-9956","Eur J Hosp Pharm","Eur J Hosp Pharm",2020,"2021","28","10.1136/ejhpharm-2020-002533","e5","","","33139317","33139317","PUBMED","Département de Pharmacie Clinique, Institut Gustave-Roussy, Villejuif, Île-de-France;Département de Pharmacie Clinique, Institut Gustave-Roussy, Villejuif, Île-de-France, France.;Service de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France."
"414","De Lorenzo S;Tovoli F;Mazzotta A;Vasuri F;Edeline J;Malvi D;Boudjema K;Renzulli M;Jeddou H;D'Errico A;Turlin B;Cescon M;Uguen T;Granito A;Lièvre A;Brandi G","De Lorenzo, Stefania;Tovoli, Francesco;Mazzotta, Alessandro;Vasuri, Francesco;Edeline, Julien;Malvi, Deborah;Boudjema, Karim;Renzulli, Matteo;Jeddou, Heithem;D'Errico, Antonietta;Turlin, Bruno;Cescon, Matteo;Uguen, Thomas;Granito, Alessandro;Lièvre, Astrid;Brandi, Giovanni","Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role.","Cancers","Switzerland","eng","Journal Article","intrahepatic cholangiocarcinoma;liver cirrhosis;non-alcoholic fatty liver disease;non-alcoholic steatohepatitis;outcome","","","Non-alcoholic fatty liver disease (NAFLD) and its most aggressive form, non-alcoholic steatohepatitis (NASH), are causing a rise in the prevalence of hepatocellular carcinoma. Data about NAFLD/NASH and intrahepatic cholangiocarcinoma (iCCA) are few and contradictory, coming from population registries that do not correctly distinguish between NAFLD and NASH. We evaluated the prevalence of NAFLD and NASH in peritumoral tissue of resected iCCA (  = 180) and in needle biopsies of matched liver donors. Data of iCCA patients were subsequently analysed to compare NASH-related iCCA (Group A), iCCA arisen in a healthy liver (Group B) or in patients with classical iCCA risk factors (Group C). NASH was found in 22.5% of 129 iCCA patients without known risk factors and in 6.2% of matched controls (risk ratio 3.625, 95% confidence interval 1.723-7.626,   < 0.001), while NAFLD was equally represented in both groups. The overall survival of NASH-related iCCA was inferior to that of patients with healthy liver (38.5 vs. 48.1 months,   = 0.003) and similar to that of patients with known risk factors (31.9 months,   = 0.948), regardless of liver fibrosis. The multivariable Cox regression confirmed NASH as a prognostic factor (hazard ratio 1.773, 95% confidence interval 1.156-2.718,   = 0.009). We concluded that NASH (but not NAFLD) is a risk factor for iCCA and might affect its prognosis. Dissecting NASH from NAFLD by histology is necessary to correctly assess the actual role of these conditions. Prevention protocols for NASH patients should also consider the risk for iCCA and not only HCC. Mechanistic studies aimed to find a direct pathogenic link between NASH and iCCA could add further relevant information.","Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Radiology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Pathologie-Centre Hospitalier Universitaire Pontchaillou Rennes, INSERM Numecan U1241, Université de Rennes, Centre de Ressources Biologiques-BB-0033-00056, 35000 Rennes, France.;Surgery Unit, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.;Service de Hepatologie, Centre Hospitalier Universitaire Pontchaillou, 35000 Rennes, France.;Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Department of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, University of Rennes, Inserm U1242, Rennes, France.;Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2020,"2020","12","10.3390/cancers12113182",NA,"","","33138044","33138044","PUBMED","Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Department of Medical Oncology, Centre Eugène Marquis, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Radiology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Chirurgie Hépatobiliaire et Digestive, Centre Hospitalier Universitaire Pontchaillou Rennes, CIC-INSERM, Université de Rennes, 35000 Rennes, France.;Pathology Unit, S. Orsola-Malpighi Bologna Authority Hospital, 40138 Bologna, Italy.;Service de Pathologie-Centre Hospitalier Universitaire Pontchaillou Rennes, INSERM Numecan U1241, Université de Rennes, Centre de Ressources Biologiques-BB-0033-00056, 35000 Rennes, France.;Surgery Unit, Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.;Service de Hepatologie, Centre Hospitalier Universitaire Pontchaillou, 35000 Rennes, France.;Division of Internal Medicine, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.;Department of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, University of Rennes, Inserm U1242, Rennes, France.;Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy."
"415","Haas M;Houot R;Llamas-Gutierrez F;Boulland ML;Roussel M;Lamy T;Fest T;Pastoret C","Haas, Marion;Houot, Roch;Llamas-Gutierrez, Francisco;Boulland, Marie-Laure;Roussel, Mikael;Lamy, Thierry;Fest, Thierry;Pastoret, Cedric","Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation.","HemaSphere","United States","eng","Case Reports","","","","NA","Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Anatomopathologie, Pôle de Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.","NA",0,"2572-9241","Hemasphere","Hemasphere",2020,"2020","4","10.1097/HS9.0000000000000478","e478","","","33134866","33134866","PUBMED","Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Anatomopathologie, Pôle de Biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Service d'Hématologie clinique, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Laboratoire d'Hématologie, Pôle de biologie, Rennes, France."
"416","Joly F;Lefeuvre-Plesse C;Garnier-Tixidre C;Helissey C;Menneveau N;Zannetti A;Salas S;Houede N;Abadie-Lacourtoisie S;Stefani L;Nenan S;Rieger I;Durand-Zaleski I;Descotes JM;Anota A","Joly, Florence;Lefeuvre-Plesse, Claudia;Garnier-Tixidre, Claire;Helissey, Carole;Menneveau, Nathalie;Zannetti, Alain;Salas, Sebastien;Houede, Nadine;Abadie-Lacourtoisie, Sophie;Stefani, Laetitia;Nenan, Soazig;Rieger, Isabelle;Durand-Zaleski, Isabelle;Descotes, Jean-Marc;Anota, Amélie","Feasibility and efficacy of a supervised home-based physical exercise program for metastatic cancer patients receiving oral targeted therapy: study protocol for the phase II/III - UNICANCER SdS 01 QUALIOR trial.","BMC cancer","England","eng","Clinical Trial, Phase II","Adherence to treatment;Fatigue;Medico-economy;Metastatic cancer;Oral targeted therapy;Pain;Psychological and cognitive functions;Quality of life;Supervised physical exercise programs;Supportive care","Administration, Oral;Exercise Therapy;Feasibility Studies;Female;Humans;Male;Neoplasm Metastasis","Administration, Oral;Exercise Therapy;Feasibility Studies;Female;Humans;Male;Neoplasm Metastasis","Currently, oral targeted therapies are known to be effective and are frequently used to treat metastatic cancer patients, but fatigue is a frequently reported early side effect of these treatments. This fatigue may impact the patient's treatment adherence and result in a negative impact on quality of life. Physical exercise significantly improved the general well-being and quality of life of advanced cancer patients. However, there is no specific physical activity program adapted for patients with advanced disease. QUALIOR is a two-part, randomized, open-label, and multicenter with two arms phase II/III trial. Patients (phase II: n = 120; phase III: n = 312) with metastatic cancer (breast cancer, kidney cancer, lung cancer, and other cancers [including but not limited to colon cancer, melanoma, sarcoma, or hepatocarcinoma]) treated with a first- or second-line oral targeted therapy without chemotherapy will be included. Patients will be randomized (2:1) to a 3-month supervised home-based standardized physical activity program or to a recommended adapted physical activity (via a booklet). The primary objective of the phase II is to evaluate the feasibility of the supervised program. The primary objective of the phase III is the evaluation of the benefit of the supervised home-based program compare to the recommended program in terms of fatigue and quality of life at 3 months. The secondary objectives aim to evaluate the impact of the supervised program on fatigue over time, pain, physical capacities, psychosocial and cognitive functions, general quality of life, frequency of dose reduction and patients' adherence to the targeted therapy, overall survival, and progression-free survival. This study will also evaluate the medico-economic impact of supervised program compared to the recommended adapted physical activity program. The aim of this study is to evaluate home-based physical exercise program for metastatic cancer patients treated with oral targeted therapies to help patients to cope with fatigue and improve quality of life. This trial was registered in ClinicalTrials.gov since May 2017 ( NCT03169075 ).","Centre François Baclesse et CHU Côte de Nacre, Caen;Centre Eugène Marquis, Rennes, France.;Institut Daniel Hollard, Grenoble, France.;HIA Begin, Saint Mandé, France.;CHRU de Besançon, Besançon, France.;CH, Cholet, France.;CHU La Timone, Marseille, France.;Institut de Cancérologie du Gard, Nîmes, France.;ICO René Gauducheau, Nantes, France.;CH Annecy Genevois, Pringy, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Hôpital de l'Hôtel-Dieu, Paris, France.;CAMI Sport et Cancer, Neuilly sur seine, France.;CHRU de Besançon, Besançon, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2020,"2020","20","10.1186/s12885-020-07381-4","975","","","33036567","33036567","PUBMED","Centre François Baclesse et CHU Côte de Nacre, Caen;Centre Eugène Marquis, Rennes, France.;Institut Daniel Hollard, Grenoble, France.;HIA Begin, Saint Mandé, France.;CHRU de Besançon, Besançon, France.;CH, Cholet, France.;CHU La Timone, Marseille, France.;Institut de Cancérologie du Gard, Nîmes, France.;ICO René Gauducheau, Nantes, France.;CH Annecy Genevois, Pringy, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Hôpital de l'Hôtel-Dieu, Paris, France.;CAMI Sport et Cancer, Neuilly sur seine, France.;CHRU de Besançon, Besançon, France."
"417","Pangault C;Amé-Thomas P;Rossille D;Dulong J;Caron G;Nonn C;Chatonnet F;Desmots F;Launay V;Lamy T;Fest T;Tarte K","Pangault, Céline;Amé-Thomas, Patricia;Rossille, Delphine;Dulong, Joëlle;Caron, Gersende;Nonn, Céline;Chatonnet, Fabrice;Desmots, Fabienne;Launay, Vincent;Lamy, Thierry;Fest, Thierry;Tarte, Karin","Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse.","Cancers","Switzerland","eng","Journal Article","B cells;Tfh;follicular lymphoma;mesenchymal stromal cells","","","Follicular lymphoma (FL), the most frequent indolent non-Hodgkin's B cell lymphoma, is considered as a prototypical centrocyte-derived lymphoma, dependent on a specific microenvironment mimicking the normal germinal center (GC). In agreement, several FL genetic alterations affect the crosstalk between malignant B cells and surrounding cells, including stromal cells and follicular helper T cells (Tfh). In our study, we sought to deconvolute this complex FL supportive synapse by comparing the transcriptomic profiles of GC B cells, Tfh, and stromal cells, isolated from normal versus FL tissues, in order to identify tumor-specific pathways. In particular, we highlighted a high expression of   and   in FL B cells that could favor the activation of FL Tfh overexpressing IFNG, able in turn to stimulate FL B cells without triggering MHC (major histocompatibility) class II expression. Moreover, the glycoprotein clusterin was found up-regulated in FL stromal cells and could promote FL B cell adhesion. Finally, besides its expression on Tfh, CD200 was found overexpressed on tumor B cells and could contribute to the induction of the immunosuppressive enzyme indoleamine-2,3 dioxygenase by CD200R-expressing dendritic cells. Altogether our findings led us to outline the contribution of major signals provided by the FL microenvironment and their interactions with malignant FL B cells.","UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Immunologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service Hématologie Clinique, Centre Hospitalier Yves Le Fol, F-22000 Saint Brieuc, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Service Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Immunologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2020,"2020","12","10.3390/cancers12102865",NA,"PGA1 RF20170205386;ANR-11-INSB-005;PLBIO-18-060","Association pour la Recherche sur le Cancer;Infrastructure Program eCellFrance;Institut National Du Cancer","33028033","33028033","PUBMED","UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Immunologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Service Hématologie Clinique, Centre Hospitalier Yves Le Fol, F-22000 Saint Brieuc, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Service Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Hématologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;UMR_S 1236, Univ Rennes, INSERM, Établissement Français du Sang (EFS) Bretagne, LabEx IGO, F-35000 Rennes, France.;Laboratoire Immunologie, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Laboratoire Suivi Immunologique des Thérapeutiques Innovantes (SITI), Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France."
"418","Blangis F;Taylor M;Adamsbaum C;Devillers A;Gras-Le Guen C;Launay E;Bossuyt PM;Cohen JF;Chalumeau M","Blangis, Flora;Taylor, Melissa;Adamsbaum, Catherine;Devillers, Anne;Gras-Le Guen, Christèle;Launay, Elise;Bossuyt, Patrick M;Cohen, Jérémie F;Chalumeau, Martin","Add-on bone scintigraphy after negative radiological skeletal survey for the diagnosis of skeletal injury in children suspected of physical abuse: a systematic review and meta-analysis.","Archives of disease in childhood","England","eng","Journal Article","child abuse;imaging","Child, Preschool;Humans;Infant;Bias;Bone and Bones;Interdisciplinary Communication;Mass Screening;Physical Abuse;Radiography;Radionuclide Imaging;Surveys and Questionnaires","Child, Preschool;Humans;Infant;Bias;Bone and Bones;Interdisciplinary Communication;Mass Screening;Physical Abuse;Radiography;Radionuclide Imaging;Surveys and Questionnaires","To systematically assess the extent to which bone scintigraphy (BS) could improve the detection rate of skeletal injury in children suspected of physical abuse with an initial negative radiological skeletal survey (RSS). We searched MEDLINE and Web of Science for series of ≥20 children suspected of physical abuse who underwent RSS and add-on BS. We assessed the risk of bias and the heterogeneity and performed random-effects meta-analyses. After screening 1140 unique search results, we reviewed 51 full-text articles, and included 7 studies (783 children, mostly ≤3 years old). All studies were of either high or unclear risk of bias. Substantial heterogeneity was observed in meta-analyses. The summary detection rate of skeletal injury with RSS alone was 52% (95% CI 37 to 68). The summary absolute increase in detection rate with add-on BS was 10 percentage points (95% CI 6 to 15); the summary relative detection rate was 1.19 (95% CI 1.13 to 1.25); the summary number of children with a negative RSS who needed to undergo a BS to detect one additional child with skeletal injury (number needed to test) was 3 (95% CI 2 to 7). From the available evidence, add-on BS in young children suspected of physical abuse with a negative RSS might allow for a clinically significant improvement of the detection rate of children with skeletal injury, for a limited number of BS procedures required. The quality of the reviewed evidence was low, pointing to the need for high-quality studies in this field.","Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Department of Pediatric Radiology, AP-HP, Bicêtre hospital, F-94270 Le Kremlin Bicêtre, France.;Department of Nuclear Medicine, Centre Eugène Marquis, F-35000 Rennes, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of Pediatric Emergency Care, Nantes University Hospital, F-44000 Nantes, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of Pediatric Emergency Care, Nantes University Hospital, F-44000 Nantes, France.;Department of Clinical Epidemiology, Biostatistics and Bioinformatics, University of Amsterdam, Amsterdam, The Netherlands.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.","NA",0,"1468-2044","Arch Dis Child","Arch Dis Child",2020,"2021","106","10.1136/archdischild-2020-319065","361-366","","","32998873","32998873","PUBMED","Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Department of Pediatric Radiology, AP-HP, Bicêtre hospital, F-94270 Le Kremlin Bicêtre, France.;Department of Nuclear Medicine, Centre Eugène Marquis, F-35000 Rennes, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of Pediatric Emergency Care, Nantes University Hospital, F-44000 Nantes, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Inserm CIC 1413, Nantes University Hospital, F-44000 Nantes, France.;Department of Pediatric Emergency Care, Nantes University Hospital, F-44000 Nantes, France.;Department of Clinical Epidemiology, Biostatistics and Bioinformatics, University of Amsterdam, Amsterdam, The Netherlands.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France.;Obstetrical, Perinatal and Pediatric Epidemiology Research team, Epidemiology and Statistics Research Center, Université de Paris, INSERM, F-75004 Paris, France.;Department of General Pediatrics and Pediatric Infectious Diseases, AP-HP, Necker-Enfants Malades Hospital, Université de Paris, F-75015 Paris, France."
"419","Bartsch R;Dieras V;Cortes J;Müller V;Ruhstaller T","Bartsch, Rupert;Dieras, Veronique;Cortes, Javier;Müller, Volkmar;Ruhstaller, Thomas","ASCO 2020.","Breast care (Basel, Switzerland)","Switzerland","eng","Journal Article","","","","NA","Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria.;Centre Eugène-Marquis, Rennes, France.;IOB Institute of Oncology, Quiron Group, Madrid, Spain.;Department of Obstetrics and Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Breast Center Eastern Switzerland, St. Gallen, Switzerland.","NA",0,"1661-3791","Breast Care (Basel)","Breast Care (Basel)",2020,"2020","15","10.1159/000510051","433-436","","","32982656","32982656","PUBMED","Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria.;Centre Eugène-Marquis, Rennes, France.;IOB Institute of Oncology, Quiron Group, Madrid, Spain.;Department of Obstetrics and Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Breast Center Eastern Switzerland, St. Gallen, Switzerland."
"420","Mollin M;Beaumel S;Vigne B;Brault J;Roux-Buisson N;Rendu J;Barlogis V;Catho G;Dumeril C;Fouyssac F;Monnier D;Gandemer V;Revest M;Brion JP;Bost-Bru C;Jeziorski E;Eitenschenck L;Jarrasse C;Drillon Haus S;Houachée-Chardin M;Hancart M;Michel G;Bertrand Y;Plantaz D;Kelecic J;Traberg R;Kainulainen L;Fauré J;Fieschi F;Stasia MJ","Mollin, M;Beaumel, S;Vigne, B;Brault, J;Roux-Buisson, N;Rendu, J;Barlogis, V;Catho, G;Dumeril, C;Fouyssac, F;Monnier, D;Gandemer, V;Revest, M;Brion, J-P;Bost-Bru, C;Jeziorski, E;Eitenschenck, L;Jarrasse, C;Drillon Haus, S;Houachée-Chardin, M;Hancart, M;Michel, G;Bertrand, Y;Plantaz, D;Kelecic, J;Traberg, R;Kainulainen, L;Fauré, J;Fieschi, F;Stasia, M J","Clinical, functional and genetic characterization of 16 patients suffering from chronic granulomatous disease variants - identification of 11 novel mutations in CYBB.","Clinical and experimental immunology","England","eng","Journal Article","NADPH oxidase;NOX;X-linked CGD variants;clinical severity","Adult;Cell Line;Exons;Female;Granulomatous Disease, Chronic;Humans;Male;Membrane Glycoproteins;Mutation, Missense;NADPH Oxidase 2;Neutrophils;Young Adult","Adult;Cell Line;Exons;Female;Granulomatous Disease, Chronic;Humans;Male;Membrane Glycoproteins;Mutation, Missense;NADPH Oxidase 2;Neutrophils;Young Adult","Chronic granulomatous disease (CGD) is a rare inherited disorder in which phagocytes lack nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity. The most common form is the X-linked CGD (X91-CGD), caused by mutations in the CYBB gene. Clinical, functional and genetic characterizations of 16 CGD cases of male patients and their relatives were performed. We classified them as suffering from different variants of CGD (X91  , X91  or X91  ), according to NADPH oxidase 2 (NOX2) expression and NADPH oxidase activity in neutrophils. Eleven mutations were novel (nine X91  -CGD and two X91  -CGD). One X91  -CGD was due to a new and extremely rare double missense mutation Thr208Arg-Thr503Ile. We investigated the pathological impact of each single mutation using stable transfection of each mutated cDNA in the NOX2 knock-out PLB-985 cell line. Both mutations leading to X91  -CGD were also novel; one deletion, c.-67delT, was localized in the promoter region of CYBB; the second c.253-1879A>G mutation activates a splicing donor site, which unveils a cryptic acceptor site leading to the inclusion of a 124-nucleotide pseudo-exon between exons 3 and 4 and responsible for the partial loss of NOX2 expression. Both X91  -CGD mutations were characterized by a low cytochrome b  expression and a faint NADPH oxidase activity. The functional impact of new missense mutations is discussed in the context of a new three-dimensional model of the dehydrogenase domain of NOX2. Our study demonstrates that low NADPH oxidase activity found in both X91  -CGD patients correlates with mild clinical forms of CGD, whereas X91  -CGD and X91  -CGD cases remain the most clinically severe forms.","Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Département d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France.;Laboratoire d'Immunologie Cellulaire, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Service d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pôle Médecine Aigue et Communautaire, Service d'Infectiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Service de Pédiatrie et Onco-hématologie, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.;Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Klinicki Bolnicki Centar Zagreb, Zagreb, Croatia.;Hospital of Lithuanian University of Health Sciences, Kauno Klinikos, Kaunas, Lithuania.;Department of Pediatrics, University Hospital of Turku, Turku, Finland.;Faculty of Medicine Turku, University of Turku, Turku, Finland.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France.","NA",0,"1365-2249","Clin Exp Immunol","Clin Exp Immunol",2020,"2021","203","10.1111/cei.13520","247-266","","","32954498","32954498","PUBMED","Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Département d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Nancy, Vandoeuvre-lès-Nancy, France.;Laboratoire d'Immunologie Cellulaire, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Service d'Onco-hématologie Pédiatrique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service des Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pôle Médecine Aigue et Communautaire, Service d'Infectiologie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Service de Pédiatrie, Centre Hospitalier Annecy Genevois, Pringy, France.;Service de Pédiatrie et Onco-hématologie, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Département Urgences Post-urgences, CHU Montpellier, Pathogenesis and Control of Chronic Infections, INSERM, Université de Montpellier, Montpellier, France.;Service de Pédiatrie et Hématologie Pédiatrique, Centre Hospitalier Universitaire La Timone, Marseille, France.;Institut d'Hématologie et d'Oncologie Pédiatrique, Hospices Civiles de Lyon, Lyon, France.;Département de Pédiatrie, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France.;Klinicki Bolnicki Centar Zagreb, Zagreb, Croatia.;Hospital of Lithuanian University of Health Sciences, Kauno Klinikos, Kaunas, Lithuania.;Department of Pediatrics, University Hospital of Turku, Turku, Finland.;Faculty of Medicine Turku, University of Turku, Turku, Finland.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Grenoble, France.;Grenoble Institut Neurosciences, Université Grenoble Alpes, Inserm U1216, Grenoble, France.;Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France.;Pôle de Biologie, Centre Hospitalier Universitaire Grenoble Alpes, CGD Diagnosis and Research Centre (CDiReC), Grenoble, France.;Univ. Grenoble Alpes, CEA, CNRS, IBS, F-38044, Grenoble, France."
"421","Mortier CP;Farny M;Bouget J;Le Duff M","Mortier, Charles-Patrick;Farny, Maxime;Bouget, Jacques;Le Duff, Michel","Analgesic consumption evolution at the emergency department of a university hospital (2006-2017): a defined daily doses based analysis.","European journal of hospital pharmacy : science and practice","England","eng","Journal Article","acute pain;clinical audit;drug formulary management;pain management;quality in health care","Analgesics;Analgesics, Non-Narcotic;Analgesics, Opioid;Dose-Response Relationship, Drug;Drug Administration Schedule;Emergency Service, Hospital;Hospitals, University;Humans;Pain Management;Pain Measurement","Analgesics;Analgesics, Non-Narcotic;Analgesics, Opioid;Dose-Response Relationship, Drug;Drug Administration Schedule;Emergency Service, Hospital;Hospitals, University;Humans;Pain Management;Pain Measurement","Pain management in the emergency department (ED) is a key issue that must be regularly evaluated. Practice evaluation gold standard remains patient file analysis, but is highly time consuming. The aim of this study is to evaluate the interest of a defined daily dose (DDD) based analysis in the evaluation of pain management in the ED. A local indicator was elaborated based on the DDD concept: the defined dose per admission (DDA). Unlike the DDD that corresponds to a standardised total dose administered over a day, the DDA represents the average total dose administrated to a patient throughout the stay in the ED. A DDA was assigned to every analgesic, from step 1 to step 3. Oral and injectable forms were studied, but transdermal forms were not considered. DDA values were assimilated to the existing DDDs when these were officially established by the WHO. When values were not defined by the WHO, mean values observed in local practice were selected. Annual numbers of patients admitted to the ED and quantities of each analgesic supplied by the pharmacy ward were annually extracted from respective data files. Paediatric patients being treated at a specific separate ED, only adults were considered throughout the study. Raw quantities of analgesics used each year were converted to their equivalent amounts in DDA, and then expressed in numbers of DDA per 100 admissions (DDA/100A). This indicator allowed us to describe relative evolutions of analgesics prescriptions from 2006 to 2017. Analgesic overall use rose from 18.4 to 30.2 DDA/100A between 2006 and 2017, representing a prescription increase of 64%. Throughout the study, step 1 analgesics rose from 10.8 to 19.3 DDA/100A (+79%), step 3 from 1.8 to 5.4 (+200%) and step 2 remained stable around 5.6 DDA/100A. The integration of orodispersible paracetamol tablets in 2013 allowed us to halve the consumption of injectable paracetamol in the long term and had no effect on classic paracetamol oral forms such as tablets or capsules. Tramadol increased from 41% to 78% among step 2 analgesics after the withdrawal of dextropropoxyphene in 2011. Codeine use shows a steady decline from 1.9 DDA/100A in 2011 to 0.72 in 2017. The DDA concept appears to be an effective tool for assessing long-term analgesic-use trends at hospital EDs. This tool can also mitigate one major bias at EDs, that is the lack of traceability of analgesic administration in emergency contexts. This tool could be adjusted by integrating the average length of stay in the ED.","Pharmaceutical Information Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pharmacy and Therapeutic Committee, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Emergency Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pharmaceutical Information Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"2047-9956","Eur J Hosp Pharm","Eur J Hosp Pharm",2018,"2020","27","10.1136/ejhpharm-2018-001749","271-275","","","32839258","32839258","PUBMED","Pharmaceutical Information Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pharmacy and Therapeutic Committee, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Emergency Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Pharmaceutical Information Department, Centre Hospitalier Universitaire de Rennes, Rennes, France."
"422","Boissier E;Senage T;Babuty A;Gouin-Thibault I;Rozec B;Roussel JC;Sigaud M;Ternisien C;Trossaert M;Fouassier M;Lakhal K","Boissier, Elodie;Senage, Thomas;Babuty, Antoine;Gouin-Thibault, Isabelle;Rozec, Bertrand;Roussel, Jean-Christian;Sigaud, Marianne;Ternisien, Catherine;Trossaert, Marc;Fouassier, Marc;Lakhal, Karim","Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.","Anesthesia and analgesia","United States","eng","Journal Article","","Blood Coagulation;Blood Coagulation Tests;Chondroitin Sulfates;Dermatan Sulfate;Drug Monitoring;Factor Xa Inhibitors;Fondaparinux;France;Heparitin Sulfate;Humans;Predictive Value of Tests;Pyrazoles;Pyridones;Reproducibility of Results;Retrospective Studies;Rivaroxaban","Blood Coagulation;Blood Coagulation Tests;Chondroitin Sulfates;Dermatan Sulfate;Drug Monitoring;Factor Xa Inhibitors;Fondaparinux;France;Heparitin Sulfate;Humans;Predictive Value of Tests;Pyrazoles;Pyridones;Reproducibility of Results;Retrospective Studies;Rivaroxaban","Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitor-specific assays are scarcely available, contrary to heparin anti-Xa assay. We assessed whether the heparin anti-Xa assay can (1) be used as a screening test to rule out apixaban, rivaroxaban, fondaparinux, and danaparoid levels that contraindicate invasive procedures according to current guidelines (>30 ng·mL-1, >30 ng·mL-1, >0.1 µg·mL-1, and >0.1 IU·mL-1, respectively), (2) quantify the anticoagulant level if found significant, that is, if it exceeded the abovementioned threshold. In the derivation cohort then in the validation cohort, via receiver operating characteristics (ROC) curve analysis, we evaluated the ability of heparin anti-Xa assay to detect levels of factor-Xa inhibitors above or below the abovementioned safety thresholds recommended for an invasive procedure (screening test). Among samples with relevant levels of factor-Xa inhibitor, we determined the conversion factor linking the measured level and heparin anti-Xa activity in a derivation cohort. In a validation cohort, the estimated level of each factor-Xa inhibitor was thus inferred from heparin anti-Xa activity. The agreement between measured and estimated levels of factor-Xa inhibitors was assessed. Among 989 (355 patients) and 756 blood samples (420 patients) in the derivation and validation cohort, there was a strong linear relationship between heparin anti-Xa activities and factor-Xa inhibitors measured level (r = 0.99 [95% confidence interval {CI}, 0.99-0.99]). In the derivation cohort, heparin anti-Xa activity ≤0.2, ≤0.3, <0.1, <0.1 IU·mL-1 reliably ruled out a relevant level of apixaban, rivaroxaban, fondaparinux, and danaparoid, respectively (area under the ROC curve ≥0.99). In the validation cohort, these cutoffs yielded excellent classification accuracy (≥96%). If this screening test indicated relevant level of factor-Xa inhibitor, estimated and measured levels closely agreed (Lin's correlation coefficient close to its maximal value: 95% CI, 0.99-0.99). More than 96% of the estimated levels fell into the predefined range of acceptability (ie, 80%-120% of the measured level). A unique simple test already widely used to assay heparin was also useful for quantifying these 4 other anticoagulants. Both clinical and economic impacts of these findings should be assessed in a specific study.","From the Laboratoire d'Hématologie.;Service de Chirurgie Thoracique et Cardio-Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) n°1246, Study of Perinatal, paediatric and adolescent Health: Epidemiological Research and Evaluation (SPHERE) unit, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Anesthésie-réanimation, hôpital Laënnec, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut du Thorax, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.;Service de Chirurgie Thoracique et Cardio-Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service d'Anesthésie-réanimation, hôpital Laënnec, Centre Hospitalier Universitaire de Nantes, Nantes, France.","NA",0,"1526-7598","Anesth Analg","Anesth Analg",2020,"2021","132","10.1213/ANE.0000000000005114","707-716","","","32833716","32833716","PUBMED","From the Laboratoire d'Hématologie.;Service de Chirurgie Thoracique et Cardio-Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut National de la Santé et de la Recherche Médicale (INSERM) n°1246, Study of Perinatal, paediatric and adolescent Health: Epidemiological Research and Evaluation (SPHERE) unit, Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Anesthésie-réanimation, hôpital Laënnec, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Institut du Thorax, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université de Nantes, Nantes, France.;Service de Chirurgie Thoracique et Cardio-Vasculaire, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;From the Laboratoire d'Hématologie.;Centre de traitement de l'hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Service d'Anesthésie-réanimation, hôpital Laënnec, Centre Hospitalier Universitaire de Nantes, Nantes, France."
"423","Rugo HS;Dieras V;Cortes J;Patt D;Wildiers H;O'Shaughnessy J;Zamora E;Yardley DA;Carter GC;Sheffield KM;Li L;Andre VAM;Li XI;Frenzel M;Huang YJ;Dickler MN;Tolaney SM","Rugo, Hope S;Dieras, Veronique;Cortes, Javier;Patt, Debra;Wildiers, Hans;O'Shaughnessy, Joyce;Zamora, Esther;Yardley, Denise A;Carter, Gebra Cuyun;Sheffield, Kristin M;Li, Li;Andre, Valerie A M;Li, Xiaohong I;Frenzel, Martin;Huang, Yu-Jing;Dickler, Maura N;Tolaney, Sara M","Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1.","Breast cancer research and treatment","Netherlands","eng","Journal Article","Abemaciclib;Electronic health records;Metastatic breast cancer;Overall survival;Real-world control arm;Real-world evidence;Retrospective study;Single-arm trial","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Proportional Hazards Models;Receptor, ErbB-2;Vinorelbine","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Proportional Hazards Models;Receptor, ErbB-2;Vinorelbine","In MONARCH 1 (NCT02102490), single-agent abemaciclib demonstrated promising efficacy activity and tolerability in a population of heavily pretreated women with refractory HR+, HER2- metastatic breast cancer (MBC). To help interpret these results and put in clinical context, we compared overall survival (OS) and duration of therapy (DoT) between MONARCH 1 and a real-world single-agent chemotherapy cohort. The real-world chemotherapy cohort was created from a Flatiron Health electronic health records-derived database based on key eligibility criteria from MONARCH 1. The chemotherapies included in the cohort were single-agent capecitabine, gemcitabine, eribulin, or vinorelbine. Results were adjusted for baseline demographics and clinical differences using Mahalanobis distance matching (primary analysis) and entropy balancing (sensitivity analysis). OS and DoT were analyzed using the Kaplan-Meier method and Cox proportional hazards regression. A real-world single-agent chemotherapy cohort (n = 281) with eligibility criteria similar to the MONARCH 1 population (n = 132) was identified. The MONARCH 1 (n = 108) cohort was matched to the real-world chemotherapy cohort (n = 108). Median OS was 22.3 months in the abemaciclib arm versus 13.6 months in the matched real-world chemotherapy cohort with an estimated hazard ratio (HR) of 0.54. The median DoT was 4.1 months in MONARCH 1 compared to 2.9 months in the real-world chemotherapy cohort with HR of 0.76. This study demonstrates an approach to create a real-world chemotherapy cohort suitable to serve as a comparator for trial data. These exploratory results suggest a survival advantage and place the benefit of abemaciclib monotherapy in clinical context.","Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;Centre Eugene Marquis UNICANCER, Rennes Cedex, France.;IOB Institute of Oncology, Quironsalud Group, Madrid, Spain.;IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain.;Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.;Texas Oncology, Austin, TX, USA.;US Oncology, Dallas, TX, USA.;Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium.;Texas Oncology, US Oncology, Baylor University Medical Center, Dallas, TX, USA.;Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.;Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Dana-Farber Cancer Institute, Boston, MA, USA.","NA",0,"1573-7217","Breast Cancer Res Treat","Breast Cancer Res Treat",2020,"2020","184","10.1007/s10549-020-05838-5","161-172","","","32789591","32789591","PUBMED","Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;Centre Eugene Marquis UNICANCER, Rennes Cedex, France.;IOB Institute of Oncology, Quironsalud Group, Madrid, Spain.;IOB Institute of Oncology, Quironsalud Group, Barcelona, Spain.;Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.;Texas Oncology, Austin, TX, USA.;US Oncology, Dallas, TX, USA.;Department of General Medical Oncology, University Hospital Gasthuisberg, Leuven, Belgium.;Texas Oncology, US Oncology, Baylor University Medical Center, Dallas, TX, USA.;Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.;Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Eli Lilly and Company, Indianapolis, IN, USA.;Dana-Farber Cancer Institute, Boston, MA, USA."
"424","Blanc-Durand F;Lefeuvre-Plesse C;Ray-Coquard I;Chaltiel D;Floquet A;Meriaux É;Berton D;Bello-Roufai D;Guillemet C;Dupre PF;Faller É;Alexandre J;Hardy-Bressard AC;Collard O;Fabbro M;Provansal M;Kalbacher E;Genestie C;Pautier P","Blanc-Durand, Félix;Lefeuvre-Plesse, Claudia;Ray-Coquard, Isabelle;Chaltiel, Dan;Floquet, Anne;Meriaux, Émeline;Berton, Dominique;Bello-Roufai, Diana;Guillemet, Cécile;Dupre, Pierre-François;Faller, Émilie;Alexandre, Jérôme;Hardy-Bressard, Anne-Claire;Collard, Olivier;Fabbro, Michel;Provansal, Magali;Kalbacher, Elsa;Genestie, Catherine;Pautier, Patricia","Dose-intensive regimen treatment for small-cell carcinoma of the ovary of hypercalcemic type (SCCOHT).","Gynecologic oncology","United States","eng","Journal Article","","Adolescent;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Small Cell;Chemoradiotherapy, Adjuvant;Cisplatin;Cyclophosphamide;Cytoreduction Surgical Procedures;Disease-Free Survival;Dose-Response Relationship, Drug;Doxorubicin;Etoposide;Female;Humans;Hypercalcemia;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Ovarian Neoplasms;Ovary;Prospective Studies;Retrospective Studies;Stem Cell Transplantation;Transplantation, Autologous;Young Adult","Adolescent;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Carcinoma, Small Cell;Chemoradiotherapy, Adjuvant;Cisplatin;Cyclophosphamide;Cytoreduction Surgical Procedures;Disease-Free Survival;Dose-Response Relationship, Drug;Doxorubicin;Etoposide;Female;Humans;Hypercalcemia;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Ovarian Neoplasms;Ovary;Prospective Studies;Retrospective Studies;Stem Cell Transplantation;Transplantation, Autologous;Young Adult","Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is a rare and rapidly lethal disease affecting young women. Cytoreductive surgery associated with chemotherapy followed by a high dose chemotherapy regimen (HDC) demonstrated improved outcomes in a unique prospective and several retrospective studies, and this report aimed to confirm these results in an independent and larger cohort. Between 2006 and 2018, we conducted a multicentric prospective study on 44 women diagnosed with SCCOHT. Patients were treated homogeneously with optimal cytoreductive surgery and chemotherapy protocol for four to six cycles (PAVEP). In case of complete response, patients received HDC with stem-cell support, followed by pelvic radiotherapy. The primary endpoint was the event-free survival (EFS) in the per-protocol cohort. Secondary analysis explored the effect of HDC with outcomes. Mean age at diagnosis was 33 years old (range 13.8-75.8). 14 patients presented with stage FIGO I, 21 with stage III and 9 with stage IV. Median follow-up was 53.4 months. 38 patients underwent optimal surgery with up to 6 cycles of PAVEP. 30 received HDC, and 21 pelvic radiotherapy. 21 relapses were reported leading to death for 18 patients. Median EFS in the per-protocol cohort was 18.2 months, and 2-year EFS rate was 40%. HDC was significantly associated with better overall survival (p < .001). Grades 3/4 adverse events were frequent but, in most cases, manageable, although one grade-5 adverse-event occurred during HDC. Intensive regimen containing multidrug chemotherapy, HDC and pelvic radiotherapy, for the management of SCCOHT, demonstrated encouraging survival and should be proposed for all patients. However, the significant toxicity cost associated is of concern and it should be restricted to expert centers.","Gynecology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif, France.;Centre Eugène-Marquis, avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Centre Léon-Bérard, 28 Promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Institut Bergonié, 229 cours de l'Argonne, 33000 Bordeaux, France.;Centre François-Baclesse, 3 avenue du Général-Harris, 14000 Caen, France.;Institut de Cancérologie de l'Ouest - René-Gauducheau, Boulevard Pr Jacques-Monod, 44800 Saint-Herblain, France.;Institut Curie - Centre René-Huguenin, 35 rue Dailly, 92210 Saint-Cloud, France.;Centre Henri-Becquerel, 1 rue d'Amiens, 76038 Rouen, France.;Centre hospitalier régional universitaire Morvan de Brest, 2 Avenue Foch, 29200 Brest, France.;Hôpital de Hautepierre, 1 avenue Molière, 67200 Strasbourg, France.;Hôpital Cochin-Port Royal, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.;Hôpital Privé des Côtes d'Armor, 10 rue François-Jacob, 22190 Plérin, France.;Institut de Cancérologie de la Loire - Lucien-Neuwirth, 108 bis avenue Albert-Raimond, 42270 SaintPriest-en-Jarez, France.;Institut du Cancer de Montpellier, 208 rue des Apothicaires, 34298 Montpellier, France.;Institut Paoli-Calmettes, 232 boulevard de Sainte-Marguerite, 13009 Marseille, France.;CHRU Jean-Minjoz, 3 boulevard Alexander-Fleming, 25030 Besançon, France.;Pathology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif, France.;Gynecology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2020,"2020","159","10.1016/j.ygyno.2020.07.019","129-135","","","32723678","32723678","PUBMED","Gynecology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif, France.;Centre Eugène-Marquis, avenue de la Bataille Flandres-Dunkerque, 35000 Rennes, France.;Centre Léon-Bérard, 28 Promenade Léa-et-Napoléon-Bullukian, 69008 Lyon, France.;Department of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France.;Institut Bergonié, 229 cours de l'Argonne, 33000 Bordeaux, France.;Centre François-Baclesse, 3 avenue du Général-Harris, 14000 Caen, France.;Institut de Cancérologie de l'Ouest - René-Gauducheau, Boulevard Pr Jacques-Monod, 44800 Saint-Herblain, France.;Institut Curie - Centre René-Huguenin, 35 rue Dailly, 92210 Saint-Cloud, France.;Centre Henri-Becquerel, 1 rue d'Amiens, 76038 Rouen, France.;Centre hospitalier régional universitaire Morvan de Brest, 2 Avenue Foch, 29200 Brest, France.;Hôpital de Hautepierre, 1 avenue Molière, 67200 Strasbourg, France.;Hôpital Cochin-Port Royal, 27 rue du Faubourg Saint-Jacques, 75014 Paris, France.;Hôpital Privé des Côtes d'Armor, 10 rue François-Jacob, 22190 Plérin, France.;Institut de Cancérologie de la Loire - Lucien-Neuwirth, 108 bis avenue Albert-Raimond, 42270 SaintPriest-en-Jarez, France.;Institut du Cancer de Montpellier, 208 rue des Apothicaires, 34298 Montpellier, France.;Institut Paoli-Calmettes, 232 boulevard de Sainte-Marguerite, 13009 Marseille, France.;CHRU Jean-Minjoz, 3 boulevard Alexander-Fleming, 25030 Besançon, France.;Pathology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif, France.;Gynecology Unit, Institut Gustave-Roussy, 114 rue Édouard-Vaillant, 94800 Villejuif"
"425","Lemaignen A;Bernard L;Tattevin P;Bru JP;Duval X;Hoen B;Brunet-Houdard S;Mainardi JL;Caille A","Lemaignen, Adrien;Bernard, Louis;Tattevin, Pierre;Bru, Jean-Pierre;Duval, Xavier;Hoen, Bruno;Brunet-Houdard, Solène;Mainardi, Jean-Luc;Caille, Agnes","Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials.","BMJ open","England","eng","Clinical Trial Protocol","adult;anti-bacterial agents;infective endocarditis;oral administration;randomised controlled trial","Anti-Bacterial Agents;Endocarditis;Enterococcus;Humans;Neoplasm Recurrence, Local;Prospective Studies;Quality of Life;Randomized Controlled Trials as Topic;Staphylococcus","Anti-Bacterial Agents;Endocarditis;Enterococcus;Humans;Neoplasm Recurrence, Local;Prospective Studies;Quality of Life;Randomized Controlled Trials as Topic;Staphylococcus","Left-sided infective endocarditis (IE) is a serious infection with a heavy burden for patients and healthcare system. Oral switch after initial intravenous antibiotic therapy may reduce costs and improve patients' discomfort without increasing unfavourable outcomes. We describe the methodology of two simultaneously conducted open-label randomised trials aiming to assess non-inferiority of oral switch as compared with entirely intravenous antibiotic therapy for the treatment of left-sided IE. Two simultaneous multicentre open-label prospective randomised trials assessing non-inferiority of oral switch during antibiotic treatment as compared with entirely intravenous therapy in patients with left-sided IE are ongoing. One trial is dedicated to left-sided IE caused by multisusceptible staphylococci (Relais Oral Dans le traitement des Endocardites à staphylocoques ou streptOcoques (RODEO)-1) and the other is dedicated to left-sided IE caused by susceptible streptococci or enterococci (RODEO-2). It is planned to randomise 324 patients in each trial after an initial course of at least 10 days of intravenous antibiotic therapy either to continue intravenous antibiotic therapy or to switch to oral antibiotic therapy. The primary outcome is treatment failure within 3 months after the end of antibiotic treatment, a composite outcome defined by all-cause death and/or symptomatic embolic events and/or unplanned valvular surgery and/or microbiological relapse (with the primary pathogen). Secondary outcomes include patient quality of life, echocardiographic outcome, costs and efficiency associated with IE care. Statistical analysis will be performed with a non-inferiority margin of 10% and a one-sided 2.5% type I error. Written informed consent will be obtained from all participants. This study was approved by Tours Research ethics committee (CPP TOURS-Region Centre-Ouest 1, 2015-R26, 23 February 2016). Study findings will be published in peer-reviewed journals and disseminated through presentation at relevant national and international conferences. EudraCT Number: 2015-002371-16 and NCT02701608; NCT02701595.","Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Université de Tours, Faculté de Médecine, PRES Centre-Val de Loire Université, Tours, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours;Service de Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service d'infectiologie et de médecine interne, Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy, Rhône-Alpes, France.;INSERM Clinical Investigation Center 1425, IAME 1138, Universite Paris Diderot, Sorbonne Paris-Cité, Paris, Île-de-France, France.;Service de Maladies Infectieuses et Tropicales, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.;Service de Maladies Infectieuses et Tropicales, CHRU de Nancy, Vandoeuvre-les-Nancy, France.;Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.;Service de Microbiologie, APHP, Hôpital Européen Georges Pompidou, Paris, France.;Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.;INSERM CIC1415, CHRU de Tours, Tours, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2020,"2020","10","10.1136/bmjopen-2019-033540","e033540","","","32665381","32665381","PUBMED","Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours, France.;Université de Tours, Faculté de Médecine, PRES Centre-Val de Loire Université, Tours, France.;Service de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Régional Universitaire de Tours, Tours;Service de Maladies Infectieuses et de Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Service d'infectiologie et de médecine interne, Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy, Rhône-Alpes, France.;INSERM Clinical Investigation Center 1425, IAME 1138, Universite Paris Diderot, Sorbonne Paris-Cité, Paris, Île-de-France, France.;Service de Maladies Infectieuses et Tropicales, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France.;Service de Maladies Infectieuses et Tropicales, CHRU de Nancy, Vandoeuvre-les-Nancy, France.;Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.;Service de Microbiologie, APHP, Hôpital Européen Georges Pompidou, Paris, France.;Unité d'Evaluation Médico-Economique, EA7505, Education Ethique, Santé, Centre Hospitalier Régional Universitaire de Tours, Université de Tours, Tours, Centre, France.;INSERM CIC1415, CHRU de Tours, Tours, France."
"426","Andrade E;Quinlan L;Harte R;Byrne D;Fallon E;Kelly M;Casey S;Kirrane F;O'Connor P;O'Hora D;Scully M;Laffey J;Pladys P;Beuchée A;ÓLaighin G","Andrade, Evismar;Quinlan, Leo;Harte, Richard;Byrne, Dara;Fallon, Enda;Kelly, Martina;Casey, Siobhan;Kirrane, Frank;O'Connor, Paul;O'Hora, Denis;Scully, Michael;Laffey, John;Pladys, Patrick;Beuchée, Alain;ÓLaighin, Gearóid","Novel Interface Designs for Patient Monitoring Applications in Critical Care Medicine: Human Factors Review.","JMIR human factors","Canada","eng","Journal Article","accuracy;anesthesiology;critical care;ecological display;graphical display;interface design;performance;response time;satisfaction;situation awareness;usability","","","The patient monitor (PM) is one of the most commonly used medical devices in hospitals worldwide. PMs are used to monitor patients' vital signs in a wide variety of patient care settings, especially in critical care settings, such as intensive care units. An interesting observation is that the design of PMs has not significantly changed over the past 2 decades, with the layout and structure of PMs more or less unchanged, with incremental changes in design being made rather than transformational changes. Thus, we believe it well-timed to review the design of novel PM interfaces, with particular reference to usability and human factors. This paper aims to review innovations in PM design proposed by researchers and explore how clinicians responded to these design changes. A literature search of relevant databases, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, identified 16 related studies. A detailed description of the interface design and an analysis of each novel PM were carried out, including a detailed analysis of the structure of the different user interfaces, to inform future PM design. The test methodologies used to evaluate the different designs are also presented. Most of the studies included in this review identified some level of improvement in the clinician's performance when using a novel display in comparison with the traditional PM. For instance, from the 16 reviewed studies, 12 studies identified an improvement in the detection and response times, and 10 studies identified an improvement in the accuracy or treatment efficiency. This indicates that novel displays have the potential to improve the clinical performance of nurses and doctors. However, the outcomes of some of these studies are weakened because of methodological deficiencies. These deficiencies are discussed in detail in this study. More careful study design is warranted to investigate the user experience and usability of future novel PMs for real time vital sign monitoring, to establish whether or not they could be used successfully in critical care. A series of recommendations on how future novel PM designs and evaluations can be enhanced are provided.","Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Physiology, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;General Practice, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation, University Hospital Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Intensive Care Unit, University Hospital Galway, Galway, Ireland.;University Hospital Galway, Galway, Ireland.;General Practice, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation, University Hospital Galway, Galway, Ireland.;School of Psychology, National University of Ireland, Galway, Galway, Ireland.;Anaesthesia, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, National University of Ireland, Galway, Galway, Ireland.;Anaesthesia, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, National University of Ireland, Galway, Galway, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.","NA",0,"2292-9495","JMIR Hum Factors","JMIR Hum Factors",2019,"2020","7","10.2196/15052","e15052","","","32618574","32618574","PUBMED","Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;Physiology, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland.;General Practice, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation, University Hospital Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Mechanical Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Intensive Care Unit, University Hospital Galway, Galway, Ireland.;University Hospital Galway, Galway, Ireland.;General Practice, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Irish Centre for Applied Patient Safety and Simulation, University Hospital Galway, Galway, Ireland.;School of Psychology, National University of Ireland, Galway, Galway, Ireland.;Anaesthesia, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, National University of Ireland, Galway, Galway, Ireland.;Anaesthesia, School of Medicine, National University of Ireland, Galway, Galway, Ireland.;Department of Anaesthesia & Intensive Care Medicine, National University of Ireland, Galway, Galway, Ireland.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes (CHU Rennes), Rennes, France.;Faculté de Médicine de l'Université de Rennes, Rennes, France.;Electrical & Electronic Engineering, School of Engineering, National University of Ireland, Galway, Galway, Ireland.;Human Movement Laboratory, CÚRAM Centre for Research in Medical Devices, National University of Ireland, Galway, Galway, Ireland."
"427","Ducroux C;Renaud N;Bourcier R;Marnat G;Sibon I;Gory B;Richard S;Dargazanli C;Arquizan C;Eugene F;Vannier S;Labreuche J;Walker G;Blanc R;Obadia M;Consoli A;Lapergue B;Fahed R","Ducroux, Célina;Renaud, Nicolas;Bourcier, Romain;Marnat, Gaultier;Sibon, Igor;Gory, Benjamin;Richard, Sébastien;Dargazanli, Cyril;Arquizan, Caroline;Eugene, Francois;Vannier, Stephane;Labreuche, Julien;Walker, Gregory;Blanc, Raphaël;Obadia, Mickael;Consoli, Arturo;Lapergue, Bertrand;Fahed, Robert","Embolus Retriever with Interlinked Cages (ERIC) versus conventional stent retrievers for thrombectomy: a propensity score-based analysis.","Journal of neurointerventional surgery","England","eng","Comparative Study","stroke;thrombectomy","Aged;Aged, 80 and over;Brain Ischemia;Cohort Studies;Embolism;Female;Humans;Male;Middle Aged;Propensity Score;Prospective Studies;Registries;Retrospective Studies;Stents;Stroke;Thrombectomy;Treatment Outcome","Aged;Aged, 80 and over;Brain Ischemia;Cohort Studies;Embolism;Female;Humans;Male;Middle Aged;Propensity Score;Prospective Studies;Registries;Retrospective Studies;Stents;Stroke;Thrombectomy;Treatment Outcome","The Embolus Retriever with Interlinked Cages (ERIC) is one of the latest devices for thrombectomies. It has several architectural features that are supposed to enhance its ability to remove clots and prevent distal emboli. We aimed to compare ERIC with standard stent retrievers (SRs) using propensity score (PS) matching. The clinical and radiological data of all consecutive patients treated with ERIC or standard FDA-approved stent retrievers were collected from a prospective multicenter registry. We compared procedural outcomes (recanalization rates according to the modified Thrombolysis In Cerebral Infarction (mTICI) score and procedural complications) and clinical outcomes (modified Rankin Scale (mRS) and mortality at 3 months). Matching of the populations with PS was performed to account for differences in baseline characteristics. A total of 1230 patients were included. In both the PS-matched cohort (195 ERIC patients, 630 SR patients) and the inverse probability of treatment weighting PS-adjusted cohort (206 ERIC patients, 1024 SR patients) there was no difference in terms of successful recanalization (modified TICI score ≥2b), good clinical outcome (mRS=0-2 or equal to pre-stroke mRS), or mortality at 3 months. Patients treated with first-line ERIC had a higher rate of complete recanalization (mTICI 3); however, they also required more passes and more frequent rescue therapy than the SR patient group. In a large multicenter registry with PS matching, the ERIC device provided equivalent angiographic and clinical results to conventional SRs. URL: http://www.clinicaltrials.gov Unique identifier: NCT03776877.","Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.;Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Interventional and Diagnostic Neuroradiology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Neurology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Diagnostic and Interventional Neuroradiology, Centre Hospitalier Régional Universitaire de Nancy, Nancy, Lorraine, France.;Neurology Stroke Unit, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Neuroradiology, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, Occitanie, France.;Neurology, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France.;Neuroradiology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Biostatistics, Centre Hospitalier Universitaire de Lille, Lille, France.;Department of Medicine - Division of Neurology, Ottawa Hospital, Ottawa, Ontario, Canada.;Department of Medicine - Division of Neurology, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.;Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, Île-de-France, France.;Neuroradiology, Foch Hospital, Suresnes, Île-de-France, France.;Neurology, Foch Hospital, Suresnes, France.;Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris;Department of Medicine - Division of Neurology, Ottawa Hospital, Ottawa, Ontario, Canada.","NA",0,"1759-8486","J Neurointerv Surg","J Neurointerv Surg",2020,"2021","13","10.1136/neurintsurg-2020-016289","255-260","","","32606101","32606101","PUBMED","Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.;Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Neuroradiology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Interventional and Diagnostic Neuroradiology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Neurology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, Aquitaine, France.;Diagnostic and Interventional Neuroradiology, Centre Hospitalier Régional Universitaire de Nancy, Nancy, Lorraine, France.;Neurology Stroke Unit, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France.;Neuroradiology, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, Occitanie, France.;Neurology, Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France.;Neuroradiology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Neurology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Biostatistics, Centre Hospitalier Universitaire de Lille, Lille, France.;Department of Medicine - Division of Neurology, Ottawa Hospital, Ottawa, Ontario, Canada.;Department of Medicine - Division of Neurology, Royal Columbian Hospital, New Westminster, British Columbia, Canada.;Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.;Neurology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, Île-de-France, France.;Neuroradiology, Foch Hospital, Suresnes, Île-de-France, France.;Neurology, Foch Hospital, Suresnes, France.;Interventional Neuroradiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris;Department of Medicine - Division of Neurology, Ottawa Hospital, Ottawa, Ontario, Canada."
"428","Cortés J;Diéras V;Lorenzen S;Montemurro F;Riera-Knorrenschild J;Thuss-Patience P;Allegrini G;De Laurentiis M;Lohrisch C;Oravcová E;Perez-Garcia JM;Ricci F;Sakaeva D;Serpanchy R;Šufliarský J;Vidal M;Irahara N;Wohlfarth C;Aout M;Gelmon K","Cortés, Javier;Diéras, Véronique;Lorenzen, Sylvie;Montemurro, Filippo;Riera-Knorrenschild, Jorge;Thuss-Patience, Peter;Allegrini, Giacomo;De Laurentiis, Michelino;Lohrisch, Caroline;Oravcová, Eva;Perez-Garcia, Jose M;Ricci, Francesco;Sakaeva, Dina;Serpanchy, Rosanne;Šufliarský, Jozef;Vidal, Maria;Irahara, Natsumi;Wohlfarth, Christine;Aout, Mounir;Gelmon, Karen","Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.","JAMA oncology","United States","eng","Clinical Trial, Phase I","","Ado-Trastuzumab Emtansine;Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Middle Aged;Receptor, ErbB-2;Treatment Outcome","Ado-Trastuzumab Emtansine;Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Capecitabine;Female;Humans;Middle Aged;Receptor, ErbB-2;Treatment Outcome","ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. To determine maximum tolerated doses (MTDs) of trastuzumab emtansine (T-DM1) plus capecitabine in patients with previously treated ERBB2-positive mBC and locally advanced/metastatic gastric cancer (LA/mGC) (phase 1) and the efficacy and safety of this combination vs T-DM1 alone in patients with mBC (phase 2). The MTD in phase 1 was assessed using a 3 + 3 design with capecitabine dose modification. Phase 2 was an open-label, randomized, international multicenter study of patients with mBC treated with T-DM1 plus capecitabine or T-DM1 alone. Eligible patients had previously treated ERBB2-positive mBC or LA/mGC with no prior chemotherapy treatment for advanced disease. Patients in the phase 1 mBC cohort received capecitabine (750 mg/m2, 700 mg/m2, or 650 mg/m2 twice daily, days 1-14 of a 3-week cycle) plus T-DM1 3.6 mg/kg every 3 weeks. Patients with LA/mGC received capecitabine at the mBC phase 1 MTD, de-escalating as needed, plus T-DM1 2.4 mg/kg weekly. In phase 2, patients with mBC were randomized (1:1) to receive capecitabine (at the phase 1 MTD) plus T-DM1 or T-DM1 alone. The phase 1 primary objective was to identify the MTD of capecitabine plus T-DM1. The phase 2 primary outcome was investigator-assessed overall response rate (ORR). In phase 1, the median (range) age was 54.0 (37-71) and 57.5 (53-70) years for patients with mBC and patients with LA/mGC, respectively. The capecitabine MTD was identified as 700 mg/m2 in 11 patients with mBC and 6 patients with LA/mGC evaluable for dose-limiting toxic effects. In phase 2, between October 2014 and April 2016, patients with mBC (median [range] age, 52.0 [28-80] years) were randomized to receive combination therapy (n = 81) or T-DM1 (n = 80). The ORR was 44% (36 of 81 patients) and 36% (29 of 80 patients) in the combination and T-DM1 groups, respectively (difference, 8.2%; 90% CI, -4.5 to 20.9; P = .34; clinical cutoff, May 31, 2017). Adverse events (AEs) were reported in 78 of 82 patients (95%) in the combination group, with 36 (44%) experiencing grade 3-4 AEs, and 69 of 78 patients (88%) in the T-DM1 group, with 32 (41%) experiencing grade 3-4 AEs. No grade 5 AEs were reported. Adding capecitabine to T-DM1 did not statistically increase ORR associated with T-DM1 in patients with previously treated ERBB2-positive mBC. The combination group reported more AEs, but with no unexpected toxic effects. ClinicalTrials.gov Identifier: NCT01702558.","Quirónsalud Group, IOB Institute of Oncology, Madrid, Spain.;Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Centre Eugène Marquis, Rennes, France.;Institut Curie, Paris, France.;Hematology/Medical Oncology, 3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.;Klinik für Hämatologie, Onkologie und Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldingerstraße, Marburg, Germany.;Department of Haematology, Oncology and Tumorimmunology, Campus Virchow-Klinikum, Charité-University Medicine Berlin, Berlin, Germany.;Division of Medical Oncology, Department of Oncology, Pontedera Hospital, Azienda L Toscana Nord Ovest, Pisa, Italy.;Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale"", Napoli, Italy.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.;Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain.;Institut Curie, Paris, France.;Department of Chemotherapy, Republican Clinical Oncology Center, Ufa, Russia.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.;National Cancer Institute, Bratislava, Slovak Republic.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;Now with Novartis, Basel, Switzerland.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;University of British Columbia, Vancouver, British Columbia, Canada.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2020,"2020","6","10.1001/jamaoncol.2020.1796","1203-1209","","","32584367","32584367","PUBMED","Quirónsalud Group, IOB Institute of Oncology, Madrid, Spain.;Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Centre Eugène Marquis, Rennes, France.;Institut Curie, Paris, France.;Hematology/Medical Oncology, 3rd Department of Internal Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.;Klinik für Hämatologie, Onkologie und Immunologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldingerstraße, Marburg, Germany.;Department of Haematology, Oncology and Tumorimmunology, Campus Virchow-Klinikum, Charité-University Medicine Berlin, Berlin, Germany.;Division of Medical Oncology, Department of Oncology, Pontedera Hospital, Azienda L Toscana Nord Ovest, Pisa, Italy.;Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS ""Fondazione G. Pascale"", Napoli, Italy.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.;Quirónsalud Group, IOB Institute of Oncology, Barcelona, Spain.;Institut Curie, Paris, France.;Department of Chemotherapy, Republican Clinical Oncology Center, Ufa, Russia.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic.;National Cancer Institute, Bratislava, Slovak Republic.;Vall d'Hebron Institute of Oncology, Barcelona, Spain.;Translational Genomics and Targeted Therapeutics in Solid Tumors Group, IDIBAPS, Barcelona, Spain.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;F. Hoffmann-La Roche Ltd, Basel, Switzerland.;Now with Novartis, Basel, Switzerland.;BC Cancer, Vancouver Cancer Centre, Vancouver, British Columbia, Canada.;University of British Columbia, Vancouver, British Columbia, Canada."
"429","Cofais C;Veillard D;Farges C;Baldeyrou M;Jarno P;Somme D;Corvol A","Cofais, Cécilia;Veillard, David;Farges, Céline;Baldeyrou, Marion;Jarno, Pascal;Somme, Dominique;Corvol, Aline","COVID-19 Epidemic: Regional Organization Centered on Nursing Homes.","Journal of the American Geriatrics Society","United States","eng","Letter","","Aged;COVID-19;Cooperative Behavior;France;Homes for the Aged;Humans;Nursing Homes;Pandemics;Regional Health Planning;SARS-CoV-2","Aged;COVID-19;Cooperative Behavior;France;Homes for the Aged;Humans;Nursing Homes;Pandemics;Regional Health Planning;SARS-CoV-2","NA","Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Structure Régionale d'Appui, CAPPs Bretagne, Rennes, France.;Service des Urgences, SAMU, SMUR. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses et réanimation médicale. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Structure Régionale d'Appui, CAPPs Bretagne, Rennes, France.;Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;UFR Médecine, Université de Rennes 1, Rennes, France.;UMR 6051, ARENES, CNRS/IEP, Rennes, France.;Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;UFR Médecine, Université de Rennes 1, Rennes, France.;UMR 6051, ARENES, CNRS/IEP, Rennes, France.","NA",0,"1532-5415","J Am Geriatr Soc","J Am Geriatr Soc",2020,"2020","68","10.1111/jgs.16687","2191-2193","","","32557563","32557563","PUBMED","Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Structure Régionale d'Appui, CAPPs Bretagne, Rennes, France.;Service des Urgences, SAMU, SMUR. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Maladies Infectieuses et réanimation médicale. Centre Hospitalier Universitaire de Rennes, Rennes, France.;Structure Régionale d'Appui, CAPPs Bretagne, Rennes, France.;Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;UFR Médecine, Université de Rennes 1, Rennes, France.;UMR 6051, ARENES, CNRS/IEP, Rennes, France.;Service de Gériatrie. Centre Hospitalier Universitaire de Rennes, Rennes, France.;UFR Médecine, Université de Rennes 1, Rennes, France.;UMR 6051, ARENES, CNRS/IEP, Rennes, France."
"430","Saade A;Styczynski J;Cesaro S","Saade, Anastasia;Styczynski, Jan;Cesaro, Simone","BK virus infection in allogeneic hematopoietic cell transplantation: An update on pathogenesis, immune responses, diagnosis and treatments.","The Journal of infection","England","eng","Journal Article","BK polyoma virus;Hematopoietic cell transplantation;Hemorrhagic cystitis","BK Virus;Cystitis;Hematopoietic Stem Cell Transplantation;Humans;Immunity;Polyomavirus Infections","BK Virus;Cystitis;Hematopoietic Stem Cell Transplantation;Humans;Immunity;Polyomavirus Infections","In hematopoietic cell transplantation (HCT) patients, BK polyomavirus (BKPyV) infection results in significant morbidity mainly due to hemorrhagic cystitis (HC). Despite increased knowledge acquired over recent decades, no treatment has shown effectiveness in the management of organ damage in HCT allografts. This review summarizes the current knowledge on BKPyV, from the virus constitution to the pathophysiology and immune-related mechanisms. We next focus on BKPyV-induced HC in HCT to discuss the benefit of monitoring BKPyV viruria and viremia in the management of patients. At last, we review currently used therapeutics, along with future promising therapies to propose clinical and practical guidelines and further interesting research areas.","Department of Hematology, Ponchaillou, Centre Hospitalier Universitaire de Rennes;Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.;Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Italy.","NA",0,"1532-2742","J Infect","J Infect",2019,"2020","81","10.1016/j.jinf.2020.06.009","372-382","","","32526327","32526327","PUBMED","Department of Hematology, Ponchaillou, Centre Hospitalier Universitaire de Rennes;Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, Bydgoszcz, Poland.;Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata Verona, Italy."
"431","Painvin B;Guillot P;Verdier MC;Gacouin A;Maamar A","Painvin, Benoit;Guillot, Pauline;Verdier, Marie-Clémence;Gacouin, Arnaud;Maamar, Adel","Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.","Intensive care medicine","United States","eng","Letter","","Acute Kidney Injury;Aged;Betacoronavirus;COVID-19;Coronavirus Infections;Creatinine;Critical Illness;Dose-Response Relationship, Drug;Drug Monitoring;Female;Half-Life;Humans;Hydroxychloroquine;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral;SARS-CoV-2;COVID-19 Drug Treatment","Acute Kidney Injury;Aged;Betacoronavirus;COVID-19;Coronavirus Infections;Creatinine;Critical Illness;Dose-Response Relationship, Drug;Drug Monitoring;Female;Half-Life;Humans;Hydroxychloroquine;Intensive Care Units;Male;Middle Aged;Pandemics;Pneumonia, Viral;SARS-CoV-2;COVID-19 Drug Treatment","NA","Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Laboratoire de Pharmacologie Biologique, Centre Hospitalier Universitaire Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.","NA",0,"1432-1238","Intensive Care Med","Intensive Care Med",2020,"2020","46","10.1007/s00134-020-06142-y","1772-1773","","","32514594","32514594","PUBMED","Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Laboratoire de Pharmacologie Biologique, Centre Hospitalier Universitaire Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France.;Service de Maladies Infectieuses et Réanimation Médicale, Centre Hospitalier Universitaire de Rennes, Hôpital Pontchaillou, 2 rue Henri le Guilloux, 35033, Rennes Cedex 9, France.;Faculté de Médecine, Université de Rennes 1, Unité INSERM CIC 1414, IFR 140, Rennes, France."
"432","Denis F;Galmiche S;Dinh A;Fontanet A;Scherpereel A;Benezit F;Lescure FX","Denis, Fabrice;Galmiche, Simon;Dinh, Aurélien;Fontanet, Arnaud;Scherpereel, Arnaud;Benezit, Francois;Lescure, François-Xavier","Epidemiological Observations on the Association Between Anosmia and COVID-19 Infection: Analysis of Data From a Self-Assessment Web Application.","Journal of medical Internet research","Canada","eng","Journal Article","COVID-19;anosmia;epidemiological surveillance;epidemiology;outbreak;self-assessment;surveillance;symptoms;web application","Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;COVID-19;Coronavirus Infections;Disease Outbreaks;France;Humans;Middle Aged;Olfaction Disorders;Pandemics;Pneumonia, Viral;SARS-CoV-2;Self-Assessment;Surveys and Questionnaires;Young Adult","Adolescent;Adult;Aged;Aged, 80 and over;Betacoronavirus;COVID-19;Coronavirus Infections;Disease Outbreaks;France;Humans;Middle Aged;Olfaction Disorders;Pandemics;Pneumonia, Viral;SARS-CoV-2;Self-Assessment;Surveys and Questionnaires;Young Adult","We developed a self-assessment and participatory surveillance web application for coronavirus disease (COVID-19), which was launched in France in March 2020. Our objective was to determine if self-reported symptoms could help monitor the dynamics of the COVID-19 outbreak in France. Users were asked questions about underlying conditions, sociodemographic status, zip code, and COVID-19 symptoms. Depending on the symptoms reported and the presence of coexisting disorders, users were told to either stay at home, contact a general practitioner (GP), or call an emergency phone number. Data regarding COVID-19-related hospitalizations were retrieved from the Ministry of Health. As of March 29, 2020, the application was opened 4,126,789 times; 3,799,535 electronic questionnaires were filled out; and 2,477,174 users had at least one symptom. In total, 34.8% (n=1,322,361) reported no symptoms. The remaining users were directed to self-monitoring (n=858,878, 22.6%), GP visit or teleconsultation (n=1,033,922, 27.2%), or an emergency phone call (n=584,374, 15.4%). Emergency warning signs were reported by 39.1% of participants with anosmia, a loss of the sense of smell (n=127,586) versus 22.7% of participants without anosmia (n=1,597,289). Anosmia and fever and/or cough were correlated with hospitalizations for COVID-19 (Spearman correlation coefficients=0.87 and 0.82, respectively; P<.001 for both). This study suggests that anosmia may be strongly associated with COVID-19 and its severity. Despite a lack of medical assessment and virological confirmation, self-checking application data could be a relevant tool to monitor outbreak trends. ClinicalTrials.gov NCT04331171; https://clinicaltrials.gov/ct2/show/NCT04331171.","Inter-regional Cancer Institut Jean Bernard, Le Mans, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Service de maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, Garches, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Service de pneumologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Service de maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes Pointchaillou, Rennes, France.;Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital and University of Paris, Assistance Publique - Hôpitaux de Paris, Paris, France.;Team DesCID, Infection, Antimicrobials, Modelling, Evolution - U1137, French Institute for Health and Medical Research, Institut national de la santé et de la recherche médicale, Paris, France.","NA",0,"1438-8871","J Med Internet Res","J Med Internet Res",2020,"2020","22","10.2196/19855","e19855","","","32496206","32496206","PUBMED","Inter-regional Cancer Institut Jean Bernard, Le Mans, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Service de maladies infectieuses et tropicales, Hôpital Raymond Poincaré, Assistance Publique - Hôpitaux de Paris, Garches, France.;Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.;Service de pneumologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Service de maladies infectieuses et réanimation médicale, Centre Hospitalier Universitaire de Rennes Pointchaillou, Rennes, France.;Infectious and Tropical Diseases Department, Bichat-Claude Bernard University Hospital and University of Paris, Assistance Publique - Hôpitaux de Paris, Paris, France.;Team DesCID, Infection, Antimicrobials, Modelling, Evolution - U1137, French Institute for Health and Medical Research, Institut national de la santé et de la recherche médicale, Paris, France."
"433","Hage C;Michaëlsson E;Kull B;Miliotis T;Svedlund S;Linde C;Donal E;Daubert JC;Gan LM;Lund LH","Hage, Camilla;Michaëlsson, Erik;Kull, Bengt;Miliotis, Tasso;Svedlund, Sara;Linde, Cecilia;Donal, Erwan;Daubert, Jean-Claude;Gan, Li-Ming;Lund, Lars H","Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients.","ESC heart failure","England","eng","Journal Article","Endothelial dysfunction;Heart failure with preserved ejection fraction;Microvascular inflammation;Myeloperoxidase;Prognosis","Aged;Biomarkers;Female;Heart Failure;Humans;Inflammation;Male;Middle Aged;Peroxidase;Stroke Volume","Aged;Biomarkers;Female;Heart Failure;Humans;Inflammation;Male;Middle Aged;Peroxidase;Stroke Volume","In heart failure (HF) with preserved ejection fraction (HFpEF), microvascular inflammation is proposed as an underlying mechanism. Myeloperoxidase (MPO) is associated with vascular dysfunction and prognosis in congestive HF. MPO, MPO-related biomarkers, and echocardiography were assessed in 86 patients, 4-8 weeks after presentation with acute HF (EF ≥ 45%), and in 46 healthy controls. Patients were followed up for median 579 days (Q1;Q3 276;1178) regarding the composite endpoint all-cause mortality or HF hospitalization. Patients were 73 years old, 51% were female, EF was 64% (Q1;Q3 58;68), E/e' was ratio 10.8 (8.3;14.0), and left atrial volume index (LAVI) was 43 mL/m  (38;52). Controls were 60 (57;62) years old (vs. patients; P < 0.001), 24% were female (P = 0.005), and left ventricular EF was 63% (59;66; P = 0.790). MPO was increased in HFpEF compared with controls, 101 (81;132) vs. 86 (74;101 ng/mL, P = 0.015), as was uric acid 369 (314;439) vs. 289 (252;328 μmol/L, P < 0.001), calprotectin, asymmetric dimethyl arginine (ADMA), and symmetric dimethyl arginine (SDMA), while arginine was decreased. MPO correlated with uric acid (r = 0.26; P = 0.016). In patients with E/e' > 14, uric acid and SDMA were elevated (421 vs. 344 μM, P = 0.012; 0.54 vs. 0.47 μM, P = 0.039, respectively), and MPO was 121 vs. 98 ng/mL (P = 0.090). The ratios of arginine/ADMA (112 vs. 162; P < 0.001) and ADMA/SDMA (1.36 vs. 1.17; P = 0.002) were decreased in HFpEF patients, suggesting reduced NO availability and increased enzymatic clearance of ADMA, respectively. Uric acid independently predicted the endpoint [hazard ratio (HR) 3.76 (95% CI 1.19-11.85; P = 0.024)] but not MPO [HR 1.48 (95% CI 0.70-3.14; P = 0.304)] or the other biomarkers. In HFpEF, MPO-dependent oxidative stress reflected by uric acid and calprotectin is increased, and SDMA is associated with diastolic dysfunction and uric acid with outcome. This suggests microvascular neutrophil involvement mirroring endothelial dysfunction, a central component of the HFpEF syndrome and a potential treatment target.","Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2019,"2020","7","10.1002/ehf2.12700","1534-1546","00556-2009;20110120;20080409;20100419;2013-23897-104604-23;NA","Stockholm County Council;Stockholm County Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Research Council;Center for Gender Medicine, Karolinska Institutet;Medtronic Bakken Research Center;Fédération Française de Cardiologie/Société Française de Cardiologie","32424988","32424988","PUBMED","Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Research and Early Development Cardiovascular Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.;Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.;Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.;Heart and Vascular Theme, Heart Failure Section, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden."
"434","Tao Y;Auperin A;Blanchard P;Alfonsi M;Sun XS;Rives M;Pointreau Y;Castelli J;Graff P;Wong Hee Kam S;Thariat J;Veresezan O;Heymann S;Renard-Oldrini S;Lafond C;Cornely A;Casiraghi O;Boisselier P;Lapeyre M;Biau J;Bourhis J","Tao, Yungan;Auperin, Anne;Blanchard, Pierre;Alfonsi, Marc;Sun, Xu-Shan;Rives, Michel;Pointreau, Yoann;Castelli, Joël;Graff, Pierre;Wong Hee Kam, Stéphanie;Thariat, Juliette;Veresezan, Ovidiu;Heymann, Steve;Renard-Oldrini, Sophie;Lafond, Cédrik;Cornely, Alexandre;Casiraghi, Odile;Boisselier, Pierre;Lapeyre, Michel;Biau, Julian;Bourhis, Jean","Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.","Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology","Ireland","eng","Clinical Trial, Phase III","Cisplatin;Concurrent chemoradiotherapy;Dose escalation;Head and neck cancer;IMRT;Intensity-modulated radiotherapy","Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Humans;Radiotherapy Dosage;Radiotherapy, Intensity-Modulated;Squamous Cell Carcinoma of Head and Neck","Chemoradiotherapy;Cisplatin;Head and Neck Neoplasms;Humans;Radiotherapy Dosage;Radiotherapy, Intensity-Modulated;Squamous Cell Carcinoma of Head and Neck","Concurrent chemoradiotherapy (CRT) is the standard of care (SoC) in locally advanced (LA) head and neck squamous cell carcinomas (HNSCC). This trial was designed to test whether dose-escalated IMRT and cisplatin could improve locoregional control without increasing complications over 3D-radiotherapy. Patients were randomized between 70 Gy/35F in 7 weeks with 3D-RT (Arm A) versus 75 Gy/35F with IMRT (Arm B). Both arms received 50 Gy in 25 fractions followed by a sequential boost of 20 Gy/10F in Arm A and 25 Gy/10F to gross tumor volume in Arm B, as well as 3 cycles of cisplatin at 100 mg/m2 during RT. The primary endpoint was locoregional progression (LRP). 188 patients were randomized: 85% oropharynx and 73% stage IVa. P16 status was documented for 137 oropharyngeal tumors with P16+ in 53 (39%) patients; and 90% were smokers. Median follow-up was 60.5 months. Xerostomia was markedly decreased in arm B (p < 0.0001). The 1-year grade ≥2 xerostomia (RTOG criteria) was 63% vs 23% and 3-year 45% vs 11% in arms A and B, respectively. Xerostomia LENT-SOMA scale was also reduced in arm B. Dose-escalated IMRT did not reduce LRP with an adjusted HR of 1.13 [95%CI = 0.64-1.98] (p = 0.68). Survival was not different (adjusted HR: 1.19 [95%CI = 0.78-1.81], p = 0.42). No interaction between p16 and treatment effect was found. Dose-escalated IMRT did not improve LRC in LA-HNSCC patients treated with concomitant CRT over standard 3D-RT. This trial reinforces the evidence showing IMRT reduces xerostomia in LA-HNSCC treated with radiotherapy. Clinicaltrial.gov: NCT00158678.","Gustave-Roussy Cancer Campus Grand Paris, Villejuif;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Institut Sainte Catherine, Avignon, France.;Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.;Institut Claudius Regaud, Toulouse, France.;Centre Jean Bernard, Le Mans, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.;AP-HM Hôpital de la Timone, Marseille, France.;Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Clinique Sainte Anne, Strasbourg, France.;Centre Alexis Vautrin, Nancy, France.;Centre Jean Bernard, Le Mans, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.;Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne","NA",0,"1879-0887","Radiother Oncol","Radiother Oncol",2020,"2020","150","10.1016/j.radonc.2020.05.021","18-25","","","32417348","32417348","PUBMED","Gustave-Roussy Cancer Campus Grand Paris, Villejuif;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; INSERM 1018, Villefjuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Institut Sainte Catherine, Avignon, France.;Hopital Nord Franche-Comté de Montbéliard & CHRU de Besançon, France.;Institut Claudius Regaud, Toulouse, France.;Centre Jean Bernard, Le Mans, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud, Toulouse, France; Centre Alexis Vautrin, Nancy, France.;AP-HM Hôpital de la Timone, Marseille, France.;Centre Antoine Lacassagne, Nice, France; Centre francois Baclesse, Caen, France.;Centre Henri Becquerel, Rouen, France.;Clinique Sainte Anne, Strasbourg, France.;Centre Alexis Vautrin, Nancy, France.;Centre Jean Bernard, Le Mans, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France.;Centre Eugène Marquis, Rennes, France; Institut du Cancer de Montpellier, France.;Centre Alexis Vautrin, Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Gustave-Roussy Cancer Campus Grand Paris, Villejuif, France; CHUV Lausanne"
"435","Frank S;Carton M;Dubot C;Campone M;Pistilli B;Dalenc F;Mailliez A;Levy C;D'Hondt V;Debled M;Vermeulin T;Coudert B;Perrin C;Gonçalves A;Uwer L;Ferrero JM;Eymard JC;Petit T;Mouret-Reynier MA;Patsouris A;Guesmia T;Bachelot T;Robain M;Cottu P","Frank, Sophie;Carton, Matthieu;Dubot, Coraline;Campone, Mario;Pistilli, Barbara;Dalenc, Florence;Mailliez, Audrey;Levy, Christelle;D'Hondt, Véronique;Debled, Marc;Vermeulin, Thomas;Coudert, Bruno;Perrin, Christophe;Gonçalves, Anthony;Uwer, Lionel;Ferrero, Jean-Marc;Eymard, Jean-Christophe;Petit, Thierry;Mouret-Reynier, Marie-Ange;Patsouris, Anne;Guesmia, Tahar;Bachelot, Thomas;Robain, Mathieu;Cottu, Paul","Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Age;Breast cancer;Metastatic disease;Overall survival;Real-world data","Adult;Age Distribution;Breast Neoplasms;Cohort Studies;Early Detection of Cancer;Female;France;Humans;Middle Aged;Prognosis;Receptor, ErbB-2;Retrospective Studies;Survival Analysis;Triple Negative Breast Neoplasms","Adult;Age Distribution;Breast Neoplasms;Cohort Studies;Early Detection of Cancer;Female;France;Humans;Middle Aged;Prognosis;Receptor, ErbB-2;Retrospective Studies;Survival Analysis;Triple Negative Breast Neoplasms","Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)). ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Among 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were <40, 40-60 and > 60 y respectively. Pts <40 had significantly more aggressive presentations than other age groups: more frequent HER2+ (25.7 vs 15.3% in >60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts <40, 40-60 and > 60y, respectively (p < 0.0001). Compared to pts <40y, older pts had a statistically significant higher risk of death (all causes of death included), although of limited clinical value (HR = 1.1, IC 95%:1.01-1.20). There was a significant trend for better OS in pts <40y with HER2+ and luminal diseases. A possible explanation is a greater use of anti-Her2 therapies as first-line treatments: 86.6, 81.9 and 74.9% for pts <40, 40-60 and > 60y, respectively (p < 0.0001). Although young age seems associated with more aggressive presentations at diagnosis of MBC, it has no deleterious effect on OS in this large series.","Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut de Cancérologie de l'Ouest, site René Gauducheau, Site Hospitalier Nord, Boulevard Jacques Monod, 44800, Saint-Herblain;Gustave Roussy, 39, Rue Camille Desmoulins, 94800, Villejuif;Institut Claudius Régaud, 1, Av Irène Joliot Curie, 31059, Toulouse;Centre Oscar Lambret, 3, Rue Frédéric Combemale, 59000, Lille;Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen;Institut du Cancer de Montpellier, 208, Av. Apothicaires, 34298, Montpellier;Institut Bergonié, 229, Cours de l'Argonne, 33000, Bordeaux;Centre Henri Becquerel, Rue d'Amiens, 76038, Rouen;Centre Georges-François Leclerc, 1, Rue du Professeur Marion, 21079, Dijon;Centre Eugène Marquis, Avenue de la Bataille Flandre Dunkerque, 35042, Rennes;Institut Paoli-Calmettes, 232, BD Ste Marguerite, 13009, Marseille;Institut de Cancérologie de Lorraine, 6, Avenue Bourgogne, 54519, Vandoeuvre les Nancy;Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189, Nice;Institut Godinot, 1, Rue du Général Koenig, 51726, Reims;Centre Paul Strauss, 3, Rue de la Porte de l'Hôpital, 67065, Strasbourg;Centre Jean Perrin, 58, Rue Montalembert, 63011, Clermont Ferrand;Institut de Cancérologie de l'Ouest, site Paul Papin, 15, Rue André Boquel, 49055, Angers;R&D Unicancer, 67 avenue Fontainebleau 94270 Le Kremlin Bicêtre;Centre Léon Bérard, 28, Rue Laennec, 69008, Lyon;R&D Unicancer, 67 avenue Fontainebleau 94270 Le Kremlin Bicêtre;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris","NA",0,"1532-3080","Breast","Breast",2020,"2020","52","10.1016/j.breast.2020.04.009","50-57","","","32380440","32380440","PUBMED","Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris;Institut de Cancérologie de l'Ouest, site René Gauducheau, Site Hospitalier Nord, Boulevard Jacques Monod, 44800, Saint-Herblain;Gustave Roussy, 39, Rue Camille Desmoulins, 94800, Villejuif;Institut Claudius Régaud, 1, Av Irène Joliot Curie, 31059, Toulouse;Centre Oscar Lambret, 3, Rue Frédéric Combemale, 59000, Lille;Centre François Baclesse, 3, Avenue du Général Harris, 14000, Caen;Institut du Cancer de Montpellier, 208, Av. Apothicaires, 34298, Montpellier;Institut Bergonié, 229, Cours de l'Argonne, 33000, Bordeaux;Centre Henri Becquerel, Rue d'Amiens, 76038, Rouen;Centre Georges-François Leclerc, 1, Rue du Professeur Marion, 21079, Dijon;Centre Eugène Marquis, Avenue de la Bataille Flandre Dunkerque, 35042, Rennes;Institut Paoli-Calmettes, 232, BD Ste Marguerite, 13009, Marseille;Institut de Cancérologie de Lorraine, 6, Avenue Bourgogne, 54519, Vandoeuvre les Nancy;Centre Antoine Lacassagne, 33, Avenue de Valombrose, 06189, Nice;Institut Godinot, 1, Rue du Général Koenig, 51726, Reims;Centre Paul Strauss, 3, Rue de la Porte de l'Hôpital, 67065, Strasbourg;Centre Jean Perrin, 58, Rue Montalembert, 63011, Clermont Ferrand;Institut de Cancérologie de l'Ouest, site Paul Papin, 15, Rue André Boquel, 49055, Angers;R&D Unicancer, 67 avenue Fontainebleau 94270 Le Kremlin Bicêtre;Centre Léon Bérard, 28, Rue Laennec, 69008, Lyon;R&D Unicancer, 67 avenue Fontainebleau 94270 Le Kremlin Bicêtre;Institut Curie, Paris-Saint Cloud, 26, Rue d'Ulm, 75005, Paris"
"436","Girard A;Saint-Jalmes H;Chaboub N;Le Reste PJ;Metais A;Devillers A;Le Jeune F;Palard-Novello X","Girard, Antoine;Saint-Jalmes, Hervé;Chaboub, Nibras;Le Reste, Pierre-Jean;Metais, Alice;Devillers, Anne;Le Jeune, Florence;Palard-Novello, Xavier","Optimization of time frame binning for FDOPA uptake quantification in glioma.","PloS one","United States","eng","Clinical Trial","","Adult;Aged;Biological Transport;Brain;Brain Neoplasms;Female;Glioma;Humans;Kinetics;Male;Middle Aged;Monte Carlo Method;Phenylalanine;Positron-Emission Tomography;Radiopharmaceuticals;Young Adult","Adult;Aged;Biological Transport;Brain;Brain Neoplasms;Female;Glioma;Humans;Kinetics;Male;Middle Aged;Monte Carlo Method;Phenylalanine;Positron-Emission Tomography;Radiopharmaceuticals;Young Adult","3,4-dihydroxy-6-[18F]fluoro-L-phenylalanine (FDOPA) uptake quantification in glioma assessment can be distorted using a non-optimal time frame binning of time-activity curves (TAC). Under-sampling or over-sampling dynamic PET images induces significant variations on kinetic parameters quantification. We aimed to optimize temporal time frame binning for dynamic FDOPA PET imaging. Fourteen patients with 33 tumoral TAC with biopsy-proven gliomas were analysed. The mean SUVmax tumor-to-brain ratio (TBRmax) were compared at 20 min and 35 min post-injection (p.i). Five different time frame samplings within 20 min were compared: 11x10sec-6x15sec-5x20sec-3x300sec; 8x15sec- 2x30sec- 2x60sec- 3x300sec; 6x20sec- 8x60sec- 2x300sec; 10x30sec- 3x300sec and 4x45sec- 3x90sec- 5x150sec. The reversible single-tissue compartment model with blood volume parameter (VB) was selected using the Akaike information criterion. K1 values extracted from 1024 noisy simulated TAC using Monte Carlo method from the 5 different time samplings were compared to a target K1 value as the objective, which is the average of the K1 values extracted from the 33 lesions using an imaging-derived input function for each patient. The mean TBRmax was significantly higher at 20 min p.i. than at 35 min p.i (respectively 1.4 +/- 0.8 and 1.2 +/- 0.6; p <0.001). The target K1 value was 0.161 mL/ccm/min. The 8x15sec- 2x30sec- 2x60sec- 3x300sec time sampling was the optimal time frame binning. K1 values extracted using this optimal time frame binning were significantly different with K1 values extracted from the other time frame samplings, except with K1 values obtained using the 11x10sec- 6x15sec -5x20sec-3x300sec time frame binning. This optimal sampling schedule design (8x15sec- 2x30sec- 2x60sec- 3x300sec) could be used to minimize bias in quantification of FDOPA uptake in glioma using kinetic analysis.","Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France.;Department of Neurosurgery, CHU Rennes, Rennes, France.;Department of Pathology, CHU Rennes, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes, Department of Nuclear Medicine, CLCC Eugène Marquis, ""Behavior and Basal Ganglia"" research unit, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2020,"2020","15","10.1371/journal.pone.0232141","e0232141","","","32320440","32320440","PUBMED","Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France.;Department of Neurosurgery, CHU Rennes, Rennes, France.;Department of Pathology, CHU Rennes, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes, Department of Nuclear Medicine, CLCC Eugène Marquis, ""Behavior and Basal Ganglia"" research unit, France.;Department of Nuclear Medicine, Univ Rennes, CLCC Eugène Marquis, Inserm, LTSI - UMR 1099 research unit, Rennes, France."
"437","Edeline J;Garin E","Edeline, Julien;Garin, Etienne","Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90….","Journal of hepatology","Netherlands","eng","Editorial","Hepatocellular carcinoma;Radioembolization;SIRT;Yttrium-90","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Lung;Yttrium Radioisotopes","Humans;Carcinoma, Hepatocellular;Liver Neoplasms;Lung;Yttrium Radioisotopes","NA","Medical Oncology, Centre Eugène Marquis, Rennes;Nuclear Medicine, Centre Eugène Marquis, Rennes, France.","NA",0,"1600-0641","J Hepatol","J Hepatol",2020,"2020","72","10.1016/j.jhep.2020.03.026","1046-1048","","","32276729","32276729","PUBMED","Medical Oncology, Centre Eugène Marquis, Rennes;Nuclear Medicine, Centre Eugène Marquis, Rennes, France."
"438","Deleuze A;Saout J;Dugay F;Peyronnet B;Mathieu R;Verhoest G;Bensalah K;Crouzet L;Laguerre B;Belaud-Rotureau MA;Rioux-Leclercq N;Kammerer-Jacquet SF","Deleuze, Antoine;Saout, Judikaël;Dugay, Frédéric;Peyronnet, Benoit;Mathieu, Romain;Verhoest, Gregory;Bensalah, Karim;Crouzet, Laurence;Laguerre, Brigitte;Belaud-Rotureau, Marc-Antoine;Rioux-Leclercq, Nathalie;Kammerer-Jacquet, Solène-Florence","Immunotherapy in Renal Cell Carcinoma: The Future Is Now.","International journal of molecular sciences","Switzerland","eng","Journal Article","PD-1;PD-L1;biomarkers;emerging drugs;immune checkpoint inhibitors;immunotherapy;ongoing trials;renal cell carcinoma","Animals;Carcinoma, Renal Cell;Clinical Trials as Topic;Humans;Immune Checkpoint Inhibitors;Immunotherapy;Kidney Neoplasms","Animals;Carcinoma, Renal Cell;Clinical Trials as Topic;Humans;Immune Checkpoint Inhibitors;Immunotherapy;Kidney Neoplasms","Renal cell carcinoma is the third type of urologic cancer and has a poor prognosis with 30% of metastatic patients at diagnosis. The antiangiogenics and targeted immunotherapies led to treatment remodeling emphasizing the role of the tumour microenvironment. However, long-term responses are rare with a high rate of resistance. New strategies are emerging to improve the efficacy and the emerging drugs are under evaluation in ongoing trials. With the different treatment options, there is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients. Owing to the limitations of programmed death-ligand 1 (PD-L1), the most studied immunohistochemistry biomarkers, and of the tumor mutational burden, the identification of more reliable markers is an unmet need. New technologies could help in this purpose.","Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Cytogenetics, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Cytogenetics, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Pathology, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Pathology, University Hospital, 35000 Rennes, France.","NA",0,"1422-0067","Int J Mol Sci","Int J Mol Sci",2020,"2020","21","10.3390/ijms21072532",NA,"","","32260578","32260578","PUBMED","Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Cytogenetics, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Urology, University Hospital, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Cytogenetics, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Pathology, University Hospital, 35000 Rennes, France.;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), IRSET (Institut de recherche en santé, environnement et travail), UMR 1085, 35000 Rennes, France.;Department of Pathology, University Hospital, 35000 Rennes, France."
"439","Sanchis-Borja M;Ricordel C;Chiappa AM;Hureaux J;Odier L;Jeannin G;Descourt R;Gervais R;Monnet I;Auliac JB;Chouaïd C","Sanchis-Borja, Mateo;Ricordel, Charles;Chiappa, Anne Marie;Hureaux, José;Odier, Luc;Jeannin, Gaelle;Descourt, Renaud;Gervais, Radj;Monnet, Isabelle;Auliac, Jean-Bernard;Chouaïd, Christos","Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.","Lung cancer (Amsterdam, Netherlands)","Ireland","eng","Journal Article","Encephalitis;Immunotherapy;Lung cancer;Management","Aged;Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Encephalitis;Female;Follow-Up Studies;Humans;Immunotherapy;Lung Neoplasms;Male;Middle Aged;Prognosis;Retrospective Studies","Aged;Antineoplastic Agents, Immunological;Carcinoma, Non-Small-Cell Lung;Encephalitis;Female;Follow-Up Studies;Humans;Immunotherapy;Lung Neoplasms;Male;Middle Aged;Prognosis;Retrospective Studies","Using immune-checkpoint inhibitors (ICIs) to manage cancer is associated with various immune-related adverse events. Central and/or peripheral neurological disorders are rare and potentially serious. We analyzed the characteristics of non-small-cell lung cancer (NSCLC) patients who developed immune-related encephalitis under anti-programmed-death protein-1 or its ligand (PD-1/PD-L1). Clinical, biological and radiological characteristics of ICI-treated NSCLC patients with immune-related encephalitis, from 6 centers, were evaluated retrospectively. The 6 centers included 9 patients: all men, all smokers, median (range) age 67 (48-77) years, 78% adenocarcinomas, first- or second-line ICI for 5 and 4 patients, respectively. Two patients had non-active cerebral metastases at ICI onset. A median of 5 (1-22) ICI infusions preceded neurological symptoms, the most frequent being confusion (78%), fever (45%) and cerebellar ataxia (33%). CSF analyses revealed a median white blood cell count of 22/mm  (1-210/mm ), with hyperlymphocytosis in 8 patients and high protein levels in all. All bacteriological and virological analyses were negative. Cerebral MRI was considered normal for 5 patients; 4 patients had FLAIR hypersignals consistent with brain parenchyma inflammation. Three patients required intensive care. All patients received corticosteroids (different doses), a median of 8.5 (6-18) days post-onset. Corticosteroids achieved rapid symptom regression without sequelae in 8 patients. The last patient, with the longest time until corticosteroid introduction, died. ICIs were never restarted in any patient. Immune encephalitis, a rare but serious complication of anti-PD-1/PD-L1 therapy, carries a good prognosis when managed with early corticosteroids.","Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Centre Hospitalier de Cornouailles, Quimper, France.;Service de Pneumologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Pneumologie, Centre Hospitalier de Villefranche-sur-Soane, Villefranche-sur-Soane, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Oncologie, Centre Anti-Cancéreux François-Baclesse, Caen, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.","NA",0,"1872-8332","Lung Cancer","Lung Cancer",2019,"2020","143","10.1016/j.lungcan.2020.03.006","36-39","","","32200139","32200139","PUBMED","Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil;Service de Pneumologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Centre Hospitalier de Cornouailles, Quimper, France.;Service de Pneumologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service de Pneumologie, Centre Hospitalier de Villefranche-sur-Soane, Villefranche-sur-Soane, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Clermont Ferrand, Clermont Ferrand, France.;Service de Pneumologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Oncologie, Centre Anti-Cancéreux François-Baclesse, Caen, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.;Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France."
"440","Meneret P;Girard A;Pagenault M;Riffaud L;Palard-Novello X","Meneret, Pierre;Girard, Antoine;Pagenault, Mael;Riffaud, Laurent;Palard-Novello, Xavier","Different manifestations detected with 68Ga-DOTATOC PET/CT in patients with Von Hippel-Lindau disease: A case report.","Nuklearmedizin. Nuclear medicine","Germany","eng","Case Reports","","Humans;Positron Emission Tomography Computed Tomography;von Hippel-Lindau Disease;Octreotide;Organometallic Compounds;Female;Male;Radiopharmaceuticals;Adult","Humans;Positron Emission Tomography Computed Tomography;von Hippel-Lindau Disease;Octreotide;Organometallic Compounds;Female;Male;Radiopharmaceuticals;Adult","NA","Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Gastroenterology, CHU Rennes, France.;Neurosurgery, CHU Rennes, France.;Centre Eugene Marquis, Rennes, France.","NA",0,"2567-6407","Nuklearmedizin","Nuklearmedizin",2020,"2020","59","10.1055/a-1132-5104","332-334","","","32193881","32193881","PUBMED","Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Nuclear Medicine, Centre Eugene Marquis, Rennes, France.;Gastroenterology, CHU Rennes, France.;Neurosurgery, CHU Rennes, France.;Centre Eugene Marquis, Rennes, France."
"441","Adams S;Diéras V;Barrios CH;Winer EP;Schneeweiss A;Iwata H;Loi S;Patel S;Henschel V;Chui SY;Rugo HS;Emens LA;Schmid P","Adams, S;Diéras, V;Barrios, C H;Winer, E P;Schneeweiss, A;Iwata, H;Loi, S;Patel, S;Henschel, V;Chui, S Y;Rugo, H S;Emens, L A;Schmid, P","Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.","Annals of oncology : official journal of the European Society for Medical Oncology","England","eng","Clinical Trial, Phase III","atezolizumab;health-related quality of life;nab-paclitaxel;patient function;patient-reported outcomes;triple-negative breast cancer","Albumins;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Humans;Paclitaxel;Patient Reported Outcome Measures;Quality of Life;Triple Negative Breast Neoplasms","Albumins;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Humans;Paclitaxel;Patient Reported Outcome Measures;Quality of Life;Triple Negative Breast Neoplasms","Metastatic triple-negative breast cancer (mTNBC) is incurable. A key treatment goal is providing palliation while maintaining patients' health-related quality of life (HRQoL). IMpassion130 demonstrated progression-free survival benefit with atezolizumab + nab-paclitaxel (A + nP) versus placebo + nab-paclitaxel (Pl + nP) in first-line treatment of mTNBC patients with programmed death-ligand 1 positive (PD-L1+) tumors. We report data on patient-reported outcomes (PROs), which capture patient perspectives of treatment. Patients with untreated advanced or mTNBC received atezolizumab (840 mg) or placebo every 2 weeks in combination with nab-paclitaxel (100 mg/m ) on days 1, 8, and 15 of each 28-day cycle until progression or intolerance. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) and its Breast Cancer Module (QLQ-BR23) on day 1 of each cycle, at end of treatment, and every 4 weeks during 1 year of follow-up. Time-to-deterioration (TTD) in HRQoL (first ≥10-point decrease from baseline lasting two cycles) was a secondary end point. Exploratory end points included TTD in functioning and mean and mean change from baseline scores in HRQoL, functioning, and disease- and treatment-related symptoms. Baseline completion of PROs was 92% (QLQ-C30) and 89% (QLQ-BR23) and remained >80% through cycle 20 in intent-to-treat (ITT) and PD-L1+ patients. No differences between arms in median TTD in PD-L1+ patients were observed for HRQoL {hazard ratio (HR) 0.94 [95% confidence interval (CI) 0.69-1.28]} or physical [HR 1.02 (95% CI 0.76-1.37)] or role [HR 0.77 (95% CI 0.57-1.04)] functioning. Mean baseline scores for A + nP versus Pl + nP for HRQoL (67.5 versus 65.0) and physical (82.8 versus 79.4) and role (73.7 versus 71.7) functioning were comparable between arms and throughout the course of treatment, with no clinically meaningful (≥10 point) changes from baseline until patients discontinued treatment. No differences in clinically meaningful worsening in treatment symptoms (fatigue, diarrhea, or nausea/vomiting) were observed between arms. Results in ITT patients were similar. A + nP as first-line treatment for mTNBC delayed progression without compromising patients' day-to-day functioning or HRQoL or worsening treatment symptoms. CLINICALTRIAL. NCT02425891.","Department of Medicine, Perlmutter Breast Cancer Center, New York University Langone Medical Center, New York;Department of Medical Oncology, Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;Department of Oncology, Centro de Pesquisa Clinica HSL, PUCRS, Porto Alegre, Brazil.;Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA.;Division of Gynecologic Oncology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.;Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.;Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia.;Genentech, Inc., South San Francisco, USA.;F. Hoffmann-La Roche, Ltd, Basel, Switzerland.;Genentech, Inc., South San Francisco, USA.;Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, USA.;Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK.","NA",0,"1569-8041","Ann Oncol","Ann Oncol",2019,"2020","31","10.1016/j.annonc.2020.02.003","582-589","","","32178964","32178964","PUBMED","Department of Medicine, Perlmutter Breast Cancer Center, New York University Langone Medical Center, New York;Department of Medical Oncology, Institut Curie, Paris and Centre Eugène Marquis, Rennes, France.;Department of Oncology, Centro de Pesquisa Clinica HSL, PUCRS, Porto Alegre, Brazil.;Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA.;Division of Gynecologic Oncology, University Hospital and German Cancer Research Center Heidelberg, Heidelberg, Germany.;Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.;Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia.;Genentech, Inc., South San Francisco, USA.;F. Hoffmann-La Roche, Ltd, Basel, Switzerland.;Genentech, Inc., South San Francisco, USA.;Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, USA.;Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, USA.;Department of Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK."
"442","Casadiego-Peña C;Torres-Minacapilli M;Najera M;Ferrer P;Chajon E;Marsiglia H","Casadiego-Peña, Camila;Torres-Minacapilli, Marcelo;Najera, Manuel;Ferrer, Pedro;Chajon, Enrique;Marsiglia, Hugo","Difference in toxicity between HIV-positive and HIV-negative patients with squamous-cell cancer of the anal canal treated with concomitant radio-chemotherapy.","Journal of gastrointestinal oncology","China","eng","Journal Article","HIV;anal canal cancer (ACC);radio-chemotherapy (RTCT)","","","The incidence of squamous cell carcinoma of the anal canal has been increasing over the last 30 years. HIV has been found to be a risk factor for the development of this disease; radio-chemotherapy (RTCT) may also be more toxic than in HIV-negative patients. The study aims at assessing whether there are any differences in terms of toxicity between HIV-positive and HIV-negative patients treated with concomitant RTCT. Search in MEDLINE, EMBASE, CENTRAL (via Cochrane Library-Wiley), DARE, LILACS bibliographic databases. Experimental and analytical observational studies with at least two comparative arms were included: squamous-cell (SC) anal-canal cancer (ACC) treated with RTCT in HIV-positive   HIV-negative patients. Fifteen publications, 14 retrospective studies and 1 systematic review, were found. All radiotherapy (RT) techniques and all chemotherapeutic agents used to manage this disease were included. No differences were found in terms of duration (P=0.67) and dose (P=0.53) of RT, while CT results were contradictory. Acute and hematological toxicities were significantly higher in HIV-positive patients, while gastrointestinal, dermatological and chronic toxicities did not significantly differ between the two groups. Given the high heterogeneity of the studies, no objective comparison could be made between studies that included antiretrovirals and those that did not. HIV-positive patients may be at higher risk for acute and hematological toxicity than HIV-negative patients. A precise conclusion cannot be drawn on the use of antiretrovirals, given the high heterogeneity of data.","International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.;Centre Eugene Marquis, Rennes, France.;International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.","NA",0,"2078-6891","J Gastrointest Oncol","J Gastrointest Oncol",2020,"2020","11","10.21037/jgo.2020.01.05","23-35","","","32175102","32175102","PUBMED","International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile.;Centre Eugene Marquis, Rennes, France.;International Master in Advanced Radiotherapy, International Atomic Energy Agency (IAEA)-Fundacion Arturo Lopez Perez (FALP)-Los Andes University, Santiago, Chile.;Instituto Oncologico Fundacion Arturo Lopez Perez (FALP), Santiago, Chile."
"443","Neviere Z;De La Motte Rouge T;Floquet A;Johnson A;Berthet P;Joly F","Neviere, Zoé;De La Motte Rouge, Thibault;Floquet, Anne;Johnson, Alison;Berthet, Pascaline;Joly, Florence","How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors.","Therapeutic advances in medical oncology","England","eng","Journal Article","PARP inhibitors;breast cancer;genetic counseling;ovarian cancer;prostate cancer","","","Poly(ADP-ribose)polymerase (PARP) inhibitors are targeted therapy for cancers with homologous repair deficiency (HRD). They were first approved for ovarian cancer and have changed current treatment strategies. They have also demonstrated efficacy in HER2-negative metastatic breast cancer and advanced prostate cancer with   or   mutations. Patients with somatic and/or germline   mutations benefit more from these treatments than other patients. Nowadays, the diagnosis of HRD is largely based on germline genetic testing, which is performed after an in-person genetic counseling session, even for patients without any family history of cancer. However, with the increasing number of PARP inhibitor indications across different tumor types, rapid access to oncogenetic consultations will become a challenge. To meet this demand, tumor genomic testing could be offered at initial diagnosis. Telephone counseling and other referral systems could replace in-person consultations for certain subgroups of patients deemed to have a low risk of harboring a germline mutation. This article reviews international guidelines for genetic counseling testing. We herein propose new care pathways for breast, prostate and ovarian cancers, including tumor genomic testing at initial diagnosis in order to help triage genetic counseling referrals.","Oncology Department, Centre François Baclesse, avenue du général Harris, Caen 14076, France.;Oncology Department, Centre Eugène Marquis, Rennes, France.;Oncology Department, Institut Bergonié, Bordeaux, France.;Oncology Department, Centre François Baclesse, Caen, France.;Oncologenetic Department, Centre François Baclesse, Caen, France.;Oncology Department, Centre François Baclesse, Caen, France.","NA",0,"1758-8340","Ther Adv Med Oncol","Ther Adv Med Oncol",2018,"2020","12","10.1177/1758835919897530","1758835919897530","","","32165926","32165926","PUBMED","Oncology Department, Centre François Baclesse, avenue du général Harris, Caen 14076, France.;Oncology Department, Centre Eugène Marquis, Rennes, France.;Oncology Department, Institut Bergonié, Bordeaux, France.;Oncology Department, Centre François Baclesse, Caen, France.;Oncologenetic Department, Centre François Baclesse, Caen, France.;Oncology Department, Centre François Baclesse, Caen, France."
"444","Deluche E;Antoine A;Bachelot T;Lardy-Cleaud A;Dieras V;Brain E;Debled M;Jacot W;Mouret-Reynier MA;Goncalves A;Dalenc F;Patsouris A;Ferrero JM;Levy C;Lorgis V;Vanlemmens L;Lefeuvre-Plesse C;Mathoulin-Pelissier S;Petit T;Uwer L;Jouannaud C;Leheurteur M;Lacroix-Triki M;Courtinard C;Perol D;Robain M;Delaloge S","Deluche, Elise;Antoine, Alison;Bachelot, Thomas;Lardy-Cleaud, Audrey;Dieras, Veronique;Brain, Etienne;Debled, Marc;Jacot, William;Mouret-Reynier, Marie Ange;Goncalves, Anthony;Dalenc, Florence;Patsouris, Anne;Ferrero, Jean Marc;Levy, Christelle;Lorgis, Veronique;Vanlemmens, Laurence;Lefeuvre-Plesse, Claudia;Mathoulin-Pelissier, Simone;Petit, Thierry;Uwer, Lionel;Jouannaud, Christelle;Leheurteur, Marianne;Lacroix-Triki, Magali;Courtinard, Coralie;Perol, David;Robain, Mathieu;Delaloge, Suzette","Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.","European journal of cancer (Oxford, England : 1990)","England","eng","Journal Article","HER2;Metastatic breast cancer;Overall survival;Real life;Subtypes","Abdominal Neoplasms;Adolescent;Adult;Age Factors;Aged;Bone Neoplasms;Brain Neoplasms;Breast;Breast Neoplasms;Disease-Free Survival;Female;France;Humans;Kaplan-Meier Estimate;Lymphatic Metastasis;Middle Aged;Prognosis;Progression-Free Survival;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Skin Neoplasms;Young Adult","Abdominal Neoplasms;Adolescent;Adult;Age Factors;Aged;Bone Neoplasms;Brain Neoplasms;Breast;Breast Neoplasms;Disease-Free Survival;Female;France;Humans;Kaplan-Meier Estimate;Lymphatic Metastasis;Middle Aged;Prognosis;Progression-Free Survival;Receptor, ErbB-2;Receptors, Estrogen;Receptors, Progesterone;Retrospective Studies;Skin Neoplasms;Young Adult","Real-world data inform the outcome comparisons and help the development of new therapeutic strategies. To this end, we aimed to describe the full characteristics and outcomes in the Epidemiological Strategy and Medical Economics (ESME) cohort, a large national contemporary observational database of patients with metastatic breast cancer (MBC). Women aged ≥18 years with newly diagnosed MBC and who initiated MBC treatment between January 2008 and December 2016 in one of the 18 French Comprehensive Cancer Centers (N = 22,109) were included. We assessed the full patients' characteristics, first-line treatments, overall survival (OS) and first-line progression-free survival, as well as updated prognostic factors in the whole cohort and among the 3 major subtypes: hormone receptor positive and HER2-negative (HR+/HER2-, n = 13,656), HER2-positive (HER2+, n = 4017) and triple-negative (n = 2963) tumours. The median OS of the whole cohort was 39.5 months (95% confidence interval [CI], 38.7-40.3). Five-year OS was 33.8%. OS differed significantly between the 3 subtypes (p < 0.0001) with a median OS of 43.3 (95% CI, 42.5-44.5) in HR+/HER2-; 50.1 (95% CI, 47.6-53.1) in HER2+; and 14.8 months (95% CI, 14.1-15.5) in triple-negative subgroups, respectively. Beyond performance status, the following variables had a constant significant negative prognostic impact on OS in the whole cohort and among subtypes: older age at diagnosis of metastases (except for the triple-negative subtype), metastasis-free interval between 6 and 24 months, presence of visceral metastases and number of metastatic sites ≥ 3. The ESME program represents a unique large-scale real-life cohort on MBC. This study highlights important situations of high medical need within MBC patients. DATABASE REGISTRATION: clinicaltrials.gov Identifier NCT032753.","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France; Department of Medical Oncology, CHU de Limoges, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, Rennes, 35000, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, Paris & Saint-Cloud, 75005, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, Bordeaux, 33000, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, Montpellier, 34298, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, Clermont Ferrand, 63011, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, Marseille, 13009, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, Toulouse, 31059, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, Angers, 49055, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, Nice, 06189, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, Caen, 14000, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, Dijon, 21079, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, Lille, 59000, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, Rennes, 35000, France.;INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, 33000, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, Strasbourg, 67000, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, Vandœuvre-lès-Nancy, 54519, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, Reims, 51100, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, Rouen, 76000, France.;Department of BioPathology, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, Paris, 75654, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, Paris, 75654, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800","NA",0,"1879-0852","Eur J Cancer","Eur J Cancer",2019,"2020","129","10.1016/j.ejca.2020.01.016","60-70","","","32135312","32135312","PUBMED","Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France; Department of Medical Oncology, CHU de Limoges, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, Rennes, 35000, France.;Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, Paris & Saint-Cloud, 75005, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de L'Argonne, Bordeaux, 33000, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, Montpellier, 34298, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, Clermont Ferrand, 63011, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, Marseille, 13009, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, Toulouse, 31059, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest Nantes & Angers, 15 Rue André Boquel, Angers, 49055, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, Nice, 06189, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, Caen, 14000, France.;Department of Medical Oncology, Institut de Cancérologie de Bourgogne, Dijon, 21079, France.;Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, Lille, 59000, France.;Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, Rennes, 35000, France.;INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, 33000, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, Strasbourg, 67000, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, Vandœuvre-lès-Nancy, 54519, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, Reims, 51100, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, Rouen, 76000, France.;Department of BioPathology, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, Paris, 75654, France.;Department of Biostatistics, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, Lyon, 69008, France.;Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, Paris, 75654, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, 94800"
"445","André V;Durier V;Beuchée A;Roué JM;Lemasson A;Hausberger M;Sizun J;Henry S","André, Vanessa;Durier, Virginie;Beuchée, Alain;Roué, Jean-Michel;Lemasson, Alban;Hausberger, Martine;Sizun, Jacques;Henry, Séverine","Higher tactile sensitivity in preterm infants at term-equivalent age: A pilot study.","PloS one","United States","eng","Comparative Study","","Adult;Brain;Female;Gestational Age;Humans;Infant, Newborn;Infant, Premature;Male;Photic Stimulation;Pilot Projects;Touch Perception","Adult;Brain;Female;Gestational Age;Humans;Infant, Newborn;Infant, Premature;Male;Photic Stimulation;Pilot Projects;Touch Perception","Despite a growing body of research on perinatal sensory abilities, data on the extent of tactile sensitivity and more particularly passive touch (i.e. sensitivity to a stimulation imposed on the skin) are relatively limited, and the development and processing of tactile function are still thus little known. This question is particularly of high importance for infants with atypical early development such as those born prematurely who are exposed to many sensory (including tactile) stimulations (being in a hospital setting) during a critical period of brain development and those born at early term whose birth occurs at the precise time of cortical reorganization, in particular in the sensory areas. Some parents and health-care providers have for instance reported that children born prematurely exhibit atypical (e.g. higher) sensitivity to ""benign"" tactile stimuli. In the present study, we hypothesized that preterm and early-term infants may show altered tactile sensitivity. We compared the behavioral responses around term-equivalent age of infants born either pre-term, early-term or at term to the application of a light (0.008 grams) mechanical stimulus. We found that almost all preterm infants perceive this tactile stimulus, contrarily to the two other groups of infants. This extreme tactile sensitivity may be due to experiential, maturational or more likely both processes. We also compared the tactile sensitivity of these infants to that of adults. We found that adults were irresponsive to the light mechanical stimulus. This finding opens not only new insights in understanding development of tactile processing, but also new lines of thought about the particular sensory world of premature and early-term infants and hence about the potential impact of early care practices.","Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2019,"2020","15","10.1371/journal.pone.0229270","e0229270","","","32134950","32134950","PUBMED","Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France.;Unité de Soins Intensifs Néonatals, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.;Univ Rennes, Normandie Univ, CNRS, EthoS (Éthologie Animale et Humaine)-UMR 6552, Rennes, France."
"446","Lenck C;Chopin N;Gouy S;Bonsang-Kitzis H;Martinez-Gomez C;Radosevic-Robin N;Martin S;Lefeuvre-Plesse C;Lambaudie E;Leblanc E;Guyon F;Classe JM;Ramanah R;Beurrier F;Angeles MA;Pomel C;Joly F;de la Motte Rouge T;Provansal M;Lesoin A;Floquet A;Berton D;Kalbacher E;Chakiba C;Meeus P;Selle F;Treilleux I;Lecuru F;Pautier P;Ray-Coquard I","Lenck, C;Chopin, N;Gouy, S;Bonsang-Kitzis, H;Martinez-Gomez, C;Radosevic-Robin, N;Martin, S;Lefeuvre-Plesse, C;Lambaudie, E;Leblanc, E;Guyon, F;Classe, J-M;Ramanah, R;Beurrier, F;Angeles, M A;Pomel, C;Joly, F;de la Motte Rouge, T;Provansal, M;Lesoin, A;Floquet, A;Berton, D;Kalbacher, E;Chakiba, C;Meeus, P;Selle, F;Treilleux, I;Lecuru, F;Pautier, P;Ray-Coquard, I","The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.","Gynecologic oncology","United States","eng","Journal Article","Granulosa cell tumor;National network;Rare cancer;Recurrence;Sex cord stromal tumor;Surgery","Adolescent;Adult;Aged;Aged, 80 and over;Child;Cohort Studies;Female;France;Granulosa Cell Tumor;Guideline Adherence;Gynecologic Surgical Procedures;Humans;Middle Aged;Neoplasm Staging;Ovarian Neoplasms;Rare Diseases;Retrospective Studies;Young Adult","Adolescent;Adult;Aged;Aged, 80 and over;Child;Cohort Studies;Female;France;Granulosa Cell Tumor;Guideline Adherence;Gynecologic Surgical Procedures;Humans;Middle Aged;Neoplasm Staging;Ovarian Neoplasms;Rare Diseases;Retrospective Studies;Young Adult","The French national rare gynecological tumor network has been established to improve the quality of care through offering expertise in double reading histological diagnosis, reviewing cases and guiding management of these tumors through specialized multidisciplinary tumor boards and online clinical guidelines (www.ovaire-rare.com). The aim of this study is to evaluate the impact of the development and implementation of this network by assessing the conformity of medical practice with the guidelines concerning the granulosa cell tumors (GCTs). This is a French nationwide study, including 463 patients (out of the 639 identified patients) with a definitive diagnosis of GCT between 2011 and 2016. Surgical practices were analyzed for conformity with the current guidelines (www.ovaire-rare.org). Medical records, surgical and pathological reports were systematically analyzed. Total conformity was defined by a conservative (unilateral salpingo-oophorectomy) or radical surgery (hysterectomy and bilateral salpingo-oophorectomy) including surgical staging (omentectomy, peritoneal biopsies and peritoneal cytology) according to the FIGO stage. Partial conformity referred to a conservative or radical surgery without surgical staging and non-conformity was defined as a non-optimal surgery as recommended by the guidelines. Median age at diagnosis was 49 years old (range 10-89). The median size of tumor was 94 mm (range 5-400). Radical surgery was performed in 240 patients (52%); while a fertility-sparing surgery was performed in 98 cases (21%). A surgical staging was performed in 76 cases (16%) and an evaluation of the endometrium in 289 cases (62%). Surgery was fully compliant with the guidelines in 65 patients (14%), partially compliant in 213 patients (46%), non-compliant in 137 patients (30%) and not assessable in 48 cases (10%). A statistically significant difference for compliance was observed in restaging surgery (p < 0,001), radical surgery (p = 0,017) and the period (before or after) of the implementation of the network (p < 0,001). Survival analyses did not allow us to demonstrate a significant difference in overall survival nor in PFS although there was a trend in favor of optimal surgery compared to incomplete/non optimal surgery. Surgical management's conformity to the guidelines increases over time from 2011 to 2016. According to this study, the implementation of a national network dedicated to rare gynecologic tumors seems to significantly improve the surgical management of the patients with ovarian granulosa cell tumors.","Surgery, Centre Léon Bérard, Lyon;Surgery, Centre Léon Bérard, Lyon, France.;Surgery, Gustave Roussy, Villejuif, and GINECO Group, France.;Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Georges Pompidou, Paris, France.;Surgery, Institut universitaire du cancer, Toulouse, France.;Pathology, Centre Jean Perrin, Clermont-Ferrand, and GINECO Group, France.;Surgery, Centre François Baclesse, Caen, France.;Medical Oncology, Centre Eugene Marquis, Rennes, and GINECO Group, France.;Surgery, Institut Paoli Calmettes, Marseille, France.;Surgery, Centre Oscar Lambret, Lille, France.;Surgery, Institut Bergonié, Bordeaux, and GINECO Group, France.;Surgery, Institut de cancérologie de l'Ouest, Nantes, and GINECO Group, France.;Surgery, CHRU de Besançon, Hôpital Jean Minjoz, Besançon, France.;Surgery, Centre Léon Bérard, Lyon, France.;Surgery, Institut universitaire du cancer, Toulouse, France.;Surgery, Centre Jean Perrin, Clermont-Ferrand, and GINECO Group, France.;Medical Oncology, Centre Francois Baclesse, Caen, and GINECO Group, France.;Medical Oncology, Centre Eugene Marquis, Rennes, and GINECO Group, France.;Medical Oncology, Institut Paoli Calmettes, Marseille, and GINECO Group, France.;Medical Oncology, Centre Oscar Lambret, Lille, and GINECO Group, France.;Medical Oncology, Institut Bergonié, Bordeaux, and GINECO Group, France.;Medical Oncology, Institut de Cancérologie de l'Ouest (site René Gauducheau), Nantes, and GINECO Group, France.;Medical Oncology, CHRU de Besançon, Hôpital Jean Minjoz, Besançon, and GINECO Group, France.;Medical Oncology, Institut Bergonié, Bordeaux, and GINECO Group, France.;Surgery, Centre Léon Bérard, Lyon, France.;Medical Oncology, Groupe hospitalier Diaconesses Croix Saint Simon, Hôpital de La Croix Saint Simon, Paris, and GINECO group, France.;Pathology, Centre Léon Bérard, Lyon, and GINECO Group, France.;Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Georges Pompidou, Paris, France.;Medical Oncology, Gustave Roussy, Villejuif, and GINECO Group, France.;Medical Oncology, Centre Léon Bérard, Lyon, and GINECO Group, France; University Claude Bernard Lyon 1, HESPER EA7425, Lyon","NA",0,"1095-6859","Gynecol Oncol","Gynecol Oncol",2019,"2020","157","10.1016/j.ygyno.2020.02.012","78-84","","","32131977","32131977","PUBMED","Surgery, Centre Léon Bérard, Lyon;Surgery, Centre Léon Bérard, Lyon, France.;Surgery, Gustave Roussy, Villejuif, and GINECO Group, France.;Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Georges Pompidou, Paris, France.;Surgery, Institut universitaire du cancer, Toulouse, France.;Pathology, Centre Jean Perrin, Clermont-Ferrand, and GINECO Group, France.;Surgery, Centre François Baclesse, Caen, France.;Medical Oncology, Centre Eugene Marquis, Rennes, and GINECO Group, France.;Surgery, Institut Paoli Calmettes, Marseille, France.;Surgery, Centre Oscar Lambret, Lille, France.;Surgery, Institut Bergonié, Bordeaux, and GINECO Group, France.;Surgery, Institut de cancérologie de l'Ouest, Nantes, and GINECO Group, France.;Surgery, CHRU de Besançon, Hôpital Jean Minjoz, Besançon, France.;Surgery, Centre Léon Bérard, Lyon, France.;Surgery, Institut universitaire du cancer, Toulouse, France.;Surgery, Centre Jean Perrin, Clermont-Ferrand, and GINECO Group, France.;Medical Oncology, Centre Francois Baclesse, Caen, and GINECO Group, France.;Medical Oncology, Centre Eugene Marquis, Rennes, and GINECO Group, France.;Medical Oncology, Institut Paoli Calmettes, Marseille, and GINECO Group, France.;Medical Oncology, Centre Oscar Lambret, Lille, and GINECO Group, France.;Medical Oncology, Institut Bergonié, Bordeaux, and GINECO Group, France.;Medical Oncology, Institut de Cancérologie de l'Ouest (site René Gauducheau), Nantes, and GINECO Group, France.;Medical Oncology, CHRU de Besançon, Hôpital Jean Minjoz, Besançon, and GINECO Group, France.;Medical Oncology, Institut Bergonié, Bordeaux, and GINECO Group, France.;Surgery, Centre Léon Bérard, Lyon, France.;Medical Oncology, Groupe hospitalier Diaconesses Croix Saint Simon, Hôpital de La Croix Saint Simon, Paris, and GINECO group, France.;Pathology, Centre Léon Bérard, Lyon, and GINECO Group, France.;Surgery, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Georges Pompidou, Paris, France.;Medical Oncology, Gustave Roussy, Villejuif, and GINECO Group, France.;Medical Oncology, Centre Léon Bérard, Lyon, and GINECO Group, France; University Claude Bernard Lyon 1, HESPER EA7425, Lyon"
"447","Bellec J;Arab-Ceschia F;Castelli J;Lafond C;Chajon E","Bellec, J;Arab-Ceschia, F;Castelli, J;Lafond, C;Chajon, E","ITV versus mid-ventilation for treatment planning in lung SBRT: a comparison of target coverage and PTV adequacy by using in-treatment 4D cone beam CT.","Radiation oncology (London, England)","England","eng","Comparative Study","4D-CBCT;Geometric uncertainties;ITV;Lung cancer;Mid-ventilation;Planning strategy;Respiratory motions;Stereotactic body radiation therapy (SBRT)","Cone-Beam Computed Tomography;Four-Dimensional Computed Tomography;Humans;Lung Neoplasms;Radiosurgery;Radiotherapy Planning, Computer-Assisted;Radiotherapy, Intensity-Modulated","Cone-Beam Computed Tomography;Four-Dimensional Computed Tomography;Humans;Lung Neoplasms;Radiosurgery;Radiotherapy Planning, Computer-Assisted;Radiotherapy, Intensity-Modulated","The internal target volume (ITV) approach and the mid-ventilation (MidV) concept are the two main respiratory motion-management strategies under free breathing. The purpose of this work was to compare the actual in-treatment target coverage during volumetric modulated arctherapy (VMAT) delivered through both ITV-based and MidV-based planning target volume (PTV) and to provide knowledge in choosing the optimal PTV for stereotactic body radiotherapy (SBRT) for lung lesions. Thirty-two lung cancer patients treated by a VMAT technique were included in the study. For each fraction, the mean time-weighted position of the target was localized by using a 4-dimensional cone-beam CT (4D-CBCT)-based image guidance procedure. The respiratory-correlated location of the gross tumor volume (GTV) during treatment delivery was determined for each fraction by using in-treatment 4D-CBCT images acquired concurrently with VMAT delivery (4D-CBCT ). The GTV was delineated from each of the ten respiratory phase-sorted 4D-CBCT  datasets for each fraction. We defined target coverage as the average percentage of the GTV included within the PTV during the patient's breathing cycle averaged over the treatment course. Target coverage and PTVs were reported for a MidV-based PTV (PTV ) using dose-probabilistic margins and three ITV-based PTVs using isotropic margins of 5 mm (PTV ), 4 mm (PTV ) and 3 mm (PTV ). The in-treatment baseline displacements and target motion amplitudes were reported to evaluate the impact of both parameters on target coverage. Overall, 100 4D-CBCT  images were analyzed. The mean target coverage was 98.6, 99.6, 98.9 and 97.2% for PTV , PTV , PTV  and PTV , respectively. All the PTV margins led to a target coverage per treatment higher than 95% in at least 90% of the evaluated cases. Compared to PTV , PTV , PTV  and PTV  had mean PTV reductions of 16, 19 and 33%, respectively. When implementing VMAT with 4D-CBCT-based image guidance, an ITV-based approach with a tighter margin than the commonly used 5 mm margin remains an alternative to the MidV-based approach for reducing healthy tissue exposure in lung SBRT. Compared to PTV , PTV  significantly reduced the PTV while still maintaining an adequate in-treatment target coverage.","Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes;Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Radiotherapy Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Inserm, U1099, F-35000, Rennes, France.;Université de Rennes-1, LTSI, F-35000, Rennes, France.;Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Inserm, U1099, F-35000, Rennes, France.;Université de Rennes-1, LTSI, F-35000, Rennes, France.;Radiotherapy Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.","NA",0,"1748-717X","Radiat Oncol","Radiat Oncol",2019,"2020","15","10.1186/s13014-020-01496-5","54","","","32127010","32127010","PUBMED","Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes;Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Radiotherapy Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Inserm, U1099, F-35000, Rennes, France.;Université de Rennes-1, LTSI, F-35000, Rennes, France.;Medical Physics Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France.;Inserm, U1099, F-35000, Rennes, France.;Université de Rennes-1, LTSI, F-35000, Rennes, France.;Radiotherapy Department, Centre Eugène Marquis, avenue de La Bataille Flandres Dunkerque - CS 44229, F-35042, Rennes, France."
"448","Aref-Eshghi E;Kerkhof J;Pedro VP;Barat-Houari M;Ruiz-Pallares N;Andrau JC;Lacombe D;Van-Gils J;Fergelot P;Dubourg C;Cormier-Daire V;Rondeau S;Lecoquierre F;Saugier-Veber P;Nicolas G;Lesca G;Chatron N;Sanlaville D;Vitobello A;Faivre L;Thauvin-Robinet C;Laumonnier F;Raynaud M;Alders M;Mannens M;Henneman P;Hennekam RC;Velasco G;Francastel C;Ulveling D;Ciolfi A;Pizzi S;Tartaglia M;Heide S;Héron D;Mignot C;Keren B;Whalen S;Afenjar A;Bienvenu T;Campeau PM;Rousseau J;Levy MA;Brick L;Kozenko M;Balci TB;Siu VM;Stuart A;Kadour M;Masters J;Takano K;Kleefstra T;de Leeuw N;Field M;Shaw M;Gecz J;Ainsworth PJ;Lin H;Rodenhiser DI;Friez MJ;Tedder M;Lee JA;DuPont BR;Stevenson RE;Skinner SA;Schwartz CE;Genevieve D;Sadikovic B","Aref-Eshghi, Erfan;Kerkhof, Jennifer;Pedro, Victor P;Barat-Houari, Mouna;Ruiz-Pallares, Nathalie;Andrau, Jean-Christophe;Lacombe, Didier;Van-Gils, Julien;Fergelot, Patricia;Dubourg, Christèle;Cormier-Daire, Valerie;Rondeau, Sophie;Lecoquierre, François;Saugier-Veber, Pascale;Nicolas, Gaël;Lesca, Gaetan;Chatron, Nicolas;Sanlaville, Damien;Vitobello, Antonio;Faivre, Laurence;Thauvin-Robinet, Christel;Laumonnier, Frederic;Raynaud, Martine;Alders, Mariëlle;Mannens, Marcel;Henneman, Peter;Hennekam, Raoul C;Velasco, Guillaume;Francastel, Claire;Ulveling, Damien;Ciolfi, Andrea;Pizzi, Simone;Tartaglia, Marco;Heide, Solveig;Héron, Delphine;Mignot, Cyril;Keren, Boris;Whalen, Sandra;Afenjar, Alexandra;Bienvenu, Thierry;Campeau, Philippe M;Rousseau, Justine;Levy, Michael A;Brick, Lauren;Kozenko, Mariya;Balci, Tugce B;Siu, Victoria Mok;Stuart, Alan;Kadour, Mike;Masters, Jennifer;Takano, Kyoko;Kleefstra, Tjitske;de Leeuw, Nicole;Field, Michael;Shaw, Marie;Gecz, Jozef;Ainsworth, Peter J;Lin, Hanxin;Rodenhiser, David I;Friez, Michael J;Tedder, Matt;Lee, Jennifer A;DuPont, Barbara R;Stevenson, Roger E;Skinner, Steven A;Schwartz, Charles E;Genevieve, David;Sadikovic, Bekim","Evaluation of DNA Methylation Episignatures for Diagnosis and Phenotype Correlations in 42 Mendelian Neurodevelopmental Disorders.","American journal of human genetics","United States","eng","Journal Article","DNA methylation;EpiSign;VUS classification;episignature;molecular diagnostics;uncertain clinical cases","Cohort Studies;DNA Methylation;Genetic Heterogeneity;Humans;Neurodevelopmental Disorders;Phenotype;Syndrome","Cohort Studies;DNA Methylation;Genetic Heterogeneity;Humans;Neurodevelopmental Disorders;Phenotype;Syndrome","Genetic syndromes frequently present with overlapping clinical features and inconclusive or ambiguous genetic findings which can confound accurate diagnosis and clinical management. An expanding number of genetic syndromes have been shown to have unique genomic DNA methylation patterns (called ""episignatures""). Peripheral blood episignatures can be used for diagnostic testing as well as for the interpretation of ambiguous genetic test results. We present here an approach to episignature mapping in 42 genetic syndromes, which has allowed the identification of 34 robust disease-specific episignatures. We examine emerging patterns of overlap, as well as similarities and hierarchical relationships across these episignatures, to highlight their key features as they are related to genetic heterogeneity, dosage effect, unaffected carrier status, and incomplete penetrance. We demonstrate the necessity of multiclass modeling for accurate genetic variant classification and show how disease classification using a single episignature at a time can sometimes lead to classification errors in closely related episignatures. We demonstrate the utility of this tool in resolving ambiguous clinical cases and identification of previously undiagnosed cases through mass screening of a large cohort of subjects with developmental delays and congenital anomalies. This study more than doubles the number of published syndromes with DNA methylation episignatures and, most significantly, opens new avenues for accurate diagnosis and clinical assessment in individuals affected by these disorders.","Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A5C1, Canada.;Groupe DI, French Rare Disease Network filière AnDDI-Rare France.;Autoinflammatory and Rare Diseases Unit, Medical Genetic Department for Rare Diseases and Personalized Medicine, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Autoinflammatory and Rare Diseases Unit, Medical Genetic Department for Rare Diseases and Personalized Medicine, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Institut de Génétique Moléculaire de Montpellier (IGMM), University Montpellier, CNRS-UMR5535, 34090 Montpellier, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Medical Genetics, Paris Descartes University, INSERM UMR 1163, Imagine Institute, Necker Enfants Malades Hospital, 75015 Paris, France.;Department of Medical Genetics, Paris Descartes University, INSERM UMR 1163, Imagine Institute, Necker Enfants Malades Hospital, 75015 Paris, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, Dijon University Hospital, 21000 Dijon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon, 21000, Dijon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon, 21000, Dijon, France.;UMR 1253, iBrain, Universite de Tours, Inserm, 37200 Tours, France; Centre Hospitalier Universitaire de Tours, Service de Genetique, 37000 Tours, France.;UMR 1253, iBrain, Universite de Tours, Inserm, 37200 Tours, France; Centre Hospitalier Universitaire de Tours, Service de Genetique, 37000 Tours, France.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, 1012 WX, the Netherlands.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Unit of Genetics, APHP Sorbonne University, Trousseau Hospital, 75012 Paris, France.;Unit of Genetics, APHP Sorbonne University, Trousseau Hospital, 75012 Paris, France.;Department of Molecular Genetics, Cochin Hospital, 75014 Paris, France.;Department of Pediatrics, University of Montreal, Montreal, QC H3T1J4, Canada.;Department of Pediatrics, University of Montreal, Montreal, QC H3T1J4, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Genetic Division, Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.;Genetic Division, Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.;Department of Pediatrics, Division of Medical Genetics, Western University, London, ON N6A 3K7; Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON N6A5W9, Canada.;Department of Pediatrics, Division of Medical Genetics, Western University, London, ON N6A 3K7; Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON N6A5W9, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A5W9 Canada; St. Joseph's Health Care London, London, ON N6A5W9 Canada.;Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A5W9 Canada; St. Joseph's Health Care London, London, ON N6A5W9 Canada.;Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.;Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Donders Center for Medical Neuroscience, 6525 GA Nijmegen, the Netherlands.;Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Donders Center for Medical Neuroscience, 6525 GA Nijmegen, the Netherlands.;Genetics of Learning Disability Service, Hunter Genetics, Waratah, NSW 2298, Australia.;School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.;School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia; South Australian Health and Medical Research Institute, Adelaide, SA 5005, Australia.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Children's Health Research Institute, London, ON N6A3K7, Canada; Department of Biochemistry, Western University, London, ON N6A3K7, Canada.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Medical Genetic Department for Rare Diseases and Personalized Medicine, Reference Center AD SOOR, AnDDI-RARE, Groupe DI, Inserm U1183-Institute for Regenerative Medicine and Biotherapy, Montpellier University, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7","NA",0,"1537-6605","Am J Hum Genet","Am J Hum Genet",2019,"2020","106","10.1016/j.ajhg.2020.01.019","356-370","","","32109418","32109418","PUBMED","Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON N6A5C1, Canada.;Groupe DI, French Rare Disease Network filière AnDDI-Rare France.;Autoinflammatory and Rare Diseases Unit, Medical Genetic Department for Rare Diseases and Personalized Medicine, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Autoinflammatory and Rare Diseases Unit, Medical Genetic Department for Rare Diseases and Personalized Medicine, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Institut de Génétique Moléculaire de Montpellier (IGMM), University Montpellier, CNRS-UMR5535, 34090 Montpellier, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Medical Genetics Department, Inserm U1211, Reference Center AD SOOR, AnDDI-RARE, Bordeaux University, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Medical Genetics, Paris Descartes University, INSERM UMR 1163, Imagine Institute, Necker Enfants Malades Hospital, 75015 Paris, France.;Department of Medical Genetics, Paris Descartes University, INSERM UMR 1163, Imagine Institute, Necker Enfants Malades Hospital, 75015 Paris, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Department of Genetics and Reference Center for Developmental Disorders, F 76000, Normandy Center for Genomic and Personalized Medicine, 76183 Rouen, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Department of Medical Genetics, University Hospital of Lyon, 69007 Lyon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Unité Fonctionnelle Innovation en Diagnostic génomique des maladies rares, FHU-TRANSLAD, Dijon University Hospital, 21000 Dijon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon, 21000, Dijon, France.;Inserm, UMR1231, Equipe GAD, Bâtiment B3, Université de Bourgogne Franche Comté, 15 boulevard du Maréchal de Lattre de Tassigny, 21000, Dijon Cedex, France; Centre de Référence Déficiences Intellectuelles de Causes Rares, CHU Dijon, 21000, Dijon, France.;UMR 1253, iBrain, Universite de Tours, Inserm, 37200 Tours, France; Centre Hospitalier Universitaire de Tours, Service de Genetique, 37000 Tours, France.;UMR 1253, iBrain, Universite de Tours, Inserm, 37200 Tours, France; Centre Hospitalier Universitaire de Tours, Service de Genetique, 37000 Tours, France.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Amsterdam University Medical Center, University of Amsterdam, Department of Clinical Genetics, Amsterdam Reproduction and Development Research Institute, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.;Department of Pediatrics, Academic Medical Center, University of Amsterdam, Amsterdam, 1012 WX, the Netherlands.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Université de Paris, Epigénétique et Destin Cellulaire, CNRS, 75013 Paris, France.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00146 Rome, Italy.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Department of Genetics, Referral Center for Intellectual Disabilities, APHP Sorbonne University, Pitié Salpêtrière Hospital, 75013 Paris, France.;Unit of Genetics, APHP Sorbonne University, Trousseau Hospital, 75012 Paris, France.;Unit of Genetics, APHP Sorbonne University, Trousseau Hospital, 75012 Paris, France.;Department of Molecular Genetics, Cochin Hospital, 75014 Paris, France.;Department of Pediatrics, University of Montreal, Montreal, QC H3T1J4, Canada.;Department of Pediatrics, University of Montreal, Montreal, QC H3T1J4, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Genetic Division, Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.;Genetic Division, Department of Pediatrics, McMaster University, Hamilton, ON L8S4K1, Canada.;Department of Pediatrics, Division of Medical Genetics, Western University, London, ON N6A 3K7; Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON N6A5W9, Canada.;Department of Pediatrics, Division of Medical Genetics, Western University, London, ON N6A 3K7; Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, ON N6A5W9, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada.;Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A5W9 Canada; St. Joseph's Health Care London, London, ON N6A5W9 Canada.;Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A5W9 Canada; St. Joseph's Health Care London, London, ON N6A5W9 Canada.;Center for Medical Genetics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.;Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Donders Center for Medical Neuroscience, 6525 GA Nijmegen, the Netherlands.;Department of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands; Donders Center for Medical Neuroscience, 6525 GA Nijmegen, the Netherlands.;Genetics of Learning Disability Service, Hunter Genetics, Waratah, NSW 2298, Australia.;School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia.;School of Medicine, Robinson Research Institute, University of Adelaide, Adelaide, SA 5005, Australia; South Australian Health and Medical Research Institute, Adelaide, SA 5005, Australia.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7, Canada.;Children's Health Research Institute, London, ON N6A3K7, Canada; Department of Biochemistry, Western University, London, ON N6A3K7, Canada.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Greenwood Genetic Center, Greenwood, SC 29646, USA.;Medical Genetic Department for Rare Diseases and Personalized Medicine, Reference Center AD SOOR, AnDDI-RARE, Groupe DI, Inserm U1183-Institute for Regenerative Medicine and Biotherapy, Montpellier University, Centre Hospitalier Universitaire de Montpellier, 34090 Montpellier, France.;Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON N6A5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A3K7"
"449","Contou D;Coudroy R;Colin G;Tadié JM;Cour M;Sonneville R;Mekontso Dessap A;de Prost N","Contou, Damien;Coudroy, Rémi;Colin, Gwenhaël;Tadié, Jean-Marc;Cour, Martin;Sonneville, Romain;Mekontso Dessap, Armand;de Prost, Nicolas","Pneumococcal purpura fulminans in asplenic or hyposplenic patients: a French multicenter exposed-unexposed retrospective cohort study.","Critical care (London, England)","England","eng","Journal Article","Asplenia;Overwhelming post-splenectomy infection;Purpura fulminans;Sepsis;Streptococcus pneumoniae","Adult;Aged;Amputation, Surgical;Bacteremia;Female;Humans;Intensive Care Units;Male;Middle Aged;Patient Admission;Pneumococcal Infections;Purpura Fulminans;Retrospective Studies;Splenectomy;Streptococcus pneumoniae","Adult;Aged;Amputation, Surgical;Bacteremia;Female;Humans;Intensive Care Units;Male;Middle Aged;Patient Admission;Pneumococcal Infections;Purpura Fulminans;Retrospective Studies;Splenectomy;Streptococcus pneumoniae","Pneumococcal infections remain the main cause of overwhelming post-splenectomy infections, and purpura fulminans may develop in almost 20% of patients with overwhelming post-splenectomy infection. We aimed at describing the impact of asplenia/hyposplenia on the clinical features and the outcomes of adult patients admitted to the intensive care unit (ICU) for pneumococcal purpura fulminans. A 17-year national multicenter retrospective cohort study included adult patients admitted to 55 French ICUs for an infectious purpura fulminans from 2000 to 2016. Patients with pneumococcal purpura fulminans were analyzed according to the absence or presence of asplenia/hyposplenia. Among the 306 patients admitted to the ICU for purpura fulminans, 67 (22%) had a pneumococcal purpura fulminans, of whom 34 (51%) had asplenia (n = 29/34, 85%) or hyposplenia (n = 5/34, 15%) and 33 (49%) had eusplenia. The prevalence of pneumococcal purpura fulminans was seven times higher in asplenic/hyposplenic patients compared to eusplenic patients with purpura fulminans (n = 34/39, 87% vs. n = 33/267, 12%; p < 0.001). The median time interval between the occurrence of asplenia/hyposplenia and ICU admission was 20 [9-32] years. Pneumococcal vaccine coverage was 35% in asplenic/hyposplenic patients. Purpura was more frequently reported before ICU admission in asplenic/hyposplenic patients (n = 25/34, 73% vs. n = 13/33, 39%; p = 0.01). The rate of bacteremia did not differ between asplenic/hyposplenic and eusplenic patients (n = 31/34, 91% vs n = 27/33, 82%; p = 0.261). SAPS II (60 ± 14 vs. 60 ± 18; p = 0.244) and SOFA (13 [1-5] vs. 14 [1-4, 6]; p = 0.48) scores did not differ between asplenic/hyposplenic and eusplenic patients. There were no significant differences between asplenic/hyposplenic and eusplenic patients regarding the rate of limb amputation (n = 9/34, 26% vs. 15/33, 45%; p = 0.11) and hospital mortality (n = 20/34, 59% vs. n = 15/33, 45%; p = 0.27). Half of pneumococcal purpura fulminans episodes occurred in asplenic or hyposplenic patients. Pneumococcal vaccine coverage was reported in one third of asplenic/hyposplenic patients. Half of pneumococcal purpura fulminans episodes occurred more than 20 years after splenectomy. Outcomes of pneumococcal purpura fulminans did not show significant differences between patients with or without asplenia or hyposplenia, although the small number of patients included limited our power to detect potential differences between groups.","Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil;Service de réanimation médicale, Centre Hospitalier Universitaire de Poitiers, 2 Rue de la Milétrie, 86021, Poitiers, France.;INSERM CIC 1402, ALIVE Group, Université de Poitiers, Poitiers, France.;Service de réanimation médico-chirurgicale, Centre hospitalier départemental de Vendée, Boulevard Stéphane Moreau, 85925, La Roche-sur-Yon, France.;Service de réanimation médicale, Centre Hospitalier Universitaire de Rennes, 2 rue Henri le Guilloux, 35033, Rennes, France.;Service de réanimation médicale, Hospices Civils de Lyon, Groupement Hospitalier Edouard Herriot, 3 quai des Célestins, 69002, Lyon, France.;Service de réanimation médicale, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, 46, rue Henri Huchard, 75877, Paris Cedex 18, France.;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil, France.;Service de réanimation médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France.;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil, France.;Service de réanimation médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France.","NA",0,"1466-609X","Crit Care","Crit Care",2019,"2020","24","10.1186/s13054-020-2769-y","68","","","32102696","32102696","PUBMED","Service de réanimation polyvalente, Centre Hospitalier Victor Dupouy, 69, rue du Lieutenant-Colonel Prud'hon, 95100, Argenteuil;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil;Service de réanimation médicale, Centre Hospitalier Universitaire de Poitiers, 2 Rue de la Milétrie, 86021, Poitiers, France.;INSERM CIC 1402, ALIVE Group, Université de Poitiers, Poitiers, France.;Service de réanimation médico-chirurgicale, Centre hospitalier départemental de Vendée, Boulevard Stéphane Moreau, 85925, La Roche-sur-Yon, France.;Service de réanimation médicale, Centre Hospitalier Universitaire de Rennes, 2 rue Henri le Guilloux, 35033, Rennes, France.;Service de réanimation médicale, Hospices Civils de Lyon, Groupement Hospitalier Edouard Herriot, 3 quai des Célestins, 69002, Lyon, France.;Service de réanimation médicale, Hôpital Bichat-Claude Bernard, Assistance Publique-Hôpitaux de Paris, 46, rue Henri Huchard, 75877, Paris Cedex 18, France.;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil, France.;Service de réanimation médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France.;Groupe de recherche clinique CARMAS, Université Paris Est Créteil, Créteil, France.;Service de réanimation médicale, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000, Créteil, France."
"450","Paracha N;Reyes A;Diéras V;Krop I;Pivot X;Urruticoechea A","Paracha, Noman;Reyes, Adriana;Diéras, Véronique;Krop, Ian;Pivot, Xavier;Urruticoechea, Ander","Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.","Breast cancer research and treatment","Netherlands","eng","Journal Article","Capecitabine;Lapatinib;Locally advanced;Neratinib;Pertuzumab;Trastuzumab emtansine","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Bridged-Ring Compounds;Female;Humans;Molecular Targeted Therapy;Network Meta-Analysis;Receptor, ErbB-2;Taxoids;Trastuzumab;Treatment Outcome","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Bridged-Ring Compounds;Female;Humans;Molecular Targeted Therapy;Network Meta-Analysis;Receptor, ErbB-2;Taxoids;Trastuzumab;Treatment Outcome","In the absence of head-to-head trial data, network meta-analysis (NMA) was used to compare trastuzumab emtansine (T-DM1) with other approved treatments for previously treated patients with unresectable or metastatic HER2-positive breast cancer (BC). Systematic reviews were conducted of published controlled trials of treatments for unresectable or metastatic HER2-positive BC with early relapse (≤ 6 months) following adjuvant therapy or progression after trastuzumab (Tras) + taxane published from January 1998 to January 2018. Random-effects NMA was conducted for overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and safety endpoints. The NMA included regimens from seven randomized controlled trials: T-DM1 and combinations of Tras, capecitabine (Cap), lapatinib (Lap), neratinib, or pertuzumab (Per; unapproved). OS results favored T-DM1 over approved comparators: hazard ratio (HR) (95% credible interval [95% CrI]) vs Cap 0.68 (0.39, 1.10), LapCap 0.76 (0.51, 1.07), TrasCap 0.78 (0.44, 1.19). PFS trends favored T-DM1 over all other treatments: HR (95% CrI) vs Cap 0.38 (0.19, 0.74), LapCap 0.65 (0.40, 1.10), TrasCap 0.62 (0.34, 1.18); ORR with T-DM1 was more favorable than with all approved treatments. In surface under cumulative ranking curve (SUCRA) analysis T-DM1 ranked highest for all efficacy outcomes. Discontinuation due to adverse events was less likely with T-DM1 than with all comparators except neratinib. In general, gastrointestinal side effects were less likely and elevated liver transaminases and thrombocytopenia more likely with T-DM1 than with comparators. The efficacy and tolerability profiles of T-DM1 are generally favorable compared with other treatments for unresectable or metastatic HER2-positive BC.","F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070, Basel;F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070, Basel, Switzerland.;Centre Eugène Marquis, Rennes, France.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.;Paul Strauss Centre, Regional Institute of Cancer, Strasbourg, France.;Onkologikoa Foundation, San Sebastián, Spain.","NA",0,"1573-7217","Breast Cancer Res Treat","Breast Cancer Res Treat",2019,"2020","180","10.1007/s10549-020-05577-7","597-609","","","32100144","32100144","PUBMED","F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070, Basel;F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070, Basel, Switzerland.;Centre Eugène Marquis, Rennes, France.;Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.;Paul Strauss Centre, Regional Institute of Cancer, Strasbourg, France.;Onkologikoa Foundation, San Sebastián, Spain."
"451","Thoré P;Girerd B;Jaïs X;Savale L;Ghigna MR;Eyries M;Levy M;Ovaert C;Servettaz A;Guillaumot A;Dauphin C;Chabanne C;Boiffard E;Cottin V;Perros F;Simonneau G;Sitbon O;Soubrier F;Bonnet D;Remy-Jardin M;Chaouat A;Humbert M;Montani D","Thoré, Pierre;Girerd, Barbara;Jaïs, Xavier;Savale, Laurent;Ghigna, Maria-Rosa;Eyries, Mélanie;Levy, Marilyne;Ovaert, Caroline;Servettaz, Amélie;Guillaumot, Anne;Dauphin, Claire;Chabanne, Céline;Boiffard, Emmanuel;Cottin, Vincent;Perros, Frédéric;Simonneau, Gérald;Sitbon, Olivier;Soubrier, Florent;Bonnet, Damien;Remy-Jardin, Martine;Chaouat, Ari;Humbert, Marc;Montani, David",NA,"The European respiratory journal","England","eng","Journal Article","","Adolescent;Adult;Aged;Bone Diseases, Developmental;Child;Child, Preschool;Female;France;Hip;Humans;Infant;Infant, Newborn;Ischium;Lung Transplantation;Male;Middle Aged;Mutation;Patella;Phenotype;Pulmonary Arterial Hypertension;Retrospective Studies;Survival Rate;T-Box Domain Proteins;Vascular Resistance;Young Adult","Adolescent;Adult;Aged;Bone Diseases, Developmental;Child;Child, Preschool;Female;France;Hip;Humans;Infant;Infant, Newborn;Ischium;Lung Transplantation;Male;Middle Aged;Mutation;Patella;Phenotype;Pulmonary Arterial Hypertension;Retrospective Studies;Survival Rate;T-Box Domain Proteins;Vascular Resistance;Young Adult"," mutation causes small patella syndrome (SPS) and/or pulmonary arterial hypertension (PAH). The characteristics and outcomes of PAH associated with   mutations are largely unknown. We report the clinical, functional, radiologic, histologic and haemodynamic characteristics and outcomes of heritable PAH patients carrying a   mutation from the French pulmonary hypertension (PH) network. 20 patients were identified in 17 families. They were characterised by a median age at diagnosis of 29 years (0-76 years) and a female to male ratio of three. Most of the patients (70%) were in New York Heart Association (NYHA) functional class III or IV with a severe haemodynamic impairment (median pulmonary vascular resistance (PVR) of 13.6 (6.2-41.8) Wood units). Skeletal signs of SPS were present in 80% of cases. Half of the patients had mild restrictive or obstructive limitation and diffusing capacity of the lung for carbon monoxide (   ) was decreased in all patients. High-resolution computed tomography (HRCT) showed bronchial abnormalities, peri-bronchial cysts, mosaic distribution and mediastinal lymphadenopathies. PAH therapy was associated with significant clinical improvement. At follow-up (median 76 months), two patients had died and two had undergone lung transplantation. One-year, three-year and five-year event-free survival rates were 100%, 94% and 83%, respectively. Histologic examination of explanted lungs revealed alveolar growth abnormalities, major pulmonary vascular remodelling similar to that observed in idiopathic pulmonary arterial hypertension (IPAH) and accumulation of cholesterol crystals within the lung parenchyma. PAH due to   mutations may occur with or without skeletal abnormalities across a broad age range from birth to late adulthood. PAH is usually severe and associated with bronchial and parenchymal abnormalities.","Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Inserm UMR_S 1116, Défaillance Cardiovasculaire Aigüe et Chronique, Faculté de Médecine de Nancy, Université de Lorraine, Nancy, France.;These authors contributed equally.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;These authors contributed equally.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Service d'Anatomopathologie, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, UF d'Oncogénétique et Angiogénétique Moléculaire, Département de Génétique, Groupement Hospitalier Pitié Salpêtrière-Charles Foix, Hôpital Pitié Salpêtrière, Paris, France.;Assistance Publique-Hôpitaux de Paris, Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France.;Assistance Publique-Hôpitaux de Marseille, Service Médico-Chirurgical de Cardiologie Pédiatrique et Congénitale, Hôpital de la Timone, Marseille, France.;Centre Hospitalier Universitaire de Reims, Service de Médecine Interne, Maladies Infectieuses et Immunologie Clinique, Hôpital Robert Debré, Reims, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie et Maladies Vasculaires, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Centre Cardio-Pneumologique, Rennes, France.;Centre Hospitalier Départemental de Vendée, Service de Cardiologie, Hôpital de La Roche sur Yon, La Roche sur Yon, France.;Centre Hospitalier Universitaire de Lyon HCL, Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares, Groupement Hospitalier Est, Hôpital Louis Pradel, Bron, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Service d'Anatomopathologie, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France.;Centre Hospitalier Universitaire de Lille, Service d'Imagerie Thoracique, Hôpital Albert Calmette, Lille, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Inserm UMR_S 1116, Défaillance Cardiovasculaire Aigüe et Chronique, Faculté de Médecine de Nancy, Université de Lorraine, Nancy, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.","NA",0,"1399-3003","Eur Respir J","Eur Respir J",2019,"2020","55","10.1183/13993003.02340-2019",NA,"","","32079640","32079640","PUBMED","Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Inserm UMR_S 1116, Défaillance Cardiovasculaire Aigüe et Chronique, Faculté de Médecine de Nancy, Université de Lorraine, Nancy, France.;These authors contributed equally.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;These authors contributed equally.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Service d'Anatomopathologie, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, UF d'Oncogénétique et Angiogénétique Moléculaire, Département de Génétique, Groupement Hospitalier Pitié Salpêtrière-Charles Foix, Hôpital Pitié Salpêtrière, Paris, France.;Assistance Publique-Hôpitaux de Paris, Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France.;Assistance Publique-Hôpitaux de Marseille, Service Médico-Chirurgical de Cardiologie Pédiatrique et Congénitale, Hôpital de la Timone, Marseille, France.;Centre Hospitalier Universitaire de Reims, Service de Médecine Interne, Maladies Infectieuses et Immunologie Clinique, Hôpital Robert Debré, Reims, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Service de Cardiologie et Maladies Vasculaires, Hôpital Gabriel Montpied, Clermont-Ferrand, France.;Centre Hospitalier Universitaire de Rennes, Service de Cardiologie et Maladies Vasculaires, Centre Cardio-Pneumologique, Rennes, France.;Centre Hospitalier Départemental de Vendée, Service de Cardiologie, Hôpital de La Roche sur Yon, La Roche sur Yon, France.;Centre Hospitalier Universitaire de Lyon HCL, Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares, Groupement Hospitalier Est, Hôpital Louis Pradel, Bron, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Service d'Anatomopathologie, Hôpital Marie Lannelongue, Le Plessis Robinson, France.;Assistance Publique-Hôpitaux de Paris, Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades, Paris, France.;Centre Hospitalier Universitaire de Lille, Service d'Imagerie Thoracique, Hôpital Albert Calmette, Lille, France.;Centre Hospitalier Régional Universitaire de Nancy, Département de Pneumologie, Hôpital de Brabois, Vandoeuvre-lès-Nancy, France.;Inserm UMR_S 1116, Défaillance Cardiovasculaire Aigüe et Chronique, Faculté de Médecine de Nancy, Université de Lorraine, Nancy, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.;Assistance Publique-Hôpitaux de Paris, Dept of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre;School of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.;INSERM UMR_S 999, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Hôpital Marie Lannelongue, Le Plessis-Robinson, France."
"452","Lerebours F;Pulido M;Fourme E;Debled M;Becette V;Bonnefoi H;Rivera S;MacGrogan G;Mouret-Reynier MA;de Lara CT;Pierga JY;Breton-Callu C;Venat-Bouvet L;Mathoulin-Pélissier S;de la Motte Rouge T;Dalenc F;Sigal B;Bachelot T;Lemonnier J;Quenel-Tueux N","Lerebours, Florence;Pulido, Marina;Fourme, Emmanuelle;Debled, Marc;Becette, Véronique;Bonnefoi, Hervé;Rivera, Sofia;MacGrogan, Gaetan;Mouret-Reynier, Marie-Ange;de Lara, Christine Tunon;Pierga, Jean-Yves;Breton-Callu, Christel;Venat-Bouvet, Laurence;Mathoulin-Pélissier, Simone;de la Motte Rouge, Thibault;Dalenc, Florence;Sigal, Brigitte;Bachelot, Thomas;Lemonnier, Jérôme;Quenel-Tueux, Nathalie","Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials.","British journal of cancer","England","eng","Clinical Trial, Phase II","","Aged;Breast Neoplasms;Female;Humans;Neoadjuvant Therapy;Prognosis;Survival Analysis;Time Factors","Aged;Breast Neoplasms;Female;Humans;Neoadjuvant Therapy;Prognosis;Survival Analysis;Time Factors","Few data are available on survival and predictive factors in early breast cancer (BC) patients treated with neoadjuvant endocrine therapy (NET). This is a pooled analysis of two multicentre, randomised non-comparative phase 2 clinical trials evaluating neoadjuvant anastrozole and fulvestrant efficacy for postmenopausal HR+/HER2- breast cancer patients: HORGEN (NCT00871858) and CARMINA02 (NCT00629616) studies. In total, 236 patients were included in CARMINA02 and HORGEN trials. Modified intention-to-treat analysis was available for 217 patients. Median follow-up was 65.2 months. Relapse-free survival (RFS) and overall survival (OS) at 5 years were 83.7% (95% CI: 77.9-88) and 92.7% (95% CI: 88.2-95.6), respectively, with no difference between treatment arms. On univariate analysis, tumour staging (T2 vs T3-4; p = 0.0001), Ki-67 at surgery (≤10% vs >10%; p = 0.0093), pathological tumour size (pT1-2 vs pT3-4; p = 0.0012) and node status (pN negative vs positive; p = 0.007), adjuvant chemotherapy (p = 0.0167) and PEPI score (PEPI group I + II vs III; p = 0.0004) were associated with RFS. No events were observed in patients with pathological response according to the Sataloff classification. Multivariate analysis showed that preoperative endocrine prognostic index (PEPI) group III was associated with significantly worse RFS (p = 0.0069, hazard ratio = 3.33 (95% CI: 1.39-7.98)). Postmenopausal HR+/HER2- breast cancer patients receiving NET generally have a favourable outcome. The PEPI score identifies a subset of patients of poorer prognosis who are candidates for further additional treatment.","Institut Curie, Saint Cloud;Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC 14.01, Bordeaux, France.;Institut Curie, Saint Cloud, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Institut Bergonié, Bordeaux, France.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Institut Bergonié, Bordeaux, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Institut Bergonié, Bordeaux, France.;CHU, Limoges, France.;Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC 14.01, Bordeaux, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Institut Curie, Paris, France.;Centre Léon Bérard, Lyon, France.;R&D UNICANCER, UCBG, Paris, France.;Institut Bergonié, Bordeaux, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2019,"2020","122","10.1038/s41416-020-0733-x","759-765","","","32001832","32001832","PUBMED","Institut Curie, Saint Cloud;Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC 14.01, Bordeaux, France.;Institut Curie, Saint Cloud, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Institut Bergonié, Bordeaux, France.;Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.;Institut Bergonié, Bordeaux, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut Bergonié, Bordeaux, France.;Institut Curie, Paris, France.;Institut Bergonié, Bordeaux, France.;CHU, Limoges, France.;Clinical and Epidemiological Research Unit, Institut Bergonié, INSERM CIC 14.01, Bordeaux, France.;Centre Eugène Marquis, Rennes, France.;Institut Claudius Regaud-IUCT Oncopole, Toulouse, France.;Institut Curie, Paris, France.;Centre Léon Bérard, Lyon, France.;R&D UNICANCER, UCBG, Paris, France.;Institut Bergonié, Bordeaux, France."
"453","Boilève A;Maillard A;Wagner M;Dromain C;Laurent C;Dupont Bierre E;Le Sourd S;Audemar F;Ulusakarya A;Guerin-Meyer V;Smisth D;Pezzella V;De Baere T;Goere D;Gelli M;Taieb J;Boige V","Boilève, Alice;Maillard, Aline;Wagner, Mathilde;Dromain, Clarisse;Laurent, Christophe;Dupont Bierre, Eric;Le Sourd, Samuel;Audemar, Franck;Ulusakarya, Ayhan;Guerin-Meyer, Veronique;Smisth, Denis;Pezzella, Veronica;De Baere, Thierry;Goere, Diane;Gelli, Maximiliano;Taieb, Julien;Boige, Valérie","Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol.","BMC cancer","England","eng","Clinical Trial, Phase II","Colorectal cancer;Hepatic arterial infusion;Liver metastases;Liver resection;Oxaliplatin;Randomized trial","Antineoplastic Combined Chemotherapy Protocols;Clinical Protocols;Colorectal Neoplasms;Female;Hepatic Artery;Humans;Induction Chemotherapy;Infusions, Intra-Arterial;Liver Neoplasms;Male","Antineoplastic Combined Chemotherapy Protocols;Clinical Protocols;Colorectal Neoplasms;Female;Hepatic Artery;Humans;Induction Chemotherapy;Infusions, Intra-Arterial;Liver Neoplasms;Male","Approximately 40% of colorectal cancer patients will develop colorectal liver metastases (CRLM). The most effective approach to increase long-term survival is CRLM complete resection. Unfortunately, only 10-15% of CRLM are initially considered resectable. The objective response rates (ORR) after current first-line systemic chemotherapy (sys-CT) regimens range from 40 to 80% and complete resection rates (CRR) range from 25 to 50% in patients with initially unresectable CRLM. When CRLM patients are not amenable to complete resection after induction of sys-CT, ORRs obtained with second-line sys-CT are much lower (between 10 and 30%) and consequently CRRs are also low (< 10%). Hepatic arterial infusion (HAI) oxaliplatin may represent a salvage therapy in patients with CRLM unresectable after one or more sys-CT regimens with ORRs and CRRs up to 60 and 30%, respectively. This study is designed to evaluate the efficacy of an intensification strategy based on HAI oxaliplatin combined with sys-CT as a salvage treatment in patients with CRLM unresectable after at least 2 months of first-line induction sys-CT. Our main objective is to investigate the efficacy, in term of CRR (R0-R1), of treatment intensification in patients with liver-only CRLM not amenable to curative-intent resection (and/or ablation) after at least 2 months of induction sys-CT. Patients will receive either HAI oxaliplatin plus systemic FOLFIRI plus targeted therapy (i.e. anti-EGFR antibody or bevacizumab) or conventional sys-CT plus targeted therapy (i.e. anti-EGFR or antiangiogenic antibody). Secondary objectives are to compare: progression-free survival, overall survival, objective response rate, depth of response, feasibility of delivering HAI oxaliplatin including HAI catheter-related complications, and toxicity (NCI-CTCAE v4.0). This study is a multicenter, randomized, comparative phase II trial (power, 80%; two-sided alpha-risk, 5%). Patients will be randomly assigned in a 1:1 ratio to receive HAI oxaliplatin combined with systemic FOLFIRI plus targeted therapy (experimental arm) or the best sys-CT plus targeted therapy on the basis of their first-line prior sys-CT history and current guidelines (control arm). One hundred forty patients are required to account for non-evaluable patients. ClinicalTrials.gov, (NCT03164655). Trial registration date: 11th May 2017.","Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif Cedex;Department of statistics and epidemiology, Villejuif, France.;Centre for Research in Epidemiology and Population Health (team 2), INSERM U1018, Paris-Saclay University, Villejuif, France.;Department of radiology, CHU Pitié Salpétrière, Paris, France.;Department of radiology, Centre Hospitalier et Universitaire Vaudois, Lausanne, Switzerland.;Department of hepatogastroenterology, Hôpital Haut Levêque, Pessac, France.;Department of digestive surgery, CHP Saint Grégoire, Saint-Grégoire, France.;Department of medical oncology, Centre Eugène-Marquis, Rennes, France.;Department of hepatogastroenterology, Centre hospitalier Côte Basque, Bayonne, France.;Department of medical oncology, Hôpital Paul Brousse, Villejuif, France.;Department of medical oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of hepatogastroenterology, Hôpital Haut Levêque, Pessac, France.;R&D Unicancer, Paris, France.;Department of interventional radiology, Gustave Roussy, Villejuif, France.;Department of Surgical Oncology, Hôpital Saint Louis, Paris, France.;Department of Surgical Oncology, Gustave Roussy, Villejuif, France.;Department of digestive oncology, Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University, Paris, France.;Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif Cedex, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2019,"2020","20","10.1186/s12885-020-6571-7","74","PHRC-K-2015-2506","National Institute of Cancer (INCa)","32000724","32000724","PUBMED","Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif Cedex;Department of statistics and epidemiology, Villejuif, France.;Centre for Research in Epidemiology and Population Health (team 2), INSERM U1018, Paris-Saclay University, Villejuif, France.;Department of radiology, CHU Pitié Salpétrière, Paris, France.;Department of radiology, Centre Hospitalier et Universitaire Vaudois, Lausanne, Switzerland.;Department of hepatogastroenterology, Hôpital Haut Levêque, Pessac, France.;Department of digestive surgery, CHP Saint Grégoire, Saint-Grégoire, France.;Department of medical oncology, Centre Eugène-Marquis, Rennes, France.;Department of hepatogastroenterology, Centre hospitalier Côte Basque, Bayonne, France.;Department of medical oncology, Hôpital Paul Brousse, Villejuif, France.;Department of medical oncology, Institut de Cancerologie de l'Ouest, Angers, France.;Department of hepatogastroenterology, Hôpital Haut Levêque, Pessac, France.;R&D Unicancer, Paris, France.;Department of interventional radiology, Gustave Roussy, Villejuif, France.;Department of Surgical Oncology, Hôpital Saint Louis, Paris, France.;Department of Surgical Oncology, Gustave Roussy, Villejuif, France.;Department of digestive oncology, Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University, Paris, France.;Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif Cedex, France."
"454","Lamarca A;Edeline J;McNamara MG;Hubner RA;Nagino M;Bridgewater J;Primrose J;Valle JW","Lamarca, Angela;Edeline, Julien;McNamara, Mairéad G;Hubner, Richard A;Nagino, Masato;Bridgewater, John;Primrose, John;Valle, Juan W","Current standards and future perspectives in adjuvant treatment for biliary tract cancers.","Cancer treatment reviews","Netherlands","eng","Journal Article","Adjuvant;Biliary tract cancer;Chemotherapy;Cholangiocarcinoma;Gallbladder cancer","Antineoplastic Combined Chemotherapy Protocols;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Humans;Practice Guidelines as Topic;Prognosis","Antineoplastic Combined Chemotherapy Protocols;Biliary Tract Neoplasms;Chemotherapy, Adjuvant;Humans;Practice Guidelines as Topic;Prognosis","Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60-70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies. Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community. This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored.","Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.;Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.;Department of Medical Oncology, UCL Cancer Institute, London, United Kingdom.;Department of Surgery, University of Southampton, Southampton, United Kingdom.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester","NA",0,"1532-1967","Cancer Treat Rev","Cancer Treat Rev",2019,"2020","84","10.1016/j.ctrv.2019.101936","101936","16281;4273","Cancer Research UK;Cancer Research UK","31986437","31986437","PUBMED","Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.;Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.;Department of Medical Oncology, UCL Cancer Institute, London, United Kingdom.;Department of Surgery, University of Southampton, Southampton, United Kingdom.;Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester"
"455","Hage C;Wärdell E;Linde C;Donal E;Lam CSP;Daubert C;Lund LH;Månsson-Broberg A","Hage, Camilla;Wärdell, Eva;Linde, Cecilia;Donal, Erwan;Lam, Carolyn S P;Daubert, Claude;Lund, Lars H;Månsson-Broberg, Agneta","Circulating neuregulin1-β in heart failure with preserved and reduced left ventricular ejection fraction.","ESC heart failure","England","eng","Journal Article","Coronary artery disease;HFpEF;HFrEF;Neuregulin1-β;Prognosis","Endothelial Cells;Heart Failure;Humans;Prognosis;Stroke Volume;Ventricular Function, Left","Endothelial Cells;Heart Failure;Humans;Prognosis;Stroke Volume;Ventricular Function, Left","Neuregulin1-β (NRG1-β) is released from microvascular endothelial cells in response to inflammation with compensatory cardioprotective effects. Circulating NRG1-β is elevated in heart failure (HF) with reduced ejection fraction (HFrEF) but not studied in HF with preserved EF (HFpEF). Circulating NRG1-β was quantified in 86 stable patients with HFpEF (EF ≥45% and N-terminal pro-brain natriuretic peptide >300 ng/L), in 86 patients with HFrEF prior to and after left ventricular assist device (LVAD) and/or heart transplantation (HTx) and in 21 healthy controls. Association between NRG1-β and the composite outcome of all-cause mortality/HF hospitalization in HFpEF and all-cause mortality/HTx/LVAD implantation in HFrEF with and without ischaemia assessed as macrovascular coronary artery disease was assessed. In HFpEF, median (25th-75th percentile) NRG1-β was 6.5 (2.1-11.3) ng/mL; in HFrEF, 3.6 (2.1-7.6) ng/mL (P = 0.035); after LVAD, 1.7 (0.9-3.6) ng/mL; after HTx 2.1 (1.4-3.6) ng/mL (overall P < 0.001); and in controls, 29.0 (23.1-34.3) ng/mL (P = 0.001). In HFrEF, higher NRG1-β was associated with worse outcomes (hazard ratio per log increase 1.45, 95% confidence interval 1.04-2.03, P = 0.029), regardless of ischaemia. In HFpEF, the association of NRG1-β with outcomes was modified by ischaemia (log-rank P = 0.020; P  = 0.553) such that only in ischaemic patients, higher NRG1-β was related to worse outcomes. In contrast, in patients without ischaemia, higher NRG1-β trended towards better outcomes (hazard ratio 0.71, 95% confidence interval 0.48-1.05, P = 0.085). Neuregulin1-β was reduced in HFpEF and further reduced in HFrEF. The opposing relationships of NRG1-β with outcomes in non-ischaemic HFpEF compared with HFrEF and ischaemic HFpEF may indicate compensatory increases of cardioprotective NRG1-β from microvascular endothelial dysfunction in the former (non-ischaemic HFpEF), but this compensatory mechanism is overwhelmed by the presence of ischaemia in the latter (HFrEF and ischaemic HFpEF).","Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Huddinge, Huddinge, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;National Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore.;University Medical Centre Groningen, Groningen, The Netherlands.;The George Institute for Global Health, Sydney, Australia.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Huddinge, Huddinge, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2019,"2020","7","10.1002/ehf2.12615","445-455","20110120;00556-2009;20110610;20090376;20110406;20080498;20100419;20080409;2013-23897-104604-23","Stockholm County Council;Stockholm County Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Research Council;Medtronic Bakken Research Center, Maastricht, The Netherlands;Fédération Française de Cardiologie/Société Française de Cardiologie, France;Center for Gender Medicine Karolinska Institutet, Stockholm Sweden","31981321","31981321","PUBMED","Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Huddinge, Huddinge, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;National Heart Centre Singapore, Duke-National University of Singapore, Singapore, Singapore.;University Medical Centre Groningen, Groningen, The Netherlands.;The George Institute for Global Health, Sydney, Australia.;Département de Cardiologie & CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Medicine, Karolinska Institutet - Solna, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet - Huddinge, Huddinge, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, SE-171 76, Stockholm, Sweden."
"456","Roussel M;Lhomme F;Roe CE;Bartkowiak T;Gravelle P;Laurent C;Fest T;Irish JM","Roussel, Mikael;Lhomme, Faustine;Roe, Caroline E;Bartkowiak, Todd;Gravelle, Pauline;Laurent, Camille;Fest, Thierry;Irish, Jonathan M","Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas.","Cancer immunology, immunotherapy : CII","Germany","eng","Journal Article","Germinal center;Lymphoma;Mass cytometry;Tumor-associated macrophages","Adult;Aged;Female;Flow Cytometry;Germinal Center;Humans;Lymphoma, Large B-Cell, Diffuse;Macrophages;Male;Middle Aged;Young Adult","Adult;Aged;Female;Flow Cytometry;Germinal Center;Humans;Lymphoma, Large B-Cell, Diffuse;Macrophages;Male;Middle Aged;Young Adult","Tumor-associated macrophage and T-cell subsets are implicated in the pathogenesis of diffuse large B-cell lymphoma, follicular lymphoma, and classical Hodgkin lymphoma. Macrophages provide essential mechanisms of tumor immune evasion through checkpoint ligand expression and secretion of suppressive cytokines. However, normal and tumor-associated macrophage phenotypes are less well characterized than those of tumor-infiltrating T-cell subsets, and it would be especially valuable to know whether the polarization state of macrophages differs across lymphoma tumor microenvironments. Here, an established mass cytometry panel designed to characterize myeloid-derived suppressor cells and known macrophage maturation and polarization states was applied to characterize B-lymphoma tumors and non-malignant human tissue. High-dimensional single-cell analyses were performed using dimensionality reduction and clustering tools. Phenotypically distinct intra-tumor macrophage subsets were identified based on abnormal marker expression profiles that were associated with lymphoma tumor types. While it had been proposed that measurement of CD163 and CD68 might be sufficient to reveal macrophage subsets in tumors, results here indicated that S100A9, CCR2, CD36, Slan, and CD32 should also be measured to effectively characterize lymphoma-specific tumor macrophages. Additionally, the presence of phenotypically distinct, abnormal macrophage populations was closely linked to the phenotype of intra-tumor T-cell populations, including PD-1 expressing T cells. These results further support the close links between macrophage polarization and T-cell functional state, as well as the rationale for targeting tumor-associated macrophages in cancer immunotherapies.","Laboratoire Hématologie, CHU Pontchaillou, Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 2 rue Henri Le Guilloux, 35033, Rennes;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840, USA.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840, USA.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.;Service Anatomie et Cytologie Pathologiques and UMR1037, Toulouse, France.;Service Anatomie et Cytologie Pathologiques and UMR1037, Toulouse, France.;Laboratoire Hématologie, CHU Pontchaillou, Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 2 rue Henri Le Guilloux, 35033, Rennes, France.;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN","NA",0,"1432-0851","Cancer Immunol Immunother","Cancer Immunol Immunother",2018,"2020","69","10.1007/s00262-019-02464-z","407-420","P41 GM076263;K00 CA212447;U01 TR002625;U54 CA217450;R01 CA226833","NIGMS NIH HHS;NCI NIH HHS;NCATS NIH HHS;NCI NIH HHS;NCI NIH HHS","31919622","31919622","PUBMED","Laboratoire Hématologie, CHU Pontchaillou, Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 2 rue Henri Le Guilloux, 35033, Rennes;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840, USA.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840, USA.;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA.;Service Anatomie et Cytologie Pathologiques and UMR1037, Toulouse, France.;Service Anatomie et Cytologie Pathologiques and UMR1037, Toulouse, France.;Laboratoire Hématologie, CHU Pontchaillou, Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 2 rue Henri Le Guilloux, 35033, Rennes, France.;INSERM, UMR U1236, Université Rennes 1, EFS Bretagne, Equipe Labellisée Ligue Contre Le Cancer, Rennes, France.;Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, 740B Preston Building, 2220 Pierce Avenue, Nashville, TN, 37232-6840;Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN"
"457","Angeles MA;Mallet E;Rouanet P;Cabarrou B;Méeus P;Lambaudie E;Foucher F;Narducci F;Loaec C;Gouy S;Guyon F;Marchal F;Gladieff L;Martínez-Gómez C;Migliorelli F;Martinez A;Ferron G","Angeles, Martina Aida;Mallet, Estelle;Rouanet, Philippe;Cabarrou, Bastien;Méeus, Pierre;Lambaudie, Eric;Foucher, Fabrice;Narducci, Fabrice;Loaec, Cécile;Gouy, Sebastien;Guyon, Frederic;Marchal, Frédéric;Gladieff, Laurence;Martínez-Gómez, Carlos;Migliorelli, Federico;Martinez, Alejandra;Ferron, Gwenael","Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies.","International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","England","eng","Comparative Study","anterior pelvic exenteration;body image;continent urinary reconstruction;global health;gynecologic cancer;incontinent urinary reconstruction","Adult;Aged;Female;France;Genital Neoplasms, Female;Humans;Middle Aged;Pelvic Exenteration;Postoperative Complications;Prospective Studies;Quality of Life;Retrospective Studies;Urinary Diversion","Adult;Aged;Female;France;Genital Neoplasms, Female;Humans;Middle Aged;Pelvic Exenteration;Postoperative Complications;Prospective Studies;Quality of Life;Retrospective Studies;Urinary Diversion","Pelvic exenteration and its reconstructive techniques have been associated with high postoperative morbidity and a negative impact on patient quality of life. The aim of our study was to compare postoperative complications and quality of life in patients undergoing continent compared with non-continent urinary diversion after pelvic exenteration for gynecologic malignancies. We designed a multicenter study of patients from 10 centers who underwent an anterior or total pelvic exenteration with urinary reconstruction for histologically confirmed persistent or recurrent gynecologic malignancy after previous treatment with radiotherapy. From January 2005 to September 2008, we included patients retrospectively, and from September 2008 to May 2009, patients were included prospectively which allowed collection of quality of life data. Demographic, surgical, and follow-up data were analyzed. Postoperative complications were classified according to the Clavien-Dindo classification. Quality of life was assessed using the European Organization for Research and Treatment of Cancer (EORTC)-QLQ-C30 (V.3.0) and EORTC-QLQ-OV28 quality of life questionnaires. We compared patients who underwent a continent urinary diversion with those who underwent a non-continent reconstruction. We included 148 patients, 92 retrospectively and 56 prospectively. Among them, 77.4% had recurrent disease and 22.6% persistent disease after the primary treatment. In 70 patients, a urinary continent diversion was performed, and 78 patients underwent a non-continent diversion. Median age of the continent and incontinent groups was 53.5 (range 33-78) years and 57 (26-79) years, respectively. There were no significant differences between the continent and non-continent groups in median length of hospitalization (28.5 vs 26 days, P=0.19), postoperative grade III-IV complications (42.9% vs 42.3%, P=0.95), complications needing surgical (27.9% vs 34.6%, P=0.39) or radiological (14.7% vs 12.8%, P=0.74) intervention, and complication type (digestive (23.2% vs 16.7%, P=0.32) and urinary (15.9% vs 16.7%, P=0.91)). There were no significant differences between the groups in global health, global quality of life, and body image perception scores 1 year after surgery. Continent and incontinent urinary reconstructions are equivalent in terms of postoperative complications and quality of life scores.","Surgical Oncology, Institut Claudius Regaud IUCT-oncopole, Toulouse, Occitanie, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, Provence-Alpes-Côte d'Azu, France.;Department of Surgical Oncology, Institut régional du Cancer de Montpellier, Montpellier, France.;Biostatistics Unit, Institut Claudius Regaud, Toulouse, Occitanie, France.;Department of Surgical Oncology, Institut Léon Bérard, Lyon, France.;Institut Paoli-Calmettes, Marseille, France.;Department of Surgical Oncology, Centre Eugene Marquis, Rennes, Bretagne, France.;Gynecology, Centre Oscar Lambret, lille, France.;Institut de Cancerologie de l'Ouest, Nantes, France.;Institut Gustave-Roussy, Villejuif, Île-de-France, France.;Institut Bergonie, Bordeaux, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, Lorraine, France.;Medical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France.;Surgical Oncology, Institut Claudius Regaud IUCT-oncopole, Toulouse, Occitanie, France.;INSERM CRCT 1, Toulouse, France.;Department of Women, Children and Adolescents, Hopitaux Universitaires de Geneve, Geneva, Switzerland.;INSERM CRCT 1, Toulouse, France.;Institut Claudius Regaud, Toulouse, Occitanie, France.;Institut Claudius Regaud, Toulouse, Occitanie;INSERM CRCT 19, Toulouse, France.","NA",0,"1525-1438","Int J Gynecol Cancer","Int J Gynecol Cancer",2019,"2020","30","10.1136/ijgc-2019-000863","233-240","","","31796531","31796531","PUBMED","Surgical Oncology, Institut Claudius Regaud IUCT-oncopole, Toulouse, Occitanie, France.;Surgical Oncology, Centre Antoine-Lacassagne, Nice, Provence-Alpes-Côte d'Azu, France.;Department of Surgical Oncology, Institut régional du Cancer de Montpellier, Montpellier, France.;Biostatistics Unit, Institut Claudius Regaud, Toulouse, Occitanie, France.;Department of Surgical Oncology, Institut Léon Bérard, Lyon, France.;Institut Paoli-Calmettes, Marseille, France.;Department of Surgical Oncology, Centre Eugene Marquis, Rennes, Bretagne, France.;Gynecology, Centre Oscar Lambret, lille, France.;Institut de Cancerologie de l'Ouest, Nantes, France.;Institut Gustave-Roussy, Villejuif, Île-de-France, France.;Institut Bergonie, Bordeaux, France.;Surgical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, Lorraine, France.;Medical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France.;Surgical Oncology, Institut Claudius Regaud IUCT-oncopole, Toulouse, Occitanie, France.;INSERM CRCT 1, Toulouse, France.;Department of Women, Children and Adolescents, Hopitaux Universitaires de Geneve, Geneva, Switzerland.;INSERM CRCT 1, Toulouse, France.;Institut Claudius Regaud, Toulouse, Occitanie, France.;Institut Claudius Regaud, Toulouse, Occitanie;INSERM CRCT 19, Toulouse, France."
"458","Darlix A;Louvel G;Fraisse J;Jacot W;Brain E;Debled M;Mouret-Reynier MA;Goncalves A;Dalenc F;Delaloge S;Campone M;Augereau P;Ferrero JM;Levy C;Fumet JD;Lecouillard I;Cottu P;Petit T;Uwer L;Jouannaud C;Leheurteur M;Dieras V;Robain M;Chevrot M;Pasquier D;Bachelot T","Darlix, Amélie;Louvel, Guillaume;Fraisse, Julien;Jacot, William;Brain, Etienne;Debled, Marc;Mouret-Reynier, Marie Ange;Goncalves, Anthony;Dalenc, Florence;Delaloge, Suzette;Campone, Mario;Augereau, Paule;Ferrero, Jean Marc;Levy, Christelle;Fumet, Jean-David;Lecouillard, Isabelle;Cottu, Paul;Petit, Thierry;Uwer, Lionel;Jouannaud, Christelle;Leheurteur, Marianne;Dieras, Véronique;Robain, Mathieu;Chevrot, Michaël;Pasquier, David;Bachelot, Thomas","Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.","British journal of cancer","England","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Breast Neoplasms, Male;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Kinetics;Male;Middle Aged;Neoplasm Metastasis;Nervous System Neoplasms;Prognosis;Receptor, ErbB-2;Triple Negative Breast Neoplasms;Young Adult","Adult;Aged;Aged, 80 and over;Breast Neoplasms, Male;Disease-Free Survival;Female;Humans;Kaplan-Meier Estimate;Kinetics;Male;Middle Aged;Neoplasm Metastasis;Nervous System Neoplasms;Prognosis;Receptor, ErbB-2;Triple Negative Breast Neoplasms;Young Adult","Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient's prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan-Meier method). CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2-/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR- (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8-92.0). The median CNSM-FS was 10.8 months (95% CI: 16.5-17.9) among patients who developed CNS metastases. Molecular subtype was independently associated with CNSM-FS (HR = 3.45, 95% CI: 3.18-3.75, triple-negative and HER2-/HR+ tumours). After a 30-month follow-up, median OS after CNS metastasis diagnosis was 7.9 months (95% CI: 7.2-8.4). OS was independently associated with subtypes: median OS was 18.9 months (HR = 0.57, 95% CI: 0.50-0.64) for HER2+/HR+ , 13.1 months (HR = 0.72, 95% CI: 0.65-0.81) for HER2+/HR-, 4.4 months (HR = 1.55, 95% CI: 1.42-1.69) for triple-negative and 7.1 months for HER2-/HR+ patients (p <0.0001). Tumour molecular subtypes strongly impact incidence, kinetics and prognosis of CNS metastases in MBC patients. NCT03275311.","Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier;Department of Radiation Therapy, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Biometrics Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut du Cancer de Montpellier, University of Montpellier 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard-Vaillant, 94800, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Boulevard Jacques Monod, 44805, Saint Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 15 rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de valambrose, 06189, Nice, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079, Dijon, France.;Department of Radiation Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000, Strasbourg, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Radiation Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Research and Development, Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Research and Development, Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Academic Department of Radiation Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.","NA",0,"1532-1827","Br J Cancer","Br J Cancer",2019,"2019","121","10.1038/s41416-019-0619-y","991-1000","","","31719684","31719684","PUBMED","Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier;Department of Radiation Therapy, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.;Biometrics Unit, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut du Cancer de Montpellier (ICM), University of Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.;Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Institut du Cancer de Montpellier, University of Montpellier 208 Rue des Apothicaires, 34298, Montpellier, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France.;Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.;Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard-Vaillant, 94800, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest Centre René Gauducheau, Boulevard Jacques Monod, 44805, Saint Herblain, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, 15 rue André Boquel, 49055, Angers, France.;Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de valambrose, 06189, Nice, France.;Department of Medical Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000, Caen, France.;Department of Medical Oncology, Centre Georges François Leclerc, 1 rue Professeur Marion, 21079, Dijon, France.;Department of Radiation Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, 75005, Paris & Saint-Cloud, France.;Department of Medical Oncology, Centre Paul Strauss, 3 Rue de la Porte de l'Hôpital, 67000, Strasbourg, France.;Medical Oncology Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France.;Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue du Général Koenig, 51100, Reims, France.;Department of Medical Oncology, Centre Henri Becquerel, Rue d'Amiens, 76000, Rouen, France.;Department of Radiation Oncology, Centre Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, 35000, Rennes, France.;Department of Research and Development, Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Department of Research and Development, Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.;Academic Department of Radiation Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.;Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France."
"459","Launey Y;Fryer TD;Hong YT;Steiner LA;Nortje J;Veenith TV;Hutchinson PJ;Ercole A;Gupta AK;Aigbirhio FI;Pickard JD;Coles JP;Menon DK","Launey, Yoann;Fryer, Tim D;Hong, Young T;Steiner, Luzius A;Nortje, Jurgens;Veenith, Tonny V;Hutchinson, Peter J;Ercole, Ari;Gupta, Arun K;Aigbirhio, Franklin I;Pickard, John D;Coles, Jonathan P;Menon, David K","Spatial and Temporal Pattern of Ischemia and Abnormal Vascular Function Following Traumatic Brain Injury.","JAMA neurology","United States","eng","Journal Article","","Adult;Brain Injuries, Traumatic;Brain Ischemia;Cerebrovascular Circulation;Female;Humans;Image Interpretation, Computer-Assisted;Male;Middle Aged;Positron-Emission Tomography;Young Adult","Adult;Brain Injuries, Traumatic;Brain Ischemia;Cerebrovascular Circulation;Female;Humans;Image Interpretation, Computer-Assisted;Male;Middle Aged;Positron-Emission Tomography;Young Adult","Ischemia is an important pathophysiological mechanism after traumatic brain injury (TBI), but its incidence and spatiotemporal patterns are poorly characterized. To comprehensively characterize the spatiotemporal changes in cerebral physiology after TBI. This single-center cohort study uses 15oxygen positron emission tomography data obtained in a neurosciences critical care unit from February 1998 through July 2014 and analyzed from April 2018 through August 2019. Patients with TBI requiring intracranial pressure monitoring and control participants were recruited. Cerebral blood flow (CBF), cerebral blood volume (CBV), cerebral oxygen metabolism (CMRO2), and oxygen extraction fraction. Ratios (CBF/CMRO2 and CBF/CBV) were calculated. Ischemic brain volume was compared with jugular venous saturation and brain tissue oximetry. A total of 68 patients with TBI and 27 control participants were recruited. Results from 1 patient with TBI and 7 health volunteers were excluded. Sixty-eight patients with TBI (13 female [19%]; median [interquartile range (IQR)] age, 29 [22-47] years) underwent 90 studies at early (day 1 [n = 17]), intermediate (days 2-5 [n = 54]), and late points (days 6-10 [n = 19]) and were compared with 20 control participants (5 female [25%]; median [IQR] age, 43 [31-47] years). The global CBF and CMRO2 findings for patients with TBI were less than the ranges for control participants at all stages (median [IQR]: CBF, 26 [22-30] mL/100 mL/min vs 38 [29-49] mL/100 mL/min; P < .001; CMRO2, 62 [55-71] μmol/100 mL/min vs 131 [101-167] μmol/100 mL/min; P < .001). Early CBF reductions showed a trend of high oxygen extraction fraction (suggesting classical ischemia), but this was inconsistent at later phases. Ischemic brain volume was elevated even in the absence of intracranial hypertension and highest at less than 24 hours after TBI (median [IQR], 36 [10-82] mL), but many patients showed later increases (median [IQR] 6-10 days after TBI, 24 [4-42] mL; across all points: patients, 10 [5-39] mL vs control participants, 1 [0-3] mL; P < 001). Ischemic brain volume was a poor indicator of jugular venous saturation and brain tissue oximetry. Patients' CBF/CMRO2 ratio was higher than controls (median [IQR], 0.42 [0.35-0.49] vs 0.3 [0.28-0.33]; P < .001) and their CBF/CBV ratio lower (median [IQR], 7.1 [6.4-7.9] vs 12.3 [11.0-14.0]; P < .001), suggesting abnormal flow-metabolism coupling and vascular reactivity. Patients' CBV was higher than controls (median [IQR], 3.7 [3.4-4.1] mL/100 mL vs 3.0 [2.7-3.6] mL/100 mL; P < .001); although values were lower in patients with intracranial hypertension, these were still greater than controls (median [IQR], 3.7 [3.2-4.0] vs 3.0 [2.7-3.6] mL/100 mL; P = .002), despite more profound reductions in partial pressure of carbon dioxide (median [IQR], 4.3 [4.1-4.6] kPa vs 4.7 [4.3-4.9] kPa; P = .001). Ischemia is common early, detectable up to 10 days after TBI, possible without intracranial hypertension, and inconsistently detected by jugular or brain tissue oximetry. There is substantial between-patient and within-patient pathophysiological heterogeneity; ischemia and hyperemia commonly coexist, possibly reflecting abnormalities in flow-metabolism coupling. Increased CBV may contribute to intracranial hypertension but can coexist with abnormal CBF/CBV ratios. These results emphasize the need to consider cerebrovascular pathophysiological complexity when managing patients with TBI.","Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesia and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesiology, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University of Basel, Basel, Switzerland.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesia, Norfolk and Norwich University Hospitals National Health Service Foundation Trust, Norwich, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Birmingham Acute Care Research Group, Department of Critical Care Medicine, Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom.;Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.","NA",0,"2168-6157","JAMA Neurol","JAMA Neurol",2019,"2020","77","10.1001/jamaneurol.2019.3854","339-349","G0900903;G9439390;G0600986;G0001237;093267","Medical Research Council;Medical Research Council;Medical Research Council;Medical Research Council;Wellcome Trust","31710336","31710336","PUBMED","Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesia and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesiology, University Hospital Basel, Basel, Switzerland.;Department of Clinical Research, University of Basel, Basel, Switzerland.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Department of Anaesthesia, Norfolk and Norwich University Hospitals National Health Service Foundation Trust, Norwich, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Birmingham Acute Care Research Group, Department of Critical Care Medicine, Queen Elizabeth Hospital, University of Birmingham, Birmingham, United Kingdom.;Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom.;Division of Anaesthesia, Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom."
"460","Gougis P;Carton M;Tchokothe C;Campone M;Dalenc F;Mailliez A;Levy C;Jacot W;Debled M;Leheurteur M;Bachelot T;Hennequin A;Perrin C;Gonçalves A;Uwer L;Eymard JC;Petit T;Mouret-Reynier MA;Chamorey E;Simon G;Saghatchian M;Cailliot C;Le Tourneau C","Gougis, P;Carton, M;Tchokothe, C;Campone, M;Dalenc, F;Mailliez, A;Levy, C;Jacot, W;Debled, M;Leheurteur, M;Bachelot, T;Hennequin, A;Perrin, C;Gonçalves, A;Uwer, L;Eymard, J C;Petit, T;Mouret-Reynier, M A;Chamorey, E;Simon, G;Saghatchian, M;Cailliot, C;Le Tourneau, C","CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.","Breast (Edinburgh, Scotland)","Netherlands","eng","Journal Article","Breast cancer;Growth rate;Metastatic recurrence;Real-life data","Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Databases, Factual;Female;Follow-Up Studies;France;Humans;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Progression-Free Survival;Retrospective Studies;Risk Factors;Survival Analysis;Time Factors;Triple Negative Breast Neoplasms","Adult;Aged;Aged, 80 and over;Biomarkers, Tumor;Breast Neoplasms;Databases, Factual;Female;Follow-Up Studies;France;Humans;Middle Aged;Neoplasm Metastasis;Neoplasm Recurrence, Local;Progression-Free Survival;Retrospective Studies;Risk Factors;Survival Analysis;Time Factors;Triple Negative Breast Neoplasms","The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such as expression of estrogen receptor are known predictive factors of TFMR. The CinéBreast study aimed to identify predictive factors of the time to TFMR. The French Epidemiological Strategy and Medical Economics (ESME) Metastatic Breast Cancer (MBC) Database (NCT03275311) was used, which contains data from a cohort of metastatic breast cancer patients from 2008 to 2016 using retrospective data collection. It is a national multi-centre database. The impact of TFMR on overall survival (OS) since first metastasis was also evaluated. Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence. Median follow up was 56 months. Median TFMR was 59 months (<24: 20%, 24-60: 31%, 60-120: 25%, >120: 24%). HER2+ and TNBC were respectively 4 times and 12 times (p < 0.0001) more likely to have a recurrence within 2 years when compared to the luminal subgroup. Short TFMR and HR-/HER2-subtype significantly correlated with a poor OS in multivariate analysis. Some patients with MBC (20% in HER2+, 10% in ER+/HER2-and <5% in the ER-/HER2-) were long-term survivors in all 3 subgroups. In this large-scale real-life data study, patients with a TNBC metastatic recurrence had a shorter TFMR. Short TFMR significantly correlated with worse overall survival.","Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; Department of Clinical Pharmacology, Centre D'Investigation Clinique Paris-Est, AP-HP, Pitié-Salpêtrière Hospital, PSL University, CLIP² Galilée, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Nantes and Angers, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Breast Cancer, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Henri Becquerel Centre, Rouen, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Center Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Godinot, Reims, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Biostatistics, Centre Antoine Lacassagne, Nice, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; U900 INSERM Research Unit, Saint-Cloud","NA",0,"1532-3080","Breast","Breast",2019,"2020","49","10.1016/j.breast.2019.10.004","17-24","","","31675683","31675683","PUBMED","Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; Department of Clinical Pharmacology, Centre D'Investigation Clinique Paris-Est, AP-HP, Pitié-Salpêtrière Hospital, PSL University, CLIP² Galilée, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Medical Oncology, Institut de Cancérologie de L'Ouest, Nantes and Angers, France.;Department of Medical Oncology, Institut Claudius Regaud, Toulouse, France.;Department of Breast Cancer, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Institut Du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Institut Bergonié, Bordeaux, France.;Department of Medical Oncology, Henri Becquerel Centre, Rouen, France.;Department of Biostatistics, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Center Georges François Leclerc, Dijon, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.;Department of Medical Oncology, Centre Jean Godinot, Reims, France.;Department of Medical Oncology, Centre Paul Strauss, Strasbourg, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont Ferrand, France.;Department of Biostatistics, Centre Antoine Lacassagne, Nice, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Biostatistics, Institut Curie, Saint-Cloud, France.;Department of Research and Development, R&D Unicancer, Paris, France.;Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; U900 INSERM Research Unit, Saint-Cloud"
"461","Edeline J;Touchefeu Y;Guiu B;Farge O;Tougeron D;Baumgaertner I;Ayav A;Campillo-Gimenez B;Beuzit L;Pracht M;Lièvre A;Le Sourd S;Boudjema K;Rolland Y;Boucher E;Garin E","Edeline, Julien;Touchefeu, Yann;Guiu, Boris;Farge, Olivier;Tougeron, David;Baumgaertner, Isabelle;Ayav, Ahmet;Campillo-Gimenez, Boris;Beuzit, Luc;Pracht, Marc;Lièvre, Astrid;Le Sourd, Samuel;Boudjema, Karim;Rolland, Yan;Boucher, Eveline;Garin, Etienne","Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.","JAMA oncology","United States","eng","Clinical Trial, Phase II","","Aged;Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Cholangiocarcinoma;Female;Humans;Male;Middle Aged;Neoplasm Recurrence, Local;Treatment Outcome","Aged;Antineoplastic Combined Chemotherapy Protocols;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Cholangiocarcinoma;Female;Humans;Male;Middle Aged;Neoplasm Recurrence, Local;Treatment Outcome","Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have a poor prognosis. Selective internal radiotherapy (SIRT) is a promising treatment option for hepatic tumors, but no prospective studies of combination SIRT with chemotherapy have been published to our knowledge. To determine the response rate after SIRT combined with chemotherapy in patients with unresectable ICC. This phase 2 clinical trial, the Yttrium-90 Microspheres in Cholangiocarcinoma (MISPHEC) trial, included patients with unresectable ICC who have never received chemotherapy or intra-arterial therapy and were treated at 7 centers which had experience with SIRT between November 12, 2013, and June 21, 2016. Statistical analysis was performed from March 31, 2017, to June 17, 2019. Concomitant first-line chemotherapy with cisplatin, 25 mg/m2, and gemcitabine, 1000 mg/m2 (gemcitabine reduced to 300 mg/m2 for the cycles just before and after SIRT), on days 1 and 8 of a 21-day cycle for 8 cycles. Selective internal radiotherapy was administered during cycle 1 (1 hemiliver disease) or cycles 1 and 3 (disease involving both hemilivers) using glass Y90 microspheres. Response rate at 3 months according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Secondary end points were toxic effects, progression-free survival, overall survival, disease control rate, and response rate according to Choi criteria. Of 41 patients included in the study, 26 (63%) were male, with a mean (SD) age of 64.0 (10.7) years. Response rate according to RECIST was 39% (90% CI, 26%-53%) at 3 months according to local review and was confirmed at 41% as best response by central review; disease control rate was 98%. According to Choi criteria, the response rate was 93%. After a median follow-up of 36 months (95% CI, 26-52 months), median progression-free survival was 14 months (95% CI, 8-17 months), with progression-free survival rates of 55% at 12 months and 30% at 24 months. Median overall survival was 22 months (95% CI, 14-52 months), with overall survival rates of 75% at 12 months and 45% at 24 months. Of 41 patients, 29 (71%) had grades 3 to 4 toxic effects; 9 patients (22%) could be downstaged to surgical intervention, with 8 (20%) achieving R0 (microscopic-free margins) surgical resection. After a median of 46 months (95% CI, 31 months to not reached) after surgery, median relapse-free survival was not reached among patients who underwent resection. Combination chemotherapy and SIRT had antitumor activity as first-line treatment of unresectable ICC, and a significant proportion of patients were downstaged to surgical intervention. A phase 3 trial is ongoing.","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Université Rennes, IndianaSERM, IndianaRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Rennes, France.;Centre Hospitalier Universitaire Nantes, Nantes, France.;Centre Hospitalier Universitaire Montpellier, Montpellier, France.;Centre Hospitalier Universitaire Beaujon, Clichy, France.;Centre Hospitalier Universitaire Poitiers, Poitiers, France.;Centre Hospitalier Universitaire Mondor, Créteil, France.;Centre Hospitalier Universitaire Nancy, Nancy, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM, LTSI U1099, Université Rennes 1, Rennes, France.;Radiology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Univ Rennes, Inserm, Regional Cancer Center Eugène Marquis, Chemistry Oncogenesis Stress Signaling-UMR1242, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Hepatobiliary Surgery, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Radiology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine, Centre Eugène Marquis, Rennes, France.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2019,"2020","6","10.1001/jamaoncol.2019.3702","51-59","","","31670746","31670746","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Université Rennes, IndianaSERM, IndianaRA, Centre de Lutte contre le Cancer Eugène Marquis, Institut NUMECAN (Nutrition Metabolisms and Cancer), Rennes, France.;Centre Hospitalier Universitaire Nantes, Nantes, France.;Centre Hospitalier Universitaire Montpellier, Montpellier, France.;Centre Hospitalier Universitaire Beaujon, Clichy, France.;Centre Hospitalier Universitaire Poitiers, Poitiers, France.;Centre Hospitalier Universitaire Mondor, Créteil, France.;Centre Hospitalier Universitaire Nancy, Nancy, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;INSERM, LTSI U1099, Université Rennes 1, Rennes, France.;Radiology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Univ Rennes, Inserm, Regional Cancer Center Eugène Marquis, Chemistry Oncogenesis Stress Signaling-UMR1242, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Hepatobiliary Surgery, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;Radiology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Nuclear Medicine, Centre Eugène Marquis, Rennes, France."
"462","Bacle A;Belaz S;Potin S;Gangneux JP","Bacle, Astrid;Belaz, Sorya;Potin, Sophie;Gangneux, Jean-Pierre","A case report of photodermatoses induced by the antifungal drug terbinafine.","European journal of hospital pharmacy : science and practice","England","eng","Case Reports","clinical pharmacist;drug-induced photosensitivity;medication reconciliation;pharmaceutical advice;terbinafine","","","Terbinafine is an antifungaldrug(inhibitor of ergosterol synthesis) known to induce skin reactions. A 58-year-old female was treated with terbinafine for onychomycosis. On the fifth day of treatment a skin rash emerged on her sun-exposed areas. Biological testing did not find any allergic signs. Other skin reactions are well known with terbinafine, but we depict here, a case of photosensitisation induced by treatment, generally unknown for this antifungal. This side effect can be prevented by medication reconciliation and pharmaceutical advice from the clinical pharmacist.","Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"2047-9956","Eur J Hosp Pharm","Eur J Hosp Pharm",2018,"2019","26","10.1136/ejhpharm-2018-001683","288-289","","","31656618","31656618","PUBMED","Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service Hospitalo-Universitaire de Pharmacie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Univ Rennes, CHU Rennes, F-35000 Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France."
"463","Bedin M;Boyer O;Servais A;Li Y;Villoing-Gaudé L;Tête MJ;Cambier A;Hogan J;Baudouin V;Krid S;Bensman A;Lammens F;Louillet F;Ranchin B;Vigneau C;Bouteau I;Isnard-Bagnis C;Mache CJ;Schäfer T;Pape L;Gödel M;Huber TB;Benz M;Klaus G;Hansen M;Latta K;Gribouval O;Morinière V;Tournant C;Grohmann M;Kuhn E;Wagner T;Bole-Feysot C;Jabot-Hanin F;Nitschké P;Ahluwalia TS;Köttgen A;Andersen CBF;Bergmann C;Antignac C;Simons M","Bedin, Mathilda;Boyer, Olivia;Servais, Aude;Li, Yong;Villoing-Gaudé, Laure;Tête, Marie-Josephe;Cambier, Alexandra;Hogan, Julien;Baudouin, Veronique;Krid, Saoussen;Bensman, Albert;Lammens, Florie;Louillet, Ferielle;Ranchin, Bruno;Vigneau, Cecile;Bouteau, Iseline;Isnard-Bagnis, Corinne;Mache, Christoph J;Schäfer, Tobias;Pape, Lars;Gödel, Markus;Huber, Tobias B;Benz, Marcus;Klaus, Günter;Hansen, Matthias;Latta, Kay;Gribouval, Olivier;Morinière, Vincent;Tournant, Carole;Grohmann, Maik;Kuhn, Elisa;Wagner, Timo;Bole-Feysot, Christine;Jabot-Hanin, Fabienne;Nitschké, Patrick;Ahluwalia, Tarunveer S;Köttgen, Anna;Andersen, Christian Brix Folsted;Bergmann, Carsten;Antignac, Corinne;Simons, Matias","Human C-terminal CUBN variants associate with chronic proteinuria and normal renal function.","The Journal of clinical investigation","United States","eng","Clinical Trial","Chronic kidney disease;Genetic diseases;Genetics;Nephrology","Albuminuria;Anemia, Megaloblastic;Female;Humans;Kidney Tubules, Proximal;Malabsorption Syndromes;Male;Mutation;Proteinuria;Receptors, Cell Surface;Vitamin B 12 Deficiency","Albuminuria;Anemia, Megaloblastic;Female;Humans;Kidney Tubules, Proximal;Malabsorption Syndromes;Male;Mutation;Proteinuria;Receptors, Cell Surface;Vitamin B 12 Deficiency","BACKGROUNDProteinuria is considered an unfavorable clinical condition that accelerates renal and cardiovascular disease. However, it is not clear whether all forms of proteinuria are damaging. Mutations in CUBN cause Imerslund-Gräsbeck syndrome (IGS), which is characterized by intestinal malabsorption of vitamin B12 and in some cases proteinuria. CUBN encodes for cubilin, an intestinal and proximal tubular uptake receptor containing 27 CUB domains for ligand binding.METHODSWe used next-generation sequencing for renal disease genes to genotype cohorts of patients with suspected hereditary renal disease and chronic proteinuria. CUBN variants were analyzed using bioinformatics, structural modeling, and epidemiological methods.RESULTSWe identified 39 patients, in whom biallelic pathogenic variants in the CUBN gene were associated with chronic isolated proteinuria and early childhood onset. Since the proteinuria in these patients had a high proportion of albuminuria, glomerular diseases such as steroid-resistant nephrotic syndrome or Alport syndrome were often the primary clinical diagnosis, motivating renal biopsies and the use of proteinuria-lowering treatments. However, renal function was normal in all cases. By contrast, we did not found any biallelic CUBN variants in proteinuric patients with reduced renal function or focal segmental glomerulosclerosis. Unlike the more N-terminal IGS mutations, 37 of the 41 proteinuria-associated CUBN variants led to modifications or truncations after the vitamin B12-binding domain. Finally, we show that 4 C-terminal CUBN variants are associated with albuminuria and slightly increased GFR in meta-analyses of large population-based cohorts.CONCLUSIONCollectively, our data suggest an important role for the C-terminal half of cubilin in renal albumin reabsorption. Albuminuria due to reduced cubilin function could be an unexpectedly common benign condition in humans that may not require any proteinuria-lowering treatment or renal biopsy.FUNDINGATIP-Avenir program, Fondation Bettencourt-Schueller (Liliane Bettencourt Chair of Developmental Biology), Agence Nationale de la Recherche (ANR) Investissements d'avenir program (ANR-10-IAHU-01) and NEPHROFLY (ANR-14-ACHN-0013, to MS), Steno Collaborative Grant 2018 (NNF18OC0052457, to TSA and MS), Heisenberg Professorship of the German Research Foundation (KO 3598/5-1, to AK), Deutsche Forschungsgemeinschaft (DFG) Collaborative Research Centre (SFB) KIDGEM 1140 (project 246781735, to CB), and Federal Ministry of Education and Research (BMB) (01GM1515C, to CB).","Laboratory of Epithelial Biology and Disease and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Pediatric Nephrology and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Nephrology, Necker Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.;Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;Laboratory of Epithelial Biology and Disease and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and.;Department of Pediatric Nephrology and.;Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Centre Hospitalier Universitaire de Rouen, Rouen, France.;Department of Pediatric Nephrology, Hospices Civils de Lyon, Bron, France.;Centre Hospitalier Universitaire de Rennes, INSERM U1085 IRSET-9, Rennes, France.;Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Nephrology, Pitié Salpetrière Hospital, Paris, France.;Children's Hospital, Medical University Graz, Graz, Austria.;Renal Division, University Medical Center Freiburg, Freiburg, Germany.;Department of Pediatric Kidney, Liver and Metabolic Disease, Hannover Medical School, Hannover, Germany.;Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Kindernephrologie Dachau, Dachau, Germany.;Department of Child and Adolescent Medicine, University Medical Center Marburg-Giessen, Marburg, Germany.;KfH-Nierenzentrum für Kinder und Jugendliche und Clementine-Kinderhospital, Frankfurt, Germany.;KfH-Nierenzentrum für Kinder und Jugendliche und Clementine-Kinderhospital, Frankfurt, Germany.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Mainz, Germany.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Steno Diabetes Center Copenhagen, Gentofte, Denmark.;Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;Department of Biomedicine, Aarhus University, Aarhus, Denmark.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Mainz, Germany.;Renal Division, Department of Medicine, University Hospital Freiburg, Freiburg, Germany.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Laboratory of Epithelial Biology and Disease and.","NA",0,"1558-8238","J Clin Invest","J Clin Invest",2019,"2020","130","10.1172/JCI129937","335-344","","","31613795","31613795","PUBMED","Laboratory of Epithelial Biology and Disease and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Pediatric Nephrology and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Nephrology, Necker Hospital, Assistance Publique Hôpitaux de Paris (APHP), Paris, France.;Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;Laboratory of Epithelial Biology and Disease and.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and Transplantation, Robert-Debré Hospital, APHP, Paris, France.;Department of Pediatric Nephrology and.;Department of Pediatric Nephrology and.;Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Centre Hospitalier Universitaire de Rouen, Rouen, France.;Department of Pediatric Nephrology, Hospices Civils de Lyon, Bron, France.;Centre Hospitalier Universitaire de Rennes, INSERM U1085 IRSET-9, Rennes, France.;Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Department of Nephrology, Pitié Salpetrière Hospital, Paris, France.;Children's Hospital, Medical University Graz, Graz, Austria.;Renal Division, University Medical Center Freiburg, Freiburg, Germany.;Department of Pediatric Kidney, Liver and Metabolic Disease, Hannover Medical School, Hannover, Germany.;Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.;Kindernephrologie Dachau, Dachau, Germany.;Department of Child and Adolescent Medicine, University Medical Center Marburg-Giessen, Marburg, Germany.;KfH-Nierenzentrum für Kinder und Jugendliche und Clementine-Kinderhospital, Frankfurt, Germany.;KfH-Nierenzentrum für Kinder und Jugendliche und Clementine-Kinderhospital, Frankfurt, Germany.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Mainz, Germany.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Bioinformatic Platform, INSERM UMR 1163, Institut Imagine, Paris, France.;Bioinformatics Core Facility, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Université de Paris, Paris, France.;Steno Diabetes Center Copenhagen, Gentofte, Denmark.;Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.;Department of Biomedicine, Aarhus University, Aarhus, Denmark.;Center for Human Genetics, Bioscientia, Ingelheim, Germany.;Center for Human Genetics, Mainz, Germany.;Renal Division, Department of Medicine, University Hospital Freiburg, Freiburg, Germany.;Laboratory of Hereditary Kidney Disease, Imagine Institute, INSERM U1163, Université de Paris, Paris, France.;Department of Genetics, Necker Hospital, APHP, Paris, France.;Laboratory of Epithelial Biology and Disease and."
"464","Labeur TA;Berhane S;Edeline J;Blanc JF;Bettinger D;Meyer T;Van Vugt JLA;Ten Cate DWG;De Man RA;Eskens FALM;Cucchetti A;Bonnett LJ;Van Delden OM;Klümpen HJ;Takkenberg RB;Johnson PJ","Labeur, Tim A;Berhane, Sarah;Edeline, Julien;Blanc, Jean-Frederic;Bettinger, Dominik;Meyer, Tim;Van Vugt, Jeroen L A;Ten Cate, David W G;De Man, Robert A;Eskens, Ferry A L M;Cucchetti, Alessandro;Bonnett, Laura J;Van Delden, Otto M;Klümpen, Heinz-Josef;Takkenberg, R Bart;Johnson, Philip J","Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.","Liver international : official journal of the International Association for the Study of the Liver","United States","eng","Journal Article","hepatocellular carcinoma;model;prediction;prognosis;sorafenib;survival","Aged;Antineoplastic Agents;Bilirubin;Carcinoma, Hepatocellular;Female;Humans;Liver Neoplasms;Male;Middle Aged;Phenylurea Compounds;Predictive Value of Tests;Prognosis;Reproducibility of Results;Retrospective Studies;Risk Factors;Serum Albumin, Human;Sorafenib;Survival Analysis;alpha-Fetoproteins","Aged;Antineoplastic Agents;Bilirubin;Carcinoma, Hepatocellular;Female;Humans;Liver Neoplasms;Male;Middle Aged;Phenylurea Compounds;Predictive Value of Tests;Prognosis;Reproducibility of Results;Retrospective Studies;Risk Factors;Serum Albumin, Human;Sorafenib;Survival Analysis;alpha-Fetoproteins","The 'Prediction Of Survival in Advanced Sorafenib-treated HCC' (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular carcinoma (HCC) treated with sorafenib in clinical trials but requires validation in daily clinical practice. This study aimed to validate, compare and optimize this model for survival prediction. Patients treated with sorafenib for HCC at five tertiary European centres were retrospectively staged according to the PROSASH model. In addition, the optimized PROSASH-II model was developed using the data of four centres (training set) and tested in an independent dataset. These models for overall survival (OS) were then compared with existing prognostic models. The PROSASH model was validated in 445 patients, showing clear differences between the four risk groups (OS 16.9-4.6 months). A total of 920 patients (n = 615 in training set, n = 305 in validation set) were available to develop PROSASH-II. This optimized model incorporated fewer and less subjective parameters: the serum albumin, bilirubin and alpha-foetoprotein, and macrovascular invasion, extrahepatic spread and largest tumour size on imaging. Both PROSASH and PROSASH-II showed improved discrimination (C-index 0.62 and 0.63, respectively) compared with existing prognostic scores (C-index ≤0.59). In HCC patients treated with sorafenib, individualized prediction of survival and risk group stratification using baseline prognostic and predictive parameters with the PROSASH model was validated. The refined PROSASH-II model performed at least as good with fewer and more objective parameters. PROSASH-II can be used as a tool for tailored treatment of HCC in daily practice and to define pre-planned subgroups for future studies.","Cancer Center Amsterdam, Amsterdam, The Netherlands.;Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Biostatistics, University of Liverpool, Liverpool, UK.;Department of Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, CHU Hôpital Saint André, Bordeaux, France.;Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.;UCL Cancer Institute, University College London, London, UK.;Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.;Department of Biostatistics, University of Liverpool, Liverpool, UK.;Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.","NA",0,"1478-3231","Liver Int","Liver Int",2019,"2020","40","10.1111/liv.14270","215-228","","Department of Health","31579990","31579990","PUBMED","Cancer Center Amsterdam, Amsterdam, The Netherlands.;Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Biostatistics, University of Liverpool, Liverpool, UK.;Department of Oncology, Centre Eugène Marquis, Rennes, France.;Department of Hepatology, CHU Hôpital Saint André, Bordeaux, France.;Department of Medicine II, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.;UCL Cancer Institute, University College London, London, UK.;Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Medical Oncology, Erasmus MC University Medical Center, Rotterdam, The Netherlands.;Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.;Department of Biostatistics, University of Liverpool, Liverpool, UK.;Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.;Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK."
"465","Thille AW;Muller G;Gacouin A;Coudroy R;Decavèle M;Sonneville R;Beloncle F;Girault C;Dangers L;Lautrette A;Cabasson S;Rouzé A;Vivier E;Le Meur A;Ricard JD;Razazi K;Barberet G;Lebert C;Ehrmann S;Sabatier C;Bourenne J;Pradel G;Bailly P;Terzi N;Dellamonica J;Lacave G;Danin PÉ;Nanadoumgar H;Gibelin A;Zanre L;Deye N;Demoule A;Maamar A;Nay MA;Robert R;Ragot S;Frat JP","Thille, Arnaud W;Muller, Grégoire;Gacouin, Arnaud;Coudroy, Rémi;Decavèle, Maxens;Sonneville, Romain;Beloncle, François;Girault, Christophe;Dangers, Laurence;Lautrette, Alexandre;Cabasson, Séverin;Rouzé, Anahita;Vivier, Emmanuel;Le Meur, Anthony;Ricard, Jean-Damien;Razazi, Keyvan;Barberet, Guillaume;Lebert, Christine;Ehrmann, Stephan;Sabatier, Caroline;Bourenne, Jeremy;Pradel, Gael;Bailly, Pierre;Terzi, Nicolas;Dellamonica, Jean;Lacave, Guillaume;Danin, Pierre-Éric;Nanadoumgar, Hodanou;Gibelin, Aude;Zanre, Lassane;Deye, Nicolas;Demoule, Alexandre;Maamar, Adel;Nay, Mai-Anh;Robert, René;Ragot, Stéphanie;Frat, Jean-Pierre","Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial.","JAMA","United States","eng","Journal Article","","Age Factors;Aged;Airway Extubation;Combined Modality Therapy;Confidence Intervals;Female;France;Hospital Mortality;Humans;Intensive Care Units;Intubation, Intratracheal;Male;Noninvasive Ventilation;Outcome Assessment, Health Care;Oxygen;Patient Discharge;Respiratory Insufficiency;Retreatment;Ventilator Weaning","Age Factors;Aged;Airway Extubation;Combined Modality Therapy;Confidence Intervals;Female;France;Hospital Mortality;Humans;Intensive Care Units;Intubation, Intratracheal;Male;Noninvasive Ventilation;Outcome Assessment, Health Care;Oxygen;Patient Discharge;Respiratory Insufficiency;Retreatment;Ventilator Weaning","High-flow nasal oxygen may prevent postextubation respiratory failure in the intensive care unit (ICU). The combination of high-flow nasal oxygen with noninvasive ventilation (NIV) may be an optimal strategy of ventilation to avoid reintubation. To determine whether high-flow nasal oxygen with prophylactic NIV applied immediately after extubation could reduce the rate of reintubation, compared with high-flow nasal oxygen alone, in patients at high risk of extubation failure in the ICU. Multicenter randomized clinical trial conducted from April 2017 to January 2018 among 641 patients at high risk of extubation failure (ie, older than 65 years or with an underlying cardiac or respiratory disease) at 30 ICUs in France; follow-up was until April 2018. Patients were randomly assigned to high-flow nasal oxygen alone (n = 306) or high-flow nasal oxygen alternating with NIV (n = 342) immediately after extubation. The primary outcome was the proportion of patients reintubated at day 7; secondary outcomes included postextubation respiratory failure at day 7, reintubation rates up until ICU discharge, and ICU mortality. Among 648 patients who were randomized (mean [SD] age, 70 [10] years; 219 women [34%]), 641 patients completed the trial. The reintubation rate at day 7 was 11.8% (95% CI, 8.4%-15.2%) (40/339) with high-flow nasal oxygen and NIV and 18.2% (95% CI, 13.9%-22.6%) (55/302) with high-flow nasal oxygen alone (difference, -6.4% [95% CI, -12.0% to -0.9%]; P = .02). Among the 11 prespecified secondary outcomes, 6 showed no significant difference. The proportion of patients with postextubation respiratory failure at day 7 (21% vs 29%; difference, -8.7% [95% CI, -15.2% to -1.8%]; P = .01) and reintubation rates up until ICU discharge (12% vs 20%, difference -7.4% [95% CI, -13.2% to -1.8%]; P = .009) were significantly lower with high-flow nasal oxygen and NIV than with high-flow nasal oxygen alone. ICU mortality rates were not significantly different: 6% with high-flow nasal oxygen and NIV and 9% with high-flow nasal oxygen alone (difference, -2.4% [95% CI, -6.7% to 1.7%]; P = .25). In mechanically ventilated patients at high risk of extubation failure, the use of high-flow nasal oxygen with NIV immediately after extubation significantly decreased the risk of reintubation compared with high-flow nasal oxygen alone. ClinicalTrials.gov Identifier: NCT03121482.","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Groupe Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat-Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de La Rochelle, Service de Réanimation, La Rochelle, France.;Centre Hospitalier Universitaire de Lille, Centre de Réanimation, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Hôpitaux universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, site Emile Muller, Service de Réanimation Médicale, Mulhouse, France.;Centre Hospitalier Départemental de Vendée, Service de Médecine Intensive Réanimation, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Centre Hospitalier Henri Mondor d'Aurillac, Service de Réanimation, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Nice, Réanimation Médico-Chirurgicale Archet 2, INSERM U 1065, Nice, France.;Centre Hospitalier Universitaire de Poitiers, Réanimation Chirurgicale, Poitiers, France.;Hôpital Tenon, Réanimation et USC médico-chirurgicale, CARMAS, AP-HP, Faculté de médecine Sorbonne Université, Collegium Galilée, Paris, France.;Centre Hospitalier Emile Roux, Service de Réanimation, Le Puy en Velay, France.;Hôpital Lariboisière, Réanimation Médicale et Toxicologique, AP-HP, INSERM UMR-S 942, Paris, France.;Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France.;Groupe Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.","NA",0,"1538-3598","JAMA","JAMA",2019,"2019","322","10.1001/jama.2019.14901","1465-1475","","","31577036","31577036","PUBMED","Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Groupe Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Hôpital Bichat-Claude Bernard, Médecine Intensive Réanimation, AP-HP, Université Paris Diderot, Paris, France.;Centre Hospitalier Universitaire d'Angers, Département de Médecine Intensive Réanimation, Université d'Angers, Angers, France.;Centre Hospitalier Universitaire de Rouen, Hôpital Charles Nicolle, Département de Réanimation Médicale, Normandie Université, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France.;Centre Hospitalier Universitaire Félix Guyon, Service de Réanimation Polyvalente, Saint Denis de la Réunion, France.;Centre Hospitalier Universitaire de Clermont-Ferrand, Hôpital Gabriel Montpied, Service de Réanimation Médicale, Clermont-Ferrand, France.;Centre Hospitalier de La Rochelle, Service de Réanimation, La Rochelle, France.;Centre Hospitalier Universitaire de Lille, Centre de Réanimation, Université de Lille, Lille, France.;Hôpital Saint-Joseph Saint-Luc, Réanimation Polyvalente, Lyon, France.;Centre Hospitalier Universitaire de Nantes, Médecine Intensive Réanimation, Nantes, France.;Hôpital Louis Mourier, Réanimation Médico-Chirurgicale, AP-HP, INSERM, Université Paris Diderot, UMR IAME 1137, Sorbonne Paris Cité, Colombes, France.;Hôpitaux universitaires Henri Mondor, Service de Réanimation Médicale DHU A-TVB, AP-HP, Créteil, France.;Groupe Hospitalier Régional Mulhouse Sud Alsace, site Emile Muller, Service de Réanimation Médicale, Mulhouse, France.;Centre Hospitalier Départemental de Vendée, Service de Médecine Intensive Réanimation, La Roche Sur Yon, France.;Centre Hospitalier Régional Universitaire de Tours, Médecine Intensive Réanimation, CIC 1415, Réseau CRICS-Trigger SEP, Centre d'étude des pathologies respiratoires, INSERM U1100, Université de Tours, Tours, France.;Centre Hospitalier de Pau, Service de Réanimation, Pau, France.;Centre Hospitalier Universitaire La Timone 2, Médecine Intensive Réanimation, Réanimation des Urgences, Aix-Marseille Université, Marseille, France.;Centre Hospitalier Henri Mondor d'Aurillac, Service de Réanimation, Aurillac, France.;Centre Hospitalier Universitaire de Brest, Médecine Intensive Réanimation, Brest, France.;Centre Hospitalier Universitaire Grenoble Alpes, Médecine Intensive Réanimation, INSERM, Université Grenoble-Alpes, U1042, HP2, Grenoble, France.;Centre Hospitalier Universitaire de Nice, Médecine Intensive Réanimation, Archet 1, Université Cote d'Azur, Nice, France.;Centre Hospitalier de Versailles, Service de Réanimation Médico-Chirurgicale, Le Chesnay, France.;Centre Hospitalier Universitaire de Nice, Réanimation Médico-Chirurgicale Archet 2, INSERM U 1065, Nice, France.;Centre Hospitalier Universitaire de Poitiers, Réanimation Chirurgicale, Poitiers, France.;Hôpital Tenon, Réanimation et USC médico-chirurgicale, CARMAS, AP-HP, Faculté de médecine Sorbonne Université, Collegium Galilée, Paris, France.;Centre Hospitalier Emile Roux, Service de Réanimation, Le Puy en Velay, France.;Hôpital Lariboisière, Réanimation Médicale et Toxicologique, AP-HP, INSERM UMR-S 942, Paris, France.;Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie, Médecine Intensive et Réanimation (Département R3S), AP-HP, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Sorbonne Université, Paris, France.;Centre Hospitalier Universitaire de Rennes, Hôpital Ponchaillou, Service des Maladies Infectieuses et Réanimation Médicale, Rennes, France.;Groupe Hospitalier Régional d'Orléans, Médecine Intensive Réanimation, Orléans, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France.;Centre Hospitalier Universitaire de Poitiers, Médecine Intensive Réanimation, Poitiers, France.;INSERM Centre d'Investigation Clinique 1402 ALIVE, Université de Poitiers, Poitiers, France."
"466","Beaumont J;Acosta O;Devillers A;Palard-Novello X;Chajon E;de Crevoisier R;Castelli J","Beaumont, J;Acosta, O;Devillers, A;Palard-Novello, X;Chajon, E;de Crevoisier, R;Castelli, J","Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers.","EJNMMI research","Germany","eng","Journal Article","Locally advanced head and neck cancers;Radiomics;Radiotherapy;Recurrence prediction;Voxel-based analysis","","","Overall, 40% of patients with a locally advanced head and neck cancer (LAHNC) treated by chemoradiotherapy (CRT) present local recurrence within 2 years after the treatment. The aims of this study were to characterize voxel-wise the sub-regions where tumor recurrence appear and to predict their location from pre-treatment  F-fluorodeoxyglucose (FDG) positron emission tomography (PET) images. Twenty-six patients with local failure after treatment were included in this study. Local recurrence volume was identified by co-registering pre-treatment and recurrent PET/CT images using a customized rigid registration algorithm. A large set of voxel-wise features were extracted from pre-treatment PET to train a random forest model allowing to predict local recurrence at the voxel level. Out of 26 expert-assessed registrations, 15 provided enough accuracy to identify recurrence volumes and were included for further analysis. Recurrence volume represented on average 23% of the initial tumor volume. The MTV with a threshold of 50% of SUVmax plus a 3D margin of 10 mm covered on average 89.8% of the recurrence and 96.9% of the initial tumor. SUV and MTV alone were not sufficient to identify the area of recurrence. Using a random forest model, 15 parameters, combining radiomics and spatial location, were identified, allowing to predict the recurrence sub-regions with a median area under the receiver operating curve of 0.71 (range 0.14-0.91). As opposed to regional comparisons which do not bring enough evidence for accurate prediction of recurrence volume, a voxel-wise analysis of FDG-uptake features suggested a potential to predict recurrence with enough accuracy to consider tailoring CRT by dose escalation within likely radioresistant regions.","Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes","NA",0,"2191-219X","EJNMMI Res","EJNMMI Res",2019,"2019","9","10.1186/s13550-019-0556-z","90","","","31535233","31535233","PUBMED","Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes, France.;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes, France.;Univ Rennes, CLCC Eugène Marquis, INSERM, LTSI - UMR 1099, 35000, Rennes;Department of Radiotherapy, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, 35000, Rennes"
"467","Nguyen Phuc Thu T;Hernández AI;Costet N;Patural H;Pichot V;Carrault G;Beuchée A","Nguyen Phuc Thu, Trang;Hernández, Alfredo I;Costet, Nathalie;Patural, Hugues;Pichot, Vincent;Carrault, Guy;Beuchée, Alain","Improving methodology in heart rate variability analysis for the premature infants: Impact of the time length.","PloS one","United States","eng","Journal Article","","Cluster Analysis;Diagnosis, Computer-Assisted;Electrocardiography;Female;Heart Rate;Heart Rate Determination;Humans;Infant;Infant, Newborn;Infant, Premature;Linear Models;Longitudinal Studies;Male;Nonlinear Dynamics;Principal Component Analysis;Signal Processing, Computer-Assisted;Time Factors","Cluster Analysis;Diagnosis, Computer-Assisted;Electrocardiography;Female;Heart Rate;Heart Rate Determination;Humans;Infant;Infant, Newborn;Infant, Premature;Linear Models;Longitudinal Studies;Male;Nonlinear Dynamics;Principal Component Analysis;Signal Processing, Computer-Assisted;Time Factors","Heart rate variability (HRV) has been emerging in neonatal medicine. It may help for the early diagnosis of pathology and estimation of autonomous maturation. There is a lack of standardization and automation in the selection of the sequences to analyze and some features have not been explored in this specific population. The main objective of this study was to analyze the impact of the time length of the sequences on the estimation of linear and non-linear HRV features, including horizontal visibility graphs (HVG). HRV features were repeatedly measured with linear and non-linear methods on 2-, 5-, 10-minute sequences selected from the longest 15-min sequence and recorded on a weekly basis in 39 infants less than 31 weeks at birth. The associations between HRV measurements were analyzed through principal component analysis and k-means clustering. The effects of the time lengths on HRV measurements and post-menstrual age (PMA) were analyzed by linear mixed effect model for repeated measures. The domains of analysis were concordant for their descriptive parameters of short (rMSSD, SD1 and HF) and long-term (SD, SD2 and LF) variability. α1 was correlated with the LF/HF and SD2/SD1. DC and AC were correlated with short-term variability estimates and significantly increased with GA and PMA. Shortening the windows of analysis increased the random measurement error for all the features and increased the bias for all but short term features and HVGs. The linear and non-linear measurements of HRV are correlated each other. Shortening the windows of analysis increased the random error for all the features and increased the bias for all but short term features and HVGs. Short-term HRV can be an index for evaluating the maturation in whatever sequence length.","Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Pôle Mère-Enfants, Réanimation Néonatale - Hôpital Nord, Centre Hospitalier Universitaire Saint-Etienne, Saint-Etienne, France.;Système nerveux autonome - Epidémiologie Physiologie Ingénierie Santé (SNA-EPIS 4607), Université Jean Monnet, Saint-Etienne, France.;Système nerveux autonome - Epidémiologie Physiologie Ingénierie Santé (SNA-EPIS 4607), Université Jean Monnet, Saint-Etienne, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2019,"2019","14","10.1371/journal.pone.0220692","e0220692","","","31398196","31398196","PUBMED","Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Pôle Mère-Enfants, Réanimation Néonatale - Hôpital Nord, Centre Hospitalier Universitaire Saint-Etienne, Saint-Etienne, France.;Système nerveux autonome - Epidémiologie Physiologie Ingénierie Santé (SNA-EPIS 4607), Université Jean Monnet, Saint-Etienne, France.;Système nerveux autonome - Epidémiologie Physiologie Ingénierie Santé (SNA-EPIS 4607), Université Jean Monnet, Saint-Etienne, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France.;Laboratoire Traitement du Signal et de l'Image (LTSI - UMR 1099), Université de Rennes 1, Centre Hospitalier Universitaire de Rennes, Inserm, Rennes, France."
"468","Pujol P;De La Motte Rouge T;Penault-Llorca F","Pujol, Pascal;De La Motte Rouge, Thibault;Penault-Llorca, Frédérique","From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.","Diagnostics (Basel, Switzerland)","Switzerland","eng","Journal Article","cancer predisposing genes;secondary findings;somatic analysis","","","The expanding use of tumor genome analysis by next generation sequencing to drive target therapies has led to increased germline findings in genes predisposing to hereditary cancer. These putative germline findings obtained from theranostic analyses, such as   gene testing, large panels, whole-exome, or whole-genome sequencing, need to be managed carefully and in an anticipated way with the patient. Before the genetic analysis of a tumor, specific information should be given to patients, who should be aware that the results may have extra-therapeutic medical issues for themselves and relatives. We previously published a list of 36 actionable genes predisposing to cancer for which informing the patient is recommended prior to pangenomic germline analysis because of available screening or preventive strategies. Here, we report clinical practice considerations and schemes for managing germline findings in tumor analyses, including written informed consent and a multidisciplinary approach involving an oncologist, molecular biologist/pathologist, and geneticist in case of germline findings. A somatic result showing a deleterious mutation in a known predisposing gene in a patient who has consented to this purpose should result in referral to a geneticist who is part of the multidisciplinary team. At any time of the somatic analysis process, the patient may have access to a geneticist consultation if additional information is required. This framework will optimally manage both personalized theranostic issues and specific preventive strategies for individuals and relatives; it will also simplify and accelerate the process of genetic testing.","Department of Cancer Genetics, University Hospital of Montpellier, 34000 Montpellier;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of pathology, Centre Jean Perrin, 63000 Clermont-Ferrand, France.","NA",0,"2075-4418","Diagnostics (Basel)","Diagnostics (Basel)",2019,"2019","9","10.3390/diagnostics9030083",NA,"","","31357515","31357515","PUBMED","Department of Cancer Genetics, University Hospital of Montpellier, 34000 Montpellier;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes, France.;Department of pathology, Centre Jean Perrin, 63000 Clermont-Ferrand, France."
"469","Arnaud A;Laraqui Hossini S;Tunon de Lara S;Dobremez E;Chateil JF;Harper L","Arnaud, Alexis;Laraqui Hossini, Samia;Tunon de Lara, Sara;Dobremez, Eric;Chateil, Jean-François;Harper, Luke","Managing children with hydronephrosis: common pitfall during ultrasound follow-up to remember.","Archives of disease in childhood","England","eng","Journal Article","hydronephrosis;paediatrician;ultrasound","Continuity of Patient Care;Humans;Hydronephrosis;Infant;Infant, Newborn;Kidney Pelvis;Prospective Studies;Ultrasonography","Continuity of Patient Care;Humans;Hydronephrosis;Infant;Infant, Newborn;Kidney Pelvis;Prospective Studies;Ultrasonography","NA","Paediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Radiology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.","NA",0,"1468-2044","Arch Dis Child","Arch Dis Child",2019,"2020","105","10.1136/archdischild-2019-317386","610-611","","","31300410","31300410","PUBMED","Paediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Radiology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Paediatric Surgery, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France."
"470","Diéras V;Harbeck N;Joy AA;Gelmon K;Ettl J;Verma S;Lu DR;Gauthier E;Schnell P;Mori A;Rugo HS;Finn RS","Diéras, Véronique;Harbeck, Nadia;Joy, Anil Abraham;Gelmon, Karen;Ettl, Johannes;Verma, Sunil;Lu, Dongrui R;Gauthier, Eric;Schnell, Patrick;Mori, Ave;Rugo, Hope S;Finn, Richard S","Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.","The oncologist","England","eng","Journal Article","Breast cancer;Hematologic;Neutropenia;Palbociclib;Safety","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Receptor, ErbB-2","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Receptor, ErbB-2","PALOMA-2 confirmed that first-line palbociclib + letrozole improved progression-free survival (hazard ratio, 0.58; 95% confidence interval, 0.46-0.72) in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). This analysis evaluated palbociclib-associated hematologic adverse events (AEs) and provides insight on managing these AEs. Postmenopausal women with ER+/HER2- ABC were randomly assigned 2:1 to letrozole (2.5 mg daily continuously) plus oral palbociclib (125 mg daily; 3 weeks on/1 week off) or placebo. Safety assessments were performed at baseline, days 1 and 15 (first two cycles) and day 1 of subsequent cycles, and included white blood cell, platelet, and absolute neutrophil count (ANC). PALOMA-2 randomized 666 women to palbociclib + letrozole (  = 444) or placebo + letrozole (n = 222). Neutropenia was the most common AE (95.3%) with palbociclib (grade 3, 55.6%; grade 4, 11.5%) and was managed by dose modifications; progression-free survival was similar between patients who experienced grade ≥ 3 neutropenia versus those who did not. Median (range) time to onset of neutropenia with palbociclib + letrozole was 15 (12-700) days (grade ≥ 3, 28.0 [12-854] days); median duration of each neutropenia episode grade ≥ 3 was 7.0 days. Asian ethnicity and low baseline ANC were associated with increased risk of grade 3/4 neutropenia with palbociclib (  < .001). Palbociclib + letrozole was generally well tolerated. Neutropenia, the most frequently reported AE in women with ER+/HER2- ABC, was mostly transient and manageable by dose modifications in patients who experienced grade ≥ 3 neutropenia, without appearing to compromise efficacy. (Pfizer; NCT01740427) IMPLICATIONS FOR PRACTICE: Palbociclib demonstrated an acceptable safety profile in PALOMA-2 in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) receiving first-line palbociclib + letrozole. Although hematologic adverse events (AEs) are typically expected with anticancer therapies and are often clinically significant, palbociclib-related hematologic AEs, particularly neutropenia (most frequent AE), were transient/manageable by dose reduction, interruption, or cycle delay, which is in contrast to the more profound neutropenia associated with chemotherapy. Palbociclib dose adjustments decreased hematologic AE severity without appearing to compromise efficacy, supporting palbociclib + letrozole as a first-line treatment for ER+/HER2- ABC.","Department of Medical Oncology, Centre Eugène Marquis, Rennes;Brustzentrum der Universität München, Munich, Germany.;Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.;British Columbia Cancer Agency, Vancouver, British Columbia, Canada.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität, München, Munich, Germany.;University of Calgary, Calgary, Alberta, Canada.;Pfizer Inc., La Jolla, California, USA.;Pfizer Inc., San Francisco, California, USA.;Pfizer Inc., New York New York, USA.;Pfizer s.r.l., Milan, Italy.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.;David Geffen School of Medicine at UCLA, Santa Monica, California, USA.","NA",0,"1549-490X","Oncologist","Oncologist",2019,"2019","24","10.1634/theoncologist.2019-0019","1514-1525","","","31217344","31217344","PUBMED","Department of Medical Oncology, Centre Eugène Marquis, Rennes;Brustzentrum der Universität München, Munich, Germany.;Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.;British Columbia Cancer Agency, Vancouver, British Columbia, Canada.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität, München, Munich, Germany.;University of Calgary, Calgary, Alberta, Canada.;Pfizer Inc., La Jolla, California, USA.;Pfizer Inc., San Francisco, California, USA.;Pfizer Inc., New York New York, USA.;Pfizer s.r.l., Milan, Italy.;University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.;David Geffen School of Medicine at UCLA, Santa Monica, California, USA."
"471","Boisson M;Corbi P;Kerforne T;Camilleri L;Debauchez M;Demondion P;Eljezi V;Flecher E;Lepelletier D;Leprince P;Nesseler N;Nizou JY;Roussel JC;Rozec B;Ruckly S;Lucet JC;Timsit JF;Mimoz O","Boisson, Matthieu;Corbi, Pierre;Kerforne, Thomas;Camilleri, Lionel;Debauchez, Mathieu;Demondion, Pierre;Eljezi, Vedat;Flecher, Erwan;Lepelletier, Didier;Leprince, Pascal;Nesseler, Nicolas;Nizou, Jacques Yves;Roussel, Jean Christian;Rozec, Bertrand;Ruckly, Stéphane;Lucet, Jean-Christophe;Timsit, Jean-François;Mimoz, Olivier","Multicentre, open-label, randomised, controlled clinical trial comparing 2% chlorhexidine-70% isopropanol and 5% povidone iodine-69% ethanol for skin antisepsis in reducing surgical-site infection after cardiac surgery: the CLEAN 2 study protocol.","BMJ open","England","eng","Journal Article","cardiac surgery;chlorhexidine;povidone iodine;skin antisepsis;surgical-site infection","2-Propanol;Administration, Topical;Anti-Infective Agents, Local;Antisepsis;Cardiac Surgical Procedures;Chlorhexidine;Clinical Protocols;Ethanol;Humans;Povidone-Iodine;Preoperative Care;Surgical Wound Infection;Treatment Outcome","2-Propanol;Administration, Topical;Anti-Infective Agents, Local;Antisepsis;Cardiac Surgical Procedures;Chlorhexidine;Clinical Protocols;Ethanol;Humans;Povidone-Iodine;Preoperative Care;Surgical Wound Infection;Treatment Outcome","Surgical-site infection (SSI) is the second most frequent cause of healthcare-associated infection worldwide and is associated with increased morbidity, mortality and healthcare costs. Cardiac surgery is clean surgery with low incidence of SSI, ranging from 2% to 5%, but with potentially severe consequences.Perioperative skin antisepsis with an alcohol-based antiseptic solution is recommended to prevent SSI, but the superiority of chlorhexidine (CHG)-alcohol over povidone iodine (PVI)-alcohol, the two most common alcohol-based antiseptic solutions used worldwide, is controversial. We aim to evaluate whether 2% CHG-70% isopropanol is more effective than 5% PVI-69% ethanol in reducing the incidence of reoperation after cardiac surgery. The CLEAN 2 study is a multicentre, open-label, randomised, controlled clinical trial of 4100 patients undergoing cardiac surgery. Patients will be randomised in 1:1 ratio to receive either 2% CHG-70% isopropanol or 5% PVI-69% ethanol for perioperative skin preparation. The primary endpoint is the proportion of patients undergoing any re-sternotomy between day 0 and day 90 after initial surgery and/or any reoperation on saphenous vein/radial artery surgical site between day 0 and day 30 after initial surgery. Data will be analysed on the intention-to-treat principle. This protocol has been approved by an independent ethics committee and will be carried out according to the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. The results of this study will be disseminated through presentation at scientific conferences and publication in peer-reviewed journals. EudraCT 2017-005169-33 and NCT03560193.","Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;INSERM U1070, Universite de Poitiers UFR Medecine et Pharmacie, Poitiers, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Cardiothoracic Surgery Unit, Institut Mutualiste Montsouris, Paris, France.;Cardiothoracic Surgery Unit, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infection Control Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Cardiothoracic Surgery Unit, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infection Control Unit, Institut Mutualiste Montsouris, Paris, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Anesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM UMR 1137, Universite Paris Diderot UFR de Medecine Site Xavier-Bichat, Paris, France.;Infection Control Unit, Hopital Bichat - Claude-Bernard, Paris, France.;Iame, INSERM, Paris, France.;INSERM UMR 1137, Universite Paris Diderot UFR de Medecine Site Xavier-Bichat, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Hopital Bichat - Claude-Bernard, Paris, France.;INSERM U1070, Universite de Poitiers UFR Medecine et Pharmacie, Poitiers, France.;Emergency Department and Prehospital Care, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2019,"2019","9","10.1136/bmjopen-2018-026929","e026929","","","31213447","31213447","PUBMED","Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;INSERM U1070, Universite de Poitiers UFR Medecine et Pharmacie, Poitiers, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Cardiothoracic Surgery Unit, Institut Mutualiste Montsouris, Paris, France.;Cardiothoracic Surgery Unit, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infection Control Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Cardiothoracic Surgery Unit, Hopitaux Universitaires Pitie Salpetriere-Charles Foix, Paris, France.;Anaesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Infection Control Unit, Institut Mutualiste Montsouris, Paris, France.;Cardiothoracic Surgery Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Anesthesia and Intensive Care Unit, Centre Hospitalier Universitaire de Nantes, Nantes, France.;INSERM UMR 1137, Universite Paris Diderot UFR de Medecine Site Xavier-Bichat, Paris, France.;Infection Control Unit, Hopital Bichat - Claude-Bernard, Paris, France.;Iame, INSERM, Paris, France.;INSERM UMR 1137, Universite Paris Diderot UFR de Medecine Site Xavier-Bichat, Paris, France.;Medical and Infectious Diseases Intensive Care Unit, Hopital Bichat - Claude-Bernard, Paris, France.;INSERM U1070, Universite de Poitiers UFR Medecine et Pharmacie, Poitiers, France.;Emergency Department and Prehospital Care, Centre Hospitalier Universitaire de Poitiers, Poitiers, France."
"472","Löfström U;Hage C;Savarese G;Donal E;Daubert JC;Lund LH;Linde C","Löfström, Ulrika;Hage, Camilla;Savarese, Gianluigi;Donal, Erwan;Daubert, Jean-Claude;Lund, Lars H;Linde, Cecilia","Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction.","ESC heart failure","England","eng","Journal Article","Echocardiography;Framingham criteria;Heart failure with preserved ejection fraction;Natriuretic peptides;Prognosis","Aged;Aged, 80 and over;Female;Heart Failure;Hospitalization;Humans;Male;Prognosis;Prospective Studies;Stroke Volume","Aged;Aged, 80 and over;Female;Heart Failure;Hospitalization;Humans;Male;Prognosis;Prospective Studies;Stroke Volume","This study aims to assess prognostic impact of Framingham criteria for heart failure (FC-HF) in patients with stable heart failure (HF) with preserved ejection fraction (HFpEF). In the prospective Karolinska-Rennes (KaRen) study, we assessed stable HFpEF patients after an acute HF episode. We evaluated associations between the four descriptive models of HFpEF and the composite endpoint of all-cause mortality and HF hospitalization. The descriptive models were FC-HF alone, FC-HF + natriuretic peptides (NPs) according to the PARAGON trial, FC-HF + NPs + echocardiographic HFpEF criteria according to European Society of Cardiology HF guidelines, and FC-HF + NPs + echocardiographic criteria according to the PARAGON trial. Out of the 539 patients enrolled in KaRen, 438 returned for the stable state revisit after 4-8 weeks, 13 (2.4%) patients died before the planned follow-up, and 88 patients (16%) declined or were unable to return. Three hundred ninety-nine patients have FC registered at follow-up, and among these, the four descriptive models were met in 107 (27%), 82 (22%), 61 (21%), and 69 (22%) patients, and not met in 292 (73%). The 107 patients that had FC-HF at stable state (descriptive model 1) could also be part of the other models because all patients in models 1-4 had to fulfil the FC-HF. The patients in model 0 did not fulfil the criteria for FC-HF but could have single FC. Of single FC, only pleural effusion predicted the endpoint [hazard ratio (HR) 3.38, 95% confidence interval (CI) 1.47-7.76, P = 0.004]. Patients without FC-HF had better prognosis than patients meeting FC-HF. The unadjusted associations between the four HFpEF descriptive models and the endpoint were HR 1.54, 95% CI 1.14-2.09, P = 0.005; HR 1.71, 95% CI 1.24-2.36, P = 0.002; HR 1.95, 95% CI 1.36-2.81, P = 0.001; and HR 2.05, 95% CI 1.45-2.91, P < 0.001, for descriptive models 1-4, respectively. No descriptive model independently predicted the endpoint. In ambulatory HFpEF patients, a quarter met FC-HF, while most met NP and echocardiography criteria for HF. Residual FC-HF tended to be associated with increased risk for mortality and HF hospitalization, further strengthened by NPs and echocardiographic criteria, highlighting its role in clinical risk assessment.","Department of Cardiology, Capio St. Göran's Hospital, 112 81, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, University of Rennes 1, Rennes, France.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.","NA",0,"2055-5822","ESC Heart Fail","ESC Heart Fail",2019,"2019","6","10.1002/ehf2.12458","830-839","20110610;20090376;20110120;00556-2009;20110406;20080498;20100419;20080409;2013-23897-104604-23","Stockholm County Council;Stockholm County Council;Stockholm County Council;Stockholm County Council;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Heart Lung Foundation;Swedish Research Council;Center for Gender Medicine Karolinska Institutet, Stockholm, Sweden;Medtronic Bakken Research Center, Maastricht, The Netherlands;Fédération Française de Cardiologie/Société Française de Cardiologie, France","31207140","31207140","PUBMED","Department of Cardiology, Capio St. Göran's Hospital, 112 81, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Département de Cardiologie and CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Faculté de Médecine, University of Rennes 1, Rennes, France.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden.;Department of Medicine, Karolinska Institutet, Stockholm, Sweden.;Heart and Vascular Theme, Karolinska University Hospital, Stockholm, Sweden."
"473","Deplanche M;Mouhali N;Nguyen MT;Cauty C;Ezan F;Diot A;Raulin L;Dutertre S;Langouet S;Legembre P;Taieb F;Otto M;Laurent F;Götz F;Le Loir Y;Berkova N","Deplanche, Martine;Mouhali, Nassim;Nguyen, Minh-Thu;Cauty, Chantal;Ezan, Frédéric;Diot, Alan;Raulin, Lesly;Dutertre, Stephanie;Langouet, Sophie;Legembre, Patrick;Taieb, Frederic;Otto, Michael;Laurent, Frédéric;Götz, Friedrich;Le Loir, Yves;Berkova, Nadia","Staphylococcus aureus induces DNA damage in host cell.","Scientific reports","England","eng","Journal Article","","Acetylcysteine;Arthritis, Infectious;Bacterial Toxins;Cell Line, Tumor;DNA Damage;DNA Repair;Etoposide;G2 Phase Cell Cycle Checkpoints;Genomic Islands;Guanine;HeLa Cells;Histones;Host-Pathogen Interactions;Humans;Lipoproteins;Osteitis;Osteoblasts;Oxidative Stress;Phosphorylation;Protein Processing, Post-Translational;Reactive Oxygen Species;Staphylococcal Infections;Staphylococcus aureus","Acetylcysteine;Arthritis, Infectious;Bacterial Toxins;Cell Line, Tumor;DNA Damage;DNA Repair;Etoposide;G2 Phase Cell Cycle Checkpoints;Genomic Islands;Guanine;HeLa Cells;Histones;Host-Pathogen Interactions;Humans;Lipoproteins;Osteitis;Osteoblasts;Oxidative Stress;Phosphorylation;Protein Processing, Post-Translational;Reactive Oxygen Species;Staphylococcal Infections;Staphylococcus aureus","Staphylococcus aureus causes serious medical problems in human and animals. Here we show that S. aureus can compromise host genomic integrity as indicated by bacteria-induced histone H2AX phosphorylation, a marker of DNA double strand breaks (DSBs), in human cervix cancer HeLa and osteoblast-like MG-63 cells. This DNA damage is mediated by alpha phenol-soluble modulins (PSMα ), while a specific class of lipoproteins (Lpls), encoded on a pathogenicity island in S. aureus, dampens the H2AX phosphorylation thus counteracting the DNA damage. This DNA damage is mediated by reactive oxygen species (ROS), which promotes oxidation of guanine forming 7,8-dihydro-8-oxoguanine (8-oxoG). DNA damage is followed by the induction of DNA repair that involves the ATM kinase-signaling pathway. An examination of S. aureus strains, isolated from the same patient during acute initial and recurrent bone and joint infections (BJI), showed that recurrent strains produce lower amounts of Lpls, induce stronger DNA-damage and prompt the G2/M transition delay to a greater extent that suggest an involvement of these mechanisms in adaptive processes of bacteria during chronicization. Our findings redefine our understanding of mechanisms of S. aureus-host interaction and suggest that the balance between the levels of PSMα and Lpls expression impacts the persistence of the infection.","STLO, INRA, Agrocampus Ouest, Rennes, France.;STLO, INRA, Agrocampus Ouest, Rennes, France.;Microbial Genetics, University of Tübingen, Tübingen, Germany.;STLO, INRA, Agrocampus Ouest, Rennes, France.;Univ Rennes, Inserm, EHESP, Irset UMR_S 1085, F-35000, Rennes, France.;Centre International de Recherche en Infectiologie, INSERM U1111, CNRS, Université Lyon 1, Lyon, France.;Centre National de Référence des Staphylocoques, Lyon, France.;CNRS, Inserm, BIOSIT-UMS 3480, MRic, Université de Rennes, Rennes, France.;CNRS, Inserm, BIOSIT-UMS 3480, MRic, Université de Rennes, Rennes, France.;Univ Rennes, Inserm, EHESP, Irset UMR_S 1085, F-35000, Rennes, France.;Centre Eugène Marquis, Equipe Ligue Contre Le Cancer, Rennes, France.;IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.;Laboratory of Human Bacterial Pathogenesis, US National Institutes of Health, Bethesda, Maryland, 20892, USA.;Centre International de Recherche en Infectiologie, INSERM U1111, CNRS, Université Lyon 1, Lyon, France.;Centre National de Référence des Staphylocoques, Lyon, France.;Microbial Genetics, University of Tübingen, Tübingen, Germany.;STLO, INRA, Agrocampus Ouest, Rennes, France.;STLO, INRA, Agrocampus Ouest, Rennes","NA",0,"2045-2322","Sci Rep","Sci Rep",2019,"2019","9","10.1038/s41598-019-44213-3","7694","ZIA AI000904","Intramural NIH HHS","31118484","31118484","PUBMED","STLO, INRA, Agrocampus Ouest, Rennes, France.;STLO, INRA, Agrocampus Ouest, Rennes, France.;Microbial Genetics, University of Tübingen, Tübingen, Germany.;STLO, INRA, Agrocampus Ouest, Rennes, France.;Univ Rennes, Inserm, EHESP, Irset UMR_S 1085, F-35000, Rennes, France.;Centre International de Recherche en Infectiologie, INSERM U1111, CNRS, Université Lyon 1, Lyon, France.;Centre National de Référence des Staphylocoques, Lyon, France.;CNRS, Inserm, BIOSIT-UMS 3480, MRic, Université de Rennes, Rennes, France.;CNRS, Inserm, BIOSIT-UMS 3480, MRic, Université de Rennes, Rennes, France.;Univ Rennes, Inserm, EHESP, Irset UMR_S 1085, F-35000, Rennes, France.;Centre Eugène Marquis, Equipe Ligue Contre Le Cancer, Rennes, France.;IRSD, Université de Toulouse, INSERM, INRA, ENVT, UPS, Toulouse, France.;Laboratory of Human Bacterial Pathogenesis, US National Institutes of Health, Bethesda, Maryland, 20892, USA.;Centre International de Recherche en Infectiologie, INSERM U1111, CNRS, Université Lyon 1, Lyon, France.;Centre National de Référence des Staphylocoques, Lyon, France.;Microbial Genetics, University of Tübingen, Tübingen, Germany.;STLO, INRA, Agrocampus Ouest, Rennes, France.;STLO, INRA, Agrocampus Ouest, Rennes"
"474","Limia CM;Sauzay C;Urra H;Hetz C;Chevet E;Avril T","Limia, Celia Maria;Sauzay, Chloé;Urra, Hery;Hetz, Claudio;Chevet, Eric;Avril, Tony","Emerging Roles of the Endoplasmic Reticulum Associated Unfolded Protein Response in Cancer Cell Migration and Invasion.","Cancers","Switzerland","eng","Journal Article","ATF6;ER stress;IRE1;PERK;cancer;cell invasion;cell migration","","","Endoplasmic reticulum (ER) proteostasis is often altered in tumor cells due to intrinsic (oncogene expression, aneuploidy) and extrinsic (environmental) challenges. ER stress triggers the activation of an adaptive response named the Unfolded Protein Response (UPR), leading to protein translation repression, and to the improvement of ER protein folding and clearance capacity. The UPR is emerging as a key player in malignant transformation and tumor growth, impacting on most hallmarks of cancer. As such, the UPR can influence cancer cells' migration and invasion properties. In this review, we overview the involvement of the UPR in cancer progression. We discuss its cross-talks with the cell migration and invasion machinery. Specific aspects will be covered including extracellular matrix (ECM) remodeling, modification of cell adhesion, chemo-attraction, epithelial-mesenchymal transition (EMT), modulation of signaling pathways associated with cell mobility, and cytoskeleton remodeling. The therapeutic potential of targeting the UPR to treat cancer will also be considered with specific emphasis in the impact on metastasis and tissue invasion.","Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, 8380453 Santiago;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, 8380453 Santiago;The Buck Institute for Research in Aging, Novato, CA 94945;Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Rennes Brain Cancer Team (REACT), 35042 Rennes;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Rennes Brain Cancer Team (REACT), 35042 Rennes","NA",0,"2072-6694","Cancers (Basel)","Cancers (Basel)",2019,"2019","11","10.3390/cancers11050631",NA,"","","31064137","31064137","PUBMED","Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, 8380453 Santiago;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Biomedical Neuroscience Institute, University of Chile, 8380453 Santiago;Center for Geroscience, Brain Health and Metabolism (GERO), 8380453 Santiago;Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, 8380453 Santiago;The Buck Institute for Research in Aging, Novato, CA 94945;Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Rennes Brain Cancer Team (REACT), 35042 Rennes;Proteostasis & Cancer Team, Institut National de la Santé Et la Recherche Médicale U1242 Chemistry, Oncogenesis, Stress and Signaling, Université de Rennes, 35042 Rennes;Centre Eugène Marquis, 35042 Rennes;Rennes Brain Cancer Team (REACT), 35042 Rennes"
"475","Cabridain C;Aubert H;Kaeffer B;Badon V;Boivin M;Dochez V;Winer N;Faurel-Paul E;Planche L;Riochet D;Maruani A;Perrotin F;Droitcourt C;Lassel L;Tching-Sin M;Rogers NK;Bodinier M;Barbarot S","Cabridain, Clémentine;Aubert, Hélène;Kaeffer, Bertrand;Badon, Virginie;Boivin, Marion;Dochez, Vincent;Winer, Norbert;Faurel-Paul, Elodie;Planche, Lucie;Riochet, David;Maruani, Annabel;Perrotin, Franck;Droitcourt, Catherine;Lassel, Linda;Tching-Sin, Martine;Rogers, Natasha K;Bodinier, Marie;Barbarot, Sebastien","Effectiveness of an antenatal maternal supplementation with prebiotics for preventing atopic dermatitis in high-risk children (the PREGRALL study): protocol for a randomised controlled trial.","BMJ open","England","eng","Clinical Trial Protocol","dermatology;eczema;paediatric dermatology","Dermatitis, Atopic;Dietary Supplements;Double-Blind Method;Female;Humans;Infant;Infant, Newborn;Male;Maternal Nutritional Physiological Phenomena;Multicenter Studies as Topic;Prebiotics;Pregnancy;Pregnant People;Prenatal Care;Randomized Controlled Trials as Topic;Treatment Outcome","Dermatitis, Atopic;Dietary Supplements;Double-Blind Method;Female;Humans;Infant;Infant, Newborn;Male;Maternal Nutritional Physiological Phenomena;Multicenter Studies as Topic;Prebiotics;Pregnancy;Pregnant People;Prenatal Care;Randomized Controlled Trials as Topic;Treatment Outcome","Atopic dermatitis (AD) is a chronic inflammatory disease affecting 10%-15% of children in Europe. There is a need for new primary preventive therapeutic strategies in at-risk populations. Recent research has indicated that atopic diseases are associated with a disrupted gut microbial 'balance' in early life raising the possibility that interventions which yield optimal patterns of microflora could improve host's health. Prebiotics, sugars with immunomodulatory properties that stimulate the diversity of the digestive microbiota, are ideal candidates for such research. So far, most clinical trials have focused on improving infant gut colonisation postnatally. However, prenatal life is a crucial period during which different tolerance mechanisms are put in place. We aim to determine whether antenatal prebiotics supplementation prevents AD in high-risk children. This is a randomised, multicentre, double-blind, trial to evaluate the effectiveness of antenatal prebiotic maternal supplementation (galacto-oligosaccharide/inulin) in pregnant women versus placebo on the occurrence of AD at 1 year of age in at-risk children (defined as having a maternal history of atopic disease). Participating women will be randomised to daily ingestion of a prebiotics or placebo (maltodextrin) from 20 weeks' gestation until delivery. The primary outcome is the prevalence of AD at 1 year of age, using the version of the UK Working Party Diagnostic Criteria optimised for preventive studies. Key secondary endpoints are AD severity, quality of life and prebiotics tolerance. The target sample size is 376 women (188 patients per group) which will provide 80% power to detect a 33% reduction of the risk of AD in the verum group (α=0.05). The primary analysis will be based on the intention-to-treat principle. Results will be presented in peer-reviewed journals and at international conferences. Ethics approval for the study was obtained from the institutional ethical review board of 'Comité de Protection des Personnes Sud Ouest-Outre-Mer III' of the University Hospital Centre of Bordeaux (2017/13). NCT03183440; Pre-results.","UMR PhAN, INRA Centre Angers-Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;UMR PhAN, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Department of Clinical Research, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Platform Methodology and Biostatistics, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, Pays de la Loire, France.;HUGOPEREN, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre, France.;Clinical Investigation Center-INSERM 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre, France.;Department of Obstetrics, Gynecology and Fetal Medicine, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;Maternité Olympe de Gouges, Hopital Bretonneau, Tours, Centre, France.;Department of Dermatology, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Universite de Rennes 1, Rennes, Bretagne, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pharmacy, Centre Hospitalier Universitaire de Nantes, Nantes, UK.;Centre of Evidence Based Dermatology, University of Nottingham School of Medicine, Nottingham, UK.;BIA UR1268, INRA Centre Angers-Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2019,"2019","9","10.1136/bmjopen-2018-024974","e024974","","","31005913","31005913","PUBMED","UMR PhAN, INRA Centre Angers-Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;UMR PhAN, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;CIC FEA, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Department of Clinical Research, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Platform Methodology and Biostatistics, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, Pays de la Loire, France.;HUGOPEREN, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre, France.;Clinical Investigation Center-INSERM 1415, Centre Hospitalier Regional Universitaire de Tours, Tours, Centre, France.;Department of Obstetrics, Gynecology and Fetal Medicine, Centre Hospitalier Regional Universitaire de Tours, Tours, France.;Maternité Olympe de Gouges, Hopital Bretonneau, Tours, Centre, France.;Department of Dermatology, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Universite de Rennes 1, Rennes, Bretagne, France.;Obstetrics and Gynecology Department, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pharmacy, Centre Hospitalier Universitaire de Nantes, Nantes, UK.;Centre of Evidence Based Dermatology, University of Nottingham School of Medicine, Nottingham, UK.;BIA UR1268, INRA Centre Angers-Nantes, Nantes, Pays de la Loire, France.;Department of Dermatology, Centre Hospitalier Universitaire de Nantes, Nantes, Pays de la Loire, France."
"476","Kammerer-Jacquet SF;Deleuze A;Saout J;Mathieu R;Laguerre B;Verhoest G;Dugay F;Belaud-Rotureau MA;Bensalah K;Rioux-Leclercq N","Kammerer-Jacquet, Solène-Florence;Deleuze, Antoine;Saout, Judikaël;Mathieu, Romain;Laguerre, Brigitte;Verhoest, Gregory;Dugay, Frédéric;Belaud-Rotureau, Marc-Antoine;Bensalah, Karim;Rioux-Leclercq, Nathalie","Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.","International journal of molecular sciences","Switzerland","eng","Journal Article","PD-1;PD-L1;biomarker;immune checkpoint inhibition;immunotherapy;renal cell carcinoma;tumour mutational burden","Animals;Biomarkers, Tumor;Carcinoma, Renal Cell;Humans;Immunotherapy;Programmed Cell Death 1 Receptor","Animals;Biomarkers, Tumor;Carcinoma, Renal Cell;Humans;Immunotherapy;Programmed Cell Death 1 Receptor","Renal cell carcinoma encompass distinct diseases with different pathologic features and distinct molecular pathways. Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway alone or in combination have greatly changed clinical management of metastatic renal cell carcinoma, now competing with antiangiogenic drugs in monotherapy for first-line treatment. However, long-term response rates are low, and biomarkers are needed to predict treatment response. Quantification of PD-L1 expression by immunohistochemistry was developed as a promising biomarker in clinical trials, but with many limitations (different antibodies, tumour heterogeneity, specimens, and different thresholds of positivity). Other biomarkers, including tumour mutational burden and molecular signatures, are also developed and discussed in this review.","Department of Pathology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Cytogenetics, University Hospital, F-35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Cytogenetics, University Hospital, F-35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Department of Pathology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes","NA",0,"1422-0067","Int J Mol Sci","Int J Mol Sci",2019,"2019","20","10.3390/ijms20071692",NA,"","","30987368","30987368","PUBMED","Department of Pathology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Department of Medical Oncology, Centre Eugene Marquis, 35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Cytogenetics, University Hospital, F-35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes;Department of Cytogenetics, University Hospital, F-35000 Rennes;Department of Urology, University Hospital, 35000 Rennes;Department of Pathology, University Hospital, 35000 Rennes;Université Rennes, Inserm, EHESP (Ecole des Hautes Etudes en Santé Publique), Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes"
"477","Delva F;Laurent F;Paris C;Belacel M;Brochard P;Bylicki O;Chouaïd C;Clin B;Dewitte JD;Le Denmat V;Gehanno JF;Lacourt A;Margery J;Verdun-Esquer C;Mathoulin-Pélissier S;Pairon JC","Delva, Fleur;Laurent, François;Paris, Christophe;Belacel, Milia;Brochard, Patrick;Bylicki, Olivier;Chouaïd, Christos;Clin, Benedicte;Dewitte, Jean-Dominique;Le Denmat, Véronique;Gehanno, Jean-François;Lacourt, Aude;Margery, Jacques;Verdun-Esquer, Catherine;Mathoulin-Pélissier, Simone;Pairon, Jean-Claude","LUCSO-1-French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol.","BMJ open","England","eng","Clinical Trial Protocol","lung neoplasms;mass screening;occupational exposure;tomography scanners, X-ray computed","Aged;Carcinogens;Early Detection of Cancer;Female;France;Humans;Lung Neoplasms;Male;Middle Aged;Occupational Exposure;Pilot Projects;Radiation Dosage;Risk Assessment;Risk Factors;Smokers;Tomography, X-Ray Computed","Aged;Carcinogens;Early Detection of Cancer;Female;France;Humans;Lung Neoplasms;Male;Middle Aged;Occupational Exposure;Pilot Projects;Radiation Dosage;Risk Assessment;Risk Factors;Smokers;Tomography, X-Ray Computed","Guidelines concerning the follow-up of subjects occupationally exposed to lung carcinogens, published in France in 2015, recommended the setting up of a trial of low-dose chest CT lung cancer screening in subjects at high risk of lung cancer. To evaluate the organisation of low-dose chest CT lung cancer screening in subjects occupationally exposed to lung carcinogens and at high risk of lung cancer. This trial will be conducted in eight French departments by six specialised reference centres (SRCs) in occupational health. In view of the exploratory nature of this trial, it is proposed to test initially the feasibility and acceptability over the first 2 years in only two SRCs then in four other SRCs to evaluate the organisation. The target population is current or former smokers with more than 30 pack-years (who have quit smoking for less than 15 years), currently or previously exposed to International Agency for Research on Cancer group 1 lung carcinogens, and between the ages of 55 and 74 years. The trial will be conducted in the following steps: (1) identification of subjects by a screening invitation letter; (2) evaluation of occupational exposure to lung carcinogens; (3) evaluation of the lung cancer risk level and verification of eligibility; (4) screening procedure: annual chest CT scans performed by specialised centres and (5) follow-up of CT scan abnormalities. This protocol study has been approved by the French Committee for the Protection of Persons. The results from this study will be submitted to peer-reviewed journals and reported at suitable national and international meetings. NCT03562052; Pre-results.","Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;EPICENE, INSERM U1219, Bordeaux, France.;Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Intercommunal de Creteil, Creteil, Île-de-France, France.;Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Department of Pneumologie, Hopital d'Instruction des Armees Percy, Clamart, France.;Centre Hospitalier Intercommunal de Creteil, Creteil, Île-de-France, France.;Centre Hospitalier Universitaire de Caen, Caen, France.;Centre Hospitalier Régional Universitaire (CHRU) de Brest, Brest, France.;Centre Hospitalier Régional Universitaire (CHRU) de Brest, Brest, France.;Centre Hospitalier Universitaire de Rouen, Rouen, France.;EPICENE, INSERM U1219, Bordeaux, France.;Department of Pneumologie, Hopital d'Instruction des Armees Percy, Clamart, France.;Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Institut Bergonie, Bordeaux, France.;Pneumologie et pathologie professionnelle, Centre Hospitalier Intercommunal de Créteil, Créteil Cedex, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2019,"2019","9","10.1136/bmjopen-2018-025026","e025026","","","30904859","30904859","PUBMED","Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;EPICENE, INSERM U1219, Bordeaux, France.;Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Intercommunal de Creteil, Creteil, Île-de-France, France.;Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Department of Pneumologie, Hopital d'Instruction des Armees Percy, Clamart, France.;Centre Hospitalier Intercommunal de Creteil, Creteil, Île-de-France, France.;Centre Hospitalier Universitaire de Caen, Caen, France.;Centre Hospitalier Régional Universitaire (CHRU) de Brest, Brest, France.;Centre Hospitalier Régional Universitaire (CHRU) de Brest, Brest, France.;Centre Hospitalier Universitaire de Rouen, Rouen, France.;EPICENE, INSERM U1219, Bordeaux, France.;Department of Pneumologie, Hopital d'Instruction des Armees Percy, Clamart, France.;Service de médecine du travail et de pathologies professionnelles, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.;Institut Bergonie, Bordeaux, France.;Pneumologie et pathologie professionnelle, Centre Hospitalier Intercommunal de Créteil, Créteil Cedex, France."
"478","Ben Aim L;Pigny P;Castro-Vega LJ;Buffet A;Amar L;Bertherat J;Drui D;Guilhem I;Baudin E;Lussey-Lepoutre C;Corsini C;Chabrier G;Briet C;Faivre L;Cardot-Bauters C;Favier J;Gimenez-Roqueplo AP;Burnichon N","Ben Aim, Laurène;Pigny, Pascal;Castro-Vega, Luis Jaime;Buffet, Alexandre;Amar, Laurence;Bertherat, Jérôme;Drui, Delphine;Guilhem, Isabelle;Baudin, Eric;Lussey-Lepoutre, Charlotte;Corsini, Carole;Chabrier, Gérard;Briet, Claire;Faivre, Laurence;Cardot-Bauters, Catherine;Favier, Judith;Gimenez-Roqueplo, Anne-Paule;Burnichon, Nelly","Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma.","Journal of medical genetics","England","eng","Journal Article","mosaicism;next generation sequencing;paraganglioma;pheochromocytoma;somatic mutations","Alleles;Biomarkers, Tumor;Genetic Association Studies;Genetic Predisposition to Disease;Genetic Testing;Genetic Variation;Genotype;Germ-Line Mutation;High-Throughput Nucleotide Sequencing;Humans;Mutation;Paraganglioma;Pheochromocytoma;Sequence Analysis, DNA","Alleles;Biomarkers, Tumor;Genetic Association Studies;Genetic Predisposition to Disease;Genetic Testing;Genetic Variation;Genotype;Germ-Line Mutation;High-Throughput Nucleotide Sequencing;Humans;Mutation;Paraganglioma;Pheochromocytoma;Sequence Analysis, DNA","Knowing the genetic status of patients affected by paragangliomas and pheochromocytomas (PPGL) is important for the guidance of their management and their relatives. Our objective was to improve the diagnostic performances of PPGL genetic testing by next-generation sequencing (NGS). We developed a custom multigene panel, which includes 17 PPGL genes and is compatible with both germline and tumour DNA screening. The NGS assay was first validated in a retrospective cohort of 201 frozen tumour DNAs and then applied prospectively to 623 DNAs extracted from leucocytes, frozen or paraffin-embedded PPGL tumours. In the retrospective cohort, the sensitivity of the NGS assay was evaluated at 100% for point and indels mutations and 86% for large rearrangements. The mutation rate was re-evaluated from 65% (132/202) to 78% (156/201) after NGS analysis. In the prospective cohort, NGS detected not only germline and somatic mutations but also co-occurring variants and mosaicism. A mutation was identified in 74% of patients for whom both germline and tumour DNA were available. The analysis of 824 DNAs from patients with PPGL demonstrated that NGS assay significantly improves the performances of PPGL genetic testing compared with conventional methods, increasing the rate of identified mutations and identifying rare genetic mechanisms.","Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Institut de Biochimie & Biologie Moléculaire, CHU Lille, F-59037 Lille, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;Centerfor Rare Adrenal Diseases, Endocrinology Department, CochinHospital, Assistance Publique Hôpitaux de Paris, F-75014, Paris, France.;CNRS (UMR8104)/Inserm (U1016), Cochin Institute, Paris Descartes University, F-75014, Paris, France.;L'institut du thorax, Department of Endocrinology, Centre Hospitalier Universitaire Nantes, F-44000 Nantes, France.;Service d'Endocrinologie-Diabétologie-Nutrition, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Rennes, France.;Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Gustave Roussy, Villejuif, Île-de-France, France.;INSERMUMR 1185, Université Paris Sud, F-94276, Le Kremlin-Bicêtre, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University Cancer Institute, F-75013, Paris, France.;Medical Genetics Department, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France.;Service de Médecine Interne, Endocrinologie, Nutrition, CHU de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Endocrinology Department, Centre Hospitalier Universitaire d'Angers, Angers, France.;Medical Oncogenetics, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service d'Endocrinologie, CHU Lille, Lille, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.","NA",0,"1468-6244","J Med Genet","J Med Genet",2018,"2019","56","10.1136/jmedgenet-2018-105714","513-520","","","30877234","30877234","PUBMED","Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Institut de Biochimie & Biologie Moléculaire, CHU Lille, F-59037 Lille, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Hypertension Unit, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;Centerfor Rare Adrenal Diseases, Endocrinology Department, CochinHospital, Assistance Publique Hôpitaux de Paris, F-75014, Paris, France.;CNRS (UMR8104)/Inserm (U1016), Cochin Institute, Paris Descartes University, F-75014, Paris, France.;L'institut du thorax, Department of Endocrinology, Centre Hospitalier Universitaire Nantes, F-44000 Nantes, France.;Service d'Endocrinologie-Diabétologie-Nutrition, Centre Hospitalier Universitaire de Rennes, Hôpital Sud, Rennes, France.;Service de Médecine Nucléaire et de Cancérologie Endocrinienne, Gustave Roussy, Villejuif, Île-de-France, France.;INSERMUMR 1185, Université Paris Sud, F-94276, Le Kremlin-Bicêtre, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University Cancer Institute, F-75013, Paris, France.;Medical Genetics Department, Centre Hospitalier Regional Universitaire de Montpellier, Montpellier, Languedoc-Roussillon, France.;Service de Médecine Interne, Endocrinologie, Nutrition, CHU de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.;Endocrinology Department, Centre Hospitalier Universitaire d'Angers, Angers, France.;Medical Oncogenetics, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service d'Endocrinologie, CHU Lille, Lille, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France.;Genetics department, Assistance Publique-Hôpitaux de Paris, Hôpitaleuropéen Georges Pompidou, F-75015, Paris, France.;Faculté de Médecine, Paris Descartes University, PRES Sorbonne ParisCité, F-75006 Paris, France.;UMR970, Paris-Cardiovascular research Center, INSERM, F-75015, Paris, France."
"479","Quillien V;Carpentier AF;Gey A;Avril T;Tartour E;Sejalon F;Campillo-Gimenez B;Vauleon E","Quillien, Véronique;Carpentier, Antoine F;Gey, Alain;Avril, Tony;Tartour, Eric;Sejalon, Floraly;Campillo-Gimenez, Boris;Vauleon, Elodie","Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.","Cancer immunology, immunotherapy : CII","Germany","eng","Clinical Trial","Bevacizumab;Biomarker;Glioblastoma;Neutrophils;Regulatory T cells","Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Immunological;Bevacizumab;Brain Neoplasms;Female;Glioblastoma;Humans;Kaplan-Meier Estimate;Leukocyte Count;Male;Middle Aged;Neoplasm Recurrence, Local;Neutrophils;Prospective Studies;T-Lymphocytes, Regulatory","Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Immunological;Bevacizumab;Brain Neoplasms;Female;Glioblastoma;Humans;Kaplan-Meier Estimate;Leukocyte Count;Male;Middle Aged;Neoplasm Recurrence, Local;Neutrophils;Prospective Studies;T-Lymphocytes, Regulatory","Bevacizumab (Bv) remains frequently prescribed in glioblastoma (GBM) patients, especially at recurrence. We conducted a prospective clinical trial with 29 recurrent GBM patients treated with Bv alone with a longitudinal follow-up of different circulating immune cells [complete blood count, myeloid-derived suppressor cells (MDSCs), classical, intermediate, non-classical and Tie2 monocytes, VEGFR1+ and regulatory T cells (Treg)]. We observed a significant increase for leucocytes, neutrophils, eosinophils and classical monocytes and a decrease for the fraction of Treg during the treatment. The best prognostic values for survival under Bv were obtained for basal neutrophils and Treg. Counts below 3.9 G/L for neutrophils and above 0.011 G/L for Treg were associated with an overall survival of 17.5 and 19.9 months, respectively, as compared with 5.4 and 5.6 months, respectively, for counts above and below these cutoffs (p = 0.004 and p < 0.001). No prognostic impact was observed for neutrophils in a retrospective cohort of 26 patients treated with nitrosoureas alone. In another retrospective validation cohort of 61 GBM patients treated at recurrence with a Bv-containing regimen, an interaction was observed between neutrophils and corticosteroid intake. The predictive value of neutrophils on survival under Bv was lost in patients treated with corticosteroids, when steroid-free patients with a low neutrophil count had a particularly long median survival of 3.4 years. These two simply accessible criteria (basal neutrophils and steroid intake) could be used to reserve this relatively costly treatment for patients likely to be the most responsive to Bv and prevent unnecessary side effects in others.","Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes;Hôpital Saint-Louis, AP-HP, Paris, France.;Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.;INSERM U970, Universite Paris Descartes, Paris, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes, France.;Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.;INSERM U970, Universite Paris Descartes, Paris, France.;Hôpital Saint-Louis, AP-HP, Paris, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;INSERM U1099, Université de Rennes 1, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes, France.","NA",0,"1432-0851","Cancer Immunol Immunother","Cancer Immunol Immunother",2018,"2019","68","10.1007/s00262-019-02317-9","871-882","angiogenesis and tumour grant","Roche","30830269","30830269","PUBMED","Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes;Hôpital Saint-Louis, AP-HP, Paris, France.;Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.;INSERM U970, Universite Paris Descartes, Paris, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes, France.;Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France.;INSERM U970, Universite Paris Descartes, Paris, France.;Hôpital Saint-Louis, AP-HP, Paris, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;INSERM U1099, Université de Rennes 1, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.;Chemistry Oncogenesis Stress Signaling Laboratory, INSERM U1242, Université de Rennes 1, Rennes, France."
"480","Pérol D;Robain M;Arveux P;Mathoulin-Pélissier S;Chamorey E;Asselain B;Berchery D;Gourgou S;Breton M;Delaine-Clisant S;Mons M;Diéras V;Carton M;Guizard AV;Laborde L;Laurent C;Loeb A;Mouret-Reynier MA;Parent D;Perrocheau G;Campion L;Velten M;Cailliot C;Ezzalfani M;Simon G","Pérol, David;Robain, Mathieu;Arveux, Patrick;Mathoulin-Pélissier, Simone;Chamorey, Emmanuel;Asselain, Bernard;Berchery, Delphine;Gourgou, Sophie;Breton, Mathias;Delaine-Clisant, Stéphanie;Mons, Muriel;Diéras, Véronique;Carton, Matthieu;Guizard, Anne-Valérie;Laborde, Lilian;Laurent, Carine;Loeb, Agnès;Mouret-Reynier, Marie-Ange;Parent, Damien;Perrocheau, Geneviève;Campion, Loïc;Velten, Michel;Cailliot, Christian;Ezzalfani, Monia;Simon, Gaëtane","The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).","BMJ open","England","eng","Journal Article","data platform;epidemiology;metastatic breast cancer;patient medical record;quality control;real-world data","Aged;Breast Neoplasms;Disease Progression;Female;France;Humans;Longitudinal Studies;Middle Aged;Neoplasm Metastasis;Registries;Research Design;Retrospective Studies","Aged;Breast Neoplasms;Disease Progression;Female;France;Humans;Longitudinal Studies;Middle Aged;Neoplasm Metastasis;Registries;Research Design;Retrospective Studies","The currently ongoing Epidemiological Strategy and Medical Economics (ESME) research programme aims at centralising real-life data on oncology care for epidemiological research purposes. We draw on results from the metastatic breast cancer (MBC) cohort to illustrate the methodology used for data collection in the ESME research programme. All consecutive ≥18 years patients with MBC treatment initiated between 2008 and 2014 in one of the 18 French Comprehensive Cancer Centres were selected. Diagnostic, therapeutic and follow-up data (demographics, primary tumour, metastatic disease, treatment patterns and vital status) were collected through the course of the disease. Data collection is updated annually. With a recruitment target of 30 000 patients with MBC by 2019, we currently screened a total of 45 329 patients, and >16 700 patients with a metastatic disease treatment initiated after 2008 have been selected. 20.7% of patients had an hormone receptor (HR)-negative MBC, 73.7% had a HER2-negative MBC and 13.9% were classified as triple-negative BC (ie, HER2 and HR status both negative). Median follow-up duration from MBC diagnosis was 48.55 months for the whole cohort. These real-world data will help standardise the management of MBC and improve patient care. A dozen of ancillary research projects have been conducted and some of them are already accepted for publication or ready to be issued. The ESME research programme is expanding to ovarian cancer and advanced/metastatic lung cancer. Our ultimate goal is to achieve a continuous link to the data of the cohort to the French national Health Data System for centralising data on healthcare reimbursement (drugs, medical procedures), inpatient/outpatient stays and visits in primary/secondary care settings. NCT03275311; Pre-results.","Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;R&D UNICANCER, Paris, France.;Registre des cancers du sein de Côte d'Or, centre Georges-François-Leclerc, Dijon, France.;Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Centre Antoine-Lacassagne, Nice, France.;University Paris Sud, Paris, France.;Institut Claudius Regaud, Toulouse, France.;Institut régional du Cancer Montpellier, Montpellier, France.;Centre Eugene Marquis, Rennes, France.;Clinical Research Unit, Centre Oscar Lambret, Lille, France.;Gustave Roussy, Villejuif, France.;Ensemble Hospitalier de l'Institut Curie, Paris & Saint-Cloud, France.;Ensemble Hospitalier de l'Institut Curie, Paris & Saint-Cloud, France.;Centre François Baclesse, Caen, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancerologie de Lorraine, Vandoeuvre-les-Nancy, France.;Centre Henri Becquerel, Rouen, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut Jean Godinot, Reims, France.;Institut de Cancérologie de l'Ouest, Nantes & Angers, France.;Institut de Cancérologie de l'Ouest, Nantes & Angers, France.;Centre Paul Strauss, Strasbourg, France.;R&D UNICANCER, Paris, France.;Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;R&D UNICANCER, Paris, France.","NA",0,"2044-6055","BMJ Open","BMJ Open",2019,"2019","9","10.1136/bmjopen-2018-023568","e023568","","","30796119","30796119","PUBMED","Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;R&D UNICANCER, Paris, France.;Registre des cancers du sein de Côte d'Or, centre Georges-François-Leclerc, Dijon, France.;Clinical and Epidemiological Research Unit, INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Center, Bordeaux, France.;Centre Antoine-Lacassagne, Nice, France.;University Paris Sud, Paris, France.;Institut Claudius Regaud, Toulouse, France.;Institut régional du Cancer Montpellier, Montpellier, France.;Centre Eugene Marquis, Rennes, France.;Clinical Research Unit, Centre Oscar Lambret, Lille, France.;Gustave Roussy, Villejuif, France.;Ensemble Hospitalier de l'Institut Curie, Paris & Saint-Cloud, France.;Ensemble Hospitalier de l'Institut Curie, Paris & Saint-Cloud, France.;Centre François Baclesse, Caen, France.;Institut Paoli-Calmettes, Marseille, France.;Institut de Cancerologie de Lorraine, Vandoeuvre-les-Nancy, France.;Centre Henri Becquerel, Rouen, France.;Centre Jean Perrin, Clermont-Ferrand, France.;Institut Jean Godinot, Reims, France.;Institut de Cancérologie de l'Ouest, Nantes & Angers, France.;Institut de Cancérologie de l'Ouest, Nantes & Angers, France.;Centre Paul Strauss, Strasbourg, France.;R&D UNICANCER, Paris, France.;Biostatistic Unit, Clinical Research and Innovation Department, Centre Léon Bérard, Lyon, France.;R&D UNICANCER, Paris, France."
"481","Rugo HS;Finn RS;Diéras V;Ettl J;Lipatov O;Joy AA;Harbeck N;Castrellon A;Iyer S;Lu DR;Mori A;Gauthier ER;Bartlett CH;Gelmon KA;Slamon DJ","Rugo, H S;Finn, R S;Diéras, V;Ettl, J;Lipatov, O;Joy, A A;Harbeck, N;Castrellon, A;Iyer, S;Lu, D R;Mori, A;Gauthier, E R;Bartlett, C Huang;Gelmon, K A;Slamon, D J","Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.","Breast cancer research and treatment","Netherlands","eng","Clinical Trial, Phase III","Breast cancer;Cyclin-dependent kinase inhibitor;ER+;HER2−;Letrozole;Palbociclib","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Double-Blind Method;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen;Treatment Outcome","Antineoplastic Combined Chemotherapy Protocols;Breast Neoplasms;Double-Blind Method;Female;Humans;Letrozole;Piperazines;Postmenopause;Pyridines;Quality of Life;Receptor, ErbB-2;Receptors, Estrogen;Treatment Outcome","In the initial PALOMA-2 (NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. Herein, we report results overall and by subgroups with extended follow-up. In this double-blind, phase 3 study, post-menopausal women with ER+/HER2- ABC who had not received prior systemic therapy for their advanced disease were randomized 2:1 to palbociclib-letrozole or placebo-letrozole. Endpoints include investigator-assessed PFS (primary), safety, and patient-reported outcomes (PROs). After a median follow-up of approximately 38 months, median PFS was 27.6 months for palbociclib-letrozole (n = 444) and 14.5 months for placebo-letrozole (n = 222) (HR 0.563; 1-sided P < 0.0001). All subgroups benefited from palbociclib treatment. The improvement of PFS with palbociclib-letrozole was maintained in the next 2 subsequent lines of therapy and delayed the use of chemotherapy (40.4 vs. 29.9 months for palbociclib-letrozole vs. placebo-letrozole). Safety data were consistent with the known profile. Patients' quality of life was maintained. With approximately 15 months of additional follow-up, palbociclib plus letrozole continued to demonstrate improved PFS compared with placebo plus letrozole in the overall population and across all patient subgroups, while the safety profile remained favorable and quality of life was maintained. These data confirm that palbociclib-letrozole should be considered the standard of care for first-line therapy in patients with ER+/HER2- ABC, including those with low disease burden or long disease-free interval. Sponsored by Pfizer; ClinicalTrials.gov: NCT01740427.","Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Department of Medical Oncology, Institut Curie, Paris, France.;Centre Eugène Marquis, Rennes, France.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia.;Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.;Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany.;Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA.;Patient and Health Impact, Pfizer Inc, New York, NY, USA.;Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.;Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy.;Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA.;Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA.;Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.","NA",0,"1573-7217","Breast Cancer Res Treat","Breast Cancer Res Treat",2018,"2019","174","10.1007/s10549-018-05125-4","719-729","","","30632023","30632023","PUBMED","Department of Medicine (Hematology/Oncology), University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, 2nd Floor, San Francisco, CA, 94115;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA.;Department of Medical Oncology, Institut Curie, Paris, France.;Centre Eugène Marquis, Rennes, France.;Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universität München, Munich, Germany.;Republican Clinical Oncology Dispensary, State Budget Medical Institution, Ufa, Russia.;Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.;Department of Obstetrics and Gynecology, Brustzentrum der Universität München (LMU), Munich, Germany.;Breast Cancer Center, Memorial Cancer Institute, Hollywood, FL, USA.;Patient and Health Impact, Pfizer Inc, New York, NY, USA.;Clinical Statistics, Pfizer Inc, La Jolla, CA, USA.;Global Product Development, Clinical, Pfizer S.r.l, Milan, Italy.;Global Product Development, Clinical, Pfizer Inc, San Francisco, CA, USA.;Global Product Development, Clinical, Pfizer Inc, Collegeville, PA, USA.;Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.;Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, CA, USA."
"482","Poirier C;Lavenu A;Bertaud V;Campillo-Gimenez B;Chazard E;Cuggia M;Bouzillé G","Poirier, Canelle;Lavenu, Audrey;Bertaud, Valérie;Campillo-Gimenez, Boris;Chazard, Emmanuel;Cuggia, Marc;Bouzillé, Guillaume","Real Time Influenza Monitoring Using Hospital Big Data in Combination with Machine Learning Methods: Comparison Study.","JMIR public health and surveillance","Canada","eng","Journal Article","Sentinelles network;big data;electronic health records;influenza;infodemiology;infoveillance;machine learning","","","Traditional surveillance systems produce estimates of influenza-like illness (ILI) incidence rates, but with 1- to 3-week delay. Accurate real-time monitoring systems for influenza outbreaks could be useful for making public health decisions. Several studies have investigated the possibility of using internet users' activity data and different statistical models to predict influenza epidemics in near real time. However, very few studies have investigated hospital big data. Here, we compared internet and electronic health records (EHRs) data and different statistical models to identify the best approach (data type and statistical model) for ILI estimates in real time. We used Google data for internet data and the clinical data warehouse eHOP, which included all EHRs from Rennes University Hospital (France), for hospital data. We compared 3 statistical models-random forest, elastic net, and support vector machine (SVM). For national ILI incidence rate, the best correlation was 0.98 and the mean squared error (MSE) was 866 obtained with hospital data and the SVM model. For the Brittany region, the best correlation was 0.923 and MSE was 2364 obtained with hospital data and the SVM model. We found that EHR data together with historical epidemiological information (French Sentinelles network) allowed for accurately predicting ILI incidence rates for the entire France as well as for the Brittany region and outperformed the internet data whatever was the statistical model used. Moreover, the performance of the two statistical models, elastic net and SVM, was comparable.","Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre d'Investigation Clinique de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France.;INSERM, U1099, Rennes, France.;Comprehensive Cancer Regional Center, Eugene Marquis, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Université de Lille, Lille, France.;Public Health Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France.","NA",0,"2369-2960","JMIR Public Health Surveill","JMIR Public Health Surveill",2018,"2018","4","10.2196/11361","e11361","","","30578212","30578212","PUBMED","Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre d'Investigation Clinique de Rennes, Université de Rennes 1, Rennes, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France.;INSERM, U1099, Rennes, France.;Comprehensive Cancer Regional Center, Eugene Marquis, Rennes, France.;Centre d'Etudes et de Recherche en Informatique Médicale EA2694, Université de Lille, Lille, France.;Public Health Department, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France.;Laboratoire Traitement du Signal et de l'Image, Université de Rennes 1, Rennes, France.;INSERM, U1099, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Données Cliniques, Rennes, France."
"483","Fagherazzi G;El Fatouhi D;Fournier A;Gusto G;Mancini FR;Balkau B;Boutron-Ruault MC;Kurth T;Bonnet F","Fagherazzi, Guy;El Fatouhi, Douae;Fournier, Agnès;Gusto, Gaelle;Mancini, Francesca Romana;Balkau, Beverley;Boutron-Ruault, Marie-Christine;Kurth, Tobias;Bonnet, Fabrice","Associations Between Migraine and Type 2 Diabetes in Women: Findings From the E3N Cohort Study.","JAMA neurology","United States","eng","Journal Article","","Adult;Aged;Diabetes Mellitus, Type 2;Female;Humans;Incidence;Middle Aged;Migraine Disorders;Prevalence;Proportional Hazards Models;Prospective Studies;Risk Factors;Surveys and Questionnaires","Adult;Aged;Diabetes Mellitus, Type 2;Female;Humans;Incidence;Middle Aged;Migraine Disorders;Prevalence;Proportional Hazards Models;Prospective Studies;Risk Factors;Surveys and Questionnaires","Little is known about the associations between migraine and type 2 diabetes and the temporality of the association between these 2 diseases. To evaluate the association between migraine and type 2 diabetes incidence as well as the evolution of the prevalence of active migraine before and after type 2 diabetes diagnosis. We used data from the E3N cohort study, a French prospective population-based study initiated in 1990 on a cohort of women born between 1925 and 1950. The E3N study participants are insured by a health insurance plan that mostly covers teachers. From the eligible women in the E3N study, we included those who completed the 2002 follow-up questionnaire with information available on migraine. We then excluded prevalent cases of type 2 diabetes, leaving a final sample of women who were followed up between 2004 and 2014. All potential occurrences of type 2 diabetes were identified through a drug reimbursement database. Statistical analyses were performed in March 2018. Self-reported migraine occurrence. Pharmacologically treated type 2 diabetes. From the 98 995 women in the study, 76 403 women completed the 2002 follow-up survey. Of these, 2156 were excluded because they had type 2 diabetes, leaving 74 247 women. Participants had a mean (SD) age of 61 (6) years at baseline, and all were free of type 2 diabetes. During 10 years of follow-up, 2372 incident type 2 diabetes cases occurred. A lower risk of type 2 diabetes was observed for women with active migraine compared with women with no migraine history (univariate hazard ratio, 0.80 [95% CI, 0.67-0.96], multivariable-adjusted hazard ratio, 0.70 [95% CI, 0.58-0.85]). We also observed a linear decrease in active migraine prevalence from 22% (95% CI, 16%-27%) to 11% (95% CI, 10%-12%) during the 24 years prior to diabetes diagnosis, after adjustment for potential type 2 diabetes risk factors. A plateau of migraine prevalence around 11% was then observed for 22 years after diagnosis. We observed a lower risk of developing type 2 diabetes for women with active migraine and a decrease in active migraine prevalence prior to diabetes diagnosis. Further targeted research should focus on understanding the mechanisms involved in explaining these findings.","Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Versailles Saint Quentin University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Institute of Public Health Charité-Universitätsmedizin Berlin, Berlin, Germany.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.","NA",0,"2168-6157","JAMA Neurol","JAMA Neurol",2018,"2019","76","10.1001/jamaneurol.2018.3960","257-263","","","30556831","30556831","PUBMED","Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM), Versailles Saint Quentin University, Villejuif, France.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Institute of Public Health Charité-Universitätsmedizin Berlin, Berlin, Germany.;Center for Research in Epidemiology and Population Health, UMR 1018, Institut National de la Santé et de la Recherche Médicale (INSERM) U1018, Paris-South Paris Saclay University, Gustave Roussy Institute, Villejuif, France.;Paris-South Paris Saclay University, Villejuif, France.;Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France."
"484","Liang X;Briaux A;Becette V;Benoist C;Boulai A;Chemlali W;Schnitzler A;Baulande S;Rivera S;Mouret-Reynier MA;Bouvet LV;De La Motte Rouge T;Lemonnier J;Lerebours F;Callens C","Liang, Xu;Briaux, Adrien;Becette, Véronique;Benoist, Camille;Boulai, Anais;Chemlali, Walid;Schnitzler, Anne;Baulande, Sylvain;Rivera, Sofia;Mouret-Reynier, Marie-Ange;Bouvet, Laurence Venat;De La Motte Rouge, Thibaut;Lemonnier, Jérôme;Lerebours, Florence;Callens, Céline","Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609).","Journal of hematology & oncology","England","eng","Clinical Trial, Phase II","Breast cancer;Endocrine therapy;Immunity;Lipid metabolism;RNA sequencing;Somatic mutation;TILs;Targeted NGS","Aged;Anastrozole;Antineoplastic Agents, Hormonal;Breast Neoplasms;DNA, Neoplasm;Female;Fulvestrant;Gene Expression Profiling;Humans;Lymphocytes, Tumor-Infiltrating;Neoadjuvant Therapy;Postmenopause;Prognosis;RNA, Neoplasm;Th1 Cells","Aged;Anastrozole;Antineoplastic Agents, Hormonal;Breast Neoplasms;DNA, Neoplasm;Female;Fulvestrant;Gene Expression Profiling;Humans;Lymphocytes, Tumor-Infiltrating;Neoadjuvant Therapy;Postmenopause;Prognosis;RNA, Neoplasm;Th1 Cells","Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis. Gene expression profiling using RNA sequencing was performed in 86 pre-NET and post-NET tumor samples. Targeted next-generation sequencing of 91 candidate breast cancer-associated genes was performed on DNA samples from 89 patients. Molecular data were correlated with radiological response and relapse-free survival. The transcriptional profile of tumors to NET in responders involved immune-associated genes enriched in activated Th1 pathway, which remained unchanged in non-responders. Immune response was confirmed by analysis of tumor-infiltrating lymphocytes (TILs). The percentage of TILs was significantly increased post-NET compared to pre-NET samples in responders (p = 0.0071), but not in non-responders (p = 0.0938). Gene expression revealed that lipid metabolism was the main molecular function related to prognosis, while PPARγ is the most important upstream regulator gene. The most frequently mutated genes were PIK3CA (48.3%), CDH1 (20.2%), PTEN (15.7%), TP53 (10.1%), LAMA2 (10.1%), BRCA2 (9.0%), MAP3K1 (7.9%), ALK (6.7%), INPP4B (6.7%), NCOR1 (6.7%), and NF1 (5.6%). Cell cycle and apoptosis pathway and PIK3CA/AKT/mTOR pathway were altered significantly more frequently in non-responders than in responders (p = 0.0017 and p = 0.0094, respectively). The average number of mutations per sample was significantly higher in endocrine-resistant tumors (2.88 vs. 1.64, p = 0.03), but no difference was observed in terms of prognosis. ESR1 hotspot mutations were detected in 3.4% of treatment-naive tumors. The Th1-related immune system and lipid metabolism appear to play key roles in the response to endocrine therapy and prognosis in HR-positive/HER2-negative breast cancer. Deleterious somatic mutations in the cell cycle and apoptosis pathway and PIK3CA/AKT/mTOR pathway may be relevant for clinical management. This trial is registered with ClinicalTrials.gov ( NCT00629616 ) on March 6, 2008, retrospectively registered.","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Department of Biopathology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Institut Curie Genomics of Excellence (ICGex) Platform, Curie Institute, PSL Research University, Paris, France.;Department of Radiotherapy, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, CHU, Limoges, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;R&D Unicancer, UCBG, Paris, France.;Department of Medical Oncology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris","NA",0,"1756-8722","J Hematol Oncol","J Hematol Oncol",2018,"2018","11","10.1186/s13045-018-0670-9","124","","","30305115","30305115","PUBMED","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Department of Biopathology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris, France.;Institut Curie Genomics of Excellence (ICGex) Platform, Curie Institute, PSL Research University, Paris, France.;Department of Radiotherapy, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, CHU, Limoges, France.;Department of Medical Oncology, Centre Eugene Marquis, Rennes, France.;R&D Unicancer, UCBG, Paris, France.;Department of Medical Oncology, Curie Institute, René Huguenin Hospital, Saint-Cloud, France.;Pharmacogenomic Unit, Department of Genetics, Curie Institute, PSL Research University, Paris"
"485","Lancellotti P;Magne J;Dulgheru R;Clavel MA;Donal E;Vannan MA;Chambers J;Rosenhek R;Habib G;Lloyd G;Nistri S;Garbi M;Marchetta S;Fattouch K;Coisne A;Montaigne D;Modine T;Davin L;Gach O;Radermecker M;Liu S;Gillam L;Rossi A;Galli E;Ilardi F;Tastet L;Capoulade R;Zilberszac R;Vollema EM;Delgado V;Cosyns B;Lafitte S;Bernard A;Pierard LA;Bax JJ;Pibarot P;Oury C","Lancellotti, Patrizio;Magne, Julien;Dulgheru, Raluca;Clavel, Marie-Annick;Donal, Erwan;Vannan, Mani A;Chambers, John;Rosenhek, Raphael;Habib, Gilbert;Lloyd, Guy;Nistri, Stefano;Garbi, Madalina;Marchetta, Stella;Fattouch, Khalil;Coisne, Augustin;Montaigne, David;Modine, Thomas;Davin, Laurent;Gach, Olivier;Radermecker, Marc;Liu, Shizhen;Gillam, Linda;Rossi, Andrea;Galli, Elena;Ilardi, Federica;Tastet, Lionel;Capoulade, Romain;Zilberszac, Robert;Vollema, E Mara;Delgado, Victoria;Cosyns, Bernard;Lafitte, Stephane;Bernard, Anne;Pierard, Luc A;Bax, Jeroen J;Pibarot, Philippe;Oury, Cécile","Outcomes of Patients With Asymptomatic Aortic Stenosis Followed Up in Heart Valve Clinics.","JAMA cardiology","United States","eng","Journal Article","","Aged;Aged, 80 and over;Aortic Valve Stenosis;Asymptomatic Diseases;Canada;Death, Sudden, Cardiac;Disease Management;Disease-Free Survival;Europe;Female;Humans;Male;Middle Aged;Prospective Studies;Registries;Retrospective Studies;United States;Watchful Waiting","Aged;Aged, 80 and over;Aortic Valve Stenosis;Asymptomatic Diseases;Canada;Death, Sudden, Cardiac;Disease Management;Disease-Free Survival;Europe;Female;Humans;Male;Middle Aged;Prospective Studies;Registries;Retrospective Studies;United States;Watchful Waiting","The natural history and the management of patients with asymptomatic aortic stenosis (AS) have not been fully examined in the current era. To determine the clinical outcomes of patients with asymptomatic AS using data from the Heart Valve Clinic International Database. This registry was assembled by merging data from prospectively gathered institutional databases from 10 heart valve clinics in Europe, Canada, and the United States. Asymptomatic patients with an aortic valve area of 1.5 cm2 or less and preserved left ventricular ejection fraction (LVEF) greater than 50% at entry were considered for the present analysis. Data were collected from January 2001 to December 2014, and data were analyzed from January 2017 to July 2018. Natural history, need for aortic valve replacement (AVR), and survival of asymptomatic patients with moderate or severe AS at entry followed up in a heart valve clinic. Indications for AVR were based on current guideline recommendations. Of the 1375 patients included in this analysis, 834 (60.7%) were male, and the mean (SD) age was 71 (13) years. A total of 861 patients (62.6%) had severe AS (aortic valve area less than 1.0 cm2). The mean (SD) overall survival during medical management (mean [SD] follow up, 27 [24] months) was 93% (1%), 86% (2%), and 75% (4%) at 2, 4, and 8 years, respectively. A total of 104 patients (7.6%) died under observation, including 57 patients (54.8%) from cardiovascular causes. The crude rate of sudden death was 0.65% over the duration of the study. A total of 542 patients (39.4%) underwent AVR, including 388 patients (71.6%) with severe AS at study entry and 154 (28.4%) with moderate AS at entry who progressed to severe AS. Those with severe AS at entry who underwent AVR did so at a mean (SD) of 14.4 (16.6) months and a median of 8.7 months. The mean (SD) 2-year and 4-year AVR-free survival rates for asymptomatic patients with severe AS at baseline were 54% (2%) and 32% (3%), respectively. In those undergoing AVR, the 30-day postprocedural mortality was 0.9%. In patients with severe AS at entry, peak aortic jet velocity (greater than 5 m/s) and LVEF (less than 60%) were associated with all-cause and cardiovascular mortality without AVR; these factors were also associated with postprocedural mortality in those patients with severe AS at baseline who underwent AVR (surgical AVR in 310 patients; transcatheter AVR in 78 patients). In patients with asymptomatic AS followed up in heart valve centers, the risk of sudden death is low, and rates of overall survival are similar to those reported from previous series. Patients with severe AS at baseline and peak aortic jet velocity of 5.0 m/s or greater or LVEF less than 60% have increased risks of all-cause and cardiovascular mortality even after AVR. The potential benefit of early intervention should be considered in these high-risk patients.","GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.;Cardiology Department, Centre Hospitalier Universitaire de Limoges, Hôpital Dupuytren, Pôle Coeur-Poumon-Rein, Limoges, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Cardiologie and LTSI INSERM U 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, Georgia.;Guy's and St Thomas Hospitals, London, United Kingdom.;Department of Cardiology, Medical University of Vienna, Vienna, Austria.;Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Marseille, France.;Assistance Publique-Hopitaux Marseille, La Timone Hospital, Cardiology Department, Marseille, France.;Barts Heart Centre Echo Lab, St Bartholomew's Hospital, London, United Kingdom.;Cardiology Service, CMSR Veneto Medica, Altavilla Vicentina, Italy.;King's Health Partners, King's College Hospital NHS Foundation Trust, London, United Kingdom.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Department of Cardiovascular Surgery, GVM Care and Research, Maria Eleonora Hospital, Palermo, Italy.;Department of Surgery and Cancer, University of Palermo, Palermo, Italy.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, Georgia.;Morristown Medical Center, Morristown, New Jersey.;Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy.;Cardiologie and LTSI INSERM U 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Department of Cardiology, Medical University of Vienna, Vienna, Austria.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Centrum voor Hart en Vaatziekten, Universitair Ziekenhuis Brussel and In Vivo Cellular and Molecular Imaging Laboratory, Brussels, Belgium.;Centre Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique Haut-Lévêque, Pessac, France.;Cardiology Department, University of Tours Hospital, Tours, France.;University François Rabelais, Tours, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.","NA",0,"2380-6591","JAMA Cardiol","JAMA Cardiol",2018,"2018","3","10.1001/jamacardio.2018.3152","1060-1068","","","30285058","30285058","PUBMED","GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.;Cardiology Department, Centre Hospitalier Universitaire de Limoges, Hôpital Dupuytren, Pôle Coeur-Poumon-Rein, Limoges, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Cardiologie and LTSI INSERM U 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, Georgia.;Guy's and St Thomas Hospitals, London, United Kingdom.;Department of Cardiology, Medical University of Vienna, Vienna, Austria.;Aix-Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Marseille, France.;Assistance Publique-Hopitaux Marseille, La Timone Hospital, Cardiology Department, Marseille, France.;Barts Heart Centre Echo Lab, St Bartholomew's Hospital, London, United Kingdom.;Cardiology Service, CMSR Veneto Medica, Altavilla Vicentina, Italy.;King's Health Partners, King's College Hospital NHS Foundation Trust, London, United Kingdom.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Department of Cardiovascular Surgery, GVM Care and Research, Maria Eleonora Hospital, Palermo, Italy.;Department of Surgery and Cancer, University of Palermo, Palermo, Italy.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;Centre Hospitalier Universitaire de Lille, Departments of Clinical Physiology and Echocardiography and Cardiovascular Surgery, Lille, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, Georgia.;Morristown Medical Center, Morristown, New Jersey.;Section of Cardiology, Department of Medicine, University of Verona, Verona, Italy.;Cardiologie and LTSI INSERM U 1099, Centre Hospitalier Universitaire de Rennes, Université de Rennes 1, Rennes, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;Department of Cardiology, Medical University of Vienna, Vienna, Austria.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Centrum voor Hart en Vaatziekten, Universitair Ziekenhuis Brussel and In Vivo Cellular and Molecular Imaging Laboratory, Brussels, Belgium.;Centre Hospitalier Universitaire de Bordeaux, Hôpital Cardiologique Haut-Lévêque, Pessac, France.;Cardiology Department, University of Tours Hospital, Tours, France.;University François Rabelais, Tours, France.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium.;Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.;Québec Heart and Lung Institute, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Québec, Canada.;GIGA Cardiovascular Sciences, Department of Cardiology, Heart Valve Clinic, University of Liège Hospital, Centre Hospitalier Universitaire du Sart Tilman, Liège, Belgium."
"486","Chauhan N;Bukovcan J;Boucher E;Cosgrove D;Edeline J;Hamilton B;Kulik L;Master F;Salem R","Chauhan, Nikhil;Bukovcan, Janet;Boucher, Eveline;Cosgrove, David;Edeline, Julien;Hamilton, Bonnie;Kulik, Laura;Master, Fayaz;Salem, Riad","Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.","JMIR research protocols","Canada","eng","Journal Article","carcinoma, hepatocellular;clinical trial, phase III;hepatocellular carcinoma;microspheres;randomized controlled trial;research design;sorafenib;yttrium radioisotopes","","","Globally, hepatocellular carcinoma is the second most common cause of cancer deaths. It remains challenging to intensify cancer treatment without impairing liver function. The objective of the TheraSphere in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (STOP-HCC) study is to examine the hypothesis that transarterial radioembolization (TheraSphere yttrium-90 glass microspheres) combined with standard first-line treatment with sorafenib will improve outcomes over treatment with sorafenib alone in unresectable hepatocellular carcinoma. The STOP-HCC study is the largest international, multicenter, prospective study of intra-arterial treatment in combination with sorafenib in unresectable hepatocellular carcinoma. Here we report the study design. STOP-HCC is a prospective, phase 3, open-label, randomized controlled study conducted across up to 105 sites in North America, Europe, and Asia. Eligible adults have unresectable hepatocellular carcinoma and a life expectancy of at least 12 weeks, 1 or more unidimensional measurable lesions, Child-Pugh score 7 points or less, and Eastern Cooperative Oncology Group Performance Status score 1 or lower, and are candidates for treatment with sorafenib. Presence of branch portal vein tumor thrombosis is permitted. Patients were randomly assigned in a 1:1 ratio to receive either sorafenib alone or transarterial radioembolization followed by sorafenib within 2 to 6 weeks. The primary outcome is overall survival. Secondary outcomes are time to progression, time to untreatable progression, time to symptomatic progression, tumor response, quality of life, and adverse event occurrence. The study is an adaptive trial, comprising a group-sequential design with 2 interim analyses with 520 patients, and an option to increase the sample size to 700 patients at the second interim analysis. The sample size of 520 patients allows for 417 deaths to give 80% power to detect an increase in median overall survival from 10.7 months for the sorafenib group (based on the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol [SHARP] trial) to 14.2 months for the transarterial radioembolization+sorafenib group (hazard ratio 0.754) with 2-sided alpha of .05. The increased sample size of 700 patients allows for 564 deaths to give 80% power to detect a smaller difference in median overall survival from 10.7 months for the sorafenib group to 13.7 months for the transarterial radioembolization+sorafenib group (hazard ratio 0.781). Enrollment for the study completed in September 2017. Results of the first and second interim analyses were reviewed by the Independent Data Monitoring Committee. The recommendation of the committee, at both interim analyses, was to continue the study without any changes. The STOP-HCC study will contribute toward the establishment of the role of combination therapy with transarterial radioembolization and sorafenib in the treatment of unresectable hepatocellular carcinoma with and without branch portal vein tumor thrombosis. ClinicalTrials.gov NCT01556490; https://clinicaltrials.gov/ct2/show/NCT01556490 (Archived by WebCite at http://www.webcitation.org/7188iygKs). RR1-10.2196/11234.","Research and Development, BTG International Group Companies, London, United Kingdom.;Research and Development, BTG International Group Companies, London, United Kingdom.;Research and Development, BTG International Group Companies, London, United Kingdom.;Division of Medical Oncology, Compass Oncology, Vancouver Cancer Center, Vancouver, WA, United States.;Department of Oncology, Centre Eugene Marquis, Rennes, France.;Research and Development, BTG International Group Companies, London, United Kingdom.;Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern Memorial Hospital, Chicago, IL, United States.;Research and Development, BTG International Group Companies, London, United Kingdom.;Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, IL, United States.;Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, IL, United States.;Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, IL, United States.","NA",0,"1929-0748","JMIR Res Protoc","JMIR Res Protoc",2018,"2018","7","10.2196/11234","e11234","","","30111528","30111528","PUBMED","Research and Development, BTG International Group Companies, London, United Kingdom.;Research and Development, BTG International Group Companies, London, United Kingdom.;Research and Development, BTG International Group Companies, London, United Kingdom.;Division of Medical Oncology, Compass Oncology, Vancouver Cancer Center, Vancouver, WA, United States.;Department of Oncology, Centre Eugene Marquis, Rennes, France.;Research and Development, BTG International Group Companies, London, United Kingdom.;Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern Memorial Hospital, Chicago, IL, United States.;Research and Development, BTG International Group Companies, London, United Kingdom.;Section of Interventional Radiology, Department of Radiology, Northwestern University, Chicago, IL, United States.;Division of Hematology and Oncology, Department of Medicine, Northwestern University, Chicago, IL, United States.;Division of Transplant Surgery, Department of Surgery, Northwestern University, Chicago, IL, United States."
"487","Jaksic N;Chajon E;Bellec J;Corre R;Ricordel C;de Latour B;Lena H;Schick U;de Crevoisier R;Castelli J","Jaksic, Nicolas;Chajon, Enrique;Bellec, Julien;Corre, Romain;Ricordel, Charles;de Latour, Bertrand;Lena, Hervé;Schick, Ulrike;de Crevoisier, Renaud;Castelli, Joël","Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.","Radiation oncology (London, England)","England","eng","Evaluation Study","Acceleration;IMRT;NSCLC;Radiotherapy;SMART","Aged;Carcinoma, Non-Small-Cell Lung;Esophagitis;Esophagus;Female;Humans;Lung;Lung Neoplasms;Male;Positron Emission Tomography Computed Tomography;Quality Improvement;Radiation Dose Hypofractionation;Radiation Injuries;Radiation Pneumonitis;Radiotherapy, Intensity-Modulated;Retrospective Studies;Treatment Outcome","Aged;Carcinoma, Non-Small-Cell Lung;Esophagitis;Esophagus;Female;Humans;Lung;Lung Neoplasms;Male;Positron Emission Tomography Computed Tomography;Quality Improvement;Radiation Dose Hypofractionation;Radiation Injuries;Radiation Pneumonitis;Radiotherapy, Intensity-Modulated;Retrospective Studies;Treatment Outcome","We aimed to evaluate the toxicity, loco-regional control (LRC) and overall survival (OS) associated with accelerated intensity-modulated radiotherapy (IMRT) for locally advanced lung cancer. Seventy-three patients were consecutively treated with IMRT from November 2011 to August 2016. A total dose of 66 Gy was delivered using two different schedules of radiotherapy: simultaneous modulated accelerated radiotherapy (SMART) (30 × 2.2 Gy, across 6 weeks) with or without chemotherapy, or moderate hypofractionated radiotherapy (HRT) (24 × 2.75 Gy, across 4 weeks) in patients unfit to receive concomitant chemotherapy. Data on esophageal and pulmonary toxicities, LRC and OS were prospectively collected. The median follow-up duration was 44 months. Severe pneumonitis and esophagitis (grade 3-4) were observed in 7% and 1% of patients respectively, with only one case of grade 4 (pneumonitis). Overall, the 1-year and 2-year LRCs were 76% [95 confidence interval (CI)%: 66-87%] and 62% [95 CI%: 49-77%] respectively. The 1 and 2-year OS rates were 72% [95% CI: 63-83%] and 54% [95 CI%: 43-68%] respectively. None parameters were correlated with LRC or OS. In particular, no difference was observed between patients treated with SMART and H-RT (p = 0.26 and 0.6 respectively), with a 1-year LRC of 74% [95 CI%: 62-86%] for SMART and 91% [95 CI%: 74-100%] for H-RT. No significant differences were observed in the toxicity rates associated with each of the RT schedules. Accelerated IMRT for locally advanced lung cancer is associated with low toxicities and high LRC. Moderate hypofractionated RT, by decreasing the total treatment time, may be promising in improving clinical outcomes.","Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes;Université de Rennes 1, Rennes;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Service de chirurgie thoracique, Clinique Saint Laurent, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Département de Radiothérapie, CHRU Brest, Brest, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Université de Rennes 1, Rennes, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Université de Rennes 1, Rennes, France.","NA",0,"1748-717X","Radiat Oncol","Radiat Oncol",2018,"2018","13","10.1186/s13014-018-1094-y","147","","","30103774","30103774","PUBMED","Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes;Université de Rennes 1, Rennes;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Service de chirurgie thoracique, Clinique Saint Laurent, Rennes, France.;Service de pneumologie CHU Pontchaillou, Rennes, France.;Département de Radiothérapie, CHRU Brest, Brest, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Université de Rennes 1, Rennes, France.;Département de Radiothérapie, Centre Eugène Marquis, Rue de la Bataille Flandres Dunkerque, Rennes, France.;Université de Rennes 1, Rennes, France."
"488","Baldassari S;Picard F;Verbeek NE;van Kempen M;Brilstra EH;Lesca G;Conti V;Guerrini R;Bisulli F;Licchetta L;Pippucci T;Tinuper P;Hirsch E;de Saint Martin A;Chelly J;Rudolf G;Chipaux M;Ferrand-Sorbets S;Dorfmüller G;Sisodiya S;Balestrini S;Schoeler N;Hernandez-Hernandez L;Krithika S;Oegema R;Hagebeuk E;Gunning B;Deckers C;Berghuis B;Wegner I;Niks E;Jansen FE;Braun K;de Jong D;Rubboli G;Talvik I;Sander V;Uldall P;Jacquemont ML;Nava C;Leguern E;Julia S;Gambardella A;d'Orsi G;Crichiutti G;Faivre L;Darmency V;Benova B;Krsek P;Biraben A;Lebre AS;Jennesson M;Sattar S;Marchal C;Nordli DR;Lindstrom K;Striano P;Lomax LB;Kiss C;Bartolomei F;Lepine AF;Schoonjans AS;Stouffs K;Jansen A;Panagiotakaki E;Ricard-Mousnier B;Thevenon J;de Bellescize J;Catenoix H;Dorn T;Zenker M;Müller-Schlüter K;Brandt C;Krey I;Polster T;Wolff M;Balci M;Rostasy K;Achaz G;Zacher P;Becher T;Cloppenborg T;Yuskaitis CJ;Weckhuysen S;Poduri A;Lemke JR;Møller RS;Baulac S","Baldassari, Sara;Picard, Fabienne;Verbeek, Nienke E;van Kempen, Marjan;Brilstra, Eva H;Lesca, Gaetan;Conti, Valerio;Guerrini, Renzo;Bisulli, Francesca;Licchetta, Laura;Pippucci, Tommaso;Tinuper, Paolo;Hirsch, Edouard;de Saint Martin, Anne;Chelly, Jamel;Rudolf, Gabrielle;Chipaux, Mathilde;Ferrand-Sorbets, Sarah;Dorfmüller, Georg;Sisodiya, Sanjay;Balestrini, Simona;Schoeler, Natasha;Hernandez-Hernandez, Laura;Krithika, S;Oegema, Renske;Hagebeuk, Eveline;Gunning, Boudewijn;Deckers, Charles;Berghuis, Bianca;Wegner, Ilse;Niks, Erik;Jansen, Floor E;Braun, Kees;de Jong, Daniëlle;Rubboli, Guido;Talvik, Inga;Sander, Valentin;Uldall, Peter;Jacquemont, Marie-Line;Nava, Caroline;Leguern, Eric;Julia, Sophie;Gambardella, Antonio;d'Orsi, Giuseppe;Crichiutti, Giovanni;Faivre, Laurence;Darmency, Veronique;Benova, Barbora;Krsek, Pavel;Biraben, Arnaud;Lebre, Anne-Sophie;Jennesson, Mélanie;Sattar, Shifteh;Marchal, Cécile;Nordli, Douglas R;Lindstrom, Kristin;Striano, Pasquale;Lomax, Lysa Boissé;Kiss, Courtney;Bartolomei, Fabrice;Lepine, Anne Fabienne;Schoonjans, An-Sofie;Stouffs, Katrien;Jansen, Anna;Panagiotakaki, Eleni;Ricard-Mousnier, Brigitte;Thevenon, Julien;de Bellescize, Julitta;Catenoix, Hélène;Dorn, Thomas;Zenker, Martin;Müller-Schlüter, Karen;Brandt, Christian;Krey, Ilona;Polster, Tilman;Wolff, Markus;Balci, Meral;Rostasy, Kevin;Achaz, Guillaume;Zacher, Pia;Becher, Thomas;Cloppenborg, Thomas;Yuskaitis, Christopher J;Weckhuysen, Sarah;Poduri, Annapurna;Lemke, Johannes R;Møller, Rikke S;Baulac, Stéphanie","The landscape of epilepsy-related GATOR1 variants.","Genetics in medicine : official journal of the American College of Medical Genetics","United States","eng","Journal Article","DEPDC5;Focal cortical dysplasia;Genetic focal epilepsy;SUDEP;mTORC1 pathway","Adolescent;Brugada Syndrome;Child;Child, Preschool;DNA Copy Number Variations;Epilepsy;Female;GTPase-Activating Proteins;Genetic Predisposition to Disease;Humans;INDEL Mutation;Infant;Infant, Newborn;Loss of Function Mutation;Male;Mechanistic Target of Rapamycin Complex 1;Multiprotein Complexes;Pedigree;Repressor Proteins;Seizures;Signal Transduction;Tumor Suppressor Proteins","Adolescent;Brugada Syndrome;Child;Child, Preschool;DNA Copy Number Variations;Epilepsy;Female;GTPase-Activating Proteins;Genetic Predisposition to Disease;Humans;INDEL Mutation;Infant;Infant, Newborn;Loss of Function Mutation;Male;Mechanistic Target of Rapamycin Complex 1;Multiprotein Complexes;Pedigree;Repressor Proteins;Seizures;Signal Transduction;Tumor Suppressor Proteins","To define the phenotypic and mutational spectrum of epilepsies related to DEPDC5, NPRL2 and NPRL3 genes encoding the GATOR1 complex, a negative regulator of the mTORC1 pathway METHODS: We analyzed clinical and genetic data of 73 novel probands (familial and sporadic) with epilepsy-related variants in GATOR1-encoding genes and proposed new guidelines for clinical interpretation of GATOR1 variants. The GATOR1 seizure phenotype consisted mostly in focal seizures (e.g., hypermotor or frontal lobe seizures in 50%), with a mean age at onset of 4.4 years, often sleep-related and drug-resistant (54%), and associated with focal cortical dysplasia (20%). Infantile spasms were reported in 10% of the probands. Sudden unexpected death in epilepsy (SUDEP) occurred in 10% of the families. Novel classification framework of all 140 epilepsy-related GATOR1 variants (including the variants of this study) revealed that 68% are loss-of-function pathogenic, 14% are likely pathogenic, 15% are variants of uncertain significance and 3% are likely benign. Our data emphasize the increasingly important role of GATOR1 genes in the pathogenesis of focal epilepsies (>180 probands to date). The GATOR1 phenotypic spectrum ranges from sporadic early-onset epilepsies with cognitive impairment comorbidities to familial focal epilepsies, and SUDEP.","Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Clinical Neurosciences, University Hospitals and Medical School of Geneva, Geneva, Switzerland.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Service de Génétique, Hospices Civils de Lyon - GHE; CNRS UMR 5292, INSERM U1028, CNRL, et Université Claude Bernard Lyon 1, GHE, Lyon, France.;Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.;Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Medical Genetics Unit, Polyclinic Sant' Orsola-Malpighi University Hospital, Bologna, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Department of Neurology-centre de référence des épilepsies rares, University Hospital of Strasbourg, Strasbourg, France.;Department of Pediatrics - centre de référence des épilepsies rares, University Hospital of Strasbourg, Strasbourg, France.;IGBMC, INSERM, CNRS, Strasbourg University, Strasbourg, France.;IGBMC, INSERM, CNRS, Strasbourg University, Strasbourg, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Leiden University Medical Center, Leiden, The Netherlands.;Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands.;Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands.;Department of Neurology, Academic Center for Epileptology Kempenhaeghe, Heeze, The Netherlands.;Danish Epilepsy Centre, Dianalund, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology and Rehabilitation, Tallinn Children's Hospital, Tallinn, Estonia.;Department of Neurology and Rehabilitation, Tallinn Children's Hospital, Tallinn, Estonia.;Danish Epilepsy Centre, Dianalund, Denmark.;Unit of Medical Genetics, CHU La Réunion, Saint Pierre, F-97448, France.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan CHU Toulouse, Toulouse, France.;Institute of Neurology, Department of Medical and Surgical Sciences, University Magna Græcia, Catanzaro, Italy.;Epilepsy Center, Clinic of Nervous System Diseases, University of Foggia, Riuniti Hospital, Foggia, Italy.;Department of Pediatrics, Institute of Medicine, University Hospital of Udine, Udine, Italy.;Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU de Dijon et Université de Bourgogne, Dijon, France.;Service de neurophysiologie et pédiatrie 1, CHU de Dijon, Dijon, France.;Department of Paediatric Neurology, Motol University Hospital, 2nd faculty of medicine Charles University, Prague, Czech Republic.;Department of Paediatric Neurology, Motol University Hospital, 2nd faculty of medicine Charles University, Prague, Czech Republic.;Centre Hospitalier Universitaire de Rennes, F-35000, Rennes, France.;CHU Reims, Hôpital Maison Blanche, Pôle de Biologie, Service de Génétique, Reims, F-51092, France.;CHU Reims, American Memorial Hospital, Service de Pédiatrie, REIMS, F-51092, France.;Department of Pediatric Neurology, Rady Children's Hospital/University of California, San Diego, California, USA.;Service d'Epileptologie Clinique, CHU de Bordeaux, France.;Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.;Division of Genetics and Metabolism, Phoenix Children's Hospital, Phoenix, Arizona, USA.;Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, ""G. Gaslini"" Institute, Genova, Italy.;Department of Medicine, Divisions of Neurology and Respirology, Queen's University, Kingston, Ontario, Canada.;Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada.;Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada.;Pediatric Neurology Department, Timone Hospital, APHM, Marseille, France.;Pediatric Neurology Department, Timone Hospital, APHM, Marseille, France.;Department of Pediatric Neurology, Antwerp University Hospital, Edegem, Belgium.;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Neurogenetics Research Group, Laarbeeklaan 101, 1090, Brussels, Belgium.;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Neurogenetics Research Group, Laarbeeklaan 101, 1090, Brussels, Belgium.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Unité d'épileptologie, Service de Neurologie, CHU, 49033, Angers, France.;Inserm UMR 1231 GAD Team, Genetics of Developmental Anomalies, et FHU-TRANSLAD, CHU/Université de Bourgogne-Franche Comté, Dijon, France.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Clinique Bernoise, Crans-, Montana, Switzerland.;Institute of Human Genetics, University Hospital, Magdeburg, Germany.;Epilepsy Center for Children, Brandenburg Medical School, University Hospital, Neuruppin, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.;Department of Pediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany.;Department of Pediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany.;Institut de Systématique, Evolution, Biodiversité, ISYEB, UMR 7205 CNRS MNHN UPMC EPHE, Paris, France.;The Saxon Epilepsy Center Kleinwachau, Radeberg, Germany.;Kinderneurologisches Zentrum, Düsseldorf-Gerresheim, Sana Kliniken, Düsseldorf, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA.;Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Boston Children's Hospital, Boston, Massachusetts, USA.;Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.;Neurogenetics Group, VIB-Department of Molecular Genetics, University of Antwerp, Antwerp, Belgium.;Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA.;Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Boston Children's Hospital, Boston, Massachusetts, USA.;Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.;Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.;Danish Epilepsy Centre, Dianalund; Institute for Regional Health research, University of Southern Denmark, Odense, Denmark.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris;INSERM, U1127, F-75013, Paris;CNRS, UMR 7225, F-75013, Paris;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris","NA",0,"1530-0366","Genet Med","Genet Med",2018,"2019","21","10.1038/s41436-018-0060-2","398-408","682345;K12 NS098482","European Research Council;NINDS NIH HHS","30093711","30093711","PUBMED","Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Clinical Neurosciences, University Hospitals and Medical School of Geneva, Geneva, Switzerland.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Service de Génétique, Hospices Civils de Lyon - GHE; CNRS UMR 5292, INSERM U1028, CNRL, et Université Claude Bernard Lyon 1, GHE, Lyon, France.;Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.;Pediatric Neurology, Neurogenetics, and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, Florence, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Medical Genetics Unit, Polyclinic Sant' Orsola-Malpighi University Hospital, Bologna, Italy.;IRCCS, Istituto delle Scienze Neurologiche of Bologna; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.;Department of Neurology-centre de référence des épilepsies rares, University Hospital of Strasbourg, Strasbourg, France.;Department of Pediatrics - centre de référence des épilepsies rares, University Hospital of Strasbourg, Strasbourg, France.;IGBMC, INSERM, CNRS, Strasbourg University, Strasbourg, France.;IGBMC, INSERM, CNRS, Strasbourg University, Strasbourg, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Pediatric Neurosurgery, Fondation Rothschild, F-75019, Paris, France.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, WC1N 3BG, and Chalfont Centre for Epilepsy, Bucks, UK.;Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Stichting Epilepsie Instellingen Nederland, Zwolle/Heemstede, The Netherlands.;Leiden University Medical Center, Leiden, The Netherlands.;Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands.;Department of Child Neurology, Brain Center Rudolf Magnus, University Medical Center, Utrecht, The Netherlands.;Department of Neurology, Academic Center for Epileptology Kempenhaeghe, Heeze, The Netherlands.;Danish Epilepsy Centre, Dianalund, University of Copenhagen, Copenhagen, Denmark.;Department of Neurology and Rehabilitation, Tallinn Children's Hospital, Tallinn, Estonia.;Department of Neurology and Rehabilitation, Tallinn Children's Hospital, Tallinn, Estonia.;Danish Epilepsy Centre, Dianalund, Denmark.;Unit of Medical Genetics, CHU La Réunion, Saint Pierre, F-97448, France.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris, France.;INSERM, U1127, F-75013, Paris, France.;CNRS, UMR 7225, F-75013, Paris, France.;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris, France.;Service de Génétique Médicale, Pavillon Lefebvre, Hôpital Purpan CHU Toulouse, Toulouse, France.;Institute of Neurology, Department of Medical and Surgical Sciences, University Magna Græcia, Catanzaro, Italy.;Epilepsy Center, Clinic of Nervous System Diseases, University of Foggia, Riuniti Hospital, Foggia, Italy.;Department of Pediatrics, Institute of Medicine, University Hospital of Udine, Udine, Italy.;Centre de Référence Anomalies du Développement et Syndromes Malformatifs et FHU TRANSLAD, CHU de Dijon et Université de Bourgogne, Dijon, France.;Service de neurophysiologie et pédiatrie 1, CHU de Dijon, Dijon, France.;Department of Paediatric Neurology, Motol University Hospital, 2nd faculty of medicine Charles University, Prague, Czech Republic.;Department of Paediatric Neurology, Motol University Hospital, 2nd faculty of medicine Charles University, Prague, Czech Republic.;Centre Hospitalier Universitaire de Rennes, F-35000, Rennes, France.;CHU Reims, Hôpital Maison Blanche, Pôle de Biologie, Service de Génétique, Reims, F-51092, France.;CHU Reims, American Memorial Hospital, Service de Pédiatrie, REIMS, F-51092, France.;Department of Pediatric Neurology, Rady Children's Hospital/University of California, San Diego, California, USA.;Service d'Epileptologie Clinique, CHU de Bordeaux, France.;Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.;Division of Genetics and Metabolism, Phoenix Children's Hospital, Phoenix, Arizona, USA.;Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, ""G. Gaslini"" Institute, Genova, Italy.;Department of Medicine, Divisions of Neurology and Respirology, Queen's University, Kingston, Ontario, Canada.;Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada.;Kingston Health Sciences Centre, Kingston, Ontario, K7L 2V7, Canada.;Pediatric Neurology Department, Timone Hospital, APHM, Marseille, France.;Pediatric Neurology Department, Timone Hospital, APHM, Marseille, France.;Department of Pediatric Neurology, Antwerp University Hospital, Edegem, Belgium.;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Neurogenetics Research Group, Laarbeeklaan 101, 1090, Brussels, Belgium.;Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Neurogenetics Research Group, Laarbeeklaan 101, 1090, Brussels, Belgium.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Unité d'épileptologie, Service de Neurologie, CHU, 49033, Angers, France.;Inserm UMR 1231 GAD Team, Genetics of Developmental Anomalies, et FHU-TRANSLAD, CHU/Université de Bourgogne-Franche Comté, Dijon, France.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Paediatric Clinical Epileptology, Sleep disorders and Functional Neurology, University Hospitals of Lyon (HCL), Lyon, France.;Clinique Bernoise, Crans-, Montana, Switzerland.;Institute of Human Genetics, University Hospital, Magdeburg, Germany.;Epilepsy Center for Children, Brandenburg Medical School, University Hospital, Neuruppin, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital, Tübingen, Germany.;Department of Pediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany.;Department of Pediatric Neurology, Children's Hospital Datteln, Witten/Herdecke University, Datteln, Germany.;Institut de Systématique, Evolution, Biodiversité, ISYEB, UMR 7205 CNRS MNHN UPMC EPHE, Paris, France.;The Saxon Epilepsy Center Kleinwachau, Radeberg, Germany.;Kinderneurologisches Zentrum, Düsseldorf-Gerresheim, Sana Kliniken, Düsseldorf, Germany.;Bethel Epilepsy Centre, Bielefeld, Germany.;Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA.;Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Boston Children's Hospital, Boston, Massachusetts, USA.;Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.;Neurogenetics Group, VIB-Department of Molecular Genetics, University of Antwerp, Antwerp, Belgium.;Department of Neurology, F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA.;Division of Epilepsy and Clinical Neurophysiology and Epilepsy Genetics Program, Boston Children's Hospital, Boston, Massachusetts, USA.;Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.;Institute of Human Genetics, University of Leipzig Hospitals and Clinics, Leipzig, Germany.;Danish Epilepsy Centre, Dianalund; Institute for Regional Health research, University of Southern Denmark, Odense, Denmark.;Sorbonne Université, UPMC Univ Paris 06, UMR S 1127, F-75013, Paris;INSERM, U1127, F-75013, Paris;CNRS, UMR 7225, F-75013, Paris;Institut du Cerveau et de la Moelle épinière (ICM), Hôpital Pitié-Salpêtrière, F-75013, Paris;Department of Genetics, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, F-75013, Paris"
"489","Le KS;Amé-Thomas P;Tarte K;Gondois-Rey F;Granjeaud S;Orlanducci F;Foucher ED;Broussais F;Bouabdallah R;Fest T;Leroux D;Yadavilli S;Mayes PA;Xerri L;Olive D","Le, Kieu-Suong;Amé-Thomas, Patricia;Tarte, Karin;Gondois-Rey, Françoise;Granjeaud, Samuel;Orlanducci, Florence;Foucher, Etienne D;Broussais, Florence;Bouabdallah, Reda;Fest, Thierry;Leroux, Dominique;Yadavilli, Sapna;Mayes, Patrick A;Xerri, Luc;Olive, Daniel",NA,"Blood advances","United States","eng","Journal Article","","CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Cell Differentiation;Cytokines;Female;Gene Expression Regulation, Neoplastic;Hodgkin Disease;Humans;Inducible T-Cell Co-Stimulator Protein;Male;Neoplasm Proteins;Receptors, CXCR5","CD4-Positive T-Lymphocytes;CD8-Positive T-Lymphocytes;Cell Differentiation;Cytokines;Female;Gene Expression Regulation, Neoplastic;Hodgkin Disease;Humans;Inducible T-Cell Co-Stimulator Protein;Male;Neoplasm Proteins;Receptors, CXCR5","A better characterization of T-cell subsets in the microenvironment of classical Hodgkin lymphoma (cHL) would help to develop immunotherapies. Using multicolor flow cytometry, we identified in 6 of 43 cHL tissue samples a previously unrecognized subset of CD8 T cells coexpressing CXCR5 and inducible T-cell costimulator (ICOS) molecules (CD8 ). These cells shared phenotypic features with follicular helper T (T ) cells including low CCR7 expression together with high expression of B-cell lymphoma-6, programmed cell death 1, B and T lymphocyte attenuator, CD200, and OX40. They had deficient cytotoxicity, low interferon-γ secretion, and common functional properties with intratumoral CD4  T  cells, such as production of interleukin-4 (IL-4), IL-21, CXCL13, and capacity to sustain B cells. Gene profiling analysis showed a significant similarity between the signatures of CD8  T cells and CD4  T  cells. Benign lymphadenitis tissues (n = 8) were devoid of CD8  cells. Among the 35 B-cell lymphoma tissues analyzed, including follicular lymphomas (n = 13), diffuse large cell lymphomas (n = 12), marginal zone lymphomas (MZLs; n = 3), mantle cell lymphomas (n = 3), and chronic lymphocytic leukemias (n = 4), only 1 MZL sample contained CD8  cells. Lymphoma tumors with CD8  cells shared common histopathological features including residual germinal centers, and contained high amounts of activated CD8  cells. These data demonstrate a CD8 T-cell differentiation pathway leading to the acquisition of some T  similarities. They suggest a particular immunoediting process with global CD8 activation acting mainly, but not exclusively, in HL tumors.","Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut Albert Bonniot, Grenoble, France; and.;Immuno-Oncology and Combination Discovery Performance Unit, Oncology Research and Development, GlaxoSmithKline, Collegeville, PA.;Immuno-Oncology and Combination Discovery Performance Unit, Oncology Research and Development, GlaxoSmithKline, Collegeville, PA.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.","NA",0,"2473-9537","Blood Adv","Blood Adv",2018,"2018","2","10.1182/bloodadvances.2018017244","1889-1900","","","30087107","30087107","PUBMED","Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;LabEx IGO, Equipe Labellisée Ligue Contre le Cancer, Etablissement Français du Sang Bretagne, Université de Rennes 1, Unité Mixte de Recherche U1236, INSERM, Rennes, France.;Pôle Biologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut Albert Bonniot, Grenoble, France; and.;Immuno-Oncology and Combination Discovery Performance Unit, Oncology Research and Development, GlaxoSmithKline, Collegeville, PA.;Immuno-Oncology and Combination Discovery Performance Unit, Oncology Research and Development, GlaxoSmithKline, Collegeville, PA.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;Institut Paoli-Calmettes, Marseille, France.;Centre de Recherche en Cancérologie de Marseille, Centre National de la Recherche Scientifique U7258/INSERM U1068, Marseille, France.;Faculté de Médecine, Aix Marseille Université, Marseille, France.;Institut Paoli-Calmettes, Marseille, France."
"490","Nguyen TB;Delalande O;Rouaud I;Ferron S;Chaillot L;Pedeux R;Tomasi S","Nguyen, Thi-Bach-Le;Delalande, Olivier;Rouaud, Isabelle;Ferron, Solenn;Chaillot, Laura;Pedeux, Rémy;Tomasi, Sophie",NA,"Molecules (Basel, Switzerland)","Switzerland","eng","Journal Article","Paenibacillus odorifer;Rhizocarpon geographicum;bioconversion;tert-butylphenols","Animals;Benzhydryl Compounds;Cell Line;Cell Line, Tumor;Humans;Magnetic Resonance Spectroscopy;Mice;Paenibacillus","Animals;Benzhydryl Compounds;Cell Line;Cell Line, Tumor;Humans;Magnetic Resonance Spectroscopy;Mice;Paenibacillus","Two compounds ( ) and ( ) containing  -butylphenol groups were, for the first time, produced during the culture of  , a bacterial strain associated with the crustose lichen,  . Their entire structures were identified by one-dimensional (1D) and two-dimensional (2D) NMR and high-resolution electrospray ionisation mass spectrometry (HRESIMS) spectroscopic analyses. Among them, Compound   exhibited significant cytotoxicity against B16 murine melanoma and HaCaT human keratinocyte cell lines with micromolar half maximal inhibitory concentration (IC ) values. Furthermore, after supplementation studies, a putative biosynthesis pathway was proposed for Compound   throughout a bioconversion by this bacterial strain of butylated hydroxyanisole (BHA), an antioxidant polymer additive.","University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;University of Rennes 1, CNRS, IGDR-UMR 6290, F-35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;Chemistry, Oncogenesis, Stress, Signaling, Centre Eugène Marquis, Université de Rennes 1, INSERM U1242, 35000 Rennes;Chemistry, Oncogenesis, Stress, Signaling, Centre Eugène Marquis, Université de Rennes 1, INSERM U1242, 35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes","NA",0,"1420-3049","Molecules","Molecules",2018,"2018","23","10.3390/molecules23081951",NA,"","","30081602","30081602","PUBMED","University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;University of Rennes 1, CNRS, IGDR-UMR 6290, F-35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes;Chemistry, Oncogenesis, Stress, Signaling, Centre Eugène Marquis, Université de Rennes 1, INSERM U1242, 35000 Rennes;Chemistry, Oncogenesis, Stress, Signaling, Centre Eugène Marquis, Université de Rennes 1, INSERM U1242, 35000 Rennes;University of Rennes 1, CNRS, ISCR-UMR 6226, F-35000 Rennes"
"491","Morschhauser F;Salles G;Le Gouill S;Tilly H;Thieblemont C;Bouabdallah K;Fabiani B;Ménard C;Tarte K;Cartron G;Houot R","Morschhauser, Franck;Salles, Gilles;Le Gouill, Steven;Tilly, Herve;Thieblemont, Catherine;Bouabdallah, Krimo;Fabiani, Bettina;Ménard, Cédric;Tarte, Karin;Cartron, Guillaume;Houot, Roch","An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.","Blood","United States","eng","Clinical Trial, Phase I","","Administration, Oral;Adult;Aged;Aged, 80 and over;Angiogenesis Inhibitors;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Female;Humans;Lenalidomide;Lymphoma, B-Cell;Lymphoma, Follicular;Male;Maximum Tolerated Dose;Middle Aged;Neoplasm Recurrence, Local","Administration, Oral;Adult;Aged;Aged, 80 and over;Angiogenesis Inhibitors;Antibodies, Monoclonal, Humanized;Antineoplastic Agents, Immunological;Antineoplastic Combined Chemotherapy Protocols;Female;Humans;Lenalidomide;Lymphoma, B-Cell;Lymphoma, Follicular;Male;Maximum Tolerated Dose;Middle Aged;Neoplasm Recurrence, Local","Obinutuzumab is a type II anti-CD20 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity better than rituximab. Given promising results with lenalidomide and rituximab, this phase 1b study assessed the safety and efficacy of lenalidomide combined with obinutuzumab (GALEN). Patients age ≥18 years with relapsed or refractory (R/R) follicular lymphoma (FL) after rituximab-containing therapy received escalating doses (10 [n = 7], 15 [n = 3], 20 [n = 6], and 25 mg [n = 3]) of daily oral lenalidomide on days 1 to 21 of cycle 1 and on days 2 to 22 of cycles 2 to 6 (28-day cycles). Obinutuzumab 1000 mg IV was administered on days 8, 15, and 22 (cycle 1) and on day 1 (cycles 2-6). Dose was escalated in a 3 + 3 design based on dose-limiting toxicity (DLT) during cycle 1 to establish the maximum tolerated dose (MTD). We observed 164 adverse events (AEs), of which 139 were grade 1/2. The most common AEs were constipation (52.6%), neutropenia (47.4%), and asthenia (36.8%); 64.3% (9 of 14) of the grade 3/4 AEs were neutropenia/neutrophil decrease, but without any febrile neutropenia. Four DLTs occurred in 2 patients, all deemed unrelated to treatment. MTD was not reached. Twelve patients (63.2%) responded: 8 complete, 3 unconfirmed complete, and 1 partial response. Oral lenalidomide plus obinutuzumab is well tolerated and effective in R/R FL. The recommended dose of lenalidomide was established at 20 mg based on the risk of grade 3/4 neutropenia from cycle 2. This trial was registered at www.clinicaltrials.gov as #NCT01582776.","Service des Maladies du Sang, Centre Hospitalier Régional Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Université de Lille, Lille, France.;Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University of Lyon, Pierre-Benite, France.;Department of Haematology, Centre Hospitalier Universitaire Nantes, Nantes, France.;Département d'Hématologie, U1245, Centre Henri Becquerel, Université de Rouen, Rouen, France.;Hemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U728, Hospital Saint-Louis, Institut Universitaire d'Hematologie, Paris, France.;Service d'Hématologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.;Hopital Saint-Antoine, AP-HP, Paris, France.;Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France.;Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes, France.;Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France.;Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes, France.;UMR 5235, Centre Hospitalier Universitaire, University of Montpellier, Montpellier, France; and.;Haematology Department, Centre Hospitalier Universitaire Rennes, Rennes, France.","NA",0,"1528-0020","Blood","Blood",2018,"2018","132","10.1182/blood-2018-05-853499","1486-1494","","","30068505","30068505","PUBMED","Service des Maladies du Sang, Centre Hospitalier Régional Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Université de Lille, Lille, France.;Hematology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, University of Lyon, Pierre-Benite, France.;Department of Haematology, Centre Hospitalier Universitaire Nantes, Nantes, France.;Département d'Hématologie, U1245, Centre Henri Becquerel, Université de Rouen, Rouen, France.;Hemato-Oncology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U728, Hospital Saint-Louis, Institut Universitaire d'Hematologie, Paris, France.;Service d'Hématologie et de Thérapie Cellulaire, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.;Hopital Saint-Antoine, AP-HP, Paris, France.;Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France.;Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes, France.;Unité Mixte de Recherche (UMR) S1236, INSERM, University of Rennes, Etablissement Français du Sang, Rennes, France.;Suivi Immunologique des Thérapeutiques Innovantes, Centre Hospitalier Universitaire de Rennes, Etablissement Français du Sang, Rennes, France.;UMR 5235, Centre Hospitalier Universitaire, University of Montpellier, Montpellier, France; and.;Haematology Department, Centre Hospitalier Universitaire Rennes, Rennes, France."
"492","Matusali G;Houzet L;Satie AP;Mahé D;Aubry F;Couderc T;Frouard J;Bourgeau S;Bensalah K;Lavoué S;Joguet G;Bujan L;Cabié A;Avelar G;Lecuit M;Le Tortorec A;Dejucq-Rainsford N","Matusali, Giulia;Houzet, Laurent;Satie, Anne-Pascale;Mahé, Dominique;Aubry, Florence;Couderc, Thérèse;Frouard, Julie;Bourgeau, Salomé;Bensalah, Karim;Lavoué, Sylvain;Joguet, Guillaume;Bujan, Louis;Cabié, André;Avelar, Gleide;Lecuit, Marc;Le Tortorec, Anna;Dejucq-Rainsford, Nathalie","Zika virus infects human testicular tissue and germ cells.","The Journal of clinical investigation","United States","eng","Journal Article","Innate immunity;Sex hormones;Urology;Virology","Animals;Chlorocebus aethiops;Germ Cells;Humans;Male;Mice;Mice, Knockout;Testis;Vero Cells;Virus Replication;Zika Virus;Zika Virus Infection","Animals;Chlorocebus aethiops;Germ Cells;Humans;Male;Mice;Mice, Knockout;Testis;Vero Cells;Virus Replication;Zika Virus;Zika Virus Infection","Zika virus (ZIKV) is a teratogenic mosquito-borne flavivirus that can be sexually transmitted from man to woman. The finding of high viral loads and prolonged viral shedding in semen suggests that ZIKV replicates within the human male genital tract, but its target organs are unknown. Using ex vivo infection of organotypic cultures, we demonstrated here that ZIKV replicates in human testicular tissue and infects a broad range of cell types, including germ cells, which we also identified as infected in semen from ZIKV-infected donors. ZIKV had no major deleterious effect on the morphology and hormonal production of the human testis explants. Infection induced a broad antiviral response but no IFN upregulation and minimal proinflammatory response in testis explants, with no cytopathic effect. Finally, we studied ZIKV infection in mouse testis and compared it to human infection. This study provides key insights into how ZIKV may persist in semen and alter semen parameters, as well as a valuable tool for testing antiviral agents.","Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Institut Pasteur, Biology of Infection Unit, Paris, France.;Inserm U1117, Paris, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Caribéen de Médecine de la Reproduction-CECOS CHU de Pointe-à-Pitre, Pointe-à-Pitre, France.;Research Group on Human Fertility EA 3694, University Paul Sabatier Toulouse III - CECOS, Hôpital Paule de Viguier, CHU Toulouse, Toulouse, France.;Inserm Centre d'Investigation Clinique 1424, Centre Hospitalier Universitaire de Martinique, and Service de maladies infectieuses, Centre Hospitalier Universitaire de Martinique, Fort de France, France.;Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, Brazil.;Institut Pasteur, Biology of Infection Unit, Paris, France.;Inserm U1117, Paris, France.;Paris-Descartes University, Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Paris, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.","NA",0,"1558-8238","J Clin Invest","J Clin Invest",2018,"2018","128","10.1172/JCI121735","4697-4710","","","30063220","30063220","PUBMED","Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Institut Pasteur, Biology of Infection Unit, Paris, France.;Inserm U1117, Paris, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Service d'Urologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Caribéen de Médecine de la Reproduction-CECOS CHU de Pointe-à-Pitre, Pointe-à-Pitre, France.;Research Group on Human Fertility EA 3694, University Paul Sabatier Toulouse III - CECOS, Hôpital Paule de Viguier, CHU Toulouse, Toulouse, France.;Inserm Centre d'Investigation Clinique 1424, Centre Hospitalier Universitaire de Martinique, and Service de maladies infectieuses, Centre Hospitalier Universitaire de Martinique, Fort de France, France.;Department of Morphology, Federal University of Minas Gerais, Belo Horizonte, Brazil.;Institut Pasteur, Biology of Infection Unit, Paris, France.;Inserm U1117, Paris, France.;Paris-Descartes University, Department of Infectious Diseases and Tropical Medicine, Necker-Enfants Malades University Hospital, Paris, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France.;Université de Rennes, Inserm, École des hautes études en santé publique (EHESP), Institut de recherche en santé, environnement et travail (Irset) - UMR_S1085, Rennes, France."
"493","Boissier E;Genebrier S;Lakhal K;Nedelec-Gac F;Trossaërt M;Ternisien C;Gouin-Thibault I","Boissier, Elodie;Genebrier, Steve;Lakhal, Karim;Nedelec-Gac, Fabienne;Trossaërt, Marc;Ternisien, Catherine;Gouin-Thibault, Isabelle","Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature.","Thrombosis and haemostasis","Germany","eng","Letter","","Administration, Oral;Blood Specimen Collection;Drug Monitoring;Drug Stability;Factor Xa;Factor Xa Inhibitors;France;Humans;Predictive Value of Tests;Protein Stability;Pyrazoles;Pyridones;Reproducibility of Results;Rivaroxaban;Temperature;Time Factors","Administration, Oral;Blood Specimen Collection;Drug Monitoring;Drug Stability;Factor Xa;Factor Xa Inhibitors;France;Humans;Predictive Value of Tests;Protein Stability;Pyrazoles;Pyridones;Reproducibility of Results;Rivaroxaban;Temperature;Time Factors","NA","Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Anesthésie-Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"2567-689X","Thromb Haemost","Thromb Haemost",2018,"2018","118","10.1055/s-0038-1661391","1488-1490","","","29960274","29960274","PUBMED","Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Anesthésie-Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Centre de Traitement de l'Hémophilie, Centre Hospitalier Universitaire de Nantes, Nantes, France.;Hématologie Biologique, Centre Hospitalier Universitaire de Rennes, Rennes, France."
"494","Palard-Novello X;Blin AL;Le Jeune F;Garin E;Salaün PY;Devillers A;Gambarota G;Querellou S;Bourguet P;Saint-Jalmes H","Palard-Novello, Xavier;Blin, Anne-Lise;Le Jeune, Florence;Garin, Etienne;Salaün, Pierre-Yves;Devillers, Anne;Gambarota, Giulio;Querellou, Solène;Bourguet, Patrick;Saint-Jalmes, Hervé",NA,"EJNMMI research","Germany","eng","Journal Article","18FCholine;Kinetic analysis;Positron emission tomography;Prostate cancer","","","Suboptimal temporal sampling of time-activity curves (TAC) from dynamic  F-fluoromethylcholine (FCH) PET images may introduce bias in quantification of FCH uptake in prostate cancer assessment. We sought to define an optimal temporal sampling protocol for dynamic FCH PET imaging. Seven different time samplings were tested: 5 × 60″, 10 × 30″, 15 × 15″-1 × 75″, 6 × 10″-8 × 30″, 12 × 5″-8 × 30″; 10 × 5″-4 × 10″-3 × 20″-5 × 30″, and 8 × 3″-8 × 12″-6 × 30″. First, the irreversible and reversible one-tissue compartment model with blood volume parameter (VB) (respectively, 1T1K+VB and 1T2k+VB, with K1 = transfer coefficient from the arterial blood to the tissue compartment and k2 = transfer coefficient from the tissue compartment to the arterial blood) were compared for 37 lesions from 32 patients who underwent FCH PET imaging for initial or recurrence assessment of prostate cancer, and the model was selected using the Akaike information criterion. To determine the optimal time sampling, K1 values extracted from 1000 noisy-simulated TAC using Monte Carlo method from the seven different time samplings were compared to a target K1 value which is the average of the K1 values extracted from the 37 lesions using an imaging-derived input function for each patient. K1 values extracted with the optimal time sampling for each tumoral lesion were compared to K1 values extracted from each of the other time samplings for the 37 lesions. The 1T2k + VB model was selected. The target K1 value as the objective was 0.506 mL/ccm/min (range 0.216-1.246). Results showed a significant difference between K1 values from the simulated TAC with the seven different time samplings analyzed. The closest K1 value from the simulated TAC to the target K1 value was obtained by the 12 × 5″-8 × 30″ time sampling. Concerning the clinical validation, K1 values extracted from the optimal time sampling (12 × 5″-8 × 30″) were significantly different with K1 values extracted from the other time samplings, except for the comparison with K1 values extracted from the 10 × 5″-4 × 10″-3 × 20″-5 × 30″ time sampling. A two-phase framing of dynamic PET reconstruction with frame durations of 5 s (blood phase) and 30 s (tissue phase) could be used to sample the TAC for uptake quantification in prostate cancer assessment.","LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes-EA 4712, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;UMR 124, Univ Rennes, Inserm, Rennes, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.;University of Bretagne Occidentale-EA 3878, Brest, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.;University of Bretagne Occidentale-EA 3878, Brest, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.","NA",0,"2191-219X","EJNMMI Res","EJNMMI Res",2018,"2018","8","10.1186/s13550-018-0410-8","49","","","29904817","29904817","PUBMED","LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;Univ Rennes-EA 4712, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;UMR 124, Univ Rennes, Inserm, Rennes, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.;University of Bretagne Occidentale-EA 3878, Brest, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Hospitalier Universitaire, Brest, France.;University of Bretagne Occidentale-EA 3878, Brest, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France.;LTSI-UMR1099, Univ Rennes, Inserm, F-35000, Rennes, France.;Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France."
"495","Droitcourt C;Kerbrat S;Rault C;Botrel MA;Happe A;Garlantezec R;Guillot B;Schleich JM;Oger E;Dupuy A","Droitcourt, Catherine;Kerbrat, Sandrine;Rault, Caroline;Botrel, Marie-Anne;Happe, André;Garlantezec, Ronan;Guillot, Bernard;Schleich, Jean-Marc;Oger, Emmanuel;Dupuy, Alain","Safety of Oral Propranolol for Infantile Hemangioma.","Pediatrics","United States","eng","Journal Article","","Administration, Oral;Bradycardia;Bronchitis;Child, Preschool;Cohort Studies;Databases, Factual;Hemangioma;Humans;Hypoglycemia;Hypotension;Infant;Infant, Newborn;Propranolol;Risk Management;Soft Tissue Neoplasms;Vasodilator Agents","Administration, Oral;Bradycardia;Bronchitis;Child, Preschool;Cohort Studies;Databases, Factual;Hemangioma;Humans;Hypoglycemia;Hypotension;Infant;Infant, Newborn;Propranolol;Risk Management;Soft Tissue Neoplasms;Vasodilator Agents","The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe. A survey of a nationwide, claim-based observational cohort of children <3 years old, with at least 1 delivery of oral propranolol between July 2014 and June 2016, was performed by using the database of the French National Health Insurance system. Standardized morbidity ratios (SMRs) were calculated by using, from the same database, a representative random sample of nonexposed subjects. The main outcomes were hospitalizations for cardiovascular (conduction disorders, bradycardia, and hypotension), respiratory (bronchial hyperactivity and bronchospasm), or metabolic events (hypoglycemia and hyperkalaemia), identified through the hospitalization diagnostic codes of the  . The main analysis was conducted separately on ""healthy"" children (  = 1484), that is, free from of any prespecified underlying disease and on children with 1 of these underlying diseases (  = 269). In all, 1753 patients <3 years of age had at least 2 deliveries of oral propranolol. In the healthy population, we observed 2 cardiovascular events (SMR = 2.8 [0-6.7]), 51 respiratory events (SMR = 1.7 [1.2-2.1]), and 3 metabolic events (SMR = 5.1 [0-10.9]). In the population with an underlying disease (mainly congenital heart disease), we observed 11 cardiovascular events leading to an SMR of 6.0 (2.5-9.6). SMRs were not significantly raised for respiratory or metabolic events in this ""nonhealthy"" population. In this study on a large continuous nationwide claims database, we confirm the safety profile of oral propranolol in healthy children to be good.","University of Rennes, Rennes;Departments of Dermatology.;Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 1414, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, Rennes, France.;Public Health.;Institut de Recherche en Santé, Environnement et Travail, Unité Mixte de Recherche 1085, Rennes, France; and.;Department of Dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Cardiology, and.;University of Rennes, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;Centre of Pharmacovigilance, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Rennes, Rennes, France.;Departments of Dermatology.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.","NA",0,"1098-4275","Pediatrics","Pediatrics",2018,"2018","141","10.1542/peds.2017-3783",NA,"","","29844139","29844139","PUBMED","University of Rennes, Rennes;Departments of Dermatology.;Institut National de la Santé et de la Recherche Médicale, Centre d'Investigation Clinique 1414, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;University of Rennes, Rennes, France.;Public Health.;Institut de Recherche en Santé, Environnement et Travail, Unité Mixte de Recherche 1085, Rennes, France; and.;Department of Dermatology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.;Cardiology, and.;University of Rennes, Rennes, France.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France.;Centre of Pharmacovigilance, Centre Hospitalier Universitaire de Rennes, Rennes, France.;University of Rennes, Rennes, France.;Departments of Dermatology.;University of Rennes, EA 7449 REPERES Pharmacoepidemiology and Health Services Research, Rennes, France."
"496","Gauthé M;Richard-Molard M;Rigault E;Buecher B;Mariani P;Bellet D;Cacheux W;Lièvre A","Gauthé, Mathieu;Richard-Molard, Marion;Rigault, Eugénie;Buecher, Bruno;Mariani, Pascale;Bellet, Dominique;Cacheux, Wulfran;Lièvre, Astrid","Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.","BMC cancer","England","eng","Journal Article","Anal carcinoma;CYFRA 21-1;Prognosis;Recurrence;Tumour marker","Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Anus Neoplasms;Biomarkers, Tumor;Carcinoma, Squamous Cell;Chemoradiotherapy;Female;Follow-Up Studies;Humans;Kaplan-Meier Estimate;Keratin-19;Male;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Proportional Hazards Models;ROC Curve;Treatment Outcome","Adult;Aged;Aged, 80 and over;Antigens, Neoplasm;Anus Neoplasms;Biomarkers, Tumor;Carcinoma, Squamous Cell;Chemoradiotherapy;Female;Follow-Up Studies;Humans;Kaplan-Meier Estimate;Keratin-19;Male;Middle Aged;Neoplasm Recurrence, Local;Neoplasm Staging;Prognosis;Proportional Hazards Models;ROC Curve;Treatment Outcome","We aimed to assess the prognostic value of CYFRA 21-1 in a series of patients with anal canal squamous cell carcinoma treated by radiation-based therapy. All patients with anal cancer referred between September 2005 and July 2013 were considered. Patients with diagnosis of anal squamous cell carcinoma and in whom pre- and post-treatment serum CYFRA 21-1 levels were available were included. Serum CYFRA 21-1 levels at initial workup and after therapy were collected. Survival rates were estimated using the Kaplan-Meier method. Cox regression analysis was used to evaluate prognostic variables for prediction of outcomes. Eighty-two patients were included. Median follow-up was 60 months (range: 8-128). Pre-treatment serum CYFRA 21-1 levels were significantly correlated with tumour stage (p < 0.001). Normal post-treatment serum CYFRA 21-1 level was significantly correlated with tumour complete response (p = 0.004). Elevated post-treatment serum CYFRA 21-1 level was significantly associated with poorer progression-free survival (p = 0.02) and overall survival (p = 0.003). T stage and post-treatment serum CYFRA 21-1 were independent prognostic factors for overall survival (p = 0.04 and 0.03, respectively). Serum CYFRA 21-1 appears to be a useful marker for the monitoring of anal squamous cell carcinoma patients. Elevated post-treatment value appears to be correlated with treatment failure.","Médecine nucléaire, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris;Médecine nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, 4 rue de la Chine, 75020, Paris;Université Pierre et Marie Curie, 4 Place Jussieu, Paris;Département de radiothérapie, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 2 rue Henri Le Guilloux, Rennes, 35033, France.;Faculté de Médecine, Université de Rennes 1, 2 avenue du Pr. Léon Bernard, 35043, Rennes, France.;INSERM U1242, COSS (chemistry, oncogenesis, stress and signaling), , Rue Bataille Flandres-Dunkerque, 35043, Rennes, France.;Département d'oncologie médicale, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Département de chirurgie oncologique, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Laboratoire d'oncobiologie, Département de biopathologie, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Département d'oncologie médicale, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Unité de pharmacogénomique, département de génétique, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 2 rue Henri Le Guilloux, Rennes, 35033, France.;Faculté de Médecine, Université de Rennes 1, 2 avenue du Pr. Léon Bernard, 35043, Rennes, France.;Département d'oncologie médicale, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.","NA",0,"1471-2407","BMC Cancer","BMC Cancer",2017,"2018","18","10.1186/s12885-018-4335-4","417","","","29653564","29653564","PUBMED","Médecine nucléaire, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris;Médecine nucléaire, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, 4 rue de la Chine, 75020, Paris;Université Pierre et Marie Curie, 4 Place Jussieu, Paris;Département de radiothérapie, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 2 rue Henri Le Guilloux, Rennes, 35033, France.;Faculté de Médecine, Université de Rennes 1, 2 avenue du Pr. Léon Bernard, 35043, Rennes, France.;INSERM U1242, COSS (chemistry, oncogenesis, stress and signaling), , Rue Bataille Flandres-Dunkerque, 35043, Rennes, France.;Département d'oncologie médicale, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Département de chirurgie oncologique, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Laboratoire d'oncobiologie, Département de biopathologie, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Département d'oncologie médicale, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France.;Unité de pharmacogénomique, département de génétique, Institut Curie, Hôpital Paris, 26 rue d'Ulm, 75005, Paris, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 2 rue Henri Le Guilloux, Rennes, 35033, France.;Faculté de Médecine, Université de Rennes 1, 2 avenue du Pr. Léon Bernard, 35043, Rennes, France.;Département d'oncologie médicale, Institut Curie, Hôpital René Huguenin, 35 rue Dailly, 92210, Saint-Cloud, France."
"497","Autier B;Dion S;Robert-Gangneux F","Autier, Brice;Dion, Sarah;Robert-Gangneux, Florence",NA,"Journal of clinical pathology","England","eng","Journal Article","infections;liver;toxoplasma;transplantation","Animals;Brain;DNA, Protozoan;Disease Models, Animal;Female;Heart;Liver;Liver Transplantation;Mice;Parasite Load;Risk Assessment;Risk Factors;Toxoplasma;Toxoplasmosis, Congenital","Animals;Brain;DNA, Protozoan;Disease Models, Animal;Female;Heart;Liver;Liver Transplantation;Mice;Parasite Load;Risk Assessment;Risk Factors;Toxoplasma;Toxoplasmosis, Congenital","Toxoplasmosis following liver transplant with donor-recipient mismatch is rare, but is often life-threatening. However, there are no data on the frequency of cyst carriage in the liver, nor consensual chemoprophylaxis guidelines. This study aimed at describing frequency and localisation of   cysts in the liver in a mouse model of chronic infection to predict the risk in liver transplantation. Heart, brain and liver lobes of 21 mice chronically infected with   were collected for DNA extraction and amplification of   rep529 sequence by real-time PCR. Parasite DNA was detected in the liver of 19/21 mice (90.5%), with no preferential anatomical localisation, but with higher parasite loads in the papillary process. Parasite loads in the liver were far lower than in brain and heart. The number of infected lobes was inversely correlated to the total liver weight, but was independent of the brain parasite load and of the parasite strain. The liver is a frequent site of cyst carriage, confirming that transplantation of an organ from a seropositive donor to seronegative recipient is at high risk for acquired toxoplasmosis. Systematic serological screening prior to transplantation and chemoprophylaxis in patients at risk are fully justified.","Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut de recherche en santé, environnement et travail, Inserm U0185, Rennes, France.;Université Rennes 1, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut de recherche en santé, environnement et travail, Inserm U0185, Rennes, France.;Université Rennes 1, Rennes, France.","NA",0,"1472-4146","J Clin Pathol","J Clin Pathol",2018,"2018","71","10.1136/jclinpath-2018-205066","763-766","","","29535213","29535213","PUBMED","Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut de recherche en santé, environnement et travail, Inserm U0185, Rennes, France.;Université Rennes 1, Rennes, France.;Laboratoire de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Institut de recherche en santé, environnement et travail, Inserm U0185, Rennes, France.;Université Rennes 1, Rennes, France."
"498","Lévêque M;Penna A;Le Trionnaire S;Belleguic C;Desrues B;Brinchault G;Jouneau S;Lagadic-Gossmann D;Martin-Chouly C","Lévêque, Manuella;Penna, Aubin;Le Trionnaire, Sophie;Belleguic, Chantal;Desrues, Benoît;Brinchault, Graziella;Jouneau, Stéphane;Lagadic-Gossmann, Dominique;Martin-Chouly, Corinne","Phagocytosis depends on TRPV2-mediated calcium influx and requires TRPV2 in lipids rafts: alteration in macrophages from patients with cystic fibrosis.","Scientific reports","England","eng","Journal Article","","Adolescent;Adult;Calcium;Cells, Cultured;Cystic Fibrosis;Female;Humans;Macrophages;Male;Membrane Microdomains;Middle Aged;Phagocytosis;TRPV Cation Channels","Adolescent;Adult;Calcium;Cells, Cultured;Cystic Fibrosis;Female;Humans;Macrophages;Male;Membrane Microdomains;Middle Aged;Phagocytosis;TRPV Cation Channels","Whereas many phagocytosis steps involve ionic fluxes, the underlying ion channels remain poorly defined. As reported in mice, the calcium conducting TRPV2 channel impacts the phagocytic process. Macrophage phagocytosis is critical for defense against pathogens. In cystic fibrosis (CF), macrophages have lost their capacity to act as suppressor cells and thus play a significant role in the initiating stages leading to chronic inflammation/infection. In a previous study, we demonstrated that impaired function of CF macrophages is due to a deficient phagocytosis. The aim of the present study was to investigate TRPV2 role in the phagocytosis capacity of healthy primary human macrophage by studying its activity, its membrane localization and its recruitment in lipid rafts. In primary human macrophages, we showed that P. aeruginosa recruits TRPV2 channels at the cell surface and induced a calcium influx required for bacterial phagocytosis. We presently demonstrate that to be functional and play a role in phagocytosis, TRPV2 might require a preferential localization in lipid rafts. Furthermore, CF macrophage displays a perturbed calcium homeostasis due to a defect in TRPV2. In this context, deregulated TRPV2-signaling in CF macrophages could explain their defective phagocytosis capacity that contribute to the maintenance of chronic infection.","Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;URL440-COSS, Centre Eugène Marquis, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Chemical contaminant immunity and inflammation, F-35043, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes;University of Rennes 1, UMS Biosit, F-35000, Rennes","NA",0,"2045-2322","Sci Rep","Sci Rep",2017,"2018","8","10.1038/s41598-018-22558-5","4310","","","29523858","29523858","PUBMED","Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;URL440-COSS, Centre Eugène Marquis, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Centre de Ressource et de Compétences de la Mucoviscidose, F-35064, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Chemical contaminant immunity and inflammation, F-35043, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes, France.;University of Rennes 1, UMS Biosit, F-35000, Rennes, France.;Research Institute for Environmental and Occupational Health (IRSET) INSERM U1085, team 'Stress, Membrane and Signaling, F-35043, Rennes;University of Rennes 1, UMS Biosit, F-35000, Rennes"
"499","Michaud K;de Tayrac M;D'Astous M;Paquet C;Gould PV;Saikali S","Michaud, Karine;de Tayrac, Marie;D'Astous, Myreille;Paquet, Claudie;Gould, Peter Vincent;Saikali, Stéphan","Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.","PloS one","United States","eng","Journal Article","","Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Oligodendroglioma;Proto-Oncogene Proteins c-myc;Survival Rate","Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 9;Cyclin D1;Cyclin-Dependent Kinase Inhibitor p16;Disease-Free Survival;Female;Gene Expression Regulation, Neoplastic;Humans;Male;Middle Aged;Oligodendroglioma;Proto-Oncogene Proteins c-myc;Survival Rate","To study the presence of 9p deletion and p16, cyclin D1 and Myc expression and their respective diagnostic and prognostic interest in oligodendrogliomas. We analyzed a retrospective series of 40 consecutive anaplastic oligodendrogliomas (OIII) from a single institution and compared them to a control series of 10 low grade oligodendrogliomas (OII). Automated FISH analysis of chromosome 9p status and immunohistochemistry for p16, cyclin D1 and Myc was performed for all cases and correlated with clinical and histological data, event free survival (EFS) and overall survival (OS). Chromosome 9p deletion was observed in 55% of OIII (22/40) but not in OII. Deletion was highly correlated to EFS (median = 29 versus 53 months, p<0.0001) and OS (median = 48 versus 83 months, p<0.0001) in both the total cohort and the OIII population. In 9p non-deleted oligodendrogliomas, p16 hyperexpression correlated with a shorter OS (p = 0.02 in OII and p = 0.0001 in OIII) whereas lack of p16 expression was correlated to a shorter EFS and OS in 9p deleted OIII (p = 0.001 and p = 0.0002 respectively). Expression of Cyclin D1 was significantly higher in OIII (median expression 45% versus 14% for OII, p = 0.0006) and was correlated with MIB-1 expression (p<0.0001), vascular proliferation (p = 0.002), tumor necrosis (p = 0.04) and a shorter EFS in the total cohort (p = 0.05). Hyperexpression of Myc was correlated to grade (median expression 27% in OII versus 35% in OIII, p = 0.03), and to a shorter EFS in 9p non-deleted OIII (p = 0.01). Chromosome 9p deletion identifies a subset of OIII with significantly worse prognosis. The combination of 9p status and p16 expression level identifies two distinct OIII populations with divergent prognosis. Hyperexpression of Bcl1 and Myc appears highly linked to anaplasia but the prognostic value is unclear and should be investigated further.","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.","NA",0,"1932-6203","PLoS One","PLoS One",2017,"2018","13","10.1371/journal.pone.0193213","e0193213","","","29489901","29489901","PUBMED","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada."
"500","Launey Y;Seguin P","Launey, Yoann;Seguin, Philippe","Is traumatic intracranial haemorrhage a specific risk factor for atrial fibrillation?","Heart (British Cardiac Society)","England","eng","Letter","Heart Disease","Anticoagulants;Atrial Fibrillation;Humans;Intracranial Hemorrhage, Traumatic;Intracranial Hemorrhages;Risk Factors;Stroke","Anticoagulants;Atrial Fibrillation;Humans;Intracranial Hemorrhage, Traumatic;Intracranial Hemorrhages;Risk Factors;Stroke","NA","Department of Anaesthetics and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anaesthetics and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"1468-201X","Heart","Heart",2018,"2018","104","10.1136/heartjnl-2017-312260","450","","","29440454","29440454","PUBMED","Department of Anaesthetics and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Anaesthetics and Critical Care Medicine, Centre Hospitalier Universitaire de Rennes, Rennes, France."
"501","Cacheux W;Dangles-Marie V;Rouleau E;Lazartigues J;Girard E;Briaux A;Mariani P;Richon S;Vacher S;Buecher B;Richard-Molard M;Jeannot E;Servant N;Farkhondeh F;Mariani O;Rio-Frio T;Roman-Roman S;Mitry E;Bieche I;Lièvre A","Cacheux, Wulfran;Dangles-Marie, Virginie;Rouleau, Etienne;Lazartigues, Julien;Girard, Elodie;Briaux, Adrien;Mariani, Pascale;Richon, Sophie;Vacher, Sophie;Buecher, Bruno;Richard-Molard, Marion;Jeannot, Emmanuelle;Servant, Nicolas;Farkhondeh, Fereshteh;Mariani, Odette;Rio-Frio, Thomas;Roman-Roman, Sergio;Mitry, Emmanuel;Bieche, Ivan;Lièvre, Astrid","Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.","Oncotarget","United States","eng","Journal Article","anal squamous cell carcinoma;signalling pathway;somatic mutation, copy number alteration;whole exome sequencing","","","Anal squamous cell carcinomas (ASCC) are rare tumours in humans. The etiological role of HPV infection is now well established but little is known about the molecular landscape and signalling pathways involved in the pathogenesis of this cancer. Here we report the results from a whole exome sequencing of a homogeneous group of 20 treatment-naive ASCC. A total of 2422 somatic single nucleotide variations (SNV) were found, with an overall moderate rate of somatic mutations per tumour (median: 105 relevant SNV per tumour) but a high mutational load in 3 tumours. The mutational signatures associated with age and APOBEC were observed in 100% and 60% of tumours respectively. The most frequently mutated genes were   (25%) followed by   (15%),   (15%)  and   (15%), the two last ones having never been described in ASCC. The main copy number alterations were gains of chromosome 3q (affecting  ) and losses of chromosome 11q (affecting  . The combined analysis of somatic mutations and copy number alterations show that recurrent alterations of the PI3K/AKT/mTOR pathway are frequent (60%) in these tumours, as well as potentially targetable alterations of other signalling pathways that have never been described in ASCC such as chromatin remodelling (45%) and ubiquitin mediated proteolysis (35%). These results highlight the possible implication of these aberrant signalling pathways in anal carcinogenesis and suggest promising new therapeutic approaches in ASCC. The high somatic mutation burden found in some tumours, suggesting an elevated neoantigen load could also predict sensitivity of ASCC to immunotherapy.","Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;IFR71, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 75270 Paris, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Plateforme de bioinfomatique, Centre de recherche de l'Institut Curie, 75248 Paris Cedex 05, INSERM, U900 Paris, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de chirurgie oncologique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Centre de recherche de l'Institut Curie, UMR144 Cell migration and invasion team, 75248 Paris Cedex 05, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département d'oncologie Médicale, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de radiothérapie, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Pathologie, Institut Curie, 75248 Paris Cedex 05, France.;Département de Pathologie, Institut Curie, 75248 Paris Cedex 05, France.;Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;EA 7331, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 75270 Paris, France.;Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 35033 Rennes Cedex 09, Université de Rennes 1, Faculté de Médecine, 35043 Rennes, France.;Inserm ER440-Oncogenesis, Stress and Signaling, Rue Bataille Flandres-Dunkerque, 35042 Rennes, France.","NA",0,"1949-2553","Oncotarget","Oncotarget",2017,"2018","9","10.18632/oncotarget.23066","464-476","","","29416628","29416628","PUBMED","Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;IFR71, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 75270 Paris, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Plateforme de bioinfomatique, Centre de recherche de l'Institut Curie, 75248 Paris Cedex 05, INSERM, U900 Paris, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de chirurgie oncologique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Centre de recherche de l'Institut Curie, UMR144 Cell migration and invasion team, 75248 Paris Cedex 05, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département d'oncologie Médicale, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de radiothérapie, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;Département de Pathologie, Institut Curie, 75248 Paris Cedex 05, France.;Département de Pathologie, Institut Curie, 75248 Paris Cedex 05, France.;Institut Curie Genomics of Excellence (ICGex) Platform, Institut Curie, 75248 Paris Cedex 05, France.;Département de Recherche Translationnelle, Centre de Recherche de l'Institut Curie, 75248 Paris Cedex 05, France.;Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Département de Génétique, Unité de pharmacogénomique, Ensemble Hospitalier de l'Institut Curie, 75248 Paris Cedex 05, France.;EA 7331, Faculté des sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Sorbonne Paris Cité, 75270 Paris, France.;Département d'oncologie médicale, Ensemble Hospitalier de l'Institut Curie, Hôpital René Huguenin, Saint-Cloud, 92210 Saint-Cloud, France.;Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Rennes, 35033 Rennes Cedex 09, Université de Rennes 1, Faculté de Médecine, 35043 Rennes, France.;Inserm ER440-Oncogenesis, Stress and Signaling, Rue Bataille Flandres-Dunkerque, 35042 Rennes, France."
"502","Garban F;Guyard A;Labussière H;Bulabois CE;Marchand T;Mounier C;Caillot D;Bay JO;Coiteux V;Schmidt-Tanguy A;Le Niger C;Robin C;Ladaique P;Lapusan S;Deconinck E;Rolland C;Foote AM;François A;Jacquot C;Tardivel R;Tiberghien P;Bosson JL","Garban, Frédéric;Guyard, Audrey;Labussière, Helene;Bulabois, Claude-Eric;Marchand, Tony;Mounier, Christiane;Caillot, Denis;Bay, Jacques-Olivier;Coiteux, Valérie;Schmidt-Tanguy, Aline;Le Niger, Catherine;Robin, Christine;Ladaique, Patrick;Lapusan, Simona;Deconinck, Eric;Rolland, Carole;Foote, Alison M;François, Anne;Jacquot, Chantal;Tardivel, René;Tiberghien, Pierre;Bosson, Jean-Luc","Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial.","JAMA oncology","United States","eng","Journal Article","","Adult;Aged;Blood Platelets;Blood Safety;Disease Transmission, Infectious;Disinfection;Equivalence Trials as Topic;Female;France;Hematologic Diseases;Hemostasis;Hemostatics;Hospitals, University;Humans;Male;Middle Aged;Platelet Transfusion;Thrombocytopenia","Adult;Aged;Blood Platelets;Blood Safety;Disease Transmission, Infectious;Disinfection;Equivalence Trials as Topic;Female;France;Hematologic Diseases;Hemostasis;Hemostatics;Hospitals, University;Humans;Male;Middle Aged;Platelet Transfusion;Thrombocytopenia","Pathogen reduction of platelet concentrates may reduce transfusion-transmitted infections but is associated with qualitative impairment, which could have clinical significance with regard to platelet hemostatic capacity. To compare the effectiveness of platelets in additive solution treated with amotosalen-UV-A vs untreated platelets in plasma or in additive solution in patients with thrombocytopenia and hematologic malignancies. The Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process (EFFIPAP) study was a randomized, noninferiority, 3-arm clinical trial performed from May 16, 2013, through January 21, 2016, at 13 French tertiary university hospitals. Clinical signs of bleeding were assessed daily until the end of aplasia, transfer to another department, need for a specific platelet product, or 30 days after enrollment. Consecutive adult patients with bone marrow aplasia, expected hospital stay of more than 10 days, and expected need of platelet transfusions were included. At least 1 transfusion of platelets in additive solution with amotosalen-UV-A treatment, in plasma, or in additive solution. The proportion of patients with grade 2 or higher bleeding as defined by World Health Organization criteria. Among 790 evaluable patients (mean [SD] age, 55 [13.4] years; 458 men [58.0%]), the primary end point was observed in 126 receiving pathogen-reduced platelets in additive solution (47.9%; 95% CI, 41.9%-54.0%), 114 receiving platelets in plasma (43.5%; 95% CI, 37.5%-49.5%), and 120 receiving platelets in additive solution (45.3%; 95% CI, 39.3%-51.3%). With a per-protocol population with a prespecified margin of 12.5%, noninferiority was not achieved when pathogen-reduced platelets in additive solution were compared with platelets in plasma (4.4%; 95% CI, -4.1% to 12.9%) but was achieved when the pathogen-reduced platelets were compared with platelets in additive solution (2.6%; 95% CI, -5.9% to 11.1%). The proportion of patients with grade 3 or 4 bleeding was not different among treatment arms. Although the hemostatic efficacy of pathogen-reduced platelets in thrombopenic patients with hematologic malignancies was noninferior to platelets in additive solution, such noninferiority was not achieved when comparing pathogen-reduced platelets with platelets in plasma. clinicaltrials.gov Identifier: NCT01789762.","University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Etablissement Français du Sang, Grenoble, France.;Centre d'Investigation Clinique 1406-Innovation Technologique, Institut national de la santé et de la recherche médicale, Grenoble, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Service d'Hématologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Lille, Lille, France.;Service d'Hématologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Hématologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.;Service d'Hématologie, Institut Paoli Calmettes, Marseille, France.;Service d'Hématologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, Paris, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Cellule Publication, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, Rennes, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Unité mixte de recherche 1098, Institut national de la santé et de la recherche médicale, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Centre d'Investigation Clinique 1406-Innovation Technologique, Institut national de la santé et de la recherche médicale, Grenoble, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.","NA",0,"2374-2445","JAMA Oncol","JAMA Oncol",2018,"2018","4","10.1001/jamaoncol.2017.5123","468-475","","","29392283","29392283","PUBMED","University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Etablissement Français du Sang, Grenoble, France.;Centre d'Investigation Clinique 1406-Innovation Technologique, Institut national de la santé et de la recherche médicale, Grenoble, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Service d'Hématologie, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service d'Hématologie, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Lille, Lille, France.;Service d'Hématologie, Centre Hospitalier Universitaire d'Angers, Angers, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Brest, Brest, France.;Service d'Hématologie, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France.;Service d'Hématologie, Institut Paoli Calmettes, Marseille, France.;Service d'Hématologie, Hôpital Saint-Antoine, Assistance Publique Hôpitaux de Paris, Paris, France.;Service d'Hématologie, Centre Hospitalier Universitaire de Besançon, Besançon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Cellule Publication, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Etablissement Français du Sang, Rennes, France.;Etablissement Français du Sang, La Plaine Saint-Denis, France.;Unité mixte de recherche 1098, Institut national de la santé et de la recherche médicale, Université de Franche-Comté, Etablissement Français du Sang, Besançon, France.;University Grenoble Alpes, Centre National de Recherche Scientifique, Techniques de l'Ingénierie Médicale et de la Complexité-Institut Mathématiques Appliquées de Grenoble 38000, Grenoble, France.;Centre d'Investigation Clinique 1406-Innovation Technologique, Institut national de la santé et de la recherche médicale, Grenoble, France.;Service de Biostatistiques, Centre Hospitalier Universitaire de Grenoble Alpes, Grenoble, France."
"503","Pinto A;Alfadhel M;Akroyd R;Atik Altınok Y;Bernabei SM;Bernstein L;Bruni G;Caine G;Cameron E;Carruthers R;Cochrane B;Daly A;de Boer F;Delaunay S;Dianin A;Dixon M;Drogari E;Dubois S;Evans S;Gribben J;Gugelmo G;Heidenborg C;Hunjan I;Kok IL;Kumru B;Liguori A;Mayr D;Megdad E;Meyer U;Oliveira RB;Pal A;Pozzoli A;Pretese R;Rocha JC;Rosenbaum-Fabian S;Serrano-Nieto J;Sjoqvist E;Timmer C;White L;van den Hurk T;van Rijn M;Zweers H;Ziadlou M;MacDonald A","Pinto, A;Alfadhel, M;Akroyd, R;Atik Altınok, Y;Bernabei, S M;Bernstein, L;Bruni, G;Caine, G;Cameron, E;Carruthers, R;Cochrane, B;Daly, A;de Boer, F;Delaunay, S;Dianin, A;Dixon, M;Drogari, E;Dubois, S;Evans, S;Gribben, J;Gugelmo, G;Heidenborg, C;Hunjan, I;Kok, I L;Kumru, B;Liguori, A;Mayr, D;Megdad, E;Meyer, U;Oliveira, R B;Pal, A;Pozzoli, A;Pretese, R;Rocha, J C;Rosenbaum-Fabian, S;Serrano-Nieto, J;Sjoqvist, E;Timmer, C;White, L;van den Hurk, T;van Rijn, M;Zweers, H;Ziadlou, M;MacDonald, A","International practices in the dietary management of fructose 1-6 biphosphatase deficiency.","Orphanet journal of rare diseases","England","eng","Journal Article","Dietary restrictions;Fasting tolerance;Fructose 1,6 bisphosphatase deficiency;Uncooked cornstarch","Acidosis, Lactic;Cross-Sectional Studies;Dietary Carbohydrates;Dietary Supplements;Fasting;Fructose-1,6-Diphosphatase Deficiency;Humans;Hypoglycemia;Surveys and Questionnaires","Acidosis, Lactic;Cross-Sectional Studies;Dietary Carbohydrates;Dietary Supplements;Fasting;Fructose-1,6-Diphosphatase Deficiency;Humans;Hypoglycemia;Surveys and Questionnaires","In fructose 1,6 bisphosphatase (FBPase) deficiency, management aims to prevent hypoglycaemia and lactic acidosis by avoiding prolonged fasting, particularly during febrile illness. Although the need for an emergency regimen to avoid metabolic decompensation is well established at times of illness, there is uncertainty about the need for other dietary management strategies such as sucrose or fructose restriction. We assessed international differences in the dietary management of FBPase deficiency. A cross-sectional questionnaire (13 questions) was emailed to all members of the Society for the Study of Inborn Errors of Metabolism (SSIEM) and a wide database of inherited metabolic disorder dietitians. Thirty-six centres reported the dietary prescriptions of 126 patients with FBPase deficiency. Patients' age at questionnaire completion was: 1-10y, 46% (n = 58), 11-16y, 21% (n = 27), and >16y, 33% (n = 41). Diagnostic age was: <1y, 36% (n = 46); 1-10y, 59% (n = 74); 11-16y, 3% (n = 4); and >16y, 2% (n = 2). Seventy-five per cent of centres advocated dietary restrictions. This included restriction of: high sucrose foods only (n = 7 centres, 19%); fruit and sugary foods (n = 4, 11%); fruit, vegetables and sugary foods (n = 13, 36%). Twenty-five per cent of centres (n = 9), advised no dietary restrictions when patients were well. A higher percentage of patients aged >16y rather than ≤16y were prescribed dietary restrictions: patients aged 1-10y, 67% (n = 39/58), 11-16y, 63% (n = 17/27) and >16y, 85% (n = 35/41). Patients classified as having a normal fasting tolerance increased with age from 30% in 1-10y, to 36% in 11-16y, and 58% in >16y, but it was unclear if fasting tolerance was biochemically proven. Twenty centres (56%) routinely prescribed uncooked cornstarch (UCCS) to limit overnight fasting in 47 patients regardless of their actual fasting tolerance (37%). All centres advocated an emergency regimen mainly based on glucose polymer for illness management. Although all patients were prescribed an emergency regimen for illness, use of sucrose and fructose restricted diets with UCCS supplementation varied widely. Restrictions did not relax with age. International guidelines are necessary to help direct future dietary management of FBPase deficiency.","Birmingham Women's and Children's Hospital, Birmingham;King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Genetic Division, Department of Pediatrics, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia.;National Metabolic Service, Starship Child Health and Auckland City Hospital, Auckland, New Zealand.;Pediatric Metabolism Department, Ege University Medical Faculty, Izmir, Turkey.;Children's Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy.;IMD Nutrition, Children's Hospital Colorado, Aurora, CO, USA.;Azienda Ospedaliero Universitaria Meyer, Florence, Italy.;Mid Yorks NHS Trust, Yorkshire, UK.;Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.;Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.;Royal Hospital for Children, Glasgow, Scotland, UK.;Birmingham Women's and Children's Hospital, Birmingham, UK.;Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, PO BOX 30.001, 9700 RB, Groningen, The Netherlands.;Centre hospitalier Universitaire de Rennes, Rennes, France.;Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Verona, Italy.;Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.;Unit of Metabolic Diseases, Choremio Research Laboratory, 1st Department of Paediatrics, University of Athens Medical School, ""Aghia Sophia"" Children's Hospital, Athens, Greece.;Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France.;Birmingham Women's and Children's Hospital, Birmingham, UK.;Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Verona, Italy.;Karolinska University Hospital, Stockholm, Sweden.;Bradford Teaching Hospital NHS Foundation Trust, Bradford, UK.;Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.;Department of Nutrition and Diet, Gaziantep Cengiz Gökçek Obstetrics and Pediatric Hospital, Gaziantep, Turkey.;Children's Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy.;Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria.;Metabolic Nutrition Clinics. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.;Clinic of Paediatric Kidney, Liver and Metabolic Diseases, Medical School Hannover, Hannover, Germany.;Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brazil.;Akademiska children's hospital, Uppsala, Sweden.;Guglielmo Da Saliceto's Hospital, Piacenza, Italy.;Fondazione MBBM, San Gerardo Hospital, Monza, Italy.;Centro de Referência de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal.;Centro de Genética Médica, Centro Hospitalar do Porto (CHP), Porto, Portugal.;Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal.;Centre for Health Technology and Services Research (CINTESIS), Porto, Portugal.;University Children's Hospital Freiburg, Freiburg, Germany.;Hospital Regional Universitario Málaga, Málaga, Spain.;Children's Hospital, University Hospital, Lund, Sweden.;Academic Medical Center Amsterdam, Amsterdam, Netherlands.;Sheffield Children's Hospital, Sheffield, UK.;Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.;Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, PO BOX 30.001, 9700 RB, Groningen, The Netherlands.;Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.;Nutrition Department at International campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.;Birmingham Women's and Children's Hospital, Birmingham, UK.","NA",0,"1750-1172","Orphanet J Rare Dis","Orphanet J Rare Dis",2017,"2018","13","10.1186/s13023-018-0760-3","21","","","29370874","29370874","PUBMED","Birmingham Women's and Children's Hospital, Birmingham;King Abdullah International Medical Research Centre, King Saud bin Abdulaziz University for Health Sciences, Genetic Division, Department of Pediatrics, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs (NGHA), Riyadh, Saudi Arabia.;National Metabolic Service, Starship Child Health and Auckland City Hospital, Auckland, New Zealand.;Pediatric Metabolism Department, Ege University Medical Faculty, Izmir, Turkey.;Children's Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy.;IMD Nutrition, Children's Hospital Colorado, Aurora, CO, USA.;Azienda Ospedaliero Universitaria Meyer, Florence, Italy.;Mid Yorks NHS Trust, Yorkshire, UK.;Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.;Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK.;Royal Hospital for Children, Glasgow, Scotland, UK.;Birmingham Women's and Children's Hospital, Birmingham, UK.;Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, PO BOX 30.001, 9700 RB, Groningen, The Netherlands.;Centre hospitalier Universitaire de Rennes, Rennes, France.;Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Verona, Italy.;Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.;Unit of Metabolic Diseases, Choremio Research Laboratory, 1st Department of Paediatrics, University of Athens Medical School, ""Aghia Sophia"" Children's Hospital, Athens, Greece.;Centre de référence des maladies héréditaires du métabolisme, Hôpital Necker Enfants Malades, Paris, France.;Birmingham Women's and Children's Hospital, Birmingham, UK.;Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.;Department of Pediatrics, Regional Centre for Newborn Screening, Diagnosis and Treatment of Inherited Metabolic Diseases and Congenital Endocrine Diseases, University Hospital of Verona, Verona, Italy.;Karolinska University Hospital, Stockholm, Sweden.;Bradford Teaching Hospital NHS Foundation Trust, Bradford, UK.;Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.;Department of Nutrition and Diet, Gaziantep Cengiz Gökçek Obstetrics and Pediatric Hospital, Gaziantep, Turkey.;Children's Hospital Bambino Gesù, Division of Artificial Nutrition, Rome, Italy.;Ernährungsmedizinische Beratung, Universitätsklinik für Kinder- und Jugendheilkunde, Salzburg, Austria.;Metabolic Nutrition Clinics. King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.;Clinic of Paediatric Kidney, Liver and Metabolic Diseases, Medical School Hannover, Hannover, Germany.;Centro de Referência em Erros Inatos do Metabolismo, Universidade Federal de São Paulo, São Paulo, Brazil.;Akademiska children's hospital, Uppsala, Sweden.;Guglielmo Da Saliceto's Hospital, Piacenza, Italy.;Fondazione MBBM, San Gerardo Hospital, Monza, Italy.;Centro de Referência de Doenças Hereditárias do Metabolismo, Centro Hospitalar do Porto - CHP, Porto, Portugal.;Centro de Genética Médica, Centro Hospitalar do Porto (CHP), Porto, Portugal.;Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal.;Centre for Health Technology and Services Research (CINTESIS), Porto, Portugal.;University Children's Hospital Freiburg, Freiburg, Germany.;Hospital Regional Universitario Málaga, Málaga, Spain.;Children's Hospital, University Hospital, Lund, Sweden.;Academic Medical Center Amsterdam, Amsterdam, Netherlands.;Sheffield Children's Hospital, Sheffield, UK.;Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.;Division of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, PO BOX 30.001, 9700 RB, Groningen, The Netherlands.;Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands.;Nutrition Department at International campus, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.;Birmingham Women's and Children's Hospital, Birmingham, UK."
"504","Benguerfi S;Thepault F;Lena H;Ricordel C","Benguerfi, Soraya;Thepault, Fanny;Lena, Hervé;Ricordel, Charles","Spontaneous splenic rupture as a rare complication of G-CSF injection.","BMJ case reports","England","eng","Case Reports","lung cancer (oncology);unwanted effects / adverse reactions","Adenocarcinoma;Adenocarcinoma of Lung;Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Brain Neoplasms;Female;Granulocyte Colony-Stimulating Factor;Humans;Injections;Laparoscopy;Lung Neoplasms;Middle Aged;Peritoneal Dialysis;Rupture, Spontaneous;Splenic Rupture;Syncope;Treatment Outcome","Adenocarcinoma;Adenocarcinoma of Lung;Antineoplastic Combined Chemotherapy Protocols;Bone Neoplasms;Brain Neoplasms;Female;Granulocyte Colony-Stimulating Factor;Humans;Injections;Laparoscopy;Lung Neoplasms;Middle Aged;Peritoneal Dialysis;Rupture, Spontaneous;Splenic Rupture;Syncope;Treatment Outcome","Splenic rupture is an infrequent and underdiagnosed side effect of granylocyte colony-stimulating factor (G-CSF). We report the case of a 54-year-old woman with brain and bone metastasis in a lung adenocarcinoma who was admitted for faintness 28 days after a G-CSF injection. Abdominal CT scan confirmed the diagnosis of splenic rupture. A conservative treatment was chosen using a peritoneal cleansing during laparoscopic surgery. Clinicians should be aware of this rare toxicity as it could be severe, but easily reversible using appropriate surgical treatment. Even if prognosis remains poor for patients with lung cancer, invasive procedures could be considered in this rapidly evolving setting, especially in case of reversible adverse event.","Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2018,"2018","2018","10.1136/bcr-2017-222561",NA,"","","29330272","29330272","PUBMED","Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Chemistry Oncogenesis and Stress Signaling, INSERM U1242, Universite de Rennes 1, Rennes, France."
"505","Kristensen DM;Desdoits-Lethimonier C;Mackey AL;Dalgaard MD;De Masi F;Munkbøl CH;Styrishave B;Antignac JP;Le Bizec B;Platel C;Hay-Schmidt A;Jensen TK;Lesné L;Mazaud-Guittot S;Kristiansen K;Brunak S;Kjaer M;Juul A;Jégou B","Kristensen, David Møbjerg;Desdoits-Lethimonier, Christèle;Mackey, Abigail L;Dalgaard, Marlene Danner;De Masi, Federico;Munkbøl, Cecilie Hurup;Styrishave, Bjarne;Antignac, Jean-Philippe;Le Bizec, Bruno;Platel, Christian;Hay-Schmidt, Anders;Jensen, Tina Kold;Lesné, Laurianne;Mazaud-Guittot, Séverine;Kristiansen, Karsten;Brunak, Søren;Kjaer, Michael;Juul, Anders;Jégou, Bernard","Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism.","Proceedings of the National Academy of Sciences of the United States of America","United States","eng","Journal Article","endocrine disruption;endocrinology;hypogonadism;ibuprofen;reproduction","Adult;Analgesics, Non-Narcotic;Cell Line;Gene Expression;Humans;Hypogonadism;Ibuprofen;In Vitro Techniques;Leydig Cells;Luteinizing Hormone;Male;Middle Aged;Prostaglandins;Sertoli Cells;Testosterone","Adult;Analgesics, Non-Narcotic;Cell Line;Gene Expression;Humans;Hypogonadism;Ibuprofen;In Vitro Techniques;Leydig Cells;Luteinizing Hormone;Male;Middle Aged;Prostaglandins;Sertoli Cells;Testosterone","Concern has been raised over increased male reproductive disorders in the Western world, and the disruption of male endocrinology has been suggested to play a central role. Several studies have shown that mild analgesics exposure during fetal life is associated with antiandrogenic effects and congenital malformations, but the effects on the adult man remain largely unknown. Through a clinical trial with young men exposed to ibuprofen, we show that the analgesic resulted in the clinical condition named ""compensated hypogonadism,"" a condition prevalent among elderly men and associated with reproductive and physical disorders. In the men, luteinizing hormone (LH) and ibuprofen plasma levels were positively correlated, and the testosterone/LH ratio decreased. Using adult testis explants exposed or not exposed to ibuprofen, we demonstrate that the endocrine capabilities from testicular Leydig and Sertoli cells, including testosterone production, were suppressed through transcriptional repression. This effect was also observed in a human steroidogenic cell line. Our data demonstrate that ibuprofen alters the endocrine system via selective transcriptional repression in the human testes, thereby inducing compensated hypogonadism.","Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Biology, Faculty of Science, University of Copenhagen, 2100 Copenhagen, Denmark.;Institute of Metagenomics, BGI-Shenzhen, Shenzhen 518083, China.;Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark;EDMaRC (International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health), Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.","NA",0,"1091-6490","Proc Natl Acad Sci U S A","Proc Natl Acad Sci U S A",2018,"2018","115","10.1073/pnas.1715035115","E715-E724","","","29311296","29311296","PUBMED","Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;DTU Bio and Health Informatics, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;L'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France.;Unité de coordination hospitalière des prélèvements d'organes et de tissus, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France.;Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France.;Department of Biology, Faculty of Science, University of Copenhagen, 2100 Copenhagen, Denmark.;Institute of Metagenomics, BGI-Shenzhen, Shenzhen 518083, China.;Danish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 1165 Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.;Institute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital, 2400 Copenhagen NV, Denmark.;Center for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark.;Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark;EDMaRC (International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health), Rigshospitalet, University of Copenhagen, DK-2200 Copenhagen, Denmark.;Université de Rennes I, Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France."
"506","Rigault E;Lenoir L;Bouguen G;Pagenault M;Lièvre A;Garin E;Siproudhis L;Bretagne JF","Rigault, Eugénie;Lenoir, Laurence;Bouguen, Guillaume;Pagenault, Mael;Lièvre, Astrid;Garin, Etienne;Siproudhis, Laurent;Bretagne, Jean-François",NA,"Endoscopy international open","Germany","eng","Journal Article","","",""," The relevance of incidental colorectal focal   F-FDG PET/CT uptake is debatable. All patients who were referred for colonoscopy because of incidental colonic focal FDG uptake were included in this retrospective study.  PET/CT imaging characteristics were reviewed by a nuclear physician who was blinded to endoscopic and histopathological findings to determine the location of FDG uptake sites and to measure the maximum standardized uptake values (SUVmax) and metabolic volume (MV). Endoscopic findings were categorized as malignant lesions (ML), high-risk polyps (HRP), low-risk polyps (LRP) or other non-neoplastic lesions (NNL).  Seventy patients with 84 foci of FDG uptake were included. The proportions of true-positive (lesions found at colonoscopy at the same location) and false-positive (no lesion at colonoscopy) PET/CT findings were 65.5 % (n = 55) and 34.5 % (n = 29). Median SUVmax values did not differ between true-positive and false-positive findings (    = 0.27). Median MV30 values differed significantly between true-positive (5.5 cm   , [3.3 - 10.9 cm   ]) and false-positive (9.7 cm   , [5.2 - 40.8 cm   ]) findings (    = 0.015). Among the 55 true-positive FDG uptake sites, there were 14 (25.5 %) malignant lesions, 30 (54.5 %) HRP, 4 (7.3 %) LRP, and 7 (12.7 %) NNL. Median MV30 values differed significantly between advanced neoplasia (5.0 cm   , [2.9 - 9.7 cm   ]) and other endoscopic findings (9.4 cm   , [5.2 - 39.8 cm   ]) (    = 0.001); the AUROC was 0.71. By per-colonic segment analysis, the distribution of true-positive, false-negative, false-positive, and true-negative FDG PET/CT findings was as follows: 21.5 %, 14.2 %, 11.5 %, and 52.8 %, respectively.  Our study demonstrates that follow-up complete colonoscopy is mandatory in all patients with incidental colorectal focal   F-FDG PET/CT uptake.","Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service de Médecine Nucléaire, Centre Eugène Marquis, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service de Médecine Nucléaire, Centre Eugène Marquis, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.","NA",0,"2364-3722","Endosc Int Open","Endosc Int Open",2017,"2017","5","10.1055/s-0043-116384","E924-E930","","","28924601","28924601","PUBMED","Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service de Médecine Nucléaire, Centre Eugène Marquis, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service de Médecine Nucléaire, Centre Eugène Marquis, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes.;Service des Maladies de l'Appareil Digestif, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes."
"507","Curtit E;Pivot X;Henriques J;Paget-Bailly S;Fumoleau P;Rios M;Bonnefoi H;Bachelot T;Soulié P;Jouannaud C;Bourgeois H;Petit T;Tennevet I;Assouline D;Mathieu MC;Jacquin JP;Lavau-Denes S;Darut-Jouve A;Ferrero JM;Tarpin C;Lévy C;Delecroix V;Trillet-Lenoir V;Cojocarasu O;Meunier J;Pierga JY;Kerbrat P;Faure-Mercier C;Blanché H;Sahbatou M;Boland A;Bacq D;Besse C;Thomas G;Deleuze JF;Pauporté I;Romieu G;Cox DG","Curtit, Elsa;Pivot, Xavier;Henriques, Julie;Paget-Bailly, Sophie;Fumoleau, Pierre;Rios, Maria;Bonnefoi, Hervé;Bachelot, Thomas;Soulié, Patrick;Jouannaud, Christelle;Bourgeois, Hugues;Petit, Thierry;Tennevet, Isabelle;Assouline, David;Mathieu, Marie-Christine;Jacquin, Jean-Philippe;Lavau-Denes, Sandrine;Darut-Jouve, Ariane;Ferrero, Jean-Marc;Tarpin, Carole;Lévy, Christelle;Delecroix, Valérie;Trillet-Lenoir, Véronique;Cojocarasu, Oana;Meunier, Jérôme;Pierga, Jean-Yves;Kerbrat, Pierre;Faure-Mercier, Céline;Blanché, Hélène;Sahbatou, Mourad;Boland, Anne;Bacq, Delphine;Besse, Céline;Thomas, Gilles;Deleuze, Jean-François;Pauporté, Iris;Romieu, Gilles;Cox, David G","Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.","Breast cancer research : BCR","England","eng","Journal Article","Breast cancer;Genetic variant;Prognosis;Risk score;Single nucleotide polymorphism","Adult;Aged;Aged, 80 and over;Alleles;Biomarkers, Tumor;Breast Neoplasms;Clinical Trials, Phase III as Topic;Cohort Studies;Female;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Staging;Polymorphism, Single Nucleotide;Prognosis;Randomized Controlled Trials as Topic;Survival Analysis;Tumor Burden;Young Adult","Adult;Aged;Aged, 80 and over;Alleles;Biomarkers, Tumor;Breast Neoplasms;Clinical Trials, Phase III as Topic;Cohort Studies;Female;Genetic Association Studies;Genetic Predisposition to Disease;Genotype;Humans;Middle Aged;Neoplasm Grading;Neoplasm Metastasis;Neoplasm Staging;Polymorphism, Single Nucleotide;Prognosis;Randomized Controlled Trials as Topic;Survival Analysis;Tumor Burden;Young Adult","Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer. A 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS. The median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1-97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival. In a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients' outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis. PHARE cohort: NCT00381901 , Sept. 26, 2006 - SIGNAL cohort: INCa RECF1098, Jan. 28, 2009.","Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon;Department of Medical Oncology, University Hospital Jean Minjoz, 3, boulevard Alexandre Fleming, 25030, Besancon Cedex;Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Georges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France.;Institut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France.;Institut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Centre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France.;Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France.;Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France.;Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France.;Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.;Centre Henri Becquerel, rue d'Amiens, 76038, Rouen, France.;Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France.;Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.;Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France.;Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France.;Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France.;Centre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France.;Institut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Centre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France.;Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France.;Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France.;Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France.;Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France.;Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France.;Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Oncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France.;Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France.","NA",0,"1465-542X","Breast Cancer Res","Breast Cancer Res",2016,"2017","19","10.1186/s13058-017-0888-4","98","","","28830573","28830573","PUBMED","Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon;Department of Medical Oncology, University Hospital Jean Minjoz, 3, boulevard Alexandre Fleming, 25030, Besancon Cedex;Hôpital Jean-Minjoz, Centre Hospitalier Universitaire, UMR 1098 INSERM-EFS-Université de Bourgogne Franche-Comté, Boulevard Fleming, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Centre Hospitalier Universitaire, Unité de Méthodologie et de Qualité de Vie en Cancérologie, 2 place St Jacques, 25000, Besançon, France.;Georges-François Leclerc, 1 Rue du Professeur Marion, 21000, Dijon, France.;Institut de Cancérologie de Lorraine - Alexis Vautrin, département d'Oncologie Médicale, 6, avenue de Bourgogne, 54511, Vandoeuvre Les Nancy Cedex, France.;Institut Bergonié, Département d'Oncologie Médicale, 229 Cours de l'Argonne, 33000, Bordeaux, France.;Centre Léon Bérard, Département de Cancérologie Médicale, 28 rue Laënnec, Lyon Cedex 08, France.;Institut de Cancérologie de l'Ouest, Service Oncologie Médicale, 2 rue Moll, 49993, Angers Cedex 09, France.;Institut Jean Godinot, Service Oncologie Médicale, 1 rue du Général Koenig, 51056, Reims cedex, France.;Clinique Victor Hugo-Centre Jean Bernard, 18 rue Victor Hugo, 72015, Le Mans Cedex 2, France.;Centre Paul Strauss, Service d'Oncologie Médicale, 3 rue de la Porte de l'Hôpital, 67065, Strasbourg Cedex, France.;Centre Henri Becquerel, rue d'Amiens, 76038, Rouen, France.;Institut Daniel Hollard, Service Oncologie Médicale, 8 rue du Docteur Calmette, 38028, Grenoble Cedex 01, France.;Institut Gustave Roussy, Comité de Pathologie mammaire, 39 rue Camille Desmoulins, 94805, Villejuif Cedex, France.;Institut de Cancérologie Lucien Neuwirth, Service Oncologie Médicale, 108 bis avenue Albert Raimond, 42270, Saint Priest en Jarez, France.;Centre Hospitalier de Limoges, Service d'Oncologie Médicale, 2 avenue Martin Luther King, 87042, Limoges Cedex, France.;Clinique Drévon, Centre d'oncologie et de radiothérapie du Parc, 18 cours du général de Gaulle, 21000, Dijon, France.;Centre Antoine Lacassagne, Département Oncologie Médicale, 33 avenue de Valombrose, 06189, Nice Cedex 02, France.;Institut Paoli-Calmettes, Département d'Oncologie Médicale, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.;Centre François Baclesse, 3 avenue du Général Harris, 14076, Caen Cedex 5, France.;Centre Etienne Dolet, Pôle Mutualiste, Service Oncologie Médicale, 11 boulevard Georges Charpak, 44606, Saint Nazaire, France.;Centre Hospitalier Lyon Sud, Service d'Oncologie Médicale, 165 chemin du Grand Revoyet, 69495, Pierre-Benite Cedex, France.;Centre Hospitalier Le Mans, Service d'Onco-Hématologie et Médecine interne, 194 avenue Rubillard, 72037, Le Mans Cedex, France.;Centre Hospitalier Régional d'Orléans, Service d'Oncologie médicale, 1 rue Porte Madeleine, 45032, Orleans Cedex 1, France.;Institut Curie, Department of Medical Oncology, 26 rue d'Ulm, 75248, Paris Cedex 05, France.;Centre Eugène Marquis, Service Oncologie médicale, Rue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Laënnec, Lyon Cedex 08, France.;Centre d'Etudes du Polymorphisme Humain, 27 rue Juliette Dodu, 75010, Paris, France.;Centre National du Génotypage, 2 rue Gaston Crémieux, CP 5721, 91057, Evry Cedex, France.;Institut National du Cancer, Direction de la Recherche, 52 avenue Morizet, 92513, Boulogne-Billancourt, France.;Oncologie Sénologie, ICM Institut Régional du Cancer, 34298, Montpellier Cedex, France.;Centre de Recherche en Cancérologie de Lyon, INSERM U1052 - Centre Léon Bérard, 28 rue Laennec, 69373, Lyon, France."
"508","Sesé L;Nunes H;Cottin V;Sanyal S;Didier M;Carton Z;Israel-Biet D;Crestani B;Cadranel J;Wallaert B;Tazi A;Maître B;Prévot G;Marchand-Adam S;Guillot-Dudoret S;Nardi A;Dury S;Giraud V;Gondouin A;Juvin K;Borie R;Wislez M;Valeyre D;Annesi-Maesano I","Sesé, Lucile;Nunes, Hilario;Cottin, Vincent;Sanyal, Shreosi;Didier, Morgane;Carton, Zohra;Israel-Biet, Dominique;Crestani, Bruno;Cadranel, Jacques;Wallaert, Benoit;Tazi, Abdellatif;Maître, Bernard;Prévot, Grégoire;Marchand-Adam, Sylvain;Guillot-Dudoret, Stéphanie;Nardi, Annelyse;Dury, Sandra;Giraud, Violaine;Gondouin, Anne;Juvin, Karine;Borie, Raphael;Wislez, Marie;Valeyre, Dominique;Annesi-Maesano, Isabella","Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis.","Thorax","England","eng","Journal Article","acute exacerbation;air pollution;idiopathic pulmonary fibrosis;ozone;particulate matter","Aged;Air Pollutants;Air Pollution;Environmental Exposure;Female;France;Humans;Idiopathic Pulmonary Fibrosis;Longitudinal Studies;Male;Middle Aged;Nitrogen Dioxide;Ozone;Particulate Matter;Proportional Hazards Models;Risk Factors;Time Factors","Aged;Air Pollutants;Air Pollution;Environmental Exposure;Female;France;Humans;Idiopathic Pulmonary Fibrosis;Longitudinal Studies;Male;Middle Aged;Nitrogen Dioxide;Ozone;Particulate Matter;Proportional Hazards Models;Risk Factors;Time Factors","Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding to various profiles: stability, physiological disease progression and rapid decline. A minority of patients experience acute exacerbations (AEs). A recent study suggested that ozone and nitrogen dioxide might contribute to the occurrence of AE. We hypothesised that outdoor air pollution might influence the natural history of IPF. Patients were selected from the French cohort COhorte FIbrose (COFI), a national multicentre longitudinal prospective cohort of IPF (n=192). Air pollutant levels were assigned to each patient from the air quality monitoring station closest to the patient's geocoded residence. Cox proportional hazards model was used to evaluate the impact of air pollution on AE, disease progression and death. Onset of AEs was significantly associated with an increased mean level of ozone in the six preceding weeks, with an HR of 1.47 (95% CI 1.13 to 1.92) per 10 µg/m  (p=0.005). Cumulative levels of exposure to particulate matter PM  and PM  were above WHO recommendations in 34% and 100% of patients, respectively. Mortality was significantly associated with increased levels of exposure to PM  (HR=2.01, 95% CI 1.07 to 3.77) per 10 µg/m  (p=0.03), and PM  (HR=7.93, 95% CI 2.93 to 21.33) per 10 µg/m  (p<0.001). This study suggests that air pollution has a negative impact on IPF outcomes, corroborating the role of ozone on AEs and establishing, for the first time, the potential role of long-term exposure to PM  and PM  on overall mortality.","EPAR, Université Pierre et Marie, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, Hôpital Louis Pradel, Lyon, France.;EPAR, Université Pierre et Marie, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital HEGP, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Tenon, Paris, France.;Service de Pneumologie, Hôpital Albert Calmette, Lille, France.;Service de Pneumologie, AP-HP, Hôpital Saint-Louis, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Henri-Mondor, Créteil, France.;Service de Pneumologie, Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service de Pneumologie, Hôpital Bretonneau Centre Hospitalier Universitaire de Tours, Paris, France.;Service de Pneumologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Nouvel Hôpital Civil, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de Pneumologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de Pneumologie, AP-HP, Hôpital Ambroise Paré, Boulogne, France.;Service de Pneumologie, Hôpital Jean Minjoz, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Pneumologie, AP-HP, Hôpital HEGP, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Tenon, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;EPAR, Université Pierre et Marie, Paris, France.","NA",0,"1468-3296","Thorax","Thorax",2017,"2018","73","10.1136/thoraxjnl-2017-209967","145-150","","","28798214","28798214","PUBMED","EPAR, Université Pierre et Marie, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, Hôpital Louis Pradel, Lyon, France.;EPAR, Université Pierre et Marie, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Service de Pneumologie, AP-HP, Hôpital HEGP, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Tenon, Paris, France.;Service de Pneumologie, Hôpital Albert Calmette, Lille, France.;Service de Pneumologie, AP-HP, Hôpital Saint-Louis, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Henri-Mondor, Créteil, France.;Service de Pneumologie, Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;Service de Pneumologie, Hôpital Bretonneau Centre Hospitalier Universitaire de Tours, Paris, France.;Service de Pneumologie, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Service de Pneumologie, Nouvel Hôpital Civil, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France.;Service de Pneumologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France.;Service de Pneumologie, AP-HP, Hôpital Ambroise Paré, Boulogne, France.;Service de Pneumologie, Hôpital Jean Minjoz, Centre Hospitalier Universitaire de Besançon, Besançon, France.;Service de Pneumologie, AP-HP, Hôpital HEGP, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Bichat, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Tenon, Paris, France.;Service de Pneumologie, AP-HP, Hôpital Avicenne, Bobigny, France.;Université Paris, Bobigny, France.;EPAR, Université Pierre et Marie, Paris, France."
"509","Tomasini P;Brosseau S;Mazières J;Merlio JP;Beau-Faller M;Mosser J;Wislez M;Ouafik L;Besse B;Rouquette I;Debieuvre D;Escande F;Westeel V;Audigier-Valette C;Missy P;Langlais A;Morin F;Moro-Sibilot D;Zalcman G;Barlesi F","Tomasini, Pascale;Brosseau, Solenn;Mazières, Julien;Merlio, Jean-Philippe;Beau-Faller, Michèle;Mosser, Jean;Wislez, Marie;Ouafik, L'Houcine;Besse, Benjamin;Rouquette, Isabelle;Debieuvre, Didier;Escande, Fabienne;Westeel, Virginie;Audigier-Valette, Clarisse;Missy, Pascale;Langlais, Alexandra;Morin, Frank;Moro-Sibilot, Denis;Zalcman, Gérard;Barlesi, Fabrice",NA,"The European respiratory journal","England","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Cohort Studies;Disease-Free Survival;ErbB Receptors;Female;France;Humans;Lung Neoplasms;Male;Middle Aged;Multivariate Analysis;Protein Kinase Inhibitors;Survival Rate","Adult;Aged;Aged, 80 and over;Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Cohort Studies;Disease-Free Survival;ErbB Receptors;Female;France;Humans;Lung Neoplasms;Male;Middle Aged;Multivariate Analysis;Protein Kinase Inhibitors;Survival Rate","Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of   wild-type ( -wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment of  wt NSCLC and there is a need to reassess the role of EGFR-TKIs in this setting.The Biomarkers France study is a large nationwide cohort of NSCLC patients tested for   mutations. We used this database to collect clinical, biological, treatment and outcome data on  wt patients who received second-line treatment with either EGFR-TKIs or chemotherapy.Among 1278 patients, 868 received chemotherapy and 410 received an EGFR-TKI. Median overall survival and progression-free survival were longer with chemotherapy than with an EGFR-TKI. Overall survival was 8.38   4.99 months, respectively (hazard ratio 0.70, 95% CI 0.59-0.83; p<0.0001) and progression-free survival was 4.30   2.83 months, respectively (hazard ratio 0.66, 95% CI 0.57-0.77; p<0.0001).This study is helpful to guide a multiline treatment strategy for  wt NSCLC patients. Immunotherapy is approved for second-line treatment. For third-line treatment, chemotherapy results in longer overall survival and progression-free survival, and should be preferred to EGFR-TKIs.","Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.;Inserm U911 CRO2, Aix-Marseille Université, Marseille, France.;These two authors contributed equally to the work.;Service d'Oncologie Thoracique, CIC 1425-CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Paris, France.;Université Paris-Diderot, Paris, France.;These two authors contributed equally to the work.;Pôle Voies Respiratoires, Service de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Toulouse, France.;Pôle Biologie et Anatomie Pathologique, Centre Hospitalier Universitaire de Bordeaux, Pessac, France.;Histologie et Pathologie Moléculaires des Tumeurs, Université de Bordeaux, Bordeaux, France.;Laboratoire de Biochimie et de Biologie Moléculaire et Plateforme de Génomique des Cancers, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Plateforme INCA, Rennes, France.;Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Universités, UPMC Université 06, GRC 04, Theranoscan, Paris, France.;Service de Transfert d'Oncologie Biologique, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.;Département de Médecine, Gustave Roussy Cancer Campus, Villejuif, France.;Oncopôle, Service d'Anatomie Pathologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse, France.;Service de Pneumologie, Hôpital Emile Muller, GHRMSA, Mulhouse, France.;Laboratoire de Biochimie et Biologie Moléculaire, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Service de Pneumologie, Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz, Besançon, France.;Service de Pneumologie, Centre Hospitalier Sainte Musse, Toulon, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Unité d'Oncologie Thoracique, Clinique de Pneumologie, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.;Service d'Oncologie Thoracique, CIC 1425-CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Paris, France.;Université Paris-Diderot, Paris, France.;Inserm U830 ""Génétique et biologie des cancers"", Centre de Recherche, Institut Curie, Paris, France.;Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille;Inserm U911 CRO2, Aix-Marseille Université, Marseille, France.","NA",0,"1399-3003","Eur Respir J","Eur Respir J",2017,"2017","50","10.1183/13993003.00514-2017",NA,"","","28798090","28798090","PUBMED","Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.;Inserm U911 CRO2, Aix-Marseille Université, Marseille, France.;These two authors contributed equally to the work.;Service d'Oncologie Thoracique, CIC 1425-CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Paris, France.;Université Paris-Diderot, Paris, France.;These two authors contributed equally to the work.;Pôle Voies Respiratoires, Service de Pneumologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Toulouse, France.;Pôle Biologie et Anatomie Pathologique, Centre Hospitalier Universitaire de Bordeaux, Pessac, France.;Histologie et Pathologie Moléculaires des Tumeurs, Université de Bordeaux, Bordeaux, France.;Laboratoire de Biochimie et de Biologie Moléculaire et Plateforme de Génomique des Cancers, Centre Hospitalier Universitaire de Strasbourg, Hôpital de Hautepierre, Strasbourg, France.;Service de Génétique Moléculaire et Génomique, Centre Hospitalier Universitaire de Rennes, Plateforme INCA, Rennes, France.;Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Sorbonne Universités, UPMC Université 06, GRC 04, Theranoscan, Paris, France.;Service de Transfert d'Oncologie Biologique, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France.;Département de Médecine, Gustave Roussy Cancer Campus, Villejuif, France.;Oncopôle, Service d'Anatomie Pathologique, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse, Toulouse, France.;Service de Pneumologie, Hôpital Emile Muller, GHRMSA, Mulhouse, France.;Laboratoire de Biochimie et Biologie Moléculaire, Centre de Biologie Pathologie, Centre Hospitalier Régional Universitaire de Lille, Lille, France.;Service de Pneumologie, Centre Hospitalier Régional Universitaire de Besançon, Hôpital Jean Minjoz, Besançon, France.;Service de Pneumologie, Centre Hospitalier Sainte Musse, Toulon, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Intergroupe Francophone de Cancérologie Thoracique, Paris, France.;Unité d'Oncologie Thoracique, Clinique de Pneumologie, Centre Hospitalier Universitaire Grenoble-Alpes, Grenoble, France.;Service d'Oncologie Thoracique, CIC 1425-CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Paris, France.;Université Paris-Diderot, Paris, France.;Inserm U830 ""Génétique et biologie des cancers"", Centre de Recherche, Institut Curie, Paris, France.;Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Assistance Publique Hôpitaux de Marseille, Aix-Marseille Université, Marseille;Inserm U911 CRO2, Aix-Marseille Université, Marseille, France."
"510","Ballouhey Q;Binet A;Varlet F;Baudry M;Dubois R;Héry G;Podevin G;Abbo O;Arnaud A;Barras M;Guerin F;Reinberg O;Piolat C;Fourcade L","Ballouhey, Quentin;Binet, Aurélien;Varlet, François;Baudry, Manon;Dubois, Rémi;Héry, Géraldine;Podevin, Guillaume;Abbo, Olivier;Arnaud, Alexis;Barras, Marc;Guerin, Florent;Reinberg, Olivier;Piolat, Christian;Fourcade, Laurent","Management of Polypoid Gallbladder Lesions in Children: A Multicenter Study.","European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie","United States","eng","Journal Article","","Adenoma;Adolescent;Child;Child, Preschool;Cholecystectomy;Conservative Treatment;Female;Follow-Up Studies;Gallbladder Neoplasms;Humans;Male;Polyps;Retrospective Studies;Treatment Outcome;Ultrasonography;Watchful Waiting","Adenoma;Adolescent;Child;Child, Preschool;Cholecystectomy;Conservative Treatment;Female;Follow-Up Studies;Gallbladder Neoplasms;Humans;Male;Polyps;Retrospective Studies;Treatment Outcome;Ultrasonography;Watchful Waiting"," Polypoid lesions of the gallbladder (PLG) are relatively common in adults, while they are very rare in children. The use of high-quality ultrasonography leads to increased detection of PLG, although less than 20 pediatric cases of primary PLG have been reported in the literature. The aim of this study was to address the experience of PLG management in children.  A retrospective multicenter review of children with ultrasonographically defined PLG between 2006 and 2016 was performed. The data from 12 pediatric surgery centers were compiled for this purpose.  Eighteen patients (mean age: 10.4 ± 4.1 years) were included and managed according to each center's protocols. Cholecystectomy was performed for nine symptomatic patients. Histopathology conclusively revealed four tubular and five papillary adenomas, with a median size of 12 mm (ranging from 3 to 35 mm). Nine asymptomatic children were monitored by sonography over a 24-month (ranging from 12 to 66 months) follow-up period. The median PLG size was 7 mm (ranging from 3 to 9 mm). Two lesions disappeared after 1 and 2 years of follow-up, respectively. None of the patients developed symptoms or malignant transformation.  This report confirms appropriate use of a conservative approach with annual clinical and ultrasound follow-up for small-sized and isolated PLG in children given the absence of malignancy and potential vanishing entities. Surgical treatment should be considered in case of lesions larger than 10 mm in size or when they are associated with symptoms.","Department of Pediatric Surgery, Hôpital des Enfants, Toulouse, France.;Department of Pediatric Surgery, CHU Tours, Tours, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, Rhône-Alpes, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Department of Pediatric Surgery, CHU Marseille, Marseille, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pediatric Surgery, CHRU de Brest, Brest, Bretagne, France.;Department of Pediatric Surgery, Hopital Bicetre, Le Kremlin-Bicetre, Île-de-France, France.;Department of Pediatric Surgery, Bibliotheque Cantonale et Universitaire Lausanne, Lausanne, Switzerland.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Grenoble, Grenoble, Rhône-Alpes, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.","NA",0,"1439-359X","Eur J Pediatr Surg","Eur J Pediatr Surg",2017,"2018","28","10.1055/s-0037-1604114","6-11","","","28669133","28669133","PUBMED","Department of Pediatric Surgery, Hôpital des Enfants, Toulouse, France.;Department of Pediatric Surgery, CHU Tours, Tours, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, Rhône-Alpes, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Lyon, Lyon, Rhône-Alpes, France.;Department of Pediatric Surgery, CHU Marseille, Marseille, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire d'Angers, Angers, Pays de la Loire, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Toulouse, Toulouse, Midi-Pyrénées, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.;Department of Pediatric Surgery, CHRU de Brest, Brest, Bretagne, France.;Department of Pediatric Surgery, Hopital Bicetre, Le Kremlin-Bicetre, Île-de-France, France.;Department of Pediatric Surgery, Bibliotheque Cantonale et Universitaire Lausanne, Lausanne, Switzerland.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Grenoble, Grenoble, Rhône-Alpes, France.;Department of Pediatric Surgery, Centre Hospitalier Universitaire de Limoges, Limoges, Limousin, France."
"511","Delobel JB;Gnep K;Ospina JD;Beckendorf V;Chira C;Zhu J;Bossi A;Messai T;Acosta O;Castelli J;de Crevoisier R","Delobel, Jean-Bernard;Gnep, Khemara;Ospina, Juan David;Beckendorf, Véronique;Chira, Ciprian;Zhu, Jian;Bossi, Alberto;Messai, Taha;Acosta, Oscar;Castelli, Joël;de Crevoisier, Renaud","Nomogram to predict rectal toxicity following prostate cancer radiotherapy.","PloS one","United States","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Dose-Response Relationship, Radiation;Humans;Male;Middle Aged;Nomograms;Prostatic Neoplasms;Radiotherapy, Image-Guided;Radiotherapy, Intensity-Modulated;Rectum;Risk Assessment;Time Factors","Adult;Aged;Aged, 80 and over;Dose-Response Relationship, Radiation;Humans;Male;Middle Aged;Nomograms;Prostatic Neoplasms;Radiotherapy, Image-Guided;Radiotherapy, Intensity-Modulated;Rectum;Risk Assessment;Time Factors","To identify predictors of acute and late rectal toxicity following prostate cancer radiotherapy (RT), while integrating the potential impact of RT technique, dose escalation, and moderate hypofractionation, thus enabling us to generate a nomogram for individual prediction. In total, 972 patients underwent RT for localized prostate cancer, to a total dose of 70 Gy or 80 Gy, using two different fractionations (2 Gy or 2.5 Gy/day), by means of several RT techniques (3D conformal RT [3DCRT], intensity-modulated RT [IMRT], or image-guided RT [IGRT]). Multivariate analyses were performed to identify predictors of acute and late rectal toxicity. A nomogram was generated based on the logistic regression model used to predict the 3-year rectal toxicity risk, with its accuracy assessed by dividing the cohort into training and validation subgroups. Mean follow-up for the entire cohort was 62 months, ranging from 6 to 235. The rate of acute Grade ≥2 rectal toxicity was 22.2%, decreasing when combining IMRT and IGRT, compared to 3DCRT (RR = 0.4, 95%CI: 0.3-0.6, p<0.01). The 5-year Grade ≥2 risks for rectal bleeding, urgency/tenesmus, diarrhea, and fecal incontinence were 9.9%, 4.5%, 2.8%, and 0.4%, respectively. The 3-year Grade ≥2 risk for overall rectal toxicity increased with total dose (p<0.01, RR = 1.1, 95%CI: 1.0-1.1) and dose per fraction (2Gy vs. 2.5Gy) (p = 0.03, RR = 3.3, 95%CI: 1.1-10.0), and decreased when combining IMRT and IGRT (RR = 0.50, 95% CI: 0.3-0.8, p<0.01). Based on these three parameters, a nomogram was generated. Dose escalation and moderate hypofractionation increase late rectal toxicity. IMRT combined with IGRT markedly decreases acute and late rectal toxicity. Performing combined IMRT and IGRT can thus be envisaged for dose escalation and moderate hypofractionation. Our nomogram predicts the 3-year rectal toxicity risk by integrating total dose, fraction dose, and RT technique.","Dept. of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Escuela de Estadística, Universidad Nacional de Colombia, Medellin, Colombia.;Centre Alexis Vautrin, Vandoeuvre les Nancy, France.;Centre Alexis Vautrin, Vandoeuvre les Nancy, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Laboratory of Image Science and Technology, Southeast University, Nanjing, PR China.;Centre de Recherche en Information Biomédicale Sino-Français (CRIBs), Rennes, France.;Institut Gustave-Roussy, Villejuif, France.;Institut Gustave-Roussy, Villejuif, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;Centre de Recherche en Information Biomédicale Sino-Français (CRIBs), Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2017,"2017","12","10.1371/journal.pone.0179845","e0179845","","","28640871","28640871","PUBMED","Dept. of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Escuela de Estadística, Universidad Nacional de Colombia, Medellin, Colombia.;Centre Alexis Vautrin, Vandoeuvre les Nancy, France.;Centre Alexis Vautrin, Vandoeuvre les Nancy, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Laboratory of Image Science and Technology, Southeast University, Nanjing, PR China.;Centre de Recherche en Information Biomédicale Sino-Français (CRIBs), Rennes, France.;Institut Gustave-Roussy, Villejuif, France.;Institut Gustave-Roussy, Villejuif, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;LTSI, Inserm U1099, Université de Rennes 1, Rennes, France.;Centre Eugene Marquis, Rennes, France.;Centre de Recherche en Information Biomédicale Sino-Français (CRIBs), Rennes, France."
"512","Davies MA;Saiag P;Robert C;Grob JJ;Flaherty KT;Arance A;Chiarion-Sileni V;Thomas L;Lesimple T;Mortier L;Moschos SJ;Hogg D;Márquez-Rodas I;Del Vecchio M;Lebbé C;Meyer N;Zhang Y;Huang Y;Mookerjee B;Long GV","Davies, Michael A;Saiag, Philippe;Robert, Caroline;Grob, Jean-Jacques;Flaherty, Keith T;Arance, Ana;Chiarion-Sileni, Vanna;Thomas, Luc;Lesimple, Thierry;Mortier, Laurent;Moschos, Stergios J;Hogg, David;Márquez-Rodas, Iván;Del Vecchio, Michele;Lebbé, Céleste;Meyer, Nicolas;Zhang, Ying;Huang, Yingjie;Mookerjee, Bijoyesh;Long, Georgina V",NA,"The Lancet. Oncology","England","eng","Clinical Trial, Phase II","","Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Female;Fever;Headache;Humans;Imidazoles;Magnetic Resonance Imaging;Male;Melanoma;Middle Aged;Mutation;Oximes;Prospective Studies;Proto-Oncogene Proteins B-raf;Pyridones;Pyrimidinones;Stroke Volume;Young Adult","Adult;Aged;Aged, 80 and over;Antineoplastic Combined Chemotherapy Protocols;Brain Neoplasms;Female;Fever;Headache;Humans;Imidazoles;Magnetic Resonance Imaging;Male;Melanoma;Middle Aged;Mutation;Oximes;Prospective Studies;Proto-Oncogene Proteins B-raf;Pyridones;Pyrimidinones;Stroke Volume;Young Adult","Dabrafenib plus trametinib improves clinical outcomes in BRAF -mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAF -mutant melanoma brain metastases. This ongoing, multicentre, multicohort, open-label, phase 2 study evaluated oral dabrafenib (150 mg twice per day) plus oral trametinib (2 mg once per day) in four patient cohorts with melanoma brain metastases enrolled from 32 hospitals and institutions in Europe, North America, and Australia: (A) BRAF -positive, asymptomatic melanoma brain metastases, with no previous local brain therapy, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; (B) BRAF -positive, asymptomatic melanoma brain metastases, with previous local brain therapy, and an ECOG performance status of 0 or 1; (C) BRAF -positive, asymptomatic melanoma brain metastases, with or without previous local brain therapy, and an ECOG performance status of 0 or 1; and (D) BRAF -positive, symptomatic melanoma brain metastases, with or without previous local brain therapy, and an ECOG performance status of 0, 1, or 2. The primary endpoint was investigator-assessed intracranial response in cohort A in the all-treated-patients population. Secondary endpoints included intracranial response in cohorts B, C, and D. This study is registered with ClinicalTrials.gov, number NCT02039947. Between Feb 28, 2014, and Aug 5, 2016, 125 patients were enrolled in the study: 76 patients in cohort A; 16 patients in cohort B; 16 patients in cohort C; and 17 patients in cohort D. At the data cutoff (Nov 28, 2016) after a median follow-up of 8·5 months (IQR 5·5-14·0), 44 (58%; 95% CI 46-69) of 76 patients in cohort A achieved an intracranial response. Intracranial response by investigator assessment was also achieved in nine (56%; 95% CI 30-80) of 16 patients in cohort B, seven (44%; 20-70) of 16 patients in cohort C, and ten (59%; 33-82) of 17 patients in cohort D. The most common serious adverse events related to study treatment were pyrexia for dabrafenib (eight [6%] of 125 patients) and decreased ejection fraction (five [4%]) for trametinib. The most common grade 3 or worse adverse events, regardless of study drug relationship, were pyrexia (four [3%] of 125) and headache (three [2%]). Dabrafenib plus trametinib was active with a manageable safety profile in this melanoma population that was consistent with previous dabrafenib plus trametinib studies in patients with BRAF -mutant melanoma without brain metastases, but the median duration of response was relatively short. These results provide evidence of clinical benefit with dabrafenib plus trametinib and support the need for additional research to further improve outcomes in patients with melanoma brain metastases. Novartis.","Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX;Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France.;Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.;Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France.;Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.;Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona, Spain.;Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.;Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.;Oncologie Dermatologique, Centre Eugène Marquis, Rennes, France.;Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille, France.;Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.;Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid, Spain.;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris, France.;Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2017,"2017","18","10.1016/S1470-2045(17)30429-1","863-873","R01 CA154710;T32 CA009666","NCI NIH HHS;NCI NIH HHS","28592387","28592387","PUBMED","Melanoma Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX;Service de Dermatologie Générale et Oncologique, Hôpital A Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France; EA 4340, Université Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France.;Gustave Roussy, Département de Médecine Oncologique, Service de Dermatologie et Université Paris-Sud, Faculté de Médecine, Villejuif, France.;Service de Dermatologie, Centre Hospitalo-Universitaire Timone, Aix Marseille University, Marseille, France.;Developmental Therapeutics and Melanoma Programs, Massachusetts General Hospital Cancer Center, Boston, MA, USA.;Department of Medical Oncology, Hospital Clinic of Barcelona, Carrer de Villarroel, Barcelona, Spain.;Melanoma and Oesophageal Oncology Unit, Veneto Oncology Institute-IRCCS, Padova, Italy.;Service de Dermatologie, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.;Oncologie Dermatologique, Centre Eugène Marquis, Rennes, France.;Clinique de Dermatologie, Unité d'Onco-Dermatologie, Le Centre Hospitalier Régional Universitaire de Lille, University Lille 2, Lille, France.;Melanoma Program, Medical Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.;Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.;Servicio de Oncología Médica; Hospital General Universitario Gregorio Marañon, Madrid, Spain.;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.;APHP Dermatology and CIC Departments, INSERM U976, University Paris Diderot, Hôpital Saint Louis Paris, Paris, France.;Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.;Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia."
"513","Robert C;Pasquier L;Cohen D;Fradin M;Canitano R;Damaj L;Odent S;Tordjman S","Robert, Cyrille;Pasquier, Laurent;Cohen, David;Fradin, Mélanie;Canitano, Roberto;Damaj, Léna;Odent, Sylvie;Tordjman, Sylvie","Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy.","International journal of molecular sciences","Switzerland","eng","Journal Article","autism;child psychiatric and psychological assessment;clinical genetics;genetic disorders;hierarchical diagnostic strategy;neuropediatric evaluation","Autism Spectrum Disorder;Genetic Diseases, Inborn;Genetic Predisposition to Disease;Humans","Autism Spectrum Disorder;Genetic Diseases, Inborn;Genetic Predisposition to Disease;Humans","Progress in epidemiological, molecular and clinical genetics with the development of new techniques has improved knowledge on genetic syndromes associated with autism spectrum disorder (ASD). The objective of this article is to show the diversity of genetic disorders associated with ASD (based on an extensive review of single-gene disorders, copy number variants, and other chromosomal disorders), and consequently to propose a hierarchical diagnostic strategy with a stepwise evaluation, helping general practitioners/pediatricians and child psychiatrists to collaborate with geneticists and neuropediatricians, in order to search for genetic disorders associated with ASD. The first step is a clinical investigation involving: (i) a child psychiatric and psychological evaluation confirming autism diagnosis from different observational sources and assessing autism severity; (ii) a neuropediatric evaluation examining neurological symptoms and developmental milestones; and (iii) a genetic evaluation searching for dysmorphic features and malformations. The second step involves laboratory and if necessary neuroimaging and EEG studies oriented by clinical results based on clinical genetic and neuropediatric examinations. The identification of genetic disorders associated with ASD has practical implications for diagnostic strategies, early detection or prevention of co-morbidity, specific treatment and follow up, and genetic counseling.","Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), University of Rennes 1 and Centre Hospitalier Guillaume Régnier, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Hospital-University Department of Child and Adolescent Psychiatry, Pitié-Salpétrière Hospital, Paris 6 University, 75013 Paris;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Division of Child and Adolescent Neuropsychiatry, University Hospital of Siena, 53100 Siena;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), University of Rennes 1 and Centre Hospitalier Guillaume Régnier, 35200 Rennes;Laboratory of Psychology of Perception, University Paris Descartes, 75270 Paris","NA",0,"1422-0067","Int J Mol Sci","Int J Mol Sci",2016,"2017","18","10.3390/ijms18030618",NA,"","","28287497","28287497","PUBMED","Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), University of Rennes 1 and Centre Hospitalier Guillaume Régnier, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Hospital-University Department of Child and Adolescent Psychiatry, Pitié-Salpétrière Hospital, Paris 6 University, 75013 Paris;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Division of Child and Adolescent Neuropsychiatry, University Hospital of Siena, 53100 Siena;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Service de Génétique Clinique, Centre de Référence Maladies Rares Anomalies du Développement (Centre Labellisé pour les Anomalies du Développement de l'Ouest: CLAD Ouest), Hôpital Sud, Centre Hospitalier Universitaire de Rennes, 35200 Rennes;Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), University of Rennes 1 and Centre Hospitalier Guillaume Régnier, 35200 Rennes;Laboratory of Psychology of Perception, University Paris Descartes, 75270 Paris"
"514","Launey Y;Duteurtre B;Larmet R;Nesseler N;Tawa A;Mallédant Y;Seguin P","Launey, Yoann;Duteurtre, Benjamin;Larmet, Raphaëlle;Nesseler, Nicolas;Tawa, Audrey;Mallédant, Yannick;Seguin, Philippe","Risk factors for mortality in postoperative peritonitis in critically ill patients.","World journal of critical care medicine","United States","eng","Journal Article","Mortality;Postoperative peritonitis;Risk factors;Surgery","","","To identify the risk factors for mortality in intensive care patients with postoperative peritonitis (POP). This was a retrospective analysis using a prospective database that includes all patients hospitalized in a surgical intensive care unit for POP from September 2006 to August 2011. The data collected included demographics, comorbidities, postoperative severity parameters, bacteriological findings, adequacy of antimicrobial therapy and surgical treatments. Adequate source control was defined based on a midline laparotomy, infection source control and intraoperative peritoneal lavage. The number of reoperations needed was also recorded. A total of 201 patients were included. The overall mortality rate was 31%. Three independent risk factors for mortality were identified: The Simplified Acute Physiological II Score (OR = 1.03; 95%CI: 1.02-1.05,   < 0.001), postoperative medical complications (OR = 6.02; 95%CI: 1.95-18.55,   < 0.001) and the number of reoperations (OR = 2.45; 95%CI: 1.16-5.17,   = 0.015). Surgery was considered as optimal in 69% of the cases, but without any significant effect on mortality. The results from the large cohort in this study emphasize the role of the initial postoperative severity parameters in the prognosis of POP. No predefined criteria for optimal surgery were significantly associated with increased mortality, although the number of reoperations appeared as an independent risk factor of mortality.","Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.","NA",0,"2220-3141","World J Crit Care Med","World J Crit Care Med",2016,"2017","6","10.5492/wjccm.v6.i1.48","48-55","","","28224107","28224107","PUBMED","Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France.;Yoann Launey, Benjamin Duteurtre, Raphaëlle Larmet, Nicolas Nesseler, Audrey Tawa, Yannick Mallédant, Philippe Seguin, Anesthésie Réanimation 1, Centre Hospitalier Universitaire de Rennes, F-35000 Rennes, France."
"515","Flynn RJ;Legembre P","Flynn, Robin J;Legembre, Patrick","Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?","Annals of translational medicine","China","eng","Journal Article","","","","NA","Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.;Centre Eugène Marquis, Equipe Ligue Contre Le Cancer, Rue Bataille Flandres Dunkerque, 35042 Rennes, France.","NA",0,"2305-5839","Ann Transl Med","Ann Transl Med",2016,"2016","4","10.21037/atm.2016.12.35","554","","","28149915","28149915","PUBMED","Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.;Centre Eugène Marquis, Equipe Ligue Contre Le Cancer, Rue Bataille Flandres Dunkerque, 35042 Rennes, France."
"516","Michaud K;de Tayrac M;D'Astous M;Duval C;Paquet C;Samassekou O;Gould PV;Saikali S","Michaud, Karine;de Tayrac, Marie;D'Astous, Myreille;Duval, Céline;Paquet, Claudie;Samassekou, Oumar;Gould, Peter Vincent;Saikali, Stéphan","Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.","PloS one","United States","eng","Journal Article","","Adult;Chromosomes, Human;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 10;Chromosomes, Human, Pair 19;Chromosomes, Human, Pair 9;Female;Humans;Male;Middle Aged;Molecular Diagnostic Techniques;Oligodendroglioma;Practice Guidelines as Topic;Prognosis;Retrospective Studies;Survival Analysis;World Health Organization","Adult;Chromosomes, Human;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 10;Chromosomes, Human, Pair 19;Chromosomes, Human, Pair 9;Female;Humans;Male;Middle Aged;Molecular Diagnostic Techniques;Oligodendroglioma;Practice Guidelines as Topic;Prognosis;Retrospective Studies;Survival Analysis;World Health Organization","To study the feasibility and the diagnostic and prognostic interest of automated analysis of 1p, 19q, 9p and 10q status by FISH technique in oligodendroglial tumors. We analyzed a retrospective series of 33 consecutive gliomas with oligodendroglial histology (originally diagnosed as 24 oligodendrogliomas and 9 oligoastrocytomas). For all cases, automated FISH analysis of 1p, 19q, 9p and 10q status were performed and compared to clinical and histological data, ATRX, IDH1R132H and alpha-internexin status (studied by immunohistochemistry) and overall survival (OS). Manual analysis of 9p and 10q status were also performed and compared to automated analysis to verify the concordance of the two methods. The 33 gliomas were reclassified into 13 low-grade oligodendrogliomas (OII), 10 anaplastic oligodendrogliomas (OIII), 3 diffuse astrocytomas (AII), 3 anaplastic astrocytomas (AIII) and 4 glioblastomas (GBM) according to the WHO 2016 histological criteria. The 1p and/or 19q imbalanced status were restricted to astrocytomas with no correlation to their grade or their OS. Chromosome 9p deletion was restricted to OIII (70%) and GBM (100%) and was correlated with a shorter OS in the total cohort (p = 0.0007), the oligodendroglioma cohort (p = 0.03) and the astrocytoma cohort (p = 0.001). Concordance between 9p manual and automated analysis was satisfactory (81%, κ = 0.69). Chromosome 10q deletion was restricted to GBMs (50%) and was correlated with a poor OS in both the total cohort (p = 0.003) and the astrocytoma (AS) cohort (p = 0.04). Concordance between manual and automated analysis was satisfactory (79%, κ = 0.62). Automated analysis of 1p, 19q, 9p and 10q status by FISH is a reliable technique which allows for refined classification of oligodendroglial tumors. 1p and/or 19q imbalanced status is evidence of astrocytic differentiation. 9p deletion is found in high grade oligodendrogliomas and astrocytomas with a poor OS. 10q is related to GBM status and a poor OS.","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.","NA",0,"1932-6203","PLoS One","PLoS One",2016,"2016","11","10.1371/journal.pone.0168728","e0168728","","","28030632","28030632","PUBMED","Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Genomic and Molecular Genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada."
"517","Lefebvre C;Bachelot T;Filleron T;Pedrero M;Campone M;Soria JC;Massard C;Lévy C;Arnedos M;Lacroix-Triki M;Garrabey J;Boursin Y;Deloger M;Fu Y;Commo F;Scott V;Lacroix L;Dieci MV;Kamal M;Diéras V;Gonçalves A;Ferrerro JM;Romieu G;Vanlemmens L;Mouret Reynier MA;Théry JC;Le Du F;Guiu S;Dalenc F;Clapisson G;Bonnefoi H;Jimenez M;Le Tourneau C;André F","Lefebvre, Celine;Bachelot, Thomas;Filleron, Thomas;Pedrero, Marion;Campone, Mario;Soria, Jean-Charles;Massard, Christophe;Lévy, Christelle;Arnedos, Monica;Lacroix-Triki, Magali;Garrabey, Julie;Boursin, Yannick;Deloger, Marc;Fu, Yu;Commo, Frédéric;Scott, Véronique;Lacroix, Ludovic;Dieci, Maria Vittoria;Kamal, Maud;Diéras, Véronique;Gonçalves, Anthony;Ferrerro, Jean-Marc;Romieu, Gilles;Vanlemmens, Laurence;Mouret Reynier, Marie-Ange;Théry, Jean-Christophe;Le Du, Fanny;Guiu, Séverine;Dalenc, Florence;Clapisson, Gilles;Bonnefoi, Hervé;Jimenez, Marta;Le Tourneau, Christophe;André, Fabrice","Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.","PLoS medicine","United States","eng","Journal Article","","Breast Neoplasms;Exome;Female;Humans;Mutation;Neoplasm Metastasis;Retrospective Studies;Sequence Analysis, DNA","Breast Neoplasms;Exome;Female;Humans;Mutation;Neoplasm Metastasis;Retrospective Studies;Sequence Analysis, DNA","Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available on the genomic profile of this disease. This study aims to decipher mutational profiles of mBC using next-generation sequencing. Whole-exome sequencing was performed on 216 tumor-blood pairs from mBC patients who underwent a biopsy in the context of the SAFIR01, SAFIR02, SHIVA, or Molecular Screening for Cancer Treatment Optimization (MOSCATO) prospective trials. Mutational profiles from 772 primary breast tumors from The Cancer Genome Atlas (TCGA) were used as a reference for comparing primary and mBC mutational profiles. Twelve genes (TP53, PIK3CA, GATA3, ESR1, MAP3K1, CDH1, AKT1, MAP2K4, RB1, PTEN, CBFB, and CDKN2A) were identified as significantly mutated in mBC (false discovery rate [FDR] < 0.1). Eight genes (ESR1, FSIP2, FRAS1, OSBPL3, EDC4, PALB2, IGFN1, and AGRN) were more frequently mutated in mBC as compared to eBC (FDR < 0.01). ESR1 was identified both as a driver and as a metastatic gene (n = 22, odds ratio = 29, 95% CI [9-155], p = 1.2e-12) and also presented with focal amplification (n = 9) for a total of 31 mBCs with either ESR1 mutation or amplification, including 27 hormone receptor positive (HR+) and HER2 negative (HER2-) mBCs (19%). HR+/HER2- mBC presented a high prevalence of mutations on genes located on the mechanistic target of rapamycin (mTOR) pathway (TSC1 and TSC2) as compared to HR+/HER2- eBC (respectively 6% and 0.7%, p = 0.0004). Other actionable genes were more frequently mutated in HR+ mBC, including ERBB4 (n = 8), NOTCH3 (n = 7), and ALK (n = 7). Analysis of mutational signatures revealed a significant increase in APOBEC-mediated mutagenesis in HR+/HER2- metastatic tumors as compared to primary TCGA samples (p < 2e-16). The main limitations of this study include the absence of bone metastases and the size of the cohort, which might not have allowed the identification of rare mutations and their effect on survival. This work reports the results of the analysis of the first large-scale study on mutation profiles of mBC. This study revealed genomic alterations and mutational signatures involved in the resistance to therapies, including actionable mutations.","INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Inserm U1052, Lyon, France.;Biostatistics Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;R&D UNICANCER, Paris, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Translational research laboratory and biobank, Gustave Roussy, Villejuif, France.;Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.;Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Clinical Research, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;UNICANCER Biobanking Center, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, INSERM U916, Bordeaux, France.;R&D UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;EA7285, Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.","NA",0,"1549-1676","PLoS Med","PLoS Med",2016,"2016","13","10.1371/journal.pmed.1002201","e1002201","","","28027327","28027327","PUBMED","INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre Léon Bérard, Inserm U1052, Lyon, France.;Biostatistics Department, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Drug Development Department (DITEP), Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Centre François Baclesse, Caen, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;R&D UNICANCER, Paris, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;Bioinformatics core facility, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Biology and Pathology, Translational research laboratory and biobank, Gustave Roussy, Villejuif, France.;Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.;Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.;Department of Clinical Research, Centre Antoine Lacassagne, Nice, France.;Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.;Department of Medical Oncology, Centre Oscar Lambret, Lille, France.;Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.;Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.;Department of Medical Oncology, Centre Eugène Marquis, Rennes, France.;Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.;Department of Medical Oncology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.;UNICANCER Biobanking Center, Centre Léon Bérard, Lyon, France.;Department of Medical Oncology, Institut Bergonié, Université de Bordeaux, INSERM U916, Bordeaux, France.;R&D UNICANCER, Paris, France.;Department of Medical Oncology, Institut Curie, Paris & Saint-Cloud, France.;EA7285, Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.;INSERM Unit U981, Gustave Roussy, Villejuif, France.;Department of Medical Oncology, Gustave Roussy, Villejuif, France.;Faculté de Médecine, Université Paris Sud, Kremlin-Bicêtre, France."
"518","Zhu J;Simon A;Haigron P;Lafond C;Acosta O;Shu H;Castelli J;Li B;De Crevoisier R","Zhu, Jian;Simon, Antoine;Haigron, Pascal;Lafond, Caroline;Acosta, Oscar;Shu, Huazhong;Castelli, Joel;Li, Baosheng;De Crevoisier, Renaud","The benefit of using bladder sub-volume equivalent uniform dose constraints in prostate intensity-modulated radiotherapy planning.","OncoTargets and therapy","New Zealand","eng","Journal Article","IMRT;equivalent uniform dose;prostate","","","To assess the benefits of bladder wall sub-volume equivalent uniform dose (EUD) constraints in prostate cancer intensity-modulated radiotherapy (IMRT) planning. Two IMRT plans, with and without EUD constraints on the bladder wall, were generated using beams that deliver 80 Gy to the prostate and 46 Gy to the seminal vesicles and were compared in 53 prostate cancer patients. The bladder wall was defined as the volume between the external manually delineated wall and a contraction of 7 mm apart from it. The bladder wall was then separated into two parts: the internal-bladder wall (bla-in) represented by the portion of the bladder wall that intersected with the planning target volume (PTV) plus 5 mm extension; the external-bladder wall (bla-ex) represented by the remaining part of the bladder wall. In the IMRT plan with EUD constraints, the values of "" "" parameter for the EUD models were 10.0 for bla-in and 2.3 for bla-ex. The plans with and without EUD constraints were compared in terms of dose-volume histograms, 5-year bladder and rectum normal tissue complication probability values, as well as tumor control probability (TCP) values. The use of bladder sub-volume EUD constraints decreased both the doses to the bladder wall ( : 22.76% vs 19.65%,  : 39.82 Gy vs 35.45 Gy) and the 5-year bladder complication probabilities (≥LENT/SOMA Grade 2: 20.35% vs 17.96%; bladder bleeding: 10.63% vs 8.64%). The doses to the rectum wall and the rectum complication probabilities were also slightly decreased by the EUD constraints compared to physical constraints only. The minimal dose and the   of PTV  were, however, slightly decreased by EUD optimization, nevertheless without significant difference in TCP values between the two plans, and the PTV parameters finally respected the Groupe d'Etude des Tumeurs Uro-Génitales recommendations. Separating the bladder wall into two parts with appropriate EUD optimization may reduce bladder toxicity in prostate IMRT. Combining biological constraints with physical constraints in the organs at risk at the inverse planning step of IMRT may improve the dose distribution.","Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.","NA",0,"1178-6930","Onco Targets Ther","Onco Targets Ther",2016,"2016","9","10.2147/OTT.S116508","7537-7544","","","28003767","28003767","PUBMED","Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1.;Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France.;Laboratory of Image Science and Technology, Southeast University, Nanjing, Jiangsu; Department of Radiation Oncology, Shandong Cancer Hospital & Institute, Jinan; Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China.;Centre de Recherche en Information Biomédicale Sino-français, Nanjing, People's Republic of China; Institut National de la Sante et de la Recherche Medicale, U1099; Laboratory of Signal and Image Processing (LTSI), University of Rennes 1; Department of Radiotherapy, Centre Eugène Marquis, Rennes, France."
"519","Coiro S;Porot G;Rossignol P;Ambrosio G;Carluccio E;Tritto I;Huttin O;Lemoine S;Sadoul N;Donal E;Zannad F;Girerd N","Coiro, Stefano;Porot, Guillaume;Rossignol, Patrick;Ambrosio, Giuseppe;Carluccio, Erberto;Tritto, Isabella;Huttin, Olivier;Lemoine, Simon;Sadoul, Nicolas;Donal, Erwan;Zannad, Faiez;Girerd, Nicolas","Prognostic value of pulmonary congestion assessed by lung ultrasound imaging during heart failure hospitalisation: A two-centre cohort study.","Scientific reports","England","eng","Journal Article","","Aged;Arterial Pressure;Atrial Fibrillation;Cohort Studies;Female;Heart Failure;Hospitalization;Humans;Lung;Male;Prognosis;Stroke Volume;Systole;Ultrasonography","Aged;Arterial Pressure;Atrial Fibrillation;Cohort Studies;Female;Heart Failure;Hospitalization;Humans;Lung;Male;Prognosis;Stroke Volume;Systole;Ultrasonography","Pulmonary congestion assessed at discharge by lung ultrasonography predicts poor prognosis in heart failure (HF) patients. We investigated the association of B-lines with indices of hemodynamic congestion [BNP, E/e', pulmonary systolic arterial pressure (PAPs)] in HF patients, and their prognostic value overall and according to concomitant atrial fibrillation (AF), reduced (≤40%) ejection fraction (EF), and timing of quantification during hospitalisation for heart failure (HHF). In 110 HHF patients, B-lines were highly discriminative of BNP >400 pg/ml (AUC ≥ 0.80 for all), and moderately discriminative of PAPs >50 mmHg (AUC = 0.68, 0.56 to 0.80); conversely, B-lines poorly discriminated average E/e' ≥ 15, except at discharge. B-line count significantly predicted mid-term recurrent HHF or death (overall and in subgroups), regardless of AF status, EF, and timing of quantification during HHF (all p for interaction >0.10). regardless, B-lines ≥30 at discharge were most predictive of outcome (HR = 7.11, 2.06-24.48; p = 0.002) while B-lines ≥45 early during HHF were most predictive of outcome (HR = 9.20, 1.82-46.61; p = 0.007). Lung ultrasound was able to identify patients with high BNP levels, but not with increased E/e', also showing a prognostic role regardless of AF status, EF or timing of quantification; best B-line cut-off appears to vary according to the timing of quantification during hospitalization.","Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Département de Cardiologie &CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2016,"2016","6","10.1038/srep39426","39426","","","27995971","27995971","PUBMED","Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Division of Cardiology, University of Perugia, School of Medicine, Via S. Andrea delle fratte, Perugia, Italy.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;Département de Cardiologie &CIC-IT U 804, Centre Hospitalier Universitaire de Rennes, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INSERM, Centre d'Investigations Cliniques 9501, Université de Lorraine, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France.;INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN network, Nancy, France.;Departement de Cardiologie, CHU de Nancy, Institut Lorrain du cœur et des vaisseaux, Nancy, France."
"520","Van der Auwera G;Bart A;Chicharro C;Cortes S;Davidsson L;Di Muccio T;Dujardin JC;Felger I;Paglia MG;Grimm F;Harms G;Jaffe CL;Manser M;Ravel C;Robert-Gangneux F;Roelfsema J;Töz S;Verweij JJ;Chiodini PL","Van der Auwera, Gert;Bart, Aldert;Chicharro, Carmen;Cortes, Sofia;Davidsson, Leigh;Di Muccio, Trentina;Dujardin, Jean-Claude;Felger, Ingrid;Paglia, Maria Grazia;Grimm, Felix;Harms, Gundel;Jaffe, Charles L;Manser, Monika;Ravel, Christophe;Robert-Gangneux, Florence;Roelfsema, Jeroen;Töz, Seray;Verweij, Jaco J;Chiodini, Peter L","Comparison of Leishmania typing results obtained from 16 European clinical laboratories in 2014.","Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin","Sweden","eng","Journal Article","Typing;hsp70;kinetoplast DNA;leishmaniasis;mini-exon;rDNA ITS1","DNA, Kinetoplast;DNA, Protozoan;DNA, Ribosomal;Europe;Genotype;HSP70 Heat-Shock Proteins;Humans;Israel;Laboratories;Leishmania;Leishmaniasis;Polymerase Chain Reaction;Polymorphism, Restriction Fragment Length;Sensitivity and Specificity;Turkey","DNA, Kinetoplast;DNA, Protozoan;DNA, Ribosomal;Europe;Genotype;HSP70 Heat-Shock Proteins;Humans;Israel;Laboratories;Leishmania;Leishmaniasis;Polymerase Chain Reaction;Polymorphism, Restriction Fragment Length;Sensitivity and Specificity;Turkey","Leishmaniasis is endemic in southern Europe, and in other European countries cases are diagnosed in travellers who have visited affected areas both within the continent and beyond. Prompt and accurate diagnosis poses a challenge in clinical practice in Europe. Different methods exist for identification of the infecting Leishmania species. Sixteen clinical laboratories in 10 European countries, plus Israel and Turkey, conducted a study to assess their genotyping performance. DNA from 21 promastigote cultures of 13 species was analysed blindly by the routinely used typing method. Five different molecular targets were used, which were analysed with PCR-based methods. Different levels of identification were achieved, and either the Leishmania subgenus, species complex, or actual species were reported. The overall error rate of strains placed in the wrong complex or species was 8.5%. Various reasons for incorrect typing were identified. The study shows there is considerable room for improvement and standardisation of Leishmania typing. The use of well validated standard operating procedures is recommended, covering testing, interpretation, and reporting guidelines. Application of the internal transcribed spacer 1 of the rDNA array should be restricted to Old World samples, while the heat-shock protein 70 gene and the mini-exon can be applied globally.","Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.;Academic Medical Center, Amsterdam, The Netherlands.;Instituto de Salud Carlos III, Madrid, Spain.;Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, UNL, Lisbon, Portugal.;The Public Health Agency of Sweden, Stockholm, Sweden.;Istituto Superiore di Sanità, Rome, Italy.;Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.;Biomedical Sciences, Antwerp University, Antwerp, Belgium.;Swiss Tropical and Public Health Institute, Basel, Switzerland.;University of Basel, Basel, Switzerland.;National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, Italy.;Institute of Parasitology, University of Zürich, Zürich, Switzerland.;Institute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.;Hebrew University, Hadassah Medical Centre, Jerusalem, Israel.;United Kingdom National External Quality Assessment Service, London, United Kingdom.;University of Montpellier, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.;Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Turkey.;St. Elisabeth Hospital, Tilburg, The Netherlands.;Hospital for Tropical Diseases, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.","NA",0,"1560-7917","Euro Surveill","Euro Surveill",2016,"2016","21","10.2807/1560-7917.ES.2016.21.49.30418",NA,"","","27983510","27983510","PUBMED","Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.;Academic Medical Center, Amsterdam, The Netherlands.;Instituto de Salud Carlos III, Madrid, Spain.;Global Health and Tropical Medicine, GHTM, Instituto de Higiene e Medicina Tropical, UNL, Lisbon, Portugal.;The Public Health Agency of Sweden, Stockholm, Sweden.;Istituto Superiore di Sanità, Rome, Italy.;Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.;Biomedical Sciences, Antwerp University, Antwerp, Belgium.;Swiss Tropical and Public Health Institute, Basel, Switzerland.;University of Basel, Basel, Switzerland.;National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, Italy.;Institute of Parasitology, University of Zürich, Zürich, Switzerland.;Institute of Tropical Medicine and International Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.;Hebrew University, Hadassah Medical Centre, Jerusalem, Israel.;United Kingdom National External Quality Assessment Service, London, United Kingdom.;University of Montpellier, Montpellier, France.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands.;Ege University, Faculty of Medicine, Department of Parasitology, Izmir, Turkey.;St. Elisabeth Hospital, Tilburg, The Netherlands.;Hospital for Tropical Diseases, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom."
"521","Gutzmer R;Rivoltini L;Levchenko E;Testori A;Utikal J;Ascierto PA;Demidov L;Grob JJ;Ridolfi R;Schadendorf D;Queirolo P;Santoro A;Loquai C;Dreno B;Hauschild A;Schultz E;Lesimple TP;Vanhoutte N;Salaun B;Gillet M;Jarnjak S;De Sousa Alves PM;Louahed J;Brichard VG;Lehmann FF","Gutzmer, R;Rivoltini, L;Levchenko, E;Testori, A;Utikal, J;Ascierto, P A;Demidov, L;Grob, J J;Ridolfi, R;Schadendorf, D;Queirolo, P;Santoro, A;Loquai, C;Dreno, B;Hauschild, A;Schultz, E;Lesimple, T P;Vanhoutte, N;Salaun, B;Gillet, M;Jarnjak, S;De Sousa Alves, P M;Louahed, J;Brichard, V G;Lehmann, F F","Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.","ESMO open","England","eng","Journal Article","PRAME antigen;cancer immunotherapy;immunogenicity;metastatic melanoma;safety","","","The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Adverse events (AEs), including predefined dose-limiting toxicity (DLT) and the anti-PRAME humoral response (ELISA), were coprimary end points. Cellular immune responses were evaluated using in vitro assays. 66 patients were treated (20, 24 and 22 in the respective cohorts). AEs considered by the investigator to be causally related were mostly grade 1 or 2 injection site symptoms, fatigue, chills, fever and headache. Two DLTs (grade 3 brain oedema and proteinuria) were recorded in two patients in two cohorts (cohorts 2 and 3). All patients had detectable anti-PRAME antibodies after four immunisations. Percentages of patients with predefined PRAME-specific-CD4+T-cell responses after four immunisations were similar in each cohort. No CD8+ T-cell responses were detected. The PRAME immunotherapeutic had an acceptable safety profile and induced similar anti-PRAME-specific humoral and cellular immune responses in all cohorts. As per protocol, the phase II study segment was initiated to further evaluate the 500 µg PRAME immunotherapeutic dose. NCT01149343, Results.","Skin Cancer Center Hannover , Hannover Medical School , Hannover , Germany.;Unit of Immunotherapy of Human Tumors , Fondazione RCCS Istituto Nazionale dei Tumori , Milan , Italy.;Petrov Research Institute of Oncology , St. Petersburg , Russia.;Istituto Europeo Di Oncologia , Milano , Italy.;Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.;Melanoma, Cancer Immunotherapy and Innovative Therapies Unit , Istituto Nazionale Tumori Fondazione Pascale , Naples , Italy.;Cancer Research Center , Moscow , Russia.;Aix Marseille University Hôpital de la Timone, Service de Dermatologie , Marseille , France.;Immunotherapy Unit , Romagna Cancer Institute IRST- IRCCS , Meldola , Italy.;Department of Dermatology , University Hospital Essen , Essen , Germany.;Istituto Nazionale per la Ricerca sul Cancro Oncologia Medica , Genova , Italy.;Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS , Rozzano , Italy.;Department of Dermatology , University of Mainz , Mainz , Germany.;Dermatology Clinic , Hôpital Hôtel-Dieu, CHU Nantes , Nantes , France.;Department of Dermatology , Skin Cancer Center, Schleswig-Holstein University Hospital , Kiel , Germany.;Department of Dermatology , Paracelsus Medical University, Klinikum Nuremberg , Nuremberg , Germany.;Département d'Oncologie Médicale , Centre Eugène Marquis , Rennes , France.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines, Rixensart, Belgium; Vianova-Biosciences, Lasne, Belgium.;GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium.","NA",0,"2059-7029","ESMO Open","ESMO Open",2016,"2016","1","10.1136/esmoopen-2016-000068","e000068","","","27843625","27843625","PUBMED","Skin Cancer Center Hannover , Hannover Medical School , Hannover , Germany.;Unit of Immunotherapy of Human Tumors , Fondazione RCCS Istituto Nazionale dei Tumori , Milan , Italy.;Petrov Research Institute of Oncology , St. Petersburg , Russia.;Istituto Europeo Di Oncologia , Milano , Italy.;Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.;Melanoma, Cancer Immunotherapy and Innovative Therapies Unit , Istituto Nazionale Tumori Fondazione Pascale , Naples , Italy.;Cancer Research Center , Moscow , Russia.;Aix Marseille University Hôpital de la Timone, Service de Dermatologie , Marseille , France.;Immunotherapy Unit , Romagna Cancer Institute IRST- IRCCS , Meldola , Italy.;Department of Dermatology , University Hospital Essen , Essen , Germany.;Istituto Nazionale per la Ricerca sul Cancro Oncologia Medica , Genova , Italy.;Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS , Rozzano , Italy.;Department of Dermatology , University of Mainz , Mainz , Germany.;Dermatology Clinic , Hôpital Hôtel-Dieu, CHU Nantes , Nantes , France.;Department of Dermatology , Skin Cancer Center, Schleswig-Holstein University Hospital , Kiel , Germany.;Department of Dermatology , Paracelsus Medical University, Klinikum Nuremberg , Nuremberg , Germany.;Département d'Oncologie Médicale , Centre Eugène Marquis , Rennes , France.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium.;GSK Vaccines , Rixensart , Belgium.;GSK Vaccines, Rixensart, Belgium; Vianova-Biosciences, Lasne, Belgium.;GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium."
"522","Charpentier P;Mouriaux F","Charpentier, Pierre;Mouriaux, Frederic","Total recovery of optic nerve sheath meningioma.","BMJ case reports","England","eng","Case Reports","","Adult;Diagnosis, Differential;Dose Fractionation, Radiation;Female;Humans;Magnetic Resonance Imaging;Meningioma;Optic Nerve Neoplasms;Radiotherapy, Intensity-Modulated;Recovery of Function;Visual Acuity;Visual Fields","Adult;Diagnosis, Differential;Dose Fractionation, Radiation;Female;Humans;Magnetic Resonance Imaging;Meningioma;Optic Nerve Neoplasms;Radiotherapy, Intensity-Modulated;Recovery of Function;Visual Acuity;Visual Fields","We reported the case of a 43-year-old woman with a rapid progressive visual loss. The diagnosis of primary optic nerve sheath meningioma was made thanks to atypia evolution, clinical and radiological findings. The patient was treated with an intensity-modulated radiotherapy of 50.4 Gy in 28 fractions 2 months after the diagnosis. Visual acuity and visual field were completely recovered after 2 years of follow-up. No late side effects of irradiation were recorded.","Centre Hospitalier Universitaire de Rennes, ille et Vilaine, Rennes, Catalunya, Girona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France.","NA",0,"1757-790X","BMJ Case Rep","BMJ Case Rep",2016,"2016","2016","10.1136/bcr-2016-215532",NA,"","","27769976","27769976","PUBMED","Centre Hospitalier Universitaire de Rennes, ille et Vilaine, Rennes, Catalunya, Girona, Spain.;Centre Hospitalier Universitaire de Rennes, Rennes, Bretagne, France."
"523","Quillien V;Lavenu A;Ducray F;Joly MO;Chinot O;Fina F;Sanson M;Carpentier C;Karayan-Tapon L;Rivet P;Entz-Werle N;Legrain M;Zalcman EL;Levallet G;Escande F;Ramirez C;Chiforeanu D;Vauleon E;Figarella-Branger D","Quillien, Véronique;Lavenu, Audrey;Ducray, François;Joly, Marie-Odile;Chinot, Olivier;Fina, Frédéric;Sanson, Marc;Carpentier, Catherine;Karayan-Tapon, Lucie;Rivet, Pierre;Entz-Werle, Natacha;Legrain, Michèle;Zalcman, Emmanuèle Lechapt;Levallet, Guenaelle;Escande, Fabienne;Ramirez, Carole;Chiforeanu, Dan;Vauleon, Elodie;Figarella-Branger, Dominique","Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.","Oncotarget","United States","eng","Journal Article","MGMT;glioblastoma;promoter methylation;prospective trial;pyrosequencing","Adult;Aged;Brain Neoplasms;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Dacarbazine;Disease-Free Survival;Female;Glioblastoma;Humans;Male;Middle Aged;Promoter Regions, Genetic;Prospective Studies;Reproducibility of Results;Sequence Analysis, DNA;Temozolomide;Tumor Suppressor Proteins;Young Adult","Adult;Aged;Brain Neoplasms;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Dacarbazine;Disease-Free Survival;Female;Glioblastoma;Humans;Male;Middle Aged;Promoter Regions, Genetic;Prospective Studies;Reproducibility of Results;Sequence Analysis, DNA;Temozolomide;Tumor Suppressor Proteins;Young Adult","The goal of this prospective multicentric trial was to validate a technique that allowed for MGMT promoter methylation analysis in routine clinical practice. The MGMT status of 139 glioblastoma patients, whom had received standard first line treatment, was determined using pyrosequencing (PSQ) and a semi-quantitative Methylation-specific PCR (sqMS-PCR) method, using both frozen and formalin-fixed paraffin-embedded FFPE samples. Eight participating centers locally performed the analysis, including external quality controls. There was a strong correlation between results from FFPE and frozen samples. With cut-offs of 12% and 13%, 98% and 91% of samples were identically classified with PSQ and sqMS-PCR respectively. In 12% of cases frozen samples were excluded because they had a low percentage of tumor cells. In 5-6% of cases the analysis was not feasible on FFPE samples. The optimized risk cut-offs were higher in both techniques when using FFPE samples, in comparison to frozen samples. For sqMS-PCR, we validated a cut-off between 13-15% to dichotomize patients. For PSQ, patients with a low level of methylation (<= 8%) had a median progression-free survival under 9 months, as compared with more than 15.5 months for those with a level above 12%. For intermediate values (9-12%), more discordant results between FFPE and frozen samples were observed and there was not a clear benefit of temozolomide treatment, which indicated a ""grey zone"". MGMT status can reliably be investigated in local laboratories. PSQ is the ideal choice as proven by strong interlaboratory reproducibility, along with threshold agreements across independent studies.","Centre Eugène Marquis, F-35042 Rennes, France.;Université Rennes 1, Faculté de Médecine, F-35043 Rennes, France.;INSERM CIC 0203, Université de Rennes 1, F-35043 Rennes, France.;Hospices Civils de Lyon, F- 69394, Lyon, Cedex, France.;Université de Lyon1, F-69622 Villeurbanne, France.;Hospices Civils de Lyon, F- 69394, Lyon, Cedex, France.;Université de Lyon1, F-69622 Villeurbanne, France.;CHU Timone, F-13385 Marseille, France.;Faculté de Médecine Secteur Nord, F-13916 Marseille, France.;Sorbonne Universités UPMC Université Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France.;Sorbonne Universités UPMC Université Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France.;INSERM U1084, Université de Poitiers, F-86021 Poitiers, France.;CHU de Poitiers, F-86021 Poitiers, France.;CHU de Poitiers, F-86021 Poitiers, France.;CHRU Hautepierre, F67098 Strasbourg, France.;EA 3430, Progression Tumorale et Microenvironnement, Approches Translationnelles et Épidémiologie, Université de Strasbourg, F-67000 Strasbourg, France.;CHRU Hautepierre, F67098 Strasbourg, France.;CHU Caen, Département de Pathologie, F-14000 Caen, France.;CHU Caen, Département de Pathologie, F-14000 Caen, France.;CHRU de Lille, F-59037 Lille, France.;CHRU de Lille, F-59037 Lille, France.;CHU de Rennes, F-35000 Rennes, France.;Centre Eugène Marquis, F-35042 Rennes, France.;CHU Timone, F-13385 Marseille, France.;INSERM U911 CRO2, Université de la Méditerranée, F-13385 Marseille, France.","NA",0,"1949-2553","Oncotarget","Oncotarget",2016,"2016","7","10.18632/oncotarget.11322","61916-61929","","","27542245","27542245","PUBMED","Centre Eugène Marquis, F-35042 Rennes, France.;Université Rennes 1, Faculté de Médecine, F-35043 Rennes, France.;INSERM CIC 0203, Université de Rennes 1, F-35043 Rennes, France.;Hospices Civils de Lyon, F- 69394, Lyon, Cedex, France.;Université de Lyon1, F-69622 Villeurbanne, France.;Hospices Civils de Lyon, F- 69394, Lyon, Cedex, France.;Université de Lyon1, F-69622 Villeurbanne, France.;CHU Timone, F-13385 Marseille, France.;Faculté de Médecine Secteur Nord, F-13916 Marseille, France.;Sorbonne Universités UPMC Université Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France.;Sorbonne Universités UPMC Université Paris 06, INSERM CNRS, U1127, UMR 7225, ICM, F-75013 Paris, France.;INSERM U1084, Université de Poitiers, F-86021 Poitiers, France.;CHU de Poitiers, F-86021 Poitiers, France.;CHU de Poitiers, F-86021 Poitiers, France.;CHRU Hautepierre, F67098 Strasbourg, France.;EA 3430, Progression Tumorale et Microenvironnement, Approches Translationnelles et Épidémiologie, Université de Strasbourg, F-67000 Strasbourg, France.;CHRU Hautepierre, F67098 Strasbourg, France.;CHU Caen, Département de Pathologie, F-14000 Caen, France.;CHU Caen, Département de Pathologie, F-14000 Caen, France.;CHRU de Lille, F-59037 Lille, France.;CHRU de Lille, F-59037 Lille, France.;CHU de Rennes, F-35000 Rennes, France.;Centre Eugène Marquis, F-35042 Rennes, France.;CHU Timone, F-13385 Marseille, France.;INSERM U911 CRO2, Université de la Méditerranée, F-13385 Marseille, France."
"524","Monet M;Poët M;Tauzin S;Fouqué A;Cophignon A;Lagadic-Gossmann D;Vacher P;Legembre P;Counillon L","Monet, Michael;Poët, Mallorie;Tauzin, Sébastien;Fouqué, Amélie;Cophignon, Auréa;Lagadic-Gossmann, Dominique;Vacher, Pierre;Legembre, Patrick;Counillon, Laurent","The cleaved FAS ligand activates the Na(+)/H(+) exchanger NHE1 through Akt/ROCK1 to stimulate cell motility.","Scientific reports","England","eng","Journal Article","","Cell Line;Cell Movement;Fas Ligand Protein;Humans;Phosphorylation;Proto-Oncogene Proteins c-akt;Protons;Signal Transduction;Sodium-Hydrogen Exchanger 1;rho-Associated Kinases;rhoA GTP-Binding Protein","Cell Line;Cell Movement;Fas Ligand Protein;Humans;Phosphorylation;Proto-Oncogene Proteins c-akt;Protons;Signal Transduction;Sodium-Hydrogen Exchanger 1;rho-Associated Kinases;rhoA GTP-Binding Protein","Transmembrane CD95L (Fas ligand) can be cleaved to release a promigratory soluble ligand, cl-CD95L, which can contribute to chronic inflammation and cancer cell dissemination. The motility signaling pathway elicited by cl-CD95L remains poorly defined. Here, we show that in the presence of cl-CD95L, CD95 activates the Akt and RhoA signaling pathways, which together orchestrate an allosteric activation of the Na(+)/H(+) exchanger NHE1. Pharmacologic inhibition of Akt or ROCK1 independently blocks the cl-CD95L-induced migration. Confirming these pharmacologic data, disruption of the Akt and ROCK1 phosphorylation sites on NHE1 decreases cell migration in cells exposed to cl-CD95L. Together, these findings demonstrate that NHE1 is a novel molecular actor in the CD95 signaling pathway that drives the cl-CD95L-induced cell migration through both the Akt and RhoA signaling pathways.","Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Université de Bordeaux, Inserm U1045, 146 rue Léo Saignat, 33046 Bordeaux, France.;Bergonié Cancer Institute, 33000 Bordeaux, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.","NA",0,"2045-2322","Sci Rep","Sci Rep",2015,"2016","6","10.1038/srep28008","28008","","","27302366","27302366","PUBMED","Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France.;Université Rennes-1, Inserm U1085, 2 Av du Prof. Léon Bernard, 35043, Rennes, France.;Université de Bordeaux, Inserm U1045, 146 rue Léo Saignat, 33046 Bordeaux, France.;Bergonié Cancer Institute, 33000 Bordeaux, France.;Centre Eugène Marquis, Inserm ER440, Oncogenesis Stress and Signaling, Equipe Labellisée Ligue Contre Le Cancer ""Death Receptors and Tumor Escape"", rue bataille Flandres-Dunkerque, 35042 Rennes, France.;Université Nice-Sophia Antipolis, CNRS UMR7370 LP2M, Faculté de Médecine, 28 Avenue de Valombrose 06107 Nice cedex. France and Laboratories of Excellence Ion Channel Science and Therapeutics, France."
"525","Palpacuer C;Laviolle B;Boussageon R;Reymann JM;Bellissant E;Naudet F","Palpacuer, Clément;Laviolle, Bruno;Boussageon, Rémy;Reymann, Jean Michel;Bellissant, Eric;Naudet, Florian","Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials.","PLoS medicine","United States","eng","Journal Article","","Alcoholism;Humans;Naltrexone;Narcotic Antagonists;Randomized Controlled Trials as Topic;Risk Assessment;Treatment Outcome","Alcoholism;Humans;Naltrexone;Narcotic Antagonists;Randomized Controlled Trials as Topic;Risk Assessment;Treatment Outcome","Nalmefene is a recent option in alcohol dependence treatment. Its approval was controversial. We conducted a systematic review and meta-analysis of the aggregated data (registered as PROSPERO 2014:CRD42014014853) to compare the harm/benefit of nalmefene versus placebo or active comparator in this indication. Three reviewers searched for published and unpublished studies in Medline, the Cochrane Library, Embase, ClinicalTrials.gov, Current Controlled Trials, and bibliographies and by mailing pharmaceutical companies, the European Medicines Agency (EMA), and the US Food and Drug Administration. Double-blind randomized clinical trials evaluating nalmefene to treat adult alcohol dependence, irrespective of the comparator, were included if they reported (1) health outcomes (mortality, accidents/injuries, quality of life, somatic complications), (2) alcohol consumption outcomes, (3) biological outcomes, or (4) treatment safety outcomes, at 6 mo and/or 1 y. Three authors independently screened the titles and abstracts of the trials identified. Relevant trials were evaluated in full text. The reviewers independently assessed the included trials for methodological quality using the Cochrane Collaboration tool for assessing risk of bias. On the basis of the I2 index or the Cochrane's Q test, fixed or random effect models were used to estimate risk ratios (RRs), mean differences (MDs), or standardized mean differences (SMDs) with 95% CIs. In sensitivity analyses, outcomes for participants who were lost to follow-up were included using baseline observation carried forward (BOCF); for binary measures, patients lost to follow-up were considered equal to failures (i.e., non-assessed patients were recorded as not having responded in both groups). Five randomized controlled trials (RCTs) versus placebo, with a total of 2,567 randomized participants, were included in the main analysis. None of these studies was performed in the specific population defined by the EMA approval of nalmefene, i.e., adults with alcohol dependence who consume more than 60 g of alcohol per day (for men) or more than 40 g per day (for women). No RCT compared nalmefene with another medication. Mortality at 6 mo (RR = 0.39, 95% CI [0.08; 2.01]) and 1 y (RR = 0.98, 95% CI [0.04; 23.95]) and quality of life at 6 mo (SF-36 physical component summary score: MD = 0.85, 95% CI [-0.32; 2.01]; SF-36 mental component summary score: MD = 1.01, 95% CI [-1.33; 3.34]) were not different across groups. Other health outcomes were not reported. Differences were encountered for alcohol consumption outcomes such as monthly number of heavy drinking days at 6 mo (MD = -1.65, 95% CI [-2.41; -0.89]) and at 1 y (MD = -1.60, 95% CI [-2.85; -0.35]) and total alcohol consumption at 6 mo (SMD = -0.20, 95% CI [-0.30; -0.10]). An attrition bias could not be excluded, with more withdrawals for nalmefene than for placebo, including more withdrawals for safety reasons at both 6 mo (RR = 3.65, 95% CI [2.02; 6.63]) and 1 y (RR = 7.01, 95% CI [1.72; 28.63]). Sensitivity analyses showed no differences for alcohol consumption outcomes between nalmefene and placebo, but the weight of these results should not be overestimated, as the BOCF approach to managing withdrawals was used. The value of nalmefene for treatment of alcohol addiction is not established. At best, nalmefene has limited efficacy in reducing alcohol consumption.","INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;Département de Médecine Générale, Faculté de Médecine et de Pharmacie, Université de Poitiers, Poitiers, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.","NA",0,"1549-1676","PLoS Med","PLoS Med",2015,"2015","12","10.1371/journal.pmed.1001924","e1001924","","","26694529","26694529","PUBMED","INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;Département de Médecine Générale, Faculté de Médecine et de Pharmacie, Université de Poitiers, Poitiers, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France.;INSERM Centre d'Investigation Clinique 1414, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Laboratoire de Pharmacologie Expérimentale et Clinique, Faculté de Médecine, Université de Rennes 1, Rennes, France."
"526","Legembre P;Micheau O;Ségui B","Legembre, Patrick;Micheau, Olivier;Ségui, Bruno","Chemotherapy with ceramide in TNBC.","Oncoscience","United States","eng","Journal Article","CD95;EMT;TRAIL;metastasis;sphingolipids","","","NA","Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.","NA",0,"2331-4737","Oncoscience","Oncoscience",2015,"2015","2","10.18632/oncoscience.196","817-8","","","26682260","26682260","PUBMED","Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France.;Centre Eugène Marquis, rue bataille Flandres Dunkerque, Université de Rennes-1, INSERM ERL440, Equipe Labellisée Ligue Contre Le Cancer, rue bataille Flandres-Dunkerque, Rennes, France."
"527","Pierot L;Moret J;Turjman F;Herbreteau D;Raoult H;Barreau X;Velasco S;Desal H;Januel AC;Courtheoux P;Gauvrit JY;Cognard C;Molyneux A;Byrne J;Spelle L","Pierot, L;Moret, J;Turjman, F;Herbreteau, D;Raoult, H;Barreau, X;Velasco, S;Desal, H;Januel, A-C;Courtheoux, P;Gauvrit, J-Y;Cognard, C;Molyneux, A;Byrne, J;Spelle, L","WEB Treatment of Intracranial Aneurysms: Clinical and Anatomic Results in the French Observatory.","AJNR. American journal of neuroradiology","United States","eng","Journal Article","","Adult;Aged;Aneurysm, Ruptured;Cerebral Arteries;Embolization, Therapeutic;Female;Follow-Up Studies;France;Humans;Intracranial Aneurysm;Male;Middle Aged;Platelet Aggregation Inhibitors;Postoperative Complications;Prospective Studies;Recurrence;Stents;Treatment Outcome","Adult;Aged;Aneurysm, Ruptured;Cerebral Arteries;Embolization, Therapeutic;Female;Follow-Up Studies;France;Humans;Intracranial Aneurysm;Male;Middle Aged;Platelet Aggregation Inhibitors;Postoperative Complications;Prospective Studies;Recurrence;Stents;Treatment Outcome","Flow disruption with the WEB device is a new technique for the endovascular treatment of wide-neck bifurcation aneurysms. To obtain precise data regarding the safety and efficacy of this treatment with high-quality methodology, the prospective French Observatory study was conducted. Analysis of these data is presented, including 1-year follow-up. Patients with bifurcation aneurysms for which WEB treatment was indicated were included in this prospective, multicenter Good Clinical Practice study. Clinical data, including adverse events and clinical status at 1 month and 1 year, were collected and independently analyzed by a medical monitor. An independent core laboratory evaluated the anatomic results at 1 year following the procedure. Ten French neurointerventional centers included 62 patients (39 women), 33-74 years of age (mean, 56.6 ± 9.80 years) with 63 aneurysms. Aneurysm locations were the middle cerebral artery in 32 aneurysms (50.8%), anterior communicating artery in 16 (25.4%), basilar artery in 9 (14.3%), and internal carotid artery terminus in 6 (9.5%). Morbidity and mortality at 1 month were, respectively, 3.2% (2/62 patients) and 0.0% (0/62). Morbidity and mortality (unrelated to the treatment) at 1 year were, respectively, 0.0% (0/59) and 3.4% (2/59 patients). At 1 year, complete occlusion was observed in 30/58 aneurysms (51.7%); neck remnant, in 16/58 aneurysms (27.6%); and aneurysm remnant, in 12/58 aneurysms (20.7%). This prospective French Observatory study showed very good safety of aneurysm treatment with the WEB, with a high rate of adequate aneurysm occlusion at 1 year (79.3%).","From the Department of Neuroradiology (L.P.), Hôpital Maison-Blanche, Université Reims-Champagne-Ardenne, Reims;Hôpital Beaujon, (J.M., L.S.), Assistance Publique-Hôpitaux de Paris, Clichy, France.;Centre Hospitalier Universitaire de Lyon (F.T.), Lyon, France.;Centre Hospitalier Universitaire de Tours (D.H.), Tours, France.;Centre Hospitalier Universitaire de Rennes (H.R., J.-Y.G.), Rennes, France.;Centre Hospitalier Universitaire de Bordeaux (X.B.), Bordeaux, France.;Centre Hospitalier Universitaire de Poitiers (S.V.), Poitiers, France.;Centre Hospitalier Universitaire de Nantes (H.D.), Nantes, France.;Centre Hospitalier Universitaire de Toulouse (A.-C.J., C.C.), Toulouse, France.;Centre Hospitalier Universitaire de Caen (P.C.), Caen, France.;Centre Hospitalier Universitaire de Rennes (H.R., J.-Y.G.), Rennes, France.;Centre Hospitalier Universitaire de Toulouse (A.-C.J., C.C.), Toulouse, France.;Oxford Neurovascular and Neuroradiology Research Unit (A.M., J.B.), Oxford Radcliffe Hospital, Oxford, UK.;From the Department of Neuroradiology (L.P.), Hôpital Maison-Blanche, Université Reims-Champagne-Ardenne, Reims, France.;Hôpital Beaujon, (J.M., L.S.), Assistance Publique-Hôpitaux de Paris, Clichy, France.","NA",0,"1936-959X","AJNR Am J Neuroradiol","AJNR Am J Neuroradiol",2015,"2016","37","10.3174/ajnr.A4578","655-9","","","26514608","26514608","PUBMED","From the Department of Neuroradiology (L.P.), Hôpital Maison-Blanche, Université Reims-Champagne-Ardenne, Reims;Hôpital Beaujon, (J.M., L.S.), Assistance Publique-Hôpitaux de Paris, Clichy, France.;Centre Hospitalier Universitaire de Lyon (F.T.), Lyon, France.;Centre Hospitalier Universitaire de Tours (D.H.), Tours, France.;Centre Hospitalier Universitaire de Rennes (H.R., J.-Y.G.), Rennes, France.;Centre Hospitalier Universitaire de Bordeaux (X.B.), Bordeaux, France.;Centre Hospitalier Universitaire de Poitiers (S.V.), Poitiers, France.;Centre Hospitalier Universitaire de Nantes (H.D.), Nantes, France.;Centre Hospitalier Universitaire de Toulouse (A.-C.J., C.C.), Toulouse, France.;Centre Hospitalier Universitaire de Caen (P.C.), Caen, France.;Centre Hospitalier Universitaire de Rennes (H.R., J.-Y.G.), Rennes, France.;Centre Hospitalier Universitaire de Toulouse (A.-C.J., C.C.), Toulouse, France.;Oxford Neurovascular and Neuroradiology Research Unit (A.M., J.B.), Oxford Radcliffe Hospital, Oxford, UK.;From the Department of Neuroradiology (L.P.), Hôpital Maison-Blanche, Université Reims-Champagne-Ardenne, Reims, France.;Hôpital Beaujon, (J.M., L.S.), Assistance Publique-Hôpitaux de Paris, Clichy, France."
"528","Amelot A;De Cremoux P;Quillien V;Polivka M;Adle-Biassette H;Lehmann-Che J;Françoise L;Carpentier AF;George B;Mandonnet E;Froelich S","Amelot, Aymeric;De Cremoux, Patricia;Quillien, Véronique;Polivka, Marc;Adle-Biassette, Homa;Lehmann-Che, Jacqueline;Françoise, Laurence;Carpentier, Antoine F;George, Bernard;Mandonnet, Emmanuel;Froelich, Sébastien","IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.","PloS one","United States","eng","Journal Article","","Adult;Aged;Brain Neoplasms;Chi-Square Distribution;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Female;Glioblastoma;Humans;Immunohistochemistry;Isocitrate Dehydrogenase;Male;Middle Aged;Multivariate Analysis;Mutation;Outcome Assessment, Health Care;Predictive Value of Tests;Prognosis;Promoter Regions, Genetic;Retrospective Studies;Survival Analysis;Survivors;Time Factors;Tumor Suppressor Proteins","Adult;Aged;Brain Neoplasms;Chi-Square Distribution;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Female;Glioblastoma;Humans;Immunohistochemistry;Isocitrate Dehydrogenase;Male;Middle Aged;Multivariate Analysis;Mutation;Outcome Assessment, Health Care;Predictive Value of Tests;Prognosis;Promoter Regions, Genetic;Retrospective Studies;Survival Analysis;Survivors;Time Factors;Tumor Suppressor Proteins","A very small proportion of patients diagnosed with glioblastoma (GBM) survive more than 3 years. Isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations define a small subgroup of GBM patients with favourable prognosis. However, it remains controversial whether long-term survivors (LTS) are found among those IDH1/2 mutated patients. We retrospectively analyzed 207 GBM patients followed at Lariboisière Hospital (Paris) between 2005 and 2010. Clinical parameters were obtained from medical records. Mutations of IDH1/2 were analyzed in these patients, by immunohistochemistry for the R132H mutation of IDH1 and by high-resolution melting-curve analysis, followed by Sanger sequencing for IDH1 and IDH2 exon 4 mutations. Mutation rates in LTS and non-LTS groups were compared by Chi square Pearson test. Seventeen patients with survival >3 years were identified (8.2% of the total series). The median overall survival in long-term survivors was 4.6 years. Subgroup analysis found that the median age at diagnosis was significantly higher for non long-term survivors (non-LTS) compared to LTS (60 versus 51 years, p <0.03). The difference in the rate of IDH mutation between non-LTS and LTS was statistically not significant (1.16% versus 5.9%, p = 0.144). Among LTS, 10 out of 16 tumors presented a methylation of MGMT promoter. This study confirms that long-term survival in GBM patients is if at all only weakly correlated to IDH-mutation.","Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Département de Biologie, Centre Eugène Marquis, CS 44229, Rue de la Bataille Flandres Dunkerque, 35042, Rennes Cedex, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of pathology, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of pathology, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Avicennes Hospital, Department of Neurology, Bobigny, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France; IMNC, UMR 8165, Orsay, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France.","NA",0,"1932-6203","PLoS One","PLoS One",2015,"2015","10","10.1371/journal.pone.0130596","e0130596","","","26158269","26158269","PUBMED","Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Département de Biologie, Centre Eugène Marquis, CS 44229, Rue de la Bataille Flandres Dunkerque, 35042, Rennes Cedex, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of pathology, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of pathology, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), St-Louis Hospital, Department of Biochemistry, Molecular Oncology Unit, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Avicennes Hospital, Department of Neurology, Bobigny, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France; IMNC, UMR 8165, Orsay, France.;Assistance Publique-Hôpitaux de Paris (AP-HP), Lariboisière Hospital, Department of Neurosurgery, Paris, France; University Paris Diderot, Sorbonne Paris Cité, Paris, France."
"529","Duval C;de Tayrac M;Michaud K;Cabillic F;Paquet C;Gould PV;Saikali S","Duval, Céline;de Tayrac, Marie;Michaud, Karine;Cabillic, Florian;Paquet, Claudie;Gould, Peter Vincent;Saikali, Stéphan","Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.","PloS one","United States","eng","Comparative Study","","Algorithms;Automation;Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 1;Glioma;Humans;In Situ Hybridization, Fluorescence;Oligodendroglioma;Paraffin Embedding;Prospective Studies;Retrospective Studies","Algorithms;Automation;Brain Neoplasms;Chromosome Deletion;Chromosomes, Human, Pair 1;Glioma;Humans;In Situ Hybridization, Fluorescence;Oligodendroglioma;Paraffin Embedding;Prospective Studies;Retrospective Studies","To propose a new algorithm facilitating automated analysis of 1p and 19q status by FISH technique in oligodendroglial tumors with software packages available in the majority of institutions using this technique. We documented all green/red (G/R) probe signal combinations in a retrospective series of 53 oligodendroglial tumors according to literature guidelines (Algorithm 1) and selected only the most significant combinations for a new algorithm (Algorithm 2). This second algorithm was then validated on a prospective internal series of 45 oligodendroglial tumors and on an external series of 36 gliomas. Algorithm 2 utilizes 24 G/R combinations which represent less than 40% of combinations observed with Algorithm 1. The new algorithm excludes some common G/R combinations (1/1, 3/2) and redefines the place of others (defining 1/2 as compatible with normal and 3/3, 4/4 and 5/5 as compatible with imbalanced chromosomal status). The new algorithm uses the combination + ratio method of signal probe analysis to give the best concordance between manual and automated analysis on samples of 100 tumor cells (91% concordance for 1p and 89% concordance for 19q) and full concordance on samples of 200 tumor cells. This highlights the value of automated analysis as a means to identify cases in which a larger number of tumor cells should be studied by manual analysis. Validation of this algorithm on a second series from another institution showed a satisfactory concordance (89%, κ = 0.8). Our algorithm can be easily implemented on all existing FISH analysis software platforms and should facilitate multicentric evaluation and standardization of 1p/19q assessment in gliomas with reduction of the professional and technical time required.","Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of genomic and molecular genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of cytogenetics and cellular biology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.","NA",0,"1932-6203","PLoS One","PLoS One",2015,"2015","10","10.1371/journal.pone.0132125","e0132125","","","26135922","26135922","PUBMED","Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of genomic and molecular genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of cytogenetics and cellular biology, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada."
"530","Scherdel P;Botton J;Rolland-Cachera MF;Léger J;Pelé F;Ancel PY;Simon C;Castetbon K;Salanave B;Thibault H;Lioret S;Péneau S;Gusto G;Charles MA;Heude B","Scherdel, Pauline;Botton, Jérémie;Rolland-Cachera, Marie-Françoise;Léger, Juliane;Pelé, Fabienne;Ancel, Pierre Yves;Simon, Chantal;Castetbon, Katia;Salanave, Benoit;Thibault, Hélène;Lioret, Sandrine;Péneau, Sandrine;Gusto, Gaelle;Charles, Marie-Aline;Heude, Barbara","Should the WHO growth charts be used in France?","PloS one","United States","eng","Comparative Study","","Adolescent;Anthropometry;Body Weights and Measures;Child;Child, Preschool;Female;France;Growth Charts;Humans;Male;Prospective Studies;World Health Organization","Adolescent;Anthropometry;Body Weights and Measures;Child;Child, Preschool;Female;France;Growth Charts;Humans;Male;Prospective Studies;World Health Organization","Growth charts are an essential clinical tool for evaluating a child's health and development. The current French reference curves, published in 1979, have recently been challenged by the 2006 World Health Organization (WHO) growth charts. To evaluate and compare the growth of French children who were born between 1981 and 2007, with the WHO growth charts and the French reference curves currently used. Anthropometric measurements from French children, who participated in 12 studies, were analyzed: 82,151 measurements were available for 27,257 children in different age groups, from birth to 18 years. We calculated and graphically compared mean z-scores based on the WHO and French curves, for height, weight and Body Mass Index (BMI) according to age and sex. The prevalence of overweight using the WHO, the French and International Obesity Task Force definitions were compared. Our population of children was on average 0.5 standard deviations taller than the French reference population, from the first month of life until puberty age. Mean z-scores for height, weight and BMI were closer to zero based on the WHO growth charts than on the French references from infancy until late adolescence, except during the first six months. These differences not related to breastfeeding rates. As expected, the prevalence of overweight depended on the reference used, and differences varied according to age. The WHO growth charts may be appropriate for monitoring growth of French children, as the growth patterns in our large population of French children were closer to the WHO growth charts than to the French reference curves, from 6 months onwards. However, there were some limitations in the use of these WHO growth charts, and further investigation is needed.","INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; Univ. Paris-Sud, Laboratoire de biomathématique, Faculté de Pharmacie, Châtenay-Malabry, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;Univ. Paris Diderot, Sorbonne Paris Cité, Paris, AP-HP, Hôpital Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, Institut National de la Santé et de la Recherche Médicale, UMR 676, Paris, France.;Inserm UMR 1085 IRSET, Rennes, France; Université de Rennes 1, Faculté de Médecine, Rennes, France, Centre Hospitalier Universitaire de Rennes (CHU), Service d'Epidémiologie et de Santé Publique, Rennes, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Paris, France, Paris Descartes University, France.;Carmen, Inserm U1060, University of Lyon 1, INRA U1235, CRNH Rhône-Alpes, CENS, Lyon, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Univ. Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France, Inserm, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; French Agency for Food, Environmental and Occupational Health Safety (ANSES, ex-AFSSA, Dietary Survey Unit, Maisons-Alfort, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;IRSA, département Synergies, 37521 La Riche cedex, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.","NA",0,"1932-6203","PLoS One","PLoS One",2014,"2015","10","10.1371/journal.pone.0120806","e0120806","","","25761138","25761138","PUBMED","INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; Univ. Paris-Sud, Laboratoire de biomathématique, Faculté de Pharmacie, Châtenay-Malabry, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;Univ. Paris Diderot, Sorbonne Paris Cité, Paris, AP-HP, Hôpital Robert Debré, Service d'Endocrinologie Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Paris, Institut National de la Santé et de la Recherche Médicale, UMR 676, Paris, France.;Inserm UMR 1085 IRSET, Rennes, France; Université de Rennes 1, Faculté de Médecine, Rennes, France, Centre Hospitalier Universitaire de Rennes (CHU), Service d'Epidémiologie et de Santé Publique, Rennes, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé), Paris, France, Paris Descartes University, France.;Carmen, Inserm U1060, University of Lyon 1, INRA U1235, CRNH Rhône-Alpes, CENS, Lyon, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Institut de veille sanitaire (InVS), Département maladies chroniques et traumatismes, Unité de surveillance et d'épidémiologie nutritionnelle (USEN), F-94415 Saint-Maurice, France, Université Paris 13, Sorbonne Paris Cité, Centre de Recherche en Epidémiologies et Biostatistiques, Bobigny, France.;Univ. Bordeaux, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France, Inserm, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France; French Agency for Food, Environmental and Occupational Health Safety (ANSES, ex-AFSSA, Dietary Survey Unit, Maisons-Alfort, France.;Université Paris 13, INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Nutritional Epidemiology Research Team (EREN), Paris, France, Paris Descartes University, France, Inra, Cnam, Université Paris 5, Université Paris 7, Bobigny, France.;IRSA, département Synergies, 37521 La Riche cedex, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France.;INSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cité Center (CRESS), Early determinants of the child's health and development Team (ORCHAD), Paris, France, Paris Descartes University, France."
"531","Rizvi NA;Mazières J;Planchard D;Stinchcombe TE;Dy GK;Antonia SJ;Horn L;Lena H;Minenza E;Mennecier B;Otterson GA;Campos LT;Gandara DR;Levy BP;Nair SG;Zalcman G;Wolf J;Souquet PJ;Baldini E;Cappuzzo F;Chouaid C;Dowlati A;Sanborn R;Lopez-Chavez A;Grohe C;Huber RM;Harbison CT;Baudelet C;Lestini BJ;Ramalingam SS","Rizvi, Naiyer A;Mazières, Julien;Planchard, David;Stinchcombe, Thomas E;Dy, Grace K;Antonia, Scott J;Horn, Leora;Lena, Hervé;Minenza, Elisa;Mennecier, Bertrand;Otterson, Gregory A;Campos, Luis T;Gandara, David R;Levy, Benjamin P;Nair, Suresh G;Zalcman, Gérard;Wolf, Jürgen;Souquet, Pierre-Jean;Baldini, Editta;Cappuzzo, Federico;Chouaid, Christos;Dowlati, Afshin;Sanborn, Rachel;Lopez-Chavez, Ariel;Grohe, Christian;Huber, Rudolf M;Harbison, Christopher T;Baudelet, Christine;Lestini, Brian J;Ramalingam, Suresh S","Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase II","","Aged;Antibodies, Monoclonal;Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Comorbidity;Disease Progression;Disease-Free Survival;Drug Administration Schedule;Europe;Female;Humans;Infusions, Intravenous;Kaplan-Meier Estimate;Lung Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Nivolumab;Programmed Cell Death 1 Receptor;Risk Factors;Signal Transduction;Time Factors;Treatment Outcome;United States","Aged;Antibodies, Monoclonal;Antineoplastic Agents;Carcinoma, Non-Small-Cell Lung;Comorbidity;Disease Progression;Disease-Free Survival;Drug Administration Schedule;Europe;Female;Humans;Infusions, Intravenous;Kaplan-Meier Estimate;Lung Neoplasms;Male;Middle Aged;Molecular Targeted Therapy;Nivolumab;Programmed Cell Death 1 Receptor;Risk Factors;Signal Transduction;Time Factors;Treatment Outcome;United States","Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-small-cell lung cancer. We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed objective response as assessed by an independent radiology review committee. We included all treated patients in the analyses. This study is registered with ClinicalTrials.gov, number NCT01721759. Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 (14·5%, 95% CI 8·7-22·2) of 117 patients had an objective response as assessed by an independent radiology review committee. Median time to response was 3·3 months (IQR 2·2-4·8), and median duration of response was not reached (95% CI 8·31-not applicable); 13 (77%) of 17 of responses were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 6·0 months, 95% CI 4·7-10·9). 20 (17%) of 117 patients reported grade 3-4 treatment-related adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive disease. Nivolumab has clinically meaningful activity and a manageable safety profile in previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These data support the assessment of nivolumab in randomised, controlled, phase 3 studies of first-line and second-line treatment. Bristol-Myers Squibb.","Memorial Sloan-Kettering Cancer Center, New York, NY;Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;L'Institut Gustave Roussy, Villejuif, France.;University of North Carolina School of Medicine, Chapel Hill, NC, USA.;Roswell Park Cancer Institute, Buffalo, NY, USA.;H Lee Moffitt Cancer Center, Tampa, FL, USA.;Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Ospedale S Maria, Terni, Italy.;Nouvel Hôpital Civil Chru de Strasbourg, Strasbourg, France.;The Ohio State University Medical Center, Columbus, OH, USA.;Oncology Consultants, PA, Houston, TX, USA.;University of California Davis Cancer Center, Sacramento, CA, USA.;Mount Sinai Beth Israel Comprehensive Cancer Center, New York, NY, USA.;Lehigh Valley Hospital, Allentown, PA, USA.;Centre Hospitalier Universitaire de Caen, Caen, France.;Universitaetsklinik Koeln, Koeln, Germany.;Hospices Civils de Lyon, Ch Lyon Sud, Pierre Benite, France.;Ospedale Campo Di Marte, Lucca, Italy.;Istituto Toscano Tumori, Livorno, Italy.;Chi De Creteil, Creteil, France.;University Hospitals of Cleveland, Cleveland, OH, USA.;Providence Portland Medical Center, Portland, OR, USA.;University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.;Evangelische Lungenklinik Berlin, Berlin, Germany.;Klinikum der Universitaet Muenchen-Innenstadt, German Center for Lung Research, Munich, Germany.;Bristol-Myers Squibb, Princeton, NJ, USA.;Bristol-Myers Squibb, Princeton, NJ, USA.;Bristol-Myers Squibb, Princeton, NJ, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2015,"2015","16","10.1016/S1470-2045(15)70054-9","257-65","P30 CA076292","NCI NIH HHS","25704439","25704439","PUBMED","Memorial Sloan-Kettering Cancer Center, New York, NY;Hôpital Larrey, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.;L'Institut Gustave Roussy, Villejuif, France.;University of North Carolina School of Medicine, Chapel Hill, NC, USA.;Roswell Park Cancer Institute, Buffalo, NY, USA.;H Lee Moffitt Cancer Center, Tampa, FL, USA.;Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.;Centre Hospitalier Universitaire de Rennes, Rennes, France.;Ospedale S Maria, Terni, Italy.;Nouvel Hôpital Civil Chru de Strasbourg, Strasbourg, France.;The Ohio State University Medical Center, Columbus, OH, USA.;Oncology Consultants, PA, Houston, TX, USA.;University of California Davis Cancer Center, Sacramento, CA, USA.;Mount Sinai Beth Israel Comprehensive Cancer Center, New York, NY, USA.;Lehigh Valley Hospital, Allentown, PA, USA.;Centre Hospitalier Universitaire de Caen, Caen, France.;Universitaetsklinik Koeln, Koeln, Germany.;Hospices Civils de Lyon, Ch Lyon Sud, Pierre Benite, France.;Ospedale Campo Di Marte, Lucca, Italy.;Istituto Toscano Tumori, Livorno, Italy.;Chi De Creteil, Creteil, France.;University Hospitals of Cleveland, Cleveland, OH, USA.;Providence Portland Medical Center, Portland, OR, USA.;University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.;Evangelische Lungenklinik Berlin, Berlin, Germany.;Klinikum der Universitaet Muenchen-Innenstadt, German Center for Lung Research, Munich, Germany.;Bristol-Myers Squibb, Princeton, NJ, USA.;Bristol-Myers Squibb, Princeton, NJ, USA.;Bristol-Myers Squibb, Princeton, NJ, USA.;Winship Cancer Institute, Emory University, Atlanta, GA, USA."
"532","Fizazi K;Pagliaro L;Laplanche A;Fléchon A;Mardiak J;Geoffrois L;Kerbrat P;Chevreau C;Delva R;Rolland F;Theodore C;Roubaud G;Gravis G;Eymard JC;Malhaire JP;Linassier C;Habibian M;Martin AL;Journeau F;Reckova M;Logothetis C;Culine S","Fizazi, Karim;Pagliaro, Lance;Laplanche, Agnes;Fléchon, Aude;Mardiak, Josef;Geoffrois, Lionnel;Kerbrat, Pierre;Chevreau, Christine;Delva, Remy;Rolland, Frederic;Theodore, Christine;Roubaud, Guilhem;Gravis, Gwenaëlle;Eymard, Jean-Christophe;Malhaire, Jean-Pierre;Linassier, Claude;Habibian, Muriel;Martin, Anne-Laure;Journeau, Florence;Reckova, Maria;Logothetis, Christopher;Culine, Stephane","Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase III","","Adolescent;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Bleomycin;Chorionic Gonadotropin;Cisplatin;Etoposide;Female;Follow-Up Studies;Granulocyte Colony-Stimulating Factor;Humans;Ifosfamide;International Agencies;Lenograstim;Male;Mediastinal Neoplasms;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Neoplasms, Germ Cell and Embryonal;Organoplatinum Compounds;Oxaliplatin;Paclitaxel;Peritoneal Neoplasms;Precision Medicine;Prognosis;Recombinant Proteins;Survival Rate;Testicular Neoplasms;Young Adult;alpha-Fetoproteins","Adolescent;Adult;Aged;Antineoplastic Combined Chemotherapy Protocols;Biomarkers, Tumor;Bleomycin;Chorionic Gonadotropin;Cisplatin;Etoposide;Female;Follow-Up Studies;Granulocyte Colony-Stimulating Factor;Humans;Ifosfamide;International Agencies;Lenograstim;Male;Mediastinal Neoplasms;Middle Aged;Neoplasm Metastasis;Neoplasm Staging;Neoplasms, Germ Cell and Embryonal;Organoplatinum Compounds;Oxaliplatin;Paclitaxel;Peritoneal Neoplasms;Precision Medicine;Prognosis;Recombinant Proteins;Survival Rate;Testicular Neoplasms;Young Adult;alpha-Fetoproteins","Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an early tumour marker decline will improve progression-free survival for patients with germ-cell tumours. In this phase 3, multicentre, randomised trial, patients were enrolled from France (20 centres), USA (one centre), and Slovakia (one centre). Patients were eligible if they were older than 16 years, had evidence of testicular, retroperitoneal, or mediastinal non-seminomatous germ cell tumours based on histological findings or clinical evidence and highly elevated serum human chorionic gonadotropin or alfa-fetoprotein concentrations that matched International Germ Cell Cancer Consensus Group poor prognosis criteria. After one cycle of BEP (intravenous cisplatin [20 mg/m(2) per day for 5 days], etoposide [100 mg/m(2) per day for 5 days], and intramuscular or intravenous bleomycin [30 mg per day on days 1, 8, and 15]), patients' human chorionic gonadotropin and alfa-fetoprotein concentrations were measured at day 18-21. Patients with a favourable decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 additonal cycles, whereas patients with an unfavourable decline were randomly assigned (1:1) to receive either BEP (Unfav-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting of intravenous paclitaxel (175 mg/m(2) over 3 h on day 1) before BEP plus intravenous oxaliplatin (130 mg/m(2) over 3 h on day 10; two cycles), followed by intravenous cisplatin (100 mg/m(2) over 2 h on day 1), intravenous ifosfamide (2 g/m(2) over 3 h on days 10, 12, and 14), plus mesna (500 mg/m(2) at 0, 3, 7 and 11 h), and bleomycin (25 units per day, by continuous infusion for 5 days on days 10-14; two cycles), with granulocyte-colony stimulating factor (lenograstim) support. Centrally blocked computer-generated randomisation stratified by centre was used. The primary endpoint was progression-free survival and the efficacy analysis was done in the intention-to-treat population. The planned trial accrual was completed in May, 2012, and follow-up is ongoing. This study is registered with ClinicalTrials.gov, number NCT00104676. Between Nov 28, 2003, and May 16, 2012, 263 patients were enrolled and 254 were available for tumour marker assessment. Of these 51 (20%) had a favourable marker assessment, and 203 (80%) had an unfavourable tumour marker decline; 105 were randomly assigned to the Unfav-dose-dense group and 98 to the Unfav-BEP group. 3-year progression-free survival was 59% (95% CI 49-68) in the Unfav-dose-dense group versus 48% (38-59) in the Unfav-BEP group (HR 0·66, 95% CI 0·44-1·00, p=0·05). 3-year progression-free survival was 70% (95% CI 57-81) in the Fav-BEP group (HR 0·66, 95% CI 0·49-0·88, p=0·01 for progression-free survival compared with the Unfav-BEP group). More grade 3-4 neurotoxic events (seven [7%] vs one [1%]) and haematotoxic events occurred in the Unfav-dose-dense group compared with in the Unfav-BEP group; there was no difference in grade 1-2 febrile neutropenia (18 [17%] vs 18 [18%]) or toxic deaths (one [1%] in both groups). Salvage high-dose chemotherapy plus a stem-cell transplant was required in six (6%) patients in the Unfav-dose-dense group and 16 (16%) in the Unfav-BEP group. Personalised treatment with chemotherapy intensification reduces the risk of progression or death in patients with poor prognosis germ-cell tumours and an unfavourable tumour marker decline. Institut National du Cancer (Programme Hospitalier de Recherche Clinique).","Institut Gustave Roussy, Department of Cancer Medicine, Villejuif;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Institut Gustave Roussy, Department of Biostatistics, Villejuif, France.;Centre Léon Bérard, Department of Cancer Medicine, Lyon, France.;National Cancer Institute, Bratislava, Slovakia.;Centre Alexis Vautrin, Department of Cancer Medicine, Nancy, France.;Centre Eugène Marquis, Department of Cancer Medicine, Rennes, France.;Centre Claudius Regaud, Department of Cancer Medicine, Toulouse, France.;Institut de Cancérologie de l'Ouest, Department of Cancer Medicine, Angers, France.;Institut de Cancérologie de l'Ouest, Department of Cancer Medicine, Nantes, France.;Hopital Foch, Department of Cancer Medicine, Suresnes, France.;Institut Bergonié, Department of Cancer Medicine, Bordeaux, France.;Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France.;Centre Jean Godinot, Department of Cancer Medicine, Reims, France.;Centre Hospitalo-Universitaire, Department of Cancer Medicine, Brest, France.;Centre Hospitalo-Universitaire, Department of Cancer Medicine, Tours, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Institut Gustave Roussy, Department of Biostatistics, Villejuif, France.;National Cancer Institute, Bratislava, Slovakia.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Saint Louis, Department of Cancer Medicine, Paris, France.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2014,"2014","15","10.1016/S1470-2045(14)70490-5","1442-1450","P30 CA016672","NCI NIH HHS","25456363","25456363","PUBMED","Institut Gustave Roussy, Department of Cancer Medicine, Villejuif;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Institut Gustave Roussy, Department of Biostatistics, Villejuif, France.;Centre Léon Bérard, Department of Cancer Medicine, Lyon, France.;National Cancer Institute, Bratislava, Slovakia.;Centre Alexis Vautrin, Department of Cancer Medicine, Nancy, France.;Centre Eugène Marquis, Department of Cancer Medicine, Rennes, France.;Centre Claudius Regaud, Department of Cancer Medicine, Toulouse, France.;Institut de Cancérologie de l'Ouest, Department of Cancer Medicine, Angers, France.;Institut de Cancérologie de l'Ouest, Department of Cancer Medicine, Nantes, France.;Hopital Foch, Department of Cancer Medicine, Suresnes, France.;Institut Bergonié, Department of Cancer Medicine, Bordeaux, France.;Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France.;Centre Jean Godinot, Department of Cancer Medicine, Reims, France.;Centre Hospitalo-Universitaire, Department of Cancer Medicine, Brest, France.;Centre Hospitalo-Universitaire, Department of Cancer Medicine, Tours, France.;Unicancer, Paris, France.;Unicancer, Paris, France.;Institut Gustave Roussy, Department of Biostatistics, Villejuif, France.;National Cancer Institute, Bratislava, Slovakia.;University of Texas MD Anderson Cancer Center, Houston, TX, USA.;Hôpital Saint Louis, Department of Cancer Medicine, Paris, France."
"533","Crabol Y;Poiree S;Bougnoux ME;Maunoury C;Barete S;Zeller V;Arvieux C;Pineau S;Amazzough K;Lecuit M;Lanternier F;Lortholary O","Crabol, Yoann;Poiree, Sylvain;Bougnoux, Marie-Elisabeth;Maunoury, Christophe;Barete, Stéphane;Zeller, Valérie;Arvieux, Cédric;Pineau, Samuel;Amazzough, Karima;Lecuit, Marc;Lanternier, Fanny;Lortholary, Olivier","Last generation triazoles for imported eumycetoma in eleven consecutive adults.","PLoS neglected tropical diseases","United States","eng","Case Reports","","Adolescent;Adult;Antifungal Agents;Child;Exophiala;Fluorodeoxyglucose F18;Fusarium;Humans;Madurella;Magnetic Resonance Imaging;Male;Mycetoma;Positron-Emission Tomography;Proteoglycans;Retrospective Studies;Skin;Treatment Outcome;Triazoles;Voriconazole;Young Adult;beta-Glucans","Adolescent;Adult;Antifungal Agents;Child;Exophiala;Fluorodeoxyglucose F18;Fusarium;Humans;Madurella;Magnetic Resonance Imaging;Male;Mycetoma;Positron-Emission Tomography;Proteoglycans;Retrospective Studies;Skin;Treatment Outcome;Triazoles;Voriconazole;Young Adult;beta-Glucans","Optimal management of eumycetoma, a severely debilitating chronic progressive fungal infection of skin, disseminating to bone and viscera, remains challenging. Especially, optimal antifungal treatment and duration are ill defined. We conducted a monocentric retrospective study of 11 imported cases of eumycetoma treated by voriconazole or posaconazole for at least 6 months. Response to treatment was assessed through evolution of clinical and magnetic resonance imaging (MRI). (1→3) ß-D-glucan (BG) and positron emission tomography using [18F] fluorodeoxyglucose (PET/CT) results were also assessed. Identified species were Fusarium solani complex (n = 3); Madurella mycetomatis, (n = 3), and Exophiala jeanselmei, (n = 1). Moreover, two coelomycetes and one phaeohyphomycetes strains without species identification were retrieved. Serum BG and PET/CT were abnormal in 7/8 and 6/6 patients tested, respectively. Patients received last generation azoles for a mean duration of 25.9±18 months. Complete response (major clinical and MRI improvement) was observed in 5/11 patients, partial response (minor MRI improvement or stable MRI findings) in 5 and failure (MRI evidence of disease progression) in one, with a 73±39 [6-132] months mean follow-up. Relapse occurred in 2 patients after treatment discontinuation. Optimal outcome was associated with fungal species, initiation of last generation triazole therapy (<65 months since first symptoms), negative serum BG and PET/CT normalization. MRI, PET/CT and serum BG appear as promising tools to assess optimal time of antifungal treatment for eumycetoma.","Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Service d'Imagerie Médicale, Hôpital Necker-Enfants malades, Paris, France.;Laboratoire de parasito-mycologie, Hôpital Universitaire Necker-Enfants malades, CNRS URA3012, Paris, France.;Unité de Médecine Nucléaire et TEP, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France.;Service de Dermatologie, Hôpital Tenon, APHP, Université Pierre et Marie Curie, Paris, France.;Service de Médecine Interne, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Service de maladies infectieuses et réanimation médicale du Centre hospitalier universitaire de Rennes, Rennes, France.;Hôpital Universitaire de Nantes, Service des Maladies Infectieuses et Tropicales, Nantes, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Biologie des Infections, Institut Pasteur, Inserm U1117, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Mycologie Moléculaire, Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France.","NA",0,"1935-2735","PLoS Negl Trop Dis","PLoS Negl Trop Dis",2014,"2014","8","10.1371/journal.pntd.0003232","e3232","","","25299610","25299610","PUBMED","Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Service d'Imagerie Médicale, Hôpital Necker-Enfants malades, Paris, France.;Laboratoire de parasito-mycologie, Hôpital Universitaire Necker-Enfants malades, CNRS URA3012, Paris, France.;Unité de Médecine Nucléaire et TEP, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France.;Service de Dermatologie, Hôpital Tenon, APHP, Université Pierre et Marie Curie, Paris, France.;Service de Médecine Interne, Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France.;Service de maladies infectieuses et réanimation médicale du Centre hospitalier universitaire de Rennes, Rennes, France.;Hôpital Universitaire de Nantes, Service des Maladies Infectieuses et Tropicales, Nantes, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Biologie des Infections, Institut Pasteur, Inserm U1117, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France.;Centre d'Infectiologie Necker Pasteur, Université Paris Descartes, Sorbonne Paris Cité, Institut Imagine, Hôpital Universitaire Necker-Enfants malades, APHP, Paris, France; Unité de Mycologie Moléculaire, Institut Pasteur, Centre National de Référence Mycoses Invasives et Antifongiques, Paris, France."
"534","Etcheverry A;Aubry M;Idbaih A;Vauleon E;Marie Y;Menei P;Boniface R;Figarella-Branger D;Karayan-Tapon L;Quillien V;Sanson M;de Tayrac M;Delattre JY;Mosser J","Etcheverry, Amandine;Aubry, Marc;Idbaih, Ahmed;Vauleon, Elodie;Marie, Yannick;Menei, Philippe;Boniface, Rachel;Figarella-Branger, Dominique;Karayan-Tapon, Lucie;Quillien, Veronique;Sanson, Marc;de Tayrac, Marie;Delattre, Jean-Yves;Mosser, Jean","DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.","PloS one","United States","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Alkylating;Chemoradiotherapy;Cohort Studies;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Dacarbazine;Diacylglycerol Kinase;Disease-Free Survival;Female;Glioblastoma;Humans;Isocitrate Dehydrogenase;Male;Middle Aged;Nomograms;Prognosis;Promoter Regions, Genetic;Proportional Hazards Models;Retrospective Studies;Temozolomide;Tumor Suppressor Proteins;Young Adult","Adult;Aged;Aged, 80 and over;Antineoplastic Agents, Alkylating;Chemoradiotherapy;Cohort Studies;DNA Methylation;DNA Modification Methylases;DNA Repair Enzymes;Dacarbazine;Diacylglycerol Kinase;Disease-Free Survival;Female;Glioblastoma;Humans;Isocitrate Dehydrogenase;Male;Middle Aged;Nomograms;Prognosis;Promoter Regions, Genetic;Proportional Hazards Models;Retrospective Studies;Temozolomide;Tumor Suppressor Proteins;Young Adult","Consistently reported prognostic factors for glioblastoma (GBM) are age, extent of surgery, performance status, IDH1 mutational status, and MGMT promoter methylation status. We aimed to integrate biological and clinical prognostic factors into a nomogram intended to predict the survival time of an individual GBM patient treated with a standard regimen. In a previous study we showed that the methylation status of the DGKI promoter identified patients with MGMT-methylated tumors that responded poorly to the standard regimen. We further evaluated the potential prognostic value of DGKI methylation status. 399 patients with newly diagnosed GBM and treated with a standard regimen were retrospectively included in this study. Survival modelling was performed on two patient populations: intention-to-treat population of all included patients (population 1) and MGMT-methylated patients (population 2). Cox proportional hazard models were fitted to identify the main prognostic factors. A nomogram was developed for population 1. The prognostic value of DGKI promoter methylation status was evaluated on population 1 and population 2. The nomogram-based stratification of the cohort identified two risk groups (high/low) with significantly different median survival. We validated the prognostic value of DGKI methylation status for MGMT-methylated patients. We also demonstrated that the DGKI methylation status identified 22% of poorly responding patients in the low-risk group defined by the nomogram. Our results improve the conventional MGMT stratification of GBM patients receiving standard treatment. These results could help the interpretation of published or ongoing clinical trial outcomes and refine patient recruitment in the future.","CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Plate-forme Génomique Santé Biogenouest, Biosit, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Département de Biologie Médicale, Centre Eugène Marquis, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;Centre Hospitalier Universitaire d'Angers, Service de Neurochirurgie, Angers, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France.;Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire de la Timone, Service d'Anatomie Pathologie et de Neuropathologie, Université Aix-Marseille, Marseille, France; INSERM U911, Université Aix-Marseille, Marseille, France.;INSERM U935, Poitiers, France; Université de Poitiers, Poitiers, France; Centre Hospitalier Universitaire de Poitiers, Laboratoire de Cancérologie Biologique, Poitiers, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Département de Biologie Médicale, Centre Eugène Marquis, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Plate-forme Génomique Santé Biogenouest, Biosit, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2014,"2014","9","10.1371/journal.pone.0104455","e104455","","","25233099","25233099","PUBMED","CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Plate-forme Génomique Santé Biogenouest, Biosit, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Département de Biologie Médicale, Centre Eugène Marquis, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;Centre Hospitalier Universitaire d'Angers, Service de Neurochirurgie, Angers, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France.;Assistance Publique-Hôpitaux de Marseille, Centre Hospitalier Universitaire de la Timone, Service d'Anatomie Pathologie et de Neuropathologie, Université Aix-Marseille, Marseille, France; INSERM U911, Université Aix-Marseille, Marseille, France.;INSERM U935, Poitiers, France; Université de Poitiers, Poitiers, France; Centre Hospitalier Universitaire de Poitiers, Laboratoire de Cancérologie Biologique, Poitiers, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Département de Biologie Médicale, Centre Eugène Marquis, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.;Assistance Publique-Hôpitaux de Paris, Service de Neurologie 2 Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Centre de Recherche de l'Institut du Cerveau et de la Moelle Épinière, INSERM UMRS 975/CNRS UMR 7225/Université Pierre-et-Marie-Curie, Institut du Cerveau et de la Moelle Épinière, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.;CNRS, UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France; Université Rennes 1, Université Européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France; Plate-forme Génomique Santé Biogenouest, Biosit, Rennes, France; Centre Hospitalier Universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France."
"535","Duval C;de Tayrac M;Sanschagrin F;Michaud K;Gould PV;Saikali S","Duval, Céline;de Tayrac, Marie;Sanschagrin, François;Michaud, Karine;Gould, Peter Vincent;Saikali, Stéphan","ImmunoFISH is a reliable technique for the assessment of 1p and 19q status in oligodendrogliomas.","PloS one","United States","eng","Journal Article","","Adult;Aged;Aged, 80 and over;Antibodies, Antinuclear;Antibodies, Monoclonal;Brain Neoplasms;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 19;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Middle Aged;Observer Variation;Oligodendroglioma;Reproducibility of Results","Adult;Aged;Aged, 80 and over;Antibodies, Antinuclear;Antibodies, Monoclonal;Brain Neoplasms;Chromosomes, Human, Pair 1;Chromosomes, Human, Pair 19;Female;Humans;Immunohistochemistry;In Situ Hybridization, Fluorescence;Male;Middle Aged;Observer Variation;Oligodendroglioma;Reproducibility of Results","To develop a new ImmunoFISH technique for the study of oligodendrogliomas by combining a standard immunohistochemical stain using MIB-1 antibody with a standard FISH technique using commercial 1p36 and 19q13 chromosomal probes. Validation was performed by two observers on a series of 36 pre-selected oligodendrogliomas and compared to the results previously determined by FISH alone. The ImFISH technique is easy to perform and to analyze and is no more time-consuming than the usual FISH technique. Our results show that the inter-observer reliability of ImFISH is high (κ = 0.86 and 0.95 respectively for 1p and 19q). Compared to FISH, the ImFISH exhibits a very high sensitivity (∼100%) and specificity (∼90%) for 1p and/or 19q deleted cases. The sensitivity is high for normal cases (∼85%) and imbalanced cases (∼90%) with a specificity ranging between 50 and 85%. Finally, there were no significant differences between FISH and ImFISH results calculated on 60, 40 or 20 cells. Our study demonstrates the reliability of the ImFISH technique in oligodendrogliomas and emphasizes its advantage in poorly cellular tumoral specimen.","Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of genomic and molecular genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.","NA",0,"1932-6203","PLoS One","PLoS One",2014,"2014","9","10.1371/journal.pone.0100342","e100342","","","24949947","24949947","PUBMED","Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of genomic and molecular genetics, Centre Hospitalier Universitaire de Rennes, Rennes, France.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Neurosurgery, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada.;Department of Pathology, Centre Hospitalier Universitaire de Québec, Québec, Canada."
"536","Malka D;Cervera P;Foulon S;Trarbach T;de la Fouchardière C;Boucher E;Fartoux L;Faivre S;Blanc JF;Viret F;Assenat E;Seufferlein T;Herrmann T;Grenier J;Hammel P;Dollinger M;André T;Hahn P;Heinemann V;Rousseau V;Ducreux M;Pignon JP;Wendum D;Rosmorduc O;Greten TF","Malka, David;Cervera, Pascale;Foulon, Stéphanie;Trarbach, Tanja;de la Fouchardière, Christelle;Boucher, Eveline;Fartoux, Laetitia;Faivre, Sandrine;Blanc, Jean-Frédéric;Viret, Frédéric;Assenat, Eric;Seufferlein, Thomas;Herrmann, Thomas;Grenier, Julien;Hammel, Pascal;Dollinger, Matthias;André, Thierry;Hahn, Philipp;Heinemann, Volker;Rousseau, Vanessa;Ducreux, Michel;Pignon, Jean-Pierre;Wendum, Dominique;Rosmorduc, Olivier;Greten, Tim F","Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.","The Lancet. Oncology","England","eng","Clinical Trial, Phase II","","Adult;Aged;Alanine Transaminase;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Aspartate Aminotransferases;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Carcinoma;Cetuximab;Cholangiocarcinoma;Common Bile Duct Neoplasms;Deoxycytidine;Disease-Free Survival;Female;Gallbladder Neoplasms;Humans;Intention to Treat Analysis;Male;Middle Aged;Mutation;Neutropenia;Organoplatinum Compounds;Oxaliplatin;Peripheral Nervous System Diseases;Proto-Oncogene Proteins;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);ras Proteins;Gemcitabine","Adult;Aged;Alanine Transaminase;Antibodies, Monoclonal, Humanized;Antineoplastic Combined Chemotherapy Protocols;Aspartate Aminotransferases;Bile Duct Neoplasms;Bile Ducts, Intrahepatic;Carcinoma;Cetuximab;Cholangiocarcinoma;Common Bile Duct Neoplasms;Deoxycytidine;Disease-Free Survival;Female;Gallbladder Neoplasms;Humans;Intention to Treat Analysis;Male;Middle Aged;Mutation;Neutropenia;Organoplatinum Compounds;Oxaliplatin;Peripheral Nervous System Diseases;Proto-Oncogene Proteins;Proto-Oncogene Proteins B-raf;Proto-Oncogene Proteins p21(ras);ras Proteins;Gemcitabine","Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated the addition of cetuximab to chemotherapy in patients with advanced biliary cancers. In this non-comparative, open-label, randomised phase 2 trial, we recruited patients with locally advanced (non-resectable) or metastatic cholangiocarcinoma, gallbladder carcinoma, or ampullary carcinoma and a WHO performance status of 0 or 1 from 18 hospitals across France and Germany. Eligible patients were randomly assigned (1:1) centrally with a minimisation procedure to first-line treatment with gemcitabine (1000 mg/m(2)) and oxaliplatin (100 mg/m(2)) with or without cetuximab (500 mg/m(2)), repeated every 2 weeks until disease progression or unacceptable toxicity. Randomisation was stratified by centre, primary site of disease, disease stage, and previous treatment with curative intent or adjuvant therapy. Investigators who assessed treatment response were not masked to group assignment. The primary endpoint was the proportion of patients who were progression-free at 4 months, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00552149. Between Oct 10, 2007, and Dec 18, 2009, 76 patients were assigned to chemotherapy plus cetuximab and 74 to chemotherapy alone. 48 (63%; 95% CI 52-74) patients assigned to chemotherapy plus cetuximab and 40 (54%; 43-65) assigned to chemotherapy alone were progression-free at 4 months. Median progression-free survival was 6·1 months (95% CI 5·1-7·6) in the chemotherapy plus cetuximab group and 5·5 months (3·7-6·6) in the chemotherapy alone group. Median overall survival was 11·0 months (9·1-13·7) in the chemotherapy plus cetuximab group and 12·4 months (8·6-16·0) in the chemotherapy alone group. The most common grade 3-4 adverse events were peripheral neuropathy (in 18 [24%] of 76 patients who received chemotherapy plus cetuximab vs ten [15%] of 68 who received chemotherapy alone), neutropenia (17 [22%] vs 11 [16%]), and increased aminotransferase concentrations (17 [22%] vs ten [15%]). 70 serious adverse events were reported in 39 (51%) of 76 patients who received chemotherapy plus cetuximab (34 events in 19 [25%] patients were treatment-related), whereas 41 serious adverse events were reported in 25 (35%) of 71 patients who received chemotherapy alone (20 events in 12 [17%] patients were treatment-related). One patient died of atypical pneumonia related to treatment in the chemotherapy alone group. The addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance the activity of chemotherapy in patients with advanced biliary cancer, although it was well tolerated. Gemcitabine and platinum-based combination should remain the standard treatment option. Institut National du Cancer, Merck Serono.","Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris;Saint-Antoine University Hospital, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;West German Cancer Center, University Hospital Essen, Essen, Germany.;Centre Léon Bérard, Lyon, France.;Centre Eugène Marquis, Rennes, France.;Saint-Antoine University Hospital, Paris, France.;Beaujon University Hospital, Clichy, France.;Saint-André University Hospital, Bordeaux, France.;Institut Paoli-Calmette, Marseille, France.;Centre Val d'Aurelle, Montpellier, France.;Ulm University, Ulm, Germany.;National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Henri-Mondor University Hospital, Créteil, France.;Beaujon University Hospital, Clichy, France.;Halle University Hospital, Halle (Saale), Germany.;Pitié-Salpêtrière University Hospital, Paris, France.;Regensburg University Hospital, Regensburg, Germany.;University of Munich, Munich, Germany.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Saint-Antoine University Hospital, Paris, France.;Saint-Antoine University Hospital, Paris, France.;Hannover Medical School, Hannover, Germany.","NA",0,"1474-5488","Lancet Oncol","Lancet Oncol",2014,"2014","15","10.1016/S1470-2045(14)70212-8","819-28","Z99 CA999999","Intramural NIH HHS","24852116","24852116","PUBMED","Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris;Saint-Antoine University Hospital, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;West German Cancer Center, University Hospital Essen, Essen, Germany.;Centre Léon Bérard, Lyon, France.;Centre Eugène Marquis, Rennes, France.;Saint-Antoine University Hospital, Paris, France.;Beaujon University Hospital, Clichy, France.;Saint-André University Hospital, Bordeaux, France.;Institut Paoli-Calmette, Marseille, France.;Centre Val d'Aurelle, Montpellier, France.;Ulm University, Ulm, Germany.;National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Henri-Mondor University Hospital, Créteil, France.;Beaujon University Hospital, Clichy, France.;Halle University Hospital, Halle (Saale), Germany.;Pitié-Salpêtrière University Hospital, Paris, France.;Regensburg University Hospital, Regensburg, Germany.;University of Munich, Munich, Germany.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Institut Gustave Roussy, Villejuif, Université Paris Sud, Paris, France.;Saint-Antoine University Hospital, Paris, France.;Saint-Antoine University Hospital, Paris, France.;Hannover Medical School, Hannover, Germany."
"537","Sawyer E;Roylance R;Petridis C;Brook MN;Nowinski S;Papouli E;Fletcher O;Pinder S;Hanby A;Kohut K;Gorman P;Caneppele M;Peto J;Dos Santos Silva I;Johnson N;Swann R;Dwek M;Perkins KA;Gillett C;Houlston R;Ross G;De Ieso P;Southey MC;Hopper JL;Provenzano E;Apicella C;Wesseling J;Cornelissen S;Keeman R;Fasching PA;Jud SM;Ekici AB;Beckmann MW;Kerin MJ;Marme F;Schneeweiss A;Sohn C;Burwinkel B;Guénel P;Truong T;Laurent-Puig P;Kerbrat P;Bojesen SE;Nordestgaard BG;Nielsen SF;Flyger H;Milne RL;Perez JI;Menéndez P;Benitez J;Brenner H;Dieffenbach AK;Arndt V;Stegmaier C;Meindl A;Lichtner P;Schmutzler RK;Lochmann M;Brauch H;Fischer HP;Ko YD;Nevanlinna H;Muranen TA;Aittomäki K;Blomqvist C;Bogdanova NV;Dörk T;Lindblom A;Margolin S;Mannermaa A;Kataja V;Kosma VM;Hartikainen JM;Chenevix-Trench G;Lambrechts D;Weltens C;Van Limbergen E;Hatse S;Chang-Claude J;Rudolph A;Seibold P;Flesch-Janys D;Radice P;Peterlongo P;Bonanni B;Volorio S;Giles GG;Severi G;Baglietto L;McLean CA;Haiman CA;Henderson BE;Schumacher F;Le Marchand L;Simard J;Goldberg MS;Labrèche F;Dumont M;Kristensen V;Winqvist R;Pylkäs K;Jukkola-Vuorinen A;Kauppila S;Andrulis IL;Knight JA;Glendon G;Mulligan AM;Devillee P;Tollenaar RA;Seynaeve CM;Kriege M;Figueroa J;Chanock SJ;Sherman ME;Hooning MJ;Hollestelle A;van den Ouweland AM;van Deurzen CH;Li J;Czene K;Humphreys K;Cox A;Cross SS;Reed MW;Shah M;Jakubowska A;Lubinski J;Jaworska-Bieniek K;Durda K;Swerdlow A;Ashworth A;Orr N;Schoemaker M;Couch FJ;Hallberg E;González-Neira A;Pita G;Alonso MR;Tessier DC;Vincent D;Bacot F;Bolla MK;Wang Q;Dennis J;Michailidou K;Dunning AM;Hall P;Easton D;Pharoah P;Schmidt MK;Tomlinson I;Garcia-Closas M","Sawyer, Elinor;Roylance, Rebecca;Petridis, Christos;Brook, Mark N;Nowinski, Salpie;Papouli, Efterpi;Fletcher, Olivia;Pinder, Sarah;Hanby, Andrew;Kohut, Kelly;Gorman, Patricia;Caneppele, Michele;Peto, Julian;Dos Santos Silva, Isabel;Johnson, Nichola;Swann, Ruth;Dwek, Miriam;Perkins, Katherine-Anne;Gillett, Cheryl;Houlston, Richard;Ross, Gillian;De Ieso, Paolo;Southey, Melissa C;Hopper, John L;Provenzano, Elena;Apicella, Carmel;Wesseling, Jelle;Cornelissen, Sten;Keeman, Renske;Fasching, Peter A;Jud, Sebastian M;Ekici, Arif B;Beckmann, Matthias W;Kerin, Michael J;Marme, Federick;Schneeweiss, Andreas;Sohn, Christof;Burwinkel, Barbara;Guénel, Pascal;Truong, Therese;Laurent-Puig, Pierre;Kerbrat, Pierre;Bojesen, Stig E;Nordestgaard, Børge G;Nielsen, Sune F;Flyger, Henrik;Milne, Roger L;Perez, Jose Ignacio Arias;Menéndez, Primitiva;Benitez, Javier;Brenner, Hermann;Dieffenbach, Aida Karina;Arndt, Volker;Stegmaier, Christa;Meindl, Alfons;Lichtner, Peter;Schmutzler, Rita K;Lochmann, Magdalena;Brauch, Hiltrud;Fischer, Hans-Peter;Ko, Yon-Dschun;Nevanlinna, Heli;Muranen, Taru A;Aittomäki, Kristiina;Blomqvist, Carl;Bogdanova, Natalia V;Dörk, Thilo;Lindblom, Annika;Margolin, Sara;Mannermaa, Arto;Kataja, Vesa;Kosma, Veli-Matti;Hartikainen, Jaana M;Chenevix-Trench, Georgia;Lambrechts, Diether;Weltens, Caroline;Van Limbergen, Erik;Hatse, Sigrid;Chang-Claude, Jenny;Rudolph, Anja;Seibold, Petra;Flesch-Janys, Dieter;Radice, Paolo;Peterlongo, Paolo;Bonanni, Bernardo;Volorio, Sara;Giles, Graham G;Severi, Gianluca;Baglietto, Laura;McLean, Catriona A;Haiman, Christopher A;Henderson, Brian E;Schumacher, Fredrick;Le Marchand, Loic;Simard, Jacques;Goldberg, Mark S;Labrèche, France;Dumont, Martine;Kristensen, Vessela;Winqvist, Robert;Pylkäs, Katri;Jukkola-Vuorinen, Arja;Kauppila, Saila;Andrulis, Irene L;Knight, Julia A;Glendon, Gord;Mulligan, Anna Marie;Devillee, Peter;Tollenaar, Rob A E M;Seynaeve, Caroline M;Kriege, Mieke;Figueroa, Jonine;Chanock, Stephen J;Sherman, Mark E;Hooning, Maartje J;Hollestelle, Antoinette;van den Ouweland, Ans M W;van Deurzen, Carolien H M;Li, Jingmei;Czene, Kamila;Humphreys, Keith;Cox, Angela;Cross, Simon S;Reed, Malcolm W R;Shah, Mitul;Jakubowska, Anna;Lubinski, Jan;Jaworska-Bieniek, Katarzyna;Durda, Katarzyna;Swerdlow, Anthony;Ashworth, Alan;Orr, Nicholas;Schoemaker, Minouk;Couch, Fergus J;Hallberg, Emily;González-Neira, Anna;Pita, Guillermo;Alonso, M Rosario;Tessier, Daniel C;Vincent, Daniel;Bacot, Francois;Bolla, Manjeet K;Wang, Qin;Dennis, Joe;Michailidou, Kyriaki;Dunning, Alison M;Hall, Per;Easton, Doug;Pharoah, Paul;Schmidt, Marjanka K;Tomlinson, Ian;Garcia-Closas, Montserrat","Genetic predisposition to in situ and invasive lobular carcinoma of the breast.","PLoS genetics","United States","eng","Journal Article","","Breast Neoplasms;Carcinoma in Situ;Carcinoma, Lobular;Case-Control Studies;Female;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Polymorphism, Single Nucleotide","Breast Neoplasms;Carcinoma in Situ;Carcinoma, Lobular;Case-Control Studies;Female;Genetic Predisposition to Disease;Genome-Wide Association Study;Genotype;Humans;Middle Aged;Polymorphism, Single Nucleotide","Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive breast carcinomas. It is generally ER positive (ER+) and often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09-1.18), P = 6.0 × 10(-10); P-het for ILC vs IDC ER+ tumors = 1.8 × 10(-4)). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and 15 with LCIS at P<0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11, rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although there is some heterogeneity between ER+ lobular and ER+ IDC tumors. These data provide evidence for overlapping, but distinct etiological pathways within ER+ breast cancer between morphological subtypes.","Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Biomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;Department of Pathology, The University of Melbourne, Melbourne, Australia.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;NIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.;Centre Eugène Marquis, Department of Medical Oncology, Rennes, France.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.;Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.;Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Saarland Cancer Registry, Saarbrücken, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Institute of Human Genetics, Technische Universität, Munich, Germany.;Centre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.;Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.;Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.;Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.;Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.;Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.;Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;Department of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.;Peter MacCallum Cancer Center, Melbourne, Australia.;Vesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Unit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Department of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.;Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.;Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.;Laboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.;Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.;Human Genetics Division, Genome Institute of Singapore, Singapore.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.;Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.","NA",0,"1553-7404","PLoS Genet","PLoS Genet",2013,"2014","10","10.1371/journal.pgen.1004285","e1004285","U01 CA69417;UM1 CA164920;U01 CA069467;2010NOVPR61;R01 CA128978;R01 CA132839;090532/Z/09/Z;U01 CA069417;CA54281;U01 CA069638;16563;10124;CA63464;C490/A10124;P50 CA116201;16565;C1287/A12014;R01 CA063464;090532;16561;R01 CA054281;U01 CA69638;U01 CA063464;U01 CA098758;CA132839;CA098758;16459;C1287/A10118;U01 CA69467;R37 CA054281","NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Breast Cancer Now;NCI NIH HHS;NCI NIH HHS;Wellcome Trust;Wellcome Trust;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;Cancer Research UK;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;Wellcome Trust;Cancer Research UK;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;NCI NIH HHS;Cancer Research UK;Cancer Research UK;NCI NIH HHS;NCI NIH HHS","24743323","24743323","PUBMED","Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Biomedical Research Centre, King's College London, Guy's Hospital, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;London School of Hygiene and Tropical Medicine, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Department of Molecular and Applied Biosciences, University of Westminster, London, United Kingdom.;Research Oncology, Division of Cancer Studies, Kings College London, Guy's Hospital, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;The Royal Marsden NHS Foundation Trust, London, United Kingdom.;Department of Pathology, The University of Melbourne, Melbourne, Australia.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;NIHR Cambridge Biomedical Research Centre, Addenbrookes Hospital, Cambridge, United Kingdom.;Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, California, United States of America; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.;Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.;Surgery, Clinical Science Institute, National University of Ireland, Galway, Ireland.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany.;Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany; Molecular Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer, Villejuif, France; University Paris-Sud, UMRS 1018, Villejuif, France.;Université Paris Sorbonne Cité, UMR-S775 Inserm, Paris, France.;Centre Eugène Marquis, Department of Medical Oncology, Rennes, France.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Copenhagen General Population Study and Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University of Copenhagen, Copenhagen, Denmark.;Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark.;Genetic & Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Servicio de Cirugía General y Especialidades, Hospital Monte Naranco, Oviedo, Spain.;Servicio de Anatomía Patológica, Hospital Monte Naranco, Oviedo, Spain.;Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Saarland Cancer Registry, Saarbrücken, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Institute of Human Genetics, Technische Universität, Munich, Germany.;Centre for Familial Breast and Ovarian Cancer and Centre for Integrated Oncology, University Hospital Cologne, Cologne, Germany.;Division of Gynaecology and Obstetrics, Technische Universität München, Munich, Germany.;Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tübingen, Tübingen, Germany.;Institute of Pathology, Medical Faculty of the University of Bonn, Bonn, Germany.;Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.;Department of Clinical Genetics, Helsinki University Central Hospital, Helsinki, Finland.;Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.;Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.;Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.;Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.;Department of Oncology - Pathology, Karolinska Institutet, Stockholm, Sweden.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Joensuu, Finland; Cancer Center, Kuopio University Hospital, Kuopio, Finland.;Department of Genetics, QIMR Berghofer Institute of Medical Research, Brisbane, Australia.;Peter MacCallum Cancer Center, Melbourne, Australia.;Vesalius Research Center (VRC), VIB, Leuven, Belgium; Department of Oncology, University of Leuven, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;University Hospital Gashuisberg, Leuven, Belgium.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.;Unit of Molecular Bases of Genetic Risk and Genetic Testing, Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy; IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy.;Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy.;IFOM, Fondazione Istituto FIRC di Oncologia Molecolare and Cogentech Cancer Genetic Test Laboratory, Milan, Italy.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia; Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia.;Department of Pathology, The Alfred Hospital, Prahran, Victoria, Australia.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America.;Epidemiology Program, Cancer Research Center, University of Hawaii, Honolulu, Hawaii, United States of America.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Medicine, McGill University, Montreal, Quebec, Canada; Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada.;Département de médecine sociale et préventive, Département de santé environnementale et santé au travail, Université de Montréal, Montreal, Quebec, Canada.;Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec Research Center and Laval University, Quebec, Canada.;Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Faculty of Medicine (Faculty Division Ahus), UiO, Oslo, Norway.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Laboratory of Cancer Genetics and Tumor Biology, Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab/Oulu University Hospital, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Department of Oncology, Oulu University Hospital, University of Oulu, Oulu, Finland.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.;Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.;Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.;Laboratory Medicine Program, University Health Network, Toronto, Ontario; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.;Department of Human Genetics & Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.;Department of Surgical Oncology, Leiden University Medical Center, Leiden, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Family Cancer Clinic, Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, United States of America.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.;Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.;Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands.;Human Genetics Division, Genome Institute of Singapore, Singapore.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, United Kingdom.;CRUK/YCR Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield, Sheffield, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland.;Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.;Division of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom.;Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America.;Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;Human Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre [CNIO], Madrid, Spain.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.;Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.;Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.;Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.;Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.;Division of Genetics and Epidemiology, Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom."
"538","Gendronneau M;Kérourédan O;Taque S;Sixou JL;Bonnaure-Mallet M","Gendronneau, M;Kérourédan, O;Taque, S;Sixou, J L;Bonnaure-Mallet, M","Dental abnormalities and preventive oral care in Schimke immuno-osseous dysplasia.","European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry","England","eng","Case Reports","","Anodontia;Arteriosclerosis;Cariostatic Agents;Child;Child, Preschool;Dental Pulp;Fatal Outcome;Fluorides;Follow-Up Studies;Humans;Immunologic Deficiency Syndromes;Male;Nephrotic Syndrome;Oral Health;Osteochondrodysplasias;Pit and Fissure Sealants;Primary Immunodeficiency Diseases;Pulmonary Embolism;Tooth Abnormalities;Tooth Crown;Tooth Discoloration;Tooth Diseases;Tooth Root;Toothbrushing","Anodontia;Arteriosclerosis;Cariostatic Agents;Child;Child, Preschool;Dental Pulp;Fatal Outcome;Fluorides;Follow-Up Studies;Humans;Immunologic Deficiency Syndromes;Male;Nephrotic Syndrome;Oral Health;Osteochondrodysplasias;Pit and Fissure Sealants;Primary Immunodeficiency Diseases;Pulmonary Embolism;Tooth Abnormalities;Tooth Crown;Tooth Discoloration;Tooth Diseases;Tooth Root;Toothbrushing","Schimke immuno-osseous dysplasia (SIOD) is a rare, severe, autosomal recessive disorder that results in spondyloepiphyseal dysplasia, renal dysfunction, immunodeficiency, facial dysmorphism and growth failure. Little is known about oral features associated with SIOD. Some of the dental anomalies encountered are specific to SIOD and have only been reported in individuals with SIOD. This paper describes the clinical and radiographic dental manifestations of SIOD in two Caucasian brothers. Both lived to be about 10 years old. After a variety of symptoms were reported, a diagnosis of SIOD was finally made when the brothers were, respectively, 5 and 8 years old. At that time, dental anomalies, such as dyschromia, bulbous crowns, short and thin roots, had not been taken into account to establish the diagnosis. However, knowledge of the dental features characteristic of this disease could have helped make the diagnosis. Although both were caries- and periodontal disease-free, special attention was focused on prevention, including dietary counselling, plaque control, oral hygiene instructions and the use of fluoridated toothpaste. The two patients were followed every 6 months, for over 2 years (until their death), by both a private dentist and a university hospital dentist, which helped them maintain good oral health. Oral hygiene was assessed at each appointment and fissure sealants were placed by the private practitioner on their first permanent molars. This report describes dental anomalies specific to SIOD that could facilitate diagnosis. Clinicians and dentists should work in collaboration to diagnose and treat children with SIOD. These patients require regular and specific dental management because of their fragile health and their characteristic dental anomalies. Ideally, preventive visits should be scheduled every 6 months in addition to curative visits as needed.","Université Européenne de Bretagne, Université de Rennes 1 and Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"1996-9805","Eur Arch Paediatr Dent","Eur Arch Paediatr Dent",2013,"2014","15","10.1007/s40368-013-0099-3","217-21","","","24327104","24327104","PUBMED","Université Européenne de Bretagne, Université de Rennes 1 and Centre Hospitalier Universitaire de Rennes, Rennes, France."
"539","de Tayrac M;Saikali S;Aubry M;Bellaud P;Boniface R;Quillien V;Mosser J","de Tayrac, Marie;Saikali, Stephan;Aubry, Marc;Bellaud, Pascale;Boniface, Rachel;Quillien, Véronique;Mosser, Jean","Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas.","PloS one","United States","eng","Journal Article","","Biomarkers, Tumor;Brain;Brain Neoplasms;Chromatin Assembly Factor-1;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Glioblastoma;Glioma;Humans;Immunohistochemistry;LIM Domain Proteins;Neoplasm Staging;Prognosis;Receptor, Endothelin B;Receptors, Endothelin","Biomarkers, Tumor;Brain;Brain Neoplasms;Chromatin Assembly Factor-1;DNA-Binding Proteins;Gene Expression Regulation, Neoplastic;Glioblastoma;Glioma;Humans;Immunohistochemistry;LIM Domain Proteins;Neoplasm Staging;Prognosis;Receptor, Endothelin B;Receptors, Endothelin","Recent studies have highlighted the heterogeneity of gliomas and demonstrated that molecular and genetic analysis could help in their classification and in the design of treatment protocols. In a previous study we have identified a 4-gene signature highly correlated with survival of glioma patients. The aim of this study is to confirm and extend these findings by investigating the expression of these genes at the protein level and their association with outcome of patients with high grade gliomas. Immunohistochemical staining for EDN/RB, HJURP, p60/CAF-1 and PDLI4 was studied on archive materials from 96 patients (64 glioblastomas and 32 grade III gliomas). The levels of all four proteins differed significantly between grade III and grade IV tumours. The levels of the EDN/RB, HJURP and p60/CAF-1 proteins were strongly associated with overall survival (p<0.001, p<0.001 and p=0.002, respectively), whereas the one of PDLI4 was not (P=0.11). A risk criterion defined as high levels of at least two of the EDN/RB, HJURP and p60/CAF-1 proteins accurately predicted the prognosis of patients. Multivariate analysis confirmed that this criterion was an independent negative prognostic marker (hazard ratio = 2.225; 95% CI, 1.248 to 3.966, p=0.007). The expression of the EDN/RB, HJURP, p60/CAF-1 and PDLI4 proteins is disrupted in high grade gliomas and increases in the levels of these proteins are closely linked to tumour aggressiveness and poor outcome.","Centre National de la Recherche Scientifique (CNRS), Unité mixte de recherche - UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France ; Université Rennes 1, UEB - Université européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France ; CHU - Centre Hospitalier universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2013,"2013","8","10.1371/journal.pone.0073332","e73332","","","24039914","24039914","PUBMED","Centre National de la Recherche Scientifique (CNRS), Unité mixte de recherche - UMR 6290, Institut Génétique et Développement de Rennes, Rennes, France ; Université Rennes 1, UEB - Université européenne de Bretagne, Biosit, Faculté de Médecine, Rennes, France ; CHU - Centre Hospitalier universitaire de Rennes, Service de Génétique Moléculaire et Génomique, Rennes, France."
"540","Robert-Gangneux F;Drogoul AS;Rostan O;Piquet-Pellorce C;Cayon J;Lisbonne M;Herbelin A;Gascan H;Guiguen C;Samson M;Gangneux JP","Robert-Gangneux, Florence;Drogoul, Anne-Sophie;Rostan, Octavie;Piquet-Pellorce, Claire;Cayon, Jérome;Lisbonne, Mariette;Herbelin, André;Gascan, Hugues;Guiguen, Claude;Samson, Michel;Gangneux, Jean-Pierre","Invariant NKT cells drive hepatic cytokinic microenvironment favoring efficient granuloma formation and early control of Leishmania donovani infection.","PloS one","United States","eng","Journal Article","","Animals;Cytokines;Disease Models, Animal;Enzyme-Linked Immunosorbent Assay;Female;Flow Cytometry;Granuloma;Leishmaniasis, Visceral;Liver;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Natural Killer T-Cells;Transcriptome","Animals;Cytokines;Disease Models, Animal;Enzyme-Linked Immunosorbent Assay;Female;Flow Cytometry;Granuloma;Leishmaniasis, Visceral;Liver;Mice;Mice, Inbred BALB C;Mice, Inbred C57BL;Natural Killer T-Cells;Transcriptome","The development of inflammatory granulomas around infected Kupffer cells is necessary for hepatic parasite clearance during visceral leishmaniasis. Invariant NKT (iNKT) cells are predominant T cells in the mouse liver and can synthesize large quantities of IL-4 and IFN-γ, two cytokines involved in granuloma formation. This study analyzed the role of iNKT cells in the hepatic immune response during Leishmania donovani infection, using a murine model of wild-type (WT) and iNKT cell-deficient (Jα18⁻/⁻) C57BL/6 mice sacrificed 15, 30 or 60 days post-infection. We recorded hepatic parasite loads, cytokine expression, and analyzed granulomatous response by immunohistochemistry and hepatic immune cell infiltration by flow cytometry. Whereas WT animals rapidly controlled the infection and developed an inflammatory response associated with a massive influx of iNKT cells observed by flow cytometry, Jα18⁻/⁻ mice had significantly higher parasitic loads on all time points. This lack of control of parasite burden was associated with a delay in granuloma maturation (28.1% of large granulomas at day 60 versus 50.7% in WT). Cytokine transcriptome analysis showed that mRNA of 90/101 genes encoding chemokines, cytokines and their receptors, was underexpressed in Jα18⁻/⁻ mice. Detection of IL-4 and TNF-α by ELISA in liver extracts was also significantly lower in Jα18⁻/⁻ mice. Consistent with flow cytometry analysis, cytokinome profile in WT mice showed a bias of expression towards T cell-chemoattractant chemokines on D15, and displayed a switch towards expression of granulocytes and/or monocytes -chemoattractant chemokines on D60. In Jα18⁻/⁻ mice, the significantly lower expression of CXCL5, MIP-2 and CCL2 mRNA was correlated with a defect in myeloperoxidase positive-cell attraction observed by immunohistochemistry and with a lower granulocyte and monocyte infiltration in the liver, as shown by flow cytometry. These data indicate that iNKT cells play a role in early and sustained pro-inflammatory cytokine response warranting efficient organization of hepatic granulomas and parasite clearance.","Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie, Rennes","NA",0,"1932-6203","PLoS One","PLoS One",2011,"2012","7","10.1371/journal.pone.0033413","e33413","","","22457760","22457760","PUBMED","Centre Hospitalier Universitaire de Rennes, Laboratoire de Parasitologie, Rennes"
"541","Péron J;Le Jeune F;Haegelen C;Dondaine T;Drapier D;Sauleau P;Reymann JM;Drapier S;Rouaud T;Millet B;Vérin M","Péron, Julie;Le Jeune, Florence;Haegelen, Claire;Dondaine, Thibaut;Drapier, Dominique;Sauleau, Paul;Reymann, Jean-Michel;Drapier, Sophie;Rouaud, Tiphaine;Millet, Bruno;Vérin, Marc","Subthalamic nucleus stimulation affects theory of mind network: a PET study in Parkinson's disease.","PloS one","United States","eng","Journal Article","","Aged;Brain Mapping;Case-Control Studies;Deep Brain Stimulation;Emotions;Female;Fluorodeoxyglucose F18;Glucose;Humans;Limbic System;Male;Middle Aged;Parkinson Disease;Positron-Emission Tomography;Subthalamic Nucleus","Aged;Brain Mapping;Case-Control Studies;Deep Brain Stimulation;Emotions;Female;Fluorodeoxyglucose F18;Glucose;Humans;Limbic System;Male;Middle Aged;Parkinson Disease;Positron-Emission Tomography;Subthalamic Nucleus","There appears to be an overlap between the limbic system, which is modulated by subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson's disease (PD), and the brain network that mediates theory of mind (ToM). Accordingly, the aim of the present study was to investigate the effects of STN DBS on ToM of PD patients and to correlate ToM modifications with changes in glucose metabolism. To this end, we conducted (18)FDG-PET scans in 13 PD patients in pre- and post-STN DBS conditions and correlated changes in their glucose metabolism with modified performances on the Eyes test, a visual ToM task requiring them to describe thoughts or feelings conveyed by photographs of the eye region. Postoperative PD performances on this emotion recognition task were significantly worse than either preoperative PD performances or those of healthy controls (HC), whereas there was no significant difference between preoperative PD and HC. Conversely, PD patients in the postoperative condition performed within the normal range on the gender attribution task included in the Eyes test. As far as the metabolic results are concerned, there were correlations between decreased cerebral glucose metabolism and impaired ToM in several cortical areas: the bilateral cingulate gyrus (BA 31), right middle frontal gyrus (BA 8, 9 and 10), left middle frontal gyrus (BA 6), temporal lobe (fusiform gyrus, BA 20), bilateral parietal lobe (right BA 3 and right and left BA 7) and bilateral occipital lobe (BA 19). There were also correlations between increased cerebral glucose metabolism and impaired ToM in the left superior temporal gyrus (BA 22), left inferior frontal gyrus (BA 13 and BA 47) and right inferior frontal gyrus (BA 47). All these structures overlap with the brain network that mediates ToM. These results seem to confirm that STN DBS hinders the ability to infer the mental states of others and modulates a distributed network known to subtend ToM.","Clinique Neurologique, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France.","NA",0,"1932-6203","PLoS One","PLoS One",2009,"2010","5","10.1371/journal.pone.0009919","e9919","","","20360963","20360963","PUBMED","Clinique Neurologique, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France."
